PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Grishin, AV; Caplan, MJ				Grishin, AV; Caplan, MJ			ATP1AL1, a member of the non-gastric H,K-ATPase family, functions as a sodium pump	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORTICAL COLLECTING DUCT; RAT DISTAL COLON; ALPHA-SUBUNIT; GENE FAMILY; K-ATPASE; H+,K+-ATPASE; EXPRESSION; OUABAIN; NA+,K+-ATPASE; POTASSIUM	The human ATP1AL1-encoded protein (an alpha subunit of the human non-gastric H,K-ATPase) has previously been shown to assemble with the gastric H,K-ATPase beta subunit (gH,K beta) to form a functionally active ionic pump in HEK 293 cells. This pump has been found to be sensitive to both SCH 28080 and ouabain. However, the Rb-86(+)-influx mediated by the ATP1AL1-gH,K beta heterodimer in HEK 293 cells is at least 1 order of magnitude larger than the maximum ouabain-sensitive proton efflux detected in the same cells. In this study we find that the intracellular Na+ content in cells expressing ATP1AL1 and gH,K beta is two times lower than that in control HEK 293 cells in response to incubation for 3 h in the presence of 1 mu M ouabain. Moreover, analysis of net Na+ efflux in HEK 293 expressing the ATP1AL1-gH,K beta heterodimer reveals the presence of Na+ extrusion activity that is not sensitive to 1 mu M ouabain but can be inhibited by 1 mM of this drug. In contrast, ouabain-inhibitable Na+ efflux in control HEK 293 cells is similarly sensitive to either 1 mu M or 1 mM ouabain. Finally, Rb-86(+) influx through the ATP1AL1-gH,K beta complex is comparable to the 1 mM ouabain-sensitive Na+ efflux in the same cells. The data presented here suggest that the enzyme formed by ATP1AL1 and the gastric H,K-ATPase beta subunit in HEK 293 cells mediates primarily Na+,K+ rather than H+,K+ exchange.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Yale University	Grishin, AV (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, 333 Cedar St,POB 208026, New Haven, CT 06520 USA.	grishin@biomed.med.yale.edu		Caplan, Michael/0000-0001-5768-4405	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK017433] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042136] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-17433] Funding Source: Medline; NIGMS NIH HHS [GM-42136] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn KY, 1996, AM J PHYSIOL-RENAL, V271, pF314, DOI 10.1152/ajprenal.1996.271.2.F314; BuffinMeyer B, 1997, AM J PHYSIOL-RENAL, V272, pF124, DOI 10.1152/ajprenal.1997.272.1.F124; Codina J, 1998, J BIOL CHEM, V273, P7894, DOI 10.1074/jbc.273.14.7894; Codina J, 1996, J BIOL CHEM, V271, P29759, DOI 10.1074/jbc.271.47.29759; Cougnon M, 1998, P NATL ACAD SCI USA, V95, P6516, DOI 10.1073/pnas.95.11.6516; Cougnon M, 1996, J BIOL CHEM, V271, P7277, DOI 10.1074/jbc.271.13.7277; CROWSON MS, 1992, J BIOL CHEM, V267, P13740; Doucet A, 1997, EXP NEPHROL, V5, P271; DUBOSE TD, 1995, AM J PHYSIOL-RENAL, V269, pF500, DOI 10.1152/ajprenal.1995.269.4.F500; EIAMONG S, 1993, J CLIN INVEST, V91, P2385, DOI 10.1172/JCI116471; EIAMONG S, 1993, KIDNEY INT, V43, P1015, DOI 10.1038/ki.1993.143; FEJESTOTH G, 1995, AM J PHYSIOL-RENAL, V269, pF551, DOI 10.1152/ajprenal.1995.269.4.F551; FERRONE RD, 1988, AM J PHYSIOL, V254, pG898; GRISHIN AV, 1994, FEBS LETT, V349, P144, DOI 10.1016/0014-5793(94)00655-5; Grishin AV, 1996, AM J PHYSIOL-RENAL, V271, pF539, DOI 10.1152/ajprenal.1996.271.3.F539; HAYSHI M, 1987, AM J PHYSIOL, V252, pF437; Jaisser F, 1996, AM J PHYSIOL-CELL PH, V270, pC679, DOI 10.1152/ajpcell.1996.270.2.C679; JAISSER F, 1993, PFLUG ARCH EUR J PHY, V425, P446, DOI 10.1007/BF00374871; JAISSER F, 1993, J CELL BIOL, V123, P1421, DOI 10.1083/jcb.123.6.1421; Kone BC, 1998, J BIOL CHEM, V273, P2543, DOI 10.1074/jbc.273.5.2543; Kone BC, 1996, MINER ELECTROL METAB, V22, P349; Kraut JA, 1998, KIDNEY INT, V53, P958, DOI 10.1111/j.1523-1755.1998.00841.x; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; Marsy S, 1996, PFLUG ARCH EUR J PHY, V432, P494, DOI 10.1007/s004240050161; MODYANOV NN, 1995, AM J PHYSIOL, V269, pF314; PANDIYAN V, 1992, GASTROENTEROLOGY, V102, P1846, DOI 10.1016/0016-5085(92)90304-H; POLVANI C, 1988, J BIOL CHEM, V263, P16757; POLVANI C, 1989, J BIOL CHEM, V264, P17854; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; RABON EC, 1990, J BIOL CHEM, V265, P19594; RAJENDRAN VMD, 1991, AM J PHYSIOL, V261, pG1005; Sangan PC, 1997, AM J PHYSIOL-CELL PH, V272, pC685, DOI 10.1152/ajpcell.1997.272.2.C685; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TAKEGUCHI M, 1990, GASTROENTEROLOGY, V99, P1339, DOI 10.1016/0016-5085(90)91159-4; VILSEN B, 1995, FEBS LETT, V363, P179, DOI 10.1016/0014-5793(95)00313-X; WATANABE T, 1990, AM J PHYSIOL, V258, pG506, DOI 10.1152/ajpgi.1990.258.4.G506; WINGO CS, 1995, AM J PHYSIOL-RENAL, V269, pF1, DOI 10.1152/ajprenal.1995.269.1.F1; ZHOU XM, 1992, AM J PHYSIOL, V263, pF1134; ZHOU XM, 1992, AM J PHYSIOL, V263, pF43, DOI 10.1152/ajprenal.1992.263.1.F43	40	51	51	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27772	27778		10.1074/jbc.273.43.27772	http://dx.doi.org/10.1074/jbc.273.43.27772			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774385	hybrid			2022-12-27	WOS:000076549800005
J	Ko, KWS; McLeod, RS; Avramoglu, RK; Nimpf, J; FitzGerald, DJ; Vukmirica, J; Yao, ZM				Ko, KWS; McLeod, RS; Avramoglu, RK; Nimpf, J; FitzGerald, DJ; Vukmirica, J; Yao, ZM			Mutation at the processing site of chicken low density lipoprotein receptor-related protein impairs efficient endoplasmic reticulum exit, but proteolytic cleavage is not essential for its endocytic functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2-MACROGLOBULIN RECEPTOR; PSEUDOMONAS EXOTOXIN; MOLECULAR CHAPERONE; 39-KDA PROTEIN; LRP; BINDING; IDENTIFICATION; CALCIUM; LIGANDS; SUGGEST	The low density lipoprotein receptor-related protein (LRP) is synthesized as a proreceptor that undergoes post-translational proteolytic processing yielding a noncovalently associated alpha beta dimer as the mature LRP. We tested the role of processing by creating a mutant in which the P1 residue (Arg(3942)) of the consensus site for furin cleavage (Arg-Asn-Arg-Arg(3942)down arrow) was replaced with Ser in chicken LRP, Transfection of the mutant LRP (designated LRP-RS) into a Chinese hamster ovary cell line lacking endogenous LRP resulted in expression of the unprocessed full-length proreceptor. Comparison of cell lines stably expressing either the wild-type LRP (LRP-wt) or the unprocessed LRP-RS showed that at comparable expression levels, both receptors restored the sensitivity of cellular protein synthesis to Pseudomonas exotoxin A (IC50 = 25 ng/ml). Subcellular fractionation and neuraminidase treatment showed that both LRP forms were transported to the plasma membrane. In addition, LRP-RS exhibited kinetics of binding, endocytosis, and degradation of methylamine-activated alpha(2)-macroglobulin that were identical to those of LRP-wt, The internalization rate constant was similar for LRP-wt (K-e = 0.259 min(-1)) and mutant LRP-RS (K-e = 0.252 min(-1)), suggesting that it takes about 4 min for the entire surface LRP pool to be internalized. Sorting of LRP from the endosomal compartment to lysosomes or recycling to the plasma membrane were also unaltered in mutant LRP-RS, Pulse-chase analysis showed that the lack of processing of LRP had no effect on the stability of its post-endoplasmic reticulum form or on the rate of its intracellular transit from the endoplasmic reticulum to the Golgi apparatus. However, the exit of mutant LRP from the endoplasmic reticulum was retarded by the Arg(3942)-to-Ser substitution, as evidenced by prolonged retention within the endoplasmic reticulum (t(1/2) = 4 h for LRP-wt and t(1/2) > 13 h for LRP-RS).	Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Grp, Ottawa, ON K1Y 4W7, Canada; Univ Vienna, A-1010 Vienna, Austria; Bioctr, Dept Mol Genet, Vienna, Austria; NCI, Mol Biol Lab, NIH, Div Canc Biol Diag & Ctr, Bethesda, MD 20892 USA	University of Ottawa; University of Ottawa Heart Institute; University of Vienna; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yao, ZM (corresponding author), Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Grp, 40 Ruskin St, Ottawa, ON K1Y 4W7, Canada.	zyao@heartinst.on.ca	McLeod, Roger/F-8014-2015	McLeod, Roger/0000-0002-6740-5569; Nimpf, Johannes/0000-0002-9273-3492				ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; Avramoglu RK, 1998, J BIOL CHEM, V273, P6057, DOI 10.1074/jbc.273.11.6057; Brechler V, 1996, J BIOL CHEM, V271, P20636, DOI 10.1074/jbc.271.34.20636; Brown MS, 1997, NATURE, V388, P629, DOI 10.1038/41672; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; Bu GJ, 1996, J BIOL CHEM, V271, P22218, DOI 10.1074/jbc.271.36.22218; Bu GJ, 1998, J BIOL CHEM, V273, P13359, DOI 10.1074/jbc.273.21.13359; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; DESCAMPS O, 1993, J BIOL CHEM, V268, P974; FITZGERALD DJ, 1995, J CELL BIOL, V129, P1533, DOI 10.1083/jcb.129.6.1533; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; Herz Joachim, 1993, Current Opinion in Lipidology, V4, P107, DOI 10.1097/00041433-199304000-00006; HURN BAL, 1980, METHOD ENZYMOL, V128, P213; KAKEHI T, 1988, J CLIN INVEST, V81, P2020, DOI 10.1172/JCI113553; Ko K. W. S., 1997, Molecular Biology of the Cell, V8, p307A; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; NIMPF J, 1994, J BIOL CHEM, V269, P212; Obermoeller LM, 1997, J BIOL CHEM, V272, P10761; OGATA M, 1990, J BIOL CHEM, V265, P20678; Quinn KA, 1997, J BIOL CHEM, V272, P23946, DOI 10.1074/jbc.272.38.23946; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; Weaver AM, 1996, J BIOL CHEM, V271, P24894, DOI 10.1074/jbc.271.40.24894; WILEY HS, 1982, J BIOL CHEM, V257, P4222; WILLIAMS JF, 1990, J BIOL CHEM, V265, P8463; Willnow TE, 1996, BIOCHEM J, V313, P71, DOI 10.1042/bj3130071; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; WILLNOW TE, 1994, J BIOL CHEM, V269, P15827; YOSHIMASA Y, 1988, SCIENCE, V240, P784, DOI 10.1126/science.3283938; YOSHIMASA Y, 1990, J BIOL CHEM, V265, P17230	32	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27779	27785		10.1074/jbc.273.43.27779	http://dx.doi.org/10.1074/jbc.273.43.27779			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774386	hybrid			2022-12-27	WOS:000076549800006
J	Lu, Z; Cyr, DM				Lu, Z; Cyr, DM			Protein folding activity of Hsp70 is modified differentially by the Hsp40 co-chaperones Sis1 and Ydj1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; YEAST SACCHAROMYCES-CEREVISIAE; DNAJ MOLECULAR CHAPERONE; ESCHERICHIA-COLI; ATPASE ACTIVITY; DISTINCT ROLES; REACTION CYCLE; HOMOLOG; MEMBRANES; TRANSLOCATION	Specification of Hsp70 action in cellular protein metabolism may occur through the formation of specialized Hsp70:Hsp40 pairs. To test this model, we compared the ability of purified Sis1 and Ydj1 to regulate the ATPase and protein-folding activity of Hsp70 Ssa1 and Ssb1/2 proteins, Ydj1 and Sis1 could both functionally interact with Ssa1, but not the Ssb1/2 proteins, to refold luciferase, Interestingly, Ydj1:Ssa1 could promote up to four times more luciferase folding than Sis1:Ssa1, This functional difference was explored and could not be accounted for by differences in the ability of Sis1 and Ydj1 to regulate Ssa1 ATPase activity. Instead, differences in the chaperone function of Ydj1 and Sis1 were observed. Ydj1 was dramatically more effective than Sis1 at suppressing the thermally induced aggregation of luciferase, Paradoxically, Sis1 and Ydj1 could bind similar quantities of chemically denatured luciferase, The polypeptide binding domain of Sis1 was found to lie between residues 171-352 and correspond to its conserved carboxyl terminus. The conserved carboxyl terminus of Ydj1 is also known to participate in the binding of nonnative polypeptides. Thus, Ydj1 appears more efficient at assisting Ssa1 in folding luciferase because its contains a zinc finger-like region that is absent from Sis1, Ydj1 and Sis1 are structurally and functionally distinct Hsp40 proteins that can specify Ssa1 action by generating Hsp70:Hsp40 pairs that exhibit different chaperone activities.	Univ Alabama, Sch Med, Med Ctr, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Cyr, DM (corresponding author), Univ Alabama, Sch Med, Med Ctr, Dept Cell Biol, 1918 Univ Blvd, Birmingham, AL 35294 USA.			Cyr, Douglas/0000-0002-4928-3414	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056981] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM056981, R01GM56981] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Banecki B, 1996, J BIOL CHEM, V271, P14840, DOI 10.1074/jbc.271.25.14840; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; CAPLAN AJ, 1993, MOL BIOL CELL, V4, P555, DOI 10.1091/mbc.4.6.555; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; CYR DM, 1995, FEBS LETT, V359, P129, DOI 10.1016/0014-5793(95)00024-4; CYR DM, 1992, J BIOL CHEM, V267, P20927; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; CYR DM, 1994, J BIOL CHEM, V269, P9798; CYR DM, 1997, GUIDEBOOK MOL CHAPER, P89; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GEORGOPOULOS CP, 1980, MOL GEN GENET, V178, P583, DOI 10.1007/BF00337864; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HOHFELD J, 1995, CELL, V83, P589; James P, 1997, SCIENCE, V275, P387, DOI 10.1126/science.275.5298.387; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; JORDAN R, 1995, J BIOL CHEM, V270, P4563, DOI 10.1074/jbc.270.9.4563; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Lu Z, 1998, J BIOL CHEM, V273, P5970, DOI 10.1074/jbc.273.10.5970; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; Ohba M, 1997, FEBS LETT, V409, P307, DOI 10.1016/S0014-5793(97)00535-8; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SLATER MR, 1989, NUCLEIC ACIDS RES, V17, P4891, DOI 10.1093/nar/17.12.4891; SLATER MR, 1989, NUCLEIC ACIDS RES, V17, P805, DOI 10.1093/nar/17.2.805; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Terada K, 1997, J CELL BIOL, V139, P1089, DOI 10.1083/jcb.139.5.1089; UEGUCHI C, 1994, P NATL ACAD SCI USA, V91, P1054, DOI 10.1073/pnas.91.3.1054; WALL D, 1994, J BIOL CHEM, V269, P5446; WALL D, 1995, J BIOL CHEM, V270, P2139, DOI 10.1074/jbc.270.5.2139	38	183	186	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27824	27830		10.1074/jbc.273.43.27824	http://dx.doi.org/10.1074/jbc.273.43.27824			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774392	hybrid			2022-12-27	WOS:000076549800012
J	Schaffer, DV; Lauffenburger, DA				Schaffer, DV; Lauffenburger, DA			Optimization of cell surface binding enhances efficiency and specificity of molecular conjugate gene delivery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; FACTOR RECEPTOR; IN-VIVO; NUCLEIC-ACIDS; CONDENSED DNA; FIBROBLASTS; TRANSFERRIN; VECTORS; LIGAND; SYSTEM	Molecular conjugates, or polyplexes, are promising synthetic vectors for targeted, in vivo gene delivery, if their efficiency can be improved. Gaining mechanistic information on conjugate gene delivery can potentially yield significant improvements in transfer efficiency by revealing barriers to conjugate transfer from the cell surface to the nucleus. We have developed an experimental system that employs epidermal growth factor as the ligand to direct delivery of DNA encoding the green fluorescent protein to mouse fibroblasts. We report here that the initial step of delivery, binding of the conjugate to the cell surface, is a barrier to gene transfer. We examined the effects of conjugate charge, ligand cross-linker spacer length, and ligand valency on polyplex cell surface binding, internalization, and gene transfer. We find that delivery is both efficient and specific only within a relatively narrow window of conjugate charge, results that correlate with binding and internalization of radiolabeled conjugate. In addition, increasing the cross-linker length can improve binding affinity and delivery. Finally, there is a significant optimum in gene delivery as a function of ligand valency, due to saturation of receptor binding and internalization. Optimizing parameters that affect surface binding therefore improves the efficiency and specificity of molecular conjugate gene delivery.	MIT, Dept Chem Engn, Cambridge, MA 02139 USA; MIT, Ctr Biotechnol Proc Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Schaffer, DV (corresponding author), Salk Inst, LOG-G,POB 85800, San Diego, CA 92186 USA.							Ager S, 1996, HUM GENE THER, V7, P2157, DOI 10.1089/hum.1996.7.17-2157; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; CAO H, 1995, ENDOCRINOLOGY, V136, P3163, DOI 10.1210/en.136.7.3163; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; CHIOU HC, 1994, NUCLEIC ACIDS RES, V22, P5439, DOI 10.1093/nar/22.24.5439; COTTEN M, 1992, P NATL ACAD SCI USA, V89, P6094, DOI 10.1073/pnas.89.13.6094; CURIEL DT, 1991, P NATL ACAD SCI USA, V88, P8850, DOI 10.1073/pnas.88.19.8850; Douglas JT, 1996, NAT BIOTECHNOL, V14, P1574, DOI 10.1038/nbt1196-1574; FRENCH AR, 1995, J BIOL CHEM, V270, P4334, DOI 10.1074/jbc.270.9.4334; Goldman CK, 1997, NAT BIOTECHNOL, V15, P462, DOI 10.1038/nbt0597-462; HAENSLER J, 1993, BIOCONJUGATE CHEM, V4, P372, DOI 10.1021/bc00023a012; HART SL, 1995, GENE THER, V2, P552; HOLT SJ, 1995, EXP CELL RES, V217, P554, DOI 10.1006/excr.1995.1122; JIANG LW, 1990, J CELL BIOL, V110, P559, DOI 10.1083/jcb.110.3.559; KING AC, 1980, P NATL ACAD SCI-BIOL, V77, P3283, DOI 10.1073/pnas.77.6.3283; Lee RJ, 1996, J BIOL CHEM, V271, P8481, DOI 10.1074/jbc.271.14.8481; Legendre JY, 1997, BIOCONJUGATE CHEM, V8, P57, DOI 10.1021/bc960076d; MARTI U, 1991, HEPATOLOGY, V13, P15, DOI 10.1016/0270-9139(91)90210-M; MARUYAMA K, 1995, BBA-BIOMEMBRANES, V1234, P74, DOI 10.1016/0005-2736(94)00263-O; Mislick KA, 1996, P NATL ACAD SCI USA, V93, P12349, DOI 10.1073/pnas.93.22.12349; Ohno K, 1997, NAT BIOTECHNOL, V15, P763, DOI 10.1038/nbt0897-763; PERALES JC, 1994, P NATL ACAD SCI USA, V91, P4086, DOI 10.1073/pnas.91.9.4086; PLANK C, 1994, J BIOL CHEM, V269, P12918; Plank C, 1996, HUM GENE THER, V7, P1437, DOI 10.1089/hum.1996.7.12-1437; REMY JS, 1995, P NATL ACAD SCI USA, V92, P1744, DOI 10.1073/pnas.92.5.1744; Schaffer DV, 1997, TISSUE ENG, V3, P53, DOI 10.1089/ten.1997.3.53; Sosnowski BA, 1996, J BIOL CHEM, V271, P33647, DOI 10.1074/jbc.271.52.33647; STANKOVICS J, 1994, HUM GENE THER, V5, P1095, DOI 10.1089/hum.1994.5.9-1095; STARBUCK C, 1990, CHEM ENG SCI, V45, P2367, DOI 10.1016/0009-2509(90)80117-W; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; ValsesiaWittmann S, 1996, J VIROL, V70, P2059, DOI 10.1128/JVI.70.3.2059-2064.1996; WADHWA MS, 1995, BIOCONJUGATE CHEM, V6, P283, DOI 10.1021/bc00033a008; WAGNER E, 1994, ADV DRUG DELIVER REV, V14, P113, DOI 10.1016/0169-409X(94)90008-6; WAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410; Watkins SJ, 1997, GENE THER, V4, P1004, DOI 10.1038/sj.gt.3300511; Wilbur DS, 1997, BIOCONJUGATE CHEM, V8, P819, DOI 10.1021/bc970053e; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; Wolfert MA, 1996, HUM GENE THER, V7, P2123, DOI 10.1089/hum.1996.7.17-2123; WU GY, 1987, J BIOL CHEM, V262, P4429; Wyman TB, 1997, BIOCHEMISTRY-US, V36, P3008, DOI 10.1021/bi9618474; Ziady AG, 1997, AM J PHYSIOL-GASTR L, V273, pG545, DOI 10.1152/ajpgi.1997.273.2.G545	41	128	132	1	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28004	28009		10.1074/jbc.273.43.28004	http://dx.doi.org/10.1074/jbc.273.43.28004			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774415	Green Published, hybrid			2022-12-27	WOS:000076549800035
J	van der Oost, J; Schut, G; Kengen, SWM; Hagen, WR; Thomm, M; de Vos, WM				van der Oost, J; Schut, G; Kengen, SWM; Hagen, WR; Thomm, M; de Vos, WM			The ferredoxin-dependent conversion of glyceraldehyde-3-phosphate in the hyperthermophilic archaeon Pyrococcus furiosus represents a novel site of glycolytic regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; EMBDEN-MEYERHOF PATHWAY; ENZYME; OXIDOREDUCTASE; DEHYDROGENASE; GENE; PURIFICATION; EXPRESSION; THERMOTOGA; TUNGSTEN	The fermentative conversion of glucose in anaerobic hyperthermophilic Archaea is a variant of the classical Embden-Meyerhof pathway found in Bacteria and Eukarya, A major difference of the archaeal glycolytic pathway concerns the conversion of glyceraldehyde-3-phosphate, In the hyperthermophilic archaeon Pyrococcus furiosus, this reaction is catalyzed by an unique enzyme, glyceraldehyde-3-phosphate ferredoxin oxidoreductase (GAPOR), Here, we report the isolation, characterization, and transcriptional analysis of the GAPOR-encoding gene. GAPOR is related to a family of ferredoxin-dependent tungsten enzymes in (hyper)thermophilic Archaea and, in addition, to a hypothetical protein in Escherichia coli. Electron paramagnetic resonance analysis of the purified P. furiosus GAPOR protein confirms the anticipated involvement of tungsten in catalysis. During glycolysis in P. furiosus, GAPOR gene expression is induced, whereas the activity of glyceraldehyde-3-phosphate dehydrogenase is repressed, It is discussed that this unprecedented unidirectional reaction couple in the pyrococcal glycolysis and gluconeogenesis gives rise to a novel site of glycolytic regulation that might be widespread among Archaea.	Wageningen Univ Agr, Microbiol Lab, NL-6307 CT Wageningen, Netherlands; Wageningen Univ Agr, Biochem Lab, NL-6307 HA Wageningen, Netherlands; Univ Kiel, Inst Allgemeine Microbiol, D-24118 Kiel, Germany	Wageningen University & Research; Wageningen University & Research; University of Kiel	van der Oost, J (corresponding author), Wageningen Univ Agr, Microbiol Lab, Hesselink van Suchtelenweg 4, NL-6307 CT Wageningen, Netherlands.		van+der+Oost, John/Y-2548-2019; Hagen, Wilfred R./H-8918-2017	Hagen, Wilfred R./0000-0002-1609-6671; Kengen, Serve/0000-0001-6139-8946				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ausubel FM, 1998, CURRENT PROTOCOLS MO; BOYD DA, 1994, INFECT IMMUN, V62, P1156, DOI 10.1128/IAI.62.4.1156-1165.1994; Brunner NA, 1998, J BIOL CHEM, V273, P6149, DOI 10.1074/jbc.273.11.6149; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CHAN MK, 1995, SCIENCE, V267, P1463, DOI 10.1126/science.7878465; Danson M J, 1993, BIOCH ARCHAEA ARCHAE, P1; EGGEN RIL, 1994, BIOCATALYSIS, V11, P131, DOI 10.3109/10242429409034383; HABENICHT A, 1994, J MOL BIOL, V237, P165, DOI 10.1006/jmbi.1994.1217; Hethke C, 1996, NUCLEIC ACIDS RES, V24, P2369, DOI 10.1093/nar/24.12.2369; Kengen SWM, 1996, FEMS MICROBIOL REV, V18, P119; KENGEN SWM, 1994, J BIOL CHEM, V269, P17537; KENGEN SWM, 1993, EUR J BIOCHEM, V213, P305, DOI 10.1111/j.1432-1033.1993.tb17763.x; Kengen SWM, 1995, J BIOL CHEM, V270, P30453, DOI 10.1074/jbc.270.51.30453; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Kletzin A, 1996, J BACTERIOL, V178, P248, DOI 10.1128/jb.178.1.248-257.1996; Kletzin A, 1996, FEMS MICROBIOL REV, V18, P5, DOI 10.1016/0168-6445(95)00025-9; MASSEY V, 1977, J BIOL CHEM, V252, P5612; Matheson AT, 1993, BIOCH ARCHAEA ARCHAE, pVII; MUKUND S, 1995, J BIOL CHEM, V270, P8389, DOI 10.1074/jbc.270.15.8389; PIERIK AJ, 1991, EUR J BIOCHEM, V195, P505, DOI 10.1111/j.1432-1033.1991.tb15731.x; SCHAFER T, 1993, ARCH MICROBIOL, V159, P354, DOI 10.1007/BF00290918; Selig M, 1997, ARCH MICROBIOL, V167, P217, DOI 10.1007/BF03356097; Siebers B, 1998, J BACTERIOL, V180, P2137, DOI 10.1128/JB.180.8.2137-2143.1998; Thomm M, 1996, FEMS MICROBIOL REV, V18, P159; TRAUTWEIN T, 1994, EUR J BIOCHEM, V222, P1025, DOI 10.1111/j.1432-1033.1994.tb18954.x; van der Oost J, 1998, Adv Biochem Eng Biotechnol, V61, P87; Voorhorst WGB, 1996, J BIOL CHEM, V271, P20426, DOI 10.1074/jbc.271.34.20426; WOESE CR, 1977, P NATL ACAD SCI USA, V74, P5088, DOI 10.1073/pnas.74.11.5088; ZILLIG W, 1993, BIOCH ARCHAEA ARCHAE, P367; ZWICKL P, 1990, J BACTERIOL, V172, P4329, DOI 10.1128/jb.172.8.4329-4338.1990	31	83	85	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28149	28154		10.1074/jbc.273.43.28149	http://dx.doi.org/10.1074/jbc.273.43.28149			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774434	hybrid			2022-12-27	WOS:000076549800054
J	Wang, W; Boffa, PB; Bajzar, L; Walker, JB; Nesheim, ME				Wang, W; Boffa, PB; Bajzar, L; Walker, JB; Nesheim, ME			A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; CARBOXY-TERMINAL LYSINE; CLOT LYSIS; PLASMA CARBOXYPEPTIDASE; PROCARBOXYPEPTIDASE-B; COAGULATION; BINDING; TAFI; IDENTIFICATION; PURIFICATION	TAFI (thrombin-activable fibrinolysis inhibitor) is a recently described plasma zsmogen that, when exposed to the thrombin-thrombomodulin complex, is converted by proteolysis at Arg(92) to a basic carboxypeptidase that inhibits fibrinolysis (TAFIa). The studies described here were undertaken to elucidate the molecular basis for the inhibition of fibrinolysis. When TAFIa is included in a clot undergoing fibrinolysis induced by tissue plasminogen activator and plasminogen, the time to achieve lysis is prolonged, and free arginine and lysine are released over time. In addition, TAFIa prevents a 2.5-fold increase in the rate constant for plasminogen activation which occurs when fibrin is modified by plasmin in the early course of fibrin degradation. The effect is specific for the Glu- form of plasminogen, TAFIa prevents or at least attenuates positive feedback expressed through Lys-plasminogen formation during the process of fibrinolysis initiated by tissue plasminogen activator and plasminogen. TAFIa also inhibits plasmin activity in a clot and prolongs fibrinolysis initiated with plasmin, We conclude that TAFIa suppresses fibrinolysis by removing COOH-terminal lysine and arginine residues from fibrin, thereby reducing its cofactor functions in both plasminogen activation and the positive feedback conversion of Glu-plasminogen to Lys-plasminogen. At relatively elevated concentrations, it also directly inhibits plasmin.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada; Univ Vermont, Dept Biochem, Burlington, VT 05405 USA; Hamilton Civ Hosp, Res Ctr, Hamilton, ON L8V 1C3, Canada	Queens University - Canada; Queens University - Canada; University of Vermont; McMaster University	Nesheim, ME (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.		Boffa, Michael/N-6539-2019	Boffa, Michael/0000-0003-1211-3064	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046703] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-46703-6] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AOKI N, 1993, METHOD ENZYMOL, V223, P185; Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; Bajzar L, 1998, J BIOL CHEM, V273, P2792, DOI 10.1074/jbc.273.5.2792; Bajzar L, 1996, BLOOD, V88, P2093, DOI 10.1182/blood.V88.6.2093.bloodjournal8862093; Boffa MB, 1998, J BIOL CHEM, V273, P2127, DOI 10.1074/jbc.273.4.2127; Broze GJ, 1996, BLOOD, V88, P3815, DOI 10.1182/blood.V88.10.3815.bloodjournal88103815; CAMPBELL W, 1989, BIOCHEM BIOPH RES CO, V162, P933, DOI 10.1016/0006-291X(89)90762-6; DEVRIES C, 1989, J BIOL CHEM, V264, P12604; EATON DL, 1991, J BIOL CHEM, V266, P21833; FLEURY V, 1991, BIOCHEMISTRY-US, V30, P7630, DOI 10.1021/bi00244a035; GAEDE G, 1975, ANAL BIOCHEM, V66, P393, DOI 10.1016/0003-2697(75)90606-5; HENDRIKS D, 1990, BIOCHIM BIOPHYS ACTA, V1034, P86, DOI 10.1016/0304-4165(90)90157-R; Horrevoets AJG, 1997, J BIOL CHEM, V272, P2183; Horrevoets AJG, 1997, J BIOL CHEM, V272, P2176; HORTIN GL, 1988, BIOCHEM BIOPH RES CO, V155, P591, DOI 10.1016/S0006-291X(88)80535-7; KLUFT C, 1986, BLOOD, V67, P616; LENICH C, 1991, THROMB RES, V64, P69, DOI 10.1016/0049-3848(91)90206-C; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; NAKATANI Y, 1972, ANAL BIOCHEM, V49, P225, DOI 10.1016/0003-2697(72)90261-8; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NORRMAN B, 1985, EUR J BIOCHEM, V149, P193, DOI 10.1111/j.1432-1033.1985.tb08911.x; PANNELL R, 1988, J CLIN INVEST, V81, P853, DOI 10.1172/JCI113394; PANYIM S, 1969, ARCH BIOCHEM BIOPHYS, V130, P337, DOI 10.1016/0003-9861(69)90042-3; REDLITZ A, 1995, J CLIN INVEST, V96, P2534, DOI 10.1172/JCI118315; Redlitz A, 1996, CIRCULATION, V93, P1328, DOI 10.1161/01.CIR.93.7.1328; SAKHAROV DV, 1995, CIRCULATION, V92, P1883, DOI 10.1161/01.CIR.92.7.1883; Sakharov DV, 1997, J BIOL CHEM, V272, P14477, DOI 10.1074/jbc.272.22.14477; SUENSON E, 1988, BIOCHEMISTRY-US, V27, P2435, DOI 10.1021/bi00407a029; SUENSON E, 1990, J BIOL CHEM, V265, P22228; TAN AK, 1995, BIOCHEMISTRY-US, V34, P5811, DOI 10.1021/bi00017a012; WANG W, 1994, J BIOL CHEM, V269, P15937	32	336	347	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27176	27181		10.1074/jbc.273.42.27176	http://dx.doi.org/10.1074/jbc.273.42.27176			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765237	hybrid			2022-12-27	WOS:000076448000024
J	Anderson, RA; Joyce, C; Davis, M; Reagan, JW; Clark, M; Shelness, GS; Rudel, LL				Anderson, RA; Joyce, C; Davis, M; Reagan, JW; Clark, M; Shelness, GS; Rudel, LL			Identification of a form of acyl-CoA : cholesterol acyltransferase specific to liver and intestine in nonhuman primates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFRICAN-GREEN MONKEYS; CORONARY-ARTERY ATHEROSCLEROSIS; APO-B SECRETION; COENZYME-A; MOLECULAR-CLONING; DIETARY-CHOLESTEROL; ACYLCOENZYME-A; ACAT; EXPRESSION; PROTEIN	The present study demonstrates that two different forms of the intracellular cholesterol esterification enzyme acyl-CoA:cholesterol acyltransferase (ACAT) are present in the nonhuman primate hepatocyte; one is similar to that originally cloned from human genomic DNA, here termed ACAT1, while a second gene product, termed ACAT2, is reported here. The primate ACAT2 gene product was cloned from an African green monkey liver cDNA library. Sequence analysis of an isolated, full-length clone of ACAT2 cDNA identified an open reading frame encoding a 526-amino acid protein with essentially no sequence similarity to the ACAT1 cDNA over the N-terminal 101 amino acids but with 57% identity predicted over the remaining 425 amino acids. Transfection of the cloned ACAT2 cDNA into two different mammalian cell types resulted in the production of abundant ACAT activity which was sensitive to ACAT inhibitors. Northern blot analysis showed that the ACAT2 mRNA was expressed primarily in liver and intestine in monkeys. In contrast, ACAT1 mRNA was expressed in almost all tissues examined. Topologic predictions from the amino acid sequence of ACAT2 indicates that it has seven trans-membrane domains in a configuration that places the putative active site of the enzyme in the lumen of the endoplasmic reticulum. This orientation of ACAT2 in the endoplasmic reticulum membrane, in addition to its expression only in liver and intestine, suggests that this enzyme may have as a primary function, the secretion of cholesteryl esters into apoB-containing lipoproteins.	Wake Forest Univ, Sch Med, Dept Comparat Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Biochem, Arteriosclerosis Res Program, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Pathol, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University; Wake Forest University; Wake Forest University	Rudel, LL (corresponding author), Wake Forest Univ, Sch Med, Dept Comparat Med, Winston Salem, NC 27157 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049373] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49373, HL-07115] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BILLHEIMER JT, 1990, ADV CHOLESTEROL RES, P7; Cao GQ, 1996, J BIOL CHEM, V271, P14642, DOI 10.1074/jbc.271.24.14642; CARR TP, 1995, J LIPID RES, V36, P25; CARR TP, 1992, ARTERIOSCLER THROMB, V12, P1274, DOI 10.1161/01.ATV.12.11.1274; CASES S, 1997, CIRCULATION S1, V96, P230; CHANG CCY, 1995, J BIOL CHEM, V270, P29532; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; CIANFLONE KM, 1990, J LIPID RES, V31, P2045; ESSER V, 1988, J BIOL CHEM, V263, P13282; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; HASEL KW, 1991, MOL CELL BIOL, V11, P3484, DOI 10.1128/MCB.11.7.3484; HUFF MW, 1994, ARTERIOSCLER THROMB, V14, P1498, DOI 10.1161/01.ATV.14.9.1498; KLEIN RL, 1983, J LIPID RES, V24, P343; LANFORD RE, 1989, IN VITRO CELL DEV B, V25, P174; LANFORD RE, 1997, MOL METHODS MED HEPA; Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041; NICCHITTA CV, 1989, J CELL BIOL, V108, P789, DOI 10.1083/jcb.108.3.789; PAPE ME, 1995, J LIPID RES, V36, P823; PURDY BH, 1984, J CLIN INVEST, V74, P351, DOI 10.1172/JCI111430; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROST B, 1995, PROTEIN SCI, V4, P521; Rost B, 1996, METHOD ENZYMOL, V266, P525; RUDEL L, 1994, J CLIN INVEST, V93, P2463, DOI 10.1172/JCI117255; RUDEL LL, 1981, ARTERIOSCLEROSIS, V1, P144, DOI 10.1161/01.ATV.1.2.144; Rudel LL, 1997, J CLIN INVEST, V100, P74, DOI 10.1172/JCI119524; RUDEL LL, 1995, AM J CLIN NUTR, V62, p463S, DOI 10.1093/ajcn/62.2.463S; RUDEL LL, 1985, ANN NY ACAD SCI, V454, P248, DOI 10.1111/j.1749-6632.1985.tb11864.x; RUDEL LL, 1995, ARTERIOSCL THROM VAS, V15, P2101, DOI 10.1161/01.ATV.15.12.2101; RUDEL LL, 1980, USE NONHUMAN PRIMATE, P37; Sambrook J., 2002, MOL CLONING LAB MANU; STURLEY SL, 1997, CIRCULATION, V96, P441; UELMEN PJ, 1995, J BIOL CHEM, V270, P26192, DOI 10.1074/jbc.270.44.26192; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WONG MH, 1994, J BIOL CHEM, V269, P1340; Yang HY, 1996, SCIENCE, V272, P1353, DOI 10.1126/science.272.5266.1353; Yu CJ, 1996, J BIOL CHEM, V271, P24157, DOI 10.1074/jbc.271.39.24157	39	250	267	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26747	26754		10.1074/jbc.273.41.26747	http://dx.doi.org/10.1074/jbc.273.41.26747			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756918	hybrid			2022-12-27	WOS:000076373300072
J	Jensen, PH; Nielsen, MS; Jakes, R; Dotti, G; Goedert, M				Jensen, PH; Nielsen, MS; Jakes, R; Dotti, G; Goedert, M			Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; A-BETA COMPONENT; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; MEMBRANE; NACP	The presynaptic protein alpha-synuclein has been implicated in the pathogenesis of Parkinson's disease. First, two missense mutations A30P and A53T cause inheritable early onset Parkinson's disease in some families. Secondly, alpha-synuclein is present in Lewy bodies of affected nerve cells in the predominant sporadic type of Parkinson's disease as well as in dementia with Lewy bodies. We demonstrate in the rat optic system that a portion of alpha-synuclein is carried by the vesicle-moving fast component of axonal transport and that it binds to rat brain vesicles through its amino-terminal repeat region. We find alpha-synuclein with the A30P mutation of familial Parkinson's disease devoid of vesicle-binding-activity and propose that mutant alpha-synuclein may accumulate, leading to assembly into Lewy body filaments.	Univ Aarhus, Dept Med Biochem, DK-8000 Aarhus C, Denmark; European Mol Biol Lab, D-69012 Heidelberg, Germany; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	Aarhus University; European Molecular Biology Laboratory (EMBL); MRC Laboratory Molecular Biology	Jensen, PH (corresponding author), Univ Aarhus, Dept Med Biochem, Bldg 170, DK-8000 Aarhus C, Denmark.		Nielsen, Morten Schallburg/G-9498-2016; Dotti, Carlos G/I-5533-2015	Nielsen, Morten Schallburg/0000-0001-9863-9694; Dotti, Carlos G/0000-0003-4052-1719; Jensen, Poul Henning/0000-0002-4439-9020				Baba M, 1998, AM J PATHOL, V152, P879; BRADY ST, 1985, NEUROMETHODS, V1, P419; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; GOEDERT M, 1998, NEUROSCI NEWS, V1, P2; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Ince PG, 1998, BRAIN PATHOL, V8, P299; Irizarry MC, 1996, J NEUROPATH EXP NEUR, V55, P889, DOI 10.1097/00005072-199608000-00004; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; MAROTEAUX L, 1991, MOL BRAIN RES, V11, P335, DOI 10.1016/0169-328X(91)90043-W; NAKAJO S, 1993, EUR J BIOCHEM, V217, P1057, DOI 10.1111/j.1432-1033.1993.tb18337.x; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n	21	452	456	1	54	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26292	26294		10.1074/jbc.273.41.26292	http://dx.doi.org/10.1074/jbc.273.41.26292			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756856	hybrid			2022-12-27	WOS:000076373300010
J	Saleh, A; Schieltz, D; Ting, N; McMahon, SB; Litchfield, DW; Yates, JR; Lees-Miller, SP; Cole, MD; Brandl, CJ				Saleh, A; Schieltz, D; Ting, N; McMahon, SB; Litchfield, DW; Yates, JR; Lees-Miller, SP; Cole, MD; Brandl, CJ			Tra1p is a component of the yeast Ada center dot Spt transcriptional regulatory complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; ACIDIC ACTIVATION DOMAINS; TATA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE REPRESSION; GENE-EXPRESSION; DNA-REPAIR; IN-VIVO; GCN5	The yeast Ada and TBP class of Spt proteins interact in multiple complexes that are required for transcriptional regulation. We have identified Tra1p as a component of these complexes through tandem mass spectrometry analysis of proteins that associate with Ngg1p/Ada3p, TRA1 is an essential gene and encodes a 3744-amino acid protein that is a member of a group of proteins including the catalytic subunit of DNA-dependent protein kinase, ATM and TRRAP, with carboxyl-terminal regions related to phosphatidylinositol 3-kinases, The interaction between Tra1p and Ada/Spt components was verified by the reciprocal coimmunoprecipitation of Ada2p and Tra1p from whole cell extracts in one or more complexes containing Spt7p, Tra1p cofractionated with Ngg1p and Spt7p through consecutive chromatography on Mono Q, DNA-cellulose, and Superose 6 columns. Binding of Tra1p to DNA-cellulose required Ada components. The association of Tra1p with two Ada Spt complexes was suggested by its cofractionation with Ngg1p and Spt7p in two peaks on the Mono Q column. In the absence of Ada2p, the elution profile of Tra1p shifted to a distinct peak. Despite the similarity of Tra1p to a group of putative protein kinases, we have not detected protein kinase activity within immunoprecipitates of Tra1p or the Ada.Spt complexes.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA; Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Western University (University of Western Ontario); University of Washington; University of Washington Seattle; University of Calgary; Princeton University	Brandl, CJ (corresponding author), Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada.	cbrandl@julian.uwo.ca	Litchfield, David/E-4636-2015	Litchfield, David/0000-0002-2425-6620; McMahon, Steven/0000-0002-3405-1768; Lees-Miller, Susan/0000-0001-5809-2516; Saleh, Ayman M/0000-0003-1126-6018	PHS HHS [118223-02] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; Barlev NA, 1998, MOL CELL BIOL, V18, P1349, DOI 10.1128/MCB.18.3.1349; BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Brandl CJ, 1996, J BIOL CHEM, V271, P9298, DOI 10.1074/jbc.271.16.9298; BRANDL CJ, 1993, EMBO J, V12, P5255, DOI 10.1002/j.1460-2075.1993.tb06221.x; Candau R, 1996, J BIOL CHEM, V271, P5237; Cross FR, 1997, YEAST, V13, P647, DOI 10.1002/(SICI)1097-0061(19970615)13:7<647::AID-YEA115>3.0.CO;2-#; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; ESTRUCH F, 1991, NUCLEIC ACIDS RES, V19, P4873, DOI 10.1093/nar/19.18.4873; GANSHEROFF LJ, 1995, GENETICS, V139, P523; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Hampsey M, 1997, TRENDS GENET, V13, P427, DOI 10.1016/S0168-9525(97)01292-4; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Horiuchi J, 1997, MOL CELL BIOL, V17, P3220, DOI 10.1128/MCB.17.6.3220; HORIUCHI J, 1995, MOL CELL BIOL, V15, P1203; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KENNEDY RT, 1989, ANAL CHEM, V61, P1128, DOI 10.1021/ac00185a016; LALOUX I, 1990, MOL CELL BIOL, V10, P3541, DOI 10.1128/MCB.10.7.3541; LeesMiller SP, 1996, BIOCHEM CELL BIOL, V74, P503, DOI 10.1139/o96-054; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6742; Link AJ, 1997, ELECTROPHORESIS, V18, P1314, DOI 10.1002/elps.1150180808; Marcus GA, 1996, MOL CELL BIOL, V16, P3197; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Pemberton LF, 1997, J CELL BIOL, V139, P1645, DOI 10.1083/jcb.139.7.1645; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; Roberts SM, 1996, MOL CELL BIOL, V16, P3206; Roberts SM, 1997, GENETICS, V147, P451; Saleh A, 1997, J BIOL CHEM, V272, P5571, DOI 10.1074/jbc.272.9.5571; SALEH A, 1998, IN PRESS J MOL BIOL; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SIKORSKI RS, 1989, GENETICS, V122, P19; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020; YATES JR, 1994, CELL BIOL LAB HDB, V3, P380; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8	45	112	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26559	26565		10.1074/jbc.273.41.26559	http://dx.doi.org/10.1074/jbc.273.41.26559			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756893	hybrid			2022-12-27	WOS:000076373300047
J	Benov, L; Fridovich, I				Benov, L; Fridovich, I			Superoxide dependence of the toxicity of short chain sugars	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCATION END-PRODUCTS; PHYSIOLOGICAL CONDITIONS; AMINOGUANIDINE; PREVENTION; PROTEINS; AUTOXIDATION; MECHANISM; ENZYMES; STRESS; ACID	Erythrose inhibited the growth of a sodA sodB strain of Escherichia coli under aerobiosis; but did not inhibit anaerobic growth of the sodA sodB strain, or the aerobic growth of the superoxide dismutase (SOD)-competent parental strain. A SOD mimic protected the sodA sodB strain against the toxicity of erythrose as did the carbonyl-blocking reagents hydrazine and aminoguanidine. Three carbon sugars, such as glyceraldehyde and dihydroxy acetone, and the two carbon sugar glycolaldehyde, were similarly toxic in an O-2(radical anion)-dependent manner. An unidentified dialyzable component in E. coli extract augmented the oxidation of short chain sugars, and this was partially inhibitable by SOD. The toxicity of the short chain sugars appears to be because of an O-2(radical anion)-dependent oxidation to alpha,beta-dicarbonyl compounds. In keeping with this view was the O-2(radical anion)-independent toxicity of methylglyoxal.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Fridovich, I (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.		Benov, Ludmil/AAD-3714-2020	Benov, Ludmil/0000-0002-0205-0146	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL056025] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56025-03] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ansari NH, 1996, BIOCHEM MOL MED, V59, P68, DOI 10.1006/bmme.1996.0067; Batinic-Haberle I, 1998, J BIOL CHEM, V273, P24521, DOI 10.1074/jbc.273.38.24521; Booth AA, 1997, J BIOL CHEM, V272, P5430, DOI 10.1074/jbc.272.9.5430; Ceriello A, 1996, DIABETES, V45, P471, DOI 10.2337/diabetes.45.4.471; Corman B, 1998, P NATL ACAD SCI USA, V95, P1301, DOI 10.1073/pnas.95.3.1301; Demasi R, 1996, FREE RADICAL BIO MED, V20, P291, DOI 10.1016/0891-5849(95)02035-7; ERICKSON JG, 1952, J AM CHEM SOC, V74, P4706, DOI 10.1021/ja01138a506; ERIKSSON UJ, 1991, DIABETOLOGIA, V34, P325, DOI 10.1007/BF00405004; Fu MX, 1996, J BIOL CHEM, V271, P9982, DOI 10.1074/jbc.271.17.9982; GARST J, 1982, OXY RADICALS THEIR S, P125; HAGAY ZJ, 1995, AM J OBSTET GYNECOL, V173, P1036, DOI 10.1016/0002-9378(95)91323-8; HE RQ, 1995, BIOCHEM J, V309, P133, DOI 10.1042/bj3090133; HERMESLIMA M, 1995, FREE RADICAL BIO MED, V19, P381, DOI 10.1016/0891-5849(95)00015-P; Hiraku Y, 1996, CANCER RES, V56, P1786; HIRSCH J, 1992, CARBOHYD RES, V232, P125, DOI 10.1016/S0008-6215(00)90999-6; Ikeda K, 1996, BIOCHEMISTRY-US, V35, P8075, DOI 10.1021/bi9530550; IMLAY JA, 1987, J BACTERIOL, V169, P2967, DOI 10.1128/jb.169.7.2967-2976.1987; KHATAMI M, 1988, LIFE SCI, V43, P1725, DOI 10.1016/0024-3205(88)90484-5; Li YM, 1996, P NATL ACAD SCI USA, V93, P3902, DOI 10.1073/pnas.93.9.3902; LO TWC, 1994, BIOCHEM PHARMACOL, V48, P1865, DOI 10.1016/0006-2952(94)90584-3; Lovry O.H., 1951, J BIOL CHEM, V193, P265; Maniatis T, 1982, MOL CLONING LABORATO, P68; MASHINO T, 1987, ARCH BIOCHEM BIOPHYS, V254, P547, DOI 10.1016/0003-9861(87)90136-6; Meyerhof O, 1925, BIOCHEM Z, V159, P432; ROBERTSON P, 1981, ARCH BIOCHEM BIOPHYS, V207, P282, DOI 10.1016/0003-9861(81)90035-7; SAKURAI T, 1988, FEBS LETT, V236, P406, DOI 10.1016/0014-5793(88)80066-8; SMITH PR, 1992, EUR J BIOCHEM, V210, P729, DOI 10.1111/j.1432-1033.1992.tb17474.x; Smythe CV, 1932, BER DTSCH CHEM GES, V65, P819, DOI 10.1002/cber.19320650527; THORNALLEY P, 1984, BIOCHIM BIOPHYS ACTA, V797, P276, DOI 10.1016/0304-4165(84)90131-4	29	17	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25741	25744		10.1074/jbc.273.40.25741	http://dx.doi.org/10.1074/jbc.273.40.25741			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748243	hybrid			2022-12-27	WOS:000076263100034
J	Mould, AP; Burrows, L; Humphries, MJ				Mould, AP; Burrows, L; Humphries, MJ			Identification of amino acid residues that form part of the ligand-binding pocket of integrin alpha 5 beta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; CELL-ADHESION; A-DOMAIN; FIBRONECTIN; SUBUNIT; SITE; REGION; ALPHA(IIB)BETA(3); OCCUPANCY; FRAGMENTS	Arg-Arg-Glu-Thr-Ala-Trp-Ala (RRETAWA) is a novel ligand peptide for integrin alpha(5)beta(1), which blocks alpha(5)beta(1)-mediated cell adhesion to fibronectin (Koivunen, E., Wang, B., and Ruoslahti, E. (1994) J. Cell Biol. 124, 373-380), Here we ha ve localized the binding site for RRETAWA on alpha(5)beta(1) using inhibitory monoclonal antibodies (mAbs) and site-directed mutagenesis. A cyclic peptide containing this sequence (*CRRETAWAC*) had little effect on the binding of most anti-alpha(5) and anti-beta(1) mAbs to alpha(5)beta(1) but completely blocked binding of the anti-alpha(5) mAb 16 in a directly competitive manner. Hence, the binding site of RRETAWA appears to closely overlap with the epitope of mAb 16, *CRRETAWAC* also acted as a direct competitive inhibitor of the binding of Arg-Gly-Asp (RGD)-containing fibronectin fragments to alpha(5)beta(1), suggesting that the binding site for RRETAWA is also closely overlapping with that for RGD. However, differences between the binding sites of RRETAWA and RGD were apparent in that (i) RGD peptides allosterically inhibited the binding of mAb 16 to alpha(5)beta(1), and (ii) several mAbs that perturbed binding of alpha(5)beta(1) to RGD had little effect on binding of alpha(5)beta(1) to RRETAWA. A double mutation in alpha(5) (S156G/W157S) blocked the interaction of both RRETAWA and mAb 16 with alpha(5)beta(1) but had no effect on fibronectin binding or on the binding of other anti-alpha(5) mAbs. Ser(156)-Trp(157) is located near the apex of a putative loop region on the upper surface of a predicted beta-propeller structure formed by the NH2-terminal repeats of alpha(5). Our findings suggest that this sequence forms part of the ligand-binding pocket of alpha(5)beta(1). Furthermore, as Ser(156)-Trp(157) is unique to the alpha(5) subunit, it may be responsible for the specific recognition of RRETAWA by alpha(5)beta(1).	Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Manchester	Mould, AP (corresponding author), Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, 2-205 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	pmould@fs1.scg.man.ac.uk		Humphries, Martin/0000-0002-4331-6967	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AOTA S, 1994, J BIOL CHEM, V269, P24756; DANEN EHJ, 1995, J BIOL CHEM, V270, P21612, DOI 10.1074/jbc.270.37.21612; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; Humphries MJ, 1998, TRENDS CELL BIOL, V8, P78, DOI 10.1016/S0962-8924(98)80016-0; Irie A, 1997, P NATL ACAD SCI USA, V94, P7198, DOI 10.1073/pnas.94.14.7198; IRIE A, 1995, EMBO J, V14, P5550, DOI 10.1002/j.1460-2075.1995.tb00242.x; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; Kunicki TJ, 1996, J BIOL CHEM, V271, P20315, DOI 10.1074/jbc.271.34.20315; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Loftus JC, 1997, J CLIN INVEST, V99, P2302, DOI 10.1172/JCI119408; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; Mould AP, 1997, J BIOL CHEM, V272, P17283, DOI 10.1074/jbc.272.28.17283; Mould AP, 1996, J BIOL CHEM, V271, P20365, DOI 10.1074/jbc.271.34.20365; Mould AP, 1998, BIOCHEM J, V331, P821, DOI 10.1042/bj3310821; Mould AP, 1996, J CELL SCI, V109, P2613; Newham P, 1996, MOL MED TODAY, V2, P304, DOI 10.1016/1357-4310(96)10021-6; Newham P, 1998, J IMMUNOL, V160, P4508; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; Pujades C, 1997, MOL BIOL CELL, V8, P2647, DOI 10.1091/mbc.8.12.2647; SCHREINER CL, 1989, J CELL BIOL, V109, P3157, DOI 10.1083/jcb.109.6.3157; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; Takada Y, 1997, MATRIX BIOL, V16, P143, DOI 10.1016/S0945-053X(97)90002-0; TAM JP, 1991, J AM CHEM SOC, V113, P6657, DOI 10.1021/ja00017a044; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; TUCKWELL DS, 1992, BIOCHEM J, V285, P325, DOI 10.1042/bj2850325; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; TUCKWELL DS, 1994, CELL ADHES COMMUN, V2, P385, DOI 10.3109/15419069409004450; YAMADA KM, 1984, J CELL BIOL, V99, P29, DOI 10.1083/jcb.99.1.29	32	48	51	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25664	25672		10.1074/jbc.273.40.25664	http://dx.doi.org/10.1074/jbc.273.40.25664			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748233	hybrid			2022-12-27	WOS:000076263100024
J	Tse, A; Moran, RG				Tse, A; Moran, RG			Cellular folates prevent polyglutamation of 5,10-dideazatetrahydrofolate - A novel mechanism of resistance to folate antimetabolites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMATE SYNTHETASE; GLYCINAMIDE RIBONUCLEOTIDE FORMYLTRANSFERASE; MAMMALIAN FOLYLPOLYGLUTAMATE SYNTHETASE; THYMIDYLATE SYNTHASE INHIBITORS; NOVO PURINE SYNTHESIS; FOLIC-ACID; CCRF-CEM; SUBSTRATE-SPECIFICITY; MEMBRANE-TRANSPORT; POTENT INHIBITOR	Mouse L1210 cell variants were selected for resistance to 5,10-dideazatetrahydrofolate, a potent inhibitor of the first folate-dependent enzyme in de novo purine synthesis, glycinamide ribonucleotide formyltransferase. The drug-resistant phenotype selected was conditional to the folate compound used to support growth: grown on folic acid cells mere 400-fold resistant, whereas they were 2.5-fold more sensitive to 5,10-dideazatetrahydrofolate than wild-type L1210 cells when grown on folinic acid. In folic acid-containing media, polyglutamation of 5,10-dideazatetrahydrofolate was markedly reduced, yet folylpolyglutamate synthetase activity was not different from that in parental L1210 cells. Resistance was due to two changes in membrane transport: a minor increase in the K-m for 5,10-dideazatetrahydrofolate influx, and a major increase in folic acid transport. Enhanced folic acid transport resulted in an expanded cellular content of folates which blocked polyglutamation of 5,10-dideazatetrahydrofolate. We propose that polyglutamation of 5,10-dideazatetrahydrofolate is limited by feedback inhibition by cellular folates on folylpolyglutamate synthetase, an effect which reflects a mechanism in place to control the level of cellular folates. Although the primary alteration causative of resistance is different from those reported previously, all 5,10-dideazatetrahydrofolate resistance phenotypes result in decreased drug polyglutamation, reflecting the centrality of this reaction to the action of 5,10-dideazatetrahydrofolate.	Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA	Virginia Commonwealth University; Virginia Commonwealth University; University of Southern California	Moran, RG (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Box 980230, Richmond, VA 23298 USA.	rmoran@hsc.vcu.edu			NATIONAL CANCER INSTITUTE [R01CA027605] Funding Source: NIH RePORTER; NCI NIH HHS [CA 27605] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alati T, 1996, CANCER RES, V56, P2331; ANTONSSON B, 1990, ANAL BIOCHEM, V186, P8, DOI 10.1016/0003-2697(90)90563-O; ASCHELE C, 1992, CANCER RES, V52, P1855; Assaraf YG, 1997, J BIOL CHEM, V272, P17460, DOI 10.1074/jbc.272.28.17460; BALDWIN SW, 1991, BIOCHEMISTRY-US, V30, P1997, DOI 10.1021/bi00221a037; BEARDSLEY GP, 1989, J BIOL CHEM, V264, P328; Chen L, 1996, J BIOL CHEM, V271, P13077, DOI 10.1074/jbc.271.22.13077; CICHOWICZ DJ, 1987, BIOCHEMISTRY-US, V26, P513, DOI 10.1021/bi00376a025; Cunningham D, 1996, ANN ONCOL, V7, P961, DOI 10.1093/oxfordjournals.annonc.a010800; EVANS RM, 1981, CANCER RES, V41, P3288; GOLDMAN ID, 1968, J BIOL CHEM, V243, P5007; HABECK LL, 1995, MOL PHARMACOL, V48, P326; HENDERSON GB, 1990, CANCER RES, V50, P1709; JACKMAN AL, 1991, ADV ENZYME REGUL, V31, P13, DOI 10.1016/0065-2571(91)90006-8; JACKMAN AL, 1991, CANCER RES, V51, P5579; JACKMAN AL, 1993, INHIBITION THYMIDYLA, P274; JANSEN G, 1990, CANCER RES, V50, P7544; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KAN JLC, 1993, GENE, V137, P195, DOI 10.1016/0378-1119(93)90006-O; KAN JLC, 1995, J BIOL CHEM, V270, P1823, DOI 10.1074/jbc.270.4.1823; KESAVAN V, 1986, J BIOCHEM BIOPH METH, V12, P311, DOI 10.1016/0165-022X(86)90068-0; KEYOMARSI K, 1988, J BIOL CHEM, V263, P14402; KEYOMARSI K, 1986, CANCER RES, V46, P5229; MATHERLY LH, 1993, BIOCHEM PHARMACOL, V46, P2185, DOI 10.1016/0006-2952(93)90608-Y; MCGUIRE JJ, 1993, LEUKEMIA, V7, P1996; MORAN RG, 1984, ANAL BIOCHEM, V140, P326, DOI 10.1016/0003-2697(84)90174-X; MORAN RG, 1989, J BIOL CHEM, V264, P21047; MORAN RG, 1985, MOL PHARMACOL, V27, P156; MORAN RG, 1982, ANAL BIOCHEM, V122, P70, DOI 10.1016/0003-2697(82)90252-4; MORAN RG, 1976, J BIOL CHEM, V251, P3569; MORAN RG, 1979, P NATL ACAD SCI USA, V76, P1456, DOI 10.1073/pnas.76.3.1456; MORAN RG, 1984, BIOCHEMISTRY-US, V23, P4580, DOI 10.1021/bi00315a011; MORAN RG, 1992, NATIONAL CANCER I EU, V7, P91; OCONNOR BM, 1991, CANCER RES, V51, P3874; PIZZORNO G, 1995, CANCER RES, V55, P566; PIZZORNO G, 1993, J BIOL CHEM, V268, P1017; PIZZORNO G, 1991, MOL PHARMACOL, V39, P85; RAY MS, 1993, J NATL CANCER I, V85, P1154, DOI 10.1093/jnci/85.14.1154; RHEE MS, 1993, CANCER RES, V53, P2227; RINALDI DA, 1995, J CLIN ONCOL, V13, P2842, DOI 10.1200/JCO.1995.13.11.2842; Sanghani P., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P98; Sanghani SP, 1997, BIOCHEMISTRY-US, V36, P10506, DOI 10.1021/bi970825u; SCHMITZ JC, 1994, BIOCHEM PHARMACOL, V48, P319, DOI 10.1016/0006-2952(94)90103-1; Shih C, 1997, CANCER RES, V57, P1116; SIROTNAK FM, 1987, BIOCHEM PHARMACOL, V36, P1659, DOI 10.1016/0006-2952(87)90051-7; SMITH GK, 1981, BIOCHEMISTRY-US, V20, P1241, DOI 10.1021/bi00508a029; Spinella MJ, 1996, BBA-GENE STRUCT EXPR, V1305, P11, DOI 10.1016/0167-4781(95)00193-X; TAYLOR EC, 1985, J MED CHEM, V28, P914, DOI 10.1021/jm00145a012; TAYLOR EC, 1992, J MED CHEM, V35, P4450, DOI 10.1021/jm00101a023; Tse A, 1998, J BIOL CHEM, V273, P25953, DOI 10.1074/jbc.273.40.25953; ULLMAN B, 1978, P NATL ACAD SCI USA, V75, P980, DOI 10.1073/pnas.75.2.980	51	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25944	25952		10.1074/jbc.273.40.25944	http://dx.doi.org/10.1074/jbc.273.40.25944			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748271	hybrid			2022-12-27	WOS:000076263100062
J	Vu-Dac, N; Chopin-Delannoy, S; Gervois, P; Bonnelye, E; Martin, G; Fruchart, JC; Laudet, V; Staels, B				Vu-Dac, N; Chopin-Delannoy, S; Gervois, P; Bonnelye, E; Martin, G; Fruchart, JC; Laudet, V; Staels, B			The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erb alpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE-RECEPTOR; TISSUE-SELECTIVE MANNER; OB GENE-EXPRESSION; C-III EXPRESSION; ORPHAN RECEPTOR; LIPOPROTEIN METABOLISM; SIGNALING PATHWAYS; RESPONSE ELEMENT; OPPOSITE STRAND; FATTY-ACIDS	Fibrates are widely used hypolipidemic drugs which activate the nuclear peroxisome proliferator-activated receptor (PPAR) alpha and thereby alter the transcription of genes controlling lipoprotein metabolism. Fibrates influence plasma high density lipoprotein and its major protein, apolipoprotein (apo) A-I, in an opposite manner in man (increase) versus rodents (decrease), In the present study we studied the molecular mechanisms of this species-specific regulation of apoA-I expression by fibrates, In primary rat and human hepatocytes fenofibric acid, respectively, decreased and increased apoA-I mRNA levels. The absence of induction of rat apoA-I gene expression by fibrates is due to 3 nucleotide differences between the rat and the human apoA-I promoter A site, rendering a positive PPAR-response element in the human apoA-I promoter nonfunctional in rats. In contrast, rat, but not human, apoA-I transcription is repressed by the nuclear receptor Rev-erb alpha, which binds to a negative response element adjacent to the TATA box of the rat apoA-I promoter. In rats fibrates increase liver Rev-erb alpha mRNA levels >10-fold. In conclusion, the opposite regulation of rat and human apoA-I gene expression by fibrates is linked to differences in cis-elements in their respective promoters leading to repression by Rev-erb alpha of rat apoA-I and activation by PPAR alpha of human apoA-I, Finally, Rev-erb alpha is identified as a novel fibrate target gene, suggesting a role for this nuclear receptor in lipid and lipoprotein metabolism.	Inst Pasteur, Dept Atherosclerose, INSERM, U325, F-59019 Lille, France; Univ Lille 2, Fac Pharm, Lille, France; Inst Biol Lille, CNRS, UMR 319, Endocrinos Grp, Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS)	Staels, B (corresponding author), Inst Pasteur, Dept Atherosclerose, INSERM, U325, 1 Rue Calmette, F-59019 Lille, France.		Bonnelye, Edith/AAT-9134-2021; Staels, Bart/N-9497-2016	Staels, Bart/0000-0002-3784-1503				Adelmant G, 1996, P NATL ACAD SCI USA, V93, P3553, DOI 10.1073/pnas.93.8.3553; Berthou L, 1996, J CLIN INVEST, V97, P2408, DOI 10.1172/JCI118687; BERTHOU L, 1995, EUR J BIOCHEM, V232, P179, DOI 10.1111/j.1432-1033.1995.tb20797.x; BOGAZZI F, 1994, J BIOL CHEM, V269, P11683; BONNELYE E, 1994, CELL GROWTH DIFFER, V5, P1357; CASTELEIN H, 1994, J BIOL CHEM, V269, P26754; CHAN J, 1993, NUCLEIC ACIDS RES, V21, P1205, DOI 10.1093/nar/21.5.1205; CHAWLA A, 1993, J BIOL CHEM, V268, P16265; CHU RY, 1995, P NATL ACAD SCI USA, V92, P11593, DOI 10.1073/pnas.92.25.11593; DeVos P, 1996, J CLIN INVEST, V98, P1004, DOI 10.1172/JCI118860; DOWNES M, 1995, MOL ENDOCRINOL, V9, P1666, DOI 10.1210/me.9.12.1666; Downes M, 1996, NUCLEIC ACIDS RES, V24, P4379, DOI 10.1093/nar/24.22.4379; DUMAS B, 1994, MOL ENDOCRINOL, V8, P996, DOI 10.1210/me.8.8.996; Dussault I, 1997, MOL CELL BIOL, V17, P1860, DOI 10.1128/MCB.17.4.1860; FORMAN BM, 1994, MOL ENDOCRINOL, V8, P1253, DOI 10.1210/me.8.9.1253; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Fraser JD, 1997, J BIOL CHEM, V272, P13892, DOI 10.1074/jbc.272.21.13892; GINSBURG GS, 1995, J CLIN INVEST, V96, P528, DOI 10.1172/JCI118065; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAHN SE, 1992, BIOCHEM PHARMACOL, V43, P625, DOI 10.1016/0006-2952(92)90586-8; HARDING HP, 1993, MOL CELL BIOL, V13, P3113, DOI 10.1128/MCB.13.5.3113; HARDING HP, 1995, MOL CELL BIOL, V15, P4791; Haubenwallner S, 1995, J LIPID RES, V36, P2541; HERTZ R, 1993, BIOCHIMIE, V75, P257, DOI 10.1016/0300-9084(93)90085-7; Hertz R, 1996, J BIOL CHEM, V271, P218, DOI 10.1074/jbc.271.1.218; Hertz R, 1996, BIOCHEM J, V319, P241, DOI 10.1042/bj3190241; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; Hollenberg AN, 1997, J BIOL CHEM, V272, P5283, DOI 10.1074/jbc.272.8.5283; Hunter J, 1996, MOL CELL ENDOCRINOL, V116, P213, DOI 10.1016/0303-7207(95)03717-9; Jin FY, 1996, ARTERIOSCL THROM VAS, V16, P1052, DOI 10.1161/01.ATV.16.8.1052; JUGEAUBRY CE, 1995, J BIOL CHEM, V270, P18117, DOI 10.1074/jbc.270.30.18117; Kallen CB, 1996, P NATL ACAD SCI USA, V93, P5793, DOI 10.1073/pnas.93.12.5793; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LAUDET V, 1995, CURR BIOL, V5, P124, DOI 10.1016/S0960-9822(95)00031-5; LAZAR MA, 1990, J BIOL CHEM, V265, P12859; LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128; LAZAR MA, 1990, DNA CELL BIOL, V9, P77, DOI 10.1089/dna.1990.9.77; LI AP, 1992, J TISSUE CULT METHOD, V14, P139; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUSSIERCACAN S, 1989, ATHEROSCLEROSIS, V78, P167, DOI 10.1016/0021-9150(89)90221-9; MARSH JL, 1984, GENE, V32, P481, DOI 10.1016/0378-1119(84)90022-2; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MILLER NE, 1977, LANCET, V1, P965, DOI 10.1016/S0140-6736(77)92274-7; MIYAJIMA N, 1989, CELL, V57, P31, DOI 10.1016/0092-8674(89)90169-4; Miyamoto T, 1997, J BIOL CHEM, V272, P7752, DOI 10.1074/jbc.272.12.7752; MUNROE SH, 1991, J BIOL CHEM, V266, P22083; Murao K, 1997, BIOCHEMISTRY-US, V36, P301, DOI 10.1021/bi9613943; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; QUEVA C, 1992, DEVELOPMENT, V114, P125; Ren B, 1996, J BIOL CHEM, V271, P17167, DOI 10.1074/jbc.271.29.17167; RETNAKARAN R, 1994, MOL ENDOCRINOL, V8, P1234, DOI 10.1210/me.8.9.1234; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; SAKU K, 1985, J CLIN INVEST, V75, P1702, DOI 10.1172/JCI111879; Saladin R, 1996, EUR J BIOCHEM, V239, P451, DOI 10.1111/j.1432-1033.1996.0451u.x; Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SPANJAARD RA, 1994, MOL ENDOCRINOL, V8, P286, DOI 10.1210/me.8.3.286; STAELS B, 1990, ENDOCRINOLOGY, V126, P2153; Staels B, 1997, CURR PHARM DESIGN, V3, P1; STAELS B, 1995, J CLIN INVEST, V95, P705, DOI 10.1172/JCI117717; STAELS B, 1992, BIOCHIM BIOPHYS ACTA, V1123, P227, DOI 10.1016/0005-2760(92)90115-C; STAELS B, 1992, ARTERIOSCLER THROMB, V12, P286, DOI 10.1161/01.ATV.12.3.286; STAELS B, 1992, J LIPID RES, V33, P727; TAM SP, 1991, ATHEROSCLEROSIS, V91, P51, DOI 10.1016/0021-9150(91)90186-7; TIKKANEN MJ, 1992, CURR OPIN LIPIDOL, V3, P29; VANACKER JM, 1993, J VIROL, V67, P7668, DOI 10.1128/JVI.67.12.7668-7672.1993; VuDac N, 1997, J BIOL CHEM, V272, P22401, DOI 10.1074/jbc.272.36.22401; VUDAC N, 1994, J BIOL CHEM, V269, P31012; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118; Zamir I, 1996, MOL CELL BIOL, V16, P5458; Zhang B, 1996, J BIOL CHEM, V271, P9455, DOI 10.1074/jbc.271.16.9455	76	257	260	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25713	25720		10.1074/jbc.273.40.25713	http://dx.doi.org/10.1074/jbc.273.40.25713			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748239	hybrid			2022-12-27	WOS:000076263100030
J	Yun, CHC; Lamprecht, G; Forster, DV; Sider, A				Yun, CHC; Lamprecht, G; Forster, DV; Sider, A			NHE3 kinase A regulatory protein E3KARP binds the epithelial brush border Na+/H+ exchanger NHE3 and the cytoskeletal protein ezrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP-MEDIATED INHIBITION; NITRIC-OXIDE SYNTHASE; H+ EXCHANGER; PDZ PROTEIN; DOMAIN; IDENTIFICATION; PHOSPHOPROTEIN; COFACTOR; REQUIRES; PSD-95	Cyclic AMP is a major second messenger that inhibits the brush border Na+/H+ exchanger NHE3. We have previously shown that either of two related regulatory proteins, E3KARP or NHERF, is necessary for the cAMP-dependent inhibition of NHE3. in the present study, we characterized the interaction between NHE3 and E3KARP using in vitro binding assays. We found that NHE3 directly binds to E3KARP and that the entirety of the second PSD-95/Dlg/ZO-1 (PDZ) domain plus the carboxyl-terminal domain of E3KARP are required to bind NHE3. E3KARP binds an internal region within the NHE3 C-terminal cytoplasmic tail, defining a new mode of PDZ domain interaction. Analyses of cellular distribution of NHE3 and E3KARP expressed in PS120 fibroblasts show that NHE3 and E3KARP are co-localized on the plasma membrane, but not in a distinct juxtanuclear compartment in which NHE3 is predominantly expressed. The distributions of NHE3 and E3KARP were not affected by treatment with 8-bromo-cAMP. As shown earlier for the human homolog of NHERF, we also found that the cytoskeletal protein ezrin binds to the carboxyl-terminal domain of E3KARP. These results are consistent with the possibility that E3KARP and NHERF may function as scaffold proteins that bind to both NHE3 and ezrin, Since ezrin is a protein kinase A anchoring protein, we suggest that the scaffolding function of E3KARP binding to both ezrin and NHE3 localizes cAMP-dependent protein kinase in the vicinity of the cytoplasmic domain of NHE3, which is phosphorylated by elevated cAMP.	Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21205 USA	Johns Hopkins University	Yun, CHC (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol, 918 Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.	cyun@welchlink.welch.jhu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044484] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-44484] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONSON PS, 1986, CURR TOP MEMBR TRANS, V26, P57; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Cabado AG, 1996, J BIOL CHEM, V271, P3590; Couture C, 1996, J BIOL CHEM, V271, P24294, DOI 10.1074/jbc.271.39.24294; DOUSZA S, 1998, J BIOL CHEM, V273, P2035; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; Kurashima K, 1997, J BIOL CHEM, V272, P28672, DOI 10.1074/jbc.272.45.28672; Lamprecht G, 1998, GASTROENTEROLOGY, V114, pA390, DOI 10.1016/S0016-5085(98)81582-5; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; Lue RA, 1996, J CELL BIOL, V135, P1125, DOI 10.1083/jcb.135.4.1125; MOE OW, 1995, J CLIN INVEST, V96, P2187, DOI 10.1172/JCI118273; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Poulat F, 1997, J BIOL CHEM, V272, P7167, DOI 10.1074/jbc.272.11.7167; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Reczek D, 1998, J BIOL CHEM, V273, P18452, DOI 10.1074/jbc.273.29.18452; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; WEINMAN EJ, 1993, J CLIN INVEST, V92, P1781, DOI 10.1172/JCI116767; Weinman EJ, 1998, J CLIN INVEST, V101, P2199, DOI 10.1172/JCI204; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010	27	247	247	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25856	25863		10.1074/jbc.273.40.25856	http://dx.doi.org/10.1074/jbc.273.40.25856			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748260	hybrid			2022-12-27	WOS:000076263100051
J	He, HL; Qi, XM; Grossmann, J; Distelhorst, CW				He, HL; Qi, XM; Grossmann, J; Distelhorst, CW			c-Fos degradation by the proteasome - An early, Bcl-2-regulated step in apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; MOUSE LYMPHOMA-CELLS; GLUCOCORTICOID RECEPTOR; INTERSEGMENTAL MUSCLES; ENDOPLASMIC-RETICULUM; TRANSFORMING ACTIVITY; THYMOCYTE APOPTOSIS; GENE-EXPRESSION; MANDUCA-SEXTA; CA2+ FLUXES	c-Fos is a transcription factor that promotes cell growth, differentiation, and transformation. We found that c-Fos was degraded when WEHI7.2 mouse lymphoma cells were induced to undergo apoptosis with the calcium ATPase inhibitor, thapsigargin, or the glucocorticoid hormone, dexamethasone. The degradation of c-Fos preceded caspase-3 activation and apoptotic nuclear chromatin condensation and was inhibited by the proteasome inhibitors MG132, N-acetyl-leucyl-leucyl-norleucinal, and lactacystin, Stable transfection of WEHI7.2 cells with a mutant form of c-Fos that was not degraded by the proteasome inhibited apoptosis. Also, overexpression of Bcl-2 in WEHI7.2 cells blocked c-Fos degradation and inhibited apoptosis. The results indicate that proteasome-mediated degradation of c-Fos is an early, Bcl-2-regulated step in apoptosis induction by thapsigargin and dexamethasone. These findings suggest that c-Fos may have a protective action that is eliminated by proteasome-mediated degradation and preserved by Bcl-2.	Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Distelhorst, CW (corresponding author), Case Western Reserve Univ, Dept Med, BRB 329,10900 Euclid Ave, Cleveland, OH 44106 USA.				NATIONAL CANCER INSTITUTE [R01CA042755] Funding Source: NIH RePORTER; NCI NIH HHS [CA42755] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aizawa H, 1996, BIOCHEM BIOPH RES CO, V218, P224, DOI 10.1006/bbrc.1996.0039; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; CARILLO S, 1989, ONCOGENE, V9, P1079; Chen RH, 1996, ONCOGENE, V12, P1493; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; Cui HL, 1997, P NATL ACAD SCI USA, V94, P7515, DOI 10.1073/pnas.94.14.7515; CURRAN T, 1992, TRANSCRIPTIONAL REGU, P797; DAWSON SP, 1995, J BIOL CHEM, V270, P1850, DOI 10.1074/jbc.270.4.1850; DELIC J, 1993, MOL CELL BIOL, V13, P4875, DOI 10.1128/MCB.13.8.4875; Distelhorst CW, 1996, CELL CALCIUM, V19, P473, DOI 10.1016/S0143-4160(96)90056-1; DOWD DR, 1992, MOL ENDOCRINOL, V6, P1843, DOI 10.1210/me.6.11.1843; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FLOMERFELT FA, 1994, J CELL BIOL, V127, P1729, DOI 10.1083/jcb.127.6.1729; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; Grimm LM, 1996, EMBO J, V15, P3835, DOI 10.1002/j.1460-2075.1996.tb00757.x; Hafezi F, 1997, NAT MED, V3, P346, DOI 10.1038/nm0397-346; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; HermidaMatsumoto ML, 1996, J BIOL CHEM, V271, P4930; Ivanov VN, 1997, J BIOL CHEM, V272, P8558; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; JarielEncontre I, 1997, MOL BIOL REP, V24, P51, DOI 10.1023/A:1006804723722; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; JONES MEE, 1995, DEV BIOL, V169, P436, DOI 10.1006/dbio.1995.1159; Kaina B, 1997, CANCER RES, V57, P2721; KAWAHARA H, 1994, DEV BIOL, V166, P623, DOI 10.1006/dbio.1994.1342; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; LAM M, 1993, MOL ENDOCRINOL, V7, P686, DOI 10.1210/me.7.5.686; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MILLER AD, 1984, CELL, V36, P51; Nakajima T, 1996, J BIOL CHEM, V271, P24842, DOI 10.1074/jbc.271.40.24842; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Preston GA, 1996, MOL CELL BIOL, V16, P211; Qi XM, 1997, ONCOGENE, V15, P2849, DOI 10.1038/sj.onc.1201463; REALINI C, 1995, J BIOL CHEM, V270, P29664; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; RofflerTarlov S, 1996, DEVELOPMENT, V122, P1; Sadoul R, 1996, EMBO J, V15, P3845, DOI 10.1002/j.1460-2075.1996.tb00758.x; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SCHWARTZ LM, 1990, NEURON, V5, P411, DOI 10.1016/0896-6273(90)90080-Y; Shimizu S, 1996, ONCOGENE, V12, P2251; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Tabuchi A, 1996, J BIOL CHEM, V271, P31061, DOI 10.1074/jbc.271.49.31061; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHU HJ, 1995, FEBS LETT, V374, P303, DOI 10.1016/0014-5793(95)01116-V	64	62	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25015	25019		10.1074/jbc.273.39.25015	http://dx.doi.org/10.1074/jbc.273.39.25015			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737957	hybrid			2022-12-27	WOS:000076085400007
J	Taoka, S; Ohja, S; Shan, XY; Kruger, WD; Banerjee, R				Taoka, S; Ohja, S; Shan, XY; Kruger, WD; Banerjee, R			Evidence for heme-mediated redox regulation of human cystathionine beta-synthase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDEPENDENT METHIONINE SYNTHASE; ESCHERICHIA-COLI; CULTURED-CELLS; HUMAN-LIVER; RAT-LIVER; EXPRESSION; PURIFICATION; HOMOCYSTEINE; HEMOPROTEIN-H-450; CYTOCHROME-P-450	Human cystathionine beta-synthase catalyzes the first step in the catabolic removal of the toxic metabolite, homocysteine. It is unique in being dependent on both pyridoxal phosphate (PLP) and heme for activity. The reaction involves condensation of serine and homocysteine to give cystathionine. Although the role of PLP can be rationalized in analogy with other PLP dependent enzymes that catalyze beta-replacement reactions, the role of the heme is unknown. In this study, we have purified and characterized the recombinant human enzyme and have examined the effect of heme oxidation state on enzyme activity. We find that under reducing conditions, generated by addition of titanium citrate, the enzyme exhibits a 1.7-fold lower activity than under oxidizing conditions. Reoxidation of the ferrous enzyme with ferricyanide results in alleviation of inhibition. This redox-linked change in enzyme activity correlates with changes in heme oxidation state monitored by UV-visible spectroscopy. Dithiothreitol, which does not reduce the enzyme-bound heme, does not perturb enzyme activity. These studies provide the first evidence for redox-linked regulation of cystathionine beta-synthase which is heme-dependent.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA; Fox Chase Canc Ctr, Div Populat Sci, Philadelphia, PA 19046 USA	University of Nebraska System; University of Nebraska Lincoln; Fox Chase Cancer Center	Banerjee, R (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.		kruger, warren/A-6407-2008; Kruger, Warren/Y-2541-2018	kruger, warren/0000-0002-4990-3695; 	NHLBI NIH HHS [HL58984] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058984] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENESCH RE, 1955, J AM CHEM SOC, V77, P5877, DOI 10.1021/ja01627a030; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; BORCSOK E, 1982, ARCH BIOCHEM BIOPHYS, V213, P695, DOI 10.1016/0003-9861(82)90600-2; BUKOVSKA G, 1994, PROTEIN EXPRES PURIF, V5, P442, DOI 10.1006/prep.1994.1063; CHEN ZQ, 1995, J BIOL CHEM, V270, P19246, DOI 10.1074/jbc.270.33.19246; DRUMMOND JT, 1995, ANAL BIOCHEM, V228, P323, DOI 10.1006/abio.1995.1358; FINKELSTEIN JD, 1984, J BIOL CHEM, V259, P9508; FINKELSTEIN JD, 1975, BIOCHEM BIOPH RES CO, V66, P81, DOI 10.1016/S0006-291X(75)80297-X; Gonzalez JC, 1996, BIOCHEMISTRY-US, V35, P12228, DOI 10.1021/bi9615452; Goulding CW, 1997, BIOCHEMISTRY-US, V36, P15749, DOI 10.1021/bi971988l; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JONES JB, 1977, COMMUN SOIL SCI PLAN, V8, P349, DOI 10.1080/00103627709366727; KANG SS, 1992, ANNU REV NUTR, V12, P279, DOI 10.1146/annurev.nu.12.070192.001431; KASHIWAMATA S, 1970, BIOCHIM BIOPHYS ACTA, V212, P488, DOI 10.1016/0005-2744(70)90255-X; KERY V, 1995, ARCH BIOCHEM BIOPHYS, V316, P24, DOI 10.1006/abbi.1995.1005; KERY V, 1994, J BIOL CHEM, V269, P25283; KIMURA H, 1971, J BIOCHEM-TOKYO, V69, P711, DOI 10.1093/oxfordjournals.jbchem.a129520; KRAUS J, 1978, J BIOL CHEM, V253, P6523; KRAUS JP, 1993, HUM MOL GENET, V2, P1633, DOI 10.1093/hmg/2.10.1633; KRAUS JP, 1983, ARCH BIOCHEM BIOPHYS, V222, P44, DOI 10.1016/0003-9861(83)90500-3; KRUGER WD, 1994, P NATL ACAD SCI USA, V91, P6614, DOI 10.1073/pnas.91.14.6614; Lentz SR, 1997, LIFE SCI, V61, P1205, DOI 10.1016/S0024-3205(97)00392-5; MALINOW MR, 1993, CIRCULATION, V87, P1107, DOI 10.1161/01.CIR.87.4.1107; MCCULLY KS, 1983, ATHER REV, V11, P157; OMURA T, 1984, J BIOCHEM-TOKYO, V96, P1491, DOI 10.1093/oxfordjournals.jbchem.a134978; ROPER MD, 1992, ARCH BIOCHEM BIOPHYS, V298, P514, DOI 10.1016/0003-9861(92)90443-Z; Shan XY, 1998, NAT GENET, V19, P91, DOI 10.1038/ng0598-91; SKOVBY F, 1984, J BIOL CHEM, V259, P588; SKOVBY F, 1984, J BIOL CHEM, V259, P583; SUDA M, 1973, METHOD ENZYMOL, V17, P454; SVASTITS EW, 1989, BIOCHEM BIOPH RES CO, V165, P1170, DOI 10.1016/0006-291X(89)92725-3	31	214	217	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25179	25184		10.1074/jbc.273.39.25179	http://dx.doi.org/10.1074/jbc.273.39.25179			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737978	hybrid			2022-12-27	WOS:000076085400028
J	Xu, G; Kwon, G; Marshall, CA; Lin, TA; Lawrence, JC; McDaniel, ML				Xu, G; Kwon, G; Marshall, CA; Lin, TA; Lawrence, JC; McDaniel, ML			Branched-chain amino acids are essential in the regulation of PHAS-I and p70 S6 kinase by pancreatic beta-cells - A possible role in protein translation and mitogenic signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN TARGET; INSULIN RELEASE; PHOSPHORYLATION; RAPAMYCIN; ISLETS; INITIATION; TURNOVER; MUSCLE; GROWTH; INVOLVEMENT	Amino acids have been identified as important signaling molecules involved in pancreatic beta-cell proliferation, although the cellular mechanism responsible for this effect is not well defined. We previously reported that amino acids are required for glucose or exogenous insulin to stimulate phosphorylation of PHAS-I (phosphorylated heat- and acid-stable protein regulated by insulin), a recently discovered regulator of translation initiation during cell mitogenesis. Here we demonstrate that essential amino acids, in particular branched-chain amino acids (leucine, valine, and isoleucine), are largely responsible for mediating this effect. The transamination product of leucine, alpha-ketoisocaproic acid, also stimulates PHAS-I phosphorylation although the transamination products of isoleucine and valine are ineffective, Since amino acids are secretagogues for insulin secretion by beta-cells, we investigated whether endogenous insulin secreted by beta-cells is involved. Interestingly, branched-chain amino acids stimulate phosphorylation of PHAS-I independent of endogenous insulin secretion since genistein (10 mu M) and herbimycin A (1 mu M), two tyrosine kinase inhibitors in the insulin signaling pathway, exert no effect on amino acid-induced phosphorylation of PHAS-I, Furthermore, branched-chain amino acids retain their ability to induce phosphorylation of PHAS-I under conditions that block insulin secretion from beta-cells. In exploring the signaling pathway responsible for these effects, we find that rapamycin (25 nM) inhibits the ability of branched-chain amino acids to stimulate the phosphorylation of PHAS-I and p70(s6) kinase, suggesting that the mammalian target of rapamycin signaling pathway is involved. The branched-chain amino acid, leucine, also exerts similar effects on PHAS-I phosphorylation in isolated pancreatic islets. In addition, we find that amino acids are necessary for insulin-like growth factor (IGF-I) to stimulate the phosphorylation of PHAS-I indicating that a requirement for amino acids may be essential for other beta-cell growth factors in addition to insulin and IGF-I to activate this signaling pathway. We propose that amino acids, in particular branched-chain amino acids, may promote beta-cell proliferation either by stimulating phosphorylation of PHAS-I and p70(S6k) via the mammalian target of rapamycin pathway and/or by facilitating the proliferative effect mediated by growth factors such as insulin and IGF-I.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Univ Virginia, Sch Med, Dept Pharmacol, Charlottesville, VA 22908 USA	Washington University (WUSTL); University of Virginia	McDaniel, ML (corresponding author), Washington Univ, Sch Med, Dept Pathol, 660 Euclid Ave,Box 8118, St Louis, MO 63110 USA.	mcdaniel@pathology.wustl.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052753, R01DK028312] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41180] Funding Source: Medline; NIDDK NIH HHS [DK28312, DK52753] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BHATHENA SJ, 1982, DIABETES, V31, P521, DOI 10.2337/diabetes.31.6.521; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; BUSE MG, 1975, J CLIN INVEST, V56, P1250, DOI 10.1172/JCI108201; CORBETT JA, 1994, AM J PHYSIOL, V267, pC48, DOI 10.1152/ajpcell.1994.267.1.C48; Davoodi J, 1998, J BIOL CHEM, V273, P4982, DOI 10.1074/jbc.273.9.4982; ESCOLAR JC, 1987, J ENDOCRINOL, V115, P225, DOI 10.1677/joe.0.1150225; FLOYD JC, 1966, J CLIN INVEST, V45, P1487, DOI 10.1172/JCI105456; GAZDAR AF, 1980, P NATL ACAD SCI-BIOL, V77, P3519, DOI 10.1073/pnas.77.6.3519; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HELLMAN B, 1971, BIOCHEM J, V123, P513, DOI 10.1042/bj1230513; HELLMAN B, 1971, ENDOCRINOLOGY, V89, P1432, DOI 10.1210/endo-89-6-1432; Kawasome H, 1998, P NATL ACAD SCI USA, V95, P5033, DOI 10.1073/pnas.95.9.5033; KUHARA T, 1991, AM J PHYSIOL, V260, pE21, DOI 10.1152/ajpendo.1991.260.1.E21; KWON G, 1995, ENDOCRINOLOGY, V136, P4790, DOI 10.1210/en.136.11.4790; Lee ES, 1996, BIOL REPROD, V55, P1383, DOI 10.1095/biolreprod55.6.1383; LI JB, 1978, BIOCHIM BIOPHYS ACTA, V544, P351, DOI 10.1016/0304-4165(78)90103-4; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MAY ME, 1989, DIABETES METAB REV, V5, P227, DOI 10.1002/dmr.5610050303; MCDANIEL ML, 1983, METHOD ENZYMOL, V98, P182; Mendez R, 1997, MOL CELL BIOL, V17, P5184, DOI 10.1128/MCB.17.9.5184; MILNER RDG, 1969, LANCET, V1, P1075; Morley SJ, 1997, BIOCHEM SOC T, V25, P503, DOI 10.1042/bst0250503; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Patti ME, 1998, J CLIN INVEST, V101, P1519, DOI 10.1172/JCI1326; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PRENTKI M, 1983, J BIOL CHEM, V258, P4239; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; Renstrom E, 1996, J PHYSIOL-LONDON, V494, P41, DOI 10.1113/jphysiol.1996.sp021474; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; SWENNE I, 1992, DIABETOLOGIA, V35, P193, DOI 10.1007/BF00400917; Tsuruzoe K, 1998, DIABETES, V47, P621, DOI 10.2337/diabetes.47.4.621; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; Xu G, 1998, J BIOL CHEM, V273, P4485, DOI 10.1074/jbc.273.8.4485; Zhang Q, 1998, J ENDOCRINOL, V156, P573, DOI 10.1677/joe.0.1560573; Zheng XF, 1997, P NATL ACAD SCI USA, V94, P3070, DOI 10.1073/pnas.94.7.3070	45	196	200	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28178	28184		10.1074/jbc.273.43.28178	http://dx.doi.org/10.1074/jbc.273.43.28178			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774438	hybrid			2022-12-27	WOS:000076549800058
J	Korchak, HM; Rossi, RW; Kilpatrick, LE				Korchak, HM; Rossi, RW; Kilpatrick, LE			Selective role for beta-protein kinase C in signaling for O-2(radical anion) generation but not degranulation or adherence in differentiated HL60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGOCYTE NADPH OXIDASE; RESPIRATORY BURST OXIDASE; HUMAN-NEUTROPHILS; MEMBRANE ASSOCIATION; FLAVOCYTOCHROME-B; FUNCTIONAL DOMAIN; PHORBOL ESTERS; ACTIVATION; CALCIUM; P47(PHOX)	A role for protein kinase C (PKC) isotypes is implicated in the activation of phagocytic cell functions. An antisense approach was used to selectively deplete beta-PRC, both beta I- and beta II-PKC, but not alpha-PKC, delta-PKC, or zeta-PKC in HL60 cells differentiated to a neutrophil-like phenotype (dHL60 cells). Depletion of beta-PKC in dHL60 cells elicited selective inhibition of O-2(radical anion) generation triggered by fMet-Leu-Phe, immune complexes, or phorbol myristate acetate, an activator of PKC. In contrast, neither ligand-elicited beta-glucuronidase (azurophil granule) release nor adherence to fibronectin was inhibited by beta-PKC depletion. Ligand-induced phosphorylation of a subset of proteins was reduced in beta-PKC-depleted dHL60 cells. Phosphorylation of p47(phox) and translocation of p47(phox) to the membrane are essential for activation of the NADPH oxidase and generation of O-2(radical anion). beta-PKC depletion had no effect on the level of p47(phox) in dHL60 cells but did significantly decrease ligand-induced phosphorylation of this protein. Furthermore, translocation of p47(phox) to the membrane in response to phorbol myristate acetate or fMet-Leu-Phe was reduced in beta-PKC-depleted cells. These results indicate that beta-PKC is essential for signaling for O-2(radical anion) generation but not cell adherence or azurophil degranulation. Depletion of beta-PKC inhibited ligand-induced phosphorylation of p47phox, translocation of p47(phox) to the membrane, and activation of O-2(radical anion) generation.	Univ Penn, Immunol Sect, Sch Med,Dept Pediat, Joseph Stokes Jr Res Inst,Childrens Hosp Philadel, Philadelphia, PA 19104 USA; Univ Penn, Childrens Hosp Philadelphia, Sch Med, Dept Biochem Biophys,Joseph Stokes Jr Res Inst, Philadelphia, PA 19104 USA; Astra Merck, Wayne, PA 19087 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Korchak, HM (corresponding author), Univ Penn, Immunol Sect, Sch Med,Dept Pediat, Joseph Stokes Jr Res Inst,Childrens Hosp Philadel, Rm 1208C,Abramson Bldg,34th & Civic Ctr Blvd, Philadelphia, PA 19104 USA.	Korchak@email.chop.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024840] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 24840] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams ER, 1997, BIOCHEM J, V325, P249, DOI 10.1042/bj3250249; BAGGIOLINI M, 1993, FASEB J, V7, P1004, DOI 10.1096/fasebj.7.11.8396540; BOHNSACK JF, 1995, J LEUKOCYTE BIOL, V57, P592, DOI 10.1002/jlb.57.4.592; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; CURNUTTE JT, 1994, J BIOL CHEM, V269, P10813; DEAN NM, 1994, J BIOL CHEM, V269, P16416; DeLeo FR, 1996, J BIOL CHEM, V271, P17013, DOI 10.1074/jbc.271.29.17013; DEMENDEZ I, 1994, J BIOL CHEM, V269, P16326; FAUST LP, 1995, J CLIN INVEST, V96, P1499, DOI 10.1172/JCI118187; FELGNER JH, 1994, J BIOL CHEM, V269, P2550; Felgner Jiin, 1993, Methods (Orlando), V5, P67, DOI 10.1006/meth.1993.1009; Filion MC, 1997, BBA-BIOMEMBRANES, V1329, P345, DOI 10.1016/S0005-2736(97)00126-0; GAMARD CJ, 1994, CELL GROWTH DIFFER, V5, P405; GLADWIN AM, 1990, BIOCHIM BIOPHYS ACTA, V1052, P166, DOI 10.1016/0167-4889(90)90072-L; HADJOKAS N, 1992, J LEUKOCYTE BIOL, V52, P157, DOI 10.1002/jlb.52.2.157; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Inanami O, 1998, J BIOL CHEM, V273, P9539, DOI 10.1074/jbc.273.16.9539; IYER SS, 1994, J BIOL CHEM, V269, P22405; Kent JD, 1996, J IMMUNOL, V157, P4641; Keranen LM, 1997, J BIOL CHEM, V272, P25959, DOI 10.1074/jbc.272.41.25959; KORCHAK HM, 1984, J BIOL CHEM, V259, P4076; KORCHAK HM, 1988, J BIOL CHEM, V263, P11098; KORCHAK HM, 1984, J BIOL CHEM, V259, P4070; KORCHAK HM, 1984, J BIOL CHEM, V259, P7439; KORCHAK HM, 1984, FED PROC, V43, P2749; MAJUMDAR S, 1991, J BIOL CHEM, V266, P9285; MAJUMDAR S, 1993, BIOCHIM BIOPHYS ACTA, V1176, P276, DOI 10.1016/0167-4889(93)90056-U; MCPHAIL LC, 1995, P NATL ACAD SCI USA, V92, P7931, DOI 10.1073/pnas.92.17.7931; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MOSIOR M, 1995, J BIOL CHEM, V270, P25526, DOI 10.1074/jbc.270.43.25526; MUKHERJEE G, 1994, J LEUKOCYTE BIOL, V55, P685, DOI 10.1002/jlb.55.6.685; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; NAUSEEF WM, 1993, J BIOL CHEM, V268, P23646; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Park JW, 1997, J BIOL CHEM, V272, P11035; PHILLIPS WA, 1989, J BIOL CHEM, V264, P8361; ROTROSEN D, 1993, J BIOL CHEM, V268, P14256; SARGEANT S, 1997, J IMMUNOL, V159, P2877; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; Tisch D, 1996, EUR J BIOCHEM, V242, P529, DOI 10.1111/j.1432-1033.1996.0529r.x; TOKER A, 1994, J BIOL CHEM, V269, P32358; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; WARD PA, 1973, J IMMUNOL, V111, P1771; Wooten Marie W., 1993, Cytobios, V76, P19	48	99	101	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27292	27299		10.1074/jbc.273.42.27292	http://dx.doi.org/10.1074/jbc.273.42.27292			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765254	hybrid			2022-12-27	WOS:000076448000041
J	Sun, H; Karow, JK; Hickson, ID; Maizels, N				Sun, H; Karow, JK; Hickson, ID; Maizels, N			The Bloom's syndrome helicase unwinds G4 DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WERNERS-SYNDROME GENES; ESCHERICHIA-COLI RECQ; GENOME STABILITY; HOMOLOG; ENZYME; SGS1; RECOMBINATION; INTERACTS	BLM, the gene that is defective in Bloom's syndrome, encodes a protein homologous to RecQ subfamily helicases that functions as a 3'-5' DNA helicase in vitro. We now report that the BLM helicase can unwind G4 DNA. The BLM G4 DNA unwinding activity is ATP-dependent and requires a short 3' region of single-stranded DNA. Strikingly, G4 DNA is a preferred substrate of the BLM helicase, as measured both by efficiency of unwinding and by competition. These results suggest that G4 DNA may be a natural substrate of BLM in vivo and that the failure to unwind G4 DNA may cause the genomic instability and increased frequency of sister chromatid exchange characteristic of Bloom's syndrome.	Yale Univ, Dept Genet, New Haven, CT 06520 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund Labs, Oxford OX3 9DS, England	Yale University; Yale University; Cancer Research UK; University of Oxford	Maizels, N (corresponding author), Yale Univ, Dept Genet, 266 Whitney Ave, New Haven, CT 06520 USA.	nancy.maizels@yale.edu	Hickson, Ian/AAJ-7548-2020	Hickson, Ian/0000-0002-0583-566X	NATIONAL CANCER INSTITUTE [P01CA016038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039799] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA16038] Funding Source: Medline; NIGMS NIH HHS [R01 GM039799] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bennett RJ, 1998, J BIOL CHEM, V273, P9644, DOI 10.1074/jbc.273.16.9644; Ellis NA, 1996, HUM MOL GENET, V5, P1457, DOI 10.1093/hmg/5.Supplement_1.1457; Ellis NA, 1997, CURR OPIN GENET DEV, V7, P354, DOI 10.1016/S0959-437X(97)80149-9; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Lu JA, 1996, NATURE, V383, P678, DOI 10.1038/383678a0; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; Maxam A M, 1980, Methods Enzymol, V65, P499; NAKAYAMA H, 1984, MOL GEN GENET, V195, P474, DOI 10.1007/BF00341449; PURANAM KL, 1995, GENOMICS, V26, P595, DOI 10.1016/0888-7543(95)80181-K; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; SEKI M, 1995, MOL CELL BIOL, V15, P165, DOI 10.1128/MCB.15.1.165; SEN D, 1992, BIOCHEMISTRY-US, V31, P65, DOI 10.1021/bi00116a011; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; TAYLOR A, 1980, CELL, V22, P447, DOI 10.1016/0092-8674(80)90355-4; TAYLOR AF, 1995, J BIOL CHEM, V270, P24451, DOI 10.1074/jbc.270.41.24451; TAYLOR AF, 1985, J MOL BIOL, V185, P431, DOI 10.1016/0022-2836(85)90414-0; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; Watt PM, 1996, CURR BIOL, V6, P265, DOI 10.1016/S0960-9822(02)00474-8; Watt PM, 1996, GENETICS, V144, P935; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; WILLIAMSON JR, 1994, ANNU REV BIOPH BIOM, V23, P703, DOI 10.1146/annurev.bb.23.060194.003415; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	33	454	462	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27587	27592		10.1074/jbc.273.42.27587	http://dx.doi.org/10.1074/jbc.273.42.27587			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765292	hybrid			2022-12-27	WOS:000076448000079
J	Taveggia, C; Pizzagalli, A; Feltri, ML; Grinspan, JB; Kamholz, J; Wrabetz, L				Taveggia, C; Pizzagalli, A; Feltri, ML; Grinspan, JB; Kamholz, J; Wrabetz, L			MEBA derepresses the proximal myelin basic protein promoter in oligodendrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING-PROTEIN; SHIVERER MUTANT MICE; GENE-TRANSCRIPTION; NEGATIVE REGULATION; TRANSGENIC MICE; NERVOUS-SYSTEM; CELL-LINE; EXPRESSION; ELEMENTS; BRAIN	The central nervous system expression of myelin basic protein (MBP) is restricted to oligodendrocytes and is developmentally regulated; these regulatory features are transcriptionally mediated. We have previously shown that the proximal 149 nucleotides of the MBP promoter were both necessary and sufficient to activate the transcription of MBP in cultured oligodendrocytes, but not in other cell types. Sequences within the distal portion of this promoter, which contains a nuclear factor 1 (NF1) binding site, repressed activation of the MBP promoter in Cos-7 cells, but not in oligodendrocytes. We now describe a sequence upstream of and partially overlapping the NF1 site that activates the MBP promoter in oligodendrocytes, but not in Cos-7 cells. A protein complex binds to this site, designated MEBA (myelinating glia-enriched DNA binding activity), and is enriched in nuclear extracts prepared from the brain, oligodendrocytes, and Schwann cells, The amount of MEBA parallels MBP expression and myelinogenesis in the developing brain and parallels new MBP expression as purified oligodendrocytes differentiate. Mutational analyses of binding and function distinguish MEBA, an activator, from NF1, a repressor of MBP transcription, and suggest that MEBA consists of at least two proteins. Because the binding sites of MEBA and NF1 overlap, we suggest that MEBA may either compete with or modify NF1 binding, thereby activating the MBP promoter in oligodendrocytes.	San Raffaele Sci Inst, DIBIT, I-20132 Milan, Italy; San Raffaele Sci Inst, Dept Neurol, I-20132 Milan, Italy; Childrens Hosp Philadelphia, Div Neurosci Res, Philadelphia, PA 19104 USA; Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Wayne State University	Wrabetz, L (corresponding author), San Raffaele Sci Inst, DIBIT, Via Olgettina 58, I-20132 Milan, Italy.		Feltri, Maria Laura/J-5286-2018; Taveggia, Carla/AAN-4784-2020					AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; AOYAMA A, 1990, BIOCHEM BIOPH RES CO, V167, P648, DOI 10.1016/0006-291X(90)92074-A; ASIPU A, 1994, GENE, V150, P227, DOI 10.1016/0378-1119(94)90431-6; Chaudhry AZ, 1997, DEV DYNAM, V208, P313; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; DEVINEBEACH K, 1990, J BIOL CHEM, V265, P13830; FORAN DR, 1992, J NEUROSCI, V12, P4890; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Giesen K, 1997, DEVELOPMENT, V124, P2307; GOUJETZALC C, 1993, EUR J NEUROSCI, V5, P624, DOI 10.1111/j.1460-9568.1993.tb00528.x; GOW A, 1992, J CELL BIOL, V119, P605, DOI 10.1083/jcb.119.3.605; GRINSPAN JB, 1990, J NEUROSCI, V10, P1866; HAAS S, 1995, J BIOL CHEM, V270, P12503, DOI 10.1074/jbc.270.21.12503; HAAS S, 1995, J CELL BIOL, V130, P1171, DOI 10.1083/jcb.130.5.1171; HAQUE NS, 1995, J CELL PHYSIOL, V163, P321, DOI 10.1002/jcp.1041630213; HAQUE NS, 1994, J BIOL CHEM, V269, P31149; INOUE T, 1990, J BIOL CHEM, V265, P19065; KAMHOLZ J, 1992, J NEUROSCI RES, V31, P231, DOI 10.1002/jnr.490310204; LOUIS JC, 1992, J NEUROSCI RES, V31, P193, DOI 10.1002/jnr.490310125; MACGREGOR GR, 1987, SOMAT CELL MOLEC GEN, V13, P253, DOI 10.1007/BF01535207; MARTINI R, 1995, J NEUROSCI, V15, P4488; MISKIMINS R, 1992, DEV BRAIN RES, V65, P217, DOI 10.1016/0165-3806(92)90182-V; MIURA M, 1990, J NEUROCHEM, V55, P1180, DOI 10.1111/j.1471-4159.1990.tb03123.x; ORO AE, 1988, CELL, V55, P1109, DOI 10.1016/0092-8674(88)90255-3; Osada S, 1997, J BIOCHEM, V121, P355; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; ROACH A, 1983, CELL, V34, P799, DOI 10.1016/0092-8674(83)90536-6; SALMINEN M, 1995, J MOL BIOL, V253, P17, DOI 10.1006/jmbi.1995.0532; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; SCHOENHERR CJ, 1995, CURR OPIN NEUROBIOL, V5, P566, DOI 10.1016/0959-4388(95)80060-3; Shy ME, 1996, J NEUROSCI RES, V43, P511, DOI 10.1002/(SICI)1097-4547(19960301)43:5<511::AID-JNR1>3.0.CO;2-L; STEPLEWSKI A, 1995, GENE, V154, P215, DOI 10.1016/0378-1119(94)00816-B; TAMURA T, 1988, NUCLEIC ACIDS RES, V16, P11441, DOI 10.1093/nar/16.24.11441; TAMURA TA, 1989, MOL CELL BIOL, V9, P3122, DOI 10.1128/MCB.9.7.3122; TONTSCH U, 1994, P NATL ACAD SCI USA, V91, P11616, DOI 10.1073/pnas.91.24.11616; WIKTOROWICZ M, 1991, DEV NEUROSCI-BASEL, V13, P143, DOI 10.1159/000112152; WRABETZ L, 1993, J NEUROSCI RES, V36, P455, DOI 10.1002/jnr.490360412; Wrabetz L, 1998, J NEUROBIOL, V34, P10, DOI 10.1002/(SICI)1097-4695(199801)34:1<10::AID-NEU2>3.0.CO;2-F; WRABETZ LG, 1990, ANN NY ACAD SCI, V605, P354, DOI 10.1111/j.1749-6632.1990.tb42410.x; XIAO JH, 1987, EMBO J, V6, P3005, DOI 10.1002/j.1460-2075.1987.tb02606.x	44	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27741	27748		10.1074/jbc.273.42.27741	http://dx.doi.org/10.1074/jbc.273.42.27741			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765312	hybrid			2022-12-27	WOS:000076448000099
J	Wang, W; Smith, DK; Moulding, K; Chen, HM				Wang, W; Smith, DK; Moulding, K; Chen, HM			The dependence of membrane permeability by the antibacterial peptide cecropin B and its analogs, CB-1 and CB-3, on liposomes of different composition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; ANTIMICROBIAL PEPTIDES; PHOSPHOLIPID-VESICLES; SOLUTION CONFORMATION; INSECT IMMUNITY; LIPID VESICLES; DEFENSINS; PROTEINS; BINDING; SPECIFICITY	A natural antibacterial peptide, cecropin B (CB), and designed analogs, CB-1 and CB-3, were synthesized. The three peptides have different structural characteristics, with CB having one hydrophobic and one amphipathic alpha-helix, CB-1 having two amphipathic alpha-helices, and CB-3 having two hydrophobic cy-helices. These differences were used as the rationale for a study of their efficacy in breaking liposomes with different combinations of phosphatidic acid and phosphatidylcholine. Biosensor binding measurements and encapsulating dye leakage studies showed that the higher binding affinity of CB and CB-1 to the polar heads of lipids is not necessary for the peptides to be more effective at lysing lipid bilayers, especially when Liposomes have a higher phosphatidic acid content. Kinetic studies, by intrinsic and extrinsic fluorescence stopped-flow measurements, revealed two transitional steps in liposome breakage by CB and CB-1, although only one kinetic step was found for CB-3. Circular dichroism stopped-flow measurements, monitoring the formation of secondary structure in the peptides, found one kinetic step for the interaction of all of the peptides with the liposomes. Also, the cu-helical motif of the peptides was maintained after interacting with the liposomes. Based on these results, the mechanisms of liposome lysis by CB, CB-1, and CB-3 are discussed.	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Peoples R China	Hong Kong University of Science & Technology	Wang, W (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Clear Water Bay, Kowloon, Peoples R China.	bchmc@ust.hk		Smith, David/0000-0003-3608-0586				Barlett G.R., 1959, J BIOL CHEM, V234, P466; BenTal N, 1996, BIOPHYS J, V71, P3046, DOI 10.1016/S0006-3495(96)79498-5; BenTal N, 1997, BIOPHYS J, V73, P1717, DOI 10.1016/S0006-3495(97)78203-1; BenTal N, 1996, BIOPHYS J, V71, P561, DOI 10.1016/S0006-3495(96)79280-9; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BOMAN HG, 1991, CELL, V65, P205, DOI 10.1016/0092-8674(91)90154-Q; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHEN HM, 1991, J MOL BIOL, V220, P771, DOI 10.1016/0022-2836(91)90116-N; Chen HM, 1997, BBA-GEN SUBJECTS, V1336, P171, DOI 10.1016/S0304-4165(97)00024-X; CHRISTENSEN B, 1988, P NATL ACAD SCI USA, V85, P5072, DOI 10.1073/pnas.85.14.5072; CRUCIANI RA, 1991, P NATL ACAD SCI USA, V88, P3792, DOI 10.1073/pnas.88.9.3792; DURELL SR, 1992, BIOPHYS J, V63, P1623, DOI 10.1016/S0006-3495(92)81730-7; FINK J, 1989, INT J PEPT PROT RES, V33, P412; GANZ T, 1990, EUR J HAEMATOL, V44, P1; GAZIT E, 1995, BIOCHEMISTRY-US, V34, P11479, DOI 10.1021/bi00036a021; GOMES AV, 1993, BIOCHEMISTRY-US, V32, P5365, DOI 10.1021/bi00071a011; HOLAK TA, 1988, BIOCHEMISTRY-US, V27, P7620, DOI 10.1021/bi00420a008; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Hristova K, 1997, J BIOL CHEM, V272, P24224, DOI 10.1074/jbc.272.39.24224; HULTMARK D, 1982, EUR J BIOCHEM, V127, P207, DOI 10.1111/j.1432-1033.1982.tb06857.x; IWAI H, 1993, EUR J BIOCHEM, V217, P639, DOI 10.1111/j.1432-1033.1993.tb18287.x; Javadpour MM, 1996, J MED CHEM, V39, P3107, DOI 10.1021/jm9509410; Javadpour MM, 1997, BIOCHEMISTRY-US, V36, P9540, DOI 10.1021/bi961644f; JAYNES J M, 1989, Peptide Research, V2, P157; KIM JY, 1991, BIOPHYS J, V60, P135, DOI 10.1016/S0006-3495(91)82037-9; Ladokhin AS, 1997, BIOPHYS J, V72, P794, DOI 10.1016/S0006-3495(97)78713-7; Ladokhin AS, 1997, BIOPHYS J, V72, P1762, DOI 10.1016/S0006-3495(97)78822-2; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; LICHTENSTEIN A, 1991, J CLIN INVEST, V88, P93, DOI 10.1172/JCI115310; MacKenzie CR, 1997, J BIOL CHEM, V272, P5533, DOI 10.1074/jbc.272.9.5533; Mancheno JM, 1996, BIOCHEMISTRY-US, V35, P9892, DOI 10.1021/bi953058c; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MASSON L, 1994, ANAL BIOCHEM, V218, P405, DOI 10.1006/abio.1994.1199; MERRIFIELD RB, 1994, CIBA F SYMP, V186, P5; Moore AJ, 1996, J ANTIMICROB CHEMOTH, V37, P1077, DOI 10.1093/jac/37.6.1077; POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017; SEKIGNCHI M, 1994, ATLAS HUMAN TUMOR CE, P300; Silvestro L, 1997, BIOCHEMISTRY-US, V36, P11452, DOI 10.1021/bi9630826; SIPOS D, 1992, EUR J BIOCHEM, V209, P163, DOI 10.1111/j.1432-1033.1992.tb17273.x; STEINER H, 1981, NATURE, V292, P246, DOI 10.1038/292246a0; STEINER H, 1988, BIOCHIM BIOPHYS ACTA, V939, P260, DOI 10.1016/0005-2736(88)90069-7; Wiese A, 1997, BIOCHEMISTRY-US, V36, P10301, DOI 10.1021/bi970176m; WIMLEY WC, 1994, PROTEIN SCI, V3, P1362, DOI 10.1002/pro.5560030902; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	46	82	85	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27438	27448		10.1074/jbc.273.42.27438	http://dx.doi.org/10.1074/jbc.273.42.27438			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765273	hybrid			2022-12-27	WOS:000076448000060
J	Kamitani, T; Kito, K; Nguyen, HP; Wada, H; Fukuda-Kamitani, T; Yeh, ETH				Kamitani, T; Kito, K; Nguyen, HP; Wada, H; Fukuda-Kamitani, T; Yeh, ETH			Identification of three major sentrinization sites in PML	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; UBIQUITIN-LIKE PROTEIN; NUCLEAR-PORE COMPLEX; RETINOIC ACID; RAR-ALPHA; ZINC-FINGER; CONJUGATING ENZYME; RING FINGER; RECEPTOR; FUSION	Acute promyelocytic leukemia arises following a reciprocal chromosome translocation t(15;17), which generates PML-retinoic acid receptor alpha fusion proteins (PML-RAR alpha). We have shown previously that wild type PML, but not PML-RAR alpha, is covalently modified by the sentrin family of ubiquitin-like proteins (Kamitani, T., Nguyen, H. P., Kito, K., Fukuda-Kamitani, T., and Yeh, E. T. H. (1998) J. Biol. Chem. 273, 3117-3120). To understand the mechanisms underlying the differential sentrinization of PML versus PML-RAR alpha, extensive mutational analysis was carried out to determine which Lys residues are sentrinized, We show that Lys(65) in the RING finger domain, Lys(160) in the B1 Box, and Lys(490) in the nuclear localization signal contributes three major sentrinization sites. The PML mutant with Lys to Arg substitutions in all three sites is expressed normally, but cannot be sentrinized. Furthermore, the triple substitution mutant is localized predominantly to the nucleoplasm, in contrast to wild type PML, which is localized to the nuclear bodies. Thus, sentrinization of PML, in the context of the RING finger and the BI box, regulates nuclear body formation. Furthermore, we showed that sentrinization of PML-RAR alpha could be restored by overexpression of sentrin, but not by retinoic acid treatment. These studies provide novel insight into the pathobiochemistry of acute promyelocytic leukemia and the sentrinization pathway.	Univ Texas, Hlth Sci Ctr, Dept Internal Med,Res Ctr Cardiovasc Dis, Div Mol Med,Inst Mol Med Prevent Human Dis, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Yeh, ETH (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Internal Med,Res Ctr Cardiovasc Dis, Div Mol Med,Inst Mol Med Prevent Human Dis, 6431 Fannin,Suite 4-200, Houston, TX 77030 USA.	eyeh@heart.med.uth.tmc.edu	Kamitani, Tetsu/GSI-7613-2022	Kamitani, Tetsu/0000-0002-3257-9630	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045851] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45851] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; BISCHOFF FR, 1995, P NATL ACAD SCI USA, V92, P1749, DOI 10.1073/pnas.92.5.1749; Bloch DB, 1996, J BIOL CHEM, V271, P29198, DOI 10.1074/jbc.271.46.29198; Boddy MN, 1996, ONCOGENE, V13, P971; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; FujimotoNishiyama A, 1997, GENE, V195, P267, DOI 10.1016/S0378-1119(97)00172-8; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Grignani F, 1996, EMBO J, V15, P4949, DOI 10.1002/j.1460-2075.1996.tb00875.x; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; Ishov AM, 1996, J CELL BIOL, V134, P815, DOI 10.1083/jcb.134.4.815; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; KAMITANI T, 1991, CLIN IMMUNOL IMMUNOP, V58, P217, DOI 10.1016/0090-1229(91)90138-Z; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; KORIOTH F, 1995, J CELL BIOL, V130, P1, DOI 10.1083/jcb.130.1.1; LARSON RA, 1984, AM J MED, V76, P827, DOI 10.1016/0002-9343(84)90994-X; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Okura T, 1996, J IMMUNOL, V157, P4277; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Shen ZY, 1996, GENOMICS, V36, P271, DOI 10.1006/geno.1996.0462; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Yoshida H, 1996, CANCER RES, V56, P2945	44	267	269	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26675	26682		10.1074/jbc.273.41.26675	http://dx.doi.org/10.1074/jbc.273.41.26675			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756909	hybrid			2022-12-27	WOS:000076373300063
J	Rogers, MA; Winter, H; Wolf, C; Heck, M; Schweizer, J				Rogers, MA; Winter, H; Wolf, C; Heck, M; Schweizer, J			Characterization of a 190-kilobase pair domain of human type I hair keratin genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; EPITHELIAL CYTOKERATINS; EVOLUTIONARY CONSERVATION; DIFFERENTIAL EXPRESSION; INTERMEDIATE FILAMENTS; TRANSCRIPTION FACTOR; MAMMALIAN-TISSUES; BARRIER FUNCTION; SEQUENCE; IDENTIFICATION	Polymerase chain reaction-based screening of an arrayed human P1 artificial chromosome (PAC) library using primer pairs specific for the human type I hair keratins hHa3-II or hHaG, led to the isolation of two PAC clones, which covered 190 kilobase pairs (kbp) of genomic DNA and contained nine human type I hair keratin genes, one transcribed hair keratin pseudogene, as well as one orphan exon, The hair keratin genes are 4-7 kbp in size, exhibit intergenic distances of 5-8 kbp, and display the same direction of transcription. With one exception, all hair keratin genes are organized into 7 exons and 6 positionally conserved introns. On the basis of sequence homologies, the genes can be grouped into three subclusters of tandemly arranged genes. One subcluster harbors the highly related genes hHa1, hHa3-I, hHa3-II, and hHa4. A second subcluster of highly related genes comprises the novel genes hHa7 and hHa8, as well as pseudogene Psi hHaA, while the structurally less related genes hHaG, hHa5, and hHa2 are constituents of the third subcluster. As shown by reverse transcription-polymerase chain reaction, all hair keratin genes, including the pseudogene, are expressed in the human hair follicle. The transcribed pseudogene Psi hHaA contains a premature stop codon in exon 4 and exhibits aberrant pre-mRNA splicing. Evolutionary tree construction reveals an early divergence of hair keratin genes from cytokeratin genes, followed by the segregation of the genes into the three subclusters. We suspect that the 190-kbp domain contains the entire complement of human type I hair keratin genes.	German Canc Res Ctr, Res Program 2, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Rogers, MA (corresponding author), German Canc Res Ctr, Res Program 2, 5th Floor,Rm 522,Neuenheimerfeld 280, D-69120 Heidelberg, Germany.	m.rogers@dkfz-heidelberg.de	Rogers, Michael A./J-9803-2012	Rogers, Michael A./0000-0002-3728-2107				ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; Attar PS, 1997, MOL ENDOCRINOL, V11, P792, DOI 10.1210/me.11.6.792; BADER BL, 1988, EUR J CELL BIOL, V47, P300; BERTOLINO AP, 1988, J INVEST DERMATOL, V91, P541, DOI 10.1111/1523-1747.ep12476901; BERTOLINO AP, 1990, J INVEST DERMATOL, V94, P297, DOI 10.1111/1523-1747.ep12874436; BLESSING M, 1987, EMBO J, V6, P567, DOI 10.1002/j.1460-2075.1987.tb04792.x; Bowden P E, 1994, J Dermatol Sci, V7 Suppl, pS152, DOI 10.1016/0923-1811(94)90046-9; Bowden PE, 1998, J INVEST DERMATOL, V110, P158, DOI 10.1046/j.1523-1747.1998.00097.x; Ceratto N, 1997, CYTOGENET CELL GENET, V77, P169, DOI 10.1159/000134566; CHOSH LA, 1988, CELL, V53, P11; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DOU QP, 1991, P NATL ACAD SCI USA, V88, P1157, DOI 10.1073/pnas.88.4.1157; FAUS I, 1994, MOL CELL BIOL, V14, P3263, DOI 10.1128/MCB.14.5.3263; FINK P, 1995, BBA-GENE STRUCT EXPR, V1264, P12, DOI 10.1016/0167-4781(95)00122-W; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; HEID HW, 1988, DIFFERENTIATION, V37, P137, DOI 10.1111/j.1432-0436.1988.tb00805.x; HEID HW, 1988, DIFFERENTIATION, V37, P215, DOI 10.1111/j.1432-0436.1988.tb00724.x; HEID HW, 1986, DIFFERENTIATION, V32, P101, DOI 10.1111/j.1432-0436.1986.tb00562.x; HU L, 1994, J BIOL CHEM, V269, P183; HUFF CA, 1993, J BIOL CHEM, V268, P377; IMAKADO S, 1995, GENE DEV, V9, P317, DOI 10.1101/gad.9.3.317; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KAYTES PS, 1991, J INVEST DERMATOL, V97, P835, DOI 10.1111/1523-1747.ep12491511; KIM CG, 1990, MOL CELL BIOL, V10, P5958, DOI 10.1128/MCB.10.11.5958; LESSIN SR, 1988, J INVEST DERMATOL, V91, P572, DOI 10.1111/1523-1747.ep12477087; LI P, 1993, GENE DEV, V7, P2483, DOI 10.1101/gad.7.12b.2483; LYNCH MH, 1986, J CELL BIOL, V103, P2593, DOI 10.1083/jcb.103.6.2593; Mercier M, 1998, J INVEST DERMATOL, V111, P169, DOI 10.1046/j.1523-1747.1998.00234.x; Milisavljevic V, 1996, GENOMICS, V34, P134, DOI 10.1006/geno.1996.0252; MINK S, 1992, MOL CELL BIOL, V12, P4906, DOI 10.1128/MCB.12.11.4906; MOLL R, 1993, DIFFERENTIATION, V53, P75, DOI 10.1111/j.1432-0436.1993.tb00648.x; Nishida K, 1997, AM J HUM GENET, V61, P1268, DOI 10.1086/301650; ODENWALD WF, 1989, GENE DEV, V3, P158, DOI 10.1101/gad.3.2.158; POWELL B, 1992, DEVELOPMENT, V114, P417; POWELL BC, 1986, P NATL ACAD SCI USA, V83, P5048, DOI 10.1073/pnas.83.14.5048; POWELL BC, 1994, J INVEST DERMATOL, V102, P171, DOI 10.1111/1523-1747.ep12371758; RAYCHAUDHURY A, 1986, MOL CELL BIOL, V6, P539, DOI 10.1128/MCB.6.2.539; REIS A, 1994, NAT GENET, V6, P174, DOI 10.1038/ng0294-174; RIEGER M, 1988, J MOL BIOL, V204, P841, DOI 10.1016/0022-2836(88)90045-9; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; ROGERS MA, 1995, EXP CELL RES, V220, P357, DOI 10.1006/excr.1995.1326; Rogers MA, 1997, DIFFERENTIATION, V61, P187, DOI 10.1046/j.1432-0436.1997.6130187.x; Rogers MA, 1996, J INVEST DERMATOL, V107, P633, DOI 10.1111/1523-1747.ep12584243; ROGERS MA, 1995, MOL BIOL REP, V20, P155, DOI 10.1007/BF00990548; ROMANO V, 1988, CYTOGENET CELL GENET, V48, P148, DOI 10.1159/000132612; ROMANO V, 1992, GENOMICS, V14, P495, DOI 10.1016/S0888-7543(05)80250-2; ROSENBERG M, 1988, MOL CELL BIOL, V8, P722, DOI 10.1128/MCB.8.2.722; ROSENBERG M, 1991, CYTOGENET CELL GENET, V57, P33, DOI 10.1159/000133109; ROTHNAGEL JA, 1993, J INVEST DERMATOL, V101, P506, DOI 10.1111/1523-1747.ep12365886; SAVTCHENKO ES, 1990, GENOMICS, V7, P394, DOI 10.1016/0888-7543(90)90174-S; SCHMIDT MC, 1989, MOL CELL BIOL, V9, P3299, DOI 10.1128/MCB.9.8.3299; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; STEINERT PM, 1985, CELL, V42, P411, DOI 10.1016/0092-8674(85)90098-4; TOBIASCH E, 1992, DIFFERENTIATION, V50, P163, DOI 10.1111/j.1432-0436.1992.tb00671.x; TROYANOVSKY SM, 1992, EUR J CELL BIOL, V59, P127; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F; WASEEM A, 1990, GENOMICS, V7, P186; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; Wingender E, 1997, NUCLEIC ACIDS RES, V25, P265, DOI 10.1093/nar/25.1.265; Winter H, 1997, J BIOL CHEM, V272, P32345, DOI 10.1074/jbc.272.51.32345; Winter H, 1997, HUM GENET, V101, P165, DOI 10.1007/s004390050607; Winter H, 1997, NAT GENET, V16, P372, DOI 10.1038/ng0897-372; Winter H, 1996, J INVEST DERMATOL, V106, P544, DOI 10.1111/1523-1747.ep12343976; WINTER H, 1994, EXP CELL RES, V212, P190, DOI 10.1006/excr.1994.1134; YU JL, 1993, J INVEST DERMATOL, V101, pS56, DOI 10.1111/1523-1747.ep12362635; ZHOU PB, 1995, GENE DEV, V9, P700, DOI 10.1101/gad.9.6.700	68	67	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26683	26691		10.1074/jbc.273.41.26683	http://dx.doi.org/10.1074/jbc.273.41.26683			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756910	hybrid			2022-12-27	WOS:000076373300064
J	Tenneti, L; Gibbons, SJ; Talamo, BR				Tenneti, L; Gibbons, SJ; Talamo, BR			Expression and trans-synaptic regulation of P-2x4 and P-2z receptors for extracellular ATP in parotid acinar cells - Effects of parasympathetic denervation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SALIVARY-GLANDS; GATED ION CHANNELS; SUBSTANCE-P; MAST-CELLS; AMYLASE SECRETION; SUPER-SENSITIVITY; CYTOSOLIC CALCIUM; SENSORY NEURONS; P2X(7) RECEPTOR; PLASMA-MEMBRANE	Trans-synaptic regulation of muscarinic, peptidergic, and purinergic responses after denervation has been reported previously in rat parotid acinar cells (McMillian, M. K., Soltoff, S. P., Cantley, L. C., Rudel, R., and Talamo, B. R. (1993) Br. J. Pharmacol. 108, 453-461), Characteristics of the ATP-mediated responses and the effects of parasympathetic denervation were further analyzed through assay of Ca2+ influx, using fluorescence ratio imaging methods, and by analysis of P-2x receptor expression. ATP activates both a high affinity and a low affinity response with properties corresponding to the recently described P-2x4 and the P-2z (P-2x7)-type purinoceptors, respectively. Reverse transcription-polymerase chain reaction analysis reveals mRNA for P-2x4 as well as P-2x7 subtypes but not P-2x1, P-2x2, P-2x3, P-2x5, or P-2x6. P-2x4 protein also is detected by Western blotting. Distribution of the two types of ATP receptor responses on individual cells was stochastic, with both high and low affinity responses on some cells, and only a single type of response on others. Sensitivity to P-2x4-type activation also varied even among cells responsive to low concentrations of ATP. Parasympathetic denervation greatly enhanced responses, tripling the proportion of acinar cells with a P-2x4-type response and increasing the fraction of highly sensitive cells by 7-fold, Moreover, P-2x4 mRNA is significantly increased following parasympathetic denervation. These data indicate that sensitivity to ATP is modulated by neurotransmission at parasympathetic synapses, at least in part through increased expression of P-2x4 mRNA, and suggest that similar regulation may occur at other sites in the nervous system where P-2x4 receptors are widely expressed.	Tufts Univ, Sch Med, Dept Neurosci, Boston, MA 02111 USA	Tufts University	Talamo, BR (corresponding author), Tufts Univ, Sch Med, Dept Neurosci, 136 Harrison Ave, Boston, MA 02111 USA.	btalamo@opal.tufts.edu		Gibbons, Simon/0000-0001-5311-5993	NIDDK NIH HHS [P30 DK34928] Funding Source: Medline; NINDS NIH HHS [R01 NS-28556] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028556] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASKING B, 1989, ARCH ORAL BIOL, V34, P863, DOI 10.1016/0003-9969(89)90142-8; BO XN, 1995, FEBS LETT, V375, P129, DOI 10.1016/0014-5793(95)01203-Q; BOSCO D, 1988, AM J PHYSIOL, V254, pG664, DOI 10.1152/ajpgi.1988.254.5.G664; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Brandle U, 1997, FEBS LETT, V404, P294, DOI 10.1016/S0014-5793(97)00128-2; Buell G, 1996, EMBO J, V15, P55, DOI 10.1002/j.1460-2075.1996.tb00333.x; BURNSTOCK G, 1990, ANN NY ACAD SCI, V603, P1; Butcher F R, 1980, Adv Cyclic Nucleotide Res, V13, P215; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; Chiozzi P, 1997, J CELL BIOL, V138, P697, DOI 10.1083/jcb.138.3.697; COCKCROFT S, 1980, BIOCHEM J, V188, P789, DOI 10.1042/bj1880789; Collo G, 1997, NEUROPHARMACOLOGY, V36, P1277, DOI 10.1016/S0028-3908(97)00140-8; Collo G, 1996, J NEUROSCI, V16, P2495; Currie KPM, 1996, NEURON, V16, P1027, DOI 10.1016/S0896-6273(00)80126-9; DIVIRGILIO F, 1989, J IMMUNOL, V143, P1955; DIVIRGILIO F, 1995, IMMUNOL TODAY, V16, P524, DOI 10.1016/0167-5699(95)80045-X; EDWARDS FA, 1992, NATURE, V359, P144, DOI 10.1038/359144a0; EKSTROM J, 1977, ACTA PHYSIOL SCAND, V101, P329, DOI 10.1111/j.1748-1716.1977.tb06014.x; EKSTROM J, 1983, ACTA PHYSIOL SCAND, V119, P169, DOI 10.1111/j.1748-1716.1983.tb07322.x; EKSTROM J, 1982, ACTA PHYSIOL SCAND, V115, P437, DOI 10.1111/j.1748-1716.1982.tb07102.x; EKSTROM J, 1980, ACTA PHYSIOL SCAND, V108, P253, DOI 10.1111/j.1748-1716.1980.tb06531.x; EVANS RJ, 1992, NATURE, V357, P503, DOI 10.1038/357503a0; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; Ferrari D, 1996, J IMMUNOL, V156, P1531; GRIERSON JP, 1995, J BIOL CHEM, V270, P4451, DOI 10.1074/jbc.270.9.4451; Grygorczyk R, 1997, AM J PHYSIOL-CELL PH, V272, pC1058; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARDEN TK, 1995, ANNU REV PHARMACOL, V35, P541, DOI 10.1146/annurev.pharmtox.35.1.541; HURLEY TW, 1993, AM J PHYSIOL, V265, pC1472, DOI 10.1152/ajpcell.1993.265.6.C1472; JORGENSEN TD, 1995, BIOCHEM J, V312, P457, DOI 10.1042/bj3120457; KATER SB, 1978, J CELL BIOL, V79, P20, DOI 10.1083/jcb.79.1.20; LAZAROWSKI ER, 1995, BRIT J PHARMACOL, V116, P1619, DOI 10.1111/j.1476-5381.1995.tb16382.x; Lazarowski ER, 1997, J BIOL CHEM, V272, P24348, DOI 10.1074/jbc.272.39.24348; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; MCMILLIAN MK, 1993, BRIT J PHARMACOL, V108, P453, DOI 10.1111/j.1476-5381.1993.tb12825.x; MCMILLIAN MK, 1988, BIOCHEM J, V255, P291; MCMILLIAN MK, 1987, BIOCHEM BIOPH RES CO, V149, P523, DOI 10.1016/0006-291X(87)90399-8; MCMILLIAN MK, 1989, PEPTIDES, V10, P721, DOI 10.1016/0196-9781(89)90103-4; MEHANSHO H, 1985, J BIOL CHEM, V260, P4418; MERRITT JE, 1987, J BIOL CHEM, V262, P14912; Metioui M, 1996, J CELL PHYSIOL, V168, P462, DOI 10.1002/(SICI)1097-4652(199608)168:2<462::AID-JCP25>3.0.CO;2-3; MILNER P, 1990, BIOCHEM BIOPH RES CO, V170, P649, DOI 10.1016/0006-291X(90)92141-L; Moore D., 1995, CURRENT PROTOCOLS MO; NAUNTOFTE B, 1992, AM J PHYSIOL, V263, pG823, DOI 10.1152/ajpgi.1992.263.6.G823; North RA, 1997, CURR OPIN NEUROBIOL, V7, P346, DOI 10.1016/S0959-4388(97)80062-1; NUTTLE LC, 1994, J BIOL CHEM, V269, P13988; OSIPCHUK Y, 1992, NATURE, V359, P241, DOI 10.1038/359241a0; PRITCHETT DB, 1988, SCIENCE, V242, P1306, DOI 10.1126/science.2848320; Schlosser SF, 1996, P NATL ACAD SCI USA, V93, P9948, DOI 10.1073/pnas.93.18.9948; SCHNEYER CA, 1987, J AUTONOM NERV SYST, V18, P207, DOI 10.1016/0165-1838(87)90119-6; SCHNEYER CA, 1992, P SOC EXP BIOL MED, V200, P127; Schneyer LH, 1974, GASTROINTESTINAL PHY, P183; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; Seguela P, 1996, J NEUROSCI, V16, P448; SOLTOFF SP, 1989, BIOCHEM BIOPH RES CO, V165, P1279, DOI 10.1016/0006-291X(89)92741-1; Soto F, 1996, P NATL ACAD SCI USA, V93, P3684, DOI 10.1073/pnas.93.8.3684; SOTO F, 1996, BIOCHEM BIOPH RES CO, V223, P46; SPEIRS RL, 1976, ARCH ORAL BIOL, V21, P539, DOI 10.1016/0003-9969(76)90019-4; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; TATHAM PER, 1990, J GEN PHYSIOL, V95, P459, DOI 10.1085/jgp.95.3.459; TENNETI L, 1993, BIOCHEM J, V295, P255, DOI 10.1042/bj2950255; TURNER JT, 1998, IN PRESS CRIT REV OR; Ugur M, 1997, J PHYSIOL-LONDON, V498, P427, DOI 10.1113/jphysiol.1997.sp021869; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; Virginio C, 1997, NEUROPHARMACOLOGY, V36, P1285, DOI 10.1016/S0028-3908(97)00141-X; VOLKNANDT W, 1986, J NEUROCHEM, V47, P1449, DOI 10.1111/j.1471-4159.1986.tb00778.x; WILEY JS, 1990, ARCH BIOCHEM BIOPHYS, V280, P263, DOI 10.1016/0003-9861(90)90328-V; WILLEMS PHGM, 1993, CELL CALCIUM, V14, P145, DOI 10.1016/0143-4160(93)90084-J	68	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26799	26808		10.1074/jbc.273.41.26799	http://dx.doi.org/10.1074/jbc.273.41.26799			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756924	hybrid			2022-12-27	WOS:000076373300078
J	Ferrandez, A; Minambres, B; Garcia, B; Olivera, ER; Luengo, JM; Garcia, JL; Diaz, E				Ferrandez, A; Minambres, B; Garcia, B; Olivera, ER; Luengo, JM; Garcia, JL; Diaz, E			Catabolism of phenylacetic acid in Escherichia coli - Characterization of a new aerobic hybrid pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENITRIFYING PSEUDOMONAS SP; BENZOYL-COENZYME-A; MOLECULAR CHARACTERIZATION; NUCLEOTIDE-SEQUENCE; PHENOL HYDROXYLASE; POSITIVE REGULATOR; COA LIGASE; GENE MAOA; PUTIDA U; PURIFICATION	The paa cluster of Escherichia coli W involved in the aerobic catabolism of phenylacetic acid (PA) has been cloned and sequenced. It was shown to map at min 31.0 of the chromosome at the right end of the mao region responsible for the transformation of 2-phenylethylamine into PA. The 14 paa genes are organized in three transcription units: paaZ and paaABCDEFGHIJK, encoding catabolic genes; and paaXY, containing the paaX regulatory gene. The paaK gene codes for a phenylacetyl-CoA ligase that catalyzes the activation of PA to phenylacetyl-CoA (PA-CoA). The paaABCDE gene products, which may constitute a multicomponent oxygenase, are involved in PA-CoA hydroxylation. The PaaZ protein appears to catalyze the third enzymatic step, with the paaFGHIJ gene products, which show significant similarity to fatty acid beta-oxidation enzymes, likely involved in further mineralization to Krebs cycle intermediates. Three promoters, Pt, Pa, and Pr, driven the expression of genes paaZ, paaABCDEFGHIJK, and paaX, respectively, have been identified. The Pa promoter is negatively controlled by the paaX gene product. As PA-CoA is the true inducer, PaaX becomes the first regulator of an aromatic catabolic pathway that responds to a CoA derivative. The aerobic catabolism of PA in E. coli represents a novel hybrid pathway that could be a widespread way of PA catabolism in bacteria.	CSIC, Ctr Invest Biol, Dept Mol Microbiol, Madrid 28006, Spain; Univ Leon, Fac Vet, Dept Biochem & Mol Biol, Leon 24007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Universidad de Leon	Diaz, E (corresponding author), CSIC, Ctr Invest Biol, Dept Mol Microbiol, Velazquez 144, Madrid 28006, Spain.	cibdf4f@frenso.csic.es	OLIVERA, ELIAS RODRIGUEZ/H-6385-2016; Olivera, Elias Rodriguez/Q-1166-2019; Luengo, Jose M./E-1935-2016; Garcia Lopez, Jose Luis/G-9139-2015; Diaz, Eduardo/F-8605-2016	OLIVERA, ELIAS RODRIGUEZ/0000-0003-2315-8524; Olivera, Elias Rodriguez/0000-0003-2315-8524; Luengo, Jose M./0000-0002-4984-6256; Garcia Lopez, Jose Luis/0000-0002-9238-2485; Minambres Rodriguez, Baltasar/0000-0003-4590-4911; Diaz, Eduardo/0000-0002-9731-6524				Ahrazem O, 1997, CARBOHYD RES, V303, P67, DOI 10.1016/S0008-6215(97)00145-6; ALTENSCHMIDT U, 1993, J BACTERIOL, V175, P4851, DOI 10.1128/JB.175.15.4851-4858.1993; ALTENSCHMIDT U, 1992, EUR J BIOCHEM, V205, P721, DOI 10.1111/j.1432-1033.1992.tb16835.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARRECUBIETA C, 1994, J BACTERIOL, V176, P6375, DOI 10.1128/jb.176.20.6375-6383.1994; Barnes MR, 1997, J BACTERIOL, V179, P6145, DOI 10.1128/jb.179.19.6145-6153.1997; BLACK PN, 1994, BBA-LIPID LIPID MET, V1210, P123, DOI 10.1016/0005-2760(94)90113-9; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURLINGAME R, 1983, J BACTERIOL, V155, P113, DOI 10.1128/JB.155.1.113-121.1983; BURLINGAME RP, 1986, J BACTERIOL, V168, P55, DOI 10.1128/jb.168.1.55-64.1986; Chang KH, 1997, BIOCHEMISTRY-US, V36, P15650, DOI 10.1021/bi971262p; CHENG HP, 1994, J BACTERIOL, V176, P4034, DOI 10.1128/JB.176.13.4034-4042.1994; Chohnan S, 1997, APPL ENVIRON MICROB, V63, P553, DOI 10.1128/AEM.63.2.553-560.1997; COOPER RA, 1985, J GEN MICROBIOL, V131, P2753; COOPER RA, 1980, J BACTERIOL, V143, P302, DOI 10.1128/JB.143.1.302-306.1980; CORELL CC, 1992, SCIENCE, V258, P1604; CRIPPS RE, 1973, BIOCHEM J, V134, P353, DOI 10.1042/bj1340353; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; DEFRANK JJ, 1977, J BACTERIOL, V129, P1356, DOI 10.1128/JB.129.3.1356-1364.1977; DELORENZO V, 1994, METHOD ENZYMOL, V235, P386; Diaz E, 1998, J BACTERIOL, V180, P2915; DIRUSSO CC, 1992, J BIOL CHEM, V267, P8685; Dunaway-Mariano Debra, 1994, Biodegradation, V5, P259, DOI 10.1007/BF00696464; Egland PG, 1997, P NATL ACAD SCI USA, V94, P6484, DOI 10.1073/pnas.94.12.6484; Ferrandez A, 1997, FEBS LETT, V406, P23, DOI 10.1016/S0014-5793(97)00228-7; Ferrandez A, 1997, J BACTERIOL, V179, P2573, DOI 10.1128/jb.179.8.2573-2581.1997; FUJITA Y, 1989, J BIOL CHEM, V264, P4201; Gasson MJ, 1998, J BIOL CHEM, V273, P4163, DOI 10.1074/jbc.273.7.4163; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; GRUND E, 1992, APPL ENVIRON MICROB, V58, P1874, DOI 10.1128/AEM.58.6.1874-1877.1992; GUYER MS, 1983, METHOD ENZYMOL, V101, P362; Hanlon SP, 1997, MICROBIOL-UK, V143, P513, DOI 10.1099/00221287-143-2-513; Harwood CS, 1996, ANNU REV MICROBIOL, V50, P553, DOI 10.1146/annurev.micro.50.1.553; He XY, 1997, BIOCHEMISTRY-US, V36, P261, DOI 10.1021/bi961841e; HENSON JM, 1984, MOL GEN GENET, V193, P263, DOI 10.1007/BF00330678; Jaenecke S, 1996, MOL MICROBIOL, V21, P293, DOI 10.1046/j.1365-2958.1996.6411358.x; JOHNSON GR, 1995, APPL ENVIRON MICROB, V61, P3336, DOI 10.1128/AEM.61.9.3336-3346.1995; KOENIG K, 1989, APPL ENVIRON MICROB, V55, P1829, DOI 10.1128/AEM.55.7.1829-1834.1989; Kroger M, 1997, NUCLEIC ACIDS RES, V25, P39, DOI 10.1093/nar/25.1.39; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LANGKAU B, 1995, EUR J BIOCHEM, V230, P686; LIPSCOMB JD, 1994, ANNU REV MICROBIOL, V48, P371, DOI 10.1146/annurev.mi.48.100194.002103; Liu ZJ, 1997, NAT STRUCT BIOL, V4, P317, DOI 10.1038/nsb0497-317; MARTINEZBLANCO H, 1990, J BIOL CHEM, V265, P7084; MCNEIL D, 1981, J BACTERIOL, V146, P260; Minambres B, 1996, J BIOL CHEM, V271, P33531, DOI 10.1074/jbc.271.52.33531; MOHAMED MES, 1993, ARCH MICROBIOL, V159, P554, DOI 10.1007/BF00249035; MULLERNEWEN G, 1995, EUR J BIOCHEM, V228, P68, DOI 10.1111/j.1432-1033.1995.tb20230.x; Nakamura Y, 1997, NUCLEIC ACIDS RES, V25, P244, DOI 10.1093/nar/25.1.244; NAKATSU CH, 1995, MICROBIOL-UK, V141, P485, DOI 10.1099/13500872-141-2-485; NIEMETZ R, 1995, EUR J BIOCHEM, V227, P161, DOI 10.1111/j.1432-1033.1995.tb20372.x; OLIVERA ER, 1994, EUR J BIOCHEM, V221, P375, DOI 10.1111/j.1432-1033.1994.tb18749.x; Olivera ER, 1998, P NATL ACAD SCI USA, V95, P6419, DOI 10.1073/pnas.95.11.6419; Pikus JD, 1996, BIOCHEMISTRY-US, V35, P9106, DOI 10.1021/bi960456m; Powlowski J, 1997, J BIOL CHEM, V272, P945, DOI 10.1074/jbc.272.2.945; Prieto MA, 1996, J BACTERIOL, V178, P111, DOI 10.1128/jb.178.1.111-120.1996; PRIETO MA, 1993, J BACTERIOL, V175, P2162, DOI 10.1128/JB.175.7.2162-2167.1993; Prieto MA, 1997, BIOCHEM BIOPH RES CO, V232, P759, DOI 10.1006/bbrc.1997.6368; Qian H, 1997, BIOCHEMISTRY-US, V36, P495, DOI 10.1021/bi9619233; Rosche B, 1997, J BACTERIOL, V179, P3549, DOI 10.1128/jb.179.11.3549-3554.1997; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVAGE DC, 1977, ANNU REV MICROBIOL, V31, P107, DOI 10.1146/annurev.mi.31.100177.000543; Small FJ, 1997, J BIOL CHEM, V272, P24913, DOI 10.1074/jbc.272.40.24913; Spence EL, 1996, J BACTERIOL, V178, P5249, DOI 10.1128/jb.178.17.5249-5256.1996; STRINGFELLOW JM, 1995, GENE, V166, P73, DOI 10.1016/0378-1119(95)00596-8; SUGINO H, 1992, J BACTERIOL, V174, P2485, DOI 10.1128/jb.174.8.2485-2492.1992; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANDERMEER JR, 1992, MICROBIOL REV, V56, P677, DOI 10.1128/MMBR.56.4.677-694.1992; Velasco A, 1998, J BACTERIOL, V180, P1063, DOI 10.1128/JB.180.5.1063-1071.1998; VITOVSKI S, 1993, FEMS MICROBIOL LETT, V108, P1; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726; Yamashita M, 1996, J BACTERIOL, V178, P2941, DOI 10.1128/jb.178.10.2941-2947.1996; ZENK MH, 1980, ANAL BIOCHEM, V101, P182, DOI 10.1016/0003-2697(80)90058-5	75	171	193	3	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25974	25986		10.1074/jbc.273.40.25974	http://dx.doi.org/10.1074/jbc.273.40.25974			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748275	hybrid			2022-12-27	WOS:000076263100066
J	Okubo, Y; Blakesley, VA; Stannard, B; Gutkind, S; Le Roith, D				Okubo, Y; Blakesley, VA; Stannard, B; Gutkind, S; Le Roith, D			Insulin-like growth factor-I inhibits the stress-activated protein kinase/c-jun N-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAY; INDUCED APOPTOSIS; MEDIATED APOPTOSIS; NEURONAL SURVIVAL; CELL-DEATH; RECEPTOR; RAS; JNK; PHOSPHORYLATION	The pathways involved in the cellular responses to the insulin-like growth factors (IGFs) are numerous and vary according to cell type. Following activation of the IGF-I receptor, the mitogen-activated protein kinase and phosphatidylinositide 3'-kinase (PI3'K) pathways are activated and result in cellular proliferation and inhibition of apoptosis. In this study, we analyzed the IGF-I effect on the stress-activated protein kinase/c-Jun N-terminal kinase (JNK) activity using human embryonic kidney 293 cells, 293 cells transiently expressing hemagglutinin-JNK, and 293 cells stably expressing a hemagglutinin-JNK transgene, In all cell types, endogenous or transfected JNK activity was strongly stimulated by anisomycin or tumor necrosis factor-alpha, and 10 nM IGF-I pretreatment suppressed the induced JNK activity. To determine whether the effect of IGF-I on JNK activity involves the mitogen-activated protein kinase or PI3'K pathway, we used the specific MEK1 inhibitor PD098059 and the PI3'K inhibitor LY 294002. PD098059 did not alter the IGF-I suppressive effect on stressor-induced JNK activity, but LY 294002 suppressed the IGF-I effect. Moreover, in transiently transfected parental 293 cells expressing dominant-negative Akt, anisomycin-increased JNK activity was not suppressed by pretreatment with IGF-I, Our results demonstrate that the action of IGF-I on JNK in these cells is via PI3'K and Akt.	NIDDK, Diabet Branch, NIH, Bethesda, MD 20892 USA; NIDR, Lab Cellular Dev & Oncol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Le Roith, D (corresponding author), NIDDK, Diabet Branch, NIH, Rm 8S235A,Bldg 10, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482				BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Butterfield L, 1997, J BIOL CHEM, V272, P10110; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Cheng HL, 1998, J BIOL CHEM, V273, P14560, DOI 10.1074/jbc.273.23.14560; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; D'Mello SR, 1997, J NEUROSCI, V17, P1548; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Feldman EL, 1997, NEUROBIOL DIS, V4, P201, DOI 10.1006/nbdi.1997.0156; Folli F, 1996, MOL NEUROBIOL, V13, P155, DOI 10.1007/BF02740639; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Graves JD, 1996, P NATL ACAD SCI USA, V93, P13814, DOI 10.1073/pnas.93.24.13814; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Heidenreich KA, 1996, J BIOL CHEM, V271, P9891, DOI 10.1074/jbc.271.17.9891; Herrmann JL, 1997, EXP CELL RES, V234, P442, DOI 10.1006/excr.1997.3653; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Koval AP, 1998, BIOCHEM J, V330, P923; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; Liu Q, 1997, J IMMUNOL, V159, P829; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; Lopez-Ilasaca M, 1998, J BIOL CHEM, V273, P2505, DOI 10.1074/jbc.273.5.2505; LopezIlasaca M, 1997, BIOCHEM BIOPH RES CO, V232, P273, DOI 10.1006/bbrc.1997.6289; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; Marais R, 1996, CANCER SURV, V27, P101; Miller BS, 1996, BIOCHEMISTRY-US, V35, P8769, DOI 10.1021/bi952651r; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RUBIN R, 1995, LAB INVEST, V73, P311; Sakakura C, 1996, J BIOL CHEM, V271, P946, DOI 10.1074/jbc.271.2.946; Singleton JR, 1996, J BIOL CHEM, V271, P31791, DOI 10.1074/jbc.271.50.31791; Skov S, 1997, J CELL BIOL, V139, P1523, DOI 10.1083/jcb.139.6.1523; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; Tagami M, 1997, LAB INVEST, V76, P603; Werner H, 1997, CRIT REV ONCOGENESIS, V8, P71, DOI 10.1615/CritRevOncog.v8.i1.40; Wilson DJ, 1996, EUR J IMMUNOL, V26, P989, DOI 10.1002/eji.1830260505; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	49	72	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25961	25966		10.1074/jbc.273.40.25961	http://dx.doi.org/10.1074/jbc.273.40.25961			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748273	hybrid			2022-12-27	WOS:000076263100064
J	Rencurel, F; Munoz-Alonso, MJ; Girard, J; Leturque, A				Rencurel, F; Munoz-Alonso, MJ; Girard, J; Leturque, A			An unusual high-K-m hexokinase is expressed in the mhAT3F hepatoma cell line.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-KINASE GENE; FATTY-ACID-SYNTHASE; GLUCOSE-TRANSPORTER; REGULATORY PROTEIN; PANCREATIC-ISLET; RAT HEPATOCYTES; GLUCOKINASE ACTIVITY; MESSENGER-RNA; III ISOZYME; LIVER	In most hepatoma cells, the high-K-m GLUT2/glucokinase proteins are replaced by the ubiquitous low-K-m GLUT1/hexokinase type I proteins. In the mhAT3F hepatoma cells, the stimulatory effect of glucose on gene expression and glycogen accumulation was not maximal at 5 mmol/liter glucose. This response to high glucose is observed in mhAT3F cells, where GLUT2 was expressed, but not glucokinase (assessed by Northern blotting and reverse transcription-polymerase chain reaction). A low-K-m hexokinase activity (19.6 +/- 3.8 milliunits/mg of protein) was present, but a high-K-m (40 mmol/liter) hexokinase activity (13.9 +/- 2.5 milliunits/mg) was also detected in mhAT3F cells. The high-K-m hexokinase activity was dependent on both ATP (or PP,) and glucose in the assay and was recovered in a 10-50-kDa fraction after filtration. A 30-kDa protein was detected using an anti-glucokinase antibody and localized by confocal microscopy at the same sites as glucokinase in hepatocytes. In FAO cells, the high-K-m hexokinase activity and 30-kDa protein were not found. We conclude that a high-K-m hexokinase activity is present in mhAT3F cells. This might explain why the effects of glucose on gene expression were not maximal at a glucose concentration of 5 mmol/liter. A 30-kDa protein identified using an antiglucokinase antibody may be responsible for this activity present in mhAT3F cells.	CNRS, UPR1524, F-92190 Meudon, France	Centre National de la Recherche Scientifique (CNRS)	Leturque, A (corresponding author), CNRS, UPR1524, 9 Rue Jules Hetzel, F-92190 Meudon, France.		Leturque, Armelle/Q-9437-2017	Leturque, Armelle/0000-0001-6570-6387				AGIUS L, 1993, BIOCHEM J, V296, P785, DOI 10.1042/bj2960785; Agius L, 1996, J BIOL CHEM, V271, P30479, DOI 10.1074/jbc.271.48.30479; AGIUS L, 1994, BIOCHEM J, V303, P841, DOI 10.1042/bj3030841; Antoine B, 1997, J BIOL CHEM, V272, P17937, DOI 10.1074/jbc.272.29.17937; Argaud D, 1997, J BIOL CHEM, V272, P12854, DOI 10.1074/jbc.272.19.12854; ASANO T, 1992, DIABETES, V41, P22, DOI 10.2337/diabetes.41.1.22; BERRY MN, 1969, J CELL BIOL, V43, P606; Brown KS, 1997, DIABETES, V46, P179, DOI 10.2337/diabetes.46.2.179; BURCELIN R, 1992, BIOCHEM J, V288, P675, DOI 10.1042/bj2880675; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANIELS MC, 1993, MOL ENDOCRINOL, V7, P1041, DOI 10.1210/me.7.8.1041; DAVAGNINO J, 1980, J BIOL CHEM, V255, P2633; DOIRON B, 1994, J BIOL CHEM, V269, P10213; Foster JD, 1997, P SOC EXP BIOL MED, V215, P314; GIFFHORNKATZ S, 1986, EUR J BIOCHEM, V159, P513, DOI 10.1111/j.1432-1033.1986.tb09916.x; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; GROSSBARD L, 1966, J BIOL CHEM, V241, P3546; Guillam MT, 1997, NAT GENET, V17, P327, DOI 10.1038/ng1197-327; Heimberg H, 1996, P NATL ACAD SCI USA, V93, P7036, DOI 10.1073/pnas.93.14.7036; LEFRANCOISMARTINEZ AM, 1994, FASEB J, V8, P89, DOI 10.1096/fasebj.8.1.8299894; LEVRAT F, 1993, EXP CELL RES, V209, P307, DOI 10.1006/excr.1993.1315; LIANG Y, 1991, J BIOL CHEM, V266, P6999; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MEIENHOFER MC, 1987, EUR J BIOCHEM, V169, P237, DOI 10.1111/j.1432-1033.1987.tb13603.x; MELLOUL D, 1993, P NATL ACAD SCI USA, V90, P3865, DOI 10.1073/pnas.90.9.3865; NORDLIE RC, 1971, J BIOL CHEM, V246, P4807; ODoherty RM, 1996, J BIOL CHEM, V271, P20524, DOI 10.1074/jbc.271.34.20524; POSTIC C, 1993, BIOCHEM J, V293, P119, DOI 10.1042/bj2930119; PRELLER A, 1992, ARCH BIOCHEM BIOPHYS, V294, P482, DOI 10.1016/0003-9861(92)90715-9; PRIPBUUS C, 1995, EUR J BIOCHEM, V230, P309, DOI 10.1111/j.1432-1033.1995.tb20564.x; Rencurel F, 1996, BIOCHEM J, V314, P903, DOI 10.1042/bj3140903; REYES A, 1983, BIOCHEM J, V221, P311; SCHWAB DA, 1991, ARCH BIOCHEM BIOPHYS, V285, P365, DOI 10.1016/0003-9861(91)90373-Q; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; Towle HC, 1997, ANNU REV NUTR, V17, P405, DOI 10.1146/annurev.nutr.17.1.405; TOYODA Y, 1995, BIOCHEM BIOPH RES CO, V215, P467, DOI 10.1006/bbrc.1995.2488; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; VANSCHAFTINGEN E, 1994, FASEB J, V8, P414, DOI 10.1096/fasebj.8.6.8168691; VAULONT S, 1986, J BIOL CHEM, V261, P7621; VINUELA E, 1963, J BIOL CHEM, V238, P1175; Wilson JE, 1997, BIOCHEM SOC T, V25, P103, DOI 10.1042/bst0250103	41	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26187	26193		10.1074/jbc.273.40.26187	http://dx.doi.org/10.1074/jbc.273.40.26187			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748301	hybrid			2022-12-27	WOS:000076263100092
J	Wice, BM; Gordon, JI				Wice, BM; Gordon, JI			Forced expression of Id-1 in the adult mouse small intestinal epithelium is associated with development of adenomas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEIN; ACID-BINDING-PROTEIN; B-CELL DEVELOPMENT; TRANSGENIC MICE; TRANSCRIPTION FACTOR; GENE-EXPRESSION; DNA-BINDING; STEM-CELL; PANETH CELLS; MUSCLE DIFFERENTIATION	Ids are dominant-negative helix-loop-helix (HLH) proteins that play overlapping yet distinct roles in antagonizing basic HLH transcription factors. Although Ids affect myogenesis, neurogenesis, and B-cell development, little is known about their in vivo functions in epithelia, we have examined the effects of forced expression of Id-1 in the small intestinal epithelium of adult chimeric mice. 129/Sv embryonic stem cells, transfected with DNA containing Id-1 under the control of transcriptional regulatory elements that function in all intestinal epithelial cell lineages, were introduced into C57BI/6 (B6) blastocysts heterozygous for the ROSA26 marker. The B6 ROSA26/+ intestinal epithelium of the resulting adult chimeras produces Escherichia coli P-galactosidase, allowing identification of this internal control cell population. Chimeras produced from nontransfected embryonic stem cells served as additional controls. Immunohistochemical studies of the control chimeras indicated that the small intestinal epithelium supports a complex pattern of endogenous Id expression. Id-1 is restricted to the cytoplasm; levels do not decrease as descendants of multipotent intestinal stem cells differentiate. Id-2 and Id-3 are only detectable in nuclei; levels increase markedly as epithelial cells differentiate. Forced expression of Id-1 in the 129/Sv epithelium results in a decline in Id-2 and Id-3 to below the limits of immunodetection, A subset of chimeric-transgenic mice lacked growth factor- and defensin-producing Paneth cells in their 129/Sv epithelium and also developed intestinal adenomas, These changes were not present in normal control chimeras. Adenomas were composed of proliferating beta-Gal-positive and -negative epithelial cells, suggesting that they arose through cooperative interactions between 129/Sv(Id-1) and B6 ROSA26/+ cells. These chimeras provide a model for studying how perturbations in Id expression affect tumorigenesis.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL)	Gordon, JI (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Box 8103,660 S Euclid Ave, St Louis, MO 63110 USA.	jgordon@pharmdec.wustl.edu			NIDDK NIH HHS [DK 37960] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037960] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKAZAWA C, 1995, J BIOL CHEM, V270, P8730, DOI 10.1074/jbc.270.15.8730; Anand G, 1997, J BIOL CHEM, V272, P19140, DOI 10.1074/jbc.272.31.19140; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIGGS J, 1992, P NATL ACAD SCI USA, V89, P1512, DOI 10.1073/pnas.89.4.1512; BJERKNES M, 1981, AM J ANAT, V160, P51, DOI 10.1002/aja.1001600105; BJERKNES M, 1981, AM J ANAT, V160, P65, DOI 10.1002/aja.1001600106; Bjerknes M, 1997, CANCER RES, V57, P355; BRY L, 1994, P NATL ACAD SCI USA, V91, P10335, DOI 10.1073/pnas.91.22.10335; Chen BB, 1997, J BIOL CHEM, V272, P2459, DOI 10.1074/jbc.272.4.2459; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CHENG H, 1974, AM J ANAT, V141, P481, DOI 10.1002/aja.1001410404; CHENG H, 1974, AM J ANAT, V141, P503, DOI 10.1002/aja.1001410405; CHENG H, 1974, AM J ANAT, V141, P521, DOI 10.1002/aja.1001410406; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; COHN SM, 1984, J BIOL CHEM, V259, P2456; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; CROSS JC, 1995, DEVELOPMENT, V121, P2513; Darmoul D, 1996, AM J PHYSIOL-GASTR L, V271, pG68, DOI 10.1152/ajpgi.1996.271.1.G68; Deed RW, 1996, J BIOL CHEM, V271, P23603, DOI 10.1074/jbc.271.39.23603; DESPREZ PY, 1995, MOL CELL BIOL, V15, P3398; DIAS P, 1994, SEMIN DIAGN PATHOL, V11, P3; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Garabedian EM, 1997, J BIOL CHEM, V272, P23729, DOI 10.1074/jbc.272.38.23729; Gould KA, 1997, P NATL ACAD SCI USA, V94, P5848, DOI 10.1073/pnas.94.11.5848; Gould KA, 1996, GENETICS, V144, P1769; Gould KA, 1996, GENETICS, V144, P1777; Gould KA, 1996, CELL GROWTH DIFFER, V7, P1361; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GUNDERSEN K, 1994, P NATL ACAD SCI USA, V91, P3647, DOI 10.1073/pnas.91.9.3647; HAGEMANN RF, 1971, AM J ANAT, V129, P41; HALL PA, 1994, J CELL SCI, V107, P3569; HARA E, 1994, J BIOL CHEM, V269, P2139; Hermiston ML, 1996, GENE DEV, V10, P985, DOI 10.1101/gad.10.8.985; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KIM SH, 1993, J CELL BIOL, V123, P877, DOI 10.1083/jcb.123.4.877; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; LI YQ, 1994, J CELL SCI, V107, P3271; LOEFFLER M, 1993, J THEOR BIOL, V160, P471, DOI 10.1006/jtbi.1993.1031; Luna LG, 1968, MANUAL HISTOLOGIC ST, V3; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; Merritt AJ, 1997, P NATL ACAD SCI USA, V94, P13927, DOI 10.1073/pnas.94.25.13927; MULHERKAR R, 1993, BIOCHEM BIOPH RES CO, V195, P1254, DOI 10.1006/bbrc.1993.2179; MULHERKAR R, 1991, HISTOCHEMISTRY, V96, P367, DOI 10.1007/BF00271358; MURRAY SS, 1992, J BONE MINER RES, V7, P1131; Mutoh H, 1997, P NATL ACAD SCI USA, V94, P3560, DOI 10.1073/pnas.94.8.3560; Novelli MR, 1996, SCIENCE, V272, P1187, DOI 10.1126/science.272.5265.1187; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Ouellette AJ, 1996, FASEB J, V10, P1280, DOI 10.1096/fasebj.10.11.8836041; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; Potten CS, 1997, INT J EXP PATHOL, V78, P219, DOI 10.1046/j.1365-2613.1997.280362.x; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; ROBINSON GLWG, 1994, MOL CELL BIOL, V14, P6704, DOI 10.1128/MCB.14.10.6704; ROTH KA, 1990, P NATL ACAD SCI USA, V87, P6408, DOI 10.1073/pnas.87.16.6408; SCHMIDT GH, 1985, CELL, V40, P425, DOI 10.1016/0092-8674(85)90156-4; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; SHOJI W, 1994, J BIOL CHEM, V269, P5078; SHOJI W, 1995, J BIOL CHEM, V270, P24818, DOI 10.1074/jbc.270.42.24818; SIMON TC, 1993, J BIOL CHEM, V268, P18345; Simon TC, 1997, J BIOL CHEM, V272, P10652; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; SWEETSER DA, 1988, GENE DEV, V2, P1318, DOI 10.1101/gad.2.10.1318; THERRIEN M, 1993, MOL CELL BIOL, V13, P2342, DOI 10.1128/MCB.13.4.2342; TOTAFURNO J, 1987, BIOPHYS J, V52, P279, DOI 10.1016/S0006-3495(87)83215-0; TRAHAIR JF, 1989, J CELL BIOL, V109, P3231, DOI 10.1083/jcb.109.6.3231; WANG YQ, 1992, DEV DYNAM, V194, P222, DOI 10.1002/aja.1001940307; Wong MH, 1996, P NATL ACAD SCI USA, V93, P9588, DOI 10.1073/pnas.93.18.9588; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317; Zambrowicz BP, 1997, P NATL ACAD SCI USA, V94, P3789, DOI 10.1073/pnas.94.8.3789; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	83	70	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25310	25319		10.1074/jbc.273.39.25310	http://dx.doi.org/10.1074/jbc.273.39.25310			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737997	hybrid			2022-12-27	WOS:000076085400047
J	Engelmann, B; Schaipp, B; Dobner, P; Stoeckelhuber, M; Kogl, C; Siess, W; Hermetter, A				Engelmann, B; Schaipp, B; Dobner, P; Stoeckelhuber, M; Kogl, C; Siess, W; Hermetter, A			Platelet agonists enhance the import of phosphatidylethanolamine into human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR ACTIVATION; ARACHIDONIC-ACID; THROMBIN; MEMBRANE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLSERINE; THROMBOMODULIN; LIPOPROTEIN; GENERATION; VESICLES	It is unknown whether the endocytosis-independent transfer of phospholipids from lipoproteins to platelets is regulated by platelet agonists such as thrombin. The movements of the choline phospholipids phosphatidylcholine and sphingomyelin (labeled with either C-14 or the fluorescent pyrenedecanoic acid) between low density lipoproteins and platelets were unaffected by thrombin (0.5 unit/ml). In contrast, thrombin accelerated the import of diacyl phosphatidylethanolamine (PE) and alkenylacyl phosphatidylethanolamine into platelets by about 4-fold. Similarly, thrombin receptor-activating peptide (15 mu M), collagen (10 mu g/ml), and ADP (10 mu M) enhanced PE uptake. High density lipoprotein particles and egg phosphatidylcholine vesicles were also donors for stimulation of platelet PE import. Part of the [C-14]arachidonic acid-labeled PE transferred from low density lipoprotein to platelets activated by thrombin and collagen was metabolized to C-14-eicosanoids, Inhibitors of protein kinase C partially prevented thrombin-induced [C-14]PE uptake, while direct activators of protein kinase C increased incorporation of [C-14]PE into platelets. Proteinaceous factor(s) recovered in the extracellular medium from ADP- and thrombin-activated platelet suspensions were found to accelerate the transfer of pyrenedecanoic acid-labeled PE between donor and acceptor lipid vesicles. The stimulation of import of ethanolamine phospholipids led to a 2-fold enhancement of the prothrombinase activity of thrombin-activated platelets. Our study demonstrates that physiological platelet stimuli increase specifically the transfer of ethanolamine phospholipids from lipoproteins to platelets through a secretion-dependent mechanism. This might contribute to the increase of procoagulant activity of stimulated platelets.	Univ Munich, Inst Physiol, D-80336 Munich, Germany; Univ Munich, Inst Prophylaxe Kreislaufkrankheiten, D-80336 Munich, Germany; Graz Univ Technol, Inst Biochem & Lebensmittelchem, A-8010 Graz, Austria	University of Munich; University of Munich; Graz University of Technology	Engelmann, B (corresponding author), Univ Munich, Inst Physiol, Pettenkoferstr 12, D-80336 Munich, Germany.	bernd.engelmann@med.uni-muenchen.de	Siess, Wolfgang/A-6430-2009	Siess, Wolfgang/0000-0003-0698-6416				BEVERS EM, 1982, EUR J BIOCHEM, V122, P429, DOI 10.1111/j.1432-1033.1982.tb05898.x; BEVERS EM, 1983, BIOCHIM BIOPHYS ACTA, V736, P57, DOI 10.1016/0005-2736(83)90169-4; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARO IF, 1977, J CLIN INVEST, V60, P866, DOI 10.1172/JCI108841; COLARD O, 1989, BIOCHEM J, V259, P333, DOI 10.1042/bj2590333; Diaz C, 1996, J MEMBRANE BIOL, V151, P1, DOI 10.1007/s002329900051; EHRMAN ML, 1980, PROSTAGLANDINS, V20, P1103, DOI 10.1016/0090-6980(80)90063-5; Engelmann B, 1996, BIOCHEM J, V315, P781, DOI 10.1042/bj3150781; FENTON JW, 1989, SEMIN THROMB HEMOST, V15, P265, DOI 10.1055/s-2007-1002718; FREYSSINET JM, 1986, BIOCHEM J, V238, P151, DOI 10.1042/bj2380151; GALVIN JB, 1987, J BIOL CHEM, V262, P2199; GOODWIN CA, 1995, BIOCHEM J, V308, P15, DOI 10.1042/bj3080015; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; HABENICHT AJR, 1990, NATURE, V345, P634, DOI 10.1038/345634a0; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; KOLLER E, 1989, J BIOL CHEM, V264, P12412; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MUSTARD JF, 1972, BRIT J HAEMATOL, V22, P193, DOI 10.1111/j.1365-2141.1972.tb08800.x; MYHER JJ, 1989, LIPIDS, V24, P408, DOI 10.1007/BF02535148; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NOZAWA Y, 1991, BIOCHIM BIOPHYS ACTA, V1082, P219, DOI 10.1016/0005-2760(91)90197-P; PALTAUF F, 1991, METHOD ENZYMOL, V197, P134; PURDON AD, 1987, BIOCHIM BIOPHYS ACTA, V920, P205, DOI 10.1016/0005-2760(87)90096-8; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; Smeets EF, 1996, THROMB RES, V81, P419, DOI 10.1016/0049-3848(96)00014-X; SPECTOR AA, 1970, J CLIN INVEST, V49, P1489, DOI 10.1172/JCI106366; TAKAMURA H, 1987, J BIOL CHEM, V262, P2262; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; THURNHOFER H, 1990, BIOCHIM BIOPHYS ACTA, V1024, P249, DOI 10.1016/0005-2736(90)90351-N; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73; YAMASHITA T, 1991, J BIOL CHEM, V266, P3888	32	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27800	27808		10.1074/jbc.273.43.27800	http://dx.doi.org/10.1074/jbc.273.43.27800			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774389	hybrid			2022-12-27	WOS:000076549800009
J	Bonhivers, M; Carbrey, JM; Gould, SJ; Agren, P				Bonhivers, M; Carbrey, JM; Gould, SJ; Agren, P			Aquaporins in Saccharomyces - Genetic and functional distinctions between laboratory and wild-type strains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-OOCYTES; WATER CHANNELS; MIP FAMILY; FILAMENTOUS GROWTH; ESCHERICHIA-COLI; BUDDING YEAST; CEREVISIAE; PROTEINS; FACILITATOR; MEMBER	Aquaporin water channel proteins mediate the transport of water across cell membranes in numerous species. The Saccharomyces genome data base contains an open reading frame (here designated AQY1) that encodes a protein with strong homology to aquaporins. AQY1 from laboratory and wild-type strains of Saccharomyces were expressed in Xenopus oocytes to determine the coefficients of osmotic water permeability (P-f). Oocytes injected with wild-type AQY1 cRNAs exhibit high P-f values, whereas oocytes injected with AQY1 cRNAs from laboratory strains exhibit low P-f values and have reduced levels of Aqy1p due to two amino acid substitutions. When the AQY1 gene was deleted from a wild-type yeast and cells were cultured in vitro with cycled hypo-osmolar or hyper-osmolar stresses, the AQY1 null yeast showed significantly improved viability when compared with the parental wild-type strain. We conclude that Saccharomyces cerevisiae contains at least one aquaporin gene, but it is not functional in laboratory strains due to apparent negative selection pressures resulting from in vitro methods.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University	Bonhivers, M (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.	pagre@jhmi.edu	Bonhivers, Melanie/Z-5889-2019	Bonhivers, Melanie/0000-0001-9179-8473	NEI NIH HHS [EY11239] Funding Source: Medline; NHLBI NIH HHS [HL48268, HL33991] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011239] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL048268, R01HL048268, R01HL033991] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agre P, 1998, J BIOL CHEM, V273, P14659, DOI 10.1074/jbc.273.24.14659; Blomberg A, 1997, YEAST, V13, P529; Calamita G, 1997, BIOL CELL, V89, P321, DOI 10.1016/S0248-4900(97)83385-0; CALAMITA G, 1995, J BIOL CHEM, V270, P29063, DOI 10.1074/jbc.270.49.29063; Calamita G, 1998, P NATL ACAD SCI USA, V95, P3627, DOI 10.1073/pnas.95.7.3627; COFFEAU A, 1996, SCIENCE, V274, P546; DEEN PMT, 1995, J CLIN INVEST, V95, P2291, DOI 10.1172/JCI117920; DUJON B, 1993, COLD SPRING HARB SYM, V58, P357, DOI 10.1101/SQB.1993.058.01.042; Flick KM, 1997, GENE, V195, P127, DOI 10.1016/S0378-1119(97)00078-4; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Heymann JB, 1998, J STRUCT BIOL, V121, P191, DOI 10.1006/jsbi.1997.3951; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; JUNG JS, 1994, J BIOL CHEM, V269, P14648; KASHIWAGI S, 1995, BBA-BIOMEMBRANES, V1237, P189, DOI 10.1016/0005-2736(95)00124-L; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Kron SJ, 1997, TRENDS MICROBIOL, V5, P450, DOI 10.1016/S0966-842X(97)01131-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lagree V, 1998, J BIOL CHEM, V273, P12422, DOI 10.1074/jbc.273.20.12422; Laize V, 1998, FASEB J, V12, pA422; Liu HP, 1996, GENETICS, V144, P967; LUYTEN K, 1995, EMBO J, V14, P1360, DOI 10.1002/j.1460-2075.1995.tb07122.x; MAUREL C, 1994, J BIOL CHEM, V269, P11869; MORTIMER RK, 1986, GENETICS, V113, P35; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; Park JH, 1996, J MEMBRANE BIOL, V153, P171, DOI 10.1007/s002329900120; Philips J, 1997, J CELL BIOL, V138, P961, DOI 10.1083/jcb.138.5.961; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1993, J BIOL CHEM, V268, P17; ROST B, 1995, PROTEIN SCI, V4, P521; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sutherland FCW, 1997, J BACTERIOL, V179, P7790, DOI 10.1128/jb.179.24.7790-7795.1997; Varela JCS, 1996, MICROBIOL-SGM, V142, P721, DOI 10.1099/00221287-142-4-721; Walz T, 1997, NATURE, V387, P624, DOI 10.1038/42512; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; ZHANG R, 1990, J BIOL CHEM, V265, P15375	36	86	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27565	27572		10.1074/jbc.273.42.27565	http://dx.doi.org/10.1074/jbc.273.42.27565			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765289	hybrid			2022-12-27	WOS:000076448000076
J	Connor, JH; Quan, HN; Ramaswamy, NT; Zhang, LF; Barik, S; Zheng, JH; Cannon, JF; Lee, EYC; Shenolikar, S				Connor, JH; Quan, HN; Ramaswamy, NT; Zhang, LF; Barik, S; Zheng, JH; Cannon, JF; Lee, EYC; Shenolikar, S			Inhibitor-1 interaction domain that mediates the inhibition of protein phosphatase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; CAMP-REGULATED PHOSPHOPROTEIN; CATALYTIC SUBUNIT; SACCHAROMYCES-CEREVISIAE; SERINE/THREONINE PHOSPHATASES; GLYCOGEN-METABOLISM; AFFINITY-CHROMATOGRAPHY; HORMONAL-REGULATION; MUTATIONAL ANALYSIS; MOLECULAR-CLONING	Inhibitor-1 (I-l), a cyclic AMP-regulated phosphoprotein, inhibits protein phosphatase-l (PP1) activity in response to hormones. The molecular mechanism for PP1 inhibition by I-1 remains unknown. Mutation of nine acidic residues lining a proposed I-1-binding channel in rabbit PP1 alpha yielded one mutant (E256A) slightly impaired in its inhibition by I-1, with the IC50 increased by 3-fold, and one mutant (E275R) located in the beta 12-beta 13 loop that showed 4-fold enhanced inhibition by I-1. Substituting Tyr-272, a proposed binding site for the toxins okadaic acid and microcystin-LR, in the beta 12-beta 13 loop with Trp, Phe, Asp, Arg, or Ala impaired PP1 alpha inhibition by I-1 by 8-10-fold, Chemical mutagenesis of the Saccharomyces cerevisiae PP1 gene (GLC7) yielded 20 point mutations in the PP1 coding region. Two-hybrid analyses and biochemical assays of these yeast enzymes identified four additional residues in the beta 12-beta 13 loop that were required for PP1 binding and inhibition by I-1. Ten-fold higher concentrations of I-1 were required to inhibit these mutants. Finally, deletion of the beta 12-beta 13 loop from PP1 alpha maintained full enzyme activity, but attenuated inhibition by I-1 by >100-fold. These data identified the beta 12-beta 13 loop in the PP1 catalytic subunit as a domain that mediates binding and enzyme inhibition by I-1.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Univ Missouri, Sch Med, Dept Mol Microbiol & Immunol, Columbia, MO 65212 USA; Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA; Univ S Alabama, Sch Med, Dept Biochem & Mol Biol, Mobile, AL 36688 USA	Duke University; University of Missouri System; University of Missouri Columbia; University of Miami; University of South Alabama	Shenolikar, S (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, POB 3813, Durham, NC 27710 USA.	sheno001@mc.duke.edu		Connor, John/0000-0002-8867-7256; Cannon, John/0000-0001-6698-176X	NIDDK NIH HHS [DK18512, DK52054] Funding Source: Medline; NIGMS NIH HHS [GM40326] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052054, R01DK018512] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040326, R29GM040326] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1982, FEBS LETT, V147, P54, DOI 10.1016/0014-5793(82)81010-7; ALESSI DR, 1993, EUR J BIOCHEM, V213, P1055, DOI 10.1111/j.1432-1033.1993.tb17853.x; Ansai T, 1996, J BIOL CHEM, V271, P24401, DOI 10.1074/jbc.271.40.24401; Bagu JR, 1997, J BIOL CHEM, V272, P5087, DOI 10.1074/jbc.272.8.5087; Baker SH, 1997, GENETICS, V145, P615; BARTON GJ, 1994, EUR J BIOCHEM, V220, P225, DOI 10.1111/j.1432-1033.1994.tb18618.x; Beavo J A, 1974, Methods Enzymol, V38, P299; Beullens M, 1996, EUR J BIOCHEM, V239, P183, DOI 10.1111/j.1432-1033.1996.0183u.x; Blitzer RD, 1998, SCIENCE, V280, P1940, DOI 10.1126/science.280.5371.1940; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; Campos M, 1996, J BIOL CHEM, V271, P28478, DOI 10.1074/jbc.271.45.28478; CANNON JF, 1994, GENETICS, V136, P485; COHEN P, 1989, FEBS LETT, V250, P601, DOI 10.1016/0014-5793(89)80804-X; COHEN PTW, 1989, BIOCHEM J, V260, P931, DOI 10.1042/bj2600931; Dalley BK, 1996, ONCOGENE, V13, P1209; DEPAOLIROACH AA, 1994, ADV ENZYME REGUL, V34, P199, DOI 10.1016/0065-2571(94)90017-5; DESDOUITS F, 1995, BIOCHEM BIOPH RES CO, V206, P652, DOI 10.1006/bbrc.1995.1092; DESDOUITS F, 1995, J BIOL CHEM, V270, P8772, DOI 10.1074/jbc.270.15.8772; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; Endo S, 1996, BIOCHEMISTRY-US, V35, P5220, DOI 10.1021/bi952940f; Endo S, 1997, BIOCHEMISTRY-US, V36, P6986, DOI 10.1021/bi970418i; Florio T, 1996, ENDOCRINOLOGY, V137, P4409, DOI 10.1210/en.137.10.4409; FOULKES JG, 1980, FEBS LETT, V112, P21, DOI 10.1016/0014-5793(80)80117-7; FRANCOIS JM, 1992, EMBO J, V11, P87, DOI 10.1002/j.1460-2075.1992.tb05031.x; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Gupta RC, 1996, AM J PHYSIOL-HEART C, V270, pH1159, DOI 10.1152/ajpheart.1996.270.4.H1159; Helps NR, 1995, FEBS LETT, V377, P295, DOI 10.1016/0014-5793(95)01347-4; HEMMINGS HC, 1990, J BIOL CHEM, V265, P20369; HIRAGA A, 1986, EUR J BIOCHEM, V161, P763, DOI 10.1111/j.1432-1033.1986.tb10505.x; Hirano K, 1996, FEBS LETT, V389, P191, DOI 10.1016/0014-5793(96)00577-7; HIRANO K, 1995, J BIOL CHEM, V270, P19786, DOI 10.1074/jbc.270.34.19786; HOLMES CFB, 1993, CURR OPIN STRUC BIOL, V3, P934, DOI 10.1016/0959-440X(93)90159-I; Huang HB, 1997, P NATL ACAD SCI USA, V94, P3530, DOI 10.1073/pnas.94.8.3530; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Johnson D, 1997, EUR J BIOCHEM, V244, P931, DOI 10.1111/j.1432-1033.1997.00931.x; Johnson DF, 1996, EUR J BIOCHEM, V239, P317, DOI 10.1111/j.1432-1033.1996.0317u.x; KHATRA BS, 1980, FEBS LETT, V114, P253, DOI 10.1016/0014-5793(80)81127-6; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P3536, DOI 10.1073/pnas.94.8.3536; LOHSE DL, 1995, STRUCTURE, V3, P987, DOI 10.1016/S0969-2126(01)00234-9; MACDOUGALL LK, 1989, BIOCHIM BIOPHYS ACTA, V1010, P218, DOI 10.1016/0167-4889(89)90164-X; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MATSUSHIMA R, 1990, BIOCHEM BIOPH RES CO, V171, P867, DOI 10.1016/0006-291X(90)91226-I; MOORHEAD G, 1995, FEBS LETT, V362, P101, DOI 10.1016/0014-5793(95)00197-H; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; NAKIELNY S, 1991, EUR J BIOCHEM, V199, P713, DOI 10.1111/j.1432-1033.1991.tb16175.x; NEMENOFF RA, 1983, J BIOL CHEM, V258, P9437; NIMMO GA, 1978, EUR J BIOCHEM, V87, P341, DOI 10.1111/j.1432-1033.1978.tb12383.x; PARK IK, 1994, J BIOL CHEM, V269, P28919; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; Ramaswamy NT, 1998, GENETICS, V149, P57; RENOUF S, 1995, FEBS LETT, V375, P75, DOI 10.1016/0014-5793(95)01180-M; SHENOLIKAR S, 1995, SEMIN CANCER BIOL, V6, P219, DOI 10.1006/scbi.1995.0029; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; Sherman F, 1986, LAB COURSE MANUAL ME; SHIMA H, 1994, P NATL ACAD SCI USA, V91, P9267, DOI 10.1073/pnas.91.20.9267; SNYDER GL, 1992, J NEUROSCI, V12, P3071, DOI 10.1523/JNEUROSCI.12-08-03071.1992; Stark MJR, 1996, YEAST, V12, P1647, DOI 10.1002/(SICI)1097-0061(199612)12:16<1647::AID-YEA71>3.0.CO;2-Q; STUART JS, 1994, MOL CELL BIOL, V14, P896, DOI 10.1128/MCB.14.2.896; Tu JL, 1996, MOL CELL BIOL, V16, P4199; Van Eynde A, 1995, J BIOL CHEM, V270, P28068, DOI 10.1074/jbc.270.47.28068; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985; Zhang J, 1996, BIOCHEMISTRY-US, V35, P6276, DOI 10.1021/bi952954l; Zhang LF, 1997, BIOCHEMISTRY-US, V36, P8209, DOI 10.1021/bi9704865; ZHANG ZJ, 1994, J BIOL CHEM, V269, P16997; ZHANG ZJ, 1994, J BIOL CHEM, V269, P13766; ZHANG ZJ, 1993, MOL CELL BIOCHEM, V128, P113, DOI 10.1007/BF01076762	71	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27716	27724		10.1074/jbc.273.42.27716	http://dx.doi.org/10.1074/jbc.273.42.27716			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765309	hybrid			2022-12-27	WOS:000076448000096
J	Prabhakar, P; Thatte, HS; Goetz, RM; Cho, MR; Golan, DE; Michel, T				Prabhakar, P; Thatte, HS; Goetz, RM; Cho, MR; Golan, DE; Michel, T			Receptor-regulated translocation of endothelial nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLS; CAVEOLAE; LOCALIZATION; PROTEIN; PHOSPHORYLATION; PALMITOYLATION; SUBUNITS; CALCIUM; ENZYME; SITES	The endothelial nitric-oxide synthase (eNOS) is activated by transient increases in intracellular Ca2+ elicited by stimulation of diverse receptors, including bradykinin B-2 receptors on endothelial cells. eNOS and B-2 receptors are targeted to specialized signal-transducing domains in the plasma membrane termed plasmalemmal caveolae. Targeting to caveolae facilitates eNOS activation following receptor stimulation, but in resting cells, eNOS is tonically inhibited by its interactions with caveolin, the scaffolding protein in caveolae, We used a quantitative approach exploiting immunofluorescence microscopy to investigate regulation of the subcellular distribution of eNOS in endothelial cells by bradykinin and Ca2+. In resting cells, most of the eNOS is localized at the cell membrane. However, within 5 min following addition of bradykinin, nearly all the eNOS translocates to structures in the cell cytosol; following more protracted incubations with bradykinin, most of the cytosolic enzyme subsequently translocates back to the cell membrane. The bradykinin-induced internalization of eNOS is completely abrogated by the intracellular Ca2+ chelator BAPTA; conversely, Ca2+-mobilizing drugs and agonists promote eNOS translocation. These results establish that eNOS targeting to the membrane is labile and is subject to receptor-regulated Ca2+-dependent reversible translocation, providing another point for regulation of NO-dependent signaling in the vascular endothelium.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Michel, T (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiol, Thorn Bldg,Rm 1210A,75 Francis St, Boston, MA 02115 USA.	degolan@warren.med.harvard.edu; michel@calvin.bwh.harvard.edu	Goetz, Regina/M-2411-2019	Goetz, Regina/0000-0003-3681-4703; Cho, Myoung Rae/0000-0002-8191-8045				ADAMS DJ, 1989, FASEB J, V3, P2389, DOI 10.1096/fasebj.3.12.2477294; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; DUDEK R, 1995, PHARMACOLOGY, V50, P257, DOI 10.1159/000139290; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; FUKUDA S, 1995, BRAIN RES, V696, P30, DOI 10.1016/0006-8993(95)00704-T; HECKER M, 1994, BIOCHEM J, V299, P247, DOI 10.1042/bj2990247; Isshiki M, 1998, P NATL ACAD SCI USA, V95, P5009, DOI 10.1073/pnas.95.9.5009; KAO JPY, 1989, J BIOL CHEM, V264, P8179; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; LIU JW, 1995, BIOCHEMISTRY-US, V34, P12333, DOI 10.1021/bi00038a029; Liu JW, 1997, J CELL BIOL, V137, P1525, DOI 10.1083/jcb.137.7.1525; MALINSKI T, 1992, NATURE, V358, P676, DOI 10.1038/358676a0; McDonald KK, 1997, J BIOL CHEM, V272, P31213, DOI 10.1074/jbc.272.50.31213; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; MOMBOULI JV, 1995, ANNU REV PHARMACOL, V35, P679, DOI 10.1146/annurev.pa.35.040195.003335; POLLOCK JS, 1993, AM J PHYSIOL, V265, pC1379, DOI 10.1152/ajpcell.1993.265.5.C1379; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; Sase K, 1997, TRENDS CARDIOVAS MED, V7, P28, DOI 10.1016/S1050-1738(96)00121-1; SESSA WC, 1995, J BIOL CHEM, V270, P17641, DOI 10.1074/jbc.270.30.17641; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Venema VJ, 1996, BIOCHEM BIOPH RES CO, V226, P703, DOI 10.1006/bbrc.1996.1417	25	139	143	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27383	27388		10.1074/jbc.273.42.27383	http://dx.doi.org/10.1074/jbc.273.42.27383			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765266	hybrid			2022-12-27	WOS:000076448000053
J	Sakamoto, K; Nagase, T; Fukui, H; Horikawa, K; Okada, T; Tanaka, H; Sato, K; Miyake, Y; Ohara, O; Kako, K; Ishida, N				Sakamoto, K; Nagase, T; Fukui, H; Horikawa, K; Okada, T; Tanaka, H; Sato, K; Miyake, Y; Ohara, O; Kako, K; Ishida, N			Multitissue circadian expression of rat period homolog (rPer2) mRNA is governed by the mammalian circadian clock, the suprachiasmatic nucleus in the brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA; GENE; RHYTHMS; CELLS	The period (per) gene, controlling circadian rhythms in Drosophila, is expressed throughout the body in a circadian manner. A homolog of Drosophila per was isolated from rat and designated as rPer2. The rPER2 protein showed 39 and 95% amino acid identity with mPER1 and mPER2 (mouse homologs of per) proteins, respectively. A robust circadian fluctuation of rPer2 mRNA expression was discovered not only in the suprachiasmatic nucleus (SCN) of the hypothalamus but also in other tissues including eye, brain, heart, lung, spleen, liver, and kidney. Furthermore, the peripheral circadian expression of rPer2 mRNA was abolished in SCN-lesioned rats that showed behavioral arrhythmicity. These findings suggest that the multitissue circadian expression of rPer2 mRNA was governed by the mammalian brain clock SCN and also suggest that the rPer2 gene was involved in the circadian rhythm of locomotor behavior in mammals.	MITI, Agcy Ind Sci & Technol, Ishida Grp Clock Gene, Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 3058566, Japan; Nihon Univ, Sch Med, Dept Obstet & Gynecol, Tokyo, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Nihon University	Ishida, N (corresponding author), MITI, Agcy Ind Sci & Technol, Ishida Grp Clock Gene, Natl Inst Biosci & Human Technol, Higashi 1-1, Tsukuba, Ibaraki 3058566, Japan.	nishida@ccmail.nibh.go.jp	Ohara, Osamu/A-9119-2012; Ohara, Osamu/G-5448-2015	Ohara, Osamu/0000-0002-3328-9571				Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; EWER J, 1992, J NEUROSCI, V12, P3321; FRISCH B, 1994, NEURON, V12, P555, DOI 10.1016/0896-6273(94)90212-7; HALL JC, 1995, TRENDS NEUROSCI, V18, P230, DOI 10.1016/0166-2236(95)93908-G; INOUYE SIT, 1994, NEUROSCI RES, V20, P109, DOI 10.1016/0168-0102(94)90029-9; ISHIDA N, 1995, NEUROSCI RES, V23, P231, DOI 10.1016/0168-0102(95)00940-X; ISHIDA N, 1996, NEUROSCI PROT, V1, P1; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; LeSauter J, 1996, J BIOL RHYTHM, V11, P163, DOI 10.1177/074873049601100208; Matsushima A, 1996, J MOL CATAL B-ENZYM, V2, P1, DOI 10.1016/1381-1177(96)00003-3; MEIJER JH, 1989, PHYSIOL REV, V69, P671, DOI 10.1152/physrev.1989.69.3.671; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; Ohara O, 1997, DNA Res, V4, P53, DOI 10.1093/dnares/4.1.53; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; Ponting CP, 1997, CURR BIOL, V7, pR674, DOI 10.1016/S0960-9822(06)00352-6; Sakamoto K, 1998, NEUROSCI LETT, V245, P113, DOI 10.1016/S0304-3940(98)00189-X; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Silver R, 1996, NATURE, V382, P810, DOI 10.1038/382810a0; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; VOSSHALL LB, 1995, NEURON, V15, P345, DOI 10.1016/0896-6273(95)90039-X	22	255	262	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27039	27042		10.1074/jbc.273.42.27039	http://dx.doi.org/10.1074/jbc.273.42.27039			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765215	hybrid			2022-12-27	WOS:000076448000002
J	Anfosso, F; Bardin, N; Frances, V; Vivier, E; Camoin-Jau, L; Sampol, J; Dignat-George, F				Anfosso, F; Bardin, N; Frances, V; Vivier, E; Camoin-Jau, L; Sampol, J; Dignat-George, F			Activation of human endothelial cells via S-endo-1 antigen (CD146) stimulates the tyrosine phosphorylation of focal adhesion kinase p125(FAK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN SUPERFAMILY; MOLECULAR-CLONING; HUMAN-MELANOMA; SH3 DOMAINS; PAXILLIN; PROTEIN; IDENTIFICATION; SRC; GLYCOPROTEIN; EXPRESSION	S-Endo-1 antigen (CD146), a transmembrane receptor also known as MUC18/MCAM, is a member of the immunoglobulin superfamily and belongs to a group of cell adhesion molecules. CD146 is highly expressed on the whole vascular tree. We demonstrate here that engagement of CD146 on human endothelial cells isolated from cord blood results in tyrosine phosphorylation of a large panel of cellular proteins, although no tyrosine phosphorylation of CD146 was detected, In particular, CD146 cross-linking induces the tyrosine phosphorylation of the protein tyrosine kinase p125(FAK) as well as p125(FAK) association with paxillin, both events being inhibited by cytochalasin D. No direct association of CD146 with p125(FAK) was observed. Consistent with these data, CD146 associates with p59(fyn), a Src family kinase known to phosphorylate p125(FAK), The identification of a signaling pathway initiated by CD146 engagement and which includes p59(fyn), p125(FAK) and paxillin indicates that CD146 participates in outside-in signaling in endothelial cells.	UFR Pharm, Lab Hematol Immunol, F-13385 Marseille 05, France; Inst Univ France, F-13288 Marseille, France; CNRS, Ctr Immunol, INSERM, Marseille, France	Institut Universitaire de France; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Anfosso, F (corresponding author), UFR Pharm, Lab Hematol Immunol, 27 Bd Jean Moulin, F-13385 Marseille 05, France.	hematim@pharmacie.univ-mrs.fr	bardin, nathalie/G-6414-2013; Bardin, Nathalie/AAL-3663-2020; DIGNAT-GEORGE, Françoise/R-1129-2016; Vivier, Eric/F-8939-2010	Bardin, Nathalie/0000-0003-3680-082X; DIGNAT-GEORGE, Françoise/0000-0001-7006-4462; Vivier, Eric/0000-0001-7022-8287				Bardin N, 1996, BIOCHEM BIOPH RES CO, V218, P210, DOI 10.1006/bbrc.1996.0037; Bardin N, 1996, TISSUE ANTIGENS, V48, P531, DOI 10.1111/j.1399-0039.1996.tb02666.x; Batt DB, 1998, J BIOL CHEM, V273, P3408, DOI 10.1074/jbc.273.6.3408; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; BOWEN MA, 1995, J EXP MED, V181, P2213, DOI 10.1084/jem.181.6.2213; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; Calalb MB, 1996, BIOCHEM BIOPH RES CO, V228, P662, DOI 10.1006/bbrc.1996.1714; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CAMPBELL IG, 1994, CANCER RES, V54, P5761; Cary LA, 1996, J CELL SCI, V109, P1787; DONNADIEU E, 1994, J BIOL CHEM, V269, P32828; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; ILLC D, 1995, NATURE, V377, P539; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Johnson JP, 1997, INT J CANCER, V73, P769; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LAESSING U, 1994, DIFFERENTIATION, V56, P21, DOI 10.1007/s002580050017; Lampugnani MG, 1997, CURR OPIN CELL BIOL, V9, P674, DOI 10.1016/S0955-0674(97)80121-4; LEHMANN JM, 1987, CANCER RES, V47, P841; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; LUCA M, 1993, MELANOMA RES, V3, P35, DOI 10.1097/00008390-199304000-00006; MING IE, 1994, CANCER RES, V54, P2514; PANCHAMOORTHY G, 1994, MOL CELL BIOL, V14, P6372, DOI 10.1128/MCB.14.9.6372; PATCH LA, 1995, J CELL SCI, V108, P1371; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PEDUZZI JD, 1994, BRAIN RES, V640, P296, DOI 10.1016/0006-8993(94)91885-6; Pickl WF, 1997, J IMMUNOL, V158, P2107; Schaller MD, 1996, J ENDOCRINOL, V150, P1, DOI 10.1677/joe.0.1500001; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlessinger J, 1997, CELL, V91, P869, DOI 10.1016/S0092-8674(00)80477-8; SERS C, 1994, CANCER RES, V54, P5689; SERS C, 1993, P NATL ACAD SCI USA, V90, P8514, DOI 10.1073/pnas.90.18.8514; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; Shih IM, 1997, AM J PATHOL, V151, P745; Shih IM, 1997, CANCER RES, V57, P3835; Shih IM, 1996, LAB INVEST, V75, P377; Shih IM, 1996, CLIN CANCER RES, V2, P569; SHIH IM, 1994, CANCER RES, V54, P2514; SMALL SJ, 1987, J CELL BIOL, V105, P2335, DOI 10.1083/jcb.105.5.2335; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; TAIRA E, 1994, NEURON, V12, P861, DOI 10.1016/0896-6273(94)90338-7; TURNER CE, 1993, J CELL SCI, V105, P637; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; Vainio O, 1996, J CELL BIOL, V135, P1655, DOI 10.1083/jcb.135.6.1655	47	83	90	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26852	26856		10.1074/jbc.273.41.26852	http://dx.doi.org/10.1074/jbc.273.41.26852			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756930	hybrid			2022-12-27	WOS:000076373300084
J	Cantu, C; Palzkill, T				Cantu, C; Palzkill, T			The role of residue 238 of TEM-1 beta-lactamase in the hydrolysis of extended-spectrum antibiotics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SUBSTITUTIONS; 3RD-GENERATION CEPHALOSPORINS; ACTIVE-SITE; SUBSTRATE-SPECIFICITY; MUTAGENESIS; RESISTANCE; SELECTION; AZTREONAM; MUTATIONS; MUTANTS	beta-Lactamases inactivate beta-lactam antibiotics by catalyzing the hydrolysis of the amide bond in the beta-lactam ring. The plasmid-encoded class A TEM-1 beta-lactamase is a commonly encountered beta-lactamase. It is able to inactivate penicillins and cephalosporins but not extended-spectrum antibiotics. However, TEM-1-derived natural variants containing the G238S amino acid substitution display increased hydrolysis of extended-spectrum antibiotics. Two models have been proposed to explain the role of the G238S substitution in hydrolysis of extended-spectrum antibiotics. The first proposes a direct hydrogen bond of the Ser(238) Side chain to the oxime group of extended-spectrum antibiotics. The second proposes that steric conflict with surrounding residues, due to increased side chain volume, leads to a more accessible active site pocket. To assess the validity of each model, TEM-1 mutants with amino acids substitutions of Ala, Ser, Cys, Thr, Asn, and Val have been constructed. Kinetic analysis of these enzymes with penicillins and cephalosporins suggests that a hydrogen bond is necessary but not sufficient to achieve the hydrolytic activity of the G238S enzyme for the extended-spectrum antibiotics cefotaxime and ceftazidime. In addition, it appears that the new hydrogen bond interaction is to a site on the enzyme rather than directly to the extended-spectrum antibiotic. The data indicate that, for the G238S substitution, a combination of an optimal side chain volume and hydrogen bonding potential results in the most versatile and advantageous antibiotic hydrolytic spectrum for bacterial resistance to extended-spectrum antibiotics.	Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA; Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA; Baylor Coll Med, Program Struct & Computat Biol & Mol Biophys, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Palzkill, T (corresponding author), Baylor Coll Med, Dept Microbiol & Immunol, 1 Baylor Plaza, Houston, TX 77030 USA.				NIAID NIH HHS [AI32956] Funding Source: Medline; NIGMS NIH HHS [GM17581] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032956, R37AI032956, R56AI032956] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM017581] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; BUSH K, 1982, ANTIMICROB AGENTS CH, V22, P414, DOI 10.1128/AAC.22.3.414; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; Cantu C, 1996, J BIOL CHEM, V271, P22538, DOI 10.1074/jbc.271.37.22538; Cantu C, 1997, J BIOL CHEM, V272, P29144, DOI 10.1074/jbc.272.46.29144; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P7; Fersht A., 1985, ENZYME STRUCTURE MEC, P99; HULETSKY A, 1993, J BIOL CHEM, V268, P3690; JELSCH C, 1993, PROTEINS, V16, P364, DOI 10.1002/prot.340160406; KNOX JR, 1995, ANTIMICROB AGENTS CH, V39, P2593, DOI 10.1128/AAC.39.12.2593; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LABIA R, 1988, REV INFECT DIS, V10, P885; LENFANT F, 1990, BIOCHIMIE, V72, P495, DOI 10.1016/0300-9084(90)90073-P; Maveyraud L, 1996, J BIOL CHEM, V271, P10482, DOI 10.1074/jbc.271.18.10482; MINAMI S, 1980, ANTIMICROB AGENTS CH, V18, P382, DOI 10.1128/AAC.18.3.382; PALZKILL T, 1992, PROTEINS, V14, P29, DOI 10.1002/prot.340140106; PALZKILL T, 1994, MOL MICROBIOL, V12, P217, DOI 10.1111/j.1365-2958.1994.tb01011.x; Petrosino JF, 1996, J BACTERIOL, V178, P1821, DOI 10.1128/jb.178.7.1821-1828.1996; RADIKA K, 1984, ANTIMICROB AGENTS CH, V25, P479, DOI 10.1128/AAC.25.4.479; RAQUET X, 1995, PROTEINS, V23, P63, DOI 10.1002/prot.340230108; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVES I, 1995, BIOCHEMISTRY-US, V34, P11660, DOI 10.1021/bi00037a003; SIEGEL EC, 1982, MUTAT RES, V93, P25, DOI 10.1016/0027-5107(82)90122-1; SOWEK JA, 1991, BIOCHEMISTRY-US, V30, P3179, DOI 10.1021/bi00227a004; WIEDEMANN B, 1989, J ANTIMICROB CHEMOTH, V24, P1	26	39	39	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26603	26609		10.1074/jbc.273.41.26603	http://dx.doi.org/10.1074/jbc.273.41.26603			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756899	hybrid			2022-12-27	WOS:000076373300053
J	Crovello, CS; Lai, C; Cantley, LC; Carraway, KL				Crovello, CS; Lai, C; Cantley, LC; Carraway, KL			Differential signaling by the epidermal growth factor-like growth factors neuregulin-1 and neuregulin-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; PHOSPHATIDYLINOSITOL 3-KINASE; CELLULAR-RESPONSE; FACTOR RECEPTOR; ERBB RECEPTORS; NEU; HEREGULIN; EXPRESSION; DISTINCT; LIGANDS	The neuregulins comprise a subfamily of epidermal growth factor (EGF)-like growth factors that elicit diverse cellular responses by activating members of the ErbB family of receptor tyrosine kinases. Although neuregulin-1 and neuregulin-2 are both binding ligands for the ErbB3 and ErbB4 receptors, they exhibit distinct biological activities depending on cellular context. In MDA-MB-468 human mammary tumor cells, neuregulin-2 beta (NRG2 beta) inhibits cell growth, whereas neuregulin-1 beta (NRG1 beta) does not. In these cells, NRG2 beta appears to preferentially act through the EGF receptor, stimulating receptor tyrosine phosphorylation and the recruitment of phospholipase C-gamma, Cbl, SHP2, and Shc to that receptor. NRG1 beta preferentially acts through ErbB3 in these cells by stimulating the tyrosine phosphorylation and recruitment of phosphatidylinositol 3-kinase and Shc to that receptor. In MDA-MB-453 cells, both NRG1 beta and NRG2 beta stimulate the tyrosine phosphorylation of the ErbB2 and ErbB3 receptors to similar extents, but only NRG1 beta potently stimulates morphological changes consistent with their differentiation. The profiles of SH2 domain-containing proteins that are efficiently recruited to activated receptors differ for the two factors. These observations indicate that despite their overlapping receptor specificity, the neuregulins exhibit distinct biological and biochemical properties, Since both of these cell lines express only two of the known ErbB receptors, our results imply that EGF-like ligands might elicit differential signaling within the context of a single receptor heterodimer.	Beth Israel Deaconess Med Ctr, Harvard Inst Med, Div Signal Transduct, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02215 USA; Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA 92037 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Scripps Research Institute	Carraway, KL (corresponding author), Beth Israel Deaconess Med Ctr, Harvard Inst Med, Div Signal Transduct, Rm 1018,330 Brookline Ave, Boston, MA 02215 USA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NATIONAL CANCER INSTITUTE [R01CA071702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890] Funding Source: NIH RePORTER; NCI NIH HHS [CA71702] Funding Source: Medline; NIGMS NIH HHS [GM18460, R01 GM041890] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACUS SS, 1993, CANCER RES, V53, P5251; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; BURGESS TL, 1995, J BIOL CHEM, V270, P19188, DOI 10.1074/jbc.270.32.19188; Busfield SJ, 1997, MOL CELL BIOL, V17, P4007, DOI 10.1128/MCB.17.7.4007; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; CARRAWAY KL, 1995, CURR OPIN NEUROBIOL, V5, P606, DOI 10.1016/0959-4388(95)80065-4; Carraway KL, 1996, BIOESSAYS, V18, P263, DOI 10.1002/bies.950180403; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Daly JM, 1997, CANCER RES, V57, P3804; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Higashiyama S, 1997, J BIOCHEM-TOKYO, V122, P675; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; Lemke G, 1996, MOL CELL NEUROSCI, V7, P247, DOI 10.1006/mcne.1996.0019; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; Meyer D, 1997, DEVELOPMENT, V124, P3575; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; Ozaki M, 1997, NATURE, V390, P691, DOI 10.1038/37795; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; Rio C, 1997, NEURON, V19, P39, DOI 10.1016/S0896-6273(00)80346-3; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Tzahar E, 1997, EMBO J, V16, P4938, DOI 10.1093/emboj/16.16.4938; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562	41	66	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26954	26961		10.1074/jbc.273.41.26954	http://dx.doi.org/10.1074/jbc.273.41.26954			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756944	hybrid			2022-12-27	WOS:000076373300098
J	Fujita, H; Kamiguchi, K; Cho, D; Shibanuma, M; Morimoto, C; Tachibana, K				Fujita, H; Kamiguchi, K; Cho, D; Shibanuma, M; Morimoto, C; Tachibana, K			Interaction of Hic-5, a senescence-related protein, with focal adhesion kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; BINDING-SITE; SH3 DOMAIN; V-CRK; PAXILLIN; VINCULIN; PP125(FAK); INTEGRINS	Hydrogen peroxide-inducible clone (Hic)-5 is induced during the senescent process in human fibroblasts, and the overexpression of Hic-5 induces a senescence-like phenotype. Structurally, Hic-5 and paxillin, a 68-kDa cytoskeletal protein, share homology such as the LD motifs in the N-terminal half and the LIM domains in the C-terminal half, Here we show that Hic-5 binds to focal adhesion kinase (FAR) by its N-terminal domain, and is localized to focal adhesions by its C-terminal LIM domains. However, Hic-5 is not tyrosine phosphorylated either by the coexpressed FAK in COS cells or by integrin stimulation in 293T cells. Furthermore, overexpression of Hic-5 results in a decreased tyrosine phosphorylation of paxillin. These findings suggest that putative functions of Hic-5 are the recruitment of FAK to focal adhesions and a competitive inhibition of tyrosine phosphorylation of paxillin.	Harvard Univ, Sch Med, Dept Med, Dana Farber Canc Inst,Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Showa Univ, Sch Pharmaceut Sci, Dept Microbiol, Shinagawa Ku, Tokyo 142, Japan; Univ Tokyo, Inst Med Sci, Dept Clin Immunol, Minato Ku, Tokyo, Japan; Univ Tokyo, Inst Med Sci, AIDS Res Ctr, Minato Ku, Tokyo, Japan	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Showa University; University of Tokyo; University of Tokyo	Tachibana, K (corresponding author), Harvard Univ, Sch Med, Dept Med, Dana Farber Canc Inst,Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA.				NIAID NIH HHS [AI29530] Funding Source: Medline; NIAMS NIH HHS [AR33713] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR033713] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; FELLER SM, 1995, ONCOGENE, V10, P1465; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Matsuya M, 1998, J BIOL CHEM, V273, P1003, DOI 10.1074/jbc.273.2.1003; MATSUYAMA T, 1989, J EXP MED, V170, P1133, DOI 10.1084/jem.170.4.1133; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Shibanuma M, 1997, MOL CELL BIOL, V17, P1224, DOI 10.1128/MCB.17.3.1224; SHIBANUMA M, 1994, J BIOL CHEM, V269, P26767; SHIMIZU Y, 1990, J IMMUNOL, V145, P59; SIMMON MA, 1991, CELL, V67, P701; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TURNER CE, 1994, J CELL SCI, V107, P1583; WOOD CK, 1994, J CELL SCI, V107, P709	39	79	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26516	26521		10.1074/jbc.273.41.26516	http://dx.doi.org/10.1074/jbc.273.41.26516			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756887	hybrid			2022-12-27	WOS:000076373300041
J	Huang, YD; Liu, XQ; Rall, SC; Taylor, JM; von Eckardstein, A; Assmann, G; Mahley, RW				Huang, YD; Liu, XQ; Rall, SC; Taylor, JM; von Eckardstein, A; Assmann, G; Mahley, RW			Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HEPARAN-SULFATE PROTEOGLYCANS; RECEPTOR-RELATED PROTEIN; FAMILIAL COMBINED HYPERLIPIDEMIA; CORONARY HEART-DISEASE; TRANSGENIC MICE; III HYPERLIPOPROTEINEMIA; LIPOLYTIC CONVERSION; E DEFICIENCY; APO-CIII	The molecular mechanisms of hypertriglyceridemia (HTG), a common lipid metabolic disorder in humans, often of genetic origin, are not well understood. In studying the effect of apolipoprotein (apo) E on the metabolism of triglyceride-rich lipoproteins, we found that expressing high plasma levels of human apoE3 in transgenic mice lacking endogenous mouse apoE caused HTG. These transgenic animals had 3-fold higher plasma triglyceride levels, higher very law density lipoproteins (VLDL), and lower high density lipoproteins than did non-transgenics, Removing one or both low density lipoprotein receptor alleles in the apoE3-overexpressing mice caused severe HTG (8-11-fold over nontransgenics) and increased VLDL and decreased low and high density lipoproteins, and apoE3-enriched VLDL were markedly depleted in apoC-II. At least two mechanisms could explain HTG associated with apoE3 overexpression: stimulated VLDL triglyceride production and impaired VLDL lipolysis. The apoE3 mice with HTG had a 50% increase in hepatic VLDL triglyceride production. Furthermore, overexpression of apoE (E2, E3, or E4) in cultured hepatocytes (McA-RH7777 cells) correlated positively with secretion of VLDL into the medium. However, apoE3 overexpression-associated HTG was only partially explained by VLDL overproduction, as lipoprotein lipase-mediated VLDL lipolysis was also decreased 20-86% depending on apoE3 levels, most likely by displacing or masking apoC-II on the particles. In human subjects, HTG correlated positively with increased VLDL triglyceride and plasma and VLDL apoE levels. However, plasma and VLDL apoE correlated negatively with VLDL apoC-II levels and lipoprotein lipase-mediated VLDL lipolysis. Thus, optimal expression of apoE is crucial for normal metabolism of triglyceride-rich lipoproteins, and overexpression and/or accumulation of apoE may contribute to ATG by stimulating VLDL triglyceride production and by impairing VLDL lipolysis. The apoE3-overexpressing mice will be useful for studying the pathophysiology of this disorder.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94141 USA; Univ Munster, Inst Arteriosclerosis Res, D-48129 Munster, Germany	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Munster	Mahley, RW (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.				NHLBI NIH HHS [HL47660] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047660] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; Assmann G, 1996, AM J CARDIOL, V77, P1179, DOI 10.1016/S0002-9149(96)00159-2; BRUNZELL JD, 1983, J LIPID RES, V24, P147; BRUNZELL JD, 1976, METABOLISM, V25, P313, DOI 10.1016/0026-0495(76)90089-5; CHAIT A, 1978, METABOLISM, V27, P1055, DOI 10.1016/0026-0495(78)90151-8; CHAIT A, 1980, EUR J CLIN INVEST, V10, P17, DOI 10.1111/j.1365-2362.1980.tb00004.x; CHAIT A, 1977, LANCET, V1, P1176; CHUNG BH, 1983, J LIPID RES, V24, P1148; Cohn JS, 1996, ARTERIOSCL THROM VAS, V16, P149, DOI 10.1161/01.ATV.16.1.149; CONNELLY PW, 1994, J BIOL CHEM, V269, P20554; DESILVA HV, 1994, J LIPID RES, V35, P1297; DESILVA HV, 1994, J BIOL CHEM, V269, P2324; EHNHOLM C, 1984, P NATL ACAD SCI-BIOL, V81, P5566, DOI 10.1073/pnas.81.17.5566; EISENBERG S, 1984, J LIPID RES, V25, P1017; FAZIO S, 1992, J BIOL CHEM, V267, P6941; FAZIO S, 1993, J CLIN INVEST, V92, P1497, DOI 10.1172/JCI116728; Fredrickson D. S., 1978, METABOLIC BASIS INHE, P604; GOLDSTEIN JL, 1973, J CLIN INVEST, V52, P1544, DOI 10.1172/JCI107332; GOMEZCORONADO D, 1993, BIOCHIM BIOPHYS ACTA, V1167, P70, DOI 10.1016/0005-2760(93)90219-Y; HAVEL RJ, 1970, J CLIN INVEST, V49, P2017, DOI 10.1172/JCI106422; HORIE Y, 1992, J BIOL CHEM, V267, P1962; HOSPATTANKAR AV, 1984, J BIOL CHEM, V259, P318; Huang Y, 1997, ARTERIOSCL THROM VAS, V17, P2817, DOI 10.1161/01.ATV.17.11.2817; Huang YD, 1998, J BIOL CHEM, V273, P17483, DOI 10.1074/jbc.273.28.17483; Huang YD, 1996, J BIOL CHEM, V271, P29146, DOI 10.1074/jbc.271.46.29146; HUIPERS F, 1997, J CLIN INVEST, V100, P2915; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; JI ZS, 1994, J BIOL CHEM, V269, P2764; JI ZS, 1993, J BIOL CHEM, V268, P10160; KASHYAP ML, 1977, J CLIN INVEST, V60, P171, DOI 10.1172/JCI108753; MABUCHI H, 1989, METABOLISM, V38, P115, DOI 10.1016/0026-0495(89)90249-7; MAHLEY RW, 1994, ANN NY ACAD SCI, V737, P39, DOI 10.1111/j.1749-6632.1994.tb44300.x; Mahley RW, 1996, ISRAEL J MED SCI, V32, P414; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1995, METABOLIC MOL BASES, P1953; MasucciMagoulas L, 1997, SCIENCE, V275, P391, DOI 10.1126/science.275.5298.391; Nikkila E A, 1974, Horm Metab Res, VSuppl 4, P29; NIKKILA EA, 1973, LANCET, V1, P954; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Rensen PCN, 1996, J BIOL CHEM, V271, P14791, DOI 10.1074/jbc.271.25.14791; Salah D, 1997, J LIPID RES, V38, P904; SCHAEFER EJ, 1986, J CLIN INVEST, V78, P1206, DOI 10.1172/JCI112704; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; WEISGRABER KH, 1990, J BIOL CHEM, V265, P22453; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	45	169	175	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26388	26393		10.1074/jbc.273.41.26388	http://dx.doi.org/10.1074/jbc.273.41.26388			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756870	hybrid			2022-12-27	WOS:000076373300024
J	Moreland, RJ; Hanas, JS; Conaway, JW; Conaway, RC				Moreland, RJ; Hanas, JS; Conaway, JW; Conaway, RC			Mechanism of action of RNA polymerase II elongation factor elongin - Maximal stimulation of elongation requires conversion of the early elongation complex to an elongin-activable form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-SIII; RIBONUCLEIC-ACID POLYMERASE; TUMOR-SUPPRESSOR PROTEIN; INITIATION FACTOR-ALPHA; MAJOR LATE PROMOTER; TERNARY COMPLEXES; ABORTIVE INITIATION; ESCHERICHIA-COLI; CHAIN ELONGATION; FUNCTIONAL-PROPERTIES	We previously identified and purified Elongin by its ability to stimulate the rate of elongation by RNA polymerase II in vitro (Bradsher, J. N., Jackson, K. W., Conaway, R. C., and Conaway, J. W. (1993) J. Biol. Chem. 268, 25587-25593), in this report, we present evidence that stimulation of elongation by Elongin requires that the early RNA polymerase II elongation complex undergoes conversion to an Elongin-activable form. We observe (i) that Elongin does not detectably stimulate the rate of promoter-specific transcription initiation by the fully assembled preinitiation complex and (ii) that early RNA polymerase II elongation intermediates first become susceptible to stimulation by Elongin after synthesizing 8-9-nucleotide-long transcripts. Furthermore, we show that the relative inability of Elongin to stimulate elongation by early elongation intermediates correlates not with the lengths of their associated transcripts but, instead, with the presence of transcription factor IIF (TFIIF) in transcription reactions. By exploiting adenovirus 2 major late promoter derivatives that contain premelted transcriptional start sites and do not require TFIIF, TFIIE, or TFIIH for transcription initiation, rye observe (i) that Elongin is capable of strongly stimulating the rate of synthesis of trinucleotide transcripts by a subcomplex of RNA polymerase II, TBP, and TFIIB and (ii) that the ability of Elongin to stimulate synthesis of these short transcripts is substantially reduced by addition of TFIIF to transcription reactions. Here we present these findings, which are consistent with the model that maximal stimulation of elongation by Elongin requires that early elongation intermediates undergo a structural transition that includes loss of TFIIF.	Oklahoma Med Res Fdn, Program Mol & Cell Biol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; Howard Hughes Med Inst, Oklahoma City, OK 73104 USA	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; Howard Hughes Medical Institute	Conaway, RC (corresponding author), Oklahoma Med Res Fdn, Program Mol & Cell Biol, Oklahoma City, OK 73104 USA.			Conaway, Joan/0000-0002-2786-0663; Hanas, Jay/0000-0003-1922-5333	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041628, R37GM041628] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41628] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aso T, 1996, EMBO J, V15, P5557, DOI 10.1002/j.1460-2075.1996.tb00940.x; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BRADSHER JN, 1993, J BIOL CHEM, V268, P25594; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CHAMBERLIN MJ, 1995, HARVEY LECT, V88, P1; CONAWAY JW, 1993, CELL MOL BIOL RES, V39, P323; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; CONAWAY JW, 1998, BIOCHIM BIOPHYS ACTA, V1337, pM47; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; Dvir A, 1997, P NATL ACAD SCI USA, V94, P9006, DOI 10.1073/pnas.94.17.9006; Dvir A, 1996, J BIOL CHEM, V271, P7245, DOI 10.1074/jbc.271.13.7245; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; GARRETT KP, 1994, P NATL ACAD SCI USA, V91, P5237, DOI 10.1073/pnas.91.12.5237; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; Gnarra JR, 1996, BBA-REV CANCER, V1242, P201, DOI 10.1016/0304-419X(95)00012-5; GREENBLATT J, 1981, CELL, V24, P421, DOI 10.1016/0092-8674(81)90332-9; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; Gu WG, 1996, P NATL ACAD SCI USA, V93, P6935, DOI 10.1073/pnas.93.14.6935; GU WG, 1995, J BIOL CHEM, V270, P11238, DOI 10.1074/jbc.270.19.11238; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; JACOB GA, 1991, J BIOL CHEM, V266, P22537; JIANG Y, 1995, J BIOL CHEM, V270, P27332, DOI 10.1074/jbc.270.45.27332; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; LAVIALLE C, 1982, J BIOL CHEM, V257, P2458; LEWIS MK, 1982, ENZYMES, V15, P109; LUSE DS, 1987, J BIOL CHEM, V262, P14990; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; MCCLURE WR, 1978, J BIOL CHEM, V253, P8941; PAN GH, 1994, J BIOL CHEM, V269, P30101; PETERSON MG, 1991, NATURE, V354, P369; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; Reeder TC, 1996, CELL, V87, P767, DOI 10.1016/S0092-8674(00)81395-1; REINES D, 1992, J BIOL CHEM, V267, P3795; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; REINES D, 1991, J BIOL CHEM, V266, P10510; RHODES G, 1974, J BIOL CHEM, V249, P6675; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P8057, DOI 10.1073/pnas.91.17.8057; Sambrook J., 2002, MOL CLONING LAB MANU; SAMUELS M, 1984, J BIOL CHEM, V259, P2517; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; Selby CP, 1997, P NATL ACAD SCI USA, V94, P11205, DOI 10.1073/pnas.94.21.11205; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; Shilatifard A, 1997, P NATL ACAD SCI USA, V94, P3639, DOI 10.1073/pnas.94.8.3639; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; TAKAGI Y, 1995, J BIOL CHEM, V270, P24300, DOI 10.1074/jbc.270.41.24300; Takagi Y, 1996, J BIOL CHEM, V271, P25562, DOI 10.1074/jbc.271.41.25562; TAN SY, 1994, J BIOL CHEM, V269, P25684; TAN SY, 1994, BIOTECHNIQUES, V16, P824; TAN SY, 1995, P NATL ACAD SCI USA, V92, P6042, DOI 10.1073/pnas.92.13.6042; THUMMEL CS, 1990, CELL, V61, P101, DOI 10.1016/0092-8674(90)90218-4; TIMMERS HTM, 1994, EMBO J, V13, P391, DOI 10.1002/j.1460-2075.1994.tb06273.x; TSUBOI A, 1992, NUCLEIC ACIDS RES, V20, P3250, DOI 10.1093/nar/20.12.3250; UCKER DS, 1984, J BIOL CHEM, V259, P7416; VONHIPPEL PH, 1991, P NATL ACAD SCI USA, V88, P2307, DOI 10.1073/pnas.88.6.2307; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479	64	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26610	26617		10.1074/jbc.273.41.26610	http://dx.doi.org/10.1074/jbc.273.41.26610			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756900	hybrid			2022-12-27	WOS:000076373300054
J	Hourcade, DE; Mitchell, LM; Oglesby, TJ				Hourcade, DE; Mitchell, LM; Oglesby, TJ			A conserved element in the serine protease domain of complement factor B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; MOLECULAR-CLONING; SURFACE LOOPS; COMPONENT C2; BINDING-SITE; GENE; TRYPSIN; MHC; CHYMOTRYPSIN	Factor B and C2 are serine proteases that carry the catalytic sites of the complement C3 and C5 convertases. Their protease domains are activated by conformational changes that occur during convertase assembly and are deactivated upon convertase dissociation. Factor B and C2 share an 8-amino acid conserved sequence near their serine protease termini that is not seen in other serine proteases. To determine its importance, 24 factor B mutants were generated, each with a single amino acid substitution in this region. Whereas most mutants were functionally neutral, all five different substitutions of aspartic acid 715 and one phenylalanine 716 substitution severely reduced hemolytic activity. Several aspartic acid 715 mutants permitted the steps of convertase assembly including C3b-dependent factor D-mediated cleavage and activation of the high affinity C3b-binding site, but the resulting complexes did not cleave C3. Given that factor B and C2 share the same biological substrates and that part of the trypsin-like substrate specificity region is not apparent in either protein, we propose that the conserved region plays a critical role in the conformational regulation of the catalytic site and could offer a highly specific target for the therapeutic inhibition of complement.	Washington Univ, Sch Med, Div Rheumatol, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL)	Hourcade, DE (corresponding author), Washington Univ, Sch Med, Div Rheumatol, Dept Med, 660 S Euclid,Box 8045, St Louis, MO 63110 USA.	dhourcad@im.wustl.edu						BENTLEY DR, 1986, BIOCHEM J, V239, P339, DOI 10.1042/bj2390339; BROWN JR, 1966, BIOCHEM J, V101, P214, DOI 10.1042/bj1010214; CAMPBELL RD, 1983, P NATL ACAD SCI-BIOL, V80, P4464, DOI 10.1073/pnas.80.14.4464; Carroll MC, 1998, ANNU REV IMMUNOL, V16, P545, DOI 10.1146/annurev.immunol.16.1.545; COLOMBATTI A, 1991, BLOOD, V77, P2305; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; FEHLHAMMER H, 1977, J MOL BIOL, V111, P415, DOI 10.1016/S0022-2836(77)80062-4; FREER ST, 1970, BIOCHEMISTRY-US, V9, P1997, DOI 10.1021/bi00811a022; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; HORIUCHI T, 1991, J IMMUNOL, V147, P584; HOURCADE DE, 1995, J BIOL CHEM, V270, P19716, DOI 10.1074/jbc.270.34.19716; ISHIKAWA N, 1990, J BIOL CHEM, V265, P19040; KAM CM, 1987, J BIOL CHEM, V262, P3444; KATO Y, 1994, J IMMUNOL, V153, P4546; KRISTENSEN T, 1987, FASEB J, V46, P2463; Kuroda N, 1996, IMMUNOGENETICS, V44, P459, DOI 10.1007/BF02602808; LACHMANN PJ, 1975, CLIN EXP IMMUNOL, V21, P109; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; MOLE JE, 1984, J BIOL CHEM, V259, P3407; NONAKA M, 1994, J IMMUNOL, V152, P2263; PERKINS SJ, 1993, BIOCHEM J, V295, P109, DOI 10.1042/bj2950109; PEROS JP, 1995, VITIS, V34, P189; POLLEY MJ, 1967, J EXP MED, V126, P1013, DOI 10.1084/jem.126.6.1013; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; Seeger A, 1996, MOL IMMUNOL, V33, P511, DOI 10.1016/0161-5890(96)00002-8; SMITH CA, 1984, J EXP MED, V159, P324, DOI 10.1084/jem.159.1.324; TITANI K, 1975, BIOCHEMISTRY-US, V14, P1358, DOI 10.1021/bi00678a003; Tuckwell DS, 1997, BIOCHEMISTRY-US, V36, P6605, DOI 10.1021/bi963155l; UEDA A, 1987, J IMMUNOL, V138, P1143; Volanakis J., 1998, COMPLEMENT ENZYMES H, P49; Volanakis JE, 1998, HUMAN COMPLEMENT SYS, V20, P9, DOI DOI 10.1201/B14212-3	34	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25996	26000		10.1074/jbc.273.40.25996	http://dx.doi.org/10.1074/jbc.273.40.25996			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748277	hybrid			2022-12-27	WOS:000076263100068
J	Sawado, T; Hirose, F; Takahashi, Y; Sasaki, T; Shinomiya, T; Sakaguchi, K; Matsukage, A; Yamaguchi, M				Sawado, T; Hirose, F; Takahashi, Y; Sasaki, T; Shinomiya, T; Sakaguchi, K; Matsukage, A; Yamaguchi, M			The DNA replication-related element (DRE)/DRE-binding factor system is a transcriptional regulator of the Drosophila E2F gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; GROWTH-REGULATION; HOMEODOMAIN PROTEINS; POLYMERASE-ALPHA; FACTOR DREF; PROMOTER; EXPRESSION; BINDING; CYCLE; TRANSACTIVATION	Two mRNA species were observed for the Drosophila E2F (dE2F) gene, differing with regard to the first exons (exon I-a and exon 1-b), which were expressed differently during development. A single transcription initiation site for mRNA containing exon 1-b was mapped by primer extension analysis and numbered +1, We found three tandemly aligned sequences, similar 60 the DNA replication-related element (DRE; 5'-TATCGATA), which is commonly required for transcription of genes related to DNA replication and cell proliferation, in the region upstream of this site. Band mobility shift analyses using oligonucleotides containing the DRE-related sequences with or without various base substitutions revealed that two out of three DRE-related sequences are especially important for binding to the DRE-binding factor (DREF). On footprinting analysis with Kc cell nuclear extracts and a glutathione S-transferase fusion protein with the N-terminal fragment (1-125 amino acid residues) of DREF, all three DRE-related sequences were found to be protected. Transient luciferase expression assays in Kc cells demonstrated that the region containing the three DRE-related sequences is required for high promoter activity. We have established transgenic lines of Drosophila in which ectopic expression of DREF was targeted to the eye imaginal disc cells. Overexpression of DREF in eye imaginal disc cells enhanced the promoter activity of dE2F. The obtained results indicate that the DRE/DRBF system activates transcription of the dE2F gene.	Aichi Canc Ctr, Res Inst, Cell Biol Lab, Aichi 4648681, Japan; Sci Univ Tokyo, Fac Sci & Technol, Dept Appl Biol Sci, Chiba 2780022, Japan; Mitsubishi Kasei Inst Life Sci, Tokoyo 1948511, Japan	Aichi Cancer Center; Tokyo University of Science	Yamaguchi, M (corresponding author), Aichi Canc Ctr, Res Inst, Cell Biol Lab, Aichi 4648681, Japan.			Hirose, Fumiko/0000-0003-4586-4892; Yamaguchi, Masamitsu/0000-0002-6321-9750				BONDMATTHEWS B, 1988, GENE, V62, P289, DOI 10.1016/0378-1119(88)90566-5; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brook A, 1996, EMBO J, V15, P3676, DOI 10.1002/j.1460-2075.1996.tb00737.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSS DP, 1978, J EMBRYOL EXP MORPH, V45, P161; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Du W, 1996, GENE DEV, V10, P1206, DOI 10.1101/gad.10.10.1206; DURONIO RJ, 1994, DEVELOPMENT, V120, P1503; Duronio RJ, 1998, MOL CELL BIOL, V18, P141, DOI 10.1128/MCB.18.1.141; DURONIO RJ, 1995, GENE DEV, V9, P1445, DOI 10.1101/gad.9.12.1445; DYNLACHT BD, 1994, P NATL ACAD SCI USA, V91, P6359, DOI 10.1073/pnas.91.14.6359; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; Hayashi Y, 1997, J BIOL CHEM, V272, P22848, DOI 10.1074/jbc.272.36.22848; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; HIROSE F, 1991, NUCLEIC ACIDS RES, V19, P4991, DOI 10.1093/nar/19.18.4991; Hirose F, 1996, J BIOL CHEM, V271, P3930; HIROSE F, 1993, J BIOL CHEM, V268, P2092; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; LIGHTFOOT K, 1994, BRIT J CANCER, V69, P264, DOI 10.1038/bjc.1994.50; LUCKOW VA, 1993, J VIROL, V67, P4566, DOI 10.1128/JVI.67.8.4566-4579.1993; Morkel M, 1997, NATURE, V390, P567, DOI 10.1038/37507; NEUMAN E, 1995, MOL CELL BIOL, V15, P4660; Ohno K, 1996, NUCLEIC ACIDS RES, V24, P3942, DOI 10.1093/nar/24.20.3942; OHTANI K, 1994, MOL CELL BIOL, V14, P1603, DOI 10.1128/MCB.14.3.1603; ROBERTSON HM, 1988, GENETICS, V118, P461; Royzman I, 1997, GENE DEV, V11, P1999, DOI 10.1101/gad.11.15.1999; Ryu JR, 1997, NUCLEIC ACIDS RES, V25, P794, DOI 10.1093/nar/25.4.794; Sambrook J., 2002, MOL CLONING LAB MANU; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Seum C, 1996, DEVELOPMENT, V122, P1949; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Spradling A. C, 1986, DROSOPHILA PRACTICAL; Takahashi Y, 1996, J BIOL CHEM, V271, P14541, DOI 10.1074/jbc.271.24.14541; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; vanGinkel PR, 1997, J BIOL CHEM, V272, P18367, DOI 10.1074/jbc.272.29.18367; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; YAMAGUCHI M, 1990, MOL CELL BIOL, V10, P872, DOI 10.1128/MCB.10.3.872; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P15808, DOI 10.1074/jbc.270.26.15808; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P25159, DOI 10.1074/jbc.270.42.25159; Yamaguchi M, 1996, GENES CELLS, V1, P47, DOI 10.1046/j.1365-2443.1996.03003.x	44	78	79	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26042	26051		10.1074/jbc.273.40.26042	http://dx.doi.org/10.1074/jbc.273.40.26042			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748283	hybrid			2022-12-27	WOS:000076263100074
J	Roscher, A; Emsley, L; Raymond, P; Roby, C				Roscher, A; Emsley, L; Raymond, P; Roby, C			Unidirectional steady state rates of central metabolism enzymes measured simultaneously in a living plant tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAIZE ROOT-TIPS; NUCLEAR MAGNETIC-RESONANCE; NMR EXCHANGE SPECTROSCOPY; CARBOHYDRATE-METABOLISM; SUCROSE; GROWTH; RESPIRATION; INVIVO; PYROPHOSPHATE; SEEDLINGS	The unidirectional steady state reaction rates of several enzymes and metabolic fluxes of distinct processes were measured simultaneously in hypoxic maize root tips using two-dimensional phosphorus NMR exchange spectroscopy. A single spectrum monitors ATP synthesis and hydrolysis as well as the activities of four enzymes involved in key pathways of central metabolism: UDP-glucose pyrophosphorylase, phosphoglucomutase, hexose-phosphate isomerase, and enolase, The corresponding unidirectional reaction rates and net metabolic fluxes were calculated from spectral intensities. This method provides a unique picture, at enzyme resolution, of how metabolism reacts in a concerted fashion to changes in external parameters such as temperature and oxygen concentration, By increasing hypoxia via an increase in temperature, we measured the expected increase in glycolysis through enolase activity while total ATP synthesis settled. At the same time, we observed a net flux through phosphoglucomutase and UDP-glucose pyrophosphorylase toward carbohydrate synthesis. This result is discussed in relation to the current hypothesis on the turnover of cell walls and sucrose. This reaction also produces a net flux of pyrophosphate, which is needed by pyrophosphate:fructose-6-phosphate 1-phosphotransferase to work as a glycolytic enzyme.	CEA, Lab Resonance Magnet Biol Metab, F-38054 Grenoble 9, France; Univ Grenoble 1, F-38054 Grenoble 9, France; Ecole Normale Super Lyon, Lab Stereochim & Interact Mol, F-69364 Lyon 07, France; INRA, Stn Physiol Vegetale, F-33883 Villenave Dornon, France	CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Ecole Normale Superieure de Lyon (ENS de LYON); INRAE	Roby, C (corresponding author), CEA, Lab DBMS RMBM, 17 Rue Martyrs, F-38054 Grenoble 9, France.	roby@cea.fr	Emsley, Lyndon/AAS-6384-2020; Roscher, Albrecht/AGZ-4644-2022; Emsley, Lyndon/C-6108-2008	Emsley, Lyndon/0000-0003-1360-2572; Emsley, Lyndon/0000-0003-1360-2572; Roscher, Albrecht/0000-0003-2597-367X				ABEL EW, 1986, J MAGN RESON, V70, P34, DOI 10.1016/0022-2364(86)90361-6; ALGER JR, 1984, Q REV BIOPHYS, V17, P83, DOI 10.1017/S0033583500005266; Ap Rees T., 1994, Plant Cell and Environment, V17, P587, DOI 10.1111/j.1365-3040.1994.tb00151.x; ATWELL BJ, 1985, PLANT CELL ENVIRON, V8, P179, DOI 10.1111/1365-3040.ep11604603; BAILEY JE, 1991, SCIENCE, V252, P1668, DOI 10.1126/science.2047876; BALABAN RS, 1983, J BIOL CHEM, V258, P2787; Bouny JM, 1996, PLANT PHYSIOL, V111, P187, DOI 10.1104/pp.111.1.187; BRETHARTE MS, 1994, PLANT PHYSIOL, V105, P19, DOI 10.1104/pp.105.1.19; BRINDLE KM, 1988, PROG NUCL MAG RES SP, V20, P257, DOI 10.1016/0079-6565(88)80003-7; CARPITA NC, 1993, PLANT J, V3, P1, DOI 10.1111/j.1365-313X.1993.tb00007.x; DANCER JE, 1989, J PLANT PHYSIOL, V135, P197, DOI 10.1016/S0176-1617(89)80177-4; Dennis D.T., 1997, PLANT METABOLISM, P181; DENNIS DT, 1997, PLANT METABOLISM, P105; DENNIS DT, 1987, BIOCH ENERGY UTILIZA; DIEUAIDENOUBHANI M, 1995, J BIOL CHEM, V270, P13147, DOI 10.1074/jbc.270.22.13147; Douce R., 1985, MITOCHONDRIA HIGHER; Drew MC, 1997, ANNU REV PLANT PHYS, V48, P223, DOI 10.1146/annurev.arplant.48.1.223; ERNST RR, 1987, PRINCIPLES NMR ONE 2, P495; FELL DA, 1997, UNDERSTANDING CONTRO, pCH1; GARLICK PB, 1983, J MAGN RESON, V51, P536, DOI 10.1016/0022-2364(83)90306-2; GEIGENBERGER P, 1991, PLANTA, V185, P81, DOI 10.1007/BF00194518; GEIGENBERGER P, 1993, PLANTA, V189, P329, DOI 10.1007/BF00194429; GIBEAUT DM, 1991, PLANT PHYSIOL, V97, P551, DOI 10.1104/pp.97.2.551; Gillies RF, 1994, NMR PHYSL BIOMEDICIN; GUPTA RK, 1987, NMR SPECTROSCOPY CEL; HARGREAVES JA, 1988, PHYTOCHEMISTRY, V27, P1627, DOI 10.1016/0031-9422(88)80416-3; HATFIELD PM, 1997, PLANT METABOLISM, P26; HEINRICH R, 1996, REGULATION CELLULAR, P38; HILL SA, 1994, PLANTA, V192, P52, DOI 10.1007/BF00198692; HOCHACHKA PW, 1984, BIOCH ADAPTATION, P8; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Kacser H, 1987, BIOCH PLANTS, P39; KESSLER H, 1984, J MAGN RESON, V57, P331, DOI 10.1016/0022-2364(84)90136-7; KO K, 1997, PLANT METABOLISM, P17; KOCK M, 1994, ANGEW CHEM INT EDIT, V33, P332, DOI 10.1002/anie.199403321; KRUGER NJ, 1997, PLANT METABOLISM, P83; Kuchel P W, 1990, NMR Biomed, V3, P102, DOI 10.1002/nbm.1940030303; Larcher W., 1995, PHYSL PLANT ECOLOGY, P321, DOI [10.1007/978-3-642-87851-0_6, DOI 10.1007/978-3-642-87851-0_6]; LEFEBVRE DD, 1997, PLANT METABOLISM, P3; MCCONNELL HM, 1958, J CHEM PHYS, V28, P430, DOI 10.1063/1.1744152; MOHANTY B, 1993, PHYTOCHEMISTRY, V34, P75, DOI 10.1016/S0031-9422(00)90785-4; PFEFFER PE, 1989, NMR AGR; Plaxton W.C., 1997, PLANT METABOLISM, P50; Plaxton WC, 1996, ANNU REV PLANT PHYS, V47, P185, DOI 10.1146/annurev.arplant.47.1.185; RATCLIFFE RG, 1996, NUCL MAGNETIC RESONA, P1; REICH JG, 1981, ENERGY METABOLISM CE, P147; ROBERTS JKM, 1984, PLANT PHYSIOL, V74, P632, DOI 10.1104/pp.74.3.632; ROBERTS JKM, 1990, BIOCHIM BIOPHYS ACTA, V1051, P29, DOI 10.1016/0167-4889(90)90170-I; ROBERTS JKM, 1986, MOD METHOD PLANT, V2, P43; ROBY C, 1987, J BIOL CHEM, V262, P5000; ROSCHER A, 1997, THESIS J FOURIER U G; SAGLIO PH, 1984, PLANT PHYSIOL, V76, P151, DOI 10.1104/pp.76.1.151; SAINTGES V, 1991, EUR J BIOCHEM, V200, P477, DOI 10.1111/j.1432-1033.1991.tb16207.x; SALISBURY FB, 1992, PLANT PHYSIOL, P267; Smirnoff N., 1995, ENV PLANT METABOLISM; STEPHANOPOULOS G, 1991, SCIENCE, V252, P1675, DOI 10.1126/science.1904627; STITT M, 1990, ANNU REV PLANT PHYS, V41, P153, DOI 10.1146/annurev.pp.41.060190.001101; SUNG SJS, 1988, PHYSIOL PLANTARUM, V72, P650, DOI 10.1111/j.1399-3054.1988.tb09177.x; Taiz L., 1991, PLANT PHYSIOL, P265; Tofts P S, 1988, NMR Biomed, V1, P1, DOI 10.1002/nbm.1940010103; Viola R, 1996, PLANTA, V198, P179, DOI 10.1007/BF00206242; WEINER H, 1987, BIOCHIM BIOPHYS ACTA, V893, P13, DOI 10.1016/0005-2728(87)90143-5; WENDLER R, 1991, PLANTA, V183, P31, DOI 10.1007/BF00197564	64	39	40	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25053	25061		10.1074/jbc.273.39.25053	http://dx.doi.org/10.1074/jbc.273.39.25053			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737962	hybrid, Green Published			2022-12-27	WOS:000076085400012
J	Spicer, AP; Kaback, LA; Smith, TJ; Seldin, MF				Spicer, AP; Kaback, LA; Smith, TJ; Seldin, MF			Molecular cloning and characterization of the human and mouse UDP-glucose dehydrogenase genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URIDINE DIPHOSPHOGLUCOSE DEHYDROGENASE; HUMAN-SKIN FIBROBLASTS; HYALURONAN SYNTHASE; BOVINE LIVER; GLYCOSAMINOGLYCAN SYNTHESIS; CHROMOSOMAL LOCALIZATION; CONNECTIVE-TISSUE; SUGAR METABOLISM; BIOSYNTHESIS; STIMULATION	The enzyme UDP-glucose dehydrogenase (Udpgdh) (EC 1.1.1.22) converts UDP-glucose to UDP-glucuronate, a critical component of the glycosaminoglycans, hyaluronan, chondroitin sulfate, and heparan sulfate. Although Udpgdh is a comparatively well characterized enzyme, no vertebrate genes encoding this enzyme have been reported to date. We report the cloning and characterization of the human and mouse UDP-glucose dehydrogenase genes. Mouse and human cDNAs predicted proteins of 493 and 494 amino acids, 24-25 residues longer at their carboxyl termini than the previously reported bovine Udpgdh sequence. The mouse Ugdh gene is composed of 10 exons, spanning 15 kilobases, Northern analyses indicated widespread expression of the gene in embryo and adult, Through interspecific backcross analyses, we localized the Ugdh gene to mouse chromosome 5 at approximately 39 centimorgans, suggesting that the human UGDH gene is localized to chromosome 4p13-15. Results from Southern analyses strongly suggest that Udpgdh is encoded by a single gene in the mouse. Transfection of mouse Ugdh expression vectors led to an increase in detectable Udpgdh activity in mammalian cells. Preliminary expression studies indicated that proinflammatory cytokines, such as interleukin Ip, can substantially increase the expression of human UGDH in cultured human fibroblasts, suggesting that glycosaminoglycan biosynthesis may be partly regulated by the availability of activated UDP-glucuronate, as determined by relative Udpgdh expression levels.	Univ Calif Davis, Sch Med, Dept Biol Chem, Rowe Program Human Genet & Mol Med, Davis, CA 95616 USA; Albany Med Coll, Dept Med, Div Mol & Cellular Med, Albany, NY 12208 USA; Albany Med Coll, Dept Biochem & Mol Biol, Albany, NY 12208 USA; Samuel S Stratton Vet Affairs Med Ctr, Albany, NY 12208 USA	University of California System; University of California Davis; Albany Medical College; Albany Medical College	Spicer, AP (corresponding author), Univ Calif Davis, Sch Med, Dept Biol Chem, Rowe Program Human Genet & Mol Med, Tupper Hall, Davis, CA 95616 USA.	apspicer@ucdavis.edu	Smith, Terry/ABG-1360-2020	Smith, Terry/0000-0002-6279-9685	NEI NIH HHS [EY11708, EY08976] Funding Source: Medline; NHGRI NIH HHS [HG00734] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008976, R01EY011708] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000734] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Binari RC, 1997, DEVELOPMENT, V124, P2623; BISHOP D T, 1985, Genetic Epidemiology, V2, P349, DOI 10.1002/gepi.1370020404; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DeBry RW, 1996, GENOMICS, V33, P337, DOI 10.1006/geno.1996.0209; DOUGHERTY BA, 1993, J BIOL CHEM, V268, P7118; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRANZEN JS, 1980, BIOCHEMISTRY-US, V19, P6080, DOI 10.1021/bi00567a021; GAINEY PA, 1972, BIOCHEM J, V128, P215, DOI 10.1042/bj1280215; GAINEY PA, 1975, BIOCHEM J, V145, P129, DOI 10.1042/bj1450129; Green EL, 1981, GENETICS PROBABILITY, P77; GRUBB MF, 1993, BIOCHEM MOL BIOL INT, V30, P819; Hacker U, 1997, DEVELOPMENT, V124, P3565; Haerry TE, 1997, DEVELOPMENT, V124, P3055; HANDLEY CJ, 1972, BIOCHEM J, V127, P911, DOI 10.1042/bj1270911; HEMPEL J, 1994, PROTEIN SCI, V3, P1074, DOI 10.1002/pro.5560030710; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; JAENICKE R, 1986, BIOCHEMISTRY-US, V25, P7283, DOI 10.1021/bi00371a006; JANSEN PLM, 1992, HEPATOLOGY, V15, P532, DOI 10.1002/hep.1840150328; KLEWES L, 1994, J CELL PHYSIOL, V160, P539, DOI 10.1002/jcp.1041600317; KORNFELD R, 1980, BIOCH GLYCOPROTEINS; LAURENT TC, 1998, CHEM BIOL MED APPL H, V72; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; PEROZICH J, 1995, ADV EXP MED BIOL, V372, P79; Pummill PE, 1998, J BIOL CHEM, V273, P4976, DOI 10.1074/jbc.273.9.4976; SELDIN MF, 1988, J EXP MED, V167, P688, DOI 10.1084/jem.167.2.688; SMITH TJ, 1989, ENDOCR REV, V10, P366, DOI 10.1210/edrv-10-3-366; SMITH TJ, 1995, AM J PHYSIOL-CELL PH, V268, pC382, DOI 10.1152/ajpcell.1995.268.2.C382; SMITH TJ, 1984, J CLIN INVEST, V74, P2157, DOI 10.1172/JCI111642; SMITH TJ, 1991, J CLIN ENDOCR METAB, V72, P1169, DOI 10.1210/jcem-72-5-1169; SMITH TJ, 1988, METABOLISM, V37, P179, DOI 10.1016/S0026-0495(98)90015-4; Spicer AP, 1997, GENOMICS, V41, P493, DOI 10.1006/geno.1997.4696; Spicer AP, 1998, J BIOL CHEM, V273, P1923, DOI 10.1074/jbc.273.4.1923; SPICER AP, 1995, J IMMUNOL, V155, P3079; Spicer AP, 1996, J BIOL CHEM, V271, P23400, DOI 10.1074/jbc.271.38.23400; Spicer AP, 1997, J BIOL CHEM, V272, P8957; STROMINGER JL, 1954, J AM CHEM SOC, V76, P6411, DOI 10.1021/ja01653a051; SUZUKI M, 1995, BIOCHEM J, V307, P817, DOI 10.1042/bj3070817; SWEENEY C, 1993, BIOCHEM J, V290, P563, DOI 10.1042/bj2900563; Tenhaken R, 1996, PLANT PHYSIOL, V112, P1127, DOI 10.1104/pp.112.3.1127; Wang HS, 1996, J BIOL CHEM, V271, P22718, DOI 10.1074/jbc.271.37.22718; WATSON ML, 1994, METH MOL G, V5, P369; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; Wight Thomas N., 1992, Current Opinion in Cell Biology, V4, P793, DOI 10.1016/0955-0674(92)90102-I; YSART GE, 1994, BIOCHEM J, V303, P713, DOI 10.1042/bj3030713; ZALITIS J, 1969, ARCH BIOCHEM BIOPHYS, V132, P457, DOI 10.1016/0003-9861(69)90389-0; ZALITIS J, 1968, BIOCHEM BIOPH RES CO, V31, P693, DOI 10.1016/0006-291X(68)90617-7	46	123	126	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25117	25124		10.1074/jbc.273.39.25117	http://dx.doi.org/10.1074/jbc.273.39.25117			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737970	hybrid			2022-12-27	WOS:000076085400020
J	Myer, VE; Young, RA				Myer, VE; Young, RA			RNA polymerase II holoenzymes and subcomplexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							YEAST SWI/SNF COMPLEX; GENERAL TRANSCRIPTION FACTORS; SWI-SNF COMPLEX; SACCHAROMYCES-CEREVISIAE; DNA-REPAIR; MULTISUBUNIT COMPLEX; CHROMATIN STRUCTURE; CELL VIABILITY; REPEAT DOMAIN; CTD KINASE		Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Young, RA (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				Acker J, 1997, J BIOL CHEM, V272, P16815, DOI 10.1074/jbc.272.27.16815; ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; Cairns BR, 1996, MOL CELL BIOL, V16, P3308; Cairns BR, 1996, GENE DEV, V10, P2131, DOI 10.1101/gad.10.17.2131; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; Carlson M, 1997, ANNU REV CELL DEV BI, V13, P1, DOI 10.1146/annurev.cellbio.13.1.1; Chao DM, 1996, NATURE, V380, P82, DOI 10.1038/380082a0; CHEN SM, 1993, MOL CELL BIOL, V13, P831, DOI 10.1128/MCB.13.2.831; Cho H, 1997, J BIOL CHEM, V272, P11495; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; COVITZ PA, 1994, GENETICS, V138, P577; Cujec TP, 1997, MOL CELL BIOL, V17, P1817, DOI 10.1128/MCB.17.4.1817; Evangelista CC, 1996, GENETICS, V142, P1083; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FEAVER WJ, 1994, J BIOL CHEM, V269, P27549; FLANAGAN PM, 1992, P NATL ACAD SCI USA, V89, P7659, DOI 10.1073/pnas.89.16.7659; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; FUKASAWA T, 1980, J BIOL CHEM, V255, P2705; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; Gustafsson CM, 1997, J BIOL CHEM, V272, P48; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; HENGARTNER CJ, 1995, GENE DEV, V9, P897, DOI 10.1101/gad.9.8.897; HENRY NL, 1994, GENE DEV, V8, P2868, DOI 10.1101/gad.8.23.2868; INGLES CJ, 1984, P NATL ACAD SCI-BIOL, V81, P2157, DOI 10.1073/pnas.81.7.2157; JIANG YW, 1995, GENETICS, V140, P103; JIANG YW, 1992, MOL CELL BIOL, V12, P4503, DOI 10.1128/MCB.12.10.4503; JIANG YW, 1995, GENETICS, V140, P47; KHAZAK V, 1995, MOL BIOL CELL, V6, P759, DOI 10.1091/mbc.6.7.759; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; Koh SS, 1998, MOL CELL, V1, P895, DOI 10.1016/S1097-2765(00)80088-X; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; KOLODZIEJ P, 1989, MOL CELL BIOL, V9, P5387, DOI 10.1128/MCB.9.12.5387; Kuchin S, 1998, MOL CELL BIOL, V18, P1163, DOI 10.1128/MCB.18.3.1163; KUCHIN S, 1995, P NATL ACAD SCI USA, V92, P4006, DOI 10.1073/pnas.92.9.4006; Lee TI, 1998, GENE DEV, V12, P1398, DOI 10.1101/gad.12.10.1398; Lee TI, 1998, MOL CELL BIOL, V18, P4455, DOI 10.1128/MCB.18.8.4455; Lee YC, 1997, MOL CELL BIOL, V17, P4622, DOI 10.1128/MCB.17.8.4622; Li Y, 1996, METHOD ENZYMOL, V273, P172; LI Y, 1995, P NATL ACAD SCI USA, V92, P10864, DOI 10.1073/pnas.92.24.10864; LIAO SM, 1991, GENE DEV, V5, P2431, DOI 10.1101/gad.5.12b.2431; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MCKUNE K, 1993, YEAST, V9, P295, DOI 10.1002/yea.320090309; MCKUNE K, 1994, MOL CELL BIOL, V14, P4155, DOI 10.1128/MCB.14.6.4155; MCKUNE K, 1995, MOL CELL BIOL, V15, P6895; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; NASMYTH K, 1987, CELL, V49, P549, DOI 10.1016/0092-8674(87)90457-0; Neish AS, 1998, NUCLEIC ACIDS RES, V26, P847, DOI 10.1093/nar/26.3.847; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; NONET ML, 1989, GENETICS, V123, P715; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; Pan GH, 1997, J BIOL CHEM, V272, P24563, DOI 10.1074/jbc.272.39.24563; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; Piruat JI, 1997, GENETICS, V147, P1585; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Quinn J, 1996, NATURE, V379, P844, DOI 10.1038/379844a0; ROSENBLUMVOS LS, 1991, MOL CELL BIOL, V11, P5639, DOI 10.1128/MCB.11.11.5639; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SHPAKOVSKI GV, 1995, MOL CELL BIOL, V15, P4702; Singleton TL, 1998, GENE, V209, P131, DOI 10.1016/S0378-1119(98)00025-0; Song WJ, 1996, MOL CELL BIOL, V16, P115; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; STILLMAN DJ, 1994, GENETICS, V136, P781; SUROSKY RT, 1994, MOL CELL BIOL, V14, P3446, DOI 10.1128/MCB.14.5.3446; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; Svejstrup JQ, 1996, J BIOL CHEM, V271, P643, DOI 10.1074/jbc.271.2.643; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; TREICH I, 1995, MOL CELL BIOL, V15, P4240; Treich Isabelle, 1992, Gene Expression, V2, P31; WAHI M, 1995, GENETICS, V140, P79; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; WOYCHIK NA, 1990, J BIOL CHEM, V265, P17816; WOYCHIK NA, 1991, J BIOL CHEM, V266, P19053; WOYCHIK NA, 1989, MOL CELL BIOL, V9, P2854, DOI 10.1128/MCB.9.7.2854; WOYCHIK NA, 1990, GENE DEV, V4, P313, DOI 10.1101/gad.4.3.313; WOYCHIK NA, 1992, P NATL ACAD SCI USA, V89, P3999, DOI 10.1073/pnas.89.9.3999; Woychik Nancy A., 1993, Gene Expression, V3, P77; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689	94	158	160	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27757	27760		10.1074/jbc.273.43.27757	http://dx.doi.org/10.1074/jbc.273.43.27757			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774381	hybrid			2022-12-27	WOS:000076549800001
J	Verdier, F; Chretien, S; Muller, O; Varlet, P; Yoshimura, A; Gisselbrecht, S; Lacombe, C; Mayeux, P				Verdier, F; Chretien, S; Muller, O; Varlet, P; Yoshimura, A; Gisselbrecht, S; Lacombe, C; Mayeux, P			Proteasomes regulate erythropoietin receptor and signal transducer and activator of transcription 5 (STAT5) activation - Possible involvement of the ubiquitinated Cis protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOUBIQUITINATED ALPHA-GLOBIN; LEUKEMIC-CELL-LINE; TYROSINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; ASSOCIATION; INTERLEUKIN-3; PATHWAY; GROWTH; DOMAIN; KINASE	Cis is an Src homology 2 domain-containing protein, which binds to the erythropoietin receptor and decreases erythropoietin-stimulated cell proliferation. We show that Cis associates with the second tyrosine residue of the intracellular domain of the erythropoietin receptor (Tyr(401)). TWO forms of Cis with molecular masses of 32 and 37 kDa were detected, and we demonstrate that the 37-kDa protein resulted from post-translational modifications of the 32-kDa form. Anti-ubiquitin antibodies recognized the 37-kDa form of Cis and the proteasome inhibitors N-acetyl-leucyl-leucyl-norleucinal and lactacystin inhibited its degradation, showing that the 37-kDa form of Cis is a ubiquitinated protein, which seems to be rapidly degraded by the proteasome. In erythropoietin-stimulated UT-7 cells, the activation of the erythropoietin receptor and signal transducer and activator of transcription 5 (STAT5) was transient and returned to basal levels after 30-60 min of erythropoietin stimulation. In contrast, these proteins remained strongly phosphorylated, and STAT5 remained activated for at least 120 min in the presence of proteasome inhibitors. These experiments demonstrate that the proteasomes are involved in the down-regulation of the erythropoietin receptor activation signals, Because the proteasome inhibitors induced the accumulation of both the ubiquitinated form of Cis and the Cis-erythropoietin receptor complexes, our results suggest that the ubiquitinated form of Cis could be involved in the proteasome-mediated inactivation of the erythropoietin receptor.	Univ Paris 05, INSERM, U363, Inst Cochin Genet Mol, F-75014 Paris, France; Inst Natl Transfus Sanguine, F-75015 Paris, France; Kurume Univ, Inst Life Sci, Kurume, Fukuoka 839, Japan	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Kurume University	Mayeux, P (corresponding author), Hop Cochin, INSERM, U363, Inst Cochin Genet Mol, 27 Rue Faubourg St Jacques, F-75014 Paris, France.		Chretien, Stany/M-5166-2018; Yoshimura, Akihiko/K-5515-2013					AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; Chretien S, 1996, EMBO J, V15, P4174, DOI 10.1002/j.1460-2075.1996.tb00792.x; COUX O, 1996, ANNU REV BIOCHEM, V65, P807; Damen JE, 1996, EXP HEMATOL, V24, P1455; DAMEN JE, 1993, BLOOD, V81, P3204; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DUSANTERFOURT I, 1992, J BIOL CHEM, V267, P10670; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; GOBERT S, 1995, BLOOD, V86, P598, DOI 10.1182/blood.V86.2.598.bloodjournal862598; GOBERT S, 1995, EUR J BIOCHEM, V234, P75, DOI 10.1111/j.1432-1033.1995.075_c.x; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; HE TC, 1993, BLOOD, V82, P3530; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KITAMURA T, 1989, BLOOD, V73, P373; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOMATSU N, 1991, CANCER RES, V51, P341; KRIEGLER M, 1990, GENE TRANSFER EXPRES, P96; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; MAYEUX P, 1993, EUR J BIOCHEM, V216, P821, DOI 10.1111/j.1432-1033.1993.tb18203.x; MAYEUX P, 1990, FEBS LETT, V269, P167, DOI 10.1016/0014-5793(90)81145-E; MAYEUX P, 1991, J BIOL CHEM, V266, P23380; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIURA O, 1994, J BIOL CHEM, V269, P614; MIURA Y, 1994, J BIOL CHEM, V269, P29962; MUI ALF, 1992, P NATL ACAD SCI USA, V89, P10812, DOI 10.1073/pnas.89.22.10812; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; QUELLE FW, 1991, J BIOL CHEM, V266, P609; SHAEFFER JR, 1995, BIOCHEMISTRY-US, V34, P4015, DOI 10.1021/bi00012a020; SHAEFFER JR, 1994, J BIOL CHEM, V269, P22205; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Verdier F, 1997, J BIOL CHEM, V272, P26173, DOI 10.1074/jbc.272.42.26173; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Yu CL, 1997, J BIOL CHEM, V272, P14017, DOI 10.1074/jbc.272.22.14017	45	150	154	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28185	28190		10.1074/jbc.273.43.28185	http://dx.doi.org/10.1074/jbc.273.43.28185			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774439	hybrid			2022-12-27	WOS:000076549800059
J	Huang, SS; Huang, FW; Xu, J; Chen, SW; Hsu, CY; Huang, JS				Huang, SS; Huang, FW; Xu, J; Chen, SW; Hsu, CY; Huang, JS			Amyloid beta-peptide possesses a transforming growth factor-beta activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG EPITHELIAL-CELLS; ALZHEIMERS-DISEASE; CEREBRAL-HEMORRHAGE; NEURONAL CULTURES; RECEPTOR; PROTEIN; NEUROTOXICITY; AGGREGATION; TGF-BETA-1; GENE	Amyloid beta-peptide (A beta) of 39-42 amino acid residues is a major constituent of Alzheimer's disease neurite plaques. A beta aggregates (fibrils) are believed to be responsible for neuronal damage and dysfunction, as well as microglia and astrocyte activation in disease lesions by multiple mechanisms. Since A beta aggregates possess the multiple valencies of an FAED motif (20th to 23rd amino acid residues), which resembles the putative transforming growth factor-beta (TGF-beta) active site motif, we hypothesize that A beta monomers and A beta aggregates may function as TGF-beta antagonists and partial agonist, analogous to previously described monovalent and multivalent TGF-beta peptide antagonists and agonists (Huang, S. S., Liu, Q., Johnson, F. E., Konish, Y., and Huang, J. S. (1997) J. Biol. Chem. 272, 27155-27159). Here, we report that the Ap monomer, A beta-(1-40) and its fragment, containing the motif inhibit radiolabeled TGF-beta binding to cell-surface TGF-beta receptors in mink lung epithelial cells (Mv1Lu cells). A beta-(1-40)-bovine serum albumin conjugate (A beta-(1-40)-BSA), a multivalent synthetic analogue of A beta aggregates, exhibited cytotoxicity toward bovine cerebral endothelial cells and rat postmitotic differentiated hippocampal neuronal cells (H19-7 cells) and inhibitory activities of radiolabeled TGF-beta binding to TGF-beta receptors and TGF-beta-induced plasminogen activator inhibitor-1 expression, that were similar to 100-670 times more potent than those of A beta-(1-40) monomers, At less than micromolar concentrations, Ap(1-40)-BSA but not A beta-(1-40) monomers inhibited proliferation of Mv1Lu cells. Since TGF-beta is an organizer of responses to neurodegeneration and is also found in neurite plaques, the TGF-beta antagonist and partial agonist activities of A beta monomers and aggregates may play an important role in the pathogenesis of the disease.	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Study Nervous Syst Injury, St Louis, MO 63110 USA	Saint Louis University; Washington University (WUSTL); Washington University (WUSTL)	Huang, JS (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	huangjs@wpogate.slu.edu		Hsu, Chung Y./0000-0002-5632-2733	NATIONAL CANCER INSTITUTE [R01CA038808] Funding Source: NIH RePORTER; NCI NIH HHS [CA38808] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMATAYAKULCHANTLER S, 1994, J BIOL CHEM, V269, P27687; Auld DS, 1998, TRENDS NEUROSCI, V21, P43, DOI 10.1016/S0166-2236(97)01144-2; BURDICK D, 1992, J BIOL CHEM, V267, P546; EVES EM, 1992, P NATL ACAD SCI USA, V89, P4373, DOI 10.1073/pnas.89.10.4373; FINCH CE, 1993, J CELL BIOCHEM, V53, P314, DOI 10.1002/jcb.240530408; FLOOD JF, 1991, P NATL ACAD SCI USA, V88, P3363, DOI 10.1073/pnas.88.8.3363; FLOOD JF, 1994, BRAIN RES, V663, P271, DOI 10.1016/0006-8993(94)91273-4; FRASER PE, 1991, BIOPHYS J, V60, P1190, DOI 10.1016/S0006-3495(91)82154-3; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; Huang SS, 1997, J BIOL CHEM, V272, P27155, DOI 10.1074/jbc.272.43.27155; LAIHO M, 1990, J BIOL CHEM, V265, P18518; Leal SM, 1997, J BIOL CHEM, V272, P20572, DOI 10.1074/jbc.272.33.20572; Lendon CL, 1997, JAMA-J AM MED ASSOC, V277, P825, DOI 10.1001/jama.277.10.825; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; Liu QJ, 1997, J BIOL CHEM, V272, P18891, DOI 10.1074/jbc.272.30.18891; Liu YB, 1997, J NEUROCHEM, V69, P581, DOI 10.1046/j.1471-4159.1997.69020581.x; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; PERESS NS, 1995, J NEUROPATH EXP NEUR, V54, P802, DOI 10.1097/00005072-199511000-00007; PIKE CJ, 1995, J NEUROCHEM, V64, P253, DOI 10.1046/j.1471-4159.1995.64010253.x; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Prehn JHM, 1996, MOL PHARMACOL, V49, P319; PREHN JHM, 1994, P NATL ACAD SCI USA, V91, P12599, DOI 10.1073/pnas.91.26.12599; PREHN JHM, 1993, J NEUROCHEM, V60, P1665, DOI 10.1111/j.1471-4159.1993.tb13389.x; Ren RF, 1996, BRAIN RES, V732, P16, DOI 10.1016/0006-8993(96)00458-1; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; VANDERWAL EA, 1993, NEUROREPORT, V4, P69, DOI 10.1097/00001756-199301000-00018; WRIGHT JA, 1993, CRIT REV ONCOGENESIS, V4, P473; WyssCoray T, 1997, NATURE, V389, P603, DOI 10.1038/39321; Xu J, 1998, J BIOL CHEM, V273, P16521, DOI 10.1074/jbc.273.26.16521; Yaar M, 1997, J CLIN INVEST, V100, P2333, DOI 10.1172/JCI119772; Yan SD, 1997, NATURE, V389, P689; YAN SD, 1996, NATURE, V382, P682; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	37	18	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27640	27644		10.1074/jbc.273.42.27640	http://dx.doi.org/10.1074/jbc.273.42.27640			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765299	hybrid			2022-12-27	WOS:000076448000086
J	Kimura, T; Christoffels, VM; Chowdhury, S; Iwase, K; Matsuzaki, H; Mori, M; Lamers, WH; Darlington, GJ; Takiguchi, M				Kimura, T; Christoffels, VM; Chowdhury, S; Iwase, K; Matsuzaki, H; Mori, M; Lamers, WH; Darlington, GJ; Takiguchi, M			Hypoglycemia-associated hyperammonemia caused by impaired expression of ornithine cycle enzyme genes in C/EBP alpha knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT/ENHANCER-BINDING-PROTEIN; PHOSPHATE SYNTHETASE-I; AMINO-ACID SEQUENCE; RAT ARGINASE GENE; ARGININOSUCCINATE LYASE; NUCLEOTIDE-SEQUENCE; LIVER ARGINASE; LEUCINE ZIPPER; MOUSE-LIVER; PROMOTER	Ammonia produced by amino acid metabolism is detoxified through conversion into urea by the ornithine cycle in the Liver, whereas carbon skeletons of amino acids are converted to glucose by gluconeogenic enzymes. Promoter and enhancer sequences of several genes for ornithine cycle enzymes interact with members of the CCAAT/enhancer-binding protein (C/EBP) transcription factor family. Disruption of the C/EBP alpha gene in mice causes hypoglycemia associated with the impaired expression of gluconeogenic enzymes. Here we examined the expression of ornithine cycle enzyme genes in the livers of C/EBP alpha-deficient mice. mRNA levels for the first, third, fourth, and fifth enzymes of five enzymes in the cycle were decreased in C/EBP alpha-deficient mice. Protein levels for the first, second, fourth, and fifth enzymes were also decreased. In situ hybridization analysis revealed that the enzyme mRNAs were distributed normally in the periportal region but were disordered in C/EBP alpha-deficient mice with relatively higher mRNA levels in the midlobular region. Blood ammonia concentrations in the mutant mice were severalfold higher than in wild-type mice. Thus, C/EBP alpha is crucial for ammonia detoxification by ornithine cycle enzymes and for coordination of gluconeogenesis and urea synthesis.	Kumamoto Univ, Sch Med, Dept Mol Genet, Kumamoto 8620976, Japan; Kumamoto Univ, Sch Med, Dept Internal Med, Kumamoto 8620976, Japan; Univ Amsterdam, Acad Med Ctr, Dept Anat & Embryol, NL-1105 AZ Amsterdam, Netherlands; Baylor Coll Med, Dept Pathol & Mol & Human Genet, Houston, TX 77030 USA	Kumamoto University; Kumamoto University; University of Amsterdam; Academic Medical Center Amsterdam; Baylor College of Medicine	Takiguchi, M (corresponding author), Chiba Univ, Sch Med, Dept Biochem, Inohana 1-8-1, Chiba 2608670, Japan.		Lamers, Wouter H./D-2965-2012		NIDDK NIH HHS [DK 45285] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045285] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMAYA Y, 1988, J BIOCHEM-TOKYO, V103, P177, DOI 10.1093/oxfordjournals.jbchem.a122227; ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chowdhury S, 1996, EUR J BIOCHEM, V236, P500, DOI 10.1111/j.1432-1033.1996.00500.x; Croniger C, 1997, J BIOL CHEM, V272, P26306, DOI 10.1074/jbc.272.42.26306; Dingemanse MA, 1996, HEPATOLOGY, V24, P407; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; Gotoh T, 1997, J BIOL CHEM, V272, P3694, DOI 10.1074/jbc.272.6.3694; GOTOH T, 1994, J BIOCHEM-TOKYO, V115, P778, DOI 10.1093/oxfordjournals.jbchem.a124409; GRANNER D, 1990, J BIOL CHEM, V265, P10173; HOWELL BW, 1989, MOL CELL BIOL, V9, P2928, DOI 10.1128/MCB.9.7.2928; IKEMOTO M, 1990, BIOCHEM J, V270, P697, DOI 10.1042/bj2700697; JUNGAS RL, 1992, PHYSIOL REV, V72, P419, DOI 10.1152/physrev.1992.72.2.419; Kanazawa M, 1997, J BIOCHEM-TOKYO, V121, P890; KAWAMOTO S, 1987, J BIOL CHEM, V262, P6280; KIMURA A, 1993, J BIOL CHEM, V268, P11125; KOIZUMI T, 1990, LAB ANIM SCI, V40, P308; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Lee YH, 1997, MOL CELL BIOL, V17, P6014, DOI 10.1128/MCB.17.10.6014; LEMAIGRE FP, 1994, BIOCHEM J, V303, P1; MATSUBASA T, 1994, J BIOCHEM, V116, P1044, DOI 10.1093/oxfordjournals.jbchem.a124626; Matsuno F, 1996, J BIOCHEM-TOKYO, V119, P524; MOORMAN AFM, 1988, J HISTOCHEM CYTOCHEM, V36, P751, DOI 10.1177/36.7.2898495; MOORMAN AFM, 1993, HISTOCHEM J, V25, P251, DOI 10.1007/BF00159117; MOORMAN AFM, 1991, FEBS LETT, V288, P133, DOI 10.1016/0014-5793(91)81019-5; MORI M, 1979, P NATL ACAD SCI USA, V76, P5071, DOI 10.1073/pnas.76.10.5071; MORRIS SM, 1989, ARCH BIOCHEM BIOPHYS, V269, P175, DOI 10.1016/0003-9861(89)90097-0; MORRIS SM, 1992, ANNU REV NUTR, V12, P81, DOI 10.1146/annurev.nu.12.070192.000501; MURAKAMI T, 1990, MOL CELL BIOL, V10, P1180, DOI 10.1128/MCB.10.3.1180; MURAWAKI Y, 1984, CLIN CHIM ACTA, V144, P195; NISHIYORI A, 1994, J BIOL CHEM, V269, P1323; NYUNOYA H, 1985, J BIOL CHEM, V260, P9346; Shneider Benjamin L., 1996, Current Opinion in Pediatrics, V8, P495, DOI 10.1097/00008480-199610000-00013; SURH LC, 1988, NUCLEIC ACIDS RES, V16, P9352, DOI 10.1093/nar/16.19.9352; TAKIGUCHI M, 1984, P NATL ACAD SCI-BIOL, V81, P7412, DOI 10.1073/pnas.81.23.7412; Takiguchi M, 1995, BIOCHEM J, V312, P649, DOI 10.1042/bj3120649; TAKIGUCHI M, 1991, J BIOL CHEM, V266, P9186; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; YU YJ, 1995, J BIOCHEM-TOKYO, V117, P952, DOI 10.1093/oxfordjournals.jbchem.a124826; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569	45	64	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27505	27510		10.1074/jbc.273.42.27505	http://dx.doi.org/10.1074/jbc.273.42.27505			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765281	hybrid			2022-12-27	WOS:000076448000068
J	Quintana, DG; Thome, KC; Hou, ZH; Ligon, AH; Morton, CC; Dutta, A				Quintana, DG; Thome, KC; Hou, ZH; Ligon, AH; Morton, CC; Dutta, A			ORC5L, a new member of the human origin recognition complex, is deleted in uterine leiomyomas and malignant myeloid diseases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; YEAST ORIGIN; SACCHAROMYCES-CEREVISIAE; DROSOPHILA HOMOLOG; GENE; EXPRESSION; PROTEINS; XENOPUS; BINDING; SYSTEM	A new member of the human origin recognition complex (ORC) was cloned and identified as ORC5L, HsORC5p is a 50-kDa protein whose sequence is 38% identical and 62% similar to ORC5p from Drosophila melanogaster, Two alleles of ORC5L were identified, one with and one without an evolutionarily conserved purine nucleotide binding motif, HsORC5p is precipitated from cell extracts with HsORC2p and HsORC4p, indicating that it is part of the putative human ORC, The bulk of HsORC5p is in an insoluble nuclear fraction, whereas the other known human ORC subunits (HsORC1p, HsORC2p, and HsORC4p) are easily extracted in the nuclear-soluble fractions and in S100 (HsORC1p). In addition, we identified an alternatively spliced mRNA from the same locus (HsORC5T), HsORC5Tp also formed a complex with HsORC4p but not with HsORC2p, suggesting it may play a regulatory role in the assembly of different ORC subcomplexes, HsORC5, HsORC5T, and HsORC4 transcripts are abundant in spleen, ovary, and prostate in addition to tissues with high levels of DNA replication like testes and colon mucosa, implicating the human ORC proteins in functions besides DNA replication. Finally, the gene for ORC5L is located at chromosome 7, band q22, in the minimal region deleted in 10% of uterine leiomyomas and in 10-20% of acute myeloid leukemias and myelodysplastic syndromes.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol,Div Mol Oncol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Dutta, A (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol,Div Mol Oncol, Boston, MA 02115 USA.		Quintana, David G/M-5628-2018; Dutta, Anindya/P-3203-2016	Dutta, Anindya/0000-0002-4319-0073; Quintana, David G./0000-0002-4909-6686	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030498] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA060499] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007627] Funding Source: NIH RePORTER; NCI NIH HHS [CA60499, R01 CA060499-05, R01 CA060499] Funding Source: Medline; NHLBI NIH HHS [T32 HL07627] Funding Source: Medline; NICHD NIH HHS [HD30498] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Brush GS, 1995, METHOD ENZYMOL, V262, P522; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; Fischer K, 1997, BLOOD, V89, P2036, DOI 10.1182/blood.V89.6.2036; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; Hardy CFJ, 1996, MOL CELL BIOL, V16, P1832; Ishiai M, 1997, GENOMICS, V46, P294, DOI 10.1006/geno.1997.5003; Ishwad CS, 1997, GENE CHROMOSOME CANC, V19, P156, DOI 10.1002/(SICI)1098-2264(199707)19:3<156::AID-GCC4>3.0.CO;2-X; Klemm RD, 1997, CELL, V88, P493, DOI 10.1016/S0092-8674(00)81889-9; Landis G, 1997, P NATL ACAD SCI USA, V94, P3888, DOI 10.1073/pnas.94.8.3888; LeBeau MM, 1996, BLOOD, V88, P1930; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; OZISIK YY, 1993, CANCER GENET CYTOGEN, V71, P1, DOI 10.1016/0165-4608(93)90195-R; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; Quintana DG, 1997, J BIOL CHEM, V272, P28247, DOI 10.1074/jbc.272.45.28247; RAO H, 1995, P NATL ACAD SCI USA, V92, P2224, DOI 10.1073/pnas.92.6.2224; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; Schneider MC, 1996, GENOMICS, V38, P1, DOI 10.1006/geno.1996.0584; Takahara K, 1996, GENOMICS, V31, P119, DOI 10.1006/geno.1996.0018; Vanni R, 1997, GENE CHROMOSOME CANC, V18, P155, DOI 10.1002/(SICI)1098-2264(199703)18:3<155::AID-GCC1>3.0.CO;2-0; Williams AJ, 1997, AM J PATHOL, V150, P911; Williams RS, 1997, P NATL ACAD SCI USA, V94, P142, DOI 10.1073/pnas.94.1.142; Xing YP, 1997, CANCER GENET CYTOGEN, V98, P69; Zeng WR, 1997, ONCOGENE, V14, P2355, DOI 10.1038/sj.onc.1201076	36	64	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27137	27145		10.1074/jbc.273.42.27137	http://dx.doi.org/10.1074/jbc.273.42.27137			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765232	hybrid			2022-12-27	WOS:000076448000019
J	Aoki, K; Meng, GY; Suzuki, K; Takashi, T; Kameoka, Y; Nakahara, K; Ishida, R; Kasai, M				Aoki, K; Meng, GY; Suzuki, K; Takashi, T; Kameoka, Y; Nakahara, K; Ishida, R; Kasai, M			RP58 associates with condensed chromatin and mediates a sequence-specific transcriptional repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEINS; ACUTE PROMYELOCYTIC LEUKEMIA; TELOMERIC HETEROCHROMATIN; IMMUNOGLOBULIN ENHANCER; INTERACTION MOTIF; CONSERVED DOMAIN; ENCODING GENE; CELL LYMPHOMA; BTB DOMAIN; DROSOPHILA	An approximately 120-amino acid domain present generally at the NH2 termini, termed the POZ domain, is highly conserved in various proteins with zinc finger DNA binding motifs. We have isolated a novel protein sharing homology with the POZ domain of a number of zinc finger proteins, including the human BCL-6 protein. By using a binding site selection technique (CAST), a high affinity binding site of the protein was determined to be (A/C)ACATCTG(G/T) (A/C), containing the E box core sequence motif. The protein was shown to repress transcription from se promoter linked to its target sequences and was hence named RP58 (Repressor Protein with a predicted molecular mass of 58 kDa). Immunogold electron microscopic study revealed that almost all RP58 is localized in condensed chromatin regions. These observations demonstrate for the first time that a protein mediating a sequence-specific transcriptional repression associates with highly condensed chromatin. We suggest that RP58 may be involved in a molecular link between sequence-specific transcriptional repression and the organization of chromosomes in the nucleus.	Natl Inst Infect Dis, Dept Immunol, Shinjuku Ku, Tokyo 162, Japan; Natl Inst Infect Dis, Dept Pathol, Shinjuku Ku, Tokyo 162, Japan; Natl Inst Infect Dis, Div Genet Resources, Shinjuku Ku, Tokyo 162, Japan; Univ Tokyo, Sch Med, Dept Internal Med 1, Bunkyo Ku, Tokyo 113, Japan; Univ Tokyo, Sch Med, Dept Lab Med, Bunkyo Ku, Tokyo 113, Japan; Daiichi Pharmaceut Co Ltd, Tokyo R&D Ctr, New Prod Res Labs 4, Edogawa Ku, Tokyo 134, Japan	National Institute of Infectious Diseases (NIID); National Institute of Infectious Diseases (NIID); National Institute of Infectious Diseases (NIID); University of Tokyo; University of Tokyo; Daiichi Sankyo Company Limited	Kasai, M (corresponding author), Natl Inst Infect Dis, Dept Immunol, Shinjuku Ku, 1-23-1 Toyama, Tokyo 162, Japan.							ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; AOKI K, 1994, ONCOGENE, V9, P1109; Aoki K, 1997, FEBS LETT, V401, P109, DOI 10.1016/S0014-5793(96)01444-5; AOKI K, 1995, NAT GENET, V10, P167, DOI 10.1038/ng0695-167; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BORDEREAUX D, 1990, ONCOGENE, V5, P925; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CHARDIN P, 1991, NUCLEIC ACIDS RES, V19, P1431, DOI 10.1093/nar/19.7.1431; CHEN W, 1995, MOL CELL BIOL, V15, P3424; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; DIBELLO PR, 1991, GENETICS, V129, P385; DORN R, 1993, P NATL ACAD SCI USA, V90, P11376, DOI 10.1073/pnas.90.23.11376; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; Grunstein M, 1997, CURR OPIN CELL BIOL, V9, P383, DOI 10.1016/S0955-0674(97)80011-7; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; Kaplan J, 1997, NUCLEIC ACIDS RES, V25, P1108, DOI 10.1093/nar/25.6.1108; KASAI M, 1994, INT IMMUNOL, V6, P1017, DOI 10.1093/intimm/6.7.1017; KASAI M, 1992, MOL CELL BIOL, V12, P4751, DOI 10.1128/MCB.12.10.4751; Kasai M, 1997, J BIOL CHEM, V272, P11402; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; KOONIN EV, 1995, NUCLEIC ACIDS RES, V23, P4229, DOI 10.1093/nar/23.21.4229; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; MIKI T, 1994, BLOOD, V83, P26; NUMOTO M, 1993, NUCLEIC ACIDS RES, V21, P3767, DOI 10.1093/nar/21.16.3767; RAFF JW, 1994, EMBO J, V13, P5977, DOI 10.1002/j.1460-2075.1994.tb06943.x; SCHNEIDERGADICKE A, 1989, NATURE, V342, P708, DOI 10.1038/342708a0; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Seyfert VL, 1996, ONCOGENE, V12, P2331; SUGAWARA M, 1994, MOL CELL BIOL, V14, P8438, DOI 10.1128/MCB.14.12.8438; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; XIONG WC, 1993, GENE DEV, V7, P1085, DOI 10.1101/gad.7.6.1085; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	38	78	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26698	26704		10.1074/jbc.273.41.26698	http://dx.doi.org/10.1074/jbc.273.41.26698			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756912	hybrid			2022-12-27	WOS:000076373300066
J	Deguchi, M; Hata, Y; Takeuchi, M; Ide, N; Hirao, K; Yao, IK; Irie, M; Toyoda, A; Takai, Y				Deguchi, M; Hata, Y; Takeuchi, M; Ide, N; Hirao, K; Yao, IK; Irie, M; Toyoda, A; Takai, Y			BEGAIN (brain-enriched guanylate kinase-associated protein), a novel neuronal PSD-95/SAP90-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; NMDA RECEPTOR SUBUNITS; POSTSYNAPTIC DENSITY; PSD-95 FAMILY; DOMAIN; INTERACTS; HOMOLOG; BINDING; SAP102; SAP90	PSD-95/SAP90 is a synaptic membrane-associated guanylate kinase with three PDZ, one SH3, and one guanylate kinase (GK) domain. PSD-95/SAP90 binds various proteins through the PDZ domains and organizes synaptic junctions. PSD-95/SAP90 also interacts with the postsynaptic density (PSD) fraction-enriched protein, named SAPAP (also called GKAP and DAP), through the GK domain. SAPAP is Triton X-100-insoluble and recruits PSD-95/SAP90 into the Triton X-100-insoluble fraction in the transfected cells, suggesting that SAPAP may fix PSD-95/SAP90 to the PSD. Here we report a novel protein interacting with the GK domain of PSD95/SAP90, BEGAIN. BEGAIN is specifically expressed in brain and enriched in the PSD fraction. BEGAIN is Triton X-100-soluble in the transfected cells but is recruited to the Triton X-100-insoluble fraction by SAPAP when coexpressed with PSD-95/SAP90. BEGAIN may be a novel PSD component associated with the core complex of PSD-95/SAP90 and SAPAP.	ERATO, Japan Sci & Technol Corp, JCR Pharmaceut Co Ltd, Takai Biotimer Project,Nishi Ku, Kobe, Hyogo 6512241, Japan; Osaka Univ, Sch Med, Dept Biochem & Mol Biol, Suita, Osaka 565, Japan	Japan Science & Technology Agency (JST); Osaka University	Takai, Y (corresponding author), ERATO, Japan Sci & Technol Corp, JCR Pharmaceut Co Ltd, Takai Biotimer Project,Nishi Ku, 2-2-10 Murotani, Kobe, Hyogo 6512241, Japan.		Toyoda, Atsushi/AAA-5885-2020	Toyoda, Atsushi/0000-0002-0245-3244				CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; GARNER C, 1996, TRENDS CELL BIOL, V19, P429; Hata Y, 1996, J NEUROSCI, V16, P2488; HATA Y, 1998, IN PRESS NEUROSCI RE; HATTORI M, 1995, MOL CELL BIOL, V15, P552, DOI 10.1128/MCB.15.1.552; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Kennedy M B, 1993, Curr Opin Neurobiol, V3, P732, DOI 10.1016/0959-4388(93)90145-O; KENNEDY MB, 1995, TRENDS BIOCHEM SCI, V20, P350, DOI 10.1016/S0968-0004(00)89074-X; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lantz VA, 1998, J CELL BIOL, V140, P897, DOI 10.1083/jcb.140.4.897; Lau LF, 1996, J BIOL CHEM, V271, P21622, DOI 10.1074/jbc.271.35.21622; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Niethammer M, 1996, J NEUROSCI, V16, P2157; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; ZIFF EB, 1997, CELL, V19, P1163	31	68	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26269	26272		10.1074/jbc.273.41.26269	http://dx.doi.org/10.1074/jbc.273.41.26269			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756850	hybrid			2022-12-27	WOS:000076373300004
J	Oh, JI; Bowien, B				Oh, JI; Bowien, B			Structural analysis of the fds operon encoding the NAD(+)-linked formate dehydrogenase of Ralstonia eutropha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE OXIDOREDUCTASE; ELECTRON-PARAMAGNETIC RESONANCE; PROTON-TRANSLOCATING NADH; MITOCHONDRIAL COMPLEX-I; ESCHERICHIA-COLI K-12; AMINO-ACID-SEQUENCE; ALCALIGENES-EUTROPHUS; NUCLEOTIDE-SEQUENCE; REDUCING HYDROGENASE; PARACOCCUS-DENITRIFICANS	The fdsGBACD operon encoding the four subunits of the NAD(+)-reducing formate dehydrogenase of Ralstonia eutropha H16 was cloned and sequenced. Sequence comparisons indicated a high resemblance of FdsA (alpha-subunit) to the catalytic subunits of formate dehydrogenases containing a molybdenum (or tungsten) cofactor. The NH2-terminal region (residues 1-240) of FdsA, lacking in formate dehydrogenases not linked to NAD(P)(+), exhibited considerable similarity to that of NuoG of the NADH:ubiquinone oxidoreductase from Escherichia coli as well as to HoxU and the NH2-terminal segment of HndD of NAD(P)(+)-reducing hydrogenases. FdsB (beta-subunit) and FdsG (gamma-subunit) are closely related to NuoF and NuoE, respectively, as well as to HoxF and HndA. It is proposed that the NH2-terminal domain of FdsA together with FdsB and FdsG constitute a functional entity corresponding to the NADH dehydrogenase (diaphorase) part of NADH:ubiquinone oxidoreductase and the hydrogenases. No significant similarity to any known protein was observed for FdsD (delta-subunit). The predicted product of fdsC showed the highest resemblance to FdhD from E. coli, a protein required for the formation of active formate dehydrogenases in this organism. Transcription of the fds operon is subject to formate induction. A promoter structure resembling the consensus sequence of sigma(70)-dependent promoters from E. coli was identified upstream of the transcriptional start site determined by primer extension analysis.	Univ Gottingen, Inst Mikrobiol & Genet, D-37077 Gottingen, Germany	University of Gottingen	Bowien, B (corresponding author), Univ Gottingen, Inst Mikrobiol & Genet, Grisebachstr 8, D-37077 Gottingen, Germany.	bbowien@gwdg.de						ABAIBOU H, 1995, J BACTERIOL, V177, P7141, DOI 10.1128/jb.177.24.7141-7149.1995; ALLEN SJ, 1995, GENE, V162, P99, DOI 10.1016/0378-1119(95)00347-9; Ausubel FM., 1988, CURRENT PROTOCOLS MO; AXLEY MJ, 1991, P NATL ACAD SCI USA, V88, P8450, DOI 10.1073/pnas.88.19.8450; BARBER MJ, 1983, J BIOL CHEM, V258, P839; BERG BL, 1991, J BIOL CHEM, V266, P22380; BILOUS PT, 1988, MOL MICROBIOL, V2, P785, DOI 10.1111/j.1365-2958.1988.tb00090.x; BLASCO F, 1989, MOL GEN GENET, V218, P249, DOI 10.1007/BF00331275; BLASCO F, 1990, MOL GEN GENET, V222, P104, DOI 10.1007/BF00283030; BOKRANZ M, 1991, ARCH MICROBIOL, V156, P119, DOI 10.1007/BF00290984; BOWIEN B, 1990, FEMS MICROBIOL LETT, V87, P445, DOI 10.1016/0378-1097(90)90493-A; BOWIEN B, 1981, ANNU REV MICROBIOL, V35, P405, DOI 10.1146/annurev.mi.35.100181.002201; Boyington JC, 1997, SCIENCE, V275, P1305, DOI 10.1126/science.275.5304.1305; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; DESFRANCSSMALL CC, 1993, PLANT PHYSIOL, V102, P1171, DOI 10.1104/pp.102.4.1171; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEARNLEY IM, 1992, BIOCHIM BIOPHYS ACTA, V1140, P105, DOI 10.1016/0005-2728(92)90001-I; FERRY JG, 1990, FEMS MICROBIOL LETT, V87, P377, DOI 10.1111/j.1574-6968.1990.tb04940.x; FRIEDEBOLD J, 1993, J BACTERIOL, V175, P4719, DOI 10.1128/JB.175.15.4719-4728.1993; FRIEDEBOLD J, 1995, BIOL CHEM H-S, V376, P561, DOI 10.1515/bchm3.1995.376.9.561; FRIEDRICH B, 1993, ANNU REV MICROBIOL, V47, P351, DOI 10.1146/annurev.mi.47.100193.002031; FRIEDRICH CG, 1979, J GEN MICROBIOL, V115, P185, DOI 10.1099/00221287-115-1-185; FU W, 1993, BIOCHEMISTRY-US, V32, P4813, DOI 10.1021/bi00069a016; Galkin A, 1995, APPL MICROBIOL BIOT, V44, P479, DOI 10.1007/BF00169947; GLADYSHEV VN, 1994, P NATL ACAD SCI USA, V91, P7708, DOI 10.1073/pnas.91.16.7708; Gladyshev VN, 1996, J BIOL CHEM, V271, P8095, DOI 10.1074/jbc.271.14.8095; GLASER P, 1995, J BACTERIOL, V177, P1112, DOI 10.1128/jb.177.4.1112-1115.1995; HARLEY CB, 1987, NUCLEIC ACIDS RES, V15, P2343, DOI 10.1093/nar/15.5.2343; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; HOCHHEIMER A, 1995, X87969 GENBANKEMBLDD; HOLLENBERG CP, 1989, A06214 GENBANKEMBLDD; Khoroshilova N, 1997, P NATL ACAD SCI USA, V94, P6087, DOI 10.1073/pnas.94.12.6087; Kletzin A, 1996, FEMS MICROBIOL REV, V18, P5, DOI 10.1016/0168-6445(95)00025-9; KRAFFT T, 1992, EUR J BIOCHEM, V206, P503, DOI 10.1111/j.1432-1033.1992.tb16953.x; KUSIAN B, 1995, J BACTERIOL, V177, P4442, DOI 10.1128/jb.177.15.4442-4450.1995; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAWRENCE CE, 1993, SCIENCE, V262, P208, DOI 10.1126/science.8211139; LEIF H, 1995, EUR J BIOCHEM, V230, P538, DOI 10.1111/j.1432-1033.1995.tb20594.x; Lenger R, 1997, EUR J BIOCHEM, V246, P646, DOI 10.1111/j.1432-1033.1997.t01-2-00646.x; LI XL, 1996, U73807 GENBANKEMBLDD; LOENEN WAM, 1980, GENE, V10, P249, DOI 10.1016/0378-1119(80)90054-2; MALKI S, 1995, J BACTERIOL, V177, P2628, DOI 10.1128/jb.177.10.2628-2636.1995; MANDRANDBERTHELOT MA, 1988, J GEN MICROBIOL, V134, P3129; MATSUBARA H, 1992, ADV INORG CHEM, V38, P223, DOI 10.1016/S0898-8838(08)60065-3; MEJEAN V, 1994, MOL MICROBIOL, V11, P1169, DOI 10.1111/j.1365-2958.1994.tb00393.x; MEYER J, 1991, BIOCHEMISTRY-US, V309, P3697; OELMULLER U, 1990, J MICROBIOL METH, V11, P73, DOI 10.1016/0167-7012(90)90050-G; PIERSON DE, 1990, J BACTERIOL, V172, P2194, DOI 10.1128/jb.172.4.2194-2198.1990; PILKINGTON SJ, 1991, BIOCHEMISTRY-US, V30, P2166, DOI 10.1021/bi00222a021; PILKINGTON SJ, 1989, BIOCHEMISTRY-US, V28, P3257, DOI 10.1021/bi00434a021; PLUNKETT G, 1993, NUCLEIC ACIDS RES, V21, P3391, DOI 10.1093/nar/21.15.3391; POPOV VO, 1994, BIOCHEM J, V301, P625, DOI 10.1042/bj3010625; POPOV VO, 1990, BIOORG KHIM+, V16, P324; PREIS D, 1991, BIOCHIM BIOPHYS ACTA, V1090, P133, DOI 10.1016/0167-4781(91)90049-R; RUNSWICK MJ, 1989, BIOCHEMISTRY-US, V28, P9452, DOI 10.1021/bi00450a031; Sambrook J., 2002, MOL CLONING LAB MANU; Schindelin H, 1996, SCIENCE, V272, P1615, DOI 10.1126/science.272.5268.1615; SCHMITZ O, 1995, EUR J BIOCHEM, V233, P266, DOI 10.1111/j.1432-1033.1995.266_1.x; SHUBER AP, 1986, J BIOL CHEM, V261, P2942; SIDDIQUI RA, 1993, J BACTERIOL, V175, P5867, DOI 10.1128/JB.175.18.5867-5876.1993; STEWART V, 1991, J BACTERIOL, V173, P4417, DOI 10.1128/JB.173.14.4417-4423.1991; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRANBETCKE A, 1990, J BACTERIOL, V172, P2920, DOI 10.1128/jb.172.6.2920-2929.1990; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; WEIDNER U, 1993, J MOL BIOL, V233, P109, DOI 10.1006/jmbi.1993.1488; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; XU XM, 1992, ARCH BIOCHEM BIOPHYS, V296, P40, DOI 10.1016/0003-9861(92)90542-5; XU XM, 1991, BIOCHEMISTRY-US, V30, P8678, DOI 10.1021/bi00099a027; XU XM, 1991, BIOCHEMISTRY-US, V30, P6422, DOI 10.1021/bi00240a012; YAMAMOTO I, 1983, J BIOL CHEM, V258, P1826; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YANO T, 1994, BIOCHEMISTRY-US, V33, P494, DOI 10.1021/bi00168a014; ZAMBRANO IC, 1989, J BIOL CHEM, V264, P20974; ZINONI F, 1986, P NATL ACAD SCI USA, V83, P4650, DOI 10.1073/pnas.83.13.4650	74	68	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26349	26360		10.1074/jbc.273.41.26349	http://dx.doi.org/10.1074/jbc.273.41.26349			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756865	hybrid			2022-12-27	WOS:000076373300019
J	Decker, H; Rimke, T				Decker, H; Rimke, T			Tarantula hemocyanin shows phenoloxidase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTHROPOD HEMOCYANIN; EURYPELMA-CALIFORNICUM; CRYSTAL-STRUCTURE; PROPHENOLOXIDASE; ACTIVATION; TYROSINASE; RESOLUTION; PROENZYME; SEQUENCE; LIMULUS	An enzyme generally catalyzes one well defined reaction with high specificity and efficiency. We report here in contrast that the copper protein hemocyanin of the tarantula Eurypelma californicum exhibits two different functions. These occur at the same active site. While hemocyanin usually is an oxygen carrier, its function can be transformed totally to monophenoloxidase and o-diphenoloxidase activity after limited proteolysis with trypsin or chymotrypsin, N-acetyldopamine (NADA) is more effectively oxidized than L-dopa or dopamine. This irreversible functional switch of tarantula hemocyanin function is limited to the two subunits b and c of its seven subunit types. A conserved phenylalanine in the hemocyanin molecule acts as a placeholder for other substrates that are phenylalanine derivatives. The proteolytic cleavage removes an N-terminal fragment, including the critical phenylalanine residue, which opens an entrance for substrates. Therefore no new arrangement of the active site, with its two copper atoms and the mu - eta(2):eta(2) bound O-2 molecule, is necessary to develop the catalytic function.	Univ Mainz, Inst Mol Biophys, D-55128 Mainz, Germany	Johannes Gutenberg University of Mainz	Decker, H (corresponding author), Univ Mainz, Inst Mol Biophys, Welder Weg 26, D-55128 Mainz, Germany.	decker@biophysik.biologie.uni-mainz.de						Andersen Svend Olav, 1991, P123; ASPAN A, 1995, P NATL ACAD SCI USA, V92, P939, DOI 10.1073/pnas.92.4.939; BASYONI M, 1990, THESIS U MUNICH; BEINTEMA JJ, 1994, MOL BIOL EVOL, V11, P493; BELTRAMINI M, 1990, BIOCHIM BIOPHYS ACTA, V1040, P365, DOI 10.1016/0167-4838(90)90134-2; Brivio MF, 1996, COMP BIOCHEM PHYS B, V113, P281, DOI 10.1016/0305-0491(95)02025-X; Burmester T, 1996, J MOL EVOL, V42, P713, DOI 10.1007/BF02338804; DECKER H, 1990, J MOL BIOL, V211, P281, DOI 10.1016/0022-2836(90)90027-J; FUJIMOTO K, 1995, P NATL ACAD SCI USA, V92, P7769, DOI 10.1073/pnas.92.17.7769; GAYKEMA WPJ, 1984, NATURE, V309, P23, DOI 10.1038/309023a0; HAZES B, 1993, PROTEIN SCI, V2, P597; HernandezLopez J, 1996, COMP BIOCHEM PHYS C, V113, P61, DOI 10.1016/0742-8413(95)02033-0; Kopacek P, 1995, INSECT BIOCHEM MOLEC, V25, P1081, DOI 10.1016/0965-1748(95)00040-2; LAMY J, 1979, H-S Z PHYSIOL CHEM, V360, P889, DOI 10.1515/bchm2.1979.360.2.889; MAGNUS KA, 1994, PROTEINS, V19, P302, DOI 10.1002/prot.340190405; MARKL J, 1981, H-S Z PHYSIOL CHEM, V362, P1631, DOI 10.1515/bchm2.1981.362.2.1631; Markl J., 1992, Advances in Comparative and Environmental Physiology, V13, P325; Nellaiappan K, 1996, COMP BIOCHEM PHYS B, V113, P163, DOI 10.1016/0305-0491(95)02047-0; SALVATO B, 1990, LIFE CHEM REPORTS, V8, P1; SALVATO B, 1998, IN PRESS BIOCHEMISTR; SANCHEZFERRER A, 1995, BBA-PROTEIN STRUCT M, V1247, P1; SAVELNIEMANN A, 1988, J MOL BIOL, V204, P385, DOI 10.1016/0022-2836(88)90583-9; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; SOLOMON EI, 1996, CHEM REV, V96, P25; SUGUMARAN M, 1993, PARASITES PATHOGENS, V1, P317; Sugumaran Manickam, 1991, P141; VanGelder CWG, 1997, PHYTOCHEMISTRY, V45, P1309, DOI 10.1016/S0031-9422(97)00186-6; vanHolde KE, 1995, ADV PROTEIN CHEM, V47, P1, DOI 10.1016/S0065-3233(08)60545-8; VOLBEDA A, 1989, J MOL BIOL, V209, P249, DOI 10.1016/0022-2836(89)90276-3; Zlateva T, 1996, FEBS LETT, V384, P251, DOI 10.1016/0014-5793(96)00326-2	31	185	206	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25889	25892		10.1074/jbc.273.40.25889	http://dx.doi.org/10.1074/jbc.273.40.25889			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748264	hybrid			2022-12-27	WOS:000076263100055
J	Lee, CH; Leeds, P; Ross, J				Lee, CH; Leeds, P; Ross, J			Purification and characterization of a polysome-associated endoribonuclease that degrades c-myc mRNA in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; CELL-FREE-EXTRACTS; PROTEIN-SYNTHESIS; POSTTRANSCRIPTIONAL REGULATION; ENDONUCLEOLYTIC CLEAVAGE; CODING REGION; HALF-LIFE; SEQUENCES; RIBONUCLEASE; DEGRADATION	The regulation of mRNA half-lives is determined by multiple factors, including the activity of the messenger RNases (mRNases) responsible for destroying mRNA molecules. Previously, we used cell-free mRNA decay assays to identify a polysome-associated endonuclease that cleaves c-mye mRNA within the coding region. A similar activity has been solubilized and partially purified from a high salt extract of adult rat liver polysomes. Based on a correlation between protein and enzyme activity, the endonuclease is tentatively identified as a similar to 39-kDa protein. It cleaves the coding region stability determinant of c-myc mRNA with considerable specificity. Cleavages occur predominantly in an A-rich segment of the RNA. The endonuclease is resistant to RNase A inhibitors, sensitive to vanadyl ribonucleoside complex, and dependent on magnesium. In these and other respects, the soluble enzyme we have purified resembles the polysome-associated c-mye mRNase.	Univ Wisconsin, Mcardle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Ross, J (corresponding author), Univ Wisconsin, Mcardle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.							BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BONNIEU A, 1990, ONCOGENE, V5, P1585; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BREWER G, 1990, METHOD ENZYMOL, V181, P202; BROWN BD, 1993, GENE DEV, V7, P1620, DOI 10.1101/gad.7.8.1620; BROWN BD, 1990, GENE DEV, V4, P1925, DOI 10.1101/gad.4.11.1925; Chernokalskaya E, 1997, NUCLEIC ACIDS RES, V25, P735, DOI 10.1093/nar/25.4.735; ClaverieMartin F, 1997, J BIOL CHEM, V272, P13823, DOI 10.1074/jbc.272.21.13823; DALESSIO G, 1991, TRENDS BIOCHEM SCI, V16, P104, DOI 10.1016/0968-0004(91)90042-T; DOMPENCIEL RE, 1995, J BIOL CHEM, V270, P6108, DOI 10.1074/jbc.270.11.6108; DONG BH, 1995, J BIOL CHEM, V270, P4133, DOI 10.1074/jbc.270.8.4133; FUSI P, 1993, EUR J BIOCHEM, V211, P305, DOI 10.1111/j.1432-1033.1993.tb19899.x; Gruppuso PA, 1997, IN VITRO CELL DEV-AN, V33, P562; HERRICK DJ, 1994, MOL CELL BIOL, V14, P2119, DOI 10.1128/MCB.14.3.2119; Higgins CF, 1992, CURR OPIN GENET DEV, V2, P739, DOI 10.1016/S0959-437X(05)80134-0; HUA J, 1993, NUCLEIC ACIDS RES, V21, P155, DOI 10.1093/nar/21.1.155; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; LAVENU A, 1995, MOL CELL BIOL, V15, P4410; Leeds P, 1997, ONCOGENE, V14, P1279, DOI 10.1038/sj.onc.1201093; MORELLO D, 1989, ONCOGENE, V4, P955; MORELLO D, 1990, ONCOGENE, V5, P1511; Pistoi S, 1996, MOL CELL BIOL, V16, P5107; PUSKAS RS, 1982, BIOCHEMISTRY-US, V21, P4602, DOI 10.1021/bi00262a014; ROSS J, 1986, J MOL BIOL, V188, P579, DOI 10.1016/S0022-2836(86)80008-0; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SCHNEIDER R, 1993, SCIENCE, V261, P1169, DOI 10.1126/science.8356450; SCHOENBERG DR, 1997, MRNA METABOLISM POST, P217; STEER CJ, 1996, FASEB J, V10, P559; WENNBORG A, 1995, P NATL ACAD SCI USA, V92, P7322, DOI 10.1073/pnas.92.16.7322; WISDOM R, 1990, J BIOL CHEM, V265, P19015; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; Yeilding NM, 1997, MOL CELL BIOL, V17, P2698, DOI 10.1128/MCB.17.5.2698; Yeilding NM, 1996, MOL CELL BIOL, V16, P3511; Zaug AJ, 1996, NUCLEIC ACIDS RES, V24, P532, DOI 10.1093/nar/24.3.532	37	53	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25261	25271		10.1074/jbc.273.39.25261	http://dx.doi.org/10.1074/jbc.273.39.25261			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737991	hybrid			2022-12-27	WOS:000076085400041
J	Oehlen, LJWM; Cross, FR				Oehlen, LJWM; Cross, FR			Potential regulation of Ste20 function by the Cln1-Cdc28 and Cln2-Cdc28 cyclin-dependent protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHEROMONE RESPONSE PATHWAY; YEAST-CELL CYCLE; MITOGEN-ACTIVATED PROTEIN; BETA-GAMMA COMPLEX; SACCHAROMYCES-CEREVISIAE; FILAMENTOUS-GROWTH; BUDDING YEAST; SIGNAL-TRANSDUCTION; S-CEREVISIAE; MAP KINASES	The activity of the Saccharomyces cerevisiae pheromone signal transduction pathway is regulated by Cln1/2-Cdc28 cyclin-dependent kinase. High level expression of CLN2 can repress activation of the pathway by mating factor or by deletion of the alpha-subunit of the heterotrimeric G-protein. We now show that CLN2 overexpression can also repress FUS1 induction if the signaling pathway is activated at the level of the beta-subunit of the G-protein (STE4) but not when activated at the level of downstream kinases (STE20 and STE11) or at the level of the transcription factor STE12. This epistatic analysis indicates that repression of pheromone signaling pathway by Cln2-Cdc28 kinase takes place at a level around STE20. In agreement with this, a marked reduction in the electrophoretic mobility of the Ste20 protein is observed at the time in the cell cycle of maximal expression of CLN2. This mobility change is constitutive in cells overexpressing CLN2 and absent in cells lacking CLN1 and CLN2. These changes in electrophoretic mobility correlate with repression of pheromone signaling and suggest Ste20 as a target for repression of signaling by G(1) cyclins. Two morphogenic pathways for which Ste20 is essential, pseudohyphal differentiation and haploid-invasive growth, also require CLN1 and CLN2. Together with the previous observation that Cln1 and Cln2 are required for the function of Ste20 in cytokinesis, this suggests that Cln1 and Cln2 regulate the biological activity of Ste20 by promoting morphogenic functions, while inhibiting the mating factor signal transduction function.	Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Oehlen, LJWM (corresponding author), CADUS Pharmaceut Corp, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049716] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49716] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akada R, 1996, GENETICS, V143, P103; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BARDWELL L, 1994, DEV BIOL, V166, P363, DOI 10.1006/dbio.1994.1323; Benton BK, 1997, MOL CELL BIOL, V17, P5067, DOI 10.1128/MCB.17.9.5067; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; COMPANY M, 1988, MOL CELL BIOL, V8, P5299, DOI 10.1128/MCB.8.12.5299; Cook JG, 1997, NATURE, V390, P85, DOI 10.1038/36355; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; CROSS FR, 1995, CURR OPIN CELL BIOL, V7, P790, DOI 10.1016/0955-0674(95)80062-X; Cross FR, 1997, YEAST, V13, P647, DOI 10.1002/(SICI)1097-0061(19970615)13:7<647::AID-YEA115>3.0.CO;2-#; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; DIETZEL C, 1987, MOL CELL BIOL, V7, P4169, DOI 10.1128/MCB.7.12.4169; DOLAN JW, 1990, GENE DEV, V4, P492, DOI 10.1101/gad.4.4.492; ELION EA, 1995, TRENDS CELL BIOL, V5, P322, DOI 10.1016/S0962-8924(00)89055-8; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; ERREDE B, 1993, NATURE, V362, P261, DOI 10.1038/362261a0; FIELDS S, 1987, MOL CELL BIOL, V7, P3818, DOI 10.1128/MCB.7.10.3818; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; HASSON MS, 1994, MOL CELL BIOL, V14, P1054, DOI 10.1128/MCB.14.2.1054; KONOPKA JB, 1988, CELL, V54, P609, DOI 10.1016/S0092-8674(88)80005-9; Leberer E, 1996, MOL GEN GENET, V252, P608, DOI 10.1007/s004380050268; LEBERER E, 1993, MOL GEN GENET, V241, P241, DOI 10.1007/BF00284675; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; Leeuw T, 1998, NATURE, V391, P191, DOI 10.1038/34448; Levine K, 1996, MOL CELL BIOL, V16, P6794; LEW DJ, 1993, J CELL BIOL, V120, P1305, DOI 10.1083/jcb.120.6.1305; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; Lyons DM, 1996, MOL CELL BIOL, V16, P4095; Madhani HD, 1997, CELL, V91, P673, DOI 10.1016/S0092-8674(00)80454-7; MCKINNEY JD, 1993, GENE DEV, V7, P833, DOI 10.1101/gad.7.5.833; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; Oehlen LJWM, 1998, J BIOL CHEM, V273, P8556, DOI 10.1074/jbc.273.15.8556; OEHLEN LJWM, 1994, GENE DEV, V8, P1058, DOI 10.1101/gad.8.9.1058; Oehlen LJWM, 1996, MOL CELL BIOL, V16, P2830; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; Pryciak PM, 1996, MOL CELL BIOL, V16, P2614; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; Wassmann K, 1997, J BIOL CHEM, V272, P13180, DOI 10.1074/jbc.272.20.13180; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WHITEWAY M, 1990, MOL CELL BIOL, V10, P217, DOI 10.1128/MCB.10.1.217; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; ZANOLARI B, 1991, MOL CELL BIOL, V11, P5251, DOI 10.1128/MCB.11.10.5251; ZHOU ZQ, 1993, MOL CELL BIOL, V13, P2069, DOI 10.1128/MCB.13.4.2069	50	47	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25089	25097		10.1074/jbc.273.39.25089	http://dx.doi.org/10.1074/jbc.273.39.25089			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737966	hybrid			2022-12-27	WOS:000076085400016
J	Beschin, A; Bilej, M; Hanssens, F; Raymakers, J; Van Dyck, E; Revets, H; Brys, L; Gomez, J; De Baetselier, P; Timmermans, M				Beschin, A; Bilej, M; Hanssens, F; Raymakers, J; Van Dyck, E; Revets, H; Brys, L; Gomez, J; De Baetselier, P; Timmermans, M			Identification and cloning of a glucan- and liopoplysaccharide-binding protein from Eisenia foetida earthworm involved in the activation of prophenoloxidase cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANNELID NEREIS-DIVERSICOLOR; CRAYFISH BLOOD-CELLS; CELOMIC FLUID; FETIDA-ANDREI; LUMBRICUS-TERRESTRIS; MOLECULAR-CLONING; CELLULAR-IMMUNITY; SERINE PROTEASES; BOMBYX-MORI; PURIFICATION	Coelomic fluid of Eisenia foetida earthworms contains a 42-kDa protein named coelomic cytolytic factor 1 (CCF-1) that was described previously to be involved in cytolytic, opsonizing, and hemolytic properties of the coelomic fluid. Cloning and sequencing of CCF-1 reveal significant homology with the putative catalytic region of beta-1,3- and beta-1,3-1,4-glucanases. CCF-1 also displays homology with coagulation factor G from Limulus polyphemus and with Gram-negative bacteria-binding protein of Bombyx mori silkworm, two proteins involved in invertebrate defense mechanisms. We show that CCF-1 efficiently binds both beta-1,3-glucan and lipopolysaccharide, Moreover, CCF-1 participates in the activation of prophenoloxidase cascade via recognition of yeast and Gram-negative bacteria cell wall components. These results suggest that the 42-kDa CCF-1 protein of E. foetida coelomic fluid likely plays a role in the protection of earthworms against microbes.	Free Univ Brussels, Flemisch Interuniv Inst Biotechnol, Unit Cellular Immunol, B-1640 Rhode St Genese, Belgium; Acad Sci Czech Republic, Inst Microbiol, Dept Immunol, CR-14220 Prague 4, Czech Republic; NV Innogenet, B-9052 Zwijnaarde, Belgium	Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; Innogenetics NV	Beschin, A (corresponding author), Free Univ Brussels, Flemisch Interuniv Inst Biotechnol, Unit Cellular Immunol, Paardenstr 65, B-1640 Rhode St Genese, Belgium.	abeschin@vub.ac.be	Bilej, Martin/I-4564-2014; Beschin, Alain/L-2154-2014; De Baetselier, Patrick/D-3866-2014	Beschin, Alain/0000-0001-8478-6941; 				ASHIDA M, 1983, BIOCHEM BIOPH RES CO, V113, P562, DOI 10.1016/0006-291X(83)91762-X; ASPAN A, 1991, INSECT BIOCHEM, V21, P363, DOI 10.1016/0020-1790(91)90002-V; ASPAN A, 1990, INSECT BIOCHEM, V20, P709, DOI 10.1016/0020-1790(90)90085-9; Bachman ES, 1996, P NATL ACAD SCI USA, V93, P6808, DOI 10.1073/pnas.93.13.6808; BIELY P, 1985, ANAL BIOCHEM, V144, P142, DOI 10.1016/0003-2697(85)90095-8; BILEJ M, 1995, IMMUNOL LETT, V45, P123, DOI 10.1016/0165-2478(94)00248-P; Bilej M, 1998, IMMUNOL LETT, V60, P23, DOI 10.1016/S0165-2478(97)00127-2; CERENIUS L, 1994, J BIOL CHEM, V269, P29462; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALES RP, 1983, J INVERTEBR PATHOL, V42, P288, DOI 10.1016/0022-2011(83)90077-0; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P112, DOI 10.1006/abio.1994.1148; FISCHER E, 1978, ACTA HISTOCHEM, V63, P210; GRAHAM DG, 1978, J INVEST DERMATOL, V70, P113, DOI 10.1111/1523-1747.ep12541249; Johansson M.W., 1996, Progress in Molecular and Subcellular Biology, V15, P46; JOHANSSON MW, 1989, PARASITOL TODAY, V5, P171, DOI 10.1016/0169-4758(89)90139-7; LASSALLE F, 1988, COMP BIOCHEM PHYS B, V91, P187, DOI 10.1016/0305-0491(88)90133-2; Lassegues M, 1997, EUR J BIOCHEM, V246, P756, DOI 10.1111/j.1432-1033.1997.00756.x; Lee WJ, 1996, P NATL ACAD SCI USA, V93, P7888, DOI 10.1073/pnas.93.15.7888; LEIPNER C, 1993, COMP BIOCHEM PHYS B, V105, P637, DOI 10.1016/0305-0491(93)90099-Q; MCCLEARY BV, 1988, METHOD ENZYMOL, V160, P74; Milochau A, 1997, BBA-PROTEIN STRUCT M, V1337, P123, DOI 10.1016/S0167-4838(96)00160-4; MOHRIG W, 1989, ZOOL JAHRB ALLG ZOOL, V93, P303; MUTA T, 1995, J BIOL CHEM, V270, P892, DOI 10.1074/jbc.270.2.892; NAPPI AJ, 1993, PIGM CELL RES, V6, P117, DOI 10.1111/j.1600-0749.1993.tb00590.x; NAYAR JK, 1989, J MED ENTOMOL, V26, P159, DOI 10.1093/jmedent/26.3.159; NOVOTNA V, 1996, INT J BIOCHROMATOGR, V2, P37; Olafsen J.A., 1996, Advances in Comparative and Environmental Physiology, V24, P49; PAWELEK JM, 1978, NATURE, V276, P627, DOI 10.1038/276627a0; Poinar G.O. Jr., 1977, Comparative Pathobiol, V3, P69; PORCHETHENNERE E, 1987, J INVERTEBR PATHOL, V50, P58, DOI 10.1016/0022-2011(87)90146-7; PORCHETHENNERE E, 1992, CELL TISSUE RES, V269, P167, DOI 10.1007/BF00384737; ROCH P, 1991, COMP BIOCHEM PHYS B, V98, P597, DOI 10.1016/0305-0491(91)90261-B; Roch Ph., 1996, Advances in Comparative and Environmental Physiology, V23, P115; Saito T, 1997, J BIOL CHEM, V272, P30703, DOI 10.1074/jbc.272.49.30703; SEKI N, 1994, J BIOL CHEM, V269, P1370; SEYMOUR J, 1993, ANIM BIOL, V2, P1; SILVERMAN DHS, 1986, J IMMUNOL, V136, P2195; SINKORA M, 1993, CELL BIOL INT, V17, P935, DOI 10.1006/cbir.1993.1015; Smith V.J., 1996, Advances in Comparative and Environmental Physiology, V23, P75; SMITH VJ, 1991, DEV COMP IMMUNOL, V15, P251, DOI 10.1016/0145-305X(91)90018-T; SODERHALL K, 1982, J INVERTEBR PATHOL, V39, P105, DOI 10.1016/0022-2011(82)90164-1; Soderhall K., 1986, P208; SODERHALL K, 1982, DEV COMP IMMUNOL, V6, P601; Soderhall K., 1986, P251; THORNQVIST PO, 1994, DEV COMP IMMUNOL, V18, P3, DOI 10.1016/0145-305X(94)90247-X; TUCKOVA L, 1986, DEV COMP IMMUNOL, V10, P181, DOI 10.1016/0145-305X(86)90002-9; VALEMBOIS P, 1991, J INVERTEBR PATHOL, V57, P177, DOI 10.1016/0022-2011(91)90114-6; VALEMBOIS P, 1992, DEV COMP IMMUNOL, V16, P95, DOI 10.1016/0145-305X(92)90010-A; VALEMBOIS P, 1982, J INVERTEBR PATHOL, V40, P21, DOI 10.1016/0022-2011(82)90032-5; Vasta G.R., 1996, Progress in Molecular and Subcellular Biology, V17, P158; YAMAMOTO M, 1993, BIOSCI BIOTECH BIOCH, V57, P1518, DOI 10.1271/bbb.57.1518	51	154	163	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24948	24954		10.1074/jbc.273.38.24948	http://dx.doi.org/10.1074/jbc.273.38.24948			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733802	hybrid			2022-12-27	WOS:000076007300094
J	Hess, MT; Naegeli, H; Capobianco, M				Hess, MT; Naegeli, H; Capobianco, M			Stereoselectivity of human nucleotide excision repair promoted by defective hybridization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION-COUPLED REPAIR; DNA-REPAIR; PYRIMIDINE DIMERS; HUMAN FIBROBLASTS; MAMMALIAN-CELLS; ACTIVE GENE; DHFR GENE; UV DAMAGE; ADDUCTS; NUCLEASE	To assess helical parameters that dictate fast or slow removal of carcinogen-DNA adducts, we probed human nucleotide excision repair (NER) activity with DNA containing L-deoxyriboses. Unlike natural lesions such as pyrimidine dimers or base adducts, L-deoxyribonucleosides (the mirror images of normal D-deoxyribonucleosides) involve neither the addition nor the loss of covalent bonds or functional groups and hence exclude modulation of repair efficiency by adduct chemistry and size. Previous studies showed that single L-deoxyribonucleosides distort DNA backbones but are accommodated in the double helix with intact hydrogen bonding between complementary strands. Here, we found that such single L-enantiomers are rejected as excision repair substrates in a NER-proficient cell extract. However, the same L-deoxyribose moiety stimulates NER activity upon incorporation into a nonhybridizing site of one or, more effectively, two base mismatches. In contrast to single L-deoxyriboses, multiple consecutive L-deoxyriboses interfere with normal hybridization; in this case, the intrinsic derangement of base pairing was sufficient to promote the excision of a cluster of three adjacent L-deoxyribonucleosides without any requirement for mismatches. Thus, using stereoselective substrates, we demonstrate the participation of a recognition subunit that guides human NER activity to sites of defective Watson-Crick strand pairing, This conformational sensor detects labile hydrogen bonds irrespective of the type of deoxyribonucleotide modification.	Univ Zurich Tierspital, Inst Pharmacol & Toxicol, CH-8057 Zurich, Switzerland; CNR, Ist Composti Carbonio Contenenti Eteroatom & Appl, I-40129 Bologna, Italy	University of Zurich; Consiglio Nazionale delle Ricerche (CNR)	Naegeli, H (corresponding author), Univ Zurich Tierspital, Inst Pharmacol & Toxicol, Winterthurerstr 260, CH-8057 Zurich, Switzerland.	naegelih@vetpharm.unizh.ch	Capobianco, Massimo L/A-7401-2010	Capobianco, Massimo L/0000-0002-4237-1198				BLOMMERS MJJ, 1994, BIOCHEMISTRY-US, V33, P7886, DOI 10.1021/bi00191a016; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; DAMHA MJ, 1994, BIOCHEMISTRY-US, V33, P7877, DOI 10.1021/bi00191a015; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; FRITZ LK, 1995, BIOCHEMISTRY-US, V34, P13117, DOI 10.1021/bi00040a024; GAO SW, 1994, SCIENCE, V263, P1438, DOI 10.1126/science.8128226; GARBESI A, 1993, NUCLEIC ACIDS RES, V21, P4159, DOI 10.1093/nar/21.18.4159; Gunz D, 1996, J BIOL CHEM, V271, P25089, DOI 10.1074/jbc.271.41.25089; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HANSSON J, 1989, J BIOL CHEM, V264, P21788; Hess MT, 1996, NUCLEIC ACIDS RES, V24, P824, DOI 10.1093/nar/24.5.824; Hess MT, 1997, P NATL ACAD SCI USA, V94, P6664, DOI 10.1073/pnas.94.13.6664; Hess MT, 1996, CHEM BIOL, V3, P121, DOI 10.1016/S1074-5521(96)90288-4; Hess MT, 1997, MOL CELL BIOL, V17, P7069, DOI 10.1128/MCB.17.12.7069; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P12213, DOI 10.1073/pnas.91.25.12213; LAN SY, 1985, BIOCHEMISTRY-US, V24, P7771, DOI 10.1021/bi00347a041; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MATSUNAGA T, 1995, J BIOL CHEM, V270, P20862, DOI 10.1074/jbc.270.35.20862; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MITCHELL DL, 1988, PHOTOCHEM PHOTOBIOL, V48, P51; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; Moggs JG, 1997, NUCLEIC ACIDS RES, V25, P480, DOI 10.1093/nar/25.3.480; MU D, 1994, NUCLEIC ACIDS RES, V22, P4869, DOI 10.1093/nar/22.23.4869; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; Naegeli H, 1997, MECHANISMS DNA DAMAG; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SIBGHATULLAH, 1989, NUCLEIC ACIDS RES, V17, P4471, DOI 10.1093/nar/17.12.4471; SPADARI S, 1995, MOL PHARMACOL, V47, P1231; Tornaletti S, 1996, BIOESSAYS, V18, P221, DOI 10.1002/bies.950180309; Tornaletti S, 1996, MOL CARCINOGEN, V17, P192, DOI 10.1002/(SICI)1098-2744(199612)17:4<192::AID-MC2>3.0.CO;2-G; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; URATA H, 1993, J AM CHEM SOC, V115, P9852, DOI 10.1021/ja00074a083; VENEMA J, 1992, J BIOL CHEM, V267, P8852; WEI D, 1995, P NATL ACAD SCI USA, V92, P2204, DOI 10.1073/pnas.92.6.2204; Wei D, 1996, MOL CELL BIOL, V16, P3714; Wellinger RE, 1997, EMBO J, V16, P5046, DOI 10.1093/emboj/16.16.5046; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031	41	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27867	27872		10.1074/jbc.273.43.27867	http://dx.doi.org/10.1074/jbc.273.43.27867			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774397	hybrid			2022-12-27	WOS:000076549800017
J	Hsu, MH; Palmer, CNA; Song, W; Griffin, KJ; Johnson, EF				Hsu, MH; Palmer, CNA; Song, W; Griffin, KJ; Johnson, EF			A carboxyl-terminal extension of the zinc finger domain contributes to the specificity and polarity of peroxisome proliferator-activated receptor DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; ORPHAN NUCLEAR RECEPTOR; COA OXIDASE GENE; REV-ERBA-ALPHA; RESPONSE ELEMENT; DIRECT REPEATS; FATTY-ACIDS; ROR-ALPHA; BIFUNCTIONAL ENZYME; IDENTIFICATION	Heterodimers of the peroxisome proliferator-activated receptors (PPAR) and the retinoid X receptors (RXR) recognize response elements (PPREs) that exhibit the consensus sequence 5'-A(A/T)CT(A/G)GGNCAAAG(G/T)TCA-3', The consensus PPRE includes both a Fil-extension and a direct repeat (DR1) comprised of two canonical core recognition sequences (underlined) for nuclear receptor zinc fingers separated by a single nucleotide spacer. The extended binding site recognized by PPARs is very similar to sites that bind monomers of the nuclear receptors Rev-ErbA and ROR suggesting that the latter could bind to PPREs and affect gene transcription. However, Rev-ErbA and ROR bind weakly to naturally occurring PPREs relative to the consensus binding site, and significant effects on PPAR alpha transactivation of a CYP4A6-Z reporter were not observed. In contrast, PPAR/ RXR heterodimers bind to a DR2 element containing the conserved 5'-extended sequence that is recognized by dimers of ROR alpha or Rev-ErbA. PPAR alpha/RXR alpha positively regulate transcription from this element, and co-expression of Rev-ErbA blocks this effect. The nuclear receptors NGFI-B and ROR utilize a carboxyl-terminal extension (CTE) of the zinc finger DNA binding domain in their interactions with the 5'-extension of a single zinc finger-binding site. DNA binding domains (DBD) of PPARs alpha, delta, and gamma that contain the zinc finger motif and a CTE display binding to core recognition sequences that is dependent on the 5'-extended sequence found in PPREs. Unlike DBDs of other nuclear receptors that form heterodimers with RXR, the PPAR-DBDs did not exhibit cooperative binding with the DBD of RXR and exhibit the opposite polarity for binding to the direct repeat motif. In contrast to the corresponding DBD of RXR, the PPAR-DBDs bind as monomers to a single extended binding site as well as to the consensus PPRE. A chimera linking the zinc finger domain of RXR alpha to the CTE from PPAR alpha bound to a single extended binding site indicating a functional role for the CTE of PPARs in extended binding site recognition.	Scripps Res Inst, Div Biochem NX 4, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Johnson, EF (corresponding author), Scripps Res Inst, Div Biochem NX 4, Dept Mol & Expt Med, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Palmer, Colin NA/C-7053-2008	Palmer, Colin NA/0000-0002-6415-6560	NICHD NIH HHS [HD04445] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD004445] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD004445] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALDRIDGE TC, 1995, BIOCHEM J, V306, P473, DOI 10.1042/bj3060473; Austin S, 1998, CELL GROWTH DIFFER, V9, P267; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; BARDOT O, 1995, FEBS LETT, V360, P183, DOI 10.1016/0014-5793(95)00097-S; BARNES HJ, 1996, METHOD ENZYMOL, V275, P3; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CHAWLA A, 1993, J BIOL CHEM, V268, P16265; CHU RY, 1995, J BIOL CHEM, V270, P29636; DiRenzo J, 1997, MOL CELL BIOL, V17, P2166, DOI 10.1128/MCB.17.4.2166; DUMAS B, 1994, MOL ENDOCRINOL, V8, P996, DOI 10.1210/me.8.8.996; FORMAN BM, 1994, MOL ENDOCRINOL, V8, P1253, DOI 10.1210/me.8.9.1253; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GIGUERE V, 1995, MOL CELL BIOL, V15, P2517; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GRONEMEYER H, 1995, NATURE, V375, P190, DOI 10.1038/375190a0; HARDING HP, 1993, MOL CELL BIOL, V13, P3113, DOI 10.1128/MCB.13.5.3113; Harding HP, 1997, MOL ENDOCRINOL, V11, P1737, DOI 10.1210/me.11.11.1737; HARDING HP, 1995, MOL CELL BIOL, V15, P4791; HSU MH, 1995, MOL PHARMACOL, V48, P559; Ijpenberg A, 1997, J BIOL CHEM, V272, P20108, DOI 10.1074/jbc.272.32.20108; Johnson EF, 1996, FASEB J, V10, P1241, DOI 10.1096/fasebj.10.11.8836037; KATZ RW, 1994, J BIOL CHEM, V269, P18915; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; LEE MS, 1993, SCIENCE, V260, P1117, DOI 10.1126/science.8388124; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MCBROOM LDB, 1995, MOL CELL BIOL, V15, P796; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; Osada S, 1997, GENES CELLS, V2, P315, DOI 10.1046/j.1365-2443.1997.1220319.x; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; PALMER CNA, 1994, J BIOL CHEM, V269, P18083; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; RETNAKARAN R, 1994, MOL ENDOCRINOL, V8, P1234, DOI 10.1210/me.8.9.1234; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541; ZHANG XK, 1994, MOL CELL BIOL, V14, P4311, DOI 10.1128/MCB.14.6.4311	51	85	94	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27988	27997		10.1074/jbc.273.43.27988	http://dx.doi.org/10.1074/jbc.273.43.27988			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774413	hybrid			2022-12-27	WOS:000076549800033
J	Tantin, D				Tantin, D			RNA polymerase II elongation complexes containing the cockayne syndrome group B protein interact with a molecular complex containing the transcription factor IIH components xeroderma pigmentosum B and p62	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCISION-REPAIR; COUPLING FACTOR CSB/ERCC6; CDK-ACTIVATING KINASE; C-TERMINAL DOMAIN; DNA-REPAIR; ACTIVE GENES; SYNDROME CELLS; FACTOR TFIIH; PREFERENTIAL REPAIR; PROMOTER DNA	Transcription factor IIH (TFIIH) is involved both in transcription initiation by RNA polymerase II and in nucleotide excision-repair. Nucleotide excision-repair occurs at higher rates in transcriptionally active regions of the genome. Genetic studies indicate that this transcription-coupled repair is dependent on the Cockayne syndrome group A and B proteins, as well as TFIIH subunits. Previous work indicated that Cockayne syndrome group B interacts with RNA polymerase II molecules engaged in ternary complexes containing DNA and RNA. Evidence presented here indicates that this complex can interact with a factor containing the TFIIH core subunits p62 and xeroderma pigmentosum subunit B/excision repair cross-complementing 3. The targeting of TFIIH or a TFIIH-like repair factor to transcriptionally active DNA indicates a potential mechanism for transcription-coupled repair in human cells.	Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Tantin, D (corresponding author), MIT, Ctr Canc Res, 77 Massachusetts Ave,Bldg E17-529, Cambridge, MA 02139 USA.	dtantin@mit.edu			NIGMS NIH HHS [GM 46424, GM 07185] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046424] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balajee AS, 1997, P NATL ACAD SCI USA, V94, P4306, DOI 10.1073/pnas.94.9.4306; BARDWELL AJ, 1994, MOL CELL BIOL, V14, P3569, DOI 10.1128/MCB.14.6.3569; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; Dianov GL, 1997, NUCLEIC ACIDS RES, V25, P3636, DOI 10.1093/nar/25.18.3636; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; Dvir A, 1997, P NATL ACAD SCI USA, V94, P9006, DOI 10.1073/pnas.94.17.9006; Evans E, 1997, EMBO J, V16, P625, DOI 10.1093/emboj/16.3.625; Evans E, 1997, EMBO J, V16, P6559, DOI 10.1093/emboj/16.21.6559; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FLORES O, 1992, J BIOL CHEM, V267, P2786; Friedberg EC, 1996, ANNU REV BIOCHEM, V65, P15; GarciaMartinez LF, 1997, EMBO J, V16, P2836, DOI 10.1093/emboj/16.10.2836; Guzder SN, 1996, J BIOL CHEM, V271, P18314, DOI 10.1074/jbc.271.31.18314; He ZG, 1997, NUCLEIC ACIDS RES, V25, P1136, DOI 10.1093/nar/25.6.1136; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; HOIEJMAKERS JHJK, 1996, CURR OPIN GENE DEV, V6, P26; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; HUMBERT S, 1994, EMBO J, V13, P2393, DOI 10.1002/j.1460-2075.1994.tb06523.x; ITOH T, 1994, MUTAT RES, V314, P233, DOI 10.1016/0921-8777(94)90068-X; Iyer N, 1996, BIOCHEMISTRY-US, V35, P2157, DOI 10.1021/bi9524124; Larochelle S, 1998, GENE DEV, V12, P370, DOI 10.1101/gad.12.3.370; LEADON SA, 1993, P NATL ACAD SCI USA, V90, P10499, DOI 10.1073/pnas.90.22.10499; LEHMANN AR, 1995, TRENDS BIOCHEM SCI, V20, P402, DOI 10.1016/S0968-0004(00)89088-X; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; Marinoni JC, 1997, EMBO J, V16, P1093, DOI 10.1093/emboj/16.5.1093; MAYNE LV, 1982, CANCER RES, V42, P1473; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Nocentini S, 1997, J BIOL CHEM, V272, P22991, DOI 10.1074/jbc.272.37.22991; Nouspikel T, 1997, P NATL ACAD SCI USA, V94, P3116, DOI 10.1073/pnas.94.7.3116; OHKUMA Y, 1994, NATURE, V368, P160, DOI 10.1038/368160a0; PAN GH, 1994, J BIOL CHEM, V269, P30101; PARK CH, 1995, J BIOL CHEM, V270, P4896, DOI 10.1074/jbc.270.9.4896; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; Reardon JT, 1996, P NATL ACAD SCI USA, V93, P6482, DOI 10.1073/pnas.93.13.6482; REINBERG D, 1987, J BIOL CHEM, V262, P3310; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SCHMICKEL RD, 1977, PEDIATRICS, V60, P135; Selby CP, 1997, NUCLEIC ACIDS RES, V25, P787, DOI 10.1093/nar/25.4.787; Selby CP, 1997, P NATL ACAD SCI USA, V94, P11205, DOI 10.1073/pnas.94.21.11205; Selby CP, 1997, J BIOL CHEM, V272, P1885, DOI 10.1074/jbc.272.3.1885; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; TANTIN D, 1994, J BIOL CHEM, V269, P17397; Tantin D, 1997, MOL CELL BIOL, V17, P6803, DOI 10.1128/MCB.17.12.6803; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069; TIMMERS HTM, 1994, EMBO J, V13, P391, DOI 10.1002/j.1460-2075.1994.tb06273.x; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; vanOosterwijk MF, 1996, MOL CELL BIOL, V16, P4436; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; WANG ZG, 1995, MOL CELL BIOL, V15, P2288; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; You ZY, 1998, MOL CELL BIOL, V18, P2668, DOI 10.1128/MCB.18.5.2668; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479	64	72	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27794	27799		10.1074/jbc.273.43.27794	http://dx.doi.org/10.1074/jbc.273.43.27794			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774388	hybrid			2022-12-27	WOS:000076549800008
J	Yang, L; Embree, LJ; Tsai, S; Hickstein, DD				Yang, L; Embree, LJ; Tsai, S; Hickstein, DD			Oncoprotein TLS interacts with serine-arsnine proteins involved in RNA splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; HUMAN MYELOID-LEUKEMIA; C-TERMINAL DOMAIN; POLYMERASE-II; SR PROTEINS; IN-VIVO; BINDING PROTEIN; CHROMOSOMAL TRANSLOCATION; FACTOR SF2; FUSION	The gene encoding the human TLS protein, also termed FUS, is located at the site of chromosomal translocations in human leukemias and sarcomas where it forms a chimeric fusion gene with one of several different genes. To identify interacting partners of TLS, we screened a yeast two-hybrid cDNA library constructed from mouse hematopoietic cells using the C-terminal region of TLS in the bait plasmid. Two cDNAs encoding members of the serine-arginine (SR) family of proteins were isolated. The first SR protein is the mouse homolog of human splicing factor SC35, and the second SR member is a novel 183-amino acid protein that we term TASR (TLS-associated serine-arginine protein). cDNA cloning of human TASR indicated that mouse and human TASR have identical amino acid sequences. The interactions between TLS and these two SR proteins were confirmed by co-transfection and immunoprecipitation studies. In vivo splicing assays indicated that SC35 and TASR influence splice site selection of adenovirus E1A pre-mRNA. TLS may recruit SR splicing factors to specific target genes through interaction with its C-terminal region, and chromosomal translocations that truncate the C-terminal region of TLS may prevent this interaction. Thus TLS translocations may alter RNA processing and play a role in malignant transformation.	VA Puget Sound Hlth Care Syst, Med Res Serv, Seattle, WA 98108 USA; Univ Washington, Sch Med, Div Oncol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Div Mol Med, Seattle, WA 98195 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Hickstein, DD (corresponding author), VA Puget Sound Hlth Care Syst, Med Res Serv, 1660 S Columbian Way,GMR 151, Seattle, WA 98108 USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMREIN H, 1994, CELL, V76, P735, DOI 10.1016/0092-8674(94)90512-6; AYANE M, 1991, NUCLEIC ACIDS RES, V19, P1273, DOI 10.1093/nar/19.6.1273; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Chandler SD, 1997, P NATL ACAD SCI USA, V94, P3596, DOI 10.1073/pnas.94.8.3596; Cote GJ, 1997, J BIOL CHEM, V272, P1054, DOI 10.1074/jbc.272.2.1054; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; Hackl W, 1996, J MOL BIOL, V264, P843, DOI 10.1006/jmbi.1996.0681; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; Heinrichs V, 1997, P NATL ACAD SCI USA, V94, P115, DOI 10.1073/pnas.94.1.115; ICHIKAWA H, 1994, CANCER RES, V54, P2865; Jumaa H, 1997, MOL CELL BIOL, V17, P3116, DOI 10.1128/MCB.17.6.3116; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LESSNICK SL, 1995, ONCOGENE, V10, P423; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; Neugebauer KM, 1997, GENE DEV, V11, P3279, DOI 10.1101/gad.11.24.3279; PRASAD DDK, 1994, ONCOGENE, V9, P3717; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RING HJ, 1994, MOL CELL BIOL, V14, P7499, DOI 10.1128/MCB.14.11.7499; Rossi F, 1996, NATURE, V381, P80, DOI 10.1038/381080a0; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; STEPHENS C, 1987, EMBO J, V6, P2027, DOI 10.1002/j.1460-2075.1987.tb02467.x; SUN Q, 1993, GENE DEV, V7, P2598, DOI 10.1101/gad.7.12b.2598; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG J, 1995, RNA, V1, P335; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; ZAHLER AM, 1995, P NATL ACAD SCI USA, V92, P2642, DOI 10.1073/pnas.92.7.2642; Zhang D, 1998, J BIOL CHEM, V273, P18086, DOI 10.1074/jbc.273.29.18086; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; Zinszner H, 1997, J CELL SCI, V110, P1741	40	190	199	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27761	27764		10.1074/jbc.273.43.27761	http://dx.doi.org/10.1074/jbc.273.43.27761			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774382	hybrid			2022-12-27	WOS:000076549800002
J	Busch, R; Reich, Z; Zaller, DM; Sloan, V; Mellins, ED				Busch, R; Reich, Z; Zaller, DM; Sloan, V; Mellins, ED			Secondary structure composition and pH-dependent conformational changes of soluble recombinant HLA-DM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; INVARIANT CHAIN PEPTIDES; CLASS-II MOLECULES; ANTIGEN-PROCESSING MUTANT; DR MOLECULES; T-CELL; INTRACELLULAR-TRANSPORT; LYSOSOMAL PH; FC RECEPTOR; IN-VIVO	HLA-DM catalyzes the release of invariant chain fragments from newly synthesized major histocompatibility complex (MHC) class II molecules, stabilizes empty class II molecules, and edits class II-associated peptides by preferentially releasing those that are loosely bound. The ability of KLA-DM to carry out these functions in vitro is pH dependent, with an optimum at pH 4.5-5.5 and poor activity at pH 7, The structural basis for these properties of HLA-DM is unknown, Sequence homology suggests that HLA-DM resembles classical, peptide-binding MHC class II molecules. In this study, we examined whether HLA-DM has a secondary structure composition consistent with an MHC fold and whether HLA-DM changes conformation between pH 5 and pH 7. Far-UV circular dichroism (CD) spectra of recombinant soluble HLA-DM (sDM) indicate that HLA-DM belongs to the alpha/beta class of proteins and structurally resembles both MHC class I and class II molecules. The CD peak around 198 nm increases upon going from neutral to endosomal pH and drops sharply upon denaturation below pH 3.5, distinguishing at least three states of sDM: the denatured state and two highly similar folded states. Fluorescence emission spectra show a slight blue-shift and a approximate to 20% drop in intensity at pH 5 compared with pH 7. Unfolding experiments using guanidinium chloride show that the stability of sDM is somewhat reduced but not lost at pH 5. These results indicate that sDM undergoes a pH-dependent conformational change between neutral and endosomal pH. The change seems to involve both hydrogen bonding patterns and the hydrophobic core of sDM and may contribute to the pH dependence of DM activity.	Stanford Univ, Med Ctr, Dept Pediat, Stanford, CA 94305 USA; Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA; Merck Res Labs, Rahway, NJ 07065 USA	Stanford University; Howard Hughes Medical Institute; Stanford University; Merck & Company	Busch, R (corresponding author), Stanford Univ, Med Ctr, Dept Pediat, 300 Pasteur Dr, Stanford, CA 94305 USA.			Mellins, Elizabeth/0000-0003-2577-139X; Busch, Robert/0000-0002-4132-0751	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028809, R29AI028809] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-28809] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; AVVA RR, 1994, IMMUNITY, V1, P763, DOI 10.1016/S1074-7613(94)80018-9; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; Boniface JJ, 1996, J EXP MED, V183, P119, DOI 10.1084/jem.183.1.119; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BURMEISTER WP, 1994, NATURE, V372, P336, DOI 10.1038/372336a0; Busch R, 1998, J IMMUNOL, V160, P734; CHO SG, 1991, NATURE, V353, P573, DOI 10.1038/353573a0; Creighton T. E., 1993, PROTEINS STRUCTURES; Crowley MP, 1997, J EXP MED, V185, P1223, DOI 10.1084/jem.185.7.1223; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; Denzin LK, 1997, SCIENCE, V278, P106, DOI 10.1126/science.278.5335.106; Denzin LK, 1996, J EXP MED, V184, P2153, DOI 10.1084/jem.184.6.2153; DENZIN LK, 1994, IMMUNITY, V1, P595, DOI 10.1016/1074-7613(94)90049-3; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; Fremont DH, 1996, SCIENCE, V272, P1001, DOI 10.1126/science.272.5264.1001; FungLeung WP, 1996, SCIENCE, V271, P1278, DOI 10.1126/science.271.5253.1278; GASTINEL LN, 1992, P NATL ACAD SCI USA, V89, P638, DOI 10.1073/pnas.89.2.638; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GORGA JC, 1989, P NATL ACAD SCI USA, V86, P2321, DOI 10.1073/pnas.86.7.2321; GORGA JC, 1987, J BIOL CHEM, V262, P16087; GREEN JM, 1995, J IMMUNOL, V155, P3759; Guerra CB, 1998, J IMMUNOL, V160, P4289; Katz JF, 1996, J EXP MED, V184, P1747, DOI 10.1084/jem.184.5.1747; KELLY AP, 1991, NATURE, V353, P571, DOI 10.1038/353571a0; Kropshofer H, 1996, EMBO J, V15, P6144, DOI 10.1002/j.1460-2075.1996.tb01002.x; Kropshofer H, 1997, IMMUNOL TODAY, V18, P77, DOI 10.1016/S0167-5699(97)01006-2; Kropshofer H, 1997, IMMUNITY, V6, P293, DOI 10.1016/S1074-7613(00)80332-5; KROPSHOFER H, 1991, BIOCHEMISTRY-US, V30, P9177, DOI 10.1021/bi00102a008; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lightstone L, 1997, P NATL ACAD SCI USA, V94, P5772, DOI 10.1073/pnas.94.11.5772; Liljedahl M, 1998, IMMUNITY, V8, P233, DOI 10.1016/S1074-7613(00)80475-6; Martin WD, 1996, CELL, V84, P543, DOI 10.1016/S0092-8674(00)81030-2; MELLINS E, 1994, J EXP MED, V179, P541, DOI 10.1084/jem.179.2.541; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; MERELO JJ, 1994, NEUROCOMPUTING, V6, P443, DOI 10.1016/0925-2312(94)90021-3; Miyazaki T, 1996, CELL, V84, P531, DOI 10.1016/S0092-8674(00)81029-6; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; RADLEY E, 1994, J BIOL CHEM, V269, P18834; Reich Z, 1997, P NATL ACAD SCI USA, V94, P2495, DOI 10.1073/pnas.94.6.2495; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; Roche PA, 1996, SCIENCE, V274, P526, DOI 10.1126/science.274.5287.526; Runnels HA, 1996, J EXP MED, V183, P127, DOI 10.1084/jem.183.1.127; Sanderson F, 1996, IMMUNITY, V4, P87, DOI 10.1016/S1074-7613(00)80301-5; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; SHERMAN MA, 1995, IMMUNITY, V3, P197, DOI 10.1016/1074-7613(95)90089-6; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; Stang E, 1998, J IMMUNOL, V160, P4696; STROYNOWSKI I, 1995, CURR OPIN IMMUNOL, V7, P97, DOI 10.1016/0952-7915(95)80034-4; Ullrich HJ, 1997, P NATL ACAD SCI USA, V94, P13163, DOI 10.1073/pnas.94.24.13163; vanHam SM, 1997, CURR BIOL, V7, P950, DOI 10.1016/S0960-9822(06)00414-3; Vogt AB, 1996, P NATL ACAD SCI USA, V93, P9724, DOI 10.1073/pnas.93.18.9724; Weber DA, 1996, SCIENCE, V274, P618, DOI 10.1126/science.274.5287.618	55	45	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27557	27564		10.1074/jbc.273.42.27557	http://dx.doi.org/10.1074/jbc.273.42.27557			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765288	hybrid			2022-12-27	WOS:000076448000075
J	Picha, KM; Patel, SS				Picha, KM; Patel, SS			Bacteriophage T7 DNA helicase binds dTTP, forms hexamers, and binds DNA in the absence of Mg2+ - The presence of dTTP is sufficient for hexamer formation and DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; GENE-4 PROTEIN; OLIGOMERIC STRUCTURE; CRYSTAL-STRUCTURES; RAS P21; REPLICATION; RESOLUTION; HYDROLYSIS; ATP	The role of Mg2+ in dTTP hydrolysis, dTTP binding, hexamer formation, and DNA binding was studied in bacteriophage T7 DNA helicase (4A' protein). The steady state k(cat) for the dTTPase activity was 200-300-fold lower in the absence of MgCl2, but the K-m was only slightly affected, Direct dTTP binding experiments showed that the K-d of dTTP was unaffected, but the stoichiometry of dTTP binding was different in the absence of Mg2+. Two dTTPs were found to bind tightly in the absence of Mg2+ in contrast to three to four in the presence of Mg2+. I, the presence of DNA there was little difference in the stoichiometry of dTTP binding to 4A', These results indicate that Mg2+ is not necessary for dTTP binding, but Mg2+ is required for optimal hydrolysis of dTTP, Gel filtration of 4A' in the presence of dTTP without Mg2+ showed that Mg2+ was not necessary, and dTTP was sufficient for hexamer formation. The hexamers formed in the presence of dTTP without Mg2+ were capable of binding single-stranded DNA, However, the 4A' hexamers formed in the presence of dTDP with or without Mg2+ did not bind DNA, indicating that hexamer formation itself is not sufficient for DNA binding. The hexamers need to be in the correct conformation, in this case in the dTTP-bound state, to interact with the DNA. Thus, the gamma-phosphate of dTTP plays an important role in causing a conformational change in the protein that leads to stable interactions of 4A' with the DNA.	Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Patel, SS (corresponding author), Ohio State Univ, Dept Biochem, 484 W 12th Ave, Columbus, OH 43210 USA.	Patel.85@osu.edu			NIGMS NIH HHS [GM55310] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Ahnert P, 1997, J BIOL CHEM, V272, P32267, DOI 10.1074/jbc.272.51.32267; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31350; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; FINGER LR, 1982, J MOL BIOL, V156, P203, DOI 10.1016/0022-2836(82)90467-3; HINGORANI MM, 1993, BIOCHEMISTRY-US, V32, P12478, DOI 10.1021/bi00097a028; Hingorani MM, 1997, P NATL ACAD SCI USA, V94, P5012, DOI 10.1073/pnas.94.10.5012; Hingorani MM, 1996, BIOCHEMISTRY-US, V35, P2218, DOI 10.1021/bi9521497; Jezewska MJ, 1996, J BIOL CHEM, V271, P4261; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MATSON SW, 1985, J BIOL CHEM, V260, P2281; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MIWA Y, 1995, J MOL BIOL, V254, P815, DOI 10.1006/jmbi.1995.0658; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PATEL SS, 1992, J BIOL CHEM, V267, P15013; PATEL SS, 1995, BIOPHYS J, V68, pS186; PATEL SS, 1993, J BIOL CHEM, V268, P10668; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4043; SCHWEINS T, 1994, NAT STRUCT BIOL, V1, P476, DOI 10.1038/nsb0794-476; SCHWEINS T, 1995, NAT STRUCT BIOL, V2, P36, DOI 10.1038/nsb0195-36; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; Washington MT, 1996, J BIOL CHEM, V271, P26825, DOI 10.1074/jbc.271.43.26825; West SC, 1996, CELL, V86, P177, DOI 10.1016/S0092-8674(00)80088-4; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; Yu X, 1996, NAT STRUCT BIOL, V3, P740, DOI 10.1038/nsb0996-740	34	45	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27315	27319		10.1074/jbc.273.42.27315	http://dx.doi.org/10.1074/jbc.273.42.27315			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765257	hybrid			2022-12-27	WOS:000076448000044
J	Takai, H; Kanematsu, M; Yano, K; Tsuda, E; Higashio, K; Ikeda, K; Watanabe, K; Yamada, Y				Takai, H; Kanematsu, M; Yano, K; Tsuda, E; Higashio, K; Ikeda, K; Watanabe, K; Yamada, Y			Transforming growth factor-beta stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOCLAST-LIKE CELLS; MOUSE CALVARIA; CULTURES; OSTEOPETROSIS; RESORPTION; MICE; DIFFERENTIATION; OSTEOPOROSIS; CYTOKINES; DISEASE	Osteoprotegerin (OPG)/osteoclastogenesis inhibitory factor (OCIF) is a recently identified cytokine that belongs to the tumor necrosis factor receptor superfamily and regulates bone mass by inhibiting osteoclastic bone resorption. The present study was undertaken to determine whether OPG/OCIF is produced in bone microenvironment and how the expression is regulated. A transcript for OPG/OCIF at 3.1 kilobases was detected in bone marrow stromal cells (ST2 and MC3T3-G2/PA6) as well as in osteoblastic cells (MC3T3-E1). Transforming growth factor-beta 1 (TGF-beta 1) markedly increased the steady-state level of OPG/OCIF mRNA in a dose-dependent manner, while TGF-beta 1 suppressed the mRNA expression of tumor necrosis factor-related activation-induced cytokine (TRANCE)/receptor activator of NF-kappa B ligand (RANKL), a positive regulator of osteoclastogenesis to which OPG/OCIF binds. The effect of TGF-beta 1 on the expression of OPG/OCIF mRNA was transient, with a peak level at 3-6 h. The up-regulation of OPG/OCIF mRNA by TGF-beta 1 in ST2 cells did not require de novo protein synthesis and involved both a transcriptional and a post-transcriptional mechanism. Western blot analysis and an enzyme-linked immunosorbent assay revealed that TGF-beta 1 significantly increased the secretion of OPG/OCIF protein by ST2 cells at 6-24 h, In murine bone marrow cultures, TGF-beta 1 markedly inhibited the formation of tartrate-resistant acid phosphatase-positive multinucleated osteoclast like cells in the presence of 1,25-dihydroxyvitamin D-3, whose effect was significantly reversed by a neutralizing antibody against OPG/OCIF. These results suggest that TGF-beta 1 negatively regulates osteoclastogenesis, at least in part, through the induction of OPG/OCIF by bone marrow stromal cells and that the balance between OPG/OCIF and TRANCE/RANKL in local environment may be an important de terminant of osteoclastic bone resorption.	Natl Inst Longev Sci, Dept Geriatr Res, Aichi 4748522, Japan; Snow Brand Milk Prod Co Ltd, Life Sci Res Inst, Shimotsuga, Tochigi 3290521, Japan	Snow Brand Milk Products Co., Ltd.	Yamada, Y (corresponding author), Natl Inst Longev Sci, Dept Geriatr Res, 36-3 Gengo, Aichi 4748522, Japan.	yoyamada@nils.go.jp	Watanabe, Ken/I-3960-2013; Takai, Hiroyuki/B-8352-2011	Watanabe, Ken/0000-0003-0664-3915; 				Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27; CHENU C, 1988, P NATL ACAD SCI USA, V85, P5683, DOI 10.1073/pnas.85.15.5683; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIEUDONNE SC, 1991, J BONE MINER RES, V6, P479; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; HATTERSLEY G, 1991, J BONE MINER RES, V6, P165; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; JOYCE ME, 1990, J CELL BIOL, V110, P2195, DOI 10.1083/jcb.110.6.2195; KODAMA HA, 1982, J CELL PHYSIOL, V112, P89, DOI 10.1002/jcp.1041120114; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; LU X, 1989, Nucleic Acids Research, V17, P442, DOI 10.1093/nar/17.1.442; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; NODA M, 1989, ENDOCRINOLOGY, V124, P2991, DOI 10.1210/endo-124-6-2991; OGAWA M, 1988, EMBO J, V7, P1337, DOI 10.1002/j.1460-2075.1988.tb02949.x; Pacifici R, 1996, J BONE MINER RES, V11, P1043; PFEILSCHIFTER J, 1988, J CLIN INVEST, V82, P680, DOI 10.1172/JCI113647; Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308; SHINAR DM, 1990, ENDOCRINOLOGY, V126, P3153, DOI 10.1210/endo-126-6-3153; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Suda T, 1997, J BONE MINER RES, V12, P869, DOI 10.1359/jbmr.1997.12.6.869; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1373, DOI 10.1210/endo-122-4-1373; TASHJIAN AH, 1985, P NATL ACAD SCI USA, V82, P4535, DOI 10.1073/pnas.82.13.4535; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; Tsuda E, 1997, BIOCHEM BIOPH RES CO, V234, P137, DOI 10.1006/bbrc.1997.6603; UDAGAWA N, 1989, ENDOCRINOLOGY, V125, P1805, DOI 10.1210/endo-125-4-1805; WATANABE K, 1995, J CELL BIOL, V130, P1207, DOI 10.1083/jcb.130.5.1207; Yamaguchi K, 1998, J BIOL CHEM, V273, P5117, DOI 10.1074/jbc.273.9.5117; Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	37	246	260	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27091	27096		10.1074/jbc.273.42.27091	http://dx.doi.org/10.1074/jbc.273.42.27091			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765225	hybrid			2022-12-27	WOS:000076448000012
J	Takei, N; Numakawa, T; Kozaki, S; Sakai, N; Endo, Y; Takahashi, M; Hatanaka, H				Takei, N; Numakawa, T; Kozaki, S; Sakai, N; Endo, Y; Takahashi, M; Hatanaka, H			Brain-derived neurotrophic factor induces rapid and transient release of glutamate through the non-exocytotic pathway from cortical neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIPPOCAMPAL-NEURONS; SYNAPTIC TRANSMISSION; NERVOUS-SYSTEM; PLASTICITY; CA2+; BDNF; NGF; NEUROTRANSMITTER; STIMULATION; SECRETION	There is increasing interest in the involvement of neurotrophins in neural transmission and plasticity. Thus, Re investigated the effects of brain-derived neurotrophic factor (BDNF) on glutamate release from cortical neurons, Treatment of cultured cortical neurons with BDNF induced rapid and transient release of glutamate, This effect was suggested to be mediated by TrkB activation because R252a inhibited the release of glutamate and BDNF phosphorylated TrkB within 30 s, BDNF-induced glutamate release was observed even when using Ca2+-free assay buffer but was inhibited by BAPTA-AM, a cell-permeable Ca2+ chelator, Therefore, BDNF-induced glutamate release was independent of extracelluar Ca2+ but dependent on intracellular Ca2+. Because normal neurotransmitter release is exocytotic, the involvement of the exocytotic pathway in BDNF-induced glutamate release was examined. As botulinum toxin is known to cleave exocytosis-associated proteins, thereby inhibiting exocytosis, it was applied to neurons prior to the release assay. Although botulinum toxin B cleaved VAMP2 and inhibited Ca2+-triggered glutamate release, it did not inhibit the BDNF-induced release of glutamate. These results strongly suggested that BDNF induces rapid and transient release of glutamate from cortical neurons through a non-exocytotic pathway.	Kyoto Inst Technol, Dept Appl Biol, Sakyo Ku, Kyoto 606, Japan; Osaka Univ, Inst Prot Res, Div Prot Biosynthesis, Suita, Osaka 565, Japan; Osaka Prefecture Univ, Coll Agr, Dept Vet Sci, Sakai, Osaka 593, Japan; Mitsubishi Kasei Inst Life Sci, Machida, Tokyo 194, Japan	Kyoto Institute of Technology; Osaka University; Osaka Metropolitan University	Takei, N (corresponding author), Niigata Univ, Brain Res Inst, Dept Mol Neurobiol, Asahimachi 1, Niigata 9518585, Japan.	nobtak@bri.niigata-u.ac.jp						ADAMVIZI V, 1992, J NEUROCHEM, V58, P395, DOI 10.1111/j.1471-4159.1992.tb09736.x; ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; Bennett MK, 1997, CURR OPIN NEUROBIOL, V7, P316, DOI 10.1016/S0959-4388(97)80058-X; BERNINGER B, 1993, NEUROREPORT, V4, P1303, DOI 10.1097/00001756-199309150-00004; Berninger B, 1996, CURR OPIN NEUROBIOL, V6, P324, DOI 10.1016/S0959-4388(96)80115-2; Blochl A, 1996, J BIOL CHEM, V271, P21100; BLOCHL A, 1995, EUR J NEUROSCI, V7, P1220, DOI 10.1111/j.1460-9568.1995.tb01112.x; DAVIES AM, 1994, J NEUROBIOL, V25, P1334, DOI 10.1002/neu.480251103; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; Goda Y, 1997, P NATL ACAD SCI USA, V94, P769, DOI 10.1073/pnas.94.3.769; Heymach JV, 1996, J BIOL CHEM, V271, P25430, DOI 10.1074/jbc.271.41.25430; Kanai Y, 1995, NEUROREPORT, V6, P2357, DOI 10.1097/00001756-199511270-00020; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; KNIPPER M, 1994, NEUROREPORT, V5, P2433, DOI 10.1097/00001756-199412000-00007; LESSMANN V, 1994, NEUROREPORT, V6, P21; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; LINDHOLM D, 1994, J NEUROBIOL, V25, P1362, DOI 10.1002/neu.480251105; LO DC, 1995, NEURON, V15, P979, DOI 10.1016/0896-6273(95)90085-3; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; Niemann Heiner, 1994, Trends in Cell Biology, V4, P179, DOI 10.1016/0962-8924(94)90203-8; OHO C, 1995, NEUROSCI LETT, V186, P208, DOI 10.1016/0304-3940(95)11317-P; Sakai N, 1997, BRAIN RES, V778, P318, DOI 10.1016/S0006-8993(97)01052-4; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Takei N, 1997, J NEUROCHEM, V68, P370; TAKEI N, 1994, BRAIN RES, V652, P65, DOI 10.1016/0006-8993(94)90317-4; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Wildering WC, 1995, J NEUROPHYSIOL, V74, P2778, DOI 10.1152/jn.1995.74.6.2778	30	76	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27620	27624		10.1074/jbc.273.42.27620	http://dx.doi.org/10.1074/jbc.273.42.27620			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765296	hybrid			2022-12-27	WOS:000076448000083
J	Warshel, A				Warshel, A			Electrostatic origin of the catalytic power of enzymes and the role of preorganized active sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							BARRIER HYDROGEN-BONDS; SERINE PROTEASES; TRANSITION-STATE; ENZYMATIC CATALYSIS; MOLECULAR-DYNAMICS; PROTON ABSTRACTION; CARBON ACIDS; MECHANISM; ENERGY; TRIAD		Univ So Calif, Dept Chem, Los Angeles, CA 90089 USA	University of Southern California	Warshel, A (corresponding author), Univ So Calif, Dept Chem, Los Angeles, CA 90089 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024492] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 24492] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERY WJ, 1976, BIOCHEMISTRY-US, V15, P5631, DOI 10.1021/bi00670a032; AQVIST J, 1993, CHEM REV, V93, P2523, DOI 10.1021/cr00023a010; Arjunan P, 1996, J MOL BIOL, V256, P590, DOI 10.1006/jmbi.1996.0111; Ash EL, 1997, SCIENCE, V278, P1128, DOI 10.1126/science.278.5340.1128; Bahnson BJ, 1997, P NATL ACAD SCI USA, V94, P12797, DOI 10.1073/pnas.94.24.12797; Bala P, 1996, J PHYS CHEM-US, V100, P2535, DOI 10.1021/jp952642s; BASH PA, 1991, BIOCHEMISTRY-US, V30, P5826, DOI 10.1021/bi00238a003; BENKOVIC SJ, 1988, SCIENCE, V239, P1105, DOI 10.1126/science.3125607; BRUICE TC, 1971, P NATL ACAD SCI USA, V68, P658, DOI 10.1073/pnas.68.3.658; BRUICE TC, 1976, ANNU REV BIOCHEM, V45, P331, DOI 10.1146/annurev.bi.45.070176.001555; CARERI G, 1979, ANNU REV BIOPHYS BIO, V8, P69, DOI 10.1146/annurev.bb.08.060179.000441; CARTER P, 1989, PROTEINS, V6, P240, DOI 10.1002/prot.340060306; Cassidy CS, 1997, BIOCHEMISTRY-US, V36, P4576, DOI 10.1021/bi962013o; CHA Y, 1989, SCIENCE, V243, P1325, DOI 10.1126/science.2646716; CLELAND WW, 1994, SCIENCE, V264, P1887, DOI 10.1126/science.8009219; Cleland WW, 1998, J BIOL CHEM, V273, P25529, DOI 10.1074/jbc.273.40.25529; COREY DR, 1992, J AM CHEM SOC, V114, P4905, DOI 10.1021/ja00038a067; CRAIK CS, 1987, SCIENCE, V237, P909, DOI 10.1126/science.3303334; CROSBY J, 1970, J AM CHEM SOC, V92, P2891, DOI 10.1021/ja00712a048; DEWAR MJS, 1988, BIOCHEMISTRY-US, V27, P3302, DOI 10.1021/bi00409a027; DEWAR MJS, 1985, P NATL ACAD SCI USA, V82, P2225, DOI 10.1073/pnas.82.8.2225; DORIGO AE, 1988, ADV MOL MODELING, P135; Fersht A., 1985, ENZYME STRUCTURE MEC; FIFE TH, 1991, J AM CHEM SOC, V113, P7646, DOI 10.1021/ja00020a028; FREY PA, 1994, SCIENCE, V264, P1927, DOI 10.1126/science.7661899; Fuxreiter M, 1998, J AM CHEM SOC, V120, P183, DOI 10.1021/ja972326m; GAVISH B, 1979, BIOCHEMISTRY-US, V18, P1269, DOI 10.1021/bi00574a023; GERLT JA, 1993, BIOCHEMISTRY-US, V32, P11943, DOI 10.1021/bi00096a001; GERLT JA, 1993, J AM CHEM SOC, V115, P11552, DOI 10.1021/ja00077a062; Guthrie JP, 1996, CHEM BIOL, V3, P163; Hwang JK, 1996, J AM CHEM SOC, V118, P11745, DOI 10.1021/ja962007f; Jencks WP, 1986, CATALYSIS CHEM ENZYM; KIM HJ, 1992, J AM CHEM SOC, V114, P10508, DOI 10.1021/ja00052a055; KRISHTALIK LI, 1985, J THEOR BIOL, V112, P251, DOI 10.1016/S0022-5193(85)80285-X; LEATHERBARROW RJ, 1985, P NATL ACAD SCI USA, V82, P7840, DOI 10.1073/pnas.82.23.7840; Lee JK, 1997, SCIENCE, V276, P942, DOI 10.1126/science.276.5314.942; Lightstone FC, 1996, J AM CHEM SOC, V118, P2595, DOI 10.1021/ja952589l; Lightstone FC, 1997, P NATL ACAD SCI USA, V94, P8417, DOI 10.1073/pnas.94.16.8417; Lobaugh J, 1996, J CHEM PHYS, V104, P2056, DOI 10.1063/1.470962; MARCUS RA, 1956, J CHEM PHYS, V24, P966, DOI 10.1063/1.1742723; MCCAMMON JA, 1979, BIOCHEMISTRY-US, V18, P927, DOI 10.1021/bi00573a001; MENARD R, 1995, BIOCHEMISTRY-US, V34, P464, DOI 10.1021/bi00002a010; Mesecar AD, 1997, SCIENCE, V277, P202, DOI 10.1126/science.277.5323.202; MULHOLLAND AJ, 1993, PROTEIN ENG, V6, P133, DOI 10.1093/protein/6.2.133; Neria E, 1997, CHEM PHYS LETT, V267, P23, DOI 10.1016/S0009-2614(97)00068-7; Pan YP, 1998, J AM CHEM SOC, V120, P166, DOI 10.1021/ja972311o; Pan YP, 1997, J ORG CHEM, V62, P8171, DOI 10.1021/jo971290d; Pauling L., 1946, CHEM ENG NEWS, V24, P1375, DOI [10.1021/cen-v024n010.p1375, DOI 10.1021/CEN-V024N010.P1375]; RADIC Z, 1993, BIOCHEMISTRY-US, V32, P12074, DOI 10.1021/bi00096a018; Schweins T, 1996, BIOCHEMISTRY-US, V35, P14232, DOI 10.1021/bi961119g; SHOICHET BK, 1995, P NATL ACAD SCI USA, V92, P452, DOI 10.1073/pnas.92.2.452; VERNON CA, 1967, PROC R SOC SER B-BIO, V167, P389, DOI 10.1098/rspb.1967.0036; WARSHEL A, 1976, J MOL BIOL, V103, P227, DOI 10.1016/0022-2836(76)90311-9; WARSHEL A, 1984, P NATL ACAD SCI-BIOL, V81, P444, DOI 10.1073/pnas.81.2.444; WARSHEL A, 1989, BIOCHEMISTRY-US, V28, P3629, DOI 10.1021/bi00435a001; WARSHEL A, 1989, P NATL ACAD SCI USA, V86, P5820, DOI 10.1073/pnas.86.15.5820; WARSHEL A, 1988, J MOL BIOL, V201, P139, DOI 10.1016/0022-2836(88)90445-7; WARSHEL A, 1978, P NATL ACAD SCI USA, V75, P5250, DOI 10.1073/pnas.75.11.5250; Warshel A, 1996, P NATL ACAD SCI USA, V93, P13665, DOI 10.1073/pnas.93.24.13665; WARSHEL A, 1995, SCIENCE, V269, P102, DOI 10.1126/science.7661987; Warshel A, 1991, COMPUTER MODELING CH; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007; WILKS HM, 1988, SCIENCE, V242, P1541, DOI 10.1126/science.3201242; WOLFENDEN R, 1983, SCIENCE, V222, P1087, DOI 10.1126/science.6359416; YADAV A, 1991, J AM CHEM SOC, V113, P4800, DOI 10.1021/ja00013a013	65	456	459	0	42	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27035	27038		10.1074/jbc.273.42.27035	http://dx.doi.org/10.1074/jbc.273.42.27035			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765214	hybrid			2022-12-27	WOS:000076448000001
J	Kotera, J; Fujishige, K; Akatsuka, H; Imai, Y; Yanaka, N; Omori, K				Kotera, J; Fujishige, K; Akatsuka, H; Imai, Y; Yanaka, N; Omori, K			Novel alternative splice variants of cGMP-binding cGMP-specific phosphodiesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; N-TERMINAL DOMAIN; PROTEIN-KINASE; MESSENGER-RNA; NUCLEOTIDE PHOSPHODIESTERASES; MEMBRANE ASSOCIATION; CATALYTIC SUBUNIT; RPDE-6 RNPDE4A5; SMOOTH-MUSCLE; RAT-TISSUES	After our recent findings that the amino-terminal portion of rat cGMP-binding, cGMP-specific phosphodiesterase (cGB-PDE) differs from those of bovine and human cGB-PDEs, we found two forms of canine cGB-PDE cDNAs (CFPDEA1 and CFPDE5A2) in canine lung, Each contained a distinct amino-terminal sequence, CFPDE5A1, possessing an amino-terminal portion with sequence similar to those of bovine and human, and CFPDE5A2, having one similar to that of rat, Other portions coding for the cGMP binding domains and the catalytic domain mere conserved. Both CFPDE5A1 and CFPDE5A2 transcripts were detected in the cerebellum, hippocampus, retina, lung, heart, spleen, and thoracic artery. CFPDE5A1 transcripts were particularly abundant in the pylorus, whereas CFPDE5A2 transcripts were quite low in this tissue. CFPDE5A1 and CFPDE5A2 expressed in COS-7 cells had cGMP K-m values of 2.68 and 1.97 mu M, respectively, and both were inhibited by a low concentration of a cGB-PDE inhibitor, Zaprinast. Both CFPDE5A1 and CFPDE5A2 bound cGMP to their allosteric cGMP binding domains, and this cGMP binding was stimulated by 3-isobutyl-1-methylxanthine. Thus, two types of alternative splice variants of canine cGB-PDE have been identified and shown to have similar biological properties in vitro.	Tanabe Seiyaku Co Ltd, Discovery Res Lab, Toda, Saitama 3358505, Japan	Mitsubishi Tanabe Pharma Corporation	Omori, K (corresponding author), Tanabe Seiyaku Co Ltd, Discovery Res Lab, 2-50 Kawagishi-2-chome, Toda, Saitama 3358505, Japan.		Yanaka, Noriyuki/P-9096-2016					AHN HS, 1989, BIOCHEM PHARMACOL, V38, P331; BEAVO AJ, 1990, CYCLIC NUCLEOTIDE PH, V2; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Bolger GB, 1996, J BIOL CHEM, V271, P1065, DOI 10.1074/jbc.271.2.1065; BURNS F, 1992, BIOCHEM BIOPH RES CO, V189, P1389, DOI 10.1016/0006-291X(92)90228-D; BURNS F, 1992, BIOCHEM J, V283, P487, DOI 10.1042/bj2830487; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOK NJ, 1987, P NATL ACAD SCI USA, V84, P585, DOI 10.1073/pnas.84.2.585; COQUIL JF, 1985, BIOCHEM BIOPH RES CO, V127, P226, DOI 10.1016/S0006-291X(85)80148-0; Degerman E, 1997, J BIOL CHEM, V272, P6823, DOI 10.1074/jbc.272.11.6823; FRANCIS SH, 1980, J BIOL CHEM, V255, P620; FRANCIS SH, 1988, METHOD ENZYMOL, V159, P722; HAMET P, 1978, J CYCLIC NUCL PROT, V4, P281; HAMET P, 1988, METHOD ENZYMOL, V159, P710; Han P, 1997, J BIOL CHEM, V272, P16152, DOI 10.1074/jbc.272.26.16152; Huston E, 1996, J BIOL CHEM, V271, P31334, DOI 10.1074/jbc.271.49.31334; IGNARRO LJ, 1985, ANNU REV PHARMACOL, V25, P171, DOI 10.1146/annurev.pharmtox.25.1.171; Kotera J, 1997, EUR J BIOCHEM, V249, P434, DOI 10.1111/j.1432-1033.1997.t01-1-00434.x; KUKOVETZ WR, 1979, N-S ARCH PHARMACOL, V310, P129, DOI 10.1007/BF00500277; LINCOLN TM, 1983, ADV CYCL NUCL RES<D>, V15, P139; LINCOLN TM, 1976, P NATL ACAD SCI USA, V73, P2559, DOI 10.1073/pnas.73.8.2559; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; Lochhead A, 1997, J BIOL CHEM, V272, P18397, DOI 10.1074/jbc.272.29.18397; MARTIN W, 1986, J PHARMACOL EXP THER, V237, P539; McAllisterLucas LM, 1995, J BIOL CHEM, V270, P30671, DOI 10.1074/jbc.270.51.30671; MCALLISTERLUCAS LM, 1993, J BIOL CHEM, V268, P22863; MCPHEE I, 1995, BIOCHEM J, V310, P965, DOI 10.1042/bj3100965; OConnell JC, 1996, BIOCHEM J, V318, P255, DOI 10.1042/bj3180255; POLLI JW, 1994, J NEUROSCI, V14, P1251, DOI 10.1523/JNEUROSCI.14-03-01251.1994; REINHARDT RR, 1995, J CLIN INVEST, V95, P1528, DOI 10.1172/JCI117825; SCHRAMM M, 1984, SCIENCE, V225, P1350, DOI 10.1126/science.6147897; SCOTLAND G, 1995, BIOCHEM J, V308, P673, DOI 10.1042/bj3080673; SHAKUR Y, 1993, BIOCHEM J, V292, P677, DOI 10.1042/bj2920677; SOUNESS JE, 1989, BRIT J PHARMACOL, V98, P725, DOI 10.1111/j.1476-5381.1989.tb14599.x; THOMAS MK, 1990, J BIOL CHEM, V265, P14971; THOMAS MK, 1990, J BIOL CHEM, V265, P14964; Thompson W J, 1979, Adv Cyclic Nucleotide Res, V10, P69; Turko IV, 1998, BIOCHEM J, V329, P505; YAN C, 1994, J NEUROSCI, V14, P973; Yan C, 1996, J BIOL CHEM, V271, P25699, DOI 10.1074/jbc.271.41.25699; Yanaka N, 1998, EUR J BIOCHEM, V255, P391, DOI 10.1046/j.1432-1327.1998.2550391.x; Yanaka N, 1996, EUR J BIOCHEM, V237, P25, DOI 10.1111/j.1432-1033.1996.0025n.x	42	49	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26982	26990		10.1074/jbc.273.41.26982	http://dx.doi.org/10.1074/jbc.273.41.26982			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756948	hybrid			2022-12-27	WOS:000076373300102
J	Tolon, RM; Castillo, AI; Aranda, A				Tolon, RM; Castillo, AI; Aranda, A			Activation of the prolactin gene by peroxisome proliferator-activated receptor-alpha appears to be DNA binding-independent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; RETINOID-X-RECEPTOR; RAT GROWTH-HORMONE; TRANSCRIPTION FACTOR; ESTROGEN-RECEPTOR; NUCLEAR RECEPTORS; RESPONSE ELEMENTS; FATTY-ACIDS; PPAR-GAMMA; CROSS-TALK	Although the effects of the peroxisome proliferator-activated receptors (PPARs) have been studied primarily in adipocytes and liver, the wide distribution of these receptors suggests that they might also play a role in other cell types, We present evidence that PPAR activators stimulate the expression of the prolactin gene in pituitary GH4C1 cells. Transfection assays in non-pituitary HeLa cells showed that stimulation of the prolactin promoter by PPAR alpha requires the presence of the transcription factor GHF-1 (or Pit-1), Proximal promoter sequences confer responsiveness to PPAR alpha, and activation by this receptor is lost concomitantly with the response to GHF-1. Surprisingly, expression of the retinoid X receptor (RXR) abolishes stimulation by PPAR alpha, Furthermore, the promoter region that confers PPAR alpha responsiveness does not contain a PPAR response element. This suggests that the transcriptional effect of PPAR alpha might be mediated by protein-protein interactions rather than by binding of PPAR/RXR to the promoter. A direct interaction between PPAR alpha and GHF-1 was confirmed by in vitro binding studies, Expression of the coactivators SRC-1 and CREB-binding protein, which bind to PPAR, also enhanced the responsiveness of the prolactin promoter to PPAR alpha. Furthermore, CREB-binding protein also significantly increased activation by GHF-1, and both proteins associated in vitro, Thus, PPAR alpha, a receptor that normally acts as a ligand-dependent transcription factor by binding to specific DNA sequences in one context, can also stimulate the prolactin promoter by association with GHF-1 and coactivator proteins.	CSIC, Inst Invest Biomed, E-28029 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Aranda, A (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.	aaranda@iib.uam.es	Aranda, Ana/ABG-8820-2020; Castillo, Ana/I-1269-2017; Tolón, Rosa/AAA-9401-2019; Tolón, Rosa M M/N-4364-2015	Aranda, Ana/0000-0002-8338-9589; Castillo, Ana/0000-0002-2873-1206; Tolón, Rosa M M/0000-0003-1087-4505				BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BERKENSTAM A, 1992, CELL, V69, P401, DOI 10.1016/0092-8674(92)90443-G; BLANCO JCG, 1995, P NATL ACAD SCI USA, V92, P1535, DOI 10.1073/pnas.92.5.1535; BODNER M, 1987, CELL, V50, P267, DOI 10.1016/0092-8674(87)90222-4; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Castillo AI, 1998, ONCOGENE, V16, P1981, DOI 10.1038/sj.onc.1200204; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; DAY RN, 1990, MOL ENDOCRINOL, V4, P1964, DOI 10.1210/mend-4-12-1964; DiRenzo J, 1997, MOL CELL BIOL, V17, P2166, DOI 10.1128/MCB.17.4.2166; Dowell P, 1997, J BIOL CHEM, V272, P2013, DOI 10.1074/jbc.272.3.2013; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; ELSHOLTZ HP, 1992, SEMIN REPROD ENDOCR, V10, P183, DOI 10.1055/s-2007-1018875; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GarciaVillalba P, 1996, MOL CELL BIOL, V16, P318; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GUBBINS EJ, 1980, J BIOL CHEM, V255, P8655; GUTIERREZHARTMANN A, 1994, MOL ENDOCRINOL, V8, P1447, DOI 10.1210/me.8.11.1447; HADZIC E, 1995, MOL CELL BIOL, V15, P4507; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; ING NH, 1992, J BIOL CHEM, V267, P17617; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JACOB KK, 1994, J BIOL CHEM, V269, P25515; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; JUGEAUBRY CE, 1995, J BIOL CHEM, V270, P18117, DOI 10.1074/jbc.270.30.18117; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KELLER H, 1993, TRENDS ENDOCRIN MET, V4, P291, DOI 10.1016/1043-2760(93)90048-J; KELLER H, 1995, MOL ENDOCRINOL, V9, P794, DOI 10.1210/me.9.7.794; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; LEBLANC BP, 1995, GENE DEV, V9, P1811, DOI 10.1101/gad.9.15.1811; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MAURER RA, 1987, MOL CELL BIOL, V7, P4247, DOI 10.1128/MCB.7.12.4247; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MONTE D, 1995, ONCOGENE, V11, P771; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; PALOMINO T, 1998, IN PRESS FASEB J; QI JS, 1995, MOL CELL BIOL, V15, P1817; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Sanchez-Pacheco A, 1998, FEBS LETT, V422, P103, DOI 10.1016/S0014-5793(97)01609-8; SCHAUFELE F, 1992, MOL ENDOCRINOL, V6, P656, DOI 10.1210/me.6.4.656; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; THEILL LE, 1992, EMBO J, V11, P2261, DOI 10.1002/j.1460-2075.1992.tb05285.x; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; VOSS JW, 1992, CELL, V70, P527, DOI 10.1016/0092-8674(92)90422-9; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218	60	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26652	26661		10.1074/jbc.273.41.26652	http://dx.doi.org/10.1074/jbc.273.41.26652			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756906	hybrid			2022-12-27	WOS:000076373300060
J	Zhang, FX; Rubin, R; Rooney, TA				Zhang, FX; Rubin, R; Rooney, TA			N-methyl-D-aspartate inhibits apoptosis through activation of phosphatidylinositol 3-kinase in cerebellar granule neurons - A role for insulin receptor substrate-1 in the neurotrophic action of N-methyl-D-aspartate and its inhibition by ethanol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCITATORY AMINO-ACIDS; CENTRAL-NERVOUS-SYSTEM; FETAL ALCOHOL SYNDROME; PROTEIN-KINASE AKT; IGF-I RECEPTOR; GROWTH-FACTOR; GLUTAMATE RECEPTORS; CELL-DEATH; SURVIVAL; NMDA	Primary cultured rat cerebellar granule neurons underwent apoptosis when switched from medium containing 25 mM K+ to one containing 5 mM K+, N-methyl-D-aspartate (NMDA) protected granule neurons from apoptosis in medium containing 5 mM K+. Inhibition of apoptosis by NMDA was blocked by the phosphatidylinositol 3-kinase (PI 3-kinase) inhibitor LY294002, but it was unaffected by the mitogen-activated protein kinase kinase inhibitor PD 98059. The antiapoptotic action of NMDA was associated with an increase in the tyrosine phosphorylation of insulin receptor substrate 1 (IRS-1), an increase in the binding of the regulatory subunit of PI 3-kinase to IRS-1, and a stimulation of PI 3-kinase activity. In the absence of extracellular Ca2+, NMDA was unable to prevent apoptosis or to phosphorylate IRS-1 and activate PI 3-kinase. Significant inhibition of NMDA-mediated neuronal survival by ethanol (10-15%) was observed at 1 mM, and inhibition was half-maximal at 45-50 rmM. Inhibition of neuronal survival by ethanol corresponded with a marked reduction in the capacity of NMDA to increase the concentration of intracellular Ca2+, phosphorylate IRS-1, and activate PI 3-kinase, These data demonstrate that the neurotrophic action of NMDA and its inhibition by ethanol are mediated by alterations in the activity of a PI 3-kinase-dependent antiapoptotic signaling pathway.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Jefferson University	Rooney, TA (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, 1020 Locust St, Philadelphia, PA 19107 USA.	rooneyt@jeflin.tju.edu			NIAAA NIH HHS [K02 AA123, AA09976, AA10413] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009976, R29AA010413] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; BALAZS R, 1992, MOL NEUROPHARMACOL, V2, P203; Barnard EA, 1997, TRENDS PHARMACOL SCI, V18, P141, DOI 10.1016/S0165-6147(97)01053-5; BAUERMOFFETT C, 1977, BRAIN RES, V119, P249, DOI 10.1016/0006-8993(77)90310-9; Bhave SV, 1997, J NEUROCHEM, V68, P578, DOI 10.1046/j.1471-4159.1997.68020578.x; Burfoot MS, 1997, J BIOL CHEM, V272, P24183, DOI 10.1074/jbc.272.39.24183; CHOI DW, 1994, PROG BRAIN RES, V100, P47; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; D'Mello SR, 1997, J NEUROSCI, V17, P1548; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; DErcole AJ, 1996, MOL NEUROBIOL, V13, P227, DOI 10.1007/BF02740625; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FARR KL, 1988, ALCOHOL, V5, P125, DOI 10.1016/0741-8329(88)90009-2; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GALLO V, 1987, J NEUROSCI, V7, P2203; Guo DQ, 1996, J BIOL CHEM, V271, P615, DOI 10.1074/jbc.271.2.615; HACK N, 1993, NEUROSCIENCE, V57, P9, DOI 10.1016/0306-4522(93)90108-R; HOFFMAN PL, 1989, J NEUROCHEM, V52, P1937, DOI 10.1111/j.1471-4159.1989.tb07280.x; JONES KL, 1973, LANCET, V2, P999; Joyal JL, 1997, J BIOL CHEM, V272, P28183, DOI 10.1074/jbc.272.45.28183; KATO H, 1993, J BIOL CHEM, V268, P2655; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; MANEV H, 1989, MOL PHARMACOL, V36, P106; MANTHORPE M, 1986, DEV BRAIN RES, V25, P191, DOI 10.1016/0165-3806(86)90208-7; MARCUS JC, 1987, NEUROPEDIATRICS, V18, P158, DOI 10.1055/s-2008-1052471; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723, DOI 10.1152/physrev.1994.74.3.723; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; Miller TM, 1997, J BIOL CHEM, V272, P9847; Miyakawa T, 1997, SCIENCE, V278, P698, DOI 10.1126/science.278.5338.698; MORRISETT RA, 1989, ALCOHOL, V6, P415, DOI 10.1016/0741-8329(89)90013-X; Munshi HG, 1996, BIOCHEMISTRY-US, V35, P15883, DOI 10.1021/bi962107y; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; Ono T, 1997, J BIOL CHEM, V272, P14404, DOI 10.1074/jbc.272.22.14404; PANTAZIS NJ, 1995, ALCOHOL CLIN EXP RES, V19, P846, DOI 10.1111/j.1530-0277.1995.tb00957.x; PANTAZIS NJ, 1993, ALCOHOL CLIN EXP RES, V17, P1014, DOI 10.1111/j.1530-0277.1993.tb05657.x; PETERSON JE, 1994, J BIOL CHEM, V269, P27315; Peterson JE, 1996, J BIOL CHEM, V271, P31562, DOI 10.1074/jbc.271.49.31562; QUEEN SA, 1993, ALCOHOL CLIN EXP RES, V17, P887, DOI 10.1111/j.1530-0277.1993.tb00859.x; RESNICOFF M, 1994, LAB INVEST, V71, P657; RESNICOFF M, 1993, J BIOL CHEM, V268, P21777; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Sucher NJ, 1996, TRENDS PHARMACOL SCI, V17, P348, DOI 10.1016/S0165-6147(96)10046-8; Sun XJ, 1996, J BIOL CHEM, V271, P10583, DOI 10.1074/jbc.271.18.10583; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VOLK B, 1984, ACTA NEUROPATHOL, V63, P57, DOI 10.1007/BF00688471; WEGELIUS K, 1995, ACTA PHYSIOL SCAND, V154, P25, DOI 10.1111/j.1748-1716.1995.tb09882.x; WOODWARD JJ, 1990, J NEUROCHEM, V54, P712, DOI 10.1111/j.1471-4159.1990.tb01931.x; Yamada M, 1997, J BIOL CHEM, V272, P30334, DOI 10.1074/jbc.272.48.30334; YAN GM, 1994, BRAIN RES, V656, P43, DOI 10.1016/0006-8993(94)91364-1; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang FX, 1998, J NEUROCHEM, V71, P196, DOI 10.1046/j.1471-4159.1998.71010196.x; ZOU JY, 1995, ALCOHOL CLIN EXP RES, V19, P840, DOI 10.1111/j.1530-0277.1995.tb00956.x	61	66	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26596	26602		10.1074/jbc.273.41.26596	http://dx.doi.org/10.1074/jbc.273.41.26596			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756898	hybrid			2022-12-27	WOS:000076373300052
J	Barbieri, MA; Hoffenberg, S; Roberts, R; Mukhopadhyay, A; Pomrehn, A; Dickey, BF; Stahl, PD				Barbieri, MA; Hoffenberg, S; Roberts, R; Mukhopadhyay, A; Pomrehn, A; Dickey, BF; Stahl, PD			Evidence for a symmetrical requirement for Rab5-GTP in in vitro endosome-endosome fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL GTPASE RAB5; ENDOCYTIC MEMBRANE-FUSION; XANTHINE NUCLEOTIDES; GDP/GTP EXCHANGE; PROTEIN; VACUOLES; RABAPTIN-5; TRANSPORT; EFFECTOR; VESICLES	Early endosome fusion, which has been extensively characterized using an in vitro reconstitution assay, is Rab5-dependent. To examine the requirement for Rab5 on both fusion partners, we prepared cytosol and endosomes depleted of Rab5, Unlike control cytosol, Rab5-depleted cytosol was only marginally active in the in vitro endosome fusion. However, fusion could be restored by the addition of wild-type Rab5 or Rab5 D136N, a mutant whose nucleotide specificity favors xanthine over guanine. The addition of Rab5 D136N restored fusion only in the presence of XTP. In the absence of XTP or in the presence of XDP, Rab5 D136N failed to restore fusion, When fusion was carried out with endosomal vesicles depleted of Rab GTPases (by preincubation of vesicles with GDP dissociation inhibitor), together with cytosol immunodepleted of Rab5, fusion was virtually absent. We then used immunodepleted cytosol and GDP dissociation inhibitor-treated vesicles to determine whether Rab5 is required by both fusion partners. Using separate sets of endosomal vesicles, we found that priming both sets of Rab5-depleted vesicles with Rab5 Q79L, a GTPase defective mutant, substantially stimulated endosome fusion. Priming one set of vesicles with Rab5 Q79L and a second set of vesicles with Rab5 S34N failed to activate fusion. When both sets of Rab5-depleted vesicles mere primed with Rab5 D136N supplemented with XTP, endosome fusion was stimulated, similar to that observed with Rab5 Q79L. However, when one set of vesicles was preincubated with Rab5 D136N plus XTP and the second set with Rab5 D136N and XDP, no stimulation of fusion was observed. We conclude that Rab5-GTP is required on both fusion partners for docking and fusion of early endosomes. To confirm the fusion of Rab5-GTP-positive vesicles in vivo, we expressed GFP-Rab5 Q79L in fibroblasts and observed fusion of Rab5-positive vesicles. We failed to record fusion of Rab5-positive vesicles with Rab5-negative vesicles. We conclude that Rab5-GTP is required on both sets of endosomes for fusion in vitro and in living cells.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Washington University (WUSTL); Baylor College of Medicine	Stahl, PD (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA.	pstahl@cellbio.wustl.edu	Stahl, Philip/D-6315-2012					ALEXANDROV K, 1994, EMBO J, V13, P5262, DOI 10.1002/j.1460-2075.1994.tb06860.x; AlvarezDominguez C, 1996, J BIOL CHEM, V271, P13834, DOI 10.1074/jbc.271.23.13834; BARBIERI MA, 1994, J BIOL CHEM, V269, P18720; Barbieri MA, 1996, ARCH BIOCHEM BIOPHYS, V326, P64, DOI 10.1006/abbi.1996.0047; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; DIAZ R, 1988, J BIOL CHEM, V263, P6093; Gournier H, 1998, EMBO J, V17, P1930, DOI 10.1093/emboj/17.7.1930; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; HEUSER J, 1993, J CELL BIOL, V121, P1311, DOI 10.1083/jcb.121.6.1311; HOFFENBERG S, 1995, BIOCHEM BIOPH RES CO, V215, P241, DOI 10.1006/bbrc.1995.2459; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; LI GP, 1994, J BIOL CHEM, V269, P14631; LI GP, 1993, J BIOL CHEM, V268, P24475; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; MAYORGA LS, 1989, CELL REGUL, V1, P113, DOI 10.1091/mbc.1.1.113; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; NOUFFER C, 1994, ANNU REV BIOCHEM, V63, P949; Ohya T, 1998, J BIOL CHEM, V273, P613, DOI 10.1074/jbc.273.1.613; Patel SK, 1998, CELL, V92, P611, DOI 10.1016/S0092-8674(00)81129-0; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; Schmidt G, 1996, ONCOGENE, V12, P87; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Sweet DJ, 1996, J CELL BIOL, V133, P971, DOI 10.1083/jcb.133.5.971; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; Yanachkov I, 1997, MOL PHARMACOL, V51, P47, DOI 10.1124/mol.51.1.47; Yu B, 1997, J BIOL CHEM, V272, P18015, DOI 10.1074/jbc.272.29.18015	34	62	63	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25850	25855		10.1074/jbc.273.40.25850	http://dx.doi.org/10.1074/jbc.273.40.25850			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748259	hybrid			2022-12-27	WOS:000076263100050
J	Chinetti, G; Griglio, S; Antonucci, M; Torra, IP; Delerive, P; Majd, Z; Fruchart, JC; Chapman, J; Najib, J; Staels, B				Chinetti, G; Griglio, S; Antonucci, M; Torra, IP; Delerive, P; Majd, Z; Fruchart, JC; Chapman, J; Najib, J; Staels, B			Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PPAR-GAMMA; FATTY-ACIDS; CHOLESTEROL DEPOSITION; GENE-EXPRESSION; ATHEROSCLEROSIS; LIPOPROTEIN; INHIBITION; BINDING; DIFFERENTIATION	Peroxisome proliferator-activated receptors (PPARs) have been implicated in metabolic diseases, such as obesity, diabetes, and atherosclerosis, due to their activity in liver and adipose tissue on genes involved in lipid and glucose homeostasis. Here, we show that the PPAR alpha and PPAR gamma forms are expressed in differentiated human monocyte-derived macrophages, which participate in inflammation control and atherosclerotic plaque formation. Whereas PPAR alpha is already present in undifferentiated monocytes, PPAR gamma expression is induced upon differentiation into macrophages. Immunocytochemistry analysis demonstrates that PPAR alpha resides constitutively in the cytoplasm, whereas PPAR gamma is predominantly nuclear localized. Transient transfection experiments indicate that PPAR alpha and PPAR gamma are transcriptionally active after ligand stimulation. Ligand activation of PPAR gamma, but not of PPAR alpha, results in apoptosis induction of unactivated differentiated macrophages as measured by the TUNEL assay and the appearance of the active proteolytic subunits of the cell death protease caspase-3. However, both PPAR alpha and PPAR gamma ligands induce apoptosis of macrophages activated with tumor necrosis factor alpha/interferon gamma. Finally, PPAR gamma inhibits the transcriptional activity of the NF kappa B p65/RelA subunit, suggesting that PPAR activators induce macrophage apoptosis by negatively interfering with the anti-apoptotic NF kappa B signaling pathway. These data demonstrate a novel function of PPAR in human macrophages with likely consequences in inflammation and atherosclerosis.	Inst Pasteur, INSERM, U325, Dept Atherosclerose, F-59019 Lille, France; Univ Lille 2, Fac Pharm, F-59006 Lille, France; Hop La Pitie Salpetriere, INSERM, U321, F-75651 Paris 13, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; Universite de Lille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Staels, B (corresponding author), Inst Pasteur, INSERM, U325, Dept Atherosclerose, 1 Rue Calmette, F-59019 Lille, France.	Bart.Staels@pasteur-lille.fr	chinetti, giulia/Q-6901-2016; Staels, Bart/N-9497-2016	chinetti, giulia/0000-0001-8048-8138; Staels, Bart/0000-0002-3784-1503				ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; AQEL NM, 1984, ATHEROSCLEROSIS, V53, P265, DOI 10.1016/0021-9150(84)90127-8; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bjorkerud S, 1996, AM J PATHOL, V149, P367; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BROWN MS, 1990, NATURE, V343, P508, DOI 10.1038/343508a0; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Ericsson CG, 1996, LANCET, V347, P849, DOI 10.1016/S0140-6736(96)91343-4; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Frick MH, 1997, CIRCULATION, V96, P2137; GENG YJ, 1995, AM J PATHOL, V147, P251; GERRITY RG, 1979, AM J PATHOL, V95, P775; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Guyton John R., 1994, Current Opinion in Lipidology, V5, P376, DOI 10.1097/00041433-199410000-00010; HANSSON GK, 1989, ARTERIOSCLEROSIS, V9, P567, DOI 10.1161/01.ATV.9.5.567; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; ISNER JM, 1995, CIRCULATION, V91, P2703, DOI 10.1161/01.CIR.91.11.2703; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Law RE, 1996, J CLIN INVEST, V98, P1897, DOI 10.1172/JCI118991; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Libby P, 1996, CURR OPIN LIPIDOL, V7, P330, DOI 10.1097/00041433-199610000-00012; Mallat Z, 1997, CIRCULATION, V96, P424; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MINAMIKAWA J, 1909, J CLIN ENDOCR METAB, V83, P1041; MUKHERJEE R, 1994, J STEROID BIOCHEM, V51, P157, DOI 10.1016/0960-0760(94)90089-2; MUNRO JM, 1988, LAB INVEST, V58, P249; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; ROSENFELD ME, 1987, ARTERIOSCLEROSIS, V7, P9, DOI 10.1161/01.ATV.7.1.9; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROUIS M, 1990, ARTERIOSCLEROSIS, V10, P246, DOI 10.1161/01.ATV.10.2.246; Saitoh Kiyoshi, 1995, Folia Pharmacologica Japonica, V106, P41, DOI 10.1254/fpj.106.41; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; Shalev A, 1996, ENDOCRINOLOGY, V137, P4499, DOI 10.1210/en.137.10.4499; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WYLLIE AH, 1992, CANCER METAST REV, V11, P95, DOI 10.1007/BF00048057; Zhang B, 1996, MOL ENDOCRINOL, V10, P1457, DOI 10.1210/me.10.11.1457	55	790	820	0	32	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25573	25580		10.1074/jbc.273.40.25573	http://dx.doi.org/10.1074/jbc.273.40.25573			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748221	hybrid			2022-12-27	WOS:000076263100012
J	Cleland, WW; Frey, PA; Gerlt, JA				Cleland, WW; Frey, PA; Gerlt, JA			The low barrier hydrogen bond in enzymatic catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NUCLEAR MAGNETIC-RESONANCE; AB-INITIO; TRIOSEPHOSPHATE ISOMERASE; SERINE PROTEASES; ACTIVE-SITE; TRIFLUOROMETHYL KETONE; MANDELATE RACEMASE; CHYMOTRYPSIN; MECHANISM; HISTIDINE		Univ Wisconsin, Inst Enzyme Res, Madison, WI 53705 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Wisconsin System; University of Wisconsin Madison; University of Illinois System; University of Illinois Urbana-Champaign	Cleland, WW (corresponding author), Univ Wisconsin, Inst Enzyme Res, Madison, WI 53705 USA.							ABUDARI K, 1979, J AM CHEM SOC, V101, P3688, DOI 10.1021/ja00507a059; ABUDARI K, 1979, INORG CHEM, V18, P2427, DOI 10.1021/ic50199a020; BRADY K, 1990, BIOCHEMISTRY-US, V29, P7600, DOI 10.1021/bi00485a009; Cassidy CS, 1997, BIOCHEMISTRY-US, V36, P4576, DOI 10.1021/bi962013o; CLELAND WW, 1994, SCIENCE, V264, P1887, DOI 10.1126/science.8009219; FREY PA, 1994, SCIENCE, V264, P1927, DOI 10.1126/science.7661899; GarciaViloca M, 1997, J AM CHEM SOC, V119, P1081, DOI 10.1021/ja962662n; Gerlt JA, 1997, CHEM BIOL, V4, P259, DOI 10.1016/S1074-5521(97)90069-7; GERLT JA, 1993, BIOCHEMISTRY-US, V32, P11934; GILLI P, 1994, J AM CHEM SOC, V116, P909, DOI 10.1021/ja00082a011; GU Z, 1998, IN PRESS BIOCHEMISTR, V37; Guthrie JP, 1996, CHEM BIOL, V3, P163; Halkides CJ, 1996, BIOCHEMISTRY-US, V35, P15941, DOI 10.1021/bi961805f; Harris TK, 1997, BIOCHEMISTRY-US, V36, P14661, DOI 10.1021/bi972039v; Hibbert F., 1990, ADV PHYS ORG CHEM, V26, P255, DOI DOI 10.1016/S0065-3160(08)60047-7; KREEVOY MM, 1980, J AM CHEM SOC, V102, P3315, DOI 10.1021/ja00530a002; Kumar GA, 1998, J AM CHEM SOC, V120, P3159, DOI 10.1021/ja972745j; LANDRO JA, 1994, BIOCHEMISTRY-US, V33, P635, DOI 10.1021/bi00169a003; Larsen TM, 1996, BIOCHEMISTRY-US, V35, P4349, DOI 10.1021/bi952859c; LIANG TC, 1987, BIOCHEMISTRY-US, V26, P7603, DOI 10.1021/bi00398a011; LODI PJ, 1991, BIOCHEMISTRY-US, V30, P6948, DOI 10.1021/bi00242a020; Markley JL, 1996, BIOCHEMISTRY-US, V35, P11092, DOI 10.1021/bi961366k; McAllister MA, 1997, CAN J CHEM, V75, P1195, DOI 10.1139/v97-144; MELOCHE HP, 1983, J PROTEIN CHEM, V2, P399, DOI 10.1007/BF01025238; MITRA B, 1995, BIOCHEMISTRY-US, V34, P2777, DOI 10.1021/bi00009a006; NICKBARG EB, 1988, BIOCHEMISTRY-US, V27, P5948, DOI 10.1021/bi00416a019; Paetzel M, 1997, J BIOL CHEM, V272, P9994; Pan YP, 1997, J AM CHEM SOC, V119, P7561, DOI 10.1021/ja9709684; Pan YP, 1998, J AM CHEM SOC, V120, P166, DOI 10.1021/ja972311o; Pan YP, 1997, J ORG CHEM, V62, P8171, DOI 10.1021/jo971290d; Pudzianowski AT, 1997, RRD PHYS CHEM, V1, P81; Remington S. J., 1992, CURR OPIN STRUC BIOL, V2, P730, DOI 10.1016/0959-440X(92)90208-0; ROBILLAR.G, 1974, J MOL BIOL, V86, P541, DOI 10.1016/0022-2836(74)90179-X; ROBILLARD G, 1972, J MOL BIOL, V71, P507, DOI 10.1016/0022-2836(72)90366-X; SCHEINER S, 1995, J AM CHEM SOC, V117, P6970, DOI 10.1021/ja00131a020; Shan SO, 1996, P NATL ACAD SCI USA, V93, P14474, DOI 10.1073/pnas.93.25.14474; Shan SO, 1996, SCIENCE, V272, P97, DOI 10.1126/science.272.5258.97; Smallwood CJ, 1997, J AM CHEM SOC, V119, P11277, DOI 10.1021/ja972517p; STEINER T, 1994, ACTA CRYSTALLOGR B, V50, P348, DOI 10.1107/S0108768193011966; STEITZ TA, 1982, ANNU REV BIOPHYS BIO, V11, P419, DOI 10.1146/annurev.bb.11.060182.002223; TOBIN JB, 1995, BIOCHEMISTRY-US, V34, P6919, DOI 10.1021/bi00021a002; USHER KC, 1994, BIOCHEMISTRY-US, V33, P7753, DOI 10.1021/bi00191a002; Warshel A, 1996, P NATL ACAD SCI USA, V93, P13665, DOI 10.1073/pnas.93.24.13665; WARSHEL A, 1995, SCIENCE, V269, P102, DOI 10.1126/science.7661987; ZENG BF, 1991, J AM CHEM SOC, V113, P3838, DOI 10.1021/ja00010a028; Zhao QJ, 1997, BIOCHEMISTRY-US, V36, P14616, DOI 10.1021/bi971549m; Zhao QJ, 1996, P NATL ACAD SCI USA, V93, P8220, DOI 10.1073/pnas.93.16.8220	47	469	471	1	46	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25529	25532		10.1074/jbc.273.40.25529	http://dx.doi.org/10.1074/jbc.273.40.25529			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748211	hybrid			2022-12-27	WOS:000076263100002
J	Dumortier, C; Holt, JM; Meyer, TE; Cusanovich, MA				Dumortier, C; Holt, JM; Meyer, TE; Cusanovich, MA			Imidazole binding to Rhodobacter capsulatus cytochrome c(2) - Effect of site-directed mutants on ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NETWORK; HORSE	Although ligand binding in c-type cytochromes is not directly related to their physiological function, it has the potential to provide valuable information on protein stability and dynamics, particularly in the region of the methionine sixth heme ligand and the nearby peptide chain that has been implicated in electron transfer. Thus, we have measured the equilibrium and kinetics of binding of imidazole to eight mutants of Rhodobacter capsulatus cytochrome c(2) that differ in overall protein stability. We found that imidazole binding affinity varies 70-fold, but does not correlate with overall protein stability. Instead, each mutant exerts an effect at the local level, with the largest change due to mutant G95E (glycine substituted by glutamate), which shows 30-fold stronger binding as compared with the wild-type protein. The kinetics of imidazole binding are monophasic and reach saturation at high ligand concentrations for all the mutants and wild-type protein, which is attributed to a rate limiting conformational change leading to breakage of the iron-methionine bond and providing a binding site for imidazole, The mutants show as much as an 18-fold variation in the first-order rate constant for the conformational change, with the largest effect found with mutant G95E, The kinetics also show a lack of correlation with overall protein stability, but are consistent with localized effects on the dynamics of hinge region 88-102 of the protein, which changes conformation to permit ligand binding. These results are consistent with R. capsulatus cytochrome c(2) stabilizing the complex through hydrogen bonding to the imidazole, The larger effects of mutant G95E on equilibrium and kinetics are likely to be due to its location within the hinge region adjacent to heme ligand methionine 96, which is displaced by imidazole.	Univ Arizona, Dept Biochem, Tucson, AZ 85721 USA	University of Arizona	Cusanovich, MA (corresponding author), Univ Arizona, Dept Biochem, Tucson, AZ 85721 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021277] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM21277] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AXELROD HL, 1994, ACTA CRYSTALLOGR D, V50, P596, DOI 10.1107/S0907444994001319; BENNING MM, 1991, J MOL BIOL, V220, P673, DOI 10.1016/0022-2836(91)90109-J; BERGHUIS AM, 1994, J MOL BIOL, V236, P786, DOI 10.1006/jmbi.1994.1189; Caffrey MS, 1997, PROTEIN ENG, V10, P77, DOI 10.1093/protein/10.1.77; CAFFREY MS, 1991, BIOCHEMISTRY-US, V30, P4119, DOI 10.1021/bi00231a002; CAFFREY MS, 1994, BBA-BIOENERGETICS, V1187, P277, DOI 10.1016/0005-2728(94)90001-9; DAS G, 1989, P NATL ACAD SCI USA, V86, P496, DOI 10.1073/pnas.86.2.496; FERRER JC, 1993, J AM CHEM SOC, V115, P7507, DOI 10.1021/ja00069a062; GOOLEY PR, 1991, EUR J BIOCHEM, V196, P653, DOI 10.1111/j.1432-1033.1991.tb15862.x; GOOLEY PR, 1992, BIOCHEMISTERY, V31, P433; KNAPP JA, 1974, BIOCHEMISTRY-US, V13, P1289, DOI 10.1021/bi00703a036; SCHEJTER A, 1969, BIOCHEMISTRY-US, V8, P149, DOI 10.1021/bi00829a021; SUTIN N, 1972, J BIOL CHEM, V247, P6932	13	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25647	25653		10.1074/jbc.273.40.25647	http://dx.doi.org/10.1074/jbc.273.40.25647			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748230	hybrid			2022-12-27	WOS:000076263100021
J	Huang, C; Liu, JL; Haudenschild, CC; Zhan, X				Huang, C; Liu, JL; Haudenschild, CC; Zhan, X			The role of tyrosine phosphorylation of cortactin in the locomotion of endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR-1; HEMATOPOIETIC-LINEAGE; SH2 DOMAINS; C-SRC; PROTEIN; ACTIN; IDENTIFICATION; ASSOCIATION; SUBSTRATE; KINASES	Cortactin, a filamentous actin cross-linking protein and a substrate of Src protein tyrosine kinase, is phosphorylated at tyrosine residues upon stimulation by extracellular signals. We have previously demonstrated that the filamentous actin cross-linking activity of cortactin is attenuated by Src (Huang, C., Ni, Y., Gao, Y., Haudenschild, C. C,, and Zhan, X. (1997) J. Biol Chem. 272, 13911-13915). In vitro, tyrosine phosphorylation of cortactin occurs specifically within the region between the proline-rich sequence and the Src homology 3 domain. Among the nine tyrosine residues in this region, mutations at Tyr(421), Tyr(466), and Tyr(482) significantly reduced Src-meditated tyrosine phosphorylation both in vitro and in vivo. Ectopic expression of wild-type cortactin in ECV304, a spontaneously transformed human umbilical endothelial cell line, resulted in an enhanced cell migration. In contrast, overexpression of a cortactin mutant deficient in tyrosine phosphorylation impaired the migration of endothelial cells. These findings reveal an intracellular signaling mechanism whereby the motility of endothelial cells is regulated by a Src-mediated tyrosine phosphorylation of cortactin.	Amer Red Cross, Holland Lab, Dept Expt Pathol, Rockville, MD 20855 USA; George Washington Univ, Dept Anat & Cell Biol, Washington, DC 20037 USA; George Washington Univ, Dept Pathol, Washington, DC 20037 USA	American Red Cross; George Washington University; George Washington University	Zhan, X (corresponding author), Amer Red Cross, Holland Lab, Dept Expt Pathol, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.	zhanx@usa.redcross.org	Christian, Haudenschild C/D-1602-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL052753] Funding Source: NIH RePORTER; NHLBI NIH HHS [R29 HL52753] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BHATTACHARYA S, 1995, J BIOL CHEM, V270, P16781, DOI 10.1074/jbc.270.28.16781; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRUNATI AM, 1995, EUR J BIOCHEM, V229, P164, DOI 10.1111/j.1432-1033.1995.0164l.x; DEHIO C, 1995, EMBO J, V14, P2471, DOI 10.1002/j.1460-2075.1995.tb07244.x; DURIEUTRAUTMANN O, 1994, J BIOL CHEM, V269, P12536; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Garfinkel S, 1996, J CELL BIOL, V134, P783, DOI 10.1083/jcb.134.3.783; Huang C, 1997, J BIOL CHEM, V272, P19248, DOI 10.1074/jbc.272.31.19248; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; Ingber DE, 1995, J BIOMECH, V28, P1471, DOI 10.1016/0021-9290(95)00095-X; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu MY, 1996, J BIOL CHEM, V271, P7066, DOI 10.1074/jbc.271.12.7066; MAA MC, 1992, ONCOGENE, V7, P2429; MARTINZANCA D, 1986, COLD SPRING HARB SYM, V51, P983, DOI 10.1101/SQB.1986.051.01.112; Maruyama S, 1996, J BIOL CHEM, V271, P6631, DOI 10.1074/jbc.271.12.6631; Ruzzene M, 1996, BIOCHEMISTRY-US, V35, P5327, DOI 10.1021/bi9528614; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TAKAHASHI K, 1990, IN VITRO CELL DEV B, V26, P265; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Wang K, 1996, J BIOL CHEM, V271, P4304; WONG S, 1992, ONCOGENE, V7, P2407; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Yamanashi Y, 1997, J EXP MED, V185, P1387, DOI 10.1084/jem.185.7.1387; ZHAN X, 1993, J BIOL CHEM, V268, P24427; Zhan X, 1997, BLOOD, V89, P457, DOI 10.1182/blood.V89.2.457; ZHAN X, 1994, J BIOL CHEM, V269, P20221	31	234	243	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25770	25776		10.1074/jbc.273.40.25770	http://dx.doi.org/10.1074/jbc.273.40.25770			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748248	hybrid			2022-12-27	WOS:000076263100039
J	Knox, C; Sass, E; Neupert, W; Pines, O				Knox, C; Sass, E; Neupert, W; Pines, O			Import into mitochondria, folding and retrograde movement of fumarase in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; SACCHAROMYCES-CEREVISIAE; PROTEIN IMPORT; ENDOPLASMIC-RETICULUM; TRANSLOCATION; MEMBRANE; BINDING; PRODUCT; FUM1	A single translation product of the FUM1 gene encoding fumarase is distributed between the cytosol and mitochondria of Saccharomyces cerevisiae. All fumarase translation products are targeted and processed in mitochondria before distribution. Here we show that targeting of fumarase is coupled to translation and initially involves insertion of the protein across the mitochondrial membranes and processing by the matrix protease, Rapid folding of fumarase may determine its requirement for coupling of its translocation with translation and unique route of distribution. The amino termini of most fumarase molecules are translocated across the mitochondrial membranes and processed. Unlike the in vivo situation where these molecules are released into the cytosol, in vitro they remain externally attached to the mitochondria, thereby positioned for release from the organelle. Our model suggests that fumarase displays a unique mechanism of targeting and distribution, which occurs cotranslationally and involves folding and retrograde movement of the processed protein back through the translocation pore.	Hebrew Univ Jerusalem, Sch Med, Dept Mol Biol, IL-91120 Jerusalem, Israel; Univ Munich, Inst Physiol Chem, D-80336 Munich, Germany	Hebrew University of Jerusalem; University of Munich	Pines, O (corresponding author), Hebrew Univ Jerusalem, Sch Med, Dept Mol Biol, IL-91120 Jerusalem, Israel.	ophry@md2.huji.ac.il	pines, ophry/C-4086-2011	pines, ophry/0000-0001-7126-2575				ADES IZ, 1980, J BIOL CHEM, V255, P9918; Bandlow W, 1998, BIOCHEM J, V329, P359, DOI 10.1042/bj3290359; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAUM G, 1982, J BIOL CHEM, V257, P3028; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; FUJIKI M, 1991, J BIOL CHEM, V266, P6841; FUJIKI M, 1993, J BIOL CHEM, V268, P1914; GARCIA PD, 1988, J CELL BIOL, V106, P1093, DOI 10.1083/jcb.106.4.1093; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; HACHIYA N, 1995, NATURE, V376, P705, DOI 10.1038/376705a0; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HORNE DW, 1992, J NUTR, V122, P2204, DOI 10.1093/jn/122.11.2204; KANAREK L, 1964, J BIOL CHEM, V239, P2402; NELSON N, 1979, P NATL ACAD SCI USA, V76, P4365, DOI 10.1073/pnas.76.9.4365; OGG SC, 1992, MOL BIOL CELL, V3, P895, DOI 10.1091/mbc.3.8.895; OOI CE, 1992, CELL, V71, P87, DOI 10.1016/0092-8674(92)90268-H; Pines O, 1996, APPL MICROBIOL BIOT, V46, P393, DOI 10.1007/s002530050835; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SHERMAN F, 1984, METHODS YEAST GENETI; STEIN I, 1994, MOL CELL BIOL, V14, P4770, DOI 10.1128/MCB.14.7.4770; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; WACHTER C, 1994, MOL BIOL CELL, V5, P465, DOI 10.1091/mbc.5.4.465; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WU M, 1987, J BIOL CHEM, V262, P12275; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627	27	95	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25587	25593		10.1074/jbc.273.40.25587	http://dx.doi.org/10.1074/jbc.273.40.25587			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748223	hybrid			2022-12-27	WOS:000076263100014
J	Lieste, JR; Koopman, WJH; Reynen, VCJ; Scheenen, WJJM; Jenks, BC; Roubos, ER				Lieste, JR; Koopman, WJH; Reynen, VCJ; Scheenen, WJJM; Jenks, BC; Roubos, ER			Action currents generate stepwise intracellular Ca2+ patterns in a neuroendocrine cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONTANEOUS CALCIUM OSCILLATIONS; XENOPUS-LAEVIS; INOSITOL TRISPHOSPHATE; MELANOTROPE CELLS; INTERMEDIATE PITUITARY; PROOPIOMELANOCORTIN BIOSYNTHESIS; BACKGROUND ADAPTATION; ELEMENTARY EVENTS; ACTION-POTENTIALS; EXCITABLE CELLS	It is believed that specific patterns of changes in the cytosolic-free calcium concentration ([Ca2+](i)) are used to control cellular processes such as gene transcription, cell proliferation, differentiation, and secretion. me recently showed that the Ca2+ oscillations in the neuroendocrine melanotrope cells of Xenopus laevis are built up by a number of discrete Ca2+ rises, the Ca2+ steps. The origin of the Ca2+ steps and their role in the generation of long-lasting Ca2+ patterns were unclear. By simultaneous, noninvasive measuring of melanotrope plasma membrane electrical activity and the [Ca2+](i), we show that numbers, amplitude, and frequency of Ca2+ steps are variable among individual oscillations and are determined by the firing pattern and shape of the action currents. The general Na+ channel blocker tetrodotoxin had no effect on either action currents or the [Ca2+](i). Under Na+-free conditions, a depolarizing pulse of 20 mM K+ induced repetitive action currents and stepwise increases in the [Ca2+](i). The Ca2+ channelblocker CoCl2 eliminated action currents and stepwise increases in the [Ca2+](i) in both the absence and presence of high K+. We furthermore demonstrate that the speed of Ca2+ removal from the cytoplasm depends on the [Ca2+](i), also between Ca2+ steps during the rising phase of an oscillation, It is concluded that Ca2+ channels, and not Na+ channels, are essential for the generation of specific step patterns and, furthermore, that the frequency and shape of Ca2+ action currents in combination with the Ca2+ removal rate determine the oscillatory pattern.	Catholic Univ Nijmegen, Inst Cellular Signaling, Dept Cellular Anim Physiol, NL-6525 ED Nijmegen, Netherlands; Catholic Univ Nijmegen, Nijmegen Inst Neurosci, NL-6525 ED Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	Jenks, BC (corresponding author), Catholic Univ Nijmegen, Inst Cellular Signaling, Dept Cellular Anim Physiol, Toernooiveld 1, NL-6525 ED Nijmegen, Netherlands.		Koopman, Werner J.H./AAC-9668-2020; Roubos, Eric W/D-1912-2010; Scheenen, Wim/E-3674-2012; Koopman, Werner J.H./D-3592-2009	Koopman, Werner J.H./0000-0002-5340-6747; Koopman, Werner J.H./0000-0002-5340-6747				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1997, NATURE, V386, P759, DOI 10.1038/386759a0; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; Bootman M, 1997, J PHYSIOL-LONDON, V499, P307, DOI 10.1113/jphysiol.1997.sp021928; Bootman MD, 1997, CELL, V91, P367, DOI 10.1016/S0092-8674(00)80420-1; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; BRADY KD, 1994, BIOPHYS J, V66, P1697, DOI 10.1016/S0006-3495(94)80961-0; CHAY TR, 1990, BIOL CYBERN, V63, P15, DOI 10.1007/BF00202449; CHAY TR, 1990, J THEOR BIOL, V142, P305, DOI 10.1016/S0022-5193(05)80555-7; Cheek TR, 1991, CURR OPIN CELL BIOL, V3, P199, DOI 10.1016/0955-0674(91)90139-P; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COLDINGJORGENSEN M, 1992, J THEOR BIOL, V156, P309, DOI 10.1016/S0022-5193(05)80678-2; CORCUFF JB, 1993, J BIOL CHEM, V268, P22313; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Dolphin AC, 1996, TRENDS NEUROSCI, V19, P35, DOI 10.1016/0166-2236(96)81865-0; Dotman CH, 1996, ENDOCRINOLOGY, V137, P4551, DOI 10.1210/en.137.11.4551; Dotman CH, 1997, NEUROENDOCRINOLOGY, V66, P106, DOI 10.1159/000127226; DOUGLAS WW, 1980, J PHYSIOL-LONDON, V309, P623, DOI 10.1113/jphysiol.1980.sp013530; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; GUERINEAU N, 1991, ENDOCRINOLOGY, V129, P40; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Helmchen F, 1997, BIOPHYS J, V72, P1458, DOI 10.1016/S0006-3495(97)78792-7; HILLE B, 1992, IONIC CHANNELS EXCIT, P59; JENKS BG, 1993, ZOOL SCI, V10, P1; Koopman WJH, 1997, CELL CALCIUM, V22, P167, DOI 10.1016/S0143-4160(97)90010-5; LI XY, 1995, BIOPHYS J, V69, P785; Lipp P, 1996, PROG BIOPHYS MOL BIO, V65, P265, DOI 10.1016/S0079-6107(96)00014-4; LOPEZLOPEZ JR, 1995, SCIENCE, V268, P1042, DOI 10.1126/science.7754383; MOLLARD P, 1989, BIOCHEM BIOPH RES CO, V164, P1045, DOI 10.1016/0006-291X(89)91775-0; Parker I, 1996, J PHYSIOL-LONDON, V491, P663, DOI 10.1113/jphysiol.1996.sp021247; POENIE M, 1986, SCIENCE, V233, P886, DOI 10.1126/science.3755550; PRESS WH, 1992, NUMEICAL RECIPES PAS; Roubos EW, 1997, COMP BIOCHEM PHYS A, V118, P533, DOI 10.1016/S0300-9629(97)00035-2; Sabatini BL, 1998, BIOPHYS J, V74, P1549, DOI 10.1016/S0006-3495(98)77867-1; SATIN LS, 1989, PFLUG ARCH EUR J PHY, V414, P1, DOI 10.1007/BF00585619; SCHEENEN WJJM, 1994, CELL CALCIUM, V15, P36, DOI 10.1016/0143-4160(94)90102-3; SCHEENEN WJJM, 1994, PFLUG ARCH EUR J PHY, V427, P244, DOI 10.1007/BF00374530; SCHEENEN WJJM, 1994, J NEUROENDOCRINOL, V6, P457, DOI 10.1111/j.1365-2826.1994.tb00607.x; Scheenen WJJM, 1996, CELL CALCIUM, V19, P219, DOI 10.1016/S0143-4160(96)90023-8; SCHLEGEL W, 1987, NATURE, V329, P719, DOI 10.1038/329719a0; SHIBUYA I, 1993, ENDOCRINOLOGY, V132, P2176, DOI 10.1210/en.132.5.2176; SHIBUYA I, 1993, ENDOCRINOLOGY, V132, P2166, DOI 10.1210/en.132.5.2166; Thorn P, 1996, EMBO J, V15, P999, DOI 10.1002/j.1460-2075.1996.tb00436.x; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; Valentijn JA, 1997, CELL CALCIUM, V21, P241, DOI 10.1016/S0143-4160(97)90048-8; WILLIAMS PJ, 1991, BRAIN RES, V564, P12, DOI 10.1016/0006-8993(91)91345-2; YAO Y, 1995, J PHYSIOL-LONDON, V482, P533, DOI 10.1113/jphysiol.1995.sp020538	50	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25686	25694		10.1074/jbc.273.40.25686	http://dx.doi.org/10.1074/jbc.273.40.25686			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748236	hybrid			2022-12-27	WOS:000076263100027
J	Mohan, R; Rinehart, WB; Bargagna-Mohan, P; Fini, ME				Mohan, R; Rinehart, WB; Bargagna-Mohan, P; Fini, ME			Gelatinase B/lacZ transgenic mice, a model for mapping gelatinase B expression during developmental and injury related tissue remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IV COLLAGENASE GENE; MATRIX METALLOPROTEINASES; TRANSCRIPTION FACTOR; KERATIN GENE; 92-KDA; CELLS; MIGRATION; 72-KDA; MACROPHAGES; PHENOTYPE	Matrix metalloproteinases (MMPs) drive normal tissue remodeling and are implicated in a wide range of pathologies, Although MMP activity is controlled at multiple levels, the primary regulation of MMP activity is transcriptional. The transcriptional promoter elements required for MMP gene expression in cultured cells have been defined, but this has not been extended to the in vivo situation. In this paper, we show that the DNA sequences between -522 and +19 of the rabbit gelatinase B gene (MMP-9) (as characterized in the transgenic mouse line 3445) constitute a minimal promoter that drives appropriate developmental and injury-induced reporter gene expression in transgenic mice. We further show that the expression and activity of three transcription factors (NF-kappa B, AP-2, and Sp1) that control the activity of the gelatinase B promoter are selectively induced in the epithelium migrating to heal a wound. Although promoter activity parallels expression of the endogenous gene in cell cultures, we show by several criteria that cell cultures cannot model many aspects of promoter regulation in vivo. This study reveals that the transgenic mouse line 3445 might be a useful model for investigating the regulation of gelatinase B expression in vivo and for identifying and characterizing new drugs that can control gelatinase B gene transcription.	New England Med Ctr, Vis Res Labs, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Anat, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Cell Biol, Boston, MA 02111 USA	Tufts Medical Center; Tufts University; Tufts University; Tufts University	Fini, ME (corresponding author), New England Med Ctr, Vis Res Labs, 750 Washington St,POB 450, Boston, MA 02111 USA.	efini@opal.tufts.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042981] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR42981] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alexander CM, 1989, CURR OPIN CELL BIOL, V1, P974, DOI 10.1016/0955-0674(89)90068-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Backstrom JR, 1996, J NEUROSCI, V16, P7910; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BRINCKERHOFF C E, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P145; BROWN PD, 1997, MATRIX METALLOPROTEI, P243; BYRNE C, 1994, DEVELOPMENT, V120, P2369; CANETESOLER R, 1995, DEV DYNAM, V204, P30, DOI 10.1002/aja.1002040105; CANETESOLER R, 1995, DEV BRAIN RES, V88, P37; Chen TT, 1997, MOL CELL BIOL, V17, P3056, DOI 10.1128/MCB.17.6.3056; Chin JR, 1997, DEVELOPMENT, V124, P1519; CLARK RAF, 1982, J INVEST DERMATOL, V79, P264, DOI 10.1111/1523-1747.ep12500075; CUI CQ, 1994, TRANSGENIC RES, V3, P182, DOI 10.1007/BF01973986; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FINI ME, 1995, INVEST OPHTH VIS SCI, V36, P622; FINI ME, 1994, J BIOL CHEM, V269, P28620; FINI ME, 1990, INVEST OPHTH VIS SCI, V31, P1779; Fini ME, 1996, AM J PATHOL, V149, P1287; FINI ME, 1997, MATRIX METALLOPROTEI, P299; FISHER SJ, 1989, J CELL BIOL, V109, P891, DOI 10.1083/jcb.109.2.891; FREESTONE T, 1995, ARTERIOSCL THROM VAS, V15, P1145, DOI 10.1161/01.ATV.15.8.1145; FUJIKAWA LS, 1984, J CELL BIOL, V98, P128, DOI 10.1083/jcb.98.1.128; GEORGESCU HI, 1988, IN VITRO CELL DEV B, V24, P1015; GIRARD MT, 1991, INVEST OPHTH VIS SCI, V32, P2441; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Harlow E., 1988, ANTIBODIES LAB MANUA; HIBBS MS, 1987, J CLIN INVEST, V80, P1644, DOI 10.1172/JCI113253; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; Lelievre S, 1996, RECENT PROG HORM RES, V51, P417; MATSUBARA M, 1991, DEV BIOL, V147, P425, DOI 10.1016/0012-1606(91)90300-R; MATSUBARA M, 1991, INVEST OPHTH VIS SCI, V32, P92; MURPHY G, 1982, BIOCHEM J, V203, P209, DOI 10.1042/bj2030209; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; NGUYEN Q, 1993, BIOCHEM J, V295, P595, DOI 10.1042/bj2950595; Obana N, 1996, J DERMATOL SCI, V13, P83, DOI 10.1016/0923-1811(95)00506-4; OIKARINEN A, 1993, J INVEST DERMATOL, V101, P205, DOI 10.1111/1523-1747.ep12363823; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; REPONEN P, 1994, J CELL BIOL, V124, P1091, DOI 10.1083/jcb.124.6.1091; REPONEN P, 1995, DEV DYNAM, V202, P388, DOI 10.1002/aja.1002020408; SALO T, 1991, J BIOL CHEM, V266, P11436; SALO T, 1994, LAB INVEST, V70, P176; Sambrook J., 2002, MOL CLONING LAB MANU; SATO H, 1993, J BIOL CHEM, V268, P23460; SATO H, 1993, ONCOGENE, V8, P395; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Shipley JM, 1996, J BIOL CHEM, V271, P4335; Sorbi D, 1996, ARTHRITIS RHEUM-US, V39, P1747, DOI 10.1002/art.1780391019; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; Sullivan RW, 1998, J MED CHEM, V41, P413, DOI 10.1021/jm970671g; VU TH, 1997, MATRIX METALLOPROTEI, P115; WASSERMAN PM, 1993, METHOD ENZYMOL, V225, P319; West-Mays J. A., 1996, Investigative Ophthalmology and Visual Science, V37, pS354; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WOESSNER JF, 1997, MATRIX METALLOPROTEI, P1	56	88	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25903	25914		10.1074/jbc.273.40.25903	http://dx.doi.org/10.1074/jbc.273.40.25903			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748266	hybrid			2022-12-27	WOS:000076263100057
J	Ruvolo, PP; Deng, XM; Carr, BH; May, WS				Ruvolo, PP; Deng, XM; Carr, BH; May, WS			A functional role for mitochondrial protein kinase C alpha in Bcl2 phosphorylation and suppression of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; PROGRAMMED CELL-DEATH; ACTIVATES RAF-1; MEMBRANE; OVEREXPRESSION; SEQUENCE	Phosphorylation of Bc12 at serine 70 may result from activation of a classic protein kinase C (PKC) isoform and is required for functional suppression of apoptosis by Bcl2 in murine growth factor-dependent cell lines (Ito, T., Deng, X, Carr, B,, and May, W. S, (1997) J. Biol, Chem. 272, 11671-11673), Human pre-B REH cells ex press high levels of Bcl2 yet remain sensitive to the chemotherapeutic agents etoposide, cytosine arabinoside, and Adriamycin. In contrast, myeloid leukemia-derived HL60 cells express less than half the level of Bcl-2 but are >10-fold more resistant to apoptosis induced by these drugs, The mechanism responsible for this apparent dichotomy appears to involve a deficiency of mitochondrial PKC alpha since 1) HL60 but not REH cells contain highly phosphorylated Bcl2; 2) PKC alpha is the only classical isoform co-localized with Bcl2 in HL60 but not REH mitochondrial membranes; 3) the natural product and potent PKC activator bryostatin-1 induces mitochondrial localization of PKC alpha in association with Bcl2 phosphorylation and increased REH cell resistance to drug-induced apoptosis; 4) PKC alpha can directly phosphorylate wild-type but not phosphorylation-negative and loss of function S70A Bcl2 in vitro; 5) stable, forced expression of exogenous PKC alpha induces mitochondrial localization of PKC alpha, increased Bcl2 phosphorylation and a >10-fold increase in resistance to drug-induced cell death; and (6) PKC alpha-transduced cells remain highly sensitive to staurosporine, a potent PKC inhibitor. Furthermore, treatment of the PKC alpha transformants with bryostatin-1 leads to even higher levels of mitochondrial PKC alpha, Bcl2 phosphorylation, and REH cell survival following chemotherapy, While these findings strongly support a role for PKC alpha as a functional Bcl2 kinase that can enhance cell resistance to antileukemic chemotherapy, they do not exclude the possibility that another Bcl2 kinase(s) may also exist. Collectively, these findings identify a functional role for PKC alpha in Bcl2 phosphorylation and in resistance to chemotherapy and suggest a novel target for antileukemic strategies.	Univ Texas, Med Branch, Sealy Ctr Oncol & Hematol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Internal Med, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	May, WS (corresponding author), Univ Texas, Med Branch, Grad Sch Biomed Sci, Sch Med, 301 Univ Blvd, Galveston, TX 77555 USA.				NATIONAL CANCER INSTITUTE [R01CA047993, R01CA044649] Funding Source: NIH RePORTER; NCI NIH HHS [CA47993, CA44649] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAMPANA D, 1993, BLOOD, V81, P1025; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CoustanSmith E, 1996, BLOOD, V87, P1140, DOI 10.1182/blood.V87.3.1140.bloodjournal8731140; EARL DCN, 1965, BIOCHEM J, V94, P721, DOI 10.1042/bj0940721; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Ito T, 1996, NAT MED, V2, P403, DOI 10.1038/nm0496-403; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Legdeur MCJC, 1996, EXP HEMATOL, V24, P1530; LEWIN NE, 1992, BIOCHEM PHARMACOL, V43, P2007, DOI 10.1016/0006-2952(92)90644-X; MAY WS, 1994, J BIOL CHEM, V269, P26865; MURAKAMI T, 1995, CANCER RES, V55, P3093; MURRAY NR, 1994, J BIOL CHEM, V269, P21385; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; PAGANO RE, 1985, J BIOL CHEM, V260, P1909; Petit PX, 1996, FEBS LETT, V396, P7, DOI 10.1016/0014-5793(96)00988-X; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SOZERI O, 1992, ONCOGENE, V7, P2259; Volm M, 1997, MED PEDIATR ONCOL, V28, P117; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	25	395	405	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25436	25442		10.1074/jbc.273.39.25436	http://dx.doi.org/10.1074/jbc.273.39.25436			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738012	hybrid			2022-12-27	WOS:000076085400062
J	Stayner, CK; Cunliffe, HE; Ward, TA; Eccles, MR				Stayner, CK; Cunliffe, HE; Ward, TA; Eccles, MR			Cloning and characterization of the human PAX2 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL-COLOBOMA SYNDROME; HUMAN FETAL KIDNEY; WILMS-TUMOR; TRANSCRIPTION FACTOR; GENOMIC STRUCTURE; GENE-PRODUCT; EXPRESSION; MUTATION; WT1; SEQUENCE	PAX2, a member of the PAX gene family of developmental transcription factors, is expressed at high levels in the developing eyes, ears, central nervous and urogenital systems, as well as in Wilms' tumor and renal cell carcinoma. Expression of PAX2 in the urogenital system is associated with proliferating cells of the ureteric bud and the differentiating nephrogenic mesenchyme. To date, little is known about the molecular mechanisms controlling the regulation of PAX2 expression. This report describes the cloning and characterization of the human PAX2 gene promoter and localization of the transcription start sites in fetal kidney and Wilms' tumor. We identified two transcription start sites in a Wilms' tumor sample, which were found to be different from that in fetal kidney. The activity of a deletion series of the PAX2 promoter was assessed in NIH-3T3, COS-7, 293, and Madin-Darby canine kidney cells. Although some differences were observed in the activity of each promoter construct, the profile of activity for the promoter fragment series was similar in each experiment, regardless of cell type. The WT1 tumor suppressor protein, which has previously been shown to repress murine Pax2 expression in vitro, was shown to also repress expression from the human PAX2 promoter.	Univ Otago, Dept Biochem, Canc Genet Lab, Dunedin, New Zealand	University of Otago	Eccles, MR (corresponding author), Univ Otago, Dept Biochem, Canc Genet Lab, POB 56, Dunedin, New Zealand.							ANSUBEL FM, 1989, CURRENT PROTOCOLS MO; BROOME HE, 1987, MOL CELL BIOL, V7, P2988, DOI 10.1128/MCB.7.8.2988; Busslinger M, 1996, P NATL ACAD SCI USA, V93, P6129, DOI 10.1073/pnas.93.12.6129; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHEN Z, 1996, TRENDS GENET, V12, P3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRESSLER GR, 1993, NATURE, V362, P65, DOI 10.1038/362065a0; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; ECCLES MR, 1995, AM J PATHOL, V146, P40; ECCLES MR, 1992, CELL GROWTH DIFFER, V3, P279; Favor J, 1996, P NATL ACAD SCI USA, V93, P13870, DOI 10.1073/pnas.93.24.13870; Feather SA, 1997, NEPHROL DIAL TRANSPL, V12, P1354, DOI 10.1093/ndt/12.7.1354; Fu WM, 1997, GENE DEV, V11, P2066, DOI 10.1101/gad.11.16.2066; GESSLER M, 1993, GENOMICS, V17, P499, DOI 10.1006/geno.1993.1355; GNARRA JR, 1995, CANCER RES, V55, P4092; Groene Hermann-Josef, 1993, Journal of the American Society of Nephrology, V4, P465; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; JAKOBOVITS EB, 1988, MOL CELL BIOL, V8, P5549, DOI 10.1128/MCB.8.12.5549; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KELLER SA, 1994, GENOMICS, V23, P309, DOI 10.1006/geno.1994.1506; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LEPAGE P, 1993, CANCER RES, V53, P1657; Mahmoud MS, 1996, BIOCHEM BIOPH RES CO, V228, P159, DOI 10.1006/bbrc.1996.1632; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; Narahara K, 1997, J MED GENET, V34, P213, DOI 10.1136/jmg.34.3.213; Natoli TA, 1997, DEVELOPMENT, V124, P617; NORNES HO, 1990, DEVELOPMENT, V109, P797; Okladnova O, 1997, GENOMICS, V42, P452, DOI 10.1006/geno.1997.4735; PILZ AJ, 1993, MAMM GENOME, V4, P78, DOI 10.1007/BF00290430; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; ROTHENPIELER UW, 1993, DEVELOPMENT, V119, P711; RYAN G, 1995, DEVELOPMENT, V121, P867; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sanyanusin P, 1996, GENOMICS, V35, P258, DOI 10.1006/geno.1996.0350; SANYANUSIN P, 1995, NAT GENET, V9, P358, DOI 10.1038/ng0495-358; SANYANUSIN P, 1995, HUM MOL GENET, V4, P2183, DOI 10.1093/hmg/4.11.2183; Schimmenti LA, 1997, AM J HUM GENET, V60, P869; STAPLETON P, 1993, NAT GENET, V3, P292, DOI 10.1038/ng0493-292; STUART ET, 1995, HUM MOL GENET, V4, P1717, DOI 10.1093/hmg/4.suppl_1.1717; STUART ET, 1993, ANNU REV GENET, V27, P219; Torres M, 1995, DEVELOPMENT, V121, P4057; Torres MA, 1996, DEVELOPMENT, V122, P3381; WARD TA, 1994, CELL GROWTH DIFFER, V5, P1015; Winyard PJD, 1996, J CLIN INVEST, V98, P451, DOI 10.1172/JCI118811	46	25	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25472	25479		10.1074/jbc.273.39.25472	http://dx.doi.org/10.1074/jbc.273.39.25472			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738017	hybrid			2022-12-27	WOS:000076085400067
J	Vasudevan, S; Tsuruo, T; Rose, DR				Vasudevan, S; Tsuruo, T; Rose, DR			Mode of binding of anti-P-glycoprotein antibody MRK-16 to its antigen - A Crystallographic and molecular modeling study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; CRYSTAL-STRUCTURE; X-RAY; MULTIDRUG-RESISTANCE; 3-DIMENSIONAL STRUCTURES; MONOCLONAL-ANTIBODIES; CANONICAL STRUCTURES; PEPTIDE COMPLEX; PROTEIN; FAB	Monoclonal antibody MRK-16 recognizes a discontinuous extracellular epitope on the multidrug resistance-associated ATP-binding cassette transporter, P-glycoprotein. The atomic basis for specificity of this antibody is of interest because of its potential as a modulator of P-glycoprotein activity. The crystal structure of Fab MRK-16 is reported to a resolution of 2.8 Angstrom. A structure for a portion of the epitope was derived by comparison to regions of solved structures with similar primary sequence, This has permitted a proposal for the mode of binding of the peptide epitope to the antibody, in which the peptide makes specific contacts with complementarity-determining regions H1, H2, and H3 from the heavy chain and L3 from the light chain. These interactions are consistent with epitope mapping studies and with the observation that MRK-16 is specific for human class I P-glycoprotein, This result identifies side chains in MRK-16 that would be amenable to alteration in antibody engineering experiments to derive improved multidrug resistance inhibitors for clinical use during chemotherapy. In particular, Arg-H97 contacts both Glu-746 and Asp-744 of the peptide, Arg-L96 contacts Asp-743, and Thr-H33 interacts with Thr-747. All of these epitope residues were implicated in mediating specificity by epitope mapping studies.	Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 113, Japan	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Tokyo	Rose, DR (corresponding author), Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	drose@oci.utoronto.ca						AlLazikani B, 1997, J MOL BIOL, V273, P927, DOI 10.1006/jmbi.1997.1354; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOSCH I, 1996, BIOCHIM BIOPHYS ACTA, V1288, P37; BRADLEY G, 1994, CANCER METAST REV, V13, P223, DOI 10.1007/BF00689638; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1992, XPLOR VERSION 3 1; CHAN HSL, 1991, NEW ENGL J MED, V325, P1608, DOI 10.1056/NEJM199112053252304; Chan HSL, 1996, EUR J CANCER, V32A, P1051, DOI 10.1016/0959-8049(96)00085-8; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHURCHILL MEA, 1994, J MOL BIOL, V241, P534, DOI 10.1006/jmbi.1994.1530; COLMAN PM, 1988, ADV IMMUNOL, V43, P99; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DEWAN JC, 1993, BIOCHEMISTRY-US, V32, P11963, DOI 10.1021/bi00096a004; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; GEORGES E, 1993, J BIOL CHEM, V268, P1792; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; Germann UA, 1996, EUR J CANCER, V32A, P927, DOI 10.1016/0959-8049(96)00057-3; GHIARA JB, 1994, SCIENCE, V264, P82, DOI 10.1126/science.7511253; HAMADA H, 1986, P NATL ACAD SCI USA, V83, P7785, DOI 10.1073/pnas.83.20.7785; HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Janin J, 1995, PROTEINS, V23, P580, DOI 10.1002/prot.340230413; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KABAT EA, 1979, NIH PUBLICATION; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI HY, 1995, ACTA CRYSTALLOGR D, V51, P21, DOI 10.1107/S0907444994009194; Morea V, 1998, J MOL BIOL, V275, P269, DOI 10.1006/jmbi.1997.1442; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OH BH, 1993, J BIOL CHEM, V268, P11348; OSTERMEIER C, 1995, NAT STRUCT BIOL, V2, P842, DOI 10.1038/nsb1095-842; PADLAN EA, 1990, PROTEINS, V7, P112, DOI 10.1002/prot.340070203; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; RINI JM, 1993, P NATL ACAD SCI USA, V90, P6325, DOI 10.1073/pnas.90.13.6325; ROQUET F, 1992, J MOL BIOL, V223, P705, DOI 10.1016/0022-2836(92)90985-S; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SCHNEIDER WP, 1988, P NATL ACAD SCI USA, V85, P2509, DOI 10.1073/pnas.85.8.2509; SHAPIRO AB, 1995, J BIOL CHEM, V270, P16167, DOI 10.1074/jbc.270.27.16167; Shirai H, 1996, FEBS LETT, V399, P1, DOI 10.1016/S0014-5793(96)01252-5; SHOHAM M, 1993, J MOL BIOL, V232, P1169, DOI 10.1006/jmbi.1993.1469; STEHLE T, 1993, EUR J BIOCHEM, V211, P221, DOI 10.1111/j.1432-1033.1993.tb19889.x; SWAIN AL, 1989, J BIOL CHEM, V264, P16620; TSURUO T, 1989, JPN J CANCER RES, V80, P627, DOI 10.1111/j.1349-7006.1989.tb01688.x; vandenElsen JMH, 1997, PROTEINS, V29, P113; VASUDEVAN S, 1994, J MOL BIOL, V241, P736, DOI 10.1006/jmbi.1994.1548; VASUDEVAN S, 1996, CONFORMATIONAL FLEXI, P109; Watanabe T, 1997, J NATL CANCER I, V89, P512, DOI 10.1093/jnci/89.7.512; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; Zhang JT, 1996, MOL BIOL CELL, V7, P1709, DOI 10.1091/mbc.7.11.1709	57	13	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25413	25419		10.1074/jbc.273.39.25413	http://dx.doi.org/10.1074/jbc.273.39.25413			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738009	hybrid			2022-12-27	WOS:000076085400059
J	Bracher, A; Eisenreich, W; Schramek, N; Ritz, H; Gotze, E; Herrmann, A; Gutlich, M; Bacher, A				Bracher, A; Eisenreich, W; Schramek, N; Ritz, H; Gotze, E; Herrmann, A; Gutlich, M; Bacher, A			Biosynthesis of pteridines - NMR studies on the reaction mechanisms of GTP cyclohydrolase I, pyruvoyltetrahydropterin synthase, and sepiapterin reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							6-PYRUVOYL TETRAHYDROPTERIN SYNTHASE; DIHYDRONEOPTERIN TRIPHOSPHATE; TETRAHYDROBIOPTERIN; COFACTOR; ENZYME; INTERMEDIATE; PTERINS; SITE	GTP cyclohydrolase I catalyzes a ring expansion affording dihydroneopterin triphosphate from GTP. [1',2',3',4',5'-C-13(5),2'-H-2(1)]GTP was prepared enzymatically from [U-C-13(6)]glucose for use as enzyme substrate. Multinuclear NMR experiments showed that the reaction catalyzed by GTP cyclohydrolase I involves the release of a proton from C-2' of GTP that is exchanged with the bulk solvent. Subsequently, a proton is reintroduced stereospecifically from the bulk solvent. This is in line with an Amadori rearrangement mechanism. The proton introduced from solvent occupies the pro-7R position in the enzyme product. The data also confirm that the reaction catalyzed by pyruvoyltetrahydropterin synthase results in the incorporation of solvent protons into positions C-6 and C-3' of the enzyme product. On the other hand, the reaction catalyzed by sepiapterin reductase does not involve any detectable incorporation of solvent protons into tetrahydrobiopterin.	Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany	Technical University of Munich	Bacher, A (corresponding author), Tech Univ Munich, Inst Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.	Bacher@oc3gra.org.chemie.tu-muenchen.de	Eisenreich, Wolfgang/A-1258-2013	Eisenreich, Wolfgang/0000-0002-9832-8279				ARMAREGO WLF, 1984, AUST J CHEM, V37, P355, DOI 10.1071/CH9840355; Auerbach G, 1997, EMBO J, V16, P7219, DOI 10.1093/emboj/16.24.7219; BLAU N, 1983, ANAL BIOCHEM, V128, P446, DOI 10.1016/0003-2697(83)90399-8; Brown G. M., 1987, ESCHERICHIA COLI SAL, V1, P521; BURG AW, 1968, J BIOL CHEM, V243, P2349; BURGISSER DM, 1995, J MOL BIOL, V253, P358, DOI 10.1006/jmbi.1995.0558; DAWSON RCM, 1986, DATA BIOCH RES, P109; ESTELBERGER W, 1995, BBA-PROTEIN STRUCT M, V1249, P23, DOI 10.1016/0167-4838(95)00064-2; ESTELBERGER W, 1995, FEBS LETT, V357, P37, DOI 10.1016/0014-5793(94)01302-H; GHISLA S, 1990, EUR J BIOCHEM, V187, P651, DOI 10.1111/j.1432-1033.1990.tb15349.x; GHISLA S, 1987, UNCONJUGATED PTERINS, P67; HAASNOOT CAG, 1980, TETRAHEDRON, V36, P2783, DOI 10.1016/0040-4020(80)80155-4; KATOH S, 1984, BIOCHEM BIOPH RES CO, V118, P859, DOI 10.1016/0006-291X(84)91474-8; KATOH S, 1988, J BIOCHEM-TOKYO, V103, P286, DOI 10.1093/oxfordjournals.jbchem.a122262; KATOH S, 1987, J BIOCHEM-TOKYO, V101, P275, DOI 10.1093/oxfordjournals.jbchem.a121901; KELTJENS J T, 1988, Biofactors, V1, P95; KERLER F, 1990, J CELL PHYSIOL, V142, P268, DOI 10.1002/jcp.1041420208; Kisker C, 1997, ANNU REV BIOCHEM, V66, P233, DOI 10.1146/annurev.biochem.66.1.233; KWON NS, 1989, J BIOL CHEM, V264, P20496; LOPEZ MD, 1977, CHEM BIOL PTERIDINES, P53; MILSTIEN S, 1989, BIOCHEM BIOPH RES CO, V165, P845, DOI 10.1016/S0006-291X(89)80043-9; Nar H, 1995, P NATL ACAD SCI USA, V92, P12120, DOI 10.1073/pnas.92.26.12120; NAR H, 1994, EMBO J, V13, P1255, DOI 10.1002/j.1460-2075.1994.tb06377.x; NAR H, 1995, STRUCTURE, V3, P459, DOI 10.1016/S0969-2126(01)00179-4; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; PALM D, 1963, Z NATURFORSCH PT B, VB 18, P419; PALM D, 1965, Z NATURFORSCH PT B, VB 20, P32; PARKIN DW, 1987, BIOCHEMISTRY-US, V26, P913, DOI 10.1021/bi00377a036; PFLEIDERER W, 1985, FOLATES PTERINS, V2, P43; Richter G, 1997, METHOD ENZYMOL, V280, P374; SHIOTA T, 1969, BIOCHIM BIOPHYS ACTA, V192, P205, DOI 10.1016/0304-4165(69)90357-2; SHIOTA T, 1967, J BIOL CHEM, V242, P1961; SIMON H., 1964, P327; Simon H., 1970, FORTSCHR CHEM FORSCH, V14, P430; SMITH GK, 1986, J BIOL CHEM, V261, P2725; SWITCHENKO AC, 1985, J BIOL CHEM, V260, P2945; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; THONY B, 1992, BIOCHEM BIOPH RES CO, V189, P1437, DOI 10.1016/0006-291X(92)90235-D; VAN QL, 1988, BIOCHEM BIOPH RES CO, V151, P512, DOI 10.1016/0006-291X(88)90623-7; WEYGAND F, 1961, ANGEW CHEM INT EDIT, V73, P402, DOI 10.1002/ange.19610731111; WOLF WA, 1969, BIOCHIM BIOPHYS ACTA, V192, P468, DOI 10.1016/0304-4165(69)90396-1	41	55	55	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28132	28141		10.1074/jbc.273.43.28132	http://dx.doi.org/10.1074/jbc.273.43.28132			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774432	hybrid			2022-12-27	WOS:000076549800052
J	Buxbaum, JD; Liu, KN; Luo, YX; Slack, JL; Stocking, KL; Peschon, JJ; Johnson, RS; Castner, BJ; Cerretti, DP; Black, RA				Buxbaum, JD; Liu, KN; Luo, YX; Slack, JL; Stocking, KL; Peschon, JJ; Johnson, RS; Castner, BJ; Cerretti, DP; Black, RA			Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-PROTEIN; KINASE-C; HUMAN-BRAIN; TNF-ALPHA; PHOSPHORYLATION; CELL; DISINTEGRIN; DERIVATIVES; ACTIVATION; ECTODOMAIN	The amyloid protein, A beta, which accumulates in the brains of Alzheimer patients, is derived by proteolysis of the amyloid protein precursor (APP). APP can undergo endoproteolytic processing at three sites, one at the amino terminus of the A beta domain (beta-cleavage), one within the A beta domain (alpha-cleavage), and one at the carboxyl terminus of the A beta domain (gamma-cleavage). The enzymes responsible for these activities have not been unambiguously identified. By the use of gene disruption (knockout), we now demonstrate that TACE (tumor necrosis factor alpha converting enzyme), a member of the ADAM family (a disintegrin and metalloprotease-family) of proteases, plays a central role in regulated alpha-cleavage of APP. Our data suggest that TACE may be the alpha-secretase responsible for the majority of regulated alpha-cleavage in cultured cells. Furthermore, we show that inhibiting this enzyme affects both APP secretion and A beta formation in cultured cells.	CUNY Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Neurobiol, New York, NY 10029 USA; Immunex Res & Dev Corp, Seattle, WA 98101 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Buxbaum, JD (corresponding author), CUNY Mt Sinai Sch Med, Dept Psychiat, 1 Gustave L Levy Pl,Box 1230, New York, NY 10029 USA.		Buxbaum, Joseph D/G-6001-2010	Buxbaum, Joseph/0000-0001-8898-8313	NIA NIH HHS [AG14996] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG014996, R55AG014996] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 1996, BIOCHEM BIOPH RES CO, V225, P400, DOI 10.1006/bbrc.1996.1186; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; BUXBAUM JD, 1993, BIOCHEM BIOPH RES CO, V197, P639, DOI 10.1006/bbrc.1993.2527; BUXBAUM JD, 1994, P NATL ACAD SCI USA, V91, P4489, DOI 10.1073/pnas.91.10.4489; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; Caputi A, 1997, J NEUROCHEM, V68, P2523; Desdouits F, 1996, J BIOL CHEM, V271, P24670, DOI 10.1074/jbc.271.40.24670; Desdouits-Magnen J, 1998, J NEUROCHEM, V70, P524; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GABUZDA D, 1993, J NEUROCHEM, V61, P2326, DOI 10.1111/j.1471-4159.1993.tb07479.x; GILLESPIE SL, 1992, BIOCHEM BIOPH RES CO, V187, P1285, DOI 10.1016/0006-291X(92)90442-N; Hardy J, 1997, P NATL ACAD SCI USA, V94, P2095, DOI 10.1073/pnas.94.6.2095; HUNG AY, 1993, J BIOL CHEM, V268, P22959; HUNG AY, 1994, EMBO J, V13, P534, DOI 10.1002/j.1460-2075.1994.tb06291.x; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V179, P1670, DOI 10.1016/0006-291X(91)91767-7; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; Mills J, 1997, J NEUROSCI, V17, P9415; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Muller DM, 1997, LIFE SCI, V60, P985, DOI 10.1016/S0024-3205(97)00038-6; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; NITSCH RM, 1993, P NATL ACAD SCI USA, V90, P5191, DOI 10.1073/pnas.90.11.5191; Nitsch RM, 1996, J BIOL CHEM, V271, P4188; NITSCH RM, 1993, ANN NY ACAD SCI, V695, P122, DOI 10.1111/j.1749-6632.1993.tb23039.x; NITSCH RM, 1995, ARZNEIMITTEL-FORSCH, V45-1, P435; NITSCH RM, 1994, BIOCHEM PHARMACOL, V47, P1275, DOI 10.1016/0006-2952(94)90325-5; PALMERT MR, 1989, P NATL ACAD SCI USA, V86, P6338, DOI 10.1073/pnas.86.16.6338; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SILVA OABDE, 1993, NEUROSCIENCE, V57, P873, DOI 10.1016/0306-4522(93)90031-A; SISODIA S S, 1990, New Biologist, V2, P66; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; VANNOSTRAND WE, 1991, P NATL ACAD SCI USA, V88, P10302, DOI 10.1073/pnas.88.22.10302; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; XU HX, 1995, J BIOL CHEM, V270, P23243, DOI 10.1074/jbc.270.40.23243; Xu HX, 1996, P NATL ACAD SCI USA, V93, P4081, DOI 10.1073/pnas.93.9.4081; YOUNKIN SG, 1995, ANN NEUROL, V37, P287, DOI 10.1002/ana.410370303	41	821	868	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27765	27767		10.1074/jbc.273.43.27765	http://dx.doi.org/10.1074/jbc.273.43.27765			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774383	hybrid			2022-12-27	WOS:000076549800003
J	Hamilton, M; Wolfman, A				Hamilton, M; Wolfman, A			Oncogenic Ha-Ras-dependent mitogen-activated protein kinase activity requires signaling through the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; ACTIN STRESS FIBERS; TYROSINE KINASE; TRANSDUCTION PATHWAY; REGULATED KINASE; PLASMA-MEMBRANE; TGF-ALPHA; TRANSFORMATION; RAF-1; ASSOCIATION	C3H10T1/2 fibroblasts transformed by the minimal expression of oncogenic Ha-Ras (V12H10 cells) or N-Ras (K61N10 cells) have constitutive mitogen-activated protein kinase (IMAPK) activity and proliferate in serum-free medium. The constitutive MAPK activity and serum-independent proliferation of V12H10 cells are sensitive to the growth factor antagonist, suramin (Hamilton, M., and Wolfman, A. (1998) Oncogene 16, 1417-1428), suggesting that Ha-Ras-mediated regulation of the MAPK cascade is dependent upon the action of an autocrine factor. Serum-free medium conditioned by V12H10 cells contains an activity that stimulates MAPK activity in quiescent fibroblasts, This MAPK stimulatory activity could be specifically blocked by the epidermal growth factor receptor (EGFR) inhibitors, PD153035 and PD158780. These inhibitors also blocked the serum-independent proliferation of V12H10 cells. Immunodepletion of conditioned medium with antibodies to transforming growth factor alpha and EGF significantly inhibited its ability to stimulate MAPK activity. Stable transfection of EGFR-negative NR6 and EGFR-positive Swiss3T3 cells with oncogenic (G12V)Ha-Ras demonstrated that only the Ha-Ras-transfected Swiss 3T3 cells possessed constitutive MAPK activity, and this activity was sensitive to PD153035. These data suggest that autocrine activation of the EGFR is required for the regulation of the MAPK cascade in cells minimally expressing oncogenic Ha-Ras.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Hamilton, M (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	hamiltm@cesmtp.ccf.org			NIGMS NIH HHS [GM49652] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM049652, R01GM049652] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berkowitz EA, 1996, ONCOGENE, V12, P1991; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; CASTELLI C, 1994, CANCER RES, V54, P4785; Cook SJ, 1996, BIOCHEM J, V320, P237, DOI 10.1042/bj3200237; Dahring TK, 1997, J PHARMACOL EXP THER, V281, P1446; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FILMUS J, 1993, ONCOGENE, V8, P1017; FINNEY RE, 1993, CURR BIOL, V3, P805, DOI 10.1016/0960-9822(93)90214-9; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Gangarosa LM, 1997, J BIOL CHEM, V272, P18926, DOI 10.1074/jbc.272.30.18926; Hamilton M, 1998, ONCOGENE, V16, P1417, DOI 10.1038/sj.onc.1201653; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HOWE LR, 1993, J BIOL CHEM, V268, P20717; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KEHINDE EO, 1995, CANCER SURV, V23, P217; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; Marais R, 1996, CANCER SURV, V27, P101; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PIRONIN M, 1992, INT J CANCER, V51, P980, DOI 10.1002/ijc.2910510624; PROPER JA, 1982, J CELL PHYSIOL, V110, P169, DOI 10.1002/jcp.1041100210; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; RAK J, 1995, CANCER RES, V55, P4575; RAPP UR, 1991, ONCOGENE, V6, P495; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3	41	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28155	28162		10.1074/jbc.273.43.28155	http://dx.doi.org/10.1074/jbc.273.43.28155			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774435	hybrid			2022-12-27	WOS:000076549800055
J	Pellegatta, F; Chierchia, SL; Zocchi, MR				Pellegatta, F; Chierchia, SL; Zocchi, MR			Functional association of platelet endothelial cell adhesion molecule-1 and phosphoinositide 3-kinase in human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-MEDIATED ADHESION; KILLER-CELLS; PI-3-KINASE; ACTIVATION; WORTMANNIN; INHIBITOR; PECAM-1; SIGNALS; KINASE; CD31	In this paper we show that the engagement of the platelet-endothelial cell adhesion molecule-1 (PECAM-1/ CD31) up-regulates the adhesion of human neutrophils to the EA.hy926 endothelial cell line through a phosphoinositide S-kinase (PI3K)-dependent pathway. Indeed, LY294002 and wortmannin prevented the effect of PECAM-1/CD31 cross-linking on cell adhesion, at concentrations known to inhibit PI3K without affecting other kinases. Both compounds blocked neutrophil binding to murine fibroblasts transfected with human ICAM-1, to purified ICAM-1 protein, or to fibronectin, suggesting that PECAM-1/CD31-mediated up-regulation of beta 2 and beta 1 integrin-mediated adhesion is PI3K-sensitive. We also provide evidence for the association of PECAM-1/CD31 to PI3K, because PI3K was detectable in neutrophil lysates after PECAM-1/CD31 cross-linking and immunoprecipitation. PECAM-1/CD31-dependent recruitment of PI3K was suggested by the finding that the serine/threonine kinase p70 S6 kinase (S6K), a signaling protein downstream of PI3K, is activated in neutrophils upon PECAM-1/CD31 cross-linking, based on the appearance of serine phosphorylation in S6K immunoprecipitates. In turn, S6K is not directly involved in the up-regulation of integrin function because rapamycin, which can inhibit S6K independent of PI3K, did not block PECAM-1/CD31-induced adhesion of neutrophils to beta 1 and beta 2 integrin substrates. In conclusion, PECAM-1/CD31 appears to be one of the molecules functionally coupled to PI3K, suggesting that this enzyme may represent a common pathway of integrin and adhesiveness regulation in leukocytes.	San Raffaele Sci Inst, Dept Cardiol, Lab Cardiovasc Pathophysiol, Inst Ricovero & Cura Carattere Sci, I-20132 Milan, Italy; San Raffaele Sci Inst, Inst Ricovero & Cura Carattere, Lab Tumor Immunol, I-20132 Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Pellegatta, F (corresponding author), San Raffaele Sci Inst, Dept Cardiol, Lab Cardiovasc Pathophysiol, Inst Ricovero & Cura Carattere Sci, Via Olgettina 60, I-20132 Milan, Italy.	pellegatta.fabio@hsr.it		Zocchi, Maria Raffaella/0000-0002-0022-8385				BERNMAN ME, 1995, J IMMUNOL, V154, P299; BOWN EJ, 1996, CELL, V86, P517; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DELISSER HM, 1994, IMMUNOL TODAY, V15, P490, DOI 10.1016/0167-5699(94)90195-3; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Ferrero E, 1996, CANCER RES, V56, P3211; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; LEAVESLEY DI, 1994, J IMMUNOL, V153, P4673; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; Newman PJ, 1997, J CLIN INVEST, V99, P3, DOI 10.1172/JCI119129; PIALI L, 1993, EUR J IMMUNOL, V23, P2464, DOI 10.1002/eji.1830231013; Poggi A, 1996, EUR J IMMUNOL, V26, P817, DOI 10.1002/eji.1830260414; Poggi A, 1996, EUR J IMMUNOL, V26, P967, DOI 10.1002/eji.1830260502; Shimizu Y, 1996, IMMUNOL TODAY, V17, P565, DOI 10.1016/S0167-5699(96)10061-X; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; TANAKA Y, 1992, J EXP MED, V176, P245, DOI 10.1084/jem.176.1.245; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; Varon D, 1998, BLOOD, V91, P500, DOI 10.1182/blood.V91.2.500.500_500_507; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Ward SG, 1996, IMMUNOL TODAY, V17, P187, DOI 10.1016/0167-5699(96)80618-9; Zell T, 1996, J IMMUNOL, V156, P883; Zocchi MR, 1996, EUR J IMMUNOL, V26, P759, DOI 10.1002/eji.1830260406	24	71	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27768	27771		10.1074/jbc.273.43.27768	http://dx.doi.org/10.1074/jbc.273.43.27768			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774384	hybrid			2022-12-27	WOS:000076549800004
J	Kim, SD; Park, GH; Joo, WA; Paik, WK; Cook, RJ; Williams, KR				Kim, SD; Park, GH; Joo, WA; Paik, WK; Cook, RJ; Williams, KR			Identification of protein-arginine N-methyltransferase as 10-formyltetrahydrofolate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLATE-BINDING-PROTEIN; RAT-LIVER; SACCHAROMYCES-CEREVISIAE; ALDEHYDE DEHYDROGENASE; DOMAIN-STRUCTURE; TERMINAL DOMAIN; CYTOSOL-I; PURIFICATION; RNA; HYDROLASE	S-Adenosylmethionine:protein-arginine N-methyltransferase (EC 2.1.1.23; protein methylase I) transfers the methyl group of S-adenosyl-L-methionine to an arginine residue of a protein substrate. The homogeneous liver protein methylase I was subjected to tryptic digestion followed by reverse phase high performance liquid chromatography (HPLC) separation and either "online" mass spectrometric fragmentation or "off-line" Edman sequencing of selected fractions. Data base searching of both the mass spectrometric and Edman sequencing data from several peptides identified the protein methylase as 10-formyltetrahydrofolate dehydrogenase (EC 1.5.1.6; Cook, R. J., Lloyd, R. S., and Wagner, C. (1991) J. Biol. Chem. 266, 4965-4973; Swiss accession number P28037). This identification was confirmed by comparative HPLC tryptic peptide mapping and affinity chromatography of the methylase on the Ei-formyltetrahydrofolate Sepharose affinity gel used to purify the dehydrogenase. The purified rat Liver methylase had approximately 33% of the 10-formyltetrahydrofolate dehydrogenase and 36% of the aldehyde dehydrogenase activity as compared with the recombinant dehydrogenase, which also had protein methylase I activity. Polyclonal antibodies against recombinant dehydrogenase reacted with protein methylase I purified either by polyacrylamide gel electrophoresis or B-formyltetrahydrofolate affinity chromatography. In each instance there was only a single immunoreactive band at a molecular weight of similar to 106,000. Together, these results confirm the co-identity of protein-arginine methyltransferase and 10-formyltetrahydrofolate dehydrogenase.	Korea Univ, Coll Med, Dept Biochem,Grad Sch Biotechnol, Sung Buk Gu, Seoul 136701, South Korea; Ajou Univ, Sch Med, Dept Biochem, Suwon 442749, South Korea; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA	Korea University; Korea University Medicine (KU Medicine); Ajou University; Vanderbilt University; Howard Hughes Medical Institute; Yale University	Kim, SD (corresponding author), Korea Univ, Coll Med, Dept Biochem,Grad Sch Biotechnol, Sung Buk Gu, 126,5-GA Anam Dong, Seoul 136701, South Korea.	sdkim@kuccnx.korea.ac.kr	Williams, Kenneth/B-5986-2016	Williams, Kenneth/0000-0001-7792-9588	NIDDK NIH HHS [DK49563, DK15289] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK015289, R01DK015289, R01DK049563] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; BENKOVIC SJ, 1980, ANNU REV BIOCHEM, V49, P227, DOI 10.1146/annurev.bi.49.070180.001303; BOREK E, 1966, ANNU REV BIOCHEM, V35, P275, DOI 10.1146/annurev.bi.35.070166.001423; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COBIANCHI F, 1988, J BIOL CHEM, V263, P1063; COOK RJ, 1995, ARCH BIOCHEM BIOPHYS, V321, P336, DOI 10.1006/abbi.1995.1403; COOK RJ, 1991, J BIOL CHEM, V266, P4965; COOK RJ, 1986, METHOD ENZYMOL, V122, P251; COOK RJ, 1982, BIOCHEMISTRY-US, V21, P4427, DOI 10.1021/bi00261a036; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Gary JD, 1996, J BIOL CHEM, V271, P12585, DOI 10.1074/jbc.271.21.12585; GHOSH SK, 1988, J BIOL CHEM, V263, P19024; GLASS WF, 1981, SCIENCE, V211, P70, DOI 10.1126/science.7003713; GUPTA A, 1982, J BIOL CHEM, V257, P9677; Henry MF, 1996, MOL CELL BIOL, V16, P3668; JONG AYS, 1987, MOL CELL BIOL, V7, P2947, DOI 10.1128/MCB.7.8.2947; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; Kim S, 1997, BIOCHEMISTRY-US, V36, P5185, DOI 10.1021/bi9625509; KIM S, 1990, PROTEIN METHYLATION, P75; KREBS HA, 1976, BIOCHEM J, V158, P341, DOI 10.1042/bj1580341; Krupenko SA, 1997, J BIOL CHEM, V272, P10266; Krupenko SA, 1997, J BIOL CHEM, V272, P10273; KRUPENKO SA, 1995, J BIOL CHEM, V270, P519, DOI 10.1074/jbc.270.2.519; KRUPENKO SA, 1995, BIOCHEM J, V306, P651, DOI 10.1042/bj3060651; KRUPENKO SA, 1995, PROTEIN EXPRES PURIF, V6, P457, DOI 10.1006/prep.1995.1061; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPEYRE B, 1986, J BIOL CHEM, V261, P9167; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; LINDAHL R, 1984, BIOCHEM PHARMACOL, V33, P3383, DOI 10.1016/0006-2952(84)90109-6; LISCHWE MA, 1985, J BIOL CHEM, V260, P14304; LISCHWE MA, 1990, PROTEIN METHYLATION, P97; LIU Q, 1995, MOL CELL BIOL, V15, P2800; MIN H, 1988, BIOCHIM BIOPHYS ACTA, V967, P348, DOI 10.1016/0304-4165(88)90097-9; PAIK WK, 1980, PROTEIN METHYLATION, V1, P112; PERRY RP, 1976, ANNU REV BIOCHEM, V45, P605, DOI 10.1146/annurev.bi.45.070176.003133; RABINOWITZ JC, 1963, METHOD ENZYMOL, V6, P814, DOI 10.1016/0076-6879(63)06256-X; RAWAL N, 1994, BIOCHEM J, V300, P483, DOI 10.1042/bj3000483; RIOSORLANDI EM, 1986, BIOCHIM BIOPHYS ACTA, V871, P24, DOI 10.1016/0167-4838(86)90129-9; SCHIRCH D, 1994, J BIOL CHEM, V269, P24728; SCRUTTON MC, 1979, BIOCHEM J, V177, P833, DOI 10.1042/bj1770833; Siebel CW, 1996, P NATL ACAD SCI USA, V93, P13641, DOI 10.1073/pnas.93.24.13641; SMITH GM, 1981, BIOCHEMISTRY-US, V20, P4340, DOI 10.1021/bi00518a017; Stone KL, 1998, ELECTROPHORESIS, V19, P1046, DOI 10.1002/elps.1150190620; WAGNER C, 1995, ARCH BIOCHEM BIOPHYS, V316, P141, DOI 10.1006/abbi.1995.1021; WAGNER C, 1994, FOLATE HLTH DISEASE, P23; Williams K, 1997, TECH PROT CHEM, V8, P79, DOI 10.1016/S1080-8914(97)80011-7; Williams Kenneth R., 1996, P541, DOI 10.1007/978-1-60327-259-9_91; YATES JR, 1995, ANAL CHEM, V67, P3202, DOI 10.1021/ac00114a016; ZALKIN H, 1992, PROG NUCLEIC ACID RE, V42, P259, DOI 10.1016/S0079-6603(08)60578-4; ZAMIEROWSKI MM, 1977, J BIOL CHEM, V252, P933	50	5	5	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27374	27382		10.1074/jbc.273.42.27374	http://dx.doi.org/10.1074/jbc.273.42.27374			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765265	hybrid			2022-12-27	WOS:000076448000052
J	Kraus, RL; Hering, S; Grabner, M; Ostler, D; Striessnig, J				Kraus, RL; Hering, S; Grabner, M; Ostler, D; Striessnig, J			Molecular mechanism of diltiazem interaction with L-type Ca2+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY PHENYLALKYLAMINE BLOCK; SENSITIVE CALCIUM-CHANNEL; SKELETAL-MUSCLE; 1,4-DIHYDROPYRIDINE SENSITIVITY; BINDING DOMAIN; DETERMINANTS; SUBUNIT; BENZOTHIAZEPINES; INACTIVATION; PORE	Benzothiazepine Ca2+ antagonists (such as (+)-cis-diltiazem) interact with transmembrane segments IIIS6 and TVS6 in the alpha(1) subunit of L-type Ca2+ channels, We investigated the contribution of individual IIIS6 amino acid residues for diltiazem sensitivity by employing alanine scanning mutagenesis in a benzothiazepine-sensitive alpha(1) subunit chimera (AL(DIL)) expressed in Xenopus laevis oocytes, The most dramatic decrease of block by 100 mu M diltiazem (AL(DIL) 45 +/- 4.8% inhibition) during trains of 100-ms pulses (0.1 Hz, -80 mV holding potential) was found after mutation of adjacent IIIS6 residues Phe(1164)(21 +/- 3%) and Val(1165) (8.5 +/- 1.4%). Diltiazem delayed current recovery by promoting a slowly recovering current component. This effect was similar in AL(DIL) and F1164A but largely prevented in V1165A. Both mutations slowed inactivation kinetics during a pulse. The reduced diltiazem block can therefore be explained by slowing of inactivation kinetics (F1164A and V1165A) and accelerated recovery from drug block (V1165A), The bulkier diltiazem derivative benziazem still efficiently blocked V1165A. From these functional and from additional radioligand binding studies with the dihydropyridine (+)-[H-3]isradipine we propose a model in which Val(1165) controls dissociation of the bound diltiazem molecule, and where bulky substituents on the basic nitrogen of diltiazem protrude toward the adjacent dihydropyridine binding domain.	Inst Biochem Pharmakol, A-6020 Innsbruck, Austria		Striessnig, J (corresponding author), Inst Biochem Pharmakol, Peter Mayrstr 1, A-6020 Innsbruck, Austria.	joerg.striessnig@uibk.ac.at	Striessnig, Joerg/S-9334-2017	Striessnig, Joerg/0000-0002-9406-7120	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029632] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 29632] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOYETT MR, 1994, PFLUG ARCH EUR J PHY, V428, P39, DOI 10.1007/BF00374750; Brauns T, 1997, BIOCHEMISTRY-US, V36, P3625, DOI 10.1021/bi9613584; BRAUNS T, 1995, BIOCHEMISTRY-US, V34, P3461, DOI 10.1021/bi00010a039; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; GALIZZI JP, 1984, BIOCHEM BIOPH RES CO, V118, P239, DOI 10.1016/0006-291X(84)91092-1; GLOSSMANN H, 1990, REV PHYSL BIOCH PHAR, V114, P1; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; HERING S, 1993, MOL PHARMACOL, V43, P820; Hering S, 1997, P NATL ACAD SCI USA, V94, P13323, DOI 10.1073/pnas.94.24.13323; Hering S, 1996, J BIOL CHEM, V271, P24471, DOI 10.1074/jbc.271.40.24471; Hille B., 1991, IONIC CHANNELS EXCIT; HOCKERMAN GH, 1995, J BIOL CHEM, V270, P22119, DOI 10.1074/jbc.270.38.22119; Hockerman GH, 1997, J BIOL CHEM, V272, P18759, DOI 10.1074/jbc.272.30.18759; Hockerman GH, 1997, ANNU REV PHARMACOL, V37, P361, DOI 10.1146/annurev.pharmtox.37.1.361; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Johnson BD, 1996, MOL PHARMACOL, V50, P1388; Hunt J T, 1993, Bioorg Med Chem, V1, P59, DOI 10.1016/S0968-0896(00)82134-3; KIMBALL SD, 1992, J MED CHEM, V35, P780, DOI 10.1021/jm00082a020; Kraus R, 1996, J BIOL CHEM, V271, P20113, DOI 10.1074/jbc.271.33.20113; MCCLESKEY EW, 1985, P NATL ACAD SCI USA, V82, P7149, DOI 10.1073/pnas.82.20.7149; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; Sinnegger MJ, 1997, J BIOL CHEM, V272, P27686, DOI 10.1074/jbc.272.44.27686; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; Striessnig J, 1998, TRENDS PHARMACOL SCI, V19, P108, DOI 10.1016/S0165-6147(98)01171-7	24	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27205	27212		10.1074/jbc.273.42.27205	http://dx.doi.org/10.1074/jbc.273.42.27205			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765241	hybrid			2022-12-27	WOS:000076448000028
J	Mao, JH; Yuan, HD; Xie, W; Simon, MI; Wu, DQ				Mao, JH; Yuan, HD; Xie, W; Simon, MI; Wu, DQ			Specific involvement of G proteins in regulation of serum response factor-mediated gene transcription by different receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; BRUTONS-TYROSINE-KINASE; ALPHA-SUBUNITS; PHOSPHOLIPASE-C; TRANSFORMING ACTIVITY; SIGNAL-TRANSDUCTION; RGS PROTEINS; FAMILY; CELLS; RHO	Regulation of serum response factor (SRF)-mediated gene transcription by G protein subunits and G protein-coupled receptors was investigated in transfected NIH3T3 cells and in a cell line that was derived from mice lacking G alpha(q) and G alpha(11). We found that the constitutively active forms of the alpha subunits of the G(q) and G(12) class of G proteins, including G alpha(q), G alpha(11), G alpha(14), G alpha(16), G alpha(12), and G alpha(13), can activate SRF in NIH3T3 cells. me also found that the type 1 muscarinic receptor (m1R) and alpha(1)-adrenergic receptor (AR)-mediated SRF activation is exclusively dependent on G alpha(q/11), while the receptors for thrombin, lysophosphatidic acid (LPA), thromboxane A2, and endothelin can activate SRF in the absence of G alpha(q/11). Moreover, RGS12 but not RGS2, RGS4, or Axin was able to inhibit G alpha(12) and G alpha(13)-mediated SRF activation. And RGS12, but not other RGS proteins, blocked thrombin- and LPA-mediated SRF activation in the G alpha(q/11)-deficient cells. Therefore, the thrombin, LPA, thromboxane A2, and endothelin receptors may be able to couple to G alpha(12/13). On the contrary, receptors including beta(2)- and alpha(2)-ARs, m2R, the dopamine receptors type 1 and 2, angiotensin receptors types 1 and 2, and interleukin-8 receptor could not activate SRF in the presence or absence of G alpha(q/11), suggesting that these receptors cannot couple to endogenous G proteins of the G(12) or G(q) classes.	Univ Rochester, Dept Pharmacol & Physiol, Rochester, NY 14642 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	University of Rochester; California Institute of Technology	Wu, DQ (corresponding author), Univ Rochester, Dept Pharmacol & Physiol, Rochester, NY 14642 USA.	wud@pharmacol.rochester.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053162] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54167, GM53162] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; HERMOUET S, 1991, P NATL ACAD SCI USA, V88, P10455, DOI 10.1073/pnas.88.23.10455; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; Li ZM, 1997, P NATL ACAD SCI USA, V94, P13820, DOI 10.1073/pnas.94.25.13820; MacrezLepretre N, 1997, J BIOL CHEM, V272, P10095; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; Post GR, 1996, MOL BIOL CELL, V7, P1679, DOI 10.1091/mbc.7.11.1679; Sah VP, 1996, J BIOL CHEM, V271, P31185, DOI 10.1074/jbc.271.49.31185; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SINGER WD, 1994, J BIOL CHEM, V269, P19796; Snow BE, 1997, BIOCHEM BIOPH RES CO, V233, P770, DOI 10.1006/bbrc.1997.6537; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; WANGE RL, 1991, J BIOL CHEM, V266, P11409; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; WU DQ, 1995, J BIOL CHEM, V270, P9828, DOI 10.1074/jbc.270.17.9828; WU DQ, 1992, J BIOL CHEM, V267, P25798; WU DQ, 1992, J BIOL CHEM, V267, P1811; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	35	148	152	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27118	27123		10.1074/jbc.273.42.27118	http://dx.doi.org/10.1074/jbc.273.42.27118			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765229	hybrid			2022-12-27	WOS:000076448000016
J	Apletalina, E; Appel, J; Lamango, NS; Houghten, RA; Lindberg, I				Apletalina, E; Appel, J; Lamango, NS; Houghten, RA; Lindberg, I			Identification of inhibitors of prohormone convertases 1 and 2 using a peptide combinatorial library	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUENCHED FLUOROGENIC SUBSTRATE; ENZYMATIC CHARACTERIZATION; PROCESSING ENZYME; HUMAN FURIN; NEUROENDOCRINE CELLS; CLEAVAGE; 7B2; ENDOPROTEASE; PURIFICATION; SEQUENCE	A positional scanning synthetic peptide combinatorial library containing approximately 52 million hexapeptides was used to identify potential inhibitory peptides for recombinant mouse prohormone convertase 1 (PC1) and PC2 and to provide information on the specificity of these enzymes. The library surveys revealed that a P6 Leu, a P4 Arg, a P2 Lys, and a P1 Arg were most inhibitory against PC1, and a P6 Ile and a P4 Arg were most inhibitory against PC2, Using information derived from the library surveys, hexapeptide sets were synthesized and screened for inhibition of PC1 and PC2, The data obtained revealed the preference of both enzymes for a P3 Val, At P5, many substitutions were well tolerated. PC1 and PC2 proved to differ mainly in the selectivity of their S6 subsites, In PC1, this subsite displayed a strong preference toward occupation by Leu; the K-i value for peptide Ac-Leu-Leu-Arg-Val-Lys-Arg-NH2 was 28 times lower than that for peptide Ac-Ile-Ile-Arg-Val-Lys-Arg-NH2. In contrast, PC2 discriminated little between Leu and lie at P6, as evidenced by the small (1.5-fold) difference in K-i values for these two peptides, Several hexapeptides synthesized as a result of the screen were found to represent potent inhibitors of PC2 (with K-i values in the submicromolar range) and, particularly, of PC1 (with K-i values in the low nanomolar range). The most potent inhibitor, Ac-Leu-Leu-Arg-Val-Lys-Arg-NH2, proved to be the same peptide for both enzymes and inhibited PC1 and PC2 in a competitive, fast-binding manner with K-i values of 3.2 and 360 nm, respectively, The four most potent peptide inhibitors of PC1 and PC2 were also tested against soluble human furin and found to exhibit a different rank order of inhibition; for example, Ac-Leu-Leu-Arg-Val-Lys-Arg-NH2, was 440-fold less potent against furin than against PC1, with a K-i of 1400 nM.	Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Torrey Pines Inst Mol Studies, San Diego, CA 92121 USA	Louisiana State University System; Torrey Pines Institute for Molecular Studies, California	Lindberg, I (corresponding author), Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, 1901 Perdido St, New Orleans, LA 70112 USA.	ilindb@lsumc.edu	Lindberg, Iris/Q-3825-2019; Lamango, Nazarius/W-8459-2019		NATIONAL INSTITUTE ON DRUG ABUSE [R56DA005084, R01DA005084] Funding Source: NIH RePORTER; NIDA NIH HHS [DA05084, DA00204, R56 DA005084, R01 DA005084] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; ANGLIKER H, 1995, ANAL BIOCHEM, V224, P409, DOI 10.1006/abio.1995.1058; ANGLIKER H, 1995, J MED CHEM, V38, P4014, DOI 10.1021/jm00020a016; BASAK A, 1995, INT J PEPT PROT RES, V46, P228; BASAK A, 1994, INT J PEPT PROT RES, V44, P253; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; BRENNER C, 1992, P NATL ACAD SCI USA, V89, P922, DOI 10.1073/pnas.89.3.922; Dahlen JR, 1998, J BIOL CHEM, V273, P1851, DOI 10.1074/jbc.273.4.1851; EICHLER J, 1993, BIOCHEMISTRY-US, V32, P11035, DOI 10.1021/bi00092a013; EICHLER J, 1994, PEPTIDE RES, V7, P300; Eichler J, 1996, MOL DIVERS, V1, P233, DOI 10.1007/BF01715527; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; INOUYE M, 1991, ENZYME, V45, P314, DOI 10.1159/000468904; JEAN F, 1995, BIOCHEM J, V307, P689, DOI 10.1042/bj3070689; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; JEAN F, 1993, BIOCHEM J, V292, P891, DOI 10.1042/bj2920891; JEAN F, 1995, J BIOL CHEM, V270, P19225, DOI 10.1074/jbc.270.33.19225; Johanning K, 1998, J BIOL CHEM, V273, P22672, DOI 10.1074/jbc.273.35.22672; Jutras I, 1997, J BIOL CHEM, V272, P15184, DOI 10.1074/jbc.272.24.15184; Lamango NS, 1996, ARCH BIOCHEM BIOPHYS, V330, P238, DOI 10.1006/abbi.1996.0249; Lazure C, 1998, J BIOL CHEM, V273, P8572, DOI 10.1074/jbc.273.15.8572; Ledgerwood EC, 1996, BIOCHEM MOL BIOL INT, V39, P1167; Lindberg I, 1998, DNA CELL BIOL, V17, P727, DOI 10.1089/dna.1998.17.727; LINDBERG I, 1995, BIOCHEMISTRY-US, V34, P5486, DOI 10.1021/bi00016a020; LU WY, 1993, J BIOL CHEM, V268, P14583; MISUMI Y, 1990, J BIOCHEM-TOKYO, V108, P230, DOI 10.1093/oxfordjournals.jbchem.a123185; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; NAKAYAMA K, 1992, J BIOL CHEM, V267, P16335; PINILLA C, 1994, DRUG DEVELOP RES, V33, P133, DOI 10.1002/ddr.430330210; PINILLA C, 1992, BIOTECHNIQUES, V13, P901; PINILLA C, 1995, BIOPOLYMERS, V37, P221, DOI 10.1002/bip.360370306; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; RUFAUT NW, 1993, J BIOL CHEM, V268, P20291; Salvesen G, 1989, PROTEOLYTIC ENZYMES, P83; SEIDAH NG, 1994, METHOD ENZYMOL, V244, P171; VANHORSSEN AM, 1995, J BIOL CHEM, V270, P14292; YI Z, 1993, J BIOL CHEM, V268, P5615; ZHOU A, 1994, J BIOL CHEM, V269, P17440; ZHOU Y, 1994, J BIOL CHEM, V269, P18408; Zhu X, 1996, P NATL ACAD SCI USA, V93, P4919, DOI 10.1073/pnas.93.10.4919; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641	45	64	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26589	26595		10.1074/jbc.273.41.26589	http://dx.doi.org/10.1074/jbc.273.41.26589			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756897	hybrid			2022-12-27	WOS:000076373300051
J	Cases, S; Novak, S; Zheng, YW; Myers, HM; Lear, SR; Sande, E; Welch', CB; Lusis, AJ; Spencer, TA; Krause, BR; Erickson, SK; Farese, RV				Cases, S; Novak, S; Zheng, YW; Myers, HM; Lear, SR; Sande, E; Welch', CB; Lusis, AJ; Spencer, TA; Krause, BR; Erickson, SK; Farese, RV			ACAT-2, a second mammalian acyl-CoA : cholesterol acyltransferase - Its cloning, expression, and characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR LXR; COENZYME-A; MOLECULAR-CLONING; APOLIPOPROTEIN-B; LIPOPROTEIN METABOLISM; ESTERIFICATION ENZYMES; FUNCTIONAL EXPRESSION; OXIDIZED CHOLESTEROL; OXYGENATED STEROLS; LIVER	The synthesis of cholesterol esters by acyl-CoA:cholesterol acyltransferase (ACAT, EC 2.3.1.26) is an important component of cellular cholesterol homeostasis, Cholesterol ester formation also is hypothesized to be important in several physiologic processes, including intestinal cholesterol absorption, hepatic lipoprotein production, and macrophage foam cell formation in atherosclerotic lesions. Mouse tissue expression studies and the disruption of the mouse ACAT gene (Acact) have indicated that more than one ACAT exists in mammals and specifically that another enzyme is important in mouse liver and intestine. We now describe a second mammalian ACAT enzyme, designated ACAT-2, that is 44% identical to the first cloned mouse ACAT (henceforth designated ACAT-1), Infection of H5 insect cells with an ACAT-2 recombinant baculovirus resulted in expression of a similar to 46-kDa protein in cell membranes that was associated with high levels of cholesterol esterification activity. Both ACAT-1 and ACAT-2 also catalyzed the esterification of the SP-hydroxyl group of a variety of oxysterols, Cholesterol esterification activities for ACAT-1 and ACAT-2 exhibited different IC50 values when assayed in the presence of several ACAT-specific inhibitors, demonstrating that ACAT inhibitors can selectively target specific forms of ACAT, ACAT-2 was expressed primarily in mouse liver and small intestine, supporting the hypothesis that ACAT-2 contributes to cholesterol esterification in these tissues. The mouse ACAT-S gene (Acact2) maps to chromosome 15 in a region containing a quantitative trait locus influencing plasma cholesterol levels. The identification and cloning of ACAT-S will facilitate molecular approaches to understanding the role of ACAT enzymes in mammalian biology.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA; Vet Adm Med Ctr, San Francisco, CA 94121 USA; Univ Calif Los Angeles, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Dartmouth Coll, Dept Chem, Hanover, NH 03755 USA; Parke Davis Pharmaceut Res, Ann Arbor, MI 48105 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Dartmouth College; Pfizer	Farese, RV (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL042488, R01HL042488, R01HL057170, R01HL052069] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52069, R01 HL057170, HL42488, HL57170] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson RA, 1998, J BIOL CHEM, V273, P26747, DOI 10.1074/jbc.273.41.26747; BOCAN TMA, 1991, ARTERIOSCLER THROMB, V11, P1830, DOI 10.1161/01.ATV.11.6.1830; Brown AJ, 1996, J LIPID RES, V37, P320; BROWN MS, 1975, J BIOL CHEM, V250, P4025; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; Cao GQ, 1996, J BIOL CHEM, V271, P14642, DOI 10.1074/jbc.271.24.14642; CARR TP, 1995, J LIPID RES, V36, P25; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; CHENG D, 1995, J BIOL CHEM, V270, P685, DOI 10.1074/jbc.270.2.685; CORNELL R, 1977, EXP CELL RES, V109, P299, DOI 10.1016/0014-4827(77)90009-X; DIXON JL, 1993, J LIPID RES, V34, P167; DOMINICK MA, 1993, TOXICOL PATHOL, V21, P54, DOI 10.1177/019262339302100107; EMANUEL HA, 1991, J FOOD SCI, V56, P843, DOI 10.1111/j.1365-2621.1991.tb05396.x; ERICKSON SK, 1980, J LIPID RES, V21, P930; ERICKSON SK, 1986, J LIPID RES, V27, P875; Farese RV, 1996, J LIPID RES, V37, P347; FIELD FJ, 1990, GASTROENTEROLOGY, V99, P539, DOI 10.1016/0016-5085(90)91040-D; GOLDSTEIN JL, 1978, P NATL ACAD SCI USA, V75, P1877, DOI 10.1073/pnas.75.4.1877; GOODMAN DS, 1965, PHYSIOL REV, V45, P747, DOI 10.1152/physrev.1965.45.4.747; GOODMAN DS, 1964, J BIOL CHEM, V239, P1335; HAUGEN R, 1976, SCAND J GASTROENTERO, V11, P615; HUFF MW, 1994, ARTERIOSCLER THROMB, V14, P1498, DOI 10.1161/01.ATV.14.9.1498; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; JIALAL I, 1991, ARTERIOSCLER THROMB, V11, P482, DOI 10.1161/01.ATV.11.3.482; KANDUTSCH AA, 1978, SCIENCE, V201, P498, DOI 10.1126/science.663671; KINNUNEN PM, 1988, BIOCHEMISTRY-US, V27, P7344, DOI 10.1021/bi00419a025; Krause B.R., 1995, INFLAMMATION MEDIATO, P173; KRAUSE BR, 1993, J PHARMACOL EXP THER, V267, P734; Lee HT, 1996, J MED CHEM, V39, P5031, DOI 10.1021/jm960674d; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; LICHTENSTEIN AH, 1983, BIOCHIM BIOPHYS ACTA, V751, P340, DOI 10.1016/0005-2760(83)90292-8; MADUSKUIE TP, 1995, J MED CHEM, V38, P1067, DOI 10.1021/jm00007a004; MANLY KF, 1993, MAMM GENOME, V4, P303, DOI 10.1007/BF00357089; Meiner V, 1997, J LIPID RES, V38, P1928; Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041; NELSON JA, 1981, J BIOL CHEM, V256, P1067; NELSON JA, 1981, J AM CHEM SOC, V103, P6974, DOI 10.1021/ja00413a040; Oelkers P, 1998, J BIOL CHEM, V273, P26765, DOI 10.1074/jbc.273.41.26765; OSADA K, 1994, LIPIDS, V29, P555, DOI 10.1007/BF02536627; OSADA K, 1994, BIOSCI BIOTECH BIOCH, V58, P782, DOI 10.1271/bbb.58.782; PENG SK, 1987, ATHEROSCLEROSIS, V64, P1, DOI 10.1016/0021-9150(87)90047-5; PRASAD VVK, 1984, J STEROID BIOCHEM, V21, P733, DOI 10.1016/0022-4731(84)90038-4; PURCELLHUYNH DA, 1995, J CLIN INVEST, V96, P1845, DOI 10.1172/JCI118230; RICHERT L, 1983, BIOCHEM BIOPH RES CO, V117, P851, DOI 10.1016/0006-291X(83)91674-1; SAUCIER SE, 1989, J BIOL CHEM, V264, P6863; SMITH JL, 1995, J LIPID RES, V36, P641; SMITH LL, 1989, FREE RADICAL BIO MED, V7, P285, DOI 10.1016/0891-5849(89)90136-6; SUCKLING KE, 1985, J LIPID RES, V26, P647; UELMEN PJ, 1995, J BIOL CHEM, V270, P26192, DOI 10.1074/jbc.270.44.26192; Vora Jayesh, 1997, Pharmaceutical Research (New York), V14, pS505; WARDEN CH, 1993, GENOMICS, V18, P295, DOI 10.1006/geno.1993.1469; Welch CL, 1996, J LIPID RES, V37, P1406; WILSON MD, 1994, J LIPID RES, V35, P943; WOLFGANG GHI, 1995, LIFE SCI, V56, P1089, DOI 10.1016/0024-3205(95)00045-8; Yang HY, 1996, SCIENCE, V272, P1353, DOI 10.1126/science.272.5266.1353; Yang HY, 1997, J BIOL CHEM, V272, P3980, DOI 10.1074/jbc.272.7.3980; Yu CJ, 1996, J BIOL CHEM, V271, P24157, DOI 10.1074/jbc.271.39.24157; ZHANG HF, 1990, J LIPID RES, V31, P1361	59	324	341	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26755	26764		10.1074/jbc.273.41.26755	http://dx.doi.org/10.1074/jbc.273.41.26755			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756919	hybrid			2022-12-27	WOS:000076373300073
J	Konstantinidis, AK; Radhakrishnan, R; Gu, F; Rao, RN; Yeh, WK				Konstantinidis, AK; Radhakrishnan, R; Gu, F; Rao, RN; Yeh, WK			Purification, characterization, and kinetic mechanism of cyclin D1 center dot CDK4, a major target for cell cycle regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE-PRODUCT; DEPENDENT KINASES; PROTEIN; PHOSPHORYLATION; INHIBITION; STAUROSPORINE; BINDING; E2F; IDENTIFICATION; SUBSTRATE	The cyclin D1 . CDK4-pRb (retinoblastoma protein) pathway plays a central role iu the cell cycle, and its deregulation is correlated with many types of cancers. As a major drug target, we purified dimeric cyclin D1 . CDK4 complex to near-homogeneity by a four-step procedure from a recombinant baculovirus-infected insect culture, We optimized the kinase activity and stability and developed a reproducible assay. We examined several catalytic and kinetic properties of the complex and, via steady-state kinetics, derived a kinetic mechanism with a peptide (Rb-ING) and subsequently investigated the mechanistic implications with a physiologically relevant protein (Rb-21) as the phosphoacceptor. The complex bound ATP 130-fold tighter when Rb-21 instead of Rb-ING was used as the phosphoacceptor, By using staurosporine and ADP as inhibitors, the kinetic mechanism of the complex appeared to be a "single displacement or Bi-Bi" with Mg2+. ATP as the leading substrate and phosphorylated Rb-ING as the last product released. In addition, we purified a cyclin D1-CDK4 fusion protein to homogeneity by a three-step protocol from another recombinant baculovirus culture and observed similar kinetic properties and mechanisms as those from the complex. We attempted to model staurosporine in the ATP-binding site of CDK4 according to our kinetic data. Our biochemical and modeling data provide validation of both the complex and fusion protein as highly active kinases and their usefulness in antiproliferative inhibitor discovery.	Lilly Res Labs, Res Technol & Prot, Indianapolis, IN 46285 USA; Lilly Res Labs, Canc Res, Indianapolis, IN 46285 USA	Eli Lilly; Eli Lilly	Yeh, WK (corresponding author), Lilly Res Labs, Res Technol & Prot, Indianapolis, IN 46285 USA.							BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CHURGAY LM, 1995, TECHNIQUES PROTEIN C, P837; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; CORDONCARDO C, 1995, AM J PATHOL, V147, P545; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; Furet P, 1995, J COMPUT AID MOL DES, V9, P465, DOI 10.1007/BF00124317; GREER J, 1990, PROTEINS, V7, P317, DOI 10.1002/prot.340070404; GREER J, 1980, P NATL ACAD SCI-BIOL, V77, P3393, DOI 10.1073/pnas.77.6.3393; GULBINSKY JS, 1968, BIOCHEMISTRY-US, V7, P566, DOI 10.1021/bi00842a009; HAMEL PA, 1992, ONCOGENE, V7, P693; HAMMES GG, 1962, J AM CHEM SOC, V84, P2069, DOI 10.1021/ja00870a012; Heitz F, 1997, BIOCHEMISTRY-US, V36, P4995, DOI 10.1021/bi962349y; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HENSEY CE, 1994, J BIOL CHEM, V269, P1380; HIGASHI H, 1995, BIOCHEM BIOPH RES CO, V216, P520, DOI 10.1006/bbrc.1995.2653; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KARP JE, 1995, NAT MED, V1, P309, DOI 10.1038/nm0495-309; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KITAGAWA M, 1992, ONCOGENE, V7, P1067; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Lawrie AM, 1997, NAT STRUCT BIOL, V4, P796, DOI 10.1038/nsb1097-796; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; LUNBERG AS, 1998, MOL CELL BIOL, V18, P753; MEGGIO F, 1995, EUR J BIOCHEM, V234, P317, DOI 10.1111/j.1432-1033.1995.317_c.x; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORRISON JF, 1965, BIOCHEM J, V97, P37, DOI 10.1042/bj0970037; MOURAD N, 1966, J BIOL CHEM, V241, P271; NOBUYUKI F, 1994, TETRAHEDRON LETT, V35, P1251; OTTO KA, 1996, KEYST S MOL CELL BIO; Patra D, 1996, GENE DEV, V10, P1503, DOI 10.1101/gad.10.12.1503; RICE JW, 1993, BIOTECHNIQUES, V15, P1052; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SEGEL IH, 1993, ENZYME KINETICS BEHA, P505; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; SUZUKITAKAHASHI I, 1995, ONCOGENE, V10, P1691; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; Wallace AC, 1996, PROTEIN SCI, V5, P1001; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WANG NP, 1990, CELL GROWTH DIFFER, V1, P233; WHITAKER JR, 1963, ANAL CHEM, V35, P1950, DOI 10.1021/ac60205a048; WOOD HG, 1966, J BIOL CHEM, V241, P5692; Zarkowska T, 1997, ONCOGENE, V14, P249, DOI 10.1038/sj.onc.1200824; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	55	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26506	26515		10.1074/jbc.273.41.26506	http://dx.doi.org/10.1074/jbc.273.41.26506			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756886	hybrid			2022-12-27	WOS:000076373300040
J	Prekeris, R; Hernandez, RM; Mayhew, MW; White, MK; Terrian, DM				Prekeris, R; Hernandez, RM; Mayhew, MW; White, MK; Terrian, DM			Molecular analysis of the interactions between protein kinase C-epsilon and filamentous actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; TERMINAL RESIDUES; BINDING MOTIF; MUSCLE ACTIN; ACTIVATION; CELLS; LOCALIZATION; DOMAINS; IDENTIFICATION; TRANSLOCATION	Protein kinase C-epsilon (PKC-epsilon) contains a putative actin binding motif that is unique to this individual member of the PKC gene family. me have used deletion mutagenesis to determine whether this hexapeptide motif is required for the physical association of PKC-epsilon and actin. Full-length recombinant PKC-epsilon, but not PKC-beta II, -delta, -eta, or -zeta bound to filamentous actin in a phorbol ester-dependent manner. Deletion of PKC-epsilon amino acids 222-230, encompassing a putative actin binding motif, completely abrogated this binding activity. When NIH 3T3 cells overexpressing either PKC-epsilon off the deletion mutant of this isozyme were treated with phorbol ester only wild-type PKC-epsilon colocalized with actin in tomes of cell adhesion. in binary reactions, it was possible to demonstrate that purified filamentous actin is capable of directly stimulating PKC-epsilon phosphotransferase activity. These and other findings support the hypothesis that a conformationally hidden actin binding motif in the PKC-epsilon sequence becomes exposed upon activation of this isozyme aad functions as a dominant localization signal in NIH 3T3 fibroblasts. This protein-protein interaction is sufficient to maintain PKC-epsilon ire a catalytically active conformation.	E Carolina Univ, Sch Med, Dept Anat & Cell Biol, Greenville, NC 27858 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	University of North Carolina; East Carolina University; Jefferson University	Terrian, DM (corresponding author), E Carolina Univ, Sch Med, Dept Anat & Cell Biol, Greenville, NC 27858 USA.	dterrian@brody.med.ecu.edu	Hernández, Rosa/GRF-5998-2022		NIDDK NIH HHS [DK45718] Funding Source: Medline; NIEHS NIH HHS [ES8397] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045718] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008397] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AKITA Y, 1994, J BIOL CHEM, V269, P4653; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BETTACHE N, 1989, P NATL ACAD SCI USA, V86, P6028, DOI 10.1073/pnas.86.16.6028; Blobe GC, 1996, J BIOL CHEM, V271, P15823, DOI 10.1074/jbc.271.26.15823; Cacace AM, 1996, ONCOGENE, V13, P2517; Chun J, 1997, J CELL PHYSIOL, V173, P361, DOI 10.1002/(SICI)1097-4652(199712)173:3<361::AID-JCP8>3.0.CO;2-L; Chun JS, 1996, J BIOL CHEM, V271, P13008, DOI 10.1074/jbc.271.22.13008; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; Fagerstrom S, 1996, CELL GROWTH DIFFER, V7, P775; GOMEZ J, 1995, EUR J IMMUNOL, V25, P2673, DOI 10.1002/eji.1830250941; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Horowitz A, 1996, AM J PHYSIOL-CELL PH, V271, pC589, DOI 10.1152/ajpcell.1996.271.2.C589; Huang XP, 1997, J CELL SCI, V110, P1625; Hurley JH, 1997, PROTEIN SCI, V6, P477; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; Keranen LM, 1997, J BIOL CHEM, V272, P25959, DOI 10.1074/jbc.272.41.25959; Kiley SC, 1997, CELL GROWTH DIFFER, V8, P221; Lee HW, 1997, MOL PHARMACOL, V51, P439; LEHEL C, 1995, J BIOL CHEM, V270, P19651, DOI 10.1074/jbc.270.33.19651; LIAO L, 1994, BIOCHEMISTRY-US, V33, P1229, DOI 10.1021/bi00171a024; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MORNET D, 1984, P NATL ACAD SCI-BIOL, V81, P3680, DOI 10.1073/pnas.81.12.3680; MOSSAKOWSKA M, 1993, BIOCHEM J, V289, P897, DOI 10.1042/bj2890897; ODONOGHUE SI, 1992, ARCH BIOCHEM BIOPHYS, V293, P110, DOI 10.1016/0003-9861(92)90372-4; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PEARS C, 1991, BIOCHEM J, V276, P257, DOI 10.1042/bj2760257; Perletti G, 1996, BIOCHEM BIOPH RES CO, V221, P688, DOI 10.1006/bbrc.1996.0657; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; QUEST AFG, 1994, J BIOL CHEM, V269, P2000; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ReifelMiller AE, 1996, J BIOL CHEM, V271, P21666, DOI 10.1074/jbc.271.35.21666; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; SCHAAP D, 1990, EUR J BIOCHEM, V191, P431, DOI 10.1111/j.1432-1033.1990.tb19139.x; SHARKEY NA, 1985, CANCER RES, V45, P19; SOSSIN WS, 1993, TRENDS BIOCHEM SCI, V18, P207, DOI 10.1016/0968-0004(93)90189-T; VANCOMPERNOLLE K, 1991, J BIOL CHEM, V266, P15427; VUORI K, 1993, J BIOL CHEM, V268, P21459	41	106	107	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26790	26798		10.1074/jbc.273.41.26790	http://dx.doi.org/10.1074/jbc.273.41.26790			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756923	hybrid			2022-12-27	WOS:000076373300077
J	Wan, HS; Dawson, MI; Hong, WK; Lotan, R				Wan, HS; Dawson, MI; Hong, WK; Lotan, R			Overexpressed activated retinoid X receptors can mediate growth inhibitory effects of retinoids in human carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTORS; ACID RECEPTORS; CANCER CHEMOPREVENTION; SELECTIVE RETINOIDS; HORMONE RECEPTORS; RESPONSE PATHWAYS; RXR HETERODIMERS; ORPHAN RECEPTORS; BINDING; BETA	Retinoic acid receptors (RARs) and retinoid X receptors (RXRs) mediate the effects of retinoids on gene expression by binding to response elements in retinoid-sensitive genes. RAR- but not RXR-selective retinoids were found in many previous studies to suppress the growth of various cells, implicating RXR-RAR in these effects. Using a co-expression vector for identifying cells that expressed retinoid receptors transiently and 5'-bromo 2'-deoxyuridine incorporation for labeling DNA-synthesizing cells, we found that RXR-selective retinoids inhibited DNA synthesis in squamous carcinoma 1483 cells transfected with RXR alpha but not with RARs. Ligand-induced transcription of the reporter luciferase gene via the activation of RXR-RXR but not RXR-RAR correlated with growth suppression. Studies with RXR alpha deletion mutants indicated that the DNA binding and the ligand binding domains are essential for mediating growth inhibition. A point mutation in the ligand binding domain (L430F) that decreased RXR alpha homodimerization compromised its growth inhibitory function. Further, RXR alpha mutant (F313A), which functions as a constitutively active receptor, inhibited DNA synthesis in the absence of ligand. These results demonstrate that RXR homodimer activation leads to growth inhibition and suggest that transfection of RXR alpha and treatment with RXR-selective retinoids or the transfection of constitutively activated RXR alpha mutant alone may have a therapeutic potential.	Univ Texas, MD Anderson Canc Ctr, Dept Tumor Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; SRI Int, Retinoid Program, Menlo Pk, CA 94025 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; SRI International	Lotan, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Tumor Biol, Box 108, Houston, TX 77030 USA.	rlotan@notes.mdacc.tmc.edu			NCI NIH HHS [P30 CA16672, P01 CA52051, P01 CA51993] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA052051, P01CA051993, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN HW, 1995, P NATL ACAD SCI USA, V92, P422, DOI 10.1073/pnas.92.2.422; DAVIS KD, 1994, MOL CELL BIOL, V14, P7105, DOI 10.1128/MCB.14.11.7105; DAWSON MI, 1994, BLOOD, V84, P446; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FRANGIONI JV, 1994, J CELL SCI, V107, P827; GENDIMENICO GJ, 1994, J INVEST DERMATOL, V102, P676, DOI 10.1111/1523-1747.ep12374092; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gudas Lorraine J., 1994, P443; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; JIANG H, 1995, BIOCHEM PHARMACOL, V50, P669, DOI 10.1016/0006-2952(95)00183-Z; Kersten S, 1997, J BIOL CHEM, V272, P12771, DOI 10.1074/jbc.272.19.12771; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LeDouarin B, 1996, PHILOS T R SOC B, V351, P569, DOI 10.1098/rstb.1996.0056; LEHMANN JM, 1991, CANCER RES, V51, P4804; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; Li C, 1996, DNA CELL BIOL, V15, P955, DOI 10.1089/dna.1996.15.955; LI XS, 1995, J CELL PHYSIOL, V165, P449, DOI 10.1002/jcp.1041650302; Lipkin SM, 1996, J VIROL, V70, P7182, DOI 10.1128/JVI.70.10.7182-7189.1996; Liu Y, 1996, MOL CELL BIOL, V16, P1138; LOTAN R, 1995, J NATL CANCER I, V87, P1655, DOI 10.1093/jnci/87.22.1655; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; LOTAN R, 1995, CANCER RES, V55, P232; LOTAN R, 1995, RETINOIDS ONCOLOGY, P27; MADER S, 1993, J BIOL CHEM, V268, P591; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MEDIN JA, 1994, MOL CELL ENDOCRINOL, V105, P27, DOI 10.1016/0303-7207(94)90032-9; Mehta K, 1996, CELL GROWTH DIFFER, V7, P179; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; Pfahl Magnus, 1994, Seminars in Cell Biology, V5, P95, DOI 10.1006/scel.1994.1013; Pignatello MA, 1997, TOXICOL APPL PHARM, V142, P319, DOI 10.1006/taap.1996.8047; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROCHETTEEGLY C, 1992, MOL ENDOCRINOL, V6, P2197, DOI 10.1210/me.6.12.2197; ROY DY, 1995, MOL CELL BIOL, V15, P6481; SACKS PG, 1988, CANCER RES, V48, P2858; Stroup D, 1997, J BIOL CHEM, V272, P9833; Sun SY, 1997, CANCER RES, V57, P4931; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; UNDERHILL TM, 1994, MOL ENDOCRINOL, V8, P274, DOI 10.1210/me.8.3.274; Vivat V, 1997, EMBO J, V16, P5697, DOI 10.1093/emboj/16.18.5697; Willhite CC, 1996, DRUG METAB REV, V28, P105, DOI 10.3109/03602539608993994; XIAO JH, 1995, J BIOL CHEM, V270, P3001, DOI 10.1074/jbc.270.7.3001; ZHANG XK, 1994, MOL CELL BIOL, V14, P4311, DOI 10.1128/MCB.14.6.4311; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZOU CP, 1994, CANCER RES, V54, P5479	48	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26915	26922		10.1074/jbc.273.41.26915	http://dx.doi.org/10.1074/jbc.273.41.26915			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756939	hybrid			2022-12-27	WOS:000076373300093
J	Yamamoto, M; Toya, Y; Schwencke, C; Lisanti, MP; Myers, MG; Ishikawa, Y				Yamamoto, M; Toya, Y; Schwencke, C; Lisanti, MP; Myers, MG; Ishikawa, Y			Caveolin is an activator of insulin receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; SMOOTH-MUSCLE CELLS; TYROSINE PHOSPHORYLATION; MEMBRANE DOMAINS; 3T3-L1 CELLS; GENE FAMILY; EXPRESSION; PROTEIN; PURIFICATION; KINASE	Recent data have demonstrated that caveolin, a major structural protein of caveolae, negatively regulates signaling molecules localized to caveolae, The interaction of caveolin with several caveolae-associated signaling proteins is mediated by the binding of the scaffolding region of caveolin to a hydrophobic amino acid-containing region within the regulated proteins. The presence of a similar motif within the insulin receptor kinase prompted us to investigate the caveolar localization and regulation of the insulin receptor by caveolin, We found that overexpression of caveolin-3 augmented insulin-stimulated phosphorylation of insulin receptor substrate-1 in 293T cells but not the phosphorylation of insulin receptor. Peptides corresponding to the scaffolding domain of caveolin potently stimulated insulin receptor kinase activity toward insulin receptor substrate-1 or a Src-derived peptide in vitro and in a caveolin subtype-dependent fashion. Peptides from caveolin-2 exhibited no effect, whereas caveolin-1 and -3 stimulated activity 10- and 17-fold, respectively. Peptides which increased insulin receptor kinase activity did so without affecting insulin receptor auto-phosphorylation. Furthermore, the insulin receptor bound to immobilized caveolin peptides, and this binding was inhibited in the presence of free caveolin-3 peptides. Thus, we have identified a novel mechanism by which the insulin receptor is bound and activated by specific caveolin subtypes, Furthermore, these data define a new role for caveolin as an activator of signaling.	Allegheny Univ Hlth Sci, Cardiovasc & Pulm Res Inst, Pittsburgh, PA 15212 USA; Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02115 USA	Yeshiva University; Albert Einstein College of Medicine; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	Ishikawa, Y (corresponding author), Allegheny Univ Hlth Sci, Cardiovasc & Pulm Res Inst, Pittsburgh, PA 15212 USA.	yishikaw@pgh.auhs.edu	Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013	Lisanti, Michael/0000-0003-2034-1382; 	NHLBI NIH HHS [HL59139, HL59729] Funding Source: Medline; NIGMS NIH HHS [GM-50443] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL059729, P01HL059139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050443] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN J, 1998, J BIOL CHEM, V268, P7571; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GOLDBERG RI, 1987, J CELL PHYSIOL, V133, P203, DOI 10.1002/jcp.1041330202; Huppertz C, 1996, DIABETOLOGIA, V39, P1432, DOI 10.1007/s001250050595; ISHIKAWA Y, 1992, NUCLEIC ACIDS RES, V20, P4367, DOI 10.1093/nar/20.16.4367; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; KANDROR KV, 1995, J CELL BIOL, V129, P999, DOI 10.1083/jcb.129.4.999; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1995, MOL MEMBR BIOL, V12, P121, DOI 10.3109/09687689509038506; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; Mastick CC, 1997, J BIOL CHEM, V272, P20706, DOI 10.1074/jbc.272.33.20706; MASTICK CC, 1995, J CELL BIOL, V129, P1523, DOI 10.1083/jcb.129.6.1523; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; Mineo C, 1997, J BIOL CHEM, V272, P10345; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Monier S, 1996, FEBS LETT, V388, P143, DOI 10.1016/0014-5793(96)00519-4; Munoz P, 1996, J BIOL CHEM, V271, P8133, DOI 10.1074/jbc.271.14.8133; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; Oka N, 1997, J BIOL CHEM, V272, P33416, DOI 10.1074/jbc.272.52.33416; PIKE LJ, 1986, J BIOL CHEM, V261, P3782; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; Scherer PE, 1997, J BIOL CHEM, V272, P20698, DOI 10.1074/jbc.272.33.20698; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SIMIONESCU N, 1983, PHYSIOL REV, V63, P1536, DOI 10.1152/physrev.1983.63.4.1536; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; SUN XJ, 1992, J BIOL CHEM, V267, P22662; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; VILLALBA M, 1989, P NATL ACAD SCI USA, V86, P7848, DOI 10.1073/pnas.86.20.7848; WHITE MF, 1994, J BIOL CHEM, V269, P1	42	254	261	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26962	26968		10.1074/jbc.273.41.26962	http://dx.doi.org/10.1074/jbc.273.41.26962			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756945	hybrid			2022-12-27	WOS:000076373300099
J	Dickinson, JR; Harrison, SJ; Hewlins, MJE				Dickinson, JR; Harrison, SJ; Hewlins, MJE			An investigation of the metabolism of valine to isobutyl alcohol in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLE NITROGEN-SOURCE; CHAIN AMINO-ACIDS; DEHYDROGENASE COMPLEX; MITOCHONDRIAL; YEAST; CATABOLISM; HOMOLOGS; ECA39; GENE	The metabolism of valine to isobutyl alcohol in yeast was examined by C-13 nuclear magnetic resonance spectroscopy and combined gas chromatography-mass spectrometry, The product of valine transamination, alpha-ketoisovalerate, had four potential routes to isobutyl alcohol. The first, via branched-chain alpha-ketoacid dehydrogenase to isobutyryl-CoA is not required for the synthesis of isobutyl alcohol because abolition of branched-chain alpha-ketoacid dehydrogenase activity in an lpd1 disruption mutant did not prevent the formation of isobutyl alcohol. The second route, via pyruvate decarboxylase, is the one that is used because elimination of pyruvate decarboxylase activity in a pdc1 pdc5 pdc6 triple mutant virtually abolished isobutyl alcohol production. A third potential route involved alpha-ketoisovalerate reductase, but this had no role in the formation of isobutyl alcohol from alpha-hydroxyisovalerate because cell homogenates could not convert alpha-hydroxyisovalerate to isobutyl alcohol. The final possibility, use of the pyruvate decarboxylase-like enzyme encoded by YDL080c, seemed to be irrelevant, because a strain with a disruption in this gene produced wild-type levels of isobutyl alcohol. Thus there are major differences in the catabolism of leucine and valine to their respective "fusel" alcohols. Whereas in the catabolism of leucine to isoamyl alcohol the major route is via the decarboxylase encoded by YDL080c, any single isozyme of pyruvate decarboxylase is sufficient for the formation of isobutyl alcohol from valine, Finally, analysis of the C-13-labeled products revealed that the pathways of valine catabolism and leucine biosynthesis share a common pool of alpha-ketoisovalerate.	Univ Wales, Sch Pure & Appl Biol, Cardiff CF1 3TL, S Glam, Wales; Finnigan PLC, MassLab Grp, Manchester, Lancs, England; Univ Wales, Dept Chem, Cardiff CF1 3TB, S Glam, Wales	Cardiff University; Cardiff University	Dickinson, JR (corresponding author), Univ Wales, Sch Pure & Appl Biol, POB 915, Cardiff CF1 3TL, S Glam, Wales.							Bender D.A., 1975, AMINO ACID METABOLIS; Cooper T., 1982, MOL BIOL YEAST SACCH, P39, DOI DOI 10.1101/087969180.11B.39; DERRICK S, 1993, J GEN MICROBIOL, V139, P2783, DOI 10.1099/00221287-139-11-2783; DICKINSON JR, 1993, FEBS LETT, V326, P29, DOI 10.1016/0014-5793(93)81754-N; DICKINSON JR, 1986, MOL GEN GENET, V204, P103; Dickinson JR, 1997, J BIOL CHEM, V272, P26871, DOI 10.1074/jbc.272.43.26871; DICKINSON JR, 1992, J GEN MICROBIOL, V138, P2029, DOI 10.1099/00221287-138-10-2029; Eden A, 1996, J BIOL CHEM, V271, P20242, DOI 10.1074/jbc.271.34.20242; Ehrlich F, 1907, BER DTSCH CHEM GES, V40, P1027, DOI 10.1002/cber.190704001156; HOHMANN S, 1991, J BACTERIOL, V173, P7963, DOI 10.1128/jb.173.24.7963-7969.1991; Kispal G, 1996, J BIOL CHEM, V271, P24458, DOI 10.1074/jbc.271.40.24458; Lanterman MM, 1996, HUM MOL GENET, V5, P1643, DOI 10.1093/hmg/5.10.1643; Large P. J., 1986, YEAST, V2, P1; Mortimer R K, 1975, Methods Cell Biol, V11, P221, DOI 10.1016/S0091-679X(08)60325-8; Neubauer O, 1911, H-S Z PHYSIOL CHEM, V70, P326; NISHIMURA H, 1992, J BACTERIOL, V174, P4701, DOI 10.1128/JB.174.14.4701-4706.1992; REPETTO B, 1991, MOL CELL BIOL, V11, P3931, DOI 10.1128/MCB.11.8.3931; Sherman F, 1975, Methods Cell Biol, V11, P189, DOI 10.1016/S0091-679X(08)60323-4; SINCLAIR DA, 1995, GENETICS, V140, P1213; SINCLAIR DA, 1993, BIOCHEM MOL BIOL INT, V31, P911; ter Schure EG, 1998, APPL ENVIRON MICROB, V64, P1303; WEBB A. DINSMOOR, 1963, ADVAN APPL MICROBIOL, V5, P317, DOI 10.1016/S0065-2164(08)70014-5	22	134	180	0	50	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25751	25756		10.1074/jbc.273.40.25751	http://dx.doi.org/10.1074/jbc.273.40.25751			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748245	hybrid			2022-12-27	WOS:000076263100036
J	Didry, D; Carlier, MF; Pantaloni, D				Didry, D; Carlier, MF; Pantaloni, D			Synergy between actin depolymerizing factor cofilin and profilin in increasing actin filament turnover	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; ACANTHAMOEBA-CASTELLANII; PROTEIN; DYNAMICS; NUCLEOTIDE; BINDING; THYMOSIN-BETA-4; TROPOMYOSIN; ACTOPHORIN; MYOSIN	The mechanism of control of the steady state of actin assembly by actin depolymerizing factor (ADF)/cofilin and profilin has been investigated. Using TP, as an indicator of the concentration of ATP-G-actin, we show that ADF increases the concentration of ATP-G-actin at steady state. The measured higher concentration of ATP-G-actin is quantitatively consistent with the increase in treadmilling, caused by the large increase in the rate of depolymerization from the pointed ends induced by ADF (Carlier, M.-F., Laurent, V., Santolini, J., Didry, D., Melki, R., Xia, G.-X., Hong, Y., Chua, N.-H., and Pantaloni, D. (1997) J. Cell Biol. 136, 1307-1322). Experiments demonstrate that profilin synergizes with ADF to further enhance the turnover of actin filaments up to a value 125-fold higher than in pure F-actin solutions. Profilin and ADF act at the two ends of filaments in a complementary fashion to increase the processivity of treadmilling. Using the capping protein CapZ, we show that ADF increases the number of filaments at steady state by 1.3-fold, which cannot account for the 25-fold increase in turnover rate. Computer modeling of the combined actions of ADF and profilin on the dynamics of actin filaments using experimentally determined rate constants generates a distribution of the different actin species at steady state, which is in quantitative agreement with the data.	CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Carlier, MF (corresponding author), CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France.							Abe H, 1996, J CELL BIOL, V132, P871, DOI 10.1083/jcb.132.5.871; Bubb MR, 1998, CELL MOTIL CYTOSKEL, V39, P134, DOI 10.1002/(SICI)1097-0169(1998)39:2<134::AID-CM4>3.0.CO;2-6; CARLIER MF, 1984, J BIOL CHEM, V259, P9983; CARLIER MF, 1993, P NATL ACAD SCI USA, V90, P5034, DOI 10.1073/pnas.90.11.5034; Carlier MF, 1998, CURR OPIN CELL BIOL, V10, P45, DOI 10.1016/S0955-0674(98)80085-9; Carlier MF, 1996, J BIOL CHEM, V271, P9231, DOI 10.1074/jbc.271.16.9231; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; COOLEY L, 1992, CELL, V69, P173, DOI 10.1016/0092-8674(92)90128-Y; COOPER JA, 1986, J BIOL CHEM, V261, P477; Doi M., 1989, THEORY POLYM DYNAMIC; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; ISAMBERT H, 1995, J BIOL CHEM, V270, P11437, DOI 10.1074/jbc.270.19.11437; Isambert H, 1996, MACROMOLECULES, V29, P1036, DOI 10.1021/ma946418x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACIVER SK, 1991, J CELL BIOL, V115, P1611, DOI 10.1083/jcb.115.6.1611; Manseau L, 1996, DEVELOPMENT, V122, P2109; McGough A, 1997, J CELL BIOL, V138, P771, DOI 10.1083/jcb.138.4.771; MCLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18; NISHIDA E, 1984, BIOCHEMISTRY-US, V23, P5307, DOI 10.1021/bi00317a032; Oosawa F., 1975, THERMODYNAMICS POLYM; PANTALONI D, 1984, J BIOL CHEM, V259, P6274; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; PERELROIZEN I, 1995, J BIOL CHEM, V270, P1501, DOI 10.1074/jbc.270.4.1501; Perelroizen I, 1996, J BIOL CHEM, V271, P12302, DOI 10.1074/jbc.271.21.12302; Perelroizen I., 1995, Molecular Biology of the Cell, V6, p142A; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; PRING M, 1992, BIOCHEMISTRY-US, V31, P1827, DOI 10.1021/bi00121a035; Ressad F, 1998, J BIOL CHEM, V273, P20894, DOI 10.1074/jbc.273.33.20894; Schafer DA, 1996, J CELL BIOL, V135, P169, DOI 10.1083/jcb.135.1.169; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866	31	164	169	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25602	25611		10.1074/jbc.273.40.25602	http://dx.doi.org/10.1074/jbc.273.40.25602			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748225	hybrid			2022-12-27	WOS:000076263100016
J	Ohno, H; Aguilar, RC; Yeh, D; Taura, D; Saito, T; Bonifacino, JS				Ohno, H; Aguilar, RC; Yeh, D; Taura, D; Saito, T; Bonifacino, JS			The medium subunits of adaptor complexes recognize distinct but overlapping sets of tyrosine-based sorting signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; FACTOR-II RECEPTOR; MEMBRANE-PROTEIN; INTERNALIZATION SIGNALS; RAPID INTERNALIZATION; TRANSFERRIN RECEPTOR; CYTOPLASMIC TAIL; PLASMA-MEMBRANE; AP-2 COMPLEXES; MEDIUM CHAINS	Tyrosine-based sorting signals conforming to the motif YXXO (Y is tyrosine, X is any amino acid, and O is an amino acid with a bulky hydrophobic side chain (leucine, isoleucine, phenylalanine, methionine, valine)) interact with the medium (mu) subunits of clathrin adaptor (AP) complexes. We have analyzed the selectivity of interaction between YXXO signals and the mu 1, mu 2, and mu 3 (A or B) subunits of the AP-1, AP-2, and AP-3 complexes, respectively, by screening a combinatorial XYXYXXO library using the yeast two-hybrid system. All the medium subunits were found to prefer proline at position Y+2, suggesting that YXXO signals are stabilized by a bend in the polypeptide backbone. Other than for this common preference, each medium subunit favored specific sets of residues at the X and O positions; these preferences were consistent with the proposed roles of the different adaptor complexes in rapid endocytosis and lysosomal targeting. A considerable specificity overlap was also revealed by these analyses, suggesting that additional factors, such as the context of the signals, must be important determinants of recognition.	NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA; Chiba Univ, Grad Sch Med, Div Mol Genet, Chuo Ku, Chiba 2608670, Japan	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Chiba University	Bonifacino, JS (corresponding author), NICHHD, Cell Biol & Metab Branch, NIH, Bldg 18T Rm 101,18 Lib Dr,MSC 5430, Bethesda, MD 20892 USA.	juan@helix.nih.gov	Ohno, Hiroshi/L-7899-2014; Saito, Takashi/C-9684-2009	Ohno, Hiroshi/0000-0001-8776-9661; Saito, Takashi/0000-0001-9495-3547; Bonifacino, Juan S./0000-0002-5673-6370				Aguilar RC, 1997, J BIOL CHEM, V272, P27160, DOI 10.1074/jbc.272.43.27160; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Chuang E, 1997, J IMMUNOL, V159, P144; COLLAWN JF, 1991, EMBO J, V10, P3247, DOI 10.1002/j.1460-2075.1991.tb04888.x; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; Cowles CR, 1997, CELL, V91, P109, DOI 10.1016/S0092-8674(01)80013-1; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; Gough NR, 1997, J CELL BIOL, V137, P1161, DOI 10.1083/jcb.137.5.1161; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; JADOT M, 1992, J BIOL CHEM, V267, P11069; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Medley QG, 1996, P NATL ACAD SCI USA, V93, P685, DOI 10.1073/pnas.93.2.685; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Motulsky H., 1995, INTUITIVE BIOSTATIST; NAIM HY, 1994, J BIOL CHEM, V269, P3928; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; OHNO H, 1998, GENE AMST, V2, P187; Ooi CE, 1997, EMBO J, V16, P4508; PEVSNER J, 1994, GENE, V146, P279, DOI 10.1016/0378-1119(94)90306-9; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Seymour AB, 1997, MOL BIOL CELL, V8, P1316; Shiratori T, 1997, IMMUNITY, V6, P583, DOI 10.1016/S1074-7613(00)80346-5; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; Stephens DJ, 1997, J BIOL CHEM, V272, P14104, DOI 10.1074/jbc.272.22.14104; Stepp JD, 1997, J CELL BIOL, V139, P1761, DOI 10.1083/jcb.139.7.1761; Zhang Y, 1997, P NATL ACAD SCI USA, V94, P9273, DOI 10.1073/pnas.94.17.9273; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	36	202	205	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25915	25921		10.1074/jbc.273.40.25915	http://dx.doi.org/10.1074/jbc.273.40.25915			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748267	hybrid			2022-12-27	WOS:000076263100058
J	Hammerle, M; Bauer, J; Rose, M; Szallies, A; Thumm, M; Dusterhus, S; Mecke, D; Entian, KD; Wolf, DH				Hammerle, M; Bauer, J; Rose, M; Szallies, A; Thumm, M; Dusterhus, S; Mecke, D; Entian, KD; Wolf, DH			Proteins of newly isolated mutants and the amino-terminal proline are essential for ubiquitin-proteasome-catalyzed catabolite degradation of fructose-1,6-bisphosphatase of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE; YEAST FRUCTOSE-1,6-BISPHOSPHATASE; MULTIFUNCTIONAL PROTEINASE; MALATE-DEHYDROGENASE; ISOCITRATE LYASE; LACZ FUSIONS; INACTIVATION; PHOSPHORYLATION; INVIVO; SITE	Addition of glucose to cells of the yeast Saccharomyces cerevisiae growing on a non-fermentable carbon source leads to selective and rapid degradation of fructose-1,6-bisphosphatase, This so called catabolite inactivation of the enzyme is brought about by the ubiquitin-proteasome system. To identify additional components of the catabolite inactivation machinery, we isolated three mutant strains, gid1, gid2, and gid3, defective in glucose-induced degradation of fructose-1,6-bisphosphatase, All mutant strains show in addition a defect in catabolite inactivation of three other gluconeogenic enzymes: cytosolic malate dehydrogenase, isocitrate lyase, and phosphoenolpyruvate carboxykinase, These findings indicate a common mechanism for the inactivation of all four enzymes. The mutants were also impaired in degradation of short-lived N-end rule substrates, which are degraded via the ubiquitin-proteasome system. Site-directed mutagenesis of the amino-terminal proline residue yielded fructose-1,6-bisphosphatase forms that were no longer degraded via the ubiquitin-proteasome pathway. All amino termini other than proline made fructose-1,6-bisphosphatase inaccessible to degradation. However, the exchange of the amino-terminal proline had no effect on the phosphorylation of the mutated enzyme. Our findings suggest an essential function of the amino-terminal proline residue for the degradation process of fructose-1,6-bisphosphatase. Phosphorylation of the enzyme was not necessary for degradation to occur.	Univ Stuttgart, Inst Biochem, D-70569 Stuttgart, Germany; Univ Frankfurt, Inst Mikrobiol, D-60439 Frankfurt, Germany; Univ Tubingen, Inst Physiol Chem, D-72076 Tubingen, Germany	University of Stuttgart; Goethe University Frankfurt; Eberhard Karls University of Tubingen	Wolf, DH (corresponding author), Univ Stuttgart, Inst Biochem, Pfaffenwaldring 55, D-70569 Stuttgart, Germany.		Entian, Karl-Dieter/D-3080-2011; Thumm, Michael/A-8033-2015	Thumm, Michael/0000-0003-3238-4857				BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; CHIANG HL, 1991, NATURE, V350, P313, DOI 10.1038/350313a0; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CIRIACY M, 1975, MOL GEN GENET, V138, P157, DOI 10.1007/BF02428119; DIXON GH, 1959, BIOCHEM J, V72, P3; DUNTZE W, 1968, EUR J BIOCHEM, V3, P326, DOI 10.1111/j.1432-1033.1968.tb19533.x; ENTIAN KD, 1983, ARCH MICROBIOL, V134, P187, DOI 10.1007/BF00407756; Fink GR., 1970, METHODS ENZYMOL VOL, V17, P59, DOI DOI 10.1016/0076-6879(71)17167-4; FISCHER M, 1994, FEBS LETT, V355, P69, DOI 10.1016/0014-5793(94)01177-X; FUNAYAMA S, 1980, EUR J BIOCHEM, V109, P61, DOI 10.1111/j.1432-1033.1980.tb04767.x; GANCEDO JM, 1971, ARCH MIKROBIOL, V76, P132, DOI 10.1007/BF00411787; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HAARASILTA S, 1975, EUR J BIOCHEM, V52, P1, DOI 10.1111/j.1432-1033.1975.tb03966.x; HAGELE E, 1978, EUR J BIOCHEM, V83, P67, DOI 10.1111/j.1432-1033.1978.tb12069.x; HANSEN RJ, 1976, ANAL BIOCHEM, V74, P576, DOI 10.1016/0003-2697(76)90240-2; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; HOLZER H, 1976, TRENDS BIOCHEM SCI, V1, P178, DOI 10.1016/S0968-0004(76)80018-7; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LOPEZBOADO YS, 1987, ARCH MICROBIOL, V147, P231, DOI 10.1007/BF00463480; MARCUS F, 1988, J BIOL CHEM, V263, P6058; MAZON MJ, 1982, J BIOL CHEM, V257, P1128; MULLER D, 1981, BIOCHEM BIOPH RES CO, V103, P926, DOI 10.1016/0006-291X(81)90899-8; MULLER M, 1981, J BIOL CHEM, V256, P723; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; ORDIZ I, 1995, FEBS LETT, V367, P219, DOI 10.1016/0014-5793(95)00538-K; POHLIG G, 1985, J BIOL CHEM, V260, P3818; RICHTERRUOFF B, 1992, FEBS LETT, V302, P192, DOI 10.1016/0014-5793(92)80438-M; RITTENHOUSE J, 1987, J BIOL CHEM, V262, P10114; RITTENHOUSE J, 1986, J BIOL CHEM, V261, P3939; ROSE M, 1988, FEBS LETT, V241, P55, DOI 10.1016/0014-5793(88)81030-5; Sambrook J., 2002, MOL CLONING LAB MANU; SCHORK SM, 1995, J BIOL CHEM, V270, P26446, DOI 10.1074/jbc.270.44.26446; SCHORK SM, 1994, FEBS LETT, V349, P270, DOI 10.1016/0014-5793(94)00668-7; SCHORK SM, 1994, NATURE, V369, P283, DOI 10.1038/369283a0; WITT I, 1966, BIOCHIM BIOPHYS ACTA, V128, P63, DOI 10.1016/0926-6593(66)90142-1; WOLFE RG, 1956, J BIOL CHEM, V221, P61; ZWEIMULLER M, 1990, THESIS J WOLFGANG GO	40	72	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25000	25005		10.1074/jbc.273.39.25000	http://dx.doi.org/10.1074/jbc.273.39.25000			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737955	hybrid			2022-12-27	WOS:000076085400005
J	Hoke, DE; Regisford, EGC; Julian, J; Amin, A; Begue-Kirn, C; Carson, DD				Hoke, DE; Regisford, EGC; Julian, J; Amin, A; Begue-Kirn, C; Carson, DD			Murine HIP/L29 is a heparin-binding protein with a restricted pattern of expression in adult tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UTERINE EPITHELIAL-CELLS; RIBOSOMAL-PROTEIN; SYNTHETIC PEPTIDE; SULFATE; SURFACE; ATTACHMENT; ELECTROPHORESIS; PURIFICATION; RESOLUTION; CLEAVAGE	Heparin/heparan sulfate (Hp/HS)-binding proteins are implicated in a variety of cell biological processes including cell adhesion, modulation of blood coagulation, and cytokine/growth factor action. Hp/HS-interacting protein (HIP) has been identified in various adult tissues in humans. HIP supports high affinity, selective binding to Hp/HS, promotes cell adhesion, and modulates blood coagulation activities via Hp/HS-dependent mechanisms. Herein, a murine ortholog of human HIP is described that is 78.8% identical to human HIP and 99.8% identical at the cDNA level and identical at the aminoacid level to a previously described murine ribosomal protein, L29, Western blot analyses and immunohistological staining with affinity-purified antibodies generated against two distinct peptide sequences of murine HIP/L29 indicate that HIP/L29 is differentially expressed in adult murine tissues and cell types. In the normal murine mammary epithelial cell line, NMuMG, HIP/L29 is enriched in the 100,000 x g particulate fraction. HIP/L29 can be solubilized from the 100,000 x g particulate fraction with 0.8 M NaCl, suggesting that it is a peripheral membrane protein. HIP/L29 directly binds I-125-Hp in gel overlay assays and requires 0.75 M NaCl for elution from Hp-agarose. In addition, recombinant murine HIP expressed in Escherichia coli binds Hp in a saturable and highly selective manner, compared with other glycosaminoglycans including dermatan sulfate, chondroitin sulfate, keratan sulfate, and hyaluronic acid. Collectively, these data indicate that murine HIP/L29, Like its human ortholog, is a Hp-binding protein expressed in a restricted manner in adult tissues.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Biol Sci, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Carson, DD (corresponding author), Univ Delaware, Dept Biol Sci, 117 Wolf Hall, Newark, DE 19716 USA.		Kirn-Safran, Catherine/AAB-9089-2022		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025235, R37HD025235] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA-16672] Funding Source: Medline; NICHD NIH HHS [HD25235] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Antoine M, 1997, J BIOL CHEM, V272, P29475, DOI 10.1074/jbc.272.47.29475; CARSON DD, 1994, INT J BIOCHEM, V26, P1269, DOI 10.1016/0020-711X(94)90096-5; CHANG CD, 1978, INT J PEPT PROT RES, V11, P246; FARACH MC, 1987, DEV BIOL, V123, P401, DOI 10.1016/0012-1606(87)90398-8; Florkiewicz RZ, 1991, GROWTH FACTORS, V4, P265, DOI 10.3109/08977199109043912; FOX MG, 1997, DNA SEQUENCE, V7, P1235; GAYNOR JJ, 1997, INSECT BIOCHEM MOLEC, V27, P233; GIOVANNA P, 1991, MOL CELL BIOL, V11, P4796; Hasan AAK, 1998, P NATL ACAD SCI USA, V95, P3615, DOI 10.1073/pnas.95.7.3615; Jacobs AL, 1997, CANCER RES, V57, P5148; Johnston CL, 1995, J BIOL CHEM, V270, P30643, DOI 10.1074/jbc.270.51.30643; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Law PTW, 1996, BBA-GENE STRUCT EXPR, V1305, P105, DOI 10.1016/0167-4781(95)00224-3; LINDAHL U, 1978, ANNU REV BIOCHEM, V47, P385, DOI 10.1146/annurev.bi.47.070178.002125; Liu SC, 1996, J BIOL CHEM, V271, P11817, DOI 10.1074/jbc.271.20.11817; Liu SC, 1998, J BIOL CHEM, V273, P9718, DOI 10.1074/jbc.273.16.9718; Liu SC, 1997, P NATL ACAD SCI USA, V94, P1739, DOI 10.1073/pnas.94.5.1739; Liu SC, 1997, J BIOL CHEM, V272, P25856, DOI 10.1074/jbc.272.41.25856; Marchetti D, 1997, J BIOL CHEM, V272, P15891, DOI 10.1074/jbc.272.25.15891; Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5; MURAKAMI Y, 1995, NAT GENET, V10, P261, DOI 10.1038/ng0795-261; NOMUR M, 1992, TRENDS BIOCHEM SCI, V7, P92; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OSTVOLD AC, 1992, FEBS LETT, V298, P219, DOI 10.1016/0014-5793(92)80061-K; OTAKA E, 1983, MOL GEN GENET, V191, P519, DOI 10.1007/BF00425772; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; RABOUDI N, 1992, J BIOL CHEM, V267, P11930; Rohde LH, 1996, J BIOL CHEM, V271, P11824, DOI 10.1074/jbc.271.20.11824; Rohde LH, 1998, BIOL REPROD, V58, P1075, DOI 10.1095/biolreprod58.4.1075; RUDERT F, 1993, GENE, V133, P249, DOI 10.1016/0378-1119(93)90647-L; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SVOBODA M, 1992, EUR J BIOCHEM, V203, P341, DOI 10.1111/j.1432-1033.1992.tb16555.x; VANDYKE MW, 1992, GENE, V111, P99, DOI 10.1016/0378-1119(92)90608-R; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YUENLING C, 1993, BIOCHEM BIOPH RES CO, V192, P583	36	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25148	25157		10.1074/jbc.273.39.25148	http://dx.doi.org/10.1074/jbc.273.39.25148			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737974	hybrid			2022-12-27	WOS:000076085400024
J	Frost, JA; Khokhlatcheva, A; Stippec, S; White, MA; Cobb, MH				Frost, JA; Khokhlatcheva, A; Stippec, S; White, MA; Cobb, MH			Differential effects of PAK1-activating mutations reveal activity-dependent and -independent effects on cytoskeletal regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-THREONINE KINASE; BINDING PROTEIN-RHO; MOLECULAR-CLONING; ADAPTER PROTEIN; ACTIVATION; FAMILY; ACTIN; CDC42; PAK1; IDENTIFICATION	PARs are serine/threonine protein kinases that are activated by binding to Rac or Cdc42hs, Different forms of activated PAK1 have been reported to either promote membrane ruffling and focal adhesion assembly or cause focal adhesion disassembly and stress fiber dissolution. To understand the basis for these distinct morphological effects, we have examined the mechanism of mutational activation of PAK1, and characterized the effects of different active PAK1 proteins on cytoskeletal structure in vivo, We find that PAK1 contains an autoinhibitory domain that overlaps with its small G protein binding domain and that two separate activating mutations within this regulatory region each decrease autoinhibitory activity. Because only one of these mutations affects Cdc42hs binding activity, this indicates that activation of PAK1 by these mutations results from interference with the function of the autoinhibitory domain and not with small G protein binding activity. When we examined the morphological effects of these different forms of PAK1 in vivo, we found that PAK1 kinase activity was associated with disassembly of focal adhesions and actin stress fibers and that this may require interaction with potential SH3 domain-containing proteins. Lamellipodia formation and membrane ruffling caused by active PAK1 expression, however, was independent of PAK1 catalytic activity and likely requires interaction among multiple proteins binding to the PARI regulatory domain.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Frost, JA (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Frost, Jeffrey/0000-0001-9722-1536; Cobb, Melanie/0000-0003-0833-5473	NCI NIH HHS [CA71443] Funding Source: Medline; NIGMS NIH HHS [GM53032] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Leung T, 1996, MOL CELL BIOL, V16, P5313; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	25	167	171	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28191	28198		10.1074/jbc.273.43.28191	http://dx.doi.org/10.1074/jbc.273.43.28191			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774440	hybrid			2022-12-27	WOS:000076549800060
J	Ogut, O; Jin, JP				Ogut, O; Jin, JP			Developmentally regulated, alternative RNA splicing-generated pectoral muscle-specific troponin T isoforms and role of the NH2-terminal hypervariable region in the tolerance to acidosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; METAL-BINDING CLUSTER; HYPERTROPHIC CARDIOMYOPATHY; ALPHA-TROPOMYOSIN; ADULT ISOFORMS; F-ACTIN; NONPOLYMERIZABLE TROPOMYOSIN; CA2+ SENSITIVITY; DIABETIC RAT; GENE	The structure-function relationship of the alternative RNA splicing-generated NH2-terminal variable region of troponin T (TnT) is essential for understanding the physiological significance of developmental or muscle-specific TnT isoforms, Representing the hypervariable nature of the NH2-terminal region, a repeating transition metal-binding sequence (H(E/A)EAH)(4-7) (Tx) has been found in chicken fast skeletal muscle TnT, In the present study, the developmentally regulated pectoral muscle-specific expression of this novel TnT isoform has been characterized. It was found that the variable amino terminus determined the isoelectric points of the TnT isoforms expressed, and the adult muscle-specific inclusion of the Tx sequence resulted in pectoralis TnTs, which were significantly more acidic in their NH2-terminal segment versus gastrocnemius TnTs, Experiments testing the effect of pH on TnT interaction with troponin I and tropomyosin indicated that although the interaction of acidic TnT isoforms with troponin I was less sensitive to the decrease of pH than the basic TnTs, the binding affinity of acidic TnT isoforms with tropomyosin was minimally affected by the decreased pH in contrast to basic TnT isoforms, Given that the majority of adult skeletal muscles express basic fast TnT isoforms, the switching between acidic and basic TnT isoforms may play a role in the functional adaptation of muscle to acidosis.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Case Western Reserve University	Jin, JP (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, 10900 Euclid Ave, Cleveland, OH 44106 USA.	jxj12@po.cwru.edu		Jin, JP/0000-0001-9932-1063				AKELLA AB, 1995, CIRC RES, V76, P600, DOI 10.1161/01.RES.76.4.600; ANDERSON PAW, 1995, CIRC RES, V76, P681, DOI 10.1161/01.RES.76.4.681; BREITBART RE, 1986, J MOL BIOL, V188, P313, DOI 10.1016/0022-2836(86)90157-9; BRIGGS MM, 1993, DEV BIOL, V158, P503, DOI 10.1006/dbio.1993.1208; COOPER TA, 1985, J BIOL CHEM, V260, P1140; FABIATO A, 1978, J PHYSIOL-LONDON, V276, P233, DOI 10.1113/jphysiol.1978.sp012231; GAHLMANN R, 1987, J BIOL CHEM, V262, P16122; GODT RE, 1991, CAN J PHYSIOL PHARM, V69, P1692, DOI 10.1139/y91-251; Hastings KEM, 1997, CELL STRUCT FUNCT, V22, P205, DOI 10.1247/csf.22.205; HEELEY DH, 1987, J BIOL CHEM, V262, P9971; Jha PK, 1996, BIOCHEMISTRY-US, V35, P16573, DOI 10.1021/bi9622433; JIN J-P, 1991, Journal of Cell Biology, V115, p180A; JIN JP, 1990, ANN NY ACAD SCI, V588, P393, DOI 10.1111/j.1749-6632.1990.tb13243.x; JIN JP, 1994, FEBS LETT, V341, P135, DOI 10.1016/0014-5793(94)80256-4; Jin JP, 1998, GENE, V214, P121, DOI 10.1016/S0378-1119(98)00214-5; JIN JP, 1988, J BIOL CHEM, V263, P7309; JIN JP, 1992, J MOL BIOL, V227, P1269, DOI 10.1016/0022-2836(92)90540-Z; JIN JP, 1995, J BIOL CHEM, V270, P6908; JIN JP, 1989, J BIOL CHEM, V264, P14471; LAGADICGOSSMANN D, 1990, J PHYSIOL-LONDON, V422, P481, DOI 10.1113/jphysiol.1990.sp017996; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; Lin D, 1996, J CLIN INVEST, V97, P2842, DOI 10.1172/JCI118740; LIN JJC, 1985, HYBRIDOMA, V4, P223, DOI 10.1089/hyb.1985.4.223; Luo Y, 1997, BIOCHEMISTRY-US, V36, P11027, DOI 10.1021/bi962461w; MAK AS, 1983, J BIOL CHEM, V258, P4330; Malnic B, 1998, J BIOL CHEM, V273, P10594, DOI 10.1074/jbc.273.17.10594; METZGER JM, 1993, P NATL ACAD SCI USA, V90, P9036, DOI 10.1073/pnas.90.19.9036; NAKANISHI T, 1985, PEDIATR RES, V19, P482, DOI 10.1203/00006450-198505000-00015; Nickel R., 1977, ANATOMY DOMESTIC BIR; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; Ogut O, 1996, BIOCHEMISTRY-US, V35, P16581, DOI 10.1021/bi961712y; PAN BS, 1991, J BIOL CHEM, V266, P12432; PEARLSTONE JR, 1977, J BIOL CHEM, V252, P971; PEARLSTONE JR, 1982, J BIOL CHEM, V257, P587; SCHACHAT F, 1995, DEV BIOL, V171, P233, DOI 10.1006/dbio.1995.1274; Schaertl S, 1995, BIOCHEMISTRY-US, V34, P15890, DOI 10.1021/bi00049a003; SHENG ZL, 1992, J BIOL CHEM, V267, P25407; Smillie L, 1996, BIOCH SMOOTH MUSCLE, P63; SMILLIE LB, 1988, J BIOL CHEM, V263, P18816; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; SOLARO RJ, 1988, CIRC RES, V63, P779, DOI 10.1161/01.RES.63.4.779; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; TOBACMAN LS, 1987, J BIOL CHEM, V262, P4059; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; Wang J, 1997, GENE, V193, P105, DOI 10.1016/S0378-1119(97)00100-5; WANG J, 1998, IN PRESS BIOCHEMISTR, V38; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	49	44	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27858	27866		10.1074/jbc.273.43.27858	http://dx.doi.org/10.1074/jbc.273.43.27858			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774396	hybrid			2022-12-27	WOS:000076549800016
J	Sorgen, PL; Caviston, TL; Perry, RC; Cain, BD				Sorgen, PL; Caviston, TL; Perry, RC; Cain, BD			Deletions in the second stalk of F1F0-ATP synthase in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP SYNTHASE; B-SUBUNIT; ADENOSINE-TRIPHOSPHATASE; MUTAGENIC ANALYSIS; CROSS-LINKING; DELTA-SUBUNIT; F1-ATPASE; MUTATIONS; F1; TRANSPORT	In Escherichia coli F1F0-ATP synthase, the two b subunits form the second stalk spanning the distance between the membrane F-0 sector and the bulk of F-1. Current models predict that the stator should be relatively rigid and engaged in contact with F-1 at fixed points. To test this hypothesis, we constructed a series of deletion mutations in the uncF(b) gene to remove segments from the middle of the second stalk of the subunit, Mutants with deletions of 7 amino acids were essentially normal, and those with deletions of up to 11 amino acids retained considerable activity. Membranes prepared from these strains had readily detectable levels of F-1-ATPase activity and proton pumping activity. Removal of 12 or more amino acids resulted in loss of oxidative phosphorylation. Levels of membrane-associated F-1-ATPase dropped precipitously for the longer deletions, and immunoblot analysis indicated that reductions in activity correlated with reduced levels of b subunit in the membranes, Assuming the likely alpha-helical conformation for this area of the b subunit, the 11-amino acid deletion would result in shortening the subunit by approximately 16 Angstrom. Since these deletions did not prevent the b subunit from participating in productive interactions with F-1, we suggest that the b subunit is not a rigid rodlike structure, but has an inherent flexibility compatible with a dynamic role in coupling.	Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	Cain, BD (corresponding author), Univ Florida, Dept Biochem & Mol Biol, Box 100245, Gainesville, FL 32610 USA.				NIGMS NIH HHS [GM43495] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043495] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ARIS JP, 1983, J BIOL CHEM, V258, P4599; ARIS JP, 1985, J BIOL CHEM, V260, P1207; CAIN BD, 1986, J BIOL CHEM, V261, P43; CAIN BD, 1989, J BIOL CHEM, V264, P3292; Caviston TL, 1998, FEBS LETT, V429, P201, DOI 10.1016/S0014-5793(98)00597-3; DeckersHebestreit G, 1996, ANNU REV MICROBIOL, V50, P791, DOI 10.1146/annurev.micro.50.1.791; DECKERSHEBESTREIT G, 1992, J BIOL CHEM, V267, P12364; DECKERSHEBESTREIT G, 1986, EUR J BIOCHEM, V161, P225, DOI 10.1111/j.1432-1033.1986.tb10146.x; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; DUNN SD, 1992, J BIOL CHEM, V267, P7630; Dunn SD, 1998, J BIOL CHEM, V273, P8646, DOI 10.1074/jbc.273.15.8646; Fillingame RH, 1997, J EXP BIOL, V200, P217; HARTZOG PE, 1994, J BIOL CHEM, V269, P32313; HERMOLIN J, 1983, J BIOL CHEM, V258, P4550; HOPPE J, 1983, EMBO J, V2, P105, DOI 10.1002/j.1460-2075.1983.tb01389.x; Howitt SM, 1996, J BIOL CHEM, V271, P7038, DOI 10.1074/jbc.271.12.7038; JANS DA, 1984, BIOCHEM J, V221, P43, DOI 10.1042/bj2210043; JANS DA, 1983, BIOCHEM J, V211, P717, DOI 10.1042/bj2110717; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCCORMICK KA, 1993, J BIOL CHEM, V268, P24683; MCCORMICK KA, 1991, J BACTERIOL, V173, P7240, DOI 10.1128/jb.173.22.7240-7248.1991; McLachlin DT, 1997, J BIOL CHEM, V272, P21233, DOI 10.1074/jbc.272.34.21233; Nakamoto RK, 1996, J MEMBRANE BIOL, V151, P101, DOI 10.1007/s002329900061; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; PORTER ACG, 1985, J BIOL CHEM, V260, P8182; Rodgers AJW, 1997, J BIOL CHEM, V272, P31058, DOI 10.1074/jbc.272.49.31058; Sabbert D, 1997, P NATL ACAD SCI USA, V94, P4401, DOI 10.1073/pnas.94.9.4401; Sawada K, 1997, J BIOL CHEM, V272, P30047, DOI 10.1074/jbc.272.48.30047; Sorgen PL, 1998, BIOCHEMISTRY-US, V37, P923, DOI 10.1021/bi972309+; TAMARAPPOO BK, 1992, J BIOL CHEM, V267, P2370; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; WILKENS S, 1994, FEBS LETT, V354, P37, DOI 10.1016/0014-5793(94)01059-5; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908	37	83	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27873	27878		10.1074/jbc.273.43.27873	http://dx.doi.org/10.1074/jbc.273.43.27873			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774398	hybrid			2022-12-27	WOS:000076549800018
J	Zhang, LJ; Schwartz, JJ; Miller, J; Liu, J; Fritze, LMS; Shworak, NW; Rosenberg, RD				Zhang, LJ; Schwartz, JJ; Miller, J; Liu, J; Fritze, LMS; Shworak, NW; Rosenberg, RD			The retinoic acid and cAMP-dependent up-regulation of 3-O-sulfotransferase-1 leads to a dramatic augmentation of anticoagulantly active heparan sulfate biosynthesis in F9 embryonal carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE; ANTITHROMBIN-BINDING SEQUENCE; CARDIOVASCULAR-SYSTEM; CONFORMATIONAL CHANGE; FETAL DEVELOPMENT; PROTEOGLYCANS; THROMBOMODULIN; IDENTIFICATION; FETOMODULIN; PRECURSOR	Retinoic acid (RA) and dibutyryl cAMP plus theophilline (CT) trigger F9 cells to differentiate into parietal endoderm, The differentiation induces a 9-fold increase in total heparan sulfate (HStotal) biosynthesis and a 170-fold increase in anticoagulantly active HS (HSact) biosynthesis, Measurement of 3-O-sulfotransferase-1 mRNA and enzymatic activity demonstrated an increase of over 100-fold whereas determination of N-, 2-O, and 6-O-sulfotransferase enzymatic activities showed elevations of 2-, 3.5-, and 3.7-fold, respectively. HSact precursor pool measurements reveal that 30% of control F9 HStotal can be converted into HSact while only an additional 10% of RACT F9 HStotal can be transformed into HSact. Disaccharide analysis of metabolic labeled HS indicated that 32% 3-O-sulfate containing disaccharides, i.e. GlcA-anMan(R)3S and GlcA-anMan(R)3S6S, are present in HSact and 68% GlcA-anMan(R)3S and GlcA-anMan(R)3S6S are found in anticoagulantly inactive HS (HSinact). By using adenosine S'-phosphate 5'-phosphosulfate and purified 3-O-sulfotransferase-1, 30% of 3-O-sulfation occurs in HSact and 70% of 3-O-sulfation occurs in HSinact. The similar ratio of 3-O-sulfate distribution in HSact versus HSinact suggests that HSact production in the F9 system is determined by the abundance of 3-O-sulfotransferase-1 as well as the size of the HSact precursor pool. Extensively 3-O-sulfated HSinact may play an important functional role under in vivo conditions within the murine placenta.	MIT, Dept Biol, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Beth Israel Hosp, Dept Med, Boston, MA 02215 USA	Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Rosenberg, RD (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave,Bldg 68-480, Cambridge, MA 02139 USA.	rdrrosen@MIT.EDU	Shworak, Nicholas/AAJ-6770-2020	Shworak, Nicholas/0000-0001-7783-4634	NHLBI NIH HHS [5-PO1-HL41484, HL66385] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066385, P01HL041484] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATHA DH, 1985, BIOCHEMISTRY-US, V24, P6723, DOI 10.1021/bi00344a063; ATHA DH, 1987, BIOCHEMISTRY-US, V26, P6454, DOI 10.1021/bi00394a024; BAME KJ, 1989, J BIOL CHEM, V264, P8059; CASU B, 1985, ADV CARBOHYD CHEM BI, V43, P51, DOI 10.1016/S0065-2318(08)60067-0; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; FRITZ TA, 1994, J BIOL CHEM, V269, P300; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; HEALY AM, 1995, P NATL ACAD SCI USA, V92, P850, DOI 10.1073/pnas.92.3.850; IMADA M, 1987, DEV BIOL, V122, P483, DOI 10.1016/0012-1606(87)90312-5; IMADA S, 1990, DEV BIOL, V140, P113, DOI 10.1016/0012-1606(90)90058-Q; KAPOOR R, 1983, EUR J BIOCHEM, V137, P589, DOI 10.1111/j.1432-1033.1983.tb07866.x; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KUSCHE M, 1990, J BIOL CHEM, V265, P7292; LAM LH, 1976, BIOCHEM BIOPH RES CO, V69, P570, DOI 10.1016/0006-291X(76)90558-1; LINDAHL U, 1983, J BIOL CHEM, V258, P9826; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; LINHARDT RJ, 1992, J BIOL CHEM, V267, P2380; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; PEJLER G, 1987, J BIOL CHEM, V262, P5036; ROSENBERG RD, 1978, P NATL ACAD SCI USA, V75, P3065, DOI 10.1073/pnas.75.7.3065; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; ROSENBERG RD, 1979, P NATL ACAD SCI USA, V77, P6551; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; SHWORAK NW, 1994, J BIOL CHEM, V269, P24941; Shworak NW, 1996, J BIOL CHEM, V271, P27063, DOI 10.1074/jbc.271.43.27063; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; WEILERGUETTLER H, 1992, P NATL ACAD SCI USA, V89, P2155, DOI 10.1073/pnas.89.6.2155; WLAD H, 1994, J BIOL CHEM, V269, P24538; ZHANG LJ, 1995, J BIOL CHEM, V270, P27127, DOI 10.1074/jbc.270.45.27127	29	29	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27998	28003		10.1074/jbc.273.43.27998	http://dx.doi.org/10.1074/jbc.273.43.27998			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774414	hybrid			2022-12-27	WOS:000076549800034
J	Dumais, N; Barbeau, B; Olivier, M; Tremblay, MJ				Dumais, N; Barbeau, B; Olivier, M; Tremblay, MJ			Prostaglandin E-2 up-regulates HIV-1 long terminal repeat-driven gene activity in T cells via NF-kappa B-dependent and -independent signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEIN-KINASE; ARACHIDONIC-ACID; IMMUNE-RESPONSE; HUMAN MONOCYTES; SYNTHASE CYCLOOXYGENASE; PSEUDOMONAS-AERUGINOSA; ALVEOLAR MACROPHAGES; INDUCED ACTIVATION; ADENYLATE-CYCLASE	Replication of human immunodeficiency virus type-1 (HIV-1) is highly dependent on the state of activation of the infected cells and is modulated by interactions between viral and host cellular factors. Prostaglandin E-2 (PGE(2)), a pleiotropic immunomodulatory molecule, is observed at elevated levels during HIV-1 infection as well as during the course of other pathogenic infections. in 1G5, a Jurkat-derived T cell line stably transfected with a luciferase gene driven by HIV-1 long terminal repeat (LTR), we found that PGE2 markedly enhanced HIV-1 LTR-mediated reporter gene activity. Experiments have been conducted to identify second messengers involved in this PGE(2)-dependent up-regulating effect on the regulatory element of HIV-1. In this study, we present evidence indicating that signal transduction pathways induced by PGE(2) necessitate the participation of cyclic AMP, protein kinase A, and Ca2+. Experiments conducted with different HIV-1 LTR-based vectors suggested that PGE(2)-mediated activation effect on HIV-1 transcription was transduced via both NF-KB-dependent and -independent signaling pathways. The involvement of NF-KB in the PGE(2)-dependent activating effect on HIV-1 transcription was further confirmed using a KB-regulated luciferase encoding vector and by electrophoretic mobility shift assays. Results from Northern blot and flow cytometric analyses, as well as the use of a selective antagonist indicated that PGE(2) modulation of HIV-1 LTR-driven reporter gene activity in studied T lymphoid cells is transduced via the EP4 receptor subtype. These results suggest that secretion of PGE(2) by macrophages in response to infection or inflammatory activators could induce signaling events resulting in activation of proviral DNA present into T cells latently infected with HIV-1.	Ctr Hosp Univ Quebec, Ctr Rech Infectiol, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Dept Biol Med, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University	Olivier, M (corresponding author), Ctr Hosp Univ Quebec, Ctr Rech Infectiol, RC-709,Pavillon CHUL,2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.	Martin.Olivier@crchul.ulaval.ca	Barbeau, Benoit/A-1174-2010	Barbeau, Benoit/0000-0002-4108-8155				ABEL PM, 1992, FEMS MICROBIOL IMMUN, V105, P317; AGUILARCORDOVA E, 1994, AIDS RES HUM RETROV, V10, P295, DOI 10.1089/aid.1994.10.295; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; AUBERGER P, 1989, CELL SIGNAL, V1, P289, DOI 10.1016/0898-6568(89)90046-6; BAKER PE, 1981, CELL IMMUNOL, V61, P52, DOI 10.1016/0008-8749(81)90353-1; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barbeau B, 1997, J BIOL CHEM, V272, P12968, DOI 10.1074/jbc.272.20.12968; Bassuk AG, 1997, J VIROL, V71, P3563, DOI 10.1128/JVI.71.5.3563-3573.1997; BEAVO JA, 1970, MOL PHARMACOL, V6, P597; BenHur T, 1996, J NEUROVIROL, V2, P279, DOI 10.3109/13550289609146891; Bernier R, 1998, J IMMUNOL, V160, P2881; Bernier R, 1998, J GEN VIROL, V79, P1353, DOI 10.1099/0022-1317-79-6-1353; BERNIER R, 1995, J VIROL, V69, P7282, DOI 10.1128/JVI.69.11.7282-7285.1995; Berube P, 1996, J VIROL, V70, P4009; Blaschke V, 1996, FEBS LETT, V394, P39, DOI 10.1016/0014-5793(96)00928-3; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOWDHURY MIH, 1990, LANCET, V336, P247; COLEMAN RA, 1995, ADV PROSTAG THROMB L, V23, P283; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; CORREIADESA P, 1994, EUR J PHARMACOL, V271, P349, DOI 10.1016/0014-2999(94)90793-5; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DEVRIES GW, 1995, BRIT J PHARMACOL, V115, P1231; FARRELL JP, 1987, J IMMUNOL, V138, P902; Fedyk ER, 1996, P NATL ACAD SCI USA, V93, P10978, DOI 10.1073/pnas.93.20.10978; FOLEY P, 1992, IMMUNOLOGY, V75, P391; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; FREY J, 1986, EUR J BIOCHEM, V158, P85, DOI 10.1111/j.1432-1033.1986.tb09724.x; FU JY, 1990, J BIOL CHEM, V265, P16737; GENDELMAN HE, 1986, P NATL ACAD SCI USA, V83, P9759, DOI 10.1073/pnas.83.24.9759; GOLDYNE ME, 1987, PROSTAGLANDINS, V34, P783, DOI 10.1016/0090-6980(87)90060-8; GOODWIN JS, 1980, CLIN IMMUNOL IMMUNOP, V15, P106, DOI 10.1016/0090-1229(80)90024-0; GOODWIN JS, 1977, J EXP MED, V146, P1719, DOI 10.1084/jem.146.6.1719; GOODWIN JS, 1983, J CLIN IMMUNOL, V3, P295, DOI 10.1007/BF00915791; GRIFFIN DE, 1994, ANN NEUROL, V35, P592, DOI 10.1002/ana.410350513; GUELLAEN G, 1977, BIOCHIM BIOPHYS ACTA, V484, P465, DOI 10.1016/0005-2744(77)90102-4; HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081; HARAGUCHI S, 1995, IMMUNOL TODAY, V16, P595, DOI 10.1016/0167-5699(95)80083-2; HARRISON SM, 1987, BIOCHIM BIOPHYS ACTA, V925, P133, DOI 10.1016/0304-4165(87)90102-4; HEINEN E, 1986, ANN INST PASTEUR IMM, VD137, P369; HENDERSON AJ, 1995, J VIROL, V69, P5337, DOI 10.1128/JVI.69.9.5337-5344.1995; HENKE A, 1992, RES IMMUNOL, V143, P65, DOI 10.1016/0923-2494(92)80081-U; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOFMANN B, 1993, AIDS, V7, P659, DOI 10.1097/00002030-199305000-00008; HUI RT, 1995, J VIROL, V69, P8020, DOI 10.1128/JVI.69.12.8020-8026.1995; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; KERNACKI KA, 1994, J OCUL PHARMACOL, V10, P281, DOI 10.1089/jop.1994.10.281; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; KOH WS, 1995, BIOCHEM BIOPH RES CO, V206, P703, DOI 10.1006/bbrc.1995.1099; KUNO S, 1986, P NATL ACAD SCI USA, V83, P3487, DOI 10.1073/pnas.83.10.3487; KURLAND JI, 1978, J EXP MED, V147, P952, DOI 10.1084/jem.147.3.952; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; Li W, 1996, BIOCHEM BIOPH RES CO, V219, P96, DOI 10.1006/bbrc.1996.0187; LINGK DS, 1990, J IMMUNOL, V145, P449; MARGOLICK JB, 1987, J IMMUNOL, V138, P1719; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MIDULLA F, 1989, AM REV RESPIR DIS, V140, P771, DOI 10.1164/ajrccm/140.3.771; Mori K, 1996, J MOL MED-JMM, V74, P333, DOI 10.1007/BF00207510; MUNOZ E, 1990, J EXP MED, V172, P95, DOI 10.1084/jem.172.1.95; MUROI M, 1993, CELL SIGNAL, V5, P289, DOI 10.1016/0898-6568(93)90019-I; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NABEL GJ, 1994, HIV ADV RES THERAPY, V4, P1; NISHIGAKI N, 1995, FEBS LETT, V364, P339, DOI 10.1016/0014-5793(95)00421-5; NOKTA M, 1991, VIROLOGY, V181, P211, DOI 10.1016/0042-6822(91)90486-U; NOKTA MA, 1992, AIDS RES HUM RETROV, V8, P1255, DOI 10.1089/aid.1992.8.1255; ONTA T, 1993, MICROBIOL IMMUNOL, V37, P573, DOI 10.1111/j.1348-0421.1993.tb01679.x; PHIPPS RP, 1988, J LEUKOCYTE BIOL, V43, P271, DOI 10.1002/jlb.43.3.271; PHIPPS RP, 1990, IMMUNOL REV, V117, P135, DOI 10.1111/j.1600-065X.1990.tb00571.x; PINTER A, 1989, J VIROL, V63, P2674, DOI 10.1128/JVI.63.6.2674-2679.1989; RAMIS I, 1992, J CHROMATOGR-BIOMED, V575, P143, DOI 10.1016/0378-4347(92)80515-R; RAPPAPORT RS, 1982, J EXP MED, V155, P943, DOI 10.1084/jem.155.3.943; RASTOGI N, 1992, FEMS MICROBIOL IMMUN, V89, P273, DOI 10.1111/j.1574-6968.1992.tb05006.x; REINER WE, 1984, CELL IMMUNOL, V134, P556; RINCON M, 1988, EUR J IMMUNOL, V18, P1791, DOI 10.1002/eji.1830181121; RODBELL M, 1980, NATURE, V284, P17, DOI 10.1038/284017a0; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; Roper R L, 1994, Adv Prostaglandin Thromboxane Leukot Res, V22, P101; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SORRELL TC, 1989, IMMUNOL CELL BIOL, V67, P169, DOI 10.1038/icb.1989.27; STENSON WF, 1982, PROSTAGLANDINS, P39; Sun SC, 1996, MOL CELL BIOL, V16, P1058; WAHL LM, 1989, P NATL ACAD SCI USA, V86, P621, DOI 10.1073/pnas.86.2.621; WALKER C, 1983, J IMMUNOL, V130, P1770; WANG W, 1995, INFECT IMMUN, V63, P1089, DOI 10.1128/IAI.63.3.1089-1094.1995; WANG W, 1992, IMMUNOLOGY, V76, P242; Yasui H, 1997, J BIOL CHEM, V272, P28762, DOI 10.1074/jbc.272.45.28762; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	88	51	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27306	27314		10.1074/jbc.273.42.27306	http://dx.doi.org/10.1074/jbc.273.42.27306			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765256	hybrid			2022-12-27	WOS:000076448000043
J	Lee, SJ; Stull, JT				Lee, SJ; Stull, JT			Calmodulin-dependent regulation of inducible and neuronal nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; RABBIT SKELETAL-MUSCLE; BINDING DOMAIN; CELL-LINE; PHOSPHORYLASE-KINASE; ELECTRON-TRANSFER; PEPTIDE COMPLEX; PURIFICATION; ACTIVATION; RECOGNITION	Neuronal and endothelial nitric-oxide synthases depend upon Ca2+/calmodulin for activation, whereas the activity of the inducible nitric-oxide synthase is Ca2+-independent, presumably due to tightly bound calmodulin, To study these different mechanisms, a series of chimeras derived from neuronal and inducible nitric-oxide synthases were analyzed. Chimeras containing only the oxygenase domain, calmodulin-binding region, or reductase domain of inducible nitric-oxide synthase did not confer significant Ca2+-independent activity. However, each chimera was more sensitive to Ca2+ than the neuronal isoform, The calmodulin-binding region of inducible nitric-oxide synthase with either its oxygenase or reductase domains resulted in significant, but not total, Ca2+-independent activity. Co-immunoprecipitation experiments showed no calmodulin associated with the former chimera in the absence of Ca2+. Trifluoperazine also inhibited this chimera in the absence of Ca2+. The combined interactions of calmodulin bound to inducible nitric-oxide synthase calmodulin-binding region with the oxygenase domain may be weaker than with the reductase domain. Thus, Ca2+-independent activity of inducible nitric-oxide synthase appears to result from the concerted interactions of calmodulin with both the oxygenase and reductase domains in addition to the canonical calmodulin-binding region. The neuronal isoform is not regulated by a unique autoinhibitory element in its reductase domain.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Stull, JT (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	jstull@mednet.swmed.edu	Lee, Shiow-Ju/C-1380-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL006296, R37HL026043, R01HL026043] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL06296, HL26043] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; Albakri QA, 1996, J BIOL CHEM, V271, P5414, DOI 10.1074/jbc.271.10.5414; ANAGLI J, 1995, EUR J BIOCHEM, V233, P701, DOI 10.1111/j.1432-1033.1995.701_3.x; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Chen PF, 1996, J BIOL CHEM, V271, P14631, DOI 10.1074/jbc.271.24.14631; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; COOK WJ, 1994, BIOCHEMISTRY-US, V33, P15259, DOI 10.1021/bi00255a006; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; DINERMAN JL, 1993, CIRC RES, V73, P217, DOI 10.1161/01.RES.73.2.217; Forstermann U, 1996, METHOD ENZYMOL, V268, P334; GAO ZH, 1993, J BIOL CHEM, V268, P20096; Garvey EP, 1996, METHOD ENZYMOL, V268, P339; Gong CX, 1996, BRAIN RES, V741, P95, DOI 10.1016/S0006-8993(96)00904-3; GUPTA RC, 1990, MOL CELL BIOCHEM, V97, P43; HERRING BP, 1990, J BIOL CHEM, V265, P1724; HIKI K, 1992, J BIOCHEM-TOKYO, V111, P556, DOI 10.1093/oxfordjournals.jbchem.a123795; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; IKURA M, 1992, CELL CALCIUM, V13, P391, DOI 10.1016/0143-4160(92)90052-T; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P263, DOI 10.1111/j.1432-1033.1983.tb07358.x; JUMINAGA D, 1994, J BIOL CHEM, V269, P1660; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; Krueger JK, 1997, BIOCHEMISTRY-US, V36, P6017, DOI 10.1021/bi9702703; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; NEWTON DL, 1983, BIOCHEMISTRY-US, V22, P5472, DOI 10.1021/bi00293a003; Nishida CR, 1998, J BIOL CHEM, V273, P5566, DOI 10.1074/jbc.273.10.5566; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PERSECHINI A, 1994, J BIOL CHEM, V269, P16148; Persechini A, 1996, BIOCHEMISTRY-US, V35, P224, DOI 10.1021/bi952383x; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; RIVEROSMORENO V, 1995, EUR J BIOCHEM, V230, P52; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; Ruan J, 1996, J BIOL CHEM, V271, P22679, DOI 10.1074/jbc.271.37.22679; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; SESSA WC, 1994, J VASC RES, V31, P131, DOI 10.1159/000159039; SHERMAN PA, 1993, BIOCHEMISTRY-US, V32, P11600, DOI 10.1021/bi00094a017; SHERMAN PA, 1991, BIOCHEMISTRY-US, V266, P3369; Silvagno F, 1996, J BIOL CHEM, V271, P11204, DOI 10.1074/jbc.271.19.11204; Sonnenburg WK, 1995, J BIOL CHEM, V270, P30989, DOI 10.1074/jbc.270.52.30989; STEWART AA, 1983, EUR J BIOCHEM, V132, P289, DOI 10.1111/j.1432-1033.1983.tb07361.x; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; Stuehr DJ, 1996, METHOD ENZYMOL, V268, P324; SU ZZ, 1995, J BIOL CHEM, V270, P29117, DOI 10.1074/jbc.270.49.29117; TZENG E, 1995, P NATL ACAD SCI USA, V92, P11771, DOI 10.1073/pnas.92.25.11771; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435; VOGEL HJ, 1995, MOL CELL BIOCHEM, V67, P149; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008; Ye LH, 1997, J BIOL CHEM, V272, P32182, DOI 10.1074/jbc.272.51.32182; ZHANG MJ, 1995, J BIOL CHEM, V270, P20901, DOI 10.1074/jbc.270.36.20901; ZOT HG, 1989, J BIOL CHEM, V264, P15552	60	55	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27430	27437		10.1074/jbc.273.42.27430	http://dx.doi.org/10.1074/jbc.273.42.27430			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765272	hybrid			2022-12-27	WOS:000076448000059
J	Li, XD; Rhodes, TE; Ikebe, R; Kambara, T; White, HD; Ikebe, M				Li, XD; Rhodes, TE; Ikebe, R; Kambara, T; White, HD; Ikebe, M			Effects of mutations in the gamma-phosphate binding site of myosin on its motor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; ACTOMYOSIN ADENOSINE-TRIPHOSPHATASE; LIGHT-CHAIN KINASE; 3-DIMENSIONAL STRUCTURE; 2-HEADED STRUCTURE; MOLECULAR MOTOR; ACTIVE-SITE; SUBFRAGMENT-1; ATPASE; HYDROLYSIS	The role of the highly conserved residues in the gamma-phosphate binding site of myosin upon myosin motor function was studied. Each of five residues (Ser(181), Lys(185), Asn(235), Ser(236), and Arg(238)) in smooth muscle myosin was mutated. K185Q has neither a steady state ATPase nor an initial P-i burst. Although ATP and actin bind to K185Q, it is not dissociated from actin by ATP. These results indicate that the hydrolysis of bound ATP by K185Q is inhibited. S236T has nearly normal basal Mg2+-ATPase activity, initial P-i burst, ATP-induced enhancement of intrinsic tryptophan fluorescence, and ATP-induced dissociation from actin, However, the actin activation of the Mg2+-ATPase activity and actin translocation of S236T were blocked. In contrast S236A has nearly normal enzymatic properties and actin-translocating activity. These results indicate that 1) the hydroxyl group of Ser(236) is not critical as an intermediary of proton transfer during the ATP hydrolysis step, and 2) the bulk of the extra methyl group of the threonine residue in S236T blocks the acceleration of product release from the active site by actin, Arg(238), which interacts with Glu(459) at the Switch II region, was mutated to Lye and ne, respectively, R238K has essentially normal enzymatic activity and motility. In contrast, R238I does not hydrolyze ATP or support motility, although it still binds ATP. These results indicate that the charge interaction between Glu(459) and Arg(238) is critical for ATP hydrolysis by myosin, Other mutants, S181A, S181T, and N235I, showed nearly normal enzymatic and motile activity.	Univ Massachusetts, Med Ctr, Dept Physiol, Worcester, MA 01655 USA; Eastern Virginia Med Sch, Dept Biochem, Norfolk, VA 23507 USA	University of Massachusetts System; University of Massachusetts Worcester; Eastern Virginia Medical School	Ikebe, M (corresponding author), Univ Massachusetts, Med Ctr, Dept Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.	mitsuo.ikebe@ummed.edu			NHLBI NIH HHS [HL56218, HL47530] Funding Source: Medline; NIAMS NIH HHS [AR41653] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047530, R01HL056218] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAGSHAW CR, 1973, BIOCHEM J, V133, P323, DOI 10.1042/bj1330323; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; CREMO CR, 1989, J BIOL CHEM, V264, P6608; DYSON RD, 1971, BIOCHEMISTRY-US, V15, P5818; ECCLESTON JF, 1979, BIOCHEMISTRY-US, V18, P2896, DOI 10.1021/bi00580a034; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GEEVES MA, 1992, PHILOS T ROY SOC B, V336, P63, DOI 10.1098/rstb.1992.0045; GOODSON HV, 1993, P NATL ACAD SCI USA, V90, P659, DOI 10.1073/pnas.90.2.659; GRAMMER JC, 1993, BIOCHEMISTRY-US, V32, P5725, DOI 10.1021/bi00073a001; Higashihara M, 1989, J BIOL CHEM, V264, P5218; IKEBE M, 1994, J BIOL CHEM, V269, P28165; IKEBE M, 1985, J BIOL CHEM, V260, P3146; Ikebe M, 1998, J BIOL CHEM, V273, P17702, DOI 10.1074/jbc.273.28.17702; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; JIANG W, 1995, THESIS E VIRGINIA ME; JOHNSON KA, 1978, BIOCHEMISTRY-US, V17, P3432, DOI 10.1021/bi00610a002; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARUTA H, 1981, J BIOL CHEM, V256, P499; MATSUURA M, 1995, FEBS LETT, V363, P246, DOI 10.1016/0014-5793(95)00326-5; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; Onishi H, 1997, BIOCHEMISTRY-US, V36, P3767, DOI 10.1021/bi9630772; ORIELLY DR, 1992, BACULOVIRUS EXPRESSI; PATE E, 1993, J BIOL CHEM, V268, P10046; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RAYMENT I, 1994, TRENDS BIOCHEM SCI, V19, P129, DOI 10.1016/0968-0004(94)90206-2; Sata M, 1996, BIOCHEMISTRY-US, V35, P11113, DOI 10.1021/bi960435s; Shimada T, 1997, BIOCHEMISTRY-US, V36, P14037, DOI 10.1021/bi971837i; SIEMANKOWSKI RF, 1984, J BIOL CHEM, V259, P5045; SLEEP JA, 1981, J MUSCLE RES CELL M, V2, P373, DOI 10.1007/BF00711966; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; STEIN LA, 1979, BIOCHEMISTRY-US, V18, P3895, DOI 10.1021/bi00585a009; TAYLOR EW, 1977, BIOCHEMISTRY-US, V16, P732, DOI 10.1021/bi00623a027; Titus MA, 1993, CURR OPIN CELL BIOL, V5, P77, DOI 10.1016/S0955-0674(05)80011-0; TRENTHAM DR, 1976, Q REV BIOPHYS, V9, P217, DOI 10.1017/S0033583500002419; WAKABAYASHI K, 1992, SCIENCE, V258, P443, DOI 10.1126/science.1411537; WHITE HD, 1993, BIOCHEMISTRY-US, V32, P9859, DOI 10.1021/bi00088a042; WHITE HD, 1976, BIOCHEMISTRY-US, V15, P5818, DOI 10.1021/bi00671a020; WHITE HD, 1993, J BIOL CHEM, V268, P10039; YANO K, 1993, BIOCHEMISTRY-US, V32, P12054, DOI 10.1021/bi00096a016; YOUNT RG, 1992, PHILOS T ROY SOC B, V336, P55, DOI 10.1098/rstb.1992.0044; YOUNT RG, 1995, BIOPHYS J, V68, pS44	41	49	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27404	27411		10.1074/jbc.273.42.27404	http://dx.doi.org/10.1074/jbc.273.42.27404			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765269	hybrid			2022-12-27	WOS:000076448000056
J	McInnes, C; Wang, JJ; Al Moustafa, AE; Yansouni, C; O'Connor-McCourt, M; Sykes, BD				McInnes, C; Wang, JJ; Al Moustafa, AE; Yansouni, C; O'Connor-McCourt, M; Sykes, BD			Structure-based minimization of transforming growth factor-alpha (TGF-alpha) through NMR analysis of the receptor-bound ligand - Design, solution structure, and activity of TGF-alpha 8-50	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECTROSCOPY; H-1-NMR; RESTRAINTS; PROTEINS; SPECTRA; PROGRAM; SYSTEM; CELLS	The investigation of a N terminally truncated human transforming growth factor-alpha (TGF-alpha; residues 8-50) has been completed to determine the contribution of the N terminus to receptor binding and activation. The deletion protein was proposed and designed through study of NMR relaxation and nuclear Overhauser enhancement data obtained from the TGF-a-epidermal growth factor (EGF) receptor complex, which indicated that the residues N-terminal to the A loop remain flexible in receptor-bound TGF-alpha and thus suggested their lack of involvement in receptor binding (Hoyt, D. W., Harkins, R. N., Debanne, M. T., O'Connor-McCourt, M., and Sykes, B. D. (1994) Biochemistry 33, 15283-15292; McInnes, C., Hoyt, D. W., Harkins, R. N., Pagila, R. N., Debanne, M. T., O'Connor-McCourt, M., and Sykes, B. D. (1996) J. Biol. Chem. 271, 32204-32211). TGF-alpha 8-50 was shown to have approximately 10-fold lower affinity for the receptor than the native molecule in an assay quantifying the ability to compete with EGF for binding and to have a similar reduction in activity as indicated by a cell proliferation assay. NMR solution structural calculations on this molecule demonstrate correct formation of the three disulfide bonds of TGF-a 8-50 and have established the presence of native secondary structure in the B and C loops of the protein, However, some perturbation of the global fold with respect to the orientation of the subdomains was observed. These results suggest that although the N-terminal residues do not contribute directly to binding, they make a significant contribution in defining the conformation of the growth factor, which is required for complete binding and activity and is therefore significant in terms of producing native folding of TGF-a. They also show that information obtained from the receptor-bound ligand can be used to guide the design and minimization of TGF-alpha analogues. The implications of the study of TGF-alpha 8-50 for the design and synthesis of reductants of this growth factor are therefore discussed.	Univ Alberta, Heritage Med Res Ctr 713, Protein Engn Network Ctr Excellence, Edmonton, AB T6G 2S2, Canada; Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada	University of Alberta; National Research Council Canada	McInnes, C (corresponding author), Univ Alberta, Heritage Med Res Ctr 713, Protein Engn Network Ctr Excellence, Edmonton, AB T6G 2S2, Canada.		McInnes, Campbell/A-6721-2009	/0000-0002-4765-3469				BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BENNET NT, 1993, AM J SURG, V166, P75; BENNETT NT, 1993, AM J SURG, V165, P728, DOI 10.1016/S0002-9610(05)80797-4; BROWN SC, 1988, J MAGN RESON, V77, P166, DOI 10.1016/0022-2364(88)90042-X; BRUNGER AT, 1993, X PLOR VERSION 3 1; CAMPION SR, 1994, PROG NUCLEIC ACID RE, V49, P353; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; GRONWALD W, 1998, IN PRESS J BIOL NMR; HARVEY TS, 1991, EUR J BIOCHEM, V198, P555, DOI 10.1111/j.1432-1033.1991.tb16050.x; HEATH WF, 1986, P NATL ACAD SCI USA, V83, P6367, DOI 10.1073/pnas.83.17.6367; HOYT DW, 1994, BIOCHEMISTRY-US, V33, P15283, DOI 10.1021/bi00255a009; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KLINE TP, 1990, BIOCHEMISTRY-US, V29, P7805, DOI 10.1021/bi00486a005; KOHDA D, 1989, BIOCHEMISTRY-US, V28, P953, DOI 10.1021/bi00429a005; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI B, 1995, SCIENCE, V270, P1657, DOI 10.1126/science.270.5242.1657; McInnes C, 1996, J BIOL CHEM, V271, P32204, DOI 10.1074/jbc.271.50.32204; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOY FJ, 1993, BIOCHEMISTRY-US, V32, P7334, DOI 10.1021/bi00080a003; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; OKAMURA K, 1992, BIOCHEM BIOPH RES CO, V186, P1471, DOI 10.1016/S0006-291X(05)81572-4; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; Rusch Valerie, 1996, Cytokine and Growth Factor Reviews, V7, P133, DOI 10.1016/1359-6101(96)00016-0; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; TAM JP, 1991, INT J PEPT PROT RES, V38, P204; TAPPIN MJ, 1989, EUR J BIOCHEM, V179, P629, DOI 10.1111/j.1432-1033.1989.tb14594.x; VIALLET J, 1994, EXP CELL RES, V212, P36, DOI 10.1006/excr.1994.1115	34	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27357	27363		10.1074/jbc.273.42.27357	http://dx.doi.org/10.1074/jbc.273.42.27357			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765263	hybrid			2022-12-27	WOS:000076448000050
J	Nakonechny, WS; Teschke, CM				Nakonechny, WS; Teschke, CM			GroEL and GroES control of substrate flux in the in vivo folding pathway of phage P22 coat protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SUBSTITUTIONS; ESCHERICHIA-COLI; IN-VITRO; SALMONELLA PHAGE-P22; SCAFFOLDING PROTEIN; STRUCTURAL PROTEINS; CHAPERONINS; HEAD; SUBUNITS; BACTERIOPHAGE-T4	Our present understanding of the action of the chaperonins GroEL/S on protein folding is based primarily on in vitro studies, whereas the folding of proteins in the cellular milieu has not been as thoroughly investigated. We have developed a means of examining in vivo protein folding and assembly that utilizes the coat protein of bacteriophage P22, a naturally occurring substrate of GroEL/S. Here we show that amino acid substitutions in coat protein that cause a temperature-sensitive-folding (tsf) phenotype slowed assembly rates upon increasing the temperature of cell growth. Raising cellular concentrations of GroEL/S increased the rate of assembly of the tsf mutant coat proteins to nearly that of wild-type (WT) coat protein by protecting a thermolabile folding intermediate from aggregation, thereby increasing the concentration of assembly competent coat protein. The rate of release of the tsf coat proteins from the GroEL/S-coat protein ternary complex was approximately a-fold slower at non-permissive temperatures when compared with the release of WT coat protein. However, the rate of release of WT Or tsf coat proteins at each temperature remained constant regardless of GroEL/S levels. Thus, raising the cellular concentration of GroEL/S increased the amount of assembly-competent tsf coat proteins not by altering the rates of folding but by increasing the probability of GroEL/S-coat protein complex formation.	Univ Connecticut, Dept Mol & Cell Biol, Storrs, CT 06269 USA	University of Connecticut	Teschke, CM (corresponding author), Univ Connecticut, Dept Mol & Cell Biol, 75 N Eagleville Rd,U-125, Storrs, CT 06269 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053567, R29GM053567] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53567] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAZINET C, 1988, J MOL BIOL, V202, P77, DOI 10.1016/0022-2836(88)90520-7; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CASJENA S, 1974, J SUPRAMOL STRU T, V2, P22; CASJENS S, 1979, J MOL BIOL, V131, P1, DOI 10.1016/0022-2836(79)90298-5; DYK TKV, 1989, NATURE, V342, P451; EARNSHAW W, 1978, J MOL BIOL, V126, P721, DOI 10.1016/0022-2836(78)90017-7; EARNSHAW W, 1976, J MOL BIOL, V104, P387, DOI 10.1016/0022-2836(76)90278-3; EWAIT KL, 1997, CELL, V90, P491; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; Fenton WA, 1997, PROTEIN SCI, V6, P743; GALISTEO ML, 1993, BIOPHYS J, V65, P227, DOI 10.1016/S0006-3495(93)81073-7; GALISTEO ML, 1995, J BIOL CHEM, V270, P16595, DOI 10.1074/jbc.270.28.16595; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GORDON CL, 1994, J BIOL CHEM, V269, P27941; GORDON CL, 1993, J BIOL CHEM, V268, P9358; GORDON CL, 1994, GENETICS, V136, P427; Greene B, 1996, VIROLOGY, V225, P82, DOI 10.1006/viro.1996.0577; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; King J, 1996, FASEB J, V10, P57, DOI 10.1096/fasebj.10.1.8566549; KING J, 1973, J MOL BIOL, V80, P697, DOI 10.1016/0022-2836(73)90205-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lorimer GH, 1996, FASEB J, V10, P5, DOI 10.1096/fasebj.10.1.8566548; Martin J, 1997, P NATL ACAD SCI USA, V94, P1107, DOI 10.1073/pnas.94.4.1107; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MILLER AD, 1993, BIOCHEM J, V291, P139, DOI 10.1042/bj2910139; Miller J. H., 1972, EXPT MOL GENETICS, P431; NEAL BL, 1993, J BACTERIOL, V175, P7115, DOI 10.1128/jb.175.21.7115-7118.1993; PERALTA D, 1994, FEBS LETT, V339, P45, DOI 10.1016/0014-5793(94)80381-1; PRASAD BVV, 1993, J MOL BIOL, V231, P65, DOI 10.1006/jmbi.1993.1257; PREVELIGE PE, 1988, J MOL BIOL, V202, P743, DOI 10.1016/0022-2836(88)90555-4; PREVELIGE PE, 1993, BIOPHYS J, V64, P824, DOI 10.1016/S0006-3495(93)81443-7; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; SERWER P, 1978, J VIROL, V28, P917, DOI 10.1128/JVI.28.3.917-928.1978; STANIFORTH RA, 1994, FEBS LETT, V344, P129, DOI 10.1016/0014-5793(94)00348-3; TESCHKE CM, 1995, BIOCHEMISTRY-US, V34, P6815, DOI 10.1021/bi00020a028; TESCHKE CM, 1993, BIOCHEMISTRY-US, V32, P10839, DOI 10.1021/bi00091a040; Teschke CM, 1996, BIOCHEMISTRY-US, V35, P14831, DOI 10.1021/bi960860l; WINSTON F, 1979, J BACTERIOL, V137, P433, DOI 10.1128/JB.137.1.433-439.1979; ZEILSTRARYALLS J, 1993, J BACTERIOL, V175, P1134, DOI 10.1128/JB.175.4.1134-1143.1993	40	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27236	27244		10.1074/jbc.273.42.27236	http://dx.doi.org/10.1074/jbc.273.42.27236			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765246	hybrid			2022-12-27	WOS:000076448000033
J	Radebaugh, CA; Kubaska, WM; Hoffman, LH; Stiffler, K; Paule, MR				Radebaugh, CA; Kubaska, WM; Hoffman, LH; Stiffler, K; Paule, MR			A novel transcription initiation factor (TIF), TIF-IE, is required for homogeneous Acanthamoeba castellanii TIF-IB (SL1) to form a committed complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-I; TATA-BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; RDNA TRANSCRIPTION; PREINITIATION COMPLEX; GEL-ELECTROPHORESIS; FACTOR UBF; DNA; PROMOTER; TBP	The fundamental transcription initiation factor (TIF) for ribosomal RNA expression by eukaryotic RNA polymerase I, TIF-IB, has been purified to near homogeneity from Acanthamoeba castellanii using standard techniques. The purified factor consists of the TATA-binding protein and four TATA-binding protein-associated factors with relative molecular weights of 145,000, 99,000, 96,000, and 91,000. This yields a calculated native molecular weight of 460,000, which compares well with its mass determined by scanning transmission electron microscopy (493,000) and its sedimentation rate, which is close to RNA polymerase I (515,000). Both impure and nearly homogeneous TIF-IB exhibit an apparent equilibrium dissociation constant of 56 +/- 3 pM. However, although impure TIF-IB can form a promoter-DNA complex resistant to challenge by other promoter-containing DNAs, near homogeneous TIF-IB cannot do so. An additional transcription factor, dubbed TIF-IE, restores the ability of near homogeneous TIF-IB to sequester DNA into a committed complex.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA	Colorado State University	Radebaugh, CA (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA.	mpaule@vines.colostate.edu			NIGMS NIH HHS [GM22580] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022580] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATEMAN E, 1985, P NATL ACAD SCI USA, V82, P8004, DOI 10.1073/pnas.82.23.8004; BATEMAN E, 1989, MOL BIOL RNA DNA PRO, P259; BAZETTJONES DP, 1994, SCIENCE, V264, P1134, DOI 10.1126/science.8178172; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Bodeker M, 1996, MOL CELL BIOL, V16, P5572; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; DALESSIO JM, 1979, J BIOL CHEM, V254, P4085; EBERHARD D, 1993, NUCLEIC ACIDS RES, V21, P4180, DOI 10.1093/nar/21.18.4180; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; Garfin DE, 1990, METHOD ENZYMOL, P425; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GONG XL, 1995, MOL CELL BIOL, V15, P4956; GRUMMT I, 1982, NATURE, V296, P173, DOI 10.1038/296173a0; GRUMMT I, 1998, TRANSCRIPTION EUKARY, V1, P135; Hanada K, 1996, EMBO J, V15, P2217, DOI 10.1002/j.1460-2075.1996.tb00575.x; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; IIDA CT, 1985, P NATL ACAD SCI USA, V82, P1668, DOI 10.1073/pnas.82.6.1668; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KEYS DA, 1994, GENE DEV, V8, P2349, DOI 10.1101/gad.8.19.2349; Keys DA, 1996, GENE DEV, V10, P887, DOI 10.1101/gad.10.7.887; KOWNIN P, 1988, MOL CELL BIOL, V8, P747, DOI 10.1128/MCB.8.2.747; KOWNIN P, 1987, CELL, V50, P693, DOI 10.1016/0092-8674(87)90327-8; KUHN A, 1998, TRANSCRIPTION EUKARY, V1, P201; Lalo D, 1996, J BIOL CHEM, V271, P21062, DOI 10.1074/jbc.271.35.21062; Lin CW, 1996, MOL CELL BIOL, V16, P6436; LOFQUIST AK, 1993, NUCLEIC ACIDS RES, V21, P3233; MANIATIS T, 1982, MOL CLONING LABORATO, P348; MCSTAY B, 1991, EMBO J, V10, P2297, DOI 10.1002/j.1460-2075.1991.tb07766.x; MURAMATSU M, 1998, TRANSCRIPTION EUKARY, V1, P95; MURAMATSU M, 1998, TRANSCRIPTION EUKARY, V1, P295; Nomura M., 1998, TRANSCRIPTION EUKARY, P155; PAULE MR, 1990, NATURE, V344, P819, DOI 10.1038/344819a0; PAULE MR, 1998, TRANSCRIPTION EUKARY, V1, P107; PAULE MR, 1994, TRANSCRIPTION MECHAN, P83; PAULE MR, 1998, TRANSCRIPTION EUKARY, V1; Perna Peter J., 1992, Gene Expression, V2, P71; PUTNAM CD, 1994, MOL CELL BIOL, V14, P6476, DOI 10.1128/MCB.14.10.6476; RADEBAUGH CA, 1994, MOL CELL BIOL, V14, P597, DOI 10.1128/MCB.14.1.597; Radebaugh CA, 1997, J BIOL CHEM, V272, P3141, DOI 10.1074/jbc.272.6.3141; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Smith S. David, 1993, Gene Expression, V3, P229; SPINDLER SR, 1978, J BIOL CHEM, V253, P4669; Steffan JS, 1996, GENE DEV, V10, P2551, DOI 10.1101/gad.10.20.2551; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Yamamoto RT, 1996, EMBO J, V15, P3964, DOI 10.1002/j.1460-2075.1996.tb00770.x; ZOMERDIJK JCB, 1998, TRANSCRIPTION RIBOSO, V1, P121; ZOMERDIJK JCB, 1998, TRANSCRIPTION EUKARY, V1, P67	51	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27708	27715		10.1074/jbc.273.42.27708	http://dx.doi.org/10.1074/jbc.273.42.27708			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765308	hybrid			2022-12-27	WOS:000076448000095
J	Thompson, J; Pikis, A; Ruvinov, SB; Henrissat, B; Yamamoto, H; Sekiguchi, J				Thompson, J; Pikis, A; Ruvinov, SB; Henrissat, B; Yamamoto, H; Sekiguchi, J			The gene glvA of Bacillus subtilis 168 encodes a metal-requiring, NAD (H)-dependent 6-phospho-alpha-glucosidase - Assignment to family 4 of the glycosylhydrolase superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; D-PHOSPHOGALACTOSIDE GALACTOHYDROLASE; FUSOBACTERIUM-MORTIFERUM ATCC-25557; SUGAR PHOSPHOTRANSFERASE SYSTEM; AGROBACTERIUM BETA-GLUCOSIDASE; ACID-SEQUENCE SIMILARITIES; ACTIVE-SITE NUCLEOPHILE; ESCHERICHIA-COLI K-12; NUCLEOTIDE-SEQUENCE; AMINO-ACID	The gene gluA (formerly glu-1) from Bacillus subtilis has been cloned and expressed in Escherichia coli. The purified protein GlvA (449 residues, M-r = 50,513) is a unique 6-phosphoryl-O-alpha-D-glucopyranosyl:phosphoglucohydrolase (6-phospho-alpha-glucosidase) that requires both NAD(H) and divalent metal (Mn2+, Fe2+, Co2+, or Ni2+) for activity. 6-Phospho-alpha-glucosidase (EC 3.2.1.122) from B. subtilis cross-reacts with polyclonal antibody to maltose 6-phosphate hydrolase from Fusobacterium mortiferum, and the two proteins exhibit amino acid sequence identity of 73%. Estimates for the M-r of GlvA determined by SDS-polyacrylamide gel electrophoresis (51,000) and electrospray-mass spectroscopy (50,510) were in excellent agreement with the molecular weight of 50,513 deduced from the amino acid sequence. The sequence of the first 37 residues from the N terminus determined by automated analysis agreed precisely with that predicted by translation of gluA. The chromogenic and fluorogenic substrates, p-nitrophenyl-alpha-D-glucopyranoside 6-phosphate and 4-methylumbelliferyl-alpha-D-glucopyranoside 6-phosphate were used for the discontinuous assay and in situ detection of enzyme activity, respectively. Site directed mutagenesis shows that three acidic residues, Asp(41), Glu(111), and Glu(359), are required for GlvA activity. Asp(41) is located at the C terminus of a beta alpha beta fold that may constitute the dinucleotide binding domain of the protein. Glu(111) and GlU(359) may function as the catalytic acid (proton donor) and nucleophile (base), respectively, during hydrolysis of 6-phospho-alpha-glucoside substrates including maltose 6-phosphate and trehalose 6-phosphate, In metal-free buffer, GlvA exists as an inactive dimer, but in the presence of Mn2+ ion, these species associate to form the NAD(H)-dependent catalytically active tetramer, By comparative sequence alignment with its homologs, the novel 6-phospho-alpha-glucosidase from B. subtilis can be assigned to the nine-member family 4 of the glycosylhydrolase superfamily.	NIDR, Oral Infect & Immun Branch, Microbial Biochem & Genet Unit, NIH, Bethesda, MD 20892 USA; NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA; Childrens Natl Med Ctr, Dept Infect Dis, Washington, DC 20010 USA; CNRS, Struct Enzymol & Glycobiol Grp, F-13402 Marseille, France; Shinshu Univ, Fac Text Sci & Technol, Dept Appl Biol, Ueda, Nagano 386, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Children's National Health System; Centre National de la Recherche Scientifique (CNRS); Shinshu University	Thompson, J (corresponding author), NIDR, Oral Infect & Immun Branch, Microbial Biochem & Genet Unit, NIH, Bldg 30,Rm 528,Convent Dr,MSC-4350, Bethesda, MD 20892 USA.	jthompson@yoda.nidr.nih.gov	PIKIS, ANDREAS/AFU-1192-2022; Henrissat, Bernard/J-2475-2012; Sekiguchi, Junichi/F-9963-2010	Henrissat, Bernard/0000-0002-3434-8588; 				BAKER PJ, 1992, J MOL BIOL, V228, P662, DOI 10.1016/0022-2836(92)90848-E; BHUMIRATANA A, 1974, J BACTERIOL, V119, P484, DOI 10.1128/JB.119.2.484-493.1974; Bibel M, 1998, FEMS MICROBIOL LETT, V158, P9, DOI 10.1111/j.1574-6968.1998.tb12793.x; BOIZET B, 1988, GENE, V62, P249, DOI 10.1016/0378-1119(88)90563-X; Bouma CL, 1997, J BACTERIOL, V179, P4129, DOI 10.1128/jb.179.13.4129-4137.1997; BREIDT F, 1987, APPL ENVIRON MICROB, V53, P969, DOI 10.1128/AEM.53.5.969-973.1987; BURLAND V, 1993, GENOMICS, V16, P551, DOI 10.1006/geno.1993.1230; BURSTEIN C, 1971, BIOCHIM BIOPHYS ACTA, V230, P52, DOI 10.1016/0304-4165(71)90053-5; CALMES R, 1979, INFECT IMMUN, V23, P68, DOI 10.1128/IAI.23.1.68-79.1979; CASE GS, 1973, BIOCHEM J, V133, P99, DOI 10.1042/bj1330099; DANCHIN A, 1989, FEMS MICROBIOL LETT, V63, P1; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; ELHASSOUNI M, 1992, J BACTERIOL, V174, P765, DOI 10.1128/jb.174.3.765-777.1992; ERNI B, 1992, INT REV CYTOL, V137A, P127; GOTSCHE S, 1995, J BACTERIOL, V177, P2721, DOI 10.1128/jb.177.10.2721-2726.1995; GRABNITZ F, 1991, EUR J BIOCHEM, V200, P301, DOI 10.1111/j.1432-1033.1991.tb16186.x; HELFERT C, 1995, MOL MICROBIOL, V16, P111, DOI 10.1111/j.1365-2958.1995.tb02396.x; HENGSTENBERG W, 1993, FEMS MICROBIOL REV, V12, P149; HENGSTENBERG W, 1989, FEMS MICROBIOL LETT, V63, P35, DOI 10.1016/0168-6445(89)90006-5; HENGSTENBERG W, 1970, EUR J BIOCHEM, V14, P27, DOI 10.1111/j.1432-1033.1970.tb00256.x; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Ishikawa S, 1998, J BACTERIOL, V180, P1375, DOI 10.1128/JB.180.6.1375-1380.1998; JOHNSON KG, 1974, J BACTERIOL, V117, P667, DOI 10.1128/JB.117.2.667-674.1974; KEMPTON JB, 1992, BIOCHEMISTRY-US, V31, P9961, DOI 10.1021/bi00156a015; KUNDIG W, 1964, P NATL ACAD SCI USA, V52, P1067, DOI 10.1073/pnas.52.4.1067; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LEGLER G, 1990, ADV CARBOHYD CHEM BI, V48, P319, DOI 10.1016/S0065-2318(08)60034-7; LENGELER JW, 1990, PHILOS T ROY SOC B, V326, P489, DOI 10.1098/rstb.1990.0027; LILJESTROM PL, 1987, NUCLEIC ACIDS RES, V15, P2213, DOI 10.1093/nar/15.5.2213; Maurizi MR, 1998, BIOCHEMISTRY-US, V37, P7778, DOI 10.1021/bi973093e; MAURIZI MR, 1986, ARCH BIOCHEM BIOPHYS, V246, P494, DOI 10.1016/0003-9861(86)90496-0; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MIKI T, 1987, PROTEIN ENG, V1, P327, DOI 10.1093/protein/1.4.327; Nosworthy NJ, 1998, BIOCHEMISTRY-US, V37, P6718, DOI 10.1021/bi980126x; PARKER LL, 1990, GENETICS, V124, P455; PORTER EV, 1988, GENE, V62, P263; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; PRASAD I, 1973, J BACTERIOL, V114, P909, DOI 10.1128/JB.114.3.909-915.1973; RAFFERTY JB, 1995, STRUCTURE, V3, P927, DOI 10.1016/S0969-2126(01)00227-1; REIZER J, 1994, PROTEIN SCI, V3, P440; REIZER J, 1988, CRC CR REV MICROBIOL, V15, P297, DOI 10.3109/10408418809104461; RIMMELE M, 1994, J BACTERIOL, V176, P5654, DOI 10.1128/JB.176.18.5654-5664.1994; ROBRISH SA, 1994, J BACTERIOL, V176, P3250, DOI 10.1128/jb.176.11.3250-3256.1994; ROJAS A, 1995, BIOCHEM MOL BIOL INT, V35, P1223; ROSEMAN S, 1989, FEMS MICROBIOL LETT, V63, P3, DOI 10.1016/0168-6445(89)90003-X; SAIER MH, 1992, J BACTERIOL, V174, P1433, DOI 10.1128/jb.174.5.1433-1438.1992; SAIER MH, 1994, MOL MICROBIOL, V13, P755; SAIER MH, 1996, RES MICROBIOL, V147, P435; SCHAEFLER S, 1968, P NATL ACAD SCI USA, V59, P285, DOI 10.1073/pnas.59.1.285; SCHNETZ K, 1987, J BACTERIOL, V169, P2579, DOI 10.1128/jb.169.6.2579-2590.1987; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; SINNOTT ML, 1978, BIOCHEM J, V175, P539, DOI 10.1042/bj1750539; STAEDTLER P, 1995, EUR J BIOCHEM, V232, P658, DOI 10.1111/j.1432-1033.1995.658zz.x; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; TENU JP, 1972, EUR J BIOCHEM, V26, P112, DOI 10.1111/j.1432-1033.1972.tb01746.x; THOMPSON J, 1989, J BIOL CHEM, V264, P9592; Thompson J, 1997, J BACTERIOL, V179, P1636, DOI 10.1128/jb.179.5.1636-1645.1997; THOMPSON J, 1995, J BACTERIOL, V177, P2505, DOI 10.1128/jb.177.9.2505-2512.1995; Thompson J., 1987, SUGAR TRANSPORT META, P13; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tobisch S, 1997, J BACTERIOL, V179, P496, DOI 10.1128/jb.179.2.496-506.1997; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; WIESMANN C, 1995, STRUCTURE, V3, P961, DOI 10.1016/S0969-2126(01)00230-1; WILSON G, 1974, J BIOL CHEM, V249, P5586; WITHERS SG, 1992, BIOCHEMISTRY-US, V31, P9979, DOI 10.1021/bi00156a017; WITHERS SG, 1990, J AM CHEM SOC, V112, P5887, DOI 10.1021/ja00171a043; WITT E, 1993, PROTEIN ENG, V6, P913, DOI 10.1093/protein/6.8.913; Yamamoto H, 1996, MICROBIOL-SGM, V142, P1417, DOI 10.1099/13500872-142-6-1417; ZAMYATNIN AA, 1984, ANNU REV BIOPHYS BIO, V13, P145, DOI 10.1146/annurev.bb.13.060184.001045; ZHANG JK, 1994, GENE, V140, P85, DOI 10.1016/0378-1119(94)90735-8	71	67	70	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27347	27356		10.1074/jbc.273.42.27347	http://dx.doi.org/10.1074/jbc.273.42.27347			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765262	hybrid			2022-12-27	WOS:000076448000049
J	Wong, CW; Privalsky, ML				Wong, CW; Privalsky, ML			Components of the SMRT corepressor complex exhibit distinctive interactions with the POZ domain oncoproteins PLZF, PLZF-RAR alpha, and BCL-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; RETINOIC ACID RECEPTOR; NUCLEAR HORMONE RECEPTORS; PROTEIN INTERACTION MOTIF; ZINC-FINGER GENE; CENTER B-CELLS; TRANSCRIPTIONAL REPRESSION; HISTONE DEACETYLASE; N-COR; MOLECULAR PATHOGENESIS	Many transcription factors function by repressing gene transcription. For a variety of these transcription factors the ability to physically recruit auxiliary proteins, denoted corepressors, is crucial for the ability to silence gene expression. We and others have previously implicated the SMRT corepressor in the actions of the PLZF transcription factor and in the function of its oncogenic derivative, PLZF-retinoic acid receptor (RAR alpha), in promyelocytic leukemia. We report here that PLZF, and a structurally similar transcriptional repressor, BCL-6, can interact with a variety of corepressor proteins in addition to SMRT, including the mSin3A protein and (for PLZF) histone deacetylase-l. Unexpectedly, these additional interactions with corepressor components are nonequivalent for these otherwise similar oncoproteins, suggesting that transcriptional repression by BCL-6 and by PLZF may differ in mechanism. Furthermore, we demonstrate that the oncogenic PLZF-RAR alpha chimera lacks several important corepressor interaction sites that are present in the native PLZF protein. Thus the t(11;17) translocation that creates the PLZF-RAR alpha chimera generates an oncoprotein with potentially novel regulatory properties distinct from those of either parental protein. Our results demonstrate that otherwise similar transcription factors can differ notably in their interactions with the corepressor machinery.	Univ Calif Davis, Microbiol Sect, Div Biol Sci, Davis, CA 95616 USA	University of California System; University of California Davis	Privalsky, ML (corresponding author), Univ Calif Davis, Microbiol Sect, Div Biol Sci, 1 Shields Ave, Davis, CA 95616 USA.	mlprivalsky@ucdavis.edu			NATIONAL CANCER INSTITUTE [R37CA053394] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053528] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA-53394] Funding Source: Medline; NIDDK NIH HHS [R01 DK-53528] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AVANTAGGIATO V, 1995, J NEUROSCI, V15, P4927; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; Chen Z, 1996, GENE CHROMOSOME CANC, V15, P147, DOI 10.1002/(SICI)1098-2264(199603)15:3<147::AID-GCC1>3.0.CO;2-2; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; COOK M, 1995, P NATL ACAD SCI USA, V92, P2249, DOI 10.1073/pnas.92.6.2249; DALLAFAVERA R, 1994, COLD SPRING HARB SYM, V59, P117, DOI 10.1101/SQB.1994.059.01.015; DERURBERTIS F, 1991, NATURE, V384, P589; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; Downes M, 1996, NUCLEIC ACIDS RES, V24, P4379, DOI 10.1093/nar/24.22.4379; FLENGHI L, 1995, AM J PATHOL, V147, P405; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUIDEZ F, 1994, LEUKEMIA, V8, P312; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Li H, 1997, MOL ENDOCRINOL, V11, P2025, DOI 10.1210/me.11.13.2025; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Lin BC, 1997, MOL CELL BIOL, V17, P6131, DOI 10.1128/MCB.17.10.6131; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Muscat GEO, 1998, NUCLEIC ACIDS RES, V26, P2899, DOI 10.1093/nar/26.12.2899; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Pandolfi PP, 1996, HAEMATOLOGICA, V81, P472; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PRIVALSKY ML, 1990, CELL, V63, P1277, DOI 10.1016/0092-8674(90)90423-C; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; Seyfert VL, 1996, ONCOGENE, V12, P2331; Shibata H, 1997, MOL ENDOCRINOL, V11, P714, DOI 10.1210/me.11.6.714; Sitterlin D, 1997, ONCOGENE, V14, P1067, DOI 10.1038/sj.onc.1200916; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Wagner BL, 1998, MOL CELL BIOL, V18, P1369, DOI 10.1128/MCB.18.3.1369; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Wong CW, 1998, MOL CELL BIOL, V18, P5500, DOI 10.1128/MCB.18.9.5500; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Yoh SM, 1997, MOL ENDOCRINOL, V11, P470, DOI 10.1210/me.11.4.470; Zamir I, 1997, P NATL ACAD SCI USA, V94, P14400, DOI 10.1073/pnas.94.26.14400; Zamir I, 1996, MOL CELL BIOL, V16, P5458; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	60	137	139	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27695	27702		10.1074/jbc.273.42.27695	http://dx.doi.org/10.1074/jbc.273.42.27695			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765306	hybrid			2022-12-27	WOS:000076448000093
J	Angove, HC; Yoo, SJ; Munck, E; Burgess, BK				Angove, HC; Yoo, SJ; Munck, E; Burgess, BK			An all-ferrous state of the Fe protein of nitrogenase - Interaction with nucleotides and electron transfer to the MoFe protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZOTOBACTER-VINELANDII NITROGENASE; MOLYBDENUM-IRON PROTEIN; KLEBSIELLA-PNEUMONIAE NITROGENASE; PARAMAGNETIC RESONANCE; P-CLUSTERS; ADENOSINE 5'-TRIPHOSPHATE; CONFORMATIONAL-CHANGES; CIRCULAR-DICHROISM; EPR SPECTROSCOPY; FE4S4 CLUSTER	The MoFe protein of nitrogenase catalyzes the six-electron reduction of dinitrogen to ammonia. It has long been believed that this protein receives the multiple electrons it requires one at a time, from the [4Fe-4S](2+/+) couple of the Fe protein. Recently an all-ferrous [4Fe4S](0) state of the Fe protein was demonstrated suggesting instead a series of two electron steps involving the [4Fe-4S](2+/0) couple. We have examined the interactions of the [4Fe-4S](0) Fe protein with nucleotides and its ability to transfer electrons to the MoFe protein. The [4Fe45](0) Fe protein binds both MgATP and MgADP and undergoes the MgATP induced conformational change and then binds properly to the MoFe protein, as evidenced by the fact that the behavior of the 0 and +1 oxidation states in the chelation and chelation protection assays are indistinguishable. Nucleotide binding does not effect the distinctive UV/Vis, CD, or Mossbauer spectra exhibited by the [4Fe-4S](0) Fe protein; however, because the intensity of the g = 16.4 EPR signal of the [4Fe-4S](0) Fe protein is extremely sensitive to minor variations of the rhombicity parameter E/D, the EPR signal is sensitive to the binding of nucleotides. A 50:50 mixture of [4Fe-4S](2+) and [4Fe-4S](0) Fe protein results in electron self-exchange and 100% production of [4Fe-4S](2+) Fe protein, demonstrating that the +1/0 couple is fully reversible. MgATP is absolutely required for electron transfer from the [4Fe-4S](0) Fe protein to the reduced state of the MoFe protein. In that reaction both electrons are transferred and are used to reduce substrate.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Carnegie Mellon Univ, Dept Chem, Pittsburgh, PA 15213 USA	University of California System; University of California Irvine; Carnegie Mellon University	Burgess, BK (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.	bburgess@uci.edu			NIGMS NIH HHS [GM-45209] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045209] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angove HC, 1997, J AM CHEM SOC, V119, P8730, DOI 10.1021/ja9712837; ASHBY GA, 1987, BIOCHEM J, V246, P455, DOI 10.1042/bj2460455; BOLIN JT, 1993, ACS SYM SER, V535, P186; BUI PT, 1968, P NATL ACAD SCI USA, V61, P1021, DOI 10.1073/pnas.61.3.1021; Burgess BK, 1996, CHEM REV, V96, P2983, DOI 10.1021/cr950055x; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; CHEN L, 1994, J BIOL CHEM, V269, P3290; DEITS TL, 1989, J BIOL CHEM, V264, P6619; Duyvis MG, 1996, FEBS LETT, V380, P233, DOI 10.1016/0014-5793(96)00019-1; FISHER K, 1991, BIOCHEM J, V279, P81, DOI 10.1042/bj2790081; GAVINI N, 1992, J BIOL CHEM, V267, P21179; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HAGEMAN RV, 1978, P NATL ACAD SCI USA, V75, P2699, DOI 10.1073/pnas.75.6.2699; HAGEN WR, 1985, FEBS LETT, V189, P250, DOI 10.1016/0014-5793(85)81033-4; HEERING HA, 1995, EUR J BIOCHEM, V232, P811, DOI 10.1111/j.1432-1033.1995.811zz.x; Holm RH, 1996, CHEM REV, V96, P2239, DOI 10.1021/cr9500390; Howard JB, 1996, CHEM REV, V96, P2965, DOI 10.1021/cr9500545; IMAM S, 1980, FEBS LETT, V110, P35, DOI 10.1016/0014-5793(80)80016-0; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; Lanzilotta WN, 1997, BIOCHEMISTRY-US, V36, P12976, DOI 10.1021/bi9715371; Lanzilotta WN, 1996, BIOCHEMISTRY-US, V35, P16770, DOI 10.1021/bi962286j; LINDAHL PA, 1987, J BIOL CHEM, V262, P14945; LINDAHL PA, 1985, J BIOL CHEM, V260, P1160; LJONES T, 1978, BIOCHEMISTRY-US, V17, P1866, DOI 10.1021/bi00603a010; Lowe D. J., 1995, Nitrogen fixation: fundamentals and applications. Proceedings of the 10th International Congress on Nitrogen Fixation, St. Petersburg, Russia, May 28-June 3 1995., P103; LOWE DJ, 1993, BIOCHEM J, V292, P93, DOI 10.1042/bj2920093; LOWERY RG, 1989, BIOCHEMISTRY-US, V28, P1206, DOI 10.1021/bi00429a038; Ma L, 1996, J BIOL CHEM, V271, P10528, DOI 10.1074/jbc.271.18.10528; MORGAN TV, 1990, BIOCHEMISTRY-US, V29, P3077, DOI 10.1021/bi00464a026; MUNCK E, 1975, BIOCHIM BIOPHYS ACTA, V400, P32, DOI 10.1016/0005-2795(75)90124-5; ODONNELL MJ, 1978, BIOCHEM J, V173, P831, DOI 10.1042/bj1730831; ORMEJOHNSON WH, 1972, P NATL ACAD SCI USA, V69, P3142, DOI 10.1073/pnas.69.11.3142; Peters JW, 1997, BIOCHEMISTRY-US, V36, P1181, DOI 10.1021/bi9626665; PIERIK AJ, 1993, EUR J BIOCHEM, V212, P51, DOI 10.1111/j.1432-1033.1993.tb17632.x; Renner KA, 1996, BIOCHEMISTRY-US, V35, P5353, DOI 10.1021/bi960441o; ROBSON RL, 1984, FEBS LETT, V173, P394, DOI 10.1016/0014-5793(84)80812-1; Ryle MJ, 1996, J BIOL CHEM, V271, P1551, DOI 10.1074/jbc.271.3.1551; Schindelin N, 1997, NATURE, V387, P370, DOI 10.1038/387370a0; Seefeldt LC, 1997, ACCOUNTS CHEM RES, V30, P260, DOI 10.1021/ar960260e; SEEFELDT LC, 1994, ANAL BIOCHEM, V221, P379, DOI 10.1006/abio.1994.1429; SEEFELDT LC, 1992, J BIOL CHEM, V267, P6680; SMITH BE, 1974, BIOCHEM J, V137, P169, DOI 10.1042/bj1370169; SMITH BE, 1972, BIOCHEM J, V130, P641, DOI 10.1042/bj1300641; STEPHENS PJ, 1979, P NATL ACAD SCI USA, V76, P2585, DOI 10.1073/pnas.76.6.2585; STOCCHI V, 1985, ANAL BIOCHEM, V146, P118, DOI 10.1016/0003-2697(85)90405-1; SURERUS KK, 1992, J AM CHEM SOC, V114, P8579, DOI 10.1021/ja00048a034; THORNELEY RN, 1974, BIOCHIM BIOPHYS ACTA, V333, P487, DOI 10.1016/0005-2728(74)90133-9; THORNELEY RNF, 1984, BIOCHEM J, V224, P887, DOI 10.1042/bj2240887; Thorneley RNF, 1996, J BIOL INORG CHEM, V1, P576, DOI 10.1007/s007750050095; THORNELEY RNF, 1983, BIOCHEM J, V215, P393, DOI 10.1042/bj2150393; THORNELEY RNF, 1993, ACS SYM SER, V535, P290; THORNELEY RNF, 1991, BIOCHEM J, V277, P735, DOI 10.1042/bj2770735; TITTSWORTH RC, 1993, J AM CHEM SOC, V115, P9763, DOI 10.1021/ja00074a050; WALKER GA, 1974, BIOCHEMISTRY-US, V13, P2382, DOI 10.1021/bi00708a023; WATT GD, 1989, BIOCHEMISTRY-US, V28, P1844, DOI 10.1021/bi00430a062; WATT GD, 1994, J INORG BIOCHEM, V53, P281, DOI 10.1016/0162-0134(94)85115-8; WATT GD, 1986, BIOCHEMISTRY-US, V25, P8156, DOI 10.1021/bi00373a005; WATT GD, 1980, BIOCHEMISTRY-US, V19, P4926, DOI 10.1021/bi00562a035; WATT GD, 1985, BIOCHEMISTRY-US, V24, P7226, DOI 10.1021/bi00346a031; WILLING AH, 1989, J BIOL CHEM, V264, P8499; Yates M. G., 1992, BIOL NITROGEN FIXATI, P685; ZIMMERMANN R, 1978, BIOCHIM BIOPHYS ACTA, V537, P185, DOI 10.1016/0005-2795(78)90504-4; ZUMFT WG, 1973, BIOCHIM BIOPHYS ACTA, V292, P413, DOI 10.1016/0005-2728(73)90047-9	64	68	68	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26330	26337		10.1074/jbc.273.41.26330	http://dx.doi.org/10.1074/jbc.273.41.26330			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756863	hybrid			2022-12-27	WOS:000076373300017
J	Noronkoski, T; Stoineva, IB; Ivanov, IP; Petkov, DD; Mononen, I				Noronkoski, T; Stoineva, IB; Ivanov, IP; Petkov, DD; Mononen, I			Glycosylasparaginase-catalyzed synthesis and hydrolysis of beta-aspartyl peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTYLGLYCOSAMINURIA; MECHANISM; ASPARTYLGLUCOSAMINIDASE; ASSAY	beta-Aspartyl di- and tripeptides are common constituents of mammalian metabolism, but their formation and catabolism are not fully understood. In this study we provide evidence that glycosylasparaginase (aspartylglucosaminidase), an N-terminal nucleophile hydrolase involved in the hydrolysis of the N-glycosidic bond in glycoproteins, catalyzes the hydrolysis of beta-aspartyl peptides to form L-aspartic acid and amino acids or peptides. The enzyme also effectively catalyzes the synthesis of beta-aspartyl peptides by transferring the beta-aspartyl moiety from other beta-aspartyl peptides or beta-aspartylglycosylamine to a variety of amino acids and peptides. Furthermore, the enzyme can use L-asparagine as the beta-aspartyl donor in the formation of beta-aspartyl peptides, The data show that synthesis and degradation of beta-aspartyl peptides are new, significant functions of glycosylasparaginase and suggest that the enzyme could have an important role in the metabolism of beta-aspartyl peptides.	Bulgarian Acad Sci, Inst Organ Chem, Lab Biocatalysis, BG-1113 Sofia, Bulgaria; Kuopio Univ Hosp, Dept Clin Chem, FIN-70211 Kuopio, Finland; Univ Sofia, Fac Biol, Lab Bioorgan Synth, BG-1421 Sofia, Bulgaria	Bulgarian Academy of Sciences; Kuopio University Hospital; University of Sofia	Mononen, I (corresponding author), Bulgarian Acad Sci, Inst Organ Chem, Lab Biocatalysis, BG-1113 Sofia, Bulgaria.	ilkka.mononen@messi.uku.fi						Aronson NN, 1997, LYSOSOMAL STORAGE DI, P55; Arvio M, 1997, LYSOSOMAL STORAGE DI, P19; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; BUCHANAN DL, 1962, BIOCHEMISTRY-US, V1, P612, DOI 10.1021/bi00910a011; COHENANISFELD ST, 1993, J AM CHEM SOC, V115, P10531, DOI 10.1021/ja00076a010; FASTREZ J, 1973, BIOCHEMISTRY-US, V12, P2025, DOI 10.1021/bi00735a001; HANSON RW, 1964, J CHEM SOC, P836, DOI 10.1039/jr9640000836; KAARTINEN V, 1992, J BIOL CHEM, V267, P6855; KAARTINEN V, 1991, J BIOL CHEM, V266, P5860; Kaartinen V, 1996, NAT MED, V2, P1375, DOI 10.1038/nm1296-1375; KAARTINEN V, 1990, ANAL BIOCHEM, V190, P98, DOI 10.1016/0003-2697(90)90140-5; MAKINO M, 1966, BIOCHEM BIOPH RES CO, V24, P961, DOI 10.1016/0006-291X(66)90344-5; MAKINO M, 1968, J BIOCHEM, V63, P186, DOI 10.1093/oxfordjournals.jbchem.a128760; MONONEN I, 1995, FASEB J, V9, P428, DOI 10.1096/fasebj.9.5.7896015; Mononen I, 1996, BIOCHEM BIOPH RES CO, V218, P510, DOI 10.1006/bbrc.1996.0091; MONONEN IT, 1993, ANAL BIOCHEM, V208, P372, DOI 10.1006/abio.1993.1063; Noronkoski T, 1997, FEBS LETT, V412, P149, DOI 10.1016/S0014-5793(97)00761-8; OINONEN C, 1995, NAT STRUCT BIOL, V2, P1102, DOI 10.1038/nsb1295-1102; Perakyla M, 1997, J AM CHEM SOC, V119, P1189, DOI 10.1021/ja9628967; SANDBERG M, 1994, ANAL BIOCHEM, V217, P48, DOI 10.1006/abio.1994.1082; TANAKA T, 1978, J BIOCHEM-TOKYO, V84, P1147, DOI 10.1093/oxfordjournals.jbchem.a132230; TARENTINO AL, 1969, ARCH BIOCHEM BIOPHYS, V130, P295, DOI 10.1016/0003-9861(69)90036-8; TATE SS, 1981, MOL CELL BIOCHEM, V39, P357, DOI 10.1007/BF00232585; Thomas GH, 1995, METABOLIC MOL BASES, P2529	24	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26295	26297		10.1074/jbc.273.41.26295	http://dx.doi.org/10.1074/jbc.273.41.26295			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756857	hybrid			2022-12-27	WOS:000076373300011
J	Simizu, S; Takada, M; Umezawa, K; Imoto, M				Simizu, S; Takada, M; Umezawa, K; Imoto, M			Requirement of caspase-3(-like) protease-mediated hydrogen peroxide production for apoptosis induced by various anticancer drugs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; RESPIRATORY BURST OXIDASE; INDUCED CELL-DEATH; KINASE-C; ICE/CED-3 PROTEASE; CYSTEINE PROTEASE; CARCINOMA CELLS; ACTIVATION; CLEAVAGE; OXYGEN	Caspase-3 (-like) proteases play important roles in controlling mammalian apoptosis. However, the downstream events from the caspase-3(-like) protease activation to death of cells are still unclear. Previously, we reported that hydrogen peroxide (H2O2) was generated by the activation of caspase-3(-like) proteases in the process of tyrosine kinase inhibitor-induced apoptosis in human small cell lung carcinoma Ms-1. cells. In the present study, we examined whether generation of H2O2 is a critical event for the apoptotic pathway downstream of caspase-3(-like) protease activation by various anticancer drugs. Anticancer drugs such as camptothecin, vinblastine, inostamycin, and adriamycin induced activation of caspase-3(-like) proteases and apoptosis. Generation of H2O2 was commonly detected after treatment with each of the four anticancer drugs, and scavenging of H2O2 caused cells to fail to undergo apoptosis. Moreover, anticancer drug-induced H2O2 production was inhibited not only by san inhibitor of caspase-3(-like) proteases but also by diphenyleneiodonium chloride, an inhibitor of flavonoid-containing enzymes such as NADPH oxidase. However, activation of caspase-3(-like) proteases was not inhibited by diphenyleneiodonium chloride. These findings suggest that activation of caspase-3(-like) proteases by various anticancer drugs causes generation of H2O2 presumably through the activation of NADPH oxidase, thereby inducing apoptosis. Therefore, H2O2 may function as a common mediator for apoptosis induced by various anticancer drugs.	Keio Univ, Fac Sci & Technol, Dept Appl Chem, Kohoku Ku, Yokohama, Kanagawa 2238522, Japan; Rinku Gen Med Ctr, Izumisano, Osaka 5988577, Japan	Keio University	Imoto, M (corresponding author), Keio Univ, Fac Sci & Technol, Dept Appl Chem, Kohoku Ku, 3-14-1 Hiyoshi, Yokohama, Kanagawa 2238522, Japan.	imoto@applc.keio.ac.jp		Simizu, Siro/0000-0003-2949-2427				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bladier C, 1997, CELL GROWTH DIFFER, V8, P589; Brenner B, 1996, P NATL ACAD SCI USA, V93, P15376, DOI 10.1073/pnas.93.26.15376; Chen WD, 1997, ONCOGENE, V14, P1243, DOI 10.1038/sj.onc.1201096; COSSARIZZA A, 1995, EXP CELL RES, V220, P232, DOI 10.1006/excr.1995.1311; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; ElBenna J, 1996, J BIOL CHEM, V271, P6374; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; EPSTEIN RJ, 1990, J CLIN ONCOL, V8, P2062, DOI 10.1200/JCO.1990.8.12.2062; Gardner AM, 1997, FREE RADICAL BIO MED, V22, P73, DOI 10.1016/S0891-5849(96)00235-3; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Hannun YA, 1997, BLOOD, V89, P1845, DOI 10.1182/blood.V89.6.1845; HEYWORTH PG, 1990, BIOCHIM BIOPHYS ACTA, V1052, P299, DOI 10.1016/0167-4889(90)90225-3; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; IMOTO M, 1990, J NAT PROD, V53, P825, DOI 10.1021/np50070a008; IMOTO M, 1992, J BIOCHEM-TOKYO, V112, P299, DOI 10.1093/oxfordjournals.jbchem.a123894; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Islam KN, 1997, FREE RADICAL BIO MED, V22, P1007, DOI 10.1016/S0891-5849(96)00493-5; ISRAEL N, 1992, J IMMUNOL, V149, P3386; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JIAN N, 1996, CANCER, V77, P1797; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Lafon C, 1996, CELL GROWTH DIFFER, V7, P1095; Lores P, 1997, ONCOGENE, V15, P601, DOI 10.1038/sj.onc.1201378; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicolau JM, 1996, GEOMORPHOLOGY, V14, P297, DOI 10.1016/0169-555X(95)00043-5; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; ROSEN GM, 1995, FASEB J, V9, P200, DOI 10.1096/fasebj.9.2.7540156; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Scala S, 1996, CANCER RES, V56, P3737; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHNEIDER E, 1988, BIOCHIM BIOPHYS ACTA, V949, P264, DOI 10.1016/0167-4781(88)90151-0; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schulz JB, 1996, J NEUROSCI, V16, P4696; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; Simizu S, 1996, CANCER RES, V56, P4978; Simizu S, 1998, EXP CELL RES, V238, P197, DOI 10.1006/excr.1997.3823; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Tamura K, 1997, JPN J CANCER RES, V88, P218, DOI 10.1111/j.1349-7006.1997.tb00369.x; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; UHLINGER DJ, 1992, BIOCHEM BIOPH RES CO, V187, P940, DOI 10.1016/0006-291X(92)91288-2; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559	55	233	237	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26900	26907		10.1074/jbc.273.41.26900	http://dx.doi.org/10.1074/jbc.273.41.26900			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756937	hybrid			2022-12-27	WOS:000076373300091
J	Berninsone, P; Hirschberg, CB				Berninsone, P; Hirschberg, CB			Heparan sulfate/heparin N-deacetylase/N-sulfotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; SULFATE SULFOTRANSFERASE; EXPRESSION; PROTEIN; GENE; BIOSYNTHESIS; MOUSE	Glycosaminoglycan N-acetylglucosaminyl N-deacetylases/N-sulfotransferases are structurally related enzymes that play an important role in the biosynthesis of heparan sulfate and heparin. They are dual catalytic, single membrane-spanning polypeptides of approximately 850-880 amino acids that catalyze the N-deacetylation of N-acetylglucosamine of glycosaminoglycans followed by N-sulfation of the same sugar. On the basis of homologies of these proteins with other N-acetylglucosaminyl N-deacetylases involved in the biosynthesis of chitin and putative deacetylases from bacteria, we have constructed two soluble chimeras between protein A and the amino- and carboxyl-terminal halves of the above mastocytoma holoenzyme. The carboxyl-terminal chimera half (amino acids 479-880) was able to catalyze the N-sulfation of glucosamine of heparan sulfate with a similar affinity for its two substrates, adenosine 3'-phosphate 5'-phosphosulfate and heparan sulfate, as the holoenzyme. However, the reaction only occurred at 30 degrees C and not at 37 degrees C, both temperatures at which the holoenzyme was active. The V-max of the chimera was 10-20-fold slower than that of the holoenzyme. Soluble chimeras between protein A and amino acids 43-521 and 43-680 of the holoenzyme were unable to catalyze the N-deacetylation of the bacterial N-acetylglucosaminyl-glucuronic acid polymer K5 under conditions where the holoenzyme was active. The recent appearance in genome data banks of homologs to the N-sulfotransferase domain and now the direct demonstration that this domain catalyzes this reaction raises the possibility that both N-deacetylation and N-sulfation activities of the holoenzyme might have emerged as gene fusions during evolution.	Boston Univ, Goldman Sch Dent Med, Dept Mol & Cell Biol, Boston, MA 02118 USA	Boston University	Hirschberg, CB (corresponding author), Boston Univ, Goldman Sch Dent Med, Dept Mol & Cell Biol, 700 Albany St, Boston, MA 02118 USA.			Hirschberg, Carlos/0000-0003-2299-7721	NIGMS NIH HHS [GM34396] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAME KJ, 1991, J BIOL CHEM, V266, P12461; BRANDAN E, 1988, J BIOL CHEM, V263, P2417; Christodoulidou A, 1996, J BIOL CHEM, V271, P31420, DOI 10.1074/jbc.271.49.31420; Cumberledge S, 1997, TRENDS GENET, V13, P421, DOI 10.1016/S0168-9525(97)01275-4; deSouza SJ, 1996, GENES CELLS, V1, P493, DOI 10.1046/j.1365-2443.1996.d01-264.x; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; Gladwin AJ, 1996, GENOMICS, V32, P471, DOI 10.1006/geno.1996.0145; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; JOHN M, 1993, P NATL ACAD SCI USA, V90, P625, DOI 10.1073/pnas.90.2.625; KAFETZOPOULOS D, 1993, P NATL ACAD SCI USA, V90, P8005, DOI 10.1073/pnas.90.17.8005; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; LINDAHL U, 1986, TRENDS BIOCHEM SCI, V11, P221, DOI 10.1016/0968-0004(86)90011-3; MANDON E, 1994, J BIOL CHEM, V269, P11729; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; POWERS PA, 1991, GENETICS, V129, P133; ROSENTHAL E, 1995, GENE, V165, P243, DOI 10.1016/0378-1119(95)00450-K; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; WEI Z, 1993, P NATL ACAD SCI USA, V90, P3885, DOI 10.1073/pnas.90.9.3885; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	20	22	23	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25556	25559		10.1074/jbc.273.40.25556	http://dx.doi.org/10.1074/jbc.273.40.25556			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748218	hybrid, Green Submitted			2022-12-27	WOS:000076263100009
J	Chae, YK; Abildgaard, F; Chapmann, ER; Markley, JL				Chae, YK; Abildgaard, F; Chapmann, ER; Markley, JL			Lipid binding ridge on loops 2 and 3 of the C(2)A domain of synaptotagmin I as revealed by NMR spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHOLIPID-BINDING; BACKBONE ASSIGNMENT; CALCIUM-DEPENDENCE; C-2 DOMAIN; SENSITIVITY; DROSOPHILA; EXOCYTOSIS; C-2-DOMAIN; RELEASE	The C(2)A domain of synaptotagmin I, which binds Ca2+ and anionic phospholipids, serves as a Ca2+ sensor during excitation-secretion coupling. We have used multidimensional NMR to locate the region of C(2)A from rat synaptotagmin I that interacts, in the presence of Ca2+, with phosphatidylserine. Untagged, recombinant C(2)A was double-labeled with C-13 and N-15, and triple-resonance NMR data were collected from C(2)A samples containing either Ca2+ alone or Ca2+ plus 6:0 phosphatidylserine. Phospholipid binding led to changes in chemical shifts of backbone atoms in residues Arg(233) and Phe(234) of loop 3 (a loop that also binds Ca2+) and His(198), Val(205), and Phe(206) of loop 2. These residues lie along a straight line on a surface ridge of the C(2)A domain. The only other residue that exhibited appreciable chemical shift changes upon adding lipid was His(254); however, because His(254) is located on the other side of the molecule from the phospholipid docking site defined by the other residues, its shifts may result from nonspecific interactions. The results show that the "docking ridge" responsible for Ca2+-dependent membrane association is localized on the opposite side of the C(2)A domain from the transmembrane and C2B domains of synaptotagmin.	Univ Wisconsin, Dept Biochem, Natl Magnet Resonance Facil, Madison, WI 53706 USA; Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Markley, JL (corresponding author), Univ Wisconsin, Dept Biochem, Natl Magnet Resonance Facil, 433 Babcock Dr, Madison, WI 53706 USA.			Chapman, Edwin/0000-0001-9787-8140	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR002781, P41RR002301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035976, R01GM035976] Funding Source: NIH RePORTER; NCRR NIH HHS [RR02301, RR02781] Funding Source: Medline; NIGMS NIH HHS [GM35976] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Babity JM, 1997, P NATL ACAD SCI USA, V94, P2638, DOI 10.1073/pnas.94.6.2638; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; Chapman ER, 1996, J BIOL CHEM, V271, P5844, DOI 10.1074/jbc.271.10.5844; Chapman ER, 1998, J BIOL CHEM, V273, P13995, DOI 10.1074/jbc.273.22.13995; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DIANTONIO A, 1994, NEURON, V12, P909, DOI 10.1016/0896-6273(94)90342-5; Essen LO, 1997, BIOCHEMISTRY-US, V36, P2753, DOI 10.1021/bi962466t; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; Katz B., 1969, SHERRINGTON LECT; Kojima T, 1996, J BIOCHEM-TOKYO, V120, P671; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LITTLETON JT, 1994, P NATL ACAD SCI USA, V91, P10888, DOI 10.1073/pnas.91.23.10888; Littleton JT, 1998, NEURON, V21, P401, DOI 10.1016/S0896-6273(00)80549-8; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; Markley JL, 1998, PURE APPL CHEM, V70, P117, DOI 10.1351/pac199870010117; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; Mennerick S, 1996, NEURON, V17, P1241, DOI 10.1016/S0896-6273(00)80254-8; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Nalefski EA, 1997, BIOCHEMISTRY-US, V36, P12011, DOI 10.1021/bi9717340; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHELLER RH, 1995, NEURON, V14, P893; Shao XG, 1997, NEURON, V18, P133, DOI 10.1016/S0896-6273(01)80052-0; Shao XG, 1997, J BIOMOL NMR, V10, P307, DOI 10.1023/A:1018349601965; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Uellner R, 1997, EMBO J, V16, P7287, DOI 10.1093/emboj/16.24.7287; vonPoser C, 1997, J BIOL CHEM, V272, P14314, DOI 10.1074/jbc.272.22.14314; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; YAMAGUCHI T, 1993, J BIOL CHEM, V268, P27164; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P6464, DOI 10.1021/ja00093a069	44	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25659	25663		10.1074/jbc.273.40.25659	http://dx.doi.org/10.1074/jbc.273.40.25659			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748232	hybrid			2022-12-27	WOS:000076263100023
J	Raussens, V; Fisher, CA; Goormaghtigh, E; Ryan, RO; Ruysschaert, JM				Raussens, V; Fisher, CA; Goormaghtigh, E; Ryan, RO; Ruysschaert, JM			The low density lipoprotein receptor active conformation of apolipoprotein E - Helix organization in N-terminal domain-phospholipid disc particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORM INFRARED-SPECTROSCOPY; ONSET ALZHEIMER-DISEASE; AMYLOID-BETA-PEPTIDE; SECONDARY STRUCTURE; APOLIPOPHORIN-III; AQUEOUS-SOLUTION; BINDING DOMAIN; HYPERCHOLESTEROLEMIA; DIMYRISTOYLPHOSPHATIDYLCHOLINE; RECOMBINATION	Lipid association is a prerequisite for receptor interactions of apolipoprotein E (apoE), Disc complexes of the N-terminal 22-kDa apoE3 receptor binding domain and dimyristoylphosphatidylcholine display full receptor binding activity. Studies have been performed to characterize conformational adaptations of the globular, lipid-free four-helix bundle structure that culminate in stable association of its amphipathic alpha-helices with a lipid surface. Helix-lipid interactions in bilayer disc complexes can conceivably adopt two orientations: parallel or perpendicular to the phospholipid acyl chains. Evidence based on infrared dichroism, geometrical arguments, and x-ray crystallography support the view that defined helical segments in the four-helix bundle realign upon lipid association, orienting perpendicular to the phospholipid fatty acyl chains, circumscribing the bilayer disc. Thus, it is likely that paired helical segments align in tandem, presenting a convex receptor-active surface.	Univ Alberta, Dept Biochem, Lipid & Lipoprot Res Grp, Edmonton, AB T6G 2S2, Canada; Free Univ Brussels, Chim Phys Macromol Interfaces Lab, B-1050 Brussels, Belgium	University of Alberta; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Raussens, V (corresponding author), Univ Alberta, Dept Biochem, Lipid & Lipoprot Res Grp, Edmonton, AB T6G 2S2, Canada.			Goormaghtigh, Erik/0000-0002-2071-2262				AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002; DEPAUW M, 1995, BIOCHEMISTRY-US, V34, P10953, DOI 10.1021/bi00034a030; DERGUNOV AD, 1994, BIOL CHEM H-S, V375, P485; Dong LM, 1996, NAT STRUCT BIOL, V3, P718, DOI 10.1038/nsb0896-718; Fass D, 1997, NATURE, V388, P691, DOI 10.1038/41798; Fisher CA, 1997, BIOCHEM CELL BIOL, V75, P45, DOI 10.1139/bcb-75-1-45; FRINGELI UP, 1981, MEMBRANE SPECTROSCOP, P270; Goormaghtigh E, 1996, APPL SPECTROSC, V50, P1519, DOI 10.1366/0003702963904610; Goormaghtigh E, 1994, Subcell Biochem, V23, P405; GOORMAGHTIGH E, 1990, EUR J BIOCHEM, V193, P409, DOI 10.1111/j.1432-1033.1990.tb19354.x; Goormaghtigh E, 1994, Subcell Biochem, V23, P329; GOORMAGHTIGH E, 1990, MOL DESCRIPTION BIOL, V1, P285; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; INNERARITY TL, 1979, J BIOL CHEM, V254, P4186; JONAS A, 1986, METHOD ENZYMOL, V128, P553; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; NELSON CA, 1974, ANAL BIOCHEM, V59, P69, DOI 10.1016/0003-2697(74)90010-4; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RAUSSENS V, 1995, J BIOL CHEM, V270, P12542, DOI 10.1074/jbc.270.21.12542; Rogers DP, 1997, BIOCHEMISTRY-US, V36, P288, DOI 10.1021/bi961876e; RYAN RO, 1990, J LIPID RES, V31, P871; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; Wang JJ, 1997, J BIOL CHEM, V272, P17912, DOI 10.1074/jbc.272.29.17912; Weisgraber KH, 1996, FASEB J, V10, P1485, DOI 10.1096/fasebj.10.13.8940294; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WIENTZEK M, 1994, J BIOL CHEM, V269, P4605; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	33	85	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25825	25830		10.1074/jbc.273.40.25825	http://dx.doi.org/10.1074/jbc.273.40.25825			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748256	hybrid			2022-12-27	WOS:000076263100047
J	Gasparini, S; Danse, JM; Lecoq, A; Pinkasfeld, S; Zinn-Justin, S; Young, LC; de Medeiros, CCL; Rowan, EG; Harvey, AL; Menez, A				Gasparini, S; Danse, JM; Lecoq, A; Pinkasfeld, S; Zinn-Justin, S; Young, LC; de Medeiros, CCL; Rowan, EG; Harvey, AL; Menez, A			Delineation of the functional site of alpha-dendrotoxin - The functional topographies of dendrotoxins are different but share a conserved core with those of other Kv1 potassium channel-blocking toxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; DENDROASPIS-POLYLEPIS-POLYLEPIS; GATED K+ CHANNEL; ALANINE-SCANNING MUTAGENESIS; RESONANCE SOLUTION STRUCTURE; AMINO-ACID-SEQUENCES; BLACK MAMBA VENOM; SCORPION TOXINS; HIGH-AFFINITY; SEA-ANEMONE	We identified the residues that are important for the binding of alpha-dendrotoxin (alpha DTX) to Kv1 potassium channels on rat brain synaptosomal membranes, using a mutational approach based on site-directed mutagenesis and chemical synthesis. Twenty-six of its 59 residues were individually substituted by alanine. Substitutions of Lys(5) and Leu(9) decreased affinity more than 1000-fold, and substitutions of Arg(3), Arg(4), Leu(6), and Ile(8) by 5-30-fold. Substitution of Lys(5) by norleucine or ornithine also greatly altered the binding properties of alpha DTX. All of these analogs displayed similar circular dichroism spectra as compared with the wild-type alpha DTX, indicating that none of these substitutions affect the overall conformation of the toxin. Substitutions of Ser(38) and Arg(46) also reduced the affinity of the toxin but, in addition, modified its dichroic properties, suggesting that these two residues play a structural role. The other residues were excluded from the recognition site because their substitutions caused no significant affinity change. Thus, the functional site of alpha DTX includes six major binding residues, all located in its N-terminal region, with Lys5 and Leu(9) being the most important. Comparison of the functional site of alpha DTX with that of DTX-K, another dendrotoxin (Smith, L. A., Reid, P. F., Wang, F. C., Parcej, D. N., Schmidt, J. J., Olson, M. A, and Dolly, J. O. (1997) Biochemistry 36, 7690-7696), reveals that they only share the predominant lysine and probably a leucine residue; the additional functional residues differ from one toxin to the other. Comparison of the functional site of alpha DTX with those of structurally unrelated potassium channel-blocking toxins from venomous invertebrates revealed the common presence of a protruding key lysine with a close important hydrophobic residue (Leu, Tyr, or Phe) and few additional residues. Therefore, irrespective of their phylogenetic origin, all of these toxins may have undergone a functional convergence. The functional site of alpha DTX is topographically unrelated to the "antiprotease site" of the structurally analogous bovine pancreatic trypsin inhibitor.	CEA Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France; Univ Strathclyde, Strathclyde Inst Drug Res, Dept Physiol & Pharmacol, Glasgow G1 1XW, Lanark, Scotland	CEA; UDICE-French Research Universities; Universite Paris Saclay; University of Strathclyde	Menez, A (corresponding author), CEA Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France.		Aguglia, Umberto/AAB-9898-2019	Aguglia, Umberto/0000-0002-4574-2951; Rowan, Edward/0000-0002-9960-3308	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AIYAR J, 1995, NEURON, V15, P1169, DOI 10.1016/0896-6273(95)90104-3; Aiyar J, 1996, J BIOL CHEM, V271, P31013, DOI 10.1074/jbc.271.49.31013; Babbitt PC, 1997, J BIOL CHEM, V272, P30591, DOI 10.1074/jbc.272.49.30591; BERNDT KD, 1992, J MOL BIOL, V227, P757, DOI 10.1016/0022-2836(92)90222-6; BERNDT KD, 1993, J MOL BIOL, V234, P735, DOI 10.1006/jmbi.1993.1623; BLACK AR, 1986, BIOCHEM J, V237, P397, DOI 10.1042/bj2370397; BONTEMS F, 1991, SCIENCE, V254, P1521, DOI 10.1126/science.1720574; BYRNES ME, 1995, PROTEIN PEPTIDE LETT, V1, P239; CASTANEDA O, 1995, TOXICON, V33, P603, DOI 10.1016/0041-0101(95)00013-C; CHANG KJ, 1975, BIOCHIM BIOPHYS ACTA, V406, P294, DOI 10.1016/0005-2736(75)90011-5; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DANSE JM, 1994, FEBS LETT, V356, P153, DOI 10.1016/0014-5793(94)01235-0; Dauplais M, 1997, J BIOL CHEM, V272, P4302, DOI 10.1074/jbc.272.7.4302; Dolly JO, 1996, J BIOENERG BIOMEMBR, V28, P231, DOI 10.1007/BF02110698; Drakopoulou E, 1996, J BIOL CHEM, V271, P11979, DOI 10.1074/jbc.271.20.11979; ENDO T, 1991, SNAKE TOXINS, P259; GOLDSTEIN SAN, 1993, BIOPHYS J, V65, P1613, DOI 10.1016/S0006-3495(93)81200-1; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; GROSS A, 1994, NEURON, V13, P961, DOI 10.1016/0896-6273(94)90261-5; HALL A, 1994, BRIT J PHARMACOL, V113, P659; Harvey A.L., 1991, P131; HARVEY AL, 1989, BIOCHEM BIOPH RES CO, V163, P394, DOI 10.1016/0006-291X(89)92148-7; HARVEY AL, 1980, N-S ARCH PHARMACOL, V312, P1, DOI 10.1007/BF00502565; Harvey AL, 1997, GEN PHARMACOL-VASC S, V28, P7, DOI 10.1016/S0306-3623(96)00173-5; HARVEY AL, 1993, MED RES REV, V13, P81, DOI 10.1002/med.2610130104; Harvey AL, 1997, TOXICON, V35, P1263, DOI 10.1016/S0041-0101(97)00016-0; HOKAMA Y, 1976, J BIOCHEM, V79, P559, DOI 10.1093/oxfordjournals.jbchem.a131100; HOUSSET D, 1991, J MOL BIOL, V220, P757, DOI 10.1016/0022-2836(91)90115-M; HUBER R, 1974, J MOL BIOL, V89, P73, DOI 10.1016/0022-2836(74)90163-6; HURST RS, 1991, MOL PHARMACOL, V40, P572; JANIN J, 1995, BIOCHIMIE, V77, P497, DOI 10.1016/0300-9084(96)88166-1; JOUBERT FJ, 1980, H-S Z PHYSIOL CHEM, V361, P661, DOI 10.1515/bchm2.1980.361.1.661; JOUBERT FJ, 1978, EUR J BIOCHEM, V87, P191, DOI 10.1111/j.1432-1033.1978.tb12366.x; KASSELL B, 1965, BIOCHEM BIOPH RES CO, V18, P255, DOI 10.1016/0006-291X(65)90749-7; Kim M, 1997, J NEUROSCI, V17, P8213; KWONG PD, 1995, STRUCTURE, V3, P1109, DOI 10.1016/S0969-2126(01)00246-5; LANCELIN JM, 1994, NAT STRUCT BIOL, V1, P246, DOI 10.1038/nsb0494-246; LAZARENO S, 1982, BRIT J PHARMACOL, V77, pP571; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; MENEZ A, 1990, BIOCHIMIE, V72, P575, DOI 10.1016/0300-9084(90)90121-V; MENEZ A, 1992, P ROY SOC EDINB B, V99, P83, DOI 10.1017/S0269727000013075; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; Naini AA, 1996, BIOCHEMISTRY-US, V35, P6181, DOI 10.1021/bi960067s; Naranjo D, 1996, NEURON, V16, P123, DOI 10.1016/S0896-6273(00)80029-X; Ohno M, 1998, PROG NUCLEIC ACID RE, V59, P307; Owen DG, 1997, BRIT J PHARMACOL, V120, P1029, DOI 10.1038/sj.bjp.0701004; Pennington MW, 1996, BIOCHEMISTRY-US, V35, P16407, DOI 10.1021/bi962463g; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; RITONJA A, 1983, BIOCHIM BIOPHYS ACTA, V746, P138, DOI 10.1016/0167-4838(83)90067-5; Robertson B, 1996, FEBS LETT, V383, P26, DOI 10.1016/0014-5793(96)00211-6; Savarin P, 1998, BIOCHEMISTRY-US, V37, P5407, DOI 10.1021/bi9730341; Scanlon MJ, 1997, STRUCTURE, V5, P1585, DOI 10.1016/S0969-2126(97)00307-9; SCHWEITZ H, 1994, P NATL ACAD SCI USA, V91, P878, DOI 10.1073/pnas.91.3.878; SCHWEITZ H, 1995, J BIOL CHEM, V270, P25121, DOI 10.1074/jbc.270.42.25121; SCOTT VES, 1994, BIOCHEMISTRY-US, V33, P1617, DOI 10.1021/bi00173a001; Servent D, 1997, J BIOL CHEM, V272, P24279, DOI 10.1074/jbc.272.39.24279; Shamotienko OG, 1997, BIOCHEMISTRY-US, V36, P8195, DOI 10.1021/bi970237g; Shon KJ, 1998, J BIOL CHEM, V273, P33, DOI 10.1074/jbc.273.1.33; SKARZYNSKI T, 1992, J MOL BIOL, V224, P671, DOI 10.1016/0022-2836(92)90552-U; Smith LA, 1997, BIOCHEMISTRY-US, V36, P7690, DOI 10.1021/bi963105g; STOCKER M, 1991, P ROY SOC B-BIOL SCI, V245, P101, DOI 10.1098/rspb.1991.0094; STRYDOM DJ, 1981, H-S Z PHYSIOL CHEM, V362, P1377, DOI 10.1515/bchm2.1981.362.2.1377; STRYDOM DJ, 1977, BIOCHIM BIOPHYS ACTA, V491, P361, DOI 10.1016/0005-2795(77)90279-3; SWILLENS S, 1995, MOL PHARMACOL, V47, P1197; Terlau H, 1996, NATURE, V381, P148, DOI 10.1038/381148a0; TUCHSEN E, 1987, BIOCHEMISTRY-US, V26, P1918, DOI 10.1021/bi00381a020; Tudor JE, 1996, NAT STRUCT BIOL, V3, P317, DOI 10.1038/nsb0496-317; TYTGAT J, 1995, J BIOL CHEM, V270, P24776, DOI 10.1074/jbc.270.42.24776; VITA C, 1995, P NATL ACAD SCI USA, V92, P6404, DOI 10.1073/pnas.92.14.6404; YU MH, 1995, J MOL BIOL, V249, P388, DOI 10.1006/jmbi.1995.0304	71	69	71	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25393	25403		10.1074/jbc.273.39.25393	http://dx.doi.org/10.1074/jbc.273.39.25393			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738007	hybrid			2022-12-27	WOS:000076085400057
J	Mathes, C; Fleig, A; Penner, R				Mathes, C; Fleig, A; Penner, R			Calcium release-activated calcium current (I-CRAC) is a direct target for sphingosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; PROTEIN-KINASE-C; CA-2+-ACTIVATED K+ CHANNEL; INTRACELLULAR CA2+ STORES; PAROTID ACINAR-CELLS; SMOOTH-MUSCLE CELLS; MAST-CELLS; FATTY-ACIDS; CELLULAR PROLIFERATION; INOSITOL TRISPHOSPHATE	Whole cell patch-clamp recordings were made to study the regulation of the store-operated calcium release-activated calcium current (I-CRAC) by metabolites involved in the sphingomyelin pathway in RBL-2H3 cells. Sphingosine, a regulator of cell growth, inhibits I-CRAC completely within 200 s and independently from conversion to either sphingosine 1-phosphate or ceramide, Structural analogs of sphingosine, including N,N-dimethylsphingosine, DL-threo-dihydrosphingosine, and N-acetylsphingosine (C-2-ceramide) also block I-CRAC. This effect is always accompanied by an elevation of whole cell membrane capacitance. These sphingolipids appear, therefore, to accumulate in the plasma membrane and directly block I,, channels, Sphingosylphosphorylcholine also increases capacitance but does not inhibit I-CRAC, demonstrating structural specificity and that the elevation of capacitance is necessary but not sufficient for block. Nerve growth factor, which is known to break down sphingomyelin, inhibits I-CRAC and this inhibition can be antagonized by reducing sphingosine production with L-cycloserine, suggesting that I-CRAC is a physiologically relevant and direct target of sphingosine. We propose that sphingosine directly blocks I-CRAC suggesting that the sphingomyelin pathway is involved in I-CRAC regulation.	Max Planck Inst Biophys Chem, Dept Membrane Biophys, D-37077 Gottingen, Germany	Max Planck Society	Penner, R (corresponding author), Univ Hawaii, Biomed Sci Bldg A-201,1960 East West Rd, Honolulu, HI 96822 USA.	rpenner@hawaii.edu		Fleig, Andrea/0000-0001-8396-7249; Penner, Reinhold/0000-0002-5366-1537				BREITTMAYER JP, 1994, J BIOL CHEM, V269, P5054; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; CHAO CP, 1994, J BIOL CHEM, V269, P5849; CHOI OH, 1993, J IMMUNOL, V151, P5586; Choi OH, 1996, NATURE, V380, P634; CONKLIN BR, 1988, P NATL ACAD SCI USA, V85, P8698, DOI 10.1073/pnas.85.22.8698; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; DOBROWSKY RT, 1995, J BIOL CHEM, V270, P22135, DOI 10.1074/jbc.270.38.22135; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; Fatatis A, 1996, J BIOL CHEM, V271, P295, DOI 10.1074/jbc.271.1.295; FELDER CC, 1993, P NATL ACAD SCI USA, V90, P1706, DOI 10.1073/pnas.90.5.1706; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P577, DOI 10.1113/jphysiol.1982.sp014393; FLEIG A, 1995, J PHYSIOL-LONDON, V489, P41, DOI 10.1113/jphysiol.1995.sp021028; GOMEZMUNOZ A, 1995, MOL PHARMACOL, V47, P883; GRABBE J, 1994, ARCH DERMATOL RES, V287, P78, DOI 10.1007/BF00370723; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HORIGOME K, 1993, J BIOL CHEM, V268, P14881; HORIGOME K, 1994, J BIOL CHEM, V269, P2695; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HOTH M, 1993, ANN NY ACAD SCI, V70, P198; HUANG JMC, 1992, P NATL ACAD SCI USA, V89, P6452, DOI 10.1073/pnas.89.14.6452; HUDSON PL, 1994, J BIOL CHEM, V269, P21885; JACOBS LS, 1993, AM J PHYSIOL, V265, pC740, DOI 10.1152/ajpcell.1993.265.3.C740; JONES MJ, 1995, J BIOL CHEM, V270, P5007, DOI 10.1074/jbc.270.10.5007; JONES SVP, 1991, FEBS LETT, V289, P47, DOI 10.1016/0014-5793(91)80905-I; Lee TC, 1996, J BIOL CHEM, V271, P209, DOI 10.1074/jbc.271.1.209; LeviMontalcini R, 1996, TRENDS NEUROSCI, V19, P514, DOI 10.1016/S0166-2236(96)10058-8; MACKINNON R, 1989, BIOCHEMISTRY-US, V28, P8092, DOI 10.1021/bi00446a020; MERRILL AH, 1993, ADV LIPID RES, V25, P1; MOCZYDLOWSKI E, 1985, J MEMBRANE BIOL, V83, P273, DOI 10.1007/BF01868701; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; Oral H, 1997, J BIOL CHEM, V272, P4836, DOI 10.1074/jbc.272.8.4836; ORDWAY RW, 1991, TRENDS NEUROSCI, V14, P96, DOI 10.1016/0166-2236(91)90069-7; Orlati S, 1996, CELL CALCIUM, V20, P399, DOI 10.1016/S0143-4160(96)90002-0; PANDOL SJ, 1994, BBA-BIOMEMBRANES, V1195, P45, DOI 10.1016/0005-2736(94)90007-8; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PETROU S, 1994, J GEN PHYSIOL, V103, P471, DOI 10.1085/jgp.103.3.471; PITTET D, 1987, J BIOL CHEM, V262, P10072; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; Sakano S, 1996, J BIOL CHEM, V271, P11148, DOI 10.1074/jbc.271.19.11148; SCHMITT H, 1995, J MEMBRANE BIOL, V145, P233; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; Spiegel S, 1996, CHEM PHYS LIPIDS, V80, P27, DOI 10.1016/0009-3084(96)02543-1; SPIEGEL S, 1993, ADV LIPID RES, V25, P105; SUGIYA H, 1991, FEBS LETT, V286, P113, DOI 10.1016/0014-5793(91)80953-Z; SUGIYA H, 1990, CELL CALCIUM, V11, P469, DOI 10.1016/0143-4160(90)90079-A; WALDRON RT, 1994, J BIOL CHEM, V269, P11927; WANG E, 1991, J BIOL CHEM, V266, P14486; Wonderlin WF, 1996, J MEMBRANE BIOL, V154, P91, DOI 10.1007/s002329900135; WONG K, 1995, J BIOL CHEM, V270, P3056, DOI 10.1074/jbc.270.7.3056; Yatomi Y, 1996, BIOCHEMISTRY-US, V35, P626, DOI 10.1021/bi9515533; ZWEIFACH A, 1995, J BIOL CHEM, V270, P14445, DOI 10.1074/jbc.270.24.14445; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	56	102	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25020	25030		10.1074/jbc.273.39.25020	http://dx.doi.org/10.1074/jbc.273.39.25020			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737958	hybrid			2022-12-27	WOS:000076085400008
J	Gu, XJ; Trigatti, B; Xu, SZ; Acton, S; Babitt, J; Krieger, M				Gu, XJ; Trigatti, B; Xu, SZ; Acton, S; Babitt, J; Krieger, M			The efficient cellular uptake of high density lipoprotein lipids via scavenger receptor class B type I requires not only receptor-mediated surface binding but also receptor-specific lipid transfer mediated by its extracellular domain (vol 273, pg 26343, 1998)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Correction													Eckhardt, Erik/G-1567-2010; Krieger, Marco/AAE-8611-2020	Trigatti, Bernardo (Dino) L./0000-0002-4556-119X	NHLBI NIH HHS [HL52212, HL41484] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338	1	198	204	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					35388	35388		10.1074/jbc.273.41.26338	http://dx.doi.org/10.1074/jbc.273.41.26338			1	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9756864	hybrid			2022-12-27	WOS:000077719700100
J	Penado, KMY; Rudnick, G; Stephan, MM				Penado, KMY; Rudnick, G; Stephan, MM			Critical amino acid residues in transmembrane span 7 of the serotonin transporter identified by random mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPAMINE-NOREPINEPHRINE TRANSPORTERS; CATION-PI INTERACTIONS; CYTOCHROME-C-OXIDASE; MEGAPRIMER METHOD; STRUCTURAL DOMAINS; COCAINE BINDING; 2.8 ANGSTROM; SUBSTRATE; ANTIDEPRESSANTS; TRANSLOCATION	Transmembrane span 7 of the rat brain serotonin transporter was subjected to random mutagenesis, Of the 27 amino acid residues mutated, six were identified as functionally important by their sensitivity to nonconservative mutations. These residues were Asn-368 and Tyr-385, where substitutions that retained hydrogen-bonding ability were preferred; Gly-376 and Gly-384, where only glycine was accepted; Phe-380, where a phenyl ring was preferred; and Met-386, where hydrophobic substitutions were preferred. Mutations that did not preserve these structural characteristics were highly detrimental to serotonin transport activity. These six residues form a stripe that runs at an angle down the side of the putative cy-helix, lending support to this structural prediction. Mutations at some of these positions also specifically impaired transport activity under low Na+ conditions. Other mutations at nearby positions in transmembrane span 7 also impaired activity in low Na+, although the activity of the mutants in high Na+ was similar to wild type. These results suggest that at least some of the six critical residues play a role in Na+ binding or perhaps in the coupling of Na+ binding to later steps in the transport cycle. These residues may be important in other aspects of the transporter's function as well.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA	Yale University	Stephan, MM (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06510 USA.				NIDA NIH HHS [DA00224] Funding Source: Medline	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AIYAR A, 1993, BIOTECHNIQUES, V14, P366; BARIK S, 1991, BIOTECHNIQUES, V10, P489; Barker EL, 1996, MOL PHARMACOL, V50, P957; BARKER EL, 1994, MOL PHARMACOL, V46, P99; Bismuth Y, 1997, J BIOL CHEM, V272, P16096, DOI 10.1074/jbc.272.26.16096; BLAKELY RD, 1994, J EXP BIOL, V196, P263; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; Buck KJ, 1995, MOL PHARMACOL, V48, P1030; BUCK KJ, 1994, P NATL ACAD SCI USA, V91, P12584, DOI 10.1073/pnas.91.26.12584; Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; DEISENHOFER J, 1989, SCIENCE, V245, P1463, DOI 10.1126/science.245.4925.1463; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; FULLER RW, 1991, J CLIN PSYCHIAT, V52, P52; GIROS B, 1994, J BIOL CHEM, V269, P15985; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; KANNER BI, 1994, J EXP BIOL, V196, P237; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; KLEINBERGERDORON N, 1994, J BIOL CHEM, V269, P3063; KUHAR MJ, 1991, TRENDS NEUROSCI, V14, P299, DOI 10.1016/0166-2236(91)90141-G; Mager S, 1996, J NEUROSCI, V16, P5405; Mecozzi S, 1996, P NATL ACAD SCI USA, V93, P10566, DOI 10.1073/pnas.93.20.10566; Norregaard L, 1998, EMBO J, V17, P4266, DOI 10.1093/emboj/17.15.4266; Owens M J, 1996, Depress Anxiety, V4, P153, DOI 10.1002/(SICI)1520-6394(1996)4:4<153::AID-DA1>3.0.CO;2-G; PebayPeyroula E, 1997, SCIENCE, V277, P1676, DOI 10.1126/science.277.5332.1676; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Stephan MM, 1997, BIOCHEMISTRY-US, V36, P1322, DOI 10.1021/bi962150l; STRADER CD, 1989, AM J RESP CELL MOL, V1, P81, DOI 10.1165/ajrcmb/1.2.81; SUSSMAN JL, 1993, CHEM-BIOL INTERACT, V87, P187, DOI 10.1016/0009-2797(93)90042-W; TALVENHEIMO J, 1983, J BIOL CHEM, V258, P6115; TATE CG, 1994, J BIOL CHEM, V269, P26303; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; UHL GR, 1992, TRENDS NEUROSCI, V15, P265, DOI 10.1016/0166-2236(92)90068-J; WOOLVERTON WL, 1992, TRENDS PHARMACOL SCI, V13, P193, DOI 10.1016/0165-6147(92)90063-C	36	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28098	28106		10.1074/jbc.273.43.28098	http://dx.doi.org/10.1074/jbc.273.43.28098			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774428	hybrid			2022-12-27	WOS:000076549800048
J	Hime, NJ; Barter, PJ; Rye, KA				Hime, NJ; Barter, PJ; Rye, KA			The influence of apolipoproteins on the hepatic lipase-mediated hydrolysis of high density lipoprotein phospholipid and triacylglycerol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTER TRANSFER PROTEIN; A-II; APOA-II; ENZYMIC ACTIVITY; HUMAN-PLASMA; ACTIVATION; SIZE; PHOSPHATIDYLCHOLINE; TRIGLYCERIDE; CHOLESTEROL	This study describes the influence of apolipoproteins on the hepatic lipase (HL)-mediated hydrolysis of phospholipids and triacylglycerol in high density lipoproteins (HDL), HL-mediated hydrolysis was assessed in well characterized, homogeneous preparations of spherical reconstituted high density lipoproteins (rHDL), The rHDL were comparable in size and lipid composition and contained either apoA-I ((A-I)rHDL) or apoA-II ((AII)rHDL) as their sole apolipoprotein constituent. Preparations of rHDL containing only cholesteryl esters (CE) in their core, (A-I/CE)rHDL and (A-II/CE)rHDL, were used to assess phospholipid hydrolysis, Preparations of rHDL that contained triacylglycerol as their predominant core lipid, (A-I/TG)rHDL and (A-II/TG)rHDL, were used to assess both triacylglycerol and phospholipid hydrolysis, The rHDL contained trace amounts of either radiolabeled phospholipid or radiolabeled triacylglycerol, Hydrolysis was measured as the release of radiolabeled nonesterified fatty acids (NEFA) from the rHDL, Kinetic analysis showed that HL had a greater affinity for the phospholipids in (A-II/CE)rHDL (K-m(app) = 0.2 mM) than in (A-I/CE)rHDL (K-m(app) = 3.1 mM). This was also evident when hydrolysis was measured directly by quantitating NEFA mass. HL also had a greater affinity for the phospholipids and triacylglycerol in (A-II/TG)rHDL than in (A-I/TG)rHDL. The V-max for phospholipid hydrolysis was, by contrast, greater for (A-I/CE)rHDL than for (A-II/CE)rHDL: 309.3 versus 49.1 nmol of NEFA formed/ml of HL/h. Comparable V-max values were obtained for the hydrolysis of the phospholipids in (A-II/TG)rHDL and (A-I/TG)rHDL. In the case of triacylglycerol hydrolysis, the respective V-max values for (A-I/TG)rHDL and (A-II/TG)rHDL were 1154.8 and 240.2 nmol of NEFA formed/ml of HL/h, These results show that apolipoproteins have a major influence on the kinetics of HL-mediated phospholipid and triacylglycerol hydrolysis in rHDL.	Hanson Ctr Canc Res, Lipid Res Lab, Adelaide, SA 5000, Australia; Univ Adelaide, Dept Med, Adelaide, SA 5005, Australia; Royal Adelaide Hosp, Div Cardiovasc Serv, Adelaide, SA 5000, Australia	University of Adelaide; Royal Adelaide Hospital	Rye, KA (corresponding author), Hanson Ctr Canc Res, Lipid Res Lab, Level 1,Frome Rd, Adelaide, SA 5000, Australia.	karye@camtech.net.au						APPLEBAUMBOWDEN D, 1985, ARTERIOSCLEROSIS, V5, P273, DOI 10.1161/01.ATV.5.3.273; BEKAERT ED, 1992, BIOCHIM BIOPHYS ACTA, V1126, P105, DOI 10.1016/0005-2760(92)90223-I; BURSTEIN M, 1970, J LIPID RES, V11, P583; DATTA S, 1988, J BIOL CHEM, V263, P1107; DEREWENDA U, 1992, BIOCHEMISTRY-US, V31, P1532, DOI 10.1021/bi00120a034; DUVERGER N, 1994, ARTERIOSCLER THROMB, V14, P1594, DOI 10.1161/01.ATV.14.10.1594; EUGUI J, 1994, CLIN BIOCHEM, V27, P310, DOI 10.1016/0009-9120(94)90035-3; FAN JL, 1994, P NATL ACAD SCI USA, V91, P8724, DOI 10.1073/pnas.91.18.8724; FOLCH J, 1957, J BIOL CHEM, V226, P497; JAHN CE, 1981, FEBS LETT, V131, P366, DOI 10.1016/0014-5793(81)80405-X; JAHN CE, 1983, EUR J BIOCHEM, V131, P25, DOI 10.1111/j.1432-1033.1983.tb07227.x; JENSEN GL, 1982, BIOCHIM BIOPHYS ACTA, V710, P464, DOI 10.1016/0005-2760(82)90130-8; KOHLMEIER M, 1986, CLIN CHEM, V32, P63; KUBO M, 1982, J BIOCHEM-TOKYO, V92, P365; KUUSI T, 1980, ATHEROSCLEROSIS, V36, P589, DOI 10.1016/0021-9150(80)90251-8; LABODA HM, 1988, BIOCHEMISTRY-US, V27, P2313, DOI 10.1021/bi00407a011; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MOWRI HO, 1992, J LIPID RES, V33, P1269; Mowri HO, 1996, ARTERIOSCL THROM VAS, V16, P755, DOI 10.1161/01.ATV.16.6.755; PATSCH JR, 1987, J CLIN INVEST, V80, P341, DOI 10.1172/JCI113078; PIRAN U, 1979, J LIPID RES, V20, P1040; RYE KA, 1989, J LIPID RES, V30, P335; RYE KA, 1994, J BIOL CHEM, V269, P10298; Rye KA, 1996, J BIOL CHEM, V271, P4243; Rye KA, 1998, J LIPID RES, V39, P613; Rye KA, 1997, J BIOL CHEM, V272, P3953, DOI 10.1074/jbc.272.7.3953; RYE KA, 1995, J BIOL CHEM, V270, P189, DOI 10.1074/jbc.270.1.189; RYE KA, 1992, J LIPID RES, V33, P215; Sanan DA, 1997, J LIPID RES, V38, P1002; SHIRAI K, 1981, BIOCHEM BIOPH RES CO, V100, P591, DOI 10.1016/S0006-291X(81)80217-3; SPEIJER H, 1991, ATHEROSCLEROSIS, V90, P159, DOI 10.1016/0021-9150(91)90110-O; Tansey JT, 1997, BIOCHEMISTRY-US, V36, P12227, DOI 10.1021/bi970356w; THUREN T, 1991, BIOCHIM BIOPHYS ACTA, V1083, P217, DOI 10.1016/0005-2760(91)90046-K; THUREN T, 1991, J BIOL CHEM, V266, P4853; TOLLEFSON JH, 1988, AM J PHYSIOL, V255, pE894, DOI 10.1152/ajpendo.1988.255.6.E894; VANTILBEURGH H, 1993, NATURE, V362, P814, DOI 10.1038/362814a0; VERGER R, 1976, ANNU REV BIOPHYS BIO, V5, P77, DOI 10.1146/annurev.bb.05.060176.000453; WEISWEILER P, 1987, CLIN CHIM ACTA, V169, P249, DOI 10.1016/0009-8981(87)90325-1; ZHONG SB, 1994, J CLIN INVEST, V94, P2457, DOI 10.1172/JCI117614	39	39	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27191	27198		10.1074/jbc.273.42.27191	http://dx.doi.org/10.1074/jbc.273.42.27191			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765239	hybrid			2022-12-27	WOS:000076448000026
J	Iglesias, T; Waldron, RT; Rozengurt, E				Iglesias, T; Waldron, RT; Rozengurt, E			Identification of in vivo phosphorylation sites required for protein kinase D activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; PHORBOL ESTERS; CATALYTIC DOMAIN; INTACT-CELLS; C FAMILY; D PKD; DIACYLGLYCEROL; TARGET; GENES; MU	Protein kinase D (PKD) is activated by phosphorylation in intact cells stimulated by phorbol esters, cell permeant diacylglycerols, bryostatin, neuropeptides, and growth factors, but the critical activating residues in PKD have not been identified. Here, we show that substitution of Ser(744) and Ser(748) with alanine (PKD-S744A/S748A) completely blocked PKD activation induced by phorbol-12,13-dibutyrate (PDB) treatment of intact cells as assessed by autophosphorylation and exogenous syntide-2 peptide substrate phosphorylation assays. Conversely, replacement of both serine residues with glutamic acid (PKD-S744E/S748E) markedly increased basal activity (7.5-fold increase compared with wild type PKD), PKD-S744E/S748E mutant was only slightly further stimulated by PDB treatment in vivo, suggesting that phosphorylation of these two sites induces maximal PKD activation. Two-dimensional tryptic phosphopeptide analysis obtained from PKD mutants immunoprecipitated from P-32-labeled transfected COS-7 cells showed that two major spots present in the PDB-stimulated wild type PKD or the kinase-dead PKD-D733A phosphopeptide maps completely disappeared in the kinase-deficient triple mutant PKD-D733A/S744E/S748E. Our results indicate that PKD is activated by phosphorylation of residues Ser(744) and Ser(748) and thus provide the first example of a non-PH kinase that is up-regulated by phosphorylation of serine/threonine residues within the activation loop.	Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Imperial Canc Res Fund, London WC2A 3PX, England	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; Cancer Research UK	Rozengurt, E (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, 900 Vet Ave,Warren Hall,Rm 11-124, Los Angeles, CA 90095 USA.		Waldron, Richard Taliesin/ABF-2773-2020; Vacas, Teresa Iglesias/ABF-8663-2020	Waldron, Richard Taliesin/0000-0003-3151-6002; Vacas, Teresa Iglesias/0000-0002-4326-9005				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Dieterich S, 1996, FEBS LETT, V381, P183, DOI 10.1016/0014-5793(96)00116-0; Gschwendt M, 1997, J BIOL CHEM, V272, P20742, DOI 10.1074/jbc.272.33.20742; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; Matthews SA, 1997, J BIOL CHEM, V272, P20245, DOI 10.1074/jbc.272.32.20245; MOCHIZUKI H, 1993, J BIOL CHEM, V268, P9143; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Rozengurt E, 1997, BIOCHEM SOC T, V25, P565, DOI 10.1042/bst0250565; Rozengurt E, 1995, MUTAT RES-FUND MOL M, V333, P153, DOI 10.1016/0027-5107(95)00141-7; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; TODA T, 1993, EMBO J, V12, P1987, DOI 10.1002/j.1460-2075.1993.tb05848.x; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	25	155	159	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27662	27667		10.1074/jbc.273.42.27662	http://dx.doi.org/10.1074/jbc.273.42.27662			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765302	hybrid			2022-12-27	WOS:000076448000089
J	Kim, YS; Fischer, SM				Kim, YS; Fischer, SM			Transcriptional regulation of cyclooxygenase-2 in mouse skin carcinoma cells - Regulatory role of CCAAT/enhancer-binding proteins in the differential expression of cyclooxygenase-2 in normal and neoplastic tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPEROXIDE SYNTHASE-2 GENE; UPSTREAM STIMULATORY FACTOR; HUMAN COLON-CANCER; MAMMARY EPITHELIAL-CELLS; ACUTE-PHASE RESPONSE; GROWTH-FACTOR-I; DNA-BINDING; PROSTAGLANDIN SYNTHASE-2; NUCLEAR FACTOR; C/EBP-ALPHA	Many studies have suggested that overexpression of cyclooxygenase-2 (COX-2) contributes to the development of tumors in several tissues. COX-2 expression tends to be up-regulated in various types of tumors and transformed cell Lines, and the overexpression of COX-2 is caused by enhanced transcription of the gene, In an attempt to characterize the signaling pathway leading to the overexpression of COX-2 in the mouse skin carcinoma cell line JWF2, we investigated cis- and transacting factors required for COX-2 expression and demonstrated a molecular mechanism by which COX-2 is expressed differentially in normal and neoplastic tissues. Two regions of the COX-2 promoter containing an E-box and nuclear factor IL6 site were identified as the positive regulatory elements through transient transfections with luciferase reporter vectors containing the various 5'-flanking regions of the promoter. Moreover, electrophoretic mobility shift assays and cotransfection experiments showed that upstream stimulatory factors and CCAAT/enhancer-binding proteins (C/EBPs) bind to the E-box and nuclear factor IL6 site, respectively, and functionally transactivate the COX-2 promoter. me also found that C/EBP isoforms are expressed differentially during mouse skin carcinogenesis, suggesting that overexpression of COX-2 in tumors may be caused by a change in C/EBP expression levels.	Univ Texas, Md Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Fischer, SM (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, POB 389, Smithville, TX 78957 USA.							ALAM T, 1992, J BIOL CHEM, V267, P5021; An MR, 1996, MOL CELL BIOL, V16, P2295; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; BAZAN NG, 1994, P NATL ACAD SCI USA, V91, P5252, DOI 10.1073/pnas.91.12.5252; BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CALKHOVEN CF, 1994, NUCLEIC ACIDS RES, V25, P540; CAO Z, 1991, GENE DEV, V9, P168; CHANDRASEKARAN C, 1993, P NATL ACAD SCI USA, V90, P8871, DOI 10.1073/pnas.90.19.8871; CONTI CJ, 1988, CANCER RES, V48, P435; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FLODBY P, 1995, MOL CARCINOGEN, V12, P103, DOI 10.1002/mc.2940120207; GHOSH AK, 1996, ONCOGENE, V11, P589; GOPPELTSTRUEBE M, 1995, PROSTAG LEUKOTR ESS, V52, P213, DOI 10.1016/0952-3278(95)90039-X; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; HOFFMAN PW, 1995, NUCLEIC ACIDS RES, V23, P2229, DOI 10.1093/nar/23.12.2229; HUANG JH, 1994, MOL CELL BIOL, V14, P4475, DOI 10.1128/MCB.14.7.4475; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; INOUE H, 1994, FEBS LETT, V350, P51, DOI 10.1016/0014-5793(94)00731-4; JUAN TSC, 1993, P NATL ACAD SCI USA, V90, P2584, DOI 10.1073/pnas.90.7.2584; KARGMAN SL, 1995, CANCER RES, V55, P2556; KESTER M, 1994, J BIOL CHEM, V269, P22574; Kuras L, 1997, EMBO J, V16, P2441, DOI 10.1093/emboj/16.9.2441; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Lanigan TM, 1997, J BIOL CHEM, V272, P18316, DOI 10.1074/jbc.272.29.18316; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; Morris JK, 1996, J BIOL CHEM, V271, P16633, DOI 10.1074/jbc.271.28.16633; ORourke J, 1997, J BIOL CHEM, V272, P6291, DOI 10.1074/jbc.272.10.6291; Osada S, 1996, J BIOL CHEM, V271, P3891; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; RAMJI DP, 1993, NUCLEIC ACIDS RES, V21, P289, DOI 10.1093/nar/21.2.289; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; REDDY ST, 1994, J BIOL CHEM, V269, P15473; REISER OA, 1996, EXP CELL RES, V222, P304; Rho O, 1996, MOL CARCINOGEN, V17, P62, DOI 10.1002/(SICI)1098-2744(199610)17:2<62::AID-MC2>3.0.CO;2-V; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; ROSENBERG L, 1991, J NATL CANCER I, V83, P355, DOI 10.1093/jnci/83.5.355; Rundhaug JE, 1997, MOL CARCINOGEN, V20, P125, DOI 10.1002/(SICI)1098-2744(199709)20:1<125::AID-MC14>3.0.CO;2-3; SANO H, 1995, CANCER RES, V55, P3785; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; SIROIS J, 1993, J BIOL CHEM, V268, P12199; Sorli CH, 1998, P NATL ACAD SCI USA, V95, P1788, DOI 10.1073/pnas.95.4.1788; Subbaramaiah K, 1996, CANCER RES, V56, P4424; SUH O, 1993, CANCER-AM CANCER SOC, V72, P1171, DOI 10.1002/1097-0142(19930815)72:4<1171::AID-CNCR2820720407>3.0.CO;2-D; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; TIMCHENKO N, 1995, MOL CELL BIOL, V15, P1192; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Umayahara Y, 1997, J BIOL CHEM, V272, P31793, DOI 10.1074/jbc.272.50.31793; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; Watkins PJ, 1996, CANCER RES, V56, P1063; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Yin M, 1996, J BIOL CHEM, V271, P17974, DOI 10.1074/jbc.271.30.17974	64	186	191	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27686	27694		10.1074/jbc.273.42.27686	http://dx.doi.org/10.1074/jbc.273.42.27686			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765305	hybrid			2022-12-27	WOS:000076448000092
J	Guo, SY; Ives, DH				Guo, SY; Ives, DH			Functional assignment by chimera construction of the domain affecting heterotropic activation of deoxyadenosine kinase from Lactobacillus acidophilus R-26	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMPLEX VIRUS TYPE-1; DEOXYGUANOSINE KINASE; THYMIDINE KINASE; DEOXYCYTIDINE KINASE; DIRECTED MUTAGENESIS; EXPRESSION; CLONING; CDNA; BINDING; SITE	The heterodimeric subunits of deoxyadenosine kinase (dAK)-deoxyguanosine kinase (dGrK) from Lactobacillus acidophilus R-26 exhibit contrasting conformations manifested in the nearly unidirectional heterotropic activation of dAK when dGK binds deoxyguanosine. This is mediated, in part, by the conserved Ras switch I-like sequence (residues 153-161) [Guo et at. (1997) J. Biol. Chem. 272, 6890-6897]. In an attempt to identify domains differentiating the specificities of dAK and dGK, we constructed several chimeras splicing heterodimeric dAK within this region. In Chimera-III, dAK residues 120-170 were replaced by the homologous section of dGK. dAK activity was elevated 40%, but although it retained its original specificity and K-m values, it could no longer be activated by deoxyguanosine. Moreover, both the activated dAK; and the "dAK" of Chimera-ID exhibited (i) an increased K-s for the leading substrate ATP-Mg2+, suggesting the formation of intermediate enzyme species along their respective kinetic pathways, and (ii) broadened and lower pH optima for the dAK activities, These observations further indicate the importance of dAK residues 120-170, including the Ras-like segment, in catalysis and heterotropic activation. The other conformational properties of dAK (e.g. self-inactivity and MgATP being the leading substrate) were unaltered by this substitution, thus localizing the responsible domains even further upstream.	Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA	Ohio State University	Ives, DH (corresponding author), Ohio State Univ, Dept Biochem, 776 Biosci,484 W 12th Ave, Columbus, OH 43210 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049635] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49635] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROWN DG, 1995, NAT STRUCT BIOL, V2, P876, DOI 10.1038/nsb1095-876; CHAKRAVARTY R, 1984, BIOCHEMISTRY-US, V23, P6235, DOI 10.1021/bi00320a053; CHOTTINER EG, 1991, P NATL ACAD SCI USA, V88, P1531, DOI 10.1073/pnas.88.4.1531; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DEIBEL MR, 1977, J BIOL CHEM, V252, P8240; DEIBEL MR, 1977, J BIOL CHEM, V252, P8235; DEIBEL MR, 1977, DEOXYNUCLEOSIDE KINA; DURHAM JP, 1971, BIOCHIM BIOPHYS ACTA, V228, P9, DOI 10.1016/0005-2787(71)90542-9; Eriksson S, 1997, NUCLEOS NUCLEOT, V16, P653, DOI 10.1080/07328319708002930; Guo SY, 1997, J BIOL CHEM, V272, P6890, DOI 10.1074/jbc.272.11.6890; Higuchi R., 1989, PCR TECHNOLOGY, P61; HONG YS, 1995, J BIOL CHEM, V270, P6602, DOI 10.1074/jbc.270.12.6595; IKEDA S, 1986, J BIOL CHEM, V261, P5836; IKEDA S, 1994, BIOCHEMISTRY-US, V33, P13373, DOI 10.1021/bi00249a025; IKEDA S, 1985, J BIOL CHEM, V260, P2659; Ives DH, 1998, PROG NUCLEIC ACID RE, V59, P205; IVES DH, 1984, ANAL BIOCHEM, V136, P416, DOI 10.1016/0003-2697(84)90237-9; Johansson M, 1997, J BIOL CHEM, V272, P8454, DOI 10.1074/jbc.272.13.8454; Johansson M, 1996, P NATL ACAD SCI USA, V93, P7258, DOI 10.1073/pnas.93.14.7258; Kjeldgaard M, 1996, FASEB J, V10, P1347, DOI 10.1096/fasebj.10.12.8903506; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; MA GT, 1995, J BIOL CHEM, V270, P6595, DOI 10.1074/jbc.270.12.6602; Ma N, 1996, P NATL ACAD SCI USA, V93, P14385, DOI 10.1073/pnas.93.25.14385; MUNIR KM, 1992, J BIOL CHEM, V267, P6584; Segel I. H., 1975, ENZYME KINETICS, P273; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Wang LY, 1996, FEBS LETT, V390, P39, DOI 10.1016/0014-5793(96)00623-0; WILD K, 1995, FEBS LETT, V368, P289, DOI 10.1016/0014-5793(95)00680-8; Wild K, 1997, PROTEIN SCI, V6, P2097; YAN HG, 1991, BIOCHEMISTRY-US, V30, P5539, DOI 10.1021/bi00236a029	30	0	0	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26624	26630		10.1074/jbc.273.41.26624	http://dx.doi.org/10.1074/jbc.273.41.26624			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756902	hybrid			2022-12-27	WOS:000076373300056
J	Nakamura, M; Kudo, T; Narimatsu, H; Furukawa, Y; Kikuchi, J; Asakura, S; Yang, W; Iwase, S; Hatake, K; Miura, Y				Nakamura, M; Kudo, T; Narimatsu, H; Furukawa, Y; Kikuchi, J; Asakura, S; Yang, W; Iwase, S; Hatake, K; Miura, Y			Single glycosyltransferase, core 2 beta 1 -> 6-N-acetylglucosaminyltransferase, regulates cell surface sialyl-Le(x) expression level in human pre-B lymphocytic leukemia cell line KM3 treated with phorbolester	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIN GLYCOPROTEIN LIGAND-1; LEUKOCYTE ADHESION MOLECULE-1; NEOLACTO-SERIES GANGLIOSIDES; ASN-LINKED OLIGOSACCHARIDES; POLY-N-ACETYLLACTOSAMINE; P-SELECTIN; GRANULOCYTIC DIFFERENTIATION; MONOCLONAL-ANTIBODIES; INTERLEUKIN-3 GENE; ENDOTHELIAL-CELLS	Sialyl-Le(x) (sLe(x)) antigen expression recognized by KM93 monoclonal antibody was significantly down-regulated during differentiation induced by 12-O-tetradecanoylphorbol-13-acetate (TPA) in human pre-B lymphocytic leukemia cell line KM3. The sLe(x) determinants were almost exclusively expressed on O-linked oligosaccharide chains of an O-glycosylated 150-kDa glycoprotein (gp150). A low shear force cell adhesion assay showed that TPA treatment significantly inhibited E-selectin-mediated cell adhesion. Transcript and/or enzyme activity levels of alpha 1-->3-fucosyltransferase, alpha 2-->3-sialyltransferase, beta 1-->4-galactosyltransferase, and elongation beta 1-->3-N-acetylglucosaminyltransferase did not correlate with sLe(x) expression levels. However, transcript and enzyme activity levels of core 2 GlcNAc-transferase (C2GnT) were significantly down-regulated during TPA treatment. Following transfection and constitutive expression of full-length exogenous C2GnT transcript, C2GnT enzyme activities were maintained at high levels even after TPA treatment and down-regulation of cell surface sLe(x) antigen expression by TPA was completely abolished. Furthermore, in the transfected cells, the KM93 reactivity of gp150 was not reduced by TPA treatment, and the inhibition of cell adhesion by TPA was also blocked. These results suggest that sLe(x) expression is critically regulated by a single glycosyltransferase, C2GnT, during differentiation of KM3 cells.	Jichi Med Sch, Inst Hematol, Div Hemopoiesis, Minami Kawachi, Tochigi 32904, Japan; Jichi Med Sch, Div Hemostasis & Thrombosis, Res Inst Hematol, Minami Kawachi, Tochigi 32904, Japan; Soka Univ, Inst Life Sci, Div Cell Biol, Hachioji, Tokyo 192, Japan; Hitachi Koki Co Ltd, Katsuta Res Lab, Katsuta, Ibaraki 312, Japan; Jikei Univ, Sch Med, Dept Internal Med, Tokyo 105, Japan	Jichi Medical University; Jichi Medical University; Soka University; Hitachi Limited; Jikei University	Nakamura, M (corresponding author), Jichi Med Sch, Inst Hematol, Div Hemopoiesis, Minami Kawachi, Tochigi 32904, Japan.	owlmnaka@jichi.ac.jp	Furukawa, Yusuke/Y-1342-2018	Furukawa, Yusuke/0000-0002-7249-6418				BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; Breton C, 1996, GLYCOBIOLOGY, V6, pR7; BROCKHAUSEN I, 1985, BIOCHEMISTRY-US, V24, P1866, DOI 10.1021/bi00329a010; Clarke JL, 1996, J BIOL CHEM, V271, P10317, DOI 10.1074/jbc.271.17.10317; DECLERCK LS, 1994, J IMMUNOL METHODS, V172, P115, DOI 10.1016/0022-1759(94)90384-0; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; GOELZ S, 1994, J BIOL CHEM, V269, P1033; HANAI N, 1990, ANTICANCER RES, V10, P1579; IUPAC-IUB Commission on Biochemical Nomenclature, 1977, LIPIDS, V12, P455; KAWASHIMA H, 1993, J BIOL CHEM, V268, P27118; KITAGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P375, DOI 10.1006/bbrc.1993.1830; KITAGAWA S, 1989, J BIOL CHEM, V264, P16149; Knibbs RN, 1996, J CELL BIOL, V133, P911, DOI 10.1083/jcb.133.4.911; KONDO A, 1990, AGR BIOL CHEM TOKYO, V54, P2169, DOI 10.1080/00021369.1990.10870232; KUDO T, 1995, GLYCOBIOLOGY, V5, P397, DOI 10.1093/glycob/5.4.397; LASKY LA, 1995, ANNU REV BIOCHEM, V64, P113, DOI 10.1146/annurev.bi.64.070195.000553; LEE N, 1990, J BIOL CHEM, V265, P20476; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; MACHER B A, 1991, Glycobiology, V1, P577, DOI 10.1093/glycob/1.6.577; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; NAKAMURA M, 1992, J BIOL CHEM, V267, P23507; Nakamura M, 1996, GLYCOCONJUGATE J, V13, P255, DOI 10.1007/BF00731500; NAKAMURA M, 1991, CANCER RES, V51, P1940; NARIMATSU H, 1986, P NATL ACAD SCI USA, V83, P4720, DOI 10.1073/pnas.83.13.4720; Niemela R, 1998, J BIOL CHEM, V273, P4021, DOI 10.1074/jbc.273.7.4021; NOJIRI H, 1988, J BIOL CHEM, V263, P7443; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; PILARSKI LM, 1991, J IMMUNOL, V147, P136; SAKAGAMI H, 1984, LEUKEMIA RES, V8, P187, DOI 10.1016/0145-2126(84)90142-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI K, 1993, J BIOL CHEM, V268, P22782; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SAWADA R, 1993, J BIOL CHEM, V268, P12675; SCHLOSSMAN SF, 1995, LEUKOCYTE TYPING, V5, P1524; SHIMIZU Y, 1993, NATURE, V366, P630, DOI 10.1038/366630a0; Snapp KR, 1997, BLOOD, V89, P896, DOI 10.1182/blood.V89.3.896; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEEGMAIER M, 1995, NATURE, V373, P615, DOI 10.1038/373615a0; Tsuboi S, 1997, EMBO J, V16, P6364, DOI 10.1093/emboj/16.21.6364; Tsuji S, 1996, GLYCOBIOLOGY, V6, pR5; TSUNODA A, 1995, BIOCHEMISTRY-US, V34, P9356, DOI 10.1021/bi00029a011; UEMURA M, 1992, CANCER RES, V52, P6153	47	34	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26779	26789		10.1074/jbc.273.41.26779	http://dx.doi.org/10.1074/jbc.273.41.26779			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756922	hybrid			2022-12-27	WOS:000076373300076
J	Chen, DW; Frey, PA				Chen, DW; Frey, PA			Phenylalanine hydroxylase from Chromobacterium violaceum - Uncoupled oxidation of tetrahydropterin and the role of iron in hyroxylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID HYDROXYLASES; REDUCTIVE ACTIVATION; BINDING-SITES; EXPRESSION; COMPLEXES; MECHANISM; SEQUENCE; COFACTOR; CLONING; DNA	A gene encoding phenylalanine hydroxylase has been cloned from Chromobacterium violaceum and expressed in Escherichia coli. The purified phenylalanine hydroxylase contains copper, which does not support enzymatic activity, Upon removal of copper by dithiothreitol (DTT), the enzyme contains substoichiometric amounts of calcium and zinc but Little or no redox-active metal ions. The copper-depleted hydroxylase catalyzes the phenylalanine-dependent oxidation of 6,7-dimethyltetrahydropterin (DMPH4) by O-2 in a reaction in which phenylalanine is not hydroxylated and does not appear to undergo a chemical change, and hydrogen peroxide is produced. Analogs of phenylalanine also activate the oxidation of DMPH4. Both the copper-phenylalanine hydroxylase and the copper-depleted hydroxylase catalyze the hydroxylation of phenylalanine in the presence of DTT and FeSO4 in a reaction in which hydrogen peroxide is not produced. The apparent values of K-m for Fe2+ and DTT are 0.28 mu M and 1.1 mM, respectively, at 1.0 mM phenylalanine, 120 mu M DMPH4 and pH 7.4 and 23 degrees C. The apparent value of k(cat) is 14.3 s(-1) under these conditions. Glutathione, mercaptoethanol, and dihydrolipoate support the hydroxylation of phenylalanine essentially as well as DTT, Incubation of copper-depleted hydroxylase with FeSO4, phenylalanine, and DTT followed by gel permeation chromatography leads to an iron-hydroxylase containing approximately 1 molecule of iron per molecule of enzyme. The iron-hydroxylase displays an optical absorption band extending from 300 to 600 nm, and it catalyzes the hydroxylation of phenylalanine at the same maximum rate as the iron-activated hydroxylase but does not require added Fe2+. We conclude that iron participates in the hydroxylation of phenylalanine. Iron is not required for the oxidation of DMPH4, although it may exert a modest acceleration effect. A hypothetical mechanism is presented wherein the reaction of iron with the putative 4a-hydroperoxy-DMPH4 leads to 4a-hydroxy-DMPH4 and a high valent iron-oxy species. The iron-oxy species is postulated to react with phenylalanine in the hydroxylation process.	Univ Wisconsin, Grad Sch, Inst Enzyme Res, Madison, WI 53706 USA; Univ Wisconsin, Coll Agr & Biol Sci, Dept Biochem, Inst Enzyme Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Frey, PA (corresponding author), Univ Wisconsin, Coll Agr & Biol Sci, Dept Biochem, Inst Enzyme Res, 1710 Univ Ave, Madison, WI 53706 USA.				NIDDK NIH HHS [DK 26807] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026807] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AINSCOUGH EW, 1980, INORG CHEM, V19, P3655, DOI 10.1021/ic50214a018; AMANN E, 1983, GENE, V25, P167, DOI 10.1016/0378-1119(83)90222-6; AYLING J, 1973, ANAL BIOCHEM, V51, P80, DOI 10.1016/0003-2697(73)90454-5; BALASUBRAMANIAN S, 1994, BIOCHEMISTRY-US, V33, P8532, DOI 10.1021/bi00194a019; CARR RT, 1993, BIOCHEMISTRY-US, V32, P14132, DOI 10.1021/bi00214a009; CHEN DW, 1994, J BIOL CHEM, V269, P32120; DAVIS MD, 1993, ARCH BIOCHEM BIOPHYS, V304, P9, DOI 10.1006/abbi.1993.1315; DIX TA, 1988, ACCOUNTS CHEM RES, V21, P101, DOI 10.1021/ar00147a002; DIX TA, 1985, BIOCHEMISTRY-US, V24, P5389; FISHER DB, 1972, J BIOL CHEM, V247, P2250; GIBBS BS, 1993, J BIOL CHEM, V268, P8046; GOODWIN BL, 1979, AROMATIC AMINO ACID, P5; GOTTSCHALL DW, 1982, J BIOL CHEM, V257, P845; GUIBAULT GG, 1964, ANAL CHEM, V36, P2495; Hillas PJ, 1996, BIOCHEMISTRY-US, V35, P6969, DOI 10.1021/bi9606861; JENNINGS IG, 1991, P NATL ACAD SCI USA, V88, P5734, DOI 10.1073/pnas.88.13.5734; Kappock TJ, 1996, CHEM REV, V96, P2659, DOI 10.1021/cr9402034; Kaufmann S., 1962, OXYGENASES, P129; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAELIA LE, 1992, INORG CHEM, V31, P4594, DOI 10.1021/ic00048a029; MAROTA JJA, 1984, BIOCHEMISTRY-US, V23, P1303, DOI 10.1021/bi00301a044; NAKATA H, 1979, J BIOL CHEM, V254, P1829; ONISHI A, 1991, J BIOL CHEM, V266, P18454; PEMBER SO, 1987, METHOD ENZYMOL, V142, P50; PEMBER SO, 1986, BIOCHEMISTRY-US, V25, P6611, DOI 10.1021/bi00369a042; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLEIF RF, 1981, PRACTICAL METHODS MO, P98; SHIMAN R, 1985, FOLATES PTERINS, V2, P179; VOGT VM, 1970, J BIOL CHEM, V245, P4760; WALLICK DE, 1984, BIOCHEMISTRY-US, V23, P1295, DOI 10.1021/bi00301a043; ZHAO GS, 1994, P NATL ACAD SCI USA, V91, P1366, DOI 10.1073/pnas.91.4.1366	33	38	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25594	25601		10.1074/jbc.273.40.25594	http://dx.doi.org/10.1074/jbc.273.40.25594			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748224	hybrid			2022-12-27	WOS:000076263100015
J	Muth, TR; Ahn, J; Caplan, MJ				Muth, TR; Ahn, J; Caplan, MJ			Identification of sorting determinants in the C-terminal cytoplasmic tails of the gamma-aminobutyric acid transporters GAT-2 and GAT-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; POLARIZED EPITHELIAL-CELLS; AMYLOID PRECURSOR PROTEIN; MDCK CELLS; RAT-BRAIN; HIPPOCAMPAL-NEURONS; GABA TRANSPORTERS; SECRETORY PATHWAY; FC-RECEPTORS; PDZ DOMAINS	In order to perform their physiologic functions, polarized epithelial cells must target ion transport proteins to the appropriate domains of their plasma membranes. Molecular signals responsible for polarized sorting have been identified for several membrane proteins which span the bilayer once. Most ion transport proteins are polytopic, however, and little is known of the signals responsible for the targeting of this class of polypeptides. Members of the gamma-aminobutyric acid (GABA) transporter family are polytopic membrane proteins found endogenously in both epithelial cells and neurons. We have identified narrowly defined sequences which are required for the proper accumulation of two members of this transporter family in Madin-Darby canine kidney cells. The highly homologous GABA transporter isoforms, GAT-2 and GAT-3, localize to the basolateral and apical surfaces, respectively, when expressed stably in Madin-Darby canine kidney cells. We have generated deletion constructs and chimeric transporters composed of complimentary portions of GAT-2 and GAT-3. We find that information which directs their differential sorting is present in the C-terminal cytoplasmic tails of these two polypeptides. A sequence of 22 amino acids at the C terminus of GAT-2 is required for the transporter's basolateral distribution and is capable of directing GAT-3 to the basolateral surface when appended to the C terminus of this normally apical polypeptide. The deletion of 32 amino acids from the C terminus of GAT-3 causes this transporter to become mislocalized to both surfaces. Moreover, removal of the final three amino acids of GAT-3 (THF) similarly disrupts its apical sorting. The GAT-3 C-terminal sequence resembles motifs which interact with PDZ domains, raising the possibility that the steady state distribution of GAT-3 at the apical plasmalemmal surface requires a protein-protein interaction mediated by its extreme C-terminal cytoplasmic tail. These data provide the first characterization of a protein-based signal required for the apical distribution of a membrane protein.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA	Yale University; Yale University	Muth, TR (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, 333 Cedar St, New Haven, CT 06520 USA.			Muth, Theodore/0000-0002-6882-1193; Caplan, Michael/0000-0001-5768-4405	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042136] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42136] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn J, 1996, J BIOL CHEM, V271, P6917, DOI 10.1074/jbc.271.12.6917; BORDEN LA, 1992, J BIOL CHEM, V267, P21098; Borden LA, 1996, NEUROCHEM INT, V29, P335, DOI 10.1016/0197-0186(95)00158-1; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; Caplan MJ, 1997, AM J PHYSIOL-RENAL, V272, pF425, DOI 10.1152/ajprenal.1997.272.4.F425; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; Dietrich J, 1996, J BIOL CHEM, V271, P11441, DOI 10.1074/jbc.271.19.11441; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; DURKIN MM, 1995, MOL BRAIN RES, V33, P7, DOI 10.1016/0169-328X(95)00101-W; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; FERREIRA A, 1993, J NEUROSCI, V13, P3112; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; FIEDLER K, 1994, CELL, V77, P625, DOI 10.1016/0092-8674(94)90047-7; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; GOTTARDI CJ, 1993, J CELL BIOL, V121, P283, DOI 10.1083/jcb.121.2.283; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HAASS C, 1994, P NATL ACAD SCI USA, V91, P1564, DOI 10.1073/pnas.91.4.1564; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; IVERSEN LL, 1971, BRIT J PHARMACOL, V41, P571, DOI 10.1111/j.1476-5381.1971.tb07066.x; Johnson J, 1996, J COMP NEUROL, V375, P212; KANNER BI, 1983, BIOCHIM BIOPHYS ACTA, V726, P293, DOI 10.1016/0304-4173(83)90013-7; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kwon HM, 1996, BIOCHEM SOC T, V24, P853, DOI 10.1042/bst0240853; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; Odorizzi G, 1996, J CELL BIOL, V135, P139, DOI 10.1083/jcb.135.1.139; OKAMOTO CT, 1992, J BIOL CHEM, V267, P9925; Perego C, 1997, J BIOL CHEM, V272, P6584, DOI 10.1074/jbc.272.10.6584; PIETRINI G, 1994, J BIOL CHEM, V269, P4668; PIETRINI G, 1992, P NATL ACAD SCI USA, V89, P8414, DOI 10.1073/pnas.89.18.8414; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; RADIAN R, 1990, J NEUROSCI, V10, P1319; RADIAN R, 1983, BIOCHEMISTRY-US, V22, P1236, DOI 10.1021/bi00274a038; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SIMONS K, 1992, COLD SPRING HARB SYM, V57, P611, DOI 10.1101/SQB.1992.057.01.067; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649	47	79	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25616	25627		10.1074/jbc.273.40.25616	http://dx.doi.org/10.1074/jbc.273.40.25616			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748227	hybrid			2022-12-27	WOS:000076263100018
J	Wang, J; Ducret, A; Tu, YP; Kozasa, T; Aebersold, R; Ross, EM				Wang, J; Ducret, A; Tu, YP; Kozasa, T; Aebersold, R; Ross, EM			RGSZ1, a G(z)-selective RGS protein in brain - Structure, membrane association, regulation by G alpha(z) phosphorylation, and relationship to a G(z) GTPase-activating protein subfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE STRING PROTEIN; AMINO-ACID-SEQUENCES; ALPHA-SUBUNIT; PHOSPHOLIPASE C-BETA-1; KINASE-C; TRANSITION-STATE; ADP-RIBOSYLATION; BINDING PROTEIN; PERTUSSIS TOXIN; MAMMALIAN-CELLS	We cloned the cDNA for human RGSZ1, the major G(z)-selective GTPase-activating protein (GAP) in brain (Wang, J., Tu, Y., Woodson, J., Song, IL, and Ross, E. M. (1997) J. Biol, Chem. 272, 5732-5740) and a member of the RGS family of G protein GAPs. Its sequence is 83% identical to RET-RGS1 (except its N-terminal extension) and 56% identical to GAIP. Purified, recombinant RGSZ1, RET-RGS1, and GAIP each accelerated the hydrolysis of G alpha(z)-GTP over 400-fold with K-m values of similar to 2 nM. RGSZ1 was 100-fold selective for G alpha(z) over G alpha(i), unusually specific among RGS proteins. Other enzymological properties of RGSZ1, brain G(z) GAP, and RET-RGS1 were identical; GAIP differed only in Mg2+ dependence and in its slightly lower selectivity for G alpha(z). RGSZ1, RET-RGS1, and GAIP thus define a subfamily of G(z) GAPs within the RGS proteins. RGSZ1 has no obvious membrane-spanning region but is tightly membrane-bound in brain. Its regulatory activity in membranes depends on stable bilayer association. When co-reconstituted into phospholipid vesicles with G(z) and m2 muscarinic receptors, RGSZ1 increased agonist-stimulated GTPase >15-fold with EC50 <12 nM, but RGSZ1 added to the vesicle suspension was <0.1% as active. RGSZ1, RET-RGS1, and GAIP share a cysteine string sequence, perhaps targeting them to secretory vesicles and allowing them to participate in the proposed control of secretion by G(z). Phosphorylation of G alpha(z) by protein kinase C inhibited the GAP activity of RGSZ1 and other RGS proteins, providing a mechanism for potentiation of G(z) signaling by protein kinase C.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Washington; University of Washington Seattle	Ross, EM (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030355, R01GM030355] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30355] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; BLEASBY AJ, 1994, NUCLEIC ACIDS RES, V22, P3574; BRANDT DR, 1985, J BIOL CHEM, V260, P266; BRAUN JEA, 1995, NEUROPHARMACOLOGY, V34, P1361, DOI 10.1016/0028-3908(95)00114-L; Buchner E, 1997, TRENDS NEUROSCI, V20, P223, DOI 10.1016/S0166-2236(96)10082-5; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; Cowan CW, 1998, P NATL ACAD SCI USA, V95, P5351, DOI 10.1073/pnas.95.9.5351; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Druey KM, 1997, P NATL ACAD SCI USA, V94, P12851, DOI 10.1073/pnas.94.24.12851; Ducret A, 1998, PROTEIN SCI, V7, P706, DOI 10.1002/pro.5560070320; DUCRET A, 1997, P 45 ASMS C MASS SPE, P14; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; FIELDS TA, 1995, J BIOL CHEM, V270, P23119, DOI 10.1074/jbc.270.39.23119; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; GARIBAY JLR, 1991, BIOCHIM BIOPHYS ACTA, V1094, P193, DOI 10.1016/0167-4889(91)90008-L; Glick JL, 1998, J BIOL CHEM, V273, P26008, DOI 10.1074/jbc.273.40.26008; GUNDERSEN CB, 1994, J BIOL CHEM, V269, P19197; HALLAK H, 1994, J BIOL CHEM, V269, P4571; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HINTON DR, 1990, J NEUROSCI, V10, P2763; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; INGI T, 1998, IN PRESS J NEUROCHEM; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOUNSBURY KM, 1991, J BIOL CHEM, V266, P22051; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; Morales J, 1998, MOL BIOL CELL, V9, P1, DOI 10.1091/mbc.9.1.1; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; Natochin M, 1998, J BIOL CHEM, V273, P6731, DOI 10.1074/jbc.273.12.6731; NAVON SE, 1984, J BIOL CHEM, V259, P6686; NGAI PK, 1991, BIOCHEM J, V280, P805, DOI 10.1042/bj2800805; PARKER EM, 1991, J BIOL CHEM, V266, P519; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROSS EM, 1995, RECENT PROG HORM RES, V50, P207; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SINGER WD, 1994, J BIOL CHEM, V269, P19796; Srinivasa SP, 1998, P NATL ACAD SCI USA, V95, P5584, DOI 10.1073/pnas.95.10.5584; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; vandeGoor J, 1996, FEBS LETT, V380, P251, DOI 10.1016/0014-5793(96)00026-9; vanOostveen I, 1997, ANAL BIOCHEM, V247, P310, DOI 10.1006/abio.1997.2052; Wang J, 1997, J BIOL CHEM, V272, P5732, DOI 10.1074/jbc.272.9.5732; WANG J, 1995, J BIOL CHEM, V270, P6488, DOI 10.1074/jbc.270.12.6488; WANG J, 1998, G PROTEINS TECHNIQUE; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	65	109	114	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26014	26025		10.1074/jbc.273.40.26014	http://dx.doi.org/10.1074/jbc.273.40.26014			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748280	hybrid			2022-12-27	WOS:000076263100071
J	Di Lisi, R; Millino, C; Calabria, E; Altruda, F; Schiaffino, S; Ausoni, S				Di Lisi, R; Millino, C; Calabria, E; Altruda, F; Schiaffino, S; Ausoni, S			Combinatorial cis-acting elements control tissue-specific activation of the cardiac troponin I gene in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-4; HEAVY-CHAIN GENE; ENHANCER-BINDING-FACTOR; SKELETAL-MUSCLE; MOLECULAR-CLONING; HEART DEVELOPMENT; RAT-HEART; EXPRESSION; PROMOTER; DISTINCT	The cardiac troponin I gene is one of the few sarcomeric protein genes exclusively expressed in cardiac muscle. We show here that this specificity is controlled by a proximal promoter (-230/+16) in transfected cardiac cells in culture, in the adult hearts, and in transgenic animals. Functional analysis indicates that MEF2/Oct-1, Spl, and GATA regulatory elements are required for optimal gene activation because selective mutations produce weak or inactive promoters. MEF2 and Oct-1 transcription factors bind to the same APT-rich element. A mutation that blocks this binding markedly reduces gene activation in vivo and in vitro, and overexpression of MEF2A, MEF2C, and MEF2D in noncardiac cells transactivates the cardiac troponin I promoter. Disruption of these elements inactivates the cardiac troponin I promoter in cultured cardiac cells but has a less important role in transfected adult heart. Moreover, nuclear extracts from an almost pure population of adult cardiac cells contain much lower levels of GATA binding activity compared with fetal cardiac cells. These findings point to a differential role of GATA factors in the maintenance of gene expression in the adult heart as compared with the activation of cardiac genes in fetal cardiomyocytes, Overexpression of GATA family members transactivates the cardiac troponin I promoter, and GATA-5 and GATA-6 are stronger transactivators than GATA-4, a property apparently unique to the cardiac troponin I promoter. Transgenic mice carrying the -230/+126 base pair promoter express beta-galactosidase reporter gene in the heart both at early stages of cardiogenesis and in the adult animals. These results indicate that the ability of the cardiac troponin I proximal promoter to target expression of a downstream gene in the heart is also maintained when the transgene is integrated into the genome.	Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, CNR, Ctr Muscle Biol & Physiopathol, I-35121 Padua, Italy; Univ Turin, Dept Genet Biol & Med Chem, I-10126 Turin, Italy	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Turin	Ausoni, S (corresponding author), Univ Padua, Dept Biomed Sci, Via G Colombo 3, I-35121 Padua, Italy.	ausoni@civ.bio.unipd.it	Calabria, Elisa/K-3849-2014	Calabria, Elisa/0000-0001-6557-0379; Schiaffino, Stefano/0000-0002-5607-6421	Telethon [928] Funding Source: Medline	Telethon(Fondazione Telethon)		ARDATI A, 1993, EMBO J, V12, P5131, DOI 10.1002/j.1460-2075.1993.tb06208.x; AUSONI S, 1994, J BIOL CHEM, V269, P339; AUSONI S, 1991, DEVELOPMENT, V112, P1041; Bhavsar PK, 1996, GENOMICS, V35, P11, DOI 10.1006/geno.1996.0317; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BUTTRICK PM, 1993, CIRC RES, V72, P1211, DOI 10.1161/01.RES.72.6.1211; DAS HK, 1987, J BIOL CHEM, V262, P4787; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; Fishman MC, 1997, CELL, V91, P153, DOI 10.1016/S0092-8674(00)80397-9; GORZA L, 1993, DEV BIOL, V156, P253, DOI 10.1006/dbio.1993.1074; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; Gove C, 1997, EMBO J, V16, P355, DOI 10.1093/emboj/16.2.355; Grepin C, 1997, DEVELOPMENT, V124, P2387; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; GREPIN C, 1995, MOL CELL BIOL, V15, P4095; HAN TH, 1995, MOL CELL BIOL, V15, P2907; HINKLEY C, 1991, MOL CELL BIOL, V11, P641, DOI 10.1128/MCB.11.2.641; Hogan B, 1994, MANIPULATING MOUSE E; HUGHES SM, 1993, DEVELOPMENT, V118, P1137; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; KITSIS RN, 1993, METHODS MOL GENET, V1, P374; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; LEIBHAM D, 1994, MOL CELL BIOL, V14, P686, DOI 10.1128/MCB.14.1.686; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; McGrew MJ, 1996, MOL CELL BIOL, V16, P4524; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P5056, DOI 10.1128/MCB.14.8.5056; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; MURPHY AM, 1991, BIOCHEMISTRY-US, V30, P707, DOI 10.1021/bi00217a018; Murphy AM, 1997, BIOCHEM J, V322, P393, DOI 10.1042/bj3220393; NAIDU PS, 1995, MOL CELL BIOL, V15, P2707; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; PARMACEK MS, 1992, MOL CELL BIOL, V12, P1967, DOI 10.1128/MCB.12.5.1967; PRENTICE H, 1994, J MOL CELL CARDIOL, V26, P1393, DOI 10.1006/jmcc.1994.1157; Ritchie ME, 1996, J BIOL CHEM, V271, P25485; Ross RS, 1996, DEVELOPMENT, V122, P1799; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SCHREIBER E, 1990, NUCLEIC ACIDS RES, V18, P5495, DOI 10.1093/nar/18.18.5495; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; VALLINS WJ, 1990, FEBS LETT, V270, P57, DOI 10.1016/0014-5793(90)81234-F; Ventura C, 1997, J BIOL CHEM, V272, P6685, DOI 10.1074/jbc.272.10.6685; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; Weiss MJ, 1997, MOL CELL BIOL, V17, P1642, DOI 10.1128/MCB.17.3.1642; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; ZHU L, 1995, DEV BIOL, V169, P487, DOI 10.1006/dbio.1995.1163	53	71	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25371	25380		10.1074/jbc.273.39.25371	http://dx.doi.org/10.1074/jbc.273.39.25371			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738004	hybrid			2022-12-27	WOS:000076085400054
J	Germain, S; Bonnet, F; Philippe, J; Fuchs, S; Corvol, P; Pinet, F				Germain, S; Bonnet, F; Philippe, J; Fuchs, S; Corvol, P; Pinet, F			A novel distal enhancer confers chorionic expression on the human renin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NF-E2; LEUCINE ZIPPER PROTEIN; TRANSGENIC MICE; NUCLEOTIDE-SEQUENCE; JUN ENCODES; PROMOTER; BINDING; CELLS; ONCOGENE; ELEMENTS	Renin catalyzes the rate-limiting step of the renin-angiotensin system, which regulates blood pressure and electrolyte homeostasis. To determine cell-specific human renin gene control elements, the transcriptional activity of promoter regions up to position -8876 was studied in renin-expressing cells. A positive regulatory region conferring similar to 57-fold higher transcriptional activity to the human renin gene promoter in chorionic cells was identified between nucleotides -5777 and -5552, It had the orientation-independent activity typical of classical enhancers. It also conferred similar to 59-fold higher transcriptional levels from the heterologous simian virus 40 (SV40) promoter in chorionic cells and similar to 6-fold higher transcriptional levels in Calu-6 and As4.1 cells, whereas no effect was measured in non-renin-expressing cells. DNase I footprinting showed that this enhancer contains three binding sites for chorionic cell nuclear extracts. Functional analysis suggested that the activity of the enhancer is regulated by differential mechanisms in the three renin-expressing cells involving a complex arrangement of AP-1 motifs binding cell-specific members of the basic leucine zipper family of transcription factors. Thus, our results demonstrate that this enhancer plays a key role in the expression of the human renin gene in the chorion and may also be involved in its regulated expression in other tissues.	Coll France, F-75005 Paris, France; INSERM, U36, F-75005 Paris, France	UDICE-French Research Universities; PSL Research University Paris; College de France; Institut National de la Sante et de la Recherche Medicale (Inserm)	Pinet, F (corresponding author), Coll France, 3 Rue Ulm, F-75005 Paris, France.	pinet@infobiogen.fr	Germain, Stephane/E-2301-2016; Pinet, Florence/F-2892-2013; Bonnet, Fabrice/G-4255-2017	Germain, Stephane/0000-0001-5992-1275; Pinet, Florence/0000-0002-5471-1487; Bonnet, Fabrice/0000-0001-9255-8228				ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; Blank V, 1997, BLOOD, V89, P3925, DOI 10.1182/blood.V89.11.3925; BORENSZTEIN P, 1994, CIRC RES, V74, P764, DOI 10.1161/01.RES.74.5.764; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; Deveaux S, 1997, EMBO J, V16, P5654, DOI 10.1093/emboj/16.18.5654; DUNCAN KG, 1990, P NATL ACAD SCI USA, V87, P7588, DOI 10.1073/pnas.87.19.7588; FUKAMIZU A, 1989, BIOCHEM BIOPH RES CO, V165, P826, DOI 10.1016/S0006-291X(89)80040-3; GANTEN D, 1992, P NATL ACAD SCI USA, V89, P7806, DOI 10.1073/pnas.89.16.7806; Germain S, 1996, BIOCHEM J, V316, P107, DOI 10.1042/bj3160107; Germain S, 1997, FEBS LETT, V407, P177, DOI 10.1016/S0014-5793(97)00332-3; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; Konoshita T, 1996, KIDNEY INT, V50, P1515, DOI 10.1038/ki.1996.466; Lang JA, 1996, AM J PHYSIOL-RENAL, V271, pF94, DOI 10.1152/ajprenal.1996.271.1.F94; LANG JA, 1995, HYPERTENSION, V25, P704, DOI 10.1161/01.HYP.25.4.704; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; Petrovic N, 1996, J BIOL CHEM, V271, P22499, DOI 10.1074/jbc.271.37.22499; PINET F, 1988, J CLIN ENDOCR METAB, V67, P1211, DOI 10.1210/jcem-67-6-1211; POISNER AM, 1981, ENDOCRINOLOGY, V109, P1150, DOI 10.1210/endo-109-4-1150; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SIGMUND CD, 1990, J BIOL CHEM, V265, P19916; SIGMUND CD, 1990, BIOCHEM BIOPH RES CO, V170, P344, DOI 10.1016/0006-291X(90)91280-6; SKINNER SL, 1968, AM J OBSTET GYNECOL, V101, P529, DOI 10.1016/0002-9378(68)90564-4; SOUBRIER F, 1983, NUCLEIC ACIDS RES, V11, P7181, DOI 10.1093/nar/11.20.7181; TRAVERS AA, 1989, ANNU REV BIOCHEM, V58, P427, DOI 10.1146/annurev.biochem.58.1.427; Yan Y, 1997, CIRC RES, V81, P558, DOI 10.1161/01.RES.81.4.558	28	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25292	25300		10.1074/jbc.273.39.25292	http://dx.doi.org/10.1074/jbc.273.39.25292			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737995	hybrid			2022-12-27	WOS:000076085400045
J	Merlos-Suarez, A; Fernandez-Larrea, J; Reddy, P; Baselga, J; Arribas, J				Merlos-Suarez, A; Fernandez-Larrea, J; Reddy, P; Baselga, J; Arribas, J			Pro-tumor necrosis factor-alpha processing activity is tightly controlled by a component that does not affect notch processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; GROWTH-FACTOR-ALPHA; TNF RECEPTOR; L-SELECTIN; METALLOPROTEASE; MEMBRANE; INHIBITOR; DISINTEGRIN; CLEAVAGE; BETA	The extracellular domain of a heterogeneous group of transmembrane proteins can be proteolytically released from the cell surface, a process known as protein ectodomain shedding. Despite the biomedical importance of several substrates of the shedding system, such as the beta-amyloid precursor protein (beta APP), little is known about the regulation of protein ectodomain shedding, and the only protease known to be involved is the metalloprotease disintegrin, tumor necrosis factor-alpha converting enzyme (TACE). Here, we show that previously described pro-transforming growth factor-alpha shedding-defective cell mutants (M2 cells), known to be defective in ectodomain shedding of several molecules, that include beta APP, fail to shed the ectodomain of pro-TNF-alpha. The target of the mutation is a component required for TACE activity, since transfection of TACE into M2 cells has no effect on the shedding of pro-TNF-alpha and somatic cell fusions between M2 cells and TACE null cells recover the ability to shed pro-TNF-alpha, pro-transforming growth factor-alpha, and beta APP. Furthermore, we show that TACE is also necessary for the shedding of beta APP since TACE null cells show defective beta APP shedding. Biochemical evidence shows that the component that controls TACE is different from protein kinase C, the only known activator of protein ectodomain shedding, and that this component does not affect biosynthesis or processing of TACE or other metalloprotease disintegrins. The component mutated in M2 cells is likely to control only a subset of metalloprotease disintegrins involved in regulated ectodomain shedding, since Notch processing, a process known to be dependent on the activity of another metalloprotease disintegrin, Kuzbanian, is normal in M2 cells.	Hosp Gen Univ Vall Hebron, Med Oncol Serv, Lab Recerca Oncol, Barcelona 08035, Spain; Immunex Res & Dev Corp, Seattle, WA 98101 USA	Hospital Universitari Vall d'Hebron	Arribas, J (corresponding author), Hosp Gen Univ Vall Hebron, Med Oncol Serv, Lab Recerca Oncol, Psg Val Hebron 119-129, Barcelona 08035, Spain.	jarribas@hg.vhebron.es	Arribas, Joaquin/M-4482-2014	Arribas, Joaquin/0000-0002-0504-0664; Fernandez-Larrea, Juan Bautista/0000-0001-8007-8040				ADEREM A, 1995, BIOCHEM SOC T, V23, P587, DOI 10.1042/bst0230587; Arribas J, 1997, J BIOL CHEM, V272, P17160, DOI 10.1074/jbc.272.27.17160; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Couet J, 1996, J BIOL CHEM, V271, P4545; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; Kratzschmar J, 1996, J BIOL CHEM, V271, P4593; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MIGAKI GI, 1995, J EXP MED, V182, P549, DOI 10.1084/jem.182.2.549; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MULLBERG J, 1994, J IMMUNOL, V152, P4958; MULLBERG J, 1995, J IMMUNOL, V155, P5198; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Rosendahl MS, 1997, J BIOL CHEM, V272, P24588, DOI 10.1074/jbc.272.39.24588; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Tang P, 1996, BIOCHEMISTRY-US, V35, P8226, DOI 10.1021/bi952183l; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	34	82	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24955	24962		10.1074/jbc.273.38.24955	http://dx.doi.org/10.1074/jbc.273.38.24955			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733803	hybrid			2022-12-27	WOS:000076007300095
J	Berkemeyer, M; Scheibe, R; Ocheretina, O				Berkemeyer, M; Scheibe, R; Ocheretina, O			A novel, non-redox-regulated NAD-dependent malate dehydrogenase from chloroplasts of Arabidopsis thaliana L.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESEMBRYANTHEMUM-CRYSTALLINUM L; CRASSULACEAN ACID METABOLISM; FATTY-ACID; ASPARTATE-AMINOTRANSFERASE; SPINACH-CHLOROPLASTS; CARBON METABOLISM; ROOT PLASTIDS; MITOCHONDRIAL; ENZYMES; STARCH	We report a novel plastidic NAD-dependent malate dehydrogenase (EC 1.1.1.37), which is not redox-regulated in contrast to its NADP-specific counterpart (EC 1.1.1.82), Analysis of isoenzyme patterns revealed a single NAD-MDH associated with highly purified chloroplasts isolated from Arabidopsis and spinach. A cDNA clone encoding the novel enzyme was found in the Arabidopsis EST data base by sorting all putative clones for NAD dependent malate dehydrogenase. A derived amino acid sequence is very similar to mitochondrial and peroxisomal NAD-MDHs within the region coding for the mature protein but possesses a 80-amino acid long N-terminal domain with typical characteristics of a chloroplast transit peptide. In vitro synthesized labeled precursor protein was imported into the stroma of spinach chloroplasts and processed to a mature enzyme subunit of 34 kDa. Expressed in Escherichia coli, the recombinant enzyme exhibited the same distinctive isoelectric point of 5.35 as the original enzyme from Arabidopsis chloroplasts. Northern analysis revealed that the protein is expressed in both autotrophic and heterotrophic tissues. The findings reported here indicate that the "malate valve" operates not only in the illuminated chloroplasts but also in dark chloroplasts and in heterotrophic plastids and is therefore a general mechanism to maintain the optimal ratio between ATP and reducing equivalents in plastids.	Univ Osnabruck, Fachbereich Biol Chem, D-49069 Osnabruck, Germany	University Osnabruck	Ocheretina, O (corresponding author), Univ Osnabruck, Fachbereich Biol Chem, D-49069 Osnabruck, Germany.							AMINO S, 1992, Z NATURFORSCH C, V47, P545; Backhausen JE, 1998, PLANTA, V205, P359, DOI 10.1007/s004250050331; BEECKMANS S, 1981, EUR J BIOCHEM, V117, P527; Bergmeyer H. U., 1983, METHOD ENZYMAT AN, V2, P324; BIRKTOFT JJ, 1989, BIOCHEM SOC T, V17, P301, DOI 10.1042/bst0170301; BIRKTOFT JJ, 1984, PEPT PROTEIN REV, V4, P1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITER DR, 1994, PROTEIN SCI, V3, P2023, DOI 10.1002/pro.5560031115; COOPER TG, 1969, J BIOL CHEM, V244, P3507; EDWARDS GE, 1985, ANNU REV PLANT PHYS, V36, P255, DOI 10.1146/annurev.pp.36.060185.001351; FLUGGE UI, 1989, EMBO J, V8, P39, DOI 10.1002/j.1460-2075.1989.tb03346.x; GIETL C, 1992, BIOCHIM BIOPHYS ACTA, V1100, P217, DOI 10.1016/0167-4838(92)90476-T; GOODMAN MM, 1981, P NATL ACAD SCI-BIOL, V78, P1783, DOI 10.1073/pnas.78.3.1783; HEBER U, 1974, ANNU REV PLANT PHYS, V25, P393, DOI 10.1146/annurev.pp.25.060174.002141; HOLTUM JAM, 1982, PLANTA, V155, P8, DOI 10.1007/BF00402925; JARRET RL, 1986, J HERED, V77, P183, DOI 10.1093/oxfordjournals.jhered.a110212; Jorge IC, 1997, BIOCHEM GENET, V35, P155, DOI 10.1023/A:1021950008544; KANG F, 1994, PLANT J, V6, P795, DOI 10.1046/j.1365-313X.1994.6060795.x; KLEPPINGERSPARACE KF, 1992, PLANT PHYSIOL, V98, P723, DOI 10.1104/pp.98.2.723; KRAUSE HG, 1976, INTACT CHLOROPLAST, P171; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P21, DOI DOI 10.1016/0003-2697(87)90086-8; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; MacKinney G, 1941, J BIOL CHEM, V140, P315; Martin W, 1997, CURR GENET, V32, P1, DOI 10.1007/s002940050241; MCALISTERHENN L, 1988, TRENDS BIOCHEM SCI, V13, P178, DOI 10.1016/0968-0004(88)90146-6; MOURIOUX G, 1981, PLANT PHYSIOL, V67, P470, DOI 10.1104/pp.67.3.470; Neuhaus HE, 1996, BIOCHEM J, V318, P945, DOI 10.1042/bj3180945; NEUHAUS HE, 1993, BIOCHEM J, V296, P395, DOI 10.1042/bj2960395; Neuhaus HE, 1997, PLANT J, V11, P73, DOI 10.1046/j.1365-313X.1997.11010073.x; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; Nishimura M, 1996, CELL STRUCT FUNCT, V21, P387, DOI 10.1247/csf.21.387; Ocheretina O, 1997, GENE, V199, P145, DOI 10.1016/S0378-1119(97)00361-2; ROCHA V, 1968, BIOCHEM BIOPH RES CO, V31, P890, DOI 10.1016/0006-291X(68)90535-4; Sambrook J., 2002, MOL CLONING LAB MANU; SCHEIBE R, 1979, PLANT PHYSIOL, V64, P744, DOI 10.1104/pp.64.5.744; SCHEIBE R, 1988, PLANT PHYSIOL BIOCH, V26, P473; SCHEIBE R, 1981, BIOCHIM BIOPHYS ACTA, V636, P58, DOI 10.1016/0005-2728(81)90075-X; SCHEIBE R, 1987, PHYSIOL PLANTARUM, V71, P393, DOI 10.1111/j.1399-3054.1987.tb04362.x; SIEBKE K, 1991, PLANTA, V185, P337, DOI 10.1007/BF00201053; SMITH RG, 1992, PLANT PHYSIOL, V98, P1233, DOI 10.1104/pp.98.4.1233; SOMERVILLE CR, 1981, PLANT SCI LETT, V21, P89, DOI 10.1016/0304-4211(81)90073-0; STITT M, 1981, PLANT PHYSIOL, V68, P755, DOI 10.1104/pp.68.3.755; TELLER JK, 1990, J BIOL CHEM, V265, P19486; TITUS DE, 1983, PLANT PHYSIOL, V72, P402, DOI 10.1104/pp.72.2.402; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; VONHEIJNE G, 1992, TRANSPORT AND RECEPTOR PROTEINS OF PLANT MEMBRANES, P195; Wada H, 1997, P NATL ACAD SCI USA, V94, P1591, DOI 10.1073/pnas.94.4.1591; WALK RA, 1977, PLANTA, V136, P211, DOI 10.1007/BF00385987; WALKER DA, 1976, ENCYCLOPEDIA PLANT P, V3, P85; WALKER DA, 1988, USE OXYGEN ELECTRODE, P117; WEBER A, 1995, BIOCHEMISTRY-US, V34, P2621, DOI 10.1021/bi00008a028; Wenderoth I, 1997, J BIOL CHEM, V272, P26985, DOI 10.1074/jbc.272.43.26985; WILLEFORD KO, 1989, PLANT PHYSIOL, V90, P788, DOI 10.1104/pp.90.3.788; WINTER K, 1982, PLANT PHYSIOL, V69, P300, DOI 10.1104/pp.69.2.300; WOLOSIUK RA, 1977, FEBS LETT, V81, P253, DOI 10.1016/0014-5793(77)80529-2; Wright DP, 1997, PLANT PHYSIOL, V114, P1413, DOI 10.1104/pp.114.4.1413; YAMAZAKI RK, 1969, BIOCHIM BIOPHYS ACTA, V178, P11, DOI 10.1016/0005-2744(69)90127-2	58	63	69	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27927	27933		10.1074/jbc.273.43.27927	http://dx.doi.org/10.1074/jbc.273.43.27927			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774405	hybrid			2022-12-27	WOS:000076549800025
J	Boelens, WC; Cross, Y; de Ruwe, M; de Reu, L; de Jong, WW				Boelens, WC; Cross, Y; de Ruwe, M; de Reu, L; de Jong, WW			Negative charges in the C-terminal domain stabilize the alpha B-crystallin complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; CHAPERONE-LIKE ACTIVITY; A-CRYSTALLIN; MOLECULAR CHAPERONE; SUBUNIT INTERFACE; PHOSPHORYLATION; EXPRESSION; STRESS; HSP27; LENS	alpha B-Crystallin is one of the six known mammalian small heat-shock proteins (sHsps). These are characterized by the presence of a conserved sequence of 80-100 residues, which constitutes the putative C-terminal domain, Like other sHsps, alpha B-crystallin forms multimeric globular complexes, often in combination with related sHsps, Here we show that in a yeast two-hybrid system, alpha B-crystallin can specifically interact with itself as well as with alpha A-crystallin and Hsp27. Analyses of the separate domains show that the conserved C-terminal domain (C alpha B) is essential for this interaction between subunits. To try and detect residues that are important in subunit interaction, the C alpha B domain was used in a two-hybrid screen as bait to select randomly mutated C alpha B mutants. In this way we obtained nine mutants that were still able to interact with wild-type C alpha B despite the presence of up to 15 replacements, Similarly, we obtained 16 mutants that were unable to bind, because of the presence of just three to nine replacements, In binding C alpha B mutants, lysine residues were most often replaced by glutamic acid residues, and in non-binding C alpha B mutants, acidic residues were often found to be replaced by non-charged residues. This indicates that negative charges are important for subunit interaction and we propose a model to explain this role of acidic residues, Furthermore, we observed that two homologs of alpha B-crystallin, alpha A-crystallin and Hsp27, generally interact similarly with the binding and non-binding C alpha B mutants as does alpha B-crystallin, This suggests that interactions involved in the complex formation of these three sHsps are largely comparable.	Univ Nijmegen, Dept Biochem, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Boelens, WC (corresponding author), Univ Nijmegen, Dept Biochem, POB 9101, NL-6500 HB Nijmegen, Netherlands.		Boelens, Wilbert/D-8877-2012		NEI NIH HHS [EY09683] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009683] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AOYAMA A, 1993, MOL CELL BIOL, V13, P1824, DOI 10.1128/MCB.13.3.1824; BARTEL PL, 1995, METHODS ENZYMOL, V254; Berengian AR, 1997, BIOCHEMISTRY-US, V36, P9951, DOI 10.1021/bi9712347; BOELENS WC, 1995, MOL BIOL REP, V21, P75, DOI 10.1007/BF00986495; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSSEMAKERS MJG, 1992, BIOCHEM BIOPH RES CO, V182, P1254, DOI 10.1016/0006-291X(92)91866-O; CARVER JA, 1992, FEBS LETT, V311, P143, DOI 10.1016/0014-5793(92)81386-Z; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; Djabali K, 1997, J CELL SCI, V110, P2759; EHRNSPERGER M, 1997, MOL CHAPERONES LIFE, P1; Gerards WLH, 1997, J BIOL CHEM, V272, P10080; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Haley DA, 1998, J MOL BIOL, V277, P27, DOI 10.1006/jmbi.1997.1611; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Horwitz J, 1998, INT J BIOL MACROMOL, V22, P263, DOI 10.1016/S0141-8130(98)00024-5; INAGUMA Y, 1995, J BIOCHEM-TOKYO, V117, P1238, DOI 10.1093/oxfordjournals.jbchem.a124850; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KATO K, 1994, J BIOL CHEM, V269, P11274; KATO K, 1994, J BIOL CHEM, V269, P15302; KATO K, 1992, J BIOL CHEM, V267, P7718; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; LI B, 1993, FASEB J, V7, P957, DOI 10.1096/fasebj.7.10.8344494; Mchaourab HS, 1997, BIOCHEMISTRY-US, V36, P14627, DOI 10.1021/bi971700s; Mehlen P, 1997, BIOCHEM BIOPH RES CO, V241, P187, DOI 10.1006/bbrc.1997.7635; MEHLEN P, 1994, EUR J BIOCHEM, V221, P327, DOI 10.1111/j.1432-1033.1994.tb18744.x; MERCK KB, 1992, BIOCHIM BIOPHYS ACTA, V1130, P267, DOI 10.1016/0167-4781(92)90439-7; MERCK KB, 1993, MOL BIOL REP, V18, P209, DOI 10.1007/BF01674432; MERCK KB, 1993, J BIOL CHEM, V268, P1046; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; Muchowski PJ, 1997, J BIOL CHEM, V272, P2578; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; Plater ML, 1996, J BIOL CHEM, V271, P28558, DOI 10.1074/jbc.271.45.28558; RAATS JMH, 1992, EUR J CELL BIOL, V58, P108; RUSSO G, 1992, BIOCHEMISTRY-US, V31, P9279, DOI 10.1021/bi00153a022; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SIEZEN RJ, 1983, BIOCHIM BIOPHYS ACTA, V748, P56, DOI 10.1016/0167-4838(83)90027-4; Smulders RHPH, 1998, INT J BIOL MACROMOL, V22, P187, DOI 10.1016/S0141-8130(98)00016-6; Smulders RHPH, 1996, J BIOL CHEM, V271, P29060, DOI 10.1074/jbc.271.46.29060; SMULDERS RHPH, 1995, EUR J BIOCHEM, V232, P834, DOI 10.1111/j.1432-1033.1995.834zz.x; Sun TX, 1998, J BIOL CHEM, V273, P286, DOI 10.1074/jbc.273.1.286; van de Klundert FAJM, 1998, EUR J CELL BIOL, V75, P38, DOI 10.1016/S0171-9335(98)80044-7; VANDENOETELAAR PJM, 1990, BIOCHEMISTRY-US, V29, P3488, DOI 10.1021/bi00466a010; VANNOORT JM, 1995, NATURE, V375, P798, DOI 10.1038/375798a0; WISTOW G, 1985, FEBS LETT, V181, P1, DOI 10.1016/0014-5793(85)81102-9; Wotton D, 1996, J BIOL CHEM, V271, P2717, DOI 10.1074/jbc.271.5.2717; ZANTEMA A, 1992, J BIOL CHEM, V267, P12936	50	39	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28085	28090		10.1074/jbc.273.43.28085	http://dx.doi.org/10.1074/jbc.273.43.28085			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774426	hybrid			2022-12-27	WOS:000076549800046
J	Brockstedt, E; Rickers, A; Kostka, S; Laubersheimer, A; Dorken, B; Wittmann-Liebold, B; Bommert, K; Otto, A				Brockstedt, E; Rickers, A; Kostka, S; Laubersheimer, A; Dorken, B; Wittmann-Liebold, B; Bommert, K; Otto, A			Identification of apoptosis-associated proteins in a human Burkitt lymphoma cell line - Cleavage of heterogeneous nuclear ribonucleoprotein A1 by caspase 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-DIMENSIONAL ELECTROPHORESIS; MASS-SPECTROMETRY; C-MYC; BINDING; PROTEASES; DOMAIN; LOCALIZATION; HOMOLOG; ENZYME; ACTIN	Apoptosis or programmed cell death is essential in the process of controlling lymphocyte growth and selection. We identified proteins that are involved in anti-IgM antibody-mediated apoptosis using a subclone of the human Burkitt lymphoma cell line BL60, Apoptosis-associated proteins were detected by high resolution two-dimensional gel electrophoresis on a micropreparative scale. Comparison of the high resolution two dimensional gel electrophoresis protein patterns from apoptotic and non-apoptotic cells showed differences in similar to 80 spots including protein modifications. Analysis of the predominantly altered proteins was performed by internal Edman microsequencing and/or by peptide mass fingerprinting using matrix-assisted laser desorption/ionization mass spectrometry, Analysis was significantly improved by using new micropreparative high resolution two-dimensional gels employing high protein concentrations. The following 12 apoptosis-associated proteins were identified: heterogeneous nuclear ribonucleoprotein (hnRNP) A1, hnRNP C1/C2, FUSE-binding protein, dUTPase, lymphocyte-specific protein LSP1, UV excision repair protein RAD23 homologue B (HHR23B), 60 S acidic ribosomal protein P0 (L10E), heterochromatin protein 1 homologue alpha (HP1 alpha), nucleolin, lamin, neutral calponin, and actin, Fragmentation of actin, hnRNP A1, hnRNP C1/C2, 60 S acidic ribosomal protein P0, lamin, and nucleolin could be inhibited by benzyloxycarbonyl-Asp(OMe)-Glu(OMe)-Val-Asp(OMe)-fluoromethyl ketone, a selective irreversible inhibitor of CPP32 (caspase 3).	Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Humboldt Univ, Charite, Robert Rossle Klin, D-13125 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Wittmann-Liebold, B (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13125 Berlin, Germany.		Bommert, Kurt/G-9247-2011					AEBERSOLD R, 1990, ELECTROPHORESIS, V11, P540; BAZAR L, 1995, ONCOGENE, V10, P2229; Bharti AK, 1996, J BIOL CHEM, V271, P1993, DOI 10.1074/jbc.271.4.1993; Boise LH, 1996, SCIENCE, V274, P67, DOI 10.1126/science.274.5284.67; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; DUDLEY B, 1992, J BIOL CHEM, V267, P11964; ECKERSKORN C, 1988, ELECTROPHORESIS, V9, P830, DOI 10.1002/elps.1150091208; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GADSDEN MH, 1993, EMBO J, V12, P4425, DOI 10.1002/j.1460-2075.1993.tb06127.x; Gevaert K, 1995, METHODS IN PROTEIN STRUCTURE ANALYSIS, P15; GRABOWSKI DT, 1991, NUCLEIC ACIDS RES, V19, P4297, DOI 10.1093/nar/19.15.4297; HENZEL WJ, 1993, P NATL ACAD SCI USA, V90, P5011, DOI 10.1073/pnas.90.11.5011; JONGSTRABILEN J, 1992, J CELL BIOL, V118, P1443, DOI 10.1083/jcb.118.6.1443; KLOSE J, 1975, HUMANGENETIK, V26, P231; KLOSE J, 1995, ELECTROPHORESIS, V16, P1034, DOI 10.1002/elps.11501601175; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; Ladner RD, 1997, J BIOL CHEM, V272, P19072, DOI 10.1074/jbc.272.30.19072; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; Masuda H, 1996, J BIOCHEM-TOKYO, V120, P415; MELTZER NM, 1987, ANAL BIOCHEM, V160, P356, DOI 10.1016/0003-2697(87)90060-1; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Otto A, 1996, ELECTROPHORESIS, V17, P1643, DOI 10.1002/elps.1150171027; PASTERNACK MS, 1991, J BIOL CHEM, V266, P14703; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Rickers A, 1998, EUR J IMMUNOL, V28, P296, DOI 10.1002/(SICI)1521-4141(199801)28:01<296::AID-IMMU296>3.0.CO;2-4; Serin G, 1996, BIOCHIMIE, V78, P530, DOI 10.1016/0300-9084(96)84759-6; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Sugasawa K, 1997, MOL CELL BIOL, V17, P6924, DOI 10.1128/MCB.17.12.6924; Sugasawa K, 1996, MOL CELL BIOL, V16, P4852; Sugimoto K, 1996, J BIOCHEM, V120, P153; Thiede B, 1996, ELECTROPHORESIS, V17, P588, DOI 10.1002/elps.1150170330; Waterhouse N, 1996, J BIOL CHEM, V271, P29335, DOI 10.1074/jbc.271.46.29335; Whyte M, 1996, TRENDS CELL BIOL, V6, P245, DOI 10.1016/0962-8924(96)20025-X; WITTMANNLIEBOLD B, 1994, CONCEPTS PROTEIN ENG, P47; Ye QA, 1997, J BIOL CHEM, V272, P14983, DOI 10.1074/jbc.272.23.14983; YOKOTE Y, 1986, ANAL BIOCHEM, V152, P245, DOI 10.1016/0003-2697(86)90405-7	41	156	168	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28057	28064		10.1074/jbc.273.43.28057	http://dx.doi.org/10.1074/jbc.273.43.28057			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774422	hybrid			2022-12-27	WOS:000076549800042
J	Qiu, XB; Lin, YL; Thome, KC; Pian, P; Schlegel, BP; Weremowicz, S; Parvin, JD; Dutta, A				Qiu, XB; Lin, YL; Thome, KC; Pian, P; Schlegel, BP; Weremowicz, S; Parvin, JD; Dutta, A			An eukaryotic RuvB-like protein (RUVBL1) essential for growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; MEDIATED ATP HYDROLYSIS; ESCHERICHIA-COLI; BRANCH MIGRATION; RAD51 GENE; HOMOLOGOUS RECOMBINATION; CELL-CYCLE; IN-VITRO; DNA; COMPLEX	A human protein (RUVBL1), consisting of 456 amino acids (50 kDa) and highly homologous to RuvB, was identified by using the 14-kDa subunit of replication protein A (hsRPA3) as bait in a yeast two-hybrid system. RuvB is a bacterial protein involved in genetic recombination that bears structural similarity to subunits of the RF-C clamp loader family of proteins. Fluorescence in situ hybridization analysis demonstrated that the RUVBL1 gene is located at 3q21, a region with frequent rearrangements in different types of leukemia and solid tumors. RUVBL1 co-immunoprecipitated with at least three other unidentified cellular proteins and was detected in the RNA polymerase II holoenzyme complex purified over multiple chromatographic steps. In addition, two yeast homologs, scRUVBL1 and scRUVBL2 with 70 and 42% identity to RUVBL1, respectively, were revealed by screening the complete Saccharomyces cerevisiae genome sequence. Yeast with a null mutation in scRUVBL1 was nonviable. Thus RUVBL1 is an eukaryotic member of the RuvB/clamp loader family of structurally related proteins from bacteria and eukaryotes that is essential for viability of yeast.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol,Div Mol Oncol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Dutta, A (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol,Div Mol Oncol, 75 Francis St,Thorn 630, Boston, MA 02115 USA.	adutta@rics.bwh.harvard.edu	Dutta, Anindya/P-3203-2016; Parvin, Jeffrey D/C-8955-2009	Qiu, Xiao-Bo/0000-0003-2608-9376; Dutta, Anindya/0000-0002-4319-0073	NIGMS NIH HHS [GM53504] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053504] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ali RB, 1998, MOL CELL BIOL, V18, P1660, DOI 10.1128/MCB.18.3.1660; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Baumann P, 1997, EMBO J, V16, P5198, DOI 10.1093/emboj/16.17.5198; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; Eggleston AK, 1997, CELL, V89, P607, DOI 10.1016/S0092-8674(00)80242-1; Flygare J, 1996, BBA-MOL CELL RES, V1312, P231, DOI 10.1016/0167-4889(96)00040-7; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P451; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HIOM K, 1995, CELL, V80, P787, DOI 10.1016/0092-8674(95)90357-7; Kanemaki M, 1997, BIOCHEM BIOPH RES CO, V235, P64, DOI 10.1006/bbrc.1997.6729; Kashuba VI, 1997, FEBS LETT, V419, P181, DOI 10.1016/S0014-5793(97)01449-X; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; Lin CLG, 1998, NUCLEIC ACIDS RES, V26, P1466, DOI 10.1093/nar/26.6.1466; Lin YL, 1996, J BIOL CHEM, V271, P17190, DOI 10.1074/jbc.271.29.17190; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; Marrione PE, 1996, BIOCHEMISTRY-US, V35, P11228, DOI 10.1021/bi960316c; MARRIONE PE, 1995, BIOCHEMISTRY-US, V34, P9809, DOI 10.1021/bi00030a019; Mitchell AH, 1996, J BIOL CHEM, V271, P19497, DOI 10.1074/jbc.271.32.19497; MULLER B, 1993, J BIOL CHEM, V268, P17179; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Neish AS, 1998, NUCLEIC ACIDS RES, V26, P847, DOI 10.1093/nar/26.3.847; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; Rynditch A, 1997, GENE, V193, P49, DOI 10.1016/S0378-1119(97)00076-0; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; STRUCK JCR, 1988, NUCLEIC ACIDS RES, V16, P2720, DOI 10.1093/nar/16.6.2720; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Tong J, 1996, J BACTERIOL, V178, P2695, DOI 10.1128/jb.178.9.2695-2700.1996; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; WIKLER GS, 1998, J BIOL CHEM, V273, P1092; Yamamoto A, 1996, MOL GEN GENET, V251, P1; ZHAO Y, 1995, MOL CELL BIOL, V15, P4353; Zou H, 1997, CELL, V90, P87, DOI 10.1016/S0092-8674(00)80316-5	41	112	114	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27786	27793		10.1074/jbc.273.43.27786	http://dx.doi.org/10.1074/jbc.273.43.27786			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774387	hybrid			2022-12-27	WOS:000076549800007
J	Strehlow, I; Schindler, C				Strehlow, I; Schindler, C			Amino-terminal signal transducer and activator of transcription (STAT) domains regulate nuclear translocation and STAT deactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-ALPHA; TYROSINE PHOSPHORYLATION; DNA-BINDING; IFN-GAMMA; FACTOR ISGF-3; PROTEIN; RECEPTOR; GENE; PATHWAY; PHOSPHATASE	The first similar to 100 amino acids of the STAT (Signal transducer and activator of transcription) family of transcription factors share a high degree of sequence similarity. To determine whether they encode a functionally conserved domain, amino-terminal chimeric STATs were created. These chimeric STATs share a number of properties with wild-type Stat1, including a predominately cytoplasmic pattern of expression in unstimulated cells. Upon stimulation with ligand, the chimeric STATs rapidly become tyrosine-phosphorylated, dimerize, and are able to bind DNA, They are also able to heterodimerize with coexpressed wild-type Stat1. Yet in contrast to wild-type Stat1, the chimeric STATs exhibit a marked defect in deactivation. Moreover, the persistence of active chimeras correlates directly with an inability to translocate to the nucleus. The defects both in nuclear translocation and in deactivation are rescued by heterodimerization with coexpressed wild-type Stat1. This study indicates that STAT amino termini provide a signal that is important for nuclear translocation and, subsequently, deactivation, It also suggests that deactivation may depend on a prior nuclear localization event.	Columbia Univ, Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA	Columbia University; Columbia University	Schindler, C (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Microbiol, HHSC 1208,701 W 168th St, New York, NY 10032 USA.							AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; Barahmand-Pour F, 1998, J BIOL CHEM, V273, P12567, DOI 10.1074/jbc.273.20.12567; BARBIERI G, 1994, EUR J BIOCHEM, V223, P427, DOI 10.1111/j.1432-1033.1994.tb19010.x; BECKER S, 1998, SCIENCE, V394, P145; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; DAVID M, 1993, MOL CELL BIOL, V13, P7515, DOI 10.1128/MCB.13.12.7515; EILERS A, 1993, MOL CELL BIOL, V13, P3245, DOI 10.1128/MCB.13.6.3245; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; Gupta S, 1996, EMBO J, V15, P1075, DOI 10.1002/j.1460-2075.1996.tb00445.x; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; IMPROTA T, 1994, P NATL ACAD SCI USA, V91, P4776, DOI 10.1073/pnas.91.11.4776; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Lee CK, 1997, J BIOL CHEM, V272, P21872, DOI 10.1074/jbc.272.35.21872; Li XX, 1997, MOL CELL BIOL, V17, P2048, DOI 10.1128/MCB.17.4.2048; MartinezMoczygemba M, 1997, J BIOL CHEM, V272, P20070, DOI 10.1074/jbc.272.32.20070; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Pawson T, 1997, NATURE, V385, P582, DOI 10.1038/385582b0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; ROTHMAN P, 1994, IMMUNITY, V1, P457, DOI 10.1016/1074-7613(94)90088-4; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Sekimoto T, 1996, J BIOL CHEM, V271, P31017, DOI 10.1074/jbc.271.49.31017; SEKIMOTO T, 1997, EMBO J, V16, P7076; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Shuai K, 1996, MOL CELL BIOL, V16, P4932; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; STREHLOW I, 1997, GAMMA INTERFERON ANT, P61; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x; YAN H, 1996, MOL CELL BIOL, V16, P2974; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; ZIEGLER SF, 1993, MOL CELL BIOL, V13, P2384, DOI 10.1128/MCB.13.4.2384	49	79	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28049	28056		10.1074/jbc.273.43.28049	http://dx.doi.org/10.1074/jbc.273.43.28049			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774421	hybrid			2022-12-27	WOS:000076549800041
J	Yoshida, LS; Saruta, F; Yoshikawa, K; Tatsuzawa, O; Tsunawaki, S				Yoshida, LS; Saruta, F; Yoshikawa, K; Tatsuzawa, O; Tsunawaki, S			Mutation at histidine 338 of gp91(phox) depletes FAD and affects expression of cytochrome b(558) of the human NADPH oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; SUPEROXIDE-GENERATING SYSTEM; B-CELL LINES; PORCINE NEUTROPHILS; BINDING-SITE; HEAVY-CHAIN; FLAVOCYTOCHROME B(558); CYTOSOLIC COMPONENT; POINT MUTATIONS	Defective NADPH oxidase components prevent superoxide (O-2(radical anion)) generation, causing chronic granulomatous disease (CGD). X-linked CGD patients have mutations in the gene encoding the gp91(phox) subunit of cytochrome b(558) and usually lack gp91(phox) protein completely (X91(0)). gp91(phox) is considered to be a flavocytochrome that contains binding sites for NADPH, FAD, as well as heme. We here report a rare X-linked CGD patient whose neutrophils entirely failed to produce O-2(radical anion), but presented a diminished expression of gp91(phox) containing about one-third of the heme present in normal individuals by Soret absorption. Translocation of cytosolic factors p67(phox) and p47(phox) was normal. However, the FAD content in his neutrophil membranes was as low as that of X91(0) patients, suggesting complete depletion of FAD in his gp91(phox). This was in agreement with the finding that a single base substitution (C1024 to T) changed His-338 to Tyr in gp91(phox) in a predicted FAD-binding domain of the flavocytochrome model. The loss of FAD could not be corrected even after addition of reagent FAD or a FAD-rich dehydrogenase fraction isolated from normal neutrophils to the patient's membranes, in a reconstitution in vitro with normal cytosol. These results indicate that His-338 is a very critical residue for FAD incorporation into the NADPH oxidase system. This is the first such mutation found in CGD.	Childrens Natl Med Ctr, Setagaya Ku, Tokyo 1548509, Japan		Tsunawaki, S (corresponding author), Childrens Natl Med Ctr, Setagaya Ku, 3-35-31 Taishido, Tokyo 1548509, Japan.	tsunawaki-s@nch.go.jp						ARIGA T, 1994, HUM GENET, V94, P441; Bjorgvinsdottir H, 1996, BLOOD, V87, P2005, DOI 10.1182/blood.V87.5.2005.bloodjournal8752005; BOLSCHER BGJM, 1991, BLOOD, V77, P2482; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSS AR, 1982, BIOCHEM J, V204, P479, DOI 10.1042/bj2040479; CROSS AR, 1995, J BIOL CHEM, V270, P17075, DOI 10.1074/jbc.270.29.17075; CROSS AR, 1994, J BIOL CHEM, V269, P21448; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; DINAUER MC, 1989, J CLIN INVEST, V84, P2012, DOI 10.1172/JCI114393; DOUSSIERE J, 1993, BIOCHEMISTRY-US, V32, P8880, DOI 10.1021/bi00085a020; Doussiere J, 1996, BIOCHEMISTRY-US, V35, P13400, DOI 10.1021/bi960916b; DOUSSIERE J, 1995, BIOCHEMISTRY-US, V34, P1760, DOI 10.1021/bi00005a033; Finegold AA, 1996, J BIOL CHEM, V271, P31021, DOI 10.1074/jbc.271.49.31021; FRIDEN H, 1990, MOL MICROBIOL, V4, P1045, DOI 10.1111/j.1365-2958.1990.tb00677.x; FUJII H, 1992, BIOCHIM BIOPHYS ACTA, V1136, P239, DOI 10.1016/0167-4889(92)90112-O; Fujii H, 1995, FEBS LETT, V377, P345, DOI 10.1016/0014-5793(95)01372-5; HOPKINS PJ, 1992, CLIN LAB MED, V12, P277, DOI 10.1016/S0272-2712(18)30516-X; ISOGAI Y, 1991, J BIOL CHEM, V266, P13481; KNOLLER S, 1991, J BIOL CHEM, V266, P2795; KOSHKIN V, 1994, FEBS LETT, V338, P285, DOI 10.1016/0014-5793(94)80285-8; LIGHT DR, 1981, BIOCHEMISTRY-US, V20, P1468, DOI 10.1021/bi00509a010; MIKI T, 1992, J BIOL CHEM, V267, P18695; MIKI T, 1992, J BIOL CHEM, V267, P19673; NISHIDA H, 1995, FEBS LETT, V361, P97, DOI 10.1016/0014-5793(95)00161-2; NISHIMOTO Y, 1994, BIOCHEM J, V297, P585; NISIMOTO Y, 1995, J BIOL CHEM, V270, P16428, DOI 10.1074/jbc.270.27.16428; ORKIN SH, 1989, ANNU REV IMMUNOL, V7, P277; Park MY, 1997, BIOCHEM BIOPH RES CO, V234, P531, DOI 10.1006/bbrc.1997.6672; PORTER CD, 1994, BLOOD, V84, P2767; Porter CD, 1996, BIOCHEM J, V315, P571, DOI 10.1042/bj3150571; QUINN MT, 1992, J BIOL CHEM, V267, P7303; RAVEL P, 1993, BIOCHEM BIOPH RES CO, V196, P543, DOI 10.1006/bbrc.1993.2284; ROOS D, 1992, J LEUKOCYTE BIOL, V51, P164, DOI 10.1002/jlb.51.2.164; Roos D, 1996, BLOOD, V87, P1663; Roos D, 1996, IMMUNOL TODAY, V17, P517; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; Sambrook J., 2002, MOL CLONING LAB MANU; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SOMEYA A, 1993, FEBS LETT, V330, P215, DOI 10.1016/0014-5793(93)80276-Z; SUMIMOTO H, 1992, BIOCHEM BIOPH RES CO, V186, P1368, DOI 10.1016/S0006-291X(05)81557-8; TAYLOR WR, 1993, PROTEIN SCI, V2, P1675, DOI 10.1002/pro.5560021013; THRASHER AJ, 1994, BBA-MOL BASIS DIS, V1227, P1, DOI 10.1016/0925-4439(94)90100-7; TSUNAWAKI S, 1994, J EXP MED, V179, P291, DOI 10.1084/jem.179.1.291; Tsunawaki S, 1996, J EXP MED, V184, P893, DOI 10.1084/jem.184.3.893; TSUNAWAKI S, 1994, BIOCHEM BIOPH RES CO, V199, P1378, DOI 10.1006/bbrc.1994.1383; VERHOEVEN AJ, 1993, J BIOL CHEM, V268, P18593; VOLKMAN DJ, 1984, J IMMUNOL, V133, P3006; Wallach TM, 1996, BIOCHEM J, V320, P33, DOI 10.1042/bj3200033; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557; YOSHIDA LS, 1992, BIOCHIM BIOPHYS ACTA, V1135, P245; ZHOU YL, 1995, BBA-MOL CELL RES, V1265, P40, DOI 10.1016/0167-4889(94)00207-U	52	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27879	27886		10.1074/jbc.273.43.27879	http://dx.doi.org/10.1074/jbc.273.43.27879			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774399	hybrid			2022-12-27	WOS:000076549800019
J	Harrop, JA; McDonnell, PC; Brigham-Burke, M; Lyn, SD; Minton, J; Tan, KB; Dede, K; Spampanato, J; Silverman, C; Hensley, P; DiPrinzio, R; Emery, JG; Deen, K; Eichman, C; Chabot-Fletcher, M; Truneh, A; Young, PR				Harrop, JA; McDonnell, PC; Brigham-Burke, M; Lyn, SD; Minton, J; Tan, KB; Dede, K; Spampanato, J; Silverman, C; Hensley, P; DiPrinzio, R; Emery, JG; Deen, K; Eichman, C; Chabot-Fletcher, M; Truneh, A; Young, PR			Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR RECEPTOR FAMILY; DOMAIN-CONTAINING RECEPTOR; PERIPHERAL LYMPHOID ORGANS; SURFACE-PLASMON RESONANCE; FACTOR-KAPPA-B; DEATH-DOMAIN; MOLECULAR-CLONING; TNF RECEPTOR; TISSUE DISTRIBUTION	Herpesvirus entry mediator (HVEM), a member of the tumor necrosis factor (TNF) receptor family, mediates herpesvirus entry into cells during infection. Upon overexpression, HVEM activates NF-kappa B and AP-1 through a TNF receptor-associated factor (TRAF)-mediated mechanism. Using an HVEM-Fc fusion protein, we screened soluble forms of novel TNF-related proteins derived from an expressed sequence fag data base. One of these, which we designated HVEM-L, specifically bound to HVEM-Fc with an affinity of 44 nM. This association was confirmed with soluble and membrane forms of both receptor and ligand, HVEM-L mRNA is expressed in spleen, lymph nodes, macrophages, and T cells and encodes a 240-amino acid protein. A soluble, secreted form of the protein stimulates proliferation of T lymphocytes during allogeneic responses, inhibits HT-29 cell growth, and weakly stimulates NF-kappa B-dependent transcription.	SmithKline Beecham Pharmaceut, Dept Mol Biol UW2101, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Mol & Cellular Immunol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Biol Struct, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Immunopharmacol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Gene Express Sci, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Prot Biochem, King Of Prussia, PA 19406 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Young, PR (corresponding author), SmithKline Beecham Pharmaceut, Dept Mol Biol UW2101, 709 Swedeland Rd, King Of Prussia, PA 19406 USA.	Peter_R_Young@SBPHRD.com	Truneh, Alem/ABB-7891-2020; Spampanato, Jay/C-8273-2009	Spampanato, Jay/0000-0003-3968-0608				ALDERSON MR, 1994, EUR J IMMUNOL, V24, P2219, DOI 10.1002/eji.1830240943; ALZONA M, 1994, J IMMUNOL, V153, P2861; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; BAENS M, 1993, GENOMICS, V16, P214, DOI 10.1006/geno.1993.1161; BANCHEREAU J, 1994, CELL, V68, P421; BANKS TA, 1995, J IMMUNOL, V155, P1685; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; Breton JJ, 1997, J PHARMACOL EXP THER, V282, P459; Browning JL, 1996, J EXP MED, V183, P867, DOI 10.1084/jem.183.3.867; BROWNING JL, 1995, J IMMUNOL, V154, P33; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; CROWE PD, 1994, SCIENCE, V264, P707, DOI 10.1126/science.8171323; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; GODFREY WR, 1994, J EXP MED, V180, P757, DOI 10.1084/jem.180.2.757; GRUSS HJ, 1995, BLOOD, V85, P3378, DOI 10.1182/blood.V85.12.3378.bloodjournal85123378; Harrop JA, 1998, J IMMUNOL, V161, P1786; HARROP JA, 1997, LEUKOCYTE, V6, P871; Hensley P, 1996, STRUCTURE, V4, P367, DOI 10.1016/S0969-2126(96)00042-1; HINTZEN RQ, 1995, J IMMUNOL, V154, P2612; HOWARD ST, 1991, VIROLOGY, V180, P633, DOI 10.1016/0042-6822(91)90077-O; Hsu HL, 1997, J BIOL CHEM, V272, P13471, DOI 10.1074/jbc.272.21.13471; HU FQ, 1994, VIROLOGY, V204, P343, DOI 10.1006/viro.1994.1539; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Kwon BS, 1997, J BIOL CHEM, V272, P14272, DOI 10.1074/jbc.272.22.14272; KWON BS, 1989, P NATL ACAD SCI USA, V86, P1963, DOI 10.1073/pnas.86.6.1963; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Marsters SA, 1997, J BIOL CHEM, V272, P14029, DOI 10.1074/jbc.272.22.14029; Mauri DN, 1998, IMMUNITY, V8, P21, DOI 10.1016/S1074-7613(00)80455-0; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; OSHANNESSY DJ, 1994, METHOD ENZYMOL, V240, P323; OSHANNESSY DJ, 1992, ANAL BIOCHEM, V205, P132, DOI 10.1016/0003-2697(92)90589-Y; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pasparakis M, 1997, P NATL ACAD SCI USA, V94, P6319, DOI 10.1073/pnas.94.12.6319; PATERSON DJ, 1987, MOL IMMUNOL, V24, P1281, DOI 10.1016/0161-5890(87)90122-2; POLLOK KE, 1993, J IMMUNOL, V150, P771; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STAFFORD WF, 1996, BIOPHYS J, V70, P231; Tan KB, 1997, GENE, V204, P35, DOI 10.1016/S0378-1119(97)00509-X; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; VanArsdale TL, 1997, P NATL ACAD SCI USA, V94, P2460, DOI 10.1073/pnas.94.6.2460; VANLIER RAW, 1987, J IMMUNOL, V139, P1589; vonBulow GU, 1997, SCIENCE, V278, P138, DOI 10.1126/science.278.5335.138; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386	57	198	236	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27548	27556		10.1074/jbc.273.42.27548	http://dx.doi.org/10.1074/jbc.273.42.27548			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765287	hybrid			2022-12-27	WOS:000076448000074
J	Imamura, Y; Steiglitz, BM; Greenspan, DS				Imamura, Y; Steiglitz, BM; Greenspan, DS			Bone morphogenetic protein-1 processes the NH2-terminal propeptide, and a furin-like proprotein convertase processes the COOH-terminal propeptide of pro-alpha 1(V) collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCOLLAGEN C-PROTEINASE; EHLERS-DANLOS SYNDROME; V COLLAGEN; XI COLLAGEN; FIBRILLAR COLLAGEN; MOUSE FIBROBLASTS; MOLECULAR-CLONING; FIBROGENIC CELLS; MATRIX-FORMS; GENE COL5A1	Bone morphogenetic protein-1 (BMP-1) plays key roles in regulating the deposition of vertebrate extracellular matrix; it is the procollagen C-proteinase that processes the major fibrillar collagen types I-III, and it may process prolysyl oxidase to the mature enzyme necessary to the formation of covalent cross-links in collagen and elastic fibers. Type V collagen is a fibrillar collagen of low abundance that is incorporated into and helps regulate the shape and diameter of type I collagen fibrils. Here we show that, in contrast to its action on procollagens I-III, BMP-1 does not cleave the C-propeptide of pro-alpha 1 (V) homotrimers, Instead, the single BMP-1-specific cleavage site within pro-alpha 1 (V) chains, lies within the large globular N-propeptide. This cleavage site is immediately upstream of a glutamine, thus redefining the specificity of cleavage for BMP-1-like enzymes. It also produces an NH2 terminus that corresponds to an equivalent NH2 terminus on the processed matrix form of the similar alpha 1(XI) chain, thus suggesting physiological significance. Cleavage of the C-propeptide occurs efficiently in recombinant pro-alpha 1 (V) homotrimers produced in 293-EBNA human embryonic kidney cells, and this cleavage is shown to occur immediately downstream of the sequence RTRR. This is similar to sites cleaved by subtilisin-like proprotein/prohormone convertases and is shown to be specifically cleaved by the recombinant subtilisin-like proprotein/prohormone convertase furin.	Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Greenspan, DS (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, 1300 Univ Ave, Madison, WI 53706 USA.		Imamura, Yasutada/AAI-3078-2020	Imamura, Yasutada/0000-0001-6264-1709; Greenspan, Daniel/0000-0001-8096-7446	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007215] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR43621] Funding Source: Medline; NIGMS NIH HHS [T32 GM07215, GM46846] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amano S, 1996, MOL BIOL CELL, V7, P338; BERNARD M, 1988, J BIOL CHEM, V263, P17159; BIRK DE, 1988, J CELL BIOL, V106, P999, DOI 10.1083/jcb.106.3.999; BIRK DE, 1990, J CELL SCI, V95, P649; Blader P, 1997, SCIENCE, V278, P1937, DOI 10.1126/science.278.5345.1937; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BROEK DL, 1985, J BIOL CHEM, V260, P555; DUBOIS CM, 1995, J BIOL CHEM, V270, P10618, DOI 10.1074/jbc.270.18.10618; Eyre D, 1987, STRUCTURE FUNCTION C, P261; FESSLER JH, 1987, STRUCTURE FUNCTION C, P81; Fichard A, 1997, J BIOL CHEM, V272, P30083, DOI 10.1074/jbc.272.48.30083; GREENSPAN DS, 1991, J BIOL CHEM, V266, P24727; HARALSON MA, 1980, P NATL ACAD SCI-BIOL, V77, P5206, DOI 10.1073/pnas.77.9.5206; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; Hulmes DJS, 1992, ESSAYS BIOCHEM, V27, P49; KESSLER E, 1989, EUR J BIOCHEM, V186, P115, DOI 10.1111/j.1432-1033.1989.tb15184.x; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; KESSLER E, 1986, COLLAGEN REL RES, V6, P249; KIMURA T, 1989, J BIOL CHEM, V264, P13910; KLEMAN JP, 1992, EUR J BIOCHEM, V210, P329, DOI 10.1111/j.1432-1033.1992.tb17425.x; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; KUMAMOTO CA, 1981, J BIOL CHEM, V256, P7053; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee SB, 1997, J BIOL CHEM, V272, P19059, DOI 10.1074/jbc.272.30.19059; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; MAYNE R, 1993, J BIOL CHEM, V268, P9381; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; MILLER EJ, 1982, METHOD ENZYMOL, V82, P33; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MORADIAMELI M, 1994, EUR J BIOCHEM, V221, P987, DOI 10.1111/j.1432-1033.1994.tb18815.x; MORRIS NP, 1987, J BIOL CHEM, V262, P11345; MYERS JC, 1985, J BIOL CHEM, V260, P1216; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nicholls AC, 1996, J MED GENET, V33, P940, DOI 10.1136/jmg.33.11.940; NIYIBIZI C, 1993, BIOCHIM BIOPHYS ACTA, V1203, P304, DOI 10.1016/0167-4838(93)90099-D; NIYIBIZI C, 1989, FEBS LETT, V242, P314, DOI 10.1016/0014-5793(89)80492-2; OXFORD JT, 1995, J BIOL CHEM, V270, P9478, DOI 10.1074/jbc.270.16.9478; Panchenko MV, 1996, J BIOL CHEM, V271, P7113, DOI 10.1074/jbc.271.12.7113; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; PROCKOP DJ, 1994, EXTRACELLULAR MATRIX, P47; RHODES RK, 1981, COLLAGEN REL RES, V1, P337; Rousseau JC, 1996, J BIOL CHEM, V271, P23743, DOI 10.1074/jbc.271.39.23743; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; TAKAHARA K, 1994, J BIOL CHEM, V269, P32572; TAKAHARA K, 1991, J BIOL CHEM, V266, P13124; TAKAHARA K, 1995, GENOMICS, V29, P588, DOI 10.1006/geno.1995.9961; THOM JR, 1991, J BIOL CHEM, V266, P7262; Toriello HV, 1996, NAT GENET, V13, P361, DOI 10.1038/ng0796-361; TSUMAKI N, 1995, J BIOL CHEM, V270, P2372, DOI 10.1074/jbc.270.5.2372; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VUORISTO MM, 1995, J BIOL CHEM, V270, P22873, DOI 10.1074/jbc.270.39.22873; WEIL D, 1987, NUCLEIC ACIDS RES, V15, P181, DOI 10.1093/nar/15.1.181; Wenstrup RJ, 1996, HUM MOL GENET, V5, P1733, DOI 10.1093/hmg/5.11.1733; WOODBURY D, 1989, J BIOL CHEM, V264, P2735; YOSHIOKA H, 1990, J BIOL CHEM, V265, P6423; YOSHIOKA H, 1995, GENOMICS, V28, P337, DOI 10.1006/geno.1995.1151; ZHIDKOVA NI, 1993, FEBS LETT, V326, P25, DOI 10.1016/0014-5793(93)81753-M; ZHIDKOVA NI, 1995, J BIOL CHEM, V270, P9486, DOI 10.1074/jbc.270.16.9486	62	89	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27511	27517		10.1074/jbc.273.42.27511	http://dx.doi.org/10.1074/jbc.273.42.27511			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765282	hybrid			2022-12-27	WOS:000076448000069
J	Johnson, JD; Muhonen, WW; Lambeth, DO				Johnson, JD; Muhonen, WW; Lambeth, DO			Characterization of the ATP- and GTP-specific Succinyl-CoA synthetases in pigeon - The enzymes incorporate the same alpha-subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KETONE-BODY UTILIZATION; COENZYME-A SYNTHETASE; ESCHERICHIA-COLI; PHYSIOLOGICAL ROLES; THIOKINASE; MITOCHONDRIA; ASSOCIATION; SENSITIVITY; MUSCLE; HEART	Two succinyl-CoA synthetases, one highly specific for GTP/GDP and the other for ATP/ADP, have been purified to homogeneity from pigeon liver and breast muscle. The two enzymes are differentially distributed in pigeon, with only the GTP-specific enzyme detected in liver and the ATP-specific enzyme in breast muscle, Based on assays in the direction of CoA formation, the ratios of GTP specific to ATP-specific activities in kidney, brain, and heart are similar to 7, 1, and 0.1, respectively. Both enzymes have the characteristic alpha- and beta-subunits found in other succinyl-CoA synthetases. Studies of the alpha-subunit by electrophoresis, mass spectrometry, reversed-phase high performance liquid chromatography, and peptide mapping showed that it was the same in the two enzymes. Characterization of the beta-subunits by the same methods indicated that they were different, with the tryptic peptide maps providing evidence that the beta-subunits likely differ along their entire sequences. Because the two succinyl-CoA synthetases incorporate the same alpha-subunit, the determinants of nucleotide specificity must reside within the beta-subunit, Determination of the apparent Michaelis constants showed that the affinity of the GTP-specific enzyme for GDP is greater than that of the ATP-specific enzyme for ADP (7 versus 250 mu M). Rather large differences in apparent K-m values were also observed for succinate and phosphate.	Univ N Dakota, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, Grand Forks, ND 58202 USA	University of North Dakota Grand Forks	Lambeth, DO (corresponding author), Univ N Dakota, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, POB 9037, Grand Forks, ND 58202 USA.							ALLEN DA, 1986, FEBS LETT, V194, P171, DOI 10.1016/0014-5793(86)80071-0; BIRNEY MA, 1995, ARCH BIOCHEM BIOPHYS, V319, P93, DOI 10.1006/abbi.1995.1270; Bridger W. A., 1974, ENZYMES, P581; BRIDGER WA, 1971, BIOCHEM BIOPH RES CO, V42, P948, DOI 10.1016/0006-291X(71)90522-5; BUCK D, 1989, BIOCHEM J, V260, P737, DOI 10.1042/bj2600737; COLLIER GE, 1978, J BIOL CHEM, V253, P4938; GARCES E, 1969, BIOCHEMISTRY-US, V8, P633, DOI 10.1021/bi00830a026; HAMILTON ML, 1981, FEBS LETT, V123, P252, DOI 10.1016/0014-5793(81)80300-6; HANSFORD RG, 1973, FEBS LETT, V31, P317, DOI 10.1016/0014-5793(73)80130-9; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; JENKINS TM, 1988, FEBS LETT, V230, P6, DOI 10.1016/0014-5793(88)80629-X; JENKINS TM, 1986, FEBS LETT, V205, P215, DOI 10.1016/0014-5793(86)80900-0; Johnson JD, 1998, J BIOL CHEM, V273, P27580, DOI 10.1074/jbc.273.42.27580; KRIVANEK J, 1992, PHYSIOL RES, V41, P345; LABBE RF, 1965, BIOCHIM BIOPHYS ACTA, V111, P403, DOI 10.1016/0304-4165(65)90050-4; LAMBETH DO, 1993, ANAL BIOCHEM, V209, P192, DOI 10.1006/abio.1993.1102; MAJUMDAR R, 1991, BIOCHIM BIOPHYS ACTA, V1076, P86, DOI 10.1016/0167-4838(91)90223-M; MCCLELLAN JA, 1980, COMP BIOCHEM PHYS B, V67, P679, DOI 10.1016/0305-0491(80)90430-7; MURAKAMI Y, 1974, BIOCHIM BIOPHYS ACTA, V336, P252, DOI 10.1016/0005-2795(74)90402-4; NISHIMURA JS, 1986, ADV ENZYMOL RAMB, V58, P141; NISHIMURA JS, 1993, J BIOL CHEM, V268, P13717; OTTAWAY JH, 1981, INT J BIOCHEM, V13, P401, DOI 10.1016/0020-711X(81)90111-7; PEARSON PH, 1975, J BIOL CHEM, V250, P8524; Ryan DG, 1997, J BIOL CHEM, V272, P21151, DOI 10.1074/jbc.272.34.21151; SIMON EJ, 1953, J AM CHEM SOC, V75, P2520, DOI 10.1021/ja01106a522; STEINER AW, 1981, J NEUROCHEM, V37, P582; WEITZMAN PDJ, 1986, FEBS LETT, V199, P57, DOI 10.1016/0014-5793(86)81223-6; WEITZMAN PDJ, 1978, FEBS LETT, V88, P255, DOI 10.1016/0014-5793(78)80187-2; WOLODKO WT, 1994, J BIOL CHEM, V269, P10883	29	48	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27573	27579		10.1074/jbc.273.42.27573	http://dx.doi.org/10.1074/jbc.273.42.27573			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765290	hybrid			2022-12-27	WOS:000076448000077
J	Storms, SD; Rutishauser, U				Storms, SD; Rutishauser, U			A role for polysialic acid in neural cell adhesion molecule heterophilic binding to proteoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; MONOCLONAL-ANTIBODY EPITOPES; PROTEIN-TYROSINE-PHOSPHATASE; EMBRYONIC BRAIN MEMBRANES; N-CAM; HOMOPHILIC BINDING; FUNCTIONAL DETERMINANTS; NCAM; NEURONS; DOMAIN	The neural cell adhesion molecule (NCAM) is known to participate in both homophilic and heterophilic binding, the latter including mechanisms that involve interaction with proteoglycans. The polysialic acid (PSA) moiety of NCAM can serve as a negative regulator of homophilic binding, but indirect evidence has suggested that PSA can also be involved in heterophilic binding. We have examined this potential positive role for PSA in terms of the adhesion of PSA-expressing mouse F11 cells and chick embryonic brain cells to substrates composed of the purified heparan sulfate proteoglycans agrin and 6C4. This adhesion was specifically inhibited by polyclonal anti-NCAM Fab antibodies, monoclonal anti-PSA antibodies, PSA itself, and enzymatic removal of either PSA or heparan sulfate side chains. By contrast, the adhesion was not affected by chondroitinase, and cell binding to laminin was not inhibited by any of these treatments. A specific NCAM-heparan sulfate interaction in this adhesion was further indicated by its inhibition with monoclonal anti-NCAM Feb antibodies that recognize the known heparin-binding domain of NCAM and with the HBD-2 peptide derived from this region, but not with antibodies directed against other regions of the protein including the homophilic binding region. Together, the results suggest that PSA can act in vitro either as a receptor in NCAM heterophilic adhesion or as a promoter of binding between heparan sulfate proteoglycans and the NCAM heparin-binding domain.	Case Western Reserve Univ, Dept Neurosci, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Rutishauser, U (corresponding author), Mem Sloan Kettering Canc Ctr, Program Cellular Biochem & Biophys, 1275 York Ave,POB 290, New York, NY 10021 USA.	urs@ski.mskcc.org			NEI NIH HHS [EY06107] Funding Source: Medline; NICHD NIH HHS [HD18369] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD018369, R01HD018369] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY006107] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ACHESON A, 1991, J CELL BIOL, V114, P143, DOI 10.1083/jcb.114.1.143; BURG MA, 1995, J NEUROSCI RES, V41, P49, DOI 10.1002/jnr.490410107; COLE GJ, 1989, NEURON, V2, P1157, DOI 10.1016/0896-6273(89)90182-7; COLE GJ, 1986, NATURE, V320, P445, DOI 10.1038/320445a0; COLE GJ, 1986, J CELL BIOL, V102, P403, DOI 10.1083/jcb.102.2.403; COLE GJ, 1986, J CELL BIOL, V103, P1730; FRELINGER AL, 1986, J CELL BIOL, V103, P1729, DOI 10.1083/jcb.103.5.1729; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; GRUMET M, 1993, J CELL BIOL, V120, P815, DOI 10.1083/jcb.120.3.815; HALFTER W, 1993, J NEUROSCI, V13, P2863; HALFTER W, 1994, EXP CELL RES, V214, P285, DOI 10.1006/excr.1994.1260; HALLENBECK PC, 1987, J BIOL CHEM, V262, P3553; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; HOFFMAN S, 1982, J BIOL CHEM, V257, P7720; Hu HY, 1996, NEURON, V16, P735, DOI 10.1016/S0896-6273(00)80094-X; LAGENAUR C, 1987, P NATL ACAD SCI USA, V84, P7753, DOI 10.1073/pnas.84.21.7753; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; MURRAY BA, 1992, J CELL BIOL, V117, P1311, DOI 10.1083/jcb.117.6.1311; PLATIKA D, 1985, P NATL ACAD SCI USA, V82, P3499, DOI 10.1073/pnas.82.10.3499; Rabinowitz JE, 1996, P NATL ACAD SCI USA, V93, P6421, DOI 10.1073/pnas.93.13.6421; Ranheim TS, 1996, P NATL ACAD SCI USA, V93, P4071, DOI 10.1073/pnas.93.9.4071; RAO Y, 1993, J BIOL CHEM, V268, P20630; RAO Y, 1992, J CELL BIOL, V118, P937, DOI 10.1083/jcb.118.4.937; RAO Y, 1994, J BIOL CHEM, V269, P27540; REYES AA, 1990, CELL REGUL, V1, P567, DOI 10.1091/mbc.1.8.567; Rutishauser U, 1996, TRENDS NEUROSCI, V19, P422; RUTISHAUSER U, 1985, J CELL BIOL, V101, P1842, DOI 10.1083/jcb.101.5.1842; RUTISHAUSER U, 1982, P NATL ACAD SCI-BIOL, V79, P685, DOI 10.1073/pnas.79.2.685; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; Storms SD, 1996, CELL ADHES COMMUN, V3, P497, DOI 10.3109/15419069609081026; Storms SD, 1996, EXP CELL RES, V223, P385, DOI 10.1006/excr.1996.0093; STORMS SD, 1994, EXP CELL RES, V214, P100, DOI 10.1006/excr.1994.1238; TSEN G, 1995, J BIOL CHEM, V270, P3392, DOI 10.1074/jbc.270.7.3392; VIMR ER, 1984, P NATL ACAD SCI-BIOL, V81, P1971, DOI 10.1073/pnas.81.7.1971; WATANABE M, 1986, J CELL BIOL, V103, P1721, DOI 10.1083/jcb.103.5.1721	36	106	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27124	27129		10.1074/jbc.273.42.27124	http://dx.doi.org/10.1074/jbc.273.42.27124			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765230	hybrid			2022-12-27	WOS:000076448000017
J	Brekken, DL; Phillips, MA				Brekken, DL; Phillips, MA			Trypanosoma brucei gamma-glutamylcysteine synthetase - Characterization of the kinetic mechanism and the role of Cys-319 in cystamine inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ACTIVE-SITE THIOL; GLUTATHIONE SYNTHESIS; GENE; TRYPANOTHIONE; INHIBITION; BIOSYNTHESIS; PURIFICATION; SULFOXIMINE; REDUCTASE	The parasitic protozoan Trypanosoma brucei utilizes a conjugate of glutathione and spermidine, termed trypanothione, in place of glutathione to maintain cellular redox balance. The first committed step in the biosynthesis of glutathione and thereby trypanothione, is catalyzed by gamma-glutamylcysteine synthetase (gamma-GCS), We have determined the kinetic mechanism for T. brucei gamma-GCS. The kinetics are best described by a rapid equilibrium random ter-reactant mechanism, in which the model derived K-d values for the binding of L-Glu, L-alpha-aminobutyrate, and ATP to free enzyme are 2.6, 5.1, and 1.4 mM, respectively. However, significant dependences exist between the binding of some of the substrate pairs, The binding of either ATP or L-Glu to the enzyme increases the binding affinity of the other by 18-fold, whereas the binding of L-Glu or L-alpha-aminobutyrate decreases the binding affinity of the other by 6-fold, Similarly to the mammalian enzyme, cystamine is a time-dependent, irreversible inhibitor of T. brucei gamma-GCS. It has been suggested by several studies that cystamine labels an active site Cys residue essential for catalysis. Among the enzymes reported to be inactivated by cystamine, only one Cys residue is invariant (Cys-319 in T. brucei gamma-GCS). Mutation of Cys-319 to Ala in T. brucei gamma-GCS renders the enzyme insensitive to cystamine inactivation without significantly affecting the enzyme's catalytic efficiency, kinetic mechanism, or substrate affinities, These studies suggest that cystamine inactivates the enzyme by blocking substrate access to the active site and not by labeling an essential active site residue.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Phillips, MA (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Brekken, Deirdre/I-7999-2012	Brekken, Deirdre/0000-0003-2790-0108	NIAID NIH HHS [R01 AI34432] Funding Source: Medline; NIGMS NIH HHS [T32 GM07062] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034432] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007062] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARRICK BA, 1981, J EXP MED, V153, P720, DOI 10.1084/jem.153.3.720; COBLENZ A, 1995, YEAST, V11, P1171, DOI 10.1002/yea.320111207; Coulson A, 1996, BIOCHEM SOC T, V24, P289, DOI 10.1042/bst0240289; DAVIS JS, 1973, BIOCHEM J, V133, P667, DOI 10.1042/bj1330667; Dumas C, 1997, EMBO J, V16, P2590, DOI 10.1093/emboj/16.10.2590; FAIRLAMB AH, 1985, SCIENCE, V227, P1485, DOI 10.1126/science.3883489; Fairlamb Alan H., 1997, P149; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRIFFITH OW, 1982, J BIOL CHEM, V257, P13704; GRIFFITH OW, 1979, J BIOL CHEM, V254, P1205; Grondin K, 1997, EMBO J, V16, P3057, DOI 10.1093/emboj/16.11.3057; HUANG CS, 1993, J BIOL CHEM, V268, P19675; HUANG CS, 1993, J BIOL CHEM, V268, P20578; HUANG CS, 1988, P NATL ACAD SCI USA, V85, P2464, DOI 10.1073/pnas.85.8.2464; HUSSEIN AS, 1995, MOL BIOCHEM PARASIT, V72, P57, DOI 10.1016/0166-6851(94)00064-T; KOEING K, 1997, J BIOL CHEM, V272, P11908; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEBO RV, 1978, J BIOL CHEM, V253, P2615; Lueder DV, 1996, J BIOL CHEM, V271, P17485, DOI 10.1074/jbc.271.29.17485; Mehlotra RK, 1996, CRIT REV MICROBIOL, V22, P295, DOI 10.3109/10408419609105484; MEISTER A, 1989, GLUTATHIONE CHEM BIO, P368; MESHNICK SR, 1977, BIOCHEM PHARMACOL, V26, P1923, DOI 10.1016/0006-2952(77)90167-8; OHTAKE Y, 1991, YEAST, V7, P953, DOI 10.1002/yea.320070907; ORLOWSKI M, 1971, J BIOL CHEM, V246, P7095; OSTERMAN A, 1994, BIOCHEMISTRY-US, V33, P13662, DOI 10.1021/bi00250a016; SCHANDLE VB, 1981, J BIOL CHEM, V256, P7590; SCHOR NF, 1990, BIOCHEM J, V267, P291, DOI 10.1042/bj2670291; SEELIG GF, 1984, J BIOL CHEM, V259, P3534; SEELIG GF, 1982, J BIOL CHEM, V257, P5092; Segel IH, 1975, ENZYME KINETICS BEHA; SEKURA R, 1977, J BIOL CHEM, V252, P2599; SIMONDSEN RP, 1986, J BIOL CHEM, V261, P7134; SMITH AB, 1995, SCIENCE, V268, P284, DOI 10.1126/science.7716520; VANBUSKIRK GE, 1978, EUR J BIOCHEM, V85, P589; WANG CC, 1995, ANNU REV PHARMACOL, V35, P93, DOI 10.1146/annurev.pa.35.040195.000521; YAN N, 1990, J BIOL CHEM, V265, P1588; YIP B, 1976, J BIOL CHEM, V251, P3563	37	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26317	26322		10.1074/jbc.273.41.26317	http://dx.doi.org/10.1074/jbc.273.41.26317			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756861	hybrid			2022-12-27	WOS:000076373300015
J	Colussi, PA; Harvey, NL; Shearwin-Whyatt, LM; Kumar, S				Colussi, PA; Harvey, NL; Shearwin-Whyatt, LM; Kumar, S			Conversion of procaspase-3 to an autoactivating caspase by fusion to the caspase-2 prodomain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; PROTEASE; APOPTOSIS; CED-3; INHIBITION; ENCODES; COMPLEX; CRMA; GENE; P35	Caspases are cysteine proteases that play an essential role in apoptosis. Initial activation of caspases defines the hey step in apoptotic execution. Based on primary structure, caspases can be divided into two groups, those with long amino-terminal prodomains (class I), and those with relatively short prodomains (class Il). On overexpression in mammalian cells, class I caspases can induce cell death that is dependent on their autocatalytic activity. Recent studies suggest that the long prodomains in some class I caspases are able to mediate dimerization of procaspase molecules, thereby promoting autoprocessing. In this communication, we demonstrate that fusion of the prodomain of a class I caspase (Nedd2/caspase-2) with procaspase-3 greatly augments autocatalysis and apoptosis induction by the chimeric caspase-3 molecule. The chimeric caspase-3 molecules were able to form homodimers in Saccharomyces cerevisiae and were efficiently processed in transfected mammalian cells. These results provide direct evidence for a role of a class I caspase prodomain in caspase autoactivation and processing and establish a basis for functional hierarchy among the two classes of caspases.	Inst Med & Vet Sci, Hanson Ctr Canc Res, Adelaide, SA 5000, Australia	Institute Medical & Veterinary Science Australia	Kumar, S (corresponding author), Inst Med & Vet Sci, Hanson Ctr Canc Res, Frome Rd,POB 14,Rundle Mall, Adelaide, SA 5000, Australia.	sharad.kumar@imvs.sa.gov.au	Kumar, Sharad/AAX-7787-2020; Shearwin, Linda/AAD-5594-2020	Kumar, Sharad/0000-0001-7126-9814; Shearwin, Linda/0000-0002-4504-6534; Harvey, Natasha/0000-0001-9839-8966				Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Butt AJ, 1998, J BIOL CHEM, V273, P6763, DOI 10.1074/jbc.273.12.6763; Chinnaiyan A M, 1997, Semin Immunol, V9, P69, DOI 10.1006/smim.1996.0055; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Colussi PA, 1998, J BIOL CHEM, V273, P24535, DOI 10.1074/jbc.273.38.24535; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Dorstyn L, 1997, CELL DEATH DIFFER, V4, P570, DOI 10.1038/sj.cdd.4400281; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Kumar S, 1996, CELL DEATH DIFFER, V3, P255; Kumar S, 1997, CELL DEATH DIFFER, V4, P378, DOI 10.1038/sj.cdd.4400251; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MacCorkle RA, 1998, P NATL ACAD SCI USA, V95, P3655, DOI 10.1073/pnas.95.7.3655; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5	25	70	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26566	26570		10.1074/jbc.273.41.26566	http://dx.doi.org/10.1074/jbc.273.41.26566			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756894	hybrid			2022-12-27	WOS:000076373300048
J	Tamura, K; Nyui, N; Tamura, N; Fujita, T; Kihara, M; Toya, Y; Takasaki, I; Takagi, N; Ishii, M; Oda, K; Horiuchi, M; Umemura, S				Tamura, K; Nyui, N; Tamura, N; Fujita, T; Kihara, M; Toya, Y; Takasaki, I; Takagi, N; Ishii, M; Oda, K; Horiuchi, M; Umemura, S			Mechanism of angiotensin II-mediated regulation of fibronectin gene in rat vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CONVERTING ENZYME; COLLAGEN-SYNTHESIS; MOLECULAR-CLONING; CARDIAC MYOCYTES; TYROSINE KINASE; MESANGIAL CELLS; TYPE-1 RECEPTOR; AT(1) RECEPTOR; DEFICIENT MICE	This study was performed to investigate a mechanism of angiotensin II (Ang II)-mediated activation of the fibronectin (FN) gene in rat vascular smooth muscle cells. Actinomycin D and CV11974 completely inhibited Ang II-mediated increase in FN mRNA levels. Inhibitors of protein kinase C (PKC), protein-tyrosine kinase (PTK), phosphatidylinositol-specific phospholipase C, Ras, phosphatidylinositol 3-kinase, p70 S6 kinase, and Ca2+/calmodulin kinase also decreased Ang II-induced activation of FN mRNA. In contrast, cycloheximide; PD123319; or inhibitors of G(i), protein kinase A, or mitogen-activated protein kinase kinase did not affect the induction. FN promoter contained a putative AP-1 binding site (rFN/AP-1; -463 to -437), and the results of a transient transfection and electrophoretic mobility shift assay showed that Ang II enhanced rFN/AP-1 activity. CV11974 and inhibitors of PKC or PTK suppressed Ang II-mediated increases in rFN/AP-1 activity, although neither PD123319 nor a protein kinase A inhibitor affected the induction. Furthermore, mutation of rFN/AP-1 that disrupted nuclear binding suppressed Ang II-induced transcription in the native FN promoter (-1908 to +136) context. Thus, Ang II activates transcription of the FN gene through the Ang II type 1 receptor in vascular smooth muscle cells, at least in part, via the activation of AP-1 by a signaling mechanism dependent on PKC and PTK.	Yokohama City Univ, Sch Med, Dept Internal Med 2, Kanazawa Ku, Yokohama, Kanagawa 236, Japan; Yokohama City Univ, Sch Med, Dept Dermatol, Kanazawa Ku, Yokohama, Kanagawa 236, Japan; Sci Univ Tokyo, Dept Biol Sci & Technol, Noda, Chiba 278, Japan; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Cardiovasc Div, Boston, MA 02115 USA	Yokohama City University; Yokohama City University; Tokyo University of Science; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Tamura, K (corresponding author), Yokohama City Univ, Sch Med, Dept Internal Med 2, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 236, Japan.							ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Bardy N, 1996, CIRC RES, V79, P70, DOI 10.1161/01.RES.79.1.70; Berk BC, 1997, CIRC RES, V80, P607, DOI 10.1161/01.RES.80.5.607; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P59; CHOBANIAN AV, 1992, AM J CARDIOL, V69, pE3; CHOBANIAN AV, 1990, HYPERTENSION, V15, P666, DOI 10.1161/01.HYP.15.6.666; CHORNCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; CONTARD F, 1993, HYPERTENSION, V22, P665, DOI 10.1161/01.HYP.22.5.665; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1476; Dunn FW, 1997, J PHARMACOL EXP THER, V280, P447; DZAU VJ, 1993, J CARDIOVASC PHAR S1, V21, P1; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; FOLKOW B, 1982, PHYSIOL REV, V62, P347, DOI 10.1152/physrev.1982.62.2.347; FUKAMIZU A, 1991, BIOMED BIOCHIM ACTA, V50, P659; GENOVESE C, 1984, BIOCHEMISTRY-US, V23, P6210, DOI 10.1021/bi00320a049; GLAGOV S, 1994, CIRCULATION, V89, P2888, DOI 10.1161/01.CIR.89.6.2888; GLAGOV S, 1988, ARCH PATHOL LAB MED, V112, P1018; GRANDE JP, 1989, ARTERIOSCLEROSIS, V9, P446, DOI 10.1161/01.ATV.9.4.446; GRIENDLING KK, 1986, J BIOL CHEM, V261, P5901; Griendling KK, 1997, HYPERTENSION, V29, P366, DOI 10.1161/01.HYP.29.1.366; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HIMENO H, 1994, HYPERTENSION, V23, P823, DOI 10.1161/01.HYP.23.6.823; Holzmeister J, 1997, AM J PHYSIOL-HEART C, V273, pH655, DOI 10.1152/ajpheart.1997.273.2.H655; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KAGAMI S, 1994, J CLIN INVEST, V93, P2431, DOI 10.1172/JCI117251; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; KATO H, 1991, J HYPERTENS, V9, P17; Kijima K, 1996, CIRC RES, V79, P887, DOI 10.1161/01.RES.79.4.887; KIM S, 1994, BRIT J PHARMACOL, V113, P662, DOI 10.1111/j.1476-5381.1994.tb17042.x; KIM SK, 1995, CIRCULATION, V92, P88, DOI 10.1161/01.CIR.92.1.88; KOHARA K, 1992, AM J PHYSIOL, V262, pE651, DOI 10.1152/ajpendo.1992.262.5.E651; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LASSEGUE B, 1995, MOL PHARMACOL, V48, P601; LEVY BI, 1988, CIRC RES, V63, P227, DOI 10.1161/01.RES.63.1.227; Li JY, 1996, MOL ENDOCRINOL, V10, P252, DOI 10.1210/me.10.3.252; MAMUYA W, 1992, CIRC RES, V71, P1341, DOI 10.1161/01.RES.71.6.1341; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; MULVANY MJ, 1993, AM J MED, V94, pS20; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; NAKAJIMA T, 1992, MOL CELL BIOL, V12, P2837, DOI 10.1128/MCB.12.6.2837; NISHIZUKA Y, 1988, NATURE, V351, P662; ODERMATT E, 1985, P NATL ACAD SCI USA, V82, P6571, DOI 10.1073/pnas.82.19.6571; OHKUBO H, 1983, P NATL ACAD SCI-BIOL, V80, P2196, DOI 10.1073/pnas.80.8.2196; PATEL RS, 1987, EMBO J, V6, P2565, DOI 10.1002/j.1460-2075.1987.tb02545.x; RAKUGI H, 1994, CIRCULATION, V90, P449, DOI 10.1161/01.CIR.90.1.449; RAKUGI H, 1993, CIRCULATION, V87, P283, DOI 10.1161/01.CIR.87.1.283; RAYNAL F, 1984, FEBS LETT, V167, P263, DOI 10.1016/0014-5793(84)80139-8; RuizOrtega M, 1997, KIDNEY INT, V52, P1497, DOI 10.1038/ki.1997.480; SADOSHIMA J, 1995, CIRC RES, V77, P1040, DOI 10.1161/01.RES.77.6.1040; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; Saward L, 1997, CIRC RES, V81, P249, DOI 10.1161/01.RES.81.2.249; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; Seewald S, 1998, HYPERTENSION, V31, P1151, DOI 10.1161/01.HYP.31.5.1151; SHIOTA N, 1992, HYPERTENSION, V20, P168, DOI 10.1161/01.HYP.20.2.168; SIMONSON MS, 1993, J BIOL CHEM, V268, P9347; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; STUDER RK, 1995, KIDNEY INT, V48, P422, DOI 10.1038/ki.1995.310; SUGAYA T, 1995, J BIOL CHEM, V270, P18719, DOI 10.1074/jbc.270.32.18719; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; TAKASAKI I, 1990, J BIOL CHEM, V265, P21935; TAKASAKI I, 1991, J BIOL CHEM, V266, P17686; TAKASAKI I, 1992, HYPERTENSION, V20, P20, DOI 10.1161/01.HYP.20.1.20; TAKEUCHI K, 1990, BIOCHEM BIOPH RES CO, V172, P1189, DOI 10.1016/0006-291X(90)91574-C; TAMURA K, 1993, J BIOL CHEM, V268, P15024; Tamura K, 1998, AM J PHYSIOL-REG I, V275, pR1, DOI 10.1152/ajpregu.1998.275.1.R1; Tamura K, 1995, Hypertens Res, V18, P7, DOI 10.1291/hypres.18.7; TAMURA K, 1994, J CLIN INVEST, V93, P1370, DOI 10.1172/JCI117113; Tamura K, 1998, HYPERTENSION, V32, P223, DOI 10.1161/01.HYP.32.2.223; Tamura K, 1997, J BIOL CHEM, V272, P16845, DOI 10.1074/jbc.272.27.16845; TANIMOTO K, 1993, ARCH BIOCHEM BIOPHYS, V302, P409, DOI 10.1006/abbi.1993.1232; TANIMOTO K, 1994, J BIOL CHEM, V269, P31334; Wang DH, 1997, HYPERTENSION, V29, P1104, DOI 10.1161/01.HYP.29.5.1104; Wang DH, 1998, J HYPERTENS, V16, P467, DOI 10.1097/00004872-199816040-00008; WEBER H, 1994, J CLIN INVEST, V93, P788, DOI 10.1172/JCI117033; WINGENDER E, 1988, NUCLEIC ACIDS RES, V16, P1879, DOI 10.1093/nar/16.5.1879	78	44	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26487	26496		10.1074/jbc.273.41.26487	http://dx.doi.org/10.1074/jbc.273.41.26487			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756884	hybrid			2022-12-27	WOS:000076373300038
J	Kim, JC; Yoon, JB; Koo, HS; Chung, IK				Kim, JC; Yoon, JB; Koo, HS; Chung, IK			Cloning and characterization of the 5 '-flanking region for the human topoisomerase III gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR USF; LOOP-HELIX PROTEIN; RNA POLYMERASE-II; DNA TOPOISOMERASE; ACTIVATES TRANSCRIPTION; BINDING PROTEIN; REVERSE GYRASE; YY1; YEAST; PROMOTER	The human DNA topoisomerase III (hTOP3) gene encodes a topoisomerase homologous to the Escherichia coli DNA topoisomerase I subfamily. To understand the mechanisms responsible for regulating hTOP3 expression, we have cloned the 5'-flanking region of the gene coding for the hTOP3 and analyzed its promoter activity, The presence of a single transcription initiation site was suggested by primer extension analysis. The hTOP3 gene promoter is moderately high in GC content and lacks a canonical TATA box, suggesting that hTOP3 promoter has overall similarity 60 promoters of a number of housekeeping genes. Examination of the promoter sequence indicated the presence of four Sp-1 consensus binding sequences and a putative initiator element surrounding the transcription initiation site. Transient expression of a luciferase reporter gene under the control of serially deleted 5'-flanking sequences revealed that the 52-base pair region from -326 to -275 upstream of the transcription initiation site includes a positive cis-acting element(s) for the efficient expression of hTOP3 gene. On the basis of gel mobility shift and supershift assays, we demonstrated that both YY1 and USF1 transcription factors can bind 60 the 52-base pair region. When HeLa cells were transiently transfected with a mutant construct which had disabled both YY1- and USF1-binding sites, the luciferase activity was greatly reduced, suggesting that these binding elements play a functional role in the basal activation of the hTOP3 promoter. Transfection studies with mutations that selectively impaired YY1 or USF1 binding suggested that both YY1 and USF1 function as activators in the hTOP3 promoter.	Yonsei Univ, Coll Sci, Dept Biol, Bioprod Res Ctr, Seoul 120749, South Korea; Yonsei Univ, Coll Sci, Dept Biochem, Bioprod Res Ctr, Seoul 120749, South Korea	Yonsei University; Yonsei University	Chung, IK (corresponding author), Yonsei Univ, Coll Sci, Dept Biol, Bioprod Res Ctr, 134 Shinchon Dong, Seoul 120749, South Korea.	topoviro@bubble.yonsei.ac.kr		Yoon, Jong-Bok/0000-0002-3563-0702				BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BIRD A, 1985, CELL, V40, P91, DOI 10.1016/0092-8674(85)90312-5; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CONFALONIERI F, 1993, P NATL ACAD SCI USA, V90, P4753, DOI 10.1073/pnas.90.10.4753; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FARNHAM PJ, 1990, MOL CELL BIOL, V10, P1390, DOI 10.1128/MCB.10.4.1390; Fritz E, 1997, P NATL ACAD SCI USA, V94, P4538, DOI 10.1073/pnas.94.9.4538; Furlong EEM, 1996, MOL CELL BIOL, V16, P5933; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; Hanai R, 1996, P NATL ACAD SCI USA, V93, P3653, DOI 10.1073/pnas.93.8.3653; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; HYDEDERUYSCHER RL, 1991, MOL CELL BIOL, V11, P5090; KIM RA, 1995, P NATL ACAD SCI USA, V92, P2667, DOI 10.1073/pnas.92.7.2667; KIM RA, 1992, J BIOL CHEM, V267, P17178; LEE TC, 1992, MOL CELL BIOL, V12, P4209; Li W, 1998, P NATL ACAD SCI USA, V95, P1010, DOI 10.1073/pnas.95.3.1010; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LU SY, 1994, MOL CELL BIOL, V14, P6253, DOI 10.1128/MCB.14.9.6253; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; SAMBROOK J, 1989, MOL CLONING, V9, P14; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; Seki T, 1998, BBA-GENE STRUCT EXPR, V1396, P127, DOI 10.1016/S0167-4781(97)00192-9; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; SHYAMALA V, 1993, METHOD ENZYMOL, V217, P436; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; WANG JC, 1991, J BIOL CHEM, V266, P6659; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WATT PM, 1996, GENETICS, V144, P936; YANT SR, 1995, NUCLEIC ACIDS RES, V23, P4353, DOI 10.1093/nar/23.21.4353; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	51	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26130	26137		10.1074/jbc.273.40.26130	http://dx.doi.org/10.1074/jbc.273.40.26130			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748294	hybrid			2022-12-27	WOS:000076263100085
J	Kumar, S; Pandey, P; Bharti, A; Jin, SF; Weichselbaum, R; Weavers, D; Kufe, D; Kharbanda, S				Kumar, S; Pandey, P; Bharti, A; Jin, SF; Weichselbaum, R; Weavers, D; Kufe, D; Kharbanda, S			Regulation of DNA-dependent protein kinase by the Lyn tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND-BREAK REPAIR; C-ABL; IONIZING-RADIATION; PHOSPHATIDYLINOSITOL 3-KINASE; CATALYTIC SUBUNIT; CELLULAR-RESPONSE; STRESS-RESPONSE; ACTIVATION; CELLS; PHOSPHORYLATION	The Src-like protein-tyrosine kinase Lyn is activated by ionizing radiation and certain other DNA-damaging agents, whereas the DNA-dependent protein kinase (DNA-PK), consisting of the catalytic subunits (DNA-PKcs) and Ku DNA-binding components, requires DNA double-stranded breaks for activation. Here me demonstrate that Lyn associates constitutively with DNA-PKcs. The SH3 domain of Lyn interacts directly with DNA-PKcs near a leucine zipper homology domain. We also show that Lyn phosphorylates DNA-PKcs but not Ku in vitro. The interaction between Lyn and DNA-PKcs inhibits DNA-PKcs activity and the ability of DNA-PKcs to form a complex with Ku/DNA. These results support the hypothesis that there are functional interactions between Lyn and DNA-PKcs in the response to DNA damage.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Univ Chicago, Dept Radiat & Cellular Biol, Chicago, IL 60637 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Chicago; Harvard University; Harvard Medical School	Kharbanda, S (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.				NCI NIH HHS [CA55241, CA75216] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075216] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; BOUBNOV NV, 1995, MOL CELL BIOL, V15, P5700; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Hammarsten O, 1998, P NATL ACAD SCI USA, V95, P525, DOI 10.1073/pnas.95.2.525; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Huang YY, 1997, ONCOGENE, V15, P1947, DOI 10.1038/sj.onc.1201376; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; Jin SF, 1997, J BIOL CHEM, V272, P24763, DOI 10.1074/jbc.272.40.24763; Kharbanda S, 1996, P NATL ACAD SCI USA, V93, P6898, DOI 10.1073/pnas.93.14.6898; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KHARBANDA S, 1994, ONCOGENE, V9, P3005; KHARBANDA S, 1994, J BIOL CHEM, V269, P20739; Kharbanda S, 1996, CANCER RES, V56, P3617; Kharbanda S, 1997, BIOCHIM BIOPHYS ACTA, V1333, pO1; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; SHENOY S, 1992, P NATL ACAD SCI USA, V89, P7237, DOI 10.1073/pnas.89.15.7237; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0; YUAN ZM, 1995, BIOCHEMISTRY-US, V34, P1058, DOI 10.1021/bi00003a041; Yuan ZM, 1996, ONCOGENE, V13, P939; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	34	33	34	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25654	25658		10.1074/jbc.273.40.25654	http://dx.doi.org/10.1074/jbc.273.40.25654			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748231	hybrid			2022-12-27	WOS:000076263100022
J	Neet, KE				Neet, KE			Enzyme catalytic power minireview series	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Editorial Material									Finch Univ Hlth Sci Chicago Med Sch, Dept Biochem & Mol Biol, N Chicago, IL 60064 USA	Chicago Medical School	Neet, KE (corresponding author), Finch Univ Hlth Sci Chicago Med Sch, Dept Biochem & Mol Biol, 3333 Green Bay Rd, N Chicago, IL 60064 USA.							Aurora R, 1997, J BIOL CHEM, V272, P1413, DOI 10.1074/jbc.272.3.1413; Beasley JR, 1997, J BIOL CHEM, V272, P2031, DOI 10.1074/jbc.272.4.2031; BENKOVIC SJ, 1992, ANNU REV BIOCHEM, V61, P29; Dill KA, 1997, J BIOL CHEM, V272, P701, DOI 10.1074/jbc.272.2.701; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; KOSHLAND DE, 1968, ANNU REV BIOCHEM, V37, P359, DOI 10.1146/annurev.bi.37.070168.002043; Pauling L., 1946, CHEM ENG NEWS, V24, P1375, DOI [10.1021/cen-v024n010.p1375, DOI 10.1021/CEN-V024N010.P1375]; STORM DR, 1970, P NATL ACAD SCI USA, V66, P445, DOI 10.1073/pnas.66.2.445; WOLFENDEN R, 1972, ACCOUNTS CHEM RES, V5, P10, DOI 10.1021/ar50049a002	9	29	29	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25527	25528		10.1074/jbc.273.40.25527	http://dx.doi.org/10.1074/jbc.273.40.25527			2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748210	hybrid			2022-12-27	WOS:000076263100001
J	Schulteis, CT; Nagaya, N; Papazian, DM				Schulteis, CT; Nagaya, N; Papazian, DM			Subunit folding and assembly steps are interspersed during shaker potassium channel biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED K+ CHANNELS; ENDOPLASMIC-RETICULUM; XENOPUS-OOCYTES; BETA-SUBUNITS; ELECTROSTATIC INTERACTIONS; TRANSMEMBRANE SEGMENTS; CYSTEINE RESIDUES; ALPHA-SUBUNITS; TEA BLOCKADE; VOLTAGE	In the voltage-dependent Shaker K+ channel, distinct regions of the protein form the voltage sensor, contribute to the permeation pathway, and recognize compatible subunits for assembly. To investigate channel biogenesis, we disrupted the formation of these discrete functional domains with mutations, including an aminoterminal deletion, Delta 97-196, which is likely to disrupt subunit oligomerization; D316K and K374E, which prevent proper folding of the voltage sensor; and E418K and C462K which are likely to disrupt pore formation. We determined whether these mutant subunits undergo three previously identified assembly events as follows: 1) tetramerization of Shaker subunits, 2) assembly of Shaker (alpha) and cytoplasmic beta subunits, and 3) association of the amino and carboxyl termini of adjacent Shaker subunits. Delta 97-196 subunits failed to establish any of these quaternary interactions, The Delta 97-196 deletion also prevented formation of the pore. The other mutant subunits assembled into tetramers and associated with the beta subunit but did not establish proximity between the amino and carboxyl termini of adjacent subunits. The results indicate that oligomerization mediated by the amino terminus is required for subsequent pore formation and either precedes or is independent of folding of the voltage sensor. In contrast, the amino and carboxyl termini of adjacent subunits associate late during biogenesis. Because subunits with folding defects oligomerize, we conclude that Shaker channels need not assemble from pre-folded monomers. Furthermore, association with native subunits can weakly promote the proper folding of some mutant subunits, suggesting that steps of folding and assembly alternate during channel biogenesis.	Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Interdept Program Neurosci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Papazian, DM (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Physiol, Box 951751, Los Angeles, CA 90095 USA.	papazian@physiology.medsch.ucla.edu			NIGMS NIH HHS [R01 GM043459-15, GM43459, R01 GM043459-09, R01 GM043459-13, R01 GM043459, R01 GM043459-10, R01 GM043459-15S1, R01 GM043459-12, R01 GM043459-16, R01 GM043459-11, R01 GM043459-14, R01 GM043459-17] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043459] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; DEAL KK, 1994, J NEUROSCI, V14, P1666, DOI 10.1523/JNEUROSCI.14-03-01666.1994; DEMO SD, 1991, NEURON, V7, P743, DOI 10.1016/0896-6273(91)90277-7; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Hegde RS, 1997, CELL, V91, P575, DOI 10.1016/S0092-8674(00)80445-6; Hille B., 1992, IONIC CHANNELS EXCIT; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; HOPKINS WF, 1994, J NEUROSCI, V14, P1385, DOI 10.1523/JNEUROSCI.14-03-01385.1994; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Larsson HP, 1996, NEURON, V16, P387, DOI 10.1016/S0896-6273(00)80056-2; LEE TE, 1994, BIOPHYS J, V66, P667, DOI 10.1016/S0006-3495(94)80840-9; LI M, 1994, CURR BIOL, V4, P110, DOI 10.1016/S0960-9822(94)00026-6; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Liu Y, 1996, NEURON, V16, P859, DOI 10.1016/S0896-6273(00)80106-3; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; LOPEZ GA, 1994, NATURE, V367, P179, DOI 10.1038/367179a0; MACKINNON R, 1993, SCIENCE, V262, P757, DOI 10.1126/science.7694359; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; Nagaya N, 1997, J BIOL CHEM, V272, P3022, DOI 10.1074/jbc.272.5.3022; Nakahira K, 1996, J BIOL CHEM, V271, P7084, DOI 10.1074/jbc.271.12.7084; Papazian DM, 1997, NEWS PHYSIOL SCI, V12, P203; PAPAZIAN DM, 1995, NEURON, V14, P1293, DOI 10.1016/0896-6273(95)90276-7; PARCEJ DN, 1989, BIOCHEM J, V257, P899, DOI 10.1042/bj2570899; PARCEJ DN, 1992, BIOCHEMISTRY-US, V31, P11084, DOI 10.1021/bi00160a018; PEROZO E, 1994, BIOPHYS J, V66, P345, DOI 10.1016/S0006-3495(94)80783-0; PONGS O, 1995, SEMIN NEUROSCI, V7, P137, DOI 10.1006/smns.1995.0015; RHODES KJ, 1995, J NEUROSCI, V15, P5360; Rowling P J, 1993, Subcell Biochem, V21, P41; SANTACRUZTOLOZA L, 1994, BIOCHEMISTRY-US, V33, P5607, DOI 10.1021/bi00184a033; Schulteis CT, 1996, BIOCHEMISTRY-US, V35, P12133, DOI 10.1021/bi961083s; SCHULTEIS CT, 1995, BIOCHEMISTRY-US, V34, P1725, DOI 10.1021/bi00005a029; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; SCHWARZ TL, 1990, NEURON, V4, P119, DOI 10.1016/0896-6273(90)90448-O; Seoh SA, 1996, NEURON, V16, P1159, DOI 10.1016/S0896-6273(00)80142-7; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; SHEN NV, 1993, NEURON, V11, P67; Sheng ZF, 1997, BIOCHEMISTRY-US, V36, P15501; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; SLESINGER PA, 1993, NEURON, V11, P739, DOI 10.1016/0896-6273(93)90083-4; Tang CY, 1998, BIOPHYS J, V75, P1263, DOI 10.1016/S0006-3495(98)74046-9; TIMPE LC, 1988, NATURE, V331, P143, DOI 10.1038/331143a0; TiwariWoodruff SK, 1997, BIOPHYS J, V72, P1489, DOI 10.1016/S0006-3495(97)78797-6; Tu LW, 1996, J BIOL CHEM, V271, P18904, DOI 10.1074/jbc.271.31.18904; VANDONGEN AMJ, 1990, NEURON, V5, P433, DOI 10.1016/0896-6273(90)90082-Q; VERRALL S, 1992, CELL, V68, P21; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8	56	65	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26210	26217		10.1074/jbc.273.40.26210	http://dx.doi.org/10.1074/jbc.273.40.26210			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748304	hybrid			2022-12-27	WOS:000076263100095
J	Abele, R; Lampinen, M; Keinanen, K; Madden, DR				Abele, R; Lampinen, M; Keinanen, K; Madden, DR			Disulfide bonding and cysteine accessibility in the alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor subunit GluRD - Implications for redox modulation of glutamate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMDA RECEPTOR; BINDING-PROTEIN; ESCHERICHIA-COLI; LIGAND-BINDING; NITRIC-OXIDE; SITE; CHANNELS; RESIDUES; IDENTIFICATION; POTENTIATION	Redox agents elicit a wide variety of effects on the ligand affinity and channel properties of ionotropic glutamate receptors and have been proposed as potential therapeutic agents for neuropathological processes. One such effect is the dithiothreitol (DTT)-induced increase in agonist affinity of certain ionotropic glutamate receptors (GluRs), presumably due to reduction of a disulfide bridge formed between cysteine residues conserved among all GluRs. Using biochemical techniques, this disulfide is shown to exist in the ligand-binding domain of the alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor subunit GluRD, although GluRD homomeric receptors are not modulated by DTT. The disulfide is inaccessible to DTT, explaining the insensitivity of the intact receptor. Single mutants C260S and C315S show a 2-3-fold higher ligand affinity than wild-type, as observed for several intact GluRs, indicating that the affinity switch is completely contained within the ligand-binding domain. Also, mutants lacking the native disulfide show non-native oligomerization and dramatically reduced specific activity. These facts suggest that the disulfide bridge is required for the stability of the ligand-binding domain, explaining its conservation. A third cysteine residue in the ligand-binding domain exists as a free thiol, partially sequestered in a hydrophobic environment. These results provide a framework for interpreting a variety of GluR redox modulatory phenomena.	Max Planck Inst Med Res, ICSRG, D-69120 Heidelberg, Germany; Univ Helsinki, Dept Biosci, Div Biochem, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; VTT Biotechnol & Food Res, FIN-02044 Espoo, Finland	Max Planck Society; University of Helsinki; University of Helsinki; VTT Technical Research Center Finland	Madden, DR (corresponding author), Max Planck Inst Med Res, ICSRG, Jahnstr 29, D-69120 Heidelberg, Germany.		Keinanen, Kari/E-9122-2010					AIZENMAN E, 1989, NEURON, V2, P1257, DOI 10.1016/0896-6273(89)90310-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FUCHS R, 1990, NUCLEIC ACIDS RES, V18, P4319, DOI 10.1093/nar/18.15.4319; GOZLAN H, 1994, EUR J PHARMACOL, V262, pR3, DOI 10.1016/0014-2999(94)90049-3; GOZLAN H, 1995, TRENDS PHARMACOL SCI, V16, P368, DOI 10.1016/S0165-6147(00)89077-X; Gozlan H, 1996, TRENDS PHARMACOL SCI, V17, P187, DOI 10.1016/0165-6147(96)81597-5; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hsiao CD, 1996, J MOL BIOL, V262, P225, DOI 10.1006/jmbi.1996.0509; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KOHR G, 1994, NEURON, V12, P1031, DOI 10.1016/0896-6273(94)90311-5; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; LAUBE B, 1993, FEBS LETT, V335, P331, DOI 10.1016/0014-5793(93)80412-N; LEI SZ, 1992, NEURON, V8, P1087, DOI 10.1016/0896-6273(92)90130-6; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Lipton SA, 1996, TRENDS PHARMACOL SCI, V17, P186, DOI 10.1016/0165-6147(96)20028-8; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; OH BH, 1993, J BIOL CHEM, V268, P11348; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SOMMER B, 1992, TRENDS PHARMACOL SCI, V13, P291, DOI 10.1016/0165-6147(92)90088-N; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; SULLIVAN JM, 1994, NEURON, V13, P929, DOI 10.1016/0896-6273(94)90258-5; Sutcliffe MJ, 1996, BIOPHYS J, V70, P1575, DOI 10.1016/S0006-3495(96)79724-2; TERRAMANI T, 1988, MOL PHARMACOL, V34, P117; VYAS NK, 1988, SCIENCE, V242, P1290, DOI 10.1126/science.3057628; Watase K, 1997, BIOCHEM J, V322, P385, DOI 10.1042/bj3220385; WO ZG, 1995, TRENDS NEUROSCI, V18, P161; Wo ZG, 1996, MOL PHARMACOL, V50, P770	33	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25132	25138		10.1074/jbc.273.39.25132	http://dx.doi.org/10.1074/jbc.273.39.25132			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737972	hybrid			2022-12-27	WOS:000076085400022
J	Genschik, P; Drabikowski, K; Filipowicz, W				Genschik, P; Drabikowski, K; Filipowicz, W			Characterization of the Escherichia coli RNA 3 '-terminal phosphate cyclase and its sigma(54)-regulated operon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; ENHANCER-BINDING PROTEINS; HELA-CELL EXTRACT; WHEAT-GERM; TRANSCRIPTIONAL ACTIVATOR; MYXOCOCCUS-XANTHUS; 3',5'-PHOSPHODIESTER LINKAGE; POLYNUCLEOTIDE KINASE; PSEUDOMONAS-PUTIDA; FUNCTIONAL DOMAINS	The RNA 3'-terminal phosphate cyclase catalyzes the ATP-dependent conversion of the 3'-phosphate to the 2',3'-cyclic phosphodiester at the end of various RNA substrates, Recent cloning of a cDNA encoding the human cyclase indicated that genes encoding cyclase-like proteins are conserved among Eucarya, Bacteria, and Archaea, The protein encoded by the Escherichia coli gene was overexpressed and shown to have the RNA 3'-phosphate cyclase activity (Genschik, P,, Billy, E,, Swianiewicz, M,, and Filipowicz, W, (1997) EMBO J. 16, 2955-2967), Analysis of the requirements and substrate specificity of the E. coli protein, presented in this work, demonstrates that properties of the bacterial and human enzymes are similar, ATP is the best cofactor (K-m = 20 mu M), whereas GTP (K-m = 100 mu M) and other nucleoside triphosphates (NTPs) act less efficiently, The enzyme undergoes nucleotidylation in the presence of [alpha-P-32]ATP and, to a lesser extent, also in the presence of other NTPs. Comparison of 3'-phosphorylated oligoribonucleotides and oligodeoxyribonucleotides of identical sequence demonstrated that the latter are at least 300-fold poorer substrates for the enzyme. The E. coli cyclase gene, named rtcA, forms part of an uncharacterized operon containing two additional open reading frames (ORFs), The ORF positioned immediately upstream, named rtcB, encodes a protein that is also highly conserved between Eucarya, Bacteria, and Archaea. Another ORF, called rtcR, is positioned upstream of the rtcA/rtcB unit and is transcribed in the opposite direction, It encodes a protein having features of sigma(54)-dependent regulators. By overexpressing the N-terminally truncated form of RtcR, we demonstrate that this regulator indeed controls expression of rtcA and rtcB in a sigma(54)-dependent manner, Also consistent with the involvement of sigma(54) the region upstream of the transcription start site of the rtcA/rtcB mRNA contains the -12 and -24 elements, TTGCA and TGGCA, respectively, characteristic of sigma(54)-dependent promoters. The cyclase gene is nonessential as demonstrated by knockout experiments, Possible functions of the cyclase in RNA metabolism are discussed.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Filipowicz, W (corresponding author), Maulbeerstr 66, CH-4058 Basel, Switzerland.	Filipowi@fmi.ch		GENSCHIK, Pascal/0000-0002-4107-5071; Drabikowski, Krzysztof/0000-0002-1972-4493				ALEX LA, 1994, TRENDS GENET, V10, P133, DOI 10.1016/0168-9525(94)90215-1; AMITSUR M, 1987, EMBO J, V6, P2499, DOI 10.1002/j.1460-2075.1987.tb02532.x; Arn EA, 1996, J BIOL CHEM, V271, P31145, DOI 10.1074/jbc.271.49.31145; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; Blackburn P, 1982, ENZYMES, VXV, P317; BRANCH AD, 1982, SCIENCE, V217, P1147, DOI 10.1126/science.217.4565.1147; BRUN YV, 1992, GENE DEV, V6, P2395, DOI 10.1101/gad.6.12a.2395; Cases I, 1996, MOL MICROBIOL, V19, P7, DOI 10.1046/j.1365-2958.1996.345873.x; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; DODD IB, 1990, NUCLEIC ACIDS RES, V18, P5019, DOI 10.1093/nar/18.17.5019; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FERNANDEZ S, 1995, MOL MICROBIOL, V16, P205, DOI 10.1111/j.1365-2958.1995.tb02293.x; FILIPOWICZ W, 1985, P NATL ACAD SCI USA, V82, P1316, DOI 10.1073/pnas.82.5.1316; FILIPOWICZ W, 1990, METHOD ENZYMOL, V181, P499; FILIPOWICZ W, 1984, TRENDS BIOCHEM SCI, V9, P68, DOI 10.1016/0968-0004(84)90186-5; FILIPOWICZ W, 1983, CELL, V32, P547, DOI 10.1016/0092-8674(83)90474-9; FILIPOWICZ W, 1983, NUCLEIC ACIDS RES, V11, P1405, DOI 10.1093/nar/11.5.1405; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; FURNEAUX H, 1983, P NATL ACAD SCI-BIOL, V80, P3933, DOI 10.1073/pnas.80.13.3933; GANDINIATTARDI D, 1985, EMBO J, V4, P3289; GEGENHEIMER P, 1983, J BIOL CHEM, V258, P8365; Genschik P, 1997, EMBO J, V16, P2955, DOI 10.1093/emboj/16.10.2955; GOODRICH JA, 1990, NUCLEIC ACIDS RES, V18, P4993, DOI 10.1093/nar/18.17.4993; GRALLA JD, 1996, ESCHERICHIA COLI SAL, V1, P1232; GREER CL, 1983, CELL, V33, P899, DOI 10.1016/0092-8674(83)90032-6; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; Gu J, 1997, J BIOL CHEM, V272, P21989, DOI 10.1074/jbc.272.35.21989; GULATI P, 1995, J BACTERIOL, V177, P4645, DOI 10.1128/jb.177.16.4645-4651.1995; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; HUNT TP, 1985, P NATL ACAD SCI USA, V82, P8453, DOI 10.1073/pnas.82.24.8453; KESELER IM, 1995, J BACTERIOL, V177, P4638, DOI 10.1128/jb.177.16.4638-4644.1995; Keseler IM, 1997, P NATL ACAD SCI USA, V94, P1979, DOI 10.1073/pnas.94.5.1979; KIBERSTIS PA, 1985, EMBO J, V4, P817, DOI 10.1002/j.1460-2075.1985.tb03703.x; KIKUCHI Y, 1982, NUCLEIC ACIDS RES, V10, P7521, DOI 10.1093/nar/10.23.7521; KJEMS J, 1988, CELL, V54, P693, DOI 10.1016/S0092-8674(88)80014-X; KONARSKA M, 1982, P NATL ACAD SCI-BIOL, V79, P1474, DOI 10.1073/pnas.79.5.1474; KONARSKA M, 1981, NATURE, V293, P112, DOI 10.1038/293112a0; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; KUSTU S, 1991, TRENDS BIOCHEM SCI, V16, P397, DOI 10.1016/0968-0004(91)90163-P; LASKI FA, 1983, J BIOL CHEM, V258, P1974; LEE JH, 1994, J BIOL CHEM, V269, P20401; LUND E, 1992, SCIENCE, V255, P327, DOI 10.1126/science.1549778; Magasanik B., 1996, ESCHERICHIA COLI SAL, P1344; MARTINVERSTRAETE I, 1994, J MOL BIOL, V241, P178, DOI 10.1006/jmbi.1994.1487; MERRICK MJ, 1993, MOL MICROBIOL, V10, P903, DOI 10.1111/j.1365-2958.1993.tb00961.x; MORETT E, 1989, J MOL BIOL, V210, P65, DOI 10.1016/0022-2836(89)90291-X; MORETT E, 1993, J BACTERIOL, V175, P6067, DOI 10.1128/JB.175.19.6067-6074.1993; NORTH AK, 1993, J BACTERIOL, V175, P4267, DOI 10.1128/JB.175.14.4267-4273.1993; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; PERKINS KK, 1985, P NATL ACAD SCI USA, V82, P684, DOI 10.1073/pnas.82.3.684; PHIZICKY EM, 1993, TRENDS BIOCHEM SCI, V18, P31; PHIZICKY EM, 1992, J BIOL CHEM, V267, P4577; PHIZICKY EM, 1986, J BIOL CHEM, V261, P2978; PICK L, 1986, J BIOL CHEM, V261, P6694; RAUHUT R, 1990, J BIOL CHEM, V265, P18180; REINBERG D, 1985, J BIOL CHEM, V260, P6088; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWARTZ RC, 1983, J BIOL CHEM, V258, P8374; Sekiguchi J, 1997, MOL CELL, V1, P89, DOI 10.1016/S1097-2765(00)80010-6; Shingler V, 1996, MOL MICROBIOL, V19, P409, DOI 10.1046/j.1365-2958.1996.388920.x; SHINGLER V, 1995, MOL MICROBIOL, V17, P505, DOI 10.1111/j.1365-2958.1995.mmi_17030505.x; Sidrauski C, 1996, CELL, V87, P405, DOI 10.1016/S0092-8674(00)81361-6; SIDRAUSKI C, 1997, CELL, V90, P1; SNYDER L, 1995, MOL MICROBIOL, V15, P415, DOI 10.1111/j.1365-2958.1995.tb02255.x; STRANGE N, 1987, EMBO J, V6, P2811; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641; Takahashi K., 1982, ENZYMES, V15, p435 468; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; TAZI J, 1993, MOL CELL BIOL, V13, P1641, DOI 10.1128/MCB.13.3.1641; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; THOMPSON LD, 1988, J BIOL CHEM, V263, P17951; THONY B, 1989, FEMS MICROBIOL LETT, V63, P341; UHLENBECK OC, 1983, TRENDS BIOCHEM SCI, V8, P94, DOI 10.1016/0968-0004(83)90258-X; VICENTE O, 1988, EUR J BIOCHEM, V176, P431, DOI 10.1111/j.1432-1033.1988.tb14300.x; Westaway Shawn K., 1995, P79; WINGROVE JA, 1994, GENE DEV, V8, P1839, DOI 10.1101/gad.8.15.1839; Wintjens R, 1996, J MOL BIOL, V262, P294, DOI 10.1006/jmbi.1996.0514; ZILLMANN M, 1991, MOL CELL BIOL, V11, P5410, DOI 10.1128/MCB.11.11.5410	81	70	81	2	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25516	25526		10.1074/jbc.273.39.25516	http://dx.doi.org/10.1074/jbc.273.39.25516			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738023	hybrid			2022-12-27	WOS:000076085400073
J	Kiehn, J; Karle, C; Thomas, D; Yao, XZ; Brachmann, J; Kubler, W				Kiehn, J; Karle, C; Thomas, D; Yao, XZ; Brachmann, J; Kubler, W			HERG potassium channel activation is shifted by phorbol esters via protein kinase A-dependent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-QT SYNDROME; SELECTIVE INHIBITOR; INWARD RECTIFIER; K+-CHANNEL; CELLS; CURRENTS; POTENT; BLOCK; DIFFERENTIATION; MECHANISMS	We investigated the effects of the phorbol ester phorbol la-myristate 13-acetate (PMA) on the rapid component of the delayed rectifier potassium current, I-Kr, in guinea pig cardiomyocytes and found that the I-Kr current amplitude was reduced by 20% with 10 nM PMA and 44% with 100 nM PMA. The ether-a-go-go-related gene (HERG) encodes I-Kr in human heart. We expressed HERG heterologously in Xenopus oocytes and investigated the effects of PMA on the delayed rectifier potassium current. Upon application of PMA in a concentration of 100 nM, we found a similar reduction of HERG outward current amplitude by 59%. This reduction was due to a shift in the HERG activation curve by 37 mV. The ED50 for the PMA-induced shift was 9.0 nM. The inactive 4 alpha-phorbol 12-myristate 13-acetate (4 alpha-PMA) had no effect. PMA is known to act by stimulating distinct protein kinase cascades. Additional application of the specific protein kinase C inhibitors chelerythrine (10 mu M) or bisindolylmaleimide (1 mu M) could not attenuate the PMA-induced shift. In contrast, the shift by PMA was reduced significantly when the specific protein kinase A (PKA) inhibitors H89 (50 mu M) or KT5720 (2.5 mu M) were applied. Forskolin (400 mu M), an activator of the adenylate cyclase that results in PKA activation, shifted the HERG activation curve by 14 mV. Moreover the specific protein kinase C activator 1-stearoyl-2-arachidonylglycerol (10 mu M) showed no effect. Our data suggest that mainly PKA is mediating the shift of the HERG activation kinetics.	Med Univ Hosp Heidelberg, Dept Cardiol, D-69115 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Kiehn, J (corresponding author), Med Univ Hosp Heidelberg, Dept Cardiol, Bergheimerstr 58, D-69115 Heidelberg, Germany.	johannkiehn@ukl.uni-heidelberg.de	Thomas, Dierk/ABA-4706-2021; Thomas, Dierk/V-3940-2017	Thomas, Dierk/0000-0002-5687-7843; 				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BUSCH AE, 1992, SCIENCE, V255, P1705, DOI 10.1126/science.1553557; Busch AE, 1996, PFLUG ARCH EUR J PHY, V432, P1094, DOI 10.1007/s004240050240; BUTT E, 1994, EUR J PHARM-MOLEC PH, V269, P265, DOI 10.1016/0922-4106(94)90095-7; CARMELIET E, 1993, EUR HEART J, V14, P3, DOI 10.1093/eurheartj/14.suppl_H.3; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; GO M, 1987, BIOCHEM BIOPH RES CO, V144, P598; GUSOVSKY F, 1991, MOL PHARMACOL, V39, P124; Henry P, 1996, J PHYSIOL-LONDON, V495, P681, DOI 10.1113/jphysiol.1996.sp021625; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HOFFMAN R, 1991, CANCER CHEMOTH PHARM, V28, P102, DOI 10.1007/BF00689696; Hsu C, 1997, J SURG RES, V71, P161, DOI 10.1006/jsre.1997.5143; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KEATING MT, 1995, CIRCULATION, V92, P142, DOI 10.1161/01.CIR.92.1.142; KIEHN J, 1994, J CARDIOVASC PHARM, V24, P566, DOI 10.1097/00005344-199410000-00007; Kiehn J, 1996, CIRCULATION, V94, P2572, DOI 10.1161/01.CIR.94.10.2572; Liang BT, 1997, AM J PHYSIOL-HEART C, V273, pH847, DOI 10.1152/ajpheart.1997.273.2.H847; Liu YG, 1996, CIRC RES, V78, P443, DOI 10.1161/01.RES.78.3.443; Pahan K, 1997, J BIOL CHEM, V272, P7786, DOI 10.1074/jbc.272.12.7786; Quest AFG, 1996, ENZYME PROTEIN, V49, P231, DOI 10.1159/000468635; Roden DM, 1996, CIRCULATION, V94, P1996, DOI 10.1161/01.CIR.94.8.1996; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; Sanguinetti MC, 1996, P NATL ACAD SCI USA, V93, P2208, DOI 10.1073/pnas.93.5.2208; SANGUINETTI MC, 1995, CELL, V81, P1; Schultz H, 1997, J CELL PHYSIOL, V173, P310, DOI 10.1002/(SICI)1097-4652(199712)173:3<310::AID-JCP2>3.0.CO;2-Q; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; Spector PS, 1996, CIRC RES, V78, P499, DOI 10.1161/01.RES.78.3.499; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; WALSH KB, 1988, SCIENCE, V242, P67, DOI 10.1126/science.2845575	32	74	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25285	25291		10.1074/jbc.273.39.25285	http://dx.doi.org/10.1074/jbc.273.39.25285			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737994	hybrid			2022-12-27	WOS:000076085400044
J	Minetti, CASA; Blake, MS; Remeta, DP				Minetti, CASA; Blake, MS; Remeta, DP			Characterization of the structure, function, and conformational stability of PorB class 3 protein front Neisseria meningitidis - A porin with unusual physicochemical properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEINS; ESCHERICHIA-COLI; ANGSTROM RESOLUTION; BACTERIAL PORIN; OMPF PORIN; GONORRHOEAE; GENE; IDENTIFICATION; INSERTION; SEQUENCE	PorB proteins constitute the vast majority of channels in neisserial outer membranes and can be subdivided within meningococcal strains into two distinct and mutually exclusive families that are designated as class 2 and class 3 proteins. We recently characterized the functional activity and conformational stability of a PorB class 2 protein from Neisseria meningitidis (Minetti, C. A. S. A., Tai, J. Y., Blake, M. S., Pullen, J. K., Liang, S. M., and Remeta, D. P. (1997) J. Biol. Chem. 272, 10710-10720). To evaluate the structure-function relatedness among the PorB proteins, we have employed a combination of electrophoretic and spectroscopic techniques to assess the conformational stability of zwittergent-solubilized class 3 trimers, The functional, physicochemical, and structural properties of the meningococcal class 2 and class 3 proteins are comparable with the notable exception that the latter exhibits a significantly higher susceptibility to SDS. The SDS-induced dissociation and partial unfolding of PorB class 3 is characterized by a single two-state transition with a midpoint at 0.35% SDS. The native trimeric assembly dissociates reversibly, forming partially folded monomers that retain the characteristic P-sheet content of the transmembrane domain with a concomitant increase in random coil structure arising from unfolding the rigid surface loops. These results provide new insight into the elucidation of porin folding pathways and the factors that govern the overall structural stability of meningococcal proteins.	N Amer Vaccine Inc, Beltsville, MD 20705 USA; Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, Ctr Biocalorimetry, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Minetti, CASA (corresponding author), N Amer Vaccine Inc, 12103 Indian Creek Court, Beltsville, MD 20705 USA.		Minetti, Conceicao/AGD-6419-2022; Minetti, Conceicao/B-5077-2009	Minetti, Conceicao/0000-0002-9682-2898; Minetti, Conceicao/0000-0002-9682-2898; Remeta, David/0000-0002-4142-0904				BARRERA O, 1984, INFECT IMMUN, V44, P565, DOI 10.1128/IAI.44.3.565-568.1984; BASH MC, 1995, INFECT IMMUN, V63, P1484, DOI 10.1128/IAI.63.4.1484-1490.1995; BLAKE MS, 1981, INFECT IMMUN, V33, P212, DOI 10.1128/IAI.33.1.212-222.1981; BOLLA JM, 1995, J BACTERIOL, V177, P4266, DOI 10.1128/jb.177.15.4266-4271.1995; BRAY MR, 1996, PROTEIN SCI, V5, P2312; BUTCHER S, 1991, GENE, V105, P125, DOI 10.1016/0378-1119(91)90523-E; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DELVIG AA, 1995, MICROBIOL-SGM, V141, P1593, DOI 10.1099/13500872-141-7-1593; EISELE JL, 1990, J BIOL CHEM, V265, P10217; EXNER MM, 1995, INFECT IMMUN, V63, P1567, DOI 10.1128/IAI.63.4.1567-1572.1995; FEAVERS IM, 1992, INFECT IMMUN, V60, P3620, DOI 10.1128/IAI.60.9.3620-3629.1992; FOUREL D, 1994, EUR J BIOCHEM, V222, P625, DOI 10.1111/j.1432-1033.1994.tb18905.x; FRASCH CE, 1985, REV INFECT DIS, V7, P504; FRASCH CE, 1978, J BACTERIOL, V136, P1127, DOI 10.1128/JB.136.3.1127-1134.1978; FRASCH CE, 1990, P 7 INT PATH NEISS C, P213; GUTTORMSEN HK, 1993, INFECT IMMUN, V61, P4734, DOI 10.1128/IAI.61.11.4734-4742.1993; HAINES KA, 1991, J CELL BIOL, V114, P433, DOI 10.1083/jcb.114.3.433; HAINES KA, 1988, J BIOL CHEM, V263, P945; HANCOCK REW, 1990, MOL MICROBIOL, V4, P1069, DOI 10.1111/j.1365-2958.1990.tb00680.x; HITCHCOCK PJ, 1989, CLIN MICROBIOL REV, V2, pS64, DOI 10.1128/CMR.2.Suppl.S64-S65.1989; JEANTEUR D, 1991, MOL MICROBIOL, V5, P2153, DOI 10.1111/j.1365-2958.1991.tb02145.x; KOEBNIK R, 1993, J BACTERIOL, V175, P826, DOI 10.1128/JB.175.3.826-839.1993; KREUSCH A, 1994, PROTEIN SCI, V3, P58; LYNCH EC, 1984, BIOPHYS J, V45, P104, DOI 10.1016/S0006-3495(84)84127-2; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; MANDRELL RE, 1984, J IMMUNOL METHODS, V67, P1, DOI 10.1016/0022-1759(84)90080-2; MARCOVICHOUSLEY Z, 1986, BIOCHIM BIOPHYS ACTA, V869, P158; Minetti CASA, 1997, J BIOL CHEM, V272, P10710; Missiakas D, 1997, J BACTERIOL, V179, P2465, DOI 10.1128/jb.179.8.2465-2471.1997; MURAKAMI K, 1989, INFECT IMMUN, V57, P2318, DOI 10.1128/IAI.57.8.2318-2323.1989; NEUWALD AF, 1995, PROTEIN SCI, V4, P1618, DOI 10.1002/pro.5560040820; NIKAIDO H, 1994, J BIOL CHEM, V269, P3905; NIKAIDO H, 1992, MOL MICROBIOL, V6, P435, DOI 10.1111/j.1365-2958.1992.tb01487.x; NIKAIDO H, 1991, J BIOL CHEM, V266, P770; PARK K, 1992, PROTEIN SCI, V1, P1032, DOI 10.1002/pro.5560010809; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; Popp B, 1997, BIOCHEMISTRY-US, V36, P2844, DOI 10.1021/bi961745d; PORAT N, 1995, INFECT IMMUN, V63, P2164, DOI 10.1128/IAI.63.6.2164-2172.1995; QI HL, 1994, INFECT IMMUN, V62, P2432, DOI 10.1128/IAI.62.6.2432-2439.1994; RAGONE R, 1984, BIOCHEMISTRY-US, V23, P1871, DOI 10.1021/bi00303a044; ROSENBUSCH JP, 1974, J BIOL CHEM, V249, P8019; Saint N, 1996, J BIOL CHEM, V271, P20676, DOI 10.1074/jbc.271.34.20676; SCHIMID B, 1996, FEBS LETT, V381, P111; SCHINDLER M, 1984, FEBS LETT, V173, P85, DOI 10.1016/0014-5793(84)81022-4; SCHINDLER M, 1982, J CELL BIOL, V92, P742, DOI 10.1083/jcb.92.3.742; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; Song JM, 1998, BBA-BIOMEMBRANES, V1370, P289, DOI 10.1016/S0005-2736(97)00279-4; Surrey T, 1996, BIOCHEMISTRY-US, V35, P2283, DOI 10.1021/bi951216u; TOKUNAGA M, 1979, EUR J BIOCHEM, V95, P441, DOI 10.1111/j.1432-1033.1979.tb12983.x; TOMASSEN J, 1990, INFECT IMMUN, V58, P1355; TSAI CM, 1981, J BACTERIOL, V146, P69, DOI 10.1128/JB.146.1.69-78.1981; VANDERLEY P, 1991, INFECT IMMUN, V59, P2963, DOI 10.1128/IAI.59.9.2963-2971.1991; WARD MJ, 1992, FEMS MICROBIOL LETT, V94, P283, DOI 10.1111/j.1574-6968.1992.tb05332.x; WEISS MS, 1992, J MOL BIOL, V227, P493, DOI 10.1016/0022-2836(92)90903-W; WETZLER LM, 1988, J EXP MED, V168, P1883, DOI 10.1084/jem.168.5.1883; WOLFF K, 1991, FEMS MICROBIOL LETT, V83, P179, DOI 10.1016/0378-1097(91)90351-A; ZAPATA GA, 1992, MOL MICROBIOL, V6, P3493, DOI 10.1111/j.1365-2958.1992.tb01784.x	58	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25329	25338		10.1074/jbc.273.39.25329	http://dx.doi.org/10.1074/jbc.273.39.25329			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737999	hybrid			2022-12-27	WOS:000076085400049
J	Solomon, V; Lecker, SH; Goldberg, AL				Solomon, V; Lecker, SH; Goldberg, AL			The N-end rule pathway catalyzes a major fraction of the protein degradation in skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CARRIER PROTEIN; DEPENDENT PROTEOLYTIC SYSTEM; ACIDIC NH2 TERMINI; TRANSFER-RNA; AFFINITY PURIFICATION; CONJUGATING ENZYMES; PROTEASOME PATHWAY; MESSENGER-RNA; BINDING-SITES; LIGASE	In skeletal muscle, overall protein degradation involves the ubiquitin-proteasome system. One property of a protein that leads to rapid ubiquitin-dependent degradation is the presence of a basic, acidic, or bulky hydrophobic residue at its N terminus. However, in normal cells, substrates for this N-end rule pathway, which involves ubiquitin carrier protein (E2) E2(14k) and ubiquitin-protein ligase (E3) E3 alpha, have remained unclear. Surprisingly, in soluble extracts of rabbit muscle, we found that competitive inhibitors of E3 alpha markedly inhibited the I-125-ubiquitin conjugation and ATP-dependent degradation of endogenous proteins. These inhibitors appear to selectively inhibit E3 alpha; since they blocked degradation of I-125-lysozyme, a model N-end rule substrate, but did not affect the degradation of proteins whose ubiquitination involved other E3s. The addition of several E2s or E3 alpha to the muscle extracts stimulated overall proteolysis and ubiquitination, but only the stimulation by E3 alpha or E2(14k) was sensitive to these inhibitors. A similar general inhibition of ubiquitin conjugation to endogenous proteins was observed with a dominant negative inhibitor of E2(14k). Certain substrates of the N-end rule pathway are degraded after their tRNA-dependent arginylation. We found that adding RNase A to muscle extracts reduced the ATP-dependent proteolysis of endogenous proteins, and supplying tRNA partially restored this process. Finally, although in muscle extracts the N-end rule pathway catalyzes most ubiquitin conjugation, it makes only a minor contribution to overall protein ubiquitination in HeLa cell extracts.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Goldberg, AL (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.							Aristarkhov A, 1996, P NATL ACAD SCI USA, V93, P4294, DOI 10.1073/pnas.93.9.4294; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BARACOS VE, 1995, AM J PHYSIOL-ENDOC M, V268, pE996, DOI 10.1152/ajpendo.1995.268.5.E996; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BLUMENFELD N, 1994, J BIOL CHEM, V269, P9574; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; CIECHANOVER A, 1987, J CELL BIOCHEM, V34, P81, DOI 10.1002/jcb.240340203; CIECHANOVER A, 1988, J BIOL CHEM, V263, P11155; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coux O, 1998, J BIOL CHEM, V273, P8820, DOI 10.1074/jbc.273.15.8820; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; ELIAS S, 1990, J BIOL CHEM, V265, P15511; FAGAN JM, 1987, BIOCHEM J, V243, P335, DOI 10.1042/bj2430335; FERBER S, 1987, NATURE, V326, P808, DOI 10.1038/326808a0; FERBER S, 1986, J BIOL CHEM, V261, P3128; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GONDA DK, 1989, J BIOL CHEM, V264, P16700; Gonen H, 1996, J BIOL CHEM, V271, P302, DOI 10.1074/jbc.271.1.302; HEGDE AN, 1993, P NATL ACAD SCI USA, V90, P7436, DOI 10.1073/pnas.90.16.7436; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JOHNSTON NL, 1991, BIOCHEMISTRY-US, V30, P7514, DOI 10.1021/bi00244a021; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEDINA R, 1995, BIOCHEM J, V307, P631, DOI 10.1042/bj3070631; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; REISS Y, 1988, J BIOL CHEM, V263, P2693; REISS Y, 1990, J BIOL CHEM, V265, P3685; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SHKEDY D, 1994, FEBS LETT, V348, P126, DOI 10.1016/0014-5793(94)00582-6; Solomon V, 1996, J BIOL CHEM, V271, P26690, DOI 10.1074/jbc.271.43.26690; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SUNG P, 1991, J MOL BIOL, V221, P745, DOI 10.1016/0022-2836(91)80169-U; Tawa NE, 1997, J CLIN INVEST, V100, P197, DOI 10.1172/JCI119513; TAWA NE, 1994, MYOLOGY BASIC CLIN, P663; TEMPARIS S, 1994, CANCER RES, V54, P5568; TIAO G, 1994, J CLIN INVEST, V94, P2255, DOI 10.1172/JCI117588; Townsley FM, 1997, P NATL ACAD SCI USA, V94, P2362, DOI 10.1073/pnas.94.6.2362; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; WING SS, 1992, J BIOL CHEM, V267, P6495; WING SS, 1995, BIOCHEM J, V307, P639, DOI 10.1042/bj3070639	47	103	104	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25216	25222		10.1074/jbc.273.39.25216	http://dx.doi.org/10.1074/jbc.273.39.25216			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737984	hybrid			2022-12-27	WOS:000076085400034
J	Papin, C; Denouel-Galy, A; Laugier, D; Calothy, G; Eychene, A				Papin, C; Denouel-Galy, A; Laugier, D; Calothy, G; Eychene, A			Modulation of kinase activity and oncogenic properties by alternative splicing reveals a novel regulatory mechanism for B-Raf	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE CODING SEQUENCE; PROTEIN-KINASE; A-RAF; NEURORETINA CELLS; MAP KINASE; BIOCHEMICAL-PROPERTIES; PLASMA-MEMBRANE; C-MIL; GENE-PRODUCT; VIRUS TYPE-1	Members of the raf oncogene family encode serine/ threonine protein kinases, which activate the mitogen-activated protein kinase kinase MEKs (MAPK or ERK kinases) through direct interaction and phosphorylation. Several recent studies have revealed interesting differences between two members of this family, Raf-1 and B-Raf, regarding their activation, regulation, and kinase activity. In particular, B-Raf was shown to display higher MEK kinase activity than Raf-1. By using both two-hybrid analysis and coimmunoprecipitation experiments, we demonstrate here that B-Raf also markedly differs from Raf-1 by a higher affinity for MEK. We previously reported that the B-raf gene encodes multiple protein isoforms resulting from complex alternative splicing of two exons (exons 8b and 10) located upstream of E-Raf kinase domain. In the present study, we show that these naturally occurring modifications within the protein sequence markedly modulate both the biochemical and oncogenic properties of B-Raf. The presence of exon 10 sequences enhances the affinity for MEK, the basal kinase activity, as well as the mitogenic and transforming properties of full-length B-Raf, whereas the presence of exon 8b sequences seems to have opposite effects. Therefore, alternative splicing represents a novel regulatory mechanism for a protein of the Raf family.	Inst Curie, Lab 110, CNRS, Unite Mixte Rech 146, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Eychene, A (corresponding author), Inst Curie, Lab 110, CNRS, Unite Mixte Rech 146, Ctr Univ, F-91405 Orsay, France.	Alain.Eychene@curie.u-psud.fr	Eychene, Alain/M-8838-2017	EYCHENE, Alain/0000-0002-6818-7225				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; BECHADE C, 1985, NATURE, V316, P559, DOI 10.1038/316559a0; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; Bos JL, 1997, FEBS LETT, V410, P59, DOI 10.1016/S0014-5793(97)00324-4; Bosch E, 1997, ONCOGENE, V15, P1021, DOI 10.1038/sj.onc.1201270; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CALOTHY G, 1980, COLD SPRING HARB SYM, V44, P983, DOI 10.1101/SQB.1980.044.01.106; CATLING AD, 1994, J BIOL CHEM, V269, P30014; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; Denouel-Galy A, 1998, CURR BIOL, V8, P46, DOI 10.1016/S0960-9822(98)70019-3; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; EYCHENE A, 1995, ONCOGENE, V10, P1159; EYCHENE A, 1992, ONCOGENE, V7, P1315; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FELDER MP, 1991, J VIROL, V65, P3633, DOI 10.1128/JVI.65.7.3633-3640.1991; FELDER MP, 1993, J VIROL, V67, P6853, DOI 10.1128/JVI.67.11.6853-6856.1993; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEVY JB, 1989, MOL CELL BIOL, V9, P3332, DOI 10.1128/MCB.9.8.3332; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARX M, 1988, EMBO J, V7, P3369, DOI 10.1002/j.1460-2075.1988.tb03209.x; Miller J.H., 1972, EXPT MOL GENETICS; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Papin C, 1996, ONCOGENE, V12, P2213; PAPIN C, 1995, ONCOGENE, V10, P1647; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PESSAC B, 1974, SCIENCE, V185, P709, DOI 10.1126/science.185.4152.709; POUPONNOT C, 1995, MOL CELL BIOL, V15, P5563; Pritchard CA, 1996, CURR BIOL, V6, P614, DOI 10.1016/S0960-9822(02)00548-1; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; TRAVERSE S, 1994, FEBS LETT, V350, P13, DOI 10.1016/0014-5793(94)00723-3; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yu W, 1998, CURR BIOL, V8, P56, DOI 10.1016/S0960-9822(98)70020-X; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	48	87	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24939	24947		10.1074/jbc.273.38.24939	http://dx.doi.org/10.1074/jbc.273.38.24939			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733801	hybrid			2022-12-27	WOS:000076007300093
J	Crump, CM; Williams, JL; Stephens, DJ; Banting, G				Crump, CM; Williams, JL; Stephens, DJ; Banting, G			Inhibition of the interaction between tyrosine-based motifs and the medium chain subunit of the AP-2 adaptor complex by specific tyrphostins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; CYTOPLASMIC DOMAIN; INTERNALIZATION MOTIF; CELL-PROLIFERATION; MEMBRANE-PROTEIN; SORTING SIGNALS; TGN38; SEQUENCE; KINASE; ENDOCYTOSIS	Several intracellular membrane trafficking events are mediated by tyrosine-containing motifs found within the cytosolic domains of certain integral membrane proteins. Many of these tyrosine motifs conform to the consensus YXX Phi, (where Phi represents a bulky hydrophobic residue). This YXX Phi motif has been shown to interact with the medium chain subunits of adaptor complexes that generally link. relevant integral membrane protein cytosolic domains to the clathrin coat involved in vesicle formation. The motif YXX Phi, is also very similar to motifs that are targets for phosphorylation by tyrosine kinases. Tyrosine kinase inhibitors known as tyrphostins are structural analogues of tyrosine, and so it is possible that tyrphostins could also inhibit interactions between medium chains and YXX Phi, motifs. TGN38 is a type I integral membrane protein containing a tyrosine motif, YQRL, within the cytosolic domain. We have previously shown that this motif interacts directly with the medium chain subunit of the plasma membrane localized AP-2 adaptor complex (mu 2) We have investigated a range of tyrphostins and demonstrated a specific inhibition of the interaction between mu 2 and the TGN38 cytosolic domain by tyrphostin A23 through in vitro analysis and the yeast two-hybrid system. These data raise the exciting possibility that different membrane traffic events could be inhibited by specific tyrphostins.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol	Banting, G (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England.		Parish, Joanna L/L-4820-2015	Parish, Joanna L/0000-0002-7111-4211; Stephens, David/0000-0001-5297-3240; Banting, George/0000-0001-8249-1621; Crump, Colin/0000-0001-9918-9998				Aguilar RC, 1997, J BIOL CHEM, V272, P27160, DOI 10.1074/jbc.272.43.27160; Austin CD, 1996, J CELL BIOL, V135, P1471, DOI 10.1083/jcb.135.6.1471; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; Chuang E, 1997, J IMMUNOL, V159, P144; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; EBERLE W, 1991, CELL, V67, P1195; HOLEN I, 1995, J BIOL CHEM, V270, P12823, DOI 10.1074/jbc.270.21.12823; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; LYALL RM, 1989, J BIOL CHEM, V264, P14503; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; REAVES B, 1993, MOL BIOL CELL, V4, P93, DOI 10.1091/mbc.4.1.93; Roquemore EP, 1998, MOL BIOL CELL, V9, P2125, DOI 10.1091/mbc.9.8.2125; Shiratori T, 1997, IMMUNITY, V6, P583, DOI 10.1016/S1074-7613(00)80346-5; Stephens DJ, 1997, FEBS LETT, V416, P27, DOI 10.1016/S0014-5793(97)01165-4; Stephens DJ, 1997, J BIOL CHEM, V272, P14104, DOI 10.1074/jbc.272.22.14104; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WILDE A, 1994, J BIOL CHEM, V269, P7131; WONG SH, 1993, J BIOL CHEM, V268, P22853; YAISH P, 1988, SCIENCE, V242, P933, DOI 10.1126/science.3263702; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	29	22	25	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28073	28077		10.1074/jbc.273.43.28073	http://dx.doi.org/10.1074/jbc.273.43.28073			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774424	hybrid			2022-12-27	WOS:000076549800044
J	Rovner, AS				Rovner, AS			A long, weakly charged actin-binding loop is required for phosphorylation-dependent regulation of smooth muscle myosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-MEROMYOSIN; LIGHT-CHAIN; CHIMERIC SUBSTITUTIONS; ENZYMATIC-PROPERTIES; GIZZARD MYOSIN; MOTOR DOMAIN; SUBFRAGMENT-1; MECHANISM; MOVEMENT; ATPASE	Chimeric substitution of the weak actin-binding loop (ABL) from chicken skeletal muscle myosin for that of gizzard smooth muscle heavy meromyosin (HMM) causes activation of the dephosphorylated mutant (SABL HMM; Rovner, A. S., Freyzon, Y., and Trybus, K. M. (1995) J, Biol. Chem. 270, 30260-30263). The present study determined whether this loss of regulation is due to the greater positive charge density (5 versus 3 clustered lysine residues) or lesser length (14 versus 26 residues) of the mutant ABL, Charge augmentation had little effect on regulation of expressed mutants, but elimination of the 12 N-terminal amino acids from the wild-type ABL significantly increased actin-activated ATPase activity of the dephosphorylated relative to the phosphorylated molecule while conferring the ability to move actin filaments in vitro on the former. Addition of the same 12 residues to the SABL mutant increased the ratio of phosphorylated to dephosphorylated ATPase activity while imparting mild type-like regulation to motility, However, full actin activation of dephosphorylated ATPase activity required both the shorter length and greater positive charge density found in the SABL loop. These results demonstrate that, compared with skeletal, both the greater length and lesser positive charge density of the smooth muscle myosin ABL are required for proper phosphorylation-mediated regulation of the molecule.	Univ Vermont, Coll Med, Dept Mol Physiol & Biophys, Burlington, VT 05405 USA	University of Vermont	Rovner, AS (corresponding author), Univ Vermont, Coll Med, Dept Mol Physiol & Biophys, Burlington, VT 05405 USA.							CREMO CR, 1995, J BIOL CHEM, V270, P2171, DOI 10.1074/jbc.270.5.2171; Furch M, 1998, BIOCHEMISTRY-US, V37, P6317, DOI 10.1021/bi972851y; Guilford William H., 1996, Biophysical Journal, V70, pA127; Higuchi R., 1992, PCR TECHNOLOGY, P61; IKEBE M, 1994, J BIOL CHEM, V269, P28173; IKEBE M, 1983, BIOCHEMISTRY-US, V22, P4580, DOI 10.1021/bi00288a036; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; Rovner AS, 1995, J BIOL CHEM, V270, P30260, DOI 10.1074/jbc.270.51.30260; Sata M, 1997, P NATL ACAD SCI USA, V94, P91, DOI 10.1073/pnas.94.1.91; Sata M, 1996, BIOCHEMISTRY-US, V35, P11113, DOI 10.1021/bi960435s; SEIDEL JC, 1980, J BIOL CHEM, V255, P4355; Sellers JR, 1991, CURR OPIN CELL BIOL, V3, P98, DOI 10.1016/0955-0674(91)90171-T; SELLERS JR, 1982, J BIOL CHEM, V257, P3880; SELLERS JR, 1985, J BIOL CHEM, V260, P5815; SIEMANKOWSKI RF, 1985, P NATL ACAD SCI USA, V82, P658, DOI 10.1073/pnas.82.3.658; SWEENEY HL, 1994, P NATL ACAD SCI USA, V91, P1490, DOI 10.1073/pnas.91.4.1490; TAYLOR EW, 1979, CRC CR REV BIOCH MOL, V6, P103, DOI 10.3109/10409237909102562; TRYBUS KM, 1989, J CELL BIOL, V109, P2887, DOI 10.1083/jcb.109.6.2887; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; Trybus KM, 1998, J BIOL CHEM, V273, P18423, DOI 10.1074/jbc.273.29.18423; Trybus KM, 1997, P NATL ACAD SCI USA, V94, P48, DOI 10.1073/pnas.94.1.48; TRYBUS KM, 1994, J BIOL CHEM, V269, P20819; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; UYEDA TQP, 1994, NATURE, V368, P567, DOI 10.1038/368567a0; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; WAGNER PD, 1987, J BIOL CHEM, V262, P15556; YANAGISAWA M, 1987, J MOL BIOL, V198, P143, DOI 10.1016/0022-2836(87)90302-0; YANG ZH, 1995, J BIOL CHEM, V270, P24646, DOI 10.1074/jbc.270.42.24646	30	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27939	27944		10.1074/jbc.273.43.27939	http://dx.doi.org/10.1074/jbc.273.43.27939			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774407	hybrid			2022-12-27	WOS:000076549800027
J	Shields, MJ; Kubota, R; Hodgson, W; Jacobson, S; Biddison, WE; Ribaudo, RK				Shields, MJ; Kubota, R; Hodgson, W; Jacobson, S; Biddison, WE; Ribaudo, RK			The effect of human beta(2)-microglobulin on major histocompatibility complex I peptide loading and the engineering of a high affinity variant - Implications for peptide-based vaccines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-LYMPHOCYTE EPITOPES; TRANSGENIC MICE; MHC MOLECULES; CELL-SURFACE; DNA VACCINES; HAPLOTYPE FREQUENCIES; ENDOGENOUS PEPTIDES; MATRIX PEPTIDE; VIABLE CELLS; HLA GENE	The ability to directly load cell surface major histocompatibility complex (MHC) class I molecules with peptides provides a potentially powerful approach toward the development of vaccines to generate cell-mediated immunity. We demonstrate that exogenous beta(2)-microglobulin (beta(2)m) stabilizes human cell surface MHC I molecules and facilitates their loading with exogenous peptides, Additionally, using three-dimensional crystal structures and known interaction sites between MHC I heavy chains and beta(2)m, we engineered variants of human beta(2)m (h beta(2)m) with a single serine substitution at residue 55, This alteration was predicted to promote hydrophobic interactions at the MHC I heavy chain/beta(2)m interface and displace an ordered water molecule. Compared with h beta(2)m, the serine to valine substitution at residue 55 had improved ability to bind to cell surface HLA-A1, HLA-A2, and HLA-A3 molecules, facilitate exogenous peptide loading, and promote recognition by peptide-specific T cells. The inclusion of h beta(2)m or higher affinity variants when pulsing cells with MHC-restricted peptides increases the efficiency of peptide loading 50-80-fold. Therefore, the inclusion of h beta(2)m in peptide-based vaccines may increase cell surface antigen densities above thresholds that allow recognition of peptide antigens by the immune system, particularly for cryptic, subdominant, or marginally antigenic peptides.	NCI, Lab Immune Cell Biol, NIH, Bethesda, MD 20892 USA; NINDS, Neuroimmunol Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Ribaudo, RK (corresponding author), Mol Applicat Grp, 11800 Dewey Rd, Silver Spring, MD 20906 USA.	rkr@mag.com	Ribaudo, Randall/AAH-7094-2021; Kubota, Ryuji/A-7139-2009	Kubota, Ryuji/0000-0002-4158-3471				ABASTADO JP, 1993, J IMMUNOL, V151, P3569; ANDERSON KS, 1993, J IMMUNOL, V151, P3407; [Anonymous], INTRO PROTEIN STRUCT; BARRA C, 1993, J IMMUNOL, V150, P3681; Biddison WE, 1997, J IMMUNOL, V159, P2018; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BREMERS AJA, 1995, J IMMUNOTHER, V18, P77, DOI 10.1097/00002371-199508000-00001; BRODSKY FM, 1982, J IMMUNOL, V128, P129; Cook JR, 1996, J IMMUNOL, V157, P2256; DANLICZYK UG, 1994, J IMMUNOL, V153, P3533; Day PM, 1997, P NATL ACAD SCI USA, V94, P8064, DOI 10.1073/pnas.94.15.8064; DELGUERCIO MF, 1995, J IMMUNOL, V154, P685; Deng YP, 1997, J IMMUNOL, V158, P1507; Depierreux C, 1997, J IMMUNOL METHODS, V203, P77, DOI 10.1016/S0022-1759(97)00015-X; DIBRINO M, 1994, J IMMUNOL, V152, P620; DIBRINO M, 1993, J IMMUNOL, V151, P5930; DIBRINO M, 1993, P NATL ACAD SCI USA, V90, P1508, DOI 10.1073/pnas.90.4.1508; Eberl G, 1996, EUR J IMMUNOL, V26, P2709, DOI 10.1002/eji.1830261124; Edidin M, 1997, IMMUNOGENETICS, V46, P41, DOI 10.1007/s002510050240; EPSTEIN H, 1989, EUR J IMMUNOL, V19, P1575, DOI 10.1002/eji.1830190909; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Evans DT, 1997, J IMMUNOL, V159, P1374; FUKAZAWA T, 1994, J IMMUNOL, V153, P3543; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; Hansen TH, 1997, ADV IMMUNOL, V64, P105, DOI 10.1016/S0065-2776(08)60888-3; HOCHMAN JH, 1988, J IMMUNOL, V140, P2322; Honma K, 1997, J NEUROIMMUNOL, V73, P7, DOI 10.1016/S0165-5728(96)00161-0; Horig H, 1997, P NATL ACAD SCI USA, V94, P13826, DOI 10.1073/pnas.94.25.13826; JAULIN C, 1992, INT IMMUNOL, V4, P945, DOI 10.1093/intimm/4.8.945; KANE KP, 1991, EUR J IMMUNOL, V21, P2289, DOI 10.1002/eji.1830210945; KHARE SD, 1995, J EXP MED, V182, P1153, DOI 10.1084/jem.182.4.1153; KOZLOWSKI S, 1991, NATURE, V349, P74, DOI 10.1038/349074a0; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; Lustgarten J, 1997, HUM IMMUNOL, V52, P109, DOI 10.1016/S0198-8859(96)00292-3; MAN S, 1994, J IMMUNOL, V153, P4458; Manickan E, 1997, CRIT REV IMMUNOL, V17, P139, DOI 10.1615/CritRevImmunol.v17.i2.20; Montgomery DL, 1997, PHARMACOL THERAPEUT, V74, P195, DOI 10.1016/S0163-7258(97)82003-7; Mori M, 1997, TRANSPLANTATION, V64, P1017, DOI 10.1097/00007890-199710150-00014; Moss B, 1996, P NATL ACAD SCI USA, V93, P11341, DOI 10.1073/pnas.93.21.11341; OTTEN GR, 1992, J IMMUNOL, V148, P3723; PARKER KC, 1995, IMMUNOL RES, V14, P34, DOI 10.1007/BF02918496; PARKER KC, 1992, J IMMUNOL, V149, P3580; PARKER KC, 1994, J IMMUNOL, V152, P163; PEDERSEN LO, 1995, EUR J IMMUNOL, V25, P1609, DOI 10.1002/eji.1830250621; RIBAUDO RK, 1992, J IMMUNOL, V149, P2935; RIBAUDO RK, 1995, J IMMUNOL, V155, P3481; ROCK KL, 1990, P NATL ACAD SCI USA, V87, P7517, DOI 10.1073/pnas.87.19.7517; ROCK KL, 1991, P NATL ACAD SCI USA, V88, P301, DOI 10.1073/pnas.88.1.301; ROCK KL, 1993, J IMMUNOL, V150, P1244; Schipper RF, 1997, HUM IMMUNOL, V52, P54, DOI 10.1016/S0198-8859(96)00257-1; Shields MJ, 1998, J IMMUNOL, V160, P2297; Shields MJ, 1998, TISSUE ANTIGENS, V51, P567, DOI 10.1111/j.1399-0039.1998.tb02994.x; Shiver JW, 1997, VACCINE, V15, P884, DOI 10.1016/S0264-410X(96)00251-4; Sidney J, 1996, HUM IMMUNOL, V45, P79, DOI 10.1016/0198-8859(95)00173-5; SIDNEY J, 1995, J IMMUNOL, V154, P247; Sidney J, 1996, J IMMUNOL, V157, P3480; SMITH JD, 1992, P NATL ACAD SCI USA, V89, P7767, DOI 10.1073/pnas.89.16.7767; SOUSA CRE, 1995, J EXP MED, V182, P841, DOI 10.1084/jem.182.3.841; STORKUS WJ, 1987, J IMMUNOL, V138, P1657; SUGAWARA S, 1987, J IMMUNOL METHODS, V100, P83; Suhrbier A, 1997, IMMUNOL CELL BIOL, V75, P402, DOI 10.1038/icb.1997.63; TATAKE RJ, 1993, IMMUNOGENETICS, V38, P318; TAUROG JD, 1993, J IMMUNOL, V150, P4168; Trymbulak WP, 1997, IMMUNOGENETICS, V46, P418, DOI 10.1007/s002510050296; Trymbulak WP, 1997, TRANSPLANTATION, V64, P640, DOI 10.1097/00007890-199708270-00016; vanderBurg SH, 1995, HUM IMMUNOL, V44, P189, DOI 10.1016/0198-8859(95)00105-0; VITIELLO A, 1991, J EXP MED, V173, P1007, DOI 10.1084/jem.173.4.1007; VITIELLO A, 1990, SCIENCE, V250, P1423, DOI 10.1126/science.2124002; Waldburger CD, 1996, P NATL ACAD SCI USA, V93, P2629, DOI 10.1073/pnas.93.7.2629; Weiskirch LM, 1997, IMMUNOL REV, V158, P159, DOI 10.1111/j.1600-065X.1997.tb01002.x; WINTER CC, 1991, J IMMUNOL, V146, P3508; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5; Zhang C, 1997, VACCINE, V15, P1291, DOI 10.1016/S0264-410X(97)00040-6; ZHU X, 1995, SCAND J IMMUNOL, V42, P557, DOI 10.1111/j.1365-3083.1995.tb03696.x	74	24	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28010	28018		10.1074/jbc.273.43.28010	http://dx.doi.org/10.1074/jbc.273.43.28010			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774416	hybrid			2022-12-27	WOS:000076549800036
J	Guan, LS; Rauchman, M; Wang, ZY				Guan, LS; Rauchman, M; Wang, ZY			Induction of Rb-associated protein (RbAp46) by Wilms' tumor suppressor WT1 mediates growth inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-PRODUCT; NEGATIVE REGULATOR; EXPRESSION; HYBRIDIZATION; TRANSCRIPTION; POLYPEPTIDE; RECEPTOR; LOCUS; YEAST; RAS	The Wilms' tumor suppressor gene, wt1, encodes a zinc-finger transcription factor, WT1, that plays an important role in controlling urogenital development. Previously, WT1 has been shown to inhibit cell growth and to repress transcription initiated from the promoters of a number of growth-promoting genes. However, few physiological target genes that are transcriptionally activated by WT1 have been established. Using suppression subtractive hybridization polymerase chain reaction, we isolated a WT1 target gene that is up-regulated about 15-fold in cells expressing WT1. The gene was identified as retinoblastoma suppressor (Rb)-associated protein 46 (RbAp46), a nuclear protein that interacts physically with Rb and is a component of the human mSin3 co-repressor complex. Cells transfected with RbAp46 cDNA formed fewer colonies than the control cells, and RbAp46 suppressed the growth rate (by about a-fold) of transfected cells. In the developing kidney and gonad, RbAp46 exhibits an expression pattern similar to that of WT1. We conclude that RbAp46 has strong growth inhibition activity and may function as an important mediator of WT1's function.	Beth Israel Deaconess Med Ctr, Dept Med, Div Growth Regulat, Boston, MA 02215 USA; Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital	Wang, ZY (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Growth Regulat, Boston, MA 02215 USA.				NATIONAL CANCER INSTITUTE [R29CA076632] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA76632] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ach RA, 1997, PLANT CELL, V9, P1595, DOI 10.1105/tpc.9.9.1595; AUSUBEL FM, 1996, CURRENT PROTOCOLS S, V36; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Englert C, 1997, CANCER RES, V57, P1429; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; KINANE TB, 1996, J BIOL CHEM, V271, P30760; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; KUDOH T, 1995, P NATL ACAD SCI USA, V92, P4517, DOI 10.1073/pnas.92.10.4517; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; NICHOLS KE, 1995, CANCER RES, V55, P4540; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; QIAN YW, 1995, J BIOL CHEM, V270, P25507, DOI 10.1074/jbc.270.43.25507; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; ROSEN B, 1993, TRENDS GENET, V9, P162, DOI 10.1016/0168-9525(93)90162-B; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WERNER H, 1995, MOL CELL BIOL, V15, P3516; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	24	55	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27047	27050		10.1074/jbc.273.42.27047	http://dx.doi.org/10.1074/jbc.273.42.27047			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765217	hybrid			2022-12-27	WOS:000076448000004
J	Gunasinghe, SK; Hubbs, AE; Wright, CF				Gunasinghe, SK; Hubbs, AE; Wright, CF			A vaccinia virus late transcription factor with biochemical and molecular identity to a human cellular protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE; LATE GENE; LATE PROMOTER; PURIFICATION; OVEREXPRESSION; IDENTIFICATION; SEQUENCE; MUTANTS; COMPLEX; PRODUCT	A factor designated VLTF-X is required to support vaccinia virus late transcription in vitro. It has been found that a late promoter DNA binding activity cochromatographs and cosediments with VLTF-X activity. Current experiments show that VLTF-X activity is present in a variety of uninfected mammalian cell types and is indistinguishable from that recovered from infected cells based upon several criteria. VLTF-X activity from both sources displays the same purification profile over phosphocellulose and DNA affinity resins and has the same sedimentation coefficient, In addition, the factors purified from both infected and uninfected cells form protein-DNA complexes of identical electrophoretic mobility in the presence of vaccinia virus late promoter-containing DNA The affinity of these factors for the late promoter probes is identical and late promoter-specific based on competition experiments. Moreover, VLTF-X purified from both sources bound to late promoter containing DNA in the presence or absence of MgCl2 and ATP and formed complexes resistant to heat inactivation. These experiments offer proof that vaccinia virus factor VLTF-X is a host cell protein that supports transcription of the viral late genes.	Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; Armed Forces Inst Pathol, Dept Cellular Pathol, Washington, DC 20306 USA	Medical University of South Carolina; United States Department of Defense	Wright, CF (corresponding author), Med Univ S Carolina, Dept Pathol & Lab Med, 171 Ashley Ave, Charleston, SC 29425 USA.			Wright, Cynthia/0000-0003-0442-1665				ABMAYR SM, 1996, CURRENT PROTOCOLS MO; BERTHOLET C, 1986, EMBO J, V5, P1951, DOI 10.1002/j.1460-2075.1986.tb04449.x; Black EP, 1996, J VIROL, V70, P47, DOI 10.1128/JVI.70.1.47-54.1996; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROYLES SS, 1988, J BIOL CHEM, V263, P10754; BROYLES SS, 1991, J BIOL CHEM, V266, P15545; CHODOSH LA, 1996, CURRENT PROTOCOLS MO; Condit RC, 1996, VIROLOGY, V220, P10, DOI 10.1006/viro.1996.0280; DAVISON AJ, 1989, J MOL BIOL, V210, P749, DOI 10.1016/0022-2836(89)90107-1; HAGLER J, 1992, J VIROL, V66, P2982, DOI 10.1128/JVI.66.5.2982-2989.1992; Hubbs AE, 1996, J VIROL, V70, P327, DOI 10.1128/JVI.70.1.327-331.1996; KECK JG, 1993, J VIROL, V67, P5740, DOI 10.1128/JVI.67.10.5740-5748.1993; KERRIGAN LA, 1996, CURRENT PROTOCOLS MO; Kovacs GR, 1996, J VIROL, V70, P6796, DOI 10.1128/JVI.70.10.6796-6802.1996; KOVACS GR, 1994, J VIROL, V68, P3443, DOI 10.1128/JVI.68.5.3443-3447.1994; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MOSS B, 1991, J BIOL CHEM, V266, P1355; Passarelli AL, 1996, J VIROL, V70, P4444, DOI 10.1128/JVI.70.7.4444-4450.1996; ROSALES R, 1994, P NATL ACAD SCI USA, V91, P3794, DOI 10.1073/pnas.91.9.3794; ROSALES R, 1994, J BIOL CHEM, V269, P14260; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; VOS JC, 1991, EMBO J, V10, P2552; WEIR JP, 1987, J VIROL, V61, P75, DOI 10.1128/JVI.61.1.75-80.1987; WRIGHT CF, 1987, P NATL ACAD SCI USA, V84, P8883, DOI 10.1073/pnas.84.24.8883; Wright CF, 1998, J VIROL, V72, P1446, DOI 10.1128/JVI.72.2.1446-1451.1998; WRIGHT CF, 1993, J VIROL, V67, P7264, DOI 10.1128/JVI.67.12.7264-7270.1993; Zhu M, 1998, J VIROL, V72, P3893, DOI 10.1128/JVI.72.5.3893-3899.1998	27	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27524	27530		10.1074/jbc.273.42.27524	http://dx.doi.org/10.1074/jbc.273.42.27524			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765284	hybrid			2022-12-27	WOS:000076448000071
J	Liao, JF; Barthel, A; Nakatani, K; Roth, RA				Liao, JF; Barthel, A; Nakatani, K; Roth, RA			Activation of protein kinase B/Akt is sufficient to repress the glucocorticoid and cAMP induction of phosphoenolpyruvate carboxykinase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; S6 KINASE; INSULIN; EXPRESSION; AKT; TRANSLOCATION; INHIBITION; SEQUENCE; GTP	A rat hepatoma cell line, H4IIE, was stably transfected with a tamoxifen regulatable Akt-1 construct. Treatment of these cells with tamoxifen caused a rapid stimulation of Akt enzymatic activity that was comparable with the activity observed with the endogenous Akt after insulin stimulation. Prior studies have extensively documented that insulin can repress the glucocorticoid and cAMP-stimulated increase in phosphoenolpyruvate carboxykinase (PEPCK) gene transcription. Activation of this regulatable Akt with tamoxifen was found to mimic the dominant inhibitory effect of insulin on PEPCK gene transcription. Dose response curves to insulin and tamoxifen demonstrated that this response was very sensitive to Akt activation although the maximal response observed with tamoxifen activation was slightly less than that observed with insulin, indicating that the response to insulin mag also involve other sig naling cascades. The regulation of PEPCK transcription via Akt was, like that previously described for insulin, not dependent upon 70 kDa S6 kinase activity in that it was not inhibited by rapamycin, Finally, the expression of a kinase dead Akt was able to partially inhibit the ability of insulin to stimulate this response. in summary, the present results indicate that activation of Akt alone is sufficient to repress the glucocorticoid and cAMP-stimulated increase in PEPCK gene transcription.	Stanford Univ, Med Ctr, Dept Mol Pharmacol, Sch Med, Stanford, CA 94305 USA	Stanford University	Roth, RA (corresponding author), Stanford Univ, Med Ctr, Dept Mol Pharmacol, Sch Med, Stanford, CA 94305 USA.	roth@cmgm.stanford.edu		Nakatani, Kaname/0000-0001-6709-541X	NIDDK NIH HHS [DK34926, DK09293] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009293, R37DK034926, R01DK034926] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agati JM, 1998, J BIOL CHEM, V273, P18751, DOI 10.1074/jbc.273.30.18751; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BEALE EG, 1985, J BIOL CHEM, V260, P748; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Krook A, 1997, DIABETES, V46, P2110, DOI 10.2337/diabetes.46.12.2110; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Saltiel AR, 1996, AM J PHYSIOL-ENDOC M, V270, pE375, DOI 10.1152/ajpendo.1996.270.3.E375; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; Sutherland C, 1998, J BIOL CHEM, V273, P3198, DOI 10.1074/jbc.273.6.3198; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	32	113	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27320	27324		10.1074/jbc.273.42.27320	http://dx.doi.org/10.1074/jbc.273.42.27320			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765258	hybrid			2022-12-27	WOS:000076448000045
J	Mattila, P; Salminen, H; Hirvas, L; Niittymaki, J; Salo, H; Niemela, R; Fukuda, M; Renkonen, O; Renkonen, R				Mattila, P; Salminen, H; Hirvas, L; Niittymaki, J; Salo, H; Niemela, R; Fukuda, M; Renkonen, O; Renkonen, R			The centrally acting beta 1,6N-acetylglucosaminyltransferase (GlcNAc to Gal) - Functional expression, purification, and acceptor specificity of a human enzyme involved in midchain branching of linear poly-N-acetyllactosamines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; BLOOD-GROUP-I; ENDO-BETA-GALACTOSIDASE; L-SELECTIN; LYMPHOCYTE ADHESION; POLYLACTOSAMINE BACKBONES; CARBOHYDRATE STRUCTURE; GASTRIC-MUCOSA; HUMAN-SERUM; BIOSYNTHESIS	In the present experiments the cDNA coding for a truncated form of the beta 1,6N-acetylglucosaminyltransferase responsible for the conversion of linear to branched polylactosamines in human PA1 cells was expressed in Sf9 insect cells. The catalytic ectodomain of the enzyme was fused to glutathione S-transferase, allowing effective one-step purification of the glycosylated 67-74-kDa fusion protein. Typically a yield of 750 mu g of the purified protein/liter of suspension culture was obtained. The purified recombinant protein catalyzed the transfer of GlcNAc from UDP-GlcNAc to the linear tetrasaccharide Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4-GlcNAc, converting the acceptor to the branched pentasaccharide Gal beta 1-4GlcNAc beta 1-3(GlcNAc beta 1-6)Gal beta 1-4-GlcNAc as shown by matrix-assisted laser desorption/ionization time of-flight mass spectrometry, degradative experiments, and H-1 NMR spectroscopy of the product. By contrast, the recombinant enzyme did not catalyze any reaction when incubated with UDP-GlcNAc and the trisaccharide GlcNAc beta 1-3Gal beta 1-4GlcNAc. Accordingly, we call the recombinant beta 1,6-GlcNAc transferase cIGnT6 to emphasize its action at central rather than peridistal galactose residues of linear polylactosamines in the biosynthesis of blood group I antigens, Taken together this in vitro expression of I-branching enzyme, in combination with the previously cloned enzymes, beta 1,4galactosyltransferase and beta 1,3N-acetylglucosaminyltransferase, should allow the general synthesis of polylactosamines based totally on the use of recombinant enzymes.	Univ Helsinki, Dept Bacteriol & Immunol, Haartman Inst, SF-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, SF-00014 Helsinki, Finland; Burnham Inst, La Jolla, CA 92037 USA	University of Helsinki; University of Helsinki; Sanford Burnham Prebys Medical Discovery Institute	Mattila, P (corresponding author), Univ Helsinki, Dept Bacteriol & Immunol, Haartman Inst, POB 21,Haartmaninkatu 3, SF-00014 Helsinki, Finland.	pirkko.mattila@helsinki.fi						BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; BROCKHAUSEN I, 1986, EUR J BIOCHEM, V157, P463, DOI 10.1111/j.1432-1033.1986.tb09690.x; DABROWSKI U, 1984, J BIOL CHEM, V259, P7648; FEIZI T, 1979, J EXP MED, V149, P975, DOI 10.1084/jem.149.4.975; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; FUKUDA M, 1979, J BIOL CHEM, V254, P3700; FUKUDA MN, 1985, J BIOL CHEM, V260, P6623; FUKUDA MN, 1981, J BIOL CHEM, V256, P3900; GU J, 1992, J BIOL CHEM, V267, P2994; Helin J, 1997, FEBS LETT, V412, P637, DOI 10.1016/S0014-5793(97)00818-1; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; KOENDERMAN AHL, 1987, EUR J BIOCHEM, V166, P199, DOI 10.1111/j.1432-1033.1987.tb13502.x; Leppanen A, 1997, BIOCHEMISTRY-US, V36, P7026, DOI 10.1021/bi9627673; Leppanen A, 1998, J BIOL CHEM, V273, P17399, DOI 10.1074/jbc.273.28.17399; LEPPANEN A, 1991, BIOCHEMISTRY-US, V30, P9287, DOI 10.1021/bi00102a022; Leppanen A, 1997, BIOCHEMISTRY-US, V36, P13729, DOI 10.1021/bi9712807; Maaheimo H, 1997, CARBOHYD RES, V297, P145, DOI 10.1016/S0008-6215(96)00259-5; MAAHEIMO H, 1995, EUR J BIOCHEM, V234, P616, DOI 10.1111/j.1432-1033.1995.616_b.x; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; MIZOGUCHI A, 1984, J BIOL CHEM, V259, P1949; MURAMATSU T, 1978, P NATL ACAD SCI USA, V75, P2315, DOI 10.1073/pnas.75.5.2315; MURAMATSU T, 1979, SOMAT CELL GENET, V5, P753, DOI 10.1007/BF01542639; Niemela R, 1995, CARBOHYD RES, V279, P331, DOI 10.1016/0008-6215(95)00299-5; PILLER F, 1984, J BIOL CHEM, V259, P3385; Rabina J, 1997, CARBOHYD RES, V305, P491, DOI 10.1016/S0008-6215(97)00260-7; RASILO ML, 1982, EUR J BIOCHEM, V123, P397, DOI 10.1111/j.1432-1033.1982.tb19782.x; RASILO ML, 1980, PURE APPL CHEM, V52, P55, DOI 10.1351/pac198052010055; RASILO ML, 1980, CAN J BIOCHEM CELL B, V58, P384, DOI 10.1139/o80-050; RENKONEN O, 1983, BIOCHEM SOC T, V11, P265, DOI 10.1042/bst0110265; Renkonen O, 1997, GLYCOBIOLOGY, V7, P453, DOI 10.1093/glycob/7.4.453-c; RENKONEN O, 1988, BIOCHEM CELL BIOL, V66, P449, DOI 10.1139/o88-054; RENKONEN O, 1991, GLYCOCONJUGATE J, V8, P376, DOI 10.1007/BF00731351; ROMANS DG, 1980, J IMMUNOL, V124, P2807; ROPP PA, 1991, J BIOL CHEM, V266, P23863; Sakamoto Y, 1998, J BIOL CHEM, V273, P27625, DOI 10.1074/jbc.273.42.27625; Salminen H, 1997, FEBS LETT, V419, P220, DOI 10.1016/S0014-5793(97)01462-2; Sasaki K, 1997, P NATL ACAD SCI USA, V94, P14294, DOI 10.1073/pnas.94.26.14294; Seppo A, 1996, GLYCOBIOLOGY, V6, P65, DOI 10.1093/glycob/6.1.65; SEPPO A, 1990, BIOCHEM CELL BIOL, V68, P44, DOI 10.1139/o90-006; SPOONCER E, 1984, J BIOL CHEM, V259, P4792; Toppila S, 1997, EUR J IMMUNOL, V27, P1360, DOI 10.1002/eji.1830270610; TURUNEN JP, 1995, J EXP MED, V182, P1133, DOI 10.1084/jem.182.4.1133; VANDENEIJNDEN DH, 1983, J BIOL CHEM, V258, P3435; ZDEBSKA E, 1983, CARBOHYD RES, V120, P113, DOI 10.1016/0008-6215(83)88011-2; ZIELENSKI J, 1983, FEBS LETT, V158, P164, DOI 10.1016/0014-5793(83)80700-5; ZIELENSKI J, 1983, FEBS LETT, V163, P114, DOI 10.1016/0014-5793(83)81175-2	46	20	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27633	27639		10.1074/jbc.273.42.27633	http://dx.doi.org/10.1074/jbc.273.42.27633			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765298	hybrid			2022-12-27	WOS:000076448000085
J	Bae, SH; Choi, E; Lee, KH; Park, JS; Lee, SH; Seo, YS				Bae, SH; Choi, E; Lee, KH; Park, JS; Lee, SH; Seo, YS			Dna2 of Saccharomyces cerevisiae possesses a single-stranded DNA-specific endonuclease activity that is able to act on double-stranded DNA in the presence of ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CHECKPOINTS; RECBCD ENZYME; HELICASE; REPLICATION; REPAIR; RECOMBINATION; NUCLEASE; PROTEIN; BINDING; DAMAGE	To gain further insights into the biological functions of Dnaa, previously known as a cellular replicative helicase in Saccharomyces cerevisiae, we examined biochemical properties of the recombinant Dnaa protein purified to homogeneity, Besides the single-stranded (Ss) DNA-dependent ATPase activity as reported previously, we were able to demonstrate that ssDNA-specific endonuclease activity is intrinsically associated with Dna2, Moreover, Dnaa was capable of degrading duplex DNA in an ATP-dependent fashion. ATP and dATP, the only nucleotides hydrolyzed by Dnaa, served to stimulate Dnaa to utilize duplex DNA, indicating their hydrolysis is required. Dna2 was able to unwind short duplex only under the condition where the endonuclease activity was minimized. This finding implies that Dna2 unwinds only partially the 3'-end of duplex DNA and generates a stretch of ssDNA of limited length, which is subsequently cleaved by the ssDNA-specific endonuclease activity, A point mutation at the conserved ATP-binding site of Dna2 inactivated concurrently ssDNA-dependent ATPase, ATP-dependent nuclease, and helicase activities, indicating that they all reside in Dna2 itself, By virtue of its nucleolytic activities, the Dnaa protein may function in the maintenance of chromosomal integrity, such as repair or other related process, Father than in propagation of cellular replication forks.	Samsung Biomed Res Inst, Basic Res Ctr, Nucleic Acid Biochem Lab, Seoul 135230, South Korea	Sungkyunkwan University (SKKU); Samsung Medical Center	Seo, YS (corresponding author), Samsung Biomed Res Inst, Basic Res Ctr, Nucleic Acid Biochem Lab, 50 Ilwon-Dong,Kangnam-Ku, Seoul 135230, South Korea.		Seo, Yeonsoo/C-1605-2011					Anderson DG, 1997, CELL, V90, P77, DOI 10.1016/S0092-8674(00)80315-3; BUDD ME, 1995, P NATL ACAD SCI USA, V92, P7642, DOI 10.1073/pnas.92.17.7642; BUDD ME, 1995, J BIOL CHEM, V270, P26766, DOI 10.1074/jbc.270.45.26766; Budd ME, 1997, MOL CELL BIOL, V17, P2136, DOI 10.1128/MCB.17.4.2136; EGGLESTON AK, 1993, J MOL BIOL, V231, P605, DOI 10.1006/jmbi.1993.1313; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Fiorentino DF, 1997, MOL BIOL CELL, V8, P2519, DOI 10.1091/mbc.8.12.2519; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Haijema BJ, 1996, J BACTERIOL, V178, P5130, DOI 10.1128/jb.178.17.5130-5137.1996; HARLOW E, 1988, ANTIBODIES LABORATOR, P309; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hunt T, 1993, CELL CYCLE, P135; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KAROUI ME, 1998, P NATL ACAD SCI USA, V95, P626; Kaufmann WK, 1996, FASEB J, V10, P238, DOI 10.1096/fasebj.10.2.8641557; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kooistra J, 1997, MOL MICROBIOL, V23, P137, DOI 10.1046/j.1365-2958.1997.1991570.x; Kornberg A., 1992, DNA REPLICATION; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; Lydall D, 1996, CURR OPIN GENET DEV, V6, P4, DOI 10.1016/S0959-437X(96)90003-9; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MONIKA L, 1993, J BIOL CHEM, V268, P15795; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; Murray JM, 1997, MOL CELL BIOL, V17, P6868, DOI 10.1128/MCB.17.12.6868; Park JS, 1997, J BIOL CHEM, V272, P18910, DOI 10.1074/jbc.272.30.18910; Rumbaugh JA, 1997, J BIOL CHEM, V272, P22591, DOI 10.1074/jbc.272.36.22591; SANGER F, 1978, J MOL BIOL, V125, P225, DOI 10.1016/0022-2836(78)90346-7; SIKORSKI RS, 1989, GENETICS, V122, P19; THOMMES P, 1992, CHROMOSOMA, V101, P467, DOI 10.1007/BF00352468; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; Tuteja N, 1996, NAT GENET, V13, P11, DOI 10.1038/ng0596-11; WAGA S, 1994, J BIOL CHEM, V269, P10923; Weinert T, 1997, CANCER SURV, V29, P109; West SC, 1996, CELL, V86, P177, DOI 10.1016/S0092-8674(00)80088-4	38	111	112	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26880	26890		10.1074/jbc.273.41.26880	http://dx.doi.org/10.1074/jbc.273.41.26880			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756935	hybrid			2022-12-27	WOS:000076373300089
J	Gerken, TA; Owens, CL; Pasumarthy, M				Gerken, TA; Owens, CL; Pasumarthy, M			Site-specific core 1 O-glycosylation pattern of the porcine submaxillary gland mucin tandem repeat - Evidence for the modulation of glycan length by peptide sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE; AMINO-ACID-SEQUENCE; LINKED GLYCOSYLATION; MASS-SPECTROMETRY; CELL-ADHESION; UDP-GALNAC; GLYCOPROTEINS; GLYCOPEPTIDE; OLIGOSACCHARIDES; CONFORMATION	The sequence-specific O-linked core 1 ([R-1, R-2]-beta-Gal(1-3)-alpha-GalNAc-O-Ser/Thr) glycosylation pattern has been quantitatively determined for 30 of the 31 Ser/Thr residues in the 81-residue porcine submaxillary gland mucin tandem repeat. This was achieved by Edman amino acid sequencing of the isolated tandem repeat after selective removal of non-C3-substituted, peptide-linked GalNAc residues by periodate oxidation and subsequent trimming of the remaining oligosaccharides to peptide-linked GalNAc residues by mild trifluoromethanesulfonic acid/anisole treatment. The sequencing reveals 61% (range, 12-95%) of the peptide alpha-N-acetylgalactosamine (GalNAc) residues to be substituted by core 1 chains, a value in agreement with the carbon-13 NMR analysis of the native mucin, Residues with the lowest C3 substitution were typically clustered in regions of sequence with the highest densities of (glycosylated) serine or threonine. This suggests that the porcine beta 3-Gal, core 1, transferase is sensitive to peptide sequence and/or neighboring core GalNAc glycosylation in vivo, in keeping with earlier in vitro enzymatic glycosylation studios (Granovsky, M., Blielfeldt, T., Peters, S,, Paulsen, II., Meldal, M., Brockhausen, J,, and Brockhausen, I, (1994) fur. J, Biochem. 221, 1039-1046), These results demonstrate that the O-glycan structures in mucin domains are not necessarily uniformly distributed along the polypeptide core and that their lengths can be modulated by peptide sequence. The data further suggest that hydroxyamino acid spacing may contribute to the regulation of glycan length, thereby, providing a mechanism for maintaining an optimally expanded, protease resistant, mucin conformation.	Case Western Reserve Univ, Dept Pediat, WA Bernbaum Ctr Cyst Fibrosis Res, Sch Med BRB, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Mol & Microbiol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Gerken, TA (corresponding author), Case Western Reserve Univ, Dept Pediat, WA Bernbaum Ctr Cyst Fibrosis Res, Sch Med BRB, Cleveland, OH 44106 USA.	tag@glycocon.cwru.edu			NCI NIH HHS [P30-CA43703, R01 CA078834] Funding Source: Medline; NIDDK NIH HHS [R01-DK-39918, P30-DK-27651] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA043703, R01CA078834] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK027651, R01DK039918] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APOSTOLOPOULOS V, 1994, CRIT REV IMMUNOL, V14, P293, DOI 10.1615/CritRevImmunol.v14.i3-4.40; BAENZIGER JU, 1994, FASEB J, V8, P1019, DOI 10.1096/fasebj.8.13.7926366; BERMAN E, 1980, J BIOL CHEM, V255, P4407; BROCKHAUSEN I, 1990, BIOCHEMISTRY-US, V29, P10206, DOI 10.1021/bi00496a008; Bruneau N, 1997, J BIOL CHEM, V272, P27353, DOI 10.1074/jbc.272.43.27353; Burdick MD, 1997, J BIOL CHEM, V272, P24198, DOI 10.1074/jbc.272.39.24198; CARLSON DM, 1968, J BIOL CHEM, V243, P616; Clausen H, 1996, GLYCOBIOLOGY, V6, P635, DOI 10.1093/glycob/6.6.635; DEVRIES AL, 1970, J BIOL CHEM, V245, P2901; DO KY, 1994, J BIOL CHEM, V269, P23456; Eckhardt AE, 1997, J BIOL CHEM, V272, P33204, DOI 10.1074/jbc.272.52.33204; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; GERKEN TA, 1992, BIOCHEMISTRY-US, V31, P639, DOI 10.1021/bi00118a002; GERKEN TA, 1989, BIOCHEMISTRY-US, V28, P5536, DOI 10.1021/bi00439a030; GERKEN TA, 1987, BIOCHEMISTRY-US, V26, P4689, DOI 10.1021/bi00389a015; Gerken TA, 1997, J BIOL CHEM, V272, P9709; GERKEN TA, 1997, TECHNIQUES GLYCOBIOL, P247; Goletz S, 1997, RAPID COMMUN MASS SP, V11, P1387; Goletz S, 1997, GLYCOBIOLOGY, V7, P881, DOI 10.1093/glycob/7.7.881; Gooley AA, 1997, NATURE, V385, P557, DOI 10.1038/385557a0; GRANOVSKY M, 1994, EUR J BIOCHEM, V221, P1039, DOI 10.1111/j.1432-1033.1994.tb18822.x; GUPTA R, 1989, BIOCHEMISTRY-US, V28, P6114, DOI 10.1021/bi00440a058; HILKENS J, 1988, Cancer Reviews, V11-12, P25; Iwase H, 1996, J BIOCHEM-TOKYO, V120, P393; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; Kim YS, 1996, GLYCOCONJUGATE J, V13, P693, DOI 10.1007/BF00702333; KUWANO M, 1991, J CELL SCI, V98, P131; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; Manzella SM, 1996, J BIOL CHEM, V271, P12117, DOI 10.1074/jbc.271.21.12117; Muller S, 1997, J BIOL CHEM, V272, P24780, DOI 10.1074/jbc.272.40.24780; NELSON RW, 1995, J BIOL CHEM, V270, P17171, DOI 10.1074/jbc.270.29.17171; PISANO A, 1997, TECHNIQUES GLYCOBIOL, P299; PLANTNER JJ, 1975, ANAL BIOCHEM, V65, P153, DOI 10.1016/0003-2697(75)90501-1; REDDY P, 1989, J BIOL CHEM, V264, P17329; REMALEY AT, 1993, J BIOL CHEM, V268, P6785; RHJU TS, 1994, MOL BIOL INT, V34, P943; SHIMIZU Y, 1993, NATURE, V366, P630, DOI 10.1038/366630a0; SHOGREN R, 1989, BIOCHEMISTRY-US, V28, P5525, DOI 10.1021/bi00439a029; SHOGREN RL, 1987, CARBOHYD RES, V160, P317; SHOGREN RL, 1986, BIOPOLYMERS, V25, P1505, DOI 10.1002/bip.360250809; Skrincosky D, 1997, J BIOL CHEM, V272, P22695, DOI 10.1074/jbc.272.36.22695; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; TAKAYASU T, 1982, BIOCHEM BIOPH RES CO, V105, P1066, DOI 10.1016/0006-291X(82)91078-6; TIMPTE CS, 1988, J BIOL CHEM, V263, P1081; VANKLINKEN BJW, 1995, AM J PHYSIOL-GASTR L, V269, pG613, DOI 10.1152/ajpgi.1995.269.5.G613; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; Wandall HH, 1997, J BIOL CHEM, V272, P23503, DOI 10.1074/jbc.272.38.23503; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; WILLIAMSON G, 1992, EUR J BIOCHEM, V207, P661, DOI 10.1111/j.1432-1033.1992.tb17093.x; WILLIAMSON G, 1992, BIOCHEM J, V282, P423, DOI 10.1042/bj2820423; Yeh JC, 1997, GLYCOBIOLOGY, V7, P241, DOI 10.1093/glycob/7.2.241; Yoshida A, 1997, J BIOL CHEM, V272, P16884, DOI 10.1074/jbc.272.27.16884; ZHANG W, 1994, IMMUNOLOGY, V81, P137	54	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26580	26588		10.1074/jbc.273.41.26580	http://dx.doi.org/10.1074/jbc.273.41.26580			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756896	hybrid			2022-12-27	WOS:000076373300050
J	Max, M; Surya, A; Takahashi, JS; Margolskee, RF; Knox, BE				Max, M; Surya, A; Takahashi, JS; Margolskee, RF; Knox, BE			Light-dependent activation of rod transducin by pineal opsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLTRANSFERASE MESSENGER-RNA; BOVINE PHOTORECEPTOR-MEMBRANES; AVIAN MELATONIN SYNTHESIS; CHICK PINEAL; VISUAL PIGMENTS; PHOTOENDOCRINE TRANSDUCTION; RHODOPSIN GENE; CIRCADIAN OSCILLATOR; MOLECULAR-PROPERTIES; BINDING PROTEIN	The pinneal gland expresses a unique member of the opsin family (P-opsin; Max, M., McKinnon, P, J., Seidenman, K. J, Barrett, R. K., Applebury, M. L., Takahaslai, J. S., and Margolskee, R. F. (1995) Science 267, 1502-1506) that may play a role in circadian entrainment and photo-regulation of melatonin synthesis. To study the function of this protein, are epitope-tagged P-opsin was stably expressed in anembryonic chicken pineal cell line. When incubated with 11-cis-retinal, a light-sensitive pigment was formed with a lambda(max) at 462 +/- 2 nm, P-opsin bleached slowly in the dark (t(1/2) = 2 h) in the presence of 50 mM hydroxylamine. Purified P-opsin in dodecyl maltoside activated rod transducin in a light-dependent manner, catalyzing the exchange of more than 300 mol of GTP gamma S (guanosine 5'-O-(3-thiotriphosphate))/mol of P-opsin. The initial rate for activation (75 mol of GTP gamma S bound/mol of P-opsin/min at 7 mu M) increased with increasing concentrations of transducin. The addition of egg phosphatidylcholine to P-opsin had little effect on the activation kinetics; however, the intrinsic rate of decay in the absence of transducin was accelerated. These results demonstrate that P-opsin is ale efficient catalyst for activation of rod transducin and suggest that the pineal gland may contain a rodlike phototransduction cascade.	CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA; SUNY Hlth Sci Ctr, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA; Northwestern Univ, Howard Hughes Med Inst, Evanston, IL 60208 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Howard Hughes Medical Institute; Northwestern University	Max, M (corresponding author), CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, Box 1677,1425 Madison Ave, New York, NY 10029 USA.	max@msvax.mssm.edu	Takahashi, Joseph S/E-8482-2012; Takahashi, Joseph S./Y-2781-2019	Takahashi, Joseph S/0000-0003-0384-8878; Takahashi, Joseph S./0000-0003-0384-8878; Margolskee, Robert/0000-0002-9572-2887	NATIONAL EYE INSTITUTE [R01EY008467, R01EY009409, R55EY009409, R01EY011256] Funding Source: NIH RePORTER; NEI NIH HHS [EY09409, EY11256, EY08467] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AXELROD J, 1974, SCIENCE, V184, P1341, DOI 10.1126/science.184.4144.1341; Batni S, 1996, J BIOL CHEM, V271, P3179, DOI 10.1074/jbc.271.6.3179; Bernard M, 1997, J NEUROCHEM, V68, P213; Bernard M, 1997, P NATL ACAD SCI USA, V94, P304, DOI 10.1073/pnas.94.1.304; BINKLEY S, 1973, SCIENCE, V181, P273, DOI 10.1126/science.181.4096.273-a; Blackshaw S, 1997, J NEUROSCI, V17, P8083; BORNANCIN F, 1989, EUR J BIOCHEM, V184, P687, DOI 10.1111/j.1432-1033.1989.tb15068.x; BROWN MF, 1994, CHEM PHYS LIPIDS, V73, P159, DOI 10.1016/0009-3084(94)90180-5; BUBIS J, 1990, J BIOL CHEM, V265, P12995; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; DEGUCHI T, 1981, NATURE, V290, P706, DOI 10.1038/290706a0; DEGUCHI T, 1979, SCIENCE, V203, P1245, DOI 10.1126/science.424750; DEGUCHI T, 1979, NATURE, V282, P94, DOI 10.1038/282094a0; EBREY TG, 1977, VISION RES, V17, P147, DOI 10.1016/0042-6989(77)90213-9; EMEIS D, 1982, FEBS LETT, V143, P29, DOI 10.1016/0014-5793(82)80266-4; FOSTER RG, 1987, CELL TISSUE RES, V248, P161, DOI 10.1007/BF01239977; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; Gastel JA, 1998, SCIENCE, V279, P1358, DOI 10.1126/science.279.5355.1358; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hao WS, 1996, BIOCHEMISTRY-US, V35, P6251, DOI 10.1021/bi952420k; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; Hisatomi O, 1997, PHOTOCHEM PHOTOBIOL, V66, P792, DOI 10.1111/j.1751-1097.1997.tb03226.x; IMAI H, 1995, BIOCHEMISTRY-US, V34, P10525, DOI 10.1021/bi00033a026; Kawamura S, 1997, VISION RES, V37, P1867, DOI 10.1016/S0042-6989(96)00309-4; Kawamura S, 1996, GENE, V182, P213, DOI 10.1016/S0378-1119(96)00476-3; Kawamura S, 1998, VISION RES, V38, P37, DOI 10.1016/S0042-6989(97)00160-0; KHORANA HG, 1988, P NATL ACAD SCI USA, V85, P7917, DOI 10.1073/pnas.85.21.7917; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KITO Y, 1968, NATURE, V218, P955, DOI 10.1038/218955a0; KNOX BE, 1993, J PHYSIOL-LONDON, V466, P157; KUHN H, 1981, BIOCHEMISTRY-US, V20, P2410; LOLLEY RN, 1992, NEUROCHEM RES, V17, P81, DOI 10.1007/BF00966868; MACKENZIE D, 1984, BIOCHEMISTRY-US, V23, P6544, DOI 10.1021/bi00321a041; MASUDA H, 1994, TISSUE CELL, V26, P101, DOI 10.1016/0040-8166(94)90086-8; MAX M, 1995, SCIENCE, V267, P1502, DOI 10.1126/science.7878470; NATHANS J, 1992, ANNU REV GENET, V26, P403, DOI 10.1146/annurev.ge.26.120192.002155; NIKAIDO SS, 1989, NEURON, V3, P609, DOI 10.1016/0896-6273(89)90271-7; Okano T, 1997, J MOL EVOL, V44, pS91, DOI 10.1007/PL00000057; Okano T, 1997, MOL BRAIN RES, V50, P190, DOI 10.1016/S0169-328X(97)00184-8; OKANO T, 1989, BIOCHEMISTRY-US, V28, P8848, DOI 10.1021/bi00448a025; OKANO T, 1994, NATURE, V372, P94, DOI 10.1038/372094a0; OPRIAN DD, 1991, BIOCHEMISTRY-US, V30, P11367, DOI 10.1021/bi00112a002; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; PANDEY S, 1994, EXP EYE RES, V58, P605, DOI 10.1006/exer.1994.1055; Provencio I, 1998, P NATL ACAD SCI USA, V95, P340, DOI 10.1073/pnas.95.1.340; RIDGE KD, 1995, BIOCHEMISTRY-US, V34, P3261, DOI 10.1021/bi00010a016; ROBERTSON LM, 1988, J NEUROSCI, V8, P12; ROBERTSON LM, 1988, J NEUROSCI, V8, P22; ROBERTSON LM, 1990, THESIS NW U EVANSTON; SHAN D, 1994, BIOCHEMISTRY-US, V33, P13117; SHESHBERADARAN H, 1994, MOL CELL NEUROSCI, V5, P309, DOI 10.1006/mcne.1994.1037; SHICHIDA Y, 1994, BIOCHEMISTRY-US, V33, P9040, DOI 10.1021/bi00197a002; Soni BG, 1997, FEBS LETT, V406, P279, DOI 10.1016/S0014-5793(97)00287-1; Soni BG, 1998, NATURE, V394, P27, DOI 10.1038/27794; Starace DM, 1998, EXP EYE RES, V67, P209, DOI 10.1006/exer.1998.0507; Starace DM, 1997, J BIOL CHEM, V272, P1095, DOI 10.1074/jbc.272.2.1095; SUN JH, 1991, NEUROSCI LETT, V133, P97, DOI 10.1016/0304-3940(91)90066-3; SURYA A, 1995, J BIOL CHEM, V270, P5024, DOI 10.1074/jbc.270.10.5024; TAKAHASHI JS, 1989, RECENT PROG HORM RES, V45, P279; VANVEEN T, 1986, P NATL ACAD SCI USA, V83, P912; VANVEEN T, 1986, EXP BIOL, V45, P15; VIGH B, 1981, CELL TISSUE RES, V221, P451, DOI 10.1007/BF00216748; WANG SZ, 1992, BIOCHEMISTRY-US, V31, P3309, DOI 10.1021/bi00128a002; YOKOYAMA R, 1995, INVEST OPHTH VIS SCI, V36, P939; Yokoyama S, 1997, GENE, V202, P89, DOI 10.1016/S0378-1119(97)00458-7; Yoshikawa T, 1998, FEBS LETT, V424, P69, DOI 10.1016/S0014-5793(98)00139-2; YOSHIZAWA T, 1994, BIOPHYS CHEM, V50, P17, DOI 10.1016/0301-4622(94)85016-X; ZATZ M, 1988, BRAIN RES, V453, P63, DOI 10.1016/0006-8993(88)90143-6; ZATZ M, 1989, BRAIN RES, V477, P14, DOI 10.1016/0006-8993(89)91389-9; ZATZ M, 1988, BRAIN RES, V438, P199, DOI 10.1016/0006-8993(88)91339-X; ZATZ M, 1988, BRAIN RES, V453, P51, DOI 10.1016/0006-8993(88)90142-4	72	26	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26820	26826		10.1074/jbc.273.41.26820	http://dx.doi.org/10.1074/jbc.273.41.26820			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756926	hybrid			2022-12-27	WOS:000076373300080
J	Marie-Cardine, A; Hendricks-Taylor, LR; Boerth, NJ; Zhao, H; Schraven, B; Koretzky, GA				Marie-Cardine, A; Hendricks-Taylor, LR; Boerth, NJ; Zhao, H; Schraven, B; Koretzky, GA			Molecular interaction between the Fyn-associated protein SKAP55 and the SLP-78-associated phosphoprotein SLAP-130	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; TYROSINE KINASE-ACTIVITY; MICE LACKING; T-CELLS; INTERLEUKIN-2 PRODUCTION; CLONING; ACTIVATION; P59(FYN); P56(LCK); COMPLEX	It has previously been reported that in resting T-lymphocytes the protein tyrosine kinase p59(fyn) constitutively co-precipitates with four phosphoproteins of 43, 55, 85, and 120 kDa, respectively. We have recently cloned the 55-kDa protein that was termed Src kinase-associated phosphoprotein of 55 kDa (SKAP55), Here we demonstrate that the recently characterized SH2-domain-containing leukocyte protein 76-associated phosphoprotein of 130 kDa (SLAP-130) is one of the components of the Fyn complex and that it also co-precipitates with SKAP55 in human T-cells, We establish that SKAP55 and SLAP-130 associate with each other when both molecules are co expressed in COS cells. By cotransfection of truncated mutants of SKAP55 and SLAP130 as well as by using the two-hybrid selection system, we further demonstrate that the association between SLAP-130 and SKAP55 is direct and involves the Src homology 3 domain of SKAP55 and the proline-rich sequence of SLAP-130.	Heidelberg Univ, Inst Immunol, D-69120 Heidelberg, Germany; Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Interdisciplinary Grad Program Immunol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Interdisciplinary Grad Program Mol Biol, Iowa City, IA 52242 USA	Ruprecht Karls University Heidelberg; University of Iowa; University of Iowa; University of Iowa	Marie-Cardine, A (corresponding author), Heidelberg Univ, Inst Immunol, Neuenheimer Feld 305, D-69120 Heidelberg, Germany.	m71@popix.urz.uni-heidelberg.de	Koretzky, Gary/AAU-5381-2021		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007260] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053256] Funding Source: NIH RePORTER; NIAID NIH HHS [2T32 AI07260] Funding Source: Medline; NIGMS NIH HHS [R01 GM53256] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BURKHARDT AL, 1994, J BIOL CHEM, V269, P23642; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; DANIELIAN S, 1992, EUR J IMMUNOL, V22, P2915, DOI 10.1002/eji.1830221124; daSilva AJ, 1997, J IMMUNOL, V158, P2007; DASILVA AJ, 1992, MOL IMMUNOL, V29, P1417, DOI 10.1016/0161-5890(92)90215-J; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; Groves T, 1996, IMMUNITY, V5, P417, DOI 10.1016/S1074-7613(00)80498-7; LEE SK, 1994, INT IMMUNOL, V6, P1621, DOI 10.1093/intimm/6.10.1621; MarieCardine A, 1997, J BIOL CHEM, V272, P16077, DOI 10.1074/jbc.272.26.16077; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Musci MA, 1997, J IMMUNOL, V159, P1639; Musci MA, 1997, J BIOL CHEM, V272, P11674, DOI 10.1074/jbc.272.18.11674; RIGLEY K, 1995, J IMMUNOL, V154, P1136; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; Schraven B, 1997, IMMUNOL LETT, V57, P165, DOI 10.1016/S0165-2478(97)00053-9; SCHRAVEN B, 1997, KINASES PHOSPHATASES, P100; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; vanOers NSC, 1996, IMMUNITY, V5, P429, DOI 10.1016/S1074-7613(00)80499-9; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	26	81	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25789	25795		10.1074/jbc.273.40.25789	http://dx.doi.org/10.1074/jbc.273.40.25789			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748251	hybrid			2022-12-27	WOS:000076263100042
J	Mutoh, T; Tokuda, A; Inokuchi, J; Kuriyama, M				Mutoh, T; Tokuda, A; Inokuchi, J; Kuriyama, M			Glucosylceramide synthase inhibitor inhibits the action of nerve growth factor in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRK PROTOONCOGENE PRODUCT; TYROSINE KINASE-ACTIVITY; GANGLIOSIDE GM1; RETINOIC ACID; GLYCOSPHINGOLIPID SYNTHESIS; NEURITE OUTGROWTH; I RECEPTORS; PHOSPHORYLATION; PROTEIN; NEURONS	Previous studies have shown that the ceramide analogue, D-threo-1-phenyl-2-decanoylamin-3-morpholinopropanol (D-PDMP), inhibits glucosylceramide synthase and thus leads to extensive depletion of glycosphingolipids derived from glucosyl ceramide, Our previous studies have shown that cholera toxin B subunit, which specifically binds to the cell surface ganglioside GM1, and GM1 itself can enhance the action of nerve growth factor (NGF) in responsive cells by enhancing the NGF-induced autophosphorylation of the high affinity NGF receptor, Trk, Using D-PDMP, we examined the effects of the inhibition of the biosynthesis of glycosphingolipids on intracellular NGF signaling pathway. D-PDMP was found to inhibit NGF-induced neurite outgrowth of PC12 cells. Moreover, D-PDMP clearly inhibited NGF-induced autophosphorylation of Trk and prevented the activation of phosphatidylinositol 3-kinase and mitogen-activated protein kinase, downstream targets of Trk-initiated intracellular protein kinase cascades. These effects of D-PDMP were abolished by the addition of GM1 but not by the addition of other ganglioside subspecies to the culture medium. Furthermore, the effect of D-PDMP seemed to be specific for the Trk receptor, because intracellular signaling pathway of epidermal growth factor was not affected by D-PDMP, Dimethylsphingosine and the cell-permeable analogue, C-2-ceramide, did not show such a strong inhibitory effect on neurite outgrowth or on the autophosphorylation of Trk, The present results and our previous observations clearly demonstrate that Trk requires endogenous gangliosides, especially GM1, for its normal function in mediating the neurotrophic activity of NGF at least in PC12 cells.	Fukui Med Univ, Fac Med, Dept Internal Med 2, Div Neurol, Fukui 9101198, Japan; Seikagaku Corp, Tokyo Res Inst, Tokyo 207, Japan	University of Fukui; Seikagaku Corporation	Mutoh, T (corresponding author), Fukui Med Univ, Fac Med, Dept Internal Med 2, Div Neurol, 23 Shimoaizuki Matsuoka Cho, Fukui 9101198, Japan.	mutho@fmsrsa.fukui-med.ac.jp	Mutoh, Tatsuro/H-4317-2019; Inokuchi, Jin-ichi/AAW-9964-2020	Mutoh, Tatsuro/0000-0001-7712-8481; Inokuchi, Jin-ichi/0000-0002-0703-5746				CANNELLA MS, 1990, BRAIN RES, V513, P286, DOI 10.1016/0006-8993(90)90469-R; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; CUELLO AC, 1989, P NATL ACAD SCI USA, V86, P2056, DOI 10.1073/pnas.86.6.2056; DAHMS NM, 1983, J NEUROSCI, V3, P806; DOHERTY P, 1985, J NEUROCHEM, V44, P1259, DOI 10.1111/j.1471-4159.1985.tb08752.x; Farooqui T, 1997, J NEUROCHEM, V68, P2348; FELDINGHABERMANN B, 1990, BIOCHEMISTRY-US, V29, P6314, DOI 10.1021/bi00478a028; FERRARI G, 1995, J BIOL CHEM, V270, P3074, DOI 10.1074/jbc.270.7.3074; FERRARI G, 1983, BRAIN RES, V261, P215; Freischutz B, 1997, J NEUROCHEM, V68, P2070; Hartfield PJ, 1997, FEBS LETT, V401, P148, DOI 10.1016/S0014-5793(96)01460-3; INOKUCHI JI, 1987, J LIPID RES, V28, P565; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KATO H, 1993, J BIOL CHEM, V268, P2655; KATOHSEMBA R, 1984, J NEUROSCI RES, V12, P299, DOI 10.1002/jnr.490120217; Li RX, 1997, J BIOL CHEM, V272, P1349, DOI 10.1074/jbc.272.2.1349; LOEB DM, 1993, J NEUROSCI, V13, P2919; MacPhee IJ, 1997, J BIOL CHEM, V272, P23547, DOI 10.1074/jbc.272.38.23547; MASTICK CC, 1994, ENDOCRINOLOGY, V135, P214, DOI 10.1210/en.135.1.214; Mizutani A, 1996, BIOCHEM BIOPH RES CO, V222, P494, DOI 10.1006/bbrc.1996.0772; MOSKAL JR, 1980, CELL SURFACE GLYCOLI, P241; MUTOH T, 1993, J NEUROCHEM, V60, P1540, DOI 10.1111/j.1471-4159.1993.tb03319.x; MUTOH T, 1995, P NATL ACAD SCI USA, V92, P5087, DOI 10.1073/pnas.92.11.5087; MUTOH T, 1992, J NEUROCHEM, V58, P175, DOI 10.1111/j.1471-4159.1992.tb09293.x; RABIN SJ, 1995, J NEUROCHEM, V65, P347; RADIN NS, 1993, ADV LIPID RES, V26, P183; ROBSON JA, 1985, NEUROSCIENCE, V14, P1149, DOI 10.1016/0306-4522(85)90284-2; SCHWARZ A, 1995, J BIOL CHEM, V270, P10990, DOI 10.1074/jbc.270.18.10990; SHAYMAN JA, 1991, J BIOL CHEM, V266, P22968; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; SVENNERHOLM L, 1989, BIOCHIM BIOPHYS ACTA, V1005, P109, DOI 10.1016/0005-2760(89)90175-6; TOFFANO G, 1983, BRAIN RES, V261, P163, DOI 10.1016/0006-8993(83)91298-2; UEMURA K, 1991, J BIOCHEM-TOKYO, V110, P96, DOI 10.1093/oxfordjournals.jbchem.a123549; WU GS, 1995, J NEUROCHEM, V65, P1419; Yamamura S, 1997, BIOCHEM BIOPH RES CO, V236, P218, DOI 10.1006/bbrc.1997.6933; YANO H, 1993, J BIOL CHEM, V268, P25846; ZADOR IZ, 1993, J CLIN INVEST, V91, P797, DOI 10.1172/JCI116299	38	69	71	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26001	26007		10.1074/jbc.273.40.26001	http://dx.doi.org/10.1074/jbc.273.40.26001			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748278	hybrid			2022-12-27	WOS:000076263100069
J	Sanjay, A; Fu, J; Kreibich, G				Sanjay, A; Fu, J; Kreibich, G			DAD1 is required for the function and the structural integrity of the oligosaccharyltransferase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE OLIGOSACCHARYLTRANSFERASE; N-LINKED GLYCOSYLATION; APOPTOTIC CELL-DEATH; RIBOPHORIN-I; MAMMALIAN OLIGOSACCHARYLTRANSFERASE; MOLECULAR-CLONING; RIBOSOME BINDING; PROTEIN; MEMBRANE	Asparagine-linked glycosylation is a highly conserved protein modification reaction that occurs in all eukaryotic organisms. The oligosaccharyltransferase (OST), which has its active site exposed on the luminal face of the endoplasmic reticulum (ER), catalyzes the transfer of preassembled high mannose oligosaccharides onto certain asparagine residues of nascent polypeptides. The mammalian OST complex was initially thought to be composed of three transmembrane proteins, ribophorin I (RI), ribophorin II (RII), and OST48, Most recently, a small integral membrane protein of 12 kDa called DAD1 has been identified as an additional member of the mammalian OST complex. A point mutation in the DAD1 gene is responsible for the temperature-sensitive phenotype of a baby hamster kidney-derived cell line (tsBN7) that undergoes apoptosis at the non-permissive temperature. Furthermore, the mutant protein DAD1 is not detectable in tsBN7 cells 6 h after shifting the cells to the non-permissive temperature. This temperature-sensitive cell Line offered unique opportunities to study the effects caused by the loss of one OST subunit on the other three subunits and also on N-linked glycosylation, Western blot analysis of cell lysates showed that after 6 h at the non-permissive temperature, steady-state levels of the ribophorins were reduced by about 50%, and OST48 was barely detectable. On the other hand, steady-state levels of other components of the rough ER, such as the alpha-subunits of the TRAP (translocon-associated membrane protein) and the Sec61 complex, which are components of the translocation apparatus, are not affected by the instability of the OST subunits, Furthermore, N-glycosylation of the ribophorins was seriously affected 6 h after shifting the cells to the non-permissive temperature, and after 12 h they were synthesized only in the non-glycosylated form. As may be expected, this defect in the OST complex at the non-permissive temperature caused also the underglycosylation of a secretory glycoprotein, We concluded that degradation of DAD1 at the non-permissive temperature not only affects the stability of OST48 and the ribophorins but also results in the functional inactivation of the OST complex.	NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA	New York University	Kreibich, G (corresponding author), NYU, Sch Med, Dept Cell Biol, 550 1st Ave, New York, NY 10016 USA.	kreibg01@mcrcr6.med.nyu.edu						BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; CRIMAUDO C, 1987, EMBO J, V6, P75, DOI 10.1002/j.1460-2075.1987.tb04721.x; Fu J, 1997, J BIOL CHEM, V272, P29687, DOI 10.1074/jbc.272.47.29687; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HARNIKORT V, 1987, J CELL BIOL, V104, P855, DOI 10.1083/jcb.104.4.855; HARTMANN E, 1993, EUR J BIOCHEM, V214, P375, DOI 10.1111/j.1432-1033.1993.tb17933.x; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; HEESEN ST, 1993, EMBO J, V12, P279, DOI 10.1002/j.1460-2075.1993.tb05654.x; HEESEN ST, 1991, EUR J CELL BIOL, V56, P8; IVESSA NE, 1992, J CELL BIOL, V117, P949, DOI 10.1083/jcb.117.5.949; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; Kelleher DJ, 1997, P NATL ACAD SCI USA, V94, P4994, DOI 10.1073/pnas.94.10.4994; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KELLEHER DJ, 1994, J BIOL CHEM, V269, P12908; KNAUER R, 1994, FEBS LETT, V344, P83, DOI 10.1016/0014-5793(94)00356-4; KREIBICH G, 1978, J CELL BIOL, V77, P488, DOI 10.1083/jcb.77.2.488; KREIBICH G, 1978, J CELL BIOL, V77, P464, DOI 10.1083/jcb.77.2.464; KUMAR V, 1994, J BIOL CHEM, V269, P13451; LEE AS, 1992, CURR OPIN CELL BIOL, V13, P877; Makishima T, 1997, GENES CELLS, V2, P129, DOI 10.1046/j.1365-2443.1997.1070303.x; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; NAKASHIMA T, 1993, MOL CELL BIOL, V13, P6367, DOI 10.1128/MCB.13.10.6367; PEREZSALA D, 1995, J CELL PHYSIOL, V163, P523, DOI 10.1002/jcp.1041630312; PIROZZI G, 1991, BIOCHEM BIOPH RES CO, V176, P1482, DOI 10.1016/0006-291X(91)90454-F; RAPOPORT T, 1966, ANNU REV BIOCHEM, V65, P271; Reiss G, 1997, EMBO J, V16, P1164, DOI 10.1093/emboj/16.6.1164; ROSENFELD MG, 1984, J CELL BIOL, V99, P1076, DOI 10.1083/jcb.99.3.1076; SABATINI DD, 1995, METABOLIC BASIS INHE, P459; SILBERSTEIN S, 1995, J CELL BIOL, V131, P371, DOI 10.1083/jcb.131.2.371; SILBERSTEIN S, 1995, J CELL BIOL, V128, P525, DOI 10.1083/jcb.128.4.525; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; SILBERSTEIN S, 1992, J BIOL CHEM, V267, P23658; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; YU Y, 1990, J CELL BIOL, V111, P1335, DOI 10.1083/jcb.111.4.1335; [No title captured]	37	45	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26094	26099		10.1074/jbc.273.40.26094	http://dx.doi.org/10.1074/jbc.273.40.26094			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748289	hybrid			2022-12-27	WOS:000076263100080
J	Lee, YH; Yun, YD				Lee, YH; Yun, YD			HBx protein of hepatitis B virus activates Jak1-STAT signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; DNA-BINDING ACTIVITY; X-GENE; TYROSINE PHOSPHORYLATION; HEPATOCELLULAR-CARCINOMA; MAP-KINASE; TRANSCRIPTION; LIVER; CELLS; PATHWAY	The X-gene product (HBx) of the hepatitis B virus plays essential roles in viral replication and the generation of hepatocellular carcinoma. Although the mechanism for HBx action is unclear, HBx may exert its pleiotropic functions through the stimulation of signal transduction pathways including the Ras/mitogen-activated protein kinase cascade and/or inactivation of the p53 function. Here, we investigated whether HBx has the ability to activate the Jak-STAT signaling pathway. As a first step, we established stable cell lines constitutively expressing HBx, In these HBx-expressing stable cells, the tyrosine phosphorylation of various STATs, including STAT3 and -5, was constitutively enhanced by HBx, and the concomitant increase in STAT-dependent DNA binding and transcriptional activation was observed. Furthermore, HBx specifically elevated tyrosine phosphorylation and in vitro kinase activity of Jak1, but not Jak2 or Tyk2, through protein to protein interaction with Jak1. These results clearly establish HBx as the inducer of the Jak-STAT signaling pathway, and at the same time, HBx-mediated Jak-STAT activation may provide a novel mechanism for the pleiotropic functions of HBx, including transformation and promiscuous transcriptional activation.	Morgan Biotechnol Res Inst, Signal Transduct Lab, Kyunggido 449910, South Korea		Yun, YD (corresponding author), Morgan Biotechnol Res Inst, Signal Transduct Lab, 341 Pojungri, Kyunggido 449910, South Korea.		Lee, Young-Ho/G-2361-2014	Lee, Young-Ho/0000-0001-6415-4912				BARINAGA M, 1995, SCIENCE, V269, P1673, DOI 10.1126/science.7569891; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; BRUNN GJ, 1995, J BIOL CHEM, V270, P11628, DOI 10.1074/jbc.270.19.11628; Campbell GS, 1997, J BIOL CHEM, V272, P2591, DOI 10.1074/jbc.272.5.2591; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; CRESSMAN DE, 1995, HEPATOLOGY, V21, P1443, DOI 10.1016/0270-9139(95)90068-3; Cromlish JA, 1996, TRENDS MICROBIOL, V4, P270, DOI 10.1016/0966-842X(96)10046-9; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DEVIERE J, 1989, CLIN EXP IMMUNOL, V77, P221; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; HARRISON DA, 1995, EMBO J, V14, P2857, DOI 10.1002/j.1460-2075.1995.tb07285.x; HE TC, 1995, J BIOL CHEM, V270, P11055, DOI 10.1074/jbc.270.19.11055; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; Kumar V, 1996, P NATL ACAD SCI USA, V93, P5647, DOI 10.1073/pnas.93.11.5647; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; Lee H, 1995, J BIOL CHEM, V270, P31405, DOI 10.1074/jbc.270.52.31405; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MORIARTY AM, 1985, SCIENCE, V227, P429, DOI 10.1126/science.2981434; MURAKAMI S, 1994, J BIOL CHEM, V269, P15118; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; Stancato LF, 1997, MOL CELL BIOL, V17, P3833, DOI 10.1128/MCB.17.7.3833; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	39	198	205	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25510	25515		10.1074/jbc.273.39.25510	http://dx.doi.org/10.1074/jbc.273.39.25510			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738022	hybrid			2022-12-27	WOS:000076085400072
J	Berestetskaya, YV; Faure, MP; Ichijo, H; Voyno-Yasenetskaya, TA				Berestetskaya, YV; Faure, MP; Ichijo, H; Voyno-Yasenetskaya, TA			Regulation of apoptosis by alpha-subunits of G12 and G13 proteins via apoptosis signal-regulating kinase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; CELL-DEATH; COS-7 CELLS; BCL-2; ACTIVATION; PATHWAYS; RAS; MITOGEN; INDUCTION; PHOSPHORYLATION	Many growth factors and G protein-coupled receptors activate mitogen-activated protein (MAP) kinase pathways. The MAP kinase pathways are involved in the regulation of the ubiquitous process of apoptosis or programmed cell death. Two related MAP kinase kinase kinases, apoptosis-signal regulating kinase 1 (ASK1) and MAP kinase kinase kinase 1 (MEKK1), stimulate c-Jun kinase (JNK) activity and induce apoptosis, Transient transfection of dominant negative and constitutively active components of the JNK pathway in COS-7 cells showed that two G protein subunits, G alpha 12 and G alpha 13, stimulated the JNK pathway in a ASK1- and MEKK1-dependent manner. Moreover, the mutationally activated G alpha 12 and G alpha 13 stimulated the kinase activity of ASK1. Both G alpha 12 and G alpha 13 employ small GTPases, Cdc42 and Rac1, to transduce signal to MEKK1 and, subsequently, to JNK, However, activation of JNK by Cdc42 and Rac1 did not require ASK1. Additionally, ASK1 and MEKK1 are involved in the apoptosis induced by G alpha 12 and G alpha 13, We conclude that G alpha 12 and G alpha 13 can induce apoptosis using two separate MAP kinase pathways; one is initiated by ASK1, and the other is initiated by MEKK1, Furthermore, Bcl-2 can block apoptosis induced by G alpha 12 and G alpha 13. This death-sparing function was associated with increased Bcl-2 phosphorylation, suggesting that phosphorylation of Bcl-2 may be a critical mechanism protecting cells from G alpha 12- and G alpha 13-induced apoptosis.	Univ Illinois, Coll Med, Dept Pharmacol MC 868, Chicago, IL 60612 USA; Inst Canc, Dept Oral Pathol, Tokyo 113, Japan; Sugen Inc, Redwood City, CA 94063 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Voyno-Yasenetskaya, TA (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol MC 868, 835 S Wollcott Ave, Chicago, IL 60612 USA.	tvy@uic.edu		Ichijo, Hidenori/0000-0002-5005-6438				Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; Apasov SG, 1997, J IMMUNOL, V158, P5095; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; FAURE M, 1994, J BIOL CHEM, V269, P7851; Gulbins E, 1996, J BIOL CHEM, V271, P26389, DOI 10.1074/jbc.271.42.26389; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; JIMENEZ B, 1995, ONCOGENE, V10, P811; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; OLTAVI ZN, 1993, CELL, V74, P609; PACE AM, 1995, MOL BIOL CELL, V6, P1685, DOI 10.1091/mbc.6.12.1685; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sharma K, 1996, MOL ENDOCRINOL, V10, P1688, DOI 10.1210/me.10.12.1688; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Ucker D S, 1997, Adv Pharmacol, V41, P179, DOI 10.1016/S1054-3589(08)61059-5; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; WANG YS, 1993, ONCOGENE, V8, P3427; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; Yamatsuji T, 1996, SCIENCE, V272, P1349, DOI 10.1126/science.272.5266.1349; YAN GM, 1995, MOL PHARMACOL, V47, P248; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386	48	61	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27816	27823		10.1074/jbc.273.43.27816	http://dx.doi.org/10.1074/jbc.273.43.27816			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774391	hybrid			2022-12-27	WOS:000076549800011
J	Chan, CHT; Wang, JS; French, RR; Glennie, MJ				Chan, CHT; Wang, JS; French, RR; Glennie, MJ			Internalization of the lymphocytic surface protein CD22 is controlled by a novel membrane proximal cytoplasmic motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CELL ACTIVATION; DENSITY-LIPOPROTEIN RECEPTOR; ANTIGEN RECEPTOR; IMMUNOGLOBULIN SUPERFAMILY; CD22-DEFICIENT MICE; MOLECULE CD22; AMINO-ACIDS; TYROSINE; SIGNAL; ENDOCYTOSIS	CD22 is a key receptor on B-lymphocytes that modulates signaling during antigenic stimulation. We have defined a novel cytoplasmic motif in human CD22 that controls its unusually rapid turnover at the plasma membrane. Chimeric and mutated CD22 alpha cDNA vectors were constructed and stably transfected in CD22-negative Jurkat T-lymphocytic cells. Two assays were employed to measure CD22 alpha internalization: first, cytoplasmic uptake of radioiodinated anti-CD22 monoclonal antibody; and second, lethal targeting of a toxin, saporin, into cells via CD22 using bispecific F(ab')(2) ([anti-CD22 x anti-saporin]) antibody, Results showed that CD22 alpha lacking a cytoplasmic tail was not internalized and that replacement of the cytoplasmic tail of CD19 with that of CD22 alpha resulted in a chimeric molecule that behaved like CD22 alpha and internalized rapidly. Step-wise deletion of the cytoplasmic tail of CD22 alpha located the internalization motif to a polar region of 11 residues (QRRWKRTQSQQ) proximal to the plasma membrane, a part of the molecule predicted to form a coil or turn structure; Interestingly, additional CD22 mutants showed that the two glutamine residues sandwiching the serine are critical to internalization but that the serine itself is not.	Southampton Gen Hosp, Tenovus Canc Lab, Lymphoma Res Unit, Southampton SO16 6YD, Hants, England; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	University of Southampton; MRC Laboratory Molecular Biology	Glennie, MJ (corresponding author), Southampton Gen Hosp, Tenovus Canc Lab, Lymphoma Res Unit, Tremona Rd, Southampton SO16 6YD, Hants, England.							AMLOT PL, 1993, BLOOD, V82, P2624; ANDREASON GL, 1988, BIOTECHNIQUES, V6, P650; BONARDI MA, 1993, CANCER RES, V53, P3015; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; ELLIS JH, 1995, J IMMUNOL, V155, P925; FRENCH RR, 1991, CANCER RES, V51, P2353; French RR, 1996, LEUKEMIA RES, V20, P607, DOI 10.1016/0145-2126(96)00007-0; Garnier J, 1996, METHOD ENZYMOL, V266, P540; GHETIE MA, 1988, CANCER RES, V48, P2610; GLENNIE MJ, 1988, J IMMUNOL, V141, P3662; GLENNIE MJ, 1993, TUMOUR IMMUNOBIOLOGY, P225; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LAW CL, 1993, J IMMUNOL, V151, P175; LAW CL, 1994, IMMUNOL TODAY, V15, P442, DOI 10.1016/0167-5699(94)90275-5; Law CL, 1996, J EXP MED, V183, P547, DOI 10.1084/jem.183.2.547; MASON DY, 1987, BLOOD, V69, P836; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MOTTA A, 1995, J BIOL CHEM, V270, P27165, DOI 10.1074/jbc.270.45.27165; NAIM HY, 1994, J BIOL CHEM, V269, P3928; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; Otipoby KL, 1996, NATURE, V384, P634, DOI 10.1038/384634a0; PEAKER CJG, 1993, EUR J IMMUNOL, V23, P1358, DOI 10.1002/eji.1830230626; PELCHENMATTEWS A, 1991, J EXP MED, V173, P578; PEZZUTTO A, 1988, J IMMUNOL, V140, P1791; POWELL LD, 1995, J BIOL CHEM, V270, P14243, DOI 10.1074/jbc.270.24.14243; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Sato S, 1996, IMMUNITY, V5, P551, DOI 10.1016/S1074-7613(00)80270-8; SCHWARTZALBIEZ R, 1991, INT IMMUNOL, V3, P623, DOI 10.1093/intimm/3.7.623; SHAN DM, 1995, J IMMUNOL, V154, P4466; Sherbina NV, 1996, J IMMUNOL, V157, P4390; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; TEDDER TF, 1989, J IMMUNOL, V143, P712; Tedder TF, 1997, ANNU REV IMMUNOL, V15, P481, DOI 10.1146/annurev.immunol.15.1.481; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; vanderMerwe PA, 1996, J BIOL CHEM, V271, P9273, DOI 10.1074/jbc.271.16.9273; Vely F, 1997, J IMMUNOL, V159, P2075; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137	43	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27809	27815		10.1074/jbc.273.43.27809	http://dx.doi.org/10.1074/jbc.273.43.27809			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774390	hybrid			2022-12-27	WOS:000076549800010
J	Li, N; Seetharam, B				Li, N; Seetharam, B			A 69-base pair fragment derived from human transcobalamin II promoter is sufficient for high bidirectional activity in the absence of a TATA box and an initiator element in transfected cells - Role of an E box in transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-LOOP-HELIX; ADENOVIRUS MAJOR LATE; RNA POLYMERASE-II; FACTOR USF; DNA-BINDING; SYNTHASE PROMOTER; MAMMALIAN-CELLS; MULTIPLE FORMS; PROTEIN; GENE	A 69-base pair (bp) (-581/-513) fragment derived from human transcobalamin II distal promoter constructed upstream of a chloramphenicol acetyltransferase reporter gene demonstrated high bidirectional promoter activity in transfected epithelial Caco-2 cells. DNase I footprinting, gel mobility shift, supershift, and mutagenesis studies with the 69-bp fragment demonstrated that a GC box (-568/-559) and an E box (-523/-528), which interacted with Sp1/Sp3 and USF1/USF2 (where USF is upstream stimulatory factor), respectively, were required for the full transcriptional activity of this fragment. Whereas mutations in the GC box reduced the promoter activity by 50%, mutations in the E box alone or in both the E box and GC box resulted in 90% loss of transcriptional activity. The essential role of the E box in the bidirectional promoter activity was further demonstrated by transient transfection in Caco-2, K-562, and HeLa cells using a 29-bp (-541/-513) fragment that contained only the E box. Based on these results we suggest that 1) the E box is essential for both the GC box-dependent and -independent promoter activity of the 69-bp fragment, 2) cooperative interactions between Sp1/Sp3 and USFs are required for the full activation of the BS-bp promoter activity, and 3) the single E box is able to mediate bidirectional transcription in transfected cells in the absence of an obvious TATA box or a known initiator element.	Med Coll Wisconsin, Dept Med, Div Gastroenterol & Hepatol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Vet Adm Med Ctr, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Seetharam, B (corresponding author), Med Coll Wisconsin, MACC Fund Ctr, Rm 6061,8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	seethara@post.itsmcw.edu			NIDDK NIH HHS [DK-50052] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050052] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; Bradford MM, 1976, ANAL BIOCHEM, V112, P195; BUNGERT J, 1992, J MOL BIOL, V223, P885, DOI 10.1016/0022-2836(92)90250-N; CARCAMO J, 1989, J BIOL CHEM, V264, P7704; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CARTER RS, 1994, J BIOL CHEM, V269, P4381; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; COLEMAN RA, 1995, J BIOL CHEM, V270, P13850, DOI 10.1074/jbc.270.23.13850; COOPER BA, 1987, ANNU REV NUTR, V7, P291, DOI 10.1146/annurev.nu.07.070187.001451; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; Ebara S, 1997, BIOCHEM BIOPH RES CO, V240, P136, DOI 10.1006/bbrc.1997.7618; FABER PW, 1993, J BIOL CHEM, V268, P9296; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALLE JP, 1995, J BIOL CHEM, V270, P21307, DOI 10.1074/jbc.270.36.21307; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; Ikeda K, 1997, BIOCHEM BIOPH RES CO, V236, P765, DOI 10.1006/bbrc.1997.7046; JACOB E, 1980, PHYSIOL REV, V60, P918, DOI 10.1152/physrev.1980.60.3.918; KIRSCHBAUM BJ, 1992, MOL CELL BIOL, V12, P5094, DOI 10.1128/MCB.12.11.5094; KOLLMAR R, 1994, J BIOL CHEM, V269, P2252; LANS MS, 1994, J BIOL CHEM, V269, P14170; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; LI N, 1995, BIOCHEM BIOPH RES CO, V208, P756, DOI 10.1006/bbrc.1995.1402; Li N, 1998, J BIOL CHEM, V273, P16104, DOI 10.1074/jbc.273.26.16104; LIAO WC, 1994, GENE, V146, P183, DOI 10.1016/0378-1119(94)90291-7; Morris JK, 1996, J BIOL CHEM, V271, P16633, DOI 10.1074/jbc.271.28.16633; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; OUTRAM SV, 1994, J BIOL CHEM, V269, P26525; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHATT MD, 1990, EMBO J, V9, P481, DOI 10.1002/j.1460-2075.1990.tb08134.x; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHIH HM, 1994, J BIOL CHEM, V269, P9380; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; VANDERZEE CA, 1994, J BIOL CHEM, V269, P6972; WANG D, 1995, J BIOL CHEM, V270, P28716, DOI 10.1074/jbc.270.48.28716; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHAO GQ, 1993, MOL CELL BIOL, V13, P4505, DOI 10.1128/MCB.13.8.4505	51	37	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28170	28177		10.1074/jbc.273.43.28170	http://dx.doi.org/10.1074/jbc.273.43.28170			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774437	hybrid			2022-12-27	WOS:000076549800057
J	Matsumoto, N; Laub, F; Aldabe, R; Zhang, W; Ramirez, F; Yoshida, T; Terada, M				Matsumoto, N; Laub, F; Aldabe, R; Zhang, W; Ramirez, F; Yoshida, T; Terada, M			Cloning the cDNA for a new human zinc finger protein defines a group of closely related Kruppel-like transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION DOMAIN; NUCLEAR PROTEINS; GENE-EXPRESSION; FACTOR EKLF; CELLS; IDENTIFICATION; ELEMENTS; FAMILY; CONTAINS; GAL4	We have identified a novel zinc finger protein that has been named ubiquitous Kruppel-like factor (UKLF) based on structural considerations and the pattern of gene expression, UKLF was isolated by the polymerase chain reaction approach using degenerate oligonucleotides corresponding to the DNA-binding domain of erythroid Kruppel-like factor (EKLF) and cDNA prepared from human vascular endothelial cells. The carboxyl-terminal portion of UKLF contains three zinc fingers of the Cys(2)-His(2) type and binds in vitro to the CACCC motif of the beta-globin promoter and to the Spl recognition sequence. The amino-terminal portion of UKLF consists of a hydrophobic region rich in serines and a negatively charged segment with several glutamic acid residues. The first 47 amino acids of the acidic region are nearly identical to the amino-terminal portion of another Kruppel-like factor, the so-called core promoter-binding protein (CPBP) or Zf9. Like CPBP/Zf9, UKLF can function as a transcription activator in co-transfection assays. However, this activity is lost when the highly conserved amino-terminal segment is deleted. These findings indicate that UKLF and CPBP/Zf9 represent a distinct subgroup of closely related Kruppel-like activators of transcription. Mapping of the UKLF gene to chromosome 2 suggested that UKLF and CPBP/Zf9 translocated to different chromosomes following duplication from an ancestral gene.	CUNY Mt Sinai Sch Med, Brookdale Ctr Dev & Mol Biol, New York, NY 10029 USA; Natl Canc Ctr, Res Inst, Div Genet, Chuo Ku, Tokyo 1040045, Japan	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; National Cancer Center - Japan	Ramirez, F (corresponding author), CUNY Mt Sinai Sch Med, Brookdale Ctr Dev & Mol Biol, 1 Gustave L Levy Pl,Box 1126, New York, NY 10029 USA.	ramirf01@doc.mssm.edu	Aldabe, Rafael/F-3112-2015	Aldabe, Rafael/0000-0002-9461-020X	NIAMS NIH HHS [AR-38648, AR-42841] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042841, R37AR038648, R01AR038648] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; BERG JM, 1990, J BIOL CHEM, V265, P6513; Chen XY, 1996, EMBO J, V15, P5888, DOI 10.1002/j.1460-2075.1996.tb00975.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Crossley M, 1996, MOL CELL BIOL, V16, P1695; ElRouby S, 1996, ONCOGENE, V13, P2623; Friedman S L, 1996, Prog Liver Dis, V14, P101; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; IDE H, 1995, BIOCHEM J, V311, P675, DOI 10.1042/bj3110675; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; JOHNSON RJ, 1991, J CLIN INVEST, V87, P847, DOI 10.1172/JCI115089; KLEVIT RE, 1991, SCIENCE, V253, P1367, DOI 10.1126/science.1896847; Koritschoner NP, 1997, J BIOL CHEM, V272, P9573; Koritschoner NP, 1996, EUR J BIOCHEM, V236, P365, DOI 10.1111/j.1432-1033.1996.00365.x; KUHN C, 1991, AM J PATHOL, V138, P1257; Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; Lalazar A, 1997, GENE, V195, P235, DOI 10.1016/S0378-1119(97)00159-5; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; MARUYAMA IN, 1995, NUCLEIC ACIDS RES, V23, P3796, DOI 10.1093/nar/23.18.3796; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Onyango P, 1998, GENOMICS, V48, P143, DOI 10.1006/geno.1997.5124; PERKINS AC, 1995, NATURE, V375, P318; Ratziu V, 1998, P NATL ACAD SCI USA, V95, P9500, DOI 10.1073/pnas.95.16.9500; Sambrook J., 2002, MOL CLONING LAB MANU; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; Shields JM, 1998, NUCLEIC ACIDS RES, V26, P796, DOI 10.1093/nar/26.3.796; Shields JM, 1997, J BIOL CHEM, V272, P18504, DOI 10.1074/jbc.272.29.18504; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; SOGOWA K, 1993, NUCLEIC ACIDS RES, V21, P1527; Watanabe T, 1998, MOL CELL BIOL, V18, P442, DOI 10.1128/MCB.18.1.442; Yet SF, 1998, J BIOL CHEM, V273, P1026, DOI 10.1074/jbc.273.2.1026	38	101	113	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28229	28237		10.1074/jbc.273.43.28229	http://dx.doi.org/10.1074/jbc.273.43.28229			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774444	hybrid			2022-12-27	WOS:000076549800064
J	Sakamoto, Y; Taguchi, T; Tano, Y; Ogawa, T; Leppanen, A; Kinnunen, M; Aitio, O; Parmanne, P; Renkonen, O; Taniguchi, N				Sakamoto, Y; Taguchi, T; Tano, Y; Ogawa, T; Leppanen, A; Kinnunen, M; Aitio, O; Parmanne, P; Renkonen, O; Taniguchi, N			Purification and characterization of UDP-GlcNAc : Gal beta 1-4-GlcNAc beta 1-3*Gal beta 1-4Glc (NAc)-R(GlcNAc to *Gal) beta 1, 6N-acetylglucosaminyltransferase from hog small intestine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-GROUP-I; UDP-N-ACETYLGLUCOSAMINE; BETA-1,6-GLCNAC TRANSFERASE; STRUCTURAL REQUIREMENTS; CARBOHYDRATE STRUCTURE; CELL-DIFFERENTIATION; BACTEROIDES-FRAGILIS; GASTRIC-MUCOSA; MOUSE KIDNEY; BIOSYNTHESIS	A beta 1,6N-acetylglucosaminyltransferase (beta 1-6GnT) responsible for the formation of the beta 1,6-branched poly-N-acetyllactosamine structure has been purified 210,000-fold in 2.4% yield from a homogenate of hog small intestine by successive column chromatographies involving CM-Sepharose FF, Ni2+-chelating Sepharose FF, and UDP-hexanolamine-agarose, using an assay wherein pyridylaminated lacto-N-neotetraose (Gal beta 1-4GlcNAc beta 1-3Galp1-4Glc-PA) was used as an acceptor substrate, and the reaction product was Gal beta 1-4GlcNAc beta 1-3(GlcNAc beta 1-6)Gal beta 1-4Glc-PA. The apparent molecular weight of the purified enzyme was 76,000 under nonreducing conditions. The enzyme has a pH optimum at 7.0 and has no requirement for any divalent metal ions. The K-m values for pyridylaminated lacto-N-neotetraose and UDP-GlcNAc were 0.96 and 2.59 mM, respectively, For its activity, this enzyme was shown to have an absolute requirement of at least a complete LacNAc (LacNAc = Gal beta 1-4GlcNAc) residue bound to position 3 of the acceptor Gal residues, i.e. it is capable of acting only on the Gal residues of internal LacNAc units. The data strongly suggest that this enzyme could be involved in generating branches to central positions of preformed as well as growing polylactosamine chains, but not in synthesizing the distal branches to growing polylactosamine chains.	Osaka Univ, Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Ophthalmol, Suita, Osaka 5650871, Japan; RIKEN, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan; Univ Helsinki, Dept Biosci, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland	Osaka University; Osaka University; RIKEN; University of Helsinki; University of Helsinki	Taniguchi, N (corresponding author), Osaka Univ, Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan.		Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968; Parmanne, Pinja/0000-0002-4691-2107				BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; BIERHUIZEN MFA, 1994, TRENDS GLYCOSCI GLYC, V6, P17; BROCKHAUSEN I, 1986, EUR J BIOCHEM, V157, P463, DOI 10.1111/j.1432-1033.1986.tb09690.x; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; FUKUDA M, 1984, J BIOL CHEM, V259, P4782; FUKUDA M, 1979, J BIOL CHEM, V254, P3700; GU J, 1992, J BIOL CHEM, V267, P2994; HASHIMOTO Y, 1993, J BIOL CHEM, V268, P25857; Helin J, 1997, FEBS LETT, V412, P637, DOI 10.1016/S0014-5793(97)00818-1; KAPADIA A, 1981, EXP CELL RES, V131, P185, DOI 10.1016/0014-4827(81)90418-3; KEMLER R, 1977, P NATL ACAD SCI USA, V74, P4449, DOI 10.1073/pnas.74.10.4449; KOENDERMAN AHL, 1987, EUR J BIOCHEM, V166, P199, DOI 10.1111/j.1432-1033.1987.tb13502.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leppanen A, 1997, BIOCHEMISTRY-US, V36, P7026, DOI 10.1021/bi9627673; Leppanen A, 1998, J BIOL CHEM, V273, P17399, DOI 10.1074/jbc.273.28.17399; LEPPANEN A, 1991, BIOCHEMISTRY-US, V30, P9287, DOI 10.1021/bi00102a022; Leppanen A, 1997, BIOCHEMISTRY-US, V36, P13729, DOI 10.1021/bi9712807; Maaheimo H, 1997, CARBOHYD RES, V297, P145, DOI 10.1016/S0008-6215(96)00259-5; MURAMATSU T, 1978, P NATL ACAD SCI USA, V75, P2315, DOI 10.1073/pnas.75.5.2315; Natunen J, 1997, GLYCOBIOLOGY, V7, P711, DOI 10.1093/glycob/7.5.711; NIEMANN H, 1978, BIOCHEM BIOPH RES CO, V81, P1286, DOI 10.1016/0006-291X(78)91275-5; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; Oguri S, 1997, J BIOL CHEM, V272, P22721, DOI 10.1074/jbc.272.36.22721; PILLER F, 1984, J BIOL CHEM, V259, P3385; RENKONEN O, 1991, GLYCOCONJUGATE J, V8, P376, DOI 10.1007/BF00731351; ROPP PA, 1991, J BIOL CHEM, V266, P23863; SABESAN S, 1992, J AM CHEM SOC, V114, P8363, DOI 10.1021/ja00048a004; SCUDDER P, 1984, J BIOL CHEM, V259, P6586; SEKINE M, 1994, J BIOL CHEM, V269, P31143; SEKINE M, 1990, J BIOCHEM-TOKYO, V108, P103, DOI 10.1093/oxfordjournals.jbchem.a123147; SEPPO A, 1995, BIOCHEMISTRY-US, V34, P4655, DOI 10.1021/bi00014a019; VANDENEIJNDEN DH, 1993, CURR OPIN STRUC BIOL, V3, P711, DOI 10.1016/0959-440X(93)90054-O; WATANABE K, 1979, J BIOL CHEM, V254, P3221	33	12	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27625	27632		10.1074/jbc.273.42.27625	http://dx.doi.org/10.1074/jbc.273.42.27625			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765297	hybrid			2022-12-27	WOS:000076448000084
J	Sanchez-Mejorada, G; Rosales, C				Sanchez-Mejorada, G; Rosales, C			Fc gamma receptor-mediated mitogen-activated protein kinase activation in monocytes is independent of Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER-CELLS; SIGNAL-TRANSDUCTION PATHWAY; NF-KAPPA-B; TYROSINE PHOSPHORYLATION; MAP KINASE; CROSS-LINKING; FUNCTIONAL ASSOCIATION; EXTRACELLULAR SIGNALS; HIGH-AFFINITY; MOTIF ITAM	Receptors for the Fc portion of immunoglobulin molecules (FcR) present on leukocyte cell membranes mediate a large number of cellular responses that are very important in host defense, including phagocytosis, cell cytotoxicity, production and secretion of inflammatory mediators, and modulation of the immune response. Cross-linking of FcR with immune complexes leads, first to activation of protein-tyrosine kinases. The molecular events that follow and that transduce signals from these receptors to the nucleus are still poorly defined. We have investigated the signal transduction pathway from Fc receptors that leads to gene activation and production of cytokines in monocytes, Cross-linking of FcR, on the THP-1 monocytic cell line, by immune complexes resulted in both activation of the transcription factor NF-kappa B and interleukin 1 production. These responses were completely blocked by tyrosine kinase inhibitors. In contrast, expression of dominant negative mutants of Res and Raf-1, in these cells, did not have any effect on FcR-mediated nuclear factor activation, suggesting that the mitogen-activated protein kinase (MAPK) signaling pathway was not used by these receptors, However, MAPK activation was easily detected by in vitro kinase assays, after FcR cross-linking with immune complexes. Using the specific MAPK/extracellular signal-regulated kinase kinase (MAPK kinase) inhibitor PD98059, we found that MAPK activation is necessary for FcR-dependent activation of the nuclear factor NF-kappa B. These results strongly suggest that the signaling pathway from Fc receptors leading to expression of different genes important to leukocyte biology, initiates with tyrosine kinases and requires MAPK activation; but in contrast to other tyrosine kinase receptors, FcR-mediated MAPK activation does not involve Ras and Raf.	Univ Nacl Autonoma Mexico, Inst Invest Biomed, Dept Immunol, Mexico City 04510, DF, Mexico	Universidad Nacional Autonoma de Mexico	Rosales, C (corresponding author), Univ Nacl Autonoma Mexico, Inst Invest Biomed, Dept Immunol, Apto Postal 70228,Cd Univ, Mexico City 04510, DF, Mexico.	carosal@servidor.unam.mx	ROSALES, CARLOS/AAA-5206-2019	ROSALES, CARLOS/0000-0003-2568-5723				AGARWAL A, 1993, J BIOL CHEM, V268, P15900; ANEGON I, 1988, J EXP MED, V167, P452, DOI 10.1084/jem.167.2.452; AZZONI L, 1992, J EXP MED, V176, P1745, DOI 10.1084/jem.176.6.1745; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; CAMBIER JC, 1995, IMMUNOL LETT, V44, P77, DOI 10.1016/0165-2478(94)00196-X; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; CASILLAS A, 1991, J BIOL CHEM, V266, P19088; CHEN SY, 1994, ONCOGENE, V9, P2691; COGSWELL JP, 1994, J IMMUNOL, V153, P712; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DARBY C, 1994, J IMMUNOL, V152, P5429; DURDEN DL, 1995, J IMMUNOL, V154, P4039; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; ERBE DV, 1991, J IMMUNOL, V146, P3145; Galandrini R, 1996, J EXP MED, V183, P179, DOI 10.1084/jem.183.1.179; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GRAY JG, 1993, MOL CELL BIOL, V13, P6678, DOI 10.1128/MCB.13.11.6678; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; HASKILL S, 1988, J IMMUNOL, V140, P1690; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HIRASAWA N, 1995, J IMMUNOL, V154, P5391; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Isakov N, 1997, J LEUKOCYTE BIOL, V61, P6, DOI 10.1002/jlb.61.1.6; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; JabrilCuenod B, 1996, J BIOL CHEM, V271, P16268, DOI 10.1074/jbc.271.27.16268; JOHNSON GL, 1994, J CELL BIOCHEM, V54, P415, DOI 10.1002/jcb.240540408; KANAKARAJ P, 1994, J EXP MED, V179, P551, DOI 10.1084/jem.179.2.551; Karimi K, 1998, INFLAMMATION, V22, P67, DOI 10.1023/A:1022347808042; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KIENER PA, 1993, J BIOL CHEM, V268, P24442; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIAO F, 1992, P NATL ACAD SCI USA, V89, P3659, DOI 10.1073/pnas.89.8.3659; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Milella M, 1997, J IMMUNOL, V158, P3148; NINOMIYA N, 1994, J BIOL CHEM, V269, P22732; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POLAT GL, 1993, IMMUNOLOGY, V80, P287; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; Rosales C, 1996, CANCER RES, V56, P2302; SALCEDO TW, 1993, J EXP MED, V177, P1475, DOI 10.1084/jem.177.5.1475; Sanchez-Mejorada G, 1998, J LEUKOCYTE BIOL, V63, P521, DOI 10.1002/jlb.63.5.521; Santana C, 1996, J LEUKOCYTE BIOL, V60, P433, DOI 10.1002/jlb.60.4.433; SCHOONK LB, 1987, MONOCLONAL ANTIBODY; SHEN ZH, 1994, J IMMUNOL, V152, P3017; SHIRAKAWA F, 1993, MOL CELL BIOL, V13, P1332, DOI 10.1128/MCB.13.3.1332; SPORN SA, 1990, J IMMUNOL, V144, P4434; TING AT, 1992, J EXP MED, V176, P1751, DOI 10.1084/jem.176.6.1751; Trotta R, 1996, J EXP MED, V184, P1027, DOI 10.1084/jem.184.3.1027; UEHARA Y, 1991, METHOD ENZYMOL, V201, P370; UNKELESS JC, 1992, INFLAMMATION BASIC P, P497; VANDEWINKEL JGJ, 1993, IMMUNOL TODAY, V14, P215, DOI 10.1016/0167-5699(93)90166-I; VIVIER E, 1993, EUR J IMMUNOL, V23, P1872, DOI 10.1002/eji.1830230821; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG AVT, 1994, J EXP MED, V180, P1165, DOI 10.1084/jem.180.3.1165; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; ZOLA H, 1987, MONOCLONAL ANTIBODIE	64	58	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27610	27619		10.1074/jbc.273.42.27610	http://dx.doi.org/10.1074/jbc.273.42.27610			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765295	hybrid			2022-12-27	WOS:000076448000082
J	Valnickova, Z; Enghild, JJ				Valnickova, Z; Enghild, JJ			Human procarboxypeptidase U, or thrombin-activable fibrinolysis inhibitor, is a substrate for transglutaminases - Evidence for transglutaminase-catalyzed cross-linking to fibrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; PLASMA CARBOXYPEPTIDASE-B; ALPHA-2-PLASMIN INHIBITOR; STABILIZING FACTOR; GLU-PLASMINOGEN; DEGRADED FIBRIN; BINDING-SITES; FACTOR-XIIIA; PROTEIN-C; AFFINITY	Procarboxypeptidase U (EC 3.4.17.20) (pro-CpU), also known as plasma procarboxypeptidase B and thrombin-activable fibrinolysis inhibitor, is a human plasma protein that has been implicated in the regulation of fibrinolysis. In this study, we show that pro-CpU serves as a substrate for transglutaminases. Both factor XIIIa and tissue transglutaminase catalyzed the polymerization of pro-CpU and the cross-linking to fibrin as well as the incorporation of 5-dimethylaminonaphthalene-1-sulfonyl cadaverine (dansylcadaverine), [C-14]putrescine, and dansyl-PGGQQIV. These findings show that pro-CpU contains both amine acceptor (Gln) and amine donor (Lys) residues. The amine acceptor residues were identified as Gln(2), Gln(5), and Gln(292), suggesting that both the activation peptide and the mature enzyme participate in the cross-linking reaction. These observations imply that transglutaminases may mediate covalent binding of pro-CpU to other proteins and cell surfaces in vivo. In particular, factor XIIIa may cross-link pro-CpU to fibrin during the latter part of the coagulation cascade, thereby helping protect the newly formed fibrin clot from premature plasmin degradation. Moreover, the cross-linking may facilitate the activation of pro-CpU, stabilize the enzymatic activity, and protect the active enzyme from further degradation.	Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA	Duke University	Enghild, JJ (corresponding author), Duke Univ, Med Ctr, Dept Pathol, Box 3712, Durham, NC 27710 USA.	enghi001@mc.duke.edu		Enghild, Jan Johannes/0000-0001-9292-9172	NHLBI NIH HHS [HL49542] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049542] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AESCHLIMANN D, 1992, J BIOL CHEM, V267, P11316; Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; Bajzar L, 1996, BLOOD, V88, P2093, DOI 10.1182/blood.V88.6.2093.bloodjournal8862093; BALE MD, 1986, BIOCHEMISTRY-US, V25, P5667, DOI 10.1021/bi00367a048; BENDIXEN E, 1995, J BIOL CHEM, V270, P17929, DOI 10.1074/jbc.270.30.17929; BENDIXEN E, 1993, J BIOL CHEM, V268, P21962; BERBERS GAM, 1984, P NATL ACAD SCI-BIOL, V81, P7017, DOI 10.1073/pnas.81.22.7017; Boffa MB, 1998, J BIOL CHEM, V273, P2127, DOI 10.1074/jbc.273.4.2127; Broze GJ, 1996, BLOOD, V88, P3815, DOI 10.1182/blood.V88.10.3815.bloodjournal88103815; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; CHRISTENSEN U, 1985, FEBS LETT, V182, P43, DOI 10.1016/0014-5793(85)81150-9; Cote HCF, 1997, J BIOL CHEM, V272, P6194, DOI 10.1074/jbc.272.10.6194; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; EATON DL, 1991, J BIOL CHEM, V266, P21833; ENGHILD JJ, 1993, BIOCHEM J, V291, P933, DOI 10.1042/bj2910933; FLEURY V, 1991, BIOCHEMISTRY-US, V30, P7630, DOI 10.1021/bi00244a035; FRANCIS RT, 1986, J BIOL CHEM, V261, P9787; HADA M, 1986, BLOOD, V68, P95; HARPEL PC, 1985, J BIOL CHEM, V260, P4432; HIGGINS DL, 1987, BIOCHEMISTRY-US, V26, P7786, DOI 10.1021/bi00398a038; HORTIN GL, 1988, BIOCHEM BIOPH RES CO, V155, P591, DOI 10.1016/S0006-291X(88)80535-7; ICHINOSE A, 1983, FEBS LETT, V153, P369, DOI 10.1016/0014-5793(83)80645-0; JENSEN PH, 1994, J BIOL CHEM, V269, P15394; KLUFT C, 1984, THROMB RES, V33, P419, DOI 10.1016/0049-3848(84)90081-1; LORAND L, 1991, P NATL ACAD SCI USA, V88, P82, DOI 10.1073/pnas.88.1.82; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; LORAND L, 1968, BIOCHEMISTRY-US, V7, P1214, DOI 10.1021/bi00843a043; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; OZOLS J, 1990, METHOD ENZYMOL, V182, P587; PANNELL R, 1988, J CLIN INVEST, V81, P853, DOI 10.1172/JCI113394; PURVES L, 1987, BIOCHEMISTRY-US, V26, P4640, DOI 10.1021/bi00389a008; REDLITZ A, 1995, J CLIN INVEST, V96, P2534, DOI 10.1172/JCI118315; SAKATA Y, 1980, J CLIN INVEST, V65, P290, DOI 10.1172/JCI109671; SAKATA Y, 1982, J CLIN INVEST, V69, P536, DOI 10.1172/JCI110479; Sakharov DV, 1997, J BIOL CHEM, V272, P14477, DOI 10.1074/jbc.272.22.14477; SKORSTENGAARD K, 1990, FEBS LETT, V262, P269, DOI 10.1016/0014-5793(90)80208-Z; SUNDQVIST B, 1984, BIOMED MASS SPECTROM, V11, P242, DOI 10.1002/bms.1200110509; TAMAKI T, 1982, J BIOL CHEM, V257, P4767; TAN AK, 1995, BIOCHEMISTRY-US, V34, P5811, DOI 10.1021/bi00017a012; TRANTHANG C, 1986, EUR J BIOCHEM, V160, P599, DOI 10.1111/j.1432-1033.1986.tb10080.x; Valnickova Z, 1996, J BIOL CHEM, V271, P12937, DOI 10.1074/jbc.271.22.12937; WIMAN B, 1980, BIOCHEM J, V191, P229, DOI 10.1042/bj1910229	44	99	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27220	27224		10.1074/jbc.273.42.27220	http://dx.doi.org/10.1074/jbc.273.42.27220			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765243	hybrid			2022-12-27	WOS:000076448000030
J	Gu, XJ; Trigatti, B; Xu, SZ; Acton, S; Babitt, J; Krieger, M				Gu, XJ; Trigatti, B; Xu, SZ; Acton, S; Babitt, J; Krieger, M			The efficient cellular uptake of high density lipoprotein lipids via scavenger receptor class B type I requires not only receptor-mediated surface binding but also receptor-specific lipid transfer mediated by its extracellular domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE GLYCOPROTEIN; CHOLESTERYL ESTER TRANSFER; APOLIPOPROTEIN-A-I; SR-BI; SELECTIVE UPTAKE; HEPATIC LIPASE; HDL-RECEPTOR; ADRENAL-CELLS; ANIONIC PHOSPHOLIPIDS; INTRACELLULAR EVENTS	The class B type I scavenger receptor, (SR-BI), is a member of the CD36 superfamily of proteins and is a physiologically relevant, high affinity cell surface high density lipoprotein (HDL) receptor that mediates selective lipid uptake. The mechanism of selective lipid uptake is fundamentally different from that of classic receptor-mediated uptake via coated pits and vesicles (e.g. the low density lipoprotein receptor pathway) in that it involves efficient transfer of the lipids, but not the outer shell proteins, from HDL to cells. The abilities of SR-SI and CD36, both of which are class B scavenger receptors, to bind HDL and mediate cellular uptake of HDL-associated lipid when transiently expressed in COS cells were examined. For these experiments, the binding of HDL to cells was assessed using either I-125- or Alexa (a fluorescent dye)-HDL in which the apolipoproteins on the surface of the HDL particles were covalently modified, Lipid transfer was measured using HDL noncovalently labeled by the fluorescent lipid l,l'-dioctadecyl-3,3,3',3'-tetramethylindoearbocyanine perchlorate. Although both mSR-BI and human CD36 (hCD36) could mediate the binding of HDL in a punctate pattern across the surfaces of cells, only mSR-BI efficiently mediated the transfer of lipid to the cells. Analysis of point mutants established that the major sites of fatty acylation of mSR-BI are Cys(462) and Cys(470) and that fatty acylation is not required for receptor clustering, HDL binding, or efficient lipid transfer. Generation of mSR-BI/hCD36 domain swap chimeras showed that the differences in lipid uptake activities between mSR-BI and hCD36 were not due to differences between their two sets of transmembrane and cytoplasmic domains brit rather result from differences in their large extracellular loop domains. These results shaw that high affinity binding to a cell surface receptor is not sufficient to ensure efficient cellular lipid uptake from HDL. Thus, SR-BI-mediated binding combined with SR-BI-dependent facilitated transfer of lipid from the HDL particle to the cell appears to be the most likely mechanism for the bulk of the selective uptake of cholesteryl esters from HDL to the fiver and steroidogenic tissues.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Krieger, M (corresponding author), MIT, Dept Biol, Rm 68-483, Cambridge, MA 02139 USA.	krieger@mit.edu	Eckhardt, Erik/G-1567-2010; Krieger, Marco/AAE-8611-2020	Trigatti, Bernardo (Dino) L./0000-0002-4556-119X	NHLBI NIH HHS [HL52212, HL41484] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Alessio M, 1996, J BIOL CHEM, V271, P1770, DOI 10.1074/jbc.271.3.1770; ASSMANN G, 1995, METABOLIC MOL BASES, P2053; Azhar S, 1998, J CLIN ENDOCR METAB, V83, P983, DOI 10.1210/jc.83.3.983; AZHAR S, 1989, J LIPID RES, V30, P1799; AZHAR S, 1990, BIOCHIM BIOPHYS ACTA, V1047, P148, DOI 10.1016/0005-2760(90)90041-U; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; BAMBERGER M, 1983, J LIPID RES, V24, P869; Benoist F, 1997, J BIOL CHEM, V272, P23572, DOI 10.1074/jbc.272.38.23572; Calvo D, 1998, J LIPID RES, V39, P777; CALVO D, 1993, J BIOL CHEM, V268, P18929; Calvo D, 1997, ARTERIOSCL THROM VAS, V17, P2341, DOI 10.1161/01.ATV.17.11.2341; Cao GP, 1997, J BIOL CHEM, V272, P33068, DOI 10.1074/jbc.272.52.33068; deFaria E, 1996, J LIPID RES, V37, P197; Dichek HL, 1998, J BIOL CHEM, V273, P1896, DOI 10.1074/jbc.273.4.1896; Dorahy DJ, 1996, BIOCHEM J, V319, P67, DOI 10.1042/bj3190067; EISENBERG S, 1984, J LIPID RES, V25, P1017; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Fielding CJ, 1997, J LIPID RES, V38, P1503; Fluiter K, 1997, BIOCHEM J, V326, P515, DOI 10.1042/bj3260515; Fluiter K, 1998, J BIOL CHEM, V273, P8434, DOI 10.1074/jbc.273.14.8434; Foger B, 1997, J BIOL CHEM, V272, P27393, DOI 10.1074/jbc.272.43.27393; Franc NC, 1996, IMMUNITY, V4, P431, DOI 10.1016/S1074-7613(00)80410-0; Fukasawa M, 1996, EXP CELL RES, V222, P246, DOI 10.1006/excr.1996.0030; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLASS C, 1985, J BIOL CHEM, V260, P744; GLOMSET JA, 1968, J LIPID RES, V9, P155; GOLDBERG DI, 1991, J CLIN INVEST, V87, P331, DOI 10.1172/JCI114991; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GREENWALT DE, 1992, BLOOD, V80, P1105; GWYNNE JT, 1976, P NATL ACAD SCI USA, V73, P4329, DOI 10.1073/pnas.73.12.4329; GWYNNE JT, 1982, ENDOCR REV, V3, P299, DOI 10.1210/edrv-3-3-299; GWYNNE JT, 1989, J BIOL CHEM, V264, P8141; HART K, 1993, J MOL BIOL, V234, P249, DOI 10.1006/jmbi.1993.1580; Hatzopoulos AK, 1998, J LIPID RES, V39, P495; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Ji ZS, 1997, J BIOL CHEM, V272, P31285, DOI 10.1074/jbc.272.50.31285; Jian B, 1998, J BIOL CHEM, V273, P5599, DOI 10.1074/jbc.273.10.5599; Johnson MSC, 1998, ENDOCRINOLOGY, V139, P72, DOI 10.1210/en.139.1.72; Komaromy M, 1996, J BIOL CHEM, V271, P16906, DOI 10.1074/jbc.271.28.16906; KOVANEN PT, 1979, J BIOL CHEM, V254, P5498; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Krieger M, 1998, P NATL ACAD SCI USA, V95, P4077, DOI 10.1073/pnas.95.8.4077; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; LEITERSDORF E, 1984, BIOCHIM BIOPHYS ACTA, V796, P72, DOI 10.1016/0005-2760(84)90240-6; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu JQ, 1997, J CLIN ENDOCR METAB, V82, P2522, DOI 10.1210/jc.82.8.2522; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORRISON JR, 1994, J BIOL CHEM, V269, P13911; MOWRI HO, 1992, J LIPID RES, V33, P1269; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; NICHOLSON AC, 1995, ARTERIOSCL THROM VAS, V15, P269, DOI 10.1161/01.ATV.15.2.269; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; Panzenboeck U, 1997, J LIPID RES, V38, P239; PEARCE SFA, 1994, BLOOD, V84, P384; PIETERS MN, 1994, BBA-MOL BASIS DIS, V1225, P125, DOI 10.1016/0925-4439(94)90069-8; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; Plump AS, 1996, J CLIN INVEST, V97, P2660, DOI 10.1172/JCI118716; Rajapaksha WRAKJS, 1997, MOL CELL ENDOCRINOL, V134, P59, DOI 10.1016/S0303-7207(97)00173-1; REAVEN E, 1995, J LIPID RES, V36, P1602; Reaven E, 1996, J BIOL CHEM, V271, P16208, DOI 10.1074/jbc.271.27.16208; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Rigotti A, 1997, CURR OPIN LIPIDOL, V8, P181, DOI 10.1097/00041433-199706000-00009; RINNINGER F, 1993, BIOCHIM BIOPHYS ACTA, V1166, P275, DOI 10.1016/0005-2760(93)90108-L; RINNINGER F, 1988, J LIPID RES, V29, P1179; RINNINGER F, 1993, BIOCHIM BIOPHYS ACTA, V1166, P284, DOI 10.1016/0005-2760(93)90109-M; Rogers ME, 1997, J BIOL CHEM, V272, P14792, DOI 10.1074/jbc.272.23.14792; ROTHBLAT GH, 1992, J LIPID RES, V33, P1091; Ryeom SW, 1996, J BIOL CHEM, V271, P20536, DOI 10.1074/jbc.271.34.20536; Schorsch F, 1997, FEBS LETT, V414, P507, DOI 10.1016/S0014-5793(97)01061-2; SCHOUTEN D, 1990, ARTERIOSCLEROSIS, V10, P1127, DOI 10.1161/01.ATV.10.6.1127; SPARROW CP, 1990, BIOCHIM BIOPHYS ACTA, V1043, P203, DOI 10.1016/0005-2760(90)90297-B; Tao NB, 1996, J BIOL CHEM, V271, P22315, DOI 10.1074/jbc.271.37.22315; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; Varban ML, 1998, P NATL ACAD SCI USA, V95, P4619, DOI 10.1073/pnas.95.8.4619; VEGA MA, 1991, J BIOL CHEM, V266, P16818; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001; Webb NR, 1998, J BIOL CHEM, V273, P15241, DOI 10.1074/jbc.273.24.15241; Webb NR, 1997, J LIPID RES, V38, P1490; Wyne KL, 1998, J LIPID RES, V39, P518; Xu SZ, 1997, J LIPID RES, V38, P1289; ZANNIS VI, 1993, ADV HUM GENET, V21, P145	88	198	204	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26338	26348		10.1074/jbc.273.41.26338	http://dx.doi.org/10.1074/jbc.273.41.26338			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756864	hybrid			2022-12-27	WOS:000076373300018
J	Huang, LJS; Taylor, SS				Huang, LJS; Taylor, SS			Dissecting cAMP binding domain A in the R-I alpha subunit of cAMP-dependent protein kinase - Distinct subsites for recognition of cAMP and the catalytic subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SUBUNIT; CYCLIC-AMP; HOLOENZYME FORMATION; PREDICTED STRUCTURES; KINETIC MECHANISM; INHIBITOR PROTEIN; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; MUTATIONS; SITES	The two gene-duplicated cAMP binding domains in the regulatory subunits of cAMP dependent protein kinase are each comprised of an A helix, an eight-stranded beta-barrel, and a B and C helix (1). The A domain is required for high affinity binding to C, while the B domain regulates access to the A domain. Using a combination of a yeast two-hybrid screen coupled with deletion analysis, cAMP binding domain A of R-1 was dissected into two structurally and functionally distinct subsites, one that binds cAMP and another that binds the C subunit, The minimum stable subdomain required for binding to C in the 1-3 micromolar range is composed of residues 94-169, while residues 236-244, mapped to the C helix of cAMP binding domain A, were defined as a second surface necessary for high affinity (5-10 nanomolar) binding to C. This portion of the C helix, due to its position directly between the two subsites, serves as a molecular switch for either a cAMP-bound conformation or a C-bound conformation and can thus modulate interactions of cAMP binding domain A with cAMP, with C, and with cAMP binding domain B.	Univ Calif San Diego, Dept Chem & Biochem, Howard Hughes Med Inst, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego	Taylor, SS (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, Howard Hughes Med Inst, 9500 Gilman Dr 0654, La Jolla, CA 92093 USA.	staylor@ucsd.edu			NIGMS NIH HHS [GM34921, 2T32GM07240-21A1] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007240, R01GM034921] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUECHLER YJ, 1991, J BIOL CHEM, V266, P3491; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; Gibson RM, 1997, J BIOL CHEM, V272, P16343, DOI 10.1074/jbc.272.26.16343; Gibson RM, 1997, J BIOL CHEM, V272, P31998, DOI 10.1074/jbc.272.51.31998; Gibson RM, 1997, PROTEIN SCI, V6, P1825, DOI 10.1002/pro.5560060903; GLASS DB, 1989, J BIOL CHEM, V264, P8802; GORMAN KB, 1994, SOMAT CELL MOLEC GEN, V20, P301, DOI 10.1007/BF02254719; Herberg FW, 1996, BIOCHEMISTRY-US, V35, P2934, DOI 10.1021/bi951647c; HERBERG FW, 1993, PROTEIN ENG, V6, P771, DOI 10.1093/protein/6.7.771; HERBERG FW, 1994, BIOCHEMISTRY-US, V33, P7485, DOI 10.1021/bi00189a057; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; JIBUECHLER Y, 1993, J BIOL CHEM, V268, P16495; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MCKNIGHT GS, 1988, RECENT PROG HORM RES, V44, P307; OGREID D, 1981, FEBS LETT, V129, P282, DOI 10.1016/0014-5793(81)80184-6; OGREID D, 1981, FEBS LETT, V129, P287, DOI 10.1016/0014-5793(81)80185-8; ORELLANA SA, 1993, J BIOL CHEM, V268, P6843; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REED J, 1989, BIOCHEM J, V264, P371, DOI 10.1042/bj2640371; RINGHEIM GE, 1990, J BIOL CHEM, V265, P4800; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASWAT LD, 1988, J BIOL CHEM, V263, P18241; SARASWAT LD, 1988, METHOD ENZYMOL, V159, P325; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; Scott SP, 1996, PROTEIN ENG, V9, P333, DOI 10.1093/protein/9.4.333; SHABB JB, 1992, J BIOL CHEM, V267, P5723; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; SYMCOX MM, 1994, J BIOL CHEM, V269, P23025; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Walsh D.A., 2018, PEPT PROT PHOSPH, P43; WEBER IT, 1989, BIOCHEMISTRY-US, V28, P6122, DOI 10.1021/bi00440a059; WEBER IT, 1987, BIOCHEMISTRY-US, V26, P343, DOI 10.1021/bi00376a003; WEBER IT, 1982, P NATL ACAD SCI-BIOL, V79, P7679, DOI 10.1073/pnas.79.24.7679; WEN W, 1994, J BIOL CHEM, V269, P8423; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3693; Wilson JE, 1997, BIOCHEM SOC T, V25, P103, DOI 10.1042/bst0250103; Wu L, 1997, J BIOL CHEM, V272, P6994, DOI 10.1074/jbc.272.11.6994; Zetterqvist O.Z., 1990, PEPTIDES PROTEIN PHO, P171	47	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26739	26746		10.1074/jbc.273.41.26739	http://dx.doi.org/10.1074/jbc.273.41.26739			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756917	hybrid			2022-12-27	WOS:000076373300071
J	Myers, MG; Mendez, R; Shi, P; Pierce, JH; Rhoads, R; White, MF				Myers, MG; Mendez, R; Shi, P; Pierce, JH; Rhoads, R; White, MF			The COOH-terminal tyrosine phosphorylation sites on IRS-1 bind SHP-2 and negatively regulate insulin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC HOMOLOGY-2 DOMAINS; RECEPTOR SUBSTRATE FAMILY; GROWTH-FACTOR-I; PHOSPHATIDYLINOSITOL 3-KINASE; HEMATOPOIETIC-CELLS; PHOSPHOTYROSINE PROTEIN; PHOSPHATASE SHP-2; SH2 DOMAINS; YMXM MOTIFS; SH-PTP2	Activation of tyrosine kinases by numerous growth factor and cytokine receptors leads to tyrosine phosphorylation of the insulin receptor substrate (IRS)-proteins. Tyrosine-phosphorylated motifs on the IRS proteins bind to the SH2 domains in proteins that mediate down-stream signals, including phosphatidylinositol 3'-kinase, GRB-2, and SHP-2. We investigated the function of the two SHP-2 binding COOH-terminal tyrosines of IRS-l by replacing them with phenylalanine (IRS-1(FCT)). IRS-1(FCT) failed to bind SHP-2 or mediate its tyrosine phosphorylation during insulin stimulation. Although several reports suggest a critical role for SHP-2 in insulin stimulated mitogen-activated protein kinase activation and cell proliferation, IRS-1(FCT) mediated these effects normally in 32D cells. indeed, IRS-1(FCT) exhibited increased tyrosine phosphorylation, phosphatidylinositol 3'-kinase binding and activation of protein synthesis in response to insulin. These results suggest that SHP-2 attentuates the phosphorylation and downstream signal transmission of IRS-1 and that the interaction of IRS-1 and SHP-2 is an important regulatory event which attenuates insulin metabolic responses.	Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; NIH, Lab Cell & Mol Biol, Bethesda, MD 20892 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; National Institutes of Health (NIH) - USA	Myers, MG (corresponding author), Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA.	myersmg@joslab.harvard.edu		Mendez, Raul/0000-0002-1952-6905	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043808] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43808] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Carlberg K, 1997, J BIOL CHEM, V272, P15943, DOI 10.1074/jbc.272.25.15943; CASE RD, 1994, J BIOL CHEM, V269, P10467; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Comu S, 1997, J NEUROSCI, V17, P8702; Craddock BL, 1997, J BIOL CHEM, V272, P29281, DOI 10.1074/jbc.272.46.29281; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Gu HH, 1997, J BIOL CHEM, V272, P16421, DOI 10.1074/jbc.272.26.16421; HAUSDORFF SF, 1995, J BIOL CHEM, V270, P12965, DOI 10.1074/jbc.270.22.12965; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; JOVE R, 1986, J VIROL, V60, P849, DOI 10.1128/JVI.60.3.849-857.1986; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KHARITONENKOV A, 1995, J BIOL CHEM, V270, P29189, DOI 10.1074/jbc.270.49.29189; Kim HK, 1998, MOL CELL BIOL, V18, P1525, DOI 10.1128/MCB.18.3.1525; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KUHNE MR, 1994, J BIOL CHEM, V269, P15833; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; Mendez R, 1997, MOL CELL BIOL, V17, P5184, DOI 10.1128/MCB.17.9.5184; Mendez R, 1996, MOL CELL BIOL, V16, P2857; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MYERS MG, 1995, DIABETES, V44, pA49; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; Myers MG, 1996, MOL CELL BIOL, V16, P4147; MYERS MG, 1994, J BIOL CHEM, V269, P28783; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; Noguchi T, 1996, J BIOL CHEM, V271, P27652, DOI 10.1074/jbc.271.44.27652; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; Ochi F, 1997, BIOCHEM BIOPH RES CO, V239, P483, DOI 10.1006/bbrc.1997.7489; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; Perkins LA, 1996, DEV BIOL, V180, P63, DOI 10.1006/dbio.1996.0285; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; PONS S, 1995, MOL CELL BIOL, V15, P4453; Rocchi S, 1996, ENDOCRINOLOGY, V137, P4944, DOI 10.1210/en.137.11.4944; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; Servidei T, 1998, J BIOL CHEM, V273, P6233, DOI 10.1074/jbc.273.11.6233; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P22662; Symes A, 1997, CURR BIOL, V7, P697, DOI 10.1016/S0960-9822(06)00298-3; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WHITE MF, 1991, METHOD ENZYMOL, V201, P65; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, J BIOL CHEM, V270, P17716, DOI 10.1074/jbc.270.30.17716; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; Yenush L, 1996, MOL CELL BIOL, V16, P2509	55	127	129	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26908	26914		10.1074/jbc.273.41.26908	http://dx.doi.org/10.1074/jbc.273.41.26908			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756938	hybrid, Green Submitted			2022-12-27	WOS:000076373300092
J	Thelen, JJ; Muszynski, MG; Miernyk, JA; Randall, DD				Thelen, JJ; Muszynski, MG; Miernyk, JA; Randall, DD			Molecular analysis of two pyruvate dehydrogenase kinases from maize	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASES; PLANT-MITOCHONDRIA; COMPLEX; SEQUENCE; CLONING; FAMILY; PHOSPHORYLATION; EXPRESSION; IMPORT	Two maize cDNAs were isolated and sequenced that had open reading frames with approximately 37% amino acid identity to mammalian pyruvate dehydrogenase kinases. Both maize kinase sequences contain the five domains with conserved signature residues typical of procaryotic two-component histidine kinases. Sequence comparisons identified six other highly conserved motifs that are proposed to be specific to pyruvate dehydrogenase kinases. In addition, specific Trp and Cys residues are also invariant in these sequences. The maize cDNAs are 1332 (PDK1) and 1602 (PDK2) nucleotides in length, encoding polypeptides with calculated molecular masses of 38,867 and 41,327 Da that share 77% amino acid identity, Reverse transcriptase-polymerase chain reaction analysis with oligonucleotide-specific primers revealed a differential expression pattern for the two isoforms, PDK1 and PDK2 were expressed in Escherichia coli with N-terminal His(6) tags to facilitate purification. The recombinant proteins migrated at 44 and 48 kDa, respectively, during SDS-polyacrylamide gel electrophoresis. Anti-PDK1 antibodies immunoprecipitated 75% of pyruvate dehydrogenase kinase activity from a maize mitochondrial matrix fraction, and recognized a matrix protein of 43 kDa. Recombinant PDK2, expressed as a fusion with the maltose-binding protein, inactivated kinase-depleted maize pyruvate dehydrogenase complex when incubated with MgATP, coincident with incorporation of P-32 from [gamma-P-32]ATP into the alpha subunit of pyruvate dehydrogenase.	Univ Missouri, Dept Biochem, Columbia, MO 65211 USA; Univ Missouri, Dept Sci Biol, Columbia, MO 65211 USA; Pioneer Hi Bred Int Inc, Johnston, IA 50131 USA; USDA, Mycotoxin Res Unit, NCAUR, Peoria, IL 61604 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; DuPont; Pioneer Hi-Bred International, Inc.; United States Department of Agriculture (USDA)	Randall, DD (corresponding author), Univ Missouri, Dept Biochem, 117 Schweitzer Hall, Columbia, MO 65211 USA.	behemdr@showme.missouri.edu	Muszynski, Michael G./L-2843-2016	Muszynski, Michael G./0000-0002-0817-7594; Thelen, Jay/0000-0001-5995-1562				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMEMURA M, 1990, J BACTERIOL, V172, P6300, DOI 10.1128/jb.172.11.6300-6307.1990; BUDDE RJA, 1990, P NATL ACAD SCI USA, V87, P673, DOI 10.1073/pnas.87.2.673; CAMP PJ, 1985, PLANT PHYSIOL, V77, P571, DOI 10.1104/pp.77.3.571; GEMEL J, 1992, PLANT PHYSIOL, V100, P908, DOI 10.1104/pp.100.2.908; GUDI R, 1995, J BIOL CHEM, V270, P28989, DOI 10.1074/jbc.270.48.28989; HARRIS RA, 1995, ADV ENZYME REGUL, V35, P147, DOI 10.1016/0065-2571(94)00020-4; Katsube T, 1997, DNA CELL BIOL, V16, P335, DOI 10.1089/dna.1997.16.335; Luethy MH, 1996, ALPHA KETO ACID DEHY, P71; MOORE AL, 1994, ANNU REV PLANT PHYS, V45, P545, DOI 10.1146/annurev.pp.45.060194.002553; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; Popov K M, 1991, Protein Expr Purif, V2, P278, DOI 10.1016/1046-5928(91)90084-V; POPOV KM, 1992, J BIOL CHEM, V267, P13127; POPOV KM, 1993, J BIOL CHEM, V268, P26602; POPOV KM, 1994, J BIOL CHEM, V269, P29720; Randall D. D., 1996, V39, P87; REED LJ, 1974, ACCOUNTS CHEM RES, V7, P40, DOI 10.1021/ar50074a002; Rowles J, 1996, J BIOL CHEM, V271, P22376, DOI 10.1074/jbc.271.37.22376; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHULLER KA, 1993, PLANT PHYSIOL, V102, P139, DOI 10.1104/pp.102.1.139; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; Thelen JJ, 1998, PLANT PHYSIOL, V116, P1443, DOI 10.1104/pp.116.4.1443; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; Whelan J, 1997, PLANT MOL BIOL, V33, P771, DOI 10.1023/A:1005755505738; WILLIAMS M, 1979, PLANT PHYSIOL, V64, P1099, DOI 10.1104/pp.64.6.1099; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	26	37	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26618	26623		10.1074/jbc.273.41.26618	http://dx.doi.org/10.1074/jbc.273.41.26618			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756901	hybrid			2022-12-27	WOS:000076373300055
J	Fukushima, A; Okuda, A; Nishimoto, M; Seki, N; Hori, TA; Muramatsu, M				Fukushima, A; Okuda, A; Nishimoto, M; Seki, N; Hori, TA; Muramatsu, M			Characterization of functional domains of an embryonic stem cell coactivator UTF1 which are conserved and essential for potentiation of ATF-2 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR DEVELOPMENTAL TRANSITION; EARLY XENOPUS-EMBRYOS; EARLY MOUSE EMBRYOS; TRANSCRIPTION FACTOR; CARCINOMA-CELLS; DNA-BINDING; POU-DOMAIN; GLUCOCORTICOID RECEPTOR; TERATOCARCINOMA CELLS; NEGATIVE REGULATION	We have recently cloned a cDNA encoding an embryonic stem cell transcriptional coactivator termed UTF1 from the mouse F9 teratocarcinoma cell line (Okuda, A, Fukushima, A., Nishimoto, M, Orimo, A., Yamagishi, T., Nabeshima, Y., Kuro-o, M., Nabeshima, Y., Boon, a, Keaveney, M., Stunnenberg, H.G., and Muramatsu, M. (1998) EMBO J. 17, 2019-2032). Here we have cloned a cDNA for human UTF1 and identified two highly conserved domains termed conserved domain (CD)1 and CD2. Human UTF1, like that of mouse, binds to ATF-2 and the mutagenesis analyses reveal that the leucine zipper motif within the CD2 of the UTF1 and metal binding motif of ATF-2 are involved in this interaction. The factor also binds to TATA-binding protein containing complex. By means of immunoprecipitation analysis, we mapped two domains which are independently able to bind to the complex. Importantly, both domains are located within the conserved domains (one in CD1 and the other in CD2). Furthermore, transient transfection analyses point out the importance of these domains for activating ATF-2. Thus, these results suggest that these two conserved domains identified here play important roles in activating specific transcription at least in part by supporting physical interaction between the upstream factor, ATF-2, and basal transcription machinery.	Saitama Med Sch, Dept Biochem, Moroyama, Saitama 3500495, Japan; Kazusa DNA Res Inst, Lab Gene Struct 1, Chiba 292, Japan; Natl Inst Radiol Sci, Div Genet, Inage Ku, Chiba 263, Japan	Saitama Medical University; Kazusa DNA Research Institute; National Institutes for Quantum Science & Technology	Muramatsu, M (corresponding author), Saitama Med Sch, Dept Biochem, 38 Morohongo, Moroyama, Saitama 3500495, Japan.	muramasa@saitama-med.ac.jp						BRINSTER RL, 1974, J EXP MED, V140, P1049, DOI 10.1084/jem.140.4.1049; Cheng XB, 1997, MOL CELL BIOL, V17, P1407, DOI 10.1128/MCB.17.3.1407; COLBERGPOLEY AM, 1985, NATURE, V314, P713, DOI 10.1038/314713a0; COMAI L, 1994, SCIENCE, V266, P1966, DOI 10.1126/science.7801123; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; Gilbert SF, 1991, DEV BIOL; GORMAN CM, 1985, CELL, V42, P519, DOI 10.1016/0092-8674(85)90109-6; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HASEGAWA T, 1990, DIFFERENTIATION, V42, P191, DOI 10.1111/j.1432-0436.1990.tb00761.x; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; Hogan B, 1994, MANIPULATING MOUSE E; HORI T, 1990, HUM GENET, V85, P576; HOSLER BA, 1989, MOL CELL BIOL, V9, P5623, DOI 10.1128/MCB.9.12.5623; IMPERIALE MJ, 1984, MOL CELL BIOL, V4, P867, DOI 10.1128/MCB.4.5.867; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MARTIN GR, 1975, CELL, V6, P467, DOI 10.1016/0092-8674(75)90035-5; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MEIJER D, 1990, NUCLEIC ACIDS RES, V9, P2241; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MINTZ B, 1975, P NATL ACAD SCI USA, V72, P3585, DOI 10.1073/pnas.72.9.3585; MONUKI ES, 1989, NEURON, V3, P783, DOI 10.1016/0896-6273(89)90247-X; MURPHY SP, 1988, P NATL ACAD SCI USA, V85, P5587, DOI 10.1073/pnas.85.15.5587; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; Okuda A, 1998, EMBO J, V17, P2019, DOI 10.1093/emboj/17.7.2019; OKUDA A, 1987, J BIOL CHEM, V262, P3858; PAPAIOANNOU VE, 1975, NATURE, V258, P70, DOI 10.1038/258070a0; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; Schubart DB, 1996, NUCLEIC ACIDS RES, V24, P1913, DOI 10.1093/nar/24.10.1913; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WILSON AC, 1977, ANNU REV BIOCHEM, V46, P573, DOI 10.1146/annurev.bi.46.070177.003041; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; Yang XH, 1997, BIOCHEM BIOPH RES CO, V232, P336, DOI 10.1006/bbrc.1997.6284; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635	45	28	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25840	25849		10.1074/jbc.273.40.25840	http://dx.doi.org/10.1074/jbc.273.40.25840			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748258	hybrid			2022-12-27	WOS:000076263100049
J	Horowitz, A; Simons, M				Horowitz, A; Simons, M			Phosphorylation of the cytoplasmic tail of syndecan-4 regulates activation of protein kinase C alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; IDENTIFICATION; SEQUENCE; BINDING; DOMAINS	Syndecans are transmembrane proteoglycans capable of carrying both heparan and chondroitin sulfate chains. The cytoplasmic tail of syndecan-4 was recently reported to undergo in vivo phosphorylation on Ser(183) in the membrane-proximal part of the tail (Horowitz, A., and Simons, M. (1998) J. Biol. Chem. 273, 10914-10918). However, the functional consequences of this event remain unknown. The cytoplasmic tail of syndecan-4 is known to undergo multimerization and to activate protein kinase C alpha (PKC alpha), with both events depending on the presence of the commonly occurring phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2). In the present investigation we found that phosphorylation of Ser(183) produced a 10-fold reduction in the ability of syndecan-4 to activate PKC alpha, without affecting its ability to bind the PKC. Because Ser(183) is adjacent to positively charged lysine groups that resemble PIP2-binding regions in several other proteins, phosphorylation of this serine may affect the binding affinity of the syndecan-4 cytoplasmic tail to PIP2. We found that the Ser(183)-phosphorylated cytoplasmic tail of syndecan-4 has indeed a significantly lower affinity to PIP2 compared with the nonphosphorylated tail. Furthermore, Ser(183) phosphorylation abolished PIP2-dependent oligomerization of syndecan-4 cytoplasmic tails. We conclude that Ser(183) phosphorylation regulates syndecan-4-dependent activation of PKC alpha by reducing the affinity to PIP2 and inhibiting the oligomerization of syndecan-4 cytoplasmic tails. These results further support the role of syndecan-4 in signal transduction in endothelial cells.	Harvard Univ, Sch Med, Dept Med,Beth Israel Deaconess Med Ctr, Cardiovasc Div,Angiogenesis Res Ctr, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Simons, M (corresponding author), Harvard Univ, Sch Med, Depr Med,Beth Israel Deaconess Med Ctr, Cardiovasc Div,Angiogenesis Res Ctr, 330 Brookline Ave, Boston, MA 02215 USA.		Simons, Michael/G-8553-2014; Horowitz, Arie/AAT-9482-2021; Horowitz, Arie/F-4628-2015	Simons, Michael/0000-0003-0348-7734; Horowitz, Arie/0000-0001-6239-1287	NHLBI NIH HHS [P50 HL56993, HL07374, R01 HL53793] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053793, P50HL056993, T32HL007374] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACIU PC, 1995, MOL BIOL CELL, V6, P1503, DOI 10.1091/mbc.6.11.1503; DEAGOSTINI AI, 1990, J CELL BIOL, V111, P1293, DOI 10.1083/jcb.111.3.1293; Fukami K, 1996, J BIOL CHEM, V271, P2646, DOI 10.1074/jbc.271.5.2646; Glaser M, 1996, J BIOL CHEM, V271, P26187, DOI 10.1074/jbc.271.42.26187; HAARER BK, 1993, MOL CELL BIOL, V13, P7864, DOI 10.1128/MCB.13.12.7864; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Horowitz A, 1998, J BIOL CHEM, V273, P10914, DOI 10.1074/jbc.273.18.10914; Kinnunen T, 1998, J BIOL CHEM, V273, P10702, DOI 10.1074/jbc.273.17.10702; Lee D, 1998, J BIOL CHEM, V273, P13022, DOI 10.1074/jbc.273.21.13022; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Oh ES, 1997, J BIOL CHEM, V272, P11805, DOI 10.1074/jbc.272.18.11805; Oh ES, 1998, J BIOL CHEM, V273, P10624, DOI 10.1074/jbc.273.17.10624; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; SHWORAK NW, 1994, J BIOL CHEM, V269, P21204; YU FX, 1992, J BIOL CHEM, V267, P14616	16	104	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25548	25551		10.1074/jbc.273.40.25548	http://dx.doi.org/10.1074/jbc.273.40.25548			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748216	hybrid			2022-12-27	WOS:000076263100007
J	Dumin, J; Wilcox, BD; Otterness, I; Melendez, JA; Huang, CC; Jeffrey, JJ				Dumin, J; Wilcox, BD; Otterness, I; Melendez, JA; Huang, CC; Jeffrey, JJ			Serotonin-mediated production of interstitial collagenase by uterine smooth muscle cells requires inerleukin-1 alpha, but not interleukin-1 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; EPITHELIAL-CELLS; CLONING; CULTURES; PURIFICATION; ENDOMETRIUM; PARACRINE; STEROIDS; SEQUENCE; ENZYME	The activation of the gene for interstitial collagenase in myometrial smooth muscle cells is absolutely dependent upon the presence of serotonin. Our previous studies investigating the mechanisms of this induction demonstrated that the mRNAs of both interleukin-1 (IL-1) isoforms, IL-1 alpha and IL-1 beta, are induced by serotonin and that the induction of IL-1 is required for the subsequent induction of collagenase. These data provided compelling evidence that serotonin-induced IL-1 acts via an autocrine loop in activating the collagenase gene. The experiments described here were designed to examine the potential role of each IL-1 isoform in collagenase production by using neutralizing antisera specific to each isoform of the cytokine, The antisera were examined for their ability to inhibit the serotonin-dependent production of the mRNA for collagenase and of the cytokines themselves. Neutralizing antiserum against IL-1 alpha, but not against IL-1 beta, inhibited the induction of the mRNA for collagenase and of the mRNAs for both IL-1 alpha and IL-1 beta, Western analysis indicated that detectable levels of IL-1 alpha protein, but not that of IL-1 beta, are produced at the time of serotonin-dependent collagenase induction. In contrast, significant levels of IL-1 beta protein are detected only when bacterial lipopolysaccharide is added to the cells. Taken together, the results of our study indicate that IL-1 alpha, but not IL-1 beta, plays an obligatory role in multiple serotonin-mediated gene regulations in the myometrial smooth muscle cell. In addition, the data suggest that IL-1 beta production has the potential for modifying myometrial function in pathological settings, particularly that of uterine infection.	Albany Med Coll, Dept Biochem & Mol Biol, Albany, NY 12208 USA; Pfizer Inc, Cent Res, Groton, CT 06340 USA	Albany Medical College; Pfizer	Jeffrey, JJ (corresponding author), Albany Med Coll, Dept Biochem & Mol Biol, 47 New Scotland Rd, Albany, NY 12208 USA.			Melendez, Juan/0000-0001-8021-3097	NCI NIH HHS [CA77068] Funding Source: Medline; NICHD NIH HHS [HD32585, HD05291] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD005291, R01HD032585, R37HD005291] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BLAIR HC, 1986, J CELL PHYSIOL, V129, P111, DOI 10.1002/jcp.1041290116; DAVIS LG, 1986, BASIC METHODS MOL BI, P143; DIGIOVINE FS, 1990, IMMUNOL TODAY, V11, P13; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI 10.1016/S0065-2776(08)60642-2; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; FINI ME, 1994, J BIOL CHEM, V269, P11291; GRAY PW, 1986, J IMMUNOL, V137, P3644; HALME J, 1980, ARCH BIOCHEM BIOPHYS, V199, P51, DOI 10.1016/0003-9861(80)90255-6; HARKNESS RD, 1956, J PHYSIOL-LONDON, V132, P502, DOI 10.1113/jphysiol.1956.sp005543; JEFFREY JJ, 1990, J CELL PHYSIOL, V143, P396, DOI 10.1002/jcp.1041430226; JEFFREY JJ, 1991, J CELL PHYSIOL, V146, P399, DOI 10.1002/jcp.1041460310; LISAK RP, 1994, J NEUROIMMUNOL, V55, P171, DOI 10.1016/0165-5728(94)90007-8; LOMEDICO PT, 1984, NATURE, V312, P458, DOI 10.1038/312458a0; LONG NC, 1990, AM J PHYSIOL, V259, pR74; LONG NC, 1989, THERMOREGULATION RES, P78; LOPPNOW H, 1992, EXP CELL RES, V198, P283, DOI 10.1016/0014-4827(92)90381-H; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; NAGAI Y, 1966, BIOCHEMISTRY-US, V10, P988; PATEL JA, 1995, AM J RESP CELL MOL, V13, P602, DOI 10.1165/ajrcmb.13.5.7576697; QUINN CO, 1990, J BIOL CHEM, V265, P22342; ROSWIT WT, 1983, ARCH BIOCHEM BIOPHYS, V225, P285, DOI 10.1016/0003-9861(83)90032-2; RYDELEKFITZGERALD L, 1993, MOL CELL ENDOCRINOL, V91, P67, DOI 10.1016/0303-7207(93)90256-J; SCHATZ F, 1983, ENDOCRINOLOGY, V113, P1274, DOI 10.1210/endo-113-4-1274; Singer CF, 1997, P NATL ACAD SCI USA, V94, P10341, DOI 10.1073/pnas.94.19.10341; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STRICKLIN GP, 1977, BIOCHEMISTRY-US, V16, P1607, DOI 10.1021/bi00627a013; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WARNER SJC, 1987, J EXP MED, V165, P1316, DOI 10.1084/jem.165.5.1316; WARNER SJC, 1987, J IMMUNOL, V139, P1911; WESTMAYS JA, 1995, P NATL ACAD SCI USA, V92, P6768, DOI 10.1073/pnas.92.15.6768; WILCOX BD, 1994, J BIOL CHEM, V269, P29658; WILCOX BD, 1992, J BIOL CHEM, V267, P20752	33	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25488	25494		10.1074/jbc.273.39.25488	http://dx.doi.org/10.1074/jbc.273.39.25488			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738019	hybrid			2022-12-27	WOS:000076085400069
J	Lu, AL; Fawcett, WP				Lu, AL; Fawcett, WP			Characterization of the recombinant MutY homolog, an adenine DNA glycosylase, from yeast Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI MUTY; ENZYME ENDONUCLEASE-III; CATALYTIC MECHANISM; MISMATCH REPAIR; BASE-PAIR; 8-HYDROXYGUANINE 7,8-DIHYDRO-8-OXOGUANINE; MUTAGENIC SUBSTRATE; IONIZING-RADIATION; OXIDATIVE DAMAGE; EXCISION-REPAIR	The mutY homolog (SpMYH) gene from a cDNA library of Schizosaccharomyces pombe encodes a protein of 461 amino acids that displays 28 and 31% identity to Escherichia coli MutY and human MutY homolog (MYH), respectively. Expressed SpMYH is able to complement an E. coli mutY mutant to reduce the mutation rate. Similar to E. coli MutY protein, purified recombinant SpMYH expressed in E. coli has adenine DNA glycosylase and apurinic/apyrimidinic lyase activities on A/G- and A/7,8-dihydro-8-oxoguanine (8-oxoG)-containing DNA. However, both enzymes have different salt requirements and slightly different substrate specificities. SpMYH has greater glycosylase activity on 2-aminopurine/G and A/2-aminopurine but weaker activity on A/C than E. coli MutY. Both enzymes also have different substrate binding affinity and catalytic parameters. Although SpMYH has great affinity to A/8-oxoG-containing DNA as MutY, the binding affinity to A/G-containing DNA is substantially lower for SpMYH than MutY, SpMYH has similar reactivity to both A/G- and A/8-oxoG-containing DNA; however, MutY cleaves A/G-containing DNA about 3-fold more efficiently than it does A/8-oxoG-containing DNA. Thus, SpMYH is the functional eukaryotic MutY homolog responsible for reduction of 8-oxoG mutational effect.	Univ Maryland, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Lu, AL (corresponding author), Univ Maryland, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA.	aluchang@umaryland.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035132] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35132] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aburatani H, 1997, CANCER RES, V57, P2151; AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J; AU KG, 1988, P NATL ACAD SCI USA, V85, P9163, DOI 10.1073/pnas.85.23.9163; BESSHO T, 1993, J BIOL CHEM, V268, P19416; BOITEUX S, 1984, NUCLEIC ACIDS RES, V12, P549; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN T, 1990, J MOL BIOL, V212, P437, DOI 10.1016/0022-2836(90)90320-L; BROWN T, 1986, P NATL ACAD SCI USA, V83, P2402, DOI 10.1073/pnas.83.8.2402; CARBONNAUX C, 1991, BIOCHEMISTRY-US, V30, P5449, DOI 10.1021/bi00236a018; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHETSANGA CJ, 1979, NUCLEIC ACIDS RES, V6, P3673, DOI 10.1093/nar/6.11.3673; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DODSON ML, 1993, BIOCHEMISTRY-US, V32, P8284, DOI 10.1021/bi00083a032; DODSON ML, 1994, J BIOL CHEM, V269, P32709; FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533; GAO XL, 1988, J AM CHEM SOC, V110, P5178, DOI 10.1021/ja00223a045; Gogos A, 1996, BIOCHEMISTRY-US, V35, P16665, DOI 10.1021/bi960843w; HALLIWELL B, 1989, FREE RADICLAS BIOL M; HATAHET Z, 1994, J BIOL CHEM, V269, P18814; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P1403, DOI 10.1021/bi00219a034; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; Labahn J, 1996, CELL, V86, P321, DOI 10.1016/S0092-8674(00)80103-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; Lu AL, 1996, J BIOL CHEM, V271, P24138, DOI 10.1074/jbc.271.39.24138; LU AL, 1995, J BIOL CHEM, V270, P23582, DOI 10.1074/jbc.270.40.23582; LU AL, 1988, GENETICS, V118, P593; LU AL, 1988, CELL, V54, P805, DOI 10.1016/S0092-8674(88)91109-9; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MARGISON GP, 1981, P NATL ACAD SCI-BIOL, V78, P861, DOI 10.1073/pnas.78.2.861; MCGOLDRICK JP, 1995, MOL CELL BIOL, V15, P989; MICHAELS ML, 1990, NUCLEIC ACIDS RES, V18, P3841, DOI 10.1093/nar/18.13.3841; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Nash HM, 1997, CHEM BIOL, V4, P693, DOI 10.1016/S1074-5521(97)90225-8; NOELLING J, 1992, NUCLEIC ACIDS RES, V20, P6501, DOI 10.1093/NAR/20.24.6501; RADICELLA JP, 1988, P NATL ACAD SCI USA, V85, P9674, DOI 10.1073/pnas.85.24.9674; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; Slupska MM, 1996, J BACTERIOL, V178, P3885, DOI 10.1128/jb.178.13.3885-3892.1996; SU SS, 1988, J BIOL CHEM, V263, P6829; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; TCHOU J, 1993, MUTAT RES, V299, P277, DOI 10.1016/0165-1218(93)90104-L; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; TSAIWU JJ, 1992, P NATL ACAD SCI USA, V89, P8779, DOI 10.1073/pnas.89.18.8779; TSAIWU JYYJ, 1991, J BACTERIOL, V173, P1902, DOI 10.1128/jb.173.6.1902-1910.1991; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; Yamagata Y, 1996, CELL, V86, P311, DOI 10.1016/S0092-8674(00)80102-6; YEH YC, 1991, J BIOL CHEM, V266, P6480	57	69	71	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25098	25105		10.1074/jbc.273.39.25098	http://dx.doi.org/10.1074/jbc.273.39.25098			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737967	hybrid			2022-12-27	WOS:000076085400017
J	Bowman, EP; Campbell, JJ; Druey, KM; Scheschonka, A; Kehrl, JH; Butcher, EC				Bowman, EP; Campbell, JJ; Druey, KM; Scheschonka, A; Kehrl, JH; Butcher, EC			Regulation of chemotactic and proadhesive responses to chemoattractant receptors by RGS (Regulator of G-protein Signaling) family members	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; FORMYL PEPTIDE RECEPTOR; FUNCTIONAL EXPRESSION; CHEMOKINE RECEPTORS; LEUKOCYTE ADHESION; COUPLED RECEPTORS; TRANSITION-STATE; GENE-EXPRESSION; ALPHA-SUBUNITS; LYMPHOID-CELLS	Serpentine G alpha(i)-linked receptors support rapid adhesion and directed migration of leukocytes and other cell types. The intracellular mechanisms mediating and regulating chemoattractant-directed adhesion and locomotion are only now beginning to be explored. RGS (for regulator of G-protein signaling) proteins are a recently described family that regulate G alpha(i)-stimulated pathways by acting as GTPase-activating proteins. Little is known about the GTPase activity of the G alpha(i) proteins involved in adhesion and chemotaxis, or the significance of their regulation to these responses. Using transiently transfected lymphoid cells as a model system, we show that expression of RGS1, RGS3, and RGS4 inhibits chemoattractant-induced migration. In contrast, RGS2, a regulator of G alpha(q) activity, had no effect on cell migration to any chemoattractant. RGS1, RGS3, and RGS4 also reduced rapid chemoattractant-triggered adhesion, although the proadhesive response appears quantitatively less sensitive to RGS action than chemotaxis, The results suggest that the duration of the G alpha(i) signal may be a particularly important parameter in the chemotactic responses of leukocytes, and demonstrate the potential for RGS family members to regulate cellular adhesive and migratory behaviors.	Stanford Univ, Sch Med, Dept Pathol, Lab Immunol & Vasc Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Ctr Digest Dis, Dept Med, Stanford, CA 94305 USA; Dept Vet Affairs, Palo Alto Hlth Care Syst, Foothill Res Ctr, Ctr Mol Biol & Med, Palo Alto, CA 94305 USA; NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA	Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Butcher, EC (corresponding author), Stanford Univ, Sch Med, Dept Pathol, Lab Immunol & Vasc Biol, Stanford, CA 94305 USA.		Kehrl, John/AAE-6292-2019	Kehrl, John/0000-0002-6526-159X; Campbell, James/0000-0003-4252-5182	NCI NIH HHS [5T32CA090302] Funding Source: Medline; NIDDK NIH HHS [DK38707] Funding Source: Medline; NIGMS NIH HHS [GM56527] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056527] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arai H, 1997, P NATL ACAD SCI USA, V94, P14495, DOI 10.1073/pnas.94.26.14495; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BARGATZE RF, 1987, J EXP MED, V166, P1125, DOI 10.1084/jem.166.4.1125; BARGATZE RF, 1993, J EXP MED, V178, P367, DOI 10.1084/jem.178.1.367; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BOULAY F, 1991, BIOCHEMISTRY-US, V30, P2993, DOI 10.1021/bi00226a002; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Campbell JJ, 1996, J CELL BIOL, V134, P255, DOI 10.1083/jcb.134.1.255; Campbell JJ, 1997, EUR J IMMUNOL, V27, P2571, DOI 10.1002/eji.1830271016; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; Chen CH, 1997, J BIOL CHEM, V272, P8679, DOI 10.1074/jbc.272.13.8679; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Druey KM, 1997, P NATL ACAD SCI USA, V94, P12851, DOI 10.1073/pnas.94.24.12851; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; Foxman EF, 1997, J CELL BIOL, V139, P1349, DOI 10.1083/jcb.139.5.1349; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; Grant KR, 1997, IMMUNOLOGY, V90, P564, DOI 10.1046/j.1365-2567.1997.00196.x; Hall AL, 1997, J LEUKOCYTE BIOL, V62, P535, DOI 10.1002/jlb.62.4.535; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HONDA S, 1994, J IMMUNOL, V152, P4026; HONG JX, 1993, J IMMUNOL, V150, P3895; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Kitayama J, 1997, J IMMUNOL, V158, P2340; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; Mackay CR, 1996, J EXP MED, V184, P799, DOI 10.1084/jem.184.3.799; MATSUOKA M, 1993, AM J MED SCI, V306, P89, DOI 10.1097/00000441-199308000-00004; MURPHY JJ, 1990, BIOCHIM BIOPHYS ACTA, V1049, P261; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Natochin M, 1997, J BIOL CHEM, V272, P17444, DOI 10.1074/jbc.272.28.17444; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Neill JD, 1997, ENDOCRINOLOGY, V138, P843, DOI 10.1210/en.138.2.843; Neptune ER, 1997, P NATL ACAD SCI USA, V94, P14489, DOI 10.1073/pnas.94.26.14489; PALERMO DP, 1991, J BIOTECHNOL, V19, P35, DOI 10.1016/0168-1656(91)90073-5; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; Sabroe I, 1997, J IMMUNOL, V158, P1361; Sagoo MS, 1997, NATURE, V389, P392, DOI 10.1038/38750; Saitoh O, 1997, NATURE, V390, P525, DOI 10.1038/37385; SIDEROVSKI DP, 1994, DNA CELL BIOL, V13, P125, DOI 10.1089/dna.1994.13.125; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; TAKAI Y, 1993, CIBA F SYMP, V176, P128; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; WALTZ A, 1987, BIOCHEM BIOPH RES CO, V149, P755; Wang J, 1997, J BIOL CHEM, V272, P5732, DOI 10.1074/jbc.272.9.5732; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Wieland T, 1997, J BIOL CHEM, V272, P8853; WITTE ON, 1978, P NATL ACAD SCI USA, V75, P2488, DOI 10.1073/pnas.75.5.2488; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233; YOSHIMURA T, 1989, J IMMUNOL, V142, P1956; Yu JH, 1996, EMBO J, V15, P5184, DOI 10.1002/j.1460-2075.1996.tb00903.x	63	108	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28040	28048		10.1074/jbc.273.43.28040	http://dx.doi.org/10.1074/jbc.273.43.28040			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774420	hybrid			2022-12-27	WOS:000076549800040
J	Talla, E; de Mendonca, RL; Degand, I; Goffeau, A; Ghislain, M				Talla, E; de Mendonca, RL; Degand, I; Goffeau, A; Ghislain, M			Schistosoma mansoni Ca2+-ATPase SMA2 restores viability to yeast Ca2+-ATPase-deficient strains and functions in calcineurin-mediated Ca2+ tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE H+-ATPASE; PLASMA-MEMBRANE; SARCOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; CA-2+ PUMP; CALCIUM PUMPS; SARCO/ENDOPLASMIC RETICULUM; CHROMOSOMAL LOCALIZATION; TISSUE DISTRIBUTION	The sarco(endo)plasmic reticulum of animal cells contains an ATP-powered Ca2+ pump that belongs to the P-type family of membrane-bound cation-translocating enzymes. In Schistosoma mansoni, the sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) is encoded by the SMA1 and SMA2 genes. A full-length SMA2 cDNA clone was isolated, sequenced, and expressed into a yeast Ca2+-ATPase-deficient strain requiring plasmid-borne rabbit SERCA1a for viability. The S. mansoni Ca2+-ATPase supports growth of mutant cells lacking SERCA1a, indicating functional expression in yeast and a role in calcium sequestration. Subcellular fractionation showed that the SMA2 ATPase is localized in yeast internal membranes. SMA2 expression was found to be associated with thapsigargin-sensitive, Ca2+-dependent ATPase activity. The activity increased 2-fold upon calcineurin inactivation, which correlates with in vivo stimulated contribution of SMA2 in calcium tolerance. These results suggest that calcineurin controls calcium homeostasis by inhibiting Ca2+-ATPase activity in an internal compartment.	Catholic Univ Louvain, Unite Biochim Physiol, B-1348 Louvain, Belgium	Universite Catholique Louvain	Ghislain, M (corresponding author), Catholic Univ Louvain, Unite Biochim Physiol, Pl Croix Sud 2-20, B-1348 Louvain, Belgium.	ghislain@fysa.ucl.ac.be		TALLA, Emmanuel/0000-0002-7775-8296				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; APERIA A, 1992, P NATL ACAD SCI USA, V89, P7394, DOI 10.1073/pnas.89.16.7394; Ausubel F.M., 1989, CURRENT PROTOCOLS MO, V2; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BURK SE, 1989, J BIOL CHEM, V264, P18561; CAPIEAUX E, 1989, J BIOL CHEM, V264, P7437; CAPIEAUX E, 1993, J BIOL CHEM, V268, P21895; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CENTENO F, 1994, FEBS LETT, V354, P117, DOI 10.1016/0014-5793(94)01104-4; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CIOLI D, 1995, PHARMACOL THERAPEUT, V68, P35, DOI 10.1016/0163-7258(95)00026-7; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CUNHA VM, 1997, LIFE SCI, V60, P289; CUNHA VMN, 1992, MOL BIOCHEM PARASIT, V52, P167, DOI 10.1016/0166-6851(92)90049-P; CUNHA VMN, 1988, FEBS LETT, V241, P65, DOI 10.1016/0014-5793(88)81032-9; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; DAVIES TW, 1983, PARASITOLOGY, V87, P55, DOI 10.1017/S0031182000052410; DEMEIS L, 1981, TRANSPORT LIFE SCI, V2, P1; DEMENDONCA RL, 1995, MOL BIOCHEM PARASIT, V72, P129, DOI 10.1016/0166-6851(95)00078-F; DEXAERDE AD, 1995, J BIOL CHEM, V270, P23828, DOI 10.1074/jbc.270.40.23828; Dode L, 1996, BIOCHEM J, V318, P689, DOI 10.1042/bj3180689; Dode L, 1998, J BIOL CHEM, V273, P13982, DOI 10.1074/jbc.273.22.13982; ENOUF J, 1988, J BIOL CHEM, V263, P13922; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FALLON PG, 1994, PARASITOL RES, V80, P623, DOI 10.1007/BF00933013; FILOTEO AG, 1987, J BIOL CHEM, V262, P6526; FOLETTI D, 1995, FASEB J, V9, P670, DOI 10.1096/fasebj.9.8.7768360; FOOR F, 1992, NATURE, V360, P682; GOFFEAU A, 1988, METHOD ENZYMOL, V157, P528; GUNTESKIHAMBLIN AM, 1992, BIOCHEMISTRY-US, V31, P7600, DOI 10.1021/bi00148a023; HAMILTON BA, 1991, NUCLEIC ACIDS RES, V19, P1951, DOI 10.1093/nar/19.8.1951; JAMES P, 1988, J BIOL CHEM, V263, P2905; KNIGHT M, 1984, EMBO J, V3, P213, DOI 10.1002/j.1460-2075.1984.tb01786.x; LIMA SF, 1994, PARASITOLOGY, V109, P57, DOI 10.1017/S0031182000077763; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYTTON J, 1992, J BIOL CHEM, V267, P14483; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; MAGYAR A, 1990, BIOCHEM BIOPH RES CO, V173, P872, DOI 10.1016/S0006-291X(05)80867-8; Mair GR, 1998, PARASITOL TODAY, V14, P73, DOI 10.1016/S0169-4758(97)01182-4; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; NECHAY BR, 1980, J PARASITOL, V66, P596, DOI 10.2307/3280515; PALMERO I, 1989, J MOL BIOL, V210, P737, DOI 10.1016/0022-2836(89)90106-X; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; Pozos TC, 1996, MOL CELL BIOL, V16, P3730; Redman CA, 1996, PARASITOL TODAY, V12, P14, DOI 10.1016/0169-4758(96)80640-5; REVELARD P, 1991, MOL BIOCHEM PARASIT, V46, P241, DOI 10.1016/0166-6851(91)90048-B; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Sillen L, 1964, STABILITY CONSTANTS; SMITHERS SR, 1965, PARASITOLOGY, V55, P695, DOI 10.1017/S0031182000086248; Sorin A, 1997, J BIOL CHEM, V272, P9895; Stathopoulos AM, 1997, GENE DEV, V11, P3432, DOI 10.1101/gad.11.24.3432; TANIDA I, 1995, J BIOL CHEM, V270, P10113, DOI 10.1074/jbc.270.17.10113; THAPSTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466; TOYOFUKU T, 1993, J BIOL CHEM, V268, P2809; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; VERMA AK, 1988, J BIOL CHEM, V263, P14152; WACH A, 1990, EUR J BIOCHEM, V189, P675, DOI 10.1111/j.1432-1033.1990.tb15536.x; WACH A, 1991, EUR J BIOCHEM, V201, P91, DOI 10.1111/j.1432-1033.1991.tb16260.x; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; WELLS KE, 1991, EXP PARASITOL, V73, P295, DOI 10.1016/0014-4894(91)90101-2; Withee JL, 1998, GENETICS, V149, P865; WRIGHT R, 1988, J CELL BIOL, V107, P101, DOI 10.1083/jcb.107.1.101; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	81	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27831	27840		10.1074/jbc.273.43.27831	http://dx.doi.org/10.1074/jbc.273.43.27831			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774393	hybrid			2022-12-27	WOS:000076549800013
J	Suo, ZC; Johnson, KA				Suo, ZC; Johnson, KA			Selective inhibition of HIV-1 reverse transcriptase by an antiviral inhibitor, (R)-9-(2-phosphonylmethoxypropyl)adenine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-BETA; HUMAN-IMMUNODEFICIENCY-VIRUS; DEFICIENCY SYNDROME AIDS; STATE KINETIC-ANALYSIS; BASE-EXCISION-REPAIR; MITOCHONDRIAL-DNA; NUCLEAR EXTRACT; HTLV-III; FIDELITY; MECHANISM	(R)-9-(2-Phosphonylmethoxypropyl)adenine (PMPA) is an acyclic nucleoside phosphonate that has been shown to be effective in the treatment of AIDS although it has a shorter separation between the adenine and phosphorus than dideoxy-AMP and dAMP. By using presteady state kinetic methods, we examined the incorporation of the diphosphate of PMPA 2',3'-dideoxyadenosine 5'-triphosphate (ddATP), and dATP catalyzed by wild-type human immunodeficiency virus type 1 (HIV-1) reverse transcriptase, an exonuclease-deficient T7 DNA polymerase (T7 exo(-)), and wild-type rat DNA polymerase beta in order to evaluate the selectivity of PMPA as an antiviral inhibitor. With a DNA/DNA or DNA/RNA 22/43-mer duplex, the diphosphate of PMPA (PMPApp) is as effective as ddATP in reactions catalyzed by HIV-1 reverse transcriptase in that both analogs have similar substrate specificity constants (k(p)/K-d) which are only 5-fold lower than dATP. In contrast, PMPApp is a much weaker inhibitor of the reaction catalyzed by T7 exo(-) (with the DNA/DNA 22/43-mer duplex) in that PMPApp has a 5 x 10(-4)-fold lower k(d)/K-d than ddATP and dATP. The lower k(p)/K-d of PMPApp is due to a 1000-2000-fold lower incorporation rate (k(p)) and a 35-45-fold lower binding constant (K-d). Similarly, PMPApp is 800-fold less inhibitory toward polymerase beta with the DNA/DNA 22/43-mer duplex, whereas in studies with a single nucleotide gapped DNA (22-20/43-mer) PMPApp is 13-fold less inhibitory than ddATP. Although parallel studies will need to be performed using appropriate human polymerases, these results begin to define the mechanistic basis for the reported lower toxicity of PMPA in the treatment of AIDS.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Johnson, KA (corresponding author), Univ Texas, Inst Cellular & Mol Biol, Austin, TX 78712 USA.	kajl@psu.edu			NIGMS NIH HHS [GM44613] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044613] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn J, 1997, BIOCHEMISTRY-US, V36, P1100, DOI 10.1021/bi961653o; Ahn JW, 1998, BIOCHEM J, V331, P79, DOI 10.1042/bj3310079; Amaudo E, 1991, LANCET, V337, P508; BALZARINI J, 1993, ANTIMICROB AGENTS CH, V37, P332, DOI 10.1128/AAC.37.2.332; BALZARINI J, 1991, BIOCHEM BIOPH RES CO, V178, P329, DOI 10.1016/0006-291X(91)91818-W; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; Chagovetz AM, 1997, J BIOL CHEM, V272, P27501, DOI 10.1074/jbc.272.44.27501; CHEN CH, 1989, J BIOL CHEM, V264, P11934; Cherrington JM, 1996, ANTIMICROB AGENTS CH, V40, P2212, DOI 10.1128/AAC.40.9.2212; CHERRINGTON JM, 1995, ANTIVIR CHEM CHEMOTH, V6, P217, DOI 10.1177/095632029500600403; Cohen J, 1997, SCIENCE, V277, P32, DOI 10.1126/science.277.5322.32; Dawson R., 1987, BIOCHEM EDUC, V15, P97; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; GALLO RC, 1983, SCIENCE, V220, P865, DOI 10.1126/science.6601823; Graves SW, 1998, BIOCHEMISTRY-US, V37, P6050, DOI 10.1021/bi972685u; HSIEH JC, 1993, J BIOL CHEM, V268, P24607; ISAACS NS, 1987, PHYSICA ORGANIC CHEM; JENKINS TM, 1992, SCIENCE, V258, P475, DOI 10.1126/science.1411545; Johnson K. A., 1992, ENZYMES, V20, P1, DOI DOI 10.1016/S1874-6047(08)60019-0; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; KATI WM, 1992, J BIOL CHEM, V267, P25988; KELLAM P, 1992, P NATL ACAD SCI USA, V89, P1934, DOI 10.1073/pnas.89.5.1934; Kornberg A., 1992, DNA REPLICATION; LARDER BA, 1993, REVERSE TRANSCRIPTAS, P205; LINN S, 1991, CELL, V66, P185, DOI 10.1016/0092-8674(91)90608-2; MARTIN JL, 1994, ANTIMICROB AGENTS CH, V38, P2743, DOI 10.1128/AAC.38.12.2743; Mulato AS, 1997, ANTIVIR RES, V36, P91, DOI 10.1016/S0166-3542(97)00043-0; PARKER WB, 1994, J NIH RES, V6, P57; PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SENGUPTA DN, 1986, BIOCHEM BIOPH RES CO, V136, P341, DOI 10.1016/0006-291X(86)90916-2; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; STCLAIR MH, 1987, ANTIMICROB AGENTS CH, V31, P1972, DOI 10.1128/AAC.31.12.1972; STEITZ TA, 1993, CURR OPIN STRUC BIOL, V3, P31, DOI 10.1016/0959-440X(93)90198-T; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12459, DOI 10.1021/bi971217h; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; TSAI CC, 1995, SCIENCE, V270, P1197, DOI 10.1126/science.270.5239.1197; vanRompay KKA, 1996, ANTIMICROB AGENTS CH, V40, P2586, DOI 10.1128/AAC.40.11.2586; Werneburg BG, 1996, BIOCHEMISTRY-US, V35, P7041, DOI 10.1021/bi9527202; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; Zhong XJ, 1997, BIOCHEMISTRY-US, V36, P11891, DOI 10.1021/bi963181j	50	63	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27250	27258		10.1074/jbc.273.42.27250	http://dx.doi.org/10.1074/jbc.273.42.27250			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765248	hybrid			2022-12-27	WOS:000076448000035
J	Badea, TC; Niculescu, FI; Soane, L; Shin, ML; Rus, H				Badea, TC; Niculescu, FI; Soane, L; Shin, ML; Rus, H			Molecular cloning and characterization of RGC-32, a novel gene induced by complement activation in oligodendrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; TERMINAL COMPLEMENT; CEREBROSPINAL-FLUID; MULTIPLE-SCLEROSIS; COMPLEXES; PROTEINS; ATTACK; MYELIN; ABSENCE; C5B-9	Sublytic complement activation on oligodendrocytes (OLG) down-regulates expression of myelin genes and induces cell cycle in culture. Differential display (DD) was used to search for new genes whose expression is altered in response to complement and that may be involved in cell cycle activation. DD bands showing either increased or decreased mRNA expression in response to complement were identified and designated Response Genes to Complement (RGC) 1-32, RGC-1 is identical with heat shock protein 105, RGC-2 with poly(ADP-ribose) polymerase, and RGC-10 with IP-10, A new gene, RGC-32, that encodes a protein of 137 amino acids was cloned. RGC-32 has no homology with other known proteins, and contains no motif that would indicate its function. In OLG, the mRNA expression was increased by complement activation and by terminal complement complex assembly. RGC-32 protein was localized in the cytoplasm and co-immunoprecipitated with cdc2 kinase. Overexpression of RGC-32 increased DNA synthesis in OLGxC6 glioma cell hybrids. These results suggest that RGC-32 may play a role in cell cycle activation.	Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Rus, H (corresponding author), Univ Maryland, Sch Med, Dept Pathol, 10 S Pine St, Baltimore, MD 21201 USA.		Badea, Tudor Constantin/B-1654-2018; Rus, Horea/AAF-2583-2020	Badea, Tudor Constantin/0000-0003-3086-6713; 	NIAID NIH HHS [R01 AI 19006] Funding Source: Medline; NINDS NIH HHS [R0-1 NS 19906] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENZAQUEN LR, 1994, J EXP MED, V179, P985, DOI 10.1084/jem.179.3.985; CARNEY DF, 1990, J IMMUNOL, V145, P623; COMPSTON DAS, 1989, NEUROPATH APPL NEURO, V15, P307, DOI 10.1111/j.1365-2990.1989.tb01231.x; COMPSTON DAS, 1986, NEUROLOGY, V36, P1503, DOI 10.1212/WNL.36.11.1503; HALPERIN JA, 1993, J CLIN INVEST, V91, P1974, DOI 10.1172/JCI116418; Lang TJ, 1997, J NEUROCHEM, V68, P1581; LININGTON C, 1989, BRAIN, V112, P895, DOI 10.1093/brain/112.4.895; LININGTON C, 1989, ACTA NEUROPATHOL, V79, P78, DOI 10.1007/BF00308961; LIU WT, 1983, J IMMUNOL, V131, P778; NICULESCU F, 1994, J BIOL CHEM, V269, P4417; NICULESCU F, 1993, J IMMUNOL, V150, P214; Niculescu F, 1997, J IMMUNOL, V158, P4405; PIDDLESDEN SJ, 1994, J IMMUNOL, V152, P5477; Rus H, 1997, IMMUNOPHARMACOLOGY, V38, P177, DOI 10.1016/S0162-3109(97)00063-5; Rus HG, 1996, J IMMUNOL, V156, P4892; SANDERS ME, 1986, J IMMUNOL, V136, P4456; SCOLDING NJ, 1989, J NEUROL SCI, V89, P289, DOI 10.1016/0022-510X(89)90030-0; SHEARER WT, 1975, J EXP MED, V141, P736; SHIRAZI Y, 1989, J IMMUNOL, V142, P4385; SHIRAZI Y, 1993, J IMMUNOL, V150, P4581; VANGURI P, 1982, P NATL ACAD SCI-BIOL, V79, P3290, DOI 10.1073/pnas.79.10.3290; VANGURI P, 1988, J BIOL CHEM, V263, P7228; WIEDMER T, 1987, J BIOL CHEM, V262, P13674; WREN DR, 1989, P NATL ACAD SCI USA, V86, P9025, DOI 10.1073/pnas.86.22.9025	24	84	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26977	26981		10.1074/jbc.273.41.26977	http://dx.doi.org/10.1074/jbc.273.41.26977			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756947	hybrid			2022-12-27	WOS:000076373300101
J	Kallen, CB; Billheimer, JT; Summers, SA; Stayrook, SE; Lewis, M; Strauss, JF				Kallen, CB; Billheimer, JT; Summers, SA; Stayrook, SE; Lewis, M; Strauss, JF			Steroidogenic acute regulatory protein (StAR) is a sterol transfer protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOID ADRENAL-HYPERPLASIA; CARRIER PROTEIN-2; CELLS; EXPRESSION; GENE; PHOSPHOPROTEIN; PURIFICATION; BIOSYNTHESIS; CHOLESTEROL	Steroidogenic acute regulatory protein (StAR) plays a critical role in steroidogenesis by enhancing the delivery of substrate cholesterol from the outer mitochondrial membrane to the cholesterol side chain cleavage enzyme system on the inner membrane. A recombinant StAR protein lacking the first N-terminal 62 amino acid residues that includes the mitochondrial targeting sequence was shown to stimulate the transfer of cholesterol and beta-sitosterol from liposomes to heat-treated mitochondria in a dose-, time-, and temperature-dependent manner. A recombinant mutant StAR protein that cannot stimulate steroidogenesis by isolated mitochondria did not promote sterol transfer. Unlike the more promiscuous lipid transfer protein, sterol carrier protein 2 (SCP2), StAR did not stimulate phosphatidylcholine transfer in our assay system. The recombinant StAR protein increased cholesterol transfer to heat-treated microsomes as well as to heat- and trypsin-treated mitochondria. These observations demonstrate that StAR has sterol transfer activity, which may reflect an ability to enhance desorption of cholesterol from sterol-rich donor membranes. We suggest that the ability of StAR to promote sterol transfer explains its steroidogenic activity.	Univ Penn, Med Ctr, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Dupont Merck Pharmaceut Co, Wilmington, DE 19880 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; DuPont	Strauss, JF (corresponding author), 778 Clin Res Bldg,415 Curie Blvd, Philadelphia, PA 19104 USA.	jfs3@mail.med.upenn.edu	/AAE-5384-2020	Stayrook, Steven/0000-0002-1677-8293; Kallen, Caleb/0000-0002-4156-6719	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD034449] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009375] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-34449, HD-06274] Funding Source: Medline; NIDDK NIH HHS [DK-09375] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arakane F, 1997, J BIOL CHEM, V272, P32656, DOI 10.1074/jbc.272.51.32656; Arakane F, 1996, P NATL ACAD SCI USA, V93, P13731, DOI 10.1073/pnas.93.24.13731; Arakane F, 1998, J BIOL CHEM, V273, P16339, DOI 10.1074/jbc.273.26.16339; BILLHEIMER JT, 1990, BIOCHIM BIOPHYS ACTA, V1046, P136, DOI 10.1016/0005-2760(90)90180-6; BLOJ B, 1977, J BIOL CHEM, V252, P1613; Bose HS, 1996, NEW ENGL J MED, V335, P1870, DOI 10.1056/NEJM199612193352503; Caron KM, 1997, P NATL ACAD SCI USA, V94, P11540, DOI 10.1073/pnas.94.21.11540; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; EPSTEIN LF, 1991, J BIOL CHEM, V266, P19739; HARTIGAN JA, 1995, J STEROID BIOCHEM, V53, P95, DOI 10.1016/0960-0760(95)00026-V; KRUEGER RJ, 1983, J BIOL CHEM, V258, P159; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; MARTINEZ F, 1997, SUBCELL BIOCH, V28, P208; MATSUURA JE, 1993, BIOCHEMISTRY-US, V32, P567, DOI 10.1021/bi00053a023; Nakae J, 1997, HUM MOL GENET, V6, P571, DOI 10.1093/hmg/6.4.571; PON LA, 1986, J BIOL CHEM, V261, P3309; Schroeder F, 1996, P SOC EXP BIOL MED, V213, P150, DOI 10.3181/00379727-213-44047; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; SUGAWARA T, 1995, P NATL ACAD SCI USA, V92, P4778, DOI 10.1073/pnas.92.11.4778; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	20	171	175	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26285	26288		10.1074/jbc.273.41.26285	http://dx.doi.org/10.1074/jbc.273.41.26285			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756854	hybrid			2022-12-27	WOS:000076373300008
J	Pal, S; Claffey, P; Cohen, HT; Mukhopadhyay, D				Pal, S; Claffey, P; Cohen, HT; Mukhopadhyay, D			Activation of Sp1-mediated vascular permeability factor/vascular endothelial growth factor transcription requires specific interaction with protein kinase C zeta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; RENAL-CELL CARCINOMA; FACTOR EXPRESSION; V-SRC; SP1; ANGIOGENESIS; PRODUCT; RECEPTORS; ONCOGENES; MUTATIONS	The transcription factor Sp1 is ubiquitously expressed and plays a significant role in the constitutive and induced expression of a variety of mammalian genes and may even contribute to tumorigenesis. Here, we describe a novel pathway whereby Sp1 promotes the transcription of vascular permeability factor/vascular endothelial growth factor (VPF/NEGF), a potent angiogenic factor, by interacting directly and specifically with protein kinase C zeta (PKC zeta) isoform in renal cell carcinoma. PKC zeta binds and phosphorylates the zinc finger region of Sp1. Moreover, in the presence of the wild type von Hippel-Lindau gene product, the interaction of Sp1 with PKC zeta is inhibited, and in this manner steady state levels of Sp1 phosphorylation are decreased significantly. Co-transfection of renal cell carcinoma cells and human fibrosarcoma cells with a plasmid overexpressing PKC zeta and VPF/VEGF promoter luciferase constructs results in activation of Sp1-mediated transcription, whereas expression of a dominant-negative mutant of PKC zeta repressed this activation. Taken together, our results suggest a new pathway of cell signaling through PKC zeta and provide an insight into PKC zeta and Sp1-dependent transcriptional regulation of VPF/VEGF expression and thus tumor angiogenesis,	Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02215 USA; Boston Univ, Med Ctr, Dept Med, Boston, MA 02118 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Boston University	Mukhopadhyay, D (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, RN 270H,99 Brookline Ave, Boston, MA 02215 USA.							Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; BROWN LF, 1993, AM J PATHOL, V143, P1255; CHEN F, 1995, CANCER RES, V55, P4804; Cohen HT, 1997, J BIOL CHEM, V272, P2901, DOI 10.1074/jbc.272.5.2901; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; DIAZLAVIADA I, 1990, EMBO J, V9, P3907, DOI 10.1002/j.1460-2075.1990.tb07611.x; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Folkman J, 1996, SCI AM, V275, P150, DOI 10.1038/scientificamerican0996-150; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; GNARRA JR, 1993, UROL CLIN N AM, V20, P207; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Lee S, 1996, P NATL ACAD SCI USA, V93, P1770, DOI 10.1073/pnas.93.5.1770; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; MURATA Y, 1994, J BIOL CHEM, V269, P20674; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; Pal S, 1997, J BIOL CHEM, V272, P27509, DOI 10.1074/jbc.272.44.27509; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; RAK J, 1995, CANCER RES, V55, P4575; RICHARDS FM, 1995, HUM MOL GENET, V4, P2139, DOI 10.1093/hmg/4.11.2139; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; WIZIGMANNVOOS S, 1995, CANCER RES, V55, P1358; ZANG Q, 1995, CELL GROWTH DIFFER, V6, P1367	29	157	163	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26277	26280		10.1074/jbc.273.41.26277	http://dx.doi.org/10.1074/jbc.273.41.26277			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756852	hybrid			2022-12-27	WOS:000076373300006
J	Frevert, EU; Bjorbaek, C; Venable, CL; Keller, SR; Kahn, BB				Frevert, EU; Bjorbaek, C; Venable, CL; Keller, SR; Kahn, BB			Targeting of constitutively active phosphoinositide 3-kinase to GLUT4-containing vesicles in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER TRANSLOCATION; PHOSPHATIDYLINOSITOL 3-KINASE; GLUT4 TRANSLOCATION; GLYCOGEN-SYNTHASE; SKELETAL-MUSCLE; PROTEIN-KINASE; DNA-SYNTHESIS; INSULIN; ACTIVATION; ASSOCIATION	Constitutive activation of phosphoinositide S-kinase (PI3K) stimulates glucose transport and GLUT4 glucose transporter translocation to the plasma membrane in adipocytes, To determine whether a direct interaction of PI3K with GLUT4-containing vesicles (hereafter called GLUT4 vesicles) is important for the effect of insulin on GLUT4 translocation, we targeted constitutively active PI3K to GLUT4 vesicles. We fused the inter-Src homology region 2 of the regulatory p85 alpha subunit of PI3K (iSH2) either to a C-terminal sequence of GLUT4 (G4(c), amino acids 406-509) or to this region and the N-terminal tail of GLUT4 (G4(n), amino acids 1-19), resulting in the fusion proteins iSH2-G4(c) and G4(n)-iSH2-G4(c), respectively. Coexpression of the fusion proteins or untargeted iSH2 with the catalytic p110 alpha subunit of PI3K (p110) in 3T3-L1 adipocytes by adenovirus-mediated gene transfer increased total PI3K activity in homogenates 5.0-6.7-fold over nontransduced cells or cells transduced with adenovirus encoding beta-galactosidase, In contrast, PI3K activity in GLUT4 vesicles increased 11-13-fold with expression of either targeted construct and p110 but only 2-fold with the untargeted iSH2 and p110, indicating successful targeting of PI3K to GLUT4 vesicles. Both targeted and nontargeted constructs stimulated DNA synthesis to levels greater than insulin, demonstrating that both types of constructs had biologic activity in intact cells. Despite this, untargeted iSH2/p110 coexpression was more effective in stimulating 2-deoxyglucose uptake (6-fold) than either iSH2-G4c/ p110 or G4n-iSH2-G4c/p110 coexpression (both 2-fold). Only iSH2/p110 coexpression led to a significant GLUT4 translocation to the plasma membrane. Insulin-stimulated glucose transport was unaffected by any construct. Thus, a direct interaction between PI3K and GLUT4 vesicles is either not required or not sufficient for GLUT4 translocation and stimulation of glucose transport.	Beth Israel Deaconess Med Ctr, Dept Med, Div Endocrinol & Metab, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Dartmouth College	Kahn, BB (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Endocrinol & Metab, Boston, MA 02215 USA.		Bjorbaek, Christian/S-4727-2019		NIA NIH HHS [AG00924] Funding Source: Medline; NIDDK NIH HHS [R01 DK43051, R01 DK043051] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043051] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASANO T, 1992, J BIOL CHEM, V267, P19636; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; CZECH MP, 1993, J CELL BIOL, V123, P127, DOI 10.1083/jcb.123.1.127; DELVECCHIO RL, 1991, J BIOL CHEM, V266, P13278; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; FROST SC, 1985, J BIOL CHEM, V260, P2646; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; HANEY PM, 1995, J CELL BIOL, V129, P641, DOI 10.1083/jcb.129.3.641; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; KAHN BB, 1992, J CLIN INVEST, V89, P1367, DOI 10.1172/JCI115724; Katagiri H, 1996, J BIOL CHEM, V271, P16987, DOI 10.1074/jbc.271.29.16987; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KING PA, 1992, J CLIN INVEST, V90, P1568, DOI 10.1172/JCI116025; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; Kummer JL, 1998, BIOCHEM BIOPH RES CO, V246, P282, DOI 10.1006/bbrc.1998.8599; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHERE L, 1994, AM J PHYSIOL, V266, pE486, DOI 10.1152/ajpendo.1994.266.3.E486; MARSH BJ, 1995, J CELL BIOL, V130, P1081, DOI 10.1083/jcb.130.5.1081; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; OKADA T, 1994, J BIOL CHEM, V269, P3568; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; Ross SA, 1996, J BIOL CHEM, V271, P3328, DOI 10.1074/jbc.271.6.3328; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERHEY KJ, 1995, J CELL BIOL, V130, P1071, DOI 10.1083/jcb.130.5.1071; WALSH JP, 1991, P NATL ACAD SCI USA, V76, P4350; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; Yang J, 1996, BIOCHEM J, V313, P125, DOI 10.1042/bj3130125; Zierath JR, 1996, SEMIN CELL DEV BIOL, V7, P295, DOI 10.1006/scdb.1996.0038	39	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25480	25487		10.1074/jbc.273.39.25480	http://dx.doi.org/10.1074/jbc.273.39.25480			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738018	hybrid			2022-12-27	WOS:000076085400068
J	Lindahl, U; Kusche-Gullberg, M; Kjellen, L				Lindahl, U; Kusche-Gullberg, M; Kjellen, L			Regulated diversity of heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							DEACETYLASE N-SULFOTRANSFERASE; FIBROBLAST GROWTH-FACTOR; MOLECULAR-CLONING; MONOCLONAL-ANTIBODY; EXPRESSION; BINDING; BIOSYNTHESIS; LIVER; PROTEOGLYCANS; SEQUENCES		Univ Uppsala, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden; Swedish Univ Agr Sci, Dept Vet Med Chem, S-75123 Uppsala, Sweden	Uppsala University; Swedish University of Agricultural Sciences	Lindahl, U (corresponding author), Biomed Ctr, Dept Med Biochem & Microbiol, Box 575, S-75123 Uppsala, Sweden.		Kjellen, Lena/F-1362-2011; Kusche-Gullberg, Marion/P-4466-2016	Kusche-Gullberg, Marion/0000-0002-5636-1695				Abeijon C, 1997, TRENDS BIOCHEM SCI, V22, P203, DOI 10.1016/S0968-0004(97)01053-0; AIKAWA J, 1997, GLYCOBIOLOGY, V7, P1032; Brickman YG, 1998, J BIOL CHEM, V273, P4350, DOI 10.1074/jbc.273.8.4350; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cheung WF, 1996, BIOCHEMISTRY-US, V35, P5250, DOI 10.1021/bi952325b; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; EDGE ASB, 1990, J BIOL CHEM, V265, P15874; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FEDARKO NS, 1986, J CELL BIOL, V102, P587, DOI 10.1083/jcb.102.2.587; Feyzi E, 1997, J BIOL CHEM, V272, P24850, DOI 10.1074/jbc.272.40.24850; Feyzi E, 1998, J BIOL CHEM, V273, P13395, DOI 10.1074/jbc.273.22.13395; Feyzi E, 1997, J BIOL CHEM, V272, P5518, DOI 10.1074/jbc.272.9.5518; Fritz TA, 1997, GLYCOBIOLOGY, V7, P587, DOI 10.1093/glycob/7.5.587-c; GALLAGHER JT, 1985, BIOCHEM J, V230, P665, DOI 10.1042/bj2300665; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Habuchi H, 1998, J BIOL CHEM, V273, P9208, DOI 10.1074/jbc.273.15.9208; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; IOZZO RV, 1994, MATRIX BIOL, V14, P203, DOI 10.1016/0945-053X(94)90183-X; ISHIHARA M, 1993, J BIOL CHEM, V268, P20091; JACOBSSON I, 1979, J BIOL CHEM, V254, P2975; Jayson GC, 1998, J BIOL CHEM, V273, P51, DOI 10.1074/jbc.273.1.51; KATO M, 1994, J BIOL CHEM, V269, P18881; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; KJELLEN L, 1983, DIABETES, V32, P337, DOI 10.2337/diabetes.32.4.337; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kobayashi M, 1997, J BIOL CHEM, V272, P13980, DOI 10.1074/jbc.272.21.13980; Koenig A, 1998, J CLIN INVEST, V101, P877, DOI 10.1172/JCI1509; Kusche-Gullberg M, 1998, J BIOL CHEM, V273, P11902, DOI 10.1074/jbc.273.19.11902; Li JP, 1997, J BIOL CHEM, V272, P28158, DOI 10.1074/jbc.272.44.28158; LIND T, 1993, J BIOL CHEM, V268, P20705; Lindahl B, 1997, J BIOL CHEM, V272, P26091, DOI 10.1074/jbc.272.42.26091; LINDAHL B, 1995, BIOCHEM J, V306, P177, DOI 10.1042/bj3060177; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; Lindahl U., 1989, HEPARIN, P159; LORTAT-JACOB H, 1995, BIOCHEM J, V310, P497, DOI 10.1042/bj3100497; LYON M, 1994, J BIOL CHEM, V269, P11216; LYON M, 1994, J BIOL CHEM, V269, P11208; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; Machamer C E, 1991, Trends Cell Biol, V1, P141, DOI 10.1016/0962-8924(91)90001-P; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; PARTHASARATHY N, 1994, J BIOL CHEM, V269, P22391; PEJLER G, 1987, J BIOL CHEM, V262, P11413; POWERS PA, 1991, GENETICS, V129, P133; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Safaiyan F, 1998, EUR J BIOCHEM, V252, P576, DOI 10.1046/j.1432-1327.1998.2520576.x; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Spillmann D, 1998, J BIOL CHEM, V273, P15487, DOI 10.1074/jbc.273.25.15487; Stringer SE, 1997, J BIOL CHEM, V272, P20508, DOI 10.1074/jbc.272.33.20508; TURNBULL JE, 1991, BIOCHEM J, V273, P553, DOI 10.1042/bj2730553; van Kuppevelt TH, 1998, J BIOL CHEM, V273, P12960, DOI 10.1074/jbc.273.21.12960; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303; vandenBorn J, 1996, J BIOL CHEM, V271, P22802, DOI 10.1074/jbc.271.37.22802; WEI Z, 1993, P NATL ACAD SCI USA, V90, P3885, DOI 10.1073/pnas.90.9.3885	56	549	576	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					24979	24982		10.1074/jbc.273.39.24979	http://dx.doi.org/10.1074/jbc.273.39.24979			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737951	hybrid			2022-12-27	WOS:000076085400001
J	Murray, SR; Evans, CJ; von Zastrow, M				Murray, SR; Evans, CJ; von Zastrow, M			Phosphorylation is not required for dynamin-dependent endocytosis of a truncated mutant opioid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; OPIATE-RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; DOWN-REGULATION; INTERNALIZATION; AGONIST; DESENSITIZATION; SEQUESTRATION; MECHANISMS; TERMINUS	Opioid receptors are regulated within minutes after activation by G protein-coupled receptor kinase-mediated phosphorylation and dynamin-dependent endocytosis, We addressed the question of whether phosphorylation is required for opioid receptor endocytosis by examining a functional, truncated mutant delta opioid receptor (DOR344T), which is missing phosphorylation sites located in the carboxyl-terminal cytoplasmic domain, DOR344T receptors expressed in Chinese hamster ovary cells remained predominantly in the plasma membrane, even in the presence of saturating concentrations of agonist, consistent with previous studies demonstrating strongly inhibited endocytosis of truncated receptors in this cell type. In marked contrast, DOR344T receptors expressed at similar levels in human embryonal kidney (HEK) 293 cells exhibited rapid, Ligand-induced internalization either in the presence of peptide (DADLE) or alkaloid (etorphine) agonist, Quantitative assays using ELISA and flow cytometric techniques indicated that DOR344T receptors were endocytosed in HEK293 cells with similarly rapid kinetics as full-length DOR (t(1/2) < 10 min), and both full-length DOR and DOR344T mutant receptors were endocytosed by a dynamin-dependent mechanism involving clathrin-coated pits. Nevertheless, DOR344T receptors failed to undergo any detectable constitutive or agonist-induced phosphorylation in the same cells in which dynamin-dependent endocytosis was observed. These findings establish the first example of a G protein-coupled receptor that does not require phosphorylation to undergo dynamin-dependent endocytosis, and they suggest that significant cell type-specific differences exist in the biochemical requirements for ligand-induced concentration of opioid receptors in clathrin-coated pits.	Univ Calif San Francisco, Dept Psychiat, Nina Ireland Lab, LPPI, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 90024 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Los Angeles	von Zastrow, M (corresponding author), Univ Calif San Francisco, Dept Psychiat, Nina Ireland Lab, LPPI, Box 0984,401 Parnassus Ave, San Francisco, CA 94143 USA.	zastrow@itsa.ucsf.edu			NATIONAL INSTITUTE ON DRUG ABUSE [R37DA010711, R29DA010711, R01DA010711, P50DA005010] Funding Source: NIH RePORTER; NIDA NIH HHS [DA10711, DA00218, P50 DA005010] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Chu P, 1997, J BIOL CHEM, V272, P27124, DOI 10.1074/jbc.272.43.27124; Cvejic S, 1996, J BIOL CHEM, V271, P4073; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Evans CJ, 1993, BIOL BASIS SUBSTANCE, P31; Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6; Goodman O B Jr, 1998, Adv Pharmacol, V42, P429; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Haribabu B, 1997, J BIOL CHEM, V272, P28726, DOI 10.1074/jbc.272.45.28726; HEIN L, 1994, J BIOL CHEM, V269, P27719; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; Holtmann MH, 1996, J BIOL CHEM, V271, P23566, DOI 10.1074/jbc.271.38.23566; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; LAW PY, 1982, MOL PHARMACOL, V22, P1; LAW PY, 1984, J BIOL CHEM, V259, P4096; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; NESTLER EJ, 1993, CRIT REV NEUROBIOL, V7, P23; NESTLER EJ, 1993, NEURON, V11, P995, DOI 10.1016/0896-6273(93)90213-B; Okayama H, 1992, Biotechnology, V24, P270; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; PEI G, 1995, MOL PHARMACOL, V48, P173; REISINE T, 1993, TRENDS NEUROSCI, V16, P506, DOI 10.1016/0166-2236(93)90194-Q; Reisine T, 1996, ANN NY ACAD SCI, V780, P168, DOI 10.1111/j.1749-6632.1996.tb15121.x; Segredo V, 1997, J NEUROCHEM, V68, P2395; SHARMA SK, 1977, P NATL ACAD SCI USA, V74, P3365, DOI 10.1073/pnas.74.8.3365; TOWBIN H, 1984, J IMMUNOL METHODS, V72, P313, DOI 10.1016/0022-1759(84)90001-2; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; UHL GR, 1994, TRENDS NEUROSCI, V17, P89, DOI 10.1016/0166-2236(94)90110-4; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302; Zhao J, 1997, BIOCHEM BIOPH RES CO, V238, P71, DOI 10.1006/bbrc.1997.7242	31	74	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					24987	24991		10.1074/jbc.273.39.24987	http://dx.doi.org/10.1074/jbc.273.39.24987			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737953	hybrid			2022-12-27	WOS:000076085400003
J	Tell, G; Scaloni, A; Pellizzari, L; Formisano, S; Pucillo, C; Damante, G				Tell, G; Scaloni, A; Pellizzari, L; Formisano, S; Pucillo, C; Damante, G			Redox potential controls the structure and DNA binding activity of the paired domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID FRTL-5 CELLS; TRANSCRIPTION FACTOR; PAX GENES; CONFORMATIONAL-CHANGES; IN-VITRO; KAPPA-B; PROTEIN; ACTIVATION; SEQUENCE; RECOGNITION	Pax proteins are transcriptional regulators controlling a variety of cell fates during animal development. This role depends on the intact function of the paired (Prd) domain that is able to recognize specific DNA sequences. The Prd domain is composed of two distinct helix-turn-helix subdomains, PAI and RED. Molecular functions of Pax proteins are subjected to different levels of regulation involving both pre-translational and post-translational mechanisms. By using Pax-5 and Pax-8 recombinant proteins, we demonstrate that the binding activity of the Prd domain is regulated through the oxidation/reduction of conserved cysteine residues. Mass spectrometry analysis and mutagenesis experiments demonstrate that the redox regulation is accomplished through the reversible formation of an intramolecular disulfide bridge involving the cysteines present in the PAI subdomain, whereas the RED subdomain appears quite insensitive to redox potential. Circular dichroism experiments indicate that only the reduced form of the Prd domain is able to undergo the proper conformational change necessary for sequence-specific DNA binding. Nuclear extracts from different cell lines contain an activity that is able to reduce the Paired domain and, therefore, to control the DNA binding activity of this protein. Immunodepletion of nuclear extracts demonstrate that the protein Ref-1 contributes to the redox regulation of the Prd DNA binding activity. Given the modular nature of the Prd domain and the independent DNA binding specificity of the PAI and RED subdomains, we propose that this control mechanism should be involved in "switching" among different DNA sequences and therefore different target genes.	Univ Udine, Dipartimento Sci & Tecnol Biomed, I-33100 Udine, Italy; Univ Naples, CNR, Ctr Int Serv Spettrometria Massa, I-80131 Naples, Italy; CNR, Ist Ric Adattamento Bovini & Bufali Ambiente Mezz, I-80147 Naples, Italy; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II	Damante, G (corresponding author), Univ Udine, Dipartimento Sci & Tecnol Biomed, Via Gervasutta 48, I-33100 Udine, Italy.	giuseppe.damante@dstb.uniud.it	Pucillo, Carlo/A-5515-2008; Damante, Giuseppe/AAC-5200-2022	Pucillo, Carlo/0000-0002-4872-6156; Tell, Gianluca/0000-0001-8845-6448; Scaloni, Andrea/0000-0001-9362-8515; Damante, Giuseppe/0000-0003-2312-4009				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; Akamatsu Y, 1997, J BIOL CHEM, V272, P14497, DOI 10.1074/jbc.272.23.14497; ALTOMONTE M, 1993, J IMMUNOL, V151, P5115; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; Asai T, 1997, BIOCHEM BIOPH RES CO, V236, P71, DOI 10.1006/bbrc.1997.6906; BARBERIS A, 1990, GENE DEV, V4, P849, DOI 10.1101/gad.4.5.849; BJORKMAN U, 1992, ENDOCRINOLOGY, V130, P393, DOI 10.1210/en.130.1.393; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSSLINGER M, 1995, CURR OPIN GENET DEV, V5, P595, DOI 10.1016/0959-437X(95)80028-X; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; CHALEPAKIS G, 1995, GENE, V162, P267, DOI 10.1016/0378-1119(95)00345-7; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; DahlmanWright K, 1996, BIOCHEMISTRY-US, V35, P1323, DOI 10.1021/bi952409k; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; EPSTEIN JA, 1994, GENE DEV, V8, P2022, DOI 10.1101/gad.8.17.2022; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HAINAUT P, 1993, CANCER RES, V53, P4469; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HANSON I, 1995, TRENDS GENET, V11, P268, DOI 10.1016/S0168-9525(00)89073-3; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HOEFFLER WK, 1988, CELL, V53, P907, DOI 10.1016/S0092-8674(88)90409-6; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Jun S, 1996, DEVELOPMENT, V122, P2639; KALLIS GB, 1980, J BIOL CHEM, V255, P261; Kambe F, 1996, MOL ENDOCRINOL, V10, P801, DOI 10.1210/me.10.7.801; KIMURA T, 1995, ENDOCRINOLOGY, V136, P116, DOI 10.1210/en.136.1.116; Kioussi C, 1996, TRENDS GENET, V12, P84, DOI 10.1016/0168-9525(96)81411-9; Kozmik Z, 1997, EMBO J, V16, P6793, DOI 10.1093/emboj/16.22.6793; KURUCZ I, 1993, P NATL ACAD SCI USA, V90, P3830, DOI 10.1073/pnas.90.9.3830; LEHRMAN SR, 1990, BIOCHEMISTRY-US, V29, P5590, DOI 10.1021/bi00475a025; Mansouri A, 1996, DEVELOPMENT, V122, P831; Mansouri A, 1996, CURR OPIN CELL BIOL, V8, P851, DOI 10.1016/S0955-0674(96)80087-1; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; MYRSET AH, 1993, EMBO J, V12, P4625, DOI 10.1002/j.1460-2075.1993.tb06151.x; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; NELSON J W, 1986, Proteins Structure Function and Genetics, V1, P211, DOI 10.1002/prot.340010303; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; Pellizzari L, 1996, BIOCHEM J, V315, P363, DOI 10.1042/bj3150363; POLEEV A, 1992, DEVELOPMENT, V116, P611; Poleev A, 1997, EUR J BIOCHEM, V247, P860, DOI 10.1111/j.1432-1033.1997.00860.x; Scaloni A, 1998, J MOL BIOL, V277, P945, DOI 10.1006/jmbi.1998.1629; Schedl A, 1996, CELL, V86, P71, DOI 10.1016/S0092-8674(00)80078-1; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SHAPIRO DN, 1993, CANCER RES, V53, P5108; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STAPLETON P, 1993, NAT GENET, V3, P292, DOI 10.1038/ng0493-292; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; STUART ET, 1995, CLIN CANCER RES, V1, P207; STUDIER FW, 1991, METHOD ENZYMOL, V185, P60; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; VanRenterghem P, 1996, BBA-GENE STRUCT EXPR, V1307, P97, DOI 10.1016/0167-4781(96)00018-8; Vogan KJ, 1996, MOL CELL BIOL, V16, P6677; WALLIN J, 1993, MAMM GENOME, V4, P354, DOI 10.1007/BF00360584; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	66	95	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25062	25072		10.1074/jbc.273.39.25062	http://dx.doi.org/10.1074/jbc.273.39.25062			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737963	hybrid			2022-12-27	WOS:000076085400013
J	Yu, X; Wu, LJC; Bowcock, AM; Aronheim, A; Baer, R				Yu, X; Wu, LJC; Bowcock, AM; Aronheim, A; Baer, R			The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER SUSCEPTIBILITY GENE; CELL-CYCLE CONTROL; DNA-LIGASE-III; NEGATIVE MODULATION; BREAST-CANCER; E1A PROTEIN; DAMAGE; PHOSPHORYLATION; PHOSPHOPROTEIN; TRANSFORMATION	The BRCA1 tumor suppressor encodes a polypeptide with two recognizable protein motifs: a RING domain near the N terminus and two tandem BRCT domains at the C terminus. Studies of tumor-associated mutations indicate that the RING and BRCT sequences are required for BRCA1-mediated tumor suppression. In addition, recent work has shown that BRCA1 is a potent regulator of RNA transcription and that the BRCT domains are also essential for this activity. Therefore, we used the Sos recruitment system to screen for proteins that bind this critical region of BRCA1. Our results show that the BRCT domains interact in vivo with CtIP, a protein originally identified on the basis of its association with the CtBP transcriptional co-repressor, This finding suggests that BRCA1 regulates gene expression, at least in part, by modulating CtBP-mediated transcriptional repression. Moreover, the in vivo interaction between BRCA1 and CtIP is completely ablated by each of three independent tumor-associated mutations affecting the BRCT motifs of BRCA1. These results indicate that the BRCA1-CtIP interaction may be required for tumor suppression by BRCA1.	Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, McDermott Ctr Human Growth & Dev, Dallas, TX 75235 USA; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Mol Genet, IL-31096 Haifa, Israel	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Baer, R (corresponding author), Univ Texas, SW Med Ctr, Dept Microbiol, 6000 Harry Hines Blvd, Dallas, TX 75235 USA.			Bowcock, Anne/0000-0001-8691-9090; Aronheim, Ami/0000-0002-8575-4092	NCI NIH HHS [CA76334, CA60650] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060650, R01CA076334] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DEFROMENTEL CC, 1985, EXP CELL RES, V160, P83, DOI 10.1016/0014-4827(85)90238-1; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Larson JS, 1997, CANCER RES, V57, P3351; Mackey ZB, 1997, MOL CELL BIOL, V17, P989, DOI 10.1128/MCB.17.2.989; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Nash RA, 1997, BIOCHEMISTRY-US, V36, P5207, DOI 10.1021/bi962281m; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; Sollerbrant K, 1996, NUCLEIC ACIDS RES, V24, P2578, DOI 10.1093/nar/24.13.2578; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801; Tsan JT, 1997, ADV MOLEC BIOL, P217; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhang HB, 1998, CELL, V92, P433, DOI 10.1016/S0092-8674(00)80936-8	35	319	323	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25388	25392		10.1074/jbc.273.39.25388	http://dx.doi.org/10.1074/jbc.273.39.25388			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738006	hybrid			2022-12-27	WOS:000076085400056
J	Inoue, S; Lin, SL; Chang, TN; Wu, SH; Yao, CW; Chu, TY; Troy, FA; Inoue, Y				Inoue, S; Lin, SL; Chang, TN; Wu, SH; Yao, CW; Chu, TY; Troy, FA; Inoue, Y			Identification of free deaminated sialic acid (2-keto-3-deoxy-D-glycero-D-galacto-nononic acid) in human red blood cells and its elevated expression in fetal cord red blood cells and ovarian cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; CARBOHYDRATE ANTIGENS; NEURAMINIC ACID; TUMOR; GLYCOSYLATION; CHAINS; KDN; POLYSIALOGLYCOPROTEIN; SYNTHETASE; ASSAY	Chemical studies have shown the occurrence of the deaminated sialic acid 2-keto-3-deoxy-D-glycero-D-galacto-nononic acid (KDN) in paired samples of blood obtained from mothers and newborns of healthy human individuals. Most of the KDN was found in red blood cells, although low levels were detected in mononuclear cells. No N-glycolylneuraminic acid was detected. Unexpectedly, nearly all of the KDN in fetal cord and matched maternal red blood cells was present as the free sugar and comparatively little occurred conjugated or as cytidine 5'-KDN phosphate, The amount of free KDN in fetal newborn red blood cells was 2.4-fold higher than in red blood cells from the mothers or from healthy nonpregnant women. Free KDN was also identified in normal human ovaries, in ovarian tumors, and in ascites cells obtained from ovarian cancer patients. Importantly, as in fetal cord red blood cells, a distinguishing feature of KDN expression in ovarian tumor cells was an elevated level of free KDN compared with normal controls. A positive correlation was found between an increase in the ratio of free KDN/N-acetylneuraminic acid in ovarian adenocarcinomas and the stage of malignancy. This was particularly evident in tumor cells isolated from the ascites fluid. The central importance of these new findings is a-fold. First, they show that free KDN is a minor but ubiquitous sialic acid in human red blood cells and that its elevated expression in red blood cells from fetal cord blood compared with maternal red blood cells may be developmentally related to blood cell formation during embryogenesis, Second, the enhanced expression of KDN in ovarian cancer cells suggests that this sialic acid, like the alpha 2,8-linked polysialic acid glycotope, may be an oncofetal antigen in these tumors and thus could be an "early warning" signal for onset of disease and/or a marker for detection of recurrence of disease. These new findings highlight the importance of elucidating the role that KDN and KDN-containing glycoconjugates may play in normal development and malignancy.	Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; Natl Def Med Ctr, Triserv Gen Hosp, Taipei 115, Taiwan; Univ Calif Davis, Sch Med, Dept Biol Chem, Livermore, CA 95616 USA	Academia Sinica - Taiwan; National Defense Medical Center; Tri-Service General Hospital; University of California System; University of California Davis	Inoue, Y (corresponding author), Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan.	syinoue@gate.sinica.edu.tw		Chu, Tang-Yuan/0000-0003-2717-2681	NHLBI NIH HHS [DOH88-HR-805] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGATA T, 1998, 19 INT CARB S CP022; ANGATA T, 1997, THESIS U TOKYO; Feijoo C, 1997, CANCER LETT, V112, P155, DOI 10.1016/S0304-3835(96)04564-8; Fukuda M, 1996, CANCER RES, V56, P2237; GANDOUREDWARDS R, 1985, MED PATHOL, V8, P101; GLICK MC, 1991, PROG CLIN BIOL RES, V366, P267; GROGAN T, 1994, LAB INVEST, V70, pA110; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HARA S, 1989, ANAL BIOCHEM, V179, P162, DOI 10.1016/0003-2697(89)90218-2; HIGASHI H, 1985, CANCER RES, V45, P3796; Inoue S, 1996, J BIOL CHEM, V271, P24341, DOI 10.1074/jbc.271.40.24341; IWASAKI M, 1990, J BIOL CHEM, V265, P2596; KERN WF, 1993, LEUKEMIA LYMPHOMA, V12, P1, DOI 10.3109/10428199309059565; LIVINGSTON BD, 1988, J BIOL CHEM, V263, P9443; MUCHMORE EA, 1989, J BIOL CHEM, V264, P20216; MUCHMORE EA, 1992, GLYCOBIOLOGY, V2, P337, DOI 10.1093/glycob/2.4.337; MURAMATSU T, 1993, GLYCOBIOLOGY, V3, P294; NADANO D, 1986, J BIOL CHEM, V261, P1550; Panneerselvam K, 1997, J BIOL CHEM, V272, P23123, DOI 10.1074/jbc.272.37.23123; PETRIE CR, 1983, ANAL BIOCHEM, V131, P153, DOI 10.1016/0003-2697(83)90147-1; ROTH J, 1988, P NATL ACAD SCI USA, V85, P2999, DOI 10.1073/pnas.85.9.2999; Schauer R, 1997, N COMP BIOC B, V29, P243; SCOTT AA, 1994, LAB INVEST, V70, pA120; SONG Y, 1995, GLYCOBIOLOGY, V5, P207, DOI 10.1093/glycob/5.2.207; SONG Y, 1991, J BIOL CHEM, V266, P21929; SPIEGEL LB, 1992, J CHROMATOGR-BIOMED, V573, P23, DOI 10.1016/0378-4347(92)80469-7; TAKANO R, 1994, GLYCOBIOLOGY, V4, P665, DOI 10.1093/glycob/4.5.665; TERADA T, 1993, J BIOL CHEM, V268, P2640; Troy F.A., 1995, BIOL SIALIC ACIDS, P95; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25	30	65	67	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27199	27204		10.1074/jbc.273.42.27199	http://dx.doi.org/10.1074/jbc.273.42.27199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765240	hybrid			2022-12-27	WOS:000076448000027
J	Kupershmidt, S; Snyders, DJ; Raes, A; Roden, DM				Kupershmidt, S; Snyders, DJ; Raes, A; Roden, DM			A K+ channel splice variant common in human heart lacks a C-terminal domain required for expression of rapidly activating delayed rectifier current	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-QT SYNDROME; POTASSIUM CHANNEL; CARDIAC-ARRHYTHMIA; I-KR; HERG; RECTIFICATION; INACTIVATION; MYOCYTES; VOLTAGE; MECHANISMS	We have cloned HERG(USO), a C-terminal splice variant of the human ether-g-go-go-related gene (HERG), the gene encoding the rapid component of the delayed rectifier (I-Kr), from human heart, and we find that its mRNA is similar to 2-fold more abundant than that for HERG(1) (the originally described cDNA). After transfection of HERG(USO) in Ltk(-) cells, no current was observed, However, coexpression of HERG(USO) with HERG(1) modified I-Kr by decreasing its amplitude, accelerating its activation, and shifting the voltage dependence of activation 8.8 mV negative. As with HERG(USO), HERG(Delta C) (a HERG(1), construct lacking the C-terminal 462 amino acids) also produced no current in transfected cells. However, I-Kr was rescued by ligation of 104 amino acids from the C terminus of HERG(1) to the C terminus of HERG(Delta C), indicating that the C terminus of HERG(1) includes a domain (less than or equal to 104 amino acids) that is critical for faithful recapitulation of I-Kr. The lack of this C-terminal domain not only explains the finding that HERG(USO) does not generate I-Kr but also indicates a similar mechanism for hitherto-uncharacterized long QT syndrome HERG mutations that disrupt the splice site or the C-terminal. We suggest that the amplitude and gating of cardiac I-Kr depends on expression of both HERG(1) and HERG(USO).	Vanderbilt Univ, Med Ctr, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Kupershmidt, S (corresponding author), Vanderbilt Univ, Med Ctr, Sch Med, Dept Pharmacol, 532 Med Res Bldg I, Nashville, TN 37232 USA.		Kupershmidt, Sabina/AAO-5464-2021; Snyders, Dirk/A-2713-2013; Roden, Dan/ABD-5412-2021	Kupershmidt, Sabina/0000-0002-8119-2723; Snyders, Dirk/0000-0001-7142-6672; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046681, R01HL049989, R01HL047599] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47599, HL49989, HL46681] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ackerman MJ, 1997, NEW ENGL J MED, V336, P1575, DOI 10.1056/NEJM199705293362207; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; Biervert C, 1998, SCIENCE, V279, P403, DOI 10.1126/science.279.5349.403; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOY AMJ, 1996, CIRCULATION, V94, P164; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Daram P, 1997, EMBO J, V16, P3455, DOI 10.1093/emboj/16.12.3455; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; LeesMiller JP, 1997, CIRC RES, V81, P719; Li GR, 1996, CIRC RES, V78, P689, DOI 10.1161/01.RES.78.4.689; Li XD, 1997, J BIOL CHEM, V272, P705, DOI 10.1074/jbc.272.2.705; Lin CLG, 1998, NEURON, V20, P589, DOI 10.1016/S0896-6273(00)80997-6; London B, 1997, CIRC RES, V81, P870; Ludwig J, 1997, EMBO J, V16, P6337, DOI 10.1093/emboj/16.21.6337; McDonald TV, 1997, NATURE, V388, P289, DOI 10.1038/40882; Roden DM, 1996, CIRCULATION, V94, P1996, DOI 10.1161/01.CIR.94.8.1996; Sambrook J., 2002, MOL CLONING LAB MANU; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SANGUINETTI MC, 1991, CIRC RES, V68, P77, DOI 10.1161/01.RES.68.1.77; Sanguinetti MC, 1996, P NATL ACAD SCI USA, V93, P2208, DOI 10.1073/pnas.93.5.2208; Schonherr R, 1996, J PHYSIOL-LONDON, V493, P635, DOI 10.1113/jphysiol.1996.sp021410; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; Snyders DJ, 1996, MOL PHARMACOL, V49, P949; Spector PS, 1996, CIRC RES, V78, P499, DOI 10.1161/01.RES.78.3.499; Spector PS, 1996, J GEN PHYSIOL, V107, P611, DOI 10.1085/jgp.107.5.611; VESELY MR, 1997, CIRCULATION, V96, P56; Wang SM, 1996, FEBS LETT, V389, P167, DOI 10.1016/0014-5793(96)00570-4; WANG ZG, 1994, CARDIOVASC RES, V28, P1540, DOI 10.1093/cvr/28.10.1540; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Yang T, 1997, CIRC RES, V80, P782; YANG T, 1995, CIRC RES, V77, P1246, DOI 10.1161/01.RES.77.6.1246	33	125	128	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27231	27235		10.1074/jbc.273.42.27231	http://dx.doi.org/10.1074/jbc.273.42.27231			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765245	hybrid			2022-12-27	WOS:000076448000032
J	Rietzler, M; Bittner, M; Kolanus, W; Schuster, A; Holzmann, B				Rietzler, M; Bittner, M; Kolanus, W; Schuster, A; Holzmann, B			The human WD repeat protein WAIT-1 specifically interacts with the cytoplasmic tails of beta 7-integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE-1; HOMING RECEPTOR ALPHA-4-BETA-7; MUCOSAL VASCULAR ADDRESSIN; EXTRA SEX COMBS; INTEGRIN ALPHA(4)BETA(7); EPITHELIAL-CELLS; E-CADHERIN; BETA(7) INTEGRIN; BINDING PROTEIN; T-CELLS	Integrins of the beta 7 subfamily, alpha 4 beta 7 and alpha E beta 7, contribute to lymphocyte homing and to the development of protective or autoreactive immune responses at mucosal sites. The beta subunits of integrins are considered important for regulation of stimulated cell adhesion and adhesion dependent signal transduction, Using a yeast interaction trap screen, a human WD repeat protein, termed WAIT-1, was isolated that interacts with the integrin beta 7 cytoplasmic tail and is homologous to mouse EED and Drosophila ESC proteins. WAIT-1 also binds to the cytoplasmic domains of alpha 4 and alpha E but not to those of integrin beta 1, beta 2, and alpha L subunits. Association of WAIT-1 and beta 7-integrin was confirmed by coprecipitation from transiently transfected 293 cells. The binding site for WAIT-I was mapped to a short membrane-proximal region of the beta 7 cytoplasmic tail with Tyr-735 being of critical importance. Northern blot analysis revealed multiple WAIT-1-related transcripts with differential expression in circulating leukocytes, tissue-resident cells of diverse origin, and lymphoid malignancies. These results suggest that WAIT-1, together with the recently identified RACK1, may define a novel subfamily of WD repeat proteins that interact with distinct subsets of integrin cytoplasmic tails and may act as specific regulators of integrin function.	Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-81675 Munich, Germany; Univ Munich, Genzentrum, Mol Biol Lab, D-81375 Munich, Germany	Technical University of Munich; University of Munich	Holzmann, B (corresponding author), Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, Trogerstr 4A, D-81675 Munich, Germany.							Andrew DP, 1996, EUR J IMMUNOL, V26, P897, DOI 10.1002/eji.1830260427; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; Biffo S, 1997, J BIOL CHEM, V272, P30314, DOI 10.1074/jbc.272.48.30314; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Brezinschek RI, 1996, AM J PATHOL, V149, P1651; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; Chang DD, 1997, J CELL BIOL, V138, P1149, DOI 10.1083/jcb.138.5.1149; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CROWE DT, 1994, J BIOL CHEM, V269, P14411; Denisenko ON, 1997, MOL CELL BIOL, V17, P4707, DOI 10.1128/MCB.17.8.4707; Dietz SB, 1996, J CUTAN PATHOL, V23, P312, DOI 10.1111/j.1600-0560.1996.tb01303.x; Drillenburg P, 1997, AM J PATHOL, V150, P919; ERLE DJ, 1994, J IMMUNOL, V153, P517; GUTJAHR T, 1995, EMBO J, V14, P4296, DOI 10.1002/j.1460-2075.1995.tb00104.x; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hesterberg PE, 1996, GASTROENTEROLOGY, V111, P1373, DOI 10.1053/gast.1996.v111.pm8898653; HOLZMANN B, 1989, CELL, V56, P37, DOI 10.1016/0092-8674(89)90981-1; JONAS P, 1998, IN PRESS INT J CANC; KARECLA PI, 1995, EUR J IMMUNOL, V25, P852, DOI 10.1002/eji.1830250333; Kashiwagi H, 1997, J CELL BIOL, V137, P1433, DOI 10.1083/jcb.137.6.1433; KILSHAW PJ, 1991, EUR J IMMUNOL, V21, P2591, DOI 10.1002/eji.1830211041; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KRAAL G, 1995, AM J PATHOL, V147, P763; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Manie SN, 1996, BLOOD, V87, P1855; MICHIE SA, 1995, AM J PATHOL, V147, P412; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; PALS ST, 1994, GASTROENTEROLOGY, V107, P1519, DOI 10.1016/0016-5085(94)90558-4; PerezVillar JJ, 1996, IMMUNOLOGY, V89, P96, DOI 10.1046/j.1365-2567.1996.d01-706.x; Picarella D, 1997, J IMMUNOL, V158, P2099; Rott LS, 1997, J CLIN INVEST, V100, P1204, DOI 10.1172/JCI119633; Rott LS, 1996, J IMMUNOL, V156, P3727; Schumacher A, 1996, NATURE, V383, P250, DOI 10.1038/383250a0; SCHWEIGHOFFER T, 1993, J IMMUNOL, V151, P717; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; SIMONITSCH I, 1994, AM J PATHOL, V145, P1148; STRAUCH UG, 1994, INT IMMUNOL, V6, P263, DOI 10.1093/intimm/6.2.263; STREETER PR, 1988, NATURE, V331, P41, DOI 10.1038/331041a0; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TIISALA S, 1995, EUR J IMMUNOL, V25, P411, DOI 10.1002/eji.1830250216; Uhlemann AC, 1997, BIOCHEM BIOPH RES CO, V239, P68, DOI 10.1006/bbrc.1997.7429; van Lohuizen M, 1998, MOL CELL BIOL, V18, P3572, DOI 10.1128/MCB.18.6.3572; Wagner N, 1996, NATURE, V382, P366, DOI 10.1038/382366a0; Walsh GM, 1996, IMMUNOLOGY, V89, P112, DOI 10.1046/j.1365-2567.1996.d01-713.x; Yang XD, 1997, DIABETES, V46, P1542, DOI 10.2337/diabetes.46.10.1542	48	47	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27459	27466		10.1074/jbc.273.42.27459	http://dx.doi.org/10.1074/jbc.273.42.27459			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765275	hybrid			2022-12-27	WOS:000076448000062
J	Xirasagar, S; Elliott, MB; Bartolini, W; Gollnick, P; Gottlieb, PA				Xirasagar, S; Elliott, MB; Bartolini, W; Gollnick, P; Gottlieb, PA			RNA structure inhibits the TRAP (trp RNA-binding attenuation protein) RNA interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS BINDS; LEADER RNA; CRYSTAL-STRUCTURE; TELOMERIC DNA; OPERON; NUCLEOTIDES; REPRESSOR; SUBSTITUTION; TRANSCRIPTS; RECOGNITION	TRAP (trp RNA-binding attenuation protein) regulates expression of the tryptophan biosynthetic genes in response to tryptophan in Bacillus subtilis by binding to two sites containing a series of 9 or 11 (G/U)AG triplet repeats that are generally separated by two or three spacer nucleotides. Previous mutagenesis experiments have identified three TRAP residues, Lys-37, Lys-56, and Arg-58 that are essential for RNA binding. The location of these residues on the TRAP oligomer supports the proposal that RNA binds TRAP by encircling the TRAP oligomer, In this work, we show that RNAs containing 11 GAG or UAG repeats separated by CC dinucleotide spacers (((G/U)AGCC)(11)) form stable structures that inhibit binding to TRAP. This conclusion is based on the effects of temperature and Mg2+ on the affinity of TRAP for RNAs with CC spacers combined with UV hyperchromicity and circular dichroism. Furthermore, introducing the base analogue 7-deazaguanosine in the ((G/U)AGCC)(11) RNAs stabilized the TRAP-RNA interaction, This effect was associated with decreased stability of the RNA structure as measured by circular dichroism spectroscopy. The precise nature of the structure of the ((G/U)AGCC)(11) RNAs is not known but evidence is presented that it involves noncanonical interactions, We also observed that substitution of Arg-58 with Lys further reduced the ability of TRAP to interact with structured RNAs. Since in vivo function of TRAP may involve binding to structured RNAs, we suggest a potential function for this residue, which is conserved in TRAP from three different bacilli.	SUNY Buffalo, Dept Sci Biol, Buffalo, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Gottlieb, PA (corresponding author), SUNY Buffalo, Dept Sci Biol, Buffalo, NY 14260 USA.		Gottlieb, Philip/C-3113-2019	Gottlieb, Philip/0000-0003-3764-9885	NIGMS NIH HHS [GM52033] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052033] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RA, 1975, BIOCHEMISTRY-US, V14, P907, DOI 10.1021/bi00676a006; ANTSON AA, 1994, J MOL BIOL, V244, P1, DOI 10.1006/jmbi.1994.1698; ANTSON AA, 1995, NATURE, V374, P693, DOI 10.1038/374693a0; Babitzke P, 1996, J BACTERIOL, V178, P5159, DOI 10.1128/jb.178.17.5159-5163.1996; BABITZKE P, 1995, P NATL ACAD SCI USA, V92, P7916, DOI 10.1073/pnas.92.17.7916; BABITZKE P, 1993, P NATL ACAD SCI USA, V90, P133, DOI 10.1073/pnas.90.1.133; Babitzke P, 1997, MOL MICROBIOL, V26, P1, DOI 10.1046/j.1365-2958.1997.5541915.x; Baumann C, 1996, J BIOL CHEM, V271, P12269, DOI 10.1074/jbc.271.21.12269; Baumann C, 1997, J BIOL CHEM, V272, P19863, DOI 10.1074/jbc.272.32.19863; BRAHMS J, 1966, J MOL BIOL, V15, P467, DOI 10.1016/S0022-2836(66)80122-5; Brion P, 1997, ANNU REV BIOPH BIOM, V26, P113, DOI 10.1146/annurev.biophys.26.1.113; BROYDE S, 1978, NUCLEIC ACIDS RES, V5, P2729, DOI 10.1093/nar/5.8.2729; Correll CC, 1997, CELL, V91, P705, DOI 10.1016/S0092-8674(00)80457-2; Du HS, 1997, J BACTERIOL, V179, P2582, DOI 10.1128/jb.179.8.2582-2586.1997; GOLLNICK P, 1994, MOL MICROBIOL, V11, P991, DOI 10.1111/j.1365-2958.1994.tb00377.x; GOLLNICK P, 1990, P NATL ACAD SCI USA, V87, P8726, DOI 10.1073/pnas.87.22.8726; HALL KB, 1992, NUCLEIC ACIDS RES, V20, P4283, DOI 10.1093/nar/20.16.4283; HOFFMAN RJ, 1995, J BACTERIOL, V177, P839, DOI 10.1128/jb.177.3.839-842.1995; KURODA MI, 1988, J BACTERIOL, V170, P3080, DOI 10.1128/jb.170.7.3080-3088.1988; LESSER DR, 1993, P NATL ACAD SCI USA, V90, P7548, DOI 10.1073/pnas.90.16.7548; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; MAZZARELLI JM, 1992, BIOCHEMISTRY-US, V31, P5925, DOI 10.1021/bi00140a032; MERINO E, 1995, J BACTERIOL, V177, P6362, DOI 10.1128/jb.177.22.6362-6370.1995; OTRIDGE J, 1993, P NATL ACAD SCI USA, V90, P128, DOI 10.1073/pnas.90.1.128; RAMASAMY K, 1987, TETRAHEDRON LETT, V28, P5107, DOI 10.1016/S0040-4039(00)95603-X; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; SEELA F, 1982, BIOCHEMISTRY-US, V21, P4338, DOI 10.1021/bi00261a024; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; TAO JS, 1992, P NATL ACAD SCI USA, V89, P2723, DOI 10.1073/pnas.89.7.2723; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VARANI G, 1994, RNA PROTEIN INTERACT, P1; WIECZOREK A, 1994, BIOORG MED CHEM LETT, V4, P987, DOI 10.1016/S0960-894X(01)80668-5; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; YANG M, 1995, J BACTERIOL, V177, P4272, DOI 10.1128/jb.177.15.4272-4278.1995; Yang M, 1997, J MOL BIOL, V270, P696, DOI 10.1006/jmbi.1997.1149; ZHANG XL, 1993, BIOCHEMISTRY-US, V32, P11374, DOI 10.1021/bi00093a014; ZHANG XL, 1995, NUCLEIC ACIDS RES, V23, P1502, DOI 10.1093/nar/23.9.1502; Ziehler WA, 1996, BIOTECHNIQUES, V20, P622	38	19	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27146	27153		10.1074/jbc.273.42.27146	http://dx.doi.org/10.1074/jbc.273.42.27146			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765233	hybrid			2022-12-27	WOS:000076448000020
J	Cannon, WR; Benkovic, SJ				Cannon, WR; Benkovic, SJ			Solvation, reorganization energy, and biological catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							TRANSITION-STATE; ENZYMATIC CATALYSIS; DIHYDROFOLATE-REDUCTASE; PROFICIENT ENZYME; HYDROGEN; EFFICIENCY; ANTIBODY; DYNAMICS; PROTEINS		Penn State Univ, Dept Chem, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Cannon, WR (corresponding author), Penn State Univ, Dept Chem, 152 Davey Lab, University Pk, PA 16802 USA.		Cannon, William R/K-8411-2014	Cannon, William R/0000-0003-3789-7889				ALBERY WJ, 1980, ANNU REV PHYS CHEM, V31, P227, DOI 10.1146/annurev.pc.31.100180.001303; AQVIST J, 1989, BIOCHEMISTRY-US, V28, P4680; BEARNE SL, 1995, J AM CHEM SOC, V117, P9588, DOI 10.1021/ja00142a037; Benkovic S. J., 1966, BIOORGANIC MECHANISM; BRUICE TC, 1963, J AM CHEM SOC, V85, P1, DOI 10.1021/ja00884a001; Cannon WR, 1996, NAT STRUCT BIOL, V3, P821, DOI 10.1038/nsb1096-821; CARTER P, 1990, PROTEINS, V7, P335, DOI 10.1002/prot.340070405; Chabinyc ML, 1998, SCIENCE, V279, P1882, DOI 10.1126/science.279.5358.1882; CLELAND WW, 1994, SCIENCE, V264, P1887, DOI 10.1126/science.8009219; Cleland WW, 1998, J BIOL CHEM, V273, P25529, DOI 10.1074/jbc.273.40.25529; CROSBY J, 1970, J AM CHEM SOC, V92, P2891, DOI 10.1021/ja00712a048; DEWAR MJS, 1985, P NATL ACAD SCI USA, V82, P2225, DOI 10.1073/pnas.82.8.2225; FARNUM MF, 1991, BIOCHEMISTRY-US, V30, P11567, DOI 10.1021/bi00113a012; FIERKE CA, 1987, BIOCHEMISTRY-US, V26, P4085, DOI 10.1021/bi00387a052; FRAUENFELDER H, 1985, SCIENCE, V229, P337, DOI 10.1126/science.4012322; HAYNES MR, 1994, SCIENCE, V263, P646, DOI 10.1126/science.8303271; Hollfelder F, 1996, NATURE, V383, P60, DOI 10.1038/383060a0; Jonsson T, 1996, J AM CHEM SOC, V118, P10319, DOI 10.1021/ja961827p; JORGENSEN WL, 1988, ADV CHEM PHYS 2, V70, P469; KRISHTALIK L I, 1974, Molecular Biology (English Translation of Molekulyarnaya Biologiya (Moscow)), V8, P75; KRISHTALIK LI, 1980, J THEOR BIOL, V86, P757, DOI 10.1016/0022-5193(80)90309-4; KRISHTALIK LI, 1985, J THEOR BIOL, V112, P251, DOI 10.1016/S0022-5193(85)80285-X; KURZ JL, 1963, J AM CHEM SOC, V85, P987, DOI 10.1021/ja00890a035; Lee JK, 1997, SCIENCE, V276, P942, DOI 10.1126/science.276.5314.942; LIENHARD GE, 1973, SCIENCE, V180, P149, DOI 10.1126/science.180.4082.149; Lightstone FC, 1996, J AM CHEM SOC, V118, P2595, DOI 10.1021/ja952589l; McCammon JA., 1987, DYNAMICS PROTEINS NU; Mesecar AD, 1997, SCIENCE, V277, P202, DOI 10.1126/science.277.5323.202; Miller BG, 1998, J AM CHEM SOC, V120, P2666, DOI 10.1021/ja980066i; Neria E, 1997, CHEM PHYS LETT, V267, P23, DOI 10.1016/S0009-2614(97)00068-7; Nixon AE, 1997, P NATL ACAD SCI USA, V94, P1069, DOI 10.1073/pnas.94.4.1069; NORTHRUP SH, 1982, P NATL ACAD SCI-BIOL, V79, P4035, DOI 10.1073/pnas.79.13.4035; NORTHRUP SH, 1984, J AM CHEM SOC, V106, P930, DOI 10.1021/ja00316a018; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; PERUTZ MF, 1967, PROC R SOC SER B-BIO, V167, P448, DOI 10.1098/rspb.1967.0046; Quemeneur E, 1998, NATURE, V391, P301, DOI 10.1038/34687; Radzicka A, 1996, J AM CHEM SOC, V118, P6105, DOI 10.1021/ja954077c; RADZICKA A, 1995, SCIENCE, V267, P90, DOI 10.1126/science.7809611; Shan SO, 1996, P NATL ACAD SCI USA, V93, P14474, DOI 10.1073/pnas.93.25.14474; STEWART JD, 1995, NATURE, V375, P388, DOI 10.1038/375388a0; TANAKA K, 1976, CAN J CHEM, V54, P1643, DOI 10.1139/v76-234; WARSHEL A, 1984, P NATL ACAD SCI-BIOL, V81, P444, DOI 10.1073/pnas.81.2.444; WARSHEL A, 1989, P NATL ACAD SCI USA, V86, P5820, DOI 10.1073/pnas.86.15.5820; WARSHEL A, 1988, J MOL BIOL, V201, P139, DOI 10.1016/0022-2836(88)90445-7; WARSHEL A, 1978, P NATL ACAD SCI USA, V75, P5250, DOI 10.1073/pnas.75.11.5250; Warshel A, 1998, J BIOL CHEM, V273, P27035, DOI 10.1074/jbc.273.42.27035; WOLFENDEN R, 1972, ACCOUNTS CHEM RES, V5, P10, DOI 10.1021/ar50049a002; WOLFENDEN R, 1983, SCIENCE, V222, P1087, DOI 10.1126/science.6359416; YADAV A, 1991, J AM CHEM SOC, V113, P4800, DOI 10.1021/ja00013a013	49	142	142	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26257	26260		10.1074/jbc.273.41.26257	http://dx.doi.org/10.1074/jbc.273.41.26257			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756847	hybrid			2022-12-27	WOS:000076373300001
J	Gribble, FM; Proks, P; Corkey, BE; Ashcroft, FM				Gribble, FM; Proks, P; Corkey, BE; Ashcroft, FM			Mechanism of cloned ATP-sensitive potassium channel activation by oleoyl-CoA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN ACYL-COA; PANCREATIC BETA-CELLS; SULFONYLUREA RECEPTOR; INSULIN-SECRETION; K+ CURRENTS; GUANINE-NUCLEOTIDES; SKELETAL-MUSCLE; ADP/ATP CARRIER; SMOOTH-MUSCLE; MALONYL-COA	Insulin secretion from pancreatic beta cells is coupled to cell metabolism through closure of ATP-sensitive potassium (K-ATP,) channels, which comprise Kir6.2 and sulfonylurea receptor (SUR1) subunits. Although metabolic regulation of K-ATP, channel activity is believed to be mediated principally by the adenine nucleotides, other metabolic intermediates, including long chain acyl-CoA esters, may also be involved. We recorded macroscopic and single-channel currents from Xenopus oocytes expressing either Kir6.2/SUR1 or Kir6.2 Delta C36 (which forms channels in the absence of SUR1), Oleoyl-CoA (1 mu M) activated both wild-type Kir6.2/SUR1 and Kir6.2 Delta C36 macroscopic currents, similar to 2-fold, by increasing the number and open probability of Kir6.2/SUR1 and Kir6.2 Delta C36 channels. It was ineffective on the related Kir subunit Kir1.1a. Oleoyl-CoA also impaired channel inhibition by ATP, increasing the K-i values for both Kir6.2/SUR1 and Kir6.2 Delta C36 currents by similar to 3-fold. Our results indicate that activation of K-ATP channels by oleoyl-CoA results from an interaction with the Kir6.2 subunit, unlike the stimulatory effects of MgADP and diazoxide which are mediated through SUR1. The increased activity and reduced ATP sensitivity of K-ATP, channels by oleoyl-CoA might contribute to the impaired insulin secretion observed in non-insulin-dependent diabetes mellitus.	Univ Oxford, Physiol Lab, Oxford OX1 3PT, England; Boston Univ, Med Ctr, Boston, MA 02118 USA	University of Oxford; Boston University	Ashcroft, FM (corresponding author), Univ Oxford, Physiol Lab, Parks Rd, Oxford OX1 3PT, England.	frances.ashcroft@physiol.ox.ac.uk	; Corkey, Barbara/E-7712-2015	Gribble, Fiona/0000-0002-4232-2898; Corkey, Barbara/0000-0002-5467-1630; Proks, Peter/0000-0001-6097-3646	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035914, R01DK035914, R56DK035914] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK35914] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome TrustEuropean Commission)		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; Branstrom R, 1997, J BIOL CHEM, V272, P17390, DOI 10.1074/jbc.272.28.17390; Chutkow WA, 1996, DIABETES, V45, P1439, DOI 10.2337/diabetes.45.10.1439; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; FINDLAY I, 1986, PFLUG ARCH EUR J PHY, V407, P238, DOI 10.1007/BF00580683; Gribble FM, 1997, J PHYSIOL-LONDON, V498, P87, DOI 10.1113/jphysiol.1997.sp021843; Gribble FM, 1997, EMBO J, V16, P1145, DOI 10.1093/emboj/16.6.1145; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; Karschin C, 1997, FEBS LETT, V401, P59, DOI 10.1016/S0014-5793(96)01438-X; KOZLOWSKI RZ, 1989, BRIT J PHARMACOL, V97, P1039, DOI 10.1111/j.1476-5381.1989.tb12560.x; Larsson O, 1996, J BIOL CHEM, V271, P10623, DOI 10.1074/jbc.271.18.10623; NICHOLS CG, 1991, AM J PHYSIOL, V261, pH1675, DOI 10.1152/ajpheart.1991.261.6.H1675; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; OHNOSHOSAKU T, 1987, PFLUG ARCH EUR J PHY, V408, P133, DOI 10.1007/BF00581342; Paucek P, 1996, J BIOL CHEM, V271, P32084, DOI 10.1074/jbc.271.50.32084; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; Prentki M, 1996, DIABETES, V45, P273, DOI 10.2337/diabetes.45.3.273; PRENTKI M, 1997, DIABETOLOGIA, V40, P32; PROKS P, 1993, PFLUG ARCH EUR J PHY, V424, P63, DOI 10.1007/BF00375103; Quayle JM, 1997, PHYSIOL REV, V77, P1165, DOI 10.1152/physrev.1997.77.4.1165; RUOHO AE, 1989, J BIOL CHEM, V264, P4168; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; Shyng SL, 1997, J GEN PHYSIOL, V110, P141, DOI 10.1085/jgp.110.2.141; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; Trapp S, 1997, P NATL ACAD SCI USA, V94, P8872, DOI 10.1073/pnas.94.16.8872; Tucker SJ, 1998, EMBO J, V17, P3290, DOI 10.1093/emboj/17.12.3290; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; WOLDEGIORGIS G, 1989, BIOCHEM BIOPH RES CO, V161, P502, DOI 10.1016/0006-291X(89)92627-2	38	116	123	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26383	26387		10.1074/jbc.273.41.26383	http://dx.doi.org/10.1074/jbc.273.41.26383			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756869	hybrid			2022-12-27	WOS:000076373300023
J	Ohnuma, S; Hirooka, K; Tsuruoka, N; Yano, M; Ohto, C; Nakane, H; Nishino, T				Ohnuma, S; Hirooka, K; Tsuruoka, N; Yano, M; Ohto, C; Nakane, H; Nishino, T			A pathway where polyprenyl diphosphate elongates in prenyltransferase - Insight into a common mechanism of chain length determination of prenyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNDECAPRENYL PYROPHOSPHATE SYNTHETASE; ASPARTATE-RICH MOTIF; ESCHERICHIA-COLI; MOLECULAR-CLONING; MICROCOCCUS-LUTEUS; SACCHAROMYCES-CEREVISIAE; BIOSYNTHETIC-PATHWAY; PARTIAL-PURIFICATION; PRENYL TRANSFERASES; BACILLUS-SUBTILIS	Prenyltransferases catalyze the consecutive condensations of isopentenyl diphosphate to produce linear polyprenyl diphosphates. Each enzyme forms the final product with a specific chain length. The product specificity of an enzyme is thought to be determined by the structure around the unknown path through which the product elongates in the enzyme. To explore the path, we introduced a few mutations at the 5th, the 8th, and/or the 11th positions before the first aspartate-rich motif of geranylgeranyl-diphosphate synthase or farnesyl-diphosphate synthase, The side chains of these amino acids are situated on the same side of an alpha-helix. In geranylgeranyl-diphosphate synthase, a single mutated enzyme (F77S) mainly produces a C-25 product (Ohnuma, S.-I., Hirooka, K., Hemmi, H., Ishida, C., Ohto, C., and Nishino, T. (1996) J. Biol. Chem. 271, 18831-18837). A double mutated enzyme (L74G and F77G) mainly produces a C-35 compound with significant amounts of C-35 and C-40. A triple mutated enzyme (I71G, L74G, and F77G) mainly produces a C-40 compound with C-35 and C-45. Mutated farnesyl-diphosphate synthases also show similar patterns. These findings indicate that the elongating product passages on a surface of the side chains of the mutated amino acids, the original bulky amino acids had blocked the elongation, and the path is conserved in prenyltransferases. Moreover, the fact that some double and triple mutated enzymes can also form small amounts of products longer than C-50 indicates that the paths in these mutated enzymes can partially access the outer surface of the enzymes.	Tohoku Univ, Dept Biochem & Engn, Aoba Ku, Sendai, Miyagi 9808579, Japan; Toyota Motor Corp, Bio Res Labs, Toyota 4718572, Japan	Tohoku University; Toyota Motor Corporation	Ohnuma, S (corresponding author), Univ Cambridge, Dept Anat, Downing St, Cambridge CB2 3DY, England.		Hirooka, Kazutake/K-9827-2017; Tsuruoka, Naoki/L-1192-2018; Ohto, Chikara/GQB-4702-2022	Hirooka, Kazutake/0000-0001-5879-936X; Tsuruoka, Naoki/0000-0003-4052-3327; Ohnuma, Shin-ichi/0000-0002-3305-5126				ALLEN CM, 1976, ARCH BIOCHEM BIOPHYS, V175, P236, DOI 10.1016/0003-9861(76)90504-X; ANDERSON MS, 1989, J BIOL CHEM, V264, P19176; ASAI K, 1994, BIOCHEM BIOPH RES CO, V202, P340, DOI 10.1006/bbrc.1994.1933; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; BABA T, 1980, ARCH BIOCHEM BIOPHYS, V200, P474, DOI 10.1016/0003-9861(80)90379-3; BREMS DN, 1981, BIOCHEMISTRY-US, V20, P3711, DOI 10.1021/bi00516a007; CARATTOLI A, 1991, J BIOL CHEM, V266, P5854; CHEN AJ, 1994, ARCH BIOCHEM BIOPHYS, V314, P399, DOI 10.1006/abbi.1994.1459; CHEN AJ, 1994, PROTEIN SCI, V3, P600; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; CORNISH K, 1993, EUR J BIOCHEM, V218, P267, DOI 10.1111/j.1432-1033.1993.tb18374.x; ERICSSON J, 1991, J BIOL CHEM, V266, P10602; FUJII H, 1982, BIOCHIM BIOPHYS ACTA, V712, P716; FUJII H, 1982, J BIOL CHEM, V257, P4610; FUJISAKI S, 1986, J BIOCHEM-TOKYO, V99, P1327, DOI 10.1093/oxfordjournals.jbchem.a135600; FUJISAKI S, 1990, J BIOCHEM-TOKYO, V108, P995, DOI 10.1093/oxfordjournals.jbchem.a123327; HEIDE L, 1989, ARCH BIOCHEM BIOPHYS, V273, P331, DOI 10.1016/0003-9861(89)90491-8; ISHII K, 1983, BIOCHEM BIOPH RES CO, V116, P500, DOI 10.1016/0006-291X(83)90551-X; KOIKETAKESHITA A, 1995, J BIOL CHEM, V270, P18396, DOI 10.1074/jbc.270.31.18396; KOYAMA T, 1993, J BIOCHEM-TOKYO, V113, P355, DOI 10.1093/oxfordjournals.jbchem.a124051; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MATH SK, 1992, P NATL ACAD SCI USA, V89, P6761, DOI 10.1073/pnas.89.15.6761; MISAWA N, 1990, J BACTERIOL, V172, P6704, DOI 10.1128/jb.172.12.6704-6712.1990; OHNUMA S, 1991, J BIOL CHEM, V266, P23706; OHNUMA S, 1992, J BIOCHEM-TOKYO, V112, P743, DOI 10.1093/oxfordjournals.jbchem.a123969; Ohnuma S, 1996, J BIOL CHEM, V271, P18831, DOI 10.1074/jbc.271.31.18831; Ohnuma S, 1996, J BIOL CHEM, V271, P30748, DOI 10.1074/jbc.271.48.30748; Ohnuma S, 1997, J BIOL CHEM, V272, P5192, DOI 10.1074/jbc.272.8.5192; OHNUMA S, 1994, J BIOL CHEM, V269, P14792; Ohnuma S, 1997, J BIOCHEM-TOKYO, V121, P696; Ohnuma SI, 1996, J BIOL CHEM, V271, P10087, DOI 10.1074/jbc.271.17.10087; Okada K, 1997, J BACTERIOL, V179, P5992, DOI 10.1128/jb.179.19.5992-5998.1997; POULTER CD, 1982, BIOSYNTHESIS ISOPREN, P161; SAGAMI H, 1977, BIOCHEMISTRY-US, V16, P4616, DOI 10.1021/bi00640a014; Sambrook J., 2002, MOL CLONING LAB MANU; Suzuki K, 1997, J BIOCHEM, V121, P496; TAKAHASHI I, 1982, J BIOCHEM-TOKYO, V92, P1527, DOI 10.1093/oxfordjournals.jbchem.a134077; TAKAHASHI I, 1980, J BIOL CHEM, V255, P4539; TANAKA Y, 1988, Journal of Natural Rubber Research, V3, P177; TANAKA Y, 1989, J APPL POLYM SCI APP, V44, P1; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; Tarshis LC, 1996, P NATL ACAD SCI USA, V93, P15018, DOI 10.1073/pnas.93.26.15018; WILKIN DJ, 1990, J BIOL CHEM, V265, P4607	43	76	77	3	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26705	26713		10.1074/jbc.273.41.26705	http://dx.doi.org/10.1074/jbc.273.41.26705			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756913	hybrid			2022-12-27	WOS:000076373300067
J	Chen, HC; Chan, PC; Tang, MJ; Cheng, CH; Chang, TJ				Chen, HC; Chan, PC; Tang, MJ; Cheng, CH; Chang, TJ			Tyrosine phosphorylation of focal adhesion kinase stimulated by hepatocyte growth factor leads to mitogen-activated protein kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-MATRIX INTERACTIONS; SRC FAMILY KINASES; SWISS 3T3 CELLS; FACTOR-RECEPTOR; SIGNAL-TRANSDUCTION; MAP KINASE; C-MET; PHOSPHATIDYLINOSITOL 3-KINASE; COMPLEX-FORMATION; ADAPTER PROTEIN	Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase involved in integrin-mediated signal transduction pathway. In this report, we describe that the treatment of hepatocyte growth factor (HGF) stimulates a significant increase in the tyrosine phosphorylation of FAK in human embryonic kidney 293 cells. This stimulation is independent of cell adhesion or the integrity of the actin cytoskeleton, suggesting potentially different mechanisms by which the HGF receptors and integrins regulate the tyrosine phosphorylation of FAK. Our results also suggest that the activation of Src upon HGF stimulation is likely to be one, if not the only, of the mechanisms responsible for the HGF-induced tyrosine phosphorylation of FAK. Furthermore, we showed that a mutation in the Grb2 binding site Tyr-925 of FAK partially abolishes its increase in HGF-induced phosphorylation. Finally, we demonstrated that HGF stimulates the association of FAK with Grb2 in vitro and in intact cells and provided evidence that FAK might contribute to the activation of mitogen-activated protein kinase through Ras in HGF signaling by functioning as an adapter molecule.	Natl Chung Hsing Univ, Dept Zool, Taichung 40227, Taiwan; Natl Chung Hsing Univ, Coll Life Sci, Inst Biochem, Taichung 40227, Taiwan; Natl Chung Hsing Univ, Coll Agr, Dept Vet Med, Taichung 40227, Taiwan; Natl Cheng Kung Univ, Dept Physiol, Tainan 70101, Taiwan; Taichung Vet Gen Hosp, Nephrol Sect, Taichung, Taiwan	National Chung Hsing University; National Chung Hsing University; National Chung Hsing University; National Cheng Kung University; Taichung Veterans General Hospital	Chen, HC (corresponding author), Natl Chung Hsing Univ, Dept Zool, Taichung 40227, Taiwan.			Tang, Ming-Jer/0000-0002-0883-4363				BARDELLI A, 1992, ONCOGENE, V7, P1973; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Boyer B, 1997, EMBO J, V16, P5904, DOI 10.1093/emboj/16.19.5904; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1996, J CELL SCI, V109, P1787; CHEN HC, 1994, J BIOL CHEM, V269, P31229; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GIORDANO S, 1989, ONCOGENE, V4, P1983; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; Guan JL, 1996, INT REV CYTOL, V168, P81, DOI 10.1016/S0074-7696(08)60883-9; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Hamawy MM, 1997, J BIOL CHEM, V272, P30498, DOI 10.1074/jbc.272.48.30498; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HATAI M, 1994, FEBS LETT, V350, P113, DOI 10.1016/0014-5793(94)00745-4; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic D, 1996, EXP CELL RES, V222, P298, DOI 10.1006/excr.1996.0038; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; OWENS LV, 1995, CANCER RES, V55, P2752; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RANKIN S, 1994, J BIOL CHEM, V269, P704; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	56	80	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25777	25782		10.1074/jbc.273.40.25777	http://dx.doi.org/10.1074/jbc.273.40.25777			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748249	hybrid			2022-12-27	WOS:000076263100040
J	Sprong, H; Kruithof, B; Leijendekker, R; Slot, JW; van Meer, G; van der Sluijs, P				Sprong, H; Kruithof, B; Leijendekker, R; Slot, JW; van Meer, G; van der Sluijs, P			UDP-galactose : ceramide galactosyltransferase is a class I integral membrane protein of the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; GOLGI-APPARATUS; CELLS; EXPRESSION; TRANSPORT; TOPOLOGY; SURFACE; GLUCOSYLTRANSFERASE; GALACTOCEREBROSIDE; GLUCOSYLCERAMIDE	UDP-galactose:ceramide galactosyltransferase (CGalT) transfers UDP-galactose 60 ceramide to form the glycosphingolipid galactosylceramide. Galactosylceramide is the major constituent of myelin and is also highly enriched in many epithelial cells, where it is thought to play an important role in lipid and protein sorting. Although the biochemical pathways of glycosphingolipid biosynthesis are relatively well understood, the localization of the enzymes involved in these processes has remained controversial. We here have raised antibodies against CGalT and shown by immunocytochemistry on ultrathin cryosections that the enzyme is localized to the endoplasmic reticulum and nuclear envelope but not to the Golgi apparatus or the plasma membrane. In pulse-chase experiments, we have observed that newly synthesized CGalT remains sensitive to endoglycosidase H, confirming the results of the morphological localization experiments. In protease protection assays, we show that the largest part of the protein, including the amino terminus, is oriented toward the lumen of the endoplasmic reticulum. CGalT enzyme activity required import of UDP-galactose into the lumen of the endoplasmic reticulum by a UDP-galactose translocator that is present in the Golgi apparatus of CHO cells but absent in CHOlec8 cells. Finally, we show that CGalT activity previously observed in Golgi membrane fractions in vitro, in the absence of UDP-glucose, is caused by UDP-glucose:ceramide glucosyltransferase. Therefore all galactosylceramide synthesis occurs by CGalT in vivo in the lumen of the endoplasmic reticulum.	Univ Utrecht, Sch Med, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Cell Biol & Histol, NL-1100 DE Amsterdam, Netherlands	Utrecht University; University of Amsterdam; Academic Medical Center Amsterdam	van der Sluijs, P (corresponding author), Univ Utrecht, Sch Med, Dept Cell Biol, AZU Rm H02-314,Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	pvander@knoware.nl	Kruithof, Boudewijn/C-1718-2014; van Meer, Gerrit/AAH-1560-2021	Kruithof, Boudewijn/0000-0002-9604-4563; van Meer, Gerrit/0000-0002-5976-6436; Sprong, Hein/0000-0002-0218-4320				BANSAL R, 1987, J NEUROCHEM, V49, P1902, DOI 10.1111/j.1471-4159.1987.tb02453.x; Bosio A, 1996, P NATL ACAD SCI USA, V93, P13280, DOI 10.1073/pnas.93.23.13280; Bottger G, 1996, J BIOL CHEM, V271, P29191, DOI 10.1074/jbc.271.46.29191; Burger KNJ, 1996, J CELL BIOL, V133, P15, DOI 10.1083/jcb.133.1.15; Coetzee T, 1998, TRENDS NEUROSCI, V21, P126, DOI 10.1016/S0166-2236(97)01178-8; Coetzee T, 1996, CELL, V86, P209, DOI 10.1016/S0092-8674(00)80093-8; DESHMUKH DS, 1988, NEUROCHEM RES, V13, P571, DOI 10.1007/BF00973300; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FLEISCHER B, 1977, J SUPRAMOL STR CELL, V7, P79, DOI 10.1002/jss.400070108; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAKOMORI S, 1993, BIOCHEM SOC T, V21, P583, DOI 10.1042/bst0210583; HAROUSE JM, 1991, SCIENCE, V253, P320, DOI 10.1126/science.1857969; Ichikawa S, 1996, P NATL ACAD SCI USA, V93, P4638, DOI 10.1073/pnas.93.10.4638; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JASMIN BJ, 1989, P NATL ACAD SCI USA, V86, P7218, DOI 10.1073/pnas.86.18.7218; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOUL O, 1988, J NEUROCHEM, V50, P580, DOI 10.1111/j.1471-4159.1988.tb02950.x; Liou W, 1997, J CELL BIOL, V136, P61, DOI 10.1083/jcb.136.1.61; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; Miera N, 1996, J BIOCHEM-TOKYO, V120, P236; MORELL P, 1969, BIOCHEMISTRY-US, V8, P506, DOI 10.1021/bi00830a008; NESKOVIC NM, 1973, J NEUROCHEM, V20, P1419, DOI 10.1111/j.1471-4159.1973.tb00254.x; Paul P, 1996, J BIOL CHEM, V271, P2287, DOI 10.1074/jbc.271.4.2287; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; RADIN NS, 1983, METHOD ENZYMOL, V98, P613; SANDVIG K, 1994, J CELL BIOL, V126, P53, DOI 10.1083/jcb.126.1.53; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI T, 1989, METHOD ENZYMOL, V179, P559; SATO C, 1988, J NEUROCHEM, V50, P1887, DOI 10.1111/j.1471-4159.1988.tb02493.x; SCHAERENWIEMERS N, 1995, J NEUROCHEM, V65, P2267; SCHULTE S, 1995, EUR J BIOCHEM, V233, P947, DOI 10.1111/j.1432-1033.1995.947_3.x; SCHULTE S, 1993, P NATL ACAD SCI USA, V90, P10265, DOI 10.1073/pnas.90.21.10265; SIEGRIST HP, 1979, J NEUROCHEM, V33, P497, DOI 10.1111/j.1471-4159.1979.tb05180.x; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; STAHL N, 1994, J NEUROSCI RES, V38, P234, DOI 10.1002/jnr.490380214; van der Bijl P, 1996, J CELL BIOL, V132, P813, DOI 10.1083/jcb.132.5.813; van der Bijl P, 1996, BIOCHEM J, V317, P589, DOI 10.1042/bj3170589; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WARNOCK DE, 1993, J BIOL CHEM, V268, P10145; ZELLER CB, 1992, AM J PHYSIOL, V262, pC1341, DOI 10.1152/ajpcell.1992.262.6.C1341	49	133	136	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25880	25888		10.1074/jbc.273.40.25880	http://dx.doi.org/10.1074/jbc.273.40.25880			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748263	hybrid			2022-12-27	WOS:000076263100054
J	Sherwood, AL; Nguyen, AT; Whitaker, JM; Macher, BA; Stroud, MR; Holmes, EH				Sherwood, AL; Nguyen, AT; Whitaker, JM; Macher, BA; Stroud, MR; Holmes, EH			Human alpha 1,3/4-fucosyltransferases - III. A Lys/Arg residue located within the alpha 1,3-FucT motif is required for activity but not substrate binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYL-LEWIS-X; HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; MOLECULAR-CLONING; FUCOSYL-TRANSFERASE; ALPHA(1,3)-FUCOSYL-TRANSFERASE GENE; ALPHA-1,3-FUCOSYL-TRANSFERASE GENE; HELICOBACTER-PYLORI; ENZYME-ACTIVITY; ELAM-1 LIGAND; FUT3 GENE	Amino acid sequence alignment of human alpha 1,3/4-fucosyltransferases (FucTs) demonstrates that three highly conserved Lys residues are present in the catalytic domain of FucTs III, TV, V, and VI. Two of these sites are conserved in FucT VII, with the third located within the alpha 1,3-FucT motif as a conservative change to Arg at position 223. Site-directed mutagenesis experiments were conducted to change Lys(255) Of FucT V (equivalent to Arg(223) of FucT VII) to either Arg(255) or Ala(255). Enzyme assays demonstrate that the FucT V K255R mutant has a 34-fold lower specific activity than native FucT V and that the K255A mutant is inactive. Site-directed mutagenesis of FucT VII was also conducted to change Arg(223) to Lys(223) for analysis of the effect on enzyme kinetic parameters. No differences in acceptor specificities or K-m values for either substrate were observed between native FucT VII and the R223K mutant; however, the purified R223K mutant enzyme had a 2-fold increased specific activity compared with purified native FucT VII. No change in GDP-fucose-protectable pyridoxal-P/NaBH4 inactivation was observed for native or mutant FucT V or VII, further supporting the absence of involvement of this residue in sugar nucleotide binding. The results indicate that a basic residue in this position is required for enzyme activity, with a Lys residue providing higher intrinsic activity. The lack of influence of this site on substrate binding parameters and its location within the alpha 1,3-FucT motif suggest that at least some of the residues within this motif are involved in catalysis rather than substrate binding.	NW Hosp, Pacific NW Canc Fdn, Div Cell Surface Biochem, Seattle, WA 98125 USA; San Francisco State Univ, Dept Chem & Biochem, San Francisco, CA 94132 USA	California State University System; San Francisco State University	Holmes, EH (corresponding author), NW Hosp, Pacific NW Canc Fdn, Div Cell Surface Biochem, 120 Northgate Plaza,Suite 218, Seattle, WA 98125 USA.	eholmes@nwbio.org			NATIONAL CANCER INSTITUTE [R01CA070740] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR011805] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM052588] Funding Source: NIH RePORTER; NCI NIH HHS [CA70740] Funding Source: Medline; NCRR NIH HHS [RR11805] Funding Source: Medline; NIGMS NIH HHS [GM52588] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1977, Lipids, V12, P455; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BrinkmanVanderLinden ECM, 1996, J BIOL CHEM, V271, P14492, DOI 10.1074/jbc.271.24.14492; Britten CJ, 1997, BBA-GEN SUBJECTS, V1334, P57, DOI 10.1016/S0304-4165(96)00076-1; CHIEN JL, 1978, J BIOL CHEM, V253, P4031; DEVRIES T, 1995, J BIOL CHEM, V270, P8712, DOI 10.1074/jbc.270.15.8712; Elmgren A, 1997, J BIOL CHEM, V272, P21994, DOI 10.1074/jbc.272.35.21994; Ge ZM, 1997, J BIOL CHEM, V272, P21357, DOI 10.1074/jbc.272.34.21357; GERSTEN KM, 1995, J BIOL CHEM, V270, P25047, DOI 10.1074/jbc.270.42.25047; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; HADWIGER JA, 1991, P NATL ACAD SCI USA, V88, P8213, DOI 10.1073/pnas.88.18.8213; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HINDSGAUL O, 1991, J BIOL CHEM, V266, P17858; HOLMES EH, 1992, ARCH BIOCHEM BIOPHYS, V296, P562, DOI 10.1016/0003-9861(92)90611-Y; HOLMES EH, 1995, J BIOL CHEM, V270, P8145, DOI 10.1074/jbc.270.14.8145; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; Lee KP, 1996, J BIOL CHEM, V271, P32960, DOI 10.1074/jbc.271.51.32960; LEGAULT DJ, 1995, J BIOL CHEM, V270, P20987, DOI 10.1074/jbc.270.36.20987; Martin SL, 1997, J BIOL CHEM, V272, P21349, DOI 10.1074/jbc.272.34.21349; MOLLICONE R, 1994, J BIOL CHEM, V269, P20987; MOLLICONE R, 1994, J BIOL CHEM, V269, P12662; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; Nguyen AT, 1998, J BIOL CHEM, V273, P25244, DOI 10.1074/jbc.273.39.25244; NISHIHARA S, 1993, BIOCHEM BIOPH RES CO, V196, P624, DOI 10.1006/bbrc.1993.2295; Orntoft TF, 1996, J BIOL CHEM, V271, P32260, DOI 10.1074/jbc.271.50.32260; Oulmouden A, 1997, J BIOL CHEM, V272, P8764, DOI 10.1074/jbc.272.13.8764; Ozawa M, 1996, J BIOCHEM-TOKYO, V119, P302; SajdelSulkowska EM, 1997, GLYCOCONJUGATE J, V14, P249, DOI 10.1023/A:1018550023637; SASAKI K, 1994, J BIOL CHEM, V269, P14730; Smith PL, 1996, J BIOL CHEM, V271, P8250, DOI 10.1074/jbc.271.14.8250; Stroud MR, 1997, BIOCHEM BIOPH RES CO, V238, P165, DOI 10.1006/bbrc.1997.7254; Vo L, 1998, J BIOL CHEM, V273, P25250, DOI 10.1074/jbc.273.39.25250; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; Xu XH, 1996, J BIOL CHEM, V271, P8818, DOI 10.1074/jbc.271.15.8818	36	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25256	25260		10.1074/jbc.273.39.25256	http://dx.doi.org/10.1074/jbc.273.39.25256			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737990	hybrid			2022-12-27	WOS:000076085400040
J	Tu, GC; Cao, QN; Zhou, F; Israel, Y				Tu, GC; Cao, QN; Zhou, F; Israel, Y			Tetranucleotide GGGA motif in primary RNA transcripts - Novel target site for antisense design	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; C-ALPHA EXPRESSION; MESSENGER-RNA; KUPFFER CELLS; MULTIDRUG RESISTANCE; MONOCLONAL-ANTIBODY; ALCOHOLIC HEPATITIS; ALLOGRAFT-REJECTION; ESCHERICHIA-COLI; CATIONIC LIPIDS	Selecting effective antisense target sites on a given mRNA molecule constitutes a major problem in antisense therapeutics. By trial-and-error, only 1 in 18 (6%) of antisense oligonucleotides designed to target the primary RNA transcript of tumor necrosis factor-alpha (TNF-alpha) strongly inhibited TNF-alpha synthesis. Subsequent studies showed that the area in RNA targeted by antisense oligonucleotides could be moved effectively 10-15 bases in either direction from the original area. We observed that only molecules that incorporated a tetranucleotide motif TCCC (complementary to GGGA on RNA) yielded potent antisense oligonucleotides against TNF-alpha. A comprehensive literature survey showed that this motif is unwittingly present in 48% of the most potent antisense oligonucleotides reported in the literature. This finding was prospectively used to predict the sequences of additional antisense oligonucleotides for the rat TNF-alpha primary RNA transcript. Over 50% of antisense constructs (13 of 22) containing the TCCC motif were found to effectively inhibit TNF-alpha synthesis. Marked reductions in mRNA were also observed. This motif was found to be most effective when targeting introns in the primary RNA transcript, suggesting a nuclear localization for the antisense action. Predicting target sites based on the presence of this motif in primary RNA transcripts should be of value in the development on new antisense pharmacotherapy.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Univ Chile, Ctr Gene Pharmacotherapy, Santiago, Chile	Jefferson University; Universidad de Chile	Tu, GC (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, 1020 Locust St,Rm 275, Philadelphia, PA 19107 USA.	tul@jeflin.tju.edu		Israel, Yedy/0000-0003-3468-7966				Agrawal S, 1996, TRENDS BIOTECHNOL, V14, P376, DOI 10.1016/0167-7799(96)10053-6; Alahari SK, 1996, MOL PHARMACOL, V50, P808; BAUTISTA AP, 1992, J LEUKOCYTE BIOL, V51, P39, DOI 10.1002/jlb.51.1.39; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; BENNETT CF, 1994, J IMMUNOL, V152, P3530; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; Bishop MR, 1996, J CLIN ONCOL, V14, P1320, DOI 10.1200/JCO.1996.14.4.1320; CATSICAS M, 1996, ANTISENSE THERAPEUTI, P57; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; COTTER FE, 1994, ONCOGENE, V9, P3049; Crooke ST, 1996, ANNU REV PHARMACOL, V36, P107, DOI 10.1146/annurev.pa.36.040196.000543; DEAN NM, 1994, P NATL ACAD SCI USA, V91, P11762, DOI 10.1073/pnas.91.24.11762; Dean NM, 1996, BIOCHEM SOC T, V24, P623, DOI 10.1042/bst0240623; DEAN NM, 1994, J BIOL CHEM, V269, P16416; DECKER K, 1990, EUR J BIOCHEM, V192, P245, DOI 10.1111/j.1432-1033.1990.tb19222.x; dHellencourt CL, 1996, BBA-MOL BASIS DIS, V1317, P168, DOI 10.1016/S0925-4439(96)00051-8; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; FELVER ME, 1990, ALCOHOL CLIN EXP RES, V14, P255, DOI 10.1111/j.1530-0277.1990.tb00482.x; Filion MC, 1997, BBA-BIOMEMBRANES, V1329, P345, DOI 10.1016/S0005-2736(97)00126-0; Gewirtz AM, 1996, P NATL ACAD SCI USA, V93, P3161, DOI 10.1073/pnas.93.8.3161; GILES RV, 1995, ANTISENSE RES DEV, V5, P23, DOI 10.1089/ard.1995.5.23; GOODCHILD J, 1988, P NATL ACAD SCI USA, V85, P5507, DOI 10.1073/pnas.85.15.5507; Hartmann G, 1996, ANTISENSE NUCLEIC A, V6, P291, DOI 10.1089/oli.1.1996.6.291; Ho SP, 1996, NUCLEIC ACIDS RES, V24, P1901, DOI 10.1093/nar/24.10.1901; Ho SP, 1998, NAT BIOTECHNOL, V16, P59, DOI 10.1038/nbt0198-59; IMAGAWA DK, 1991, TRANSPLANTATION, V51, P57, DOI 10.1097/00007890-199101000-00008; JOHANSSON HE, 1994, NUCLEIC ACIDS RES, V22, P4591, DOI 10.1093/nar/22.22.4591; KAMIMURA S, 1995, HEPATOLOGY, V22, P1304, DOI 10.1002/hep.1840220441; LAPTEV AV, 1994, BIOCHEMISTRY-US, V33, P11033, DOI 10.1021/bi00202a024; LEE CH, 1995, SHOCK, V4, P1, DOI 10.1097/00024382-199507000-00001; LI G, 1993, J VIROL, V67, P6882, DOI 10.1128/JVI.67.11.6882-6888.1993; Lima WF, 1997, BIOCHEMISTRY-US, V36, P390, DOI 10.1021/bi962230p; Lima WF, 1997, J BIOL CHEM, V272, P626; LIMA WF, 1992, BIOCHEMISTRY-US, V31, P12055, DOI 10.1021/bi00163a013; Matteucci MD, 1996, NATURE, V384, P20; MCCLAIN CJ, 1989, HEPATOLOGY, V9, P349, DOI 10.1002/hep.1840090302; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; Milner N, 1997, NAT BIOTECHNOL, V15, P537, DOI 10.1038/nbt0697-537; Monia BP, 1996, NAT MED, V2, P668, DOI 10.1038/nm0696-668; MURCH SH, 1993, GUT, V34, P1705, DOI 10.1136/gut.34.12.1705; PERLAKY L, 1993, ANTI-CANCER DRUG DES, V8, P3; Probst JC, 1996, TRENDS GENET, V12, P290, DOI 10.1016/0168-9525(96)20009-5; RAINE CS, 1995, NAT MED, V1, P211, DOI 10.1038/nm0395-211; RATMEYER L, 1994, BIOCHEMISTRY-US, V33, P5298, DOI 10.1021/bi00183a037; SHIRAI T, 1989, AGR BIOL CHEM TOKYO, V53, P1733, DOI 10.1080/00021369.1989.10869529; STEPKOWSKI SM, 1994, J IMMUNOL, V153, P5336; Stull R A, 1993, Antisense Res Dev, V3, P295; Stull RA, 1996, ANTISENSE NUCLEIC A, V6, P221, DOI 10.1089/oli.1.1996.6.221; STULL RA, 1992, NUCLEIC ACIDS RES, V20, P3501, DOI 10.1093/nar/20.13.3501; Stutz A, 1997, MOL CELL BIOL, V17, P1759, DOI 10.1128/MCB.17.4.1759; THIERRY AR, 1993, BIOCHEM BIOPH RES CO, V190, P952, DOI 10.1006/bbrc.1993.1142; TU GC, 1995, J BIOL CHEM, V270, P28402; UHLMANN E, 1990, CHEM REV, V90, P543, DOI 10.1021/cr00102a001; vanHensbroek MB, 1996, J INFECT DIS, V174, P1091, DOI 10.1093/infdis/174.5.1091; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	56	90	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25125	25131		10.1074/jbc.273.39.25125	http://dx.doi.org/10.1074/jbc.273.39.25125			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737971	hybrid			2022-12-27	WOS:000076085400021
J	Yoshima, T; Yura, T; Yanagi, H				Yoshima, T; Yura, T; Yanagi, H			Heat shock factor 1 mediates hemin-induced hsp70 gene transcription in K562 erythroleukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; ERYTHROID-DIFFERENTIATION; LINE K562; ACTIVATION; EXPRESSION; STRESS; HSF1; PROTEIN; DOMAIN; OLIGOMERIZATION	Transcriptional induction of the hsp70 gene is mediated by heat shock factor 1 (HSF1) rapidly activated upon heat and other stresses. HSF2 has been thought to be responsible for accumulation of HSP70 during hemin-induced differentiation of human K562 erythroleukemia cells because of accompanying acquisition of HSF2 DNA binding activity. However, there has not been any direct evidence for such a functional role of HSF2. The purpose of this study is to clarify the roles of HSF1 and HSF2 in HSP70 induction in hemin-treated K562 cells. We show here that a chimeric polypeptide of HSF2 and GAL4 DNA binding domain (GAL4-BD-HSF2) was unable to induce a GAL4 binding site-containing luciferase reporter gene in response to hemin and that exogenously overproduced HSF2 also failed to increase expression of a heat shock element-containing reporter. On the contrary, expression of a GAL4-BD-HSF1 chimeric protein responded to hemin treatment as well as to heat shock, and transiently overexpressed HSF1 caused hemin-responsive induction of the reporter gene in a dose-dependent manner. These results indicate that HSF1, rather than HSF2, primarily mediates the hemin-induced transcription of the hsp70 gene.	HSP Res Inst, Shimogyo Ku, Kyoto 6008813, Japan		Yanagi, H (corresponding author), HSP Res Inst, Shimogyo Ku, Kyoto Res Pk, Kyoto 6008813, Japan.	hyanagi@hsp.co.jp						ANDERSSON LC, 1979, NATURE, V278, P364, DOI 10.1038/278364a0; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; BENSAUDE O, 1983, NATURE, V305, P331, DOI 10.1038/305331a0; BRUCE JL, 1993, CANCER RES, V53, P12; Bush KT, 1997, J BIOL CHEM, V272, P9086; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; DIMERY IW, 1983, EXP HEMATOL, V11, P601; ETLINGER JD, 1980, J BIOL CHEM, V255, P4563; GOODSON ML, 1995, MOL CELL BIOL, V15, P5288; GREEN M, 1995, MOL CELL BIOL, V15, P3354; HAAS AL, 1981, P NATL ACAD SCI-BIOL, V78, P6845, DOI 10.1073/pnas.78.11.6845; HENSOLD JO, 1990, MOL CELL BIOL, V10, P1600, DOI 10.1128/MCB.10.4.1600; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; Leppa S, 1997, J BIOL CHEM, V272, P15293, DOI 10.1074/jbc.272.24.15293; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LOZZIO BB, 1981, P SOC EXP BIOL MED, V166, P546; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; MORGAN WD, 1987, MOL CELL BIOL, V7, P1129, DOI 10.1128/MCB.7.3.1129; MURPHY SP, 1994, MOL CELL BIOL, V14, P5309, DOI 10.1128/MCB.14.8.5309; Nakai A, 1997, MOL CELL BIOL, V17, P469, DOI 10.1128/MCB.17.1.469; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; NAKAI A, 1995, MOL CELL BIOL, V15, P5268; Newton EM, 1996, MOL CELL BIOL, V16, P839; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PRICE BD, 1991, MOL CELL BIOL, V11, P3365, DOI 10.1128/MCB.11.6.3365; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; Rallu M, 1997, P NATL ACAD SCI USA, V94, P2392, DOI 10.1073/pnas.94.6.2392; RUTHERFORD T, 1981, P NATL ACAD SCI-BIOL, V78, P348, DOI 10.1073/pnas.78.1.348; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1994, BIOL REPROD, V50, P1334, DOI 10.1095/biolreprod50.6.1334; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SHI YH, 1995, MOL CELL BIOL, V15, P4309; SINGH MK, 1984, NATURE, V309, P631, DOI 10.1038/309631a0; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; Tanabe M, 1997, J BIOL CHEM, V272, P15389, DOI 10.1074/jbc.272.24.15389; THEODORAKIS NG, 1989, MOL CELL BIOL, V9, P3166, DOI 10.1128/MCB.9.8.3166; Xia WL, 1997, J BIOL CHEM, V272, P4094, DOI 10.1074/jbc.272.7.4094; Yoshima T, 1997, BIOCHEM BIOPH RES CO, V240, P228, DOI 10.1006/bbrc.1997.7662; Yoshima T, 1998, NUCLEIC ACIDS RES, V26, P2580, DOI 10.1093/nar/26.11.2580; ZAKERI ZF, 1987, MOL CELL BIOL, V7, P1791, DOI 10.1128/MCB.7.5.1791; Zhou MY, 1996, J BIOL CHEM, V271, P24769, DOI 10.1074/jbc.271.40.24769; ZUO JR, 1995, MOL CELL BIOL, V15, P4319	45	29	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25466	25471		10.1074/jbc.273.39.25466	http://dx.doi.org/10.1074/jbc.273.39.25466			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738016	hybrid			2022-12-27	WOS:000076085400066
J	Baset, HA; Ford-Hutchinson, AW; O'Neill, GP				Baset, HA; Ford-Hutchinson, AW; O'Neill, GP			Molecular cloning and functional expression of a Caenorhabditis elegans aminopeptidase structurally related to mammalian leukotriene A(4) hydrolases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; PEPTIDASE ACTIVITY; ZINC ENZYMES; SITE; RAT; POLYMERASE; INHIBITION; PROTEINS; MUTATION; LIGANDS	In a search of the Caenorhabditis elegans DNA data base, an expressed sequence tag of 327 base pairs (termed cm0lc7) with strong homology to the human leukotriene A(4) (LTA(4)) hydrolase was found. The use of cm0lc7 as a probe, together with conventional hybridization screening and anchored polymerase chain reaction techniques resulted in the cloning of the full-length 2.1 kilobase pair C. elegans LTA(4) hydrolase-like homologue, termed aminopeptidase-1 (AP-1). The AP-1 cDNA was expressed transiently as an epitope-tagged recombinant protein in COS-7 mammalian cells, purified using an anti-epitope antibody affinity resin, and tested for LTA(4) hydrolase and aminopeptidase activities. Despite the strong homology between the human LTA(4) hydrolase and C. elegans AP-1(63% similarity and 45% identity at the amino acid level), reverse-phase high pressure liquid chromatography and radioimmunoassay for LTB4 production revealed the inability of the C. elegans AP-1 to use LTA(4) as a substrate. In contrast, the C. elegans AP-1 was an efficient aminopeptidase, as demonstrated by its ability to hydrolyze a variety of amino acid p-nitroanilide derivatives. The aminopeptidase activity of C, elegans AP-1 resembled that of the human LTA(4) hydrolase/aminopeptidase enzyme with a preference for arginyl-p-nitroanilide as a substrate. Hydrolysis of the amide bond of arginyl p-nitroanilide was inhibited by bestatin with an IC50 of 2.6 +/- 1.2 mu M. The bifunctionality of the mammalian LTA(4) hydrolase is still poorly understood, as the physiological substrate for its aminopeptidase activity is yet to be discovered. Our results support the idea that the enzyme originally functioned as an aminopeptidase in lower metazoa and then developed LTA(4) hydrolase activity in more evolved organisms.	Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Pointe Claire, PQ H9R 4P8, Canada; McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada	Merck & Company; McGill University	O'Neill, GP (corresponding author), Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, POB 1005, Pointe Claire, PQ H9R 4P8, Canada.	gary_oneill1@merck.com						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AROIAN RV, 1993, MOL CELL BIOL, V13, P626, DOI 10.1128/MCB.13.1.626; Ausubel F.M., 1994, CURRENT PROTOCOLS MO, V1; BLOMSTER M, 1995, EUR J BIOCHEM, V231, P528, DOI 10.1111/j.1432-1033.1995.tb20728.x; Cadel S, 1997, P NATL ACAD SCI USA, V94, P2963, DOI 10.1073/pnas.94.7.2963; CARRIER DJ, 1988, PROSTAG LEUKOTR ESS, V34, P27, DOI 10.1016/0952-3278(88)90021-X; CORMACK BP, 1998, Patent No. 5529916; EVANS JF, 1985, J BIOL CHEM, V260, P966; FIELDS C, 1990, NUCLEIC ACIDS RES, V18, P1509, DOI 10.1093/nar/18.6.1509; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; FORDHUTCHINSON AW, 1986, LEUKOTRIENES THEIR B, P141; FUNK CD, 1987, P NATL ACAD SCI USA, V84, P6677, DOI 10.1073/pnas.84.19.6677; HAEGGSTROM JZ, 1990, BIOCHEM BIOPH RES CO, V173, P431, DOI 10.1016/S0006-291X(05)81076-9; HAEGGSTROM JZ, 1990, BIOCHEM BIOPH RES CO, V172, P965, DOI 10.1016/0006-291X(90)91540-9; KOZAK M, 1995, P NATL ACAD SCI USA, V92, P2662, DOI 10.1073/pnas.92.7.2662; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKITA N, 1992, FEBS LETT, V299, P273, DOI 10.1016/0014-5793(92)80130-9; MANCINI JA, 1995, EUR J BIOCHEM, V231, P65, DOI 10.1111/j.1432-1033.1995.tb20671.x; MANCINI JA, 1993, EUR J BIOCHEM, V218, P477, DOI 10.1111/j.1432-1033.1993.tb18399.x; MEDINA JF, 1991, BIOCHEM BIOPH RES CO, V176, P1516, DOI 10.1016/0006-291X(91)90459-K; MEDINA JF, 1991, P NATL ACAD SCI USA, V88, P7620, DOI 10.1073/pnas.88.17.7620; MINAKI M, 1989, JPN J HIST BOT, V4, P19; MINAMI M, 1995, GENE, V161, P249, DOI 10.1016/0378-1119(95)00179-A; Mueller MJ, 1996, P NATL ACAD SCI USA, V93, P5931, DOI 10.1073/pnas.93.12.5931; Nasr F, 1996, YEAST, V12, P493, DOI 10.1002/(SICI)1097-0061(199604)12:5<493::AID-YEA929>3.0.CO;2-W; OMING L, 1994, J BIOL CHEM, V269, P11269; ORNING L, 1991, J BIOL CHEM, V266, P16507; ORNING L, 1991, J BIOL CHEM, V266, P1375; ORNING L, 1992, BIOCHEMISTRY-US, V31, P4218, DOI 10.1021/bi00132a010; PAGGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119; PALAZZOLO MJ, 1990, GENE, V88, P25, DOI 10.1016/0378-1119(90)90056-W; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RADMARK O, 1990, ADV PROSTAG THROMB L, V20, P35; RAWLINGS ND, 1993, BIOCHEM J, V290, P205, DOI 10.1042/bj2900205; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; TOH H, 1990, BIOCHEM BIOPH RES CO, V171, P216, DOI 10.1016/0006-291X(90)91379-7; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VALLEE BL, 1990, P NATL ACAD SCI USA, V87, P220, DOI 10.1073/pnas.87.1.220; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; WETTERHOLM A, 1992, BIOCHIM BIOPHYS ACTA, V1123, P275, DOI 10.1016/0005-2760(92)90007-I; WETTERHOLM A, 1992, P NATL ACAD SCI USA, V89, P9141, DOI 10.1073/pnas.89.19.9141; Wetterholm A, 1996, NATO ADV SCI I A-LIF, V283, P1; WIEMANN S, 1995, BIOTECHNIQUES, V18, P688	45	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27978	27987		10.1074/jbc.273.43.27978	http://dx.doi.org/10.1074/jbc.273.43.27978			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774412	hybrid			2022-12-27	WOS:000076549800032
J	Howe, AK; Juliano, RL				Howe, AK; Juliano, RL			Distinct mechanisms mediate the initial and sustained phases of integrin-mediated activation of the Raf/MEK/mitogen-activated protein kinase cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR ACTIVATION; FOCAL ADHESION KINASE; CELL-ADHESION; SIGNAL-TRANSDUCTION; MAP KINASE; PLASMA-MEMBRANE; RAF-1 KINASE; IN-VITRO; TYROSINE PHOSPHORYLATION; PHOSPHATIDIC-ACID	Integrin-mediated adhesion to the extracellular matrix activates the canonical mitogen-activated protein kinase cascade, although the exact mechanism is not fully resolved. We show that integrin-mediated activation of Raf-l, an upstream regulator of mitogen-activated protein kinase, occurs in two phases. Efficient early activation of Raf required Raf-Ras interaction but was not affected by protein kinase C (PKC) inhibitors, while a lower, sustained level of activity was independent of Raf-Ras interaction but was reduced by PEC inhibitors. The combination of PEC inhibition and lack of Ras binding completely blocked integrin-mediated Raf activity. The activity of a membrane-bound Raf mutant that is deficient in Ras binding (Raf-R89L-CAAX) was also regulated by adhesion. Raf-R89L-CAAX activity was low in nonadherent cells, was rapidly stimulated to wild-type levels by cell. adhesion, and remained at nearly maximal levels longer than wild-type activity. The activation of wild-type and mutant Raf proteins was ablated by cytochalasin D, demonstrating that cytoskeletal organization is required for activation of Raf, even when targeted to the membrane. These data suggest distinct initial and sustained phases of integrin-mediated Raf activation that require Raf membrane localization and possibly PKC activity, respectively, and that integrin-mediated adhesion may regulate a cytoskeleton-associated factor(s) responsible for Raf activation.	Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Juliano, RL (corresponding author), Univ N Carolina, Sch Med, Dept Pharmacol, Mary Ellen Jones Bldg 920,CB 7365, Chapel Hill, NC 27599 USA.	arjay@med.unc.edu			NATIONAL CANCER INSTITUTE [T32CA009156] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026165] Funding Source: NIH RePORTER; NCI NIH HHS [CA09156-23] Funding Source: Medline; NIGMS NIH HHS [GM26165] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aplin AE, 1998, PHARMACOL REV, V50, P197; Arai H, 1996, MOL PHARMACOL, V50, P522; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; Cacace AM, 1996, ONCOGENE, V13, P2517; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Clark EA, 1996, J BIOL CHEM, V271, P14814, DOI 10.1074/jbc.271.25.14814; Couchman JR, 1996, J CELL BIOCHEM, V61, P578, DOI 10.1002/(SICI)1097-4644(19960616)61:4<578::AID-JCB11>3.0.CO;2-C; DENT P, 1995, MOL CELL BIOL, V15, P4125; DENT P, 1994, P NATL ACAD SCI USA, V91, P9544, DOI 10.1073/pnas.91.20.9544; Downward J, 1996, CANCER SURV, V27, P87; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FINNEY R, 1995, METHOD ENZYMOL, V255, P310; Ghosh S, 1997, BIOCHEM SOC T, V25, P561, DOI 10.1042/bst0250561; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; Gille J, 1996, ANN NY ACAD SCI, V797, P93, DOI 10.1111/j.1749-6632.1996.tb52952.x; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Lin TH, 1997, J BIOL CHEM, V272, P8849; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Oh ES, 1998, J BIOL CHEM, V273, P10624, DOI 10.1074/jbc.273.17.10624; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; Renshaw MW, 1996, J BIOL CHEM, V271, P21691, DOI 10.1074/jbc.271.36.21691; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; Takahashi M, 1996, J CLIN INVEST, V98, P2623, DOI 10.1172/JCI119083; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; vanDijk MCM, 1997, BIOCHEM J, V323, P693, DOI 10.1042/bj3230693; vanDijk MCM, 1997, BIOCHEM J, V325, P303, DOI 10.1042/bj3250303; VUORI K, 1993, J BIOL CHEM, V268, P21459; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Wei JY, 1998, J BIOL CHEM, V273, P5903, DOI 10.1074/jbc.273.10.5903; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273; Zou YZ, 1996, J BIOL CHEM, V271, P33592, DOI 10.1074/jbc.271.52.33592	53	75	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27268	27274		10.1074/jbc.273.42.27268	http://dx.doi.org/10.1074/jbc.273.42.27268			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765250	Green Published, hybrid			2022-12-27	WOS:000076448000037
J	Resnick, MS; Kang, BS; Luu, D; Wickham, JT; Sando, JJ; Hahn, CS				Resnick, MS; Kang, BS; Luu, D; Wickham, JT; Sando, JJ; Hahn, CS			Differential downstream functions of protein kinase C eta and -theta in EL4 mouse thymoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER; T-CELLS; PROTEOLYTIC ACTIVATION; ENDOPLASMIC-RETICULUM; GROWTH-INHIBITION; DOWN-REGULATION; ACTIN; LYMPHOCYTES; EXPRESSION; APOPTOSIS	Sensitive EW mouse thymoma cells (s-EL4) respond to phorbol esters with growth inhibition, adherence to substrate, and production of cytokines including interleukin 2. Since these cells express several of the phorbol ester-sensitive protein kinase C (PKC) isozymes, the function of each isozyme remains unclear. Previous studies demonstrated that s-EL4 cells expressed substantially more PKC eta and PKC theta than did EL4 cells resistant to phorbol esters (r-EL4). To examine potential roles for PKC eta and PKC theta in EL4 cells, wild type and constitutively active versions of the isozymes were transiently expressed using a Sindbis virus system, Expression of constitutively active PKC eta, but not PKC theta, in sand r-EL4 cells altered cell morphology and cytoskeletal structure in a manner similar to that of phorbol ester treatment, suggesting a role for PKC eta in cytoskeletal organization. Prolonged treatment of s-EL4 cells with phorbol esters results in inhibition of cell cycling along with a decreased expression of most of the PKC isozymes, including PKC theta. Introduction of virally expressed PKC theta, but not PKC eta, overcame the inhibitory effects of the prolonged phorbol ester treatment on cell cycle progression, suggesting a possible involvement of PKC theta in cell cycle regulation. These results support differential functions for PKC eta and PKC theta in T cell activation.	Univ Virginia, Bierne B Carter Ctr Immunol Res, Hlth Sci Ctr, Charlottesville, VA 22908 USA; Univ Virginia, Dept Pharmacol, Hlth Sci Ctr, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Hlth Sci Ctr, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Hahn, CS (corresponding author), Univ Virginia, Bierne B Carter Ctr Immunol Res, Hlth Sci Ctr, Box MR4-4012, Charlottesville, VA 22908 USA.	csh2s@virginia.edu			NIGMS NIH HHS [GM54572, GM31184] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054572, R01GM031184] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAIER G, 1994, EUR J BIOCHEM, V225, P195, DOI 10.1111/j.1432-1033.1994.00195.x; BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; Basu A, 1998, MOL PHARMACOL, V53, P105, DOI 10.1124/mol.53.1.105; CHIDA K, 1994, MOL CELL BIOL, V14, P3782, DOI 10.1128/MCB.14.6.3782; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; DEKKER LV, 1993, J BIOL CHEM, V268, P19498; Desrivieres S, 1997, J BIOL CHEM, V272, P2470; DwyerNield LD, 1996, AM J PHYSIOL-LUNG C, V270, pL526, DOI 10.1152/ajplung.1996.270.4.L526; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FARRAR JJ, 1980, J IMMUNOL, V125, P2555; FREIREMOAR J, 1992, ANN NY ACAD SCI, V660, P288, DOI 10.1111/j.1749-6632.1992.tb21088.x; GENDLOFF EH, 1990, PLANT MOL BIOL, V14, P575, DOI 10.1007/BF00027503; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; GREIF H, 1992, MOL CELL BIOL, V12, P1304, DOI 10.1128/MCB.12.3.1304; Griffiths G, 1996, BIOCHEM BIOPH RES CO, V222, P802, DOI 10.1006/bbrc.1996.0830; HAHN CS, 1992, P NATL ACAD SCI USA, V89, P2679, DOI 10.1073/pnas.89.7.2679; Haverstick DM, 1997, J BIOL CHEM, V272, P15426, DOI 10.1074/jbc.272.24.15426; HOMAN EC, 1991, J BIOL CHEM, V266, P5676; ISAKOV N, 1990, J BIOL CHEM, V265, P2091; KELLER H, 1995, EUR J CELL BIOL, V66, P157; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; KUPFER H, 1994, J EXP MED, V179, P1507, DOI 10.1084/jem.179.5.1507; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mihalik R, 1996, INT J BIOCHEM CELL B, V28, P925, DOI 10.1016/1357-2725(96)00020-9; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PHATAK PD, 1988, J IMMUNOL, V141, P2929; PHATAK PD, 1994, J CELL PHYSIOL, V159, P365, DOI 10.1002/jcp.1041590220; Resnick MS, 1997, CANCER RES, V57, P2209; RICE CM, 1982, J MOL BIOL, V154, P325, DOI 10.1016/0022-2836(82)90067-5; SANDO JJ, 1982, CANCER RES, V42, P1676; Sansbury HM, 1997, CARCINOGENESIS, V18, P1817, DOI 10.1093/carcin/18.9.1817; SAVART M, 1992, INT J CANCER, V52, P399, DOI 10.1002/ijc.2910520312; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; Stewart MP, 1996, J IMMUNOL, V156, P1810; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; TRACHSEL S, 1995, J LEUKOCYTE BIOL, V57, P587, DOI 10.1002/jlb.57.4.587; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101	44	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27654	27661		10.1074/jbc.273.42.27654	http://dx.doi.org/10.1074/jbc.273.42.27654			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765301	hybrid			2022-12-27	WOS:000076448000088
J	Yamakuni, T; Yamamoto, T; Hoshino, M; Song, SY; Yamamoto, H; Kunikata-Sumitomo, M; Minegishi, A; Kubota, M; Ito, M; Konishi, S				Yamakuni, T; Yamamoto, T; Hoshino, M; Song, SY; Yamamoto, H; Kunikata-Sumitomo, M; Minegishi, A; Kubota, M; Ito, M; Konishi, S			A novel protein containing cdc10/SWI6 motifs regulates expression of mRNA encoding catecholamine biosynthesizing enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-HYDROXYLASE GENE; DOPAMINE-BETA-HYDROXYLASE; NERVE GROWTH-FACTOR; PHENYLETHANOLAMINE N-METHYLTRANSFERASE; PHEOCHROMOCYTOMA CELL-LINE; CYCLIC-AMP; MESSENGER-RNA; ELONGATION FACTOR-1-ALPHA; PROMOTER ACTIVITY; NEURONS EXPRESS	Catecholaminergic (dopaminergic, noradrenergic, and adrenergic) transmitter phenotypes require the cooperative actions of four biosynthetic enzymes: tyrosine hydroxylase, aromatic L-amino acid decarboxylase, dopamine beta-hydroxylase, and phenylethanolamine N-methyltransferase, Mechanisms that control expression of these enzymes in a transmitter phenotype-specific manner, however, are poorly understood. Here, we provide evidence that overexpression of a novel cdc10/SWI6 motif-containing protein, V-1, elicits the coordinate up regulation of tyrosine hydroxylase, aromatic L-amino acid decarboxylase, and dopamine beta-hydroxylase mRNAs in the neuronal cell line PC12D, and as a result, catecholamine levels are increased. Furthermore, V-1 is strongly expressed in the cytoplasm of rat chromaffin cells of adrenal medulla, Thus, V-1 may act as a cytoplasmic protein/protein adapter and be involved in control of the catecholaminergic phenotype expression via an intracellular pathway signaling to the nucleus.	Mitsubishi Kasei Inst Life Sci, Machida, Tokyo 1948511, Japan; Yokohama City Univ, Grad Sch Integrated Sci, Lab Mol Recognit, Kanazawa Ku, Yokohama, Kanagawa 2360027, Japan; Tokyo Metropolitan Inst Med Sci, Dept Biochem Cell Res, Bunkyo Ku, Tokyo 1130021, Japan; Tokyo Inst Psychiat, Dept Psychopharmacol, Setagaya Ku, Tokyo 1560057, Japan	Yokohama City University; Tokyo Metropolitan Institute of Medical Science; Tokyo Institute of Psychiatry	Yamakuni, T (corresponding author), Mitsubishi Kasei Inst Life Sci, 11 Minamiooya, Machida, Tokyo 1948511, Japan.		Yamakuni, Tohru/AAE-3541-2019	Yamakuni, Tohru/0000-0003-3968-7949				AXELROD J, 1962, J BIOL CHEM, V237, P1657; BAETGE EE, 1981, P NATL ACAD SCI-BIOL, V78, P1269, DOI 10.1073/pnas.78.2.1269; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; Cooper J.R., 1996, BIOCH BASIS NEUROPHA, Vseventh; EBERT SN, 1994, J BIOL CHEM, V269, P20885; FRIEDMAN S, 1965, J BIOL CHEM, V240, P4763; Fujigasaki H, 1996, MOL BRAIN RES, V40, P203, DOI 10.1016/0169-328X(96)00005-8; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HATANAKA H, 1984, Neuroscience Research, V1, P253, DOI 10.1016/S0168-0102(84)80004-8; HIREMAGALUR B, 1993, J BIOL CHEM, V268, P23704; ICARDLIEPKALNS C, 1992, J NEUROSCI RES, V32, P290, DOI 10.1002/jnr.490320219; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; ISHIGURO H, 1993, J BIOL CHEM, V268, P17987; KANEDA N, 1987, BIOCHEM BIOPH RES CO, V146, P971, DOI 10.1016/0006-291X(87)90742-X; KATO T, 1981, EXPERIENTIA, V37, P809, DOI 10.1007/BF01985652; KATOHSEMBA R, 1987, J NEUROSCI RES, V17, P36, DOI 10.1002/jnr.490170106; KIM DW, 1990, GENE, V91, P217, DOI 10.1016/0378-1119(90)90091-5; KIM KS, 1993, P NATL ACAD SCI USA, V90, P3471, DOI 10.1073/pnas.90.8.3471; KIRSHNER N, 1957, BIOCHIM BIOPHYS ACTA, V24, P658, DOI 10.1016/0006-3002(57)90271-8; KOBAYASHI K, 1989, NUCLEIC ACIDS RES, V17, P1089, DOI 10.1093/nar/17.3.1089; Kumer SC, 1996, J NEUROCHEM, V67, P443; LEWIS EJ, 1983, J BIOL CHEM, V258, P4632; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; LI XM, 1994, NEUROCHEM RES, V19, P591, DOI 10.1007/BF00971335; LOVENBERG W, 1962, J BIOL CHEM, V237, P89; Menezes A, 1996, J NEUROCHEM, V67, P2316; Morin X, 1997, NEURON, V18, P411, DOI 10.1016/S0896-6273(00)81242-8; MORITA S, 1992, MOL BRAIN RES, V13, P313, DOI 10.1016/0169-328X(92)90214-V; NagamotoCombs K, 1997, J BIOL CHEM, V272, P6051, DOI 10.1074/jbc.272.9.6051; NAGATSU T, 1964, J BIOL CHEM, V239, P2910; NANKOVA B, 1994, P NATL ACAD SCI USA, V91, P5937, DOI 10.1073/pnas.91.13.5937; SABBAN EL, 1983, J BIOL CHEM, V258, P7819; SHASKUS J, 1992, J BIOL CHEM, V267, P18821; Song SY, 1996, ENDOCRINOLOGY, V137, P1423, DOI 10.1210/en.137.4.1423; TANAKA T, 1989, P NATL ACAD SCI USA, V86, P8142, DOI 10.1073/pnas.86.20.8142; TAOKA M, 1994, J BIOL CHEM, V269, P9946; TAOKA M, 1992, EUR J BIOCHEM, V207, P615, DOI 10.1111/j.1432-1033.1992.tb17088.x; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; VALARCHE I, 1993, DEVELOPMENT, V119, P881; VYAS S, 1990, EMBO J, V9, P3707, DOI 10.1002/j.1460-2075.1990.tb07583.x; ZIGMOND RE, 1989, ANNU REV NEUROSCI, V12, P415, DOI 10.1146/annurev.ne.12.030189.002215	42	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27051	27054		10.1074/jbc.273.42.27051	http://dx.doi.org/10.1074/jbc.273.42.27051			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765218	hybrid			2022-12-27	WOS:000076448000005
J	Becker, DF; Leartsakulpanich, U; Surerus, KK; Ferry, JG; Ragsdale, SW				Becker, DF; Leartsakulpanich, U; Surerus, KK; Ferry, JG; Ragsdale, SW			Electrochemical and spectroscopic properties of the iron-sulfur flavoprotein from Methanosarcina thermophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-MONOXIDE DEHYDROGENASE; ELECTRON-PARAMAGNETIC-RES; COMPLETE GENOME SEQUENCE; ACETYL COENZYME-A; METHANOBACTERIUM-THERMOAUTOTROPHICUM; HETERODISULFIDE REDUCTASE; 8-HYDROXY-5-DEAZAFLAVIN-REDUCING HYDROGENASE; SPECTROELECTROCHEMICAL CELL; CLOSTRIDIUM-THERMOACETICUM; ENZYME COMPLEX	An iron-sulfur flavoprotein (Isf) from the methanoarchaeaon Methanosarcina thermophila, which participates in electron transfer reactions required for the fermentation of acetate to methane, was characterized by electrochemistry and EPR and Mossbauer spectroscopy. The midpoint potential (E-m) of the FMN/FMNH2 couple was -0.277 V. No flavin semiquinone was observed during potentiometric titrations; however, low amounts of the radical were observed when Isf was quickly frozen after reaction with CO and the CO dehydrogenase/acetyl-CoA synthase complex from M. thermophila. Isf contained a [4Fe-4S](2+/1+) cluster with g values of 2.06 and 1.93 and an unusual split signal with g values at 1.86 and 1.82. The unusual morphology was attributed to microheterogeneity among Isf molecules. The E-m value for the 2+/1+ redox couple of the cluster was -0.394 V, Extracts from H-2-CO2-grown Methanobacterium thermoautotrophicum cells catalyzed either the H-2- or CO-dependent reduction of M. thermophila Isf, In addition, Isf homologs were found in the genomic sequences of the CO2-reducing methanoarchaea M. thermoautotrophicum and Methanococcus jannaschii. These results support a general role for Isf in electron transfer reactions of both acetate-fermenting and CO2-reducing methanoarchaea, It is suggested that Isf functions to couple electron transfer from ferredoxin to membrane-bound electron carriers, such as methanophenazine and/or b-type cytochromes.	Univ Nebraska, Beadle Ctr, Dept Biochem, Lincoln, NE 68588 USA; Penn State Univ, Eberly Coll Sci, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Univ Wisconsin, Dept Chem, Milwaukee, WI 53201 USA	University of Nebraska System; University of Nebraska Lincoln; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Wisconsin System; University of Wisconsin Milwaukee	Ragsdale, SW (corresponding author), Univ Nebraska, Beadle Ctr, Dept Biochem, Lincoln, NE 68588 USA.				NIGMS NIH HHS [1-R15-GM52666-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM052666] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abken HJ, 1998, J BACTERIOL, V180, P2027, DOI 10.1128/JB.180.8.2027-2032.1998; BARON SF, 1989, J BACTERIOL, V171, P3846, DOI 10.1128/jb.171.7.3846-3853.1989; BONAM D, 1987, J BIOL CHEM, V262, P2980; BRUSCHI M, 1988, FEMS MICROBIOL LETT, V54, P155, DOI 10.1111/j.1574-6968.1988.tb02741.x; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CHRISTNER JA, 1983, J BIOL CHEM, V258, P1157; CLEMENTS AP, 1994, J BACTERIOL, V176, P2689, DOI 10.1128/JB.176.9.2689-2693.1994; DANIELS L, 1977, J BACTERIOL, V132, P118, DOI 10.1128/JB.132.1.118-126.1977; ELLIOTT JI, 1978, ARCH BIOCHEM BIOPHYS, V190, P351, DOI 10.1016/0003-9861(78)90285-0; Ferry J.G, 2012, METHANOGENESIS ECOLO; FOX JA, 1987, BIOCHEMISTRY-US, V26, P4219, DOI 10.1021/bi00388a007; HARDER SR, 1989, ANAL BIOCHEM, V181, P283, DOI 10.1016/0003-2697(89)90244-3; HARDER SR, 1989, BIOCHEMISTRY-US, V28, P9080, DOI 10.1021/bi00449a019; HEDDERICH R, 1990, EUR J BIOCHEM, V193, P255, DOI 10.1111/j.1432-1033.1990.tb19331.x; HEIDEN S, 1994, EUR J BIOCHEM, V221, P855, DOI 10.1111/j.1432-1033.1994.tb18800.x; HEMMING A, 1985, TRENDS BIOCHEM SCI, V10, P198, DOI 10.1016/0968-0004(85)90191-4; JABLONSKI PE, 1993, J BIOL CHEM, V268, P325; JOHNSON MK, 1994, ENCY INORGANIC CHEM, P1896; KAY CJ, 1988, BIOCHEMISTRY-US, V27, P6142, DOI 10.1021/bi00416a047; KUHN W, 1983, EUR J BIOCHEM, V135, P89, DOI 10.1111/j.1432-1033.1983.tb07621.x; Kunkel A, 1997, EUR J BIOCHEM, V244, P226, DOI 10.1111/j.1432-1033.1997.00226.x; Kyrpides N C, 1996, Microb Comp Genomics, V1, P329; Latimer MT, 1996, J BIOL CHEM, V271, P24023, DOI 10.1074/jbc.271.39.24023; LINDAHL PA, 1985, J BIOL CHEM, V260, P1160; LU WP, 1994, J BIOL CHEM, V269, P9736; MaupinFurlow JA, 1996, J BACTERIOL, V178, P6849, DOI 10.1128/jb.178.23.6849-6856.1996; MEYER J, 1988, TRENDS ECOL EVOL, V3, P222, DOI 10.1016/0169-5347(88)90162-0; MIDDLETON P, 1978, EUR J BIOCHEM, V88, P135, DOI 10.1111/j.1432-1033.1978.tb12430.x; MOON BY, 1992, J MAGN RESON, V46, P247; Muh U, 1996, BIOCHEMISTRY-US, V35, P11710, DOI 10.1021/bi9601363; MUTH E, 1987, EUR J BIOCHEM, V169, P571, DOI 10.1111/j.1432-1033.1987.tb13647.x; NOLLING J, 1995, EUR J BIOCHEM, V231, P628, DOI 10.1111/j.1432-1033.1995.0628d.x; PEER CW, 1994, J BACTERIOL, V176, P6974, DOI 10.1128/JB.176.22.6974-6979.1994; RAGSDALE SW, 1987, J BIOL CHEM, V262, P14289; RUPP H, 1978, BIOCHIM BIOPHYS ACTA, V537, P255, DOI 10.1016/0005-2795(78)90509-3; SCHAUER NL, 1983, J BACTERIOL, V155, P467, DOI 10.1128/JB.155.2.467-472.1983; SCHONHEIT P, 1980, ARCH MICROBIOL, V127, P59, DOI 10.1007/BF00414356; Simianu M, 1998, BIOCHEMISTRY-US, V37, P10027, DOI 10.1021/bi9726483; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; STANKOVICH M, 1983, BIOCHEMISTRY-US, V22, P4466, DOI 10.1021/bi00288a018; STANKOVICH MT, 1980, ANAL BIOCHEM, V109, P295, DOI 10.1016/0003-2697(80)90652-1; Stiefel EI, 1994, BIOINORG CHEM, P365; WASSERFALLEN A, 1995, J BACTERIOL, V177, P2436, DOI 10.1128/jb.177.9.2436-2441.1995	43	13	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26462	26469		10.1074/jbc.273.41.26462	http://dx.doi.org/10.1074/jbc.273.41.26462			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756881	hybrid			2022-12-27	WOS:000076373300035
J	Berman, HK; O'Doherty, RM; Anderson, P; Newgard, CB				Berman, HK; O'Doherty, RM; Anderson, P; Newgard, CB			Overexpression of protein targeting to glycogen (PTG) in rat hepatocytes causes profound activation of glycogen synthesis independent of normal hormone- and substrate-mediated regulatory mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; LIVER-GLYCOGEN; HEXOKINASE-I; GLUCOSE; GLUCOKINASE; ADENOVIRUS; TRANSLOCATION; SYNTHASE; PHOSPHATASE-1; GENE	Protein targeting to glycogen (PTG), also known as PPP1R5, is a widely expressed member of a growing family of proteins that target protein phosphatase-1 (PP-1) to glycogen particles. Because PTG also binds to glycogen synthase and phosphorylase kinase, it has been suggested that it serves as a "scaffold" for efficient activation of glycogen synthesis. However, very little is known about the metabolic effects of PTG, In this study, we have used recombinant adenovirus to overexpress PTG in primary rat hepatocytes, a cell type with high glycogenic capacity. We find that overexpression of PTG potently activates glycogen synthesis in cultured hepatocytes. Surprisingly, the glycogenic effect of PTG is observed even in the complete absence of carbohydrates or insulin in the culture medium. Furthermore, glycogenolytic agents such as forskolin or glucagon are largely ineffective at activating glycogen degradation in PTG overexpressing hepatocytes, even though large increases in cAMP levels are demonstrated. These metabolic effects of PTG overexpression are accompanied by a 3.6-fold increase in glycogen synthase activation state and a 40% decrease in glycogen phosphorylase activity. Our results are consistent with a model in which PTG overexpression "locks" the hepatocyte in a glycogenic mode, presumably via its ability to promote interaction of enzymes of glycogen metabolism with PP-1.	Univ Texas, SW Med Ctr, Gifford Labs Diabet Res, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Newgard, CB (corresponding author), Univ Texas, SW Med Ctr, Gifford Labs Diabet Res, Room Y8-212,5323 Harry Hines Blvd, Dallas, TX 75235 USA.	newgard@utsw.swmed.edu			PHS HHS [1P50H2598801] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Agius L, 1996, J BIOL CHEM, V271, P30479, DOI 10.1074/jbc.271.48.30479; Armstrong CG, 1997, FEBS LETT, V418, P210, DOI 10.1016/S0014-5793(97)01385-9; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Berman HK, 1998, BIOCHEMISTRY-US, V37, P4543, DOI 10.1021/bi9726133; Brown KS, 1997, DIABETES, V46, P179, DOI 10.2337/diabetes.46.2.179; CHAN TM, 1976, ANAL BIOCHEM, V71, P96, DOI 10.1016/0003-2697(76)90014-2; Chen GX, 1996, P NATL ACAD SCI USA, V93, P14795, DOI 10.1073/pnas.93.25.14795; DOHERTY MJ, 1995, FEBS LETT, V375, P294, DOI 10.1016/0014-5793(95)01184-G; Doherty MJ, 1996, FEBS LETT, V399, P339, DOI 10.1016/S0014-5793(96)01357-9; FernandezNovell JM, 1997, BIOCHEM J, V321, P227, DOI 10.1042/bj3210227; FernandezNovell JM, 1996, EUR J BIOCHEM, V238, P570, DOI 10.1111/j.1432-1033.1996.0570z.x; Ferrer JC, 1997, FEBS LETT, V415, P249, DOI 10.1016/S0014-5793(97)01136-8; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; MAGNUSSON I, 1992, J CLIN INVEST, V90, P1323, DOI 10.1172/JCI115997; MCGARRY JD, 1987, ANNU REV NUTR, V7, P51, DOI 10.1146/annurev.nu.07.070187.000411; NEWGARD CB, 1989, CRIT REV BIOCHEM MOL, V24, P69, DOI 10.3109/10409238909082552; NEWGARD CB, 1983, J BIOL CHEM, V258, P8046; NOEL RJ, 1996, DIABET ANN, V10, P65; ODoherty RM, 1996, J BIOL CHEM, V271, P20524, DOI 10.1074/jbc.271.34.20524; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; Seoane J, 1996, J BIOL CHEM, V271, P23756, DOI 10.1074/jbc.271.39.23756; TANG PM, 1991, J BIOL CHEM, V266, P15782; TOYODA Y, 1994, BIOCHEM BIOPH RES CO, V204, P252, DOI 10.1006/bbrc.1994.2452; VillarPalasi C, 1997, FASEB J, V11, P544, DOI 10.1096/fasebj.11.7.9212078; WILSON JE, 1984, REGULATION CARBOHYDR, P45	27	64	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26421	26425		10.1074/jbc.273.41.26421	http://dx.doi.org/10.1074/jbc.273.41.26421			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756875	hybrid			2022-12-27	WOS:000076373300029
J	Hao, DY; Ohme-Takagi, M; Sarai, A				Hao, DY; Ohme-Takagi, M; Sarai, A			Unique mode of GCC box recognition by the DNA-binding domain of ethylene-responsive element-binding factor (ERF domain) in plant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AP2 DOMAIN; PROTEINS; ARABIDOPSIS; GENE; EXPRESSION; SEQUENCE; APETALA2; INTERACTS; REPRESSOR	Ethylene-responsive element-binding proteins (EREBPs)have novel DNA-binding domains (ERF domains), which are widely conserved in plants, and interact specifically with sequences containing AGCCGCC motifs (GCC box). Deletion experiments show that some flanking region at the N terminus of the conserved 59-amino acid ERF domain is required for stable binding to the GCC box. Three ERF domain-containing fragments of EREBP2, EREBP4, and AtERF1 from tobacco and Arabidopsis, bind to the sequence containing the GCC box with a high binding affinity in the pM range. The high affinity binding is conferred by a monomeric ERF domain fragment, and DNA truncation experiments show that only 11-base pair DNA containing the GCC box is sufficient for stable ERF domain interaction. Systematic DNA mutation analyses demonstrate that the specific amino acid contacts are confined within the B-base pair GCCGCC region of the GCC box, and the first G, the fourth G, and the sixth C exhibit highest binding specificity common in all three ERF domain-containing fragments studied. Other bases within the GCC box exhibit modulated binding specificity varying from protein to protein, implying that these positions are important for differential binding by different EREBPs, The conserved N-terminal half is likely responsible for formation of a stable complex with the GCC box and the divergent C-terminal half for modulating the specificity.	Inst Phys & Chem Res, Tsukuba Life Sci Ctr, Tsukuba, Ibaraki 3050074, Japan; Natl Inst Biosci & Human Technol, Plant Mol Biol Lab, Tsukuba, Ibaraki 3050046, Japan	RIKEN; National Institute of Advanced Industrial Science & Technology (AIST)	Sarai, A (corresponding author), Inst Phys & Chem Res, Tsukuba Life Sci Ctr, 3-1-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.			Ohme-Takagi, Masaru/0000-0003-2700-4119				Abeles F, 1992, ETHYLENE PLANT BIOL; Buttner M, 1997, P NATL ACAD SCI USA, V94, P5961, DOI 10.1073/pnas.94.11.5961; EYAL Y, 1993, PLANT J, V4, P225, DOI 10.1046/j.1365-313X.1993.04020225.x; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HART CM, 1993, PLANT MOL BIOL, V21, P121, DOI 10.1007/BF00039623; JOFUKU KD, 1994, PLANT CELL, V6, P1211, DOI 10.1105/tpc.6.9.1211; KATAGIRI F, 1989, NATURE, V340, P727, DOI 10.1038/340727a0; OHMETAKAGI M, 1990, PLANT MOL BIOL, V15, P941, DOI 10.1007/BF00039434; OHMETAKAGI M, 1995, PLANT CELL, V7, P173, DOI 10.1105/tpc.7.2.173; Okamuro JK, 1997, P NATL ACAD SCI USA, V94, P7076, DOI 10.1073/pnas.94.13.7076; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; Sato F, 1996, PLANT CELL PHYSIOL, V37, P249, DOI 10.1093/oxfordjournals.pcp.a028939; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Stockinger EJ, 1997, P NATL ACAD SCI USA, V94, P1035, DOI 10.1073/pnas.94.3.1035; TAKEDA Y, 1989, P NATL ACAD SCI USA, V86, P439, DOI 10.1073/pnas.86.2.439; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; WEIGEL D, 1995, PLANT CELL, V7, P388, DOI 10.1105/tpc.7.4.388; ZHOU J, 1997, EMBO J, V16, P3217	18	294	391	4	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26857	26861		10.1074/jbc.273.41.26857	http://dx.doi.org/10.1074/jbc.273.41.26857			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756931	hybrid			2022-12-27	WOS:000076373300085
J	Okano, H; Cyert, MS; Ohya, Y				Okano, H; Cyert, MS; Ohya, Y			Importance of phenylalanine residues of yeast calmodulin for target binding and activations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; SPINDLE POLE BODY; SACCHAROMYCES-CEREVISIAE; CENTRAL HELIX; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN-KINASES; PEPTIDE COMPLEX; GENES; CALCINEURIN; RESOLUTION	Recent genetic studies of yeast calmodulin (yCaM) have shown that alterations of different sets of Phe residues result in distinct functional defects (Ohya, Y., and Botstein, D. (1994) Science 263, 963-966). To examine the importance of Phe residues for target binding and activation, we purified mutant yCaMs containing single or double Phe to Ala substitutions and determined their ability to bind and activate two target proteins, calcineurin and CaM-dependent protein kinase (CaMK). Binding assays using the gel overlay technique and quantitative analyses using surface plasmon resonance measurements indicated that the binding of yCaM to calcineurin is impaired by either double mutations of F16A/F19A or a single mutation of F140A, while binding to CaMX is impaired by F89A, F92A, or F140A. These same mutant yCaMs fail to activate calcineurin and CaMK, respectively, in vitro. In addition, F19A exhibited a severe defect in activation of both enzymes. F12A activated calcineurin to only 50% of the level achieved by wild-type calmodulin but fully activated CaMX. These results suggest that each target protein requires a specific and distinct subset of Phe residues in yCaM for target binding and activation.	Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan; Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Univ Tokyo, Grad Sch Sci, Japan Sci & Technol Corp, PRESTO,Unit Proc & Combined Circuit,Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; Stanford University; Japan Science & Technology Agency (JST); University of Tokyo	Ohya, Y (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan.	ohya@biol.s.u-tokyo.ac.jp		Cyert, Martha/0000-0003-3825-7437				BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; BROCKERHOFF SE, 1994, J CELL BIOL, V124, P315, DOI 10.1083/jcb.124.3.315; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; Chin D, 1997, J BIOL CHEM, V272, P5510, DOI 10.1074/jbc.272.9.5510; Chin D, 1996, J BIOL CHEM, V271, P30465, DOI 10.1074/jbc.271.48.30465; CRAIG TA, 1987, J BIOL CHEM, V262, P3278; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; GEISER JR, 1993, MOL CELL BIOL, V13, P7913, DOI 10.1128/MCB.13.12.7913; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; LIU Y, 1991, MOL GEN GENET, V227, P52, DOI 10.1007/BF00260706; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1995, NAT STRUCT BIOL, V2, P943, DOI 10.1038/nsb1195-943; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; Meyer DF, 1996, J BIOL CHEM, V271, P11284, DOI 10.1074/jbc.271.19.11284; Moser NJ, 1996, MOL CELL BIOL, V16, P4824; OHYA Y, 1991, J BIOL CHEM, V266, P12784; OHYA Y, 1994, GENETICS, V138, P1041; OHYA Y, 1987, EUR J BIOCHEM, V168, P13, DOI 10.1111/j.1432-1033.1987.tb13380.x; OHYA Y, 1994, SCIENCE, V263, P963, DOI 10.1126/science.8310294; PAUSCH MH, 1991, EMBO J, V10, P1511, DOI 10.1002/j.1460-2075.1991.tb07671.x; PERSECHINI A, 1989, J BIOL CHEM, V264, P8052; PUTKEY JA, 1988, J BIOL CHEM, V263, P11242; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sekiya-Kawasaki M, 1998, GENETICS, V150, P43; SHACTERNOIMAN E, 1983, J BIOL CHEM, V258, P4214; SIKORSKI RS, 1989, GENETICS, V122, P19; STIRLING DA, 1994, EMBO J, V13, P4329, DOI 10.1002/j.1460-2075.1994.tb06753.x; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAKANO E, 1994, FEBS LETT, V352, P247, DOI 10.1016/0014-5793(94)00965-1; TAYLOR DA, 1991, J BIOL CHEM, V266, P21375; TITANJI VPK, 1977, BIOCHIM BIOPHYS ACTA, V481, P140, DOI 10.1016/0005-2744(77)90145-0; VANBERKUM MFA, 1990, J BIOL CHEM, V265, P3750; Withee JL, 1997, MOL BIOL CELL, V8, P263, DOI 10.1091/mbc.8.2.263; ZHANG MJ, 1994, J BIOL CHEM, V269, P15546	36	23	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26375	26382		10.1074/jbc.273.41.26375	http://dx.doi.org/10.1074/jbc.273.41.26375			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756868	hybrid			2022-12-27	WOS:000076373300022
J	Yano, M; Kanazawa, M; Terada, K; Takeya, M; Hoogenraad, N; Mori, M				Yano, M; Kanazawa, M; Terada, K; Takeya, M; Hoogenraad, N; Mori, M			Functional analysis of human mitochondrial receptor Tom20 for protein import into mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE; YEAST MITOCHONDRIA; PRECURSOR PROTEINS; HUMAN HOMOLOG; IN-VITRO; SUBUNIT; MAS20P; MOM19; TRANSLOCATION; PREPROTEINS	The mitochondrial import receptor translocase of the outer membrane of mitochondria (Tom20) consists of five segments, an N-terminal membrane-anchor segment, a linker segment rich in charged amino acids, a tetratricopeptide repeat motif a glutamine-rich segment, and a c-terminal segment, To assess the role of each segment, four C-terminally truncated mutants of the human receptor (hTom20) were constructed, and the effect of their overexpression in COS-7 cells was analyzed, Expression of a mutant lacking the tetratricopeptide repeat motif inhibited preornithine transcarbamylase (pOTC) import to the same extent as the wild-type receptor. Thus, overexpression of the membrane-anchor and the linker segments is sufficient for the inhibition of import. Expression of either the wild-type receptor or a mutant lacking the C-terminal end of 20 amino acid residues stimulated import of pOTC-green fluorescent protein (GFP), a fusion protein in which the presequene of pOTC was fused to green fluorescent protein. On the other hand, expression of mutants lacking either the glutamine-rich segment or larger deletions inhibited pOTC-GFP import. In. vitro import of pOTC was inhibited by the wild-type hTom20 and the mutant lacking the C-terminal end, but much less strongly by the mutant lacking the glutamine-rich segment. On the other hand, import of pOTC-GFP was little affected by any of the forms of hTom20. In binding assays, pOTC binding to hTom20 was only moderately decreased by the deletion of the glutamine-rich segment, whereas pOTC-GFP binding was completely lost by this deletion. Binding of pOTCN-GFP a construct that contains am additional 58 N-terminal residues of mature OTC, resembled that of pOTC, All of these results indicate that the region 106-125 containing the glutamine-rich segment of hTom20 is essential for binding and import stimulation in vivo of pOTC-GFP and for inhibition of in vitro import of pOTC. The results also indicate that this region is important for mitochondrial aggregation. The different behaviors of pOTC and the pOTC-GFP chimera toward hTom20 mutants is explicable on the basis of the conformation of the precursor proteins.	Kumamoto Univ, Sch Med, Dept Mol Genet, Kumamoto 862, Japan; Kumamoto Univ, Sch Med, Dept Pathol 2, Kumamoto 862, Japan; La Trobe Univ, Dept Biochem, Bundoora, Vic 3083, Australia	Kumamoto University; Kumamoto University; La Trobe University	Mori, M (corresponding author), Kumamoto Univ, Sch Med, Dept Mol Genet, Kuhonji 4-24-1, Kumamoto 862, Japan.		Hoogenraad, Nicholas J/C-7505-2011					GOPING IS, 1995, FEBS LETT, V373, P45; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; Hajek P, 1997, MOL CELL BIOL, V17, P7169, DOI 10.1128/MCB.17.12.7169; Hanson B, 1996, EUR J BIOCHEM, V235, P750, DOI 10.1111/j.1432-1033.1996.t01-1-00750.x; HARKNESS TAA, 1994, J CELL BIOL, V124, P637, DOI 10.1083/jcb.124.5.637; Haucke V, 1996, EMBO J, V15, P1231, DOI 10.1002/j.1460-2075.1996.tb00464.x; HAUCKE V, 1995, J BIOL CHEM, V270, P5565, DOI 10.1074/jbc.270.10.5565; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; Iwahashi J, 1997, J BIOL CHEM, V272, P18467, DOI 10.1074/jbc.272.29.18467; Kanazawa M, 1997, J BIOCHEM-TOKYO, V121, P890; KIEBLER M, 1993, J MEMBRANE BIOL, V135, P191; Lill R, 1996, TRENDS CELL BIOL, V6, P56, DOI 10.1016/0962-8924(96)81015-4; LITHGOW T, 1994, P NATL ACAD SCI USA, V91, P11973, DOI 10.1073/pnas.91.25.11973; LITHGOW T, 1995, TRENDS BIOCHEM SCI, V20, P98, DOI 10.1016/S0968-0004(00)88972-0; LITHGOW T, 1995, J BIOL CHEM, V270, P14267, DOI 10.1074/jbc.270.24.14267; McBride HM, 1996, J CELL BIOL, V134, P307, DOI 10.1083/jcb.134.2.307; MOCZKO M, 1994, J BIOL CHEM, V269, P9045; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PFANNER N, 1994, TRENDS BIOCHEM SCI, V19, P368, DOI 10.1016/0968-0004(94)90113-9; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; Schatz G, 1996, J BIOL CHEM, V271, P31763, DOI 10.1074/jbc.271.50.31763; Schleiff E, 1997, J BIOL CHEM, V272, P17784, DOI 10.1074/jbc.272.28.17784; SEKI N, 1995, FEBS LETT, V375, P307, DOI 10.1016/0014-5793(95)01229-8; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; TAKEYA M, 1988, ULTRASTRUCT PATHOL, V12, P651, DOI 10.3109/01913128809056490; Terada K, 1997, FEBS LETT, V403, P309, DOI 10.1016/S0014-5793(97)00070-7; VESTWEBER D, 1988, EMBO J, V7, P1147, DOI 10.1002/j.1460-2075.1988.tb02924.x; Yano M, 1997, J BIOL CHEM, V272, P8459, DOI 10.1074/jbc.272.13.8459	28	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26844	26851		10.1074/jbc.273.41.26844	http://dx.doi.org/10.1074/jbc.273.41.26844			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756929	hybrid			2022-12-27	WOS:000076373300083
J	Goodier, JL; Maraia, RJ				Goodier, JL; Maraia, RJ			Terminator-specific recycling of a B1-Alu transcription complex by RNA polymerase III is mediated by the RNA terminus-binding protein La	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-FETOPROTEIN GENE; INITIATION-FACTOR; EXPRESSION; SEQUENCES; ELEMENTS; PROMOTER; REGION; DOWNSTREAM; PRECURSOR; INCREASE	Efficient synthesis of many small abundant RNAs is achieved by the proficient recycling of RNA polymerase (pol) III and stable transcription complexes. Cellular Alu and related retroposons represent unusual pol III genes that are normally repressed but are activated by viral infection and other conditions. The core sequences of these elements contain pol III promoters but must rely on fortuitous downstream oligo(dT) tracts for terminator function, me show that a B1-Alu gene differs markedly from a classical pol III gene (tRNA(i)(Met)) in terminator sequence requirements. B1-Alu genes that differ only in terminator sequence context direct differential RNA 3' end formation. These genes are assembled into stable transcription complexes but differ in their ability to be recycled in the presence of the La transcription termination factor. La binds to the nascent RNA 3' UUUOH end motif that is generated by transcriptional termination within the pol III termination signal, oligo(dT). We found that the recycling efficiency of the B1-Alu genes is correlated with the ability of La to access the 3' end of the nascent transcript and protect it from 3'-5' exonucleolytic processing. These results illuminate a relationship between RNA 3' end formation and transcription termination, and La-mediated reinitiation by pol III.	NICHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Maraia, RJ (corresponding author), NICHD, Lab Mol Growth Regulat, NIH, 6-416,MSC-2753,9000 Rockville Pike, Bethesda, MD 20892 USA.		Maraia, Richard/ABC-1442-2020	Maraia, Richard/0000-0002-5209-0066				ADENIYIJONES S, 1985, NATURE, V317, P81, DOI 10.1038/317081a0; ALLISON DS, 1985, EMBO J, V4, P2657, DOI 10.1002/j.1460-2075.1985.tb03984.x; ARIAS JA, 1989, J BIOL CHEM, V264, P3223; BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; BOGENHAGEN DF, 1982, CELL, V28, P413, DOI 10.1016/0092-8674(82)90359-2; Chu WM, 1997, NUCLEIC ACIDS RES, V25, P2077, DOI 10.1093/nar/25.11.2077; CHU WM, 1995, NUCLEIC ACIDS RES, V23, P1750, DOI 10.1093/nar/23.10.1750; Chu WM, 1998, MOL CELL BIOL, V18, P58, DOI 10.1128/MCB.18.1.58; Dieci G, 1996, CELL, V84, P245, DOI 10.1016/S0092-8674(00)80979-4; Fan H, 1997, CELL, V88, P707, DOI 10.1016/S0092-8674(00)81913-3; Fan H, 1998, MOL CELL BIOL, V18, P3201, DOI 10.1128/MCB.18.6.3201; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; Goodier JL, 1997, MOL CELL BIOL, V17, P5823, DOI 10.1128/MCB.17.10.5823; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1994, TRANSCRIPTION MECHAN, P107; KOVELMAN R, 1990, GENE DEV, V4, P646, DOI 10.1101/gad.4.4.646; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LIU WM, 1995, NUCLEIC ACIDS RES, V23, P1758, DOI 10.1093/nar/23.10.1758; MARAIA R, 1988, MOL CELL BIOL, V8, P4433, DOI 10.1128/MCB.8.10.4433; MARAIA RJ, 1992, MOL CELL BIOL, V12, P1500, DOI 10.1128/MCB.12.4.1500; MARAIA RJ, 1994, MOL CELL BIOL, V14, P2147, DOI 10.1128/MCB.14.3.2147; Maraia RJ, 1996, P NATL ACAD SCI USA, V93, P3383, DOI 10.1073/pnas.93.8.3383; MARAIA RJ, 1991, NUCLEIC ACIDS RES, V19, P5695, DOI 10.1093/nar/19.20.5695; PANNING B, 1993, MOL CELL BIOL, V13, P3231, DOI 10.1128/MCB.13.6.3231; RUSSANOVA VR, 1995, MOL CELL BIOL, V15, P4282; Schmid C, 1992, CURR OPIN GENET DEV, V2, P874, DOI 10.1016/S0959-437X(05)80110-8; STEFANO JE, 1984, CELL, V36, P145, DOI 10.1016/0092-8674(84)90083-7; Studitsky VM, 1997, SCIENCE, V278, P1960, DOI 10.1126/science.278.5345.1960; Van Horn DJ, 1997, RNA, V3, P1434; Wang ZX, 1996, MOL CELL BIOL, V16, P6841; Wang ZX, 1997, GENE DEV, V11, P2371, DOI 10.1101/gad.11.18.2371; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x; WILSON ET, 1988, MOL CELL BIOL, V8, P624, DOI 10.1128/MCB.8.2.624; WILSON ET, 1985, J MOL BIOL, V183, P153, DOI 10.1016/0022-2836(85)90209-8; Yoo CJ, 1997, CELL, V89, P393, DOI 10.1016/S0092-8674(00)80220-2; YOUNG LS, 1991, MOL CELL BIOL, V11, P1382, DOI 10.1128/MCB.11.3.1382; YOUNG PR, 1982, NUCLEIC ACIDS RES, V10, P3099, DOI 10.1093/nar/10.10.3099; ZASLOFF M, 1982, J BIOL CHEM, V257, P7857	39	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26110	26116		10.1074/jbc.273.40.26110	http://dx.doi.org/10.1074/jbc.273.40.26110			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748291	hybrid			2022-12-27	WOS:000076263100082
J	Xia, Y; Tsai, AL; Berka, V; Zweier, JL				Xia, Y; Tsai, AL; Berka, V; Zweier, JL			Superoxide generation from endothelial nitric-oxide synthase - A Ca2+/calmodulin-dependent and tetrahydrobiopterin regulatory process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MECHANISM; ARGININE; PROTEIN; BINDING; INJURY; HEME	It has been previously shown that besides synthesizing nitric oxide (NO), neuronal and inducible NO synthase (NOS) generates superoxide (O-2(radical anion)) under conditions of L-arginine depletion. However, there is controversy regarding whether endothelial NOS (eNOS) can also produce O-2(radical anion). Moreover, the mechanism and control of this process are not fully understood. Therefore, we performed electron paramagnetic resonance spin-trapping experiments to directly measure and characterize the O-2(radical anion) generation from purified eNOS. With the spin trap 5,5-dimethyl-1-pyrroline-N-oxide (DMPO), prominent signals of O-2(radical anion) adduct, DMPO-OOH, were detected from eNOS in the absence of added tetrahydrobiopterin (BH4), and these were quenched by superoxide dismutase. This O-2(radical anion) formation required Ca2+/calmodulin and was blocked by the specific NOS inhibitor N-nitro-L-arginine methyl ester (L-NAME) but not its non-inhibitory enantiomer D-NAME. A parallel process of Ca2+/calmodulin-dependent NADPH oxidation was observed which was also inhibited by L-NAME but not n-NAME. Pretreatment of the enzyme with the heme blockers cyanide or imidazole also prevented O-2(radical anion) generation. BH4 exerted dose-dependent inhibition of the O-2(radical anion) signals generated by eNOS. Conversely, in the absence of BH, L-arginine did not decrease this OX generation. Thus, eNOS can also catalyze OX formation, and this appears to occur primarily at the heme center of its oxygenase domain. O-2(radical anion) synthesis from eNOS requires Ca2+/calmodulin and is primarily regulated by BH, rather than L-arginine.	Johns Hopkins Univ, Sch Med, Johns Hopkins Bayview Med Ctr, Dept Med,Div Cardiol,Mol & Cellular Biophys Labs, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Johns Hopkins Bayview Med Ctr, Electron Paramagnet Resonance Ctr, Baltimore, MD 21224 USA; Univ Texas, Sch Med, Dept Internal Med, Div Hematol, Houston, TX 77030 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; University of Texas System	Zweier, JL (corresponding author), Johns Hopkins Asthma & Allergy Ctr, LA-14,5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038324, P50HL052315, R29HL038324] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-52315, HL-38324] Funding Source: Medline; NIGMS NIH HHS [GM44911] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHEN PF, 1995, BIOCHEM BIOPH RES CO, V215, P1119, DOI 10.1006/bbrc.1995.2579; Chen PF, 1996, J BIOL CHEM, V271, P14631, DOI 10.1074/jbc.271.24.14631; COSENTINO F, 1995, CIRCULATION, V91, P139, DOI 10.1161/01.CIR.91.1.139; FINKELSTEIN E, 1982, MOL PHARMACOL, V21, P262; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GROSS SS, 1992, J BIOL CHEM, V267, P25722; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; List BM, 1997, BIOCHEM J, V323, P159, DOI 10.1042/bj3230159; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; POU S, 1992, J BIOL CHEM, V267, P24173; PRITCHARD KA, 1995, CIRC RES, V77, P510, DOI 10.1161/01.RES.77.3.510; Roubaud V, 1997, ANAL BIOCHEM, V247, P404, DOI 10.1006/abio.1997.2067; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; VasquezVivar J, 1997, BIOCHEMISTRY-US, V36, P11293, DOI 10.1021/bi971475e; Xia Y, 1996, J BIOL CHEM, V271, P10096, DOI 10.1074/jbc.271.17.10096; Xia Y, 1997, P NATL ACAD SCI USA, V94, P12705, DOI 10.1073/pnas.94.23.12705; Xia Y, 1996, P NATL ACAD SCI USA, V93, P6770, DOI 10.1073/pnas.93.13.6770; Xia Y, 1997, P NATL ACAD SCI USA, V94, P6954, DOI 10.1073/pnas.94.13.6954	25	562	573	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25804	25808		10.1074/jbc.273.40.25804	http://dx.doi.org/10.1074/jbc.273.40.25804			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748253	hybrid			2022-12-27	WOS:000076263100044
J	Malek, S; Huxford, T; Ghosh, G				Malek, S; Huxford, T; Ghosh, G			I kappa B alpha functions through direct contacts with the nuclear localization signals and the DNA binding sequences of NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC RETENTION; C-REL; V-REL; DROSOPHILA; PHOSPHORYLATION; PROTEINS; P50; DEGRADATION; ACTIVATION; INHIBITION	We have determined the binding energies of complexes formed between I kappa B alpha and the wild type and mutational variants of three different Rel/NF-kappa B dimers, namely, the p50/p65 heterodimer and homodimers of p50 and p65. We show that although a common mode of interaction exists between the Rel/NF-kappa B dimers and I kappa B alpha, I kappa B alpha binds the NF-kappa B p50/p65 heterodimer with 60- and 27-fold higher affinity than the p50 and p65 homodimers, respectively. Each of the three flexibly linked segments of the rel homology region of Rel/NF-kappa B proteins (the nuclear localization sequence, the dimerization domain, and the amino-terminal DNA binding domain) is directly engaged in forming the protein/protein interface with the ankyrin repeats and the carboxyl-terminal acidic tail/PEST sequence of I kappa B alpha. In the cell, I kappa B alpha functions to retain NF-kappa B in the cytoplasm and inhibit its DNA binding activity. These properties are a result of the direct involvement of the nuclear localization sequences and of the DNA binding region of NF-kappa B in complex with I kappa B alpha. A model of the interactions in the complex is proposed based on our observations and the crystal structures of Rel/NF-kappa B dimers and the ankyrin domains of related proteins.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Ghosh, G (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, 9600 Gilman Dr, La Jolla, CA 92093 USA.			Huxford, Tom/0000-0002-1939-7373; Malek, Shiva/0000-0002-9526-7968	NCI NIH HHS [I32 CA09523-13] Funding Source: Medline; NIGMS NIH HHS [2 T32 GM08326] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008326] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Bell S, 1996, MOL CELL BIOL, V16, P6477; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Brown K, 1997, MOL CELL BIOL, V17, P3021, DOI 10.1128/MCB.17.6.3021; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; DIEHL JA, 1993, MOL CELL BIOL, V13, P1769, DOI 10.1128/MCB.13.3.1769; ERNST MK, 1995, MOL CELL BIOL, V15, P872; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Govind S, 1996, MOL CELL BIOL, V16, P1103; Huang DB, 1997, STRUCTURE, V5, P1427, DOI 10.1016/S0969-2126(97)00293-1; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; JONSSON U, 1993, ANN BIOL CLIN-PARIS, V51, P19; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KUMAR S, 1993, P NATL ACAD SCI USA, V90, P8962, DOI 10.1073/pnas.90.19.8962; Latimer M, 1998, MOL CELL BIOL, V18, P2640, DOI 10.1128/MCB.18.5.2640; LEHMING N, 1995, P NATL ACAD SCI USA, V92, P10242, DOI 10.1073/pnas.92.22.10242; LETILLY V, 1993, BIOCHEMISTRY-US, V32, P7753, DOI 10.1021/bi00081a021; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Luh FY, 1997, NATURE, V389, P999, DOI 10.1038/40202; Luque I, 1998, MOL CELL BIOL, V18, P1213, DOI 10.1128/MCB.18.3.1213; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Rottjakob EM, 1996, J VIROL, V70, P3176, DOI 10.1128/JVI.70.5.3176-3188.1996; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; TATEI K, 1995, MOL CELL BIOL, V15, P3627; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; Venkataramani R, 1998, NAT STRUCT BIOL, V5, P74, DOI 10.1038/nsb0198-74; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339	46	136	145	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25427	25435		10.1074/jbc.273.39.25427	http://dx.doi.org/10.1074/jbc.273.39.25427			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738011	hybrid			2022-12-27	WOS:000076085400061
J	Geng, Y; Zhou, L; Thompson, WJ; Lotz, M				Geng, Y; Zhou, L; Thompson, WJ; Lotz, M			Cyclic GMP and cGMP-binding phosphodiesterase are required for interleukin-1-induced nitric oxide synthesis in human articular chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; GUANYLYL CYCLASE RECEPTORS; TUMOR-NECROSIS-FACTOR; MESSENGER-RNA; NUCLEOTIDE PHOSPHODIESTERASES; SIGNAL-TRANSDUCTION; MURINE MACROPHAGES; INTRACELLULAR CA2+; MOLECULAR-CLONING; SYNTHASE ACTIVITY	This study addressed the role of guanylyl cyclase (GC) and phosphodiesterase (PDE) in interleukin (IL)-1 activation of human articular chondrocytes, The GC inhibitors LY83583 and methylene blue dose dependently inhibited IL-1-induced nitric oxide (NO) production, inducible NO synthase (iNOS) protein, and mRNA expression. These effects of GC inhibition were consistent with the rapid induction of cGMP by IL-1, which reached maximal levels after 5 min. The effects of GC inhibitors were selective as they did not reduce IL-1-induced cyclooxygenase II protein and mRNA. An inhibitor specific for soluble GC did not affect IL-1-induced NO production, and activators of soluble GC did not induce NO. However, the expression of iNOS mRNA was induced by atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP), activators of particulate GC, indicating that particulate rather than soluble guanylyl cyclases were involved in iNOS induction. The expression of iNOS mRNA and the production of NO were induced by a slowly hydrolyzable analog of cGMP, 8-bromo-cGMP, but not by nonhydrolyzable analog, dibutyryl cGMP, suggesting that PDE rather than cGMP-dependent protein kinase mediates the cGMP effects. Chondrocytes contained extensive cGMP PDE activity. This had PDE5 biochemical features and an inhibitor profile consistent with PDES, Furthermore, the nonisoform-specific PDE inhibitor IBMX and PDES specific inhibitors suppressed IL-1-induced NO release and iNOS mRNA expression, PDE5 mRNA was constitutively expressed in chondrocytes. In addition to increasing PDE5 activities, IL-1 treatment reduced the sensitivity of PDE5 to several pharmacological inhibitors by up to 50-fold. In summary, inhibitors of either GC or PDE5 prevented IL-1 induction of iNOS; IL-1 increased the rates of both cGMP generation and hydrolysis; and exogenous PDE hydrolyzable cGMP analog induced iNOS and NO. These results suggest that increased cGMP metabolic flux is sufficient to induce iNOS, and GC and PDE5 activities are required for IL-1 induction of iNOS expression via increases in coupled cGMP synthesis and hydrolysis.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Univ S Alabama, Coll Med, Dept Pharmacol, Mobile, AL 36688 USA	Scripps Research Institute; University of South Alabama	Lotz, M (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA.	mlotz@scripps.edu			NIAMS NIH HHS [AR42438, AR43872] Funding Source: Medline; NIA NIH HHS [AG13242] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043872, R01AR042438] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMES A, 1986, J BIOL CHEM, V261, P3034; Baylor D, 1996, P NATL ACAD SCI USA, V93, P560, DOI 10.1073/pnas.93.2.560; BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036; BEASLEY D, 1994, J EXP MED, V179, P71, DOI 10.1084/jem.179.1.71; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BIANCO FJ, 1995, AM J PATHOL, V146, P75; BLANCO FJ, 1995, EXP CELL RES, V218, P319, DOI 10.1006/excr.1995.1161; BULUT V, 1993, BIOCHEM BIOPH RES CO, V195, P1134, DOI 10.1006/bbrc.1993.2162; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CHARLES IG, 1993, P NATL ACAD SCI USA, V90, P11419, DOI 10.1073/pnas.90.23.11419; CICIRELLI MF, 1985, DEV BIOL, V108, P254, DOI 10.1016/0012-1606(85)90029-6; CONQUER JA, 1992, BIOCHIM BIOPHYS ACTA, V1134, P1, DOI 10.1016/0167-4889(92)90021-3; DAWIS SM, 1988, J BIOL CHEM, V263, P8771; DONG ZY, 1993, J IMMUNOL, V151, P2717; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GARTHWAITE J, 1995, MOL PHARMACOL, V48, P184; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GENG Y, 1995, J CELL PHYSIOL, V163, P545, DOI 10.1002/jcp.1041630315; GENG Y, 1995, J CELL BIOL, V129, P1651, DOI 10.1083/jcb.129.6.1651; GENG Y, 1995, J IMMUNOL, V155, P796; GOLDBERG ND, 1983, J BIOL CHEM, V258, P9213; GREEN D, 1993, GERIATRICS, V48, P46; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; GRONICH J, 1994, J CLIN INVEST, V93, P1224, DOI 10.1172/JCI117076; HABY C, 1994, J NEUROCHEM, V62, P496; HAGIWARA H, 1994, J BIOL CHEM, V269, P10729; HARTZELL HC, 1986, NATURE, V323, P273, DOI 10.1038/323273a0; HORTELANO S, 1993, FEBS LETT, V320, P135, DOI 10.1016/0014-5793(93)80078-9; HORTELANO S, 1992, J BIOL CHEM, V267, P24937; HULKOWER KI, 1991, BIOCHEM J, V276, P157, DOI 10.1042/bj2760157; HULKOWER KI, 1991, J RHEUMATOL, V18, P110; KOIDE M, 1993, J BIOL CHEM, V268, P24959; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Kotera J, 1997, EUR J BIOCHEM, V249, P434, DOI 10.1111/j.1432-1033.1997.t01-1-00434.x; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; LOTZ M, 1994, J CELL BIOL, V124, P365, DOI 10.1083/jcb.124.3.365; LOTZ M, 1995, J RHEUMATOL, V22, P104; MACFARLAND RT, 1991, J BIOL CHEM, V266, P136; MAIER R, 1994, BBA-PROTEIN STRUCT M, V1208, P145, DOI 10.1016/0167-4838(94)90171-6; MANGANIELLO VC, 1995, ARCH BIOCHEM BIOPHYS, V322, P1, DOI 10.1006/abbi.1995.1429; MARTIN M, 1994, EUR J IMMUNOL, V24, P1566, DOI 10.1002/eji.1830240717; Martin MU, 1997, EUR CYTOKINE NETW, V8, P5; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MCALLISTERLUCAS LM, 1993, J BIOL CHEM, V268, P22863; MITCHELL PG, 1993, BIOCHEM BIOPH RES CO, V196, P1133, DOI 10.1006/bbrc.1993.2369; Moro MA, 1996, P NATL ACAD SCI USA, V93, P1480, DOI 10.1073/pnas.93.4.1480; MUNOZ E, 1992, EUR J IMMUNOL, V22, P1391, DOI 10.1002/eji.1830220610; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; PALMER RMJ, 1993, BIOCHEM BIOPH RES CO, V193, P398, DOI 10.1006/bbrc.1993.1637; Rediske J J, 1994, Osteoarthritis Cartilage, V2, P199, DOI 10.1016/S1063-4584(05)80069-X; RODBARD D, 1974, P S RAD REL PROC MED; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Schulz S, 1998, J BIOL CHEM, V273, P1032, DOI 10.1074/jbc.273.2.1032; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; STADLER J, 1991, J IMMUNOL, V147, P3915; Tamai KT, 1997, RECENT PROG HORM RES, V52, P121; THOMPSON WJ, 1991, PHARMACOL THERAPEUT, V51, P13, DOI 10.1016/0163-7258(91)90039-O; Vesely DL, 1997, AM J MED SCI, V314, P311, DOI 10.1097/00000441-199711000-00008; Wedel BJ, 1997, FEBS LETT, V410, P29, DOI 10.1016/S0014-5793(97)00358-X; WONG SKF, 1992, J CLIN INVEST, V90, P299, DOI 10.1172/JCI115862; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	66	23	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27484	27491		10.1074/jbc.273.42.27484	http://dx.doi.org/10.1074/jbc.273.42.27484			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765278	hybrid			2022-12-27	WOS:000076448000065
J	McDowall, A; Leitinger, B; Stanley, P; Bates, PA; Randi, AM; Hogg, N				McDowall, A; Leitinger, B; Stanley, P; Bates, PA; Randi, AM; Hogg, N			The I domain of integrin leukocyte function-associated antigen-1 is involved in a conformational change leading to high affinity binding to ligand intercellular adhesion molecule 1 (ICAM-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; DIVALENT-CATION; CELL-ADHESION; A-DOMAIN; ALPHA-2-BETA-1 VLA-2; ALPHA-SUBUNITS; CR3 CD11B/CD18; LFA-1; SITE; IDENTIFICATION	On T cells the leukocyte integrin leukocyte function-associated antigen-1 (LFA-1) (CD11a/CD18) can be induced to bind its ligand intercellular adhesion molecule 1 (ICAM-1) (CD54) either by increasing the affinity of the receptor with Mg2+ and EGTA or by receptor clustering following activation with phorbol ester, The existence of these two adhesion-inducing pathways implies that alternative mechanisms might exist by which LFA-1 engages ICAM-1. The LFA-1 alpha subunit I domain contains a major binding site for ICAM-1. In this study me show that soluble LFA-1 I domain blocks ICAM-1 binding of the high affinity Mg2+-induced form of LFA-1 but not the phorbol ester-induced form. Under conditions of Mg2+-activation, the soluble I domain also prevents expression of an activation dependent epitope on LFA-1, implying that it inhibits a conformational change necessary for conversion to the high affinity form of this integrin. In addition, the binding of Mg2+-activated LFA-1 to ICAM-1 is blocked by peptides covering the alpha 4-beta 3 loop, the beta 3-alpha 5 loop, and the alpha 5 helix of the I domain, whereas none of the peptides tested blocks phorbol ester-mediated adhesion. The blocking peptides localize to the same face of the crystal structure of the LFA-1 I domain and define an area that, during activation, may be involved in association of the I domain with another region of LFA-1, potentially the beta-propeller domain. This is the first evidence Linking a structural domain of an integrin, in this case the I domain, with a particular activation mechanism.	Imperial Canc Res Fund, Leukocyte Adhes Lab, London WC2A 3PX, England; Imperial Canc Res Fund, Biomolec Modelling Lab, London WC2A 3PX, England	Cancer Research UK; Cancer Research UK	Hogg, N (corresponding author), Imperial Canc Res Fund, Leukocyte Adhes Lab, Lincolns Inn Fields, London WC2A 3PX, England.	hogg@europa.lif.icnet.uk	Bates, Paul/A-1651-2011; Bates, Paul A/AAF-8561-2020	Bates, Paul A/0000-0003-0621-0925; McDowall, Alison/0000-0003-2018-1462				BERENDT AR, 1992, CELL, V68, P71, DOI 10.1016/0092-8674(92)90207-S; BERGELSON JM, 1995, CURR BIOL, V5, P615, DOI 10.1016/S0960-9822(95)00124-2; CARPINO LA, 1972, J ORG CHEM, V37, P3404, DOI 10.1021/jo00795a005; DRANSFIELD I, 1990, IMMUNOL REV, V114, P29, DOI 10.1111/j.1600-065X.1990.tb00560.x; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DRANSFIELD I, 1989, EMBO J, V8, P3759, DOI 10.1002/j.1460-2075.1989.tb08552.x; EDWARDS CP, 1995, J BIOL CHEM, V270, P12635, DOI 10.1074/jbc.270.21.12635; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; FAULL RJ, 1994, J EXP MED, V179, P1307, DOI 10.1084/jem.179.4.1307; GRAVES BJ, 1995, NAT STRUCT BIOL, V2, P181, DOI 10.1038/nsb0395-181; HOGG N, 1997, LEUCOCYTE TYPING, V6, P343; Hogg Nancy, 1994, Trends in Cell Biology, V4, P379, DOI 10.1016/0962-8924(94)90044-2; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KAMATA T, 1995, J BIOL CHEM, V270, P12531, DOI 10.1074/jbc.270.21.12531; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LANDIS RC, 1994, J CELL BIOL, V126, P529, DOI 10.1083/jcb.126.2.529; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; LOFTUS JC, 1994, J BIOL CHEM, V269, P25235; Loftus JC, 1997, J CLIN INVEST, V99, P2302, DOI 10.1172/JCI119408; LUB M, 1995, IMMUNOL TODAY, V16, P479, DOI 10.1016/0167-5699(95)80031-X; MCGUIRE SL, 1995, J BIOL CHEM, V270, P25866, DOI 10.1074/jbc.270.43.25866; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; PETER K, 1995, J EXP MED, V181, P315, DOI 10.1084/jem.181.1.315; Qu AD, 1996, STRUCTURE, V4, P931, DOI 10.1016/S0969-2126(96)00100-1; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; RANDI AM, 1994, J BIOL CHEM, V269, P12395; Rieu P, 1996, J BIOL CHEM, V271, P15858, DOI 10.1074/jbc.271.27.15858; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; Stanley P, 1998, J BIOL CHEM, V273, P3358, DOI 10.1074/jbc.273.6.3358; STANLEY P, 1994, EMBO J, V13, P1790, DOI 10.1002/j.1460-2075.1994.tb06447.x; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; Stewart M, 1996, J CELL BIOCHEM, V61, P554, DOI 10.1002/(SICI)1097-4644(19960616)61:4<554::AID-JCB8>3.0.CO;2-N; Stewart MP, 1996, J IMMUNOL, V156, P1810; Stewart MP, 1998, J CELL BIOL, V140, P699, DOI 10.1083/jcb.140.3.699; STORMS SD, 1994, EXP CELL RES, V214, P100, DOI 10.1006/excr.1994.1238; TUCKWELL D, 1995, J CELL SCI, V108, P1629; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; Zhang L, 1996, J BIOL CHEM, V271, P29953, DOI 10.1074/jbc.271.47.29953; Zhang L, 1997, J BIOL CHEM, V272, P17558, DOI 10.1074/jbc.272.28.17558; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	47	87	95	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27396	27403		10.1074/jbc.273.42.27396	http://dx.doi.org/10.1074/jbc.273.42.27396			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765268	hybrid			2022-12-27	WOS:000076448000055
J	Shi, DQ; Kellems, RE				Shi, DQ; Kellems, RE			Transcription factor AP-2 gamma regulates murine adenosine deaminase gene expression during placental development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GONADOTROPIN ALPHA-SUBUNIT; HUMAN CHORIONIC-GONADOTROPIN; HUMAN TISSUE INHIBITOR; GROWTH-FACTOR; FACTOR AP-2; MOUSE EMBRYOGENESIS; CELL-DEATH; TROPHOBLAST; MICE; AP-2-BETA	Trophoblast cells are specialized extra-embryonic cells present only in eutherian mammals. They play a major role in the implantation and placentation processes. To understand better the molecular mechanisms that control the development and function of trophoblast cells, we sought to identify the transcription factors that regulate murine adenosine deaminase (ADA) gene expression in the placenta. Here we report a detailed characterization of a placenta-specific footprinting region (FP1) in the Ada placental regulatory element. The sequence of FP1 was mapped by DNase I footprinting and was found to match a consensus AP-2 transcription factor-binding site. Electrophoretic mobility shift assays demonstrated that FP1 interacted with AP-a-like proteins. Further analysis using AP-2 antibody confirmed that AP-2 protein was indeed present in the placenta and bound to FP1. Mutation at the AP-2 site in FP1 abolished the ability of the Ada placental regulatory element to bind AP-2 proteins and failed to target chloramphenicol acetyltransferase reporter gene expression to placentas in transgenic mice, indicating that AP-2 is required for Ada expression in the placenta. In addition, RNase protection assays demonstrated that AP-S gamma was the predominant AP-2 family member expressed in the placenta. In situ hybridization analysis revealed that AP-S gamma expression was enriched in the trophoblast lineage throughout development, suggesting that AP-2 gamma may be critical for trophoblast development and differentiation.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA	University of Texas System; Baylor College of Medicine	Shi, DQ (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, 6431 Fannin St, Houston, TX 77030 USA.				NICHD NIH HHS [HD34130] Funding Source: Medline; NIDDK NIH HHS [DK46207] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD034130] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R56HD034130] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046207] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aho S, 1997, EUR J BIOCHEM, V247, P503, DOI 10.1111/j.1432-1033.1997.00503.x; ANSELL JD, 1975, EARLY DEV MANNALS, P107; Berkowitz EA, 1997, ONCOGENE, V14, P2229, DOI 10.1038/sj.onc.1201051; BILLINGTON WD, 1971, ADV REPROD PHYSIOL, V5, P27; Bischof P, 1997, Early Pregnancy, V3, P81; BLACKBURN MR, 1995, J BIOL CHEM, V270, P23891, DOI 10.1074/jbc.270.41.23891; Blackburn MR, 1997, DEVELOPMENT, V124, P3089; Blackburn MR, 1996, PROG NUCLEIC ACID RE, V55, P195, DOI 10.1016/S0079-6603(08)60194-4; Chazaud C, 1996, MECH DEVELOP, V54, P83, DOI 10.1016/0925-4773(95)00463-7; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; CROSS JC, 1995, DEVELOPMENT, V121, P2513; DECLERCK YA, 1994, GENE, V139, P185, DOI 10.1016/0378-1119(94)90753-6; ENDERS AC, 1993, J EXP ZOOL, V266, P578, DOI 10.1002/jez.1402660608; FINI ME, 1994, J BIOL CHEM, V269, P28620; Firulli AB, 1998, NAT GENET, V18, P266, DOI 10.1038/ng0398-266; GARRIDO C, 1993, GROWTH FACTORS, V8, P109, DOI 10.3109/08977199309046931; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; Hammani K, 1996, J BIOL CHEM, V271, P25498, DOI 10.1074/jbc.271.41.25498; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; Johnson W, 1997, J BIOL CHEM, V272, P15405, DOI 10.1074/jbc.272.24.15405; KNUDSEN TB, 1991, BIOL REPROD, V44, P171, DOI 10.1095/biolreprod44.1.171; KNUDSEN TB, 1988, BIOL REPROD, V39, P937, DOI 10.1095/biolreprod39.4.937; Luo JM, 1997, NATURE, V388, P778, DOI 10.1038/42022; Ma GT, 1997, DEVELOPMENT, V124, P907; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342; MIGCHIELSEN AAJ, 1995, NAT GENET, V10, P279, DOI 10.1038/ng0795-279; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; Moser M, 1997, DEV DYNAM, V208, P115, DOI 10.1002/(SICI)1097-0177(199701)208:1<115::AID-AJA11>3.0.CO;2-5; MOSER M, 1995, DEVELOPMENT, V121, P2779; Nakayama H, 1997, DEV GENET, V21, P21, DOI 10.1002/(SICI)1520-6408(1997)21:1<21::AID-DVG3>3.3.CO;2-R; NG YK, 1994, DEVELOPMENT, V120, P3257; OuladAbdelghani M, 1996, EXP CELL RES, V225, P338, DOI 10.1006/excr.1996.0184; PIJNENBORG R, 1981, PLACENTA, V2, P71, DOI 10.1016/S0143-4004(81)80042-2; Riley P, 1998, NAT GENET, V18, P271, DOI 10.1038/ng0398-271; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; SHI D, 1997, J BIOL CHEM, V272, P3334; Silins G, 1997, BIOCHEM BIOPH RES CO, V230, P413, DOI 10.1006/bbrc.1996.5979; Soares MJ, 1996, PLACENTA, V17, P277, DOI 10.1016/S0143-4004(96)90051-X; Somasundaram K, 1996, P NATL ACAD SCI USA, V93, P3088, DOI 10.1073/pnas.93.7.3088; STEGER DJ, 1993, MOL ENDOCRINOL, V7, P1579, DOI 10.1210/me.7.12.1579; STEGER DJ, 1994, MOL CELL BIOL, V14, P5592, DOI 10.1128/MCB.14.8.5592; STEGER DJ, 1991, MOL ENDOCRINOL, V5, P243, DOI 10.1210/mend-5-2-243; Tanaka M, 1997, DEV BIOL, V190, P55, DOI 10.1006/dbio.1997.8685; WAKAMIYA M, 1995, P NATL ACAD SCI USA, V92, P3673, DOI 10.1073/pnas.92.9.3673; Wang DY, 1997, J BIOL CHEM, V272, P14244, DOI 10.1074/jbc.272.22.14244; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WINSTON JH, 1992, J BIOL CHEM, V267, P13472; WITTE DP, 1991, J CELL BIOL, V115, P179, DOI 10.1083/jcb.115.1.179; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	53	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27331	27338		10.1074/jbc.273.42.27331	http://dx.doi.org/10.1074/jbc.273.42.27331			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765260	hybrid			2022-12-27	WOS:000076448000047
J	Izban, MG; Parsons, MA; Sinden, RR				Izban, MG; Parsons, MA; Sinden, RR			Template end-to-end transposition by RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RNA; ELONGATION FACTOR-SII; FACILITATED TRANSCRIPT CLEAVAGE; PROMOTE READ-THROUGH; FACTOR-S-II; TERNARY COMPLEXES; NASCENT TRANSCRIPT; CALF THYMUS; DNA; ARREST	On 5'-template strand protruding templates, promoter-initiated run-off transcription by RNA polymerase II generates discrete, 15-16-nucleotide (nt) longer than expected products whose production is abrogated by elongation factor SII (Parsons, M. A., Sinden, R. R., and Izban, M. G. (1998) J. Biol. Chem. 273, 26998-27008). We demonstrate that template terminal complexes produce these RNAs and that transcript extension is a general and salt-sensitive (250 mM) feature of run-off transcription. On 5'-overhung templates the extended run-off transcripts appear to be retained within an RNA-DNA-enzyme ternary complex, and SII facilitates resumption of transcript elongation via a dinucleotide truncation intermediate. Moreover, on one of the 5-overhung templates, the initially extended complexes spontaneously resumed transcript extension and were uniquely resistant to salt (250 mM) challenge. However, SII did not facilitate this long distance extension on all template ends. Run-off transcripts on a blunt-ended template were initially extended by 2-11 nt (roughly in 2-nt increments); SII addition either before or after extension resulted in the accumulation of a 4-5-nt extension product. Based on these findings, we propose that the initial and continuously extended RNAs reflect intermediates and successful completion of template end-to-end transposition (template switching) by RNA polymerase II, respectively. Both the template end sequence and structure influenced the success of such an event.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Dept Obstet & Gynecol, Galveston, TX 77555 USA; Texas A&M Univ, Ctr Genome Res, Inst Biosci & Technol, Dept Biochem & Biophys, Houston, TX 77030 USA	University of Texas System; University of Texas Medical Branch Galveston; Texas A&M University System	Izban, MG (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, Dept Obstet & Gynecol, Galveston, TX 77555 USA.		Sinden, Richard/AAE-3086-2019		NIGMS NIH HHS [GM50719, GM52982] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; Awrey DE, 1997, J BIOL CHEM, V272, P14747, DOI 10.1074/jbc.272.23.14747; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; Chamberlin M.J., 1994, HARVEY LECT, V88, P1; CHAN CL, 1993, J MOL BIOL, V233, P25, DOI 10.1006/jmbi.1993.1482; CIPRESPALACIN G, 1994, P NATL ACAD SCI USA, V91, P8087, DOI 10.1073/pnas.91.17.8087; DEDRICK RL, 1985, BIOCHEMISTRY-US, V24, P2245, DOI 10.1021/bi00330a019; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; Dvir A, 1997, P NATL ACAD SCI USA, V94, P9006, DOI 10.1073/pnas.94.17.9006; Gu WG, 1996, P NATL ACAD SCI USA, V93, P6935, DOI 10.1073/pnas.93.14.6935; Gu WG, 1995, J BIOL CHEM, V270, P30441, DOI 10.1074/jbc.270.51.30441; GUO HL, 1993, J BIOL CHEM, V268, P18762; HSU LM, 1995, P NATL ACAD SCI USA, V92, P11588, DOI 10.1073/pnas.92.25.11588; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; IZBAN MG, 1995, J BIOL CHEM, V270, P2290, DOI 10.1074/jbc.270.5.2290; Jeon C, 1996, P NATL ACAD SCI USA, V93, P13677, DOI 10.1073/pnas.93.24.13677; JOHNSON TL, 1994, CELL, V77, P217, DOI 10.1016/0092-8674(94)90314-X; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KANAI A, 1991, J BIOCHEM-TOKYO, V109, P674, DOI 10.1093/oxfordjournals.jbchem.a123439; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; Landick R, 1997, CELL, V88, P741, DOI 10.1016/S0092-8674(00)81919-4; LINN SC, 1991, MOL CELL BIOL, V11, P1508, DOI 10.1128/MCB.11.3.1508; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; ORLOVA M, 1995, P NATL ACAD SCI USA, V92, P4596, DOI 10.1073/pnas.92.10.4596; Parsons MA, 1998, J BIOL CHEM, V273, P26998, DOI 10.1074/jbc.273.41.26998; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; RAPPAPORT J, 1987, J BIOL CHEM, V262, P5227; Reeder TC, 1996, CELL, V87, P767, DOI 10.1016/S0092-8674(00)81395-1; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; REYNOLDS R, 1992, J MOL BIOL, V224, P53, DOI 10.1016/0022-2836(92)90575-5; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; RICE GA, 1993, NUCLEIC ACIDS RES, V21, P113, DOI 10.1093/nar/21.1.113; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P8057, DOI 10.1073/pnas.91.17.8057; Rudd MD, 1996, J BIOL CHEM, V271, P21549, DOI 10.1074/jbc.271.35.21549; Samkurashvili I, 1996, J BIOL CHEM, V271, P23495, DOI 10.1074/jbc.271.38.23495; Shilatifard A, 1997, P NATL ACAD SCI USA, V94, P3639, DOI 10.1073/pnas.94.8.3639; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; Umehara T, 1995, GENE, V167, P297, DOI 10.1016/0378-1119(95)00634-6; Uptain SM, 1997, P NATL ACAD SCI USA, V94, P13548, DOI 10.1073/pnas.94.25.13548; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; Wang DG, 1997, J BIOL CHEM, V272, P5989, DOI 10.1074/jbc.272.9.5989; WIEST DK, 1992, J BIOL CHEM, V267, P7733; ZAYCHIKOV E, 1995, P NATL ACAD SCI USA, V92, P1739, DOI 10.1073/pnas.92.5.1739	61	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					27009	27016		10.1074/jbc.273.41.27009	http://dx.doi.org/10.1074/jbc.273.41.27009			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756951	hybrid			2022-12-27	WOS:000076373300105
J	Jung, H; Rubenhagen, R; Tebbe, S; Leifker, K; Tholema, N; Quick, M; Schmid, R				Jung, H; Rubenhagen, R; Tebbe, S; Leifker, K; Tholema, N; Quick, M; Schmid, R			Topology of the Na+/Proline transporter of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOA FUSION ANALYSIS; MEMBRANE TOPOLOGY; LACTOSE PERMEASE; PSEUDOMONAS-FRAGI; NA+/H+ ANTIPORTER; PROLINE UPTAKE; PROTEINS; EXPRESSION; PROMOTER; VECTORS	Hydropathy profile analysis of the amino acid sequence of the Na+/proline transporter of Escherichia coli (PutP) suggests that the protein consists of 12 transmembrane domains (TMs) which are connected by hydrophilic loops (Nakao, T., Yamato, I., and Anraku, Y. (1987) Mol Gen., Genet. 208, 70-75). We have tested this prediction by applying a gene fusion approach in combination with a Cys accessibility analysis and site-specific proteolysis, Characterization of a series of PutP-alkaline phosphatase (PhoA) and PutP-beta-galactosidase (LacZ) hybrid proteins yields a reciprocal activity pattern of the reporter proteins that is in agreement with the topology of TMs III to XII of the 12-helix model. Placement of the PutP-PhoA and PutP-LacZ junction sites closer to the N terminus does not yield conclusive results. As a prerequisite for further topology studies, a functional PutP molecule devoid of all five native Cys residues (Cys-free PutP) is generated. Subsequently, amino acids in Cys-free PutP are replaced individually with Cys, and the accessibility of the sulfhydryl groups is analyzed. Surprisingly, Cys residues placed close to the N terminus of PutP (Ile-3 --> Cys, Thr-5 --> Cys) or into putative TM II (Ser-71 --> Cys, Glu-75 --> Cys) are highly accessible to membrane permeant and impermeant thiol reagents in intact cells. In contrast, Cys at the C terminus (Ser-502 --> Cys) reacts only with the membrane permeant but not with the impermeant reagent in intact cells. These results contradict the 12-helix motif and indicate a periplasmic location of the N terminus whereas the C terminus faces the cytoplasm. In addition, a transporter with Cys in place of Leu-37 (putative periplasmic loop (pL2) shows the same accessibility pattern as the Cys at the C terminus. Furthermore, PutP which has been purified and reconstituted into proteoliposomes in an inside-out orientation, is readily cleaved by the endoproteinase AspN before Asp-33 (pL2), Asp-112 (putative cytoplasmic loop (cL3), Asp-262 (cL7), and Asp-356 (cL9), These results suggest a cytosolic location of Asp-33 and Leu-37, thereby implying the formation of an additional TM formed by amino acids of pL2. Based on these observations, a new secondary structure model is proposed according to which the protein consists of 13 TMs with the N terminus on the outside and the C terminus facing the cytoplasm. The 13-helix structure is discussed as a common topological motif for all members of the Na+/solute cotransporter family.	Univ Osnabruck, Fachbereich Biol Chem, Arbeitsgrp Mikrobiol, D-49069 Osnabruck, Germany	University Osnabruck	Jung, H (corresponding author), Univ Osnabruck, Fachbereich Biol Chem, Arbeitsgrp Mikrobiol, Barbarastr 11, D-49069 Osnabruck, Germany.		Jung, Heinrich/K-3790-2014	Jung, Heinrich/0000-0002-5450-3063				AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOYD D, 1989, P NATL ACAD SCI USA, V86, P9446, DOI 10.1073/pnas.86.23.9446; BOYD D, 1994, MEMBRANE PROTEIN STR; BUHR A, 1993, J BIOL CHEM, V268, P11599; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CAO GQ, 1994, EMBO J, V13, P4662, DOI 10.1002/j.1460-2075.1994.tb06789.x; CHEN CC, 1985, J MEMBRANE BIOL, V84, P157, DOI 10.1007/BF01872213; Delgado-Partin VM, 1998, J BIOL CHEM, V273, P9927, DOI 10.1074/jbc.273.16.9927; DRAPEAU GR, 1980, J BIOL CHEM, V255, P839; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Haardt M, 1996, J BACTERIOL, V178, P5370, DOI 10.1128/jb.178.18.5370-5381.1996; Jung H, 1998, BIOCHEMISTRY-US, V37, P11083, DOI 10.1021/bi980684b; KABACK HR, 1993, J BIOENERG BIOMEMBR, V25, P627; Kaback HR, 1997, P NATL ACAD SCI USA, V94, P5539, DOI 10.1073/pnas.94.11.5539; Kimura T, 1996, BIOCHEMISTRY-US, V35, P15896, DOI 10.1021/bi961568g; KOMEIJI Y, 1989, FEBS LETT, V256, P135, DOI 10.1016/0014-5793(89)81733-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MILLER JH, 1972, EXPT MOL GENETICS, P54; MILLER JH, 1992, SHORT COURSE BACTERI, P439; NAKAO T, 1987, MOL GEN GENET, V208, P70, DOI 10.1007/BF00330424; NOREAU J, 1979, J BACTERIOL, V140, P911, DOI 10.1128/JB.140.3.911-916.1979; Olami Y, 1997, J BIOL CHEM, V272, P1761, DOI 10.1074/jbc.272.3.1761; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Pourcher T, 1996, BIOCHEMISTRY-US, V35, P4161, DOI 10.1021/bi9527496; Quick M, 1996, EUR J BIOCHEM, V239, P732, DOI 10.1111/j.1432-1033.1996.0732u.x; Quick M, 1997, BIOCHEMISTRY-US, V36, P4631, DOI 10.1021/bi963063w; REIZER J, 1994, BBA-REV BIOMEMBRANES, V1197, P133, DOI 10.1016/0304-4157(94)90003-5; Rothman A, 1996, J BIOL CHEM, V271, P32288, DOI 10.1074/jbc.271.50.32288; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schmid R, 1997, MICROBIOL-UK, V143, P991, DOI 10.1099/00221287-143-3-991; STALMACH ME, 1983, J BACTERIOL, V156, P481, DOI 10.1128/JB.156.2.481-486.1983; STEWART LMD, 1983, FEMS MICROBIOL LETT, V19, P161, DOI 10.1111/j.1574-6968.1983.tb00533.x; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Turk E, 1997, J MEMBRANE BIOL, V159, P1, DOI 10.1007/s002329900264; Turk E, 1996, J BIOL CHEM, V271, P1925, DOI 10.1074/jbc.271.4.1925; UJWAL ML, 1995, BIOCHEMISTRY-US, V34, P14909, DOI 10.1021/bi00045a036; VANIWAARDEN PR, 1991, BIOCHEMISTRY-US, V30, P9595, DOI 10.1021/bi00104a005; Weissborn AC, 1997, BBA-BIOMEMBRANES, V1329, P237, DOI 10.1016/S0005-2736(97)00116-8; Yamato I., 1993, ALKALI CATION TRANSP, P53; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	43	61	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26400	26407		10.1074/jbc.273.41.26400	http://dx.doi.org/10.1074/jbc.273.41.26400			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756872	hybrid			2022-12-27	WOS:000076373300026
J	Melkonyan, H; Hofmann, HA; Nacken, W; Sorg, C; Klempt, M				Melkonyan, H; Hofmann, HA; Nacken, W; Sorg, C; Klempt, M			The gene encoding the myeloid-related protein 14 (MRP14), a calcium-binding protein expressed in granulocytes and monocytes, contains a potent enhancer element in the first intron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS; CELL-DIFFERENTIATION; MAMMALIAN-CELLS; 27E10 ANTIGEN; S100 FAMILY; HL-60 CELLS; MOUSE MRP8; KAPPA-B; DNA; MACROPHAGES	Myeloid-related proteins 8 and 14 (MRP8 and MRP14) are two Ca2+-binding proteins of the S-100 family highly abundant in myelomonocytic cells, The expression is mot only dependent on the developmental status of the cell but also on the inflammatory situation in the tissue. in order to identify regulatory elements responsible for the high expression of MRP14 in myeloid cells, reporter gene constructs have been transfected into HL-60 cells, Mono Mac 6 cells, and L132 cells, We demonstrated that a DNA element in the first intron (positions 153-361) enhances the transcriptional activity of the homologous promoter and of the heterologous herpes simplex virus thymidine kinase promoter up to 37-fold. To further identify the functional site, the region between positions 153 and 192 was analyzed functionally using the thymidine kinase promoter, The region increased the expression in the same magnitude as the complete intron. This enhancer is highly conserved in time human and murine MRP genes, indicative of its involvement in the transcription of MRPs, Protein binding to the region is demonstrated using EMSA, DNA cross-linking, Southwestern blotting, and affinity purification. Affinity purification confirms that four proteins bind to the enhancer element.	Univ Munster, Inst Expt Dermatol, D-48149 Munster, Germany	University of Munster	Klempt, M (corresponding author), Univ Munster, Inst Expt Dermatol, von Esmarchstr 56, D-48149 Munster, Germany.	Klempt@uni-muenster.de						ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BHARDWAJ RS, 1992, EUR J IMMUNOL, V22, P1891, DOI 10.1002/eji.1830220732; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; BURWINKEL F, 1994, HISTOCHEMISTRY, V101, P113, DOI 10.1007/BF00269357; CHEN X, 1993, BIOCHEM BIOPH RES CO, V191, P18, DOI 10.1006/bbrc.1993.1178; CHOMCZYNSKI P, 1897, ANN BIOCH, V162, P156; CICCARONE VC, 1990, J IMMUNOL, V144, P725; COLLINS SJ, 1987, BLOOD, V70, P1233; DELABIE J, 1990, CLIN EXP IMMUNOL, V81, P123; EDGEWORTH J, 1989, NATURE, V342, P189, DOI 10.1038/342189a0; GOEBELER M, 1994, TRANSPLANTATION, V58, P355; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; HENKEL G, 1992, J IMMUNOL, V149, P3239; HESSIAN PA, 1993, J LEUKOCYTE BIOL, V53, P197, DOI 10.1002/jlb.53.2.197; KIHARANEGISHI F, 1993, MOL CELL BIOL, V13, P7747, DOI 10.1128/MCB.13.12.7747; Klempt M, 1997, FEBS LETT, V408, P81, DOI 10.1016/S0014-5793(97)00394-3; KNIGHT GB, 1987, P NATL ACAD SCI USA, V84, P8350, DOI 10.1073/pnas.84.23.8350; KUDO S, 1994, J BIOL CHEM, V269, P22969; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LAGASSE E, 1992, BLOOD, V79, P1907; LAGASSE E, 1988, MOL CELL BIOL, V8, P2402, DOI 10.1128/MCB.8.6.2402; LAGASSE E, 1994, J EXP MED, V179, P1047, DOI 10.1084/jem.179.3.1047; Lefebvre V, 1996, ANN NY ACAD SCI, V785, P284, DOI 10.1111/j.1749-6632.1996.tb56285.x; LUGERING N, 1995, CLIN EXP IMMUNOL, V101, P249; LUGERING N, 1995, EUR J CLIN INVEST, V25, P659, DOI 10.1111/j.1365-2362.1995.tb01982.x; MCKNIGHT SL, 1980, NUCLEIC ACIDS RES, V8, P5949, DOI 10.1093/nar/8.24.5949; Melkonyan H, 1996, NUCLEIC ACIDS RES, V24, P4356, DOI 10.1093/nar/24.21.4356; METCALF D, 1995, EXP HEMATOL, V23, P569; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORRIS JF, 1994, MOL CELL BIOL, V14, P1786, DOI 10.1128/MCB.14.3.1786; MURAO S, 1990, CELL GROWTH DIFFER, V1, P447; Nacken W, 1996, BBA-MOL BASIS DIS, V1315, P1, DOI 10.1016/0925-4439(95)00108-5; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; ORKIN SH, 1992, BLOOD, V80, P575; Rammes A, 1997, J BIOL CHEM, V272, P9496; Rao E, 1997, J BIOL CHEM, V272, P6722, DOI 10.1074/jbc.272.10.6722; ROTH J, 1993, BIOCHEM BIOPH RES CO, V191, P565, DOI 10.1006/bbrc.1993.1255; ROTH J, 1992, INT ARCH ALLERGY IMM, V98, P140, DOI 10.1159/000236177; ROTH J, 1994, BIOCHEM J, V301, P655, DOI 10.1042/bj3010655; ROTH J, 1993, BLOOD, V82, P1875; Sambrock J, 1989, MOL CLONING LAB MANU; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Siegenthaler G, 1997, J BIOL CHEM, V272, P9371; TEIGELKAMP S, 1991, J BIOL CHEM, V266, P13462; Tulchinsky E, 1997, J BIOL CHEM, V272, P4828, DOI 10.1074/jbc.272.8.4828; vandenBos C, 1996, J IMMUNOL, V156, P1247; WARNERBARTNICKI AL, 1993, EXP CELL RES, V204, P241, DOI 10.1006/excr.1993.1030; Wingender E, 1996, NUCLEIC ACIDS RES, V24, P238, DOI 10.1093/nar/24.1.238; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2; ZWADLO G, 1988, CLIN EXP IMMUNOL, V72, P510	52	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					27026	27032		10.1074/jbc.273.41.27026	http://dx.doi.org/10.1074/jbc.273.41.27026			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756953	hybrid			2022-12-27	WOS:000076373300107
J	Fu, YB; Ballicora, MA; Leykam, JF; Preiss, J				Fu, YB; Ballicora, MA; Leykam, JF; Preiss, J			Mechanism of reductive activation of potato tuber ADP-glucose pyrophosphorylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADPGLUCOSE PYROPHOSPHORYLASE; CHLOROPLAST FRUCTOSE-1,6-BISPHOSPHATASE; BACTERIAL GLYCOGEN; SUBUNIT STRUCTURE; BIOSYNTHESIS; EXPRESSION; MODULATION; PROTEINS; ENZYMES	The potato tuber (Solanum tuberosum L.) ADP-glucose pyrophosphorylase activity is activated by a incubation with ADP-glucose and dithiothreitol or by ATP, glucose-1-phosphate, Ca2+, and dithiothreitol. The activation was accompanied by the appearance of new sulfhydryl groups as determined with 5,5'-dithiobis(2-nitrobenzoic acid). By analyzing the activated and nonactivated enzymes on SDS-polyacrylamide gel electrophoresis under nonreducing conditions, it was found that an intermolecular disulfide bridge between the small subunits of the potato tuber enzyme was reduced during the activation. Further experiments showed that the activation was mediated via a slow reduction and subsequent rapid conformational change induced by ADP-glucose, The activation process could be reversed by oxidation with 5,5'-dithiobis(2-nitrobenzoic acid). Incubation with ADP-glucose and dithiothreitol could reactivate the oxidized enzyme. Chemical modification experiments with [C-14]iodoacetic acid and 4-vinylpyridine determined that the intermolecular disulfide bridge was located between Cys(12) of the small subunits of the potato tuber enzyme. Mutation of Cys(12) in the small subunit into either Ala or Ser eliminated the requirement of DTT on the activation and prevented the formation of the intermolecular disulfide of the potato tuber enzyme, The mutants had instantaneous activation rates as the wild-type in the reduced state. A two-step activation model is proposed.	Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Michigan State University	Preiss, J (corresponding author), Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA.	preiss@pilot.msu.edu		Ballicora, Miguel/0000-0002-5324-0724				AUSUBEL MF, 1997, CURRENT PROTOCOLS MO; BALLICORA MA, 1994, EUR J BIOCHEM, V222, P467, DOI 10.1111/j.1432-1033.1994.tb18887.x; BALLICORA MA, 1995, PLANT PHYSIOL, V109, P245, DOI 10.1104/pp.109.1.245; BUCHANAN BB, 1980, ANNU REV PLANT PHYS, V31, P341, DOI 10.1146/annurev.pp.31.060180.002013; Fu YB, 1998, PLANT PHYSIOL, V117, P989, DOI 10.1104/pp.117.3.989; GHOSH HP, 1966, J BIOL CHEM, V241, P4491; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HAUGEN TH, 1979, J BIOL CHEM, V254, P127; HERTIG CM, 1983, J BIOL CHEM, V258, P984; IGLESIAS AA, 1993, J BIOL CHEM, V268, P1081; KLECZKOWSKI LA, 1993, J BIOL CHEM, V268, P6228; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGENDRE N, 1989, PRACTICAL GUIDE PROT, P77; MORELL MK, 1987, PLANT PHYSIOL, V85, P182, DOI 10.1104/pp.85.1.182; NAKATA PA, 1994, J BIOL CHEM, V269, P30798; NAKATA PA, 1991, PLANT MOL BIOL, V17, P1089, DOI 10.1007/BF00037149; OKITA TW, 1990, PLANT PHYSIOL, V93, P785, DOI 10.1104/pp.93.2.785; Papworth C.B., 1996, STRATEGIES, V9, P3, DOI DOI 10.1080/08924562.1996.11000299; PAULE MR, 1971, J BIOL CHEM, V246, P4602; PLAXTON WC, 1987, PLANT PHYSIOL, V83, P105, DOI 10.1104/pp.83.1.105; PREISS J, 1994, PROG NUCLEIC ACID RE, V47, P299, DOI 10.1016/S0079-6603(08)60255-X; PREISS J, 1966, BIOCHEMISTRY-US, V5, P264; PREISS J, 1989, ADV MICROB PHYSIOL, V30, P183; Preiss J., 1996, PHOTOASSIMILATE DIST, V3, p63?96; Preiss J., 1988, BIOCH PLANTS, V14., P181; Preiss J, 1991, OXFORD SURVEYS PLANT, V7, P59; SCHEIBE R, 1991, PLANT PHYSIOL, V96, P1, DOI 10.1104/pp.96.1.1; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITHWHITE BJ, 1992, J MOL EVOL, V34, P449, DOI 10.1007/BF00162999; SOWOKINOS JR, 1982, PLANT PHYSIOL, V69, P1459, DOI 10.1104/pp.69.6.1459; SOWOKINOS JR, 1981, PLANT PHYSIOL, V68, P924, DOI 10.1104/pp.68.4.924; STONE KL, 1989, PRACTICAL GUIDE PROT, P423; WOLOSIUK RA, 1993, FASEB J, V7, P622, DOI 10.1096/fasebj.7.8.8500687	33	108	114	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25045	25052		10.1074/jbc.273.39.25045	http://dx.doi.org/10.1074/jbc.273.39.25045			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737961	hybrid			2022-12-27	WOS:000076085400011
J	Sato, M; Hresko, R; Mueckler, M				Sato, M; Hresko, R; Mueckler, M			Testing the charge difference hypothesis for the assembly of a eucaryotic multispanning membrane protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER; SIGNAL SEQUENCE; ESCHERICHIA-COLI; ORIENTATION; INSERTION; RESIDUES; TOPOLOGY; GLUT-1	The Glut1 glucose transporter is a glycoprotein whose membrane topology has been verified by a number of experimental observations, all of which are consistent with a 12-transmembrane helix model originally based on hydrophobicity analysis. We used Glut1 as a model multispanning membrane protein to test the Charge Difference Hypothesis (Hartmann, E., Rapoport, T. A., and Lodish, H. F. (1989) Proc. Natl. Acad. Sci. U.S.A. 86, 5786-5790), which asserts that the topology of a eucaryotic multispanning membrane protein is determined solely by the amino acid charge difference across the first transmembrane segment. The charge difference across the first transmembrane segment of Glut1 was progressively inverted in two independent series of mutants, one series in which only the number of positively charged amino acid residues in the two flanking domains was altered and the other in which only the number of negatively charged residues in the two flanking domains was changed. The results indicate that the charge difference across the first transmembrane segment does affect the topology of the protein, but that contrary to the hypothesis, it only dictates the orientation of the first transmembrane segment and the disposition of the amino terminus and the first linker domain. Charge inversion resulted in the formation of aberrant molecules in which either the first or second transmembrane segment failed to insert into the membrane. The topology of downstream regions of Glut1 was unaffected by charge inversion across the first transmembrane segment, indicating that downstream sequences are important in determining the local topological disposition of the molecule.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Mueckler, M (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	mike@cellbio.wustl.edu	Mueckler, Mike M/F-6115-2012					ALLARD WJ, 1985, J BIOL CHEM, V260, P8668; ANDREWS DW, 1992, J BIOL CHEM, V267, P7761; BELTZER JP, 1991, J BIOL CHEM, V266, P973; GAFVELIN G, 1994, CELL, V77, P401, DOI 10.1016/0092-8674(94)90155-4; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; Harley CA, 1996, J BIOL CHEM, V271, P24625, DOI 10.1074/jbc.271.40.24625; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; JOHANSSON M, 1993, MOL GEN GENET, V239, P251, DOI 10.1007/BF00281625; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; Mothes W, 1997, CELL, V89, P523, DOI 10.1016/S0092-8674(00)80234-2; Mueckler M, 1997, BIOCHEM SOC T, V25, P951, DOI 10.1042/bst0250951; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; von Heijne G, 1994, Subcell Biochem, V22, P1; vonHeijne G, 1997, MOL MICROBIOL, V24, P249, DOI 10.1046/j.1365-2958.1997.3351702.x; VonHeijne G, 1996, PROG BIOPHYS MOL BIO, V66, P113, DOI 10.1016/S0079-6107(97)85627-1; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8	20	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25203	25208		10.1074/jbc.273.39.25203	http://dx.doi.org/10.1074/jbc.273.39.25203			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737982	hybrid			2022-12-27	WOS:000076085400032
J	Vo, L; Lee, S; Marcinko, MC; Holmes, EH; Macher, BA				Vo, L; Lee, S; Marcinko, MC; Holmes, EH; Macher, BA			Human alpha 1,3/4-fucosyltransferases - II. A single amino acid at the COOH terminus of FucT III and V alters their kinetic properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYL-LEWIS-X; HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; FUCOSYL-TRANSFERASE GENES; BLOOD-GROUP-B; MOLECULAR-CLONING; ALPHA(1,3)-FUCOSYL-TRANSFERASE GENE; NEGATIVE INDIVIDUALS; DETERMINES EXPRESSION; ACCEPTOR SPECIFICITY; SELECTIN LIGAND	An analysis of the acceptor substrate specificity of domain swap mutants of human alpha 1,3/4-fucosyltransferases (FucTs) III and V has been carried out. The results demonstrate that changing Asp(336) of FucT III to Ala (as in FucT V) produced a protein (III/V-1) with a reduced activity with a variety of accepters. An analysis of the kinetic properties of FucT III and the III/V-1 mutant demonstrated that III/V-1 had a 40-fold reduction in its affinity for the H-type 1 acceptor substrate (Fuc alpha 1, 2Gal beta 1,3GlcNAc) and 4-fold reduction in its affinity for GDP-fucose when compared with FucT III. Further, the overall catalytic efficiency of III/V-1 was similar to 100-fold lower than that of FucT III with an H-type 1 acceptor substrate. The complementary domain swap resulting from the change of Ala(349) of FucT V to Asp (V/III1) produced a FucT that had higher enzyme activity with a range of acceptor substrates and had a higher affinity for an H-type 2 acceptor substrate (Fuc alpha 1,2Gal beta 1,4GlcNAc) with an 8-fold higher overall catalytic efficiency than that of FucT V. No significant change occurred in the K-m for GDP-fucose for this protein when compared with FucT V. Kinetic parameters of two other FucT domain swaps (III8/V and V-8/III), resulting in proteins that differed from FucT III and V at the NH, terminus of their catalytic domain, were not significantly different from those of the parental enzymes when H-type 1 and H-type 2 acceptor substrates were utilized. Thus, substitution of an acidic amino acid for a nonpolar amino acid (i.e. Asp versus Ala) at the COOH terminus of FucTs produces an enzyme with enhanced enzyme activities. These results, together with the results presented in the accompanying papers (Nguyen, A.T. Holmes, E. H., Whitaker, J. M., Ho, S., Shetterly, S., and Macher, B. A. (1998) J. Biol. Chem. 273, 25244-25249; Sherwood, A. L., Nguyen, A. T., Whitaker, J. M., Macher, B. A., and Holmes, E. H (1998) J. Biol. Chem. 273, 25256-25260), provide new insights into the structure/function relationships of human alpha 1,3/4-FucT enzymes.	NW Hosp, Pacific NW Canc Fdn, Seattle, WA 98125 USA; San Francisco State Univ, Dept Chem & Biochem, San Francisco, CA 94132 USA	California State University System; San Francisco State University	Holmes, EH (corresponding author), NW Hosp, Pacific NW Canc Fdn, 120 Northgate Plaza,Suite 218, Seattle, WA 98125 USA.	eholmes@nwbio.org			NATIONAL CANCER INSTITUTE [R01CA070740] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR011805] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM052588] Funding Source: NIH RePORTER; NCI NIH HHS [CA70740] Funding Source: Medline; NCRR NIH HHS [P20 RR11805] Funding Source: Medline; NIGMS NIH HHS [GM52588] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chandrasekaran EV, 1996, BIOCHEMISTRY-US, V35, P8925, DOI 10.1021/bi952194e; Costache M, 1997, J BIOL CHEM, V272, P29721, DOI 10.1074/jbc.272.47.29721; DATTA AK, 1995, J BIOL CHEM, V270, P1497, DOI 10.1074/jbc.270.4.1497; DEVRIES T, 1995, J BIOL CHEM, V270, P8712, DOI 10.1074/jbc.270.15.8712; DeVries T, 1997, GLYCOBIOLOGY, V7, P921, DOI 10.1093/glycob/7.7.921; ELMGREN A, 1993, BIOCHEM BIOPH RES CO, V196, P515, DOI 10.1006/bbrc.1993.2280; Elmgren A, 1997, J BIOL CHEM, V272, P21994, DOI 10.1074/jbc.272.35.21994; KODA Y, 1993, BLOOD, V82, P2915; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LEGAULT DJ, 1995, J BIOL CHEM, V270, P20987, DOI 10.1074/jbc.270.36.20987; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MCCURLEY RS, 1995, GENOMICS, V26, P142, DOI 10.1016/0888-7543(95)80094-3; MOLLICONE R, 1994, J BIOL CHEM, V269, P20987; MOLLICONE R, 1994, J BIOL CHEM, V269, P12662; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; Nguyen AT, 1998, J BIOL CHEM, V273, P25244, DOI 10.1074/jbc.273.39.25244; NISHIHARA S, 1994, J BIOL CHEM, V269, P29271; NISHIHARA S, 1993, BIOCHEM BIOPH RES CO, V196, P624, DOI 10.1006/bbrc.1993.2295; Orntoft TF, 1996, J BIOL CHEM, V271, P32260, DOI 10.1074/jbc.271.50.32260; Oulmouden A, 1997, J BIOL CHEM, V272, P8764, DOI 10.1074/jbc.272.13.8764; SASAKI K, 1994, J BIOL CHEM, V269, P14730; Seto NOL, 1997, J BIOL CHEM, V272, P14133, DOI 10.1074/jbc.272.22.14133; Sherwood AL, 1998, J BIOL CHEM, V273, P25256, DOI 10.1074/jbc.273.39.25256; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; Xu XH, 1996, J BIOL CHEM, V271, P8818, DOI 10.1074/jbc.271.15.8818; YADAV SP, 1991, J BIOL CHEM, V266, P698; Yamamoto F, 1996, J BIOL CHEM, V271, P10515, DOI 10.1074/jbc.271.18.10515; ZU HY, 1995, BIOCHEM BIOPH RES CO, V206, P362, DOI 10.1006/bbrc.1995.1050	31	25	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25250	25255		10.1074/jbc.273.39.25250	http://dx.doi.org/10.1074/jbc.273.39.25250			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737989	hybrid			2022-12-27	WOS:000076085400039
J	Nishida, Y; Shima, F; Sen, H; Tanaka, Y; Yanagihara, C; Yamawaki-Kataoka, Y; Kariya, K; Kataoka, T				Nishida, Y; Shima, F; Sen, H; Tanaka, Y; Yanagihara, C; Yamawaki-Kataoka, Y; Kariya, K; Kataoka, T			Coiled-coil interaction of N-terminal 36 residues of cyclase-associated protein with adenylyl cyclase is sufficient for its function in Saccharomyces cerevisiae Ras pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLINE-RICH REGION; SCHIZOSACCHAROMYCES-POMBE; YEAST; CAP; BINDING; HOMOLOG; GENES; DNA; IDENTIFICATION; ACTIVATION	In the budding yeast Saccharomyces cerevisiae, association with the 70-kDa cyclase-associated protein (CAP) is required for proper response of adenylyl cyclase to Pas proteins. We show here that a small segment comprising the N-terminal 36 amino acid residues of CAP is sufficient for association with adenylyl cyclase as well as for its function in the Ras-adenylyl cyclase pathway as assayed by the ability to confer RAS2(Val-19)-dependent heat shock sensitivity to yeast cells. The CAP-binding site of adenylyl cyclase was mapped to a segment of 119 amino acid residues near its C terminus. Both of these regions contained tandem repetitions of a heptad motif alpha XX alpha XXX (where alpha represents a hydrophobic amino acid and X represents any amino acid), suggesting a coiled-coil interaction. When mutants of CAP defective in associating with adenylyl cyclase were isolated by screening of a pool of randomly mutagenized CAP, they were found to carry substitution mutations in one of the key hydrophobic residues in the heptad repeats. Furthermore, mutations of the key hydrophobic residues in the heptad repeats of adenylyl cyclase also resulted in loss of association with CAP. These results indicate the coiled-coil mechanism as a basis of the CAP-adenylyl cyclase interaction.	Kobe Univ, Sch Med, Dept Physiol 2, Chuo Ku, Kobe, Hyogo 6500017, Japan	Kobe University	Kataoka, T (corresponding author), Kobe Univ, Sch Med, Dept Physiol 2, Chuo Ku, 7-5-1 Kusunoki-cho, Kobe, Hyogo 6500017, Japan.	kataoka@kobe-u.ac.jp						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bartel P. L., 1993, CELLULAR INTERACTION, P153; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; FEDORCHAIKEN M, 1990, CELL, V61, P329, DOI 10.1016/0092-8674(90)90813-T; FIELD J, 1990, CELL, V61, P319, DOI 10.1016/0092-8674(90)90812-S; FREEMAN NL, 1995, J BIOL CHEM, V270, P5680, DOI 10.1074/jbc.270.10.5680; Freeman NL, 1996, MOL CELL BIOL, V16, P548; GERST JE, 1991, MOL CELL BIOL, V11, P1248, DOI 10.1128/MCB.11.3.1248; GERST JE, 1992, P NATL ACAD SCI USA, V89, P4338, DOI 10.1073/pnas.89.10.4338; GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989; GRAM H, 1992, P NATL ACAD SCI USA, V89, P3576, DOI 10.1073/pnas.89.8.3576; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KAWAMUKAI M, 1992, MOL BIOL CELL, V3, P167, DOI 10.1091/mbc.3.2.167; KRAMER W, 1987, METHOD ENZYMOL, V154, P350; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIMBERGER RJ, 1990, MOL BIOCHEM PARASIT, V38, P271, DOI 10.1016/0166-6851(90)90030-P; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MATVIW H, 1992, MOL CELL BIOL, V12, P5033, DOI 10.1128/MCB.12.11.5033; MCLACHLAN AD, 1982, NATURE, V299, P226, DOI 10.1038/299226a0; MINATO T, 1994, J BIOL CHEM, V269, P20845; Rose MD., 1990, METHODS YEAST GENETI; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Shima F, 1997, MOL CELL BIOL, V17, P1057, DOI 10.1128/MCB.17.3.1057; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUZUKI N, 1990, P NATL ACAD SCI USA, V87, P8711, DOI 10.1073/pnas.87.22.8711; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOJTEK A, 1991, CELL, V66, P497, DOI 10.1016/0092-8674(81)90013-1; VOJTEK AB, 1993, J CELL SCI, V105, P777; WANG J, 1993, MOL CELL BIOL, V13, P4087, DOI 10.1128/MCB.13.7.4087; YAMAWAKIKATAOKA Y, 1989, P NATL ACAD SCI USA, V86, P5693, DOI 10.1073/pnas.86.15.5693; Yanagihara C, 1997, BIOCHEM BIOPH RES CO, V232, P503, DOI 10.1006/bbrc.1997.6326; Zelicof A, 1996, J BIOL CHEM, V271, P18243, DOI 10.1074/jbc.271.30.18243; ZELICOF A, 1993, J BIOL CHEM, V268, P13448	40	43	43	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28019	28024		10.1074/jbc.273.43.28019	http://dx.doi.org/10.1074/jbc.273.43.28019			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774417	hybrid			2022-12-27	WOS:000076549800037
J	Zong, CS; Zeng, LY; Jiang, YX; Sadowski, HB; Wang, LH				Zong, CS; Zeng, LY; Jiang, YX; Sadowski, HB; Wang, LH			Stat3 plays an important role in oncogenic Ros- and insulin-like growth factor I receptor-induced Anchorage-independent growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; DNA-BINDING ACTIVITY; SIGNAL-TRANSDUCTION PATHWAYS; CONSTITUTIVE ACTIVATION; INTERFERON-GAMMA; CELL-LINES; TRANSCRIPTION FACTORS; TARGETED DISRUPTION; ABL ONCOGENE; C-ROS	The role of signal transducers and activators of transcription (STATs) in receptor protein-tyrosine kinase (PTH)-induced cell growth and transformation was investigated using an inducible epidermal growth factor receptor-Res chimeric receptor called ER2 and a constitutively activated insulin-like growth factor I receptor called NM1, both of which are able to induce anchorage-independent growth of NM 3T3 cells. ER2 and NM1 receptor PTKs are able to cause Stat3 activation. Coexpressing the dominant negative Stat3 mutant with ER2 or NM1 in transiently or stable transfected cells resulted in a dramatic inhibition of colonies induced by these receptor PTKs and a moderate inhibition of their mitogenicity in monolayer. Therefore, Stat3 is not only important for initiation of transformation, as demonstrated by inhibition of the epidermal growth factor-inducible colony formation of the ER2 cells by the mutant, but it is also required for the maintenance of transformation, as evidenced by reversion of the NM1 transformed cells, The DNA binding and transcriptional activities of the endogenous Stat3 were greatly inhibited in the ER2 and NM1 cells co-expressing the Stat3 mutants. We conclude that activated function of Stat3 is required for the establishment and maintenance of Ros and insulin-like growth factor I receptor PTK-induced cell transformation.	Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Biochem, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Zong, CS (corresponding author), Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA.	zongc01@doc.mssm.edu			NATIONAL CANCER INSTITUTE [R01CA029339, R01CA055054] Funding Source: NIH RePORTER; NCI NIH HHS [CA55054, CA29339] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAHMANDPOUR F, 1995, FEBS LETT, V360, P29, DOI 10.1016/0014-5793(95)00072-H; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; CACACE AM, 1993, ONCOGENE, V8, P2095; Campbell GS, 1997, J BIOL CHEM, V272, P2591, DOI 10.1074/jbc.272.5.2591; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Chen J, 1997, P NATL ACAD SCI USA, V94, P2295, DOI 10.1073/pnas.94.6.2295; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Coffer PJ, 1997, ONCOGENE, V15, P2529, DOI 10.1038/sj.onc.1201429; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Fei ZL, 1997, ONCOGENE, V15, P961, DOI 10.1038/sj.onc.1201265; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; GouilleuxGruart V, 1996, BLOOD, V87, P1692; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Kang JS, 1996, MOL CELL BIOL, V16, P3370; KRAUSS RS, 1992, MOL CELL BIOL, V12, P3117, DOI 10.1128/MCB.12.7.3117; Leaman DW, 1996, MOL CELL BIOL, V16, P369; LIU DL, 1993, J VIROL, V67, P9, DOI 10.1128/JVI.67.1.9-18.1993; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MULI AL, 1995, EMBO J, V14, P1166; MULI AL, 1996, EMBO J, V15, P2425; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NECKAMEYER WS, 1985, J VIROL, V53, P879, DOI 10.1128/JVI.53.3.879-884.1985; Nielsen M, 1997, P NATL ACAD SCI USA, V94, P6764, DOI 10.1073/pnas.94.13.6764; Patel BKR, 1996, J BIOL CHEM, V271, P22175, DOI 10.1074/jbc.271.36.22175; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Sambrook J., 1989, MOL CLONING, P1666; SawkaVerhelle D, 1997, EUR J BIOCHEM, V250, P411, DOI 10.1111/j.1432-1033.1997.0411a.x; Shuai K, 1996, ONCOGENE, V13, P247; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162; WeberNordt RM, 1996, BLOOD, V88, P809; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Xiong QH, 1996, MOL CELL BIOL, V16, P1509; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zong C, 1996, EMBO J, V15, P4515, DOI 10.1002/j.1460-2075.1996.tb00829.x; ZONG CS, 1993, J VIROL, V67, P6453, DOI 10.1128/JVI.67.11.6453-6462.1993; ZONG CS, 1994, P NATL ACAD SCI USA, V91, P10982, DOI 10.1073/pnas.91.23.10982; Zong CS, 1997, J BIOL CHEM, V272, P1500, DOI 10.1074/jbc.272.3.1500	55	81	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28065	28072		10.1074/jbc.273.43.28065	http://dx.doi.org/10.1074/jbc.273.43.28065			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774423	hybrid			2022-12-27	WOS:000076549800043
J	Mallat, A; Gallois, C; Tao, JC; Habib, A; Maclouf, J; Mavier, P; Preaux, AM; Lotersztajn, S				Mallat, A; Gallois, C; Tao, JC; Habib, A; Maclouf, J; Mavier, P; Preaux, AM; Lotersztajn, S			Platelet-derived growth factor-BB and thrombin generate positive and negative signals for human hepatic stellate cell proliferation - Role of a prostaglandin/cyclic AMP pathway and cross-talk with endothelin receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; HUMAN ITO CELLS; SMOOTH-MUSCLE CELLS; FAT-STORING CELLS; INHIBITORY PROPERTIES; MEDIATED PATHWAY; LIVER-INJURY; EXPRESSION; CULTURE; CYCLOOXYGENASE	Proliferation of myofibroblastic hepatic stellate cells (HSC) in response to growth factors is essential for the development of liver fibrosis, We have reported that prostaglandins (PG) and cyclic AMP (cAMP) inhibit growth of human HSC, This PG/cAMP pathway transduces the endothelin (ET) B-mediated antiproliferative effect of endothelin-1 (ET-1) and up-regulates ETB receptors, Here, we show that platelet derived growth factor (PDGF)-BB and thrombin, although mitogenic, generate growth inhibitory PGE, in myofibroblastic human HSC, The two peptides elicit early PGE(2) and cAMP synthesis, and also promote delayed induction of cyclooxygenase (COX)-2. Both early and delayed production of PGE, counteract the mitogenic effect of PDGF-BB and thrombin because: (i) pretreatment with the COX inhibitor ibuprofen markedly enhances the mitogenic effect of both peptides; (ii) blocking early synthesis of PGE, greatly enhances extracellular signal-regulated kinase (ERK) activation by both growth factors; (iii) enhancement of DNA synthesis by ibuprofen is only lost when the inhibitor is added after COX-2 induction has occurred. Finally, PDGF-BB and thrombin raise ETB receptors through the PG pathway. Thus, ibuprofen blunts growth factor-induced increase in ETB receptors, Up regulation of the growth inhibitory ETB receptors by both mitogens may enhance the antiproliferative effect of ET-1 and thereby establish a negative feedback of their mitogenic effect. Our results shed light on novel growth inhibitory signals evoked by two mitogenic growth factors expressed during liver injury.	Hop Henri Mondor, INSERM, U99, F-94010 Creteil, France; Hop Lariboisiere, Inst Federat Rech Circulat Lariboisiere, U348, INSERM, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Mallat, A (corresponding author), Hop Henri Mondor, INSERM, U99, F-94010 Creteil, France.	mallat@im3.inserm.fr	Lotersztajn, Sophie/K-9160-2017; Habib, Aida/H-8647-2019	Habib, Aida/0000-0001-6027-0043; lotersztajn, Sophie/0000-0002-0053-7807				Albrecht DE, 1997, J BIOL CHEM, V272, P2236; Asselin E, 1996, J CELL PHYSIOL, V168, P600, DOI 10.1002/(SICI)1097-4652(199609)168:3<600::AID-JCP12>3.0.CO;2-2; Bornfeldt KE, 1997, J CLIN INVEST, V100, P875, DOI 10.1172/JCI119603; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CREMINON C, 1995, BBA-LIPID LIPID MET, V1254, P333, DOI 10.1016/0005-2760(94)00196-6; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; DAVIS BH, 1991, BIOCHEM J, V278, P43, DOI 10.1042/bj2780043; DEBLAQUIERE J, 1994, J BIOL CHEM, V269, P4812; FAILLI P, 1995, AM J PHYSIOL-CELL PH, V269, pC1133, DOI 10.1152/ajpcell.1995.269.5.C1133; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; GEERTS A, 1991, HEPATOLOGY, V13, P1193, DOI 10.1002/hep.1840130628; Graves LM, 1996, J BIOL CHEM, V271, P505, DOI 10.1074/jbc.271.1.505; HABIB A, 1993, J BIOL CHEM, V268, P23448; Houglum K, 1997, J CLIN INVEST, V99, P1322, DOI 10.1172/JCI119291; JOUNEAUX C, 1994, J BIOL CHEM, V269, P1845; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MALLAT A, 1995, J CLIN INVEST, V96, P42, DOI 10.1172/JCI118052; MALLAT A, 1995, HEPATOLOGY, V21, P1003, DOI 10.1016/0270-9139(95)90247-3; Mallat A, 1996, J HEPATOL, V25, P405, DOI 10.1016/S0168-8278(96)80130-9; Mallat A, 1996, J CLIN INVEST, V98, P2771, DOI 10.1172/JCI119103; MALLAT A, 1994, HEPATOLOGY, V20, P1589, DOI 10.1002/hep.1840200631; MANCINI R, 1992, J HEPATOL, V15, P361, DOI 10.1016/0168-8278(92)90069-2; MARRA F, 1995, HEPATOLOGY, V22, P780, DOI 10.1002/hep.1840220314; Marra F, 1997, GASTROENTEROLOGY, V112, P1297, DOI 10.1016/S0016-5085(97)70144-6; Marra F, 1998, HEPATOLOGY, V27, P462, DOI 10.1002/hep.510270221; McAnulty RJ, 1997, BIOCHEM J, V321, P639, DOI 10.1042/bj3210639; Pinzani M, 1996, GASTROENTEROLOGY, V110, P534, DOI 10.1053/gast.1996.v110.pm8566602; PINZANI M, 1994, HEPATOLOGY, V19, P701, DOI 10.1002/hep.1840190323; PINZANI M, 1992, J CLIN INVEST, V90, P642, DOI 10.1172/JCI115905; Pinzani M, 1996, AM J PATHOL, V148, P785; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003; ROZENGURT E, 1983, CELL, V34, P265, DOI 10.1016/0092-8674(83)90157-5; SCHMITTGRAFF A, 1991, AM J PATHOL, V138, P1233; Throckmorton DC, 1996, BIOCHEM BIOPH RES CO, V220, P692, DOI 10.1006/bbrc.1996.0466; VIDAL C, 1994, MOL PHARMACOL, V45, P97; VITTET D, 1992, J CELL PHYSIOL, V150, P65, DOI 10.1002/jcp.1041500110; WIN KM, 1993, HEPATOLOGY, V18, P137, DOI 10.1002/hep.1840180121; WONG L, 1994, J CLIN INVEST, V94, P1563, DOI 10.1172/JCI117497	40	89	95	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27300	27305		10.1074/jbc.273.42.27300	http://dx.doi.org/10.1074/jbc.273.42.27300			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765255	hybrid			2022-12-27	WOS:000076448000042
J	Thomas, D; Lipp, P; Berridge, MJ; Bootman, MD				Thomas, D; Lipp, P; Berridge, MJ; Bootman, MD			Hormone-evoked elementary Ca2+ signals are not stereotypic, but reflect activation of different size channel clusters and variable recruitment of channels within a cluster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL TRISPHOSPHATE; XENOPUS OOCYTES; HELA-CELLS; ENDOTHELIAL-CELLS; CARDIAC MYOCYTES; CALCIUM; EVENTS; RELEASE; PATTERNS; SPIKES	Precious studies of (InsP(3))-evoked elementary Ca2+ events suggested a hierarchy of signals; fundamental events ("Ca2+ blips") arising from single InsP(3) receptors (InsP(3)Rs), and intermediate events ("Ca2+ puffs") reflecting the coordinated opening of a cluster of InsP(3)Rs, The characteristics of such elementary Ca2+ release signals provide insights into the functional interaction and distribution of InsP(3)Rs in living cells. Therefore we investigated whether elementary Ca2+ signaling is truly represented by such stereotypic release events. A histogram of >900 events revealed a wide spread of signal amplitudes (20-600 nM; mean 216 +/- 4 nM; n = 206 cells), which cannot be explained by stochastic variation of a stereotypic Ca2+ release site. We identified elementary Ca2+ release sites with consistent amplitudes (<20% difference) and locations with variable amplitudes (similar to 500% difference). importantly, within single cells, distinct sites displayed events with significantly different mean amplitudes, Additional determinants affecting the magnitude of elementary Ca2+ release were identified to be (i) hormone concentration, (ii) day-to day variability, and (iii) a progressively decreasing Ca2+ release during prolonged stimulation. We therefore suggest that elementary Ca2+ events are not stereotypic, instead a continuum of signals can be achieved by either recruitment of entire clusters with different numbers of InsP(3)Rs or by a graded recruitment of InsP(3)Rs within a cluster.	Babraham Inst, Mol Signalling Lab, Cambridge CB2 4AT, England; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Cambridge	Lipp, P (corresponding author), Babraham Inst, Mol Signalling Lab, Cambridge CB2 4AT, England.	peterlipp@bbsrc.ac.uk	Bootman, Martin/AAB-3330-2019	Bootman, Martin/0000-0002-6447-3451				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; Bootman M, 1997, J PHYSIOL-LONDON, V499, P307, DOI 10.1113/jphysiol.1997.sp021928; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; Bootman MD, 1997, CELL, V91, P367, DOI 10.1016/S0092-8674(00)80420-1; Bootman MD, 1996, CURR BIOL, V6, P855, DOI 10.1016/S0960-9822(02)00609-7; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; Callamaras N, 1998, J PHYSIOL-LONDON, V509, P81, DOI 10.1111/j.1469-7793.1998.081bo.x; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Huser J, 1997, AM J PHYSIOL-CELL PH, V273, pC1775, DOI 10.1152/ajpcell.1997.273.5.C1775; JACOB R, 1988, NATURE, V335, P40, DOI 10.1038/335040a0; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; Lipp P, 1996, PROG BIOPHYS MOL BIO, V65, P265, DOI 10.1016/S0079-6107(96)00014-4; LIPP P, 1994, CIRC RES, V74, P979, DOI 10.1161/01.RES.74.5.979; Lipp P, 1998, J PHYSIOL-LONDON, V508, P801, DOI 10.1111/j.1469-7793.1998.801bp.x; Lipp P, 1996, J PHYSIOL-LONDON, V492, P31, DOI 10.1113/jphysiol.1996.sp021286; Lipp P, 1997, EMBO J, V16, P7166, DOI 10.1093/emboj/16.23.7166; LOPEZLOPEZ JR, 1995, SCIENCE, V268, P1042, DOI 10.1126/science.7754383; Marchant JS, 1998, J PHYSIOL-LONDON, V506P, p70P; Parker I, 1996, CELL CALCIUM, V20, P105, DOI 10.1016/S0143-4160(96)90100-1; Parker I, 1997, J PHYSIOL-LONDON, V505, P337, DOI 10.1111/j.1469-7793.1997.337bb.x; Parker I, 1996, J PHYSIOL-LONDON, V491, P663, DOI 10.1113/jphysiol.1996.sp021247; PETERSEN OH, 1994, ANNU REV PHYSIOL, V56, P297, DOI 10.1146/annurev.ph.56.030194.001501; Reber BFX, 1996, PFLUG ARCH EUR J PHY, V432, P893, DOI 10.1007/s004240050213; Shirokova N, 1997, J PHYSIOL-LONDON, V502, P3, DOI 10.1111/j.1469-7793.1997.003bl.x; Sun XP, 1998, J PHYSIOL-LONDON, V509, P67, DOI 10.1111/j.1469-7793.1998.067bo.x; Swillens S, 1998, CELL CALCIUM, V23, P291, DOI 10.1016/S0143-4160(98)90025-2; THOMAS AP, 1991, CELL CALCIUM, V12, P111, DOI 10.1016/0143-4160(91)90013-5; Tovey SC, 1998, J PHYSIOL-LONDON, V509P, p200P; YAO Y, 1995, J PHYSIOL-LONDON, V482, P533, DOI 10.1113/jphysiol.1995.sp020538	31	77	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27130	27136		10.1074/jbc.273.42.27130	http://dx.doi.org/10.1074/jbc.273.42.27130			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765231	hybrid			2022-12-27	WOS:000076448000018
J	Zhu, XG; Hanover, JA; Hager, GL; Cheng, SY				Zhu, XG; Hanover, JA; Hager, GL; Cheng, SY			Hormone-induced translocation of thyroid hormone receptors in living cells visualized using a receptor green fluorescent protein chimera	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR; L-TRIIODOTHYRONINE; GLUCOCORTICOID RECEPTOR; BINDING; LOCALIZATION; DOMAIN; GROWTH; DNA; MODULATION; MUTANTS	Thyroid hormone nuclear receptors (TRs) are ligand-dependent transcription factors that regulate growth, differentiation, and development. To understand the role of the hormone, 3,3',5-triiodo-L-thyronine (T-3), in the nuclear translocation and targeting of TRs to the regulatory sites in chromatin, we appended green fluorescent protein (GFP) to the human TR subtype beta 1 (TR beta 1). The fusion of GFP to the amino terminus of TR beta 1 protein did not alter T-3 binding or transcriptional activities of the receptor. The subcellular localization of GFP-TR beta 1 in living cells was visualized by laser-scanning confocal microscopy. In the presence of T-3, the expressed GFP-TR beta 1 was predominately localized in the nucleus, exhibiting a nuclear/cytoplasmic ratio of similar to 5.5. No GFP-TR beta 1 was detected in the nucleolus. In the absence of T-3, more GFP-TR beta 1 was present in the cytoplasm, exhibiting a nuclear/cytoplasmic ratio of similar to 1.5. In these cells, cytoplasmic GFP-TR beta 1 could be induced to enter the nucleus by T-3. The T-3-induced translocation was blocked when Lys(184)-Arg(185) in domain D of TR beta 1 was mutated to Ala(184)-Ala(185). Furthermore, the inability of the mutant TR to translocate to the nucleus correlated with the loss of most of its transcriptional activity. These results suggest that TR functions may, in part, be regulated by T-3-induced nuclear entry.	NCI, Mol Biol Lab, Bethesda, MD 20892 USA; NCI, Lab Receptor Biol & Gene Express, Bethesda, MD 20892 USA; NIDDK, Lab Cellular Biochem & Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Cheng, SY (corresponding author), Bldg 37,Rm 2D24,37 Convent Dr,MSC 4255, Bethesda, MD 20892 USA.							ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; BHAT MK, 1993, BIOCHEM BIOPH RES CO, V195, P385, DOI 10.1006/bbrc.1993.2055; Cheng Sheue-Yann, 1995, Journal of Biomedical Science, V2, P77, DOI 10.1007/BF02253060; DALMAN FC, 1990, J BIOL CHEM, V265, P3615; DEFESI CR, 1985, ENDOCRINOLOGY, V116, P2062, DOI 10.1210/endo-116-5-2062; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; HELM R, 1995, NATURE, V373, P663; HOLLEY SJ, 1995, MOL BIOL CELL, V6, P1833, DOI 10.1091/mbc.6.12.1833; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; HSU SC, 1992, EMBO J, V11, P3457, DOI 10.1002/j.1460-2075.1992.tb05425.x; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; LEE Y, 1993, J BIOL CHEM, V268, P2021; LIN KH, 1991, MOL ENDOCRINOL, V5, P485, DOI 10.1210/mend-5-4-485; Lin KH, 1996, ENDOCRINOLOGY, V137, P4073, DOI 10.1210/en.137.10.4073; LIN KH, 1991, ENDOCRINOLOGY, V128, P2601, DOI 10.1210/endo-128-5-2601; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; MEIER CA, 1993, J CLIN INVEST, V92, P1986, DOI 10.1172/JCI116793; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; OPPENHEIMER JH, 1975, ENDOCR RES COMMUN, V2, P309, DOI 10.1080/07435807509089004; OPPENHEIMER JH, 1994, EUR J ENDOCRINOL, V130, P15, DOI 10.1530/eje.0.1300015; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; PUYMIRAT J, 1992, NEUROSCI LETT, V135, P239, DOI 10.1016/0304-3940(92)90445-D; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; SAMUELS HH, 1976, P NATL ACAD SCI USA, V73, P3877, DOI 10.1073/pnas.73.11.3877; SAMUELS HH, 1979, J CLIN INVEST, V63, P1229, DOI 10.1172/JCI109418; SPINDLER BJ, 1975, J BIOL CHEM, V250, P4113; STRAIT KA, 1991, P NATL ACAD SCI USA, V88, P3887, DOI 10.1073/pnas.88.9.3887; SURKS MI, 1975, J CLIN INVEST, V55, P50, DOI 10.1172/JCI107917; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Yap N, 1996, P NATL ACAD SCI USA, V93, P4273, DOI 10.1073/pnas.93.9.4273; Zhu XG, 1997, J BIOL CHEM, V272, P9048	32	92	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27058	27063		10.1074/jbc.273.42.27058	http://dx.doi.org/10.1074/jbc.273.42.27058			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765220	hybrid			2022-12-27	WOS:000076448000007
J	Chevalier, M; King, L; Wang, CY; Gething, MJ; Elguindi, E; Blond, SY				Chevalier, M; King, L; Wang, CY; Gething, MJ; Elguindi, E; Blond, SY			Substrate binding induces depolymerization of the C-terminal peptide binding domain of murine GRP78/BiP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE HSC70; SHOCK COGNATE PROTEIN; ATPASE ACTIVITY; ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; CIRCULAR-DICHROISM; SELF-ASSOCIATION; SECONDARY STRUCTURE; UNFOLDED PROTEINS; BIP	To investigate the role of each domain in BiP/GRP78 function, we have used a full-length recombinant BiP engineered to contain two enterokinase sites; one site is located after an N-terminal FLAG epitope, and a second site has been inserted at the junction between the N- and C-terminal domains (FLAG-BiP,ent), FLAG-BiP.ent oligomerizes into multiple species that interconvert with each other in a slow, concentration- and temperature-dependent equilibrium. Binding of ATP or AMP-PNP (adenosine 5'-(beta,gamma-imino)triphosphate), but not ADP, or of a peptidic substrate induces depolymerization of FLAG-BiP,ent and stabilization of monomeric species. Enterokinase cleavage of monomeric, nucleotide-free BiP,ent results in the physical dissociation of the 44-kDa N-terminal ATPase fragment (N44,ent) from the 30-kDa C-terminal substrate binding domain (C30.ent), Upon dissociation, the freed C-terminal substrate binding domain readily undergoes self-association while N44,ent remains monomeric, Enterokinase cleavage performed in the presence of a synthetic peptide prevents oligomerization of the freed C30,ent domain. Addition of ATP during enterokinase cleavage has no effect on C30.ent oligomerization, Our data clearly indicate that binding of a specific peptide onto the C-terminal domain, or ATP onto the N-terminal domain, induces internal conformational change(s) within the C30 domain that result(s) in BiP depolymerization.	Univ Illinois, Coll Pharm, Ctr Pharmaceut Biotechnol M C 870, Chicago, IL 60607 USA; Univ Melbourne, Dept Biochem & Mol Bol, Parkville, Vic 3052, Australia	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Melbourne	Blond, SY (corresponding author), Univ Illinois, Coll Pharm, Ctr Pharmaceut Biotechnol M C 870, Mol Biol Res Bldg,900 S Ashland Ave, Chicago, IL 60607 USA.	Blond@uic.edu						Azem A, 1997, J BIOL CHEM, V272, P20901, DOI 10.1074/jbc.272.33.20901; Beggah A, 1996, J BIOL CHEM, V271, P20895, DOI 10.1074/jbc.271.34.20895; BENAROUDJ N, 1995, BIOCHEMISTRY-US, V34, P15282, DOI 10.1021/bi00046a037; Benaroudj N, 1996, J BIOL CHEM, V271, P18471, DOI 10.1074/jbc.271.31.18471; Benaroudj N, 1997, J BIOL CHEM, V272, P8744, DOI 10.1074/jbc.272.13.8744; BENAROUDJ N, 1994, EUR J BIOCHEM, V221, P121, DOI 10.1111/j.1432-1033.1994.tb18720.x; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; BRODSKY JL, 1994, BIOL HEAT SHOCK PROT, P85; CARLINO A, 1992, P NATL ACAD SCI USA, V89, P2081, DOI 10.1073/pnas.89.6.2081; CRAIG EA, 1993, SCIENCE, V260, P1902, DOI 10.1126/science.8100364; Craven RA, 1996, EMBO J, V15, P2640, DOI 10.1002/j.1460-2075.1996.tb00624.x; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; Gao BC, 1996, J BIOL CHEM, V271, P16792, DOI 10.1074/jbc.271.28.16792; GAO BC, 1995, BIOCHEMISTRY-US, V34, P11882, DOI 10.1021/bi00037a028; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; Hendershot L, 1996, P NATL ACAD SCI USA, V93, P5269, DOI 10.1073/pnas.93.11.5269; Johnson JL, 1997, CELL, V90, P201, DOI 10.1016/S0092-8674(00)80327-X; JORDAN R, 1995, J BIOL CHEM, V270, P4563, DOI 10.1074/jbc.270.9.4563; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; KOZUTSUMI Y, 1989, J CELL SCI, P115; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Little Edward, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P1; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, FEBS LETT, V336, P124, DOI 10.1016/0014-5793(93)81624-9; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; PARK K, 1993, PROTEIN SCI, V2, P325; Parsell D.A., 1994, BIOL HEAT SHOCK PROT, P457; SADIS S, 1990, BIOCHEMISTRY-US, V29, P8199, DOI 10.1021/bi00488a001; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHLENSTEDT G, 1995, J CELL BIOL, V129, P979, DOI 10.1083/jcb.129.4.979; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; SEALS JR, 1978, ANAL BIOCHEM, V90, P785, DOI 10.1016/0003-2697(78)90169-0; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Takeda S, 1996, BIOCHEMISTRY-US, V35, P4636, DOI 10.1021/bi952903o; WANG TF, 1993, J BIOL CHEM, V268, P26049; WEI JY, 1995, J BIOL CHEM, V270, P26670, DOI 10.1074/jbc.270.44.26670; WIECH H, 1993, J BIOL CHEM, V268, P7414; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; [No title captured]; [No title captured]	60	28	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26827	26835		10.1074/jbc.273.41.26827	http://dx.doi.org/10.1074/jbc.273.41.26827			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756927	hybrid			2022-12-27	WOS:000076373300081
J	Soteropoulos, P; Perlin, DS				Soteropoulos, P; Perlin, DS			Genetic probing of the stalk segments associated with M2 and M3 of the plasma membrane H+-ATPase from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; FUNCTIONAL CONSEQUENCES; CYTOPLASMIC DOMAINS; MUTATIONS; REVERTANTS; CA-2+-ATPASE; NA,K-ATPASE; BINDING; REGIONS; PUMPS	The stalk region of the H+-ATPase from Saccharomyces cerevisiae has been proposed to play a role in coupling ATP hydrolysis to proton transport. Genetic probing was used to examine the role of stalk segments S2 and S3, associated with M2 and M3, respectively. Saturation mutagenesis was used to explore the role of side group character at position Ile(183) in S2, at which an alanine substitution was shown previously to partially uncouple the enzyme (Wang, G., Tamas, M. J., Hall, BI. J., Pascual-Ahuir, A., and Perlin, D. S, (1996) J, Biol, Chem, 271, 25438-25445). Diverse side group substitutions were tolerated at this position, although three substitutions, I183N, I183R, and I183Y required second site mutations at the C terminus of the enzyme for stabilization. Substitution of glycine and proline at Ile(183) resulted in lethal phenotypes, suggesting that the backbone may be more important than side group at this position. Proline/glycine mutagenesis was used to study additional sites in S2 and S3. The substitution of proline at Gly(186) resulted in a lethal phenotype, whereas substitutions in S3 of proline or serine at Gly(270) and proline or glycine at Thr(287) resulted in viable mutants. Mutations G270P and T287P resulted in mutant enzymes that produced pronounced growth defects and ATP hydrolysis rates that were 35% and 60% lower than wild type enzyme, respectively. The mutant enzymes transported protons at rates consistent with their ATPase activity, suggesting that the growth defects observed were due to a reduced rate of ATP hydrolysis and not to uncoupling of proton transport. The prominent growth phenotypes produced by mutations G270P and T287P permitted the isolation of suppressor mutations, which restored wild type growth, Most of the suppressors either replaced the primary site mutation with alanine or restored the mild type residue by ectopic recombination with PMA2, both of which restore alpha-helical tendency. This study suggests that maintaining alpha-helical character is essential to S2 and may play an important role in S3.	Publ Hlth Res Inst City New York Inc, New York, NY 10016 USA		Perlin, DS (corresponding author), Publ Hlth Res Inst City New York Inc, 455 1st Ave, New York, NY 10016 USA.	perlin@phri.nyu.edu	Perlin, David S/K-4013-2015		NIGMS NIH HHS [GM 38225] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038225] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANAND S, 1995, BBA-BIOMEMBRANES, V1234, P127, DOI 10.1016/0005-2736(94)00281-S; ANDERSEN JP, 1995, J BIOL CHEM, V270, P908, DOI 10.1074/jbc.270.2.908; ARYSTARKHOVA E, 1992, J BIOL CHEM, V267, P13694; Auer M, 1998, NATURE, V392, P840, DOI 10.1038/33967; Bandell M, 1996, BBA-BIOMEMBRANES, V1280, P81, DOI 10.1016/0005-2736(95)00280-4; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; ERASO P, 1994, J BIOL CHEM, V269, P10393; Goldshleger R, 1997, P NATL ACAD SCI USA, V94, P9596, DOI 10.1073/pnas.94.18.9596; HARRIS SL, 1994, P NATL ACAD SCI USA, V91, P10531, DOI 10.1073/pnas.91.22.10531; HARRIS SL, 1991, J BIOL CHEM, V266, P24439; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LUTSENKO S, 1994, J BIOL CHEM, V269, P4555; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; NA SQ, 1993, J BIOL CHEM, V268, P11792; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PERLIN DS, 1986, ARCH BIOCHEM BIOPHYS, V248, P53, DOI 10.1016/0003-9861(86)90400-5; PERLIN DS, 1988, J BIOL CHEM, V263, P18118; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SETOYOUNG D, 1992, BIOCHIM BIOPHYS ACTA, V1102, P213, DOI 10.1016/0167-4838(92)90512-C; SETOYOUNG D, 1994, J BIOL CHEM, V269, P23988; SetoYoung D, 1996, J BIOL CHEM, V271, P581, DOI 10.1074/jbc.271.1.581; STOKES DL, 1994, FEBS LETT, V346, P32, DOI 10.1016/0014-5793(94)00297-5; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; VILSEN B, 1989, J BIOL CHEM, V264, P21024; WACH A, 1992, J BIOENERG BIOMEMBR, V24, P309; Wach A, 1996, BIOCHEMISTRY-US, V35, P883, DOI 10.1021/bi951998r; Wang GF, 1996, J BIOL CHEM, V271, P25438, DOI 10.1074/jbc.271.41.25438; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	34	10	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26426	26431		10.1074/jbc.273.41.26426	http://dx.doi.org/10.1074/jbc.273.41.26426			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756876	hybrid			2022-12-27	WOS:000076373300030
J	Aono, S; Ohkubo, K; Matsuo, T; Nakajima, H				Aono, S; Ohkubo, K; Matsuo, T; Nakajima, H			Redox-controlled ligand exchange of the heme in the CO-sensing transcriptional activator CooA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE GUANYLATE-CYCLASE; CAMP RECEPTOR PROTEIN; OXYGEN SENSOR FIXL; ADENOSINE-MONOPHOSPHATE RECEPTOR; RESONANCE RAMAN-SCATTERING; CAP-DNA COMPLEX; RHODOSPIRILLUM-RUBRUM; CARBON-MONOXIDE; NITRIC-OXIDE; RHIZOBIUM-MELILOTI	The transcriptional activator CooA from Rhodospirillum rubrum contains a b-type heme that acts as a CO sensor in vivo, CooA is the first example of a transcriptional regulator containing a heme as a prosthetic group and of a hemeprotein in which CO plays a physiological role, In this study, we constructed an in vivo reporter system to measure the transcriptional activator activity of CooA and prepared some CooA mutants in which a mutation was introduced at Cys, His, Met, Lys, or Tyr, Only the mutations of Cys(75) and His(77) affected the electronic absorption spectra of the heme in CooA, The electronic absorption spectra, EPR spectra, and the transcriptional activator activity of the wild-type and mutant CooA proteins indicate that 1) the thiolate derived from Cys(75) is the axial ligand in the ferric heme, but it is not coordinated to the CO-bound ferrous heme; 2) Cys(75) is protonated or displaced in the ferrous heme; and 3) His(77) is the proximal ligand in the CO-bound ferrous heme and probably also in the ferrous heme, but it is not coordinated to the ferric heme, NMR spectra reveal that the conformational change around the heme, which will trigger the activation of CooA by CO, takes place upon the binding of CO to the heme,	Japan Adv Inst Sci & Technol, Sch Mat Sci, Tatsunokuchi, Ishikawa 9231292, Japan	Japan Advanced Institute of Science & Technology (JAIST)	Aono, S (corresponding author), Japan Adv Inst Sci & Technol, Sch Mat Sci, 1-1 Asahidai, Tatsunokuchi, Ishikawa 9231292, Japan.		Ohkubo, Kei/L-5002-2019; Aono, Shigetoshi/ABD-7618-2020; Ohkubo, Kei/E-5127-2012	Ohkubo, Kei/0000-0001-8328-9249; Aono, Shigetoshi/0000-0002-2870-3694; Ohkubo, Kei/0000-0001-8328-9249				AIBA H, 1982, NUCLEIC ACIDS RES, V10, P1345, DOI 10.1093/nar/10.4.1345; ANDERSON WB, 1971, J BIOL CHEM, V246, P5928; Aono S, 1997, BIOCHEM BIOPH RES CO, V240, P783, DOI 10.1006/bbrc.1997.7746; Aono S, 1996, BIOCHEM BIOPH RES CO, V228, P752, DOI 10.1006/bbrc.1996.1727; COSSART P, 1982, NUCLEIC ACIDS RES, V10, P1363, DOI 10.1093/nar/10.4.1363; CRAVEN PA, 1979, J BIOL CHEM, V254, P8213; CRAVEN PA, 1978, J BIOL CHEM, V253, P8433; DAWSON JH, 1983, J BIOL CHEM, V258, P3637; DAWSON JH, 1982, J BIOL CHEM, V257, P3606; DAWSON JH, 1987, CHEM REV, V87, P1257; EILEN E, 1978, BIOCHEMISTRY-US, V17, P2469, DOI 10.1021/bi00606a001; Fox JD, 1996, J BACTERIOL, V178, P6200, DOI 10.1128/jb.178.21.6200-6208.1996; FULOP V, 1995, CELL, V81, P369, DOI 10.1016/0092-8674(95)90390-9; GARGES S, 1985, CELL, V41, P745, DOI 10.1016/S0092-8674(85)80055-6; GILLESGONZALEZ MA, 1994, BIOCHEMISTRY-US, V33, P8067, DOI 10.1021/bi00192a011; GILLESGONZALEZ MA, 1995, BIOCHEMISTRY-US, V34, P232, DOI 10.1021/bi00001a027; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; HAN S, 1990, P NATL ACAD SCI USA, V87, P205, DOI 10.1073/pnas.87.1.205; HASEGAWA T, 1984, J BIOCHEM-TOKYO, V96, P265, DOI 10.1093/oxfordjournals.jbchem.a134822; He YP, 1996, J BIOL CHEM, V271, P120, DOI 10.1074/jbc.271.1.120; IGNARRO LJ, 1982, BIOCHIM BIOPHYS ACTA, V718, P49, DOI 10.1016/0304-4165(82)90008-3; IGNARRO LJ, 1986, J BIOL CHEM, V261, P4997; IGNARRO LJ, 1981, ARCH BIOCHEM BIOPHYS, V208, P75, DOI 10.1016/0003-9861(81)90125-9; KERBY RL, 1995, J BACTERIOL, V177, P2241, DOI 10.1128/jb.177.8.2241-2244.1995; KERBY RL, 1992, J BACTERIOL, V174, P5284, DOI 10.1128/JB.174.16.5284-5294.1992; KIM J, 1992, P NATL ACAD SCI USA, V89, P9700, DOI 10.1073/pnas.89.20.9700; KITAGAWA T, 1975, J BIOCHEM-TOKYO, V78, P719, DOI 10.1093/oxfordjournals.jbchem.a130960; KRAKOW JS, 1973, P NATL ACAD SCI USA, V70, P2529, DOI 10.1073/pnas.70.9.2529; LOIS AF, 1993, J BIOL CHEM, V268, P4370; Martinis SA, 1996, BIOCHEMISTRY-US, V35, P14530, DOI 10.1021/bi961511u; MILLER JH, 1992, SHORT COURSE BACTERI, P71; MONSON EK, 1992, P NATL ACAD SCI USA, V89, P4280, DOI 10.1073/pnas.89.10.4280; MONSON EK, 1995, J BIOL CHEM, V270, P5243, DOI 10.1074/jbc.270.10.5243; OMURA T, 1984, J BIOCHEM-TOKYO, V96, P1491, DOI 10.1093/oxfordjournals.jbchem.a134978; Parkinson G, 1996, J MOL BIOL, V260, P395, DOI 10.1006/jmbi.1996.0409; Poulos TL, 1996, NAT STRUCT BIOL, V3, P401, DOI 10.1038/nsb0596-401; POWELL BS, 1994, NUCLEIC ACIDS RES, V22, P5765, DOI 10.1093/nar/22.25.5765; Rodgers KR, 1996, BIOCHEMISTRY-US, V35, P9539, DOI 10.1021/bi9530853; RYU S, 1993, P NATL ACAD SCI USA, V90, P75, DOI 10.1073/pnas.90.1.75; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHELVER D, 1995, J BACTERIOL, V177, P2157, DOI 10.1128/jb.177.8.2157-2163.1995; Shelver D, 1997, P NATL ACAD SCI USA, V94, P11216, DOI 10.1073/pnas.94.21.11216; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; STONE JR, 1994, BIOCHEMISTRY-US, V33, P5636, DOI 10.1021/bi00184a036; STONE JR, 1995, BIOCHEM BIOPH RES CO, V207, P572, DOI 10.1006/bbrc.1995.1226; STONE JR, 1995, BIOCHEMISTRY-US, V34, P14668, DOI 10.1021/bi00045a007; Stone JR, 1996, BIOCHEMISTRY-US, V35, P1093, DOI 10.1021/bi9519718; SVASTITS EW, 1989, BIOCHEM BIOPH RES CO, V165, P1170, DOI 10.1016/0006-291X(89)92725-3; Tahirov TH, 1996, NAT STRUCT BIOL, V3, P459, DOI 10.1038/nsb0596-459; TAKAHASHI S, 1994, BIOCHEMISTRY-US, V33, P5531, DOI 10.1021/bi00184a023; Tamura K, 1996, J AM CHEM SOC, V118, P9434, DOI 10.1021/ja9543457; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V31, P2847, DOI 10.1021/bi00126a001; Uchida T, 1998, J BIOL CHEM, V273, P19988, DOI 10.1074/jbc.273.32.19988; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; Williams PA, 1997, NATURE, V389, P406, DOI 10.1038/38775; YAMANAKA T, 1992, BIOCH BACTERIAL CYTO, P3	56	108	108	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25757	25764		10.1074/jbc.273.40.25757	http://dx.doi.org/10.1074/jbc.273.40.25757			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748246	hybrid			2022-12-27	WOS:000076263100037
J	Casamassima, A; Rozengurt, E				Casamassima, A; Rozengurt, E			Insulin-like growth factor I stimulates tyrosine phosphorylation of p130(Cas), focal adhesion kinase, and paxillin - Role of phosphatidylinositol 3 '-kinase and formation of a p130(Cas)center dot Crk complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SWISS 3T3 CELLS; PHOSPHOINOSITIDE 3-KINASE; RECEPTOR SUBSTRATE-1; ACTIN CYTOSKELETON; LYSOPHOSPHATIDIC ACID; EXTRACELLULAR-MATRIX; SIGNALING PATHWAYS; DNA-SYNTHESIS; V-SRC	Addition of insulin growth factor-I (IGF-I) to quiescent Swiss 3T3 cells rapidly induced tyrosine phosphorylation of the p130Crk-associated substrate (p130(Cas)), a novel adaptor protein localized at focal adhesions. Half-maximal effect was obtained at 0.6 nM. IGF-I also promoted the formation of a complex between p130(Cas) and c-Crk and elicited a parallel increase in the tyrosine phosphorylation of p125(Fak) and paxillin. IGF-I-induced p130(Cas), p125Fak, and paxillin tyrosine phosphorylation could be dissociated from mitogen-activated protein kinase kinase, p70(S6K), and protein kinase C activation. In contrast, the structurally unrelated phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 markedly attenuated the increase in tyrosine phosphorylation of p130(Cas), p125(Fak) and paxillin induced by IGF-I. Cytochalasin D, which disrupts the network of actin microfilaments, completely prevented tyrosine phosphorylation of p130(Cas), p125(Fak), and paxillin and the formation of a p130(Cas).Crk complex in response to IGF-I. Thus, our results identified a phosphatidylinositol 3-kinase-dependent pathway that requires the integrity of the actin cytoskeleton to induce tyrosine phosphorylation of p130(Cas), p125(Fak) and paxillin in response to IGF-I and suggest that tyrosine phosphorylation of these focal adhesion proteins, together with the recruitment of c-Crk into a complex with p130(Cas), may play a novel role in IGF-I signal transduction.	Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA; Imperial Canc Res Fund, Lincolns Inn Fields, London WC2A 3PX, England; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cancer Research UK; University of California System; University of California Los Angeles	Rozengurt, E (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, 900 Vet Ave,Warren Hall,Rm 11-124, Los Angeles, CA 90095 USA.							ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; Baron V, 1998, J BIOL CHEM, V273, P7162, DOI 10.1074/jbc.273.12.7162; BASERGA R, 1995, CANCER RES, V55, P249; Baserga R, 1997, VITAM HORM, V53, P65, DOI 10.1016/S0083-6729(08)60704-9; Baserga R, 1997, BBA-REV CANCER, V1332, pF105, DOI 10.1016/S0304-419X(97)00007-3; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; Blakesley VA, 1996, ENDOCRINOLOGY, V137, P410, DOI 10.1210/en.137.2.410; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; Brooks PC, 1997, J CLIN INVEST, V99, P1390, DOI 10.1172/JCI119298; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; Burnham MR, 1996, ONCOGENE, V12, P2467; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Cary LA, 1996, J CELL SCI, V109, P1787; Casamassima A, 1997, J BIOL CHEM, V272, P9363; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Grammer TC, 1996, CANCER SURV, V27, P271; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Ilic D, 1997, J CELL SCI, V110, P401; ILLE D, 1995, NATURE, V377, P539; KasusJacobi A, 1997, J BIOL CHEM, V272, P17166, DOI 10.1074/jbc.272.27.17166; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; KNIGHT JB, 1995, J BIOL CHEM, V270, P10199, DOI 10.1074/jbc.270.17.10199; Konstantopoulos N, 1996, J BIOL CHEM, V271, P28960, DOI 10.1074/jbc.271.46.28960; Konstantopoulos N, 1996, BIOCHEM J, V314, P387, DOI 10.1042/bj3140387; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LeRoith D, 1996, BAILLIERE CLIN ENDOC, V10, P49, DOI 10.1016/S0950-351X(96)80298-9; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Ojaniemi M, 1997, J BIOL CHEM, V272, P25993, DOI 10.1074/jbc.272.41.25993; OKADA T, 1994, J BIOL CHEM, V269, P3563; Ouwens DM, 1996, BIOCHEM J, V318, P609, DOI 10.1042/bj3180609; OWENS LV, 1995, CANCER RES, V55, P2752; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; PILLAY TS, 1995, J BIOL CHEM, V270, P991, DOI 10.1074/jbc.270.3.991; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; Rozengurt E, 1997, ESSAYS BIOCHEM, V32, P73; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; ROZENGURT E, 1995, CANCER SURV, V24, P81; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Scrimgeour AG, 1997, ENDOCRINOLOGY, V138, P2552, DOI 10.1210/en.138.6.2552; SEUFFERLEIN T, 1995, CELL GROWTH DIFFER, V6, P383; Seufferlein T, 1996, MOL BIOL CELL, V7, P1865, DOI 10.1091/mbc.7.12.1865; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343; Seufferlein T, 1996, J BIOL CHEM, V271, P21471, DOI 10.1074/jbc.271.35.21471; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; Tobe K, 1996, MOL CELL BIOL, V16, P4765; TOKER A, 1997, NATURE, V387; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TURNER CE, 1994, J CELL SCI, V107, P1583; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VUORI K, 1993, J BIOL CHEM, V268, P21459; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WENNSTROM S, 1994, ONCOGENE, V9, P651; Withers DJ, 1997, J BIOL CHEM, V272, P2509; YANO H, 1993, J BIOL CHEM, V268, P25846; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	79	91	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26149	26156		10.1074/jbc.273.40.26149	http://dx.doi.org/10.1074/jbc.273.40.26149			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748296	hybrid			2022-12-27	WOS:000076263100087
J	Iwabuchi, K; Li, B; Massa, HF; Trask, BJ; Date, T; Fields, S				Iwabuchi, K; Li, B; Massa, HF; Trask, BJ; Date, T; Fields, S			Stimulation of p53-mediated transcriptional activation by the p53-binding proteins, 53BP1 and 53BP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; DNA-BINDING SITE; TUMOR SUPPRESSION; MUTANT P53; CELL-LINE; CHECKPOINT; GROWTH; GENE; TRANSFORMATION; DOMAINS	p53 is a tumor suppressor protein that controls cell proliferation by regulating the expression of growth control genes. In a previous study, we identified two proteins, 53BP1 and 53BP2, that are able to bind to wild type but not to mutant p53 via the DNA-binding domain of p53. We isolated cDNAs expressing a full-length human 53BP1 clone, which predicts a protein of 1972 residues that can be detected in the H358 human lung carcinoma cell line. The 53BP1 and 53BP2 genes were mapped to chromosomes 15q15-21 and 1q41-42, respectively. Immunofluorescence studies showed three types of staining patterns for 53BP1 as follows: both cytoplasmic and nuclear, homogeneous nuclear, and a nuclear dot pattern. In contrast, 53BP2 localized exclusively to the cytoplasm, and this pattern did not change upon coexpression of wild type p53. Although our previous study revealed that p53 is not able to bind simultaneously to either 53BP1 or 53BP2 and to DNA carrying a consensus binding site, both 53BP1 and 53BP2 enhanced p53-mediated transcriptional activation and induced the expression of a p53-dependent protein, suggesting that these proteins might function in signal transduction pathways to promote p53 activity.	Univ Washington, Dept Genet, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Dept Med, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA; Kanazawa Med Univ, Dept Biochem, Uchinada, Ishikawa 92002, Japan; SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Kanazawa Medical University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Fields, S (corresponding author), Univ Washington, Dept Genet, Howard Hughes Med Inst, Box 357360, Seattle, WA 98195 USA.				NCI NIH HHS [CA28146, CA54699] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054699, P01CA028146] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Datta B, 1996, J BIOL CHEM, V271, P27544, DOI 10.1074/jbc.271.44.27544; DELSAL G, 1995, MOL CELL BIOL, V15, P7152; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1991, NATURE, V349, P802; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Maniatis T., 1982, MOL CLONING LAB MANU; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Reed Michael, 1993, Gene Expression, V3, P95; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; TRASK BJ, 1997, GENOME ANAL LAB MANU; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; Wise CA, 1997, GENOME RES, V7, P10, DOI 10.1101/gr.7.1.10; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	55	162	182	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26061	26068		10.1074/jbc.273.40.26061	http://dx.doi.org/10.1074/jbc.273.40.26061			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748285	hybrid			2022-12-27	WOS:000076263100076
J	Tse, A; Brigle, K; Taylor, SM; Moran, RG				Tse, A; Brigle, K; Taylor, SM; Moran, RG			Mutations in the reduced folate carrier gene which confer dominant resistance to 5,10-dideazatetrahydrofolate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENOVO PURINE SYNTHESIS; LEUKEMIA-CELL LINE; L1210 CELLS; FOLIC-ACID; MAMMALIAN-CELLS; TRANSPORT; METHOTREXATE; MURINE; 5,10-DIDEAZA-5,6,7,8-TETRAHYDROFOLATE; EXPRESSION	L1210/D3 mouse leukemia cells are resistant to 5,10-dideazatetrahydrofolate due to expansion of cellular folate pools which block polyglutamation of the drug (Tse, A., and Moran, R. G, (1998) J. Biol. Chem. 273, 25944-25952). These cells were found to have two point mutations in the reduced folate carrier (RFC), resulting in a replacement of isoleucine 48 by phenylalanine and of tryptophan 105 by glycine. Each mutation contributes to the resistance phenotype. Genomic DNA from resistant cells contained both the wild-type and mutant alleles, but wild-type message was not detected. Folic acid was a much better substrate, and 5-formyltetrahydrofolate was a poorer substrate for transport in L1210/D3 cells relative to L1210 cells. Enhanced transport of folic acid was due to a marked, approximate to 20-fold, decrease in the influx K-m. Influx of methotrexate and 5,10-dideazatetrahydrofolate were minimally altered. Transfection of mutated rfc cDNA into RFC-null L1210/A cells produced the substrate specificity and 5,10-dideazatetrahydrofolate resistance observed in the L1210/D3 line. Transfection of the mutant cDNA into wild-type cells also conferred resistance to 5,10-dideazatetrahydrofolate. We conclude that the I48F and W105G mutations in RFC caused resistance to 5,10-dideazatetrahydrofolate, that the region of the RFC protein near these two positions defines the substrate-binding site, that the wild-type allele was silenced during the multistep development of resistance, and that this mutant phenotype represents a genetically dominant trait.	Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol Toxicol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Microbiol Immunol, Richmond, VA 23298 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; University of Southern California	Moran, RG (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Box 980230, Richmond, VA 23298 USA.				NATIONAL CANCER INSTITUTE [R01CA027605] Funding Source: NIH RePORTER; NCI NIH HHS [CA 27605] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALATI T, 1996, CANCER RES, V56, P331; Assaraf YG, 1997, J BIOL CHEM, V272, P17460, DOI 10.1074/jbc.272.28.17460; BEARDSLEY GP, 1989, J BIOL CHEM, V264, P328; BRIGLE KE, 1994, BIOCHEM PHARMACOL, V47, P337, DOI 10.1016/0006-2952(94)90025-6; BRIGLE KE, 1995, J BIOL CHEM, V270, P22974, DOI 10.1074/jbc.270.39.22974; DIXON KH, 1994, J BIOL CHEM, V269, P17; GOLDMAN ID, 1968, J BIOL CHEM, V243, P5007; HENDERSON GB, 1990, CANCER RES, V50, P1709; HENDERSON GB, 1984, J BIOL CHEM, V259, P1526; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KEYOMARSI K, 1986, CANCER RES, V46, P5229; Laohavinij S, 1996, INVEST NEW DRUG, V14, P325, DOI 10.1007/BF00194536; MATHERLY LH, 1993, BIOCHEM PHARMACOL, V46, P2185, DOI 10.1016/0006-2952(93)90608-Y; MORAN RG, 1989, J BIOL CHEM, V264, P21047; MORAN RG, 1976, J BIOL CHEM, V251, P3569; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; SCHUETZ JD, 1989, J BIOL CHEM, V264, P16261; SIROTNAK FM, 1985, CANCER RES, V45, P3992; SIROTNAK FM, 1987, BIOCHEM PHARMACOL, V36, P1659, DOI 10.1016/0006-2952(87)90051-7; TAYLOR EC, 1985, J MED CHEM, V28, P914, DOI 10.1021/jm00145a012; Tolner B, 1997, GENE, V189, P1, DOI 10.1016/S0378-1119(96)00676-2; Tse A, 1998, J BIOL CHEM, V273, P25944, DOI 10.1074/jbc.273.40.25944; YOUNG C W, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P406; Zhao RB, 1998, J BIOL CHEM, V273, P7873, DOI 10.1074/jbc.273.14.7873	24	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25953	25960		10.1074/jbc.273.40.25953	http://dx.doi.org/10.1074/jbc.273.40.25953			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748272	hybrid			2022-12-27	WOS:000076263100063
J	Bass, RB; Falke, JJ				Bass, RB; Falke, JJ			Detection of a conserved alpha-helix in the kinase-docking region of the aspartate receptor by cysteine and disulfide scanning	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED CROSS-LINKING; METHYL-ACCEPTING SITES; BACTERIAL CHEMOTAXIS; ESCHERICHIA-COLI; SIGNAL-TRANSDUCTION; SERINE CHEMORECEPTOR; PROTEIN-STRUCTURE; TRANSMEMBRANE DOMAIN; CYTOPLASMIC FRAGMENT; INSULIN-RECEPTOR	The transmembrane aspartate receptor of Escherichia coli and Salmonella typhimurium propagates extracellular signals to the cytoplasm, where its cytoplasmic domain regulates the histidine kinase, CheA. Different signaling states of the cytoplasmic domain modulate the kinase autophosphorylation rate over at least a 100-fold range. Biochemical and genetic studies have implicated a specific region of the cytoplasmic domain, termed the signaling subdomain, as the region that transmits regulation from the receptor to the kinase. Here cysteine and disulfide scanning are applied to the N-terminal half of the signaling subdomain to probe its secondary structure, solvent exposure, and protein-protein interactions. The chemical reactivities of the scanned cysteines exhibit the characteristic periodicity of an alpha-helix with distinct solvent-exposed and buried faces. This helix, termed alpha 7, ranges approximately from residue 355 through 386. Activity measurements probing the effects of cysteine substitutions in vivo and in vitro reveal that both faces of helix alpha 7 are critical for kinase activation, while the buried face is especially critical for kinase down-regulation. Disulfide scanning of the region suggests that helix alpha 7 is not in direct contact with its symmetric partner (alpha 7') from the other subunit; presently, the structural element that packs against the buried face of the helix remains unidentified. Finally, a novel approach termed "protein interactions by cysteine modification" indicates that the exposed C-terminal face of helix alpha 7 provides an essential docking site for the kinase CheA or for the coupling protein CheW.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Falke, JJ (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.	falke@colorado.edu			NIGMS NIH HHS [GM40731, R01 GM040731, R01 GM040731-12] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040731] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER J, 1966, SCIENCE, V153, P708, DOI 10.1126/science.153.3737.708; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; AMES P, 1988, CELL, V55, P817, DOI 10.1016/0092-8674(88)90137-7; Ames P, 1996, MOL MICROBIOL, V19, P737, DOI 10.1046/j.1365-2958.1996.408930.x; AMES P, 1994, J BACTERIOL, V176, P6340, DOI 10.1128/jb.176.20.6340-6348.1994; BARAK R, 1992, BIOCHEMISTRY-US, V31, P1821, DOI 10.1021/bi00121a034; BAUMGARTNER JW, 1994, J BACTERIOL, V176, P1157, DOI 10.1128/JB.176.4.1157-1163.1994; Biemann HP, 1996, J BIOL CHEM, V271, P27927, DOI 10.1074/jbc.271.44.27927; BLAIR DF, 1995, ANNU REV MICROBIOL, V49, P489, DOI 10.1146/annurev.mi.49.100195.002421; BOGONEZ E, 1985, P NATL ACAD SCI USA, V82, P4891, DOI 10.1073/pnas.82.15.4891; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; BRAY D, 1993, MOL BIOL CELL, V4, P469, DOI 10.1091/mbc.4.5.469; Butler SL, 1998, BIOCHEMISTRY-US, V37, P10746, DOI 10.1021/bi980607g; CHELSKY D, 1984, ANAL BIOCHEM, V141, P143, DOI 10.1016/0003-2697(84)90437-8; Chen XM, 1997, BIOCHEMISTRY-US, V36, P11858, DOI 10.1021/bi970911u; CHERVITZ SA, 1995, J BIOL CHEM, V270, P24043, DOI 10.1074/jbc.270.41.24043; CHERVITZ SA, 1995, BIOCHEMISTRY-US, V34, P9722, DOI 10.1021/bi00030a010; Chervitz SA, 1996, P NATL ACAD SCI USA, V93, P2545, DOI 10.1073/pnas.93.6.2545; Danielson MA, 1997, J BIOL CHEM, V272, P32878, DOI 10.1074/jbc.272.52.32878; DANIELSON MA, 1997, THESIS U COLORADO BO; Egger LA, 1997, GENES CELLS, V2, P167, DOI 10.1046/j.1365-2443.1997.d01-311.x; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; FALKE JJ, 1988, J BIOL CHEM, V263, P14850; Falke JJ, 1997, ANNU REV CELL DEV BI, V13, P457, DOI 10.1146/annurev.cellbio.13.1.457; FALKE JJ, 1986, BIOPHYS J, V49, pA20; Frillingos S, 1997, BIOCHEMISTRY-US, V36, P269, DOI 10.1021/bi9618629; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; Hughson AG, 1997, PROTEIN SCI, V6, P315; Hughson AG, 1996, P NATL ACAD SCI USA, V93, P11546, DOI 10.1073/pnas.93.21.11546; Iwama T, 1997, J BIOL CHEM, V272, P13810, DOI 10.1074/jbc.272.21.13810; KEHRY MR, 1985, J BACTERIOL, V163, P983, DOI 10.1128/JB.163.3.983-990.1985; KRIKOS A, 1985, P NATL ACAD SCI USA, V82, P1326, DOI 10.1073/pnas.82.5.1326; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE GF, 1994, J BIOL CHEM, V269, P29920; LEE GF, 1995, P NATL ACAD SCI USA, V92, P5416, DOI 10.1073/pnas.92.12.5416; LeMoual H, 1996, J MOL BIOL, V261, P568, DOI 10.1006/jmbi.1996.0483; LIU JD, 1991, J BACTERIOL, V173, P4941, DOI 10.1128/jb.173.16.4941-4951.1991; LIU JD, 1989, P NATL ACAD SCI USA, V86, P8703, DOI 10.1073/pnas.86.22.8703; LONG DG, 1992, BIOCHEMISTRY-US, V31, P9904, DOI 10.1021/bi00156a007; LUPAS A, 1989, J BIOL CHEM, V264, P17337; MARUYAMA IN, 1995, J MOL BIOL, V253, P530, DOI 10.1006/jmbi.1995.0571; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MOE GR, 1989, P NATL ACAD SCI USA, V86, P5683, DOI 10.1073/pnas.86.15.5683; MOWBRAY SL, 1985, J BIOL CHEM, V260, P1711; Nara T, 1996, J BIOL CHEM, V271, P17932, DOI 10.1074/jbc.271.30.17932; NINFA EG, 1991, J BIOL CHEM, V266, P9764; Nishiyama SI, 1997, J BACTERIOL, V179, P6573, DOI 10.1128/jb.179.21.6573-6580.1997; Okumura H, 1998, J BACTERIOL, V180, P1862, DOI 10.1128/JB.180.7.1862-1868.1998; Ottemann KM, 1998, BIOCHEMISTRY-US, V37, P7062, DOI 10.1021/bi980305e; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; RUSSELL CB, 1989, J BACTERIOL, V171, P3609, DOI 10.1128/jb.171.7.3609-3618.1989; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; Seeley SK, 1996, BIOCHEMISTRY-US, V35, P5199, DOI 10.1021/bi9524979; Stock AM, 1995, CURR OPIN STRUC BIOL, V5, P744, DOI 10.1016/0959-440X(95)80006-9; Stock JB, 1996, ESCHERICHIA COLI SAL, P1103; SUNDBERG SA, 1985, J BACTERIOL, V164, P282, DOI 10.1128/JB.164.1.282-287.1985; Surette MG, 1996, J BIOL CHEM, V271, P939, DOI 10.1074/jbc.271.2.939; Surette MG, 1996, J BIOL CHEM, V271, P17966, DOI 10.1074/jbc.271.30.17966; SWANSON RV, 1994, CURR BIOL, V4, P234, DOI 10.1016/S0960-9822(00)00052-X; TATSUNO I, 1994, MOL MICROBIOL, V14, P755, DOI 10.1111/j.1365-2958.1994.tb01312.x; TERWILLIGER TC, 1984, J BIOL CHEM, V259, P7719; UTSUMI R, 1989, SCIENCE, V245, P1246, DOI 10.1126/science.2476847; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; Wu JG, 1996, BIOCHEMISTRY-US, V35, P4984, DOI 10.1021/bi9530189; WurglerMurphy SM, 1997, TRENDS BIOCHEM SCI, V22, P172, DOI 10.1016/S0968-0004(97)01036-0; Zhulin IB, 1997, BIOSCIENCE REP, V17, P335, DOI 10.1023/A:1027340813657	71	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25006	25014		10.1074/jbc.273.39.25006	http://dx.doi.org/10.1074/jbc.273.39.25006			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737956	Green Accepted, hybrid			2022-12-27	WOS:000076085400006
J	Croteau, W; Bodwell, JE; Richardson, JM; St Germain, DL				Croteau, W; Bodwell, JE; Richardson, JM; St Germain, DL			Conserved cysteines in the type 1 deiodinase selenoprotein are not essential for catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I IODOTHYRONINE 5'-DEIODINASE; COLI RNASE-T; THYROID-HORMONE; CELLULAR UPTAKE; RAT-LIVER; 3,5,3'-TRIIODOTHYRONINE; TRANSPORT; HEPATOCYTES; THYROXINE; RESIDUES	The iodothyronine deiodinases are a family of oxidoreductases that catalyze the removal of iodide from thyroid hormones. Each of the three isoforms contain selenocysteine at its active site and several cysteine residues that may be important for catalytic activity. Of particular interest in the type I deiodinase (D1) is Cys(124) which is vicinal to the selenocysteine at position 126, and Cys(194), which has been conserved in all deiodinases identified to date. In the present studies, we have characterized the functional properties of C124A, C194A, and C124A/C194A. D1 mutants, which were prepared by site-directed mutagenesis and expressed in COS-7 cells. In broken cell preparations, the sensitivity of the mutants to the selective D1 inhibitors propylthiouracil and aurothioglucose were unaltered. Mutagenesis at the Cys(124) position was associated with a 7-11-fold increase in the K-m of dithiothreitol, whereas V-max values remained largely unchanged. However, both mutations resulted in marked decreases in V-max values when glutathione or a reconstituted thioredoxin cofactor system were used in the assay. In contrast to the results of these in vitro studies, no impairment in deiodinating capability was noted in intact cells expressing equivalent levels of the mutant constructs, These studies demonstrate that Cys(124) and Cys(194) influence the reactivity of the D1 with thiol cofactors in in vitro assay systems but are not determinants of the sensitivity of the enzyme to propylthiouracil and aurothioglucose. Furthermore, the observation that the cysteine mutants are fully active in intact cells demonstrates that the results of commonly used broken cell assays do not accurately predict the activity of the D1 in intact cells and suggests that glutathione and thioredoxin are not the major thiols utilized in vivo to support D1 activity.	Dartmouth Med Sch, Dept Med, Lebanon, NH 03756 USA; Dartmouth Med Sch, Dept Physiol, Lebanon, NH 03756 USA	Dartmouth College; Dartmouth College	St Germain, DL (corresponding author), Dartmouth Med Sch, Dept Med, 1 Med Ctr Dr, Lebanon, NH 03756 USA.				NIDDK NIH HHS [DK03535, DK42271, DK45337] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045337, R01DK042271, R01DK003535] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRY MJ, 1992, ENDOCRINOLOGY, V131, P1848, DOI 10.1210/en.131.4.1848; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENG SY, 1980, P NATL ACAD SCI-BIOL, V77, P3425, DOI 10.1073/pnas.77.6.3425; CROTEAU W, 1995, J BIOL CHEM, V270, P16569, DOI 10.1074/jbc.270.28.16569; Croteau W, 1996, J CLIN INVEST, V98, P405, DOI 10.1172/JCI118806; DAVEY JC, 1995, J BIOL CHEM, V270, P26786, DOI 10.1074/jbc.270.45.26786; DAVIS JP, 1994, J BIOL CHEM, V269, P8734; DEJONG M, 1993, J CLIN ENDOCR METAB, V77, P139, DOI 10.1210/jc.77.1.139; DIETRICHS D, 1991, J BACTERIOL, V173, P5983, DOI 10.1128/jb.173.19.5983-5991.1991; GALTON VA, 1986, ENDOCRINOLOGY, V118, P1918, DOI 10.1210/endo-118-5-1918; GOSWAMI A, 1983, ENDOCRINOLOGY, V112, P1180, DOI 10.1210/endo-112-4-1180; HENNEMANN G, 1986, ENDOCRINOLOGY, V119, P1870, DOI 10.1210/endo-119-4-1870; HOFSTEE BHJ, 1952, SCIENCE, V116, P329, DOI 10.1126/science.116.3013.329; LEE H, 1971, BIOCHIM BIOPHYS ACTA, V242, P519, DOI 10.1016/0005-2744(71)90144-6; Leonard JL, 1986, THYROID HORMONE META, P189; Li ZW, 1996, J BIOL CHEM, V271, P1133, DOI 10.1074/jbc.271.2.1133; Li ZW, 1996, J BIOL CHEM, V271, P1127, DOI 10.1074/jbc.271.2.1127; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9733, DOI 10.1021/bi00155a029; MENDEL CM, 1988, ENDOCRINOLOGY, V123, P1817, DOI 10.1210/endo-123-4-1817; MICHAL G, 1983, METHOD ENZYMAT AN, V1, P86; MOORADIAN AD, 1985, ENDOCRINOLOGY, V117, P2449, DOI 10.1210/endo-117-6-2449; Rudolph F B, 1979, Methods Enzymol, V63, P138; Sato K, 1984, Horm Metab Res Suppl, V14, P30; SHARIFI J, 1992, J BIOL CHEM, V267, P12539; STGERMAIN DL, 1988, J CLIN INVEST, V81, P1476, DOI 10.1172/JCI113479; STGERMAIN DL, 1994, TRENDS ENDOCRIN MET, V5, P36, DOI 10.1016/1043-2760(94)90119-8; StGermain DL, 1997, THYROID, V7, P655; STGERMAIN DL, 1994, P NATL ACAD SCI USA, V91, P7767, DOI 10.1073/pnas.91.16.7767; STGERMAIN DL, 1994, P NATL ACAD SCI USA, V91, P11282; Sun BC, 1997, ENDOCRINOLOGY, V138, P5452, DOI 10.1210/en.138.12.5452; Winer BJ, 1971, STATISTICAL PRINCIPL, P201; YAN ZF, 1993, J BIOL CHEM, V268, P20179	32	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25230	25236		10.1074/jbc.273.39.25230	http://dx.doi.org/10.1074/jbc.273.39.25230			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737986	hybrid			2022-12-27	WOS:000076085400036
J	Lalmanach, G; Lecaille, F; Chagas, JR; Authie, E; Scharfstein, J; Juliano, MA; Gauthier, F				Lalmanach, G; Lecaille, F; Chagas, JR; Authie, E; Scharfstein, J; Juliano, MA; Gauthier, F			Inhibition of trypanosomal cysteine proteinases by their propeptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATHEPSIN-B; SUBSTRATE-SPECIFICITY; PROCATHEPSIN-B; CRUZI; PROTEASE; CONGOLENSE; PEPTIDES; REGIONS; PAPAIN; MODEL	The ability of the prodomains of trypanosomal cysteine proteinases to inhibit their active form was studied using a set of 23 overlapping 15-mer peptides covering the whole prosequence of congopain, the major cysteine proteinase of Trypanosoma congolense. Three consecutive peptides with a common 5-mer sequence YHNGA were competitive inhibitors of congopain. A shorter synthetic peptide consisting of this 5-mer sequence flanked by two Ala residues (AYHNGAA) also inhibited purified congopain. No residue critical for inhibition was identified in this sequence, but a significant improvement in K-i value was obtained upon N-terminal elongation. Procongopain-derived peptides did not inhibit lysosomal cathepsins B and L but did inhibit native cruzipain (from Dm28c clone epimastigotes), the major cysteine proteinase of Trypanosoma cruzi, the proregion of which also contains the sequence YHNGA. The positioning of the YHNGA inhibitory sequence within the prosegment of trypanosomal proteinases is similar to that covering the active site in the prosegment of cysteine proteinases, the three-dimensional structure of which has been resolved. This strongly suggests that trypanosomal proteinases, despite their long C-terminal extension, have a prosegment that folds similarly to that in related mammal and plant cysteine proteinases, resulting in reverse binding within the active site, Such reverse binding could also occur for short procongopain-derived inhibitory peptides, based on their resistance to proteolysis and their ability to retain inhibitory activity after prolonged incubation. In contrast, homologous peptides in related cysteine proteinases did not inhibit trypanosomal proteinases and were rapidly cleaved by these enzymes.	Univ Tours, Fac Med, Enzymol & Prot Chem Lab, F-37032 Tours, France; Univ Fed Sao Paulo, Escola Paulista Med, BR-04044000 Sao Paulo, Brazil; Int Livestock Res Inst, Nairobi, Kenya; Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21944 Rio De Janeiro, Brazil	Universite de Tours; Universidade Federal de Sao Paulo (UNIFESP); CGIAR; International Livestock Research Institute (ILRI); Universidade Federal do Rio de Janeiro	Lalmanach, G (corresponding author), Univ Tours, Fac Med, Enzymol & Prot Chem Lab, 2bis Bd Tonnelle, F-37032 Tours, France.		Chagas, Jair Ribeiro/AFV-6501-2022; Chagas, Jair R/A-1701-2012; Lecaille, Fabien/GRY-5313-2022	Chagas, Jair Ribeiro/0000-0002-0357-8276; Chagas, Jair R/0000-0002-0357-8276; Lecaille, Fabien/0000-0003-1060-4222; Lalmanach, Gilles/0000-0001-8562-4821				ASLUND L, 1991, MOL BIOCHEM PARASIT, V45, P345, DOI 10.1016/0166-6851(91)90103-D; Atherton E., 1990, SOLID PHASE PEPTIDE; AUTHIE E, 1992, MOL BIOCHEM PARASIT, V56, P103, DOI 10.1016/0166-6851(92)90158-G; AUTHIE E, 1994, PARASITOL TODAY, V10, P360, DOI 10.1016/0169-4758(94)90252-6; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BERTI PJ, 1995, J MOL BIOL, V246, P273, DOI 10.1006/jmbi.1994.0083; Carmona E, 1996, BIOCHEMISTRY-US, V35, P8149, DOI 10.1021/bi952736s; CAZZULO JJ, 1990, BIOCHIM BIOPHYS ACTA, V1037, P186, DOI 10.1016/0167-4838(90)90166-D; Chagas JR, 1996, FEBS LETT, V392, P233, DOI 10.1016/0014-5793(96)00822-8; Chagas JR, 1997, MOL BIOCHEM PARASIT, V88, P85, DOI 10.1016/S0166-6851(97)00085-6; Chen YM, 1996, FEBS LETT, V393, P24, DOI 10.1016/0014-5793(96)00847-2; Coulombe R, 1996, EMBO J, V15, P5492, DOI 10.1002/j.1460-2075.1996.tb00934.x; Cygler M, 1996, STRUCTURE, V4, P405, DOI 10.1016/S0969-2126(96)00046-9; DelNery E, 1997, BIOCHEM J, V323, P427, DOI 10.1042/bj3230427; FOX T, 1992, BIOCHEMISTRY-US, V31, P12571, DOI 10.1021/bi00165a005; Francis SE, 1996, MOL BIOCHEM PARASIT, V83, P189, DOI 10.1016/S0166-6851(96)02772-7; Gillmor SA, 1997, PROTEIN SCI, V6, P1603, DOI 10.1002/pro.5560060801; Groves MR, 1996, STRUCTURE, V4, P1193, DOI 10.1016/S0969-2126(96)00127-X; Kopitar G, 1996, EUR J BIOCHEM, V236, P558, DOI 10.1111/j.1432-1033.1996.00558.x; Lazo ND, 1997, BIOCHEMISTRY-US, V36, P2559, DOI 10.1021/bi963061b; LIMA APCA, 1992, MOL BIOCHEM PARASIT, V56, P335, DOI 10.1016/0166-6851(92)90183-K; MACH L, 1994, J BIOL CHEM, V269, P13036; MBAWA ZR, 1992, EUR J BIOCHEM, V204, P371, DOI 10.1111/j.1432-1033.1992.tb16646.x; MCGRATH ME, 1995, J MOL BIOL, V247, P251, DOI 10.1006/jmbi.1994.0137; MCKERROW JH, 1995, PARASITOL TODAY, V11, P279, DOI 10.1016/0169-4758(95)80039-5; MOREAU T, 1988, EUR J BIOCHEM, V173, P185, DOI 10.1111/j.1432-1033.1988.tb13983.x; NORTH MJ, 1990, PARASITOL TODAY, V6, P270, DOI 10.1016/0169-4758(90)90189-B; Plantier JC, 1998, J VIROL, V72, P677, DOI 10.1128/JVI.72.1.677-683.1998; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P461; ROSENTHAL PJ, 1991, J CLIN INVEST, V88, P1467, DOI 10.1172/JCI115456; SCHARFSTEIN J, 1986, J IMMUNOL, V137, P1336; Serveau C, 1996, BIOCHEM J, V313, P951, DOI 10.1042/bj3130951; TAO K, 1994, ARCH BIOCHEM BIOPHYS, V311, P19, DOI 10.1006/abbi.1994.1203; TAYLOR MAJ, 1995, PROTEIN ENG, V8, P59, DOI 10.1093/protein/8.1.59; Turk D, 1996, FEBS LETT, V384, P211, DOI 10.1016/0014-5793(96)00309-2	36	40	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25112	25116		10.1074/jbc.273.39.25112	http://dx.doi.org/10.1074/jbc.273.39.25112			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737969	hybrid			2022-12-27	WOS:000076085400019
J	Montano, MM; Jaiswal, AK; Katzenellenbogen, BS				Montano, MM; Jaiswal, AK; Katzenellenbogen, BS			Transcriptional regulation of the human quinone reductase gene by antiestrogen-liganded estrogen receptor-alpha and estrogen receptor-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIOXIDANT RESPONSIVE ELEMENT; DNA-PROTEIN INTERACTION; HORMONE-BINDING DOMAIN; YA-SUBUNIT GENE; INDUCIBLE EXPRESSION; ER-BETA; IDENTIFICATION; ACTIVATION; ELECTROPHILE; INDUCTION	We have previously reported that antiestrogens stimulate quinone reductase (NAD (P)H: (quinone-acceptor) oxidoreductase (QR or NQO1); EC 1.6.99.2) enzymatic activity, an action that may provide protective effects against the toxicity and mutagenicity caused by quinones, We have now investigated the transcriptional regulation of the QR gene by antiestrogens. In transfection experiments employing the 5'-flanking (863-base pair) region of the human QR gene promoter with its electrophile/antioxidant response element (EpRE/ARE) or deleted or mutated constructs, we observe that antiestrogens induced an increase in QR gene promoter reporter activity in estrogen receptor (ER) negative breast cancer and endometrial cancer cells transfected with ER, and this induction by antiestrogens was repressed by estradiol, The stimulation of QR transcriptional activity required the 31-base pair electrophile-responsive region from the human QR gene promoter and a functional ER. Intriguingly, antiestrogens were stronger activators of the QR EpRE via the ER subtype ER beta than ER alpha. Oligonucleotide gel mobility and antibody shift assays reveal that the ER binds to the EpRE but is only a minor component of the proteins bound to the EpRE in ER-containing MCF-7 breast cancer cells. While binding of ER beta to the estrogen response element was weaker when compared with ER alpha, ER beta and ER alpha showed similar binding to the EpRE, Together these findings provide evidence that QR gene regulation by the antiestrogen-occupied ER is mediated by the EpRE-containing region of the human QR gene and indicate that the ER is one of the complex of proteins that binds to the EpRE. In addition, that ERP is a more potent activator at EpRE elements than is ERa: suggests that the different levels of these two receptors in various estrogen target cells could impact importantly on the antioxidant potency of antiestrogens in different target cells. These findings have broad implications regarding the potential beneficial effects of antiestrogens since EpREs mediate the transcriptional induction of numerous genes, including QR, which encode chemoprotective detoxification enzymes.	Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA; Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA; Univ Illinois, Coll Med, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Baylor College of Medicine; University of Illinois System; University of Illinois Urbana-Champaign	Katzenellenbogen, BS (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, 524 Burrill Hall,407 S Goodwin Ave, Urbana, IL 61801 USA.	katzenel@uiuc.edu			NATIONAL CANCER INSTITUTE [R37CA018119, R01CA018119] Funding Source: NIH RePORTER; NCI NIH HHS [CA18119, CA80959] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; CHO HS, 1991, MOL ENDOCRINOL, V5, P1323, DOI 10.1210/mend-5-9-1323; FAVREAU LV, 1993, J BIOL CHEM, V268, P19875; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; Guido EC, 1996, MOL ENDOCRINOL, V10, P1178, DOI 10.1210/me.10.10.1178; Hellriegel ET, 1996, BIOCHEM PHARMACOL, V52, P1561, DOI 10.1016/S0006-2952(96)00560-6; JAISWAL AK, 1988, J BIOL CHEM, V263, P13572; JAISWAL AK, 1991, BIOCHEMISTRY-US, V30, P10647, DOI 10.1021/bi00108a007; KRAUS WL, 1994, MOL ENDOCRINOL, V8, P952, DOI 10.1210/me.8.8.952; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Montano MM, 1996, MOL ENDOCRINOL, V10, P230, DOI 10.1210/me.10.3.230; Montano MM, 1997, MOL ENDOCRINOL, V11, P330, DOI 10.1210/me.11.3.330; MONTANO MM, 1995, MOL ENDOCRINOL, V9, P814, DOI 10.1210/me.9.7.814; Montano MM, 1997, P NATL ACAD SCI USA, V94, P2581, DOI 10.1073/pnas.94.6.2581; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; NGUYEN T, 1992, J BIOL CHEM, V267, P13535; Norris JD, 1996, MOL ENDOCRINOL, V10, P1605, DOI 10.1210/mend.10.12.8961270; OSHIMA H, 1995, J BIOL CHEM, V270, P21893, DOI 10.1074/jbc.270.37.21893; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; PRESTERA T, 1993, ADV ENZYME REGUL, V33, P281; PRESTERA T, 1995, P NATL ACAD SCI USA, V92, P8965, DOI 10.1073/pnas.92.19.8965; REESE JC, 1991, J BIOL CHEM, V266, P10880; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; SIMONS SS, 1992, MOL ENDOCRINOL, V6, P995, DOI 10.1210/me.6.7.995; TALALAY P, 1989, ADV ENZYME REGUL, V28, P237, DOI 10.1016/0065-2571(89)90074-5; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; WRENN CK, 1993, J BIOL CHEM, V268, P24089; XIE T, 1995, J BIOL CHEM, V270, P6894, DOI 10.1074/jbc.270.12.6894	35	110	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25443	25449		10.1074/jbc.273.39.25443	http://dx.doi.org/10.1074/jbc.273.39.25443			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738013	hybrid			2022-12-27	WOS:000076085400063
J	Saenko, EL; Scandella, D; Yakhyaev, AV; Greco, NJ				Saenko, EL; Scandella, D; Yakhyaev, AV; Greco, NJ			Activation of factor VIII by thrombin increases its affinity for binding to synthetic phospholipid membranes and activated platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; SURFACE-PLASMON RESONANCE; COAGULATION FACTOR-VIII; PHOSPHATIDYL-L-SERINE; PORCINE FACTOR-VIII; LIGHT-CHAIN; FACTOR-IXA; FACTOR-X; VONWILLEBRAND-FACTOR; BLOOD-COAGULATION	Membrane-bound thrombin-activated factor VIII (fVIIIa) functions as a cofactor for factor IXa in the factor Xase complex. We found that binding of heterotrimeric fVIIIa (A1.A2.A3-C1-C2) to synthetic vesicles with a physiologic content of 4% phosphatidylserine (PS), 76% phosphatidylcholine, and 20% phosphatidylethanolamine occurs with a 10-fold higher affinity than that of factor VIII (fVIII), The increased affinity of fVIIIa for PS-containing membranes resulted from the reduced rate of fVIIIa dissociation from the vesicles compared with that of fVIII, Similar affinities of A3-C1-C2, A1.A2.A3-C1-C2, and A3-C1-C2.heavy chain for interaction with PS-containing membranes demonstrate that removal of the light chain (LCh) acidic region by thrombin is responsible for these increased affinities of fVIIIa and its derivatives. Similar kinetic parameters of fVIII and its LCh and C2 domain for binding to PS-containing membranes and to activated platelets indicated that the C2 domain is entirely responsible for the interaction of fVIII with membranes. We conclude that the increased fVIIIa affinity for PS-containing membranes is a result of conformational change(s) within the C2 domain upon removal of the acidic region of the LCh, This conclusion is based on the finding that binding of the monoclonal antibody ESH8 to the C2 domain, which is known to prevent this conformational transition, resulted in fVIIIa binding to PS/phosphatidylcholine/phosphatidylethanolamine vesicles (4/76/20) with a lower affinity similar to that of fVIII, In addition, stabilization of the low affinity binding conformation of the C2 domain of fVIIIa by this antibody led to an inhibition of the fVIIIa activity in the factor X activation complex.	Amer Red Cross, Jerome H Holland Lab, Rockville, MD 20855 USA	American Red Cross	Saenko, EL (corresponding author), Amer Red Cross, Jerome H Holland Lab, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055273] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55273] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBOTT AJ, 1987, BIOCHEMISTRY-US, V26, P7994, DOI 10.1021/bi00398a067; AHMAD SS, 1989, J BIOL CHEM, V264, P3244; AHMAD SS, 1989, J CLIN INVEST, V84, P824, DOI 10.1172/JCI114242; ARAI M, 1989, J CLIN INVEST, V83, P1978, DOI 10.1172/JCI114107; ATKINS JS, 1992, MOL CELL BIOCHEM, V112, P61; BARDELLE C, 1993, J BIOL CHEM, V268, P8815; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BEVERS EM, 1982, EUR J BIOCHEM, V122, P429, DOI 10.1111/j.1432-1033.1982.tb05898.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CURTIS JE, 1994, J BIOL CHEM, V269, P6246; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; EDWARDS PR, 1995, ANAL BIOCHEM, V231, P210, DOI 10.1006/abio.1995.1522; Fay PJ, 1996, J BIOL CHEM, V271, P6027, DOI 10.1074/jbc.271.11.6027; FAY PJ, 1992, J BIOL CHEM, V267, P13246; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; FAY PJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P525, DOI 10.1016/0003-9861(88)90404-3; FAY PJ, 1991, J BIOL CHEM, V266, P2172; FAY PJ, 1987, BIOCHIM BIOPHYS ACTA, V952, P181; GILBERT GE, 1993, BIOCHEMISTRY-US, V32, P9577, DOI 10.1021/bi00088a009; GILBERT GE, 1995, J BIOL CHEM, V270, P18500, DOI 10.1074/jbc.270.31.18500; GILBERT GE, 1992, J BIOL CHEM, V267, P15861; Gilbert GE, 1996, J BIOL CHEM, V271, P11120, DOI 10.1074/jbc.271.19.11120; GILBERT GE, 1990, J BIOL CHEM, V265, P815; GILBERT GE, 1991, J BIOL CHEM, V266, P17261; GRECO NJ, 1991, J BIOL CHEM, V266, P13627; HILLEUBANKS DC, 1989, P NATL ACAD SCI USA, V86, P6508, DOI 10.1073/pnas.86.17.6508; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; KALAFATIS M, 1994, BIOCHEMISTRY-US, V33, P486, DOI 10.1021/bi00168a013; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; Lapan KA, 1997, J BIOL CHEM, V272, P2082; Li X, 1997, BIOCHEMISTRY-US, V36, P10760, DOI 10.1021/bi970052+; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; LOLLAR P, 1988, BLOOD, V71, P137; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; NESHEIM M, 1991, J BIOL CHEM, V266, P17815; NESHEIM ME, 1988, J BIOL CHEM, V263, P16467; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; PLANT AL, 1995, ANAL BIOCHEM, V226, P342, DOI 10.1006/abio.1995.1234; SAENKO EL, 1995, J BIOL CHEM, V270, P13826, DOI 10.1074/jbc.270.23.13826; Saenko EL, 1997, J BIOL CHEM, V272, P18007, DOI 10.1074/jbc.272.29.18007; SAENKO EL, 1994, J BIOL CHEM, V269, P11601; Saenko EL, 1996, J BIOL CHEM, V271, P27424, DOI 10.1074/jbc.271.44.27424; SPAARGAREN J, 1995, BIOCHEM J, V310, P539, DOI 10.1042/bj3100539; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WION KL, 1985, NATURE, V317, P726, DOI 10.1038/317726a0; ZWAAL RFA, 1993, BIOCHEM SOC T, V21, P248, DOI 10.1042/bst0210248	52	76	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27918	27926		10.1074/jbc.273.43.27918	http://dx.doi.org/10.1074/jbc.273.43.27918			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774404	hybrid			2022-12-27	WOS:000076549800024
J	Zhang, YL; Spremulli, LL				Zhang, YL; Spremulli, LL			Roles of residues in mammalian mitochondrial elongation factor Ts in the interaction with mitochondrial and bacterial elongation factor Tu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; EF-TU; EXTREME THERMOPHILE; CRYSTAL-STRUCTURE; COMPLEX; THERMUS-THERMOPHILUS-HB8; DOMAIN; BOVINE	The crystal structure of the complex between Escherichia coli elongation factors Tu and Ts (EF-Tu.Ts) and subsequent mutagenesis work have provided insights into the roles of a number of residues in E. coli EF-Ts in its interaction with EF-Tu. The corresponding residues in bovine mitochondrial EF-Ts (EF-Ts-mt) have been mutated. The abilities of the resulting EF-Ts-mt derivatives to stimulate the activities of both E. coli and mitochondrial EF-Tu have been tested. Mutation of several residues in EF-Ts-mt corresponding to amino acids important for the activity off. coli EF-Ts has little or no effect on the activity of the mitochondrial factor, suggesting that these factors may use somewhat different mechanisms to promote guanine nucleotide exchange. In general, mutations that reduce the strength of the interaction between EF-Ts-mt and E. coli EF-Tu increase the ability of EF-Ts-mt to stimulate the activity of the bacterial factor. In contrast, these mutations tend to reduce the ability of EF-Ts-mt to stimulate the activity of EF-Tu(mt). For example, F19A/I20A and H176A derivatives of EF-Ts-mt are as active as E. coli EF-Ts in simulating E. coli EF-Tu. However, these mutations significantly decrease the ability of EF-Ts-mt to stimulate EF-Tu(mt).	Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Spremulli, LL (corresponding author), Univ N Carolina, Dept Chem, Campus Box 3290, Chapel Hill, NC 27599 USA.	Linda_Spremulli@unc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032734] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32734] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI KI, 1978, EUR J BIOCHEM, V92, P521, DOI 10.1111/j.1432-1033.1978.tb12774.x; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BOGESTRAND S, 1995, FEBS LETT, V368, P49, DOI 10.1016/0014-5793(95)00597-3; FOX L, 1980, J BIOL CHEM, V255, P6018; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; LI XM, 1993, NUCLEIC ACIDS RES, V21, P3745, DOI 10.1093/nar/21.16.3745; MILLER DL, 1970, BIOCHEM BIOPH RES CO, V38, P1016, DOI 10.1016/0006-291X(70)90341-4; NAKAMURA S, 1978, EUR J BIOCHEM, V92, P533, DOI 10.1111/j.1432-1033.1978.tb12775.x; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; RAVEL JM, 1969, COLD SPRING HARB SYM, V34, P321, DOI 10.1101/SQB.1969.034.01.039; Schwartzbach C J, 1996, Methods Enzymol, V264, P248, DOI 10.1016/S0076-6879(96)64025-7; SCHWARTZBACH CJ, 1991, J BIOL CHEM, V266, P16324; SCHWARTZBACH CJ, 1989, J BIOL CHEM, V264, P19125; Woriax VL, 1995, BBA-GENE STRUCT EXPR, V1264, P347, DOI 10.1016/0167-4781(95)00176-X; Woriax VL, 1997, BBA-GENE STRUCT EXPR, V1352, P91, DOI 10.1016/S0167-4781(97)00002-X; XIN H, 1995, J BIOL CHEM, V270, P17243, DOI 10.1074/jbc.270.29.17243; Xin H., 1997, BIOCHIM BIOPHYS ACTA, V1352, P101; Zhang YL, 1996, FEBS LETT, V391, P330, DOI 10.1016/0014-5793(96)00789-2; Zhang YL, 1998, J BIOL CHEM, V273, P4556, DOI 10.1074/jbc.273.8.4556; Zhang YL, 1997, J BIOL CHEM, V272, P21956, DOI 10.1074/jbc.272.35.21956	22	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28142	28148		10.1074/jbc.273.43.28142	http://dx.doi.org/10.1074/jbc.273.43.28142			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774433	Green Published, hybrid			2022-12-27	WOS:000076549800053
J	Okamoto, H; Takuwa, N; Gonda, K; Okazaki, H; Chang, K; Yatomi, Y; Shigematsu, H; Takuwa, Y				Okamoto, H; Takuwa, N; Gonda, K; Okazaki, H; Chang, K; Yatomi, Y; Shigematsu, H; Takuwa, Y			EDG1 is a functional sphingosine-l-phosphate receptor that is linked via a G(i/o) to multiple signaling pathways, including phospholipase C activation, Ca2+ mobilization, Ras-mitogen-activated protein kinase activation, and adenylate cyclase inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOPHOSPHATIDIC ACID; MOLECULAR-CLONING; COUPLED RECEPTORS; MEMBRANE-RECEPTOR; SURFACE-RECEPTOR; 2ND MESSENGER; HIGH-AFFINITY; S-PHASE; SPHINGOSINE-1-PHOSPHATE; 1-PHOSPHATE	In Chinese hamster ovary (CHO) cells transiently transfected with an expression vector for EDG1, but not an empty vector, sphingosine-l-phosphate (SP) at a concentration as low as 10(-10) M caused an increase in the intracellular free Ca2+ concentration ([Ca2+](i)) as a result of mobilization of Ca2+ from both intracellular and extracellular pools. In a CHO clone stably expressing EDG1 receptor (CBO-EDG1 cells), SP induced increases in the production of inositol phosphates and the [Ca2+](i) and inhibited forskolin-induced increase in the cellular cAMP content, all in a manner sensitive to pertussis toxin. SP also activated mitogen-activated protein kinase in CHO-EDG1 cells in pertussis toxin-sensitive and Ras-dependent manners. To evaluate the spectrum of agonists for EDG1, we used human erythroleukemia (HEL) cells, which at naive state do not respond to SP or structurally related lipids with an increase in the [Ca2+](i). In HEL cells stably expressing EDG1 receptor (HEL-EDG1 cells), SP dose-dependently increased the [Ca2+](i) with half-maximal and maximal concentration values of 10(-9) and 3 x 10(-7) M, respectively; sphingosylphosphorylcholine at exclusively high concentrations, but not sphingosine at all, also increased the [Ca2+](i). HEL-EDG1 cells bound P-32-labeled SP, which was displaced dose dependently by unlabeled SP, These results indicate that EDG1, a member of the EDG family G protein-coupled receptors, is a specific, high-affinity SP receptor.	Univ Tokyo, Sch Med, Dept Mol & Cellular Physiol, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Med, Dept Vasc Surg, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Med, Dept Plast Surg, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Med, Dept Cardiovasc Biol, Tokyo 1130033, Japan; Yamanashi Med Univ, Dept Lab Med, Yamanashi 4093898, Japan; Fdn Advancement Int Sci, Ibaraki 3050006, Japan	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; University of Yamanashi	Takuwa, Y (corresponding author), Univ Tokyo, Sch Med, Dept Mol & Cellular Physiol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	yohtakwa@m.u-tokyo.ac.jp		Yatomi, Yutaka/0000-0003-1719-4297; TAKUWA, Noriko/0000-0002-4278-2704				An SZ, 1997, FEBS LETT, V417, P279, DOI 10.1016/S0014-5793(97)01301-X; An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; Bunemann M, 1996, EMBO J, V15, P5527, DOI 10.1002/j.1460-2075.1996.tb00937.x; CHANG KG, 1995, J BIOL CHEM, V270, P26152, DOI 10.1074/jbc.270.44.26152; DESAI NN, 1991, BIOCHEM BIOPH RES CO, V181, P361, DOI 10.1016/S0006-291X(05)81427-5; DURIEUX ME, 1993, AM J PHYSIOL, V264, pC1360, DOI 10.1152/ajpcell.1993.264.5.C1360; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GOODEMOTE KA, 1995, J BIOL CHEM, V270, P10272, DOI 10.1074/jbc.270.17.10272; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Heringdorf DMZ, 1997, FEBS LETT, V410, P34, DOI 10.1016/S0014-5793(97)00320-7; HLA T, 1990, J BIOL CHEM, V265, P9308; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; MACLENNAN AJ, 1994, MOL CELL NEUROSCI, V5, P201, DOI 10.1006/mcne.1994.1024; Mitsui H, 1997, J BIOL CHEM, V272, P4904, DOI 10.1074/jbc.272.8.4904; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OKAZAKI H, 1993, BIOCHEM BIOPH RES CO, V190, P1104, DOI 10.1006/bbrc.1993.1163; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Postma FR, 1996, EMBO J, V15, P2388, DOI 10.1002/j.1460-2075.1996.tb00595.x; SADAHIRA Y, 1992, P NATL ACAD SCI USA, V89, P9686, DOI 10.1073/pnas.89.20.9686; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24334, DOI 10.1074/jbc.270.41.24334; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; vanKoppen CJ, 1996, J BIOL CHEM, V271, P2082, DOI 10.1074/jbc.271.4.2082; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; Yamaguchi F, 1996, BIOCHEM BIOPH RES CO, V227, P608, DOI 10.1006/bbrc.1996.1553; Yatomi Y, 1997, J BIOL CHEM, V272, P5291, DOI 10.1074/jbc.272.8.5291; YATOMI Y, 1995, BLOOD, V86, P193, DOI 10.1182/blood.V86.1.193.bloodjournal861193; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; Zondag GCM, 1998, BIOCHEM J, V330, P605, DOI 10.1042/bj3300605	32	235	245	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27104	27110		10.1074/jbc.273.42.27104	http://dx.doi.org/10.1074/jbc.273.42.27104			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765227	hybrid			2022-12-27	WOS:000076448000014
J	Shalom-Barak, T; Quach, J; Lotz, M				Shalom-Barak, T; Quach, J; Lotz, M			Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE PRODUCTION; C-JUN; GLUCOCORTICOID RECEPTOR; TRANSCRIPTIONAL ACTIVATION; CYTOKINE BIOSYNTHESIS; FUNCTIONAL ANTAGONISM; TERMINAL KINASE; AP-1 ACTIVITY; T-CELL; OSTEOARTHRITIS	This study examines intracellular signaling events associated with the activation of chondrocytes by the cytokine interleukin-17 (IL-17). Stimulation of normal human articular chondrocytes with IL-17 induced nitric oxide (NO) production, concomitant with an increase in transcripts and de novo translation products of the inducible nitric oxide synthase (iNOS) and cyclooxygenase-a (COX-2) genes. Several other genes associated with inflammation and cartilage degradation, such as IL-1 beta, IL-6, and stromelysin, were also up-regulated in IL-17-treated chondrocytes. Among signaling events displaying early response to IL-17 in chondrocytes were the mitogen-activated protein (MAP) kinases ERK1, ERK2, JNK, and p38. DNA binding activity of NF-kappa B was also significantly induced. IL-17 effects on NO release, as well, as iNOS, COX-2, and IL-6 protein expression, were inhibited by the anti-inflammatory drug dexamethasone, Importantly, dexamethasone blunted IL-17-dependent activation of MAP kinases, suggesting a mechanistic relationship between these activities and the aforementioned gene expression responses. Similar effects of a lesser extent were observed with the p38-specific inhibitor SB203580, These results suggest that IL-17 activation of chondrocytes is associated with and depends at least in part on the activation of MAP kinases and NF-kappa B.	Scripps Res Inst, Div Arthrit Res, La Jolla, CA 92037 USA	Scripps Research Institute	Lotz, M (corresponding author), Scripps Res Inst, Div Arthrit Res, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	mlotz@scripps.edu			NIAMS NIH HHS [AR43872] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043872] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBRECHT JC, 1992, J VIROL, V66, P5047, DOI 10.1128/JVI.66.8.5047-5058.1992; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Amin AR, 1997, J CLIN INVEST, V99, P1231, DOI 10.1172/JCI119280; AMIN AR, 1995, J EXP MED, V182, P2097, DOI 10.1084/jem.182.6.2097; Attur MG, 1997, ARTHRITIS RHEUM, V40, P1050, DOI 10.1002/art.1780400609; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BIANCO FJ, 1995, AM J PATHOL, V146, P75; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Geng Y, 1996, J CLIN INVEST, V98, P2425, DOI 10.1172/JCI119056; Grabowski PS, 1996, BRIT J RHEUMATOL, V35, P207; Jovanovic DV, 1998, J IMMUNOL, V160, P3513; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1993, ANN NY ACAD SCI, V696, P149; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; LOTZ M, 1995, J RHEUMATOL, V22, P104; LOTZ M, 1992, INT MED, V13, P55; PALMER RMJ, 1993, BIOCHEM BIOPH RES CO, V193, P398, DOI 10.1006/bbrc.1993.1637; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Rediske J J, 1994, Osteoarthritis Cartilage, V2, P199, DOI 10.1016/S1063-4584(05)80069-X; Rider LG, 1996, J IMMUNOL, V157, P2374; ROUVIER E, 1993, J IMMUNOL, V150, P5445; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Scherle PA, 1997, BIOCHEM BIOPH RES CO, V230, P573, DOI 10.1006/bbrc.1996.5985; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; STADLER J, 1991, J IMMUNOL, V147, P3915; Stein B, 1996, ANNU REP MED CHEM, V31, P289, DOI 10.1016/S0065-7743(08)60468-6; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Westacott CI, 1996, SEMIN ARTHRITIS RHEU, V25, P254, DOI 10.1016/S0049-0172(96)80036-9; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; Yao ZB, 1995, IMMUNITY, V3, P811, DOI 10.1016/1074-7613(95)90070-5; YOO ZB, 1995, J IMMUNOL, V155, P5483	46	325	365	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27467	27473		10.1074/jbc.273.42.27467	http://dx.doi.org/10.1074/jbc.273.42.27467			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765276	hybrid			2022-12-27	WOS:000076448000063
J	Stennicke, HR; Jurgensmeier, JM; Shin, H; Deveraux, Q; Wolf, BB; Yang, XH; Zhou, Q; Ellerby, HM; Ellerby, LM; Bredesen, D; Green, DR; Reed, JC; Froelich, CJ; Salvesen, GS				Stennicke, HR; Jurgensmeier, JM; Shin, H; Deveraux, Q; Wolf, BB; Yang, XH; Zhou, Q; Ellerby, HM; Ellerby, LM; Bredesen, D; Green, DR; Reed, JC; Froelich, CJ; Salvesen, GS			Pro-caspase-3 is a major physiologic target of caspase-8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; PROTEASE GRANZYME-B; CYTOCHROME-C; MITOCHONDRIAL CONTROL; APOPTOSIS; DEATH; ACTIVATION; BCL-2; CPP32; PATHWAYS	The apoptotic signal triggered by ligation of members of the death receptor family is promoted by sequential activation of caspase zymogens, We show here that in a purified system, the initiator caspases-8 and -10 directly process the executioner pro-caspase-3 with activation rates (k(cat)/K-m) of 8.7 x 10(5) and 2.8 x 10(5) M-1 s(-1), respectively, These rates are of sufficient magnitude to indicate direct processing in vivo. Differentially processed forms of caspase-3 that accumulate during its activation have similar rates of activation, activities, and specificities. The pattern and rate of caspase-3 induced activation of pro-caspase-3 in cytosolic extracts was the same as in a purified system. Moreover, immunodepletion of a putative intermediary in the pathway to activation, procaspase-9, was without consequence. Taken together these data demonstrate that the initiator caspase-8 can directly activate pro-caspase-3 without the requirement for an accelerator. The in vitro data thus help to deconvolute previous in vivo transfection studies which have debated the role of a direct versus indirect transmission of the apoptotic signal generated by ligation of death receptors.	Burnham Inst, Program Apoptosis & Cell Death Res, La Jolla, CA 92037 USA; Northwestern Univ, Evanston Hosp, Dept Med, Evanston, IL 60201 USA; La Jolla Inst Allergy & Immunol, San Diego, CA 92110 USA	Sanford Burnham Prebys Medical Discovery Institute; NorthShore University Health System; Northwestern University; La Jolla Institute for Immunology	Salvesen, GS (corresponding author), Burnham Inst, Program Apoptosis & Cell Death Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Green, Douglas R/N-8083-2018; Yang, Jim/B-3776-2010; Juergensmeier, Juliane/I-4117-2013	Green, Douglas R/0000-0002-7332-1417; 	NCI NIH HHS [CA72994] Funding Source: Medline; NHLBI NIH HHS [HL51399] Funding Source: Medline; NINDS NIH HHS [NS37878] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072994] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051399] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037878] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Ellerby HM, 1997, J NEUROSCI, V17, P6165; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; HANNA WL, 1993, PROTEIN EXPRES PURIF, V4, P398, DOI 10.1006/prep.1993.1052; Higuchi R., 1989, PCR TECHNOLOGY, P61; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Krajewska M, 1997, CANCER RES, V57, P1605; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; NEURATH H, 1989, TRENDS BIOCHEM SCI, V14, P268, DOI 10.1016/0968-0004(89)90061-3; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Talanian RV, 1997, J EXP MED, V186, P1323, DOI 10.1084/jem.186.8.1323; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Yamin TT, 1996, J BIOL CHEM, V271, P13273, DOI 10.1074/jbc.271.22.13273; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zhou Q, 1998, BIOCHEMISTRY-US, V37, P10757, DOI 10.1021/bi980893w; Zhou Q, 1997, BIOCHEM J, V324, P361, DOI 10.1042/bj3240361; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	45	613	642	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27084	27090		10.1074/jbc.273.42.27084	http://dx.doi.org/10.1074/jbc.273.42.27084			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765224	hybrid			2022-12-27	WOS:000076448000011
J	Erlenbach, I; Wess, J				Erlenbach, I; Wess, J			Molecular basis of V2 vasopressin receptor/G(s) coupling selectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEPHROGENIC DIABETES-INSIPIDUS; RANDOM SATURATION MUTAGENESIS; G-PROTEIN ACTIVATION; FUNCTIONAL EXPRESSION; CLONING; BINDING; DOMAINS; PALMITOYLATION; RHODOPSIN; RAT	The molecular mechanisms governing the coupling selectivity of G protein-coupled receptors activated by peptide ligands are not well understood. To shed light on this issue, we have used the G(q/11)-linked V1a and the G(s)-coupled V2 vasopressin peptide receptors as model systems. To explore the structural basis underlying the ability of the V2 receptor to selectively recognize G(s), we systematically substituted distinct V2 receptor segments (or single amino acids) into the V1a receptor and studied whether the resulting hybrid receptors gained the ability to mediate hormone-dependent cAMP production. This strategy appeared particularly attractive since hormone stimulation of the Via receptor has virtually no effect on intracellular cAMP levels. Functional analysis of a large number of mutant receptors transiently expressed in COS-7 cells indicated that the presence of V2 receptor sequence at the N terminus of the third intracellular loop is critical for efficient activation of G(s). More detailed mutational analysis of this receptor region showed that two polar V2 receptor residues, Gln(225) and Glu(231), play key roles in G(s) recognition. In addition, a short sequence at the N terminus of the cytoplasmic tail was found to make an important contribution to V2 receptor/G(s) coupling selectivity. We also made the novel observation that the efficiency of V2 receptor/G(s) coupling can be modulated by the length of the central portion of the third intracellular loop (rather than the specific amino acid sequence within this domain). These findings provide novel insights into the molecular mechanisms regulating peptide receptor/G protein coupling selectivity.	NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Wess, J (corresponding author), NIDDK, Bioorgan Chem Lab, NIH, Bldg 8A,Rm B1A-05, Bethesda, MD 20892 USA.	jwess@helix.nih.gov						Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; BIRNBAUMER M, 1995, J RECEPT SIGNAL TR R, V15, P131, DOI 10.3109/10799899509045213; BLIN N, 1995, J BIOL CHEM, V270, P17741, DOI 10.1074/jbc.270.30.17741; BOUVIER M, 1995, METHOD ENZYMOL, V250, P300; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURSTEIN ES, 1995, J BIOL CHEM, V270, P3141, DOI 10.1074/jbc.270.7.3141; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DORJE F, 1991, J PHARMACOL EXP THER, V256, P727; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; Higuchi R., 1989, PCR TECHNOLOGY, P61; HillEubanks D, 1996, J BIOL CHEM, V271, P3058, DOI 10.1074/jbc.271.6.3058; Innamorati G, 1996, BIOCHEM J, V314, P710; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; LASZLO FA, 1991, PHARMACOL REV, V43, P73; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; Liu J, 1996, J BIOL CHEM, V271, P8772, DOI 10.1074/jbc.271.15.8772; LIU J, 1995, J BIOL CHEM, V270, P19532, DOI 10.1074/jbc.270.33.19532; LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0; LOLAIT SJ, 1995, P NATL ACAD SCI USA, V92, P6783, DOI 10.1073/pnas.92.15.6783; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; ROSENTHAL W, 1993, J BIOL CHEM, V268, P13030; ROSS EM, 1995, CURR BIOL, V5, P107, DOI 10.1016/S0960-9822(95)00026-1; Sadeghi HM, 1997, MOL PHARMACOL, V52, P21, DOI 10.1124/mol.52.1.21; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SAVARESE TM, 1992, BIOCHEM J, V283, P1; Schoneberg T, 1996, EMBO J, V15, P1283, DOI 10.1002/j.1460-2075.1996.tb00470.x; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; Spiegel AM, 1996, ANNU REV PHYSIOL, V58, P143, DOI 10.1146/annurev.ph.58.030196.001043; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SUGIMOTO T, 1994, J BIOL CHEM, V269, P27088; THIBONNIER M, 1994, J BIOL CHEM, V269, P3304; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; WATSON S, 1994, G PROTEIN LINKED REC, P1; Wess J, 1996, CRIT REV NEUROBIOL, V10, P69, DOI 10.1615/CritRevNeurobiol.v10.i1.40; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501	42	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26549	26558		10.1074/jbc.273.41.26549	http://dx.doi.org/10.1074/jbc.273.41.26549			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756892	hybrid			2022-12-27	WOS:000076373300046
J	Glaab, WE; Risinger, JI; Umar, A; Kunkel, TA; Barrett, JC; Tindall, KR				Glaab, WE; Risinger, JI; Umar, A; Kunkel, TA; Barrett, JC; Tindall, KR			Characterization of distinct human endometrial carcinoma cell lines deficient in mismatch repair that originated from a single tumor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA; CANCER; HETERODIMER; MSH3; MUTATIONS; GENE; HOMOLOGS; PROTEINS; BINDING; DEFECTS	The role of specific mismatch repair (MMR) gene products was examined by observing several phenotypic end points in two MMR-deficient human endometrial carcinoma cell lines that were originally isolated from the same tumor. The first cell Line, HEC-1-A, contains a nonsense mutation ire the hPMS2 gene, which results in premature termination and a truncated hPMS2 protein. In addition, REC-1-A cells carry a splice mutation in the hMSH6 gene and lack wild-type hMSH6 protein, The second cell line, HEC-1-B, possesses thee same defective hMSH6 locus, However, HEC-1-B cells are heterozygous at the hPMS2 locus; that is, along with carrying the same nonsense mutation in hPMS2 as in HEC-1-A, HEC-1-B cells also contain a wild-type hPMS2 gene. initial recognition of mismatches in DNA requires either the hMSH2/hMSH6 or hMSH2/hMSH3 heterodimer, with hPMS2 functioning downstream of damage recognition. Therefore, cells defective in hPMS2 should completely lack MMR (HEC-1-A), whereas cells mutant in hMSH6 only (HEC-1-B) can potentially repair damage via the hMSH2/hMSH3 heterodimer. The data presented here in HEC-1-B cells illustrate (i) the reduction of instability at microsatellite sequences, (ii) a significant decrease in frameshift mutation rate at HPRT, and (iii) the in vitro repair of looped substrates, relative to HEC-1-A cells, illustrating the repair of frameshift intermediates by hMSH2/hMSH3 heterodimer. Furthermore, the role of hMSH2/hMSH3 heterodimer in the repair of base:base mismatches is supported by observing the reduction in base substitution mutation rate at HPRT in HEC-1-B cells (hMSH6-defective but possessing wild-type hPMS2), as compared with HEC-1-A (hMSH6/hPMS2-defective) cells, These data support a critical role for hPMS2 in human MMR, while further defining the role of the hMSH2/hMSH3 heterodimer in maintaining genomic stability in the absence of a wild-type hMSH2/hMSH6 heterodimer.	NIEHS, Lab Environm Carcinogenesis & Mutagenesis, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Genet Mol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Glaab, WE (corresponding author), Merck Res Labs, WP45-320, W Point, PA 19486 USA.	warren_glaab@merck.com	Kunkel, Thomas A./D-5088-2019	Kunkel, Thomas A./0000-0002-9900-1788				Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; Cariello NF, 1996, NUCLEIC ACIDS RES, V24, P119, DOI 10.1093/nar/24.1.119; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Eshleman JR, 1996, HUM MOL GENET, V5, P1489, DOI 10.1093/hmg/5.Supplement_1.1489; Fishel R, 1997, CURR OPIN GENET DEV, V7, P105, DOI 10.1016/S0959-437X(97)80117-7; Glaab WE, 1997, CARCINOGENESIS, V18, P1, DOI 10.1093/carcin/18.1.1; Greene CN, 1997, MOL CELL BIOL, V17, P2844, DOI 10.1128/MCB.17.5.2844; Habraken Y, 1996, CURR BIOL, V6, P1185, DOI 10.1016/S0960-9822(02)70686-6; HORII A, 1994, BIOCHEM BIOPH RES CO, V204, P1257, DOI 10.1006/bbrc.1994.2598; Johnson RE, 1996, J BIOL CHEM, V271, P7285, DOI 10.1074/jbc.271.13.7285; JOLLY DJ, 1983, P NATL ACAD SCI-BIOL, V80, P477, DOI 10.1073/pnas.80.2.477; KOI M, 1994, CANCER RES, V54, P4308; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; KURAMOTO H, 1972, AM J OBSTET GYNECOL, V114, P1012, DOI 10.1016/0002-9378(72)90861-7; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; Marra G, 1996, GASTROENTEROL CLIN N, V25, P755, DOI 10.1016/S0889-8553(05)70273-9; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NICOLAIDES NC, 1995, GENOMICS, V30, P195, DOI 10.1006/geno.1995.9885; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Prolla TA, 1996, SEMIN CANCER BIOL, V7, P241, DOI 10.1006/scbi.1996.0032; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; RISINGER JI, 1995, J BIOL CHEM, V270, P18183, DOI 10.1074/jbc.270.31.18183; Risinger JI, 1998, CANCER RES, V58, P2978; ROBERTS JD, 1993, METHODS MOL GENET, V2, P295; THOMASHOW LS, 1995, PLANT MICROBE INTERA, V1, P187; Tindall KR, 1998, MUTAT RES-FUND MOL M, V402, P15, DOI 10.1016/S0027-5107(97)00277-7; Umar A, 1998, GENETICS, V148, P1637; Umar A, 1997, CANCER RES, V57, P3949; YANG JL, 1989, GENE, V83, P347, DOI 10.1016/0378-1119(89)90121-2	34	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26662	26669		10.1074/jbc.273.41.26662	http://dx.doi.org/10.1074/jbc.273.41.26662			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756907	hybrid			2022-12-27	WOS:000076373300061
J	Hamada, K; Terashima, H; Arisawa, N; Kitada, K				Hamada, K; Terashima, H; Arisawa, N; Kitada, K			Amino acid sequence requirement for efficient incorporation of glycosylphosphatidylinositol-associated proteins into the cell wall of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-AGGLUTININ; PLASMA-MEMBRANE; ASPARTYL PROTEASE; ANCHORED PROTEIN; CROSS-LINKING; GAS1 PROTEIN; GPI ANCHOR; SIDE-CHAIN; YEAST; GENE	During cell wall biogenesis in Saccharomyces cerevisiae, some glycosylphosphatidylinositol (GPI)-attached proteins are detached from GPI moieties and bound to beta-1,6-glucan of the cell wall. The amino acid sequence requirement for the incorporation of GPI-attached proteins into the cell wall was studied by using reporter fusion proteins. Only the short omega-minus region composed of five amino acids, which is located upstream of the omega site for GPI attachment, determined the cellular localization of the GPI-associated proteins. Within the omega-minus region, amino acid residues at the omega-4 or -5 and omega-2 sites were important for the cell wall incorporation. Yap3p, a well characterized GPI-anchored plasma membrane aspartic protease, was localized in the cell wall when the omega-minus region was mutated to sequences containing Val or lie at the omega-4 or -5 site and Val or Tyr at the omega-2 site.	Nippon Roche Res Ctr, Dept Mycol, Kamakura, Kanagawa 247, Japan	Roche Holding	Kitada, K (corresponding author), Nippon Roche Res Ctr, Dept Mycol, 200 Kajiwara, Kamakura, Kanagawa 247, Japan.	kunio.kitada@roche.com						ASH J, 1995, J BIOL CHEM, V270, P20847, DOI 10.1074/jbc.270.35.20847; Benghezal M, 1996, EMBO J, V15, P6575, DOI 10.1002/j.1460-2075.1996.tb01048.x; Bourdineaud JP, 1998, MOL MICROBIOL, V27, P85, DOI 10.1046/j.1365-2958.1998.00660.x; BROWN JL, 1993, GENETICS, V133, P837; Caro LHP, 1997, YEAST, V13, P1477, DOI 10.1002/(SICI)1097-0061(199712)13:15<1477::AID-YEA184>3.0.CO;2-L; CAWLEY NX, 1995, BIOCHEMISTRY-US, V34, P7430, DOI 10.1021/bi00022a016; CONZELMANN A, 1988, EMBO J, V7, P2233, DOI 10.1002/j.1460-2075.1988.tb03063.x; De Nobel Hans, 1994, Trends in Cell Biology, V4, P42, DOI 10.1016/0962-8924(94)90003-5; EGELMITANI M, 1990, YEAST, V6, P127, DOI 10.1002/yea.320060206; FIELD MC, 1993, LIPID MODIFICATIONS, P83; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Hamada K, 1998, MOL GEN GENET, V258, P53, DOI 10.1007/s004380050706; HAMBURGER D, 1995, J CELL BIOL, V129, P629, DOI 10.1083/jcb.129.3.629; Kapteyn JC, 1997, J BACTERIOL, V179, P6279, DOI 10.1128/JB.179.20.6279-6284.1997; Kapteyn JC, 1996, GLYCOBIOLOGY, V6, P337, DOI 10.1093/glycob/6.3.337; Kinoshita T, 1995, ADV IMMUNOL, V60, P57, DOI 10.1016/S0065-2776(08)60584-2; Kitada K, 1997, CURR GENET, V31, P122, DOI 10.1007/s002940050185; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; Kitagaki H, 1997, EUR J BIOCHEM, V249, P343, DOI 10.1111/j.1432-1033.1997.t01-1-00343.x; KLIS FM, 1994, YEAST, V10, P851, DOI 10.1002/yea.320100702; Kollar R, 1997, J BIOL CHEM, V272, P17762, DOI 10.1074/jbc.272.28.17762; KOMANO H, 1995, P NATL ACAD SCI USA, V92, P10752, DOI 10.1073/pnas.92.23.10752; KONDO K, 1991, J BIOL CHEM, V266, P17537; KOWALSKI LRZ, 1995, MOL MICROBIOL, V15, P341, DOI 10.1111/j.1365-2958.1995.tb02248.x; LIPKE PN, 1989, MOL CELL BIOL, V9, P3155, DOI 10.1128/MCB.9.8.3155; LU CF, 1995, J CELL BIOL, V128, P333, DOI 10.1083/jcb.128.3.333; LU CF, 1994, MOL CELL BIOL, V14, P4825, DOI 10.1128/MCB.14.7.4825; Maniatis T., 1982, MOL CLONING LAB MANU; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MONTIJN RC, 1994, J BIOL CHEM, V269, P19338; Moukadiri I, 1997, J BACTERIOL, V179, P2154, DOI 10.1128/jb.179.7.2154-2162.1997; Muller G, 1996, MOL CELL BIOL, V16, P442; Nosjean O, 1997, BBA-REV BIOMEMBRANES, V1331, P153, DOI 10.1016/S0304-4157(97)00005-1; NUOFFER C, 1991, MOL CELL BIOL, V11, P27, DOI 10.1128/MCB.11.1.27; NUOFFER C, 1993, J BIOL CHEM, V268, P10558; ROY A, 1991, MOL CELL BIOL, V11, P4196, DOI 10.1128/MCB.11.8.4196; SCHREUDER MP, 1993, YEAST, V9, P399, DOI 10.1002/yea.320090410; Sherman F., 1986, METHODS YEAST GENETI; SHIMOI H, 1995, J BIOCHEM, V118, P302, DOI 10.1093/oxfordjournals.jbchem.a124907; SIKORSKI RS, 1989, GENETICS, V122, P19; TEUNISSEN AWRH, 1995, YEAST, V11, P1001, DOI 10.1002/yea.320111102; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; VAI M, 1991, J BIOL CHEM, V266, P12242; VANBERKEL MAA, 1994, FEBS LETT, V349, P135, DOI 10.1016/0014-5793(94)00631-8; VanderVaart JM, 1997, APPL ENVIRON MICROB, V63, P615, DOI 10.1128/AEM.63.2.615-620.1997; VANDERVAART JM, 1995, J BACTERIOL, V177, P3104, DOI 10.1128/jb.177.11.3104-3110.1995; VanderVaart JM, 1996, FEMS MICROBIOL LETT, V145, P401, DOI 10.1016/S0378-1097(96)00440-5; Vossen JH, 1997, J BACTERIOL, V179, P2202, DOI 10.1128/jb.179.7.2202-2209.1997; WOJCIECHOWICZ D, 1993, MOL CELL BIOL, V13, P2554, DOI 10.1128/MCB.13.4.2554	50	66	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26946	26953		10.1074/jbc.273.41.26946	http://dx.doi.org/10.1074/jbc.273.41.26946			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756943	hybrid			2022-12-27	WOS:000076373300097
J	Jung, K; Altendorf, K				Jung, K; Altendorf, K			Individual substitutions of clustered arginine residues of the sensor kinase KdpD of Escherichia coli modulate the ratio of kinase to phosphatase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSDUCTION MUTATIONS; SIGNAL TRANSDUCTION; OPERON EXPRESSION; KDPABC OPERON; PROTEIN; POTASSIUM; ATPASE; TURGOR; SYSTEM; INACTIVATION	Escherichia coli responds to K+ limitation or high osmolarity by induction of the kdpFABC operon coding for the high affinity K+-translocating Kdp-ATPase, KdpD, the sensor kinase of this system, is a bifunctional enzyme catalyzing the autophosphorylation by ATP and the dephosphorylation of the corresponding response regulator KdpE, Here we demonstrate that individual replacements of clustered arginine residues located close to transmembrane domain TM4 modulate the ratio of kinase to phosphatase activity. Thus KdpD-Arg(511) --> Gln is characterized by an increase in the kinase activity and a loss of the phosphatase activity. However, when Arg at position 511 is replaced with Lys, activities of the corresponding protein are comparable with wildtype KdpD, In contrast, replacement of arginine residues at positions 503, 506, or 508 with glutamine or lysine causes a decrease of the kinase and an increase of the phosphatase activities. Changes of the activities of these KdpD proteins correspond with alterations in kdpFABC expression. Thus KdpD-Arg511 --> Gin causes constitutive expression of kdpFABC. KdpD proteins with Arg replacements at positions 503, 506, or 508 are unable to respond to osmolarity, whereas the sensing of K+ limitation is not influenced. Simultaneous replacement of arginine residues 508 and 511 or 506, 508, and 511 with glutamine leads to a decrease of the phosphatase activity. However, kdpFABC expression is dependent on K+ and osmolarity, Finally, when Arg(513) is replaced with glutamine the amount of KdpD detected in the membrane is drastically reduced. These results imply that there is an equilibrium between the kinase and phosphatase activities of KdpD, which can be shifted by the replacement of one arginine residue. An electrostatic switch mechanism within the protein is proposed through which the ratio of kinase to phosphatase is regulated. Finally, these results lend support to the notion that KdpD can be activated by two distinct stimuli, K+ limitation and osmolarity.	Univ Osnabruck, Fachbereich Biol Chem, Abt Mikrobiol, D-49069 Osnabruck, Germany	University Osnabruck	Jung, K (corresponding author), Univ Osnabruck, Fachbereich Biol Chem, Abt Mikrobiol, D-49069 Osnabruck, Germany.							ALTENDORF K, 1996, BIOMEMBR, V5, P403; ASHA H, 1993, J BACTERIOL, V175, P4528, DOI 10.1128/JB.175.14.4528-4537.1993; BenTal N, 1996, BIOPHYS J, V71, P561, DOI 10.1016/S0006-3495(96)79280-9; EPSTEIN W, 1992, ACTA PHYSIOL SCAND, V146, P193; Epstein W, 1970, J BACTERIOL, V101, P836, DOI 10.1128/JB.101.3.836-843.1970; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; Jung K, 1998, J BIOL CHEM, V273, P17406, DOI 10.1074/jbc.273.28.17406; Jung K, 1997, J BIOL CHEM, V272, P10847; Jung K, 1998, BBA-BIOMEMBRANES, V1372, P311, DOI 10.1016/S0005-2736(98)00070-4; KALMAN LV, 1990, J BACTERIOL, V172, P7049, DOI 10.1128/jb.172.12.7049-7056.1990; KOLLMANN R, 1993, BIOCHIM BIOPHYS ACTA, V1143, P62, DOI 10.1016/0005-2728(93)90216-3; Kondoh S, 1997, J BIOL CHEM, V272, P19333, DOI 10.1074/jbc.272.31.19333; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIMINS LA, 1981, P NATL ACAD SCI-BIOL, V78, P464, DOI 10.1073/pnas.78.1.464; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; MILLER JF, 1992, J BACTERIOL, V174, P970, DOI 10.1128/jb.174.3.970-979.1992; Miller JH., 1992, SHORT COURSE BACTERI, P72; NAKASHIMA K, 1993, MOL MICROBIOL, V7, P109, DOI 10.1111/j.1365-2958.1993.tb01102.x; Park H, 1997, J BACTERIOL, V179, P4382, DOI 10.1128/jb.179.13.4382-4390.1997; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POLAREK JW, 1992, J BACTERIOL, V174, P2145, DOI 10.1128/JB.174.7.2145-2151.1992; Puppe W, 1996, J BIOL CHEM, V271, P25027, DOI 10.1074/jbc.271.40.25027; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUGIURA A, 1992, MOL MICROBIOL, V6, P1769, DOI 10.1111/j.1365-2958.1992.tb01349.x; SUGIURA A, 1994, MOL MICROBIOL, V14, P929, DOI 10.1111/j.1365-2958.1994.tb01328.x; SUTHERLAND L, 1986, J BACTERIOL, V168, P805, DOI 10.1128/jb.168.2.805-814.1986; VOELKNER P, 1993, EUR J BIOCHEM, V217, P1019, DOI 10.1111/j.1432-1033.1993.tb18333.x; WALDERHAUG MO, 1992, J BACTERIOL, V174, P2152, DOI 10.1128/JB.174.7.2152-2159.1992; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZIMMANN P, 1995, J BIOL CHEM, V270, P28282	33	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26415	26420		10.1074/jbc.273.41.26415	http://dx.doi.org/10.1074/jbc.273.41.26415			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756874	hybrid			2022-12-27	WOS:000076373300028
J	Lind, T; Tufaro, F; McCormick, C; Lindahl, U; Lidholt, K				Lind, T; Tufaro, F; McCormick, C; Lindahl, U; Lidholt, K			The putative tumor suppressors EXT1 and EXT2 are glycosyltransferases required for the biosynthesis of heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY MULTIPLE EXOSTOSES; GENE; CELLS; GLUCURONOSYLTRANSFERASE; IDENTIFICATION; PROTEOGLYCANS; LOCALIZATION; CLONING; FAMILY	Hereditary multiple exostoses, characterized by multiple cartilaginous tumors, is ascribed to mutations at three distinct loci, denoted EXT1-3. Here, we report the purification of a protein from bovine serum that harbored the D-glucuronyl (GlcA) and N-acetyl-D-glucosaminyl (GlcNAc) transferase activities required for biosynthesis of the glycosaminoglycan, heparan sulfate (HS). This protein was identified as EXT2. Expression of EXT2 yielded a protein with both glycosyltransferase activities. Moreover, EXT1, previously found to rescue defective HS biosynthesis (McCormick, C., Leduc, Y., Martindale, D., Mattison, K., Esford, L. E., Dyer, A. P., and Tufaro, F. (1998) Nat. Genet. 19, 158-161), was shown to elevate the low GlcA and GlcNAc transferase levels of mutant cells. Thus at least two members of the EXT family of tumor suppressors encode glycosyltransferases involved in the chain elongation step of HS biosynthesis.	Uppsala Univ, Ctr Biomed, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden; Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada	Uppsala University; University of British Columbia	Lind, T (corresponding author), Uppsala Univ, Ctr Biomed, Dept Med Biochem & Microbiol, Box 575, S-75123 Uppsala, Sweden.	Thomas.Lind@medkem.uu.se	McCormick, Craig/AAH-9069-2019	McCormick, Craig/0000-0003-2794-3722; Lind, Thomas/0000-0003-2791-688X				AHN J, 1995, NAT GENET, V11, P137, DOI 10.1038/ng1095-137; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Cheung WF, 1996, BIOCHEMISTRY-US, V35, P5250, DOI 10.1021/bi952325b; COOK A, 1993, AM J HUM GENET, V53, P71; GRUENHEID S, 1993, J VIROL, V67, P93, DOI 10.1128/JVI.67.1.93-100.1993; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HENNEKAM RCM, 1991, J MED GENET, V28, P262, DOI 10.1136/jmg.28.4.262; Jayson GC, 1998, J BIOL CHEM, V273, P51, DOI 10.1074/jbc.273.1.51; LEMERRER M, 1994, HUM MOL GENET, V3, P717, DOI 10.1093/hmg/3.5.717; LEONE NC, 1987, J HERED, V78, P171, DOI 10.1093/oxfordjournals.jhered.a110351; LIDHOLT K, 1992, BIOCHEM J, V287, P21, DOI 10.1042/bj2870021; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; LIND T, 1993, J BIOL CHEM, V268, P20705; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; NAKANISHI H, 1992, BIOCHEM J, V288, P215, DOI 10.1042/bj2880215; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PEJLER G, 1987, BIOCHEM J, V248, P69, DOI 10.1042/bj2480069; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Safaiyan F, 1998, EUR J BIOCHEM, V252, P576, DOI 10.1046/j.1432-1327.1998.2520576.x; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SCHMALE GA, 1994, J BONE JOINT SURG AM, V76A, P986, DOI 10.2106/00004623-199407000-00005; SOLOMON L, 1963, J BONE JOINT SURG BR, V45, P292, DOI 10.1302/0301-620X.45B2.292; Stickens D, 1996, NAT GENET, V14, P25, DOI 10.1038/ng0996-25; UhlinHansen L, 1997, J BIOL CHEM, V272, P3200, DOI 10.1074/jbc.272.6.3200; Van Hul W, 1998, GENOMICS, V47, P230, DOI 10.1006/geno.1997.5101; VLODAVSKY I, 1994, INVAS METAST, V14, P290; WICKLUND CL, 1995, AM J MED GENET, V55, P43, DOI 10.1002/ajmg.1320550113; WINTERBOURNE DJ, 1981, J BIOL CHEM, V256, P4310; Wise CA, 1997, GENOME RES, V7, P10, DOI 10.1101/gr.7.1.10; WU YQ, 1994, HUM MOL GENET, V3, P167, DOI 10.1093/hmg/3.1.167; Wuyts W, 1997, EUR J HUM GENET, V5, P382, DOI 10.1159/000484796; Wuyts W, 1996, HUM MOL GENET, V5, P1547, DOI 10.1093/hmg/5.10.1547	35	335	349	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26265	26268		10.1074/jbc.273.41.26265	http://dx.doi.org/10.1074/jbc.273.41.26265			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756849	hybrid			2022-12-27	WOS:000076373300003
J	Osherov, N; Yamashita, RA; Chung, YS; May, GS				Osherov, N; Yamashita, RA; Chung, YS; May, GS			Structural requirements for in vivo myosin I function in Aspergillus nidulans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCONVENTIONAL MYOSINS; YEAST; MITOSIS; ENDOCYTOSIS; PROTEINS; BINDING; DOMAIN; MODEL; GENES; ACTS	We have investigated the minimal requirements of the tail region for myosin I function in vivo using the filamentous fungus Aspergillus nidulans. The CL3 strain (McGoldrick, C. A., Gruver, C., and May, G. S. (1995) J. Cell Biol. 128, 577-587) was transformed with a variety of myoA constructs containing mutations in the IQ, TH-1-like, SH3, and proline-rich domains by frameshift or in-frame deletions of the tail domains. The resulting strains contained wild type myoA driven by the alcA promoter and a mutant myoA driven by its endogenous promoter. This strategy allowed for selective expression of the wild type and/or mutant form of MYOA by the choice of growth medium. Proper septation and hyphal branching were found to be dependent on the interaction of the IQ motifs with calmodulin, as well as, the presence of its proline-rich domain, Additionally, a single proline-rich motif was sufficient for nearly wild type MYOA function. Most surprisingly, the SH3 domain was not essential for MYOA function. These studies expand our previous knowledge of the function of MYOA to include roles in hyphal morphogenesis, septal wall formation, and cell polarity, laying the groundwork for more detailed investigations on the function of the various tail domains in MYOA.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine	May, GS (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	gsmay@bcm.tmc.edu						BAINES IC, 1995, J CELL BIOL, V130, P591, DOI 10.1083/jcb.130.3.591; Brown SS, 1997, CURR OPIN CELL BIOL, V9, P44, DOI 10.1016/S0955-0674(97)80150-0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FIDDY C, 1976, J GEN MICROBIOL, V97, P169, DOI 10.1099/00221287-97-2-169; Geli MI, 1996, SCIENCE, V272, P533, DOI 10.1126/science.272.5261.533; Goodson HV, 1996, J CELL BIOL, V133, P1277, DOI 10.1083/jcb.133.6.1277; HASSON T, 1995, CURR OPIN CELL BIOL, V7, P587, DOI 10.1016/0955-0674(95)80017-4; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Houdusse A, 1996, STRUCTURE, V4, P1475, DOI 10.1016/S0969-2126(96)00154-2; Kalabokis VN, 1996, J BIOL CHEM, V271, P26779, DOI 10.1074/jbc.271.43.26779; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAY GS, 1985, J CELL BIOL, V101, P712, DOI 10.1083/jcb.101.3.712; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; MCGOLDRICK CA, 1995, J CELL BIOL, V128, P577, DOI 10.1083/jcb.128.4.577; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; MIRABITO PM, 1993, J CELL BIOL, V120, P959, DOI 10.1083/jcb.120.4.959; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; NOVAK KD, 1995, J CELL BIOL, V131, P1205, DOI 10.1083/jcb.131.5.1205; OSMANI SA, 1987, J CELL BIOL, V104, P1495, DOI 10.1083/jcb.104.6.1495; PONTECORVO G, 1953, ADV GENET, V5, P141, DOI 10.1016/S0065-2660(08)60408-3; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; WARING RB, 1989, GENE, V79, P119, DOI 10.1016/0378-1119(89)90097-8; Wolkow TD, 1996, J CELL SCI, V109, P2179; Yamashita RA, 1998, J BIOL CHEM, V273, P14644, DOI 10.1074/jbc.273.23.14644	27	27	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					27017	27025		10.1074/jbc.273.41.27017	http://dx.doi.org/10.1074/jbc.273.41.27017			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756952	hybrid			2022-12-27	WOS:000076373300106
J	Pascuzzi, P; Hamilton, D; Bodily, K; Arias, J				Pascuzzi, P; Hamilton, D; Bodily, K; Arias, J			Auxin-induced stress potentiates trans-activation by a conserved plant basic/leucine-zipper factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; TISSUE-SPECIFIC EXPRESSION; DEFENSE GENE PROMOTER; DNA-BINDING; ARABIDOPSIS-THALIANA; SALICYLIC-ACID; OCS-ELEMENT; TRANSCRIPTION FACTORS; NUCLEAR FACTOR; TOBACCO	The promoter element activation sequence-1 (as-1) confers tissue-specific and signal-responsive transcription in plants. Hormone and chemical stress cues are thought to activate as-1-dependent transcription through specific basic/leucine-zipper proteins, termed TGA factors, that bind this element. We report here that a highly conserved TGA factor of tobacco, TGA1a, can selectively activate transcription in response to micromolar concentrations of auxin hormones or their analogs. This induction is chemically specific, as a range of other compounds tested at similar concentrations had little or no effect. Auxin was found to augment the transactivation potential of TGA1a through carboxyl-terminal residues. The amino-terminal domain of TGA1a, by gain-of-function assays, was found to both constitutively activate transcription and maximize the response to auxin, Further evidence indicates that the trans-activation potential of this domain in TGA1a is repressed, under basal conditions, by carboxyl-terminal residues. Because TGA1a and endogenous TGA factors are stimulated by auxin only at concentrations that inhibited cell growth, this response is likely to involve chemical stress.	Univ Maryland, Ctr Agr Biotechnol, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park	Arias, J (corresponding author), Univ Maryland, Ctr Agr Biotechnol, 5115 Plant Sci Bldg, College Pk, MD 20742 USA.		Pascuzzi, Pete/T-5378-2019; Hamilton, D/AAA-4616-2020	Pascuzzi, Pete/0000-0002-9316-4404				Abel S, 1996, PLANT PHYSIOL, V111, P9, DOI 10.1104/pp.111.1.9; AN GH, 1990, PLANT CELL, V2, P225, DOI 10.1105/tpc.2.3.225; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; ARIAS JA, 1993, PLANT CELL, V5, P485, DOI 10.1105/tpc.5.4.485; BENFEY PN, 1990, EMBO J, V9, P1677, DOI 10.1002/j.1460-2075.1990.tb08291.x; BILANG J, 1993, PLANT PHYSIOL, V102, P29, DOI 10.1104/pp.102.1.29; BOUCHEZ D, 1989, EMBO J, V8, P4197, DOI 10.1002/j.1460-2075.1989.tb08605.x; Chen WQ, 1996, PLANT J, V10, P955, DOI 10.1046/j.1365-313X.1996.10060955.x; DANIEL V, 1993, CRIT REV BIOCHEM MOL, V28, P173, DOI 10.3109/10409239309086794; DRON M, 1988, P NATL ACAD SCI USA, V85, P6738, DOI 10.1073/pnas.85.18.6738; Droog F, 1995, PLANT MOL BIOL, V29, P413, DOI 10.1007/BF00020974; Droog F, 1997, J PLANT GROWTH REGUL, V16, P95, DOI 10.1007/PL00006984; FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GUILFOYLE TJ, 1993, AUST J PLANT PHYSIOL, V20, P489, DOI 10.1071/PP9930489; Harlow E., 1988, ANTIBODIES LAB MANUA; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KATAGIRI F, 1992, MOL CELL BIOL, V12, P4809, DOI 10.1128/MCB.12.11.4809; KATAGIRI F, 1989, NATURE, V340, P727, DOI 10.1038/340727a0; KIM YH, 1994, PLANT MOL BIOL, V24, P105, DOI 10.1007/BF00040578; LAM E, 1995, NUCLEIC ACIDS RES, V23, P3778, DOI 10.1093/nar/23.18.3778; LAM E, 1989, P NATL ACAD SCI USA, V86, P7890, DOI 10.1073/pnas.86.20.7890; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; LIU XJ, 1994, J BIOL CHEM, V269, P668; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; MA J, 1988, NATURE, V334, P631, DOI 10.1038/334631a0; MEHDY MC, 1994, PLANT PHYSIOL, V105, P467, DOI 10.1104/pp.105.2.467; MIAO ZH, 1995, PLANT J, V7, P887, DOI 10.1046/j.1365-313X.1995.07060887.x; MIAO ZH, 1995, PLANT J, V7, P359, DOI 10.1046/j.1365-313X.1995.7020359.x; NEUHAUS G, 1994, PLANT CELL, V6, P827, DOI 10.1105/tpc.6.6.827; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; PRESTERA T, 1993, ADV ENZYME REGUL, V33, P281; RIEPING M, 1994, PLANT CELL, V6, P1087, DOI 10.1105/tpc.6.8.1087; SCHINDLER U, 1992, PLANT CELL, V4, P1309, DOI 10.1105/tpc.4.10.1309; TAKAHASHI Y, 1990, P NATL ACAD SCI USA, V87, P8013, DOI 10.1073/pnas.87.20.8013; ULMASOV T, 1994, PLANT MOL BIOL, V26, P1055, DOI 10.1007/BF00040688; vanderKop DAM, 1996, PLANT MOL BIOL, V30, P839, DOI 10.1007/BF00019016; vanderZaal BJ, 1996, PLANT PHYSIOL, V110, P79, DOI 10.1104/pp.110.1.79; WATANABE Y, 1986, VIROLOGY, V152, P414, DOI 10.1016/0042-6822(86)90143-1; Xiang CB, 1996, PLANT MOL BIOL, V32, P415, DOI 10.1007/BF00019093; YAMAZAKI K, 1990, P NATL ACAD SCI USA, V87, P7035, DOI 10.1073/pnas.87.18.7035; ZETTL R, 1994, P NATL ACAD SCI USA, V91, P689, DOI 10.1073/pnas.91.2.689; ZHANG B, 1994, P NATL ACAD SCI USA, V91, P2507, DOI 10.1073/pnas.91.7.2507	47	35	36	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26631	26637		10.1074/jbc.273.41.26631	http://dx.doi.org/10.1074/jbc.273.41.26631			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756903	hybrid			2022-12-27	WOS:000076373300057
J	Rayner, JC; Munro, S				Rayner, JC; Munro, S			Identification of the MNN2 and MNN5 mannosyltransferases required for forming and extending the mannose branches of the outer chain mannans of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II MEMBRANE-PROTEIN; GLYCOPROTEIN-BIOSYNTHESIS; GENETIC-CONTROL; MPK1-MEDIATED PATHWAYS; CHEMICAL-STRUCTURE; GOLGI COMPARTMENT; CANDIDA-ALBICANS; N-GLYCOSYLATION; YEAST; MUTANTS	The mannan structure found on the N-linked glycans of the yeast Saccharomyces cerevisiae is composed of a long backbone of alpha-1,6-linked mannose to which are attached branches consisting of two alpha-1,2-linked mannoses followed by an alpha-1,3-linked mannose. In the mutants mnn2 and mnn5, the addition of the first and second of these two mannoses, respectively, is defective. in this paper, we report the identification of the genes corresponding to these mutations. The two genes encode closely related proteins with distant homology to the known Mnn1p alpha-1,3-mannosyltransferase. We show that these proteins are localized in an early compartment of the yeast Golgi and that they are not physically associated with each other or with the two protein complexes known to be involved in synthesizing the alpha-1,6-linked backbone. The identification of Mnn2p and Mmnn5p allows us to assign Golgi proteins to all of the catalytic steps in S. cerevisiae mannan synthesis.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Munro, S (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.			Rayner, Julian/0000-0002-9835-1014; Munro, Sean/0000-0001-6160-5773				BALLOU CE, 1990, METHOD ENZYMOL, V185, P440; BALLOU CE, 1973, J BIOL CHEM, V248, P4667; BALLOU DL, 1975, J BACTERIOL, V123, P616, DOI 10.1128/JB.123.2.616-619.1975; BALLOU L, 1995, P NATL ACAD SCI USA, V92, P2790, DOI 10.1073/pnas.92.7.2790; BALLOU L, 1990, P NATL ACAD SCI USA, V87, P3368, DOI 10.1073/pnas.87.9.3368; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Calderone Richard A., 1993, Trends in Microbiology, V1, P55, DOI 10.1016/0966-842X(93)90033-N; COHEN RE, 1980, J BIOL CHEM, V255, P7700; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; Dean N, 1996, GLYCOBIOLOGY, V6, P73, DOI 10.1093/glycob/6.1.73; ESMON B, 1984, J BIOL CHEM, V259, P322; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; Guthrie C, 1991, GUIDE YEAST GENETICS; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; Harris SL, 1996, J CELL BIOL, V132, P985, DOI 10.1083/jcb.132.6.985; HAUSLER A, 1992, P NATL ACAD SCI USA, V89, P6846, DOI 10.1073/pnas.89.15.6846; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; Igual JC, 1996, EMBO J, V15, P5001, DOI 10.1002/j.1460-2075.1996.tb00880.x; Iwahara S, 1996, BIOSCI BIOTECH BIOCH, V60, P957, DOI 10.1271/bbb.60.957; JIMENEZBARBERO J, 1995, CARBOHYD RES, V272, P121, DOI 10.1016/0008-6215(95)00023-M; Jungmann J, 1998, EMBO J, V17, P423, DOI 10.1093/emboj/17.2.423; KLIS FM, 1994, YEAST, V10, P851, DOI 10.1002/yea.320100702; LEHLE L, 1995, FEBS LETT, V370, P41, DOI 10.1016/0014-5793(95)00789-C; Lussier M, 1997, YEAST, V13, P267, DOI 10.1002/(SICI)1097-0061(19970315)13:3<267::AID-YEA72>3.0.CO;2-K; Lussier M, 1997, J BIOL CHEM, V272, P15527, DOI 10.1074/jbc.272.24.15527; LUSSIER M, 1995, J CELL BIOL, V131, P913, DOI 10.1083/jcb.131.4.913; Manas P, 1997, GLYCOBIOLOGY, V7, P487, DOI 10.1093/glycob/7.4.487; Mondesert G, 1997, GENETICS, V147, P421; Munro S, 1998, TRENDS CELL BIOL, V8, P11, DOI 10.1016/S0962-8924(97)01197-5; NAGASU T, 1992, YEAST, V8, P535, DOI 10.1002/yea.320080705; NAKAJIMA T, 1994, J FERMENT BIOENG, V78, P472, DOI 10.1016/0922-338X(94)90050-7; NAKAJIMA T, 1975, P NATL ACAD SCI USA, V72, P3912, DOI 10.1073/pnas.72.10.3912; Nakamura T, 1997, MOL GEN GENET, V256, P481, DOI 10.1007/s004380050592; Nakamura T, 1996, MOL GEN GENET, V251, P211; NAKAYAMA K, 1992, EMBO J, V11, P2511, DOI 10.1002/j.1460-2075.1992.tb05316.x; Neiman AM, 1997, GENETICS, V145, P637; NILSSON B, 1987, PROTEIN ENG, V1, P107, DOI 10.1093/protein/1.2.107; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; Orlean P., 1997, MOL CELLULAR BIOL YE, V21, P229; PARKS TD, 1994, ANAL BIOCHEM, V216, P413, DOI 10.1006/abio.1994.1060; PEAT S, 1961, J CHEM SOC, P3918, DOI 10.1039/jr9610003918; Ram AFJ, 1998, J BACTERIOL, V180, P1418, DOI 10.1128/JB.180.6.1418-1424.1998; RASCHKE WC, 1973, J BIOL CHEM, V248, P4660; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROEMER T, 1994, J CELL BIOL, V127, P567, DOI 10.1083/jcb.127.2.567; ROMERO PA, 1994, YEAST, V10, P1111, DOI 10.1002/yea.320100813; Schwappach B, 1998, J BIOL CHEM, V273, P15110, DOI 10.1074/jbc.273.24.15110; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; SHIBATA N, 1995, J BIOL CHEM, V270, P1113, DOI 10.1074/jbc.270.3.1113; SIPOS G, 1995, J BIOL CHEM, V270, P19709, DOI 10.1074/jbc.270.34.19709; STRATFORD M, 1992, YEAST, V8, P635, DOI 10.1002/yea.320080807; STRAVER MH, 1993, TRENDS BIOTECHNOL, V11, P228, DOI 10.1016/0167-7799(93)90133-T; TRIMBLE RB, 1986, J BIOL CHEM, V261, P9815; VEROSTEK MF, 1995, GLYCOBIOLOGY, V5, P671, DOI 10.1093/glycob/5.7.671; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; Wang XH, 1997, J BIOL CHEM, V272, P18117, DOI 10.1074/jbc.272.29.18117; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; YIP CL, 1994, P NATL ACAD SCI USA, V91, P2723, DOI 10.1073/pnas.91.7.2723	58	97	102	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26836	26843		10.1074/jbc.273.41.26836	http://dx.doi.org/10.1074/jbc.273.41.26836			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756928	hybrid			2022-12-27	WOS:000076373300082
J	Rimon, A; Gerchman, Y; Kariv, Z; Padan, E				Rimon, A; Gerchman, Y; Kariv, Z; Padan, E			A point mutation (G338S) and its suppressor mutations affect both the pH response of the NhaA-Na+/H+ antiporter as well as the growth phenotype of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; EXPRESSION; ANT; HISTIDINE-226; SENSITIVITY; INCREASES; RESIDUES; CELLS; LYSR	pH controls the activity of the NhaA Na+/H+ antiporter of Escherichia coli. In the present work we show that replacement of glycine 338 of NhaA with serine (G338S) alleviates the pH control of the antiporter. Monitoring Na+-dependent collapse of Delta pH, to assess antiporter activity in isolated membrane vesicles, shows that the mutant protein is practically independent of pH, between pH 7 and 9, and even at pH 6 is 70% active. Similarly the purified reconstituted mutant protein catalyzes pH-independent passive efflux of Na-22 from proteoliposomes as well as Delta pH-driven influx. Whereas the native NhaA in isolated membrane vesicles is exposed to digestion by trypsin only above pH 7, the mutated protein is degraded already at pH 6.5. Delta nhaA Delta nhaB cells transformed with a plasmid encoding the pH-independent antiporter are sensitive to Na+ but not to K+ at alkaline pH, while growing in the presence of both ions at neutral pH. Several possibilities that could explain the Na+ sensitivity of the mutant at alkaline pH were excluded; Western analysis and measurement of Na+/H+ antiporter activity in membrane vesicles, isolated from cells shifted to the non-permissive growth conditions, showed neither reduced expression of G338S-NhaA nor defective activity. The finding that the mutated protein is electrogenic led to the retraction of the idea that the protein is active in vitro but not in vivo at alkaline pH, when only Delta psi exists in the cells. The Na+ concentration needed for half-maximal activity of G338S in isolated everted membrane vesicles is similar to that of the wild type. Therefore an increase in intracellular Na+ due to a reduced antiporter affinity could not explain the results. It is suggested that the loss of growth. at alkaline pH in the presence of Na+ is due to the loss of the pH control of the mutated NhaA, Indeed, in the four mutations suppressing G338S phenotype, growth at alkaline pH was restored together with the pH regulation of NhaA, Three of the four suppressor mutations cluster in helix IV,whereas the original mutation is in helix XI, suggesting that the two helixes interact.	Hebrew Univ Jerusalem, Div Microbial & Mol Ecol, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Padan, E (corresponding author), Hebrew Univ Jerusalem, Div Microbial & Mol Ecol, IL-91904 Jerusalem, Israel.		Gerchman, Yoram/F-5226-2015; Gerchman, Yoram/H-4698-2019	Gerchman, Yoram/0000-0002-8637-9589; 				CARMEL O, 1994, EMBO J, V13, P1981, DOI 10.1002/j.1460-2075.1994.tb06467.x; Carmel O, 1997, EMBO J, V16, P5922, DOI 10.1093/emboj/16.19.5922; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; GERCHMAN Y, 1993, P NATL ACAD SCI USA, V90, P1212, DOI 10.1073/pnas.90.4.1212; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; HARELBRONSTEIN M, 1994, J BIOL CHEM, V269, P3816; INOUE H, 1995, FEBS LETT, V363, P264, DOI 10.1016/0014-5793(95)00331-3; KARPEL R, 1988, J BIOL CHEM, V263, P10408; KARPEL R, 1991, J BIOL CHEM, V266, P21753; Noumi T, 1997, J BIOCHEM-TOKYO, V121, P661; Olami Y, 1997, J BIOL CHEM, V272, P1761, DOI 10.1074/jbc.272.3.1761; PADAN E, 1993, J BIOENERG BIOMEMBR, V25, P647; PADAN E, 1989, J BIOL CHEM, V264, P20297; PADAN E, 1994, BBA-BIOENERGETICS, V1185, P129, DOI 10.1016/0005-2728(94)90204-6; PADAN E, 1976, EUR J BIOCHEM, V63, P533, DOI 10.1111/j.1432-1033.1976.tb10257.x; PADAN E, 1992, ALKALI CATION TRANSP, P3; PADAN E, 1998, MICROBIOLOGY BIOCH H; PINNER E, 1992, J BIOL CHEM, V267, P11064; PINNER E, 1993, J BIOL CHEM, V268, P1729; PINNER E, 1994, J BIOL CHEM, V269, P26274; RAHAVMANOR O, 1992, J BIOL CHEM, V267, P10433; RIMON A, 1995, J BIOL CHEM, V270, P26813, DOI 10.1074/jbc.270.45.26813; ROSEN BP, 1986, METHOD ENZYMOL, V125, P328; Rothman A, 1996, J BIOL CHEM, V271, P32288, DOI 10.1074/jbc.271.50.32288; ROTHMAN A, 1997, BIOCHEMISTRY-US, V36, P14577; SCHULDINER S, 1978, BIOCHEMISTRY-US, V17, P706, DOI 10.1021/bi00597a023; Schuldiner S., 1992, ALKALI CATION TRANSP, P25; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; TAGLICHT D, 1993, J BIOL CHEM, V268, P5382; TOKUDA H, 1982, J BIOL CHEM, V257, P7; Zor T, 1996, ANAL BIOCHEM, V236, P302, DOI 10.1006/abio.1996.0171	32	63	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26470	26476		10.1074/jbc.273.41.26470	http://dx.doi.org/10.1074/jbc.273.41.26470			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756882	hybrid			2022-12-27	WOS:000076373300036
J	Stitt, BL; Xu, YM				Stitt, BL; Xu, YM			Sequential hydrolysis of ATP molecules bound in interacting catalytic sites of Escherichia coli transcription termination protein Rho	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; RNA-DNA HELICASE; PHYSICAL-PROPERTIES; PARTITION ANALYSIS; BINDING DOMAINS; POLYMERASE; F1-ATPASE; HEXAMER; PROCESSIVITY; COFACTORS	Escherichia coli transcription termination protein Rho, an RNA-dependent ATPase, disrupts transcription complexes, releasing RNA and allowing RNA polymerase to recycle. Homohexameric Rho binds three molecules of MgATP in a single class of catalytically competent sites. In rapid mix chemical quench experiments, when Rho saturated with ATP was mixed with RNA and the reaction was quenched after various times, hydrolysis of the three bound ATP molecules was not simultaneous. A hydrolysis burst of one molecule of ATP per hexamer occurred at >300 s(-1), followed by steady-state hydrolysis at 30 s(-1) per hexamer, The burst also shows that a step following ATP hydrolysis is rate-limiting for overall catalysis and requires communication among the three catalytic sites during net ATP hydrolysis. The rate of hydrolysis of radiolabeled ATP when one labeled and two unlabeled ATP molecules are bound indicates a sequential pattern of hydrolysis. Positive cooperativity of catalysis occurs among the catalytic sites of Rho; when only one ATP molecule is bound per hexamer, ATP hydrolysis upon addition of RNA is 30-fold slower than when ATP is saturating. These behaviors are comparable to those of F-1-type ATPases, with which Rho shares a number of structural features.	Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Stitt, BL (corresponding author), Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA.							ALIFANO P, 1991, CELL, V64, P553; BEAR DG, 1988, J MOL BIOL, V199, P623, DOI 10.1016/0022-2836(88)90306-3; BEAR DG, 1985, P NATL ACAD SCI USA, V82, P1911, DOI 10.1073/pnas.82.7.1911; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; CLELAND WW, 1975, BIOCHEMISTRY-US, V14, P3220, DOI 10.1021/bi00685a029; DOLAN JW, 1990, J BIOL CHEM, V265, P5747; DOMBROSKI AJ, 1988, P NATL ACAD SCI USA, V85, P2538, DOI 10.1073/pnas.85.8.2538; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; FAUS I, 1990, J MOL BIOL, V212, P53, DOI 10.1016/0022-2836(90)90304-5; GALLUPPI GR, 1980, J MOL BIOL, V138, P513, DOI 10.1016/S0022-2836(80)80016-7; GEISELMANN J, 1993, P NATL ACAD SCI USA, V90, P7754, DOI 10.1073/pnas.90.16.7754; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P121, DOI 10.1021/bi00116a018; GEISELMANN J, 1992, PROTEIN SCI, V1, P861, DOI 10.1002/pro.5560010704; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P111, DOI 10.1021/bi00116a017; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; GOGOL EP, 1991, J MOL BIOL, V221, P1127, DOI 10.1016/0022-2836(91)80116-C; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3728; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; HINGORANI MM, 1993, BIOCHEMISTRY-US, V32, P12478, DOI 10.1021/bi00097a028; Hingorani MM, 1997, P NATL ACAD SCI USA, V94, P5012, DOI 10.1073/pnas.94.10.5012; HIRATSUKA T, 1973, BIOCHIM BIOPHYS ACTA, V320, P635, DOI 10.1016/0304-4165(73)90143-8; Horiguchi T, 1997, J MOL BIOL, V269, P514, DOI 10.1006/jmbi.1997.1059; JOHNSON KA, 1995, METHOD ENZYMOL, V249, P38; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; LADINE JR, 1988, J CELL BIOL, V107, P854; Landick R, 1997, CELL, V88, P741, DOI 10.1016/S0092-8674(00)81919-4; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; LOWERYGO.C, 1974, P NATL ACAD SCI USA, V71, P2003, DOI 10.1073/pnas.71.5.2003; MCSWIGGEN JA, 1988, J MOL BIOL, V199, P609, DOI 10.1016/0022-2836(88)90305-1; MIWA Y, 1995, J MOL BIOL, V254, P815, DOI 10.1006/jmbi.1995.0658; MOTT JE, 1985, P NATL ACAD SCI USA, V82, P88, DOI 10.1073/pnas.82.1.88; NEHRKE KW, 1992, NUCLEIC ACIDS RES, V20, P6107, DOI 10.1093/nar/20.22.6107; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; O IS, 1994, J BIOL CHEM, V269, P5009; ODA T, 1972, J MOL BIOL, V71, P799; OPPERMAN T, 1994, J BACTERIOL, V176, P5033, DOI 10.1128/jb.176.16.5033-5043.1994; PLATT T, 1992, TRANSCRIPTIONAL REGU, P365; Richardson J. P., 1996, ESCHERICHIA COLI SAL, P822; RICHARDSON JP, 1982, J BIOL CHEM, V257, P5760; Richardson JP, 1996, J BIOL CHEM, V271, P1251, DOI 10.1074/jbc.271.3.1251; Rose I A, 1980, Methods Enzymol, V64, P47; ROSE IA, 1995, METHOD ENZYMOL, V249, P315; SEIFRIED SE, 1991, J MOL BIOL, V221, P1139; STEINMETZ EJ, 1994, P NATL ACAD SCI USA, V91, P1401, DOI 10.1073/pnas.91.4.1401; STITT BL, 1988, J BIOL CHEM, V263, P11130; STITT BL, 1986, J BIOL CHEM, V261, P5906; Walstrom KM, 1997, BIOCHEMISTRY-US, V36, P7993, DOI 10.1021/bi963180r; WANG Y, 1993, J BIOL CHEM, V268, P13947; Washburn RS, 1996, J MOL BIOL, V260, P332, DOI 10.1006/jmbi.1996.0404; WASHBURN RS, 1997, THESIS TEMPLE U; WEBB MR, 1982, METHOD ENZYMOL, V87, P301; Yu X, 1996, NAT STRUCT BIOL, V3, P740, DOI 10.1038/nsb0996-740	56	46	46	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26477	26486		10.1074/jbc.273.41.26477	http://dx.doi.org/10.1074/jbc.273.41.26477			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756883	hybrid			2022-12-27	WOS:000076373300037
J	Becker, W; Weber, Y; Wetzel, K; Eirmbter, K; Tejedor, FJ; Joost, HG				Becker, W; Weber, Y; Wetzel, K; Eirmbter, K; Tejedor, FJ; Joost, HG			Sequence characteristics, subcellular localization, and substrate specificity of DYRK-related kinases, a novel family of dual specificity protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME CRITICAL REGION; DOWN-SYNDROME; HUMAN HOMOLOG; SACCHAROMYCES-CEREVISIAE; NUCLEAR-LOCALIZATION; TYROSINE RESIDUES; DROSOPHILA; IDENTIFICATION; CHROMOSOME-21; GENE	DYRK1 is a dual specificity protein kinase presumably involved in brain development. Here we show that the kinase belongs to a new family of protein kinases comprising at least seven mammalian isoforms (DYRK1A, DYRK1B, DYRK1C, DYRK2, DYRK3, DYRK4A, and DYRK4B), the yeast homolog Yak1p, and the Drosophila kinase minibrain (MNB). In rat tissues, DYRK1A is expressed ubiquitously, whereas transcripts for DYRK1B, DYRK2, DYRK3, and DYRK4 were detected predominantly in testes of adult but not prepuberal rats. By fluorescence microscopy and subcellular fractionation, a green fluorescent protein (GFP) fusion protein of DYRK1A was found to accumulate in the nucleus of transfected COS-7 and HEK293 cells, whereas GFP-DYRK2 was predominantly detected in the cytoplasm. DYRK1A exhibited a punctate pattern of GFP fluorescence inside the nucleus and was co-purified with the nuclear matrix. Analysis of GFP-DYRK1A deletion constructs showed that the nuclear localization of DYRK1A was mediated by its nuclear targeting signal (amino acids 105-139) but that its characteristic subnuclear distribution depended on additional N-terminal elements (amino acids 1-104). When expressed in Escherichia coli, DYRK1A DYRK2, DYRK3, MNB, and Yak1p catalyzed their autophosphorylation on tyrosine residues. The kinases differed in their substrate specificity in that DYRK2 and DYRK3, but not DYRK1A and MNB, catalyzed phosphorylation of histone H2B, The heterogeneity of their subcellular localization and substrate specificity suggests that the kinases are involved in different cellular functions.	Rhein Westfal TH Aachen, Fak Med, Inst Pharmakol & Toxikol, D-52057 Aachen, Germany; Univ Miguel Hernandez, Inst Neurosci, Alicante 03550, Spain; CSIC, Inst Cajal, Alicante 03550, Spain	RWTH Aachen University; Universidad Miguel Hernandez de Elche; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC)	Becker, W (corresponding author), Rhein Westfal TH Aachen, Fak Med, Inst Pharmakol & Toxikol, Wendlingweg 2, D-52057 Aachen, Germany.		Becker, Walter/B-8889-2008; Joost, Hans-Georg/J-4462-2013	Becker, Walter/0000-0002-0347-4768; Joost, Hans-Georg/0000-0002-5860-606X; Tejedor, Francisco J/0000-0003-1942-2580				Banfi S, 1996, NAT GENET, V13, P167, DOI 10.1038/ng0696-167; Begley DA, 1997, GENE, V200, P35, DOI 10.1016/S0378-1119(97)00350-8; BEREZNEY R, 1975, SCIENCE, V189, P291, DOI 10.1126/science.1145202; BEREZNEY R, 1974, BIOCHEM BIOPH RES CO, V60, P1410, DOI 10.1016/0006-291X(74)90355-6; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; Chen HM, 1997, HUM GENET, V99, P262, DOI 10.1007/s004390050350; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Delabar Jean-Maurice, 1993, European Journal of Human Genetics, V1, P114; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISCHBACH KF, 1984, J EXP BIOL, V112, P65; GARRETT S, 1989, GENE DEV, V3, P1336, DOI 10.1101/gad.3.9.1336; GARRETT S, 1991, MOL CELL BIOL, V11, P4045, DOI 10.1128/MCB.11.8.4045; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Guimera J, 1996, HUM MOL GENET, V5, P1305, DOI 10.1093/hmg/5.9.1305; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HAZEL TG, 1991, MOL CELL BIOL, V11, P3239, DOI 10.1128/MCB.11.6.3239; HOULGATTE R, 1995, GENOME RES, V5, P272, DOI 10.1101/gr.5.3.272; Kentrup H, 1996, J BIOL CHEM, V271, P3488; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; MCCORMICK MK, 1989, GENOMICS, V5, P325, DOI 10.1016/0888-7543(89)90065-7; Nickerson JA, 1995, INT REV CYTOL, V162A, P67; Ohira M, 1997, GENOME RES, V7, P47, DOI 10.1101/gr.7.1.47; Pennisi E, 1996, SCIENCE, V274, P2008; PINES J, 1995, TRENDS GENET, V11, P326, DOI 10.1016/S0168-9525(00)89092-7; RAHMANI Z, 1989, P NATL ACAD SCI USA, V86, P5958, DOI 10.1073/pnas.86.15.5958; SANDER A, 1995, AM J HUM GENET, V56, P310; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Shields JM, 1997, J BIOL CHEM, V272, P18504, DOI 10.1074/jbc.272.29.18504; Shindoh N, 1996, BIOCHEM BIOPH RES CO, V225, P92, DOI 10.1006/bbrc.1996.1135; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; Smith DJ, 1997, NAT GENET, V16, P28, DOI 10.1038/ng0597-28; Song WJ, 1997, BIOCHEM BIOPH RES CO, V231, P640, DOI 10.1006/bbrc.1997.6154; Song WJ, 1996, GENOMICS, V38, P331, DOI 10.1006/geno.1996.0636; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; TEJEDOR F, 1995, NEURON, V14, P287, DOI 10.1016/0896-6273(95)90286-4; WADA K, 1991, NUCLEIC ACIDS RES, V19, P1981, DOI 10.1093/nar/19.suppl.1981; WANDEL S, 1994, FEBS LETT, V348, P114, DOI 10.1016/0014-5793(94)00558-3	39	227	242	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25893	25902		10.1074/jbc.273.40.25893	http://dx.doi.org/10.1074/jbc.273.40.25893			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748265	hybrid			2022-12-27	WOS:000076263100056
J	Cook, T; Gebelein, B; Mesa, K; Mladek, A; Urrutia, R				Cook, T; Gebelein, B; Mesa, K; Mladek, A; Urrutia, R			Molecular cloning and characterization of TIEG2 reveals a new subfamily of transforming growth factor-beta-inducible Sp1-like zinc finger-encoding genes involved in the regulation of cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SP1; BOX-BINDING PROTEIN; RICH ACTIVATION DOMAINS; KRUPPEL-LIKE FACTOR; PROMOTER REGION; RECEPTOR GENE; TGF-BETA; CYCLE REGULATION; MULTIGENE FAMILY; GC BOXES	Sp1-like zinc finger transcription factors are involved in the regulation of cell growth and differentiation. Recent evidence demonstrating that mammalian cells express novel, yet uncharacterized, Sp1-like proteins has stimulated a search for new members of this family. We and others have recently reported that the transforming growth factor (TGF)-beta-regulated gene TIEG encodes a new Sp1-like protein that inhibits cell growth in cultured cells. Here we report the identification, nuclear localization, DNA binding activity, transcriptional repression activity, and growth inhibitory effects of TIEG2, a novel TGF-beta-inducible gene related to TIEG. TIEG2 is ubiquitously expressed in human tissues, with an enrichment in pancreas and muscle. TIEG2 shares 91% homology with TIEG1 within the zinc finger region and 44% homology within the N terminus. Biochemical characterization reveals that TIEG2 is a nuclear protein, which, as predicted from the primary structure, specifically binds to an Sp1-like DNA sequence in vitro and can repress a promoter containing Sp1-Like binding sites in transfected Chinese hamster ovary epithelial cells. Furthermore, functional studies using [H-3]thymidine uptake and MTS (3-(4,3-dimethyltiazol-2 yl)-5-(3-carboxymethoxyphenyl)-2- (4-sulfophenyl) -2H-tetrazolium) assays demonstrate that the overexpression of TIEG2 in Chinese hamster ovary cells inhibits cell proliferation. Thus, TIEG2, together with TIEG1, defines a new subfamily of TGF-beta-inducible Sp1-Like proteins involved in the regulation of cell growth.	Mayo Clin & Mayo Fdn, St Marys Hosp, GI Res Unit, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Mol Neurosci, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Urrutia, R (corresponding author), Mayo Clin & Mayo Fdn, St Marys Hosp, GI Res Unit, 200 1st St SW, Rochester, MN 55905 USA.			Cook, Tiffany/0000-0002-3100-5248	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052913, T32DK007198, R56DK052913] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07198, DK52913, R01 DK052913-03, R01 DK052913] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams PD, 1997, METHOD ENZYMOL, V283, P59; Alevizopoulos A, 1997, BIOESSAYS, V19, P581, DOI 10.1002/bies.950190709; Alevizopoulos A, 1996, J BIOL CHEM, V271, P29672, DOI 10.1074/jbc.271.47.29672; ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; ARAKI E, 1991, J BIOL CHEM, V266, P3944; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BALDWIN RL, 1993, GROWTH FACTORS, V8, P23, DOI 10.3109/08977199309029131; BEITNERJOHNSON D, 1995, MOL ENDOCRINOL, V9, P1147, DOI 10.1210/me.9.9.1147; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; BIRNBAUM MJ, 1995, BIOCHEMISTRY-US, V34, P7648, DOI 10.1021/bi00023a011; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; BLOK LJ, 1995, MOL ENDOCRINOL, V9, P1610, DOI 10.1210/me.9.11.1610; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; Chiarugi V, 1997, PHARMACOL RES, V35, P257, DOI 10.1006/phrs.1997.0140; Clare SE, 1997, J BIOL CHEM, V272, P33028, DOI 10.1074/jbc.272.52.33028; Cook T, 1996, J NEUROCHEM, V67, P927; Crossley M, 1996, MOL CELL BIOL, V16, P1695; DAngelo DD, 1996, J BIOL CHEM, V271, P19696, DOI 10.1074/jbc.271.33.19696; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7345, DOI 10.1073/pnas.89.16.7345; ElRouby S, 1996, ONCOGENE, V13, P2623; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; Faraldo MLM, 1997, MOL CARCINOGEN, V20, P33, DOI 10.1002/(SICI)1098-2744(199709)20:1<33::AID-MC5>3.0.CO;2-J; FREEMAN JW, 1995, J CELL PHYSIOL, V165, P155, DOI 10.1002/jcp.1041650118; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GEISER AG, 1993, GENE, V129, P223, DOI 10.1016/0378-1119(93)90272-5; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; Gum JR, 1997, BIOCHEM J, V325, P259, DOI 10.1042/bj3250259; HAGAN G, 1992, NUCLEIC ACIDS RES, V20, P5519; Hamel W, 1996, CYTOMETRY, V25, P173, DOI 10.1002/(SICI)1097-0320(19961001)25:2<173::AID-CYTO6>3.0.CO;2-I; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Horie N, 1997, J BIOL CHEM, V272, P18375, DOI 10.1074/jbc.272.29.18375; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; Imoto M, 1998, J CELL SCI, V111, P1341; ISHII S, 1986, SCIENCE, V232, P1410, DOI 10.1126/science.3012774; JACOBS GH, 1992, EMBO J, V11, P4507, DOI 10.1002/j.1460-2075.1992.tb05552.x; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Kawachi Y, 1996, IMMUNOGENETICS, V44, P358, DOI 10.1007/BF02602780; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KLEVIT RE, 1991, SCIENCE, V253, P1367, DOI 10.1126/science.1896847; Kojima S, 1997, J BIOCHEM, V121, P389; Koritschoner NP, 1997, J BIOL CHEM, V272, P9573; Kornmann M, 1998, J CLIN INVEST, V101, P344, DOI 10.1172/JCI1323; Laniel MA, 1997, BIOCHEM CELL BIOL, V75, P427, DOI 10.1139/bcb-75-4-427; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Lin SY, 1996, MOL CELL BIOL, V16, P1668; LIN XH, 1992, J BIOL CHEM, V267, P25614; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MATSUZAWA Y, 1991, ONCOGENE, V6, P1561; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; PAGES G, 1995, J BIOL CHEM, V270, P26986, DOI 10.1074/jbc.270.45.26986; Pan GH, 1997, J BIOL CHEM, V272, P24563, DOI 10.1074/jbc.272.39.24563; Philippe J, 1997, CYTOMETRY, V29, P242, DOI 10.1002/(SICI)1097-0320(19971101)29:3<242::AID-CYTO7>3.3.CO;2-Z; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; Rolland V, 1996, J BIOL CHEM, V271, P21297, DOI 10.1074/jbc.271.35.21297; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; Subramaniam M, 1995, NUCLEIC ACIDS RES, V23, P4907, DOI 10.1093/nar/23.23.4907; Tachibana I, 1997, J CLIN INVEST, V99, P2365, DOI 10.1172/JCI119418; Tanese N, 1996, P NATL ACAD SCI USA, V93, P13611, DOI 10.1073/pnas.93.24.13611; Tau KR, 1998, ENDOCRINOLOGY, V139, P1346, DOI 10.1210/en.139.3.1346; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Yajima S, 1997, J NEUROSCI, V17, P8657; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610; Zhang Y, 1997, BBA-GENE STRUCT EXPR, V1353, P307, DOI 10.1016/S0167-4781(97)00063-8; Zhao LY, 1997, J BIOL CHEM, V272, P4869, DOI 10.1074/jbc.272.8.4869; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	71	160	166	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25929	25936		10.1074/jbc.273.40.25929	http://dx.doi.org/10.1074/jbc.273.40.25929			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748269	hybrid			2022-12-27	WOS:000076263100060
J	Hu, ZZ; Zhuang, L; Meng, JP; Dufau, ML				Hu, ZZ; Zhuang, L; Meng, JP; Dufau, ML			Transcriptional regulation of the generic promoter III of the rat prolactin receptor gene by C/EBP beta and Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; BINDING PROTEINS; FACTOR-I; EXPRESSION; MULTIPLE; ACTIVATION; ELEMENT; CLONING; DOMAIN; SITES	Three promoters are operative in the rat prolactin receptor gene as follows: promoter I (PI) and II (PII) are specific for the gonads and liver, respectively, and promoter III (PILI) is common to several tissues. To investigate the mechanisms controlling the activity of promoter III, its regulatory elements and transcription factors were characterized in gonadal and non-gonadal cells. The TATA-less PIII domain was localized to the region -437 to -179 (ATG + 1) containing the 5'-flanking region and part of the non-coding first exon, Within the promoter domain, a functional CAAT-box/enhancer binding protein (C/EBP) (-398) and an Sp1 element (-386), which bind C/EBP beta and Sp1/Sp3, respectively, contribute individually to promoter activation in gonadal and non-gonadal cells. However, significant redundancy was demonstrated between these elements in non-gonadal cells. Additionally, an element within the non-coding exon 1 (-338) is also required for promoter activity. Activation of PIII by the widely expressed Spl and C/EBP beta factors explains its common utilization in multiple tissues. Moreover, whereas the rat and mouse PIII share similar structure and function, the mouse PI lacks the functional SF-1 element and hence is inactive. These findings indicate that promoter III is of central importance in prolactin receptor gene transcription across species.	NICHD, Sect Mol Endocrinol, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Dufau, ML (corresponding author), NICHD, Sect Mol Endocrinol, Endocrinol & Reprod Res Branch, NIH, Bldg 49,Rm 6A36,49 Convent Dr,MSC 4510, Bethesda, MD 20892 USA.	dufau@helix.nih.gov						ALAM J, 1990, ANAL BIOCHEM, V188, P245, DOI 10.1016/0003-2697(90)90601-5; ASSELIN C, 1989, ONCOGENE, V4, P549; BEITNERJOHNSON D, 1995, MOL ENDOCRINOL, V9, P1147, DOI 10.1210/me.9.9.1147; Bonifacino J.S., 1984, Serono Symposia Publications from Raven Press, V9, P149; BONTHRON DT, 1988, P NATL ACAD SCI USA, V85, P1492, DOI 10.1073/pnas.85.5.1492; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; Chinery R, 1997, J BIOL CHEM, V272, P30356, DOI 10.1074/jbc.272.48.30356; Cohen HT, 1997, J BIOL CHEM, V272, P2901, DOI 10.1074/jbc.272.5.2901; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DOPPLER W, 1994, REV PHYSIOL BIOCH P, V124, P93, DOI 10.1007/BFb0031032; Eberhardt W, 1998, J IMMUNOL, V160, P4961; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAHN SL, 1989, MOL CELL BIOL, V9, P837, DOI 10.1128/MCB.9.2.837; Hoppe KL, 1998, J LIPID RES, V39, P969; Hu ZZ, 1996, J BIOL CHEM, V271, P10242, DOI 10.1074/jbc.271.17.10242; HU ZZ, 1991, BIOCHEM BIOPH RES CO, V181, P219, DOI 10.1016/S0006-291X(05)81405-6; Hu ZZ, 1997, J BIOL CHEM, V272, P14263, DOI 10.1074/jbc.272.22.14263; Hu ZZ, 1998, TRENDS ENDOCRIN MET, V9, P94, DOI 10.1016/S1043-2760(98)00027-7; Ihn H, 1997, NUCLEIC ACIDS RES, V25, P3712, DOI 10.1093/nar/25.18.3712; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; Lewis JG, 1996, P NATL ACAD SCI USA, V93, P3176, DOI 10.1073/pnas.93.8.3176; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Moldrup A, 1996, MOL ENDOCRINOL, V10, P661, DOI 10.1210/me.10.6.661; NICOLL CS, 1974, HDB PHYSIOLOGY, V4, P253; Noti JD, 1997, J BIOL CHEM, V272, P24038, DOI 10.1074/jbc.272.38.24038; Pang HL, 1998, BIOCHEM J, V333, P209, DOI 10.1042/bj3330209; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SIROIS J, 1993, J BIOL CHEM, V268, P21931; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1994, RAV S MOL C, V3, P63; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; Tanese N, 1996, P NATL ACAD SCI USA, V93, P13611, DOI 10.1073/pnas.93.24.13611; TSAIMORRIS CH, 1995, J BIOL CHEM, V270, P7487, DOI 10.1074/jbc.270.13.7487; VENEPALLY P, 1995, J BIOL CHEM, V270, P25402, DOI 10.1074/jbc.270.43.25402	44	51	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26225	26235		10.1074/jbc.273.40.26225	http://dx.doi.org/10.1074/jbc.273.40.26225			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748306	hybrid			2022-12-27	WOS:000076263100097
J	Schacke, H; Schumann, H; Hammami-Hauasli, N; Raghunath, M; Bruckner-Tuderman, L				Schacke, H; Schumann, H; Hammami-Hauasli, N; Raghunath, M; Bruckner-Tuderman, L			Two forms of collagen XVII in keratinocytes - A full-length transmembrane protein and a soluble ectodomain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BULLOUS PEMPHIGOID ANTIGEN; BENIGN EPIDERMOLYSIS-BULLOSA; BASEMENT-MEMBRANE ZONE; EXTRACELLULAR DOMAIN; BP180; GENE; AUTOANTIBODIES; AUTOANTIGEN; BPAG2; DERMATOSIS	The cDNA sequence of human collagen XVII predicts an unusual type II transmembrane protein, but a biochemical characterization of this structure has not been accomplished yet. Using domain-specific antibodies against recombinant collagen XVII fragments, we identified two molecular forms of the collagen in human skin and epithelial cells. Full-length collagen XVII appeared as a homotrimeric transmembrane molecule of three 180-kDa alpha 1(XVII) chains. The globular intracellular domain was disulfide-linked, and the N-glycosylated extracellular domain of three 120-kDa polypeptides was triple-helical at physiological temperatures. A second, soluble form of collagen XVII in keratinocyte culture media was recognized with antibodies to the ectodomain, but not the endodomain, The soluble form exhibited molecular properties of the collagen XVII ectodomain: a triple-helical, N-glycosylated molecule of three 120-kDa polypeptides, Northern blot analysis with probes spanning either the distal 5' or the distal 3' end of the collagen XVII cDNA revealed an identical 6-kb mRNA, suggesting that both the 180- and 120-kDa polypeptides were translated from the same mRNA, and that the 120-kDa polypeptide was generated post-translationally, In concert, keratinocytes harboring a homozygous nonsense mutation in the COL17A1 gene synthesized neither the 180-kDa alpha 1(XVII) chain nor the 120-kDa polypeptide. Finally, treatment of normal keratinocytes with a synthetic inhibitor of furin proprotein convertases, decanoyl-RVKR-chloromethyl ketone, prevented the generation of the 120-kDa polypeptide. These data strongly suggest that the soluble 120-kDa polypeptide represents a specifically cleaved ectodomain of collagen XVII, generated through furin-mediated proteolytic processing. Thus, collagen XVII is not only an unusual type II transmembrane collagen, but the first collagen with a specifically processed, soluble triple-helical ectodomain.	Univ Munster, Dept Dermatol, D-48149 Munster, Germany	University of Munster	Bruckner-Tuderman, L (corresponding author), Univ Munster, Dept Dermatol, Von Esmarch Str 56, D-48149 Munster, Germany.		Raghunath, Michael/E-6483-2010; Raghunath, Michael/M-2727-2019	Raghunath, Michael/0000-0002-2138-6614; 				ACTON S, 1993, J BIOL CHEM, V268, P3530; Balding SD, 1997, BIOCHEMISTRY-US, V36, P8821, DOI 10.1021/bi970675n; Balding SD, 1996, J INVEST DERMATOL, V106, P141, DOI 10.1111/1523-1747.ep12329728; Borradori L, 1997, J CELL BIOL, V136, P1333, DOI 10.1083/jcb.136.6.1333; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; BRUCKNERTUDERMAN L, 1995, J CELL BIOL, V131, P551, DOI 10.1083/jcb.131.2.551; BURGESON RE, 1993, J INVEST DERMATOL, V101, P252, DOI 10.1111/1523-1747.ep12365129; Chavanas S, 1997, J INVEST DERMATOL, V109, P74, DOI 10.1111/1523-1747.ep12276614; Darling TN, 1998, J INVEST DERMATOL, V110, P165, DOI 10.1046/j.1523-1747.1998.00103.x; Darling TN, 1997, J INVEST DERMATOL, V108, P463, DOI 10.1111/1523-1747.ep12289718; Darling TN, 1998, J INVEST DERMATOL, V110, P170, DOI 10.1046/j.1523-1747.1998.00101.x; FLOETH M, 1998, IN PRESS J INVEST DE; GAO SQ, 1994, ARCH DERMATOL, V130, P873, DOI 10.1001/archderm.130.7.873; GARTEN W, 1994, BIOCHIMIE, V76, P217, DOI 10.1016/0300-9084(94)90149-X; GASSMANN M, 1990, FASEB J, V4, P2528, DOI 10.1096/fasebj.4.8.1970792; Gatalica B, 1997, AM J HUM GENET, V60, P352; GIUDICE GJ, 1994, J INVEST DERMATOL, V102, P878, DOI 10.1111/1523-1747.ep12382738; GIUDICE GJ, 1992, J INVEST DERMATOL, V99, P243, DOI 10.1111/1523-1747.ep12616580; Hirako Y, 1996, J BIOL CHEM, V271, P13739, DOI 10.1074/jbc.271.23.13739; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; HOPKINSON SB, 1995, J CELL BIOL, V130, P117, DOI 10.1083/jcb.130.1.117; ISHIKO A, 1993, J CLIN INVEST, V91, P1608, DOI 10.1172/JCI116368; Jonkman MF, 1996, ARCH DERMATOL, V132, P145, DOI 10.1001/archderm.132.2.145; Jonkman MF, 1997, CELL, V88, P543, DOI 10.1016/S0092-8674(00)81894-2; JONKMAN MF, 1995, J CLIN INVEST, V95, P1345, DOI 10.1172/JCI117785; Kahari VM, 1997, EXP DERMATOL, V6, P199, DOI 10.1111/j.1600-0625.1997.tb00164.x; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KONIG A, 1992, J CELL BIOL, V117, P679, DOI 10.1083/jcb.117.3.679; LI KH, 1993, J BIOL CHEM, V268, P8825; LIU Z, 1993, J CLIN INVEST, V92, P2480, DOI 10.1172/JCI116856; MARINKOVICH MP, 1992, J CELL BIOL, V119, P695, DOI 10.1083/jcb.119.3.695; Marinkovich MP, 1996, J INVEST DERMATOL, V106, P734, DOI 10.1111/1523-1747.ep12345782; Masunaga T, 1997, J INVEST DERMATOL, V109, P200, DOI 10.1111/1523-1747.ep12319337; McGrath JA, 1996, J INVEST DERMATOL, V106, P771, DOI 10.1111/1523-1747.ep12345821; McGrath JA, 1996, AM J PATHOL, V148, P1787; MCGRATH JA, 1995, NAT GENET, V11, P83, DOI 10.1038/ng0995-83; MEYER LJ, 1991, J INVEST DERMATOL, V96, P991, DOI 10.1111/1523-1747.ep12476575; NISHIZAWA Y, 1993, J BIOCHEM-TOKYO, V113, P493, DOI 10.1093/oxfordjournals.jbchem.a124072; Pas HH, 1997, J INVEST DERMATOL, V108, P423, DOI 10.1111/1523-1747.ep12289703; PIHLAJANIEMI T, 1995, PROG NUCLEIC ACID RE, V50, P225, DOI 10.1016/S0079-6603(08)60816-8; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; RAGHUNATH M, 1994, J MOL BIOL, V236, P940, DOI 10.1006/jmbi.1994.1199; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; Schumann H, 1997, AM J HUM GENET, V60, P1344, DOI 10.1086/515463; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SONNENBERG A, 1991, EXP CELL RES, V197, P234, DOI 10.1016/0014-4827(91)90428-W; STAHLEBACKDAHL M, 1994, J CLIN INVEST, V93, P2022, DOI 10.1172/JCI117196; Zillikens D, 1997, J INVEST DERMATOL, V109, P573, DOI 10.1111/1523-1747.ep12337492; Zone JJ, 1998, J INVEST DERMATOL, V110, P207, DOI 10.1046/j.1523-1747.1998.00129.x; ZONE JJ, 1990, J CLIN INVEST, V85, P812, DOI 10.1172/JCI114508	51	127	129	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25937	25943		10.1074/jbc.273.40.25937	http://dx.doi.org/10.1074/jbc.273.40.25937			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748270	hybrid			2022-12-27	WOS:000076263100061
J	Turner, SJ; Domin, J; Waterfield, MD; Ward, SG; Westwick, J				Turner, SJ; Domin, J; Waterfield, MD; Ward, SG; Westwick, J			The CC chemokine monocyte chemotactic peptide-1 activates both the class I p85/p110 phosphatidylinositol 3-kinase and the class II PI3K-C2 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOATTRACTANT PROTEIN-1 RECEPTOR; MYELOID-DERIVED CELLS; BETA-GAMMA-SUBUNITS; SWISS 3T3 CELLS; PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; STIMULATED SYNTHESIS; FUNCTIONAL LIGAND; KINASE-ACTIVITY; FACTOR MCAF	The cellular effects of MCP-1 are mediated primarily by binding to CC chemokine receptor-2. We report here that MCP-1 stimulates the formation of the lipid products of phosphatidylinositol (PI) 3-kinase, namely phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate (PI 3,4,5-P-3) in THP-1 cells that can be inhibited by pertussis toxin but not wortmannin. MCP-1 also stimulates an increase in the in vitro lipid kinase activity present in immunoprecipitates of the class 1(A) p85/p110 heterodimeric PI 3-kinase, although the kinetics of activation were much slower than observed for the accumulation of PI 3,4,5-P-3. In addition, this in vitro lipid kinase activity was inhibited by wortmannin (IC50 = 4.47 +/- 1.88 nM, n = 4), and comparable concentrations of wortmannin also inhibited MCP-stimulated chemotaxis of THP-1 cells (IC50 = 11.8 +/- 4.2 nM, n = 4), indicating that p85/p110 PI 3-kinase activity is functionally relevant. MCP-1 also induced tyrosine phosphorylation of three proteins in these cells, and a fourth tyrosine-phosphorylated protein co-precipitates with the p85 subunit upon MCP-1 stimulation. In addition, MCP-1 stimulated lipid kinase activity present in immunoprecipitates of a class II PI 3-kinase (PI3K-C2 alpha) with kinetics that closely resembled the accumulation of PI 3,4,5-P-3. Moreover, this MCP-1-induced increase in PI3K-C2 alpha activity was insensitive to wortmannin but was inhibited by pertussis toxin pretreatment. Since this mirrored the effects of these inhibitors on MCP-1-stimulated increases in D-3 phosphatidylinositol lipid accumulation in vivo, these results suggest that activation of PI3K-C2 alpha rather than the p85/p110 heterodimer is responsible for mediating the in vivo formation of D-3 phosphatidylinositol lipids. These data demonstrate that MCP-1 stimulates protein tyrosine kinases as well. as at least two separate PI 3-kinase isoforms, namely the p85/p110 PI 3-kinase and PI3K-C2 alpha. This is the first demonstration that MCP-1 can stimulate PI 3-kinase activation and is also the first indication of an agonist-induced activation of the PI3K-C2 alpha enzyme. These two events may play important roles in MCP-1-stimulated signal transduction and biological consequences.	Univ Bath, Sch Pharm & Pharmacol, Pharmacol Grp, Bath BA2 7AY, Avon, England; Ludwig Inst Canc Res, London W1P 8BT, England	University of Bath; Ludwig Institute for Cancer Research	Ward, SG (corresponding author), Univ Bath, Sch Pharm & Pharmacol, Pharmacol Grp, Claverton Down, Bath BA2 7AY, Avon, England.	prssgw@bath.ac.uk	Ward, Stephen/AAE-4341-2020	Ward, Stephen G./0000-0002-6795-6002	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Bacon KB, 1996, J EXP MED, V184, P873, DOI 10.1084/jem.184.3.873; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Boring L, 1997, J CLIN INVEST, V100, P2552, DOI 10.1172/JCI119798; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; Chensue SW, 1996, J IMMUNOL, V157, P4602; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COMBADIERE C, 1995, J BIOL CHEM, V270, P29671; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Domin J, 1997, BIOCHEM J, V326, P139, DOI 10.1042/bj3260139; Dubois PM, 1996, J IMMUNOL, V156, P1356; FRANCI C, 1995, J IMMUNOL, V154, P6511; FUENTES ME, 1995, J IMMUNOL, V155, P5769; FURUTANI Y, 1989, BIOCHEM BIOPH RES CO, V159, P249, DOI 10.1016/0006-291X(89)92430-3; GarciaZepeda EA, 1996, J IMMUNOL, V157, P5613; GNN MD, 1997, J IMMUNOL, V159, P401; Gong XQ, 1997, J BIOL CHEM, V272, P11682, DOI 10.1074/jbc.272.18.11682; Grewal IS, 1997, J IMMUNOL, V159, P401; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; JACKSON TR, 1992, J BIOL CHEM, V267, P16627; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; KOCH AE, 1992, J CLIN INVEST, V90, P772, DOI 10.1172/JCI115950; Kuang YN, 1996, J BIOL CHEM, V271, P3975; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601; Matsuo T, 1996, BIOCHEM J, V315, P505, DOI 10.1042/bj3150505; MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786; NELKEN NA, 1991, J CLIN INVEST, V90, P772; Okada T, 1996, BIOCHEM J, V317, P475, DOI 10.1042/bj3170475; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Sarafi MN, 1997, J EXP MED, V185, P99, DOI 10.1084/jem.185.1.99; Shimizu Y, 1996, IMMUNOL TODAY, V17, P565, DOI 10.1016/S0167-5699(96)10061-X; SOZZANI S, 1993, J IMMUNOL, V150, P1544; Stellato C, 1997, J CLIN INVEST, V99, P926, DOI 10.1172/JCI119257; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Taub DD, 1996, J LEUKOCYTE BIOL, V59, P81, DOI 10.1002/jlb.59.1.81; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TURNER L, 1995, J IMMUNOL, V155, P2437; TURNER SJ, 1995, BRIT J PHARMACOL, V114, pP211; WARD SG, 1992, J BIOL CHEM, V267, P23862; Ward SG, 1996, IMMUNOL TODAY, V17, P187, DOI 10.1016/0167-5699(96)80618-9; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; Wright K, 1997, J BIOL CHEM, V272, P12626, DOI 10.1074/jbc.272.19.12626; ZACHARIAE COC, 1990, J EXP MED, V171, P2177, DOI 10.1084/jem.171.6.2177; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; Zhang J, 1996, J BIOL CHEM, V271, P6265, DOI 10.1074/jbc.271.11.6265; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	62	140	144	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25987	25995		10.1074/jbc.273.40.25987	http://dx.doi.org/10.1074/jbc.273.40.25987			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748276	hybrid			2022-12-27	WOS:000076263100067
J	Lee, SF; Mahasneh, A; de la Roche, M; Cote, GP				Lee, SF; Mahasneh, A; de la Roche, M; Cote, GP			Regulation of the p21-activated kinase-related Dictyostelium myosin I heavy chain kinase by autophosphorylation, acidic phospholipids, and Ca2+-calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; SUBSTRATE-SPECIFICITY; CATALYTIC DOMAIN; PHOSPHORYLATION; BINDING; ACTIN; ACTIVATION; YEAST; PAK	The Dictyostelium myosin I heavy chain kinase (MIHCK) is a member of the p21-activated kinase family (Lee, S.-F., Egelhoff, T. T,, Mahasneh, A., and Cote, G. P. (1996) J. Biol. Chem. 271, 27044-27048). MIHCK incubated with MgATP in the absence of effecters incorporates 1 mol of phosphate/mol, resulting in an similar to 40-fold increase in kinase activity, Sequence analysis of tryptic peptides has identified the major site of phosphorylation as Ser-8, A peptide and a glutathione S-transferase fusion protein containing the Ser-8 phosphorylation site were good substrates for MIHCK, indicating that MIHCK can catalyze its own activation. Guanosine 5'-3-O-(thio)triphosphate (GTP gamma S)-Rac1 stimulates MIHCK autophosphorylation and kinase activity 10-fold, Phosphatidylserine, phosphatidylinositol, and phosphatidylinositol 4,5-bisphosphate, but not phosphatidylcholine or sphingosine, were as effective as GTP gamma S-Rac1 in enhancing MIHCK autophosphorylation and activity. Acidic lipids and GTP gamma S-Rac1 induced the autophosphorylation of a similar set of sites as judged by two-dimensional tryptic peptide maps. It is proposed that GTP-Rac and acidic phospholipids function cooperatively to associate MIHCK with membranes. Ca2+-calmodulin bound MIHCK and inhibited activation by acidic phospholipids but not by GTP gamma S-Rac1. These studies reveal a number of similarities between the regulatory properties of the Dictyostelium and Acanthamoeba MIHCK, suggesting that the signaling pathways that control myosin I are conserved.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Cote, GP (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.		Mahasneh, Amjad/AAA-1732-2022	Mahasneh, Amjad/0000-0002-4931-8699				Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; BEMENT WM, 1995, CELL MOTIL CYTOSKEL, V31, P87, DOI 10.1002/cm.970310202; BENNER GE, 1995, J BIOL CHEM, V270, P21121, DOI 10.1074/jbc.270.36.21121; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRZESKA H, 1990, J BIOL CHEM, V265, P16138; Brzeska H, 1997, P NATL ACAD SCI USA, V94, P1092, DOI 10.1073/pnas.94.4.1092; BRZESKA H, 1992, J BIOL CHEM, V267, P23870; BRZESKA H, 1990, J BIOL CHEM, V265, P3591; Brzeska H, 1996, J BIOL CHEM, V271, P16983, DOI 10.1074/jbc.271.29.16983; Brzeska H, 1996, J BIOL CHEM, V271, P27056, DOI 10.1074/jbc.271.43.27056; BRZESKA H, 1992, J BIOL CHEM, V267, P4949; Coluccio LM, 1997, AM J PHYSIOL-CELL PH, V273, pC347, DOI 10.1152/ajpcell.1997.273.2.C347; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; Goodson HV, 1996, J CELL BIOL, V133, P1277, DOI 10.1083/jcb.133.6.1277; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Jung G, 1996, J CELL BIOL, V133, P305, DOI 10.1083/jcb.133.2.305; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KIM JY, 1994, J BIOL CHEM, V269, P28214; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; Lee SF, 1996, J BIOL CHEM, V271, P27044, DOI 10.1074/jbc.271.43.27044; LEE SF, 1995, J BIOL CHEM, V270, P11776, DOI 10.1074/jbc.270.20.11776; LEE SF, 1993, J BIOL CHEM, V268, P20923; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; LINDE S, 1990, J CHROMATOGR-BIOMED, V530, P29, DOI 10.1016/S0378-4347(00)82299-9; MANSER E, 1995, METHOD ENZYMOL, V256, P130; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; NOVAK KD, 1995, J CELL BIOL, V131, P1205, DOI 10.1083/jcb.131.5.1205; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; Roberts RL, 1997, CELL, V89, P1055, DOI 10.1016/S0092-8674(00)80293-7; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; SWIERCZYNSKI SL, 1995, J BIOL CHEM, V270, P13436, DOI 10.1074/jbc.270.22.13436; Szczepanowska J, 1997, P NATL ACAD SCI USA, V94, P8503, DOI 10.1073/pnas.94.16.8503; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tuazon PT, 1997, BIOCHEMISTRY-US, V36, P16059, DOI 10.1021/bi9717845; Wu C, 1997, J BIOL CHEM, V272, P30623, DOI 10.1074/jbc.272.49.30623; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; Wu CL, 1996, J BIOL CHEM, V271, P31787, DOI 10.1074/jbc.271.50.31787; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	47	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27911	27917		10.1074/jbc.273.43.27911	http://dx.doi.org/10.1074/jbc.273.43.27911			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774403	hybrid			2022-12-27	WOS:000076549800023
J	Archambault, J; Pan, GH; Dahmus, GK; Cartier, M; Marshall, N; Zhang, S; Dahmus, ME; Greenblatt, J				Archambault, J; Pan, GH; Dahmus, GK; Cartier, M; Marshall, N; Zhang, S; Dahmus, ME; Greenblatt, J			FCP1, the RAP74-interacting subunit of a human protein phosphatase that dephosphorylates the carboxyl-terminal domain of RNA polymerase IIO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION PREINITIATION COMPLEX; ESCHERICHIA-COLI SIGMA-70; MAJOR LATE PROMOTER; ACTIVATION DOMAINS; INITIATION; ELONGATION; HOLOENZYME; PHOSPHORYLATION; BINDING; PURIFICATION	TFIIF (RAP30/74) is a general initiation factor that also increases the rate of elongation by RNA polymerase II. A two-hybrid screen for RAP74 interacting proteins produced cDNAs encoding FCP1a, a novel, ubiquitously expressed human protein that interacts with the carboxyl-terminal evolutionarily conserved domain of RAP74. Related cDNAs encoding FCP1b lack a carboxyl-terminal RAP74-binding domain of FCP1a, FCP1 is an essential subunit of a RAP74-stimulated phosphatase that processively dephosphorylates the carboxyl-terminal domain of the largest RNA polymerase II subunit, FCP1 is also a stoichiometric component of a human RNA polymerase II holoenzyme complex.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1L6, Canada; Hosp Sick Children, Res Inst, Dept Genet, Toronto, ON M5G 1X8, Canada; Univ Calif Davis, Div Biol Sci, Sect Mol & Cellular Biol, Livermore, CA 95616 USA	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of California System; University of California Davis	Greenblatt, J (corresponding author), Univ Toronto, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.			Archambault, Jacques/0000-0001-8107-3428	NIGMS NIH HHS [GM-33300] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033300] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Archambault J, 1997, P NATL ACAD SCI USA, V94, P14300, DOI 10.1073/pnas.94.26.14300; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; Blau J, 1996, MOL CELL BIOL, V16, P2044; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Chambers RS, 1996, J BIOL CHEM, V271, P24498, DOI 10.1074/jbc.271.40.24498; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; Chao DM, 1996, NATURE, V380, P82, DOI 10.1038/380082a0; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; COULOMBE B, 1994, J BIOL CHEM, V269, P19962; Cujec TP, 1997, GENE DEV, V11, P2645, DOI 10.1101/gad.11.20.2645; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EMILI A, 1995, CURR OPIN GENET DEV, V5, P204, DOI 10.1016/0959-437X(95)80009-3; Fang SM, 1996, J BIOL CHEM, V271, P11703, DOI 10.1074/jbc.271.20.11703; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; Greenblatt J, 1997, CURR OPIN CELL BIOL, V9, P310, DOI 10.1016/S0955-0674(97)80002-6; HARLOW E, 1988, ANTIBODIES LABORATOR, P313; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; KANG ME, 1993, J BIOL CHEM, V268, P25033; KANG ME, 1995, J BIOL CHEM, V270, P23390, DOI 10.1074/jbc.270.40.23390; KEPHART DD, 1994, J BIOL CHEM, V269, P13536; KILLEEN MT, 1992, MOL CELL BIOL, V12, P30, DOI 10.1128/MCB.12.1.30; Kim TK, 1997, P NATL ACAD SCI USA, V94, P12268, DOI 10.1073/pnas.94.23.12268; KIM WY, 1988, J BIOL CHEM, V263, P18880; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; MARUYAMA IN, 1995, NUCLEIC ACIDS RES, V23, P3796, DOI 10.1093/nar/23.18.3796; MCCRACKEN S, 1991, SCIENCE, V253, P900, DOI 10.1126/science.1652156; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; Pan GH, 1997, J BIOL CHEM, V272, P24563, DOI 10.1074/jbc.272.39.24563; Parada CA, 1996, NATURE, V384, P375, DOI 10.1038/384375a0; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; Robert F, 1996, J BIOL CHEM, V271, P8517, DOI 10.1074/jbc.271.15.8517; SCHEISTL RH, 1989, CURR GENET, V16, P339; Sherman F, 1986, LAB COURSE MANUAL ME; SOPTA M, 1985, J BIOL CHEM, V260, P353; Svejstrup JQ, 1997, P NATL ACAD SCI USA, V94, P6075, DOI 10.1073/pnas.94.12.6075; TAN SY, 1994, J BIOL CHEM, V269, P25684; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WANG BQ, 1993, PROTEIN EXPRES PURIF, V4, P207, DOI 10.1006/prep.1993.1027; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YONAHA M, 1993, NUCLEIC ACIDS RES, V21, P273, DOI 10.1093/nar/21.2.273; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	58	128	131	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27593	27601		10.1074/jbc.273.42.27593	http://dx.doi.org/10.1074/jbc.273.42.27593			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765293	hybrid			2022-12-27	WOS:000076448000080
J	DeMott, MS; Zigman, S; Bambara, RA				DeMott, MS; Zigman, S; Bambara, RA			Replication protein A stimulates long patch DNA base excision repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5'-TERMINAL DEOXYRIBOSE PHOSPHATE; POLYMERASE-BETA; ESCHERICHIA-COLI; DAMAGED DNA; PURIFIED PROTEINS; REQUIREMENT; RESIDUES; CELLS; RECONSTITUTION; EXPRESSION	Two pathways for completion of DNA base excision repair (BER) have recently emerged. In one, called short patch BER, only the damaged nucleotide is replaced, whereas in the second, known as long patch BER, the monobasic lesion is removed along with additional downstream nucleotides. Flap endonuclease 1, which preferentially cleaves unannealed 5'-flap structures in DNA, has been shown to play a crucial role in the long patch mode of repair. This nuclease will efficiently release 5'-terminal abasic lesions as part of an intact oligonucleotide when cleavage is combined with strand displacement synthesis, Further gap filling and ligation complete repair. We reconstituted the final steps of long patch base excision repair in vitro using calf DNA polymerase epsilon to provide strand displacement synthesis, human flap endonuclease 1, and human DNA ligase I. Replication protein A is an important constituent of the DNA replication machinery. It also has been shown to interact with an early component of base excision repair: uracil glycosylase. Here we show that human replication protein A greatly stimulates long patch base excision repair.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Sch Med & Dent, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Ophthalmol, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Bambara, RA (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Sch Med & Dent, Box 712,601 Elmwood Ave, Rochester, NY 14642 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024441] Funding Source: NIH RePORTER; NEI NIH HHS [EY00459] Funding Source: Medline; NIGMS NIH HHS [GM24441] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; Biswas EE, 1997, BIOCHEMISTRY-US, V36, P5955, DOI 10.1021/bi962890u; Burns JL, 1996, J BIOL CHEM, V271, P11607, DOI 10.1074/jbc.271.20.11607; DeMott MS, 1996, J BIOL CHEM, V271, P30068, DOI 10.1074/jbc.271.47.30068; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; GEORGAKI A, 1993, NUCLEIC ACIDS RES, V21, P3659, DOI 10.1093/nar/21.16.3659; GRAVES RJ, 1992, J BIOL CHEM, V267, P14429; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Krokan HE, 1997, BIOCHEM J, V325, P1; Lin YL, 1998, J BIOL CHEM, V273, P1453, DOI 10.1074/jbc.273.3.1453; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MAZUMDER A, 1991, BIOCHEMISTRY-US, V30, P1119, DOI 10.1021/bi00218a033; Nagelhus TA, 1997, J BIOL CHEM, V272, P6561, DOI 10.1074/jbc.272.10.6561; Nakamura J, 1998, CANCER RES, V58, P222; Nealon K, 1996, NUCLEIC ACIDS RES, V24, P3763, DOI 10.1093/nar/24.19.3763; Piersen CE, 1996, J BIOL CHEM, V271, P17811, DOI 10.1074/jbc.271.30.17811; PRICE A, 1991, BIOCHEMISTRY-US, V30, P8631, DOI 10.1021/bi00099a020; RANDERATH K, 1967, METHODS ENZYMOLOGY A, V12, P323; Sandigursky M, 1998, NUCLEIC ACIDS RES, V26, P1282, DOI 10.1093/nar/26.5.1282; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; SIEGAL G, 1992, P NATL ACAD SCI USA, V89, P9377, DOI 10.1073/pnas.89.20.9377; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; TERAOKA H, 1993, J BIOL CHEM, V268, P24156; Treuner K, 1996, J MOL BIOL, V259, P104, DOI 10.1006/jmbi.1996.0305; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; Umezu K, 1998, GENETICS, V148, P989; Wang ZG, 1997, J BIOL CHEM, V272, P24064, DOI 10.1074/jbc.272.38.24064; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61	35	79	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27492	27498		10.1074/jbc.273.42.27492	http://dx.doi.org/10.1074/jbc.273.42.27492			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765279	hybrid			2022-12-27	WOS:000076448000066
J	Ghosh, JK; Peisajovich, SG; Ovadia, M; Shai, Y				Ghosh, JK; Peisajovich, SG; Ovadia, M; Shai, Y			Structure-function study of a heptad repeat positioned near the transmembrane domain of Sendai virus fusion protein which blocks virus-cell fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENTLY LABELED ANALOGS; BIOLOGICALLY-ACTIVE PEPTIDES; LEUCINE-ZIPPER STRUCTURE; PHOSPHOLIPID-MEMBRANES; PARAMYXOVIRUS FUSION; INFLUENZA-VIRUS; ENVELOPE GLYCOPROTEIN; MUTATIONAL ANALYSIS; SYNTHETIC PEPTIDES; POTENT INHIBITORS	A synthetic heptad repeat, SV-473, derived from Sendal virus fusion protein is a potent inhibitor of virus-cell fusion. In order to understand the mechanism of the inhibitory effect, we synthesized and fluorescently labeled SV-465, an extended version of SV-473 by one more heptad, its mutant peptide A(17,24)-SV-465, in which two heptadic leucines were substituted with two alanines, and its enatiomer D-SV-465, composed entirely of D-amino acids. Similar mutations in the homologous fusion protein of the Newcastle disease virus drastically reduced its activity. The data revealed that SV-465, but not A(17,24)-SV-465 or. its enantiomer, is highly active in inhibiting Sendai virus-induced hemolysis of red blood cells. None of the peptides interfere with the binding of virions to the target red blood cells as demonstrated by hemagglutinin assay. Fluorescence and circular dichroism (CD) spectroscopy indicated that: (i) only SV-465 could self-assemble in aqueous environment; (ii) only SV-465 could co-assemble with two other biologically active heptad repeats derived from Sendai virus fusion protein; (iii) SV-465 has a higher helical content than A(17,24)-SV-465 in solution, and (iv) all the peptides bind strongly to zwitterionic and negatively charged phospholipids. Polarized attenuated total reflection infrared spectroscopy revealed that they bound as monomers onto the surface of zwitterionic membranes with predominantly alpha-helical structures. The functional role of the amino acid 465-497 domain in Sendai virus-mediated membrane fusion is discussed in light of these findings.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Tel Aviv Univ, George S Wise Fac Life Sci, Dept Zool, IL-69978 Tel Aviv, Israel	Weizmann Institute of Science; Tel Aviv University	Shai, Y (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	bmshai@weizmann.weizmann.ac.il	Peisajovich, Sergio/C-6641-2011					BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BERNSTEIN HB, 1995, J VIROL, V69, P2745, DOI 10.1128/JVI.69.5.2745-2750.1995; BOSCH ML, 1989, SCIENCE, V244, P694, DOI 10.1126/science.2541505; BUCKLAND R, 1992, J GEN VIROL, V73, P1703, DOI 10.1099/0022-1317-73-7-1703; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CHAMBERS P, 1992, J GEN VIROL, V73, P1717, DOI 10.1099/0022-1317-73-7-1717; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; CHEN SSL, 1993, J VIROL, V67, P3615, DOI 10.1128/JVI.67.6.3615-3619.1993; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; DUBAY JW, 1992, J VIROL, V66, P4748, DOI 10.1128/JVI.66.8.4748-4756.1992; Durrer P, 1996, J BIOL CHEM, V271, P13417, DOI 10.1074/jbc.271.23.13417; Fass D, 1996, NAT STRUCT BIOL, V3, P465, DOI 10.1038/nsb0596-465; FREED EO, 1990, P NATL ACAD SCI USA, V87, P4650, DOI 10.1073/pnas.87.12.4650; FREED EO, 1992, P NATL ACAD SCI USA, V89, P70, DOI 10.1073/pnas.89.1.70; FREY S, 1990, BIOCHEM J, V272, P713, DOI 10.1042/bj2720713; Fringeli U P, 1981, Mol Biol Biochem Biophys, V31, P270; FUNG BKK, 1978, BIOCHEMISTRY-US, V17, P5241, DOI 10.1021/bi00617a025; Furuta RA, 1998, NAT STRUCT BIOL, V5, P612, DOI 10.1038/871; GAZIT E, 1993, BIOCHEMISTRY-US, V32, P12363, DOI 10.1021/bi00097a013; Gazit E, 1996, J MOL BIOL, V258, P860, DOI 10.1006/jmbi.1996.0293; GETHING MJ, 1978, P NATL ACAD SCI USA, V75, P2737, DOI 10.1073/pnas.75.6.2737; GETHING MJ, 1986, J CELL BIOL, V102, P11, DOI 10.1083/jcb.102.1.11; Ghosh JK, 1998, J BIOL CHEM, V273, P7252, DOI 10.1074/jbc.273.13.7252; Ghosh JK, 1997, BIOCHEMISTRY-US, V36, P15451, DOI 10.1021/bi971152i; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HARRICK NJ, 1967, INT REFLECTION SPECT; HOMMA M, 1973, J VIROL, V12, P1457, DOI 10.1128/JVI.12.6.1457-1465.1973; HORVATH CM, 1992, J VIROL, V66, P2443, DOI 10.1128/JVI.66.4.2443-2455.1992; ISHIGURO R, 1993, BIOCHEMISTRY-US, V32, P9792, DOI 10.1021/bi00088a034; JACKSON M, 1995, CRIT REV BIOCHEM MOL, V30, P95, DOI 10.3109/10409239509085140; Judice JK, 1997, P NATL ACAD SCI USA, V94, P13426, DOI 10.1073/pnas.94.25.13426; KENNEDY DW, 1983, J CELL PHYSIOL, V114, P257, DOI 10.1002/jcp.1041140302; KENNER RA, 1971, BIOCHEMISTRY-US, V10, P4433, DOI 10.1021/bi00800a013; KLENK HD, 1975, VIROLOGY, V68, P426, DOI 10.1016/0042-6822(75)90284-6; Kliger Y, 1997, J BIOL CHEM, V272, P13496, DOI 10.1074/jbc.272.21.13496; LAMB RA, 1993, VIROLOGY, V197, P1, DOI 10.1006/viro.1993.1561; Lambert DM, 1996, P NATL ACAD SCI USA, V93, P2186, DOI 10.1073/pnas.93.5.2186; Lawless MK, 1996, BIOCHEMISTRY-US, V35, P13697, DOI 10.1021/bi9606962; LEAR JD, 1987, J BIOL CHEM, V262, P6500; LOYTER A, 1982, CELL SURF REV, V8, P215; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Malashkevich VN, 1998, P NATL ACAD SCI USA, V95, P9134, DOI 10.1073/pnas.95.16.9134; MARTIN I, 1991, BIOCHEM BIOPH RES CO, V175, P872, DOI 10.1016/0006-291X(91)91646-T; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315; MURATA M, 1987, J BIOCHEM-TOKYO, V102, P957, DOI 10.1093/oxfordjournals.jbchem.a122137; NUSSBAUM O, 1984, VIROLOGY, V138, P185, DOI 10.1016/0042-6822(84)90344-1; PERETZ H, 1974, J CELL BIOL, V63, P1, DOI 10.1083/jcb.63.1.1; POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017; RAFALSKI M, 1990, BIOCHEMISTRY-US, V29, P7917, DOI 10.1021/bi00486a020; RAJARATHNAM K, 1989, BIOCHEMISTRY-US, V28, P3168, DOI 10.1021/bi00434a009; RAPAPORT D, 1991, J BIOL CHEM, V266, P23769; RAPAPORT D, 1992, J BIOL CHEM, V267, P6502; RAPAPORT D, 1994, J BIOL CHEM, V269, P15124; RAPAPORT D, 1995, EMBO J, V14, P5524, DOI 10.1002/j.1460-2075.1995.tb00239.x; REITTER JN, 1995, J VIROL, V69, P5995, DOI 10.1128/JVI.69.10.5995-6004.1995; Rimsky LT, 1998, J VIROL, V72, P986, DOI 10.1128/JVI.72.2.986-993.1998; ROTHSCHILD KJ, 1979, SCIENCE, V204, P311, DOI 10.1126/science.432645; ROTT R, 1977, CELL SURF REV, P47; SCHEID A, 1974, VIROLOGY, V57, P475, DOI 10.1016/0042-6822(74)90187-1; SCHEID A, 1977, VIROLOGY, V80, P54, DOI 10.1016/0042-6822(77)90380-4; SCHEID A, 1972, VIROLOGY, V50, P640, DOI 10.1016/0042-6822(72)90418-7; SHAI Y, 1990, J BIOL CHEM, V265, P20202; SHAI Y, 1991, J BIOL CHEM, V266, P22346; SHIMIZU YK, 1976, VIROLOGY, V71, P48, DOI 10.1016/0042-6822(76)90093-3; SLEPUSHKIN VA, 1990, BIOCHEM BIOPH RES CO, V172, P952, DOI 10.1016/0006-291X(90)90768-I; STEGMANN T, 1989, ANNU REV BIOPHYS BIO, V18, P187, DOI 10.1146/annurev.bb.18.060189.001155; Tamm LK, 1997, Q REV BIOPHYS, V30, P365, DOI 10.1017/S0033583597003375; VANINI S, 1993, AIDS, V7, P167, DOI 10.1097/00002030-199302000-00003; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P75; WILD C, 1994, P NATL ACAD SCI USA, V91, P12676, DOI 10.1073/pnas.91.26.12676; WILD C, 1995, AIDS RES HUM RETROV, V11, P323, DOI 10.1089/aid.1995.11.323; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; WU CSC, 1981, BIOCHEMISTRY-US, V20, P566, DOI 10.1021/bi00506a019; YAMADA KM, 1975, P NATL ACAD SCI USA, V72, P3158, DOI 10.1073/pnas.72.8.3158; YANG PW, 1987, BIOCHEM BIOPH RES CO, V145, P298, DOI 10.1016/0006-291X(87)91320-9; YEAGLE PL, 1993, FUSION SENDAI VIRUS; Young JK, 1998, VIROLOGY, V243, P21, DOI 10.1006/viro.1998.9044	81	42	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27182	27190		10.1074/jbc.273.42.27182	http://dx.doi.org/10.1074/jbc.273.42.27182			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765238	hybrid			2022-12-27	WOS:000076448000025
J	Hu, Y; Fisette, PL; Denlinger, LC; Guadarrama, AG; Sommer, JA; Proctor, RA; Bertics, PJ				Hu, Y; Fisette, PL; Denlinger, LC; Guadarrama, AG; Sommer, JA; Proctor, RA; Bertics, PJ			Purinergic receptor modulation of lipopolysaccharide signaling and inducible nitric-oxide synthase expression in RAW 264.7 macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR ATP; BACTERIAL LIPOPOLYSACCHARIDE; NUCLEOTIDE RECEPTOR; MYELOID LEUKOCYTES; MURINE MACROPHAGES; PROTEIN-KINASES; P-2X RECEPTOR; CELL-GROWTH; ACTIVATION; DIFFERENTIATION	Previous studies have suggested that the P2Z/P2X(7), purinergic receptor can participate in nucleotide-induced modulation of lipopolysaccharide (LPS) stimulated inflammatory mediator production. To test this hypothesis, we evaluated whether antagonism of the P2Z/P2X(7), receptor can influence LPS signaling and expression of the inducible form of nitric-oxide synthase (iNOS) in RAW 264.7 macrophages, In the present study, we demonstrate that pretreatment of RAW 264.7 macrophages with a P2Z/P2X(7) receptor antagonist, periodate oxidized adenosine 5'-triphosphate (o-ATP), substantially inhibits LPS-stimulated NO production and iNOS expression without altering cell viability. This effect on LPS-induced iNOS expression is mimicked by a pyridoxal-phosphate-based antagonist (pyridoxal-phosphate-6-azophenyl-2',4'-disuIfonic acid) of the P2Z/P2X(7) purinergic receptor, indicating that these results are not unique to o-ATP, Additionally, o-ATP prevents cell death induced by P2Z/P2X(7) receptor agonists, To ascertain how P2Z/P2X(7), receptor antagonists influence LPS signaling, we evaluated the capacity of o-ATP to regulate LPS-mediated activation of the transcription factor, nuclear factor-kappa B, and the mitogen-activated protein kinases, extracellular signal-regulated kinase (ERK) 1 and ERK2. These experiments reveal that pretreatment of RAW 264.7 cells with o-ATP attenuates the LPS stimulation of a nuclear factor-kappa B-like binding activity. Moreover, the activation of ERK1 and ERK2 by LPS, but not by the phorbol ester, phorbol Ig-myristate 13-acetate, is also blocked in RAW 264.7 cells by o-ATP pretreatment, In summary, these data suggest that the P2Z/P2X(7), receptor modulates LPS-induced macrophage activation as assessed by iNOS expression and NO production. This report implicates the P2Z/P2X(7) receptor in the control of protein kinase cascades and transcriptional processes, and these observations are likely to be important for the development of selective purinergic receptor antagonists for the treatment of septic shock.	Univ Wisconsin, Sch Med, Dept Biomol Chem, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Cellular & Mol Biol, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Med Microbiol & Immunol, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Mol & Cellular Pharmacol, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Bertics, PJ (corresponding author), Univ Wisconsin, Sch Med, Dept Biomol Chem, 1300 Univ Ave, Madison, WI 53706 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007215, T32GM008349] Funding Source: NIH RePORTER; NICHD NIH HHS [5 T32 HD07259] Funding Source: Medline; NIGMS NIH HHS [T32-GM08349, T32-GM07215] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; Bone RC, 1997, CHEST, V112, P235, DOI 10.1378/chest.112.1.235; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; BROWN C, 1995, BRIT J PHARMACOL, V116, P2413, DOI 10.1111/j.1476-5381.1995.tb15088.x; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DELUDE RL, 1994, J BIOL CHEM, V269, P22253; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; Denlinger LC, 1996, J BIOL CHEM, V271, P337, DOI 10.1074/jbc.271.1.337; Denlinger LC, 1998, INFECT IMMUN, V66, P1638, DOI 10.1128/IAI.66.4.1638-1647.1998; DIVIRGILIO F, 1995, IMMUNOL TODAY, V16, P524, DOI 10.1016/0167-5699(95)80045-X; Dubyak GR, 1996, DRUG DEVELOP RES, V39, P269, DOI 10.1002/(SICI)1098-2299(199611/12)39:3/4<269::AID-DDR6>3.0.CO;2-P; ELMOATASSIM C, 1993, J BIOL CHEM, V268, P15571; Ferrari D, 1997, J EXP MED, V185, P579, DOI 10.1084/jem.185.3.579; Ferrari D, 1997, J IMMUNOL, V159, P1451; Ferrari D, 1997, J CELL BIOL, V139, P1635, DOI 10.1083/jcb.139.7.1635; Fisette PL, 1996, DRUG DEVELOP RES, V39, P377, DOI 10.1002/(SICI)1098-2299(199611/12)39:3/4<377::AID-DDR19>3.0.CO;2-Z; Gargett CE, 1996, BIOCHEM J, V313, P529, DOI 10.1042/bj3130529; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Humphreys BD, 1996, J IMMUNOL, V157, P5627; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; Lambrecht G, 1996, J AUTON PHARMACOL, V16, P341, DOI 10.1111/j.1474-8673.1996.tb00049.x; Martin KA, 1997, MOL PHARMACOL, V51, P97, DOI 10.1124/mol.51.1.97; MURGIA M, 1993, J BIOL CHEM, V268, P8199; PROCTOR RA, 1995, VIRULENCE MECHANISMS OF BACTERIAL PATHOGENS, 2ND EDITION, P173; PROCTOR RA, 1994, P NATL ACAD SCI USA, V91, P6017, DOI 10.1073/pnas.91.13.6017; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; Rassendren F, 1997, J BIOL CHEM, V272, P5482, DOI 10.1074/jbc.272.9.5482; RESTA R, 1993, GENE, V133, P171, DOI 10.1016/0378-1119(93)90635-G; Sanghera JS, 1996, J IMMUNOL, V156, P4457; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; TONETTI M, 1995, BIOCHEM BIOPH RES CO, V214, P125, DOI 10.1006/bbrc.1995.2265; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; XIE QW, 1994, J BIOL CHEM, V269, P4705; ZIEGLERHEITBROCK HWL, 1995, IMMUNOBIOLOGY, V193, P217	36	117	119	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27170	27175		10.1074/jbc.273.42.27170	http://dx.doi.org/10.1074/jbc.273.42.27170			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765236	hybrid			2022-12-27	WOS:000076448000023
J	Khodursky, AB; Cozzarelli, NR				Khodursky, AB; Cozzarelli, NR			The mechanism of inhibition of topoisomerase IV by quinolone antibacterials	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II DNA TOPOISOMERASE; DOUBLE-STRAND BREAKS; ESCHERICHIA-COLI; STAPHYLOCOCCUS-AUREUS; PRIMARY TARGET; GENE-PRODUCT; GYRASE; REPLICATION; RESISTANCE; MUTATIONS	Topoisomerase IV (Topo IV) is a mediator of quinolone toxicity in bacteria. In this work, we demonstrate that norfloxacin, a model quinolone, converts Escherichia coli Topo IV into a poisonous adduct on DNA as opposed to inhibiting topoisomerase activity. Norfloxacin inhibition of Topo TV induces a slow decline in DNA synthesis that parallels cell death. Treatment of cells with a lethal concentration of the antibacterial did not block chromosome segregation, the phenotype of catalytic inhibition of Topo IV. Instead, norfloxacin causes DNA damage, as evidenced by the induction of the SOS pathway for DNA repair; the increase in susceptibility to the drug by mutations in genes for DNA repair pathways including recA, recB, and uvrD; and the efficient detergent-induced linearization of plasmid DNA in drug-treated cells. Wild-type and drug-resistant alleles of Topo IV are co-dominant, but we find that mutations in recA, seqA, or gyrB result in unconditional dominance of the sensitive allele, the characteristic of a poisoning mode of inhibition. These mutations either compromise chromosome integrity or force Topo TV to play a more active role in DNA unlinking in front of the replication fork. We interpret our results in terms of distinct but complementary roles of Topo IV and gyrase in DNA replication.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Khodursky, AB (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.				NIEHS NIH HHS [ESO 1896] Funding Source: Medline; NIGMS NIH HHS [GM 31657] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031657, R37GM031657] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; BELLAND RJ, 1994, MOL MICROBIOL, V14, P371, DOI 10.1111/j.1365-2958.1994.tb01297.x; BOCHNER BR, 1980, J BACTERIOL, V143, P926, DOI 10.1128/JB.143.2.926-933.1980; BROWN PO, 1979, SCIENCE, V206, P1081, DOI 10.1126/science.227059; CHAUDHURY AM, 1985, MOL GEN GENET, V201, P525, DOI 10.1007/BF00331350; Chen CR, 1996, J MOL BIOL, V258, P627, DOI 10.1006/jmbi.1996.0274; CONTRERAS A, 1992, MOL MICROBIOL, V6, P1617; Davies J, 1996, NATURE, V383, P219, DOI 10.1038/383219a0; Eckstein F., 1995, NUCLEIC ACIDS MOL BI, P115; FERRERO L, 1994, MOL MICROBIOL, V13, P641, DOI 10.1111/j.1365-2958.1994.tb00458.x; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GUDAS LJ, 1976, J MOL BIOL, V101, P459, DOI 10.1016/0022-2836(76)90240-0; HALLETT P, 1990, GENE, V93, P139, DOI 10.1016/0378-1119(90)90148-K; HANE MW, 1969, J BACTERIOL, V99, P238, DOI 10.1128/JB.99.1.238-241.1969; HOOPER DC, 1993, MECH QUINOLONE ACTIO; HOWARD MT, 1994, P NATL ACAD SCI USA, V91, P12031, DOI 10.1073/pnas.91.25.12031; HSIANG YH, 1989, J BIOL CHEM, V264, P9713; Huang WM, 1996, ANNU REV GENET, V30, P79; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KHODURSKY AB, 1995, P NATL ACAD SCI USA, V92, P11801, DOI 10.1073/pnas.92.25.11801; KRASIN F, 1981, P NATL ACAD SCI-BIOL, V78, P3450, DOI 10.1073/pnas.78.6.3450; KRASIN F, 1977, J MOL BIOL, V116, P81, DOI 10.1016/0022-2836(77)90120-6; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; Kumagai Y, 1996, ANTIMICROB AGENTS CH, V40, P710, DOI 10.1128/AAC.40.3.710; LOCKSHON D, 1985, J MOL BIOL, V181, P63, DOI 10.1016/0022-2836(85)90324-9; LU M, 1994, CELL, V77, P413, DOI 10.1016/0092-8674(94)90156-2; MA D, 1993, J BACTERIOL, V175, P6299, DOI 10.1128/JB.175.19.6299-6313.1993; MILLER JH, 1972, EXPT GENETICS; Neece SH, 1996, MOL MICROBIOL, V20, P1145, DOI 10.1111/j.1365-2958.1996.tb02635.x; Ng EY, 1996, ANTIMICROB AGENTS CH, V40, P1881, DOI 10.1128/AAC.40.8.1881; ORR E, 1979, MOL GEN GENET, V177, P103, DOI 10.1007/BF00267259; Pan XS, 1996, ANTIMICROB AGENTS CH, V40, P2321, DOI 10.1128/AAC.40.10.2321; PANG PP, 1983, J BACTERIOL, V153, P1172, DOI 10.1128/JB.153.3.1172-1179.1983; RAJI A, 1985, J BACTERIOL, V162, P1173, DOI 10.1128/JB.162.3.1173-1179.1985; Sambrook J., 2002, MOL CLONING LAB MANU; Schneider E, 1990, Adv Pharmacol, V21, P149, DOI 10.1016/S1054-3589(08)60342-7; Singer W, 1989, CONCEPTS NEUROSCI, V1, P1; SKARSTAD K, 1993, J BACTERIOL, V175, P5505, DOI 10.1128/JB.175.17.5505-5509.1993; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; Ullsperger C, 1996, J BIOL CHEM, V271, P31549, DOI 10.1074/jbc.271.49.31549; Yamagishi JI, 1996, ANTIMICROB AGENTS CH, V40, P1157, DOI 10.1128/AAC.40.5.1157; Zechiedrich EL, 1997, GENE DEV, V11, P2580, DOI 10.1101/gad.11.19.2580; ZECHIEDRICH EL, 1995, GENE DEV, V9, P2859, DOI 10.1101/gad.9.22.2859	43	134	138	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27668	27677		10.1074/jbc.273.42.27668	http://dx.doi.org/10.1074/jbc.273.42.27668			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765303	hybrid			2022-12-27	WOS:000076448000090
J	Rajakumar, RA; Thamotharan, S; Menon, RK; Devaskar, SU				Rajakumar, RA; Thamotharan, S; Menon, RK; Devaskar, SU			Sp1 and Sp3 regulate transcriptional activity of the facilitative glucose transporter isoform-3 gene in mammalian neuroblasts and trophoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; SV40 EARLY PROMOTER; GROWTH-FACTOR-I; RECEPTOR GENE; BINDING-SITES; DEVELOPMENTAL EXPRESSION; MESSENGER-RNA; MUSCLE-CELLS; MOUSE-BRAIN; RAT-BRAIN	The murine facilitative glucose transporter isoform 3 (Glut 3) is developmentally regulated and is predominantly expressed in neurons and trophoblasts. Employing the primer extension and RNase protection assays, the transcription start site (denoted as +1) of the murine Glut 3 gene was localized to 305 base pairs (bp) 5' to the ATG translation start codon. Transient transfection assays in N2A, H19-7 neuroblasts, and HRP.1 trophoblasts using sequential 5'-deletions of the murine Glut 3-luciferase fusion gene indicated that the -203 to +237 bp region with reference to the transcriptional start site contained promoter activity. Repressor function was limited to the -137 to -130 bp region within the transcriptional activation domain. The nuclear factors Spl and Sp3 bound this GC-rich region in N2A, H19-7, and HRP.1 cells. Dephosphorylation of Sp1 was essential for Glut 3 DNA binding. The related Sp3 protein also bound this same region of mouse Glut 3 in all three cell lines. Mutations of the Sp1-binding site employed in transient transfection and mobility shift assays confirmed the nature of the DNA-binding proteins, while supershift assays with anti-Sp1 and anti-Sp3 IgGs characterized the differences in the two DNA-binding proteins. Co-transfection of the Glut 3-luciferase fusion gene with or without mutations of the Sp1-binding site along with the Spl or Sp3 expression vectors in Drosophila SL2 cells confirmed a reciprocal effect, with Sp1 suppressing and Sp3 activating Glut 3 gene transcription.	Univ Pittsburgh, Sch Med, Magee Womens Res Inst, Dept Pediat,Div Neonatol & Dev Biol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Magee Womens Res Inst, Dept Pediat,Div Endocrinol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute	Devaskar, SU (corresponding author), Magee Womens Hosp, Dept Pediat, 300 Halket St, Pittsburgh, PA 15213 USA.	sdevaskar@mail.magee.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD025024, R01HD033997, R01HD025024] Funding Source: NIH RePORTER; NICHD NIH HHS [HD33997, HD25024] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMMENDOLA R, 1992, J BIOL CHEM, V267, P17944; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Baker DL, 1996, J BIOL CHEM, V271, P5921, DOI 10.1074/jbc.271.10.5921; BEITNERJOHNSON D, 1995, MOL ENDOCRINOL, V9, P1147, DOI 10.1210/me.9.9.1147; BELL GI, 1993, J BIOL CHEM, V268, P19161; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; Bigger CB, 1997, J BIOL CHEM, V272, P25976, DOI 10.1074/jbc.272.41.25976; BOILEAU P, 1995, J CLIN INVEST, V96, P309, DOI 10.1172/JCI118036; BONNY C, 1995, MOL ENDOCRINOL, V9, P1413, DOI 10.1210/me.9.10.1413; BOORSTEIN WR, 1989, METHOD ENZYMOL, V180, P347; Chen JP, 1997, J BIOL CHEM, V272, P23144, DOI 10.1074/jbc.272.37.23144; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; Daniel S, 1996, J BIOL CHEM, V271, P1385, DOI 10.1074/jbc.271.3.1385; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; DEVASKAR SU, 1992, PEDIATR RES, V31, P1, DOI 10.1203/00006450-199201000-00001; DEVASKAR SU, 1994, AM J OBSTET GYNECOL, V171, P1316, DOI 10.1016/0002-9378(94)90154-6; DEVASKAR SU, 1994, J BIOL CHEM, V269, P8445; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EHRHARDT RA, 1997, AM J PHYSIOL, V42, pR1132; EVES EM, 1992, P NATL ACAD SCI USA, V89, P4373, DOI 10.1073/pnas.89.10.4373; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Gao JG, 1996, MOL ENDOCRINOL, V10, P613, DOI 10.1210/me.10.6.613; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; HAAS S, 1993, MOL CELL BIOL, V13, P3103, DOI 10.1128/MCB.13.5.3103; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; JENSEN DE, 1995, J BIOL CHEM, V270, P6555, DOI 10.1074/jbc.270.12.6555; KIM HS, 1995, MOL ENDOCRINOL, V9, P178, DOI 10.1210/me.9.2.178; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Li RG, 1996, J BIOL CHEM, V271, P18925, DOI 10.1074/jbc.271.31.18925; LIU ML, 1992, J BIOL CHEM, V267, P11673; Madsen CS, 1997, J BIOL CHEM, V272, P6332, DOI 10.1074/jbc.272.10.6332; MAHER F, 1994, MOL CELL NEUROSCI, V5, P369, DOI 10.1006/mcne.1994.1044; MANTYCH GJ, 1993, ENDOCRINOLOGY, V133, P600, DOI 10.1210/en.133.2.600; MANTYCH GJ, 1992, ENDOCRINOLOGY, V131, P1270, DOI 10.1210/en.131.3.1270; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Maxam A M, 1980, Methods Enzymol, V65, P499; McDonough PM, 1997, J BIOL CHEM, V272, P24046, DOI 10.1074/jbc.272.38.24046; MENON RK, 1995, J BIOL CHEM, V270, P8851, DOI 10.1074/jbc.270.15.8851; MURAKAMI T, 1992, J BIOL CHEM, V267, P9300; NAGAMATSU S, 1994, BIOCHEM J, V300, P125, DOI 10.1042/bj3000125; NAGAMATSU S, 1992, J BIOL CHEM, V267, P467; OFIR R, 1995, EUR J IMMUNOL, V25, P3070, DOI 10.1002/eji.1830251113; Pantaleon M, 1997, P NATL ACAD SCI USA, V94, P3795, DOI 10.1073/pnas.94.8.3795; POSTIC C, 1994, AM J PHYSIOL, V266, pE548, DOI 10.1152/ajpendo.1994.266.4.E548; Rajakumar RA, 1996, MOL ENDOCRINOL, V10, P867, DOI 10.1210/me.10.7.867; Roder K, 1997, J BIOL CHEM, V272, P21616, DOI 10.1074/jbc.272.34.21616; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schroeder RE, 1997, PEDIATR RES, V41, P11, DOI 10.1203/00006450-199701000-00002; SENGUPTA PK, 1994, AM J HEMATOL, V46, P169, DOI 10.1002/ajh.2830460302; SOARES MJ, 1987, DEV BIOL, V124, P134, DOI 10.1016/0012-1606(87)90466-0; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; Uehara Y, 1997, AM J PHYSIOL-ENDOC M, V272, pE716, DOI 10.1152/ajpendo.1997.272.4.E716; Urabe T, 1996, J NEUROCHEM, V67, P265; VANNUCCI SJ, 1994, AM J PHYSIOL-ENDOC M, V267, pE605, DOI 10.1152/ajpendo.1994.267.4.E605; VANNUCCI SJ, 1994, J NEUROCHEM, V62, P240; WILDEMAN AG, 1984, EMBO J, V3, P3129, DOI 10.1002/j.1460-2075.1984.tb02269.x	62	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27474	27483		10.1074/jbc.273.42.27474	http://dx.doi.org/10.1074/jbc.273.42.27474			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765277	hybrid			2022-12-27	WOS:000076448000064
J	Waterborg, JH				Waterborg, JH			Dynamics of histone acetylation in Chlamydomonas reinhardtii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN STRUCTURE; CHICKEN ERYTHROCYTES; ACTIVE CHROMATIN; BINDING-SITE; CELL-CYCLE; TRANSCRIPTION; NUCLEOSOME; ALFALFA; YEAST; IDENTIFICATION	The dynamic character of core histone post-translational acetylation in the unicellular green alga Chlamydomonas reinhardtii was studied by tritiated acetate incorporation. Histone H3 is the major target of acetylation, steady state, and in pulse and pulse-chase analyses. Acetylation turnover rates were measured by tracer labeling under steady-state conditions. Half-Lives of 1.5-3 min were found for penta- to mono-acetylation of H3, dynamically acetylated to the 30% level. Twenty percent of H3 was multi-acetylated, on average with 3.2 acetyl-lysines, all with rapid turnover. Deacetylase inhibitor trichostatin A (TSA) caused doubling of average acetylation levels, primarily as penta-acetylated H3, but half of H3 was not acetylated at all. The level of histone H4 acetylation was only half that of H3 and a major fraction of mono- and di-acetylated forms appeared static. The dynamic fraction had an average half-life of 3.5 min with higher turnover rates for more highly acetylated H4 forms. TSA, inhibiting less effectively deacetylases active on H4, strongly increased multi-acetylated H4 levels and doubled average acetylation. As for H3, half of histone H4 remained unacetylated. Acetylation of histone H2B was low and of H2A was barely measurable. Despite turnover with half-lives of approximately 2 min, no increase beyond di-acetylation was seen upon TSA treatment.	Univ Missouri, Sch Biol Sci, Div Cell Biol & Biophys, Kansas City, MO 64110 USA	University of Missouri System; University of Missouri Kansas City	Waterborg, JH (corresponding author), Rm 414 BSB,5007 Rockhill Rd, Kansas City, MO 64110 USA.	waterborg@cctr.umkc.edu	Waterborg, Jakob H./J-5479-2013	Waterborg, Jakob H./0000-0002-2881-4634				ALLAN J, 1986, J MOL BIOL, V187, P591, DOI 10.1016/0022-2836(86)90337-2; ALLAN J, 1982, J CELL BIOL, V93, P285, DOI 10.1083/jcb.93.2.285; Allfrey V. G, 1977, CHROMATIN CHROMOSOME, P167; ALMOUZNI G, 1994, DEV BIOL, V165, P654, DOI 10.1006/dbio.1994.1283; An WJ, 1998, P NATL ACAD SCI USA, V95, P3396, DOI 10.1073/pnas.95.7.3396; Belyaev ND, 1997, CHROMOSOMA, V106, P193, DOI 10.1007/s004120050239; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; COVAULT J, 1980, J BIOL CHEM, V255, P9110; DarkinRattray SJ, 1996, P NATL ACAD SCI USA, V93, P13143, DOI 10.1073/pnas.93.23.13143; DAVIE JR, 1994, J CELL BIOCHEM, V55, P98, DOI 10.1002/jcb.240550112; FABRY S, 1995, CURR GENET, V28, P333, DOI 10.1007/BF00326431; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Hayes JJ, 1996, BIOCHEMISTRY-US, V35, P11931, DOI 10.1021/bi961590+; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; JACKSON V, 1975, J BIOL CHEM, V250, P4856; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; KUROCHKINA L, 1992, BIOCHEM BIOPH RES CO, V187, P261, DOI 10.1016/S0006-291X(05)81486-X; Kwon HJ, 1998, P NATL ACAD SCI USA, V95, P3356, DOI 10.1073/pnas.95.7.3356; Lechner T, 1996, BBA-PROTEIN STRUCT M, V1296, P181, DOI 10.1016/0167-4838(96)00069-6; LIN R, 1989, J CELL BIOL, V108, P1577, DOI 10.1083/jcb.108.5.1577; LOPEZRODAS G, 1991, J BIOL CHEM, V266, P18745; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Lusser A, 1997, SCIENCE, V277, P88, DOI 10.1126/science.277.5322.88; MARVIN KW, 1990, J BIOL CHEM, V265, P19839; Matthews HR, 1985, ENZYMOLOGY POSTTRANS, V2, P125; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; NELSON DA, 1982, J BIOL CHEM, V257, P1565; NELSON DA, 1983, BIOCHIM BIOPHYS ACTA, V741, P269, DOI 10.1016/0167-4781(83)90068-4; PANTAZIS P, 1982, J CELL BIOCHEM, V20, P225, DOI 10.1002/jcb.240200303; Pruss D, 1996, SCIENCE, V274, P614, DOI 10.1126/science.274.5287.614; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; SEALY L, 1978, CELL, V14, P115, DOI 10.1016/0092-8674(78)90306-9; SENDRA R, 1988, PLANT MOL BIOL, V11, P857, DOI 10.1007/BF00019525; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; THOMAS JO, 1984, J CELL SCI, P1; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; van Holde KE., 1989, SPRINGER SERIES MOL; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; WALTHER Z, 1995, NUCLEIC ACIDS RES, V23, P3756, DOI 10.1093/nar/23.18.3756; WATERBORG JH, 1991, PLANT PHYSIOL, V96, P453, DOI 10.1104/pp.96.2.453; WATERBORG JH, 1992, PLANT MOL BIOL, V18, P181, DOI 10.1007/BF00034947; WATERBORG JH, 1993, J BIOL CHEM, V268, P4912; WATERBORG JH, 1983, BIOCHEMISTRY-US, V22, P1489, DOI 10.1021/bi00275a025; WATERBORG JH, 1990, J BIOL CHEM, V265, P17157; WATERBORG JH, 1995, PLANT PHYSIOL, V109, P393, DOI 10.1104/pp.109.2.393; WATERBORG JH, 1992, BIOCHEMISTRY-US, V31, P6211, DOI 10.1021/bi00142a006; WATERBORG JH, 1990, BIOCHIM BIOPHYS ACTA, V1049, P324, DOI 10.1016/0167-4781(90)90105-B; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; ZHANG DE, 1988, BIOCHEM J, V250, P241, DOI 10.1042/bj2500241; ZHANG DE, 1988, BIOCHEM J, V250, P233, DOI 10.1042/bj2500233	56	30	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27602	27609		10.1074/jbc.273.42.27602	http://dx.doi.org/10.1074/jbc.273.42.27602			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765294	hybrid			2022-12-27	WOS:000076448000081
J	Oelkers, P; Behari, A; Cromley, D; Billheimer, JT; Sturley, SL				Oelkers, P; Behari, A; Cromley, D; Billheimer, JT; Sturley, SL			Characterization of two human genes encoding acyl coenzyme A: Cholesterol acyltransferase-related enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; RADIATION INACTIVATION; FUNCTIONAL EXPRESSION; SUBSTRATE-SPECIFICITY; ACAT INHIBITORS; COA; CELLS; ESTERIFICATION; METABOLISM; CDNA	The enzyme acyl coenzyme A:cholesterol acyltransferase 1 (ACAT1) mediates sterol esterification, a crucial component of intracellular lipid homeostasis. Two enzymes catalyze this activity in Saccharomyces cerevisiae (yeast), and several lines of evidence suggest multigene families may also exist in mammals. Using the human ACAT1 sequence to screen data bases of expressed sequence tags, we identified two novel and distinct partial human cDNAs. Full-length cDNA clones for these ACAT related gene products (ARGP) 1 and 2 were isolated from a hepatocyte (HepG2) cDNA library. ARGP1 was expressed in numerous human adult tissues and tissue culture cell lines, whereas expression of ARGP2 was more restricted, In vitro microsomal assays in a yeast strain deleted for both esterification genes and completely deficient in sterol esterification indicated that ARGP2 esterified cholesterol while ARGP1 did not, In contrast to ACAT1 and similar to liver esterification, the activity of ARGP2 was relatively resistant to a histidine active site modifier, ARGP1 is therefore a tissue-specific sterol esterification enzyme which we thus designated ACAT2, We speculate that ARGP1 participates in the coenzyme A-dependent acylation of substrate(s) other than cholesterol, Consistent with this hypothesis, ARGP1, unlike any other member of this multigene family, possesses a predicted diacylglycerol binding motif suggesting that it may perform the last acylation in triglyceride biosynthesis,	Columbia Univ Coll Phys & Surg, Inst Human Nutr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Physiol & Mol Biophys, New York, NY 10032 USA; DuPont Pharmaceut Co, Expt Stn, Wilmington, DE 19880 USA	Columbia University; Columbia University; Columbia University; DuPont	Sturley, SL (corresponding author), Columbia Univ Coll Phys & Surg, Inst Human Nutr, 650 W 168th St, New York, NY 10032 USA.			Oelkers, Peter/0000-0002-2421-472X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL007343] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07343] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AUSUBEL FM, 1987, CURRENT PROTOCOLS MO, V2; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BILLHEIMER JT, 1990, J BIOL CHEM, V265, P8632; BILLHEIMER JT, 1992, ADV CHOLESTEROL RES; BOTHAM KM, 1992, BIOCHEM SOC T, V20, P454, DOI 10.1042/bst0200454; Cao GQ, 1996, J BIOL CHEM, V271, P14642, DOI 10.1074/jbc.271.24.14642; CARR TP, 1995, J LIPID RES, V36, P25; CARR TP, 1992, ARTERIOSCLER THROMB, V12, P1275; CHANG CCY, 1995, J BIOL CHEM, V270, P29532; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; CHANG CCY, 1994, SOMAT CELL MOLEC GEN, V20, P71, DOI 10.1007/BF02257489; CIVEN M, 1982, J STEROID BIOCHEM, V16, P817, DOI 10.1016/0022-4731(82)90040-1; CORTON JM, 1992, EUR J BIOCHEM, V204, P203, DOI 10.1111/j.1432-1033.1992.tb16625.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; DOOLITTLE GM, 1982, BIOCHEMISTRY-US, V21, P674, DOI 10.1021/bi00533a014; EINARSSON K, 1989, J LIPID RES, V30, P739; ERICKSON SK, 1994, J LIPID RES, V35, P763; FIELD FJ, 1990, GASTROENTEROLOGY, V99, P539, DOI 10.1016/0016-5085(90)91040-D; GOODMAN DS, 1964, J BIOL CHEM, V239, P1335; GUO Z, 1996, CIRCULATION, V94, P35; HUFF MW, 1994, ARTERIOSCLER THROMB, V14, P1498, DOI 10.1161/01.ATV.14.9.1498; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KINNUNEN PM, 1988, BIOCHEMISTRY-US, V27, P7344, DOI 10.1021/bi00419a025; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MADUSKUIE TP, 1995, J MED CHEM, V38, P1067, DOI 10.1021/jm00007a004; Maniatis T., 1987, MOL CLONING LAB MANU; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; Matsuda H, 1996, BBA-LIPID LIPID MET, V1301, P76, DOI 10.1016/0005-2760(96)00020-3; Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041; Rost B, 1996, METHOD ENZYMOL, V266, P525; SCHOONDERWOERD K, 1990, BIOCHEM J, V268, P487, DOI 10.1042/bj2680487; Sturley SL, 1997, CURR OPIN LIPIDOL, V8, P167, DOI 10.1097/00041433-199706000-00007; TABAS I, 1996, CIRCULATION, V94, P35; TAVANI DM, 1982, J LIPID RES, V23, P774; UELMEN PJ, 1995, J BIOL CHEM, V270, P26192, DOI 10.1074/jbc.270.44.26192; VELDHUIS JD, 1985, ENDOCRINOLOGY, V116, P25, DOI 10.1210/endo-116-1-25; WARNER GJ, 1995, J BIOL CHEM, V270, P5772, DOI 10.1074/jbc.270.11.5772; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776; Yang HY, 1996, SCIENCE, V272, P1353, DOI 10.1126/science.272.5266.1353; Yang HY, 1997, J BIOL CHEM, V272, P3980, DOI 10.1074/jbc.272.7.3980; Yu CJ, 1996, J BIOL CHEM, V271, P24157, DOI 10.1074/jbc.271.39.24157	45	321	360	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26765	26771		10.1074/jbc.273.41.26765	http://dx.doi.org/10.1074/jbc.273.41.26765			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756920	hybrid			2022-12-27	WOS:000076373300074
J	Ashrafi, K; Farazi, TA; Gordon, JI				Ashrafi, K; Farazi, TA; Gordon, JI			A role for Saccharomyces cerevisiae fatty acid activation protein 4 in regulating protein N-myristoylation during entry into stationary phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA SYNTHETASE; MAMMALIAN G-PROTEIN; ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY; RESISTANT MUTANTS; GENETIC-ANALYSIS; YEAST PROTEIN; MYRISTOYLTRANSFERASE; EXPRESSION; ALPHA	Saccharomyces cerevisiae contains four known acyl-CoA synthetases (fatty acid activation proteins, Faaps), Faa1p and Faa4p activate exogenously derived fatty acids. Acyl-CoA metabolism plays a critical role in regulating protein N-myristoylation by the essential enzyme, myristoyl-CoA:protein N-myristoyltransferase (Nmt1p). In this report, we have examined whether Faa1p and Faa4p have distinct roles in affecting protein N-myristoylation as cells transition from growth in rich media to a growth-arrested state during nutrient deprivation (stationary phase). The colony-forming potential of 10 isogenic strains was defined as a function of time spent in stationary phase. These strains contained either a wild type or mutant NMTI allele, and wild type or null alleles of each FAA. Only the combination of the Nmt mutant (nmt451Dp; reduced affinity for myristoyl-CoA) and loss of Faa4p produced a dramatic loss of colony-forming units (CFU). The progressive millionfold reduction in CFU was associated with a deficiency in protein N-myristoylation that first appeared during log arithmic growth, worsened through the post-diauxic phase, and became extreme in stationary phase. Northern and Western blot analyses plus N-myristoyltransferase assays showed that Nmt is normally present only during the log and diauxic/post-diauxic periods, indicating that N-myristoylproteins present in stationary phase are "inherited" from these earlier phases. Moreover, FAA4 is the only FAA induced during the critical diauxic/early post-diauxic transition. Although substitution of nmt1-451D for NMT1 results in deficiencies in protein N-myristoylation, these deficiencies are modest and limited by compensatory responses that include augmented expression of nmt1-451D and precocious induction of FAA4 in log phase. Loss of Faa4p from nmt1-451D cells severely compromises their capacity to adequately myristoylate Nmt substrates prior to entry into stationary phase since none of the other Faaps are able to functionally compensate for its absence. To identify Nmt1p substrates that may affect maintenance of proliferative potential during stationary phase, we searched the yeast genome for known and putative N-myristoylproteins. Of the 64 genes found, 48 were successfully deleted in NMT1 cells. Removal of any one of the following nine substrates produced a loss of CFU similar to that observed in nmt1-451Dfaa4 Delta cells: Arf1p, Arf2p, Sip2p, Van1p, Ptc2p, YBL049W (homology to Snf7p), YJR114W, YKR007W, and YMR077C. These proteins provide opportunities to further define the molecular mechanisms that regulate survival during stationary phase.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL)	Gordon, JI (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Box 8103,660 S Euclid Ave, St Louis, MO 63110 USA.	jgordon@pharmsun.wustl.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038200] Funding Source: NIH RePORTER; NIAID NIH HHS [AI38200] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AbouElela S, 1996, CELL, V85, P115, DOI 10.1016/S0092-8674(00)81087-9; ABRAHAM PR, 1992, YEAST, V8, P227, DOI 10.1002/yea.320080309; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Bhatnagar RS, 1997, TRENDS CELL BIOL, V7, P14, DOI 10.1016/S0962-8924(97)10044-7; Bhatnagar RS, 1997, BIOCHEMISTRY-US, V36, P6700, DOI 10.1021/bi970311v; BITTER GA, 1984, GENE, V32, P263, DOI 10.1016/0378-1119(84)90002-7; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boutin JA, 1997, CELL SIGNAL, V9, P15, DOI 10.1016/S0898-6568(96)00100-3; Boyum R, 1997, MICROBIOL-SGM, V143, P1901, DOI 10.1099/00221287-143-6-1901; Church C, 1996, J BIOL CHEM, V271, P18499, DOI 10.1074/jbc.271.31.18499; CYERT MS, 1993, ADV PROTEIN PHOSPHAT, V7, P429; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DOHLMAN HG, 1993, P NATL ACAD SCI USA, V90, P9688, DOI 10.1073/pnas.90.20.9688; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; DURONIO RJ, 1991, J CELL BIOL, V113, P1313, DOI 10.1083/jcb.113.6.1313; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; DURONIO RJ, 1991, J BIOL CHEM, V266, P10498; DURONIO RJ, 1992, PROTEINS, V13, P41, DOI 10.1002/prot.340130105; EGNER R, 1993, J BIOL CHEM, V268, P27269; ERICKSON JR, 1993, GENETICS, V135, P655; HENGGEARONIS R, 1993, CELL, V72, P165, DOI 10.1016/0092-8674(93)90655-A; Hettema EH, 1996, EMBO J, V15, P3813, DOI 10.1002/j.1460-2075.1996.tb00755.x; JOHNSON DR, 1994, J BIOL CHEM, V269, P18037; JOHNSON DR, 1994, J CELL BIOL, V127, P751, DOI 10.1083/jcb.127.3.751; JOHNSON DR, 1994, P NATL ACAD SCI USA, V91, P10158, DOI 10.1073/pnas.91.21.10158; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; JOHNSON RS, 1994, J BIOL CHEM, V269, P21067; JONES MH, 1995, P NATL ACAD SCI USA, V92, P9687, DOI 10.1073/pnas.92.21.9687; KAHN RA, 1995, J BIOL CHEM, V270, P143, DOI 10.1074/jbc.270.1.143; KANIKENNULAT C, 1995, GENETICS, V140, P933; KANIKENNULAT C, 1990, MOL CELL BIOL, V10, P898, DOI 10.1128/MCB.10.3.898; KASSIR Y, 1978, GENETICS, V90, P49; KISHORE NS, 1991, J BIOL CHEM, V266, P8835; KNOLL LJ, 1995, J BIOL CHEM, V270, P10861, DOI 10.1074/jbc.270.18.10861; KNOLL LJ, 1994, J BIOL CHEM, V269, P16348; KNOLL LJ, 1995, J BIOL CHEM, V270, P20090, DOI 10.1074/jbc.270.34.20090; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lechler T, 1997, J CELL BIOL, V138, P95, DOI 10.1083/jcb.138.1.95; LEE KS, 1994, J BIOL CHEM, V269, P19725; Li R, 1997, J CELL BIOL, V136, P649, DOI 10.1083/jcb.136.3.649; LODGE JK, 1994, J BIOL CHEM, V269, P2996; Lodge JK, 1997, MICROBIOL-UK, V143, P357, DOI 10.1099/00221287-143-2-357; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; Murray D, 1997, STRUCTURE, V5, P985, DOI 10.1016/S0969-2126(97)00251-7; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RANDAZZO PA, 1995, METHOD ENZYMOL, V250, P394; Rudnick D.A., 1992, LIPID MODIFICATION P, P37; RUDNICK DA, 1993, P NATL ACAD SCI USA, V90, P1087, DOI 10.1073/pnas.90.3.1087; SCHULLER HJ, 1992, EUR J BIOCHEM, V203, P607, DOI 10.1111/j.1432-1033.1992.tb16590.x; SCHWEIZER E, 1970, P NATL ACAD SCI USA, V67, P660, DOI 10.1073/pnas.67.2.660; Sherman F., 1986, METHODS YEAST GENETI; SHIOZAKI K, 1994, CELL MOL BIOL RES, V40, P241; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGH N, 1985, BIOCHEMISTRY-US, V24, P6598, DOI 10.1021/bi00344a044; Stark MJR, 1996, YEAST, V12, P1647, DOI 10.1002/(SICI)1097-0061(199612)12:16<1647::AID-YEA71>3.0.CO;2-Q; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; TOWLER DA, 1988, J BIOL CHEM, V263, P1784; TU JL, 1993, GENETICS, V135, P17; VALLIER LG, 1991, GENETICS, V129, P675; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; YANG XL, 1994, EMBO J, V13, P5878, DOI 10.1002/j.1460-2075.1994.tb06933.x; Zhang LT, 1996, J BIOL CHEM, V271, P33131, DOI 10.1074/jbc.271.51.33131; ZHU DH, 1995, J BIOL CHEM, V270, P24831, DOI 10.1074/jbc.270.42.24831; ZUFFEREY R, 1995, EMBO J, V14, P4949, DOI 10.1002/j.1460-2075.1995.tb00178.x	66	76	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25864	25874		10.1074/jbc.273.40.25864	http://dx.doi.org/10.1074/jbc.273.40.25864			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748261	hybrid			2022-12-27	WOS:000076263100052
J	Kirsch, KH; Georgescu, MM; Hanafusa, H				Kirsch, KH; Georgescu, MM; Hanafusa, H			Direct binding of p130(Cas) to the guanine nucleotide exchange factor C3G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; EPIDERMAL GROWTH-FACTOR; SRC HOMOLOGY-3 DOMAIN; C-TERMINAL REGION; TYROSINE PHOSPHORYLATION; ADAPTER PROTEINS; SH3 DOMAINS; V-CRK; PTP-PEST; ACTIVATION	p130(Cas) (Cas; crk-associated substrate) belongs to a new family of docking molecules. It contains one Src homology (SH) 3 domain in its amino terminal region followed by a region containing binding motifs for SH2 and SH3 domains. To gain further insight into Cas signaling we used the SH3 domain of Cas in a two-hybrid screen to search a human placenta library for binding partners. The screen confirmed a previous finding of its binding to the focal adhesion kinase (FAK) but also identified C3G, a guanine nucleotide exchange factor. We found direct interaction between Cas and C3G in vitro and in vivo. A series of analysis with C3G deletion mutants revealed a proline-rich Gas-binding site (Ala(0)-Pro(1)-Pro(2)-Lys(3)-Pro(4)-Pro(5)-Leu(6)-Pro(7)) located NH2-terminal to the previously characterized Crk binding motifs in C3G. Mutagenesis studies showed that Pro(1), Lys(3), and Pro(4) within the ligand-binding site are critical for high affinity interaction. These results, combined with sequence alignments of proline-rich binding elements from proteins known for Cas binding, define the consensus sequence XXPXKPX which is recognized by the CasSH3 domain. Cas shows structural characteristics of a docking molecule and may serve to bring C3G to specific compartments within the cell.	Rockefeller Univ, Mol Oncol Lab, New York, NY 10021 USA	Rockefeller University	Hanafusa, H (corresponding author), Rockefeller Univ, Mol Oncol Lab, New York, NY 10021 USA.	saburo@rockvax.rockefeller.edu	Georgescu, Maria-Magdalena/AAJ-6359-2020		NCI NIH HHS [CA44356] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; Astier A, 1997, J BIOL CHEM, V272, P228; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; BOKOCH GM, 1993, BIOCHEM J, V289, P17, DOI 10.1042/bj2890017; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Casamassima A, 1997, J BIOL CHEM, V272, P9363; Chen D, 1997, J BIOL CHEM, V272, P27401, DOI 10.1074/jbc.272.43.27401; Clark EA, 1996, J BIOL CHEM, V271, P14814, DOI 10.1074/jbc.271.25.14814; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; Ishino M, 1995, ONCOGENE, V11, P2331; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Law SF, 1996, MOL CELL BIOL, V16, P3327; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; MAYRE BJ, 1998, CURR BIOL, V5, P296; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Nakamoto T, 1997, MOL CELL BIOL, V17, P3884, DOI 10.1128/MCB.17.7.3884; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; Nojima Y, 1996, Hum Cell, V9, P169; Ojaniemi M, 1997, J BIOL CHEM, V272, P25993, DOI 10.1074/jbc.272.41.25993; Okada S, 1997, J BIOL CHEM, V272, P28179, DOI 10.1074/jbc.272.45.28179; Okada S, 1996, J BIOL CHEM, V271, P25533, DOI 10.1074/jbc.271.41.25533; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; PATCH LA, 1995, J CELL SCI, V108, P1371; Petruzzelli L, 1996, J BIOL CHEM, V271, P7796, DOI 10.1074/jbc.271.13.7796; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Tanaka S, 1998, J BIOL CHEM, V273, P1281, DOI 10.1074/jbc.273.3.1281; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	52	80	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25673	25679		10.1074/jbc.273.40.25673	http://dx.doi.org/10.1074/jbc.273.40.25673			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748234	hybrid			2022-12-27	WOS:000076263100025
J	Labesse, I; Ferrari, D; Chen, ZW; Rossi, GL; Kuusk, V; McIntire, WS; Mathews, FS				Labesse, I; Ferrari, D; Chen, ZW; Rossi, GL; Kuusk, V; McIntire, WS; Mathews, FS			Crystallographic and spectroscopic studies of native, aminoquinol, and monovalent cation-bound forms of methylamine dehydrogenase from Methylobacterium extorquens AM1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY-AMINE DEHYDROGENASE; ELECTRON-TRANSFER COMPLEX; MAU GENE-CLUSTER; PARACOCCUS-DENITRIFICANS; TRYPTOPHAN TRYPTOPHYLQUINONE; THIOBACILLUS-VERSUTUS; CRYSTAL-STRUCTURE; KINETIC-PROPERTIES; PSEUDOMONAS AM1; BACTERIUM W3A1	Various monovalent cations influence the enzymatic activity and the spectroscopic properties of methylamine dehydrogenase (MADH). Here, we report the structure determination of this tryptophan tryptophylquinone-containing enzyme from Methylobacterium extorquens AM1 by high resolution x-ray crystallography (1.75 Angstrom). This first MADH crystal structure at low ionic strength is compared with the high resolution structure of the related MADH from Paracoccus denitrificans recently reported. We also describe the first structures (at 1.95 to 2.15 Angstrom resolution) of an MADH in the substrate-reduced form and in the presence of trimethylamine and of cesium, two competitive inhibitors. Polarized absorption microspectrophotometry was performed on single crystals under various redox, pH, and salt conditions. The results show that the enzyme is catalytically active in the crystal and that the cations cause the same spectral perturbations as are observed in solution. These studies lead us to propose a model for the entrance and binding of the substrate in the active site.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Dept Vet Affairs Med Ctr, Div Mol Biol, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA; Univ Parma, Ist Sci Biochim, I-43100 Parma, Italy	Washington University (WUSTL); University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Parma	Mathews, FS (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA.	mathews@biochem.wustl.edu		Labesse, Gilles/0000-0002-6861-3300	NHLBI NIH HHS [HL16251] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016251] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anthony C., 1982, BIOCH METHYLOTROPHS; Bishop GR, 1996, BIOCHEMISTRY-US, V35, P8948, DOI 10.1021/bi960404x; Bishop GR, 1997, BIOCHEMISTRY-US, V36, P13586, DOI 10.1021/bi970586a; BOULTON CA, 1979, BIOCHIM BIOPHYS ACTA, V570, P22, DOI 10.1016/0005-2744(79)90197-9; BROOKS HB, 1993, BIOCHEMISTRY-US, V32, P2725, DOI 10.1021/bi00061a034; BRUNGER AT, 1992, XPLOR VERSION 3 1; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; CHEN L, 1988, J MOL BIOL, V203, P1137, DOI 10.1016/0022-2836(88)90134-9; CHEN LY, 1993, PROTEIN SCI, V2, P147; CHEN LY, 1992, BIOCHEMISTRY-US, V31, P4959, DOI 10.1021/bi00136a006; Chen LY, 1998, J MOL BIOL, V276, P131, DOI 10.1006/jmbi.1997.1511; CHISTOSERDOV AY, 1994, J BACTERIOL, V176, P4052, DOI 10.1128/JB.176.13.4052-4065.1994; CHISTOSERDOV AY, 1994, J BACTERIOL, V176, P4073, DOI 10.1128/JB.176.13.4073-4080.1994; CHISTOSERDOV AY, 1992, BIOCHEM BIOPH RES CO, V184, P1181, DOI 10.1016/S0006-291X(05)80007-5; DAVIDSON VL, 1990, BIOCHIM BIOPHYS ACTA, V1016, P339, DOI 10.1016/0005-2728(90)90166-2; DAVIDSON VL, 1989, BIOCHEM J, V261, P107, DOI 10.1042/bj2610107; EADY RR, 1971, BIOCHEM J, V123, P757, DOI 10.1042/bj1230757; GORREN ACF, 1995, BIOCHEMISTRY-US, V34, P9748, DOI 10.1021/bi00030a012; GORREN ACF, 1994, BIOCHEMISTRY-US, V33, P12202, DOI 10.1021/bi00206a024; GORREN ACF, 1995, BIOCHEMISTRY-US, V34, P12926, DOI 10.1021/bi00040a002; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; HUIZINGA EG, 1992, BIOCHEMISTRY-US, V31, P9789, DOI 10.1021/bi00155a036; HUSAIN M, 1987, J BACTERIOL, V169, P1712, DOI 10.1128/jb.169.4.1712-1717.1987; ITO N, 1994, J MOL BIOL, V238, P794, DOI 10.1006/jmbi.1994.1335; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIRIUKHIN MY, 1990, METHOD ENZYMOL, V188, P247; KOOYSTRA PJU, 1988, EUR J BIOCHEM, V177, P345; KUUSK V, 1994, J BIOL CHEM, V269, P26136; Labesse G, 1998, BIOINFORMATICS, V14, P206, DOI 10.1093/bioinformatics/14.2.206; MCINTIRE WS, 1995, METHOD ENZYMOL, V258, P149; MCINTIRE WS, 1991, SCIENCE, V252, P817, DOI 10.1126/science.2028257; Merli A, 1996, J BIOL CHEM, V271, P9177, DOI 10.1074/jbc.271.16.9177; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OTWINOWSKI Z, 1993, DATA COLLECTION PROC; RIVETTI C, 1993, BIOCHEMISTRY-US, V32, P2888, DOI 10.1021/bi00062a021; Scrutton NS, 1996, BIOCHEM J, V319, P1; UBBINK M, 1991, EUR J BIOCHEM, V202, P1003, DOI 10.1111/j.1432-1033.1991.tb16462.x; VELLIEUX FMD, 1986, EUR J BIOCHEM, V154, P383, DOI 10.1111/j.1432-1033.1986.tb09409.x; VELLIEUX FMD, 1989, EMBO J, V8, P2171, DOI 10.1002/j.1460-2075.1989.tb08339.x; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Zhu ZY, 1998, BIOCHEM J, V329, P175, DOI 10.1042/bj3290175	43	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25703	25712		10.1074/jbc.273.40.25703	http://dx.doi.org/10.1074/jbc.273.40.25703			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748238	hybrid			2022-12-27	WOS:000076263100029
J	Wang, ZY; Melmed, S				Wang, ZY; Melmed, S			Functional map of a placenta-specific enhancer of the human leukemia inhibitory factor receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT GENE; TISSUE-SPECIFIC ENHANCER; ELEMENT-BINDING PROTEIN; IL-6 SIGNAL TRANSDUCER; FACTOR LIF RECEPTOR; CHORIONIC SOMATOMAMMOTROPIN; ADENOSINE-DEAMINASE; TARGETED DISRUPTION; CYTOKINE RECEPTORS; HUMAN ENDOMETRIUM	We recently reported a placenta-specific enhancer in the human leukemia inhibitory factor receptor (LIFR) gene and now show detailed characterization of the 226-base pair enhancer (-4625/-4400 nucleotides). Four of twenty-two mutants in linker analysis showed reduced promoter activities to 45, 30, 10, and 10%, respectively. Specific binding of region A (-4617/-4602) with nuclear extract was competed by a known Oct-1 oligo and supershifted by Oct-1 antibody. Specific binding of region B (-4549/-4535) was competed by a GATA oligo, but could not be supershifted by four GATA antibodies. Nevertheless, mutagenesis showed that critical bases in region B were identical to the GATA core motif, indicating that region B may bind to a novel GATA family transcription factor. The other two adjacent regions designated as region C (-4464/-4445) showed no known consensus binding sites, and their specific placental JEG-3 nuclear extract binding was not evident in nonplacental nuclear extracts and was not competed by a trophoblast specific element (TSE), indicating that region C is a novel placenta-specific element (PSE, CATTTCCTGAACTAGTTTTT). Footprinting localized the binding boundary of PSE-binding protein (PSEB), and three Gs were found to be important for specific PSE binding. UV cross-linking showed that PSEB had a molecular mass of similar to 160 kDa, substituting the PSE with two previously reported placenta elements TSE or chorionic somatomammotropin enhancer factor 1 (CSEF-1) motifs resulted in markedly different promoter activities, indicating that PSEB is indeed different from TSE binding protein or CSEF-1. These results are the first demonstration that a novel PSE is the major element for placenta-specific enhancer activity in human LIFR gene.	Univ Calif Los Angeles, Sch Med, Cedar Sinai Res Inst, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Melmed, S (corresponding author), Cedars Sinai Med Ctr, Div Endocrinol, 8700 Beverly Blvd,B-131, Los Angeles, CA 90048 USA.							ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BARSH GS, 1983, NUCLEIC ACIDS RES, V11, P3939, DOI 10.1093/nar/11.12.3939; BAUMANN H, 1991, J BIOL CHEM, V266, P20424; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BLACKBURN MR, 1995, J BIOL CHEM, V270, P23891, DOI 10.1074/jbc.270.41.23891; CHARNOCKJONES DS, 1994, J REPROD FERTIL, V101, P421; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; CHEM EY, 1989, GENOMICS, V4, P479; Chesnokova V, 1998, ENDOCRINOLOGY, V139, P2209, DOI 10.1210/en.139.5.2209; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DECHIARA TM, 1995, CELL, V83, P313, DOI 10.1016/0092-8674(95)90172-8; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DEUTSCH PJ, 1988, P NATL ACAD SCI USA, V85, P7922, DOI 10.1073/pnas.85.21.7922; ESCARY JL, 1993, NATURE, V363, P361, DOI 10.1038/363361a0; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GHARIB SD, 1990, ENDOCR REV, V11, P177, DOI 10.1210/edrv-11-1-177; HECKERT LL, 1995, J BIOL CHEM, V270, P26497, DOI 10.1074/jbc.270.44.26497; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; Jacquemin P, 1996, J BIOL CHEM, V271, P21775, DOI 10.1074/jbc.271.36.21775; Jacquemin P, 1997, J BIOL CHEM, V272, P12928, DOI 10.1074/jbc.272.20.12928; JACQUEMIN P, 1994, MOL CELL BIOL, V14, P93, DOI 10.1128/MCB.14.1.93; Jiang SW, 1997, MOL ENDOCRINOL, V11, P1223, DOI 10.1210/me.11.9.1223; KENDALL SK, 1995, GENE DEV, V9, P2007, DOI 10.1101/gad.9.16.2007; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KOJIMA K, 1995, HUM REPROD, V10, P1907, DOI 10.1093/oxfordjournals.humrep.a136205; KOJIMA K, 1994, BIOL REPROD, V50, P882, DOI 10.1095/biolreprod50.4.882; LI M, 1995, NATURE, V378, P724, DOI 10.1038/378724a0; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; NICKEL BE, 1990, BIOCHEM J, V267, P653, DOI 10.1042/bj2670653; ONDEK B, 1988, NATURE, V333, P40, DOI 10.1038/333040a0; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; Pennica Diane, 1996, Cytokine and Growth Factor Reviews, V7, P81, DOI 10.1016/1359-6101(96)00007-X; PITTMAN RH, 1994, J BIOL CHEM, V269, P19360; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIEMANN WP, 1995, P NATL ACAD SCI USA, V92, P5361, DOI 10.1073/pnas.92.12.5361; Shi DQ, 1997, J BIOL CHEM, V272, P2334, DOI 10.1074/jbc.272.4.2334; STEGER DJ, 1993, MOL ENDOCRINOL, V7, P1579, DOI 10.1210/me.7.12.1579; STEGER DJ, 1994, MOL CELL BIOL, V14, P5592, DOI 10.1128/MCB.14.8.5592; STEGER DJ, 1991, MOL ENDOCRINOL, V5, P243, DOI 10.1210/mend-5-2-243; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; TARTAGLIA LA, 1995, CELL, V83, P1363; THOMPSON EA, 1974, J BIOL CHEM, V249, P5373; Tsai FY, 1997, BLOOD, V89, P3636, DOI 10.1182/blood.V89.10.3636.3636_3636_3643; WAKAMIYA M, 1995, P NATL ACAD SCI USA, V92, P3673, DOI 10.1073/pnas.92.9.3673; WALKER WH, 1990, J BIOL CHEM, V265, P12940; Wang ZY, 1997, J BIOL CHEM, V272, P27957, DOI 10.1074/jbc.272.44.27957; WARE CB, 1995, DEVELOPMENT, V121, P1283; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; YAMADA K, 1995, J BIOL CHEM, V270, P25064, DOI 10.1074/jbc.270.42.25064	55	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26069	26077		10.1074/jbc.273.40.26069	http://dx.doi.org/10.1074/jbc.273.40.26069			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748286	hybrid			2022-12-27	WOS:000076263100077
J	Blanchoin, L; Pollard, TD				Blanchoin, L; Pollard, TD			Interaction of actin monomers with Acanthamoeba actophorin (ADF/cofilin) and profilin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPOLYMERIZING FACTOR; BINDING PROTEIN; F-ACTIN; NUCLEOTIDE-SEQUENCE; SKELETAL-MUSCLE; PORCINE BRAIN; ADP-ACTIN; COFILIN; PURIFICATION; FILAMENTS	Acanthamoeba actophorin is a member of ADF/cofilin family that binds both actin monomers and filaments. We used fluorescence anisotropy to study the interaction of actin monomers with recombinant actophorin labeled with rhodamine on a cysteine substituted for Serine-88. Labeled actophorin retains its affinity for actin and ability to reduce the low shear viscosity of actin filaments. At physiological ionic strength, actophorin binds Mg-ADP-actin monomers (K-d = 0.1 mu M) 40 times stronger than Mg-ATP-actin monomers. When bound to actin monomers, actophorin has no effect on elongation at either end of actin filaments by Mg-ATP-actin and slightly increases the rate of elongation at both ends by Mg-ADP-actin. Thus actophorin does not sequester actin monomers. Sedimentation equilibrium ultracentrifugation shows that actophorin and profilin compete for binding actin monomers. Actophorin and profilin have opposite effects on the rate of exchange of nucleotide bound to actin monomers. Despite the high affinity of actophorin for ADP-actin, physiological concentrations of profilin overcome the inhibition of ADP exchange by actophorin. Profilin rapidly recycles ADP-actin back to the profilin-ATP-actin pool ready for elongation of actin filaments.	Salk Inst Biol Studies, Struct Biol Lab, La Jolla, CA 92037 USA	Salk Institute	Pollard, TD (corresponding author), Salk Inst Biol Studies, Struct Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026338] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 26338] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE H, 1990, BIOCHEMISTRY-US, V29, P7420, DOI 10.1021/bi00484a010; ADAMS ME, 1990, BIOCHEMISTRY-US, V29, P7414, DOI 10.1021/bi00484a009; BAMBURG JR, 1980, FEBS LETT, V121, P178, DOI 10.1016/0014-5793(80)81292-0; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; CARLIER MF, 1987, BIOCHEM BIOPH RES CO, V143, P1069, DOI 10.1016/0006-291X(87)90361-5; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; COOPER JA, 1986, J BIOL CHEM, V261, P477; DAVIDSON MML, 1994, BIOCHEM J, V301, P41, DOI 10.1042/bj3010041; De La Cruz EM, 1996, BIOCHEMISTRY-US, V35, P14054, DOI 10.1021/bi961047t; DE LA CRUZ EM, 1995, BIOCHEMISTRY-US, V34, P5452, DOI 10.1021/bi00016a016; DRENCKHAHN D, 1986, J BIOL CHEM, V261, P2754; Hatanaka H, 1996, CELL, V85, P1047, DOI 10.1016/S0092-8674(00)81305-7; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; HAYDEN SM, 1993, BIOCHEMISTRY-US, V32, P9994, DOI 10.1021/bi00089a015; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IIDA K, 1993, GENE, V124, P115; JAMESON DM, 1995, METHOD ENZYMOL, V246, P283; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KAISER DA, 1989, CELL MOTIL CYTOSKEL, V14, P251, DOI 10.1002/cm.970140211; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LAHAM LE, 1993, J BIOL CHEM, V268, P14202; Lappalainen P, 1997, EMBO J, V16, P5520, DOI 10.1093/emboj/16.18.5520; Leonard SA, 1997, NAT STRUCT BIOL, V4, P369, DOI 10.1038/nsb0597-369; MABUCHI I, 1981, J BIOCHEM-TOKYO, V89, P1341; MACIVER SK, 1994, FEBS LETT, V347, P251, DOI 10.1016/0014-5793(94)00552-4; MACIVER SK, 1991, J CELL BIOL, V115, P1611, DOI 10.1083/jcb.115.6.1611; MACLEANFLETCHER S, 1980, CELL, V20, P329, DOI 10.1016/0092-8674(80)90619-4; McGough A, 1997, J CELL BIOL, V138, P771, DOI 10.1083/jcb.138.4.771; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; MOON AL, 1993, J CELL BIOL, V120, P421, DOI 10.1083/jcb.120.2.421; MORIYAMA K, 1992, J BIOL CHEM, V267, P7240; MORIYAMA K, 1990, J BIOL CHEM, V265, P5768; MORIYAMA K, 1990, NUCLEIC ACIDS RES, V18, P3053, DOI 10.1093/nar/18.10.3053; Mullins RD, 1998, MOL BIOL CELL, V9, P841, DOI 10.1091/mbc.9.4.841; MUNEYUKI F, 1985, J BIOCHEM-TOKYO, V97, P563, DOI 10.1093/oxfordjournals.jbchem.a135091; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P1160, DOI 10.1021/bi00326a015; OHTA Y, 1989, J BIOL CHEM, V264, P16143; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; POLLARD TD, 1984, J CELL BIOL, V99, P769, DOI 10.1083/jcb.99.3.769; QUIRK S, 1993, BIOCHEMISTRY-US, V32, P8525, DOI 10.1021/bi00084a019; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUTOH K, 1989, BIOCHEMISTRY-US, V28, P102, DOI 10.1021/bi00427a015; SUZUKI K, 1995, J BIOL CHEM, V270, P19551, DOI 10.1074/jbc.270.33.19551; TAKAGI T, 1988, J BIOL CHEM, V263, P3097; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218; YONEZAWA N, 1989, EUR J BIOCHEM, V183, P235, DOI 10.1111/j.1432-1033.1989.tb14918.x	47	144	146	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25106	25111		10.1074/jbc.273.39.25106	http://dx.doi.org/10.1074/jbc.273.39.25106			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737968	hybrid			2022-12-27	WOS:000076085400018
J	Halfter, W; Dong, SC; Schurer, B; Cole, GJ				Halfter, W; Dong, SC; Schurer, B; Cole, GJ			Collagen XVIII is a basement membrane heparan sulfate proteoglycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; DENSITY-LIPOPROTEIN-RECEPTOR; EXTRACELLULAR-MATRIX; MULTIPLE DOMAINS; CHICK-EMBRYO; BASAL LAMINA; AGRIN; EXPRESSION; PROTEIN; GENE	The present study shows that collagen XVIII is, next to perlecan and agrin, the third basal lamina heparan sulfate proteoglycan (HSPG) and the first collagen/proteoglycan with heparan sulfate side chains. By using monoclonal antibodies to an unidentified HSPG in chick, 14 cDNA clones were isolated from a chick yolk sac library. All clones had a common nucleotide sequence that was homologous to the mRNA sequences of mouse and human collagen XVIII. The deduced amino acid sequence of the chick fragment shows an 83% overall homology with the human and mouse collagen XVIII. Similar to the human and mouse homologue, the chick collagen XVIII mRNA has a size of 4.5 kilobase pairs. In Western blots, collagen XVIII appeared as a smear with a molecular mass of 300 kDa. After treatment with heparitinase, the protein was reduced in molecular mass by 120 kDa to a protein core of 180 kDa. Collagen XVIII has typical features of a collagen, such as its existence, under nondenaturing conditions, as a non-covalently linked oligomer, and a sensitivity of the core protein to collagenase digestion. It also has characteristics of an HSPG, such as long heparitinase-sensitive carbohydrate chains and a highly negative net charge. Collagen XVIII is abundant in basal laminae of the retina, epidermis, pia, cardiac and striated muscle, kidney, blood vessels, and lung. In situ hybridization showed that the main expression of collagen XVIII: HSPG in the chick embryo is in the kidney and the peripheral nervous system. As a substrate, collagen XVIII moderately promoted the adhesion of Schwann cells but had no such activity on peripheral nervous system neurons and axons.	Univ Pittsburgh, Dept Neurobiol, Pittsburgh, PA 15261 USA; Ohio State Univ, Neurobioltechnol Ctr, Columbus, OH 43210 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University System of Ohio; Ohio State University	Halfter, W (corresponding author), Univ Pittsburgh, Dept Neurobiol, 1402 E Biol Sci Tower, Pittsburgh, PA 15261 USA.	whalfer@vms.cis.pitt.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033981] Funding Source: NIH RePORTER; NINDS NIH HHS [NS33981-02] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAYNE EK, 1984, J CELL BIOL, V99, P1486, DOI 10.1083/jcb.99.4.1486; BHATTACHARYYA A, 1991, NEURON, V7, P831, DOI 10.1016/0896-6273(91)90285-8; CHIQUET M, 1984, J CELL BIOL, V98, P1937, DOI 10.1083/jcb.98.6.1937; FITCH JM, 1989, DEVELOPMENT, V105, P85; FUKAI N, 1994, METHOD ENZYMOL, V245, P3; GESEMANN M, 1995, J CELL BIOL, V128, P625, DOI 10.1083/jcb.128.4.625; Halfter W, 1998, J COMP NEUROL, V397, P89, DOI 10.1002/(SICI)1096-9861(19980720)397:1<89::AID-CNE7>3.0.CO;2-E; Halfter W, 1998, J COMP NEUROL, V397, P105, DOI 10.1002/(SICI)1096-9861(19980720)397:1<105::AID-CNE8>3.0.CO;2-4; HALFTER W, 1987, J NEUROSCI, V7, P3712; HALFTER W, 1993, J NEUROSCI, V13, P2863; Halfter W, 1997, J COMP NEUROL, V383, P1; HALFTER W, 1994, EXP CELL RES, V214, P285, DOI 10.1006/excr.1994.1260; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HASSELL JR, 1980, P NATL ACAD SCI-BIOL, V77, P4494, DOI 10.1073/pnas.77.8.4494; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; KANWAR YS, 1984, P NATL ACAD SCI-BIOL, V81, P762, DOI 10.1073/pnas.81.3.762; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; LAGENAUR C, 1987, P NATL ACAD SCI USA, V84, P7753, DOI 10.1073/pnas.84.21.7753; MA E, 1994, J NEUROSCI, V14, P2943; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; MOLLER HJ, 1993, ANAL BIOCHEM, V209, P169, DOI 10.1006/abio.1993.1098; MURAGAKI Y, 1995, P NATL ACAD SCI USA, V92, P8763, DOI 10.1073/pnas.92.19.8763; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; OH SP, 1994, P NATL ACAD SCI USA, V91, P4229, DOI 10.1073/pnas.91.10.4229; OH SP, 1994, GENOMICS, V19, P494, DOI 10.1006/geno.1994.1098; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Rehn M, 1996, GENOMICS, V32, P436, DOI 10.1006/geno.1996.0139; REHN M, 1995, J BIOL CHEM, V270, P4705, DOI 10.1074/jbc.270.9.4705; REHN M, 1994, P NATL ACAD SCI USA, V91, P4234, DOI 10.1073/pnas.91.10.4234; RUEGG MA, 1992, NEURON, V8, P691, DOI 10.1016/0896-6273(92)90090-Z; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; Saarela J, 1998, MATRIX BIOL, V16, P319, DOI 10.1016/S0945-053X(98)90003-8; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; TSEN G, 1995, J BIOL CHEM, V270, P3392, DOI 10.1074/jbc.270.7.3392; TSEN GS, 1995, J BIOL CHEM, V270, P15934, DOI 10.1074/jbc.270.27.15934; TSIM KWK, 1992, NEURON, V8, P677, DOI 10.1016/0896-6273(92)90089-V; VIGNY M, 1988, J CELL PHYSIOL, V137, P321, DOI 10.1002/jcp.1041370216; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WRIGHT TN, 1992, CURR OPIN CELL BIOL, V4, P793; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451	47	262	270	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25404	25412		10.1074/jbc.273.39.25404	http://dx.doi.org/10.1074/jbc.273.39.25404			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738008	hybrid			2022-12-27	WOS:000076085400058
J	Nakai, J; Tanabe, T; Konno, T; Adams, B; Beam, KG				Nakai, J; Tanabe, T; Konno, T; Adams, B; Beam, KG			Localization in the II-III loop of the dihydropyridine receptor of a sequence critical for excitation-contraction coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-CHANNEL BLOCKERS; SKELETAL-MUSCLE; RELEASE CHANNEL; TRANSIENTS; MYOTUBES; REGIONS; CHARGE	Skeletal and cardiac muscles express distinct isoforms of the dihydropyridine receptor (DHPR), a type of voltage-gated Ca2+ channel that is important for excitation-contraction (EC) coupling. However, entry of Ca2+ through the channel is not required for skeletal muscle-type EC coupling. Previous work (Tanabe, T., Beam, K. G., Adams, B. A., Niidome, T., and Numa, S. (1990) Nature 346, 567-569) revealed that the loop between repeats II and III (II-III loop) is an important determinant of skeletal-type EC coupling. In the present study we have further dissected the regions of the II-III loop critical for skeletal-type EC coupling by expression of cDNA constructs in dysgenic myotubes. Because Ser(687) of the skeletal II-III loop has been reported to be rapidly phosphorylated in vitro, we substituted this serine with alanine, the corresponding cardiac residue. This alanine-substituted skeletal DHPR retained the ability to mediate skeletal-type EC coupling. Weak skeletal-type EC coupling was produced by a chimeric DHPR, which was entirely cardiac except for a small amount of skeletal sequence (residues 725-742) in the II-III loop. Skeletal-type coupling was stronger when both residues 725-742 and adjacent residues were skeletal (e.g. a chimera containing skeletal residues 711-765). However, residues 725-742 appeared to be critical because skeletal-type coupling was not produced either by a chimera with skeletal residues 711-732 or by one with skeletal residues 734-765.	Colorado State Univ, Dept Anat & Neurobiol, Ft Collins, CO 80523 USA; Natl Inst Physiol Sci, Dept Informat Physiol, Okazaki, Aichi 4448585, Japan; Tokyo Med & Dent Univ, Dept Pharmacol, Bunkyo Ku, Tokyo 113, Japan; Natl Inst Physiol Sci, Physiol Res Facil, Okazaki, Aichi 4448585, Japan; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA	Colorado State University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Tokyo Medical & Dental University (TMDU); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); University of Iowa	Beam, KG (corresponding author), Colorado State Univ, Dept Anat & Neurobiol, Ft Collins, CO 80523 USA.		Tuluc, Petronel/C-2527-2011		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024444] Funding Source: NIH RePORTER; NINDS NIH HHS [NS24444] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARMSTRONG CM, 1972, BIOCHIM BIOPHYS ACTA, V267, P605, DOI 10.1016/0005-2728(72)90194-6; CHAUDHARI N, 1992, J BIOL CHEM, V267, P25636; ELHAYEK R, 1995, J BIOL CHEM, V270, P22116, DOI 10.1074/jbc.270.38.22116; GARCIA J, 1994, J GEN PHYSIOL, V103, P125, DOI 10.1085/jgp.103.1.125; GARCIA J, 1994, J GEN PHYSIOL, V103, P107, DOI 10.1085/jgp.103.1.107; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Leong P, 1998, J BIOL CHEM, V273, P7791, DOI 10.1074/jbc.273.14.7791; LU XY, 1995, J BIOL CHEM, V270, P18459, DOI 10.1074/jbc.270.31.18459; LU XY, 1994, J BIOL CHEM, V269, P6511; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; ROHRKASTEN A, 1988, J BIOL CHEM, V263, P15325; SAYERS JR, 1989, PROTEIN FUNCTION PRA, P279; Slavik KJ, 1997, AM J PHYSIOL-CELL PH, V272, pC1475, DOI 10.1152/ajpcell.1997.272.5.C1475; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1990, NATURE, V344, P451, DOI 10.1038/344451a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; Yamazawa T, 1996, EMBO J, V15, P6172, DOI 10.1002/j.1460-2075.1996.tb01005.x	22	133	133	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					24983	24986		10.1074/jbc.273.39.24983	http://dx.doi.org/10.1074/jbc.273.39.24983			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737952	hybrid			2022-12-27	WOS:000076085400002
J	Nguyen, AT; Holmes, EH; Whitaker, JM; Ho, S; Shetterly, S; Macher, BA				Nguyen, AT; Holmes, EH; Whitaker, JM; Ho, S; Shetterly, S; Macher, BA			Human alpha 1,3/4-fucosyltransferases - I. Identification of amino acids involved in acceptor substrate binding by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; LEWIS-NEGATIVE INDIVIDUALS; L-SELECTIN; ALPHA(1,3)-FUCOSYL-TRANSFERASE GENE; MOLECULAR-CLONING; P-SELECTIN; HUMAN ALPHA-1->3FUCOSYLTRANSFERASES; LEUKOCYTE TRAFFICKING; HELICOBACTER-PYLORI; ENZYME-ACTIVITY	In a previous study (Xu, Z., Vo, L., and Macher, B. A. (1996) J. Biol Chem. 271, 8818-8823), a domain swapping approach demonstrated that a region of amino acids found in human alpha 1,3/4-fucosyltransferase III (FucT III) conferred a significant increase in alpha 1,4-FucT acceptor substrate specificity into alpha 1,3-fucosyltransferase V (FucT V), which, under the same assay conditions, has extremely low alpha 1,4-FucT acceptor substrate specificity. In the current study, site-directed mutagenesis was utilized to identify which of the eight amino acids, associated with alpha 1,4-FucT acceptor substrate specificity, is/are responsible for conferring this new property. The results demonstrate that increased alpha 1,4-FucT activity with both disaccharide and glycolipid accepters can be conferred on FucT V by modifying as few as two (Asn(86) to His and Thr(87) to Ile) of the eight amino acids originally swapped from FucT III into the FucT V sequence. Neither single amino acid mutant had increased alpha 1,4-FucT activity relative to that of FucT V. Kinetic analyses of FucT V mutants demonstrated a reduced K-m for Gal beta 1,3GlcNAc (type 1) acceptor substrates compared with native FucT V. However, this was about 20-fold higher than that found for native FucT III, suggesting that other amino acids in FucT III must contribute to its overall binding site for type 1 substrates, These results demonstrate that amino acid residues near the amino terminus of the catalytic domain of FucT In: contribute to its acceptor substrate specificity.	NW Hosp, Pacific NW Canc Fdn, Seattle, WA 98125 USA; San Francisco State Univ, Dept Chem & Biochem, San Francisco, CA 94132 USA	California State University System; San Francisco State University	Holmes, EH (corresponding author), NW Hosp, Pacific NW Canc Fdn, 120 Northgate Plaza,Suite 218, Seattle, WA 98125 USA.	eholmes@nwbio.org			NCI NIH HHS [CA70740] Funding Source: Medline; NCRR NIH HHS [P20 RR11805] Funding Source: Medline; NIGMS NIH HHS [GM52588] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070740] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR011805] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM052588] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chandrasekaran EV, 1996, BIOCHEMISTRY-US, V35, P8925, DOI 10.1021/bi952194e; DEVRIES T, 1995, J BIOL CHEM, V270, P8712, DOI 10.1074/jbc.270.15.8712; DeVries T, 1997, GLYCOBIOLOGY, V7, P921, DOI 10.1093/glycob/7.7.921; ELMGREN A, 1993, BIOCHEM BIOPH RES CO, V196, P515, DOI 10.1006/bbrc.1993.2280; Elmgren A, 1997, J BIOL CHEM, V272, P21994, DOI 10.1074/jbc.272.35.21994; Ge ZM, 1997, J BIOL CHEM, V272, P21357, DOI 10.1074/jbc.272.34.21357; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOLMES EH, 1993, ARCH BIOCHEM BIOPHYS, V301, P190, DOI 10.1006/abbi.1993.1132; HOLMES EH, 1995, J BIOL CHEM, V270, P8145, DOI 10.1074/jbc.270.14.8145; KODA Y, 1993, BLOOD, V82, P2915; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LEGAULT DJ, 1995, J BIOL CHEM, V270, P20987, DOI 10.1074/jbc.270.36.20987; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; Martin SL, 1997, J BIOL CHEM, V272, P21349, DOI 10.1074/jbc.272.34.21349; Martina JA, 1998, J BIOL CHEM, V273, P3725, DOI 10.1074/jbc.273.6.3725; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MOLLICONE R, 1994, J BIOL CHEM, V269, P20987; MOLLICONE R, 1994, J BIOL CHEM, V269, P12662; Nagai K, 1997, GLYCOBIOLOGY, V7, P769, DOI 10.1093/glycob/7.6.769; Orntoft TF, 1996, J BIOL CHEM, V271, P32260, DOI 10.1074/jbc.271.50.32260; Oulmouden A, 1997, J BIOL CHEM, V272, P8764, DOI 10.1074/jbc.272.13.8764; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; Sherwood AL, 1998, J BIOL CHEM, V273, P25256, DOI 10.1074/jbc.273.39.25256; Smith PL, 1996, J BIOL CHEM, V271, P8250, DOI 10.1074/jbc.271.14.8250; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stroud MR, 1997, BIOCHEM BIOPH RES CO, V238, P165, DOI 10.1006/bbrc.1997.7254; Toki D, 1997, BIOCHEM J, V325, P63, DOI 10.1042/bj3250063; Vo L, 1998, J BIOL CHEM, V273, P25250, DOI 10.1074/jbc.273.39.25250; Watkins W M, 1980, Adv Hum Genet, V10, P1; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; Xu XH, 1996, J BIOL CHEM, V271, P8818, DOI 10.1074/jbc.271.15.8818	35	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25244	25249		10.1074/jbc.273.39.25244	http://dx.doi.org/10.1074/jbc.273.39.25244			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737988	hybrid			2022-12-27	WOS:000076085400038
J	Penc, SF; Pomahac, B; Winkler, T; Dorschner, RA; Eriksson, E; Herndon, M; Gallo, RL				Penc, SF; Pomahac, B; Winkler, T; Dorschner, RA; Eriksson, E; Herndon, M; Gallo, RL			Dermatan sulfate released after injury is a potent promoter of fibroblast growth factor-2 function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-LIKE MOLECULES; HUMAN-LUNG FIBROBLASTS; CELL-SURFACE; EXTRACELLULAR-MATRIX; HIGH-AFFINITY; FACTOR-ALPHA; COFACTOR-II; PROTEOGLYCANS; BINDING; EXPRESSION	Proteoglycans have been shown in vitro to bind multiple components of the cellular microenvironment that function during wound healing. To study the composition and function of these molecules when derived from an in vivo source, soluble proteoglycans released into human wound fluid were characterized and evaluated for influence on fibroblast growth factor-2 activity. Immunoblot analysis of wound fluid revealed the presence of syndecan-1, syndecan-4, glypican, decorin, perlecan, and versican. Sulfated glycosaminoglycan concentrations ranged from 15 to 65 mu g/ml, and treatment with chondroitinase B showed that a large proportion of the glycosaminoglycan was dermatan sulfate. The total glycosaminoglycan mixture present in wound fluid supported the ability of fibroblast growth factor-a to signal cell proliferation. Dermatan sulfate, and not heparan sulfate, was the major contributor to this activity, and dermatan sulfate bound FGF-2 with K-d = 2.48 mu M. These data demonstrate that proteoglycans released during wound repair are functionally active and provide the first evidence that dermatan sulfate is a potent mediator of fibroblast growth factor-2 responsiveness.	Boston Childrens Hosp, Div Dev & Newborn Baby, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Plast Surg, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Dept Expt Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center	Gallo, RL (corresponding author), Boston Childrens Hosp, Div Dev & Newborn Baby, Enders 950,300 Longwood Ave, Boston, MA 02115 USA.	GAllo@A1.TCH.Harvard.edu	Pomahac, Bohdan/AAH-1792-2019; Gallo, Richard L/A-8931-2009	Pomahac, Bohdan/0000-0003-3703-8240; Gallo, Richard L/0000-0002-1401-7861				ABRAHAM J, 1996, MOL CELLULAR BIOL WO; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; ASHER R, 1991, J NEUROSCI RES, V28, P410, DOI 10.1002/jnr.490280314; Aviezer D, 1997, MOL CELL BIOL, V17, P1938, DOI 10.1128/MCB.17.4.1938; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BonnehBarkay D, 1997, J BIOL CHEM, V272, P12415, DOI 10.1074/jbc.272.19.12415; CELLA G, 1992, ANGIOLOGY, V43, P59, DOI 10.1177/000331979204300107; Clark R. A. F, 1996, MOL CELLULAR BIOL WO; COOPER DM, 1994, ANN SURG, V219, P688, DOI 10.1097/00000658-199406000-00012; DAVID G, 1993, DEVELOPMENT, V119, P841; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; ELENIUS K, 1991, J CELL BIOL, V114, P585, DOI 10.1083/jcb.114.3.585; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Gallo R, 1996, J INVEST DERMATOL, V107, P676, DOI 10.1111/1523-1747.ep12365571; GALLO RL, 1994, P NATL ACAD SCI USA, V91, P11035, DOI 10.1073/pnas.91.23.11035; HAGGERTY JG, 1992, J INVEST DERMATOL, V99, P374, DOI 10.1111/1523-1747.ep12616087; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HEREMANS A, 1988, J BIOL CHEM, V263, P4731; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; Klagsbrun M, 1990, CURR OPIN CELL BIOL, V2, P857, DOI 10.1016/0955-0674(90)90084-R; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; LORIES V, 1992, J BIOL CHEM, V267, P1116; LORIES V, 1989, J BIOL CHEM, V264, P7009; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MASCELLANI G, 1993, BIOCHEM J, V296, P639, DOI 10.1042/bj2960639; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; PRIGLINGER U, 1994, J BIOL CHEM, V269, P14705; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SALMIVIRTA M, 1991, J BIOL CHEM, V266, P7733; SANANTONIO JD, 1993, BIOCHEMISTRY-US, V32, P4746, DOI 10.1021/bi00069a008; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; Stringer SE, 1997, INT J BIOCHEM CELL B, V29, P709, DOI 10.1016/S1357-2725(96)00170-7; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; Walker A, 1996, BIOCHEM J, V317, P871, DOI 10.1042/bj3170871; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; WIGHT TN, 1991, CELL BIOL EXTRACELLU, P45, DOI DOI 10.1007/978-1-4615-3770-0_3; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	48	172	178	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28116	28121		10.1074/jbc.273.43.28116	http://dx.doi.org/10.1074/jbc.273.43.28116			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774430	hybrid			2022-12-27	WOS:000076549800050
J	Kashishian, A; Howard, M; Loh, C; Gallatin, WM; Hoekstra, MF; Lai, Y				Kashishian, A; Howard, M; Loh, C; Gallatin, WM; Hoekstra, MF; Lai, Y			AKAP79 inhibits calcineurin through a site distinct from the immunophilin-binding region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; TRANSCRIPTION FACTOR NFAT1; REGULATORY SUBUNITS; ANCHORING PROTEIN; CATALYTIC SUBUNIT; NUCLEAR FACTOR; NF-AT; PHENOTYPIC SELECTION; PHOSPHATASE-ACTIVITY; NUCLEOTIDE-SEQUENCE	Targeting of protein kinases and phosphatases provides additional specificity to substrate selectivity in cellular signaling. In the case of the Ca2+/calmodulin-dependent protein phosphatase calcineurin, AKAP79 has been shown to bind calcineurin and inhibit its activity in vitro (Coghlan, V., Perrino, B. A., Howard, M., Langeberg, L. K., Hicks, J. B., Gallatin, W. M., and Scott, J. D. (1995) Science 267, 108-111). In the present study, we characterized the binding regions on calcineurin A (CnA) and AKAP79 that are important for this interaction. Residues 30-98 and 311-336 on CnA and residues 108-280 on AKAP79 were found to be important for binding. The binding of CnA by AKAP79 does not require the calcineurin B subunit, and occurs in a region distinct from where the immunosuppressant-immunophilin complex bind. AKAP79 also bound to CnA in cells transfected with AKAP79 and CnA. To determine the function of AKAP79-calcineurin interaction in intact cells, we measured the dephosphorylation and subsequent activation of NFAT, a transcription factor that is a substrate for calcineurin, Overexpression of AKAP79 inhibited NFAT dephosphorylation, resulting in a decrease in NFAT activation. These results demonstrated that AKAP79 can bind to and inhibit calcineurin activity in vivo, suggesting a physiological role for AKAP79-calcineurin interaction in NFAT-mediated signaling.	ICOS Corp, Bothell, WA 98021 USA	Icos Corporation	Lai, Y (corresponding author), ICOS Corp, 22021 20th Ave SE, Bothell, WA 98021 USA.		Mackie, Ken/E-3384-2013					BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1992, J BIOL CHEM, V267, P13376; CLARKE P, 1982, GENE, V18, P157, DOI 10.1016/0378-1119(82)90113-5; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; Dell'Acqua ML, 1998, EMBO J, V17, P2246, DOI 10.1093/emboj/17.8.2246; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Faux MC, 1997, J BIOL CHEM, V272, P17038, DOI 10.1074/jbc.272.27.17038; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Feliciello A, 1997, CURR BIOL, V7, P1011, DOI 10.1016/S0960-9822(06)00424-6; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FREUND TF, 1997, SOC NEUR ABSTR, P2010; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; HARLOW E, 1988, ANTIBODIES LAB MANUA, P593; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIN HC, 1985, GENE, V34, P123; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MILAN D, 1994, CELL, V79, P437, DOI 10.1016/0092-8674(94)90253-4; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; NEGULESCU PA, 1994, P NATL ACAD SCI USA, V91, P2873, DOI 10.1073/pnas.91.7.2873; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PERRINO BA, 1992, J BIOL CHEM, V267, P15965; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; RUFF VA, 1995, J BIOL CHEM, V270, P22602, DOI 10.1074/jbc.270.38.22602; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Sik A, 1998, P NATL ACAD SCI USA, V95, P3245, DOI 10.1073/pnas.95.6.3245; SIKKINK R, 1995, BIOCHEMISTRY-US, V34, P8348, DOI 10.1021/bi00026a016; WEBER W, 1979, FEBS LETT, V99, P62, DOI 10.1016/0014-5793(79)80249-5; Wesselborg S, 1996, J BIOL CHEM, V271, P1274, DOI 10.1074/jbc.271.3.1274; Yakel JL, 1997, TRENDS PHARMACOL SCI, V18, P124, DOI 10.1016/S0165-6147(97)01046-8	51	71	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27412	27419		10.1074/jbc.273.42.27412	http://dx.doi.org/10.1074/jbc.273.42.27412			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765270	hybrid			2022-12-27	WOS:000076448000057
J	Xu, X; Croy, JT; Zeng, WZ; Zhao, LP; Davignon, I; Popov, S; Yu, K; Jiang, HP; Offermanns, S; Muallem, S; Wilkie, TM				Xu, X; Croy, JT; Zeng, WZ; Zhao, LP; Davignon, I; Popov, S; Yu, K; Jiang, HP; Offermanns, S; Muallem, S; Wilkie, TM			Promiscuous coupling of receptors to Gq class alpha subunits and effector proteins in pancreatic and submandibular gland cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN THYROTROPIN RECEPTOR; HETEROTRIMERIC G-PROTEINS; PHOSPHOLIPASE-C-BETA; SALIVARY-GLAND; SIGNAL-TRANSDUCTION; CA2+ RELEASE; FAMILY; G(Q); CHANNELS; EXPRESSION	Mice with deficiencies in one or more Gq class alpha subunit genes were used to examine the role of the a subunit in regulating Ca2+ signaling in pancreatic and submandibular gland cells. Western blot analysis showed that these cells express three of the four Gq class subunits, G alpha q, G alpha 11, and G alpha 14 but not G alpha 15. Surprisingly, all parameters of Ca2+ signaling were identical in cells from wild type and four lines of mutant mice: 1) G alpha 11-/-, 2) G alpha 11-/-/G alpha 14-/-, 3) G alpha 14-/-/Ga15-/-, and 4) G alpha q-/-/G alpha 15-/-. These parameters included the K-app for several Gq class coupled receptors, induction of [Ca2+](i) oscillations by weak stimulation, and a biphasic [Ca2+](i) response by strong stimulation. Furthermore, Ca2+ release from internal stores and Ca2+ entry were not affected in cells from any of the mutant mice. We conclude that G alpha q, G alpha 11, and G alpha 14 promiscuously couple several receptors (m(3) muscarinic, bombesin, cholecystokinin, and alpha 1 adrenergic) to effector proteins that activate both Ca2+ release from internal stores and Ca2+ entry.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Astra Arcus USA Inc, Rochester, NY 14602 USA; Free Univ Berlin, Klinikum Benjamin Franklin, Inst Pharmacol, D-14195 Berlin, Germany	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Muallem, S (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	smuall@mednet.swmed.edu	Offermanns, Stefan/L-3313-2017	Offermanns, Stefan/0000-0001-8676-6805	NIDCR NIH HHS [DE12309] Funding Source: Medline; NIDDK NIH HHS [DK38938] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM07062] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007062] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLGEIER A, 1994, J BIOL CHEM, V269, P13733; BERRIDGE MJ, 1994, BIOCHEM J, V302, P545, DOI 10.1042/bj3020545; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Davignon I, 1996, GENOMICS, V31, P359, DOI 10.1006/geno.1996.0059; Dippel E, 1996, P NATL ACAD SCI USA, V93, P1391, DOI 10.1073/pnas.93.4.1391; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; GalvinParton PA, 1997, J BIOL CHEM, V272, P4335, DOI 10.1074/jbc.272.7.4335; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; HEPLER JR, 1994, METHOD ENZYMOL, V237, P191; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kuhn B, 1996, MOL ENDOCRINOL, V10, P1697, DOI 10.1210/me.10.12.1697; Laugwitz KL, 1996, P NATL ACAD SCI USA, V93, P116, DOI 10.1073/pnas.93.1.116; LEE CH, 1992, J BIOL CHEM, V267, P16044; Lee MG, 1997, J BIOL CHEM, V272, P15765, DOI 10.1074/jbc.272.25.15765; MacrezLepretre N, 1997, J BIOL CHEM, V272, P5261, DOI 10.1074/jbc.272.8.5261; Muallem Shmuel, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P351; MULLER S, 1993, P NATL ACAD SCI USA, V90, P10439, DOI 10.1073/pnas.90.22.10439; NAKAMURA F, 1995, J BIOL CHEM, V270, P6246, DOI 10.1074/jbc.270.11.6246; Obukhov AG, 1996, EMBO J, V15, P5833, DOI 10.1002/j.1460-2075.1996.tb00970.x; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; Offermanns S, 1997, P NATL ACAD SCI USA, V94, P14089, DOI 10.1073/pnas.94.25.14089; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; VALDEZ IH, 1991, AM J PHYSIOL, V261, pG359, DOI 10.1152/ajpgi.1991.261.2.G359; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85; Xu X, 1996, J PHYSIOL-LONDON, V491, P647, DOI 10.1113/jphysiol.1996.sp021246; XU X, 1995, J BIOL CHEM, V270, P29169, DOI 10.1074/jbc.270.49.29169; Xu X, 1997, CELL CALCIUM, V22, P217, DOI 10.1016/S0143-4160(97)90015-4; Xu X, 1996, J BIOL CHEM, V271, P24684, DOI 10.1074/jbc.271.40.24684; ZENG W, 1998, IN PRESS J BIOL CHEM	35	38	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27275	27279		10.1074/jbc.273.42.27275	http://dx.doi.org/10.1074/jbc.273.42.27275			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765251	hybrid			2022-12-27	WOS:000076448000038
J	Swaren, P; Maveyraud, L; Raquet, X; Cabantous, S; Duez, C; Pedelacq, JD; Mariotte-Boyer, S; Mourey, L; Labia, R; Nicolas-Chanoine, MH; Nordmann, P; Frere, JM; Samama, JP				Swaren, P; Maveyraud, L; Raquet, X; Cabantous, S; Duez, C; Pedelacq, JD; Mariotte-Boyer, S; Mourey, L; Labia, R; Nicolas-Chanoine, MH; Nordmann, P; Frere, JM; Samama, JP			X-ray analysis of the NMC-A beta-lactamase at 1.64-angstrom resolution, a class A carbapenemase with broad substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCUS-AUREUS PC1; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; 3RD-GENERATION CEPHALOSPORINS; ENTEROBACTER-CLOACAE; SERRATIA-MARCESCENS; MOLECULAR-STRUCTURE; EXTENDED-SPECTRUM; ACTIVE-SITE; MEROPENEM	The treatment of infectious diseases by penicillin and cephalosporin antibiotics is continuously challenged by the emergence and the dissemination of the numerous TEM and SHV mutant beta-lactamases with extended substrate profiles. These class A beta-lactamases nevertheless remain inefficient against carbapenems, the most effective antibiotics against clinically relevant pathogens. A new member of this enzyme class, NMC-A, was recently reported to hydrolyze at high rates, and hence destroy, all known beta-lactam antibiotics, including carbapenems and cephamycins. The crystal structure of NMC-A was solved to 1.64-Angstrom resolution, and reveals modifications in the topology of the substrate-binding site. While preserving the geometry of the essential catalytic residues, the active site of the enzyme presents a disulfide bridge between residues 69 and 238, and certain other structural differences compared with the other beta-lactamases. These unusual features in class A beta-lactamases involve amino acids that participate in enzyme-substrate interactions, which suggested that these structural factors should be related to the very broad substrate specificity of this enzyme. The comparison of the NMC-A structure with those of other class A enzymes and enzyme-ligand complexes, indicated that the position of Asn-132 in NMC-A provides critical additional space in the region of the protein where the poorer substrates for class A beta-lactamases, such as cephamycins and carbapenems, need to be accommodated.	Inst Pharmacol & Biol Struct, Grp Cristallog Biol, CNRS, UPR 9062, F-31077 Toulouse, France; Univ Liege, Inst Chim B6, Ctr Ingn Prot, B-4000 Liege, Belgium; Hop Lariboisiere, Serv Bacteriol Virol, F-75475 Paris 10, France; MNHN, CNRS, UMR 175, F-29000 Quimper, France; Univ Paris 05, Fac Med Paris Ouest, Microbiol Lab, F-92100 Boulogne, France; Hop Bicetre, Serv Bacteriol & Virol, F-94275 Le Kremlin Bicetre, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); University of Liege; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay	Samama, JP (corresponding author), Inst Pharmacol & Biol Struct, Grp Cristallog Biol, CNRS, UPR 9062, 205 Route Narbonne, F-31077 Toulouse, France.	samama@ipbs.fr	Pedelacq, Jean-Denis/C-6053-2011; Cabantous, Stephanie/M-3282-2014; Maveyraud, Laurent/C-6066-2011; Mourey, Lionel/B-5662-2009; Cabantous, Stephanie/AAB-5113-2020	Cabantous, Stephanie/0000-0002-8406-9421; Maveyraud, Laurent/0000-0003-4610-8319; Mourey, Lionel/0000-0002-8259-1259; Cabantous, Stephanie/0000-0002-8406-9421; PEDELACQ, Jean-Denis/0000-0002-3202-2517				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Banerjee S, 1998, BIOCHEMISTRY-US, V37, P3286, DOI 10.1021/bi972127f; BLUMER JL, 1995, SCAND J INFECT DIS, P38; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P374; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; EDWARDS JR, 1995, J ANTIMICROB CHEMOTH, V36, P1; FELICI A, 1995, ANTIMICROB AGENTS CH, V39, P192, DOI 10.1128/AAC.39.1.192; GALLENI M, 1988, BIOCHEM J, V255, P123, DOI 10.1042/bj2550123; HERZBERG O, 1991, J MOL BIOL, V217, P701, DOI 10.1016/0022-2836(91)90527-D; HUTLESKY A, 1993, J BIOL CHEM, V268, P3690; JELSCH C, 1993, PROTEINS, V16, P364, DOI 10.1002/prot.340160406; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KNOX JR, 1995, ANTIMICROB AGENTS CH, V39, P2593, DOI 10.1128/AAC.39.12.2593; KNOX JR, 1991, J MOL BIOL, V220, P435, DOI 10.1016/0022-2836(91)90023-Y; Knox JR, 1996, CHEM BIOL, V3, P937, DOI 10.1016/S1074-5521(96)90182-9; LABIA R, 1989, J ANTIMICROB CHEMOTH, V24, P219, DOI 10.1093/jac/24.suppl_A.219; LESLIE AGW, 1987, COMPUTATIONAL ASPECT, P39; LIVERMORE DM, 1992, J ANTIMICROB CHEMOTH, V29, P609, DOI 10.1093/jac/29.6.609; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MariotteBoyer S, 1996, FEMS MICROBIOL LETT, V143, P29, DOI 10.1016/0378-1097(96)00288-1; Maveyraud L, 1998, BIOCHEMISTRY-US, V37, P2622, DOI 10.1021/bi972501b; Maveyraud L, 1996, J AM CHEM SOC, V118, P7435, DOI 10.1021/ja9609718; Miyashita K, 1996, BIOORG MED CHEM LETT, V6, P319, DOI 10.1016/0960-894X(96)00022-4; NAAS T, 1994, ANTIMICROB AGENTS CH, V38, P1262, DOI 10.1128/AAC.38.6.1262; NORDMANN P, 1993, ANTIMICROB AGENTS CH, V37, P939, DOI 10.1128/AAC.37.5.939; OSUNA J, 1995, J BIOL CHEM, V270, P775, DOI 10.1074/jbc.270.2.775; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Raquet X, 1997, PROTEINS, V27, P47, DOI 10.1002/(SICI)1097-0134(199701)27:1<47::AID-PROT6>3.0.CO;2-K; RAQUET X, 1994, J MOL BIOL, V244, P625, DOI 10.1006/jmbi.1994.1756; Rasmussen BA, 1996, ANTIMICROB AGENTS CH, V40, P2080, DOI 10.1128/AAC.40.9.2080; Rasmussen BA, 1997, ANTIMICROB AGENTS CH, V41, P223, DOI 10.1128/AAC.41.2.223; Sougakoff W, 1996, J STRUCT BIOL, V116, P313, DOI 10.1006/jsbi.1996.0046; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; Strynadka NCJ, 1996, NAT STRUCT BIOL, V3, P688, DOI 10.1038/nsb0896-688; TAIBI P, 1995, J AM CHEM SOC, V117, P7600, DOI 10.1021/ja00134a003; WILSON AJC, 1949, ACTA CRYSTALLOGR, V2, P318, DOI 10.1107/S0365110X49000813; Zawadzke LE, 1995, PROTEIN ENG, V8, P1275, DOI 10.1093/protein/8.12.1275; Zawadzke LE, 1996, BIOCHEMISTRY-US, V35, P16475, DOI 10.1021/bi962242a	44	77	79	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26714	26721		10.1074/jbc.273.41.26714	http://dx.doi.org/10.1074/jbc.273.41.26714			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756914	Green Published, hybrid			2022-12-27	WOS:000076373300068
J	Chen, ZQ; Banerjee, R				Chen, ZQ; Banerjee, R			Purification of soluble cytochrome b(5) as a component of the reductive activation of porcine methionine synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PLASMA HOMOCYST(E)INE; MEGALOBLASTIC-ANEMIA; P450 REDUCTASE; RISK FACTOR; PIG-LIVER; COBALAMIN; HOMOCYSTINURIA; METABOLISM; MECHANISM	In mammals, methionine synthase plays a central role in the detoxification of the rogue metabolite homocysteine. It catalyzes a transmethylation reaction in which a methyl group is transferred from methyltetrahydrofolate to homocysteine to generate tetrahydrofolate and methionine. The vitamin B-12 cofactor cobalamin plays a direct role in this reaction by alternately accepting and donating the methyl group that is in transit from one substrate (methyltetrahydrofolate) to another (homocysteine). The reactivity of the cofactor intermediate cob(I)alamin renders the enzyme susceptible to oxidative damage. The oxidized enzyme may be returned to the catalytic turnover cycle via a reductive methylation reaction that requires S-adenosylmethionine as a methyl group donor, and a source of electrons. In this study, we have characterized an NADPH-dependent pathway for the reductive activation of porcine methionine synthase. Two proteins are required for the transfer of electrons from NADPH, one of which is microsomal and the other cytoplasmic. The cytoplasmic protein has been purified to homogeneity and is soluble cytochrome b(5). It supports methionine synthase activity in the presence of NADPH and the microsomal component in a saturable manner. In addition, purified microsomal cytochrome P450 reductase and soluble cytochrome b(5) reconstitute the activity of the porcine methionine synthase. Identification of soluble cytochrome b(5) as a member of the reductive activation system for methionine synthase describes a function for this protein in non-erythrocyte cells. In erythrocytes, soluble cytochrome b(5) functions in methemoglobin reduction. In addition, it identifies an additional locus in which genetic polymorphisms may play a role in the etiology of hyperhomocysteinemia, which is correlated with cardiovascular diseases.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Banerjee, R (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.	rbanerje@unlinfo2.unl.edu			NIDDK NIH HHS [DK45776] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNESEN E, 1995, INT J EPIDEMIOL, V24, P704, DOI 10.1093/ije/24.4.704; Auchus RJ, 1998, J BIOL CHEM, V273, P3158, DOI 10.1074/jbc.273.6.3158; Baginski ES, 1974, METH ENZYMOL; Banerjee R, 1997, CHEM BIOL, V4, P175, DOI 10.1016/S1074-5521(97)90286-6; Banerjee R, 1997, METHOD ENZYMOL, V281, P189; BANERJEE RV, 1990, BIOCHEMISTRY-US, V29, P1129, DOI 10.1021/bi00457a005; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; BRATTSTROM LE, 1984, STROKE, V15, P1012, DOI 10.1161/01.STR.15.6.1012; CHEN ZQ, 1995, J BIOL CHEM, V270, P19246, DOI 10.1074/jbc.270.33.19246; CHEN ZQ, 1994, J BIOL CHEM, V269, P27193; Dallner G, 1974, Methods Enzymol, V31, P191; DRUMMOND JT, 1993, BIOCHEMISTRY-US, V32, P9290, DOI 10.1021/bi00087a005; ELIASSON R, 1992, J BIOL CHEM, V267, P25541; ENOCH HG, 1979, J BIOL CHEM, V254, P8976; FINKELSTEIN JD, 1984, J BIOL CHEM, V259, P9508; FUJII K, 1977, ARCH BIOCHEM BIOPHYS, V178, P662, DOI 10.1016/0003-9861(77)90238-7; FUJII K, 1974, J BIOL CHEM, V249, P6745; GOYETTE P, 1994, NAT GENET, V7, P195, DOI 10.1038/ng0694-195; Gulati S, 1997, J BIOL CHEM, V272, P19171, DOI 10.1074/jbc.272.31.19171; Gulati S, 1996, HUM MOL GENET, V5, P1859, DOI 10.1093/hmg/5.12.1859; HULTQUIST DE, 1971, NATURE-NEW BIOL, V229, P252, DOI 10.1038/newbio229252a0; Jarrett JT, 1997, BIOCHEMISTRY-US, V36, P15739, DOI 10.1021/bi971987t; JENKINS CM, 1994, J BIOL CHEM, V269, P27401; Jenkins CM, 1998, BIOCHEMISTRY-US, V37, P6106, DOI 10.1021/bi973076p; KANG SS, 1992, ANNU REV NUTR, V12, P279, DOI 10.1146/annurev.nu.12.070192.001431; KRAUS JP, 1994, J INHERIT METAB DIS, V17, P383, DOI 10.1007/BF00711354; Leclerc D, 1998, P NATL ACAD SCI USA, V95, P3059, DOI 10.1073/pnas.95.6.3059; Leclerc D, 1996, HUM MOL GENET, V5, P1867, DOI 10.1093/hmg/5.12.1867; LLOYD E, 1994, BIOCHEMISTRY-US, V33, P11432, DOI 10.1021/bi00204a005; Ludwig ML, 1997, ANNU REV BIOCHEM, V66, P269, DOI 10.1146/annurev.biochem.66.1.269; MALINOW MR, 1995, CLIN CHEM, V41, P173; MALINOW MR, 1993, CIRCULATION, V87, P1107, DOI 10.1161/01.CIR.87.4.1107; MANGUM JH, 1971, BIOCHEMISTRY-US, V10, P3765, DOI 10.1021/bi00796a019; MATTHEWS RG, 1986, METHIONINE BIOSYNTHE, P697; MCCULLY KS, 1969, AM J PATHOL, V56, P111; MCCULLY KS, 1983, ATHER REV, V11, P157; OZOLS J, 1990, METHOD ENZYMOL, V182, P225; PASSON PG, 1972, BIOCHIM BIOPHYS ACTA, V275, P51, DOI 10.1016/0005-2728(72)90023-0; Peterson JA, 1986, CYTOCHROME P 450 STR, P89; POMPON D, 1984, J BIOL CHEM, V259, P5377; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; Rivera M, 1998, BIOCHEMISTRY-US, V37, P1485, DOI 10.1021/bi972390g; ROSENBLATT DS, 1984, J CLIN INVEST, V74, P2149, DOI 10.1172/JCI111641; SCHUH S, 1984, NEW ENGL J MED, V310, P686, DOI 10.1056/NEJM198403153101104; SPATZ L, 1971, P NATL ACAD SCI USA, V68, P1042, DOI 10.1073/pnas.68.5.1042; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; VanDerMark PK, 1997, BIOCHEM BIOPH RES CO, V240, P80, DOI 10.1006/bbrc.1997.7599; WALKER FA, 1988, J AM CHEM SOC, V110, P6234, DOI 10.1021/ja00226a045; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; Yamazaki H, 1996, J BIOL CHEM, V271, P27438, DOI 10.1074/jbc.271.44.27438	50	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26248	26255		10.1074/jbc.273.40.26248	http://dx.doi.org/10.1074/jbc.273.40.26248			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748308	hybrid			2022-12-27	WOS:000076263100099
J	Landis, DM; Loeb, LA				Landis, DM; Loeb, LA			Random sequence mutagenesis and resistance to 5-fluorouridine in human thymidylate synthases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; BONE-MARROW CELLS; ESCHERICHIA-COLI; GENE AMPLIFICATION; MEGAPRIMER METHOD; CRYSTAL-STRUCTURE; DRUG DESIGN; ACTIVE-SITE; SYNTHETASE; MECHANISM	Thymidylate synthase (TS) catalyzes the methylation of dUMP to dTMP and is the target for the widely used chemotherapeutic agent 5-fluorouracil. We used random sequence mutagenesis to replace 13 codons within the active site of TS and obtain variants that are resistant to 5-fluorodeoxyuridine (5-FdUR). The resulting random library was selected for its ability to complement a TS-deficient Escherichia coli strain, and sequence analysis of survivors found multiple substitutions to be tolerable within the targeted region. An independent selection of the library was carried out in the presence of 5-FdUR, resulting in a more limited spectrum of mutations. One specific mutation, C199L, was observed in more than 46% of 5-FdUR-resistant clones. A 5-FdUR-resistant triple mutant, A197V/L198I/C199F, was purified to apparent homogeneity. Kinetic studies with the substrate dUMP indicate that this mutant is similar to the wild type in regards to k(cat) and K-m values for dUMP and the cosubstrate CH2H4-folate. In contrast, equilibrium binding studies with the inhibitor, FdUMP, demonstrate that the dissociation constant (K-d) for FdUMP binding into the ternary complex was 20-fold higher than values obtained for the wild-type enzyme. This 5-FdUMP-resistant mutant, or others similarly selected, is a candidate for use in gene therapy to render susceptible normal cells resistant to the toxic effects of systemic 5-fluorouracil.	Univ Washington, Sch Med, Joseph Gottstein Mem Canc Res Lab, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Joseph Gottstein Mem Canc Res Lab, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Loeb, LA (corresponding author), Univ Washington, Sch Med, Joseph Gottstein Mem Canc Res Lab, Dept Pathol, Box 357705, Seattle, WA 98195 USA.	laloeb@u.washington.edu			NCI NIH HHS [R35-CA-39909] Funding Source: Medline; PHS HHS [5 T32 07266] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AIYAR A, 1993, BIOTECHNIQUES, V14, P366; BAPAT AR, 1983, J BIOL CHEM, V258, P4130; BARBOUR KW, 1992, MOL PHARMACOL, V42, P242; BELFORT M, 1984, J BACTERIOL, V160, P371, DOI 10.1128/JB.160.1.371-378.1984; BERGER SH, 1988, MOL PHARMACOL, V34, P480; BERGER SH, 1985, MOL PHARMACOL, V28, P461; CARR F, 1983, BLOOD, V62, P180; CARRERAS CW, 1995, ANNU REV BIOCHEM, V64, P721, DOI 10.1146/annurev.bi.64.070195.003445; CLARK JL, 1987, CANCER TREAT REP, V71, P261; CLIMIE S, 1990, J BIOL CHEM, V265, P18776; COHEN SS, 1954, P NATL ACAD SCI USA, V40, P885, DOI 10.1073/pnas.40.10.885; DAVIS ST, 1993, MOL PHARMACOL, V43, P702; DAVISSON VJ, 1989, J BIOL CHEM, V264, P9145; DEV IK, 1989, J BIOL CHEM, V264, P19132; ECKSTEIN JW, 1994, BIOCHEMISTRY-US, V33, P15086, DOI 10.1021/bi00254a018; GOULIAN M, 1980, P NATL ACAD SCI-BIOL, V77, P1956, DOI 10.1073/pnas.77.4.1956; GREM JL, 1990, CANC CHEMOTHERAPY PR, P180; HARDY LW, 1987, SCIENCE, V235, P448, DOI 10.1126/science.3099389; HARRAP KR, 1989, ADV ENZYME REGUL, V29, P161, DOI 10.1016/0065-2571(89)90099-X; HOUGHTON PJ, 1992, CANCER RES, V52, P558; HUGHEY CT, 1993, MOL PHARMACOL, V44, P316; JASTREBOFF MM, 1983, BIOCHEM PHARMACOL, V32, P2259, DOI 10.1016/0006-2952(83)90236-8; Marathi UK, 1997, CLIN CANCER RES, V3, P301; MATTHEWS DA, 1990, J MOL BIOL, V214, P923, DOI 10.1016/0022-2836(90)90346-N; MICHAELS ML, 1990, P NATL ACAD SCI USA, V87, P3957, DOI 10.1073/pnas.87.10.3957; MONTFORT WR, 1990, BIOCHEMISTRY-US, V29, P6964, DOI 10.1021/bi00482a004; MORAN RG, 1979, P NATL ACAD SCI USA, V76, P1456, DOI 10.1073/pnas.76.3.1456; MORITZ T, 1995, CANCER RES, V55, P2608; PERRY KM, 1990, PROTEINS, V8, P315, DOI 10.1002/prot.340080406; PERRY KM, 1993, BIOCHEMISTRY-US, V32, P7116, DOI 10.1021/bi00079a007; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; POGOLOTTI AL, 1986, J MED CHEM, V29, P478, DOI 10.1021/jm00154a009; RODE W, 1980, J BIOL CHEM, V255, P1305; SANTI DV, 1987, BIOCHEMISTRY-US, V26, P8606, DOI 10.1021/bi00400a017; SANTI DV, 1974, BIOCHEMISTRY-US, V13, P471, DOI 10.1021/bi00700a012; SANTI DV, 1984, FOLATES PTERINS, P345; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Schiffer CA, 1995, BIOCHEMISTRY-US, V34, P16279, DOI 10.1021/bi00050a007; Seno T, 1985, Basic Life Sci, V31, P241; SHOICHET BK, 1993, SCIENCE, V259, P1445, DOI 10.1126/science.8451640; Suzuki M, 1996, MOL DIVERS, V2, P111, DOI 10.1007/BF01718708; WAHBA AJ, 1961, J BIOL CHEM, V236, pPC11; WASHTIEN WL, 1982, MOL PHARMACOL, V21, P723; WEBBER SE, 1993, J MED CHEM, V36, P733, DOI 10.1021/jm00058a010; WILLIAMS DA, 1987, J EXP MED, V166, P210, DOI 10.1084/jem.166.1.210; ZHANG HC, 1990, BIOCHEM BIOPH RES CO, V167, P869, DOI 10.1016/0006-291X(90)90604-L	47	31	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25809	25817		10.1074/jbc.273.40.25809	http://dx.doi.org/10.1074/jbc.273.40.25809			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748254	hybrid			2022-12-27	WOS:000076263100045
J	Pai, JT; Guryev, O; Brown, MS; Goldstein, JL				Pai, JT; Guryev, O; Brown, MS; Goldstein, JL			Differential stimulation of cholesterol and unsaturated fatty acid biosynthesis in cells expressing individual nuclear sterol regulatory element-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; STEAROYL-COA DESATURASE; BOUND TRANSCRIPTION FACTOR; DIPHOSPHATE SYNTHASE GENE; LEUCINE ZIPPER PROTEIN; COENZYME-A REDUCTASE; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; CULTURED-CELLS; ADIPOCYTE DETERMINATION	Three sterol regulatory element-binding proteins (SREBP-1a, -1c, and -2) stimulate transcription of genes involved in synthesis and receptor-mediated uptake of cholesterol and fatty acids. Here, we explore the individual roles of each SREBP by preparing lines of Chinese hamster ovary (CHO) cells that express graded amounts of nuclear forms of each SREBP (designated nSREBPs) under control of a muristerone-inducible nuclear receptor system. The parental hamster cell line (M19 cells) lacks its own nSREBPs, owing to a deletion in the gene encoding the Site-a protease, which releases nSREBPs from cell membranes. By varying the concentration of muristerone, we obtained graded expression of individual nSREBPs in the range that restored lipid synthesis to near physiologic levels. The results show that nSREBP-2 produces a higher ratio of synthesis of cholesterol over fatty acids than does nSREBP-1a. This is due in part to a selective ability of low levels of nSREBP-2, but not nSREBP-1a, to activate the promoter for squalene synthase. nSREBP-1a and -2 both activate transcription of the genes encoding stearoyl-CoA desaturase-l and -2, thereby markedly enhancing the production of monounsaturated fatty acids. nSREBP-1c was inactive in stimulating any transcription at the concentrations achieved in these studies. The current data support the emerging view that the nSREBPs act in complementary ways to modulate the lipid composition of cell membranes.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Belarus Acad Sci, Inst Bioorgan Chem, Minsk 220141, BELARUS	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Academy of Sciences of Belarus (NASB); Institute of Bioorganic Chemistry of the National Academy of Sciences of Belarus	Pai, JT (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMY CM, 1989, P NATL ACAD SCI USA, V86, P3114, DOI 10.1073/pnas.86.9.3114; AOYAMA Y, 1994, BIOCHEM BIOPH RES CO, V201, P1320, DOI 10.1006/bbrc.1994.1848; BOLLAG DM, 1991, PROTEIN METHODS, P100; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BROWN MS, 1978, J BIOL CHEM, V253, P1121; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; GIL G, 1986, J BIOL CHEM, V261, P3717; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Guan GM, 1998, J BIOL CHEM, V273, P12526, DOI 10.1074/jbc.273.20.12526; Guan GM, 1997, J BIOL CHEM, V272, P10295; HASAN MT, 1994, SOMAT CELL MOLEC GEN, V20, P183, DOI 10.1007/BF02254759; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; HUA XX, 1995, GENOMICS, V25, P667, DOI 10.1016/0888-7543(95)80009-B; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; KAESTNER KH, 1989, J BIOL CHEM, V264, P14755; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; KRIEGER M, 1979, J SUPRAMOL STR CELL, V10, P467, DOI 10.1002/jss.400100409; KUSANO M, 1995, BIOL PHARM BULL, V18, P195; LIMANEK JS, 1978, P NATL ACAD SCI USA, V75, P5452, DOI 10.1073/pnas.75.11.5452; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Magana MM, 1997, J LIPID RES, V38, P1630; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; Miserez AR, 1997, GENOMICS, V40, P31, DOI 10.1006/geno.1996.4525; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; NTAMBI JM, 1988, J BIOL CHEM, V263, P17291; NTAMBI JM, 1995, PROG LIPID RES, V34, P139, DOI 10.1016/0163-7827(94)00010-J; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Rosenfeld JM, 1998, J BIOL CHEM, V273, P16112, DOI 10.1074/jbc.273.26.16112; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SATO R, 1994, J BIOL CHEM, V269, P17267; SEGE RD, 1986, MOL CELL BIOL, V6, P3268, DOI 10.1128/MCB.6.9.3268; Sessler AM, 1996, J BIOL CHEM, V271, P29854, DOI 10.1074/jbc.271.47.29854; SHECHTER I, 1992, J BIOL CHEM, V267, P8628; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1997, P NATL ACAD SCI USA, V94, P12354, DOI 10.1073/pnas.94.23.12354; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; SPEAR DH, 1992, J BIOL CHEM, V267, P14462; TANG ZL, 1994, GENE, V147, P299, DOI 10.1016/0378-1119(94)90087-6; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Waters KM, 1997, BBA-LIPID LIPID MET, V1349, P33, DOI 10.1016/S0005-2760(97)00069-6; YANG JX, 1994, GENE DEV, V8, P1910, DOI 10.1101/gad.8.16.1910; YANG JX, 1995, J BIOL CHEM, V270, P12152, DOI 10.1074/jbc.270.20.12152; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	62	185	192	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26138	26148		10.1074/jbc.273.40.26138	http://dx.doi.org/10.1074/jbc.273.40.26138			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748295	hybrid			2022-12-27	WOS:000076263100086
J	Imanaka, T; Hayashi, H; Kishi, K; Wang, LH; Ishii, K; Hazeki, O; Katada, T; Ebina, Y				Imanaka, T; Hayashi, H; Kishi, K; Wang, LH; Ishii, K; Hazeki, O; Katada, T; Ebina, Y			Reconstitution of insulin signaling pathways in rat 3Y1 cells lacking insulin receptor and insulin receptor substrate-1 - Evidence that activation of Akt is insufficient for insulin-stimulated glycogen synthesis or glucose uptake in rat 3Y1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVATION; GROWTH-FACTOR-II; 3T3-L1 ADIPOCYTES; GLUT4 TRANSLOCATION; PHOSPHOINOSITIDE 3-KINASE; DNA-SYNTHESIS; SH2 DOMAIN; PHOSPHOTYROSINE PROTEIN; HEMATOPOIETIC-CELLS	Rat 3Y1 cells have endogenous insulin-like growth factor-1 receptors and insulin receptor substrate (IRS)-2, but lack both insulin receptor (IR) and IRS-1. To investigate the role of IR and IRS-1 in effects of insulin, we transfected IR and IRS-1 expression plasmids into cells and reconstituted the insulin signaling pathways. 3Y1 cells stably expressing the c-myc epitope-tagged glucose transporter type 4 (3Y1-GLUT4myc) exhibit no effects of insulin, at physiological concentrations. The 3Y1-GLUT4myc-IR cells expressing GLUT4myc and IR responded to phosphatidylinositol 3,4,5-trisphosphate (PI-3,4,5-P-3) accumulation, Akt activation, the stimulation of DNA synthesis, and membrane ruffling but not to glycogen synthesis, glucose uptake, or GLUT4myc translocation. The further expression of IRS-1 in 3Y1-GLUT4myc-IR cells led to stimulation of glycogen synthesis but not to glucose uptake or GLUT4myc translocation in response to insulin, although NaF or phorbol la-myristate 13-acetate did trigger GLUT4myc translocation in the cells. These results suggest that, in rat 3Y1 cells, (i) IRS-1 is essential for insulin-stimulated glycogen synthesis but not for DNA synthesis, PI-3,4,5-P-3 accumulation, Akt phosphorylation, or membrane ruffling, and (ii) the accumulation of PI-3,4,5-P-3 and activation of Akt are insufficient for glycogen synthesis, glucose uptake or for GLUT4 translocation.	Univ Tokushima, Inst Enzyme Res, Div Mol Genet, Tokushima 7708503, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, Tokyo 1080071, Japan; Univ Tokyo, Fac Pharmaceut Sci, Dept Physiol Chem, Bunkyo Ku, Tokyo 1130033, Japan	Tokushima University; University of Tokyo; University of Tokyo	Ebina, Y (corresponding author), Univ Tokushima, Inst Enzyme Res, Div Mol Genet, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.		Ishii, Kazuo/M-3099-2016; Ishii, Kazuo/N-9946-2019; ishii, kazuo/K-7428-2014	Ishii, Kazuo/0000-0002-8363-8266; ishii, kazuo/0000-0001-7801-1891; Hayashi, Hideki/0000-0003-4585-6542				Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; Domin J, 1996, J BIOL CHEM, V271, P21614, DOI 10.1074/jbc.271.35.21614; EBINA Y, 1985, P NATL ACAD SCI USA, V82, P8014, DOI 10.1073/pnas.82.23.8014; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; GOLD MR, 1994, J BIOL CHEM, V269, P5403; HARE K, 1994, P NATL ACAD SCI USA, V91, P7415; HERBST JJ, 1995, J BIOL CHEM, V270, P26000, DOI 10.1074/jbc.270.43.26000; HerreraVelit P, 1997, J BIOL CHEM, V272, P16445, DOI 10.1074/jbc.272.26.16445; HESS SL, 1991, J CELL BIOCHEM, V45, P374, DOI 10.1002/jcb.240450411; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Huppertz C, 1996, DIABETOLOGIA, V39, P1432, DOI 10.1007/s001250050595; Hurel SJ, 1996, BIOCHEM J, V320, P871, DOI 10.1042/bj3200871; IKEZU T, 1995, J BIOL CHEM, V270, P29224, DOI 10.1074/jbc.270.49.29224; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; ISHII K, 1995, BIOCHEM J, V309, P813, DOI 10.1042/bj3090813; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; KAMOHARA S, 1995, P NATL ACAD SCI USA, V92, P1077, DOI 10.1073/pnas.92.4.1077; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; KANAI F, 1993, J BIOL CHEM, V268, P14523; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; Mendez R, 1996, MOL CELL BIOL, V16, P2857; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NISHIMOTO I, 1987, BIOCHEM BIOPH RES CO, V148, P403, DOI 10.1016/0006-291X(87)91125-9; OKADA T, 1994, J BIOL CHEM, V269, P3568; OKAMOTO T, 1991, J BIOL CHEM, V266, P1085; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; Quon MJ, 1996, BIOCHEM BIOPH RES CO, V226, P587, DOI 10.1006/bbrc.1996.1400; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; Todaka M, 1996, BIOCHEM J, V315, P875, DOI 10.1042/bj3150875; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442	62	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25347	25355		10.1074/jbc.273.39.25347	http://dx.doi.org/10.1074/jbc.273.39.25347			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738001	hybrid			2022-12-27	WOS:000076085400051
J	Lee, C; Yim, MB; Chock, PB; Yim, HS; Kang, SO				Lee, C; Yim, MB; Chock, PB; Yim, HS; Kang, SO			Oxidation-reduction properties of methylglyoxal-modified protein in relation to free radical generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCATION END-PRODUCTS; ASCORBIC-ACID; AUTOXIDATIVE GLYCOSYLATION; PHYSIOLOGICAL CONDITIONS; HYDROGEN-PEROXIDE; GLYOXALASE SYSTEM; DIABETES-MELLITUS; MAILLARD REACTION; OXIDANT STRESS; CROSS-LINKING	Oxidation-reduction properties of methylglyoxal-modified protein in relation to free radical generation were investigated. Glycation of bovine serum albumin by methylglyoxal generated the protein-bound free radical, probably the cation radical of the cross-linked Schiff base, as observed in the reaction of methylglyoxal with L-alanine (Yim, H.-S., Kang, S.-O., Bah, Y. C., Chock, P. B., and Yim, M. B. (1995) J. Biol. Chem. 270, 28228-28233) or with N-alpha-acetyl-L-lysine. The glycated bovine serum albumin showed increased electrophoretic mobility suggesting that the basic residues, such as lysine, were modified by methylglyoxal. The glycated protein reduced ferricytochrome c to ferrocytochrome c in the absence of oxygen or added metal ions. This reduction of cytochrome c was accompanied by a large increase in the amplitude of the electron paramagnetic resonance signal originated from the protein-bound free radical. In addition, the glycated protein catalyzed the oxidation of ascorbate in the presence of oxygen, whereas the protein free radical signal disappeared. These results indicate that glycation of protein generates active centers for catalyzing one-electron oxidation-reduction reactions. This active center, which exhibits enzyme-like characteristic, was suggested to be the cross-linked Schiff base/the cross-linked Schiff base radical cation of the protein. It mimics the characteristics of the metal-catalyzed oxidation system. The glycated bovine serum albumin cross-linked further to the cytochrome c in the absence of methylglyoxal. The cross-linked cytochrome c maintains its oxidation-reduction properties. These results together indicate that glycated proteins accumulated in vivo provide stable active sites for catalyzing the formation of free radicals.	Seoul Natl Univ, Coll Nat Sci, Dept Microbiol, Biophys Lab, Seoul 151742, South Korea; Seoul Natl Univ, Res Ctr Mol Microbiol, Seoul 151742, South Korea; NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA	Seoul National University (SNU); Seoul National University (SNU); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Kang, SO (corresponding author), Seoul Natl Univ, Coll Nat Sci, Dept Microbiol, Biophys Lab, Seoul 151742, South Korea.	kangsaou@plaza.snu.ac.kr						AFANASEV IB, 1987, J CHEM SOC PERK T 2, P281, DOI 10.1039/p29870000281; Ahmed MU, 1997, BIOCHEM J, V324, P565, DOI 10.1042/bj3240565; AMICI A, 1989, J BIOL CHEM, V264, P3341; BRINKMANN E, 1995, J CHEM SOC P2, P1; CABELLI DE, 1983, J PHYS CHEM-US, V87, P1809, DOI 10.1021/j100233a031; CHEUNG ST, 1979, BIOCHEM BIOPH RES CO, V90, P940, DOI 10.1016/0006-291X(79)91918-1; Elgawish A, 1996, J BIOL CHEM, V271, P12964, DOI 10.1074/jbc.271.22.12964; GASCOYNE PRC, 1980, INT J QUANTUM CHEM S, V7, P93; GORDILLO E, 1989, J BIOL CHEM, V264, P17024; Inoue Y, 1995, Adv Microb Physiol, V37, P177, DOI 10.1016/S0065-2911(08)60146-0; JIANG ZY, 1990, FEBS LETT, V268, P69, DOI 10.1016/0014-5793(90)80974-N; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; LO TWC, 1994, J BIOL CHEM, V269, P32299; MCLAUGHLIN JA, 1980, P NATL ACAD SCI USA, V77, P489; MCLELLAN AC, 1994, CLIN SCI, V87, P21, DOI 10.1042/cs0870021; MONNIER VM, 1984, P NATL ACAD SCI-BIOL, V81, P583, DOI 10.1073/pnas.81.2.583; MONNIER VM, 1981, SCIENCE, V211, P491, DOI 10.1126/science.6779377; MULLARKEY CJ, 1990, BIOCHEM BIOPH RES CO, V173, P932, DOI 10.1016/S0006-291X(05)80875-7; NADEZHDIN AD, 1979, CAN J CHEM, V57, P3017, DOI 10.1139/v79-491; Nagaraj RH, 1996, J BIOL CHEM, V271, P19338, DOI 10.1074/jbc.271.32.19338; NISHIKIMI M, 1975, BIOCHEM BIOPH RES CO, V63, P463, DOI 10.1016/0006-291X(75)90710-X; PHILLIPS SA, 1993, BIOCHEM PHARMACOL, V46, P805, DOI 10.1016/0006-2952(93)90488-I; PHILLIPS SA, 1993, EUR J BIOCHEM, V212, P101, DOI 10.1111/j.1432-1033.1993.tb17638.x; REYNOLDS T. M., 1963, ADVAN FOOD RES, V12, P1; SAKURAI T, 1988, FEBS LETT, V236, P406, DOI 10.1016/0014-5793(88)80066-8; THORNALLEY P, 1984, BIOCHIM BIOPHYS ACTA, V797, P276, DOI 10.1016/0304-4165(84)90131-4; VLASSARA H, 1983, DIABETES, V32, P670, DOI 10.2337/diabetes.32.7.670; WELLSKNECHT KJ, 1995, BIOCHEMISTRY-US, V34, P3702, DOI 10.1021/bi00011a027; WellsKnecht KJ, 1996, NEPHROL DIAL TRANSPL, V11, P41; WESTWOOD ME, 1994, J BIOL CHEM, V269, P32293; WOLFF SP, 1987, BIOCHEM J, V245, P243, DOI 10.1042/bj2450243; YAN SD, 1994, J BIOL CHEM, V269, P9889; YIM HS, 1995, J BIOL CHEM, V270, P28228	33	129	133	3	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25272	25278		10.1074/jbc.273.39.25272	http://dx.doi.org/10.1074/jbc.273.39.25272			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737992	hybrid			2022-12-27	WOS:000076085400042
J	Parman, T; Chen, GM; Wells, PG				Parman, T; Chen, GM; Wells, PG			Free radical intermediates of phenytoin and related teratogens - Prostaglandin H synthase-catalyzed bioactivation electron paramagnetic resonance spectrometry, and photochemical product analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE DNA-DAMAGE; IN-VITRO; N-BROMOSUCCINIMIDE; CD-1 MICE; DRUG-METABOLISM; CHAIN CARRIERS; ACID; LIPOXYGENASE; EMBRYOTOXICITY; INHIBITION	Phenytoin and related xenobiotics can be bioactivated by embryonic prostaglandin H synthase (PHS) to a teratogenic free radical intermediate. The mechanism of free radical formation was evaluated using photolytic oxidation with sodium persulfate and by EPR spectrometry. Characterization of the products by mass spectrometry suggested that phenytoin photolyzes to a nitrogen-centered radical that rapidly undergoes ring opening to form a carbon-centered radical. PHS-1 was incubated with teratogen (phenytoin, mephenytoin, trimethadione, phenobarbital, and major metabolites) or its vehicle and the free radical spin trap alpha-phenyl-N-t-butylnitrone, and incubations were analyzed by EPR spectrometry. There was no alpha-phenyl-N-t-butylnitrone radical adduct in control incubations. For phenytoin, a putative unstable nitrogen-centered radical adduct and a stable carbon-centered radical adduct were detected. Free radical spin adducts also were detected for all other teratogens and metabolites except carbamazepine. The PHS inhibitor eicosatetraynoic acid abolished the free radical EPR signal. Incubation of 2'-deoxyguanosine with phenytoin and PHS-1 resulted in a 5-fold increase in its oxidation to 8-hydroxy-2'-deoxyguanosine. This is the first direct chemical evidence for PHS-catalyzed bioactivation of phenytoin and related teratogens to a free radical intermediate that initiates DNA oxidation, which may constitute a common molecular mechanism of teratologic initiation.	Univ Toronto, Fac Pharm, Toronto, ON M5S 2S2, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON M5S 2S2, Canada; Univ Guelph, Dept Clin Studies, Guelph, ON N1G 2W1, Canada	University of Toronto; University of Toronto; University of Guelph	Wells, PG (corresponding author), Univ Toronto, Fac Pharm, 19 Russell St, Toronto, ON M5S 2S2, Canada.	pg.wells@utoronto.ca						AMES BN, 1989, FREE RADICAL RES COM, V7, P121, DOI 10.3109/10715768909087933; ARLEN RR, 1990, FASEB J, V4, P608; BIRKETT DJ, 1993, TRENDS PHARMACOL SCI, V14, P292, DOI 10.1016/0165-6147(93)90043-J; CHOW YL, 1984, REV CHEM INTERMED, V5, P325, DOI 10.1007/BF03155672; CHOW YL, 1989, J ORG CHEM, V54, P530, DOI 10.1021/jo00264a005; CHOW YL, 1987, J ORG CHEM, V52, P1931, DOI 10.1021/jo00386a008; CLAYSON DB, 1994, MUTAT RES, V317, P25, DOI 10.1016/0165-1110(94)90010-8; COFFEY JW, 1982, FED PROC, V41, P1551; DOWNING DT, 1972, BIOCHIM BIOPHYS ACTA, V280, P343, DOI 10.1016/0005-2760(72)90102-6; Fantel AG, 1996, TERATOLOGY, V53, P196, DOI 10.1002/(SICI)1096-9926(199603)53:3<196::AID-TERA7>3.0.CO;2-2; Finnell RH, 1995, TERATOLOGY, V52, P324, DOI 10.1002/tera.1420520603; HAGEMAN WE, 1986, PROSTAGLANDINS, V32, P563, DOI 10.1016/0090-6980(86)90038-9; Halliwell B., 1989, FREE RADICAL BIO MED, P18; HAMMARSTROM S, 1977, BIOCHIM BIOPHYS ACTA, V487, P517, DOI 10.1016/0005-2760(77)90221-1; HANSEN DK, 1991, P SOC EXP BIOL MED, V197, P361; HANSEN DK, 1992, P SOC EXP BIOL MED, V199, P501; JUCHAU MR, 1992, DRUG METAB REV, V24, P195, DOI 10.3109/03602539208996293; KASAI H, 1986, CARCINOGENESIS, V7, P1849, DOI 10.1093/carcin/7.11.1849; Kim PM, 1997, J PHARMACOL EXP THER, V280, P200; Kim PM, 1996, MOL PHARMACOL, V49, P172; KLEIN KL, 1984, PROSTAGLANDINS, V27, P659, DOI 10.1016/0090-6980(84)90005-4; KUKREJA RC, 1986, CIRC RES, V59, P612, DOI 10.1161/01.RES.59.6.612; KUPFER A, 1981, J PHARMACOL EXP THER, V218, P193; KUPFER A, 1979, CLIN RES, V27, P235; LAPOSA RR, 1995, TOXICOLOGIST, V15, P161; LAPOSA RR, 1996, FUNDAM APPL TOXIC S1, V30, P195; LIND J, 1993, J PHYS CHEM-US, V97, P1610, DOI 10.1021/j100110a023; LIU L, 1995, FREE RADICAL BIO MED, V19, P639, DOI 10.1016/0891-5849(95)00082-9; LUNING U, 1985, TETRAHEDRON, V41, P4289, DOI 10.1016/S0040-4020(01)97200-X; March J., 1992, ADV ORG CHEM, P897; MIRANDA AF, 1994, TOXICOL APPL PHARM, V124, P230, DOI 10.1006/taap.1994.1027; NICOL CJ, 1995, NAT GENET, V10, P181, DOI 10.1038/ng0695-181; Ozolins TRS, 1996, J PHARMACOL EXP THER, V277, P945; PARMAN T, 1996, FUNDAM APPL TOX 2 S1, V30, P1260; PEARSON PG, 1991, CHEM RES TOXICOL, V4, P436, DOI 10.1021/tx00022a007; RUDD NL, 1979, J PEDIATR-US, V94, P835, DOI 10.1016/S0022-3476(79)80173-0; SEIP M, 1976, ACTA PAEDIATR SCAND, V65, P617, DOI 10.1111/j.1651-2227.1976.tb04941.x; SHIGENAGA MK, 1990, METHOD ENZYMOL, V186, P521; SHRINER RL, 1964, SYSTEMATIC IDENTIFIC, P289; SKELL PS, 1978, ACCOUNTS CHEM RES, V11, P381, DOI 10.1021/ar50130a003; SLATTER JG, 1991, CHEM RES TOXICOL, V4, P157, DOI 10.1021/tx00020a006; SPECTOR A, 1989, EXP EYE RES, V49, P685, DOI 10.1016/S0014-4835(89)80063-6; SPEIDEL BD, 1972, LANCET, V2, P839; SPITZ DR, 1987, J CELL PHYSIOL, V131, P364, DOI 10.1002/jcp.1041310308; SUN FF, 1981, PROSTAGLANDINS, V21, P333, DOI 10.1016/0090-6980(81)90151-9; VACA CE, 1988, MUTAT RES, V195, P137, DOI 10.1016/0165-1110(88)90022-X; VANWAUWE J, 1983, PROSTAGLANDINS, V26, P725, DOI 10.1016/0090-6980(83)90057-6; WELLS PG, 1982, J PHARMACOL EXP THER, V221, P228; Wells PG, 1996, CRIT REV BIOCHEM MOL, V31, P1, DOI 10.3109/10409239609110574; WELLS PG, 1989, TOXICOL APPL PHARM, V97, P406, DOI 10.1016/0041-008X(89)90245-7; Wells PG, 1997, MUTAT RES-FUND MOL M, V396, P65, DOI 10.1016/S0027-5107(97)00175-9; WELLS PG, 1991, TOXICOLOGIST, V11, P1131; WELLS PG, 1997, HANDB EXP PHARM I, V124, P453; WELLS PG, 1997, COMPREHENSIVE TOXICO, V10, P489; Winn LM, 1997, FREE RADICAL BIO MED, V22, P607, DOI 10.1016/S0891-5849(96)00340-1; Winn LM, 1995, EUR J NEUROL, V2, P5; YU WK, 1995, TOXICOL APPL PHARM, V131, P1, DOI 10.1006/taap.1995.1040; ZHANG YH, 1990, CAN J CHEM, V68, P1668, DOI 10.1139/v90-260	58	66	70	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25079	25088		10.1074/jbc.273.39.25079	http://dx.doi.org/10.1074/jbc.273.39.25079			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737965	hybrid			2022-12-27	WOS:000076085400015
J	Tang, SJ; Suen, TC; McInnes, RR; Buchwald, M				Tang, SJ; Suen, TC; McInnes, RR; Buchwald, M			Association of the TLX-2 homeodomain and 14-3-3 eta signaling proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; T-CELL LEUKEMIA; IN-VIVO; 14-3-3-PROTEINS ASSOCIATE; SERINE PHOSPHORYLATION; HOMEOBOX GENE; HOX11 GENE; KINASE; EXPRESSION; RAF	Homeodomain proteins play important roles in various developmental processes, and their functions are modulated by polypeptide cofactors. Here we report that both in vitro and in vivo 14-3-3 eta is associated with the TLX-2 homeodomain transcription factor that is required for mouse embryogenesis. Expression of 14-3-3 eta shifts the predominant localization of TLX-2 in COS cells from the cytoplasm to the nucleus. Tlx-2 and 14-3-3 eta are expressed in the developing peripheral nervous system with spatially and temporally overlapping patterns, and they are also coexpressed in PC12 cells. Increased expression of either gene by transfection considerably inhibited nerve growth factor-induced neurite outgrowth of PC12 cells, and cotransfection of both genes led to a synergistic effect of suppression. These findings define 14-3-3 eta as a functional modulator of the TLX-2 homeodomain transcription factor and suggest that the in vivo function of TLX-2 in neural differentiation is likely regulated by signaling mediated by 14-3-3 eta.	Hosp Sick Children, Res Inst, Dept Genet, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Buchwald, M (corresponding author), Hosp Sick Children, Res Inst, Dept Genet, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	buchwald@sickkids.on.ca						Agulnick AD, 1996, NATURE, V384, P270, DOI 10.1038/384270a0; AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; Chang HC, 1997, GENE DEV, V11, P1132, DOI 10.1101/gad.11.9.1132; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; DEAR TN, 1995, DEVELOPMENT, V121, P2909; Du XP, 1996, J BIOL CHEM, V271, P7362, DOI 10.1074/jbc.271.13.7362; DUBE ID, 1991, BLOOD, V78, P2996; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; Guichet A, 1997, NATURE, V385, P548, DOI 10.1038/385548a0; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; Kockel L, 1997, GENE DEV, V11, P1140, DOI 10.1101/gad.11.9.1140; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; LICHTSTEINER S, 1995, EMBO J, V14, P3937, DOI 10.1002/j.1460-2075.1995.tb00065.x; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; Meller N, 1996, MOL CELL BIOL, V16, P5782; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; RAJU K, 1993, MECH DEVELOP, V44, P51, DOI 10.1016/0925-4773(93)90016-Q; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; ROBERTS CWM, 1994, NATURE, V368, P747, DOI 10.1038/368747a0; Roberts RL, 1997, CELL, V89, P1055, DOI 10.1016/S0092-8674(00)80293-7; Rommel C, 1997, MECH DEVELOP, V64, P95, DOI 10.1016/S0925-4773(97)00052-X; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; Teng KK, 1994, CELL BIOL LAB HDB, P218; UM M, 1995, MOL CELL BIOL, V15, P5007; Vandromme M, 1996, TRENDS BIOCHEM SCI, V21, P59, DOI 10.1016/S0968-0004(96)80182-4; Vincenz C, 1996, J BIOL CHEM, V271, P20029, DOI 10.1074/jbc.271.33.20029; WATANABE M, 1991, MOL BRAIN RES, V10, P151, DOI 10.1016/0169-328X(91)90105-7; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; YU U, 1997, NATURE, V358, P552; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang HL, 1996, P NATL ACAD SCI USA, V93, P1764, DOI 10.1073/pnas.93.5.1764; Zhu AH, 1996, J BIOL CHEM, V271, P20993, DOI 10.1074/jbc.271.35.20993	51	32	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25356	25363		10.1074/jbc.273.39.25356	http://dx.doi.org/10.1074/jbc.273.39.25356			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738002	hybrid			2022-12-27	WOS:000076085400052
J	Voziyan, PA; Tieman, BC; Low, CM; Fisher, MT				Voziyan, PA; Tieman, BC; Low, CM; Fisher, MT			Changing the nature of the initial chaperonin capture complex influences the substrate folding efficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DODECAMERIC GLUTAMINE-SYNTHETASE; ESCHERICHIA-COLI; MOLECULAR CHAPERONES; NONNATIVE FORMS; ATPASE CYCLE; GROEL; PROTEIN; BINDING; RHODANESE; MECHANISM	For the chaperonin substrates, rhodanese, malate dehydrogenase (MDH), and glutamine synthetase (GS), the folding efficiencies, and the lifetimes of folding intermediates were measured with either the nucleotide-free GroEL or the activated ATP.GroEL.GroES chaperonin complex. With both nucleotide-free and activated complex, the folding efficiency of rhodanese and MDH remained high over a large range of GroEL to substrate concentration ratios (up to 1:1). In contrast, the folding efficiency of GS began to decline at ratios lower than 8:1. At ratios where the refolding yields were initially the same, only a relatively small increase (1.6-fold) in misfolding kinetics of MDR was observed with either the nucleotide-free or activated chaperonin complex. For rhodanese, no change was detected with either chaperonin complex. In contrast, GS lost its ability to interact with the chaperonin system at an accelerated rate (8-fold increase) when the activated complex instead of the nucleotide-free complex was used to rescue the protein from misfolding, Our data demonstrate that the differences in the refolding yields are related to the intrinsic folding kinetics of the protein substrates. We suggest that the early kinetic events at the substrate level ultimately govern successful chaperonin-substrate interactions and play a crucial role in dictating polypeptide flux through the chaperonin system. Our results also indicate that an accurate assessment of the transient properties of folding intermediates that dictate the initial chaperonin-substrate interactions requires the use of the activated complex as the interacting chaperonin species.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center	Fisher, MT (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.	mfisher1@kumc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM049309] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49309] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIRD BA, 1988, BIOCHIM BIOPHYS ACTA, V956, P30, DOI 10.1016/0167-4838(88)90294-4; BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P2767; Buchberger A, 1996, J MOL BIOL, V261, P328, DOI 10.1006/jmbi.1996.0465; Buckle AM, 1997, P NATL ACAD SCI USA, V94, P3571, DOI 10.1073/pnas.94.8.3571; Burston SG, 1996, NATURE, V383, P96, DOI 10.1038/383096a0; Chan HS, 1996, PROTEINS, V24, P345; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; Clark AC, 1997, J MOL BIOL, V268, P512, DOI 10.1006/jmbi.1997.0969; Corrales FJ, 1996, P NATL ACAD SCI USA, V93, P4509, DOI 10.1073/pnas.93.9.4509; Eisenstein E, 1998, METHOD ENZYMOL, V290, P119, DOI 10.1016/S0076-6879(98)90011-8; Farr GW, 1997, CELL, V89, P927, DOI 10.1016/S0092-8674(00)80278-0; Fenton WA, 1997, PROTEIN SCI, V6, P743; FISHER MT, 1992, J BIOL CHEM, V267, P1872; FISHER MT, 1994, J BIOL CHEM, V269, P13629; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; FISHER MT, 1994, J BIOL CHEM, V269, P29598; FISHER MT, 1996, BIOCHEMISTRY MOSC, V63, P382; Goldberg MS, 1997, P NATL ACAD SCI USA, V94, P1080, DOI 10.1073/pnas.94.4.1080; GOLUBINOFF P, 1989, NATURE, V342, P884; GRAGEROV A, 1992, P NATL ACAD SCI USA, V89, P10341, DOI 10.1073/pnas.89.21.10341; Gross M, 1996, PROTEIN SCI, V5, P2506, DOI 10.1002/pro.5560051213; HOROWITZ PM, 1992, J BIOL CHEM, V267, P23596; Jaenicke R, 1996, CURR TOP CELL REGUL, V34, P209, DOI 10.1016/S0070-2137(96)80008-2; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LEHNINGER AL, 1982, PRINCIPLES BIOCH, P373; LILIE H, 1995, P NATL ACAD SCI USA, V92, P8100, DOI 10.1073/pnas.92.18.8100; LIN S, 1995, J BIOL CHEM, V270, P1011; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; Perrett S, 1997, J MOL BIOL, V269, P892, DOI 10.1006/jmbi.1997.1081; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; Ranson NA, 1997, J MOL BIOL, V266, P656, DOI 10.1006/jmbi.1996.0815; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; STANIFORTH RA, 1994, BIOCHEM J, V300, P651, DOI 10.1042/bj3000651; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; Todd MJ, 1996, P NATL ACAD SCI USA, V93, P4030, DOI 10.1073/pnas.93.9.4030; VITTANEN PV, 1992, PROTEIN SCI, V1, P363; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; WOOLFOLK CA, 1966, ARCH BIOCHEM BIOPHYS, V116, P177, DOI 10.1016/0003-9861(66)90026-9; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Zahn R, 1996, SCIENCE, V271, P642, DOI 10.1126/science.271.5249.642; ZAHN R, 1994, J MOL BIOL, V242, P165, DOI 10.1006/jmbi.1994.1567	47	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25073	25078		10.1074/jbc.273.39.25073	http://dx.doi.org/10.1074/jbc.273.39.25073			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737964	hybrid			2022-12-27	WOS:000076085400014
J	Wang, D; Sul, HS				Wang, D; Sul, HS			Insulin stimulation of the fatty acid synthase promoter is mediated by the phosphatidylinositol 3-kinase pathway - Involvement of protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; RAT ADIPOSE-CELLS; SIGNAL-TRANSDUCTION; 3T3-L1 ADIPOCYTES; GENE-EXPRESSION; 1-PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; GLUT4 TRANSLOCATION; OKADAIC ACID; ACTIVATION	Fatty acid synthase (FAS) is a critical enzyme in de novo lipogenesis. It catalyzes the seven steps in the conversion of malonyl-CoA and acetyl-CoA to palmitate, We have shown that the rate of FAS transcription is induced dramatically when fasted animals are refed with a high carbohydrate, fat-free diet or when streptozotocin-diabetic mice are given insulin. The FAS promoter was up-regulated by insulin through the proximal insulin response sequence containing an E-box motif at the -65-base pair position. Binding of upstream stimulatory factors to the -65 E-box is functionally required for insulin regulation of the FAS promoter. In the present study, we characterized signaling pathways in the insulin stimulation of FAS transcription using specific inhibitors for various signaling molecules and transfecting engineered phosphatidylinositol (PI) 3-kinase subunits and protein kinase B (PKB)/Akt, PD98059 and rapamycin, which inhibit MAP kinase and P70 S6 kinase, respectively, had little effect on the insulin-stimulated FAS promoter activity in 3T3-L1 adipocytes, On the other hand, wortmannin and LY294002, which specifically inactivate PI 3-kinase, strongly inhibited the insulin-stimulated FAS promoter activity. As shown in RNase protection assays, LY294002 also inhibited insulin stimulation of the endogenous FAS mRNA levels in 3T3-L1 adipocytes, Cotransfection of expression vectors for the constitutively active P110 subunit of PI 3-kinase resulted in an elevated FAS promoter activity in the absence of insulin and a loss of further insulin stimulation. Transfecting a dominant negative P85 subunit of PI 3-kinase decreased FAS promoter activity and blocked insulin stimulation. Furthermore, cotransfected wild-type PKB/Akt increased FAS promoter activity in the absence of insulin and a loss of insulin responsiveness of the FAS promoter. On the other hand, kinase-dead PKB/Akt acted in a dominant negative manner to decrease the FAS promoter activity and abolished its insulin responsiveness. These results demonstrate that insulin stimulation of fatty acid synthase promoter is mediated by the PI 3-kinase pathway and that PKB/Abt is involved as a downstream effector.	Univ Calif Berkeley, Dept Nutr Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Sul, HS (corresponding author), Univ Calif Berkeley, Dept Nutr Sci, Berkeley, CA 94720 USA.	hsul@nature.berkeley.edu	Han, Zaiqi/AAI-2233-2019		NIDDK NIH HHS [DK-36264] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036264] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; HAAVIK J, 1989, FEBS LETT, V251, P36, DOI 10.1016/0014-5793(89)81424-3; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HILLGARTNER F, 1995, PHYSIOL REV, V75, P47, DOI 10.1152/physrev.1995.75.1.47; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Kahn BB, 1998, CELL, V92, P593, DOI 10.1016/S0092-8674(00)81125-3; KINGSTON RE, 1989, CURRENT PROTOCOLS MO; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; Kurschner C, 1997, BIOCHEM BIOPH RES CO, V231, P333, DOI 10.1006/bbrc.1997.6097; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; MOUSTAID N, 1993, BIOCHEM J, V292, P767, DOI 10.1042/bj2920767; MOUSTAID N, 1994, J BIOL CHEM, V269, P5629; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; PAULAUSKIS JD, 1989, BIOCHEM BIOPH RES CO, V158, P690, DOI 10.1016/0006-291X(89)92776-9; PAULAUSKIS JD, 1988, J BIOL CHEM, V263, P7049; Pognonec P, 1997, ONCOGENE, V14, P2091, DOI 10.1038/sj.onc.1201046; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; Soncini M, 1995, J BIOL CHEM, V270, P30339, DOI 10.1074/jbc.270.51.30339; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; Sul HS, 1998, ANNU REV NUTR, V18, P331, DOI 10.1146/annurev.nutr.18.1.331; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; Sutherland C, 1998, J BIOL CHEM, V273, P3198, DOI 10.1074/jbc.273.6.3198; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VOLPE JJ, 1976, PHYSIOL REV, V56, P339, DOI 10.1152/physrev.1976.56.2.339; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WANG D, 1995, J BIOL CHEM, V270, P28716, DOI 10.1074/jbc.270.48.28716; Wang D, 1997, J BIOL CHEM, V272, P26367, DOI 10.1074/jbc.272.42.26367	52	114	118	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25420	25426		10.1074/jbc.273.39.25420	http://dx.doi.org/10.1074/jbc.273.39.25420			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738010	hybrid			2022-12-27	WOS:000076085400060
J	Yeung, MC; Lau, AS				Yeung, MC; Lau, AS			Tumor suppressor p53 as a component of the tumor necrosis factor-induced, protein kinase PKR-mediated apoptotic pathway in human promonocytic U937 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; WILD-TYPE P53; LEUKEMIC-CELLS; FACTOR-ALPHA; EXPRESSION; DEATH; INDUCTION; CYCLE; INTERLEUKIN-6; INVOLVEMENT	Despite what is known about the early signaling events in tumor necrosis factor (TNF) alpha-induced apoptosis, characterization of the downstream events remains largely undefined. It is now known that a crosstalk exists between the interferon and TNF-alpha pathways. This linkage allows recruitment of the cell proliferation suppressor PKR (dsRNA-dependent protein kinase) from the interferon pathway to play a pivotal role in TNF-alpha-induced apoptosis. In this study, we took advantage of the differential TNF-alpha susceptibilities of human promonocytic U937 subclones, deficient in or overexpressing PKR, to further characterize the role of PKR in apoptosis. By reverse transcription-polymerase chain reaction, we demonstrated that TNF-alpha transiently induces the tumor suppressor p53 in U937 cells. This p53 induction lags behind the TNF-alpha induction of PKR by 1 h. By cell viability determination, ultrastructural studies, apoptotic DNA laddering, and antisense techniques, it was shown that inhibition of p53 expression in PKR-overexpressing U937 cells abrogates the TNF-alpha-induced apoptosis in these cells. Conversely, overexpressing wild type p53 in PKR-deficient U937 cells confers the susceptibility of these cells to TNF-alpha-induced apoptosis. This latter result indicates that p53 induction is an event downstream of TNF-alpha-induced up-regulation of PKR, thereby further establishing the critical role of p53 in TNF-alpha-induced apoptosis in U937 cells. PKR-overexpressing U937 cells were found to possess a constitutively higher level of p53, which partly explains why these cells spontaneously undergo apoptosis even without TNF-alpha treatment. Finally, a model is presented on the interplay between PKR and p53 in effecting TNF-alpha-induced apoptosis in U937 cells.	San Francisco Gen Hosp, Dept Pediat, Moses Grossman Infect Dis Lab, San Francisco, CA 94110 USA; Univ Calif San Francisco, San Francisco, CA 94110 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Lau, AS (corresponding author), San Francisco Gen Hosp, Dept Pediat, Moses Grossman Infect Dis Lab, Rm 6E6,1001 Potrero Ave, San Francisco, CA 94110 USA.							Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; DANOVA M, 1990, LEUKEMIA RES, V14, P417, DOI 10.1016/0145-2126(90)90027-7; DER SD, 1995, P NATL ACAD SCI USA, V92, P8841, DOI 10.1073/pnas.92.19.8841; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; Kishi K, 1993, Gan To Kagaku Ryoho, V20, P1107; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Lahdenpohja N, 1998, J IMMUNOL, V160, P1354; LEVINE AJ, 1994, J LAB CLIN MED, V123, P817; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; REIHSAUS E, 1990, ONCOGENE, V5, P137; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; Serfas MS, 1997, CELL GROWTH DIFFER, V8, P951; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Takizawa T, 1996, J VIROL, V70, P8128, DOI 10.1128/JVI.70.11.8128-8132.1996; Takizawa T, 1996, Nihon Rinsho, V54, P1836; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WU HY, 1994, J BIOL CHEM, V269, P20067; Yeung MC, 1998, AIDS, V12, P349, DOI 10.1097/00002030-199804000-00002; YEUNG MC, 1995, AIDS, V9, P137, DOI 10.1097/00002030-199509020-00004; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451; YIN DL, 1995, NEUROSURGERY, V37, P758, DOI 10.1227/00006123-199510000-00021; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHU YM, 1994, BRIT J CANCER, V69, P468, DOI 10.1038/bjc.1994.85	34	73	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25198	25202		10.1074/jbc.273.39.25198	http://dx.doi.org/10.1074/jbc.273.39.25198			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737981	hybrid			2022-12-27	WOS:000076085400031
J	Adam, L; Vadlamudi, R; Kondapaka, SB; Chernoff, J; Mendelsohn, J; Kumar, R				Adam, L; Vadlamudi, R; Kondapaka, SB; Chernoff, J; Mendelsohn, J; Kumar, R			Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEU DIFFERENTIATION FACTOR; HEPATOCYTE GROWTH-FACTOR; TYROSINE KINASE; BREAST-CANCER; GENE-PRODUCT; PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; FACTOR RECEPTOR; PROTO-ONCOGENE; EXPRESSION	The mechanisms through which heregulin (HRG) regulates the activities of breast cancer cells are currently unknown. We demonstrate that HRG stimulation of noninvasive breast cancer cells enhanced the conversion of globular to filamentous actin and the formation of membrane ruffles, stress fibers, filopodia, and lamellipodia and accompanied by increased cell migration, In addition, HRG; triggered a rapid stimulation of p21-activated kinasel (PAK1) activity and its redistribution into the leading edges of motile cells. The HRG-induced stimulation of PAK1 kinase activity followed phosphatidylinositol-3 kinase (PI-3 kinase) activation. Inhibition of PI-3 kinase activity blocked the activation of PAK1 kinase and also blocked cell migration in response to HRG., Furthermore, direct inhibition of PAK1 functions by the dominant-negative mutant suppressed the capacity of HRG to reorganize actin cytoskeleon structures. We also demonstrated that HRG stimulation promoted physical interactions between PAK1, actin, and human epidermal growth factor receptor 2 (HER2) receptors, and these interactions were dependent on the activation of PI-3 kinase, The blockade of HER2 receptor by an anti-HERB monoclonal antibody resulted in the inhibition of HRG-mediated stimulation of PI-3 kinase/PAK pathway and also the formation of motile actin cytoskeleton structures but not extracellular signal-regulated kinases, These findings suggest a role of PI-3 kinase/PAK1-dependent reorganization of the cortical actin cytoskeleton in HRG-mediated increased cell migration, and these changes may have significant consequences leading to enhanced invasion by breast cancer cells.	Univ Texas, MD Anderson Cancer Ctr, Cell Growth Regulat Sect, Cell Growth Regulat Lab, Houston, TX 77030 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	University of Texas System; UTMD Anderson Cancer Center; Fox Chase Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Cell Growth Regulat Sect, Cell Growth Regulat Lab, 1515 Holcombe Blvd,Box 36, Houston, TX 77030 USA.	rkumar@notes.mdacc.tmc.edu	Chernoff, Jonathan/I-7631-2014	Chernoff, Jonathan/0000-0002-4803-7836	NATIONAL CANCER INSTITUTE [U01CA065746, R01CA065746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054168] Funding Source: NIH RePORTER; NCI NIH HHS [CA65746] Funding Source: Medline; NIGMS NIH HHS [GM54168] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM L, 1994, INT J CANCER, V59, P262, DOI 10.1002/ijc.2910590219; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; BENZ CC, 1993, BREAST CANCER RES TR, V24, P85; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; FAN Z, 1993, J BIOL CHEM, V268, P21073; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HEIDARAN MA, 1990, ONCOGENE, V5, P1265; HooshmandRad R, 1997, EXP CELL RES, V234, P434, DOI 10.1006/excr.1997.3636; HORAN T, 1995, J BIOL CHEM, V270, P24604, DOI 10.1074/jbc.270.41.24604; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Jones FE, 1996, CELL GROWTH DIFFER, V7, P1031; KIM HH, 1994, J BIOL CHEM, V269, P24747; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; KUMAR R, 1992, P NATL ACAD SCI USA, V89, P6599, DOI 10.1073/pnas.89.14.6599; KUMAR R, 1991, MOL CELL BIOL, V11, P979, DOI 10.1128/MCB.11.2.979; KUMAR R, 1995, J CELL BIOCHEM, V62, P102; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MARTE BM, 1994, CELL GROWTH DIFFER, V5, P239; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215	38	258	262	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28238	28246		10.1074/jbc.273.43.28238	http://dx.doi.org/10.1074/jbc.273.43.28238			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774445	hybrid			2022-12-27	WOS:000076549800065
J	Pasqualini, E; Caillol, N; Panicot, L; Mas, E; Lloubes, R; Lombardo, D				Pasqualini, E; Caillol, N; Panicot, L; Mas, E; Lloubes, R; Lombardo, D			Molecular cloning of the oncofetal isoform of the human pancreatic bile salt-dependent lipase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-ESTER HYDROLASE; LINKED OLIGOSACCHARIDE; SUBSTRATE-SPECIFICITY; STIMULATED LIPASE; ACTIVATED LIPASE; CELL-LINES; PROTEIN; PURIFICATION; GENE; EXPRESSION	Specific transcripts for bile salt-dependent lipase (BSDL), a 100-kDa glycoprotein secreted by the human pancreas, were immunodetected in BxPC-3 and SOJ-6 pancreatic tumoral cell lines. Sequencing of fragments, obtained by mRNA reverse transcription and amplification, confirmed the presence of BSDL transcripts in these cancer cells. The protein was detected in lysates of pancreatic tumoral cells, where it was mainly associated with membranes. Only a minute amount of the enzyme was detected in the culture media. Immunofluorescence studies demonstrated that in SOJ-6 cells, BSDL colocates with the p58 Golgi protein and suggested that the protein may be sequestrated within the Golgi compartment, These results demonstrated that BSDL is expressed in human pancreatic tumoral cells and cannot be secreted (or for the least very poorly). Subsequently, a cDNA covering the entire sequence of BSDL was obtained by reverse transcription-polymerase chain reaction. The sequence of this cDNA indicated that the N-terminal domain encoded by exons 1-10 was identical to that of BSDL expressed by the human normal pancreas, However, the sequence corresponding to exon 11, which should code for the 16 tandem-repeated identical mucin-like sequences of BSDL, was deleted by 330 base pairs (bp) and encoded only 6 of these repeated sequences. We conclude that this truncated variant of BSDL would be its oncofetal form, referred to as feto-acinar pancreatic protein. We then investigated whether the deletion of 330 bp affected the secretion of the protein. For this purpose, the cDNA corresponding to the mature form of the BSDL variant expressed in SOJ-6 cells was cloned into an expression/secretion vector and transfected into CHO-K1 cells. Results indicated that the variant of BSDL isolated from SOJ-6 cells was expressed and secreted by transfected cells. However, the level of BSDL secreted by these transfected CHO-K1 cells was significantly higher than that observed for SOJ-6 cells. Consequently, the retention of the oncofetal variant of BSDL observed in human pancreatic tumoral cells might not result from inherent properties of the protein.	Fac Med Timone, INSERM, U260, F-13385 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Lombardo, D (corresponding author), Fac Med Timone, INSERM, U260, 27 Blv Jean Moulin, F-13385 Marseille, France.	Dominique.Lombardo@medecine.univ-mrs.fr	Panicot-Dubois, Laurence/E-3030-2016; Mas, Eric/O-9569-2017; Mas, Eric/AAC-9837-2022	Panicot-Dubois, Laurence/0000-0003-0848-5009; Mas, Eric/0000-0002-8925-9195; LLOUBES, Roland/0000-0002-9520-1053				ABOUAKIL N, 1993, J BIOL CHEM, V268, P25755; ABOUAKIL N, 1988, BIOCHIM BIOPHYS ACTA, V961, P299, DOI 10.1016/0005-2760(88)90077-X; ALBERS GHR, 1987, DIFFERENTIATION, V34, P210, DOI 10.1111/j.1432-0436.1987.tb00068.x; BABA T, 1991, BIOCHEMISTRY-US, V30, P500, DOI 10.1021/bi00216a028; BRUNEAU N, 1995, EUR J BIOCHEM, V233, P209, DOI 10.1111/j.1432-1033.1995.209_1.x; Bruneau N, 1997, J BIOL CHEM, V272, P27353, DOI 10.1074/jbc.272.43.27353; BRUNEAU N, 1995, J BIOL CHEM, V270, P13524, DOI 10.1074/jbc.270.22.13524; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CUBILLA AL, 1979, SEMIN ONCOL, V6, P285; DELAPORTE PL, 1986, HISTOCHEMISTRY, V86, P211, DOI 10.1007/BF00493390; ESCRIBANO MJ, 1989, J BIOL CHEM, V264, P21865; FONTAINE RN, 1991, BIOCHEMISTRY-US, V30, P7008, DOI 10.1021/bi00242a028; FRAZIER ML, 1990, PANCREAS, V5, P507, DOI 10.1097/00006676-199009000-00002; GJELLESVIK DR, 1992, BIOCHIM BIOPHYS ACTA, V1124, P123, DOI 10.1016/0005-2760(92)90088-D; GOLDBERG E, 1972, J BIOL CHEM, V247, P2044; GUY O, 1978, BIOCHEMISTRY-US, V17, P1669, DOI 10.1021/bi00602a014; GUY O, 1981, EUR J BIOCHEM, V117, P457; HANSSON L, 1993, J BIOL CHEM, V268, P26692; IMPERIAL S, 1988, BIOCHIM BIOPHYS ACTA, V967, P25, DOI 10.1016/0304-4165(88)90184-5; KUMAR BV, 1992, BIOCHEMISTRY-US, V31, P6077, DOI 10.1021/bi00141a017; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMBARDO D, 1980, BIOCHIM BIOPHYS ACTA, V611, P136, DOI 10.1016/0005-2744(80)90049-2; LOMBARDO D, 1978, BIOCHIM BIOPHYS ACTA, V527, P142, DOI 10.1016/0005-2744(78)90263-2; LOMBARDO D, 1980, BIOCHIM BIOPHYS ACTA, V611, P147, DOI 10.1016/0005-2744(80)90050-9; Mas E, 1997, EUR J BIOCHEM, V243, P299, DOI 10.1111/j.1432-1033.1997.0299a.x; MAS E, 1993, BIOCHEM J, V289, P609, DOI 10.1042/bj2890609; Mas E, 1997, GLYCOBIOLOGY, V7, P745, DOI 10.1093/glycob/7.6.745; MIRALLES F, 1993, EUR J CELL BIOL, V60, P115; MISZCZUKJAMSKA B, 1991, FEBS LETT, V294, P175, DOI 10.1016/0014-5793(91)80662-M; NILSSON J, 1993, GENOMICS, V17, P416, DOI 10.1006/geno.1993.1341; Pasqualini E, 1997, BIOCHEM J, V327, P527, DOI 10.1042/bj3270527; RAUSCHER E, 1981, BER OSTERR GES KLIN, V4, P150; REUE K, 1991, J LIPID RES, V32, P267; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROUDANI S, 1994, EUR J CELL BIOL, V65, P132; ROUDANI S, 1995, BBA-GENE STRUCT EXPR, V1264, P141, DOI 10.1016/0167-4781(95)00141-3; SHIMIZU H, 1990, ONCOLOGIA, V23, P83; WANG CS, 1995, BIOCHEMISTRY-US, V34, P10639, DOI 10.1021/bi00033a039; ZUKER M, 1991, NUCLEIC ACIDS RES, V19, P2707, DOI 10.1093/nar/19.10.2707	40	23	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28208	28218		10.1074/jbc.273.43.28208	http://dx.doi.org/10.1074/jbc.273.43.28208			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774442	hybrid			2022-12-27	WOS:000076549800062
J	Rae, TD; Goff, HM				Rae, TD; Goff, HM			The heme prosthetic group of lactoperoxidase - Structural characteristics of heme 1 and heme 1-peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; NATURAL PORPHYRIN DERIVATIVES; HUMAN MYELOPEROXIDASE; ELECTRONIC-STRUCTURE; AUTOLYTIC CLEAVAGE; PROTOHEME-IX; ACTIVE-SITE; PEROXIDASE; COMPLEXES; SPECTROSCOPY	The heme prosthetic group from the bovine milk enzyme lactoperoxidase (LPO), termed heme 1, is isolated through an approach that combines proteolytic hydrolysis and reverse-phase high performance liquid chromatographic separation of the resulting digest. Application of different proteases yields either a peptide-bound heme (with trypsin and chymotrypsin) or a peptide-free heme (with proteinase K). Both heme 1 and heme 1-peptide species were investigated by paramagnetic H-1 NMR spectroscopy, electrospray mass spectrometry, and peptide sequence analysis. Paramagnetic H-1 MMR experiments on the low spin bis(cyano)-Fe(III)heme 1 complex conclusively define the heme 1 structure as a 1,5-bis(hydroxymethyl) derivative of heme b. The electrospray mass spectrum of heme 1 confirms the two-site hydroxyl functionalization on this heme, Paramagnetic H-1 NMR spectra of the high spin bis(dimethyl sulfoxide)-Fe(III) complexes of the isolated heme species provide information regarding peptide content. Sequence analyses of peptides released from two heme 1-peptide species by base hydrolysis suggest that heme-protein ester linkages in lactoperoxidase occur between the two hydroxyl groups of heme 1 and the carboxylic side chains of glutamate 275 and aspartate 125, These results confirm the earlier reported structural proposal (Rae, T, D., and Goff, H. M. (1996) J. Am. Chem. Soc. 118, 2103-2104).	Univ Iowa, Dept Chem, Iowa City, IA 52242 USA	University of Iowa	Goff, HM (corresponding author), Univ Iowa, Dept Chem, Iowa City, IA 52242 USA.							Andersson LA, 1996, J BIOL CHEM, V271, P3406, DOI 10.1074/jbc.271.7.3406; BANCI L, 1992, COORDIN CHEM REV, V120, P1, DOI 10.1016/0010-8545(92)80045-S; Borhan B, 1996, FRESEN J ANAL CHEM, V354, P490; BUDD DL, 1979, J AM CHEM SOC, V101, P6091, DOI 10.1021/ja00514a036; CALS MM, 1991, EUR J BIOCHEM, V198, P733, DOI 10.1111/j.1432-1033.1991.tb16073.x; CARLSTROM A, 1969, ACTA CHEM SCAND, V23, P171, DOI 10.3891/acta.chem.scand.23-0171; CHATFIELD MJ, 1988, J AM CHEM SOC, V110, P6352, DOI 10.1021/ja00227a013; DePillis GD, 1997, J BIOL CHEM, V272, P8857; DEROPP JS, 1991, J AM CHEM SOC, V113, P4348, DOI 10.1021/ja00011a058; DUGAD LB, 1990, J AM CHEM SOC, V112, P1386, DOI 10.1021/ja00160a015; DUGAD LB, 1990, J BIOL CHEM, V265, P7173; DULL TJ, 1990, DNA CELL BIOL, V9, P499, DOI 10.1089/dna.1990.9.499; EDMAN LW, 1984, J IMMUNOASSY, V5, P29; Everse J.E.K.E., 1991, PEROXIDASES CHEM BIO, VI; FENNA R, 1995, ARCH BIOCHEM BIOPHYS, V316, P653, DOI 10.1006/abbi.1995.1086; GIOIA L, 1996, J BIOL INORG CHEM, V1, P476; GOFF HM, 1985, BIOCHEM BIOPH RES CO, V133, P794, DOI 10.1016/0006-291X(85)90974-X; HULTQUIST DE, 1963, J BIOL CHEM, V238, P2843; HURST JK, 1991, PEROXIDASES CHEM BIO, V1, P37; ISAAC MF, 1993, INORG CHEM, V32, P4030, DOI 10.1021/ic00071a011; KOHLER H, 1988, ARCH BIOCHEM BIOPHYS, V264, P438, DOI 10.1016/0003-9861(88)90309-8; Kooter IM, 1997, J AM CHEM SOC, V119, P11542, DOI 10.1021/ja9725460; La Mar G.N., 1993, BIOL MAGN RESON, P1; LAMAR GN, 1978, J AM CHEM SOC, V100, P8085, DOI 10.1021/ja00494a010; LICOCCIA S, 1989, J AM CHEM SOC, V111, P6087, DOI 10.1021/ja00198a017; MORELL DB, 1963, BIOCHIM BIOPHYS ACTA, V71, P157, DOI 10.1016/0006-3002(63)90994-6; NICHOL AW, 1987, BIOCHEM J, V247, P147, DOI 10.1042/bj2470147; Pruitt K.M., 1985, IMMUNOLOGY SERIES, V27; Rae TD, 1996, J AM CHEM SOC, V118, P2103, DOI 10.1021/ja952650m; SIEVERS G, 1979, BIOCHIM BIOPHYS ACTA, V579, P181, DOI 10.1016/0005-2795(79)90097-7; TAYLOR KL, 1992, J BIOL CHEM, V267, P25282; TAYLOR KL, 1995, ARCH BIOCHEM BIOPHYS, V316, P635, DOI 10.1006/abbi.1995.1083; VANGEET AL, 1970, ANAL CHEM, V42, P679, DOI 10.1021/ac60288a022; YONETANI T, 1967, J BIOL CHEM, V242, P5008; YU C, 1986, J MAGN RESON, V67, P346, DOI 10.1016/0022-2364(86)90440-3; [No title captured]	36	55	58	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27968	27977		10.1074/jbc.273.43.27968	http://dx.doi.org/10.1074/jbc.273.43.27968			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774411	hybrid			2022-12-27	WOS:000076549800031
J	Bouzier, AK; Goodwin, R; de Gannes, FMP; Valeins, H; Voisin, P; Canioni, P; Merle, M				Bouzier, AK; Goodwin, R; de Gannes, FMP; Valeins, H; Voisin, P; Canioni, P; Merle, M			Compartmentation of lactate and glucose metabolism in C6 glioma cells - A C-13 and H-1 NMR study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASTROCYTES; HEART; <1-C-13>GLUCOSE; MITOCHONDRIAL; FLUORESCENCE; NEURONS; FATE	C-13 and H-1 NMR spectroscopy was used to investigate the metabolism of L-lactate and D-glucose in C6 glioma cells, The changing of lactate and glucose concentration in the extracellular medium of C6 glioma cells incubated with 5.5 mM glucose and 11 mM lactate indicated a net production of lactate as the consequence of an active aerobic glycolysis. The C-13 enrichments of various metabolites were determined after 4-h cell incubation in media containing both substrates, each of them being alternatively labeled in the form of either [3-C-13]L-lactate or [1-C-13]D-glucose. Using 11 mM [3-C-13]L-lactate, the enrichment of glutamate C4, 69%, was found higher than that of alanine C3, 32%, when that of acetyl-CoA C2 was 78%. These results indicated that exogenous lactate was the major substrate for the oxidative metabolism of the cells, Nevertheless, an active glycolysis occurred, leading to a net lactate production. This lactate was, however, metabolically different from the exogenous lactate as both lactate species did not mix into a unique compartment, The results were actually consistent with the concept of the existence of two pools of both lactate and pyruvate, wherein one pool was closely connected with exogenous lactate and was the main fuel for the oxidative metabolism, and the other pool was closely related to aerobic glycolysis.	Univ Victor Segalen, CNRS, UMR 5536, Lab Res Magnet Syst Biol, F-33076 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux	Canioni, P (corresponding author), Univ Victor Segalen, CNRS, UMR 5536, Lab Res Magnet Syst Biol, 146 Rue Leo Saignat, F-33076 Bordeaux, France.		de Gannes, Florence Poulletier/B-9827-2011	Bouzier-Sore, Anne-Karine/0000-0002-3470-0940				ARGILES JM, 1988, MOL CELL BIOCHEM, V81, P3; Brand K, 1997, J BIOENERG BIOMEMBR, V29, P355, DOI 10.1023/A:1022498714522; CLEGG JS, 1990, ARCH BIOCHEM BIOPHYS, V278, P452, DOI 10.1016/0003-9861(90)90284-6; Damico LA, 1996, J MOL CELL CARDIOL, V28, P989, DOI 10.1006/jmcc.1996.0092; DRINGEN R, 1995, DEV NEUROSCI-BASEL, V17, P63, DOI 10.1159/000111275; HENRIKSON RL, 1984, DEV NEUROSCI, V1, P226; LEWANDOWSKI ED, 1992, BIOCHEMISTRY-US, V31, P8916, DOI 10.1021/bi00152a031; LIU ZJ, 1987, PLANT PHYSIOL, V84, P1385, DOI 10.1104/pp.84.4.1385; Lovry O.H., 1951, J BIOL CHEM, V193, P265; LUST WD, 1975, MOL CELL BIOCHEM, V8, P169, DOI 10.1007/BF01792767; Magistretti PJ, 1996, CEREB CORTEX, V6, P50, DOI 10.1093/cercor/6.1.50; MALLOY CR, 1990, BIOCHEMISTRY-US, V29, P6756, DOI 10.1021/bi00481a002; MARTIN M, 1993, EUR J BIOCHEM, V217, P617, DOI 10.1111/j.1432-1033.1993.tb18284.x; McKenna MC, 1996, J NEUROCHEM, V66, P386; Merle M, 1996, EUR J BIOCHEM, V239, P742, DOI 10.1111/j.1432-1033.1996.0742u.x; MUSGROVE E, 1986, CYTOMETRY, V7, P347, DOI 10.1002/cyto.990070409; OVADI J, 1996, CHANNELLING INTERMED, P237; PEUHKURINEN KJ, 1983, BIOCHEM J, V210, P193, DOI 10.1042/bj2100193; PIANET I, 1991, EUR J BIOCHEM, V195, P87, DOI 10.1111/j.1432-1033.1991.tb15679.x; Portais JC, 1996, BIOCHIMIE, V78, P155, DOI 10.1016/0300-9084(96)89500-9; PORTAIS JC, 1993, EUR J BIOCHEM, V217, P457, DOI 10.1111/j.1432-1033.1993.tb18265.x; Ross B D, 1988, NMR Biomed, V1, P20, DOI 10.1002/nbm.1940010105; SCHWARTZ JP, 1975, MOL CELL BIOCHEM, V9, P67, DOI 10.1007/BF01732197; STJOHN PA, 1986, J NEUROSCI, V6, P1492; THOLEY G, 1981, J NEUROCHEM, V36, P77, DOI 10.1111/j.1471-4159.1981.tb02379.x; VAUPEL P, 1992, NMR BIOMED, V5, P220, DOI 10.1002/nbm.1940050505; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309	27	58	60	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27162	27169		10.1074/jbc.273.42.27162	http://dx.doi.org/10.1074/jbc.273.42.27162			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765235	hybrid			2022-12-27	WOS:000076448000022
J	Pfeiffer, S; Mayer, B				Pfeiffer, S; Mayer, B			Lack of tyrosine nitration by peroxynitrite generated at physiological pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE AUTOXIDATION; CARBON-DIOXIDE; AQUEOUS-SOLUTION; CATALYZED OXIDATION; IN-VIVO; SUPEROXIDE; KINETICS; NITROTYROSINE; HYDROXYLATION; MECHANISM	Nitration of tyrosine residues of proteins has been suggested as a marker of peroxynitrite-mediated tissue injury in inflammatory conditions. The nitration reaction has been extensively studied in vitro by bolus addition of authentic peroxynitrite, an experimental approach hardly reflecting in vivo situations in which the occurrence of peroxynitrite is thought to result from continuous generation of (NO)-N-. and O-2(radical anion) at physiological pH, In the present study, we measured the nitration of free tyrosine by (NO)-N-. and O-2(radical anion) generated at web defined rates from the donor compound (Z)-1-[N-[3-aminopropyl]-N-[4-(3-aminopropylammonio)butyl]-amino]-diazen-1-ium-1,2-diolate] (spermine NONOate) and the xanthine oxidase reaction, respectively. The results were compared with the established nitration reaction triggered by authentic peroxynitrite, Bolus addition of peroxynitrite (1 mM) to tyrosine (1 mM) at pH 7.4 yielded 36.77 +/- 1.67 mu M 3-nitrotyrosine, corresponding to a recovery of about 4%. However, peroxynitrite formed from (NO)-N-. and O-2(radical anion), which were generated at equal rates (similar to 5 mu M X min(-1)) from 1 mM spermine NONOate, 28 milliunits/ml xanthine oxidase, and 1 mM hypoxanthine was much less efficient (0.67 +/- 0.01 mu M; similar to 0.07% of total product flow). At O-2(radical anion) fluxes exceeding the (NO)-N-. release rates, 3-nitrotyrosine formation was below the detection limit of the high performance Liquid chromatography method (<0.06 mu M) Nitration was most efficient (similar to 0.3%) with the (NO)-N-. donor alone, i.e. without concomitant generation of O-2(radical anion). Nitration by (NO)-N-. had a pH optimum of 8.2, increased progressively with increasing tyrosine concentrations (0.1-2 mM), and was not enhanced by NaHCO3 (up to 20 mar), indicating that it was mediated by (NO2)-N-. rather than peroxynitrite, Our results argue against peroxynitrite produced from (NO)-N-. and O-2(radical anion) as a mediator of tyrosine nitration in vivo.	Karl Franzens Univ Graz, Inst Pharmakol & Toxikol, A-8010 Graz, Austria	University of Graz	Pfeiffer, S (corresponding author), Karl Franzens Univ Graz, Inst Pharmakol & Toxikol, Univ Platz 2, A-8010 Graz, Austria.	silvia.pfeiffer@kfunigraz.ac.at	Mayer, Bernd/B-9391-2008	Mayer, Bernd/0000-0002-2921-3494				Akaike T, 1996, P NATL ACAD SCI USA, V93, P2448, DOI 10.1073/pnas.93.6.2448; Bagasra O, 1995, P NATL ACAD SCI USA, V92, P12041, DOI 10.1073/pnas.92.26.12041; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; Berlett BS, 1998, P NATL ACAD SCI USA, V95, P2784, DOI 10.1073/pnas.95.6.2784; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; CROW JP, 1994, FREE RADICAL BIO MED, V16, P331, DOI 10.1016/0891-5849(94)90034-5; Crow JP, 1997, NITRIC OXIDE-BIOL CH, V1, P145, DOI 10.1006/niox.1996.0113; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V333, P49, DOI 10.1006/abbi.1996.0363; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; EISERICH JP, 1995, BIOCHEM J, V310, P745, DOI 10.1042/bj3100745; Eiserich JP, 1996, J BIOL CHEM, V271, P19199, DOI 10.1074/jbc.271.32.19199; Feelisch M., 1989, J CARDIOVASC PHARM, V14, P13; GOLDSTEIN S, 1995, J AM CHEM SOC, V117, P12078, DOI 10.1021/ja00154a007; Goodwin DC, 1998, J BIOL CHEM, V273, P8903, DOI 10.1074/jbc.273.15.8903; Gow A, 1996, ARCH BIOCHEM BIOPHYS, V333, P42, DOI 10.1006/abbi.1996.0362; Gunther MR, 1997, J BIOL CHEM, V272, P17086, DOI 10.1074/jbc.272.27.17086; HADDAD IY, 1993, AM J PHYSIOL, V265, pL555, DOI 10.1152/ajplung.1993.265.6.L555; HALFPENNY E, 1952, J CHEM SOC, P939, DOI 10.1039/jr9520000939; Halliwell B, 1997, FEBS LETT, V411, P157, DOI 10.1016/S0014-5793(97)00469-9; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; KAUR H, 1994, FEBS LETT, V350, P9, DOI 10.1016/0014-5793(94)00722-5; Kelm M, 1997, J BIOL CHEM, V272, P9922; KHARITONOV VG, 1994, J BIOL CHEM, V269, P5881; KIGUGAWA K, 1994, FREE RADICAL BIO MED, V16, P273; KOOY NW, 1994, FREE RADICAL BIO MED, V16, P149, DOI 10.1016/0891-5849(94)90138-4; KOOY NW, 1995, AM J RESP CRIT CARE, V151, P1250; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; KUKOVETZ WR, 1989, J CARDIOVASC PHARM, V14, pS40, DOI 10.1097/00005344-198914110-00008; Lemercier JN, 1997, ARCH BIOCHEM BIOPHYS, V345, P160, DOI 10.1006/abbi.1997.0240; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; Lymar SV, 1996, CHEM RES TOXICOL, V9, P845, DOI 10.1021/tx960046z; Lymar SV, 1996, BIOCHEMISTRY-US, V35, P7855, DOI 10.1021/bi960331h; Lymar SV, 1998, INORG CHEM, V37, P294, DOI 10.1021/ic970946i; MALINSKI T, 1993, J CEREBR BLOOD F MET, V13, P355, DOI 10.1038/jcbfm.1993.48; Mannick EE, 1996, CANCER RES, V56, P3238; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; MAYER B, 1992, J NEUROCHEM, V59, P2024; MAYER B, 1997, TRENDS BIOCHEM SCI, V22, P453; Miles AM, 1996, J BIOL CHEM, V271, P40, DOI 10.1074/jbc.271.1.40; Pfeiffer S, 1997, J BIOL CHEM, V272, P3465, DOI 10.1074/jbc.272.6.3465; Pfeiffer S, 1997, FREE RADICAL BIO MED, V22, P787, DOI 10.1016/S0891-5849(96)00407-8; PRUTZ WA, 1985, ARCH BIOCHEM BIOPHYS, V243, P125, DOI 10.1016/0003-9861(85)90780-5; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; Saleh D, 1997, AM J RESP CRIT CARE, V155, P1763, DOI 10.1164/ajrccm.155.5.9154889; Schmidt K, 1997, N-S ARCH PHARMACOL, V355, P457, DOI 10.1007/PL00004969; TSAI JHM, 1994, J AM CHEM SOC, V116, P4115, DOI 10.1021/ja00088a072; Uppu RM, 1996, ARCH BIOCHEM BIOPHYS, V327, P335, DOI 10.1006/abbi.1996.0131; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; VANDERVLIET A, 1995, ARCH BIOCHEM BIOPHYS, V319, P341, DOI 10.1006/abbi.1995.1303; VANDERVLIET A, 1994, FEBS LETT, V339, P89, DOI 10.1016/0014-5793(94)80391-9; Wink DA, 1997, J BIOL CHEM, V272, P11147; XIE QW, 1994, J LEUKOCYTE BIOL, V56, P576, DOI 10.1002/jlb.56.5.576	58	156	157	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27280	27285		10.1074/jbc.273.42.27280	http://dx.doi.org/10.1074/jbc.273.42.27280			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765252	hybrid			2022-12-27	WOS:000076448000039
J	Diarra-Mehrpour, M; Sarafan, N; Bourguignon, J; Bonnet, F; Bost, F; Martin, JP				Diarra-Mehrpour, M; Sarafan, N; Bourguignon, J; Bonnet, F; Bost, F; Martin, JP			Human inter-alpha-trypsin inhibitor heavy chain H3 gene - Genomic organization, promoter analysis, and gene linkage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUMULUS EXTRACELLULAR-MATRIX; COVALENTLY CROSS-LINKS; AMINO-ACID-SEQUENCE; HUMAN-PLASMA; CELL-LINE; HEPG2 CELLS; PROTEIN; FAMILY; ALPHA-1-MICROGLOBULIN; PRECURSOR	To understand more about the human inter-alpha-trypsin inhibitor heavy chain H3 (ITIH3) expression and the relationship between this gene and the family of other ITI heavy chain genes, an analysis of the structure of the ITIH3 gene and its promoter region was performed. This gene is a single copy gene, 14 kilobase pair in length and consists of 22 exons, ITIH3 shares highly conserved exon size and intron-exon borders with other ITI heavy chain genes. We determined that the human ITIH1, ITIH3, and ITIH4 genes are closely linked within a 45-kilobase pair. They are arranged in the order of H1-H3-H4, with the ITIH4 gene transcribed in the opposite direction. A model for the evolution of the ITI heavy chain gene family is presented that involves multiple rounds of gene duplication plus inversion events. The minimum promoter region (-135 to +75) is identified in HepG2 cells. The transient transfection study in various cell lines indicates that the activity of the ITIH3 promoter is not liver-specific. DNase I footprinting, mobility shift assays, and cotransfection experiments reveal a functional CCAAT/enhancer-binding protein site (C/EBP, -1344 to -1305) which interacts with C/EBP alpha and C/EBP beta factors. The latter factors control the transcription of the ITIH3 gene positively.	Fac Med, INSERM, U295, Lab Physiopathol & Genet Renale & Pulm, F-76183 Rouen, France; Univ Rouen, IFR Physicochim & Biol Syst Integres 61, F-76821 Mont St Aignan, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rouen Normandie	Diarra-Mehrpour, M (corresponding author), Fac Med, INSERM, U295, Lab Physiopathol & Genet Renale & Pulm, 22 Blvd Gambetta, F-76183 Rouen, France.	maryam.diarra-mehropour@univ-rouen.fr	BOST, Frederic/AAN-4691-2020; Mehrpour, Maryam/D-8640-2017	BOST, Frederic/0000-0003-4509-4701; mehrpour, maryam/0000-0002-5002-1366				ALLROBYN JA, 1990, MOL CELL BIOL, V10, P6544, DOI 10.1128/MCB.10.12.6544; BAKKER O, 1991, NUCLEIC ACIDS RES, V19, P1213, DOI 10.1093/nar/19.6.1213; BOST F, 1993, EUR J BIOCHEM, V218, P283, DOI 10.1111/j.1432-1033.1993.tb18376.x; Bost F, 1998, EUR J BIOCHEM, V252, P339, DOI 10.1046/j.1432-1327.1998.2520339.x; BOURGUIGNON J, 1989, BIOCHEM J, V261, P305, DOI 10.1042/bj2610305; BOURGUIGNON J, 1993, EUR J BIOCHEM, V212, P771, DOI 10.1111/j.1432-1033.1993.tb17717.x; BRAUCH H, 1990, GENE CHROMOSOME CANC, V1, P240, DOI 10.1002/gcc.2870010309; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P743; CASTILLO GM, 1993, FEBS LETT, V318, P292, DOI 10.1016/0014-5793(93)80531-X; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN L, 1992, J BIOL CHEM, V267, P12380; CHEN L, 1994, J BIOL CHEM, V269, P28282; CHIAO PJ, 1992, MOL CARCINOGEN, V5, P219, DOI 10.1002/mc.2940050309; CHOIMIURA NH, 1995, J BIOCHEM, V117, P400, DOI 10.1093/jb/117.2.400; DAVEAU M, 1993, BIOCHEM J, V292, P485, DOI 10.1042/bj2920485; DIARRAMEHRPOUR M, 1994, BBA-GENE STRUCT EXPR, V1219, P551, DOI 10.1016/0167-4781(94)90087-6; DIARRAMEHRPOUR M, 1989, EUR J BIOCHEM, V179, P147, DOI 10.1111/j.1432-1033.1989.tb14532.x; DIARRAMEHRPOUR M, 1990, EUR J BIOCHEM, V191, P131, DOI 10.1111/j.1432-1033.1990.tb19102.x; DIARRAMEHRPOUR M, 1992, BIOCHIM BIOPHYS ACTA, V1132, P114, DOI 10.1016/0167-4781(92)90065-8; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENGHILD JJ, 1991, J BIOL CHEM, V266, P747; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GEBHARD W, 1988, FEBS LETT, V229, P63, DOI 10.1016/0014-5793(88)80798-1; GONZALEZRAMON N, 1995, FEBS LETT, V371, P227, DOI 10.1016/0014-5793(95)00882-A; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; HELLER DL, 1988, MOL CELL BIOL, V8, P2797, DOI 10.1128/MCB.8.7.2797; HERON A, 1994, BIOCHEM J, V302, P573, DOI 10.1042/bj3020573; HOCHSTRASSER K, 1976, H-S Z PHYSIOL CHEM, V357, P153, DOI 10.1515/bchm2.1976.357.1.153; HUTADILOK N, 1988, ANN RHEUM DIS, V47, P377, DOI 10.1136/ard.47.5.377; JESSEN TE, 1988, FEBS LETT, V230, P195, DOI 10.1016/0014-5793(88)80670-7; JOHNSON PF, 1994, LIVER GENE EXPRESSIO, P231; KAUMEYER JF, 1986, NUCLEIC ACIDS RES, V14, P7839, DOI 10.1093/nar/14.20.7839; KOBAYASHI H, 1995, J BIOL CHEM, V270, P8361, DOI 10.1074/jbc.270.14.8361; KOBAYASHI H, 1995, INT J CANCER, V63, P455, DOI 10.1002/ijc.2910630326; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; MAESTRO R, 1993, CANCER RES, V53, P5775; Maniatis T., 1982, MOL CLONING; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MORELLE W, 1994, EUR J BIOCHEM, V221, P881, DOI 10.1111/j.1432-1033.1994.tb18803.x; NISHIMURA H, 1995, FEBS LETT, V357, P207; ODUM L, 1992, INT J BIOCHEM, V24, P215, DOI 10.1016/0020-711X(92)90249-Z; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POTEMPA J, 1989, J BIOL CHEM, V264, P15109; PU PX, 1994, BIOCHIM BIOPHYS ACTA, V1208, P338; QUEEN C, 1984, NUCLEIC ACIDS RES, V12, P581, DOI 10.1093/nar/12.1Part2.581; RAYMONDJEAN M, 1991, NUCLEIC ACIDS RES, V19, P6145, DOI 10.1093/nar/19.22.6145; ROUET P, 1992, J BIOL CHEM, V267, P20765; ROUET P, 1995, NUCLEIC ACIDS RES, V23, P395, DOI 10.1093/nar/23.3.395; Saguchi K, 1996, J BIOCHEM, V119, P898; Salier JP, 1996, BIOCHEM J, V315, P1, DOI 10.1042/bj3150001; Samadani U, 1996, MOL CELL BIOL, V16, P6273; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARAFAN N, 1995, EUR J BIOCHEM, V227, P808, DOI 10.1111/j.1432-1033.1995.tb20205.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THOGERSEN IB, 1995, J BIOL CHEM, V270, P18700; TOBE T, 1995, CYTOGENET CELL GENET, V71, P296, DOI 10.1159/000134130; ZHAO M, 1995, J BIOL CHEM, V270, P26657, DOI 10.1074/jbc.270.44.26657	57	15	16	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26809	26819		10.1074/jbc.273.41.26809	http://dx.doi.org/10.1074/jbc.273.41.26809			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756925	hybrid			2022-12-27	WOS:000076373300079
J	Kobayashi, M; Ohara-Nemoto, Y; Kaneko, M; Hayakawa, H; Sekiguchi, M; Yamamoto, K				Kobayashi, M; Ohara-Nemoto, Y; Kaneko, M; Hayakawa, H; Sekiguchi, M; Yamamoto, K			Potential of Escherichia coli GTP cyclohydrolase II for hydrolyzing 8-oxo-dGTP, a mutagenic substrate for DNA synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONTANEOUS MUTATIONS; ENDONUCLEASE-VIII; OXYGEN RADICALS; MTH1 PROTEIN; MUTT PROTEIN; CLONING; GENE; GUANINE; CDNA; PURIFICATION	MutT protein of Escherichia coli prevents the occurrence of A:T --> C:G transversion by hydrolyzing an oxidized form of dGTP, 8-oxo-7,8-dihydro-2'-deoxyguanosine 5'-triphosphate (8-oxo-dGTP), which is produced by active oxygen species. In a search for mutT-related genes, we found that the ribA gene, encoding GTP cyclohydrolase II, is able to reduce the increased level of mutation frequency of the mutT strain to almost the normal level, provided that the gene product is overproduced. Purified preparations of Escherichia coli GTP cyclohydrolase II protein as well as the histidine hexamer-tagged recombinant GTP cyclohydrolase II protein efficiently hydrolyze 8-oxo-dGTP and 8-oxo-GTP, producing 8-oxo-dGMP and 8-oxo-GMP, respectively. dGTP was not hydrolyzed by these preparations; GTP cyclohydrolase II catalyzes conversion of GTP to 2,5-diamino-6-hydroxy-4-(5-phosphoribosylamino)-pyrimidine, which constitutes the first step for riboflavin synthesis. The K-m values for the three types of guanine nucleotides, GTP, 8-oxo-GTP, and 8-oxo-dGTP, were almost the same. In the mutT(-) background, ribA(-) cells showed higher spontaneous mutation frequencies as compared with that of ribA(+) cells. Thus, GTP cyclohydrolase II, the ribA gene product, has a potential to protect genetic material from the untoward effects of endogenous oxygen radicals.	Tohoku Univ, Grad Sch Sci, Inst Biol, Sendai, Miyagi 9808578, Japan; Iwate Med Univ, Sch Dent, Dept Microbiol, Morioka, Iwate 0208505, Japan; Kyushu Univ, Sch Med, Dept Biochem, Fukuoka 8128582, Japan; Fukuoka Dent Coll, Dept Biol, Fukuoka 8140193, Japan	Tohoku University; Iwate Medical University; Kyushu University; Fukuoka Dental College (FDC)	Yamamoto, K (corresponding author), Tohoku Univ, Grad Sch Sci, Inst Biol, Sendai, Miyagi 9808578, Japan.							Aburatani H, 1997, CANCER RES, V57, P2151; AKASAKA S, 1992, MOL GEN GENET, V235, P173, DOI 10.1007/BF00279358; AKASAKA S, 1991, MUTAT RES, V254, P27, DOI 10.1016/0921-8777(91)90037-P; AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J; AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; BESSHO T, 1993, P NATL ACAD SCI USA, V90, P8901, DOI 10.1073/pnas.90.19.8901; BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; CAI JP, 1995, CARCINOGENESIS, V16, P2343, DOI 10.1093/carcin/16.10.2343; COX EC, 1969, J BACTERIOL, V100, P390, DOI 10.1128/JB.100.1.390-397.1969; CUPPLES CG, 1989, P NATL ACAD SCI USA, V86, P5345, DOI 10.1073/pnas.86.14.5345; FARR SB, 1991, MICROBIOL REV, V55, P561, DOI 10.1128/MMBR.55.4.561-585.1991; FOOR F, 1975, J BIOL CHEM, V250, P3545; Foor F, 1980, Methods Enzymol, V66, P303; HALLIWELL B, 1991, FEBS LETT, V281, P9, DOI 10.1016/0014-5793(91)80347-6; HAYAKAWA H, 1995, BIOCHEMISTRY-US, V34, P89, DOI 10.1021/bi00001a011; KAKUMA T, 1995, J BIOL CHEM, V270, P25942, DOI 10.1074/jbc.270.43.25942; KASAI H, 1984, JPN J CANCER RES, V75, P1037; Koh YS, 1996, MOL GEN GENET, V251, P591, DOI 10.1007/s004380050206; Luria SE, 1943, GENETICS, V28, P491; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MEDIGUE C, 1991, J MOL BIOL, V222, P851, DOI 10.1016/0022-2836(91)90575-Q; MELAMEDE RJ, 1994, BIOCHEMISTRY-US, V33, P1255, DOI 10.1021/bi00171a028; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; RICHTER G, 1993, J BACTERIOL, V175, P4045, DOI 10.1128/JB.175.13.4045-4051.1993; Saito Y, 1997, J BACTERIOL, V179, P3783, DOI 10.1128/jb.179.11.3783-3785.1997; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; SHIBUTANI S, 1991, NATURE, V349, P432; SLATER TF, 1984, BIOCHEM J, V222, P1; Taddei F, 1997, SCIENCE, V278, P128, DOI 10.1126/science.278.5335.128; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; TSAIWU JJ, 1992, P NATL ACAD SCI USA, V89, P8779, DOI 10.1073/pnas.89.18.8779; WINANS SC, 1985, J BACTERIOL, V161, P1219, DOI 10.1128/JB.161.3.1219-1221.1985; Yakushiji H, 1997, MUTAT RES-DNA REPAIR, V384, P181, DOI 10.1016/S0921-8777(97)00025-6; Yamamoto K, 1997, J RADIAT RES, V38, P1, DOI 10.1269/jrr.38.1; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274	36	44	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26394	26399		10.1074/jbc.273.41.26394	http://dx.doi.org/10.1074/jbc.273.41.26394			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756871	hybrid			2022-12-27	WOS:000076373300025
J	Liu, MY; Xie, Z; Price, DH				Liu, MY; Xie, Z; Price, DH			A human RNA polymerase II transcription termination factor is a SWI2/SNF2 family member	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPAIR COUPLING FACTOR; DNA-STIMULATED ATPASE; BINDING PROTEIN; RELEASE FACTOR; DROSOPHILA; ELONGATION; PURIFICATION; MECHANISMS; SEQUENCES; COMPLEXES	We obtained protein sequence information from Drosophila factor 2, an ATP-dependent RNA polymerase II transcription termination factor, and discovered that it was identical to a SWI2/SNF2 family member called lodestar. Portions of putative human and Caenorhabditis elegans homologues were found in the sequence data bases and a complete cDNA for the human factor was generated using polymerase chain reaction techniques. Recombinant human factor 2 was produced in a baculovirus expression system, purified, and characterized. Similar to the authentic Drosophila factor, the human factor displayed a strong double-stranded DNA-dependent ATPase activity that was inhibited by single-stranded DNA and exhibited RNA polymerase II termination activity. Both factors were able to work on elongation complexes from either species. We discuss the mechanism of termination by factor 2 and the implications for the role of factor 2 in cellular activities.	Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Vanderbilt Univ, Dept Mol Physiol & Biophys, Howard Hughes Med Inst, Nashville, TN 37232 USA	University of Iowa; Howard Hughes Medical Institute; Vanderbilt University	Price, DH (corresponding author), Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA.		Price, David H/F-6173-2010	Liu, Mingyi/0000-0002-8101-8522; Price, David/0000-0002-5597-385X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035500] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35500] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; Auble DT, 1997, MOL CELL BIOL, V17, P4842, DOI 10.1128/MCB.17.8.4842; BACHMANN M, 1990, CELL, V60, P85, DOI 10.1016/0092-8674(90)90718-T; BENTLEY DL, 1995, CURR OPIN GENET DEV, V5, P210, DOI 10.1016/0959-437X(95)80010-7; BRENDEL V, 1992, P NATL ACAD SCI USA, V89, P2002, DOI 10.1073/pnas.89.6.2002; Collins AR, 1997, ENVIRON MOL MUTAGEN, V29, P152; Deng L, 1998, GENE DEV, V12, P538, DOI 10.1101/gad.12.4.538; Deng L, 1996, J BIOL CHEM, V271, P19556, DOI 10.1074/jbc.271.32.19556; GIRDHAM CH, 1991, GENE DEV, V5, P1786, DOI 10.1101/gad.5.10.1786; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; LENNON GG, 1995, GENOMICS, V33, P151; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Mason SW, 1997, EMBO J, V16, P163, DOI 10.1093/emboj/16.1.163; Mason SW, 1997, J MOL BIOL, V268, P229, DOI 10.1006/jmbi.1997.0976; PLATT T, 1994, MOL MICROBIOL, V11, P983, DOI 10.1111/j.1365-2958.1994.tb00376.x; PRICE DH, 1987, J BIOL CHEM, V262, P3244; Reeder RH, 1997, TRENDS BIOCHEM SCI, V22, P473, DOI 10.1016/S0968-0004(97)01133-X; RICHARDSON JP, 1993, CRIT REV BIOCHEM MOL, V28, P1, DOI 10.3109/10409239309082571; Richmond E, 1996, NUCLEIC ACIDS RES, V24, P3685, DOI 10.1093/nar/24.19.3685; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; Selby CP, 1997, NUCLEIC ACIDS RES, V25, P787, DOI 10.1093/nar/25.4.787; Selby CP, 1997, J BIOL CHEM, V272, P1885, DOI 10.1074/jbc.272.3.1885; SELBY CP, 1995, J BIOL CHEM, V270, P4890, DOI 10.1074/jbc.270.9.4890; SELBY CP, 1995, J BIOL CHEM, V270, P4882, DOI 10.1074/jbc.270.9.4882; SHERMOEN AW, 1991, CELL, V67, P303, DOI 10.1016/0092-8674(91)90182-X; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; VANGOOL AJ, 1994, EMBO J, V13, P5361, DOI 10.1002/j.1460-2075.1994.tb06871.x; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Xie Z, 1997, J BIOL CHEM, V272, P31902, DOI 10.1074/jbc.272.50.31902; Xie Z, 1996, J BIOL CHEM, V271, P11043, DOI 10.1074/jbc.271.19.11043; Xie Z, 1998, J BIOL CHEM, V273, P3771, DOI 10.1074/jbc.273.6.3771	36	42	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25541	25544		10.1074/jbc.273.40.25541	http://dx.doi.org/10.1074/jbc.273.40.25541			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748214	hybrid			2022-12-27	WOS:000076263100005
J	Mounkes, LC; Zhong, W; Cipres-Palacin, G; Heath, TD; Debs, RJ				Mounkes, LC; Zhong, W; Cipres-Palacin, G; Heath, TD; Debs, RJ			Proteoglycans mediate cationic Liposome-DNA complex-based gene delivery in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; RECEPTOR-RELATED PROTEIN; FIBROBLAST GROWTH; CELL-SURFACE; EXPRESSION; MATRIX; DEGRADATION; MECHANISM; RELEASE; BINDING	The factors controlling cationic liposome-DNA complex (CLDC)-based gene transfer in cells and in animals are poorly understood. me found that cell surface heparin/heparan sulfate-bearing proteoglycans mediate CLDC-based gene transfer and expression both in cultured cells and following intravenous gene delivery into animals. CLDC did not transfect Raji cells, which lack proteoglycans, but did efficiently transfect Raji cells stably transfected with the proteoglycan, syndecan-1, Fucoidan, heparin, or dextran sulfate, all of which are highly anionic polysaccharides, each blocked CLDC-mediated transfection both in cultured cells and following intravenous injection into mice, but had no effect on transfection by either recombinant adenovirus infection or electroporation. Intravenous pretreatment of mice with heparinases, which specifically cleave heparan sulfate molecules from cell surface proteoglycans, blocked intravenous, CLDC-mediated transfection in mice, confirming that proteoglycans mediate CLDC gene delivery in vivo. Modulation of proteoglycan expression may prove useful in controlling the efficiency of, as well as targeting the sites of, CLDC-based gene transfer in animals.	Calif Pacific Med Res Inst, San Francisco, CA 94115 USA; Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA	California Pacific Medical Center; California Pacific Medical Center Research Institute; University of Wisconsin System; University of Wisconsin Madison	Debs, RJ (corresponding author), Calif Pacific Med Res Inst, Stern Bldg,2330 Clay St, San Francisco, CA 94115 USA.				NATIONAL CANCER INSTITUTE [R01CA058914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049550, R01DK045917] Funding Source: NIH RePORTER; NCI NIH HHS [CA58914] Funding Source: Medline; NIDDK NIH HHS [DK49550, DK45917] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM, 1988, MOL REPROD DEV; Batra RK, 1997, J BIOL CHEM, V272, P11736, DOI 10.1074/jbc.272.18.11736; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; CANONICO AE, 1994, J APPL PHYSIOL, V77, P415, DOI 10.1152/jappl.1994.77.1.415; Cole GJ, 1996, PERSPECT DEV NEUROBI, V3, P359; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Friend DS, 1996, BBA-BIOMEMBRANES, V1278, P41, DOI 10.1016/0005-2736(95)00219-7; GALLAGHER JT, 1994, EUR J CLIN CHEM CLIN, V32, P239; GOTTE M, 1995, EUR J CELL BIOL, V66, P226; GRAHAM FL, 1995, MOL BIOTECHNOL, V3, P207, DOI 10.1007/BF02789331; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Imai K, 1997, BIOCHEM J, V322, P809, DOI 10.1042/bj3220809; JI ZS, 1995, J LIPID RES, V36, P583; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KNOWLES MR, 1995, NEW ENGL J MED, V333, P823, DOI 10.1056/NEJM199509283331302; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P9307, DOI 10.1074/jbc.270.16.9307; LabatMoleur F, 1996, GENE THER, V3, P1010; LIU Y, 1995, J BIOL CHEM, V270, P24864, DOI 10.1074/jbc.270.42.24864; Liu Y, 1997, NAT BIOTECHNOL, V15, P167, DOI 10.1038/nbt0297-167; Mahley RW, 1996, ISRAEL J MED SCI, V32, P414; Mamo JCL, 1996, BIOCHEMISTRY-US, V35, P10210, DOI 10.1021/bi960188s; Mislick KA, 1996, P NATL ACAD SCI USA, V93, P12349, DOI 10.1073/pnas.93.22.12349; MUIR H, 1995, BIOESSAYS, V17, P1039, DOI 10.1002/bies.950171208; NIETFELD JJ, 1993, EXPERIENTIA, V49, P456, DOI 10.1007/BF01923589; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; PATEL M, 1993, AIDS RES HUM RETROV, V9, P167, DOI 10.1089/aid.1993.9.167; PRICE P, 1995, IMMUNOL CELL BIOL, V73, P308, DOI 10.1038/icb.1995.47; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; ROUGHLEY PJ, 1994, MICROSC RES TECHNIQ, V28, P385, DOI 10.1002/jemt.1070280505; Sambrook J., 2002, MOL CLONING LAB MANU; Sawitzky D, 1996, MED MICROBIOL IMMUN, V184, P155, DOI 10.1007/BF02456129; SIVARAM P, 1995, J BIOL CHEM, V270, P29760; SOLODIN I, 1995, BIOCHEMISTRY-US, V34, P13537, DOI 10.1021/bi00041a033; STEWART MJ, 1992, HUM GENE THER, V3, P267, DOI 10.1089/hum.1992.3.3-267; Templeton NS, 1997, NAT BIOTECHNOL, V15, P647, DOI 10.1038/nbt0797-647; Thierry AR, 1997, GENE THER, V4, P226, DOI 10.1038/sj.gt.3300350; THIERRY AR, 1995, P NATL ACAD SCI USA, V92, P9742, DOI 10.1073/pnas.92.21.9742; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989; Xu YH, 1996, BIOCHEMISTRY-US, V35, P5616, DOI 10.1021/bi9602019; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Zelphati O, 1996, P NATL ACAD SCI USA, V93, P11493, DOI 10.1073/pnas.93.21.11493; ZHOU XH, 1994, BBA-BIOMEMBRANES, V1189, P195, DOI 10.1016/0005-2736(94)90066-3; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073	46	203	210	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26164	26170		10.1074/jbc.273.40.26164	http://dx.doi.org/10.1074/jbc.273.40.26164			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748298	hybrid			2022-12-27	WOS:000076263100089
J	Rao, S; Karray, S; Gackstetter, ER; Koshland, ME				Rao, S; Karray, S; Gackstetter, ER; Koshland, ME			Myocyte enhancer factor-related B-MEF2 is developmentally expressed in B cells and regulates the immunoglobulin J chain promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX TRANSCRIPTION FACTORS; DNA-BINDING SPECIFICITY; GENE-EXPRESSION; MEF2 PROTEIN; MUSCLE; ACTIVATION; DIFFERENTIATION; ELEMENT; KINASE; SEQUENCE	Immunoglobulin J chain gene expression is induced by the delivery of a lymphokine signal to antigen-activated B cells in a primary immune response. A major interleukin 2 (IL-2)-responsive region that contains two adjacent control elements (JA and JB) exists within the J chain promoter. Transcription factor PU.1 positively regulates J chain gene expression by binding to one of the control elements (JB) in the J chain promoter. In the present study we have determined that a myocyte enhancer factor 2 (MEF2)-related nuclear factor, named B-MEF2, positively regulates the J chain gene promoter activity via the second control element (JA), An in vitro translated MEF2 family member, MEF2C, was found to bind the JA site with identical properties as endogenously expressed B-MEF2 in B cell lines. Moreover, in vivo experiments showed that a dominant negative mutant of MEF2C blocked B-MEF2 regulation of the J chain promoter. Consistent with its role as positive regulator of J chain gene expression, B-MEF2 levels were enhanced in highly differentiated B cells. In addition, induction of an IL-2-responsive presecretor cell line BCL1 with IL-2 or IL-5 (which up-regulates J chain gene expression) resulted in an increased expression of B-MEF2. We conclude that a MEF2-related transcriptional factor, B-MEF2, acts as a stage-specific positive regulator of J chain gene expression in the B cell lineage.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Immunol, Berkeley, CA 94720 USA; Inst Pasteur, Dept Immunol, F-75015 Paris, France	University of California System; University of California Berkeley; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Rao, S (corresponding author), PE Appl Biosyst, 850 Lincoln Ctr Dr, Foster City, CA 94404 USA.	RaoSU@PEABD.com		Karray, Saoussen/0000-0003-0107-4039				BLACK BL, 1995, J BIOL CHEM, V270, P2889, DOI 10.1074/jbc.270.7.2889; BLACKMAN M, 1986, CELL, V46, P609; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; CHAMBERS AE, 1992, EMBO J, V11, P4981, DOI 10.1002/j.1460-2075.1992.tb05605.x; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DODUO E, 1995, NUCLEIC ACIDS RES, V23, P4267; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HAN TH, 1995, MOL CELL BIOL, V15, P2907; Kang CJ, 1998, IMMUNITY, V8, P285, DOI 10.1016/S1074-7613(00)80534-8; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; KOSHLAND ME, 1985, ANNU REV IMMUNOL, V3, P425; LANSFORD RD, 1992, P NATL ACAD SCI USA, V89, P5966, DOI 10.1073/pnas.89.13.5966; LEIFER D, 1994, NEUROSCIENCE, V63, P1067, DOI 10.1016/0306-4522(94)90573-8; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; MCFADDEN HJ, 1991, P NATL ACAD SCI USA, V88, P11027, DOI 10.1073/pnas.88.24.11027; MINIE ME, 1986, MOL CELL BIOL, V6, P4031, DOI 10.1128/MCB.6.11.4031; Molkentin JD, 1996, MOL CELL BIOL, V16, P3814; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; NAKANISHI K, 1984, J EXP MED, V160, P1736, DOI 10.1084/jem.160.6.1736; NILES MJ, 1995, P NATL ACAD SCI USA, V92, P2884, DOI 10.1073/pnas.92.7.2884; NURRISH SJ, 1995, MOL CELL BIOL, V15, P4076; Ornatsky OI, 1996, J BIOL CHEM, V271, P24927, DOI 10.1074/jbc.271.40.24927; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; Subramanian SV, 1996, MECH DEVELOP, V57, P103, DOI 10.1016/0925-4773(96)00542-4; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; YUN K, 1996, CURR OPIN CELL BIOL, V6, P877	37	34	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26123	26129		10.1074/jbc.273.40.26123	http://dx.doi.org/10.1074/jbc.273.40.26123			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748293	hybrid			2022-12-27	WOS:000076263100084
J	Tlapak-Simmons, VL; Kempner, ES; Baggenstoss, BA; Weigel, PH				Tlapak-Simmons, VL; Kempner, ES; Baggenstoss, BA; Weigel, PH			The active streptococcal hyaluronan synthases (HASs) contain a single HAS monomer and multiple cardiolipin molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION TARGET ANALYSIS; GROUP-A STREPTOCOCCI; ACID SYNTHASE; PROTEIN-KINASE; INACTIVATION; MEMBRANE; CLONING; SUBUNIT; BINDING; WEIGHT	The functional sizes of the two streptococcal hyaluronan synthases (HASs) were determined by radiation inactivation analysis of isolated membranes. The native enzymes in membranes from Group A Streptococcus pyogenes HAS and Group C Streptococcus equisimilis HAS were compared with the recombinant proteins expressed in Escherichia coli membranes. Based on their amino acid sequences, the masses of these four proteins as monomers are similar to 48 kDa. In all cases, loss of enzyme activity was a simple single exponential function with increasing radiation dose. The functional sizes calculated from these data were identical for the four HASs at similar to 64 kDa. In contrast, the sizes of the proteins estimated by the loss of antibody reactivity on Western blots were essentially identical at 41 kDa for the four RAS species, consistently lower than the functional size by similar to 23 kDa. Matrix-assisted laser desorption time of flight mass spectrometry analysis of purified S. pyogenes HAS-H-6 and S. equisimilis HAS-H-6 gave masses that differed by <0.07% from the predicted monomer sizes, which confirms that neither protein is posttranslationally modified or covalently attached to another protein. Ongoing studies indicate that the purified HAS enzymes require cardiolipin (CL) for maximal activity and stability. When irradiated membranes were detergent solubilized and the extracts were incubated with exogenous CL, the residual level of HAS activity increased. Consequently, the calculated functional size decreased by similar to 23 kDa to the expected size of the RAS monomer. The similar to 23-kDa larger size of the functional HAS enzyme, compared with the HAS monomer, is due, therefore, to CL molecules. We propose that the active streptococcal IIA syntheses are monomers in complex with similar to 16 CL molecules.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; NIAMS, Phys Biol Lab, NIH, Bethesda, MD 20892 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Weigel, PH (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA.				NIGMS NIH HHS [GM35978] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035978] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAUREGARD G, 1980, BIOCHEM BIOPH RES CO, V96, P1290, DOI 10.1016/0006-291X(80)90091-1; Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P432, DOI 10.1002/rcm.1290031207; BENNETT JA, 1995, NEURON, V14, P373, DOI 10.1016/0896-6273(95)90293-7; BOYER TD, 1992, ANAL BIOCHEM, V207, P51, DOI 10.1016/0003-2697(92)90498-V; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHUPIN V, 1995, FEBS LETT, V373, P239, DOI 10.1016/0014-5793(95)01054-I; CRATER DL, 1995, J BIOL CHEM, V270, P18452, DOI 10.1074/jbc.270.31.18452; DeAngelis PL, 1997, SCIENCE, V278, P1800, DOI 10.1126/science.278.5344.1800; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEANGELIS PL, 1993, J BIOL CHEM, V268, P14568; DeAngelis PL, 1995, DEV BIOL STAND, V85, P225; DeAngelis PL, 1996, BIOCHEMISTRY-US, V35, P9768, DOI 10.1021/bi960154k; DEVES R, 1998, PHYSIOL REV, V78, P545; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; Fraser JRE, 1997, J INTERN MED, V242, P27, DOI 10.1046/j.1365-2796.1997.00170.x; Fulop C, 1997, ARCH BIOCHEM BIOPHYS, V337, P261, DOI 10.1006/abbi.1996.9793; HARMON JT, 1985, METHOD ENZYMOL, V117, P65; Harwood C., 1990, MOL BIOL METHODS BAC, P1; HELDERMON C, 1996, MOL BIOL CELL, V7, P55; HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9; HOFFMANN B, 1994, J BIOL CHEM, V269, P1940; Itano N, 1996, J BIOL CHEM, V271, P9875, DOI 10.1074/jbc.271.17.9875; ITO K, 1977, CELL, V11, P551, DOI 10.1016/0092-8674(77)90073-3; KASTRAU DHW, 1994, EUR J BIOCHEM, V222, P293, DOI 10.1111/j.1432-1033.1994.tb18868.x; KEMPNER ES, 1993, TRENDS BIOCHEM SCI, V18, P236, DOI 10.1016/0968-0004(93)90169-N; KEMPNER ES, 1986, ANAL BIOCHEM, V156, P140, DOI 10.1016/0003-2697(86)90165-X; KLEENE R, 1993, BIOCHIM BIOPHYS ACTA, V1154, P283, DOI 10.1016/0304-4157(93)90003-7; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; Kumari K, 1997, J BIOL CHEM, V272, P32539, DOI 10.1074/jbc.272.51.32539; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; Malhotra R, 1996, BIOCHEM J, V314, P297, DOI 10.1042/bj3140297; Matsushima H, 1996, J NEUROCHEM, V67, P317; MCINTYRE JO, 1983, J BIOL CHEM, V258, P953; Meyer K, 1934, J BIOL CHEM, V107, P629; Miller JH, 1998, ARCH BIOCHEM BIOPHYS, V352, P281, DOI 10.1006/abbi.1998.0604; NOGAE I, 1990, GENE, V96, P161, DOI 10.1016/0378-1119(90)90248-P; Paradies G, 1997, BBA-BIOENERGETICS, V1319, P5, DOI 10.1016/S0005-2728(97)00012-1; Peng B, 1996, J BIOL CHEM, V271, P32233, DOI 10.1074/jbc.271.50.32233; PESTKA S, 1983, J BIOL CHEM, V258, P9706; PHILIPSON LH, 1984, J BIOL CHEM, V259, P5017; POTIER M, 1991, BIOCHEMISTRY-US, V30, P8151, DOI 10.1021/bi00247a009; PREHM P, 1984, BIOCHEM J, V220, P597, DOI 10.1042/bj2200597; ROSS AC, 1993, J LIPID RES, V34, P1201; Schmidt KH, 1996, MED MICROBIOL IMMUN, V184, P169, DOI 10.1007/PL00008248; Schwarz D, 1996, J BIOL CHEM, V271, P12840, DOI 10.1074/jbc.271.22.12840; Sheng YH, 1996, J IMMUNOL, V157, P3744; Shyjan AM, 1996, J BIOL CHEM, V271, P23395, DOI 10.1074/jbc.271.38.23395; Spicer AP, 1996, J BIOL CHEM, V271, P23400, DOI 10.1074/jbc.271.38.23400; Spicer AP, 1997, J BIOL CHEM, V272, P8957; STEVENS BR, 1990, P NATL ACAD SCI USA, V87, P1456, DOI 10.1073/pnas.87.4.1456; SUGAHARA K, 1979, J BIOL CHEM, V254, P6252; Toole BP, 1990, CURR OPIN CELL BIOL, V2, P839, DOI 10.1016/0955-0674(90)90081-O; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRISCOTT MX, 1986, J BIOL CHEM, V261, P6004; VANDERIJN I, 1992, J BIOL CHEM, V267, P24302; VIA DP, 1992, P NATL ACAD SCI USA, V89, P6780, DOI 10.1073/pnas.89.15.6780; Watanabe K, 1996, J BIOL CHEM, V271, P22945, DOI 10.1074/jbc.271.38.22945; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WESSELS MR, 1991, P NATL ACAD SCI USA, V88, P8317, DOI 10.1073/pnas.88.19.8317	61	70	82	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26100	26109		10.1074/jbc.273.40.26100	http://dx.doi.org/10.1074/jbc.273.40.26100			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748290	hybrid			2022-12-27	WOS:000076263100081
J	Gomez-Lorenzo, MG; Garcia-Bustos, JF				Gomez-Lorenzo, MG; Garcia-Bustos, JF			Ribosomal P-protein stalk function is targeted by sordarin antifungals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACIDIC PHOSPHOPROTEINS; CYCLOHEXIMIDE RESISTANCE; EUKARYOTIC RIBOSOMES; MOLECULAR-CLONING; RNA AUTOANTIBODY; YEAST GENE; DOMAIN; TRANSFORMATION; BINDING; MOIETY	Sordarin derivatives are remarkably selective inhibitors of fungal protein synthesis. Available evidence points to a binding site for these inhibitors on elongation factor 2, but high affinity binding requires the presence of ribosomes. The gene mutated in one of the two isolated complementation groups of Saccharomyces cerevisiae mutants resistant to the sordarin derivative GM193663 has now been identified. It is RPP0, encoding the essential protein of the large ribosomal subunit stalk rpP0. Resistant mutants are found to retain most of the binding capacity for the drug, indicating that mutations in rpP0 endow the ribosome with the capacity to perform translation elongation in the presence of the inhibitor. Other proteins of the ribosomal stalk influence the expression of resistance, pointing to a wealth of interactions between stalk components and elongation factors, The involvement of multiple elements of the translation machinery in the mode of action of sordarin antifungals may explain the large selectivity of these compounds, even though the individual target components are highly conserved proteins.	Glaxo Wellcome SA, Dept Res, Tres Cantos 28760, Spain	GlaxoSmithKline	Garcia-Bustos, JF (corresponding author), Glaxo Wellcome SA, Dept Res, Severo Ochoa 2, Tres Cantos 28760, Spain.	jfg32652@glaxowellcome.co.uk		Gomez Lorenzo, Maria de Gracia/0000-0003-2065-1145; Garcia-Bustos, Jose/0000-0002-6310-796X				Ballesta JPG, 1996, PROG NUCLEIC ACID RE, V55, P157, DOI 10.1016/S0079-6603(08)60193-2; CARRASCO L, 1973, BIOCHIM BIOPHYS ACTA, V319, P209, DOI 10.1016/0005-2787(73)90011-7; COVAL SJ, 1995, J ANTIBIOT, V48, P1171, DOI 10.7164/antibiotics.48.1171; FRIED HM, 1982, NUCLEIC ACIDS RES, V10, P3133, DOI 10.1093/nar/10.10.3133; FRIED HM, 1981, P NATL ACAD SCI-BIOL, V78, P238, DOI 10.1073/pnas.78.1.238; Gudkov AT, 1997, FEBS LETT, V407, P253, DOI 10.1016/S0014-5793(97)00361-X; Guthrie C, 1991, GUIDE YEAST GENETICS; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Justice MC, 1998, J BIOL CHEM, V273, P3148, DOI 10.1074/jbc.273.6.3148; KAUFER NF, 1983, NUCLEIC ACIDS RES, V11, P3123; KAWAI S, 1992, J BACTERIOL, V174, P254, DOI 10.1128/jb.174.1.254-262.1992; Kinsman OS, 1998, J ANTIBIOT, V51, P41, DOI 10.7164/antibiotics.51.41; LARKIN JC, 1983, NUCLEIC ACIDS RES, V11, P403, DOI 10.1093/nar/11.2.403; LILJAS A, 1990, RIBOSOME, P309; MACCONNELL WP, 1982, J BIOL CHEM, V257, P5359; Mager WH, 1997, NUCLEIC ACIDS RES, V25, P4872, DOI 10.1093/nar/25.24.4872; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; REMACHA M, 1992, J BIOL CHEM, V267, P12061; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SANTOS C, 1995, J BIOL CHEM, V270, P20608, DOI 10.1074/jbc.270.35.20608; SANTOS C, 1994, J BIOL CHEM, V269, P15689; Schneider G, 1995, NAT PROD LETT, V7, P309, DOI 10.1080/10575639508043227; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; UCHIUMI T, 1990, J BIOL CHEM, V265, P89; UCHIUMI T, 1986, EUR J BIOCHEM, V156, P37, DOI 10.1111/j.1432-1033.1986.tb09545.x; UCHIUMI T, 1994, EMBO J, V13, P3389, DOI 10.1002/j.1460-2075.1994.tb06641.x; UCHIUMI T, 1992, J BIOL CHEM, V267, P19179; Uchiumi T, 1997, J BIOL CHEM, V272, P3302, DOI 10.1074/jbc.272.6.3302; Verschoor A, 1996, J CELL BIOL, V133, P495, DOI 10.1083/jcb.133.3.495; Wilson KS, 1998, CELL, V92, P131, DOI 10.1016/S0092-8674(00)80905-8	31	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25041	25044		10.1074/jbc.273.39.25041	http://dx.doi.org/10.1074/jbc.273.39.25041			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737960	hybrid			2022-12-27	WOS:000076085400010
J	Li, YM; Franklin, G; Cui, HM; Svensson, K; He, XB; Adam, G; Ohlsson, R; Pfeifer, S				Li, YM; Franklin, G; Cui, HM; Svensson, K; He, XB; Adam, G; Ohlsson, R; Pfeifer, S			The H19 transcript is associated with polysomes and may regulate IGF2 expression in trans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-II; BECKWITH-WIEDEMANN-SYNDROME; IMPRINTED GENES; WILMS-TUMOR; MOUSE; RNA; DELETION; OVERGROWTH	The imprinted H19 gene produces a fully processed transcript that does not exhibit any conserved open reading frame between mouse and man. Although transcriptional control elements associated with the mouse H19 locus have been shown to control the neighboring Igf2 gene in cis, the prevailing view is that the cytoplasmic H19 transcript does not display any function. In contrast to earlier reports, we show here that the H19 transcript is associated with polysomes in a variety of cell types, in both mouse and man. A possible transfunction of the H19 gene is suggested by a reciprocal correlation in trans between cytoplasmic H19 and IGF2 mRNA levels, as well as IGF2 mRNA translatability. We discuss these results in terms of their challenge to the prevailing dogma on the function of the enigmatic H19 gene, as well as with respect to the ontogeny of the Becknith-Wiedemann syndrome, and propose that the human H19 gene is an antagonist of IGF2 expressivity in trans.	Uppsala Univ, Dept Anim Dev & Genet, S-75236 Uppsala, Sweden; Univ Uppsala Hosp, Dept Pediat, S-75185 Uppsala, Sweden	Uppsala University; Uppsala University; Uppsala University Hospital	Pfeifer, S (corresponding author), Uppsala Univ, Dept Anim Dev & Genet, Norbyvagen 18A, S-75236 Uppsala, Sweden.		Cui, Hengmi/A-2598-2008					Adam GIR, 1996, DEVELOPMENT, V122, P839; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; COTE GB, 1995, GENOMIC IMPRINTING C, P252; Cui HM, 1997, CANCER RES, V57, P4469; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; EKSTROM TJ, 1995, DEVELOPMENT, V121, P309; EKSTROM TJ, 1995, MOL REPROD DEV, V41, P177, DOI 10.1002/mrd.1080410208; FEINBERG AP, 1994, COLD SPRING HARB SYM, V59, P357, DOI 10.1101/SQB.1994.059.01.040; FRANKLIN GC, 1991, EMBO J, V10, P1365, DOI 10.1002/j.1460-2075.1991.tb07656.x; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; He LM, 1998, ONCOGENE, V16, P113, DOI 10.1038/sj.onc.1201501; HEDBORG F, 1994, AM J PATHOL, V145, P802; Joubel A, 1996, CELL MOL BIOL, V42, P1159; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; NYSTROM A, 1994, EUR J PEDIATR, V153, P574, DOI 10.1007/BF02190661; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OHLSSON R, 1989, EMBO J, V8, P1993, DOI 10.1002/j.1460-2075.1989.tb03606.x; OHLSSON R, 1994, DEVELOPMENT, V120, P361; RACHMILEWITZ J, 1995, ONCOGENE, V11, P863; Reeve AE, 1996, MED PEDIATR ONCOL, V27, P470; Ripoche MA, 1997, GENE DEV, V11, P1596, DOI 10.1101/gad.11.12.1596; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; THEODORAKIS NG, 1988, J BIOL CHEM, V263, P14579; TILGHMAN SM, 1993, COLD SPRING HARB SYM, V58, P287, DOI 10.1101/SQB.1993.058.01.034; TYCKO B, 1994, AM J PATHOL, V144, P431; TYCKO B, 1998, GENOMIC IMPRINTING I; WALSH C, 1994, MECH DEVELOP, V46, P55, DOI 10.1016/0925-4773(94)90037-X; Webber AL, 1998, NATURE, V391, P711, DOI 10.1038/35655; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61	31	95	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28247	28252		10.1074/jbc.273.43.28247	http://dx.doi.org/10.1074/jbc.273.43.28247			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774446	hybrid			2022-12-27	WOS:000076549800066
J	Trevino, RJ; Tsalkova, T; Kramer, G; Hardesty, B; Chirgwin, JM; Horowitz, PM				Trevino, RJ; Tsalkova, T; Kramer, G; Hardesty, B; Chirgwin, JM; Horowitz, PM			Truncations at the NH2 terminus of rhodanese destabilize the enzyme and decrease its heterologous expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE LIVER RHODANESE; INTRACELLULAR PROTEIN DEGRADATION; ESCHERICHIA-COLI; TRANSCRIPTION TRANSLATION; RAPID DEGRADATION; PRECURSOR PROTEIN; BACTERIAL-CELLS; STABILITY; INACTIVATION; GROEL	Rhodanese mutants containing sequential NH2-terminal deletions were constructed to test the distinct contributions of this region of the protein to expression, folding, and stability. The results indicate that the first 11 residues are nonessential for folding to the active conformation, but they are necessary for attaining an active, stable structure when expressed in Escherichia coli, Rhodanese species with up to 9 residues deleted were expressed and purified. Kinetic parameters for the mutants were similar to those of the full-length enzyme. Compared with shorter truncations, mutants missing 7 or 9 residues were (a) increasingly inactivated by urea denaturation, (b) more susceptible to inactivation by dithiothreitol, (c) less able to be reactivated, and (d) less rapidly inactivated by incubation at 37 degrees C, Immunoprecipitation showed that mutants lacking 10-23 NH2-terminal amino acids were expressed as inactive species of the expected size but were rapidly eliminated. Cell-free transcription/translation at 37 degrees C showed mutants deleted through residue 9 were enzymatically active, but they were inactive when deleted further, just as in vivo, However, at 30 degrees C in vitro, both Delta 1-10 and Delta 1-11 showed considerable activity. Truncations in the NH2 terminus affect the chemical stability of the distantly located active site. Residues Ser-11 through Gly-22, which form the NH2-proximal alpha-helix, contribute to folding to an active conformation, to resisting degradation during heterologous expression, and to chemical stability in vitro.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA; Univ Texas, Hlth Sci Ctr, Dept Med Endocrinol, San Antonio, TX 78284 USA; Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Austin	Horowitz, PM (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.	horowitz@bioc02.uthscsa.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25177] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIRD BA, 1988, J BIOL CHEM, V263, P15270; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BALTSCHEFFSKY H, 1981, MITOCHONDRIA MICROSO, P519; BOGGARAM V, 1985, BIOCHEM BIOPH RES CO, V130, P407, DOI 10.1016/0006-291X(85)90431-0; CANNELLA C, 1983, FEBS LETT, V162, P180, DOI 10.1016/0014-5793(83)81074-6; COSTA M, 1977, BIOCHEM BIOPH RES CO, V78, P596, DOI 10.1016/0006-291X(77)90221-2; DUNGAN JM, 1993, J PROTEIN CHEM, V12, P311, DOI 10.1007/BF01028193; Gliubich F, 1996, J BIOL CHEM, V271, P21054, DOI 10.1074/jbc.271.35.21054; GOFF SA, 1985, CELL, V41, P587, DOI 10.1016/S0092-8674(85)80031-3; GOLDBERG AL, 1974, ANNU REV BIOCHEM, V43, P835, DOI 10.1146/annurev.bi.43.070174.004155; GOLDBERG AL, 1976, ANNU REV BIOCHEM, V45, P747, DOI 10.1146/annurev.bi.45.070176.003531; HAMMEN PK, 1994, BIOCHEMISTRY-US, V33, P8610, DOI 10.1021/bi00194a028; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HOL WGJ, 1983, FUND APPL TOXICOL, V3, P370, DOI 10.1016/S0272-0590(83)80007-4; HOROWITZ PM, 1989, J BIOL CHEM, V264, P3311; HOROWITZ PM, 1993, ACS SYM SER, V516, P167; HOROWITZ PM, 1978, ANAL BIOCHEM, V86, P751, DOI 10.1016/0003-2697(78)90803-5; KANDROR O, 1995, EMBO J, V14, P6021, DOI 10.1002/j.1460-2075.1995.tb00290.x; KANDROR O, 1994, J BIOL CHEM, V269, P23575; KIM SK, 1975, BIOCHEM BIOPH RES CO, V67, P433, DOI 10.1016/0006-291X(75)90334-4; KUDLICKI W, 1995, J BIOL CHEM, V270, P10650, DOI 10.1074/jbc.270.18.10650; KUDLICKI W, 1992, ANAL BIOCHEM, V206, P389, DOI 10.1016/0003-2697(92)90383-I; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUO GX, 1993, J BIOL CHEM, V268, P10246; MARGULIS L, 1970, ORIGIN EUKARYOTIC CE, P178; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; MENDOZA JA, 1991, J BIOL CHEM, V266, P13587; MENDOZA JA, 1994, J PROTEIN CHEM, V13, P15, DOI 10.1007/BF01891988; MERRILL GA, 1993, J BIOL CHEM, V268, P15611; MERRILL GA, 1992, J PROTEIN CHEM, V11, P193, DOI 10.1007/BF01025225; MILLER DM, 1992, BIOCHIM BIOPHYS ACTA, V1121, P286, DOI 10.1016/0167-4838(92)90158-A; MILLER DM, 1991, J BIOL CHEM, V266, P4686; MILLERMARTINI DM, 1994, J BIOL CHEM, V269, P12414; MILLERMARTINI DM, 1994, J BIOL CHEM, V269, P3423; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; PACE CN, 1990, TRENDS BIOTECHNOL, V8, P93, DOI 10.1016/0167-7799(90)90146-O; PAKULA AA, 1986, P NATL ACAD SCI USA, V83, P8829, DOI 10.1073/pnas.83.23.8829; PARSELL DA, 1989, J BIOL CHEM, V264, P7590; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHERMAN MY, 1992, EMBO J, V11, P71; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; TREVINO RJ, 1993, BIOTECHNIQUES, V15, P366; TSALKOVA T, 1993, BIOCHEMISTRY-US, V32, P3377, DOI 10.1021/bi00064a022; Waltner M, 1996, J BIOL CHEM, V271, P21226, DOI 10.1074/jbc.271.35.21226; WALTNER M, 1995, J BIOL CHEM, V270, P26311, DOI 10.1074/jbc.270.44.26311; Westley J, 1981, Methods Enzymol, V77, P285; ZUBAY G, 1973, ANNU REV GENET, V7, P267, DOI 10.1146/annurev.ge.07.120173.001411	50	14	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27841	27847		10.1074/jbc.273.43.27841	http://dx.doi.org/10.1074/jbc.273.43.27841			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774394	hybrid			2022-12-27	WOS:000076549800014
J	Wu, CL; Leeuw, T; Leberer, E; Thomas, DY; Whiteway, M				Wu, CL; Leeuw, T; Leberer, E; Thomas, DY; Whiteway, M			Cell cycle- and Cln2p-Cdc28p-dependent phosphorylation of the yeast Ste20p protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; PHEROMONE RESPONSE; S-PHASE; MOLECULAR CHARACTERIZATION; TRANSDUCIN HOMOLOG; FILAMENTOUS GROWTH; BINDING PROTEIN; DNA-SYNTHESIS; G1 CYCLINS	Ste20p from Saccharomyces cerevisiae is a member of the Ste20/p21-activated protein kinase family of protein kinases. The Ste20p kinase is post-translationally modified by phosphorylation in a cell cycle-dependent manner, as judged by the appearance of phosphatase-sensitive species with reduced mobility on SDS-polyacrylamide gel electrophoresis. This modification is maximal during S phase, and correlates with the accumulation of Ste20p fused to green fluorescent protein at the site of bud emergence. Overexpression of Cln2p, but not Clb2p or Clb5p, causes a quantitative shift of Ste20p to the reduced mobility form, and this shift is dependent on Cdc28p activity. The post-translational mobility shift can be generated in vitro by incubation of Ste20p with immunoprecipitated Cln2p kinase complexes, but not by immunoprecipitated Clb2p or Clb5p kinase complexes. Ste20p is therefore a substrate for the Cdc28p kinase, and undergoes a Cln2p-Cdc28p mediated mobility shift as cells initiate budding and DNA replication. In cells that express only the Cln2p G(1) cyclin, minor overexpression of Ste20p causes aberrant morphology, suggesting a proper coordination of Ste20p and Cln-Cdc28p activity may be required for the control of cell shape.	Natl Res Council Canada, Biotechnol Res Inst, Eukaryot Genet Grp, Montreal, PQ H4P 2R2, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 2B2, Canada; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada; McGill Univ, Dept Biol, Montreal, PQ H3A 2B2, Canada	National Research Council Canada; McGill University; McGill University; McGill University	Whiteway, M (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, Eukaryot Genet Grp, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.		Thomas, David/M-7661-2017	Thomas, David/0000-0002-8854-762X				BUCKINGTHROM E, 1973, EXP CELL RES, V76, P99, DOI 10.1016/0014-4827(73)90424-2; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CROSS FR, 1995, CURR OPIN CELL BIOL, V7, P790, DOI 10.1016/0955-0674(95)80062-X; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DIRICK L, 1995, EMBO J, V14, P4803, DOI 10.1002/j.1460-2075.1995.tb00162.x; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; FITCH I, 1992, MOL BIOL CELL, V3, P805, DOI 10.1091/mbc.3.7.805; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; Goodson HV, 1996, J CELL BIOL, V133, P1277, DOI 10.1083/jcb.133.6.1277; HARTWELL LH, 1973, EXP CELL RES, V76, P111, DOI 10.1016/0014-4827(73)90425-4; HARTWELL LH, 1985, GENETICS, V110, P381; Henchoz S, 1997, GENE DEV, V11, P3046, DOI 10.1101/gad.11.22.3046; HEREFORD LM, 1974, J MOL BIOL, V84, P445, DOI 10.1016/0022-2836(74)90451-3; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; IMIGER S, 1995, CELL, V81, P269; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBERER E, 1993, MOL GEN GENET, V241, P241, DOI 10.1007/BF00284675; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; Leeuw T, 1998, NATURE, V391, P191, DOI 10.1038/34448; LEEUW T, 1995, SCIENCE, V270, P1210, DOI 10.1126/science.270.5239.1210; LEW DJ, 1992, CELL, V69, P317, DOI 10.1016/0092-8674(92)90412-6; LEW DJ, 1995, CURR OPIN GENET DEV, V5, P17, DOI 10.1016/S0959-437X(95)90048-9; LEW DJ, 1993, J CELL BIOL, V120, P1305, DOI 10.1083/jcb.120.6.1305; Lim HH, 1996, MOL GEN GENET, V253, P138, DOI 10.1007/s004380050306; Lim HH, 1998, CURR BIOL, V8, P231, DOI 10.1016/S0960-9822(98)70088-0; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; Maniatis T., 1982, MOL CLONING LAB MANU; MCKINNEY JD, 1993, GENE DEV, V7, P833, DOI 10.1101/gad.7.5.833; Mosch HU, 1996, P NATL ACAD SCI USA, V93, P5352, DOI 10.1073/pnas.93.11.5352; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; OEHLEN LJWM, 1994, GENE DEV, V8, P1058, DOI 10.1101/gad.8.9.1058; PATTERSON M, 1986, MOL CELL BIOL, V6, P1590, DOI 10.1128/MCB.6.5.1590; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; RICHARDSON H, 1992, GENE DEV, V6, P2021, DOI 10.1101/gad.6.11.2021; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; Rose MD., 1990, METHODS YEAST GENETI; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHULTZ J, 1995, CURR OPIN GENET DEV, V5, P31, DOI 10.1016/S0959-437X(95)90050-0; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SETHI N, 1991, MOL CELL BIOL, V11, P5592, DOI 10.1128/MCB.11.11.5592; STUART D, 1995, GENE DEV, V9, P2780, DOI 10.1101/gad.9.22.2780; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Wassmann K, 1997, J BIOL CHEM, V272, P13180, DOI 10.1074/jbc.272.20.13180; Wittenberg C, 1996, CURR OPIN CELL BIOL, V8, P223, DOI 10.1016/S0955-0674(96)80069-X; Wu C, 1997, J BIOL CHEM, V272, P30623, DOI 10.1074/jbc.272.49.30623; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; YOON HJ, 1991, P NATL ACAD SCI USA, V88, P3574, DOI 10.1073/pnas.88.9.3574	59	40	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28107	28115		10.1074/jbc.273.43.28107	http://dx.doi.org/10.1074/jbc.273.43.28107			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774429	hybrid			2022-12-27	WOS:000076549800049
J	Cessna, SG; Chandra, S; Low, PS				Cessna, SG; Chandra, S; Low, PS			Hypo-osmotic shock of tobacco cells stimulates Ca2+ fluxes deriving first from external and then internal Ca2+ stores	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY VOLUME DECREASE; CALCIUM-RELEASE CHANNEL; DEPENDENT ANION CHANNEL; CYCLIC ADP-RIBOSE; PLASMA-MEMBRANE; ABSCISIC-ACID; GUARD-CELLS; ENDOPLASMIC-RETICULUM; CYTOSOLIC CALCIUM; OXIDATIVE BURST	Hypo-osmotic shock of aequorin-transformed tobacco cells induces a biphasic cytosolic Ca2+ influx. Because both phases of Ca2+ entry are readily blocked by Ca2+ channel inhibitors, we conclude that the Ca2+ transients are mediated by Ca2+ channels. Evidence that the first but not second Ca2+ transient derives from external Ca2+ stores is that the first but not second influx is (i) eliminated by membrane-impermeable Ca2+ chelators, (ii) enlarged by supplementation of the medium with excess Ca2+, and (iii) reduced by the addition of competitive cations such as Mg2+ and Mn2+. Furthermore, entry of Ca-45 during osmotic shock is prevented by inhibitors of the first but not second phase of Ca2+ entry. Evidence that the second wave of Ca2+ influx stems from release of intracellular Ca2+ is based on the above data plus observations that probable modulators of intracellular Ca2+ channels selectively block this phase of Ca2+ influx. Finally, a mechanism of communication between the two Ca2+ release pathways has become apparent, since perturbations that elevate or reduce the first Ca2+ transient lead to a compensating diminution/elevation of the second and vice versa. These data thus suggest that osmotic shock leads to the sequential opening of extracellular followed by intracellular Ca2+ stores and that these Ca2+ release pathways are internally compensated.	Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Low, PS (corresponding author), Purdue Univ, Dept Chem, 1393 Brown Bldg, W Lafayette, IN 47907 USA.	lowps@omni.cc.purdue.edu		Low, Philip/0000-0001-9042-5528; Cessna, Stephen/0000-0001-7233-8711				ALLEN DG, 1977, SCIENCE, V195, P996, DOI 10.1126/science.841325; ALLEN GJ, 1995, SCIENCE, V268, P735, DOI 10.1126/science.7732384; ATKINSON MM, 1990, PLANT PHYSIOL, V92, P215, DOI 10.1104/pp.92.1.215; BarbierBrygoo H, 1997, TRENDS PLANT SCI, V2, P214, DOI 10.1016/S1360-1385(97)89546-5; Batiza AF, 1996, J BIOL CHEM, V271, P23357, DOI 10.1074/jbc.271.38.23357; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Borle A B, 1986, Methods Enzymol, V124, P90; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; BROWN GR, 1992, BIOCHEM J, V282, P309, DOI 10.1042/bj2820309; CALVERT CM, 1995, J BIOL CHEM, V270, P7272, DOI 10.1074/jbc.270.13.7272; Chandra S, 1997, J BIOL CHEM, V272, P28274, DOI 10.1074/jbc.272.45.28274; Chen XF, 1997, PLANT J, V11, P363, DOI 10.1046/j.1365-313X.1997.11030363.x; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COSGROVE DJ, 1991, PLANTA, V186, P143, DOI 10.1007/BF00201510; Digonnet C, 1997, DEVELOPMENT, V124, P2867; DING JP, 1993, PLANT J, V3, P83, DOI 10.1111/j.1365-313X.1993.tb00013.x; GELLI A, 1993, PLANT PHYSIOL, V102, P1139, DOI 10.1104/pp.102.4.1139; Gelli A, 1997, PLANT PHYSIOL, V113, P269, DOI 10.1104/pp.113.1.269; GILROY S, 1993, J CELL SCI, V106, P453; Gong M, 1998, PLANT PHYSIOL, V116, P429, DOI 10.1104/pp.116.1.429; Grabov A, 1997, PLANT J, V12, P203, DOI 10.1046/j.1365-313X.1997.12010203.x; Haussinger D, 1996, BIOCHEM J, V313, P697; Hirschi KD, 1996, P NATL ACAD SCI USA, V93, P8782, DOI 10.1073/pnas.93.16.8782; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Ishii T, 1996, J PHYSIOL-LONDON, V493, P371, DOI 10.1113/jphysiol.1996.sp021389; JOHANNES E, 1995, J MEMBRANE BIOL, V146, P211; KLUSENER B, 1995, EMBO J, V14, P2708, DOI 10.1002/j.1460-2075.1995.tb07271.x; Knight H, 1996, PLANT CELL, V8, P489, DOI 10.1105/tpc.8.3.489; Knight H, 1997, PLANT J, V12, P1067, DOI 10.1046/j.1365-313X.1997.12051067.x; KNIGHT MR, 1991, NATURE, V352, P524, DOI 10.1038/352524a0; KONISHI M, 1987, J PHYSIOL-LONDON, V383, P269; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Leckie CP, 1998, J EXP BOT, V49, P339, DOI 10.1093/jexbot/49.suppl_1.339; Legue V, 1997, PLANT PHYSIOL, V114, P789, DOI 10.1104/pp.114.3.789; LEMTIRICHLIEH F, 1994, J MEMBRANE BIOL, V137, P99; Levine A, 1996, CURR BIOL, V6, P427, DOI 10.1016/S0960-9822(02)00510-9; MA JJ, 1993, J GEN PHYSIOL, V102, P1031, DOI 10.1085/jgp.102.6.1031; MARTEN I, 1992, EMBO J, V11, P3569, DOI 10.1002/j.1460-2075.1992.tb05440.x; McAinsh MR, 1998, TRENDS PLANT SCI, V3, P32, DOI 10.1016/S1360-1385(97)01150-3; MCCARTY NA, 1991, J MEMBRANE BIOL, V123, P149, DOI 10.1007/BF01998085; Muir SR, 1997, J EXP BOT, V48, P589, DOI 10.1093/jxb/48.Special_Issue.589; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PEETERS GA, 1989, AM J PHYSIOL, V256, pC351, DOI 10.1152/ajpcell.1989.256.2.C351; Pierson ES, 1996, DEV BIOL, V174, P160, DOI 10.1006/dbio.1996.0060; Pineros M, 1997, J EXP BOT, V48, P551, DOI 10.1093/jxb/48.Special_Issue.551; PRICE AH, 1994, PLANT CELL, V6, P1301, DOI 10.1105/tpc.6.9.1301; Pugin A, 1997, PLANT CELL, V9, P2077, DOI 10.1105/tpc.9.11.2077; RATHORE KS, 1991, DEV BIOL, V148, P612, DOI 10.1016/0012-1606(91)90278-B; Roberts DM, 1993, CURR OPIN CELL BIOL, V5, P242, DOI 10.1016/0955-0674(93)90110-C; Schulz-Lessdorf B, 1994, Symp Soc Exp Biol, V48, P99; SCHWARTZ A, 1995, PLANT PHYSIOL, V109, P651, DOI 10.1104/pp.109.2.651; SEDBROCK JC, PLANT PHYSL, V111, P243; SUBBAIAH CC, 1994, PLANT CELL, V6, P1747, DOI 10.1105/tpc.6.12.1747; Tahtiharju S, 1997, PLANTA, V203, P442, DOI 10.1007/s004250050212; Takahashi K, 1997, PLANT PHYSIOL, V113, P587, DOI 10.1104/pp.113.2.587; Taylor AR, 1996, PLANT CELL, V8, P2015; Thomine S, 1997, J MEMBRANE BIOL, V159, P71, DOI 10.1007/s002329900270; TINEL H, 1994, AM J PHYSIOL, V267, pF130, DOI 10.1152/ajprenal.1994.267.1.F130; WARD JM, 1995, PLANT CELL, V7, P833, DOI 10.1105/tpc.7.7.833; Wu X, 1997, J MEMBRANE BIOL, V158, P127, DOI 10.1007/s002329900250; Wu Y, 1997, SCIENCE, V278, P2126, DOI 10.1126/science.278.5346.2126; Xu HX, 1998, PLANT CELL, V10, P585, DOI 10.1105/tpc.10.4.585; YAHRAUS T, 1995, PLANT PHYSIOL, V109, P1259, DOI 10.1104/pp.109.4.1259; ZHA XH, 1995, AM J PHYSIOL-CELL PH, V269, pC923, DOI 10.1152/ajpcell.1995.269.4.C923; Zimmermann S, 1997, P NATL ACAD SCI USA, V94, P2751, DOI 10.1073/pnas.94.6.2751; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	67	59	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27286	27291		10.1074/jbc.273.42.27286	http://dx.doi.org/10.1074/jbc.273.42.27286			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765253	hybrid			2022-12-27	WOS:000076448000040
J	Chiaberge, S; Cassarino, E; Mangiarotti, G				Chiaberge, S; Cassarino, E; Mangiarotti, G			The phosphorylation of protein S6 modulates the interaction of the 40 S ribosomal subunit with the 5 '-untranslated region of a Dictyostelium pre-spore-specific mRNA and controls its stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISCOIDEUM MESSENGER-RNAS; CELL-DIFFERENTIATION; STALK CELL; CAMP; EXPRESSION; KINASE; GENES	AC914 mRNA, a pre-spore-specific mRNA that accumulates only in the post-aggregation stage of development, is transcribed constitutively as shown by nuclear run-off experiments and by fusing its promoter to the luciferase reporter gene. The same mRNA disappears quickly from disaggregated cells. If the 5'-untranslated region (5'UTR) of the constitutively expressed Actin 15 mRNA is substituted for the 5'UTR of AC914 mRNA, this can no longer be destabilized and accumulates both in growing and disaggregated cells. If the 5'UTR of AC914 mRNA is substituted for the 5'UTR of Actin 15 mRNA, the latter accumulates only in aggregated cells. Pactamycin, but not other inhibitors of protein synthesis, prevents AC914 mRNA from being destabilized in disaggregated cells, suggesting a role of 40 S subunits in the destabilization. This has been confirmed by using an in vitro system in which the in vice stability of different mRNAs is reproduced. A protein kinase A-dependent phosphorylation of ribosomal protein S6 determines whether 40 S subunits are capable or not of destabilizing AC914 mRNA in the in vitro system.	Univ Turin, Dept Clin & Biol Sci, Osped S Luigi, I-10043 Orbassano, To, Italy	University of Turin	Mangiarotti, G (corresponding author), Univ Turin, Dept Clin & Biol Sci, Osped S Luigi, I-10043 Orbassano, To, Italy.							ANJARD C, 1992, DEVELOPMENT, V115, P785; BARKLIS E, 1983, CELL, V32, P1139, DOI 10.1016/0092-8674(83)90297-0; BLUMBERG DD, 1980, DEV BIOL, V78, P285, DOI 10.1016/0012-1606(80)90337-1; BOZZARO S, 1984, EMBO J, V3, P193, DOI 10.1002/j.1460-2075.1984.tb01783.x; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; CECCARELLI A, 1991, CELL, V65, P983, DOI 10.1016/0092-8674(91)90550-I; CECCARELLI A, 1987, NUCLEIC ACIDS RES, V15, P7463, DOI 10.1093/nar/15.18.7463; Chattopadhyay S, 1996, P NATL ACAD SCI USA, V93, P8284, DOI 10.1073/pnas.93.16.8284; CHUNG S, 1981, CELL, V24, P785, DOI 10.1016/0092-8674(81)90104-5; COLOMA A, 1980, CELL, V28, P346; Das B, 1996, EUR J BIOCHEM, V235, P613, DOI 10.1111/j.1432-1033.1996.00613.x; HOPPER NA, 1993, DEVELOPMENT, V119, P147; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; JERMYN KA, 1989, NATURE, V340, P144, DOI 10.1038/340144a0; JULIANI MH, 1983, FEBS LETT, V154, P400, DOI 10.1016/0014-5793(83)80191-4; KAEMPFER R, 1970, NATURE, V228, P534, DOI 10.1038/228534a0; KAEMPFER R, 1968, J MOL BIOL, V31, P273; Kudlicki W, 1997, FOLD DES, V2, P101, DOI 10.1016/S1359-0278(97)00014-X; LLOYD M, 1988, DEV GENET, V11, P391; MANGIAROTTI G, 1971, J MOL BIOL, V60, P441, DOI 10.1016/0022-2836(71)90180-X; MANGIAROTTI G, 1981, NUCLEIC ACIDS RES, V9, P947, DOI 10.1093/nar/9.4.947; Mangiarotti G, 1997, J BIOL CHEM, V272, P19682, DOI 10.1074/jbc.272.32.19682; MANGIAROTTI G, 1982, DEV BIOL, V89, P82, DOI 10.1016/0012-1606(82)90296-2; MANGIAROTTI G, 1983, NATURE, V301, P616, DOI 10.1038/301616a0; MANGIAROTTI G, 1989, DEVELOPMENT, V106, P473; MANGIAROTTI G, 1985, P NATL ACAD SCI USA, V82, P5786, DOI 10.1073/pnas.82.17.5786; MANGIAROTTI G, 1967, J MOL BIOL, V29, P395, DOI 10.1016/0022-2836(67)90107-6; ROSS J, 1987, J BIOL CHEM, V262, P9374; Sambrook J., 2002, MOL CLONING LAB MANU; SCHLESSINGER D, 1967, P NATL ACAD SCI USA, V58, P1782, DOI 10.1073/pnas.58.4.1782; SOMMERMAN J, 1991, J BIOL CHEM, V266, P23091; VREKEN P, 1992, NUCLEIC ACIDS RES, V20, P2503, DOI 10.1093/nar/20.10.2503	32	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27070	27075		10.1074/jbc.273.42.27070	http://dx.doi.org/10.1074/jbc.273.42.27070			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765222	hybrid			2022-12-27	WOS:000076448000009
J	Franco, P; Massa, O; Garcia-Rocha, R; Chiaradonna, F; Iaccarino, C; Correas, I; Mendez, E; Avila, J; Blasi, F; Stoppelli, MP				Franco, P; Massa, O; Garcia-Rocha, R; Chiaradonna, F; Iaccarino, C; Correas, I; Mendez, E; Avila, J; Blasi, F; Stoppelli, MP			Protein kinase C-dependent in vivo phosphorylation of prourokinase leads to the formation of a receptor competitive antagonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; CARCINOMATOUS CELL-LINE; UROKINASE RECEPTOR; PRO-UROKINASE; BINDING; CLEAVAGE; GENE; VITRONECTIN; SPECIFICITY; SENSITIVITY	We recently reported that in vivo phosphorylation of urokinase-type plasminogen activator on Ser(138/303) prevents its catalytic independent ability to promote myelomonocytic cell adherence and motility, me now show that Ca2+ activated, phospholipid-dependent protein kinase C from rat brain phosphorylates in vitro a peptide corresponding to prourokinase residues 133-143 (DGKKPSSPPEE) and the full-length molecule on Ser(138/139). The in vivo involvement of the protein kinase C isoenzyme family is supported by the finding that inhibition of kinase C activity prevents prourokinase phosphorylation on Ser(138/303) in A431 human carcinoma cells. Conversely, a short treatment of A431 cells with phorbol myristate acetate increases the extent of phosphorylated prourokinase and, concomitantly, affects its function; under these conditions, the capability of prourokinase to up-regulate U937 monocyte-like cell adherence is severely impaired, although receptor binding is unaltered. By the aid of a "phosphorylation-like" variant (Se-138 to Glu) we show that modification of Ser(138) is sufficient to confer to prourokinase the antagonistic properties observed following in vivo stimulation of protein kinase C activity. These observations provide the first evidence that protein kinase C directs the formation of a receptor competitive antagonist by regulating the in vivo phosphorylation state of prourokinase.	IIGB, CNR, I-80125 Naples, Italy; Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol, E-28049 Madrid, Spain; Univ Milan, Dipartimento Genet, I-20132 Milan, Italy; Ist Sci San Raffaele, Dept Biol & Biotechnol, I-20132 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); Autonomous University of Madrid; University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Stoppelli, MP (corresponding author), IIGB, CNR, Via Marconi 10, I-80125 Naples, Italy.	stoppelli@iigbna.iigb.na.cnr.it	Avila, Jesus/I-2610-2015; Correas, Isabel/O-4061-2018; Franco, Paola/O-5897-2015; CHIARADONNA, Ferdinando/K-4959-2016	Avila, Jesus/0000-0002-6288-0571; Correas, Isabel/0000-0002-2286-186X; Franco, Paola/0000-0002-3289-7284; CHIARADONNA, Ferdinando/0000-0001-8529-2732; IACCARINO, Ciro/0000-0003-1619-7146; Blasi, Francesco/0000-0001-9406-1784				Ando Y, 1996, J CELL PHYSIOL, V167, P500, DOI 10.1002/(SICI)1097-4652(199606)167:3<500::AID-JCP14>3.0.CO;2-7; ANDREASEN PA, 1986, J BIOL CHEM, V261, P7644; BARLATI S, 1991, FEBS LETT, V281, P137, DOI 10.1016/0014-5793(91)80377-F; BARLATI S, 1995, FEBS LETT, V363, P170, DOI 10.1016/0014-5793(95)00312-W; BASTANI B, 1995, BBA-MOL CELL RES, V1269, P307, DOI 10.1016/0167-4889(95)00120-0; Besser D, 1997, ONCOGENE, V14, P705, DOI 10.1038/sj.onc.1200879; BLASI F, 1994, FIBRINOLYSIS, V8, P182, DOI 10.1016/0268-9499(94)90716-1; Carriero MV, 1997, CLIN CANCER RES, V3, P1299; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Ellis V, 1996, J BIOL CHEM, V271, P14779, DOI 10.1074/jbc.271.25.14779; Franco P, 1997, J CELL BIOL, V137, P779, DOI 10.1083/jcb.137.3.779; FRANCO P, 1992, J BIOL CHEM, V267, P19369; Gechtman Z, 1997, EUR J BIOCHEM, V243, P493, DOI 10.1111/j.1432-1033.1997.0493a.x; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; HOGAN MV, 1995, J NEUROCHEM, V65, P2022; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lengyel E, 1996, J BIOL CHEM, V271, P23176, DOI 10.1074/jbc.271.38.23176; Li CH, 1995, J BIOL CHEM, V270, P30282, DOI 10.1074/jbc.270.51.30282; MASTRONICOLA MR, 1990, FEBS LETT, V266, P109, DOI 10.1016/0014-5793(90)81519-T; MASTRONICOLA MR, 1992, FIBRINOLYSIS, V6, P117; MIMURO J, 1987, BLOOD, V70, P721; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NOLLI ML, 1986, THROMB HAEMOSTASIS, V56, P214; NOWAK UK, 1993, BIOCHEMISTRY-US, V32, P298, DOI 10.1021/bi00052a038; ORSINI G, 1991, EUR J BIOCHEM, V195, P691, DOI 10.1111/j.1432-1033.1991.tb15755.x; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PICONE R, 1989, J CELL BIOL, V108, P693, DOI 10.1083/jcb.108.2.693; RAND MD, 1994, BLOOD, V83, P2180; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; Schreuder H, 1997, NATURE, V386, P194, DOI 10.1038/386194a0; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; STOPPELLI MP, 1986, J CELL BIOL, V102, P1035; TAKAHASHI K, 1992, BIOCHEM BIOPH RES CO, V182, P1473, DOI 10.1016/0006-291X(92)91900-B; TAKAHASHI K, 1992, BIOCHEM BIOPH RES CO, V182, P1466, DOI 10.1016/0006-291X(92)91899-2; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; WALSH MP, 1984, BIOCHEM J, V224, P117, DOI 10.1042/bj2240117; WALTZ DA, 1993, J CLIN INVEST, V91, P1541, DOI 10.1172/JCI116360	46	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27734	27740		10.1074/jbc.273.42.27734	http://dx.doi.org/10.1074/jbc.273.42.27734			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765311	hybrid			2022-12-27	WOS:000076448000098
J	Lin, Y; Tang, H; Nomura, T; Dorjsuren, D; Hayashi, N; Wei, WX; Ohta, T; Roeder, R; Murakami, S				Lin, Y; Tang, H; Nomura, T; Dorjsuren, D; Hayashi, N; Wei, WX; Ohta, T; Roeder, R; Murakami, S			The hepatitis B virus X protein is a co-activator of activated transcription that modulates the transcription machinery and distal binding activators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; LONG TERMINAL REPEAT; NF-KAPPA-B; HBX PROTEIN; HEPATOCELLULAR-CARCINOMA; SIGNALING PATHWAY; TRANS-ACTIVATION; GENE PRODUCT; KINASE-C; PROMOTER	Hepatitis B virus X protein (HBx) transactivates viral and cellular genes through a wide variety of cis-elements, but the mechanism has not been well elucidated. Evidence for nuclear events in HBx transactivation has been reported. Here we examine the role of HBx in modulation of transcription with a transient transfection system and an in vitro transcription assay. Reporters bearing Gal4-binding sites were applied to avoid the effects of endogenous transcription factors with or without signaling processes. The Gal4-DNA binding domain fused form of HBx exhibited no effect on Gal4-responsive reporters. However, HBx augmented activated transcription by transcriptional activators, suggesting HBx retains a co-activator but not a transcriptional activator function. The functional domain for co-activation was the same as that for HBx transactivation, and the transcription factor IIB and RNA polymerase II subunit B-interacting sites of HBx, which were critical for HBx transactivation, were shown to be crucial for the co-activation function. Importantly, HBx stimulated transcription on templates bearing the X responsive elements in vitro with endogenous activators. These results imply that HBx acts as a co-activator that modulates transcriptional machinery and distal-binding activators, which may explain one of the mechanisms of transactivation by HBx when localized in nuclei.	Kanazawa Univ, Canc Res Inst, Dept Mol Biol, Kanazawa, Ishikawa 9200934, Japan; Rockefeller Univ, New York, NY 10021 USA; Natl Inst Genet, Mishima, Shizuoka 4110801, Japan	Kanazawa University; Rockefeller University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Murakami, S (corresponding author), Kanazawa Univ, Canc Res Inst, Dept Mol Biol, Takara Machi 13-1, Kanazawa, Ishikawa 9200934, Japan.	semuraka@kenroku.kanazawa-u.ac.jp		Hayashi, Naoyuki/0000-0001-9626-3689				ANTUNOVIC J, 1993, CELL MOL BIOL RES, V39, P463; ASPINALL S, 1986, J GEN VIROL, V67, P2315, DOI 10.1099/0022-1317-67-11-2315; AUFIERO B, 1990, EMBO J, V9, P497, DOI 10.1002/j.1460-2075.1990.tb08136.x; AVANTAGGIATI ML, 1993, ONCOGENE, V8, P1567; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Blau J, 1996, MOL CELL BIOL, V16, P2044; BUENDIA MA, 1992, ADV CANCER RES, V59, P167, DOI 10.1016/S0065-230X(08)60306-1; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; CHEONG JH, 1995, EMBO J, V14, P142; Chou S, 1997, MOL CELL BIOL, V17, P6794, DOI 10.1128/MCB.17.12.6794; CROSS JC, 1993, P NATL ACAD SCI USA, V90, P8078, DOI 10.1073/pnas.90.17.8078; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; DUFLOT A, 1995, HEPATOLOGY, V21, P1483, DOI 10.1016/0270-9139(95)90448-4; EMAMI KH, 1995, MOL CELL BIOL, V15, P5906; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FISCHER M, 1995, VIRUS GENES, V10, P99, DOI 10.1007/BF01724303; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GONZALEZAMARO R, 1994, J EXP MED, V179, P841, DOI 10.1084/jem.179.3.841; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; Haviv I, 1998, MOL CELL BIOL, V18, P1562, DOI 10.1128/MCB.18.3.1562; Haviv I, 1996, EMBO J, V15, P3413, DOI 10.1002/j.1460-2075.1996.tb00707.x; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HU KQ, 1990, P NATL ACAD SCI USA, V87, P7140, DOI 10.1073/pnas.87.18.7140; Huang JK, 1996, J VIROL, V70, P5582, DOI 10.1128/JVI.70.8.5582-5591.1996; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Lin Y, 1997, J BIOL CHEM, V272, P7132, DOI 10.1074/jbc.272.11.7132; Lin Y, 1997, CANCER RES, V57, P5137; LIU X, 1995, MOL CELL BIOL, V15, P6474; LUBER B, 1991, VIROLOGY, V184, P808, DOI 10.1016/0042-6822(91)90458-N; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MAHE Y, 1991, J BIOL CHEM, V266, P13759; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MURAKAMI S, 1994, J BIOL CHEM, V269, P15118; MURAKAMI S, 1994, VIROLOGY, V199, P243, DOI 10.1006/viro.1994.1119; NATOLI G, 1994, MOL CELL BIOL, V14, P989, DOI 10.1128/MCB.14.2.989; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; SETO E, 1989, VIROLOGY, V173, P764, DOI 10.1016/0042-6822(89)90594-1; SETO E, 1988, P NATL ACAD SCI USA, V85, P8286, DOI 10.1073/pnas.85.21.8286; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SIDDIQUI A, 1987, P NATL ACAD SCI USA, V84, P2513, DOI 10.1073/pnas.84.8.2513; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; TUGIZOV SM, 1993, VIRUS RES, V30, P189, DOI 10.1016/0168-1702(93)90006-9; TWU JS, 1989, P NATL ACAD SCI USA, V86, P5168, DOI 10.1073/pnas.86.13.5168; UNGER T, 1990, EMBO J, V9, P1889, DOI 10.1002/j.1460-2075.1990.tb08315.x; Wang HD, 1997, MOL CELL BIOL, V17, P6838, DOI 10.1128/MCB.17.12.6838; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	55	46	46	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27097	27103		10.1074/jbc.273.42.27097	http://dx.doi.org/10.1074/jbc.273.42.27097			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765226	hybrid			2022-12-27	WOS:000076448000013
J	Walkey, CJ; Yu, LQ; Agellon, LB; Vance, DE				Walkey, CJ; Yu, LQ; Agellon, LB; Vance, DE			Biochemical and evolutionary significance of phospholipid methylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE; CHOLINE-DEFICIENCY; RAT HEPATOCYTES; LIVER; CHOLESTEROL; PLASMA; BRAIN; MONOMETHYLETHANOLAMINE; DIMETHYLETHANOLAMINE; ETHANOLAMINE	All nucleated mammalian cells synthesize phosphatidylcholine from choline via the CDP-choline pathway. Hepatocytes have a second pathway for the synthesis of phosphatidylcholine, a stepwise methylation of phosphatidylethanolamine, catalyzed by phosphatidylethanolamine N-methyltransferase and encoded by the Pempt gene. We report that when Pempt deficient mice were fed a choline-deficient diet for 3 days, severe liver pathology occurred apparently due to a lack of phosphatidylcholine biosynthesis. The hepatic concentration of phosphatidylcholine decreased by 50% compared with wild type mice on the diet. The levels of plasma triacylglycerols and cholesterol were decreased by greater than 90% in the Pempt-deficient mice. We suggest that the Pempt gene has been maintained during evolution to provide phosphatidylcholine when dietary choline is insufficient, as might occur during starvation or pregnancy.	Univ Alberta, Lipid & Lipoprot Res Grp, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta	Vance, DE (corresponding author), Univ Alberta, Lipid & Lipoprot Res Grp, Edmonton, AB T6G 2S2, Canada.							Albright CD, 1996, FASEB J, V10, P510, DOI 10.1096/fasebj.10.4.8647350; ANDRIAMAMPANDRY C, 1992, BIOCHEM J, V288, P267, DOI 10.1042/bj2880267; ANDRIAMAMPANDRY C, 1989, BIOCHEM J, V264, P555, DOI 10.1042/bj2640555; ANDRIAMAMPANDRY C, 1991, J NEUROCHEM, V56, P1845, DOI 10.1111/j.1471-4159.1991.tb03439.x; BARTLETT GR, 1959, J BIOL CHEM, V234, P366; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BREMER J, 1960, BIOCHIM BIOPHYS ACTA, V43, P477, DOI 10.1016/0006-3002(60)90470-4; BREMER J, 1960, BIOCHIM BIOPHYS ACTA, V37, P173, DOI 10.1016/0006-3002(60)90104-9; Glickman Robert M., 1994, P391; HAINES DSM, 1966, CAN J BIOCHEM CELL B, V44, P45, DOI 10.1139/o66-006; Houweling M, 1997, BBA-LIPID LIPID MET, V1346, P1, DOI 10.1016/S0005-2760(97)00011-8; KENNEDY EP, 1989, PHOSPHATIDYLCHOLINE, P1; KIEFT KA, 1991, J LIPID RES, V32, P859; Kuipers F, 1997, Subcell Biochem, V28, P295; MARSHALL WJ, 1995, CLIN CHEM, P231; Savendahl L, 1997, AM J CLIN NUTR, V66, P622, DOI 10.1093/ajcn/66.3.622; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shin OH, 1997, J CELL BIOCHEM, V64, P196, DOI 10.1002/(SICI)1097-4644(199702)64:2<196::AID-JCB3>3.0.CO;2-S; SNYDER F, 1959, BIOCHIM BIOPHYS ACTA, V34, P244; Torchia EC, 1997, EUR J CELL BIOL, V74, P190; VANCE DE, 1988, PROG LIPID RES, V27, P61, DOI 10.1016/0163-7827(88)90005-7; Vance DE, 1997, BBA-LIPID LIPID MET, V1348, P142, DOI 10.1016/S0005-2760(97)00108-2; Walkey CJ, 1997, P NATL ACAD SCI USA, V94, P12880, DOI 10.1073/pnas.94.24.12880; YAO Z, 1990, BIOCHEM CELL BIOL, V68, P552, DOI 10.1139/o90-079; YAO ZM, 1988, J BIOL CHEM, V263, P2998; ZEISEL SH, 1994, ANNU REV NUTR, V14, P269, DOI 10.1146/annurev.nu.14.070194.001413; ZEISEL SH, 1995, J NUTR, V125, P3049; ZEISEL SH, 1990, J NUTR BIOCHEM, V1, P332, DOI 10.1016/0955-2863(90)90001-2	28	180	183	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27043	27046		10.1074/jbc.273.42.27043	http://dx.doi.org/10.1074/jbc.273.42.27043			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765216	hybrid			2022-12-27	WOS:000076448000003
J	Dietrich, J; Geisler, C				Dietrich, J; Geisler, C			T cell receptor zeta allows stable expression of receptors containing the CD3 gamma leucine-based receptor-sorting motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER-CELLS; ANTIGEN RECEPTOR; DOWN-REGULATION; ALPHA-CHAIN; COMPLEX; MICE; CONSEQUENCES; TRANSDUCTION; SYNTHESIZE; ACTIVATION	The leucine-based motif in the T cell receptor (TCR) subunit CD3 gamma constitutes a strong internalization signal. In fully assembled TCR this motif is inactive unless phosphorylated, In contrast, the motif is constitutively active in CD4/CD3 gamma and Tac/CD3 gamma chimeras independently of phosphorylation and leads to rapid internalization and sorting of these chimeras to lysosomal degradation. Because the TCR zeta chain rescues incomplete TCR complexes from lysosomal degradation and allows stable surface expression of fully assembled TCR, we addressed the question whether TCR zeta has the potential to mask the CD3 gamma leucine-based motif. By studying CD4/CD3 gamma and CD16/CD3 gamma chimeras, we found that CD16/CD3 gamma chimeras associated with TCR zeta. The CD16/CD3 gamma-TCR zeta complexes were stably expressed at the cell surface and had a low spontaneous internalization rate, indicating that the leucine-based motif in these complexes was inactive. In contrast, the CD4/CD3 gamma chimeras did not associate with TCR zeta, and the leucine-based motif in these chimeras was constitutively active resulting in a high spontaneous internalization rate and low expression of the chimeras at the cell surface. Thus, our data demonstrate that TCR zeta allows stable cell surface expression of receptors containing CD3 gamma leucine-based motifs by its potential to mask such motifs.	Univ Copenhagen, Panum Inst, Inst Med Microbiol & Immunol, DK-2200 Copenhagen, Denmark	University of Copenhagen	Geisler, C (corresponding author), Univ Copenhagen, Panum Inst, Inst Med Microbiol & Immunol, Bldg 18-3,Blegdamsvej 3C, DK-2200 Copenhagen, Denmark.	cgtcr@biobase.dk	Geisler, Carsten/A-7056-2012	Geisler, Carsten/0000-0002-8472-0771				ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; Backstrom BT, 1997, EUR J IMMUNOL, V27, P1433; Bremnes T, 1998, J BIOL CHEM, V273, P8638, DOI 10.1074/jbc.273.15.8638; Dietrich J, 1996, J CELL BIOL, V132, P299, DOI 10.1083/jcb.132.3.299; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; Dietrich J, 1996, J BIOL CHEM, V271, P11441, DOI 10.1074/jbc.271.19.11441; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; GEISLER C, 1992, J IMMUNOL, V148, P2437; GEISLER C, 1992, J IMMUNOL, V148, P3469; Hou XH, 1996, J BIOL CHEM, V271, P22815, DOI 10.1074/jbc.271.37.22815; KLAUSNER RD, 1990, CURR TOP MEMBR TRANS, V36, P31; KRISSANSEN GW, 1986, EMBO J, V5, P1799, DOI 10.1002/j.1460-2075.1986.tb04429.x; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LITTMAN DR, 1987, NATURE, V325, P453, DOI 10.1038/325453a0; LIU CP, 1993, EMBO J, V12, P4863, DOI 10.1002/j.1460-2075.1993.tb06176.x; LOVE PE, 1993, SCIENCE, V261, P918, DOI 10.1126/science.7688481; Luton F, 1997, J IMMUNOL, V158, P4162; MALISSEN M, 1993, EMBO J, V12, P4347, DOI 10.1002/j.1460-2075.1993.tb06119.x; MOINGEON P, 1992, P NATL ACAD SCI USA, V89, P1492, DOI 10.1073/pnas.89.4.1492; PARNES JR, 1989, ADV IMMUNOL, V44, P265, DOI 10.1016/S0065-2776(08)60644-6; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; SAITO T, 1987, J IMMUNOL, V139, P625; SAITO T, 1987, NATURE, V325, P125, DOI 10.1038/325125a0; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; TRANSY C, 1989, P NATL ACAD SCI USA, V86, P7108, DOI 10.1073/pnas.86.18.7108; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x	30	38	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26281	26284		10.1074/jbc.273.41.26281	http://dx.doi.org/10.1074/jbc.273.41.26281			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756853	hybrid			2022-12-27	WOS:000076373300007
J	Dessauer, CW; Tesmer, JJG; Sprang, SR; Gilman, AG				Dessauer, CW; Tesmer, JJG; Sprang, SR; Gilman, AG			Identification of a G(i alpha) binding site on type V adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP ACCUMULATION; PROTEIN ALPHA-SUBUNIT; BETA-GAMMA-SUBUNITS; CYTOSOLIC DOMAINS; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; DISCRETE REGIONS; ESCHERICHIA-COLI; AMINO-TERMINUS; RAT-BRAIN	The stimulatory G protein alpha subunit G(s alpha) binds within a cleft in adenylyl cyclase formed by the alpha 1-alpha 2 and alpha 3-beta 4 loops of the C-2 domain. The pseudosymmetry of the C-1 and C-2 domains of adenylyl cyclase suggests that the homologous inhibitory alpha subunit G(i alpha) could bind to the analogous cleft within C-1. We demonstrate that myristoylated guanosine 5'-3-O-(thio)triphosphate-G(i alpha 1) forms a stable complex with the C-1 (but not the C-2) domain of type V adenylyl cyclase. Mutagenesis of the membrane-bound enzyme identified residues whose alteration either increased or substantially decreased the IC50 for inhibition by G(i alpha 1). These mutations suggest binding of G(i alpha) within the cleft formed by the alpha 2 and alpha 3 helices of C-1, analogous to the G(s alpha) binding site in C-2. Adenylyl cyclase activity reconstituted by mixture of the C-1 and C-2 domains of type V adenylyl cyclase was also inhibited by G(i alpha). The C-1b domain of the type V enzyme contributed to affinity for G(i alpha), but the source of C-2 had little effect. Mutations in this soluble system faithfully reflected the phenotypes observed with the membrane-bound enzyme. The pseudosymmetrical structure of adenylyl cyclase permits bidirectional regulation of activity by homologous G protein alpha subunits.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gilman, AG (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA.		; Dessauer, Carmen/N-6933-2018	Tesmer, John/0000-0003-1125-3727; Dessauer, Carmen/0000-0003-1210-4280	NIDDK NIH HHS [DK46371] Funding Source: Medline; NIGMS NIH HHS [GM34497] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046371, R56DK046371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antoni F A, 1998, Adv Second Messenger Phosphoprotein Res, V32, P153; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; CHEN JQ, 1993, J BIOL CHEM, V268, P12253; Chen YB, 1997, P NATL ACAD SCI USA, V94, P14100, DOI 10.1073/pnas.94.25.14100; Dessauer CW, 1996, CLIN SCI, V91, P527, DOI 10.1042/cs0910527; Dessauer CW, 1997, J BIOL CHEM, V272, P22272, DOI 10.1074/jbc.272.35.22272; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; Dessauer CW, 1996, J BIOL CHEM, V271, P16967, DOI 10.1074/jbc.271.28.16967; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; Grishina G, 1997, J BIOL CHEM, V272, P20619, DOI 10.1074/jbc.272.33.20619; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KATADA T, 1982, J BIOL CHEM, V257, P3739; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; LEE E, 1994, METHOD ENZYMOL, V237, P146; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LINDER ME, 1990, J BIOL CHEM, V265, P8243; Magee Tony, 1992, Trends in Cell Biology, V2, P318, DOI 10.1016/0962-8924(92)90172-J; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; RANDAZZO PA, 1995, J BIOL CHEM, V270, P14809, DOI 10.1074/jbc.270.24.14809; Scholich K, 1997, P NATL ACAD SCI USA, V94, P2915, DOI 10.1073/pnas.94.7.2915; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; Summers MD, 1987, TEXAS AGR EXPT STATI; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Taussig Ronald, 1998, Advances in Second Messenger and Phosphoprotein Research, V32, P81; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; WATSON PA, 1994, J BIOL CHEM, V269, P28893; Wayman GA, 1996, MOL CELL BIOL, V16, P6075; Wei J, 1996, J BIOL CHEM, V271, P24231, DOI 10.1074/jbc.271.39.24231; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; WU ZL, 1993, J BIOL CHEM, V268, P23766; Xia ZG, 1997, CURR OPIN NEUROBIOL, V7, P391, DOI 10.1016/S0959-4388(97)80068-2; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941; Yan SZ, 1997, J BIOL CHEM, V272, P18849, DOI 10.1074/jbc.272.30.18849; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0; Zimmermann G, 1998, J BIOL CHEM, V273, P6968, DOI 10.1074/jbc.273.12.6968; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	49	118	121	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25831	25839		10.1074/jbc.273.40.25831	http://dx.doi.org/10.1074/jbc.273.40.25831			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748257	hybrid			2022-12-27	WOS:000076263100048
J	Dierks, T; Miech, C; Hummerjohann, J; Schmidt, B; Kertesz, MA; von Figura, K				Dierks, T; Miech, C; Hummerjohann, J; Schmidt, B; Kertesz, MA; von Figura, K			Posttranslational formation of formylglycine in prokaryotic sulfatases by modification of either cysteine or serine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA; ENDOPLASMIC-RETICULUM; PROTEIN MODIFICATION; ESCHERICHIA-COLI; ARYLSULFATASE; GENE; CONVERSION; CLONING; BINDING; ATSA	Eukaryotic sulfatases carry an alpha-formylglycine residue that is essential for activity and is located within the catalytic site. This formylglycine is generated by posttranslational modification of a conserved cysteine residue. The arylsulfatase gene of Pseudomonas aeruginosa also encodes a cysteine at the critical position. This protein could be expressed in active form in a sulfatase-deficient strain of P. aeruginosa, thereby restoring growth on aromatic sulfates as sole sulfur source, and in Escherichia coli, Analysis of the mature protein expressed in E. coli revealed the presence of formylglycine at the expected position, showing that the cysteine is also converted to formylglycine in a prokaryotic sulfatase. Substituting the relevant cysteine by a serine codon in the P. aeruginosa gene led to expression of inactive sulfatase protein, lacking the formylglycine. The machinery catalyzing the modification of the Pseudomonas sulfatase in E. coli therefore resembles the eukaryotic machinery, accepting cysteine but not serine as a modification substrate, By contrast, in the arylsulfatase of Klebsiella pneumoniae a formylglycine is found generated by modification of a serine residue. The expression of both the Klebsiella and the Pseudomonas sulfatases as active enzymes in E. coli suggests that two modification systems are present, or that a common modification system is modulated by a cofactor.	Univ Gottingen, Inst Biochem & Mol Zellbiol, Biochem Abt 2, D-37073 Gottingen, Germany; ETH Zentrum, Inst Microbiol, CH-8092 Zurich, Switzerland	University of Gottingen; Swiss Federal Institutes of Technology Domain; ETH Zurich	Dierks, T (corresponding author), Univ Gottingen, Inst Biochem & Mol Zellbiol, Biochem Abt 2, Gosslerstr 12D, D-37073 Gottingen, Germany.	dierks@ukb2-00.uni-bc.gwdg.de	Kertesz, Michael/A-6720-2011; Dierks, Thomas/A-3596-2012; KERTESZ, Michael/Q-7642-2019	Kertesz, Michael/0000-0003-2112-4451; Dierks, Thomas/0000-0001-6426-1339; KERTESZ, Michael/0000-0003-2112-4451				BEIL S, 1995, EUR J BIOCHEM, V229, P385, DOI 10.1111/j.1432-1033.1995.0385k.x; Bond CS, 1997, STRUCTURE, V5, P277, DOI 10.1016/S0969-2126(97)00185-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; DANIELS DL, 1992, SCIENCE, V257, P771, DOI 10.1126/science.1379743; Dierks T, 1998, FEBS LETT, V423, P61, DOI 10.1016/S0014-5793(98)00065-9; Dierks T, 1997, P NATL ACAD SCI USA, V94, P11963, DOI 10.1073/pnas.94.22.11963; Dierks T, 1996, EMBO J, V15, P6931, DOI 10.1002/j.1460-2075.1996.tb01085.x; Dodgson K.S., 1982, SULFATASES MICROBIAL; Eichhorn E, 1997, J BIOL CHEM, V272, P23031, DOI 10.1074/jbc.272.37.23031; FRANCO B, 1995, CELL, V81, P15, DOI 10.1016/0092-8674(95)90367-4; HOLLOWAY BW, 1955, J GEN MICROBIOL, V13, P572, DOI 10.1099/00221287-13-3-572; HORN JM, 1988, J BACTERIOL, V170, P1637, DOI 10.1128/jb.170.4.1637-1650.1988; Hummerjohann J, 1998, MICROBIOL-SGM, V144, P1375, DOI 10.1099/00221287-144-5-1375; Kolodny E.H., 1995, METABOLIC MOL BASES, V7th, P2693; KOVACH ME, 1994, BIOTECHNIQUES, V16, P800; Lukatela G, 1998, BIOCHEMISTRY-US, V37, P3654, DOI 10.1021/bi9714924; Miech C, 1998, J BIOL CHEM, V273, P4835, DOI 10.1074/jbc.273.9.4835; MUROOKA Y, 1990, J BACTERIOL, V172, P2131, DOI 10.1128/jb.172.4.2131-2140.1990; Parenti G, 1997, CURR OPIN GENET DEV, V7, P386, DOI 10.1016/S0959-437X(97)80153-0; Recksiek R, 1998, J BIOL CHEM, V273, P6096, DOI 10.1074/jbc.273.11.6096; SCHMIDT B, 1995, CELL, V82, P271, DOI 10.1016/0092-8674(95)90314-3; Selmer T, 1996, EUR J BIOCHEM, V238, P341, DOI 10.1111/j.1432-1033.1996.0341z.x; von Figura K, 1998, BIOESSAYS, V20, P505, DOI 10.1002/(SICI)1521-1878(199806)20:6<505::AID-BIES9>3.0.CO;2-K	24	93	101	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25560	25564		10.1074/jbc.273.40.25560	http://dx.doi.org/10.1074/jbc.273.40.25560			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748219	hybrid			2022-12-27	WOS:000076263100010
J	Gutknecht, R; Manni, M; Mao, QC; Erni, B				Gutknecht, R; Manni, M; Mao, QC; Erni, B			The glucose transporter of Escherichia coli with circularly permuted domains is active in vivo and in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL PHOSPHOTRANSFERASE SYSTEM; DEHYDROGENASE MULTIENZYME COMPLEX; FUNCTIONAL RECONSTITUTION; N-ACETYLGLUCOSAMINE; PROTEIN; PHOSPHOENOLPYRUVATE; PURIFICATION; GENE; PHOSPHORYLATION; CONSTRUCTION	The bacterial phosphotranaferase system (PTS) consists of two energy-coupling soluble proteins (enzyme I and HPr) and a large number of inner membrane transporters (enzymes II) that mediate concomitant phosphorylation and translocation of sugars and hexitols, The transporters consist of three functional units (IIA, IIB, IIC), which occur either as protein subunits or domains of a multidomain polypeptide, The membrane-spanning HC domain contains the substrate binding site; IIA and IIB are phosphorylation domains that transfer phosphate from HPr to the transported sugar. The transporter complexes of the PTS are good examples for variation of design by modular assembly of domains and subunits. The domain order is IIC-IIB in the membrane subunit of the Escherichia coli glucose transporter (IICBGlc) and IIB-IIC in Salmonella typhimurium sucrose transporter (IIBCSer). The phosphorylation domain of IICBGlc was translocated from the carboxyl-terminal to the amino-terminal end of the IIC domain, and the activity of the circularly permuted form was optimized by variation of the length and the composition of the interdomain linker. IIBapC(Glc) with an alanine-proline-rich interdomain linker has 70% of the control specific activity after purification and reconstitution into proteoliposomes. These results indicate that the aminoterminal end of IICBGlc must be on the cytoplasmic side of the inner membrane, that membrane insertion of the IIC domain is insensitive to the modification of its amino-terminal end, and that a domain swap as it could occur by a single DNA translocation event can rapidly lead to a functional protein, However, IIB could not be substituted for by glucokinase. Fusion proteins between the IIC domain and glucokinase do not transport and phosphorylate glucose in an ATP dependent mechanism, although the IIC moiety displays transport activity upon complementation with soluble subclonal IIB, and the glucokinase moiety retains ATP-dependent non-vectorial kinase activity. This indicates that IIC and IIB are two cooperative units and not only sequentially acting upon a common substrate, and that translocation of glucose must be conformationally coupled to the phosphorylation/dephosphorylation cycle of IIB.	Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland	University of Bern	Erni, B (corresponding author), Univ Bern, Dept Chem & Biochem, Freiestr 3, CH-3012 Bern, Switzerland.	erni@ibc.unibe.ch						BUHR A, 1993, J BIOL CHEM, V268, P11599; BUHR A, 1994, J BIOL CHEM, V269, P23437; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Eberstadt M, 1996, BIOCHEMISTRY-US, V35, P11286, DOI 10.1021/bi960492l; EBNER R, 1988, MOL MICROBIOL, V2, P9, DOI 10.1111/j.1365-2958.1988.tb00002.x; ERNI B, 1992, INT REV CYTOL, V137A, P127; ERNI B, 1989, FEMS MICROBIOL LETT, V63, P13, DOI 10.1016/0168-6445(89)90004-1; ERNI B, 1982, J BIOL CHEM, V257, P13726; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; Gemmecker G, 1997, BIOCHEMISTRY-US, V36, P7408, DOI 10.1021/bi963053v; GREEN JDF, 1992, J BIOL CHEM, V267, P23484; Henikoff S, 1997, SCIENCE, V278, P609, DOI 10.1126/science.278.5338.609; HUMMEL U, 1992, PROTEIN SCI, V1, P356; KUNDIG W, 1971, J BIOL CHEM, V246, P1393; Lanz R, 1998, J BIOL CHEM, V273, P12239, DOI 10.1074/jbc.273.20.12239; LENGELER JW, 1994, BBA-BIOENERGETICS, V1188, P1, DOI 10.1016/0005-2728(94)90017-5; MAO QC, 1995, J BIOL CHEM, V270, P5258, DOI 10.1074/jbc.270.10.5258; MAO QC, 1995, J BIOL CHEM, V270, P18295, DOI 10.1074/jbc.270.31.18295; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MEINS M, 1993, J BIOL CHEM, V268, P11604; Meyer D, 1997, J BACTERIOL, V179, P1298, DOI 10.1128/jb.179.4.1298-1306.1997; Mukhija S, 1996, J BIOL CHEM, V271, P14819, DOI 10.1074/jbc.271.25.14819; NUOFFER C, 1988, J BIOL CHEM, V263, P6647; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; Postma P.W., 1996, ESCHERICHIA COLI SAL, P1149; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; Ramirez BE, 1995, P NATL ACAD SCI USA, V92, P11949, DOI 10.1073/pnas.92.26.11949; REIZER A, 1991, J MOL EVOL, V33, P179, DOI 10.1007/BF02193633; REIZER J, 1994, PROTEIN SCI, V3, P440; Reizer J, 1996, RES MICROBIOL, V147, P458, DOI 10.1016/0923-2508(96)84000-9; REIZER J, 1996, MICROB COMP GENOMICS, V1, P53; ROBIEN MA, 1992, BIOCHEMISTRY-US, V31, P3463, DOI 10.1021/bi00128a021; Saier M H Jr, 1996, Microb Comp Genomics, V1, P129; SAIER MH, 1992, J BACTERIOL, V174, P1433, DOI 10.1128/jb.174.5.1433-1438.1992; SAIER MH, 1994, MOL MICROBIOL, V13, P755; WU LF, 1990, J MOL BIOL, V213, P687, DOI 10.1016/S0022-2836(05)80256-6	39	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25745	25750		10.1074/jbc.273.40.25745	http://dx.doi.org/10.1074/jbc.273.40.25745			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748244	hybrid			2022-12-27	WOS:000076263100035
J	Koudssi, F; Lopez, JE; Villegas, S; Long, CS				Koudssi, F; Lopez, JE; Villegas, S; Long, CS			Cardiac fibroblasts arrest at the G1/S restriction point in response to interleukin (IL)-1 beta - Evidence for IL-1 beta-induced hypophosphorylation of the retinoblastoma protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; COLLAGEN GENE-EXPRESSION; GROWTH-FACTOR-BETA; CELL-CYCLE ARREST; DEPENDENT KINASE INHIBITOR; MESSENGER-RNA EXPRESSION; SMOOTH-MUSCLE CELLS; NITRIC-OXIDE; ANGIOTENSIN-II; IN-VITRO	Although responsible for only approximately one-third of the overall myocardial mass, the interstitial fibroblasts of the heart serve a fundamental role in establishing the functional integrity of myocardium and are the major source of myocardial extracellular matrix production. Their importance in clinical medicine is underscored by the observation that fibroblast numbers increase in response to several pathologic circumstances that are associated with an increase in extracellular matrix production such as long standing hypertension and myocardial injury/infarction. Up to the present time, however, there has been little information available on either the kinetics of the cardiac fibroblast cell cycle, or the fundamental mechanisms that regulate its entry into and exit from the cell cycle. Previous work from our laboratory examining the effects of interleukin (IL)-1 beta on myocardial growth and gene expression in culture indicated that cardiac fibroblasts have a diminished capacity to synthesize DNA in response to mitogen in the presence of this cytokine. The mechanism of IL-1 beta action was not clear, however, and could have resulted from action at several different points in the cell cycle, The investigations described in this report indicate that IL-1 beta exerts its effect on the fibroblast cell cycle at multiple levels through altering the expression of cardiac fibroblast cyclins, cyclin-dependent kinases, and their inhibitors, which ultimately affect the phosphorylation of the retinoblastoma gene product.	Vet Affairs Med Ctr, Div Cardiol, San Francisco, CA 94121 USA; Vet Affairs Med Ctr, Res Serv, San Francisco, CA 94121 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco	Long, CS (corresponding author), Denver Hlth Med Ctr, Cardiol Sect, Box 0960,777 Bannock St, Denver, CO 80204 USA.	clong@dhha.org		Long, Carlin/0000-0001-7251-2847	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059428, R01HL058974] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59428, HL58974] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; BALLIGAND JL, 1994, J BIOL CHEM, V269, P27580; Ballou LR, 1996, BBA-LIPID LIPID MET, V1301, P273, DOI 10.1016/0005-2760(96)00004-5; BHAMBI B, 1991, AM J PATHOL, V139, P1131; Bick RJ, 1997, AM J PHYSIOL-HEART C, V272, pH1937, DOI 10.1152/ajpheart.1997.272.4.H1937; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRILLA CG, 1993, EUR HEART J, V14, P57; BUTT RP, 1995, ANN NY ACAD SCI, V752, P387, DOI 10.1111/j.1749-6632.1995.tb17446.x; CAMPBELL SE, 1995, J MOL CELL CARDIOL, V27, P1545, DOI 10.1016/S0022-2828(95)90359-3; CAO L, 1995, HYPERTENSION, V25, P227, DOI 10.1161/01.HYP.25.2.227; CARROLL EP, 1989, CARDIOVASC RES, V23, P655, DOI 10.1093/cvr/23.8.655; CASTRO A, 1994, BIOCHEM BIOPH RES CO, V201, P1072, DOI 10.1006/bbrc.1994.1814; Chandrasekar B, 1996, BIOCHEM BIOPH RES CO, V223, P365, DOI 10.1006/bbrc.1996.0900; CHAPMAN D, 1990, CIRC RES, V67, P787, DOI 10.1161/01.RES.67.4.787; CLEUTJENS JPM, 1995, J MOL CELL CARDIOL, V27, P1281, DOI 10.1016/S0022-2828(05)82390-9; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; CONTARD F, 1991, LAB INVEST, V64, P65; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DINARELLO CA, 1994, EUR CYTOKINE NETW, V5, P517; DONOHUE TJ, 1994, CIRCULATION, V89, P799, DOI 10.1161/01.CIR.89.2.799; Dostal DE, 1996, MOL CELL BIOCHEM, V157, P15; EGHBALI M, 1992, BASIC RES CARDIOL, V87, P183; EGHBALI M, 1991, CIRC RES, V69, P483, DOI 10.1161/01.RES.69.2.483; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; FAN GS, 1995, CELL GROWTH DIFFER, V6, P1463; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FLANDERS KC, 1993, J CLIN INVEST, V92, P404, DOI 10.1172/JCI116581; Frimm CD, 1996, J MOL CELL CARDIOL, V28, P1279; Galea J, 1996, ARTERIOSCL THROM VAS, V16, P1000, DOI 10.1161/01.ATV.16.8.1000; GRANA X, 1995, ONCOGENE, V11, P211; GUARDA E, 1993, CARDIOVASC RES, V27, P2130, DOI 10.1093/cvr/27.12.2130; HARDING P, 1995, HYPERTENSION, V25, P421, DOI 10.1161/01.HYP.25.3.421; HERSKOWITZ A, 1995, AM J PATHOL, V146, P419; HOSENPUD JD, 1989, J HEART TRANSPLANT, V8, P460; HSUEH WA, 1995, ADV EXP MED BIOL, V377, P217; ISGAARD J, 1994, HYPERTENSION, V23, P884, DOI 10.1161/01.HYP.23.6.884; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; Kacimi R, 1997, CIRCULATION, V96, P1937, DOI 10.1161/01.CIR.96.6.1937; KATSUURA G, 1989, ENDOCRINOLOGY, V124, P3125, DOI 10.1210/endo-124-6-3125; KATWA LC, 1993, CARDIOVASC RES, V27, P2125, DOI 10.1093/cvr/27.12.2125; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KO TC, 1995, ONCOGENE, V10, P177; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Kumar A, 1996, J EXP MED, V183, P949, DOI 10.1084/jem.183.3.949; LADOUX A, 1993, BIOCHEM BIOPH RES CO, V195, P1005, DOI 10.1006/bbrc.1993.2144; Lagoo AS, 1996, J HEART LUNG TRANSPL, V15, P206; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAULEDERKIND SJF, 1995, J EXP MED, V182, P599, DOI 10.1084/jem.182.2.599; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEVY AP, 1995, CIRC RES, V76, P758, DOI 10.1161/01.RES.76.5.758; LIBBY P, 1988, J CLIN INVEST, V81, P487, DOI 10.1172/JCI113346; LONG CS, 1991, CELL REGUL, V2, P1081, DOI 10.1091/mbc.2.12.1081; LONG CS, 1993, CLIN RES, V41, pA145; Long CS, 1996, TRENDS CARDIOVAS MED, V6, P217, DOI 10.1016/S1050-1738(96)00090-4; MARCZIN N, 1993, AM J PHYSIOL, V265, pH1014, DOI 10.1152/ajpheart.1993.265.3.H1014; Masamune A, 1996, J BIOL CHEM, V271, P9368, DOI 10.1074/jbc.271.16.9368; MASSAGUE J, 1995, CURR OPIN GENET DEV, V5, P91, DOI 10.1016/S0959-437X(95)90059-4; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; Morgan DO, 1992, CURR OPIN GENET DEV, V2, P33, DOI 10.1016/S0959-437X(05)80318-1; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; ONeill LAJ, 1995, INT J CLIN LAB RES, V25, P169, DOI 10.1007/BF02592694; PALMER JN, 1995, J CLIN INVEST, V95, P2555, DOI 10.1172/JCI117956; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; Patten M, 1996, J BIOL CHEM, V271, P21134, DOI 10.1074/jbc.271.35.21134; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QIN XQ, 1995, MOL CELL BIOL, V15, P742; ROBERTS AB, 1992, MOL ENDOCRINOL, V6, P1921, DOI 10.1210/me.6.11.1921; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SAKLATVALA J, 1995, BRIT MED BULL, V51, P402, DOI 10.1093/oxfordjournals.bmb.a072969; Saklatvala J, 1996, PHILOS T ROY SOC B, V351, P151, DOI 10.1098/rstb.1996.0011; SAMIEI M, 1991, J BIOL CHEM, V266, P14889; SARZANI R, 1991, HYPERTENSION, V17, P888, DOI 10.1161/01.HYP.17.6.888; Schreur KD, 1997, AM J PHYSIOL-HEART C, V272, pH2591, DOI 10.1152/ajpheart.1997.272.6.H2591; SEN S, 1990, J BIOL CHEM, V265, P16635; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shioi T, 1997, CIRC RES, V81, P664; SHIOI T, 1996, CIRCULATION, V94, P658; TAKAHASHI N, 1994, J CLIN INVEST, V94, P1470, DOI 10.1172/JCI117485; THAIK CM, 1995, J CLIN INVEST, V96, P1093, DOI 10.1172/JCI118095; Thompson NL, 1988, GROWTH FACTORS, V1, P91, DOI 10.3109/08977198809000251; TSUJINO M, 1994, CIRCULATION, V90, P375, DOI 10.1161/01.CIR.90.1.375; VILLARREAL FJ, 1992, AM J PHYSIOL, V262, pH1861, DOI 10.1152/ajpheart.1992.262.6.H1861; WAHLANDER H, 1992, HYPERTENSION, V19, P25, DOI 10.1161/01.HYP.19.1.25; WEBER KT, 1995, EUR HEART J, V16, P24, DOI 10.1093/eurheartj/16.suppl_C.24; Weber KT, 1995, EUR HEART J, V16, P12, DOI 10.1093/eurheartj/16.suppl_N.12; WEBER KT, 1989, J AM COLL CARDIOL, V13, P1637, DOI 10.1016/0735-1097(89)90360-4; Weber KT, 1996, CLIN CARDIOL, V19, P447, DOI 10.1002/clc.4960190602; YAO JL, 1992, CIRC RES, V71, P831, DOI 10.1161/01.RES.71.4.831; Yue P, 1998, AM J PHYSIOL-HEART C, V275, pH250, DOI 10.1152/ajpheart.1998.275.1.H250	99	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25796	25803		10.1074/jbc.273.40.25796	http://dx.doi.org/10.1074/jbc.273.40.25796			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748252	hybrid			2022-12-27	WOS:000076263100043
J	McKenzie, D; Bartz, J; Mirwald, J; Olander, D; Marsh, R; Aiken, J				McKenzie, D; Bartz, J; Mirwald, J; Olander, D; Marsh, R; Aiken, J			Reversibility of scrapie inactivation is enhanced by copper	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASE-RESISTANT STATE; AVIAN PRION PROTEIN; ALZHEIMERS-DISEASE; IN-VIVO; INFECTIVITY; CONVERSION; AGENT; PEPTIDES; EXPOSURE; REGIONS	The only known difference between the cellular (PrPC) and scrapie-specific (PrPSc) isoforms of the prion protein is conformational. Because disruption of PrPSc structure decreases scrapie infectivity, restoration of the disease-specific conformation should restore infectivity. In this study, disruption of PrPSc (as monitored by the loss of proteinase K resistance) by guanidine hydrochloride (GdnHCl) resulted in decreased infectivity. Upon dilution of the GdnHCl, protease resistance of PrP was restored and infectivity was regained. The addition of copper facilitated restoration of both infectivity and protease resistance of PrP in a subset of samples that did not renature by the simple dilution of the GdnHCl, These data demonstrate that loss of scrapie infectivity can be a reversible process and that copper can enhance this restoration of proteinase K resistance and infectivity.	Univ Wisconsin, Dept Anim Hlth & Biomed Sci, Madison, WI 53517 USA	University of Wisconsin System; University of Wisconsin Madison	McKenzie, D (corresponding author), Univ Wisconsin, Dept Anim Hlth & Biomed Sci, 1655 Linden Dr, Madison, WI 53517 USA.		McKenzie, Debbie/G-4459-2015	McKenzie, Debbie/0000-0002-9291-6977; Bartz, Jason/0000-0003-4081-7886; Aiken, Judd/0000-0001-6119-4521				ANDRASI E, 1995, ARCH GERONTOL GERIAT, V21, P89, DOI 10.1016/0167-4943(95)00643-Y; BOLTON DC, 1987, ARCH BIOCHEM BIOPHYS, V258, P579, DOI 10.1016/0003-9861(87)90380-8; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; Caughey B, 1995, CHEM BIOL, V2, P807, DOI 10.1016/1074-5521(95)90087-X; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; DICKINSO.AG, 1969, NATURE, V222, P892, DOI 10.1038/222892a0; DIRINGER H, 1983, NATURE, V306, P476, DOI 10.1038/306476a0; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940; GERLACH M, 1994, J NEUROCHEM, V63, P793, DOI 10.1046/j.1471-4159.1994.63030793.x; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V207, P621, DOI 10.1006/bbrc.1995.1233; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V214, P993, DOI 10.1006/bbrc.1995.2384; KIMBERLIN RH, 1977, J GEN VIROL, V34, P295, DOI 10.1099/0022-1317-34-2-295; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; MARSH RF, 1978, FED PROC, V37, P2076; MCKENZIE D, 1994, J VIROL, V68, P7534, DOI 10.1128/JVI.68.11.7534-7536.1994; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; Miura T, 1996, FEBS LETT, V396, P248, DOI 10.1016/0014-5793(96)01104-0; Multhaup G, 1996, SCIENCE, V271, P1406, DOI 10.1126/science.271.5254.1406; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P2793, DOI 10.1073/pnas.90.7.2793; SAFAR J, 1993, J BIOL CHEM, V268, P20276; SAS INSTITUTE INC., 1989, SAS STAT US GUID VER, V2; SAS&REG; Procedures, 1990, VERSION 6; SHIN RW, 1994, J NEUROSCI, V14, P7221; Taylor DM, 1996, J GEN VIROL, V77, P811, DOI 10.1099/0022-1317-77-4-811; Tobler I, 1996, NATURE, V380, P639, DOI 10.1038/380639a0	31	117	120	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25545	25547		10.1074/jbc.273.40.25545	http://dx.doi.org/10.1074/jbc.273.40.25545			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748215	hybrid			2022-12-27	WOS:000076263100006
J	Zhang, BL; Zheng, Y				Zhang, BL; Zheng, Y			Negative regulation of rho family GTPases Cdc42 and Rac2 by homodimer formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTORS; TRANSITION-STATE ANALOG; ACTIVATING PROTEINS; BINDING PROTEINS; MAST-CELLS; DROSOPHILA; COMPLEX; ORGANIZATION; ENDOCYTOSIS; OUTGROWTH	The Rho family GTPases are tightly regulated between the active GTP-bound state and the inactive GDP-bound state in a variety of signal transduction processes. Here the Rho family members Cdc42, Rac2, and RhoA were found to form reversible homodimers in both the GTP- and the GDP-bound states. The homophilic interaction of Cdc42 and Rac2, but not RhoA, in the GTP-bound state, caused a significant stimulation of the intrinsic GTPase activity, i.e. the activated form of Cdc42 and Rac2 acts as GTPase-activating proteins toward Cdc42-GTP or Rac2-GTP. The dimerization of the GTPases appeared to be mediated by the carboxyl-terminal polybasic domain, and the specific GTPase-activating effects of Cdc42 and Rac2 were also attributed to the structural determinant(s) in the same region of the molecules. Moreover, similar to the case of Cdc42 and Cdc42GAP interaction, Cdc42-GDP interacted with tetrafluoroaluminate and Cdc42-GTP gamma S (guanosine 5'-3-O-(thio)triphosphate) to form a transition state complex of the GTPase-activating reaction in which the carboxylterminal determinant(s) of the GTP gamma S-bound Cdc42 plays a critical role. These results provide a rationale for the fast rate of intrinsic GTP hydrolysis by Cdc42 and Rac and suggest that dimerization may play a role in the negative regulation of specific Rho family GTPases mediated by the carboxyl-terminal polybasic domain.	Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Zheng, Y (corresponding author), Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA.	yzheng@utmem1.utmem.edu	Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053943] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53943] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmadian MR, 1997, FEBS LETT, V408, P315, DOI 10.1016/S0014-5793(97)00422-5; Bourne HR, 1997, NATURE, V389, P673, DOI 10.1038/39470; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Davis CR, 1998, J BIOL CHEM, V273, P849, DOI 10.1074/jbc.273.2.849; Eaton S, 1996, J CELL BIOL, V135, P1277, DOI 10.1083/jcb.135.5.1277; Feltham JL, 1997, BIOCHEMISTRY-US, V36, P8755, DOI 10.1021/bi970694x; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Hoffman GR, 1998, J BIOL CHEM, V273, P4392, DOI 10.1074/jbc.273.8.4392; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; Li R, 1997, J BIOL CHEM, V272, P32830, DOI 10.1074/jbc.272.52.32830; Li R, 1997, J BIOL CHEM, V272, P4671, DOI 10.1074/jbc.272.8.4671; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; Murphy AM, 1996, J CELL BIOL, V133, P617, DOI 10.1083/jcb.133.3.617; Noel JP, 1997, NAT STRUCT BIOL, V4, P677, DOI 10.1038/nsb0997-677; Norman JC, 1996, MOL BIOL CELL, V7, P1429, DOI 10.1091/mbc.7.9.1429; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; OSullivan AJ, 1996, MOL BIOL CELL, V7, P397, DOI 10.1091/mbc.7.3.397; PASTERIS NG, 1994, CELL, V79, P669; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; SCHMALZING G, 1995, J CELL BIOL, V130, P1319, DOI 10.1083/jcb.130.6.1319; Sprang SR, 1997, SCIENCE, V277, P329, DOI 10.1126/science.277.5324.329; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; Wei YY, 1997, NAT STRUCT BIOL, V4, P699, DOI 10.1038/nsb0997-699; Zhang BL, 1997, J BIOL CHEM, V272, P21999, DOI 10.1074/jbc.272.35.21999; Zhang BL, 1998, BIOCHEMISTRY-US, V37, P5249, DOI 10.1021/bi9718447; Zhang BL, 1998, J BIOL CHEM, V273, P8776, DOI 10.1074/jbc.273.15.8776; Zheng Y, 1996, J BIOL CHEM, V271, P33169, DOI 10.1074/jbc.271.52.33169; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; Zheng Y, 1996, J BIOL CHEM, V271, P23815, DOI 10.1074/jbc.271.39.23815	42	58	57	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25728	25733		10.1074/jbc.273.40.25728	http://dx.doi.org/10.1074/jbc.273.40.25728			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748241	hybrid			2022-12-27	WOS:000076263100032
J	Shimokata, K; Kitada, S; Ogishima, T; Ito, A				Shimokata, K; Kitada, S; Ogishima, T; Ito, A			Role of alpha-subunit of mitochondrial processing peptidase in substrate recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-ORNITHINE TRANSCARBAMYLASE; RAT-LIVER; MALATE-DEHYDROGENASE; YEAST MITOCHONDRIA; BETA-SUBUNIT; PROTEOLYTIC CLEAVAGE; PRECURSOR PROTEINS; ARGININE RESIDUES; EXTENSION PEPTIDE; SYNTHETIC PEPTIDE	Mitochondrial processing peptidase is a heterodimer consisting of alpha-mitochondrial processing peptidase (alpha-MPP) and beta-MPP. We investigated the role of alpha-MPP in substrate recognition using a recombinant yeast MPP. Disruption of amino acid residues between 10 and 129 of the alpha-MPP did not essentially impair binding activity with beta-MPP and processing activity, whereas truncation of the C-terminal 41 amino acids led to a significant loss of binding and processing activity. Several acidic amino acids in the region conserved among the enzymes hom various species were mutated to asparagine or glutamine, and effects on processing of the precursors were analyzed. Glu(353) is required for processing of malate dehydrogenase, aspartate aminotransferase, and adrenodoxin precursors. Glu(377) and Asp(378) are needed only for the processing of aspartate aminotransferase and adrenodoxin precursors, both of which have a longer extension peptide than the others studied. However, processing of the yeast alpha-MPP precursor, which has a short extension peptide of nine amino acids, was not affected by these mutations. Thus, effects of substitution of acidic amino acids on the processing differed with the precursor protein and depended on length of the extension peptides. alpha-MPP may function as a substrate-recognizing subunit by interacting mainly with basic amino acids at a region distal to the cleavage site in precursors with a longer extension peptide.	Kyushu Univ, Fac Sci, Dept Chem, Higashi Ku, Fukuoka 8128581, Japan	Kyushu University	Ito, A (corresponding author), Kyushu Univ, Fac Sci, Dept Chem, Higashi Ku, Fukuoka 8128581, Japan.	a.itoscc@mbox.nc.kyushu-u.ac.jp						ARRETZ M, 1994, J BIOL CHEM, V269, P4959; ARRETZ M, 1991, BIOMED BIOCHIM ACTA, V50, P4; BRAUN HP, 1995, TRENDS BIOCHEM SCI, V20, P171, DOI 10.1016/S0968-0004(00)88999-9; BRAUN HP, 1992, EMBO J, V11, P3219, DOI 10.1002/j.1460-2075.1992.tb05399.x; CHU TW, 1987, J BIOL CHEM, V262, P12806; CONBOY JG, 1982, BIOCHEM BIOPH RES CO, V105, P1, DOI 10.1016/S0006-291X(82)80002-8; EMMERMANN M, 1993, J BIOL CHEM, V268, P18936; ERIKSSON AC, 1992, BIOCHIM BIOPHYS ACTA, V1140, P208, DOI 10.1016/0005-2728(92)90010-Y; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P7; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HORWICH AL, 1985, P NATL ACAD SCI USA, V82, P4930, DOI 10.1073/pnas.82.15.4930; JENSEN RE, 1988, EMBO J, V7, P3863, DOI 10.1002/j.1460-2075.1988.tb03272.x; JOH T, 1987, BIOCHEMISTRY-US, V26, P2515, DOI 10.1021/bi00383a017; KITADA S, 1995, J BIOCHEM-TOKYO, V117, P1148, DOI 10.1093/oxfordjournals.jbchem.a124836; KITADA S, 1993, BIOCHEM BIOPH RES CO, V190, P289, DOI 10.1006/bbrc.1993.1044; KLEIBER J, 1990, P NATL ACAD SCI USA, V87, P7978, DOI 10.1073/pnas.87.20.7978; KUMAMOTO T, 1989, J BIOCHEM-TOKYO, V105, P72, DOI 10.1093/oxfordjournals.jbchem.a122622; Luciano P, 1997, J MOL BIOL, V272, P213, DOI 10.1006/jmbi.1997.1231; MCADA PC, 1982, J BIOL CHEM, V257, P3177; MORI M, 1980, P NATL ACAD SCI-BIOL, V77, P7044, DOI 10.1073/pnas.77.12.7044; NIIDOME T, 1994, J BIOL CHEM, V269, P24719; Ogishima T, 1995, J BIOL CHEM, V270, P30322, DOI 10.1074/jbc.270.51.30322; OU WJ, 1994, J BIOL CHEM, V269, P24673; OU WJ, 1989, EMBO J, V8, P2605, DOI 10.1002/j.1460-2075.1989.tb08400.x; PACES V, 1993, P NATL ACAD SCI USA, V90, P5355, DOI 10.1073/pnas.90.11.5355; PALMISANO A, 1995, INT J BIOCHEM CELL B, V27, P507, DOI 10.1016/1357-2725(95)00013-F; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; POLLOCK RA, 1988, EMBO J, V7, P3493, DOI 10.1002/j.1460-2075.1988.tb03225.x; RAWLINGS ND, 1991, BIOCHEM J, V275, P389, DOI 10.1042/bj2750389; SAAVEDRAALANIS VM, 1994, J BIOL CHEM, V269, P9284; SCHNEIDER H, 1990, J BIOL CHEM, V265, P9881; SCHULTE U, 1989, NATURE, V339, P147, DOI 10.1038/339147a0; Shimokata K, 1997, J BIOCHEM-TOKYO, V122, P1019; Song MC, 1996, J BIOCHEM-TOKYO, V120, P1163; Striebel HM, 1996, ARCH BIOCHEM BIOPHYS, V335, P211, DOI 10.1006/abbi.1996.0500; WITTE C, 1988, EMBO J, V7, P1439, DOI 10.1002/j.1460-2075.1988.tb02961.x; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x; YANG M, 1991, J BIOL CHEM, V266, P6416	40	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25158	25163		10.1074/jbc.273.39.25158	http://dx.doi.org/10.1074/jbc.273.39.25158			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737975	hybrid			2022-12-27	WOS:000076085400025
J	Yang, J; Liang, XS; Niu, TQ; Meng, WY; Zhao, ZZ; Zhou, GW				Yang, J; Liang, XS; Niu, TQ; Meng, WY; Zhao, ZZ; Zhou, GW			Crystal structure of the catalytic domain of protein-tyrosine phosphatase SHP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; MOTH-EATEN MICE; SIGNAL-TRANSDUCTION; SH2 DOMAINS; PURIFICATION; RECRUITMENT; ACTIVATION; MUTATIONS; SH-PTP2; SHPTP2	The crystal structures of the protein-tyrosine phosphatase SHP-1 catalytic domain and the complex it forms with the substrate analogue tungstate have been determined and refined to crystallographic R values of 0.209 at 2.5 Angstrom resolution and 0.207 at 2.8 Angstrom resolution, respectively. Despite low sequence similarity, the catalytic domain of SKP-1 shows high similarity in secondary and tertiary structures with other protein-tyrosine phosphatases (PTPs). In contrast-to the conformational changes observed in the crystal structures of PTP1B and Yersinia PTP, the WPD loop (Trp(419)-Pro(428)) in the catalytic domain of SHP-1 moves away from the substrate binding pocket after binding the tungstate ion. Sequence alignment and structural analysis suggest that the residues in the WPD loop, especially the amino acid following Asp(421), are critical for the movement of WPD loop on binding substrates and the specific activity of protein-tyrosine phosphatases. Our mutagenesis and kinetic measurements have supported this hypothesis.	Univ Massachusetts, Med Ctr, Program Mol Med, Worcester, MA 01605 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA	University of Massachusetts System; University of Massachusetts Worcester; Vanderbilt University	Zhou, GW (corresponding author), Univ Massachusetts, Med Ctr, Program Mol Med, Worcester, MA 01605 USA.	zhou@ummed.edu						BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BIGNON JS, 1994, CLIN IMMUNOL IMMUNOP, V73, P168, DOI 10.1006/clin.1994.1185; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, XPLOR MANUAL VERSION; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; HARDER KW, 1994, BIOCHEM J, V298, P395, DOI 10.1042/bj2980395; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Hoffmann KMV, 1997, J BIOL CHEM, V272, P27505, DOI 10.1074/jbc.272.44.27505; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liang XS, 1997, J STRUCT BIOL, V120, P201, DOI 10.1006/jsbi.1997.3927; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; O'Reilly AM, 1998, MOL CELL BIOL, V18, P161, DOI 10.1128/MCB.18.1.161; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; Roussel A, 1990, ACTA CRYSTALLOGR A, V46, pC66; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; SU XD, 1994, NATURE, V370, P575, DOI 10.1038/370575a0; Tenev T, 1997, J BIOL CHEM, V272, P5966, DOI 10.1074/jbc.272.9.5966; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; ZHANG ZY, 1992, J BIOL CHEM, V267, P23759; ZHANG ZY, 1993, BIOCHEMISTRY-US, V32, P9340, DOI 10.1021/bi00087a012; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040; ZHANG ZY, 1995, J BIOL CHEM, V270, P11199, DOI 10.1074/jbc.270.19.11199; ZHAO ZZ, 1993, J BIOL CHEM, V268, P2816	38	102	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28199	28207		10.1074/jbc.273.43.28199	http://dx.doi.org/10.1074/jbc.273.43.28199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774441	hybrid			2022-12-27	WOS:000076549800061
J	Renne, C; Kallen, KJ; Mullberg, J; Jostock, T; Grotzinger, J; Rose-John, S				Renne, C; Kallen, KJ; Mullberg, J; Jostock, T; Grotzinger, J; Rose-John, S			A new type of cytokine receptor antagonist directly targeting gp130	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; ANTI-INTERLEUKIN-6 MONOCLONAL-ANTIBODY; HUMAN MYELOMA CELLS; HUMAN INTERLEUKIN-6; ONCOSTATIN-M; HUMAN IL-6; SOLUBLE RECEPTORS; TRANSGENIC MICE; GROWTH-FACTORS; ACTIVATION	The interleukin-6-type family of cytokines bind to receptor complexes that share gp130 as a common signal-transducing subunit. So far, receptor antagonists for interleukin-6-type cytokines have been constructed that still bind to the specific ligand binding subunit of the receptor complex, but have lost the ability to stimulate gp130. Such receptor antagonists compete for a specific receptor of a member of the cytokine family. Interleukin 6 only binds to gp130 when complexed with the interleukin-6 receptor that exists as a membrane bound and soluble molecule. Here we have constructed fusion proteins that consist of the soluble form of the human interleukin-6 receptor covalently linked to interleukin-6 receptor antagonists. These fusion proteins directly bind to gp130, Moreover, at concentrations of 10-50 nM they completely neutralize not only the biological activity of interleukin-6 but also of other cytokines of the interleukin-6-type family that act via gp130 homodimers or gp130/LIF-R heterodimers. Therefore, these gp130 targeting cytokine antagonists might be useful therapeutic tools in disease states that are related to cytokines of the interleukin-g family.	Univ Mainz, Abt Pathophysiol, Med Klin 1, D-55101 Mainz, Germany; Klinikum RWTH Aachen, Inst Biochem, D-52057 Aachen, Germany	Johannes Gutenberg University of Mainz; RWTH Aachen University; RWTH Aachen University Hospital	Rose-John, S (corresponding author), Univ Mainz, Med Klin Pathophysiol 1, Obere Zahlbacher Str 63, D-55101 Mainz, Germany.		Rose-John, Stefan/A-7998-2010	Rose-John, Stefan/0000-0002-7519-3279				AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; ALI SA, 1995, BIOTECHNIQUES, V18, P745; Baumann H, 1996, J IMMUNOL, V157, P284; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BRAKENHOFF JPJ, 1990, J IMMUNOL, V145, P561; BRAKENHOFF JPJ, 1994, J BIOL CHEM, V269, P86; CASTELL J, 1990, EUR J BIOCHEM, V189, P113, DOI 10.1111/j.1432-1033.1990.tb15466.x; Ciapponi L, 1995, J BIOL CHEM, V270, P31249, DOI 10.1074/jbc.270.52.31249; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DEBETS R, 1994, IMMUNOL TODAY, V15, P455, DOI 10.1016/0167-5699(94)90187-2; DEHON FD, 1994, J EXP MED, V180, P2395, DOI 10.1084/jem.180.6.2395; Ehlers M, 1996, J INTERF CYTOK RES, V16, P569, DOI 10.1089/jir.1996.16.569; EHLERS M, 1994, J IMMUNOL, V153, P1744; EHLERS M, 1995, J BIOL CHEM, V270, P8158, DOI 10.1074/jbc.270.14.8158; Fischer M, 1997, NAT BIOTECHNOL, V15, P142, DOI 10.1038/nbt0297-142; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; HIRATA Y, 1989, J IMMUNOL, V143, P2900; Ichihara M, 1997, BLOOD, V90, P165; Kallen K J, 1997, Expert Opin Investig Drugs, V6, P237, DOI 10.1517/13543784.6.3.237; KLEIN B, 1991, BLOOD, V78, P1198; Krebs B, 1998, J BIOL CHEM, V273, P2858, DOI 10.1074/jbc.273.5.2858; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MACKIEWICZ A, 1992, J IMMUNOL, V149, P2021; Marz P, 1998, P NATL ACAD SCI USA, V95, P3251, DOI 10.1073/pnas.95.6.3251; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; MULLBERG J, 1993, EUR J IMMUNOL, V23, P473, DOI 10.1002/eji.1830230226; Oppmann B, 1996, J IMMUNOL METHODS, V195, P153, DOI 10.1016/0022-1759(96)00110-X; Pennica D, 1996, NEURON, V17, P63, DOI 10.1016/S0896-6273(00)80281-0; Peters M, 1996, J EXP MED, V183, P1399, DOI 10.1084/jem.183.4.1399; Peters M, 1997, J EXP MED, V185, P755, DOI 10.1084/jem.185.4.755; Romano M, 1997, IMMUNITY, V6, P315, DOI 10.1016/S1074-7613(00)80334-9; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; Sambrook J., 2002, MOL CLONING LAB MANU; SAVINO R, 1994, EMBO J, V13, P5863, DOI 10.1002/j.1460-2075.1994.tb06931.x; SAVINO R, 1994, EMBO J, V13, P1357, DOI 10.1002/j.1460-2075.1994.tb06389.x; Sporeno E, 1996, BLOOD, V87, P4510, DOI 10.1182/blood.V87.11.4510.bloodjournal87114510; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; UDAGAWA N, 1995, J EXP MED, V182, P1461, DOI 10.1084/jem.182.5.1461; Vernallis AB, 1997, J BIOL CHEM, V272, P26947, DOI 10.1074/jbc.272.43.26947; WENDLING D, 1993, J RHEUMATOL, V20, P259; Xu GY, 1997, J MOL BIOL, V268, P468, DOI 10.1006/jmbi.1997.0933; ZHANG XG, 1994, J EXP MED, V179, P1337, DOI 10.1084/jem.179.4.1337	42	29	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27213	27219		10.1074/jbc.273.42.27213	http://dx.doi.org/10.1074/jbc.273.42.27213			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765242	hybrid			2022-12-27	WOS:000076448000029
J	An, WJ; van Holde, K; Zlatanova, J				An, WJ; van Holde, K; Zlatanova, J			The non-histone chromatin protein HMG1 protects linker DNA on the side opposite to that protected by linker histones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4-WAY JUNCTION DNA; CHROMOSOMAL-PROTEINS; H1; TRANSCRIPTION; COMPETITION; NUCLEOSOMES; BINDING; B4	Linker histones and HMG1/2 constitute the two major proteins that bind to linker DNA in chromatin. While the location of linker histones on the nucleosome has attracted considerable research effort, only a few studies have addressed the location of HMG1 in the particles. In this study, we use a procedure based on micrococcal nuclease digestion of reconstituted nucleosomal particles to which HMG1 has been bound, followed by analysis of the protected DNA by restriction nuclease digestion, to locate the HMG1 binding site. Nucleosomal particles were reconstituted on a 235-base pair DNA fragment, which is known to be a strong nucleosome positioning sequence. The results unequivocally show that HMG1 protects linker DNA on one side of the core particle. Importantly, and possibly of physiological relevance, the linker DNA site protected by HMG1 was located on the side opposite to that already shown to be protected by linker histone binding.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Bulgarian Acad Sci, Inst Genet, BU-1113 Sofia, Bulgaria	Oregon State University; Bulgarian Academy of Sciences	Zlatanova, J (corresponding author), Argonne Natl Lab, Bldg 202-A253,9700 S Cass Ave, Argonne, IL 60439 USA.	zlatanoj@everest.bim.anl.gov	Zlatanova, Jordanka/B-3273-2009		FOGARTY INTERNATIONAL CENTER [R03TW000568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050276] Funding Source: NIH RePORTER; FIC NIH HHS [TW00568] Funding Source: Medline; NIGMS NIH HHS [GM50276] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1990, J CHROMATOGR-BIOMED, V530, P39, DOI 10.1016/S0378-4347(00)82300-2; ADAMS CC, 1995, MOL CELL BIOL, V15, P1405; An WJ, 1998, NUCLEIC ACIDS RES, V26, P4042, DOI 10.1093/nar/26.17.4042; An WJ, 1998, P NATL ACAD SCI USA, V95, P3396, DOI 10.1073/pnas.95.7.3396; CraneRobinson C, 1997, TRENDS BIOCHEM SCI, V22, P75, DOI 10.1016/S0968-0004(97)01013-X; DONG F, 1990, P NATL ACAD SCI USA, V87, P5724, DOI 10.1073/pnas.87.15.5724; Hill DA, 1997, NUCLEIC ACIDS RES, V25, P3523, DOI 10.1093/nar/25.17.3523; JACKSON JB, 1981, BIOCHEMISTRY-US, V20, P1042, DOI 10.1021/bi00507a060; JACKSON JB, 1979, BIOCHEMISTRY-US, V18, P3739, DOI 10.1021/bi00584a015; Nightingale K, 1996, EMBO J, V15, P548, DOI 10.1002/j.1460-2075.1996.tb00387.x; Sera T, 1998, MOL CELL BIOL, V18, P3668, DOI 10.1128/MCB.18.7.3668; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; TATCHELL K, 1977, BIOCHEMISTRY-US, V16, P5295, DOI 10.1021/bi00643a021; Ura K, 1996, EMBO J, V15, P4959, DOI 10.1002/j.1460-2075.1996.tb00876.x; VARGAWEISZ P, 1994, BIOCHEM BIOPH RES CO, V203, P1904, DOI 10.1006/bbrc.1994.2410; Wong JM, 1997, EMBO J, V16, P7130, DOI 10.1093/emboj/16.23.7130; Yaneva J, 1997, P NATL ACAD SCI USA, V94, P13448, DOI 10.1073/pnas.94.25.13448; Zlatanova J, 1996, PROG NUCLEIC ACID RE, V52, P217, DOI 10.1016/S0079-6603(08)60968-X; ZLATANOVA J, 1992, J CELL SCI, V103, P889	19	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26289	26291		10.1074/jbc.273.41.26289	http://dx.doi.org/10.1074/jbc.273.41.26289			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756855	hybrid			2022-12-27	WOS:000076373300009
J	Brown, GM; Huckerby, TN; Bayliss, MT; Nieduszynski, IA				Brown, GM; Huckerby, TN; Bayliss, MT; Nieduszynski, IA			Human aggrecan keratan sulfate undergoes structural changes during adolescent development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ARTICULAR-CARTILAGE; AGE-RELATED-CHANGES; ANION-EXCHANGE CHROMATOGRAPHY; JOINT DISEASE; II DIGESTION; ALPHA(1-3)-LINKED FUCOSE; PROTEOGLYCAN STRUCTURE; SYNOVIAL-FLUID; OLIGOSACCHARIDES; OSTEOARTHRITIS	Alkaline borohydride-reduced keratan sulfate chains were isolated from human articular cartilage aggrecan from individuals of various ages (0-85 years old). The chains were structurally characterized using H-1 NMR spectroscopy, gel permeation chromatography, and oligosaccharide profiling (after digestion with the enzymes keratanase and keratanase II). The results show that from birth to early adolescence (0-9 years) the levels of alpha(l-3)-fucosylation, alpha(2-3)-sialylation, and galactose sulfation increase. Also, the weight-average molecular weight of the chains increases. During maturation (9-18 years) the levels of fucosylation and galactose sulfation continue to increase and alpha(2-6)-sialylation of the chains occurs. In adult life (18-85 years) there is little change in the weight-average molecular weight of the chains, and the levels of fucosylation, sialylation, and sulfation remain fairly constant.	Univ Lancaster, Inst Environm & Biol Sci, Dept Biol Sci, Lancaster LA1 4YQ, England; Univ Lancaster, Sch Phys & Chem, Ctr Polymer, Lancaster LA1 4YA, England; Univ London Royal Vet Coll, Dept Vet Basic Sci, London NW1 0TU, England	Lancaster University; Lancaster University; University of London; University of London Royal Veterinary College	Brown, GM (corresponding author), Univ Lancaster, Inst Environm & Biol Sci, Dept Biol Sci, Lancaster LA1 4YQ, England.							ALWAN WH, 1990, RES VET SCI, V49, P56, DOI 10.1016/S0034-5288(18)31046-4; ASHWELL G, 1974, ADV ENZYMOL RAMB, V41, P99; BAYLISS MT, 1978, BIOCHEM J, V176, P683, DOI 10.1042/bj1760683; BAYLISS MT, 1990, BIOCHEM SOC T, V18, P799, DOI 10.1042/bst0180799; BAYLISS MT, 1980, STUDIES JOINT DISEAS, V1, P2; BAYLISS MT, 1985, DEGENERATIVE JOINTS, V2, P13; BHAVANANDAN VP, 1968, J BIOL CHEM, V243, P1052; BJELLE A, 1975, CONNECT TISSUE RES, V3, P141, DOI 10.3109/03008207509152172; BROWN GM, 1992, BIOCHEM J, V286, P235, DOI 10.1042/bj2860235; BROWN GM, 1994, EUR J BIOCHEM, V224, P281, DOI 10.1111/j.1432-1033.1994.00281.x; BROWN GM, 1994, BIOCHEMISTRY-US, V33, P4836, DOI 10.1021/bi00182a012; BROWN GM, 1995, GLYCOBIOLOGY, V5, P311, DOI 10.1093/glycob/5.3.311; Brown GM, 1996, BIOCHEM J, V319, P137, DOI 10.1042/bj3190137; CARLSON DM, 1968, J BIOL CHEM, V243, P616; CARROLL G, 1991, RHEUMATOL INT, V11, P63, DOI 10.1007/BF00291147; DICKENSON JM, 1990, ANAL BIOCHEM, V190, P271, DOI 10.1016/0003-2697(90)90192-C; DICKENSON JM, 1990, BIOCHEM J, V269, P55, DOI 10.1042/bj2690055; DINGLE JT, 1975, ANN RHEUM DIS, V34, P303, DOI 10.1136/ard.34.4.303; Fawthrop F, 1997, ANN RHEUM DIS, V56, P119, DOI 10.1136/ard.56.2.119; FEIZI T, 1989, KERATAN SULPHATE CHE, P21; GREILING H, 1973, CONNECTIVE TISSUE AG, P160; HARDINGHAM T, 1990, SEMIN ARTHRITIS RHEU, V20, P12, DOI 10.1016/0049-0172(90)90044-G; HASCALL VC, 1972, J BIOL CHEM, V247, P4529; HEINEGARD D, 1985, SCAND J CLIN LAB INV, V45, P421, DOI 10.1080/00365518509155238; HEINEGARD D, 1977, J BIOL CHEM, V252, P1971; HELMINEN HJ, 1987, JOINT LOADING, P29; HONDA S, 1981, ANAL BIOCHEM, V113, P130, DOI 10.1016/0003-2697(81)90055-5; HUCKERBY TN, 1991, GLYCOCONJUGATE J, V8, P39, DOI 10.1007/BF00731641; KAPLAN D, 1959, NATURE, V182, P1267; LIEPOLD HR, 1989, ARTHRITIS RHEUM, V32, P312; LOHMANDER LS, 1986, ANAL BIOCHEM, V154, P75, DOI 10.1016/0003-2697(86)90498-7; LOHMANDER LS, 1980, J BIOL CHEM, V255, P6084; MEHMET H, 1986, EUR J BIOCHEM, V157, P385, DOI 10.1111/j.1432-1033.1986.tb09680.x; MEHRABAN F, 1991, ARTHRITIS RHEUM, V34, P383, DOI 10.1002/art.1780340403; NIEDUSZYNSKI IA, 1990, BIOCHEM J, V271, P243, DOI 10.1042/bj2710243; RATCLIFFE A, 1988, ANN RHEUM DIS, V47, P826, DOI 10.1136/ard.47.10.826; ROUGHLEY PJ, 1980, J BIOL CHEM, V255, P217; SANTER V, 1982, BIOCHIM BIOPHYS ACTA, V716, P277, DOI 10.1016/0304-4165(82)90017-4; SPECTOR TD, 1992, ANN RHEUM DIS, V51, P1134, DOI 10.1136/ard.51.10.1134; SWEET MBE, 1979, ARCH BIOCHEM BIOPHYS, V198, P439, DOI 10.1016/0003-9861(79)90518-6; TAI GH, 1994, CARBOHYD RES, V255, P303, DOI 10.1016/S0008-6215(00)90987-X; TAI GH, 1991, BIOCHEM J, V273, P307, DOI 10.1042/bj2730307; THEOCHARIS DA, 1985, BIOCHIM BIOPHYS ACTA, V841, P131, DOI 10.1016/0304-4165(85)90283-1; THONAR EJMA, 1991, J RHEUMATOL, V18, P24; THONAR EJMA, 1981, ARCH BIOCHEM BIOPHYS, V208, P535, DOI 10.1016/0003-9861(81)90542-7; THONAR EJMA, 1985, ARTHRITIS RHEUM, V28, P1367, DOI 10.1002/art.1780281209; THORNTON DJ, 1989, BIOCHEM J, V260, P277, DOI 10.1042/bj2600277	47	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26408	26414		10.1074/jbc.273.41.26408	http://dx.doi.org/10.1074/jbc.273.41.26408			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756873	hybrid			2022-12-27	WOS:000076373300027
J	Morel, Y; Barouki, R				Morel, Y; Barouki, R			Down-regulation of cytochrome P450 1A1 gene promoter by oxidative stress - Critical contribution of nuclear factor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; NF-KAPPA-B; TRANSCRIPTION FACTOR; FACTOR-I; HYDROGEN-PEROXIDE; REDOX REGULATION; CONSENSUS SEQUENCE; HUMAN HEPATOCYTES; PRIMARY CULTURE; PROTEIN-KINASE	Oxidative stress interferes with several cellular functions, in particular transcriptional regulation, We show here that the human cytochrome P450 1A1 (CYP1A1) is down-regulated at the transcriptional level by oxidative stress. Basal as well as 2,3,7,8-tetrachloro-p-dioxin-induced promoter activities are strongly impaired by H2O2 treatment or glutathione depletion with L-buthionine-(S,R)-sulfoximine. Tumor necrosis factor cu inhibits CYP1A1 expression, and this inhibition is prevented by the antioxidant pyrrolidine dithiocarbamate, We show that these regulations depend on the integrity of the nuclear factor 1 (NFI) site located in the proximal promoter. We therefore examined the redox regulation of this transcription factor. Treatment of human HepG2 or rat H4 hepatoma cells with H2O2 or L-buthionine-(S,R)-sulfoximine inactivates the binding of the NFI transcription factor to its DNA consensus sequence. Furthermore, H2O2 treatment leads to a dose-dependent decrease of reporter gene expressions driven by promoters containing NFI binding sites. Glutathione depletion and catalase inhibition also repress a NFI-driven promoter. Under the same conditions, the CP-1 transcription factor activity is not affected by oxidative stress. Thus, NFI seems particularly sensitive to oxidative stress. This accounts, at least partially, for the regulation of cyp1A1 gene expression.	Ctr Univ St Peres, INSERM, U490, F-75006 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Barouki, R (corresponding author), Ctr Univ St Peres, INSERM, U490, 45 Rue Saints Peres, F-75006 Paris, France.		morel, yves/C-4757-2017					ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ABDELRAZZAK Z, 1994, MOL PHARMACOL, V46, P1100; ADAMSON GM, 1992, ARCH BIOCHEM BIOPHYS, V294, P223, DOI 10.1016/0003-9861(92)90161-O; AEBI HE, 1974, METHOD ENZYMAT AN, P277; Alevizopoulos A, 1996, J BIOL CHEM, V271, P29672, DOI 10.1074/jbc.271.47.29672; ANANIA FA, 1995, HEPATOLOGY, V21, P1640, DOI 10.1002/hep.1840210624; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BANDYOPADHYAY S, 1994, J BIOL CHEM, V269, P29949; Bandyopadhyay S, 1998, J BIOL CHEM, V273, P392, DOI 10.1074/jbc.273.1.392; BARKER CW, 1994, J BIOL CHEM, V269, P3985; BOISJOYEUX B, 1994, BIOCHEM J, V301, P49, DOI 10.1042/bj3010049; BOUCHER PD, 1995, MOL CELL BIOL, V15, P5144; CARDINAUX JR, 1994, J BIOL CHEM, V269, P32947; COURTOIS SJ, 1990, NUCLEIC ACIDS RES, V18, P57, DOI 10.1093/nar/18.1.57; DESCHATRETTE J, 1980, CELL, V19, P1043, DOI 10.1016/0092-8674(80)90095-1; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Duval DL, 1996, MOL PHARMACOL, V50, P277; FANDREY J, 1994, BIOCHEM J, V303, P507, DOI 10.1042/bj3030507; FEILLEUXDUCHE S, 1994, BIOCHEM J, V297, P497, DOI 10.1042/bj2970497; Gao B, 1996, MOL CELL BIOL, V16, P5997; Garlatti M, 1996, J BIOL CHEM, V271, P32629, DOI 10.1074/jbc.271.51.32629; Gergel D, 1997, ARCH BIOCHEM BIOPHYS, V337, P239, DOI 10.1006/abbi.1996.9765; GERGEL D, 1995, J BIOL CHEM, V270, P20922, DOI 10.1074/jbc.270.36.20922; GRANTLEY DC, 1997, BIOCHEM BIOPH RES CO, V238, P338; GretherBeck S, 1996, P NATL ACAD SCI USA, V93, P14586, DOI 10.1073/pnas.93.25.14586; GRONOSTAJSKI RM, 1985, P NATL ACAD SCI USA, V81, P4013; Guyton KZ, 1996, BIOCHEM J, V314, P547, DOI 10.1042/bj3140547; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; JONES KW, 1990, MOL CELL BIOL, V10, P5098, DOI 10.1128/MCB.10.10.5098; Kadlubar F.F., 1987, MAMMALIAN CYTOCHROME, P81; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P543, DOI 10.1042/bj3070543; KRUSE U, 1994, FEBS LETT, V348, P46, DOI 10.1016/0014-5793(94)00585-0; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; Massaad C, 1997, MOL PHARMACOL, V51, P285, DOI 10.1124/mol.51.2.285; Mendelson KG, 1996, P NATL ACAD SCI USA, V93, P12908, DOI 10.1073/pnas.93.23.12908; MICHIELS C, 1988, EUR J BIOCHEM, V177, P435, DOI 10.1111/j.1432-1033.1988.tb14393.x; MIHM S, 1995, FASEB J, V9, P246, DOI 10.1096/fasebj.9.2.7781927; MUNTANERELAT J, 1995, HEPATOLOGY, V22, P1143; Nakshatri H, 1996, J BIOL CHEM, V271, P28784, DOI 10.1074/jbc.271.46.28784; Nose K, 1996, BIOCHEM J, V316, P381, DOI 10.1042/bj3160381; NOVAK A, 1992, J BIOL CHEM, V267, P12986; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Osada S, 1997, BIOCHEM BIOPH RES CO, V238, P744, DOI 10.1006/bbrc.1997.7382; Park JYK, 1996, P NATL ACAD SCI USA, V93, P2322, DOI 10.1073/pnas.93.6.2322; Parks D, 1997, NUCLEIC ACIDS RES, V25, P1289, DOI 10.1093/nar/25.6.1289; Pennisi E, 1997, SCIENCE, V275, P1567, DOI 10.1126/science.275.5306.1567; Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; Vasiliou V, 1995, BIOCHEM PHARMACOL, V50, P2057, DOI 10.1016/0006-2952(95)02108-6; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; Whitlock JP, 1996, FASEB J, V10, P809, DOI 10.1096/fasebj.10.8.8666157; [No title captured]	63	166	168	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26969	26976		10.1074/jbc.273.41.26969	http://dx.doi.org/10.1074/jbc.273.41.26969			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756946	hybrid			2022-12-27	WOS:000076373300100
J	Wu, SK; Luan, P; Matteson, J; Zeng, K; Nishimura, N; Balch, WE				Wu, SK; Luan, P; Matteson, J; Zeng, K; Nishimura, N; Balch, WE			Molecular role for the Rab binding platform of guanine nucleotide dissociation inhibitor in endoplasmic reticulum to Golgi transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR TRANSPORT; QUANTITATIVE-ANALYSIS; MEMBRANE ASSOCIATION; PROTEIN-TRANSPORT; GDP/GTP EXCHANGE; GDP; GTP; CHOROIDEREMIA; COMPARTMENTS; COMPLEX	Guanine nucleotide dissociation inhibitor (GDI) regulates the recycling of Rab GTPases involved in vesicle targeting and fusion. We have analyzed the requirement for conserved amino acid residues in the binding of Rab1A and the function of GDI in transport of cargo between the endoplasmic reticulum (ER) and the Golgi apparatus. Using a new approach to monitor GDI-Rab interactions based on the change in fluorescence associated with the release of methylanthraniloyl guanosine di(tri)phosphate-GDP (mGDP) from Rab, we show that residues previously implicated in the binding of the synapse-specific Rab3A, including Gln-236, Arg-240, and Thr-248, are essential for the binding of Rab1A. Mutation of each of these residues has potent effects on the ability of GDI to remove Rab1A from membranes and inhibit ER to Golgi transport in vitro, Given the sequence divergence between Rab1A and 3A (35% identity), these residues are proposed to play a general role in GDI function in the cell. In contrast, several other residues found within or flanking the Rab-binding region were found to have differential effects in the recognition and recycling of Rab1A and 3A, and therefore direct selective interaction of GDI with individual Rab proteins. Intriguingly, mutation of one residue, Arg-70, led to a reduction of Rab1A binding, failed to extract Rab1A from membranes in vitro, yet bound membranes tightly and potently inhibited ER to Golgi transport. These results provide evidence that novel membrane-associated factor(s) mediate Rab-independent GDI interaction with membranes.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Balch, WE (corresponding author), Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA.				NIGMS NIH HHS [GM33301] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033301] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDROV K, 1994, EMBO J, V13, P5262, DOI 10.1002/j.1460-2075.1994.tb06860.x; ANDERS DA, 1993, CELL, V73, P1091; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CREMERS FPM, 1994, J BIOL CHEM, V269, P2111; D'Adamo P, 1998, NAT GENET, V19, P134, DOI 10.1038/487; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; DIRACSVEJSTRUP AB, 1994, J BIOL CHEM, V269, P15427; DiracSvejstrup AB, 1997, EMBO J, V16, P465, DOI 10.1093/emboj/16.3.465; ELAZAR Z, 1994, J BIOL CHEM, V269, P794; GARRETT MD, 1994, EMBO J, V13, P1718, DOI 10.1002/j.1460-2075.1994.tb06436.x; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; NISHIMURA N, 1994, J BIOL CHEM, V269, P14191; NOUFFER C, 1997, MOL BIOL CELL, V8, P1305; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; NUOFFER C, 1995, METHOD ENZYMOL, V257, P3; Overmeyer JH, 1998, MOL BIOL CELL, V9, P223, DOI 10.1091/mbc.9.1.223; PETER F, 1994, J CELL BIOL, V126, P1393, DOI 10.1083/jcb.126.6.1393; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; SASAKI T, 1991, MOL CELL BIOL, V11, P2909, DOI 10.1128/MCB.11.5.2909; SASAKI T, 1990, J BIOL CHEM, V265, P2333; Schalk I, 1996, NATURE, V381, P42, DOI 10.1038/381042a0; SEABRA MC, 1995, J BIOL CHEM, V270, P24420, DOI 10.1074/jbc.270.41.24420; Seabra MC, 1996, J BIOL CHEM, V271, P14398, DOI 10.1074/jbc.271.24.14398; SHAPIRO AD, 1995, J BIOL CHEM, V270, P11085, DOI 10.1074/jbc.270.19.11085; SHISHEVA A, 1994, J BIOL CHEM, V269, P23865; SHISHEVA A, 1995, EUR J CELL BIOL, V68, P143; SHISHEVA A, 1994, MOL CELL BIOL, V14, P3459, DOI 10.1128/MCB.14.5.3459; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; STEELEMORTIMER O, 1993, FEBS LETT, V329, P313, DOI 10.1016/0014-5793(93)80244-O; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; WALDHERR M, 1993, NAT GENET, V3, P193, DOI 10.1038/ng0393-193; WILSON AL, 1993, J BIOL CHEM, V268, P14561; WILSON CN, 1996, SOUTH CULT, V2, P271, DOI 10.1353/scu.1996.0002; Wu SK, 1996, TRENDS BIOCHEM SCI, V21, P472, DOI 10.1016/S0968-0004(96)10062-1; YANG CZ, 1994, J BIOL CHEM, V269, P31891	45	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26931	26938		10.1074/jbc.273.41.26931	http://dx.doi.org/10.1074/jbc.273.41.26931			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756941	hybrid			2022-12-27	WOS:000076373300095
J	Macias-Silva, M; Hoodless, PA; Tang, SJ; Buchwald, M; Wrana, JL				Macias-Silva, M; Hoodless, PA; Tang, SJ; Buchwald, M; Wrana, JL			Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING-GROWTH-FACTOR; TGF-BETA RECEPTOR; MAD-RELATED PROTEIN; MESODERM-INDUCING SIGNALS; DIFFERENTIAL EXPRESSION; DROSOPHILA-MELANOGASTER; NEURAL DIFFERENTIATION; OSTEOGENIC PROTEIN-1; EPIDERMAL INDUCTION; ACTIVIN RECEPTORS	BMP7 and activin are members of the transforming growth factor beta superfamily. Here we characterize endogenous activin and BMP7 signaling pathways in P19 embryonic carcinoma cells. We show that BMP7 and activin bind to the same type II receptors, ActRII and IIB, but recruit distinct type I receptors into heteromeric receptor complexes. The major BMP7 type I receptor observed was ALK2, while activin bound exclusively to ALK4 (ActRIB). BMP7 and activin elicited distinct biological responses and activated different Smad pathways. BMP7 stimulated phosphorylation of endogenous Smad1 and 5, formation of complexes with Smad4 and induced the promoter for the homeobox gene, Tlx2. In contrast, activin induced phosphorylation of Smad2, association with Smad4, and induction of the activin response element from the Xenopus Mix.2 gene. Biochemical analysis revealed that constitutively active ALK2 associated with and phosphorylated Smad1 on the COOH-terminal SSXS motif, and also regulated Smad5 and Smad8 phosphorylation. Activated ALK2 also induced the Tlx2 promoter in the absence of BMP7. Furthermore, we show that ALK1 (TSRI), an orphan receptor that is closely related to ALK2 also mediates Smad1 signaling. Thus, ALK1 and ALK2 induce Smad1-dependent pathways and ALK2 functions to mediate BMP7 but not activin signaling.	Hosp Sick Children, Program Dev Biol, Div Gastroenterol, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Genet, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Wrana, JL (corresponding author), Hosp Sick Children, Program Dev Biol, Div Gastroenterol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	jwrana@sickkids.on.ca	Wrana, Jeffrey/F-8857-2013	Macias-Silva, Marina/0000-0002-3972-0983; Hoodless, Pamela/0000-0003-1371-0725				Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Arkell R, 1997, DEVELOPMENT, V124, P1; Armes NA, 1997, DEVELOPMENT, V124, P3797; Attisano L, 1996, MOL CELL BIOL, V16, P1066; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; Attisano Liliana, 1996, Cytokine and Growth Factor Reviews, V7, P327, DOI 10.1016/S1359-6101(96)00042-1; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Chang CB, 1997, DEVELOPMENT, V124, P827; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen Y, 1997, P NATL ACAD SCI USA, V94, P12938, DOI 10.1073/pnas.94.24.12938; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; Frisch A, 1998, DEVELOPMENT, V125, P431; Glozak MA, 1996, DEV BIOL, V179, P458, DOI 10.1006/dbio.1996.0275; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; HASHIMOTO M, 1990, BIOCHEM BIOPH RES CO, V173, P193, DOI 10.1016/S0006-291X(05)81040-X; HAWLEY SHB, 1995, GENE DEV, V9, P2923, DOI 10.1101/gad.9.23.2923; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HEMMATIBRIVANLOU A, 1995, DEV GENET, V17, P78, DOI 10.1002/dvg.1020170109; Hoodless PA, 1997, DEV GENES EVOL, V207, P19, DOI 10.1007/s004270050088; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Hoodless PA, 1998, CURR TOP MICROBIOL, V228, P235; Howell M, 1997, EMBO J, V16, P7411, DOI 10.1093/emboj/16.24.7411; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Ladher R, 1996, DEVELOPMENT, V122, P2385; LETSOU A, 1995, CELL, V80, P899, DOI 10.1016/0092-8674(95)90293-7; LIU F, 1995, MOL CELL BIOL, V15, P3479; LYONS KM, 1995, MECH DEVELOP, V50, P71, DOI 10.1016/0925-4773(94)00326-I; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Marazzi G, 1997, DEV BIOL, V186, P127, DOI 10.1006/dbio.1997.8576; Massague J, 1996, CANCER SURV, V27, P41; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Nakao A, 1997, J BIOL CHEM, V272, P2896, DOI 10.1074/jbc.272.5.2896; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nishitoh H, 1996, J BIOL CHEM, V271, P21345, DOI 10.1074/jbc.271.35.21345; Onichtchouk D, 1996, DEVELOPMENT, V122, P3045; Roelen BAJ, 1997, INT J DEV BIOL, V41, P541; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; Rotin D, 1998, CURR TOP MICROBIOL, V228, P115; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; Suzuki A, 1997, DEVELOPMENT, V124, P3037; Suzuki A, 1997, DEV BIOL, V189, P112, DOI 10.1006/dbio.1997.8652; Suzuki A, 1997, BIOCHEM BIOPH RES CO, V232, P153, DOI 10.1006/bbrc.1997.6219; Tang SJ, 1998, DEVELOPMENT, V125, P1877; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; TENDIJKE P, 1993, ONCOGENE, V8, P2879; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; TSUCHIDA K, 1993, P NATL ACAD SCI USA, V90, P11242, DOI 10.1073/pnas.90.23.11242; VANDENEIJNDENVANRAAIJ AJM, 1992, DEV BIOL, V154, P356, DOI 10.1016/0012-1606(92)90074-Q; VIDRICAIRE G, 1994, DEVELOPMENT, V120, P115; Watabe T, 1995, GENE DEV, V9, P3038, DOI 10.1101/gad.9.24.3038; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; Wrana J, 1997, NATURE, V388, P28, DOI 10.1038/40290; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1; WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944; Yamamoto N, 1997, BIOCHEM BIOPH RES CO, V238, P574, DOI 10.1006/bbrc.1997.7325; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940	74	386	420	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25628	25636		10.1074/jbc.273.40.25628	http://dx.doi.org/10.1074/jbc.273.40.25628			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748228	hybrid			2022-12-27	WOS:000076263100019
J	Begum, N; Ragolia, L; Rienzie, J; McCarthy, M; Duddy, N				Begum, N; Ragolia, L; Rienzie, J; McCarthy, M; Duddy, N			Regulation of mitogen-activated protein kinase phosphatase-1 induction by insulin in vascular smooth muscle cells - Evaluation of the role of the nitric oxide signaling pathway and potential defects in hypertension	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE-PHOSPHATASE; DNA-SYNTHESIS; RAT; EXPRESSION; STRESS; MKP-1; STIMULATION; CASCADE; PHOSPHORYLATION	In this study, we examined the regulation of mitogen-activated protein kinase phosphatase (MKP-1) expression by insulin in primary vascular smooth muscle cell cultures. Insulin caused a rapid time- and dose-dependent induction of MKP-1 mRNA and protein expression. Blockade of nitric-oxide synthase (NOS) with N-G-monomethyl-L-arginine acetate, and cGMP with RpcGMP, completely inhibited MKP-1 expression. Insulin-mediated MKP-1 expression was preceded by inducible NOS (iNOS) induction and cGMP production. Blockade of phosphatidylinositol 3-kinase (PI3-kinase) signaling with wortmannin inhibited insulin-mediated iNOS protein induction, cGMP production, and MKP-1 expression To evaluate potential interactions between NOS and the mitogen-activated protein kinase (MAPK) signaling pathways, we employed PD98059 and SB203580, two specific inhibitors of ERKs and p38 MAPK. These inhibitors abolished the effect of insulin on MKP-1 expression. Only PD98059 inhibited insulin-mediated iNOS protein induction. Vascular smooth muscle cells from spontaneous hypertensive rats exhibited a marked decrease in MKP-1 induction due to defects in insulin-induced iNOS expression because of reductions in PI3-kinase activity. Treatment with sodium nitroprusside and 8-bromo-cGMP restored MKP-1 mRNA expression to levels comparable with controls. We conclude that insulin-induced MKP-1 expression is mediated by PI3-kinase-initiated signals, leading to the induction of iNOS and elevated cGMP levels that stimulates MKP-1 expression.	Winthrop Univ Hosp, Diabet Res Lab, Mineola, NY 11501 USA; SUNY Stony Brook, Sch Med, Stony Brook, NY 11794 USA	Winthrop University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Begum, N (corresponding author), Winthrop Univ Hosp, Diabet Res Lab, 259 1st St, Mineola, NY 11501 USA.		Ragolia, Louis/AAW-2383-2021	Ragolia, Louis/0000-0002-8292-5159				Bakris GL, 1996, ENDOCRINOL VASCULATU, P341; BARON AD, 1995, J CLIN INVEST, V96, P786, DOI 10.1172/JCI118124; Begum N, 1998, AM J PHYSIOL-CELL PH, V275, pC42, DOI 10.1152/ajpcell.1998.275.1.C42; Begum N, 1996, J BIOL CHEM, V271, P31166, DOI 10.1074/jbc.271.49.31166; Begum N, 1996, EUR J BIOCHEM, V238, P214, DOI 10.1111/j.1432-1033.1996.0214q.x; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; Cook SJ, 1997, J BIOL CHEM, V272, P13309, DOI 10.1074/jbc.272.20.13309; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; DUFF JL, 1993, J BIOL CHEM, V268, P26037; FOLLI F, 1992, J BIOL CHEM, V267, P22171; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KAUFMAN PB, 1995, HDB MOL CELLULAR MET, P65; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Kusari AB, 1997, MOL ENDOCRINOL, V11, P1532, DOI 10.1210/me.11.10.1532; Lai KH, 1996, J CLIN INVEST, V98, P1560, DOI 10.1172/JCI118949; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Molloy CJ, 1996, J CLIN INVEST, V97, P1173, DOI 10.1172/JCI118531; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Ragolia L, 1997, J BIOL CHEM, V272, P23653, DOI 10.1074/jbc.272.38.23653; REAVEN GM, 1995, PHYSIOL REV, V75, P473, DOI 10.1152/physrev.1995.75.3.473; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHERRER U, 1994, J CLIN INVEST, V94, P2511, DOI 10.1172/JCI117621; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEINBERG HO, 1994, J CLIN INVEST, V94, P1172, DOI 10.1172/JCI117433; STOUT RW, 1992, EUR J EPIDEMIOL, V8, P134, DOI 10.1007/BF00145365; Sugimoto T, 1996, J BIOL CHEM, V271, P544, DOI 10.1074/jbc.271.1.544; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; VINTERS HV, 1987, DIABETES METAB, V13, P294; Zeng GY, 1996, J CLIN INVEST, V98, P894, DOI 10.1172/JCI118871; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	40	78	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25164	25170		10.1074/jbc.273.39.25164	http://dx.doi.org/10.1074/jbc.273.39.25164			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737976	hybrid			2022-12-27	WOS:000076085400026
J	Chen, M; She, HY; Davis, EM; Spicer, CM; Kim, L; Ren, RB; Le Beau, MM; Li, W				Chen, M; She, HY; Davis, EM; Spicer, CM; Kim, L; Ren, RB; Le Beau, MM; Li, W			Identification of Nck family genes, chromosomal localization, expression, and signaling specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; ADAPTER PROTEIN NCK; ALDRICH SYNDROME PROTEIN; SH2 DOMAIN; FACTOR RECEPTOR; DOCKING PROTEIN; KINASE PAK1; TYROSINE; BINDING; CELLS	Already a dozen molecules share binding to the Src homology (SH) 3 domains of human Nck, an SH3-SH3-SH3-SH2 adapter protein. We reason that there may be multiple gene members of Nck to accommodate the large binding repertoires. Here we report identification of novel human and mouse Nck genes and rename them as the Nck alpha and Nck beta genes (including the human Nck alpha, human Nck beta, mouse Nck alpha, and mouse Nck beta genes). Nck alpha and Nck beta share 68% amino acid identity, whereas the two Nck alpha and two Nck beta across the species show 96% identity to each other. The human Nck beta gene is mapped to 2q12, whereas the human Nck alpha gene has previously been mapped at 3q21. Antibodies specifically against Nck alpha and Nck beta detect Nck alpha and Nck beta with an identical molecular mass in the same cells of various origins. Ectopically expressed Nck beta, but not its SH2 domain mutant, strongly inhibits epidermal growth factor- and platelet-derived growth factor-stimulated DNA synthesis. Consistently, epidermal growth factor receptor and platelet-derived growth factor receptor preferentially interact with Nck beta over Nck alpha in vitro. This study indicates that Nck is a multiple gene family and that each gene may have its own signaling specificity. Because previous anti-Nck (human Nck alpha) antibodies cross-react with Nck beta, reassessment of those studies with specific Nck genes would be necessary.	Univ Chicago, Dept Pharmacol & Physiol Sci, Ben May Inst Canc Res, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Univ Chicago, Sect Hematol & Oncol, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Brandeis Univ, Dept Biol, Waltham, MA 02254 USA; Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02254 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago; Brandeis University; Brandeis University	Li, W (corresponding author), Univ Chicago, Dept Pharmacol & Physiol Sci, Ben May Inst Canc Res, 5841 S Maryland,MC6027, Chicago, IL 60637 USA.	wli@ben-may.bsd.uchicago.edu			NATIONAL CANCER INSTITUTE [R01CA065567, R01CA068008] Funding Source: NIH RePORTER; NCI NIH HHS [CA65567, CA40046, CA68008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CHOU MM, 1995, J BIOL CHEM, V270, P7359, DOI 10.1074/jbc.270.13.7359; Choudhury GG, 1996, AM J PHYSIOL-RENAL, V270, pF295, DOI 10.1152/ajprenal.1996.270.2.F295; Clemens JC, 1996, J BIOL CHEM, V271, P17002, DOI 10.1074/jbc.271.29.17002; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HU P, 1994, MOL CELL BIOL, V14, P2577, DOI 10.1128/MCB.14.4.2577; HU QJ, 1995, MOL CELL BIOL, V15, P1169; HUEBNER K, 1994, GENOMICS, V22, P281, DOI 10.1006/geno.1994.1385; Kitamura Y, 1997, BIOCHEM J, V322, P873, DOI 10.1042/bj3220873; Kochhar KS, 1996, CANCER LETT, V104, P163, DOI 10.1016/0304-3835(96)04244-9; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Lawe DC, 1997, ONCOGENE, V14, P223, DOI 10.1038/sj.onc.1200821; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI W, 1991, CELL REGUL, V2, P641, DOI 10.1091/mbc.2.8.641; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Lussier G, 1997, J BIOL CHEM, V272, P2688, DOI 10.1074/jbc.272.5.2688; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; Matuoka K, 1997, BIOCHEM BIOPH RES CO, V239, P488, DOI 10.1006/bbrc.1997.7492; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; Park D, 1997, MOL CELLS, V7, P231; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Rockow S, 1996, ONCOGENE, V12, P2351; ROWLEY JD, 1990, P NATL ACAD SCI USA, V87, P9358, DOI 10.1073/pnas.87.23.9358; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; She HY, 1997, MOL BIOL CELL, V8, P1709, DOI 10.1091/mbc.8.9.1709; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Tanaka M, 1997, P NATL ACAD SCI USA, V94, P4493, DOI 10.1073/pnas.94.9.4493; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Tang JP, 1997, ONCOGENE, V15, P1823, DOI 10.1038/sj.onc.1201351; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3	53	69	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25171	25178		10.1074/jbc.273.39.25171	http://dx.doi.org/10.1074/jbc.273.39.25171			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737977	hybrid			2022-12-27	WOS:000076085400027
J	Lee, CH; Chinpaisal, C; Wei, LN				Lee, CH; Chinpaisal, C; Wei, LN			A novel nuclear receptor heterodimerization pathway mediated by orphan receptors TR2 and TR4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; MAJOR LATE PROMOTER; RETINOIC ACID; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; RESPONSE ELEMENT; HORMONE-RECEPTOR; GENE-EXPRESSION; I GENE; SUPERFAMILY	A unique heterodimerization pathway involving orphan receptors TR2 and TR4 is demonstrated. TR2 and TR4 preferentially form heterodimers in solution as well as on DNA elements containing a direct repeat-5 (DR5), The in vitro interaction between TR2 and TR4 is demonstrated by the yeast and the mammalian two-hybrid interaction assays, the pull-down assay, and the gel mobility shift assay, The in vivo interaction is demonstrated by following the intracellular localization of fusion receptors tagged with a green fluorescent protein, The dimerization is mediated by the ligand binding domains, and the three leucine residues on helix 10 of TR2 are critical for this interaction. In addition, coexpression of these two receptors exerts a much stronger repressive activity on a DR5-containing reporter than expressing either receptor alone. In the developing testis, TR2 and TR4 are coexpressed in the same testicular cell populations and exhibit a parallel pattern of expression along development. The preferential heterodimerization between TR2 and TR4 and their coexistence in specific germ cell populations suggest a physiological role of TR2/TR4 heterodimers in germ cell development.	Univ Minnesota, Dept Pharmacol, Sch Med, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Wei, LN (corresponding author), Univ Minnesota, Dept Pharmacol, Sch Med, 3-249 Millard Hall,435 Delaware St SE, Minneapolis, MN 55455 USA.				NIDA NIH HHS [DA08131, DA11190] Funding Source: Medline; NIDDK NIH HHS [DK46866] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046866] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011190, P01DA008131] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CHANG CS, 1994, P NATL ACAD SCI USA, V91, P6040, DOI 10.1073/pnas.91.13.6040; Chinpaisal C, 1998, J BIOL CHEM, V273, P18077, DOI 10.1074/jbc.273.29.18077; Chinpaisal C, 1997, BIOCHEMISTRY-US, V36, P14088, DOI 10.1021/bi971598z; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; FENG JQ, 1995, J BIOL CHEM, V270, P28364, DOI 10.1074/jbc.270.47.28364; Hamilton BA, 1996, NATURE, V379, P736, DOI 10.1038/379736a0; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HIROSE T, 1995, BIOCHEM BIOPH RES CO, V211, P83, DOI 10.1006/bbrc.1995.1781; HIROSE T, 1994, MOL ENDOCRINOL, V8, P1667, DOI 10.1210/me.8.12.1667; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; HUGLY S, 1988, ENDOCRINOLOGY, V122, P1390, DOI 10.1210/endo-122-4-1390; Lee CH, 1996, MOL REPROD DEV, V44, P305, DOI 10.1002/(SICI)1098-2795(199607)44:3&lt;305::AID-MRD4&gt;3.0.CO;2-Q; Lee CH, 1997, J ENDOCRINOL, V152, P245, DOI 10.1677/joe.0.1520245; LEE HJ, 1995, J BIOL CHEM, V270, P5434, DOI 10.1074/jbc.270.10.5434; Lee HJ, 1996, J BIOL CHEM, V271, P10405, DOI 10.1074/jbc.271.17.10405; LEE HJ, 1995, J BIOL CHEM, V270, P30129; LIN TM, 1995, J BIOL CHEM, V270, P30121; Liu WH, 1995, P NATL ACAD SCI USA, V92, P12480, DOI 10.1073/pnas.92.26.12480; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Okuda A, 1998, EMBO J, V17, P2019, DOI 10.1093/emboj/17.7.2019; PHILIPPE K, 1995, CELL, V83, P859; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SIITERI JE, 1992, BIOL REPROD, V46, P284, DOI 10.1095/biolreprod46.2.284; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Wei LN, 1996, J BIOL CHEM, V271, P5073; WHITE R, 1993, TRANSCRIPTION FACTOR, P143; ZHAO LJ, 1995, RECOMBINANT DNA METH, V2, P323	30	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25209	25215		10.1074/jbc.273.39.25209	http://dx.doi.org/10.1074/jbc.273.39.25209			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737983	hybrid			2022-12-27	WOS:000076085400033
J	Miyazawa, K; Backstrom, G; Leppanen, O; Persson, C; Wernstedt, C; Hellman, U; Heldin, CH; Ostman, A				Miyazawa, K; Backstrom, G; Leppanen, O; Persson, C; Wernstedt, C; Hellman, U; Heldin, CH; Ostman, A			Role of immunoglobulin-like domains 2-4 of the platelet-derived growth factor alpha-receptor in ligand-receptor complex assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR PDGF RECEPTOR; BETA-RECEPTOR; BB BINDING; TYROSINE KINASE; EXTRACELLULAR DOMAIN; CRYSTAL-STRUCTURE; AMINO-ACIDS; FACTOR-AA; DIMERIZATION; IDENTIFICATION	Platelet-derived growth factor (PDGF) is a dimeric protein that exerts its effects through tyrosine Kinase alpha- and beta-receptors. The extracellular part of each receptor is composed of five Ig-like domains. Recombinant forms of a-receptor domains 1-4 (alpha RD1-4), 1-3 (alpha RD1-3), and 1 and 2 (alpha RD1-2) were prepared after expression in Chinese hamster ovary cells and were used to study the assembly of soluble ligand-receptor complexes. When incubated with micromolar concentrations of PDGF, both alpha RD1-3 and alpha RD1-4 formed complexes of 1:2 molar composition, i.e. one dimeric PDGF molecule bound two soluble receptors, alpha RD1-3, in contrast to alpha RD1-4, formed detectable 1:1 complexes under conditions of ligand excess. alpha RD1-4 displayed an increased ability to form 1:2 complexes as compared with alpha RD1-3 under conditions of limiting concentrations of ligand. We thus conclude that Ig-like domain 4-mediated receptor-receptor interactions contribute to 1:2 PDGF.alpha RD1-4 complex formation. Since alpha RD1-4 and alpha RD1-3 were equipotent in blocking binding of subnanomolar concentrations of PDGF to cell-surface receptors, we also conclude that this effect is predominantly achieved through formation of Ig-like domain 4-independent 1:1 ligand-receptor complexes. Finally, since alpha RD1-2 bound PDGF-BB with high affinity, whereas PDGF-AA was bound only with low affinity, we conclude that Ig-like domain 3 of the PDGF alpha-receptor contains epitopes of particular importance for PDGF-AA binding and that most of the PDGF-BB-binding epitopes reside in Ig-like domains 1 and 2.	Ludwig Inst Canc Res, S-75124 Uppsala, Sweden	Ludwig Institute for Cancer Research	Ostman, A (corresponding author), Ludwig Inst Canc Res, POB 595, S-75124 Uppsala, Sweden.		MIYAZAWA, KEIJI/I-9713-2014					ANDERSSON M, 1995, GROWTH FACTORS, V12, P159, DOI 10.3109/08977199509028962; Barleon B, 1997, J BIOL CHEM, V272, P10382; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BLECHMAN JM, 1995, CELL, V80, P105; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CHANG JY, 1985, EUR J BIOCHEM, V151, P217, DOI 10.1111/j.1432-1033.1985.tb09091.x; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; CLEMENTS JM, 1991, EMBO J, V10, P4113, DOI 10.1002/j.1460-2075.1991.tb04988.x; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DUAN DSR, 1991, J BIOL CHEM, V266, P413; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; FRETTO LJ, 1993, J BIOL CHEM, V268, P3625; GALLAND F, 1993, ONCOGENE, V8, P1233; GEBBINK MFBG, 1995, J CELL BIOL, V131, P251, DOI 10.1083/jcb.131.1.251; HEIDARAN MA, 1990, J BIOL CHEM, V265, P18741; HEIDARAN MA, 1992, J BIOL CHEM, V267, P2884; HEIDARAN MA, 1995, FASEB J, V9, P140, DOI 10.1096/fasebj.9.1.7821753; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HERREN B, 1993, J BIOL CHEM, V268, P15088; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; LAROCHELLE WJ, 1992, J BIOL CHEM, V267, P17074; Lokker NA, 1997, J BIOL CHEM, V272, P33037, DOI 10.1074/jbc.272.52.33037; MAHADEVAN D, 1995, J BIOL CHEM, V270, P27595, DOI 10.1074/jbc.270.46.27595; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; Omura T, 1997, J BIOL CHEM, V272, P12676, DOI 10.1074/jbc.272.19.12676; OSTMAN A, 1991, J BIOL CHEM, V266, P10073; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; ROONEY BC, 1994, FEBS LETT, V339, P181, DOI 10.1016/0014-5793(94)80411-7; Shulman T, 1997, J BIOL CHEM, V272, P17400, DOI 10.1074/jbc.272.28.17400; TERMAN BI, 1991, ONCOGENE, V6, P1677; VASSBOTN FS, 1992, J BIOL CHEM, V267, P15635; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Yokote K, 1996, J BIOL CHEM, V271, P30942, DOI 10.1074/jbc.271.48.30942; YU JC, 1994, J BIOL CHEM, V269, P10668	40	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25495	25502		10.1074/jbc.273.39.25495	http://dx.doi.org/10.1074/jbc.273.39.25495			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738020	hybrid			2022-12-27	WOS:000076085400070
J	Blagoveshchenskaya, AD; Hewitt, EW; Cutler, DF				Blagoveshchenskaya, AD; Hewitt, EW; Cutler, DF			A balance of opposing signals within the cytoplasmic tail controls the lysosomal targeting of P-selectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRANULE MEMBRANE-PROTEIN; EPIDERMAL GROWTH-FACTOR; REGULATED SECRETORY PATHWAY; WEIBEL-PALADE BODIES; TRANS-GOLGI NETWORK; DI-LEUCINE MOTIF; PLASMA-MEMBRANE; ENDOTHELIAL-CELLS; ENDOCYTIC PATHWAY; EPITHELIAL-CELLS	The 35-amino acid cytoplasmic tail of the adhesion receptor P-selectin is subdivided into stop transfer, C1 and C2 domains. It contains structural signals needed for targeting this protein to specialized secretory organelles and to lysosomes. Recently, using site-directed mutagenesis of horseradish peroxidase-P-selectin chimeras, we have uncovered a novel sequence within the C1 domain, KCPL, that mediates sorting from early, transferrin-positive endosomes to lysosomes and therefore operates as a positive lysosomal targeting signal (Blagoveshchenskaya, A. D., Norcott, J. P., and Cutler, D. F. (1998) J. Biol. Chem. 273, 2729-2737). In the current study, we examined lysosomal targeting by both subcellular fractionation and an intracellular proteolysis assay and found that a balance of positive and negative signals is required for proper lysosomal sorting of P-selectin. First, we have found that within the sequence KCPL, Cys-766 plays a major role along with Pro-767, whereas Lys-765 and Leu-768 make no contribution to promoting lysosomal targeting. In addition, horseradish peroxidase-P-selectin chimeras were capable of acylation in vivo with [H-3]palmitic acid at Cys-766, since no labeling of a chimera in which Cys-766 was replaced with Ala was detected. Second, analysis of mutations within the C2 domain revealed that substitution of two sequences, YGVF and DPSP, causes an increase in both lysosomal targeting and intracellular proteolysis suggesting the presence of lysosomal avoidance signals. The inhibition or promotion of lysosomal targeting resulted from alterations in endosomal sorting since internalization was not changed in parallel with lysosomal delivery. Analysis of the double mutants KCPL/YGVF or KCPL/DPSP revealed that although the positive lysosomal targeting signal operates in the early/sorting transferrin-positive endosomes, the negative lysosomal targeting (lysosomal avoidance) signals act at later stages of the endocytic pathway, most likely in late endosomal compartments.	UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England; UCL, Dept Biochem, London WC1E 6BT, England	University of London; University College London; University of London; University College London	Cutler, DF (corresponding author), UCL, MRC, Mol Cell Biol Lab, Gower St, London WC1E 6BT, England.	d.cutler@ucl.ac.uk		Hewitt, Eric/0000-0002-6238-6303; Cutler, Daniel/0000-0002-4288-7530	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERMAN CL, 1986, J CLIN INVEST, V78, P130, DOI 10.1172/JCI112542; Blagoveshchenskaya AD, 1998, J BIOL CHEM, V273, P2729, DOI 10.1074/jbc.273.5.2729; BONFANTI R, 1989, BLOOD, V73, P1109; Bonifacino JS, 1996, P ASSOC AM PHYSICIAN, V108, P285; Bright NA, 1997, J CELL SCI, V110, P2027; CHEN HJ, 1993, J BIOL CHEM, V268, P22338; DISDIER M, 1992, MOL BIOL CELL, V3, P309, DOI 10.1091/mbc.3.3.309; Dittrich E, 1996, J BIOL CHEM, V271, P5487, DOI 10.1074/jbc.271.10.5487; DUNCAN JR, 1988, J CELL BIOL, V106, P617, DOI 10.1083/jcb.106.3.617; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FUJIMOTO T, 1993, BLOOD, V82, P1758; FUJIMOTO T, 1993, J BIOL CHEM, V268, P11394; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; GREEN SA, 1994, J CELL BIOL, V124, P435, DOI 10.1083/jcb.124.4.435; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; HAMBURGER SA, 1990, BLOOD, V75, P550; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HATTORI R, 1989, J BIOL CHEM, V264, P7768; Heijnen HFG, 1998, BLOOD, V91, P2313, DOI 10.1182/blood.V91.7.2313.2313_2313_2325; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KAWATE N, 1994, J BIOL CHEM, V269, P30651; KOEDAM JA, 1992, J CELL BIOL, V116, P617, DOI 10.1083/jcb.116.3.617; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; Kornilova E, 1996, J BIOL CHEM, V271, P30340, DOI 10.1074/jbc.271.48.30340; KORNILOVA ES, 1992, ONCOGENE, V7, P511; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; MARKS MS, 1995, J CELL BIOL, V131, P351, DOI 10.1083/jcb.131.2.351; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MELLMAN I, 1984, J CELL BIOL, V98, P1170, DOI 10.1083/jcb.98.4.1170; Mullock BM, 1998, J CELL BIOL, V140, P591, DOI 10.1083/jcb.140.3.591; NEUTRA MR, 1985, J HISTOCHEM CYTOCHEM, V33, P1134, DOI 10.1177/33.11.2997327; Norcott JP, 1996, J CELL BIOL, V134, P1229, DOI 10.1083/jcb.134.5.1229; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; PELCHENMATTHEWS A, 1992, J CELL BIOL, V117, P279, DOI 10.1083/jcb.117.2.279; PONNAMBALAM S, 1994, J CELL BIOL, V125, P253, DOI 10.1083/jcb.125.2.253; Riezman H, 1997, CELL, V91, P731, DOI 10.1016/S0092-8674(00)80461-4; Robinson MS, 1996, CELL, V84, P13, DOI 10.1016/S0092-8674(00)80988-5; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; ROSE JK, 1984, P NATL ACAD SCI-BIOL, V81, P2050, DOI 10.1073/pnas.81.7.2050; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; Schweizer A, 1996, J CELL BIOL, V132, P577, DOI 10.1083/jcb.132.4.577; SCHWEIZER A, 1995, J BIOL CHEM, V270, P9638, DOI 10.1074/jbc.270.16.9638; Schweizer A, 1997, P NATL ACAD SCI USA, V94, P14471, DOI 10.1073/pnas.94.26.14471; SETIADI H, 1995, J BIOL CHEM, V270, P26818, DOI 10.1074/jbc.270.45.26818; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; SUBRAMANIAM M, 1993, MOL BIOL CELL, V4, P791, DOI 10.1091/mbc.4.8.791; Subtil A, 1997, J CELL BIOL, V136, P583, DOI 10.1083/jcb.136.3.583; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VANDEURS B, 1993, EUR J CELL BIOL, V61, P208; VANDEURS B, 1995, EUR J CELL BIOL, V66, P309; VEIT M, 1991, J VIROL, V65, P2491, DOI 10.1128/JVI.65.5.2491-2500.1991; Zwart DE, 1996, J BIOL CHEM, V271, P907, DOI 10.1074/jbc.271.2.907	59	22	23	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27896	27903		10.1074/jbc.273.43.27896	http://dx.doi.org/10.1074/jbc.273.43.27896			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774401	hybrid			2022-12-27	WOS:000076549800021
J	Eder, AM; Dominguez, L; Franke, TF; Ashwell, JD				Eder, AM; Dominguez, L; Franke, TF; Ashwell, JD			Phosphoinositide 3-kinase regulation of T cell receptor-mediated interleukin-2 gene expression in normal T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; GLYCOGEN-SYNTHASE KINASE-3; PHOSPHATIDYLINOSITOL 3-KINASE; IL-2 GENE; SIGNAL-TRANSDUCTION; BOVINE BRAIN; ACTIVATION; WORTMANNIN; AKT; INHIBITION	Phosphoinositide (PI) 3-kinase has been implicated in T cell receptor (TCR) signaling, either as a positive or a negative regulatory molecule. Here, we show that for normal mouse lymph node T cells, PI 3-kinase activity is required for interleukin-2 (IL-2) production following TCR-mediated activation. Furthermore, in normal T cells, inhibition of PI 3-kinase prevented activation of enzymes in the extracellular signal-regulated protein kinase (ERK) signaling pathway (MEK-1 and ERK-2). Overexpression of a dominant-negative mutant of PI 3-kinase and pharmacological inhibitors of PI 3-kinase prevented transcriptional activation of AP-1 and NF-AT, transcription factors regulated by ERK-2 and pivotal for IL-2 gene expression. Although a constitutively active form of Akt kinase, a downstream mediator of PI 3-kinase function, enhanced TCR-induced IL-2 gene transcription, it could not bypass the requirement for PI 3-kinase activity. Therefore, PI 3-kinase is likely to be involved in signaling for IL-2 production in at least two steps in the TCR-initiated signaling pathway.	NCI, Lab Immune Cell Biol, NIH, Bethesda, MD 20892 USA; Univ Santiago de Compostela, Dept Biochem & Mol Biol, Santiago De Compostela 15706, Spain; Columbia Univ, Dept Pharmacol, New York, NY 10032 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Universidade de Santiago de Compostela; Columbia University	Ashwell, JD (corresponding author), NCI, Lab Immune Cell Biol, NIH, Bldg 10,Rm 1B40, Bethesda, MD 20892 USA.							Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CARRERA AC, 1994, J BIOL CHEM, V269, P19435; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; deAos I, 1997, J BIOL CHEM, V272, P25310, DOI 10.1074/jbc.272.40.25310; delPeso L, 1997, SCIENCE, V278, P687; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; EXLEY M, 1994, J BIOL CHEM, V269, P15140; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; Jascur T, 1997, J BIOL CHEM, V272, P14483, DOI 10.1074/jbc.272.22.14483; KLIPPEL A, 1993, MOL CELL BIOL, V13, P5560, DOI 10.1128/MCB.13.9.5560; LIPS DL, 1989, J BIOL CHEM, V264, P8759; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; OKADA T, 1994, J BIOL CHEM, V269, P3563; PETRAK D, 1994, J IMMUNOL, V153, P2046; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Reif K, 1997, CURR BIOL, V7, P285, DOI 10.1016/S0960-9822(06)00151-5; RUDD CE, 1994, IMMUNOL TODAY, V15, P225, DOI 10.1016/0167-5699(94)90248-8; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; Shi J, 1997, J IMMUNOL, V158, P4688; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOKER A, 1994, J BIOL CHEM, V269, P32358; TRUITT KE, 1995, J IMMUNOL, V155, P4702; UEDA Y, 1995, INT IMMUNOL, V7, P957, DOI 10.1093/intimm/7.6.957; Vanhaesebroeck B, 1996, CANCER SURV, V27, P249; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; vonWillebrand M, 1996, EUR J BIOCHEM, V235, P828; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WARD SG, 1992, EUR J IMMUNOL, V22, P45, DOI 10.1002/eji.1830220108; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Whitehurst CE, 1996, J IMMUNOL, V156, P1020; WYMANN M, 1994, BIOCHEM J, V298, P517, DOI 10.1042/bj2980517; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; YANO H, 1993, J BIOL CHEM, V268, P25846	50	60	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28025	28031		10.1074/jbc.273.43.28025	http://dx.doi.org/10.1074/jbc.273.43.28025			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774418	hybrid			2022-12-27	WOS:000076549800038
J	Sowka, S; Hsieh, LS; Krebitz, M; Akasawa, A; Martin, BM; Starrett, D; Peterbauer, CK; Scheiner, O; Breiteneder, H				Sowka, S; Hsieh, LS; Krebitz, M; Akasawa, A; Martin, BM; Starrett, D; Peterbauer, CK; Scheiner, O; Breiteneder, H			Identification and cloning of Prs a 1, a 32-kDa endochitinase and major allergen of avocado, and its expression in the yeast Pichia pastoris	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-RUBBER LATEX; ANTIFUNGAL ACTIVITY; HEVEA-BRASILIENSIS; IGE-BINDING; CHITINASES; PLANT; HYPERSENSITIVITY; PATHOGENS; SEQUENCE; PROTEINS	Avocado, the fruit of the tropical tree Persea americana, is a source of allergens that can elicit diverse IgE-mediated reactions including anaphylaxis in sensitized individuals. We characterized a 32-kDa major avocado allergen, Prs a 1, which is recognized by 15 out of 20 avocado- and/or latex-allergic patients. Natural Prs a 1 was purified, and its N-terminal and two tryptic peptide sequences were determined. We isolated the Prs al encoding cDNA by PCR using degenerate primers and 5'-rapid amplification of cDNA ends. The Prs a 1 cDNA coded for an endochitinase of 326 amino acids with a leader peptide of 25 amino acids. We expressed Prs a 1 in the yeast Pichia pastoris at 50 mg/liter of culture medium. The recombinant Prs a I showed endochitinase activity, inhibited growth and branching of Fusarium oxysporum hyphae, and possessed IgE binding capacity. IgE cross-reactivity with latex proteins including a 20-kDa allergen, most likely prohevein, was demonstrated, providing an explanation for the commonly observed cross-sensitization between avocado and latex proteins. Sequence comparison showed that Prs a 1 and prohevein had 70% similarity in their chitin-binding domains. Characterization of chitinases as allergens has implications for engineering transgenic crops with increased levels of chitinases.	Univ Vienna, Dept Gen & Expt Pathol, A-1090 Vienna, Austria; Div Oncol Drug Prod, Rockville, MD 20852 USA; Natl Childrens Hosp, Dept Allergy, Setagaya Ku, Tokyo 154, Japan; NIMH, Clin Neurosci Branch, Unit Mol Struct, Bethesda, MD 20892 USA; SE Missouri State Univ, Dept Biol, Cape Girardeau, MO 63701 USA	University of Vienna; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Breiteneder, H (corresponding author), Univ Vienna, Dept Gen & Expt Pathol, AKH-EBO-3Q,Waehringer Guertel 18-20, A-1090 Vienna, Austria.	Heimo.Breiteneder@akh-mien.ac.at	Moussa, Luciana/M-2257-2013	Peterbauer, Clemens/0000-0002-8033-198X				AHLROTH M, 1995, J ALLERGY CLIN IMMUN, V96, P167, DOI 10.1016/S0091-6749(95)70004-8; ALENIUS H, 1995, CLIN EXP ALLERGY, V25, P659, DOI 10.1111/j.1365-2222.1995.tb01114.x; Alenius H, 1996, J IMMUNOL, V156, P1618; Beezhold DH, 1996, CLIN EXP ALLERGY, V26, P416, DOI 10.1046/j.1365-2222.1996.d01-334.x; BERGHEM LER, 1974, EUR J BIOCHEM, V46, P295, DOI 10.1111/j.1432-1033.1974.tb03621.x; BLANCO C, 1994, ANN ALLERGY, V73, P309; BLANCO C, 1994, ALLERGY, V49, P454, DOI 10.1111/j.1398-9995.1994.tb00839.x; Brehler R, 1997, ALLERGY, V52, P404, DOI 10.1111/j.1398-9995.1997.tb01019.x; BREITENEDER H, 1995, EUR J BIOCHEM, V233, P484, DOI 10.1111/j.1432-1033.1995.484_2.x; BROEKAERT W, 1990, P NATL ACAD SCI USA, V87, P7633, DOI 10.1073/pnas.87.19.7633; BURKS AW, 1995, J CLIN INVEST, V96, P1715, DOI 10.1172/JCI118216; D'Auzac J., 1989, PHYSL RUBBER TREE LA; *EUR COMM, 1997, STUD NUTR FACT FOOD, P93; FILZ RJ, 1987, BIOCHEM BIOPH RES CO, V146, P870; FLACH J, 1992, EXPERIENTIA, V48, P701, DOI 10.1007/BF02124285; Grison R, 1996, NAT BIOTECHNOL, V14, P643, DOI 10.1038/nbt0596-643; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; LAVAUD F, 1995, J ALLERGY CLIN IMMUN, V95, P557, DOI 10.1016/S0091-6749(95)70318-7; LEAH R, 1991, J BIOL CHEM, V266, P1564; LEUNG PSC, 1994, J ALLERGY CLIN IMMUN, V94, P882, DOI 10.1016/0091-6749(94)90156-2; LIN W, 1994, BIOTECHNOLOGY, V12, P686; MARTIN MN, 1991, PLANT PHYSIOL, V95, P469, DOI 10.1104/pp.95.2.469; MELCHERS LS, 1994, PLANT J, V5, P469, DOI 10.1046/j.1365-313X.1994.5040469.x; MIKKOLA J, 1997, J ALLERGY CLIN IMMUN, V99, P342; Nordlee JA, 1996, NEW ENGL J MED, V334, P688, DOI 10.1056/NEJM199603143341103; Posch A, 1997, J ALLERGY CLIN IMMUN, V99, P385, DOI 10.1016/S0091-6749(97)70057-5; ROBERTS WK, 1986, BIOCHIM BIOPHYS ACTA, V880, P161, DOI 10.1016/0304-4165(86)90076-0; ROBERTS WK, 1988, J GEN MICROBIOL, V134, P169; SHUGAR D, 1952, BIOCHIM BIOPHYS ACTA, V8, P302, DOI 10.1016/0006-3002(52)90045-0; SLATER JE, 1997, ALLERGY ALLERGIC DIS, V2, P981; STARRETT DA, 1993, PLANT PHYSIOL, V103, P227, DOI 10.1104/pp.103.1.227; STINTZI A, 1993, BIOCHIMIE, V75, P687, DOI 10.1016/0300-9084(93)90100-7; TELEZDIAZ G, 1995, ALLERGY PROC, V16, P241, DOI 10.2500/108854195778702594; Turjanmaa K, 1996, ALLERGY, V51, P593, DOI 10.1111/j.1398-9995.1996.tb04678.x; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VANEKKREBITZ M, 1995, BIOCHEM BIOPH RES CO, V214, P538, DOI 10.1006/bbrc.1995.2320; WIRTH SJ, 1990, J MICROBIOL METH, V12, P197, DOI 10.1016/0167-7012(90)90031-Z; YOUNG E, 1994, LANCET, V343, P1127, DOI 10.1016/S0140-6736(94)90234-8; [No title captured]	39	78	85	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28091	28097		10.1074/jbc.273.43.28091	http://dx.doi.org/10.1074/jbc.273.43.28091			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774427	hybrid			2022-12-27	WOS:000076549800047
J	Chiba, Y; Suzuki, M; Yoshida, S; Yoshida, A; Ikenaga, H; Takeuchi, M; Jigami, Y; Ichishima, K				Chiba, Y; Suzuki, M; Yoshida, S; Yoshida, A; Ikenaga, H; Takeuchi, M; Jigami, Y; Ichishima, K			Production of human compatible high mannose-type (Man(5)GlcNAc(2)) sugar chains in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN ERYTHROPOIETIN; LUMINAL ER PROTEINS; 1,2-ALPHA-D-MANNOSIDASE GENE; GLYCOPROTEIN-BIOSYNTHESIS; LINKED OLIGOSACCHARIDES; NUCLEOTIDE-SEQUENCE; ASPERGILLUS-SAITOI; MEDIATED RETRIEVAL; CARBOXYPEPTIDASE-Y; MOLECULAR-CLONING	A yeast mutant capable of producing Man(5)GlNAc(2) human compatible sugar chains ore glycoproteins was constructed. An expression vector for alpha-1,2-mannosidase with the "HDEL" endoplasmic reticulum retention/retrieval tag was designed and expressed in Saccharomyces cerevisiae. An in vitro alpha-1,2-mannosidase assay and Western blot analysis showed that it was successfully localized in the endoplasmic reticulum. A triple mutant yeast lacking three glycosyltransferase activities was then transformed with an alpha-1,2-mannosidase expression vector. The oligosaccharide structures of carboxypeptidase Y as well as cell surface glycoproteins were analyzed, and the recombinant yeast was shown to produce a series of high mannose-type sugar chains including Man(5)GlcNAc(2). This is the first report of a recombinant S. cerevisiae able to produce Man(5)GlcNAc(2)-oligosaccharides, the intermediate for hybrid-type and complex-type sugar chains.	Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Natl Inst Biosci & Human Technol, Ibaraki 3050046, Japan; Sohka Univ, Fac Engn, Dept Bioengn, Tokyo 1920003, Japan	Kirin Brewery Company Limited; National Institute of Advanced Industrial Science & Technology (AIST)	Takeuchi, M (corresponding author), Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanazawa Ku, 1-13-5 Fukuura, Yokohama, Kanagawa 2360004, Japan.		Chiba, Yasunori/L-7993-2018	Chiba, Yasunori/0000-0002-6401-5071				ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; CAMIRAND A, 1991, J BIOL CHEM, V266, P15120; Cowles CR, 1997, EMBO J, V16, P2769, DOI 10.1093/emboj/16.10.2769; Fujita A, 1997, BIOCHEM BIOPH RES CO, V238, P779, DOI 10.1006/bbrc.1997.7389; FUKUDA MN, 1989, BLOOD, V73, P84; GAYNOR EC, 1994, J CELL BIOL, V127, P653, DOI 10.1083/jcb.127.3.653; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; HEESEN ST, 1991, EUR J CELL BIOL, V56, P8; HERSCOVICS A, 1994, J BIOL CHEM, V269, P9864; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; INOUE T, 1995, BBA-PROTEIN STRUCT M, V1253, P141, DOI 10.1016/0167-4838(95)00195-6; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHANSEN JT, 1976, CARLSBERG RES COMMUN, V41, P1, DOI 10.1007/BF02908689; KONDO A, 1990, AGR BIOL CHEM TOKYO, V54, P2169, DOI 10.1080/00021369.1990.10870232; KUBOTA S, 1977, J BIOCHEM-TOKYO, V81, P197, DOI 10.1093/oxfordjournals.jbchem.a131436; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAL A, 1994, J BIOL CHEM, V269, P9872; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LUSSIER M, 1995, J CELL BIOL, V131, P913, DOI 10.1083/jcb.131.4.913; NAKANISHISHINDO Y, 1993, J BIOL CHEM, V268, P26338; PEAT S, 1961, J CHEM SOC, P29, DOI 10.1039/jr9610000029; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; SIKORSKI RS, 1989, GENETICS, V122, P19; SPIVAK JL, 1989, BLOOD, V73, P90; TAKEUCHI M, 1989, P NATL ACAD SCI USA, V86, P7819, DOI 10.1073/pnas.86.20.7819; TAKEUCHI M, 1991, Glycobiology, V1, P337, DOI 10.1093/glycob/1.4.337; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tremblay LO, 1998, GLYCOBIOLOGY, V8, P585, DOI 10.1093/glycob/8.6.585; TRIMBLE RB, 1983, J BIOL CHEM, V258, P2562; VIDA TA, 1990, J CELL BIOL, V111, P2871, DOI 10.1083/jcb.111.6.2871; WANG JL, 1981, J TOXICOL ENV HEALTH, V8, P639, DOI 10.1080/15287398109530098; YIP CL, 1994, P NATL ACAD SCI USA, V91, P2723, DOI 10.1073/pnas.91.7.2723; YOSHIDA T, 1995, BBA-GENE STRUCT EXPR, V1263, P159, DOI 10.1016/0167-4781(95)00101-L	37	102	145	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26298	26304		10.1074/jbc.273.41.26298	http://dx.doi.org/10.1074/jbc.273.41.26298			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756858	hybrid			2022-12-27	WOS:000076373300012
J	Overkleeft, HS; Renkema, GH; Neele, J; Vianello, P; Hung, IO; Strijland, A; van der Burg, AM; Koomen, GJ; Pandit, UK; Aerts, JMFG				Overkleeft, HS; Renkema, GH; Neele, J; Vianello, P; Hung, IO; Strijland, A; van der Burg, AM; Koomen, GJ; Pandit, UK; Aerts, JMFG			Generation of specific deoxynojirimycin-type inhibitors of the non-lysosomal glucosylceramidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAUCHER DISEASE; N-BUTYLDEOXYNOJIRIMYCIN; GLYCOLIPID BIOSYNTHESIS; ENDOPLASMIC-RETICULUM; GLUCOCEREBROSIDASE; PURIFICATION; GLUCOSIDASE; CELLS; 2ND	The existence of a non-lysosomal glucosylceramidase in human cells has been documented (van Weely, S,, Brandsma, M., Strijland, A., Tager, J, M., and Aerts, J. M, F, G. (1993) Biochim, Biophys, Acta 1181, 55-62), Hypothetically, the activity of this enzyme, which is localized near the cell surface, may influence ceramide-mediated signaling processes. To obtain insight in the physiological importance of the non-lysosomal glucosylceramidase, the availability of specific inhibitors would be helpful. Here we report on the generation of hydrophobic deoxynojirimycin (DNM) derivatives that potently inhibit the enzyme. The inhibitors were designed on the basis of the known features of the non-lysosomal glucosylceramidase and consist of a DNM moiety, an N-alkyl spacer, and a large hydrophobic group that promotes insertion in membranes, In particular, N-(5-adamantane-1-yl-methoxy)pentyl)-DNM is a very powerful inhibitor of the non-lysosomal glucosylceramidase at nanomolar concentrations. At such concentrations, the lysosomal glucocerebrosidase and alpha-glucosidase, the glucosylceramide synthase, and the N-linked glycan-trimming alpha-glucosidases of the endoplasmic reticulum are not affected.	Univ Amsterdam, Acad Med Ctr, Dept Biochem, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Dept Organ Chem, NL-1100 DE Amsterdam, Netherlands; Univ Milan, Ist Chim Farmaceut & Tossicol, Milan, Italy	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; University of Milan	Aerts, JMFG (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Biochem, POB 22700, NL-1100 DE Amsterdam, Netherlands.		Renkema, Herma/L-1489-2015; Aerts, Johannes/A-1028-2009	Renkema, Herma/0000-0002-8174-6538; Aerts, Johannes/0000-0001-8168-2565; Overkleeft, Herman/0000-0001-6976-7005				Abe A, 1996, BBA-LIPID LIPID MET, V1299, P333, DOI 10.1016/0005-2760(95)00217-0; BARTON NW, 1990, P NATL ACAD SCI USA, V87, P1913, DOI 10.1073/pnas.87.5.1913; Beutler E., 1995, METABOLIC MOL BASES, P2641; BOESHAGEN H, 1989, Patent No. 315017; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; FURBISH FS, 1981, BIOCHIM BIOPHYS ACTA, V673, P425, DOI 10.1016/0304-4165(81)90474-8; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HETTKAMP H, 1984, EUR J BIOCHEM, V142, P85, DOI 10.1111/j.1432-1033.1984.tb08253.x; HOLLAK CEM, 1994, J CLIN INVEST, V93, P1288, DOI 10.1172/JCI117084; LEGLER G, 1985, BIOL CHEM H-S, V366, P1113, DOI 10.1515/bchm3.1985.366.2.1113; OSIECKINEWMAN KM, 1986, ENZYME, V35, P147, DOI 10.1159/000469336; OVERKLEEFT HS, 1994, TETRAHEDRON, V50, P4215, DOI 10.1016/S0040-4020(01)86715-6; PLATT FM, 1994, J BIOL CHEM, V269, P27108; Platt FM, 1997, SCIENCE, V276, P428, DOI 10.1126/science.276.5311.428; PLATT FM, 1994, J BIOL CHEM, V269, P8362; STOTZ H, 1990, THESIS U BONN BONN G; TULP A, 1993, ELECTROPHORESIS, V14, P1295, DOI 10.1002/elps.11501401198; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; VANWEELY S, 1991, BIOCHIM BIOPHYS ACTA, V1096, P301, DOI 10.1016/0925-4439(91)90066-I; VANWEELY S, 1993, BIOCHIM BIOPHYS ACTA, V1181, P55, DOI 10.1016/0925-4439(93)90090-N; WANNER MJ, 1995, J ORG CHEM, V60, P5634, DOI 10.1021/jo00122a052	23	151	172	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26522	26527		10.1074/jbc.273.41.26522	http://dx.doi.org/10.1074/jbc.273.41.26522			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756888	hybrid, Green Published			2022-12-27	WOS:000076373300042
J	Straub, T; Grue, P; Uhse, A; Lisby, M; Knudsen, BR; Tange, TO; Westergaard, O; Boege, F				Straub, T; Grue, P; Uhse, A; Lisby, M; Knudsen, BR; Tange, TO; Westergaard, O; Boege, F			The RNA-splicing factor PSF/p54(nrb) controls DNA-topoisomerase I activity by a direct interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION; BINDING; PURIFICATION; ASSOCIATION; MODULATION; CLONING; PSF	DNA-topoisomerase I has been implied in RNA splicing because it catalyzes RNA strand transfer and activates serine/arginine-rich RNA-splicing factors by phosphorylation. Here, we demonstrate a direct interaction between topoisomerase I and pyrimidine tract binding protein-associated splicing factor (PSF), a cofactor of RNA splicing, which forms heterodimers with its smaller homolog, the nuclear RNA-binding protein of 54 kDa (p54(nrb)), Topoisomerase I, PSF, and p54(nrb) copurified in a 1:1:1 ratio from human A431 cell nuclear extracts. Specific binding of topoisomerase I to PSF (but not p54(nrb)) was demonstrated by coimmunoprecipitation and by far Western blotting, in which renatured blots were probed with biotinylated topoisomerase I. Chemical cross-linking of pure topoisomerase I revealed monomeric, dimeric, and trimeric enzyme forms, whereas in the presence of PSF/p54(nrb) the enzyme was cross-linked into complexes larger than homotrimers. When topoisomerase I was complexed with PSF/p54(nrb) it was 16-fold more active than the pure enzyme, which could be stimulated 5- and 16-fold by the addition of recombinant PSF or native PSF/p54(nrb), respectively. A physiological role of this stimulatory mechanism seems feasible, because topoisomerase I and PSF showed a patched colocalization in A431 cell nuclei, which varied with cell cycle.	Univ Wurzburg, Med Poliklin, D-97070 Wurzburg, Germany; Univ Aarhus, Dept Biol Mol & Struct, DK-8000 Aarhus C, Denmark	University of Wurzburg; Aarhus University	Boege, F (corresponding author), Univ Wurzburg, Med Poliklin, Klin Str 6-8, D-97070 Wurzburg, Germany.		Straub, Tobias/B-2023-2009; Lisby, Michael/K-9814-2014; Boege, Fritz/H-3261-2019	Straub, Tobias/0000-0002-0547-0453; Lisby, Michael/0000-0002-4830-5247; Knudsen, Birgitta Ruth/0000-0002-3484-3802				Bharti AK, 1996, J BIOL CHEM, V271, P1993, DOI 10.1074/jbc.271.4.1993; Boege F, 1996, J BIOL CHEM, V271, P2262, DOI 10.1074/jbc.271.4.2262; DONG BH, 1993, NUCLEIC ACIDS RES, V21, P4085, DOI 10.1093/nar/21.17.4085; Gobert C, 1996, BIOCHEMISTRY-US, V35, P5778, DOI 10.1021/bi952327w; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; Knudsen BR, 1996, J CHROMATOGR B, V684, P307, DOI 10.1016/0378-4347(96)00152-1; KORDIYAK GJ, 1994, BIOCHEMISTRY-US, V33, P13484, DOI 10.1021/bi00249a037; Lanza A, 1996, J BIOL CHEM, V271, P6978, DOI 10.1074/jbc.271.12.6978; LIU LF, 1983, METHOD ENZYMOL, V100, P171; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; Meyer KN, 1997, J CELL BIOL, V136, P775, DOI 10.1083/jcb.136.4.775; PATTON JG, 1993, GENE DEV, V7, P393, DOI 10.1101/gad.7.3.393; PEREZ I, 1997, EUKARYOTIC MRNA PROC, P127; POMMIER Y, 1995, MUTAT RES-DNA REPAIR, V337, P135, DOI 10.1016/0921-8777(95)00019-G; ROSE KM, 1988, CHROMOSOMA, V96, P411, DOI 10.1007/BF00303034; Rossi F, 1996, NATURE, V381, P80, DOI 10.1038/381080a0; SAALEM A, 1998, P AM ASSOC CANC RES, V39, P373; Sekiguchi J, 1997, J BIOL CHEM, V272, P15721, DOI 10.1074/jbc.272.25.15721; Simmons DT, 1996, VIROLOGY, V222, P365, DOI 10.1006/viro.1996.0433; STEVNSNER T, 1993, CARCINOGENESIS, V14, P1841, DOI 10.1093/carcin/14.9.1841; TSAO YP, 1993, CANCER RES, V53, P5908; ZHANG H, 1988, P NATL ACAD SCI USA, V85, P1060, DOI 10.1073/pnas.85.4.1060; ZHANG WW, 1993, BIOCHEM J, V290, P267, DOI 10.1042/bj2900267	23	74	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26261	26264		10.1074/jbc.273.41.26261	http://dx.doi.org/10.1074/jbc.273.41.26261			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756848	hybrid			2022-12-27	WOS:000076373300002
J	Huang, SS; Cerullo, MA; Huang, FW; Huang, JS				Huang, SS; Cerullo, MA; Huang, FW; Huang, JS			Activated thyroglobulin possesses a transforming growth factor-beta activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENTARY-DNA; CRYSTAL-STRUCTURE; RECEPTOR; CELLS; GROWTH-FACTOR-BETA-2; THYROCYTES; RESOLUTION; SEQUENCE; KINASE	Thyroglobulin (Tg), the thyroid hormone precursor, is a major protein component in the thyroid gland and may have other important functions. Here, we show that bovine Tg inhibited I-125-labeled transforming growth factor-beta(1) (I-125-TGF-beta(1)) binding to cell-surface TGF-beta receptors in mink lung epithelial cells with an IC50 of similar to 300 nM. After disuccinimidyl suberate (DSS) modification, reduction/alkylation, treatment with 8 M urea, 0.1% SDS, or acidic pH (pH 4-5), Tg exhibited a similar to 5-10-fold increase of I-125-TGF-beta(1) binding inhibitory activity with IC50 of similar to 30-60 nM. This inhibitory activity was an intrinsic property of the Tg and could not be segregated from Tg protein by 5% SDS-polyacrylamide gel electrophoresis or by immunoprecipitation using antiserum to Tg. Untreated Tg did not affect DNA synthesis but blocked the TGF-beta-induced inhibition of DNA synthesis in mink lung epithelial cells. After DSS activation, Tg possessed TGF-beta agonist activity and inhibited DNA synthesis of mink lung epithelial cells and rat thyroid cells. The activated Tg also exerted a small but significant TGF-beta agonist activity in transcriptional activation of plasminogen activator inhibitor-1. These results suggest that Tg possesses an authentic TGF-beta activity which can be induced by chemical modifications and treatments with denaturing agents and acidic pH.	St Louis Univ, Med Ctr, Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Huang, JS (corresponding author), St Louis Univ, Med Ctr, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.				NCI NIH HHS [CA 38808] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038808] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALVINO CG, 1995, ENDOCRINOLOGY, V136, P3179, DOI 10.1210/en.136.8.3179; Berndorfer U, 1996, J CLIN ENDOCR METAB, V81, P1918, DOI 10.1210/jc.81.5.1918; Hinck AP, 1996, BIOCHEMISTRY-US, V35, P8517, DOI 10.1021/bi9604946; Huang SS, 1997, J BIOL CHEM, V272, P27155, DOI 10.1074/jbc.272.43.27155; HUANG SS, 1988, J BIOL CHEM, V263, P1535; Leal SM, 1997, J BIOL CHEM, V272, P20572, DOI 10.1074/jbc.272.33.20572; LEMANSKY P, 1992, EUR J BIOCHEM, V209, P111, DOI 10.1111/j.1432-1033.1992.tb17267.x; LISSITZKY S, 1984, J ENDOCRINOL INVEST, V7, P65, DOI 10.1007/BF03348380; Liu QJ, 1997, J BIOL CHEM, V272, P18891, DOI 10.1074/jbc.272.30.18891; MALTHIERY Y, 1987, EUR J BIOCHEM, V165, P491, DOI 10.1111/j.1432-1033.1987.tb11466.x; MALTHIERY Y, 1989, BIOCHIMIE, V71, P195, DOI 10.1016/0300-9084(89)90057-6; MARRIQ C, 1980, EUR J BIOCHEM, V111, P33; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MERCKEN L, 1985, NATURE, V316, P647, DOI 10.1038/316647a0; MIQUELIS R, 1993, J CELL BIOL, V123, P1695, DOI 10.1083/jcb.123.6.1695; Mziaut H, 1996, ENDOCRINOLOGY, V137, P1370, DOI 10.1210/en.137.4.1370; ODA Y, 1993, J BIOL CHEM, V268, P27318; OGRADY P, 1991, BIOCHEM BIOPH RES CO, V179, P378, DOI 10.1016/0006-291X(91)91381-L; ROBERTS AB, 1991, PEPTIDE GROWTH FACTO, V1, P419; SALVATORE G, 1964, J BIOL CHEM, V239, P3267; SCHLUNEGGER MP, 1993, J MOL BIOL, V231, P445, DOI 10.1006/jmbi.1993.1293; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SHIMASAKI S, 1991, Progress in Growth Factor Research, V3, P243, DOI 10.1016/0955-2235(91)90003-M; VALENTE WA, 1983, ENDOCRINOLOGY, V112, P71, DOI 10.1210/endo-112-1-71; VANHERLE AJ, 1979, NEW ENGL J MED, V301, P307, DOI 10.1056/NEJM197908093010605; WOHL SM, 1994, J EXP MED, V180, P1587; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WRIGHT JA, 1993, CRIT REV ONCOGENESIS, V4, P473; YINGLING JM, 1995, BBA-REV CANCER, V1242, P115, DOI 10.1016/0304-419X(95)00007-2; Zheng G, 1998, ENDOCRINOLOGY, V139, P1462, DOI 10.1210/en.139.3.1462	30	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26036	26041		10.1074/jbc.273.40.26036	http://dx.doi.org/10.1074/jbc.273.40.26036			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748282	hybrid			2022-12-27	WOS:000076263100073
J	Kim, YH; Choi, CY; Lee, SJ; Conti, MA; Kim, Y				Kim, YH; Choi, CY; Lee, SJ; Conti, MA; Kim, Y			Homeodomain-interacting protein kinases, a novel family of co-repressors for homeodomain transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SPECIFICITY; HOMEOBOX GENES; EXTRADENTICLE; FTZ; EXPRESSION; SYSTEM; NK-2	A novel family of cofactors that differentially interact with homeoproteins have been identified via a yeast two-hybrid screen. The proteins contain a conserved protein kinase domain that is separated from a domain that interacts with homeoproteins and hence are termed homeodomain-interacting protein kinases (HIPKs): HIPK1, HIPK2, and HIPK3, We show that HIPKs are nuclear kinases using GFP-HIPK fusion constructs. The DNA binding activity of the NK-3 homeoprotein is greatly enhanced by HIPK2, but this effect is independent of its phosphorylation by HIPK2. In cultured cells, HIPKs localize to nuclear speckles and potentiate the repressor activities of NK homeoproteins. The co-repressor activity of HIPKs depends on both its homeodomain interaction domain and a co-repressor domain that maps to the N terminus. Thus, HIPKs represent a heretofore undescribed family of co-repressors for homeodomain transcription factors.	NHLBI, LMC, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Kim, Y (corresponding author), NHLBI, LMC, NIH, Bldg 10,Rm 8N228,10 Ctr Dr MSC1762, Bethesda, MD 20892 USA.			Lee, Seung-Jae/0000-0002-5155-5335				Burglin T.R, 1994, EVOLUTION HOMEOBOX G, P27; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Copeland JWR, 1996, NATURE, V379, P162, DOI 10.1038/379162a0; Guichet A, 1997, NATURE, V385, P548, DOI 10.1038/385548a0; HANKS SK, 1995, PROTEIN KINASE FACTS, P7; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; HEDLEY ML, 1995, P NATL ACAD SCI USA, V92, P11524, DOI 10.1073/pnas.92.25.11524; Hong SB, 1997, GENE, V198, P373, DOI 10.1016/S0378-1119(97)00340-5; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; KIM YS, 1989, P NATL ACAD SCI USA, V86, P7716, DOI 10.1073/pnas.86.20.7716; KRAUSE HM, 1989, EMBO J, V8, P1197, DOI 10.1002/j.1460-2075.1989.tb03492.x; Lee YM, 1997, J BIOL CHEM, V272, P17531, DOI 10.1074/jbc.272.28.17531; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Schott JJ, 1998, SCIENCE, V281, P108, DOI 10.1126/science.281.5373.108; SCHUBERT FR, 1995, MECH DEVELOP, V51, P99, DOI 10.1016/0925-4773(95)00358-8; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; Yu Y, 1997, NATURE, V385, P552, DOI 10.1038/385552a0	24	241	257	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25875	25879		10.1074/jbc.273.40.25875	http://dx.doi.org/10.1074/jbc.273.40.25875			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748262	hybrid			2022-12-27	WOS:000076263100053
J	Yang, YN; Turner, RS; Gaut, JR				Yang, YN; Turner, RS; Gaut, JR			The chaperone BiP/GRP78 binds to amyloid precursor protein and decreases A beta 40 and A beta 42 secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; BETA-PROTEIN; ENDOPLASMIC-RETICULUM; IN-VIVO; INTRACELLULAR PRODUCTION; HUMAN NEURONS; NT2N CELLS; PRESENILIN-1; BIP; PEPTIDE	Recent studies of cellular amyloid precursor protein (APP) metabolism demonstrate a beta-/gamma-secretase pathway resident to the endoplasmic reticulum (ER)/Golgi resulting in intracellular generation of soluble APP (APPs beta) and A beta 42 peptide. Thus, these intracellular compartments may be key sites of amyloidogenic APP metabolism and Alzheimer's disease pathogenesis. We hypothesized that the ER chaperone immunoglobulin binding protein (BiP/GRP78) binds to and facilitates correct folding of nascent APP. Metabolic labeling and immunoprecipitation of transiently transfected human embryonic kidney 293 cells demonstrated co-precipitation of APP with GRP78, revealing their transient interaction in the ER. Maturation of cellular APP was impaired by this interaction. Furthermore, the levels of APPs, A beta 40, and A beta 42 recovered in conditioned medium were lower compared with cells transfected with APP alone. Coexpression with APP of GRP78 T37G, an ATPase mutant, almost completely blocked cellular APP maturation as well as recovery of APPs, A beta 40, and A beta 42 in conditioned medium. The inhibitory effects of GRP78 and GRP78 T37G on A beta 40 and A beta 42 secretion mere magnified by co-expression with the Swedish mutation of APP (K670N/M671L). Collectively, these data suggest a transient and direct interaction of GRP78 with APP in the ER that modulates intracellular APP maturation and processing and may facilitate its correct folding.	Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Neurol, Ann Arbor, MI 48109 USA; Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Michigan System; University of Michigan	Gaut, JR (corresponding author), Univ Michigan, Inst Gerontol, 300 NIB 974-2007, Ann Arbor, MI 48109 USA.	jrgaut@umich.edu	Turner, Raymond Scott/G-2263-2011	Turner, Raymond Scott/0000-0001-7534-2935	NATIONAL INSTITUTE ON AGING [P50AG008671] Funding Source: NIH RePORTER; NIA NIH HHS [P50 AG08671, P50 AG008671] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Forman MS, 1997, J BIOL CHEM, V272, P32247, DOI 10.1074/jbc.272.51.32247; FULLER SJ, 1995, BIOCHEMISTRY-US, V34, P8091, DOI 10.1021/bi00025a015; GAUT JR, 1993, J BIOL CHEM, V268, P7248; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAAS IG, 1994, EXPERIENTIA, V50, P1012, DOI 10.1007/BF01923455; Hardy J, 1997, P NATL ACAD SCI USA, V94, P2095, DOI 10.1073/pnas.94.6.2095; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; He XY, 1998, J BIOL CHEM, V273, P10741, DOI 10.1074/jbc.273.17.10741; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Hendershot L, 1996, P NATL ACAD SCI USA, V93, P5269, DOI 10.1073/pnas.93.11.5269; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Suzuki T, 1998, J BIOL CHEM, V273, P10083, DOI 10.1074/jbc.273.17.10083; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tienari PJ, 1997, P NATL ACAD SCI USA, V94, P4125, DOI 10.1073/pnas.94.8.4125; Turner RS, 1996, J BIOL CHEM, V271, P8966, DOI 10.1074/jbc.271.15.8966; WEI JY, 1995, J BIOL CHEM, V270, P26677, DOI 10.1074/jbc.270.44.26677; WERTKIN AM, 1993, P NATL ACAD SCI USA, V90, P9513, DOI 10.1073/pnas.90.20.9513; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Yan SD, 1997, NATURE, V389, P689	33	165	176	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25552	25555		10.1074/jbc.273.40.25552	http://dx.doi.org/10.1074/jbc.273.40.25552			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748217	hybrid			2022-12-27	WOS:000076263100008
J	Rao, AW; Ceresa, BP; Santeler, SR; Pessin, JE				Rao, AW; Ceresa, BP; Santeler, SR; Pessin, JE			Expression of a dominant interfering dynamin mutant in 3T3L1 adipocytes inhibits GLUT4 endocytosis without affecting insulin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSIVE GLUCOSE-TRANSPORTER; PLECKSTRIN HOMOLOGY DOMAIN; COATED VESICLE FORMATION; ISOLATED RAT ADIPOCYTES; SKELETAL-MUSCLE; MEDIATED ENDOCYTOSIS; INTRACELLULAR SEQUESTRATION; STIMULATED TRANSLOCATION; SUBCELLULAR TRAFFICKING; RECEPTOR SUBSTRATE-1	To examine the role of clathrin-coated vesicle endocytosis in insulin receptor signaling and GLUT4 trafficking, we used recombinant adenovirus to express a dominant interfering mutant of dynamin (K44A/dynamin) in 3T3L1 adipocytes, Functional expression of K44A/dynamin, as measured by inhibition of transferrin receptor internalization, did not affect insulin-stimulated insulin receptor autophosphorylation, Shc tyrosine phosphorylation, or mitogen-activated protein kinase activation. Although the tyrosine phosphorylation of insulin receptor substrate-1 was slightly reduced, correlating with a 25% decrease in insulin receptor substrate-1-associated phosphatidylinositol 3-kinase activity, insulin-stimulated Akt kinase activation was unaffected. In contrast, expression of K44A/dynamin resulted in the cell-surface accumulation of GLUT4 under basal conditions and an inhibition of GLUT4 endocytosis without affecting insulin-stimulated GLUT4 exocytosis. These data demonstrate that disruption of clathrin-mediated endocytosis does not significantly perturb insulin receptor signal transduction pathways. Furthermore, K44A/dynamin expression causes an accumulation of GLUT4 at the cell surface, suggesting that GLUT4 vesicles exist in at least two distinct intracellular compartments, one that undergoes continuous recycling and a second that is responsive to insulin.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	Pessin, JE (corresponding author), Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033823, R01DK033823, P30DK025295] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33823, DK25295] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDO A, 1994, EMBO J, V13, P3033, DOI 10.1002/j.1460-2075.1994.tb06602.x; Araki S, 1996, BIOCHEM J, V315, P153, DOI 10.1042/bj3150153; Baron V, 1998, ENDOCRINOLOGY, V139, P3034, DOI 10.1210/en.139.6.3034; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Bevan AP, 1997, J BIOL CHEM, V272, P26833, DOI 10.1074/jbc.272.43.26833; BEVAN AP, 1995, J BIOL CHEM, V270, P10784, DOI 10.1074/jbc.270.18.10784; Biener Y, 1996, J BIOL CHEM, V271, P29489, DOI 10.1074/jbc.271.46.29489; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; Chen D, 1997, J BIOL CHEM, V272, P27401, DOI 10.1074/jbc.272.43.27401; CODERRE L, 1995, J BIOL CHEM, V270, P27584, DOI 10.1074/jbc.270.46.27584; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; CZECH MP, 1993, J BIOL CHEM, V268, P9187; CZECH MP, 1993, J CELL BIOL, V123, P127, DOI 10.1083/jcb.123.1.127; Damke H, 1996, FEBS LETT, V389, P48, DOI 10.1016/0014-5793(96)00517-0; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DECAMILLI P, 1995, CURR OPIN NEUROBIOL, V5, P559, DOI 10.1016/0959-4388(95)80059-X; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; Dobson SP, 1996, FEBS LETT, V393, P179, DOI 10.1016/0014-5793(96)00879-4; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; Garippa RJ, 1996, J BIOL CHEM, V271, P20660, DOI 10.1074/jbc.271.34.20660; Gnudi L, 1997, MOL ENDOCRINOL, V11, P67, DOI 10.1210/me.11.1.67; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HELLERHARRISON RA, 1995, J BIOL CHEM, V270, P24442, DOI 10.1074/jbc.270.41.24442; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; KUBLAOUI B, 1995, J BIOL CHEM, V270, P59, DOI 10.1074/jbc.270.1.59; LAMB JE, 1983, J BIOL CHEM, V258, P8751; Lin HC, 1997, J BIOL CHEM, V272, P25999, DOI 10.1074/jbc.272.41.25999; MARSHALL BA, 1993, J BIOL CHEM, V268, P26193; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; MIKI H, 1994, J BIOL CHEM, V269, P5489; MOULE SK, 1997, AM J CARDIOL, V80, P41; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; MUNOZ P, 1995, BIOCHEM J, V307, P273, DOI 10.1042/bj3070273; NISHIMURA H, 1993, J BIOL CHEM, V268, P19246; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; Omata W, 1997, BIOCHEM BIOPH RES CO, V241, P401, DOI 10.1006/bbrc.1997.7810; PIPER RC, 1993, J CELL BIOL, V121, P1221, DOI 10.1083/jcb.121.6.1221; PIPER RC, 1991, AM J PHYSIOL, V260, P570; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; STEPHENS JM, 1995, ENDOCR REV, V16, P529, DOI 10.1210/er.16.4.529; Turinsky J, 1996, BIOCHEM J, V313, P215, DOI 10.1042/bj3130215; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; VERHEY KJ, 1993, J CELL BIOL, V123, P137, DOI 10.1083/jcb.123.1.137; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Volchuk A, 1998, J BIOL CHEM, V273, P8169, DOI 10.1074/jbc.273.14.8169; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; YANG J, 1993, J BIOL CHEM, V268, P4600; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005	66	101	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25450	25457		10.1074/jbc.273.39.25450	http://dx.doi.org/10.1074/jbc.273.39.25450			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738014	hybrid			2022-12-27	WOS:000076085400064
J	Zhou, JS; Cribbs, L; Yi, JX; Shirokov, R; Perez-Reyes, E; Rios, E				Zhou, JS; Cribbs, L; Yi, JX; Shirokov, R; Perez-Reyes, E; Rios, E			Molecular cloning and functional expression of a skeletal muscle dihydropyridine receptor from Rana catesbeiana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM-CHANNEL; DEPENDENT PROTEIN-KINASE; 2 SIZE FORMS; CA2+ CHANNELS; ALPHA-1 SUBUNIT; BETA-SUBUNIT; ACTIVATION; INACTIVATION; SEQUENCE; FIBERS	In skeletal muscle the dihydropyridine receptor is the voltage sensor for excitation-contraction coupling and an L-type Ca2+ channel. We cloned a dihydropyridine receptor (named Fg alpha 1S) from frog skeletal muscle, where excitation-contraction coupling has been studied most extensively. Fg alpha 1S contains 5600 base pairs coding for 1688 amino acids. It is highly homologous with, and of the same length as, the C-truncated form predominant in rabbit muscle. The primary sequence has every feature needed to be an L-type Ca2+ channel and a skeletal-type voltage sensor. Currents expressed in tsA201 cells had rapid activation (5-10 ms half-time) and Ca2+ dependent inactivation. Although functional expression of the full Fg alpha 1S was difficult, the chimera consisting of Fg alpha 1S domain I in the rabbit cardiac Ca channel had high expression and a rapidly activating current. The slow native activation is therefore not determined solely by the alpha 1 subunit sequence. Its Ca2+-dependent inactivation strengthens the notion that in rabbit skeletal muscle this capability is inhibited by a C-terminal stretch (Adams, B., and Tanabe, T, (1997) J. Gen. Physiol. 110, 379-389). This molecule constitutes a new tool for studies of excitation-contraction coupling, gating, modulation, and gene expression.	Rush Univ, Dept Mol Biophys & Physiol, Chicago, IL 60612 USA; Loyola Univ, Dept Physiol, Maywood, IL 60153 USA	Rush University; Loyola University Chicago	Rios, E (corresponding author), Rush Univ, Dept Mol Biophys & Physiol, 1750 W Harrison, Chicago, IL 60612 USA.	erios@rush.edu			NIAMS NIH HHS [AR43113] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043113] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adams B, 1997, J GEN PHYSIOL, V110, P379, DOI 10.1085/jgp.110.4.379; ARMSTRONG CM, 1972, BIOCHIM BIOPHYS ACTA, V267, P605, DOI 10.1016/0005-2728(72)90194-6; ARREOLA J, 1987, J PHYSIOL-LONDON, V393, P307, DOI 10.1113/jphysiol.1987.sp016825; AVILASAKAR AJ, 1986, J MUSCLE RES CELL M, V7, P291, DOI 10.1007/BF01753649; BEAM KG, 1992, NATURE, V360, P169, DOI 10.1038/360169a0; Berjukow S, 1996, BRIT J PHARMACOL, V118, P748, DOI 10.1111/j.1476-5381.1996.tb15463.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COTA G, 1986, J PHYSIOL-LONDON, V370, P151, DOI 10.1113/jphysiol.1986.sp015927; COTA G, 1983, J PHYSIOL-LONDON, V338, P395, DOI 10.1113/jphysiol.1983.sp014679; DEJONGH KS, 1989, P NATL ACAD SCI USA, V86, P8585; DEJONGH KS, 1991, P NATL ACAD SCI USA, V88, P10778, DOI 10.1073/pnas.88.23.10778; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FELDMEYER D, 1990, J PHYSIOL-LONDON, V425, P347, DOI 10.1113/jphysiol.1990.sp018107; Ferreira G, 1997, J GEN PHYSIOL, V109, P449, DOI 10.1085/jgp.109.4.449; GARCIA J, 1990, PFLUG ARCH EUR J PHY, V417, P114, DOI 10.1007/BF00370779; GARCIA J, 1990, PFLUG ARCH EUR J PHY, V416, P210, DOI 10.1007/BF00370245; Garcia J, 1997, BIOPHYS J, V72, P2515, DOI 10.1016/S0006-3495(97)78896-9; GRABNER M, 1991, P NATL ACAD SCI USA, V88, P727, DOI 10.1073/pnas.88.3.727; HOGAN K, 1994, GENOMICS, V24, P608, DOI 10.1006/geno.1994.1677; Johnson BD, 1997, J NEUROSCI, V17, P1243; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; LAI Y, 1990, J BIOL CHEM, V265, P20839; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; Peterson BZ, 1996, J BIOL CHEM, V271, P5293, DOI 10.1074/jbc.271.10.5293; Ren DJ, 1997, J BIOL CHEM, V272, P22393, DOI 10.1074/jbc.272.36.22393; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; ROHRKASTEN A, 1988, J BIOL CHEM, V263, P15325; ROTMAN EI, 1995, J BIOL CHEM, V270, P16371, DOI 10.1074/jbc.270.27.16371; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1991, NATURE, V352, P800, DOI 10.1038/352800a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; TANG SQ, 1993, J BIOL CHEM, V268, P13026; TANG SQ, 1993, NEURON, V11, P1013, DOI 10.1016/0896-6273(93)90215-D; TOMASELLI GF, 1993, CIRC RES, V72, P491, DOI 10.1161/01.RES.72.3.491; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; WANG ZY, 1995, J PHYSIOL-LONDON, V486, P131, DOI 10.1113/jphysiol.1995.sp020797; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; Zhou JM, 1997, P NATL ACAD SCI USA, V94, P2301, DOI 10.1073/pnas.94.6.2301; ZONG ZQ, 1994, BIOCHEM BIOPH RES CO, V201, P1117, DOI 10.1006/bbrc.1994.1821	48	7	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25503	25509		10.1074/jbc.273.39.25503	http://dx.doi.org/10.1074/jbc.273.39.25503			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738021	hybrid			2022-12-27	WOS:000076085400071
J	Lakins, J; Bennett, SAL; Chen, JH; Arnold, JM; Morrissey, C; Wong, P; O'Sullivan, J; Tenniswood, M				Lakins, J; Bennett, SAL; Chen, JH; Arnold, JM; Morrissey, C; Wong, P; O'Sullivan, J; Tenniswood, M			Clusterin biogenesis is altered during apoptosis in the regressing rat ventral prostate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CELL-DEATH; SULFATED GLYCOPROTEIN-2; MESSENGER-RNA; MOLECULAR-CLONING; APOLIPOPROTEIN-J; GENE-EXPRESSION; TESTIS FLUID; BRAIN; PURIFICATION; COMPLEMENT	Clusterin was first characterized as an apoptosis-associated transcript after it was identified as testosterone-repressed prostate message (TRPM-2) that is expressed in the epithelial cells of the regressing rat ventral prostate. Increases in clusterin mRNA and protein have been consistently detected in apoptotic cell death paradigms, establishing clusterin gene expression as a prominent marker of apoptotic cell loss. However, enhanced protein expression has also been reported in surviving cells. This ambiguity makes it difficult to define the contribution of clusterin to apoptosis. To address this problem, a panel of polyclonal and monoclonal antibodies were raised against the clusterin alpha-chain, beta-chain, and mixed alpha/beta epitopes. These antibodies detect changes in the biogenesis of clusterin during apoptosis by Western analysis and immunohistochemistry. A 42-kDa glyco/isoform of clusterin appears to be up-regulated in dying epithelial cells. This glyco/isoform is apparently generated as a result of apoptosis-induced stimulation of a normal but under-utilized, synthetic pathway. These data demonstrate that clusterin synthesized by apoptotic cells can be immunologically distinguished from clusterin synthesized by surviving cells in damaged tissue.	Adirondack Biomed Res Inst, Lake Placid, NY 12946 USA; Carleton Univ, Inst Neurosci, Ottawa, ON K1S 5B6, Canada; Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada; Univ Coll Dublin, Dublin 4, Ireland	Carleton University; University of Alberta; University College Dublin	Tenniswood, M (corresponding author), Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA.			O'Sullivan, Jacintha/0000-0001-8622-9858; Tenniswood, Martin/0000-0001-7896-4019	NCI NIH HHS [CA69233-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069233] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHUJA HS, 1994, BIOCHEM CELL BIOL, V72, P523, DOI 10.1139/o94-070; Appel D, 1996, EUR J CELL BIOL, V70, P142; BENNETT SAL, 1995, ACTA NEUROPATHOL, V89, P126; BLASCHUK O, 1983, J BIOL CHEM, V258, P7714; Boggs LN, 1996, J NEUROCHEM, V67, P1324; BURSCH W, 1995, ARCH TOXICOL, V69, P253, DOI 10.1007/s002040050167; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; CHOIMIURA NH, 1992, ACTA NEUROPATHOL, V83, P260, DOI 10.1007/BF00296787; DANIK M, 1991, P NATL ACAD SCI USA, V88, P8577, DOI 10.1073/pnas.88.19.8577; DESILVA HV, 1990, BIOCHEMISTRY-US, V29, P5380, DOI 10.1021/bi00474a025; ENGLISH HF, 1985, PROSTATE, V7, P41, DOI 10.1002/pros.2990070106; ENGLISH HF, 1987, PROSTATE, V11, P229, DOI 10.1002/pros.2990110304; FRENCH LE, 1992, J CLIN INVEST, V90, P1919, DOI 10.1172/JCI116069; GRISWOLD MD, 1986, BIOCHEMISTRY-US, V25, P7265, DOI 10.1021/bi00371a003; HARTMANN K, 1991, J BIOL CHEM, V266, P9924; HELVERING LM, 1993, CANCER LETT, V71, P133, DOI 10.1016/0304-3835(93)90108-L; JENNE DE, 1992, TRENDS BIOCHEM SCI, V17, P154, DOI 10.1016/0968-0004(92)90325-4; JENNE DE, 1989, P NATL ACAD SCI USA, V86, P7123, DOI 10.1073/pnas.86.18.7123; Kapron JT, 1997, PROTEIN SCI, V6, P2120; KIRSZBAUM L, 1989, EMBO J, V8, P711, DOI 10.1002/j.1460-2075.1989.tb03430.x; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P13070, DOI 10.1074/jbc.270.22.13070; LEGER JG, 1987, BIOCHEM BIOPH RES CO, V147, P196, DOI 10.1016/S0006-291X(87)80106-7; LEGER JG, 1988, PROSTATE, V13, P131, DOI 10.1002/pros.2990130205; LITTLE SA, 1995, TERATOLOGY, V52, P41, DOI 10.1002/tera.1420520106; MARINELLI M, 1994, BIOCHEM CELL BIOL, V72, P515, DOI 10.1139/o94-069; MAY PC, 1992, MOL BRAIN RES, V15, P33, DOI 10.1016/0169-328X(92)90148-5; MAY PC, 1990, NEURON, V5, P831, DOI 10.1016/0896-6273(90)90342-D; MAY PC, 1993, ANN NY ACAD SCI, V679, P236; Moallem SA, 1996, BIOL REPROD, V55, P281, DOI 10.1095/biolreprod55.2.281; MONTPETIT ML, 1986, PROSTATE, V8, P25, DOI 10.1002/pros.2990080105; ODA T, 1994, BIOCHEM BIOPH RES CO, V204, P1131, DOI 10.1006/bbrc.1994.2580; PASHEN W, 1994, NEUROSCI LETT, V180, P5; ROULEAU M, 1990, MOL ENDOCRINOL, V4, P2003, DOI 10.1210/mend-4-12-2003; SENSIBAR JA, 1995, CANCER RES, V55, P2431; SENSIBAR JA, 1990, PROSTATE, V16, P263, DOI 10.1002/pros.2990160310; TENNISWOOD MP, 1992, CANCER METAST REV, V11, P197, DOI 10.1007/BF00048064; WILSON MR, 1994, CLUSTERIN FUNCTION V, P75; WONG P, 1993, J BIOL CHEM, V268, P5021; WONG P, 1994, BIOCHEM CELL BIOL, V72, P439, DOI 10.1139/o94-058; WU DG, 1989, J BIOL CHEM, V264, P17469; ZLOKOVIC BV, 1994, BIOCHEM BIOPH RES CO, V205, P1431, DOI 10.1006/bbrc.1994.2825	41	100	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27887	27895		10.1074/jbc.273.43.27887	http://dx.doi.org/10.1074/jbc.273.43.27887			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774400	hybrid			2022-12-27	WOS:000076549800020
J	Binstadt, BA; Billadeau, DD; Jevremovic, D; Williams, BL; Fang, N; Yi, TL; Koretzky, GA; Abraham, RT; Leibson, PJ				Binstadt, BA; Billadeau, DD; Jevremovic, D; Williams, BL; Fang, N; Yi, TL; Koretzky, GA; Abraham, RT; Leibson, PJ			SLP-76 is a direct substrate of SHP-1 recruited to killer cell inhibitory receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; FC-RECEPTOR; NK CELLS; ACTIVATION; ZAP-70; SYK; KINASES; RECOGNITION	Activation of immune system cells via antigen-, Fc-, or natural killer cell-triggering-receptor stimulation is aborted by co-engagement of inhibitory receptors, Negative signaling by killer cell inhibitory receptors and related receptors depends on the Src homology 2 (SH2)-containing protein tyrosine phosphatase SHP-1, Using a combination of direct binding and functional assays, we demonstrated that the SH2 domain-containing leukocyte protein 76 (SLP-76) is a specific target for dephosphorylation by SHP-1 in T cells and natural killer cells. Furthermore, we showed that tyrosine-phosphorylated SLP-76 is required for optimal activation of cytotoxic lymphocytes, suggesting that the targeted dephosphorylation of SLP-76 by SHP-1 is an important mechanism for the negative regulation of immune cell activation by inhibitory receptors.	Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Interdisciplinary Grad Program Immunol, Iowa City, IA 52242 USA; Cleveland Clin Fdn, Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA	Mayo Clinic; University of Iowa; University of Iowa; University of Iowa; Cleveland Clinic Foundation	Leibson, PJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA.	leibson.paul@mayo.edu	Binstadt, Bryce/N-1305-2013; Koretzky, Gary/AAU-5381-2021	Binstadt, Bryce/0000-0003-3127-3856; Jevremovic, Dragan/0000-0002-1792-5822	NATIONAL CANCER INSTITUTE [R01CA047752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM053256, R01GM047286, R01GM053256] Funding Source: NIH RePORTER; NCI NIH HHS [CA47752] Funding Source: Medline; NIGMS NIH HHS [GM47286, GM53256] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Binstadt BA, 1996, IMMUNITY, V5, P629, DOI 10.1016/S1074-7613(00)80276-9; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; Blery M, 1997, J BIOL CHEM, V272, P8989; Brown MG, 1997, IMMUNOL REV, V155, P53, DOI 10.1111/j.1600-065X.1997.tb00939.x; Brumbaugh KM, 1997, J EXP MED, V186, P1965, DOI 10.1084/jem.186.12.1965; Burshtyn DN, 1997, J BIOL CHEM, V272, P13066, DOI 10.1074/jbc.272.20.13066; Burshtyn DN, 1997, TRENDS CELL BIOL, V7, P473, DOI 10.1016/S0962-8924(97)01167-7; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; Cambier JC, 1997, P NATL ACAD SCI USA, V94, P5993, DOI 10.1073/pnas.94.12.5993; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; Colonna M, 1997, IMMUNOL REV, V155, P127, DOI 10.1111/j.1600-065X.1997.tb00945.x; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; DANDREA A, 1995, J IMMUNOL, V155, P2306; DAVID M, 1995, MOL CELL BIOL, V15, P7050; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; Fang N, 1996, J IMMUNOL, V157, P3769; FARGNOLI J, 1995, J BIOL CHEM, V270, P26533, DOI 10.1074/jbc.270.44.26533; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Fry AM, 1996, J EXP MED, V184, P295, DOI 10.1084/jem.184.1.295; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Gupta N, 1997, J EXP MED, V186, P473, DOI 10.1084/jem.186.3.473; HendricksTaylor LR, 1997, J BIOL CHEM, V272, P1363, DOI 10.1074/jbc.272.2.1363; HIPPEN KL, 1993, BIOCHEMISTRY-US, V32, P12405, DOI 10.1021/bi00097a019; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; JAIO H, 1996, MOL CELL BIOL, V16, P6985; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; Lanier LL, 1997, IMMUNITY, V6, P371, DOI 10.1016/S1074-7613(00)80280-0; Lanier LL, 1998, NATURE, V391, P703, DOI 10.1038/35642; LANKESTER AC, 1995, J BIOL CHEM, V270, P20305, DOI 10.1074/jbc.270.35.20305; Law CL, 1996, MOL CELL BIOL, V16, P1305; Leibson PJ, 1997, IMMUNITY, V6, P655, DOI 10.1016/S1074-7613(00)80441-0; Long EO, 1997, CURR OPIN IMMUNOL, V9, P344, DOI 10.1016/S0952-7915(97)80080-5; Mizuno K, 1996, J EXP MED, V184, P457, DOI 10.1084/jem.184.2.457; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Neel BG, 1997, CURR OPIN IMMUNOL, V9, P405, DOI 10.1016/S0952-7915(97)80088-X; Olcese L, 1996, J IMMUNOL, V156, P4531; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; PERUSSIA B, 1984, J IMMUNOL, V132, P1410; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; Scharenberg AM, 1996, CELL, V87, P961, DOI 10.1016/S0092-8674(00)81790-0; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TING AT, 1995, J BIOL CHEM, V270, P16415, DOI 10.1074/jbc.270.27.16415; Valiante NM, 1996, J EXP MED, V184, P2243, DOI 10.1084/jem.184.6.2243; Vely F, 1997, J IMMUNOL, V159, P2075; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; WINDEBANK KP, 1988, J IMMUNOL, V141, P3951; Wu J, 1997, J EXP MED, V185, P1877, DOI 10.1084/jem.185.10.1877; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040	59	103	107	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27518	27523		10.1074/jbc.273.42.27518	http://dx.doi.org/10.1074/jbc.273.42.27518			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765283	hybrid			2022-12-27	WOS:000076448000070
J	Klein, DE; Lee, A; Frank, DW; Marks, MS; Lemmon, MA				Klein, DE; Lee, A; Frank, DW; Marks, MS; Lemmon, MA			The pleckstrin homology domains of dynamin isoforms require oligomerization for high affinity phosphoinositide binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; RECEPTOR-MEDIATED ENDOCYTOSIS; COATED VESICLE FORMATION; PH DOMAIN; ACIDIC PHOSPHOLIPIDS; DIMERIZATION MODULE; CRYSTAL-STRUCTURE; NERVE-TERMINALS; GTPASE ACTIVITY; CROSS-LINKING	The dynamins are 100-kDa GTPases involved in the scission event required for formation of endocytotic vesicles. The two main described mammalian dynamins (dynamin-1 and dynamin-2) both contain a pleckstrin homology (PH) domain, which has been implicated in dynamin binding to (and activation by) acidic phospholipids, most notably phosphoinositides. We demonstrate that the PH domains of both dynamin isoforms require oligomerization for high affinity phosphoinositide binding. Strong phosphoinositide binding was detected only when the PH domains were dimerized by fusion to glutathione S-transferase, or via a single engineered intermolecular disulfide bond. Phosphoinositide binding specificities agreed reasonably with reported effects of different phospholipids on dynamin GTPase activity. Although they differ in their ability to inhibit rapid endocytosis in adrenal chromaffin cells, the dynamin-1 and dynamin-2 PH domains showed identical phosphoinositide binding specificities. Since oligomerization is required for binding of the dynamin PH domain to phosphoinositides, it follows that PH domain mediated phosphoinositide binding will favor oligomerization of intact dynamin (which has an inherent tendency to self-associate). We propose that the dynamin PH domain thus mediates the observed cooperative binding of dynamin to membranes containing acidic phospholipids and promotes the self-assembly that is critical for both stimulation of its GTPase activity and its ability to achieve membrane scission.	Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Johnson Res Fdn, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Lemmon, MA (corresponding author), Univ Penn, Sch Med, Dept Biochem & Biophys, A606 Richards Bldg,3700 Hamilton Walk, Philadelphia, PA 19104 USA.		Marks, Michael S/Q-7223-2019	Marks, Michael S/0000-0001-7435-7262; Lemmon, Mark/0000-0002-3379-5319; Klein, Daryl/0000-0002-7188-0450	NIAID NIH HHS [1R21AI42617-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI042617] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARTALEJO CJ, 1997, EMBO J, V15, P1565; Barylko B, 1998, J BIOL CHEM, V273, P3791, DOI 10.1074/jbc.273.6.3791; Burks DJ, 1997, J BIOL CHEM, V272, P27716, DOI 10.1074/jbc.272.44.27716; Carr JF, 1997, J BIOL CHEM, V272, P28030, DOI 10.1074/jbc.272.44.28030; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; Damke H, 1996, FEBS LETT, V389, P48, DOI 10.1016/0014-5793(96)00517-0; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; FERGUSON KM, 1995, NAT STRUCT BIOL, V2, P715, DOI 10.1038/nsb0995-715; Fukuda M, 1996, J BIOL CHEM, V271, P18838, DOI 10.1074/jbc.271.31.18838; Fushman D, 1997, J MOL BIOL, V266, P173, DOI 10.1006/jmbi.1996.0771; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Inouye C, 1997, SCIENCE, V278, P103, DOI 10.1126/science.278.5335.103; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; LEE GF, 1995, P NATL ACAD SCI USA, V92, P3391, DOI 10.1073/pnas.92.8.3391; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; Lin HC, 1997, J BIOL CHEM, V272, P25999, DOI 10.1074/jbc.272.41.25999; MARGOLIS B, 1995, DNA CLONING, V2, P1; Maru Y, 1996, J BIOL CHEM, V271, P15353, DOI 10.1074/jbc.271.26.15353; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; MCTIGUE MA, 1995, J MOL BIOL, V246, P21, DOI 10.1006/jmbi.1994.0061; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; Nagel W, 1998, J BIOL CHEM, V273, P14853, DOI 10.1074/jbc.273.24.14853; NAKATA T, 1993, J CELL SCI, V105, P1; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Riley LG, 1996, PROTEIN ENG, V9, P223, DOI 10.1093/protein/9.2.223; RON D, 1992, BIOTECHNIQUES, V13, P866; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SCAIFE R, 1990, J CELL BIOL, V111, P3023, DOI 10.1083/jcb.111.6.3023; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TIMM D, 1994, NAT STRUCT BIOL, V1, P782, DOI 10.1038/nsb1194-782; TORTORELLA D, 1994, ANAL BIOCHEM, V217, P176, DOI 10.1006/abio.1994.1106; Tudyka T, 1997, PROTEIN SCI, V6, P2180; TUMA PL, 1994, J BIOL CHEM, V269, P30842; TUMA PL, 1993, J BIOL CHEM, V268, P17240; TUMA PL, 1995, J BIOL CHEM, V270, P26707, DOI 10.1074/jbc.270.44.26707; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; VALLEE RB, 1995, TRENDS CELL BIOL, V5, P43, DOI 10.1016/S0962-8924(00)88937-0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Warnock Dale E., 1996, Bioessays, V18, P885, DOI 10.1002/bies.950181107; WARNOCK DE, 1995, EMBO J, V14, P1322, DOI 10.1002/j.1460-2075.1995.tb07118.x; Warnock DE, 1996, J BIOL CHEM, V271, P22310, DOI 10.1074/jbc.271.37.22310; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; YAN H, 1995, ANAL BIOCHEM, V231, P455, DOI 10.1006/abio.1995.0080; Zheng J, 1996, J MOL BIOL, V255, P14, DOI 10.1006/jmbi.1996.0002	60	168	169	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27725	27733		10.1074/jbc.273.42.27725	http://dx.doi.org/10.1074/jbc.273.42.27725			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765310	hybrid			2022-12-27	WOS:000076448000097
J	Ko, JL; Liu, HC; Minnerath, SR; Loh, HH				Ko, JL; Liu, HC; Minnerath, SR; Loh, HH			Transcriptional regulation of mouse mu-opioid receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MORPHINE-INDUCED ANALGESIA; BOX-BINDING-PROTEINS; TATA-LESS PROMOTER; MESSENGER-RNA; MOLECULAR-CLONING; CONTROL ELEMENT; TFIID COMPLEX; MICE LACKING; EXPRESSION; SP1	Previously, the existence of dual promoters was reported in mouse CL-opioid receptor (mor) gene, with mor transcription in the mouse brain predominantly initiated by the proximal promoter. In this study, we further analyzed the proximal promoter region, base pairs -450 to -249, to identify cis-DNA regulatory elements and trans-acting protein factors that are important for mor promoter activity. The results revealed that a mor inverted GA (iGA) motif and a canonical Spl binding site are required for the promoter activity. Using electrophoretic mobility shift analysis, we identified nuclear proteins that specifically bind to the mor iGA motif and that are immunologically related to Spl and Sp3. Mutation of the mor iGA motif, resulting in a loss of Sp binding, led to a 50% decrease in activity. Mutation of the canonical Spl binding site yielded a lesser (approximately 25%) loss of activity. Mutation of both motifs together resulted in an approximately 70% decrease in activity. In cotransfection assays using Drosophila SL2 cells, Spl trans-activated the promoter in a manner dependent on the presence of mor iGA and canonical Spl binding motifs. Sp3 can also trans-activate the promoter, and furthermore, Spl and Sp3 can trans-activate the mor promoter additively. Our results suggest that combined or cooperative interaction of Sp transcription factors within the proximal promoter is necessary for activation of mor gene transcription.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Ko, JL (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 3-249 Millard Hall,435 Delaware St SE, Minneapolis, MN 55455 USA.	koxxx001@maroon.tc.umn.edu			NATIONAL INSTITUTE ON DRUG ABUSE [R01DA001583, P01DA005695, R37DA001583] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00546, DA-01583, DA-05695] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Azaryan AV, 1996, NEUROCHEM RES, V21, P1411, DOI 10.1007/BF02532382; BALL HJ, 1995, J BIOL CHEM, V270, P27272, DOI 10.1074/jbc.270.45.27272; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Conn KJ, 1996, J BIOL CHEM, V271, P28853, DOI 10.1074/jbc.271.46.28853; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DELFS JM, 1994, J NEUROCHEM, V63, P777; DELFS JM, 1994, J COMP NEUROL, V345, P46, DOI 10.1002/cne.903450104; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hyman SE, 1996, SCIENCE, V273, P611, DOI 10.1126/science.273.5275.611; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JOHNSON DR, 1995, BIOTECHNIQUES, V19, P190; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Ko JL, 1997, BIOCHEM BIOPH RES CO, V234, P351, DOI 10.1006/bbrc.1997.6640; KORNER M, 1989, NEURON, V3, P563, DOI 10.1016/0896-6273(89)90266-3; Kovarik A, 1996, J BIOL CHEM, V271, P18140, DOI 10.1074/jbc.271.30.18140; KOVARIK A, 1993, J BIOL CHEM, V268, P9917; KRAUS J, 1995, BIOCHEM BIOPH RES CO, V215, P591, DOI 10.1006/bbrc.1995.2505; Lee SH, 1996, J BIOL CHEM, V271, P25292, DOI 10.1074/jbc.271.41.25292; LIANG YB, 1995, BRAIN RES, V679, P82, DOI 10.1016/0006-8993(95)00222-C; Maekawa K, 1996, PAIN, V64, P365, DOI 10.1016/0304-3959(95)00132-8; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Maldonado R, 1997, NATURE, V388, P586, DOI 10.1038/41567; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; MIN BH, 1994, P NATL ACAD SCI USA, V91, P9081, DOI 10.1073/pnas.91.19.9081; MINAMI M, 1995, NEUROSCI RES, V23, P121, DOI 10.1016/0168-0102(95)00933-K; MOTEJLEK K, 1994, J BIOL CHEM, V269, P15265; NESTLER EJ, 1994, BRAIN RES BULL, V35, P521, DOI 10.1016/0361-9230(94)90166-X; Parks CL, 1996, J BIOL CHEM, V271, P4417; PECORINO LT, 1991, MOL CELL BIOL, V11, P3139, DOI 10.1128/MCB.11.6.3139; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; Ronnekleiv OK, 1996, NEUROSCI LETT, V216, P129; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SCHOENHERR CJ, 1995, CURR OPIN NEUROBIOL, V5, P566, DOI 10.1016/0959-4388(95)80060-3; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Solecki D, 1997, J BIOL CHEM, V272, P5579, DOI 10.1074/jbc.272.9.5579; Sora I, 1997, P NATL ACAD SCI USA, V94, P1544, DOI 10.1073/pnas.94.4.1544; Tanese N, 1996, P NATL ACAD SCI USA, V93, P13611, DOI 10.1073/pnas.93.24.13611; Wood P. L., 1988, OPIATE RECEPTORS, P307	45	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27678	27685		10.1074/jbc.273.42.27678	http://dx.doi.org/10.1074/jbc.273.42.27678			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765304	hybrid			2022-12-27	WOS:000076448000091
J	Koussevitzky, S; Ne'eman, E; Sommer, A; Steffens, JC; Harel, E				Koussevitzky, S; Ne'eman, E; Sommer, A; Steffens, JC; Harel, E			Purification and properties of a novel chloroplast stromal peptidase - Processing of polyphenol oxidase and other imported precursors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPHYLL-A/B PROTEIN; OXYGEN-EVOLVING COMPLEX; PEA-CHLOROPLASTS; MOLECULAR-CLONING; ESCHERICHIA-COLI; TRANSFER SIGNALS; TRANSPORT; PATHWAY; PLANTS; IDENTIFICATION	Polyphenol oxidases (PPOs) are nuclear-encoded chloroplast proteins that are targeted to the thylakoid lumen by a bipartite presequence. The N-terminal part of this sequence is removed by a stromal processing peptidase (SPP), and the resulting intermediate is translocated across the thylakoid and processed to the mature protein. A 4800-fold-purified SPP processed a PPO precursor (pPPO) at a site identical to that occurring in organelle, The in vitro product of SPP action on pPPO was further processed and translocated by thylakoids. This SPP processed other precursors but was inactive toward those of light-harvesting chlorophyll binding proteins. The enzyme appeared to be a metalloendopeptidase, like previously reported SPPs, However, it differed in substrate specificity, apparent size, and, most significantly, cleavage site of pPPO. Whereas the processing sites of lumen proteins determined so far were relatively distant from the hydrophobic core of the thylakoid targeting domain, pPPO was cleaved immediately before this domain, Cleavage removed the twin arginine motif characteristic of thylakoid targeting domains of lumen proteins, which are translocated by the Delta pH-dependent pathway, The possible significance of these observations to PPO translocation mechanism is discussed. It is suggested that several SPPs may exist in chloroplasts with preferences for different subsets of precursors.	Hebrew Univ Jerusalem, Dept Plant Sci, IL-91904 Jerusalem, Israel; Cornell Univ, Dept Plant Breeding, Ithaca, NY 14853 USA	Hebrew University of Jerusalem; Cornell University	Harel, E (corresponding author), Hebrew Univ Jerusalem, Dept Plant Sci, IL-91904 Jerusalem, Israel.	eitanamm@vms.huji.ac.il						ABAD MS, 1991, PLANT PHYSIOL, V96, P1220, DOI 10.1104/pp.96.4.1220; ABAD MS, 1989, PLANT PHYSIOL, V90, P117, DOI 10.1104/pp.90.1.117; BASSHAM DC, 1991, J BIOL CHEM, V266, P23606; BASSHAM DC, 1994, EUR J BIOCHEM, V221, P523, DOI 10.1111/j.1432-1033.1994.tb18764.x; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Bogsch E, 1997, EMBO J, V16, P3851, DOI 10.1093/emboj/16.13.3851; BOSS PK, 1995, PLANT MOL BIOL, V27, P429, DOI 10.1007/BF00020197; BROCK IW, 1993, PLANT MOL BIOL, V23, P717, DOI 10.1007/BF00021527; CASHMORE AR, 1984, P NATL ACAD SCI-BIOL, V81, P2960, DOI 10.1073/pnas.81.10.2960; CHADDOCK AM, 1995, EMBO J, V14, P2715, DOI 10.1002/j.1460-2075.1995.tb07272.x; CHITNIS PR, 1986, J CELL BIOL, V102, P982, DOI 10.1083/jcb.102.3.982; Cline K, 1996, ANNU REV CELL DEV BI, V12, P1, DOI 10.1146/annurev.cellbio.12.1.1; COHEN Y, 1992, FEBS LETT, V302, P15, DOI 10.1016/0014-5793(92)80273-J; CONSTABEL CP, 1995, P NATL ACAD SCI USA, V92, P407, DOI 10.1073/pnas.92.2.407; CREIGHTON AM, 1995, J BIOL CHEM, V270, P1663, DOI 10.1074/jbc.270.4.1663; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; DRY IB, 1994, PLANT MOL BIOL, V26, P495, DOI 10.1007/BF00039560; HIND G, 1995, BIOCHEMISTRY-US, V34, P8157, DOI 10.1021/bi00025a022; JAMES HE, 1989, J BIOL CHEM, V264, P19573; JOY RW, 1995, PLANT PHYSIOL, V107, P1083, DOI 10.1104/pp.107.4.1083; KOHORN BD, 1986, J CELL BIOL, V102, P972, DOI 10.1083/jcb.102.3.972; LAMPPA GK, 1987, J CELL BIOL, V105, P2641, DOI 10.1083/jcb.105.6.2641; Leheny EA, 1998, PLANT PHYSIOL, V116, P805, DOI 10.1104/pp.116.2.805; Lindahl M, 1996, J BIOL CHEM, V271, P29329, DOI 10.1074/jbc.271.46.29329; LIU XQ, 1986, PLANT PHYSIOL, V81, P603, DOI 10.1104/pp.81.2.603; LUBBEN TH, 1986, P NATL ACAD SCI USA, V83, P5502, DOI 10.1073/pnas.83.15.5502; MAYER AM, 1987, PHYTOCHEMISTRY, V26, P11; MAYER AM, 1979, PHYTOCHEMISTRY, V18, P193, DOI 10.1016/0031-9422(79)80057-6; MAYER AM, 1991, FOOD ENZYMOLOGY, P373; MEADOWS JW, 1991, PLANT MOL BIOL, V16, P1085, DOI 10.1007/BF00016082; MUSGROVE JE, 1989, PLANT PHYSIOL, V90, P1616, DOI 10.1104/pp.90.4.1616; NEWMAN SM, 1993, PLANT MOL BIOL, V21, P1035, DOI 10.1007/BF00023601; OBLONG JE, 1992, EMBO J, V11, P4401, DOI 10.1002/j.1460-2075.1992.tb05540.x; Ostersetzer O, 1996, EUR J BIOCHEM, V236, P932, DOI 10.1111/j.1432-1033.1996.00932.x; PAULSEN H, 1990, PLANTA, V181, P204, DOI 10.1007/BF02411539; PECKER I, 1992, P NATL ACAD SCI USA, V89, P4962, DOI 10.1073/pnas.89.11.4962; PICHERSKY E, 1988, PLANT MOL BIOL, V11, P69, DOI 10.1007/BF00016015; Richter S, 1998, P NATL ACAD SCI USA, V95, P7463, DOI 10.1073/pnas.95.13.7463; Robinson C, 1997, TRENDS PLANT SCI, V2, P431, DOI 10.1016/S1360-1385(97)90027-3; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; Sommer A, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL III, P827; SOMMER A, 1994, PLANT PHYSIOL, V105, P1301, DOI 10.1104/pp.105.4.1301; Steffens J. C., 1994, Genetic engineering of plant secondary metabolism., P275; SU QX, 1994, BIOCHEM J, V300, P787, DOI 10.1042/bj3000787; SU QX, 1993, EUR J BIOCHEM, V217, P1039, DOI 10.1111/j.1432-1033.1993.tb18335.x; Thipyapong P, 1997, PLANT PHYSIOL, V115, P409, DOI 10.1104/pp.115.2.409; VAUGHN KC, 1988, PHYSIOL PLANTARUM, V72, P659, DOI 10.1111/j.1399-3054.1988.tb09180.x; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; YALOVSKY S, 1992, J BIOL CHEM, V267, P20689	49	36	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27064	27069		10.1074/jbc.273.42.27064	http://dx.doi.org/10.1074/jbc.273.42.27064			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765221	hybrid			2022-12-27	WOS:000076448000008
J	Tang, Y; Tie, F; Boros, I; Harrod, R; Glover, M; Giam, CZ				Tang, Y; Tie, F; Boros, I; Harrod, R; Glover, M; Giam, CZ			An extended alpha-helix and specific amino acid residues opposite the DNA-binding surface of the cAMP response element binding protein basic domain are important for human T cell lymphotropic retrovirus type I Tax binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-I; CYCLIC-AMP; TRANSACTIVATOR TAX; 21-BASE-PAIR REPEATS; CRYSTAL-STRUCTURE; CREB BINDING; TRANSCRIPTIONAL ACTIVATOR; BZIP PROTEINS; ENHANCER; COMPLEX	The human T cell lymphotropic retrovirus type I (HTLV-I) trans-activator, Tax, interacts specifically with the basic-domain/leucine-zipper (bZip) protein, cAMP response element binding protein (CREB), bound to the viral Tax-responsive element consisting of three imperfect 21-base pair repeats, each with a cAMP response element core flanked by G/C-rich sequences. Here, the minimal CREB-bZip necessary for Tax binding is shown to be composed of amino acid residues 280 341, The Tax-CREB interaction involves an uninterrupted and extended a-helix in CREB that spans most of its basic domain to include amino acid residues localized to the NH, terminus of the DNA binding region. Mutational analyses indicate that three residues, Arg(284), Met(291), and Glu(299) unique to this region of the CREB/activating transcription factor-1 subfamily of bZip proteins, constitute the contact surface for Tax, Amino acid substitutions in these positions had little impact on CREB-bZip binding to DNA but abrogated its binding to Tax. Each of the contact residues for Tax are spaced approximately two helical turns apart on the side of the bZip helix directly opposite to that of the invariant DNA-binding residues. Molecular modeling reveals the Tax-contact residues to be near the minor groove of the G/C-rich DNA in the al-base pair repeat. They most likely position Tax for minor groove contact with the G/C-rich sequences.	Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Bethesda, MD 20814 USA; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada	Uniformed Services University of the Health Sciences - USA; University of Alberta	Giam, CZ (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.			Boros, Imre/0000-0001-8504-9687	NATIONAL CANCER INSTITUTE [R01CA075688, R01CA048709] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA48709, R0 CA/GM 75688] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADYA N, 1994, P NATL ACAD SCI USA, V91, P5642, DOI 10.1073/pnas.91.12.5642; Adya N, 1994, MOL CELL BIOL, V14, P456; Bantignies F, 1996, MOL CELL BIOL, V16, P2174; BOROS IM, 1995, VIROLOGY, V214, P207, DOI 10.1006/viro.1995.9939; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; CANN AJ, 1996, VIROLOGY, P1849; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DERSE D, 1987, J VIROL, V61, P2462, DOI 10.1128/JVI.61.8.2462-2471.1987; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; GIAM CZ, 1989, J BIOL CHEM, V264, P15236; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOREN I, 1995, J VIROL, V69, P5806, DOI 10.1128/JVI.69.9.5806-5811.1995; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KELLER W, 1995, J MOL BIOL, V254, P657, DOI 10.1006/jmbi.1995.0645; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lenzmeier BA, 1998, MOL CELL BIOL, V18, P721, DOI 10.1128/MCB.18.2.721; MONTAGNE J, 1990, EMBO J, V9, P957, DOI 10.1002/j.1460-2075.1990.tb08194.x; OGATA RT, 1979, J MOL BIOL, V132, P709, DOI 10.1016/0022-2836(79)90384-X; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; ROSEN CA, 1987, P NATL ACAD SCI USA, V84, P4919, DOI 10.1073/pnas.84.14.4919; Shnyreva M, 1996, J VIROL, V70, P7478, DOI 10.1128/JVI.70.11.7478-7484.1996; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; Tie F, 1996, J VIROL, V70, P8368, DOI 10.1128/JVI.70.12.8368-8374.1996; Yin MJ, 1996, J MOL BIOL, V264, P20, DOI 10.1006/jmbi.1996.0620; YIN MJ, 1995, J VIROL, V69, P6209, DOI 10.1128/JVI.69.10.6209-6218.1995; Yin MJ, 1996, MOL CELL BIOL, V16, P3156; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	38	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27339	27346		10.1074/jbc.273.42.27339	http://dx.doi.org/10.1074/jbc.273.42.27339			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765261	hybrid			2022-12-27	WOS:000076448000048
J	Ten Hagen, BG; Hagen, FK; Balys, MM; Beres, TM; Van Wuyckhuyse, B; Tabak, LA				Ten Hagen, BG; Hagen, FK; Balys, MM; Beres, TM; Van Wuyckhuyse, B; Tabak, LA			Cloning and expression of a novel, tissue specifically expressed member of the UDP-GalNAc : polypeptide N-acetylgalactosaminyltransferase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-D-GALACTOSAMINE; ACETYL-D-GALACTOSAMINE; MOLECULAR-CLONING; CHROMOSOMAL LOCALIZATION; CDNA CLONING; MUCIN; IDENTIFICATION; GENE; SITE; MUTAGENESIS	We report the cloning and expression of the fifth member of the mammalian UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase (ppGaNTase) family. Degenerate polymerase chain reaction amplification and hybridization screening of a rat sublingual gland (RSLG) cDNA library were used to identify a novel iso form termed ppGaNTase-T5. Conceptual translation of the cDNA reveals a uniquely long stem region not observed for other members of this enzyme family. Recombinant proteins expressed transiently in COS7 cells displayed transferase activity in vitro, Relative activity and substrate preferences of ppGaNTase-T5 were compared with previously identified isoforms (ppGaNTase-T1, -T3, and -T4); ppGaNTase-T5 and -T4 glycosylated a restricted subset of peptides whereas ppGaNTase-T1 and -T3 glycosylated a broader range of substrates. Northern blot analysis revealed that ppGaNTase TB is expressed in a highly tissue-specific manner; abundant expression was seen in the RSLG, with lesser amounts of message in the stomach, small intestine, and colon. Therefore, the pattern of expression of ppGaNTase-T5 is the most restricted of all isoforms examined thus far. The identification of this novel isoform underscores the diversity and complexity of the family of genes controlling O-linked glycosylation.	Univ Rochester, Med Ctr, Ctr Oral Biol, Rochester Inst Biomed Sci, Rochester, NY 14642 USA	University of Rochester	Tabak, LA (corresponding author), Univ Rochester, Med Ctr, Ctr Oral Biol, Rochester Inst Biomed Sci, 601 Elmwood Ave,Box 611, Rochester, NY 14642 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE008108, R01DE008108] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-08108] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALBONE EF, 1994, J BIOL CHEM, V269, P16845; BEDNARCZUK TA, 1991, BIOTECHNIQUES, V10, P478; Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; DOWBENKO D, 1993, J BIOL CHEM, V268, P4525; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GUM JR, 1994, J BIOL CHEM, V269, P2440; Hagen FK, 1998, J BIOL CHEM, V273, P8268, DOI 10.1074/jbc.273.14.8268; Hagen FK, 1997, J BIOL CHEM, V272, P13843, DOI 10.1074/jbc.272.21.13843; HAGEN FK, 1993, J BIOL CHEM, V268, P18960; Hennet T, 1995, P NATL ACAD SCI USA, V92, P12070, DOI 10.1073/pnas.92.26.12070; HOMA FL, 1993, J BIOL CHEM, V268, P12609; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KINLOCH RA, 1995, P NATL ACAD SCI USA, V92, P263, DOI 10.1073/pnas.92.1.263; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Moore DD, 1995, GLOB MOB SURV; Nehrke K, 1996, J BIOL CHEM, V271, P7061, DOI 10.1074/jbc.271.12.7061; OHMORI H, 1994, J BIOL CHEM, V269, P17833; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHEKELS LL, 1995, BIOCHEM J, V311, P775, DOI 10.1042/bj3110775; SORENSEN T, 1995, J BIOL CHEM, V270, P24166, DOI 10.1074/jbc.270.41.24166; Wandall HH, 1997, J BIOL CHEM, V272, P23503, DOI 10.1074/jbc.272.38.23503; Wragg S, 1997, BIOCHEM J, V328, P193, DOI 10.1042/bj3280193; Zara J, 1996, BIOCHEM BIOPH RES CO, V228, P38, DOI 10.1006/bbrc.1996.1613	25	111	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27749	27754						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765313				2022-12-27	WOS:000076448000100
J	Wang, SF; Miura, K; Miksicek, RJ; Segraves, WA; Raikhel, AS				Wang, SF; Miura, K; Miksicek, RJ; Segraves, WA; Raikhel, AS			DNA binding and transactivation characteristics of the mosquito ecdysone receptor-Ultraspiracle complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE; RESPONSE ELEMENTS; DROSOPHILA-MELANOGASTER; DIRECT REPEATS; GLUCOCORTICOID RECEPTOR; ECDYSTEROID RECEPTOR; SUPERFAMILY MEMBERS; NUCLEAR RECEPTOR; AEDES-AEGYPTI; RETINOIC ACID	The steroid hormone 20-hydroxyecdysone is a key regulatory factor, controlling blood-meal triggered egg maturation in mosquitoes. To elucidate the ecdysone hierarchy governing this event, we cloned and characterized the ecdysone receptor (AaEcR) and the nuclear receptor Ultraspiracle (AaUSP), a retinoid X receptor homologue, from the mosquito, Aedes aegypti, which form a functional complex capable of ligand and DNA binding. Here we analyzed the DNA-binding properties of the AaEcR AaUSP heterodimer with respect to the effects of nucleotide sequence, orientation, and spacing between half-sites in natural Drosophila and synthetic ecdysone response element (EcREs). By using an electrophoretic gel mobility shift assay, we showed that AaEcR AaUSP exhibits a broad binding specificity, forming complexes with inverted (IR) and direct (DR) repeats of the nuclear receptor response element half-site consensus sequence AGGTCA separated by spacers of variable length. A single nucleotide spacer was optimal for both imperfect (IRhsp-1) and perfect (IRper-1) inverted repeats; adding or removing 1 base pair in an IRhsp-1 spacer practically abolished binding. However, changing the half-site to the consensus sequence AG;GTCA (IRper-1) increased binding of AaEcR AaUSP 10-fold over IRhsp-1 and, at the same time, reduced the stringency of the spacer length requirement, with IRper-1 to IRper-5 showing detectable binding. Spacer length was less important in DRs of AGGTCA (DR-0 to DR-5); although 4 bp was optimal, DR-3 and DR-5 bound AaEcR AaUSP almost as efficiently as DR-4. Furthermore, AaEcR AaUSP also bound DRs separated by 11-13 nucleotide spacers. Competition experiments and direct estimation of binding affinity (K-d) indicated that, given identical consensus half-sites and an optimal spacer, the AaEcR AaUSP heterodimer bound an Tl with higher affinity than a DR. Co-transfection assays utilizing CV-1 cells demonstrated that the mosquito EcR.USP heterodimer is capable of transactivating reporter constructs containing either IR-1 or DR-4. The levels of transactivation are correlated with the respective binding affinities of the response elements (IRper-1 > DR-4 > IRhsp-1). Taken together, these analyses predict broad variability in the EcREs of mosquito ecdysone-responsive genes.	Michigan State Univ, Dept Entomol, Genet Program, E Lansing, MI 48824 USA; Michigan State Univ, Dept Entomol, Cell & Mol Biol Program, E Lansing, MI 48824 USA; Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; Yale Univ, Dept Biol, New Haven, CT 06520 USA	Michigan State University; Michigan State University; Michigan State University; Yale University	Raikhel, AS (corresponding author), Michigan State Univ, Dept Entomol, Genet Program, S-150 Plant Biol Bldg, E Lansing, MI 48824 USA.	araikhel@pilot.cl.msu.edu	Miksicek, Richard/AAC-7319-2020		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036959] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-36959] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANTONIEWSKI C, 1994, MOL CELL BIOL, V14, P4465, DOI 10.1128/MCB.14.7.4465; ANTONIEWSKI C, 1993, INSECT BIOCHEM MOLEC, V23, P105, DOI 10.1016/0965-1748(93)90088-A; Antoniewski C, 1995, MOL GEN GENET, V249, P545, DOI 10.1007/BF00290580; Aumais JP, 1996, J BIOL CHEM, V271, P12568, DOI 10.1074/jbc.271.21.12568; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BOWNES M, 1986, ANNU REV ENTOMOL, V31, P507, DOI 10.1146/annurev.en.31.010186.002451; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CHERBAS L, 1991, GENE DEV, V5, P120, DOI 10.1101/gad.5.1.120; Cherbas P, 1996, METAMORPHOSIS POSTEM, P175; CHO WL, 1991, P NATL ACAD SCI USA, V88, P10821, DOI 10.1073/pnas.88.23.10821; CHO WL, 1995, INSECT BIOCHEM MOLEC, V25, P19, DOI 10.1016/0965-1748(94)00045-J; CHRISTIANSON AMK, 1992, P NATL ACAD SCI USA, V89, P11503, DOI 10.1073/pnas.89.23.11503; COONEY AJ, 1994, MECHANISM STEROID HO, P25; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DAVINO PP, 1995, MOL CELL ENDOCRINOL, V113, P1; DEITSCH KW, 1995, INSECT BIOCHEM MOLEC, V25, P449, DOI 10.1016/0965-1748(94)00082-A; DHADIALLA TS, 1994, PERSPECTIVES IN COMPARATIVE ENDOCRINOLOGY, P275; DHADIALLA TS, 1990, J BIOL CHEM, V265, P9924; Elke C, 1997, ARCH INSECT BIOCHEM, V35, P59, DOI 10.1002/(SICI)1520-6327(1997)35:1/2<59::AID-ARCH6>3.3.CO;2-O; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; Hagedorn H.H., 1989, P279; HENRICH VC, 1990, NUCLEIC ACIDS RES, V18, P4143, DOI 10.1093/nar/18.14.4143; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HORNER MA, 1995, DEV BIOL, V168, P490, DOI 10.1006/dbio.1995.1097; Kapitskaya M, 1996, MOL CELL ENDOCRINOL, V121, P119, DOI 10.1016/0303-7207(96)03847-6; KATO S, 1995, MOL CELL BIOL, V15, P5858; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; LEHMANN M, 1995, EMBO J, V14, P716, DOI 10.1002/j.1460-2075.1995.tb07050.x; LIN YG, 1993, DEV BIOL, V155, P558, DOI 10.1006/dbio.1993.1052; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARTINEZ E, 1991, EMBO J, V10, P263, DOI 10.1002/j.1460-2075.1991.tb07946.x; RAIKHEL AS, 1998, IN PRESS AM ZOOL; Riddiford L.M., 1985, P37; RIDDIHOUGH G, 1987, EMBO J, V6, P3729, DOI 10.1002/j.1460-2075.1987.tb02707.x; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Segraves William A., 1994, Seminars in Cell Biology, V5, P105, DOI 10.1006/scel.1994.1014; SOKAL RR, 1987, INTRO BIOSTATISTICS, P437; Swevers L, 1996, INSECT BIOCHEM MOLEC, V26, P217, DOI 10.1016/0965-1748(95)00097-6; THOMAS HE, 1993, NATURE, V362, P471, DOI 10.1038/362471a0; Thummel CS, 1996, TRENDS GENET, V12, P306, DOI 10.1016/0168-9525(96)10032-9; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Vogtli M, 1998, NUCLEIC ACIDS RES, V26, P2407, DOI 10.1093/nar/26.10.2407; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F	54	65	67	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27531	27540		10.1074/jbc.273.42.27531	http://dx.doi.org/10.1074/jbc.273.42.27531			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765285	hybrid			2022-12-27	WOS:000076448000072
J	Klenova, EM; Fagerlie, S; Filippova, GN; Kretzner, L; Goodwin, GH; Loring, G; Neiman, PE; Lobanenkov, VV				Klenova, EM; Fagerlie, S; Filippova, GN; Kretzner, L; Goodwin, GH; Loring, G; Neiman, PE; Lobanenkov, VV			Characterization of the chicken CTCF genomic locus, and initial study of the cell cycle-regulated promoter of the gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC GENE; TRANSCRIPTIONAL REPRESSION; MESSENGER-RNA; SEQUENCE REQUIREMENTS; FUNCTIONAL-ANALYSIS; BINDING-SITES; EXPRESSION; PROTEIN; YY1; IDENTIFICATION	CTCF is a multifunctional transcription factor encoded by a novel candidate tumor suppressor gene (Filippova, G. N., Lindblom, A., Meinke, L. J., Klenova, E. M., Neiman, P. E., Collins, S. J., Doggett, N. D., and Lobanenkov, V, V, (1998) Genes Chromosomes Cancer 22, 26-36), We characterized genomic organization of the chicken CTCF (chCTCF) gene, and studied the chCTCF promoter, Genomic locus of chCTCF contains a CC-rich untranslated exon separated from seven coding exons by a long intron, The 2-kilobase pair region upstream of the major transcription start site contains a CpG island marked by a "Not-knot" that includes sequence motifs characteristic of a TATA-less promoter of housekeeping genes. When fused upstream of a reporter chloramphenicol acetyltransferase gene, it acts as a strong transcriptional promoter in transient transfection experiments. The minimal 180-base pair chCTCF promoter region that is fully sufficient to confer high level transcriptional activity to the reporter contains high affinity binding element for the transcription factor YY1, This element is strictly conserved in chicken, mouse, and human CTCF genes. Mutations in the core nucleotides of the YY1 element reduce transcriptional activity of the minimal chCTCF promoter, indicating that the conserved YY1-binding sequence is critical for transcriptional regulation of vertebrate CTCF genes, We also noted in the chCTCF promoter several elements previously characterized in cell cycle-regulated genes, including the "cell cycle-dependent element" and "cell cycle gene homology region" motifs shown to be important for S/G(2)-specific up-regulation of cdc25C, cdc2, cyclin A, and Plk (polo-like kinase) gene promoters, Presence of the cell cycle-dependent element/cell cycle gene homology region element suggested that chCTCF expression may be cell cycle-regulated. We show that both levels of the endogenous chCTCF mRNA, and the activity of the stably transfected chCTCF promoter constructs, increase in S/G(2) cells.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Univ S Dakota, Sch Med, Vermillion, SD 57069 USA; Inst Canc Res, McElwain Labs, Sutton SM2 5NG, Surrey, England	Fred Hutchinson Cancer Center; University of Oxford; University of South Dakota; University of London; Institute of Cancer Research - UK	Lobanenkov, VV (corresponding author), Fred Hutchinson Canc Res Ctr, Suite C2-023,1100 Fairview Ave N, Seattle, WA 98109 USA.	vlobanen@fred.fhcrc.org	Lobanenkov, Victor V./AGQ-8903-2022; Lobanenkov, Victor/ABD-5710-2021	Lobanenkov, Victor/0000-0001-6665-3635	NCI NIH HHS [R01 CA68360, CA20068, CA71732] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA020068, R01CA071732, R01CA068360] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMOUYEL P, 1989, J VIROL, V63, P3382, DOI 10.1128/JVI.63.8.3382-3388.1989; BEUG H, 1982, J CELL PHYSIOL, P195; BIEGALKE BJ, 1991, VIROLOGY, V183, P381, DOI 10.1016/0042-6822(91)90151-Z; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Burcin M, 1997, MOL CELL BIOL, V17, P1281, DOI 10.1128/MCB.17.3.1281; CHALLONER PB, 1989, MOL CELL BIOL, V9, P902, DOI 10.1128/MCB.9.3.902; Chang CS, 1997, J LIGHTWAVE TECHNOL, V15, P1225; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COHEN D, 1991, J BIOL CHEM, V266, P2239; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; Filippova GN, 1998, GENE CHROMOSOME CANC, V22, P26, DOI 10.1002/(SICI)1098-2264(199805)22:1<26::AID-GCC4>3.0.CO;2-9; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; GESSLER M, 1992, GENOMICS, V12, P807, DOI 10.1016/0888-7543(92)90313-H; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; GUPTA KC, 1984, NUCLEIC ACIDS RES, V12, P3829, DOI 10.1093/nar/12.9.3829; HARRIS LC, 1991, NUCLEIC ACIDS RES, V19, P6163, DOI 10.1093/nar/19.22.6163; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HYDEDERUYSCHER RP, 1995, NUCLEIC ACIDS RES, V23, P4457, DOI 10.1093/nar/23.21.4457; ICHINOSE H, 1992, BIOCHEMISTRY-US, V31, P11546, DOI 10.1021/bi00161a036; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612; LABASTIE MC, 1994, GENOMICS, V21, P1, DOI 10.1006/geno.1994.1217; LANFRANCONE L, 1992, GENOMICS, V12, P720, DOI 10.1016/0888-7543(92)90301-8; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; Liu NS, 1997, NUCLEIC ACIDS RES, V25, P4915, DOI 10.1093/nar/25.24.4915; LOBANENKOV VV, 1986, EUR J BIOCHEM, V159, P181, DOI 10.1111/j.1432-1033.1986.tb09850.x; LOBANENKOV VV, 1990, ONCOGENE, V5, P1743; LOBANENKOV VV, 1989, GENE REGULATION AIDS, P45; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MOSCOVICI C, 1982, EXPRESSION DIFFERENT, P435; NAZERIAN K, 1975, J NATL CANCER I, V54, P453; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sanger F, 1992, Biotechnology, V24, P104; Schug J., 1997, TESS TRANSCRIPTION E; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SMALE S.T., 1994, TRANSCRIPTION MECHAN, P63; SOLOVYEV V, 1997, ISMB, V5, P294; SUGARMAN JL, 1995, MOL CELL BIOL, V15, P3282; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; Uchiumi T, 1997, J BIOL CHEM, V272, P9166; Usheva A, 1996, P NATL ACAD SCI USA, V93, P13571, DOI 10.1073/pnas.93.24.13571; Vostrov AA, 1997, J BIOL CHEM, V272, P33353, DOI 10.1074/jbc.272.52.33353; YANT SR, 1995, NUCLEIC ACIDS RES, V23, P4353, DOI 10.1093/nar/23.21.4353; YE JP, 1994, NUCLEIC ACIDS RES, V22, P5672, DOI 10.1093/nar/22.25.5672; ZENZIEGREGORY B, 1992, J BIOL CHEM, V267, P2823; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	57	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26571	26579		10.1074/jbc.273.41.26571	http://dx.doi.org/10.1074/jbc.273.41.26571			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756895	hybrid			2022-12-27	WOS:000076373300049
J	Dick, TP; Nussbaum, AK; Deeg, M; Heinemeyer, W; Groll, M; Schirle, M; Keilholz, W; Stevanovic, S; Wolf, DH; Huber, R; Rammensee, HG; Schild, H				Dick, TP; Nussbaum, AK; Deeg, M; Heinemeyer, W; Groll, M; Schirle, M; Keilholz, W; Stevanovic, S; Wolf, DH; Huber, R; Rammensee, HG; Schild, H			Contribution of proteasomal beta-subunits to the cleavage of peptide substrates analyzed with yeast mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; 20S PROTEASOME; ANTIGEN PRESENTATION; PROTEOLYTIC ACTIVITY; INTERFERON-GAMMA; BRANCHED-CHAIN; DEGRADATION; LACTACYSTIN; DESTRUCTION; ACIDOPHILUM	Proteasomes generate peptides that can be presented by major histocompatibility complex (MHC) class I molecules in vertebrate cells. Using yeast 20 S proteasomes carrying different inactivated beta-subunits, we investigated the specificities and contributions of the different beta-subunits to the degradation of polypeptide substrates containing MHC class I ligands and addressed the question of additional proteolytically active sites apart from the active beta-subunits, We found a clear correlation between the contribution of the different subunits to the cleavage of fluorogenic and long peptide substrates, with beta 5/Pre2 cleaving after hydrophobic, beta 2/Pup1 after basic, and beta 1/Pre3 after acidic residues, but with the exception that beta 2/Pup1 and beta 1/Pre3 can also cleave after some hydrophobic residues. All proteolytic activities including the "branched chain amino acid-preferring" component are associated with beta 5/Pre2, beta 1/Pre3, or beta 2/Pup1, arguing against additional proteolytic sites. Because of the high homology between yeast and mammalian 20 S proteasomes in sequence and subunit topology and the conservation of cleavage specificity between mammalian and yeast proteasomes, our results can be expected to also describe most of the proteolytic activity of mammalian 20 S proteasomes leading to the generation of MHC class I ligands.	Univ Tubingen, Inst Cell Biol, Dept Immunol, D-72076 Tubingen, Germany; Univ Stuttgart, Inst Biochem, D-70569 Stuttgart, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ Hosp, Med Res Ctr, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; University of Stuttgart; Max Planck Society; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Schild, H (corresponding author), Univ Tubingen, Inst Cell Biol, Dept Immunol, Morgenstelle 15, D-72076 Tubingen, Germany.		Groll, Michael/C-1174-2010; Groll, Michael/F-5572-2015					Arendt CS, 1997, P NATL ACAD SCI USA, V94, P7156, DOI 10.1073/pnas.94.14.7156; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; CARDOZO C, 1992, BIOCHEMISTRY-US, V31, P7373, DOI 10.1021/bi00147a023; Cardozo C, 1996, ARCH BIOCHEM BIOPHYS, V334, P113, DOI 10.1006/abbi.1996.0436; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Craiu A, 1997, P NATL ACAD SCI USA, V94, P10850, DOI 10.1073/pnas.94.20.10850; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; DEL VM, 1991, CELL, V66, P1145; Dick TP, 1996, CELL, V86, P253, DOI 10.1016/S0092-8674(00)80097-5; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FIGUEIREDOPEREIRA ME, 1995, ARCH BIOCHEM BIOPHYS, V317, P69, DOI 10.1006/abbi.1995.1137; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; GROETTRUP M, 1995, J BIOL CHEM, V270, P23808, DOI 10.1074/jbc.270.40.23808; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HARPUR AG, 1993, IMMUNOL LETT, V35, P235, DOI 10.1016/0165-2478(93)90188-8; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; Hisamatsu H, 1996, J EXP MED, V183, P1807, DOI 10.1084/jem.183.4.1807; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Kopp F, 1997, P NATL ACAD SCI USA, V94, P2939, DOI 10.1073/pnas.94.7.2939; Lehner PJ, 1996, CURR OPIN IMMUNOL, V8, P59, DOI 10.1016/S0952-7915(96)80106-3; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Niedermann G, 1997, J EXP MED, V186, P209, DOI 10.1084/jem.186.2.209; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; ORLOWSKI M, 1989, BIOCHEMISTRY-US, V28, P9270, DOI 10.1021/bi00450a006; Reidlinger J, 1997, J BIOL CHEM, V272, P24899, DOI 10.1074/jbc.272.40.24899; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SAVORY PJ, 1993, BIOCHEM J, V296, P601, DOI 10.1042/bj2960601; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Seemuller E, 1996, NATURE, V382, P468, DOI 10.1038/382468a0; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; VINITSKY A, 1994, J BIOL CHEM, V269, P29860; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0	34	210	215	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25637	25646		10.1074/jbc.273.40.25637	http://dx.doi.org/10.1074/jbc.273.40.25637			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748229	hybrid			2022-12-27	WOS:000076263100020
J	Miquel, K; Pradines, A; Terce, F; Selmi, S; Favre, G				Miquel, K; Pradines, A; Terce, F; Selmi, S; Favre, G			Competitive inhibition of choline phosphotransferase by geranylgeraniol and farnesol inhibits phosphatidylcholine synthesis and induces apoptosis in human lung adenocarcinoma A549 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; PROTEIN-KINASE-C; MITOGENIC GROWTH-FACTORS; HAMSTER OVARY CELLS; HMG-COA REDUCTASE; MEVALONATE METABOLISM; HL-60 CELLS; TYROSINE PHOSPHORYLATION; TRANSFORMED-CELLS; NUCLEAR RECEPTOR	We have previously shown that, among various isoprenoids, farnesol and geranylgeraniol specifically induced actin fiber disorganization, growth inhibition, and apoptosis in human lung adenocarcinoma A549 cells (Miquel, K., Pradines, A. and Favre, G. (1996) Biochem. Biophys. Res. Commun. 225, 869-876). Here we demonstrate that isoprenoid-induced apoptosis was preceded by an arrest in G(0)/G(1) phase. The isoprenoid effects were independent of protein prenylation and of mitogen-activated protein kinase activity. Moreover, geranylgeraniol and farnesol induced a rapid inhibition of phosphatidylcholine biosynthesis at the last step of the CDP-choline pathway controlled by choline phosphotransferase and not at the level of CTP:phosphocholine cytidylyltransferase, the key enzyme of the pathway. Inhibition of choline phosphotransferase was confirmed by in vitro assays on microsomal fractions, which clearly showed that the isoprenoids acted by competitive inhibition with the diacylglycerol binding. Exogenous phosphatidylcholine addition prevented all the biological effects of the isoprenoids, including actin fiber disorganization and apoptosis, suggesting that inhibition of phosphatidylcholine biosynthesis might be the primary event of the isoprenoid action. These data demonstrate the molecular mechanism of geranylgeraniol and farnesol effects and suggest that the mevalonate pathway, leading notably to prenylated proteins, might be linked to the control of cell proliferation through the regulation of phosphatidylcholine biosynthesis.	Inst Claudius Regaud, Lab Oncol Cellulaire & Mol, Fac Pharmaceut Sci, F-31052 Toulouse, France; Inst Claudius Regaud, Ctr Lutte Contre Canc, F-31052 Toulouse, France; Hop Purpan, INSERM, U326, F-31059 Toulouse, France	UNICANCER; Institut Claudius Regaud; UNICANCER; Institut Claudius Regaud; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Favre, G (corresponding author), Inst Claudius Regaud, Lab Oncol Cellulaire & Mol, Fac Pharmaceut Sci, 20-24 Rue Pont St Pierre,EA 2048, F-31052 Toulouse, France.		FAVRE, Gilles/K-9189-2014; Tercé, François/M-5863-2018; Pradines, Anne/M-3935-2014	FAVRE, Gilles/0000-0002-2344-1883; Tercé, François/0000-0003-4488-2167; Pradines, Anne/0000-0002-2449-678X				BANSAL VS, 1994, ARCH BIOCHEM BIOPHYS, V315, P393, DOI 10.1006/abbi.1994.1516; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOGGS KP, 1995, J BIOL CHEM, V270, P7757, DOI 10.1074/jbc.270.13.7757; BOGGS KP, 1995, J BIOL CHEM, V270, P11612, DOI 10.1074/jbc.270.19.11612; BRADFUTE DL, 1994, J BIOL CHEM, V269, P6645; BRADFUTE DL, 1992, J BIOL CHEM, V267, P18308; BROWN MS, 1980, J LIPID RES, V21, P505; Burke YD, 1997, LIPIDS, V32, P151, DOI 10.1007/s11745-997-0019-y; CHAKRABARTI R, 1991, J BIOL CHEM, V266, P12216; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CORRELL CC, 1994, J BIOL CHEM, V269, P17390; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; Cuthbert JA, 1997, CANCER RES, V57, P3498; ESKO JD, 1980, P NATL ACAD SCI-BIOL, V77, P5192, DOI 10.1073/pnas.77.9.5192; Forman BM, 1997, P NATL ACAD SCI USA, V94, P10588, DOI 10.1073/pnas.94.20.10588; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; GanaWeisz ML, 1997, BIOCHEM BIOPH RES CO, V239, P900, DOI 10.1006/bbrc.1997.7582; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HAUG JS, 1994, BBA-MOL CELL RES, V1223, P133, DOI 10.1016/0167-4889(94)90082-5; HOUWELING M, 1991, BIOCHEM J, V278, P347, DOI 10.1042/bj2780347; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; Jackowski S, 1996, J BIOL CHEM, V271, P20219, DOI 10.1074/jbc.271.34.20219; JONES KD, 1994, BIOCHEM BIOPH RES CO, V205, P1681, DOI 10.1006/bbrc.1994.2861; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; KOTHAPALLI R, 1993, LIPIDS, V28, P969, DOI 10.1007/BF02537116; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; Masuda Y, 1997, INT J CANCER, V71, P691, DOI 10.1002/(SICI)1097-0215(19970516)71:4<691::AID-IJC29>3.0.CO;2-D; McGuire TF, 1996, J BIOL CHEM, V271, P27402, DOI 10.1074/jbc.271.44.27402; Meigs TE, 1997, ARCH BIOCHEM BIOPHYS, V345, P1, DOI 10.1006/abbi.1997.0200; Meigs TE, 1996, J BIOL CHEM, V271, P7916, DOI 10.1074/jbc.271.14.7916; MEIGS TE, 1995, EXP CELL RES, V219, P461, DOI 10.1006/excr.1995.1253; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; MELNYKOVYCH G, 1992, BIOCHEM BIOPH RES CO, V186, P543, DOI 10.1016/S0006-291X(05)80842-3; Miquel K, 1996, BIOCHEM BIOPH RES CO, V225, P869, DOI 10.1006/bbrc.1996.1265; Miquel K, 1997, CANCER RES, V57, P1846; Nakajo S, 1996, BIOCHEM BIOPH RES CO, V226, P741, DOI 10.1006/bbrc.1996.1423; OHIZUMI H, 1995, J BIOCHEM-TOKYO, V117, P11, DOI 10.1093/oxfordjournals.jbchem.a124695; PEREZSALA D, 1994, BIOCHEM BIOPH RES CO, V199, P1209, DOI 10.1006/bbrc.1994.1359; Polverino AJ, 1997, J BIOL CHEM, V272, P7013, DOI 10.1074/jbc.272.11.7013; REEDQUIST KA, 1995, BIOCHEM BIOPH RES CO, V211, P665, DOI 10.1006/bbrc.1995.1863; Rusnak JM, 1996, EXP CELL RES, V224, P189, DOI 10.1006/excr.1996.0127; Sebti SM, 1997, PHARMACOL THERAPEUT, V74, P103, DOI 10.1016/S0163-7258(97)00014-4; SLEIGHT R, 1980, J BIOL CHEM, V255, P644; TERCE F, 1994, J LIPID RES, V35, P2130; TESSNER TG, 1991, J BIOL CHEM, V266, P16261; TRONCHERE H, 1994, BBA-LIPID LIPID MET, V1212, P137, DOI 10.1016/0005-2760(94)90248-8; VANCE DE, 1981, METHOD ENZYMOL, V71, P571; VOGT A, 1995, J BIOL CHEM, V270, P660, DOI 10.1074/jbc.270.2.660; Vogt A, 1996, ONCOGENE, V13, P1991; VOZIYAN PA, 1993, BIOCHEM J, V295, P757, DOI 10.1042/bj2950757; WARDEN CH, 1985, J BIOL CHEM, V260, P6006; WARDEN CH, 1984, BIOCHIM BIOPHYS ACTA, V792, P270, DOI 10.1016/0005-2760(84)90194-2; YASUGI E, 1995, BIOCHEM BIOPH RES CO, V216, P848, DOI 10.1006/bbrc.1995.2699; YAZLOVITSKAYA EM, 1995, CANCER LETT, V88, P179, DOI 10.1016/0304-3835(94)03635-V	54	117	120	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26179	26186		10.1074/jbc.273.40.26179	http://dx.doi.org/10.1074/jbc.273.40.26179			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748300	hybrid			2022-12-27	WOS:000076263100091
J	Moussaoui, M; Nogues, MV; Guasch, A; Barman, T; Travers, F; Cuchillo, CM				Moussaoui, M; Nogues, MV; Guasch, A; Barman, T; Travers, F; Cuchillo, CM			The subsites structure of bovine pancreatic ribonuclease a accounts for the abnormal kinetic behavior with cytidine 2 ',3 '-cyclic phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; BINDING SUBSITES; ALLOSTERIC MODEL; ENZYME; CLEAVAGE; ENERGETICS; EXISTENCE; CATALYSIS; COMPLEX	The kinetics of the hydrolysis of cytidine 2',3'-cyclic phosphate (C>p) to 3'-CMP by ribonuclease A are multiphasic at high substrate concentrations. We have investigated these kinetics by determining 3'-CMP formation both spectrophotometrically and by a highly specific and quantitative chemical sampling method. With the use of RNase A derivatives that lack a functional p(2) binding subsite, evidence is presented that the abnormal kinetics with the native enzyme are caused by the sequential binding of the substrate to the several subsites that make up the active site of ribonuclease, The evidence is based on the following points. 1) Some of the unusual features found with native RNase A and C>p as substrate disappear when the derivatives lacking a functional p(2) binding subsite are used. 2) The k(cat)/K-m values with oligocytidylic acids of increasing lengths tending in C>p) show a behavior that parallels the specific velocity with C>p at high concentrations: increase in going from the monomer to the trimer, a decrease from tetramer to hexamer, and then an increase in going to poly(C), 3) Adenosine increases the k(cat) obtained with a fixed concentration of C>p as substrate. 4) High concentrations of C>p protect the enzyme from digestion with subtilisin, which results in a more compact molecule, implying large substrate concentration-induced conformational changes. The data for the hydrolysis of C>p by RNase A can be fitted to a fifth order polynomial that has been derived from a kinetic scheme based on the sequential binding of several monomeric substrate molecules.	Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Bellaterra 08193, Spain; Univ Autonoma Barcelona, Inst Biol Fonamental Vicent Villar Palasi, Bellaterra 08193, Spain; CNRS, INSERM, U128, F-34293 Montpellier 5, France	Autonomous University of Barcelona; Autonomous University of Barcelona; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Nogues, MV (corresponding author), Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Bellaterra 08193, Spain.	ibbm1@cc.uab.es	Moussaoui, Mohammed/A-5172-2013; Guasch, Alicia/ABH-3427-2020; Moussaoui, Mohammed/Y-7259-2019; Nogues, M. Victoria/H-6100-2015	Moussaoui, Mohammed/0000-0001-6694-7692; Moussaoui, Mohammed/0000-0001-6694-7692; Nogues, M. Victoria/0000-0002-7104-0961				ALONSO J, 1986, ARCH BIOCHEM BIOPHYS, V246, P681, DOI 10.1016/0003-9861(86)90324-3; ARNOTT S, 1976, J MOL BIOL, V106, P735, DOI 10.1016/0022-2836(76)90262-X; ARUS C, 1982, BIOCHEMISTRY-US, V21, P4290, DOI 10.1021/bi00261a018; BARDSLEY WG, 1975, BIOCHEM J, V149, P313, DOI 10.1042/bj1490313; BOIX E, 1994, J BIOL CHEM, V269, P2529; BOQUE L, 1994, J BIOL CHEM, V269, P19707; BRUNGER AT, 1985, P NATL ACAD SCI USA, V82, P8458, DOI 10.1073/pnas.82.24.8458; CRESTFIELD AM, 1962, ARCH BIOCHEM BIOPHYS, P217; CROOK EM, 1960, BIOCHEM J, V74, P234, DOI 10.1042/bj0740234; CUATRECASAS P, 1968, SCIENCE, V162, P1491, DOI 10.1126/science.162.3861.1491; Cuchillo C. M., 1997, RIBONUCLEASES STRUCT, P272; CUCHILLO CM, 1993, FEBS LETT, V333, P207, DOI 10.1016/0014-5793(93)80654-D; DELLORENS R, 1989, PROTEIN ENG, V2, P417, DOI 10.1093/protein/2.6.417; EFTINK MR, 1983, BIOCHEMISTRY-US, V22, P5123, DOI 10.1021/bi00291a011; FERSHT A, 1985, ENZYME STRUCTURE MEC, P147; FONTECILLACAMPS JC, 1994, J BIOL CHEM, V269, P21526; GUASCH A, 1989, J CHROMATOGR, V473, P281, DOI 10.1016/S0021-9673(00)91311-6; GUASCH A, 1984, INT J BIOCHEM, V16, P1071, DOI 10.1016/0020-711X(84)90090-9; HAFFNER PH, 1973, BIOCHEMISTRY-US, V12, P1608, DOI 10.1021/bi00732a023; IRIE M, 1984, J BIOCHEM-TOKYO, V96, P89, DOI 10.1093/oxfordjournals.jbchem.a134833; JANER M, 1990, Protein Engineering, V3, P369; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; MARKUS G, 1968, J BIOL CHEM, V243, P4070; MCPHERSON A, 1986, SCIENCE, V232, P765, DOI 10.1126/science.3961503; Moussaoui M, 1996, J BIOL CHEM, V271, P4687; NOGUES MV, 1995, BBA-PROTEIN STRUCT M, V1253, P16, DOI 10.1016/0167-4838(95)00138-K; PARES X, 1991, ESSAYS BIOCHEM, V26, P89; PARES X, 1980, EUR J BIOCHEM, V105, P571, DOI 10.1111/j.1432-1033.1980.tb04534.x; PICCOLI R, 1984, J BIOL CHEM, V259, P693; RICHARDS FM, 1959, J BIOL CHEM, V234, P1459; RICHARDS FM, 1971, ENZYMES, V4, P647; RICHARDSON RM, 1988, BIOCHIM BIOPHYS ACTA, V953, P70, DOI 10.1016/0167-4838(88)90010-6; SELA M, 1957, BIOCHIM BIOPHYS ACTA, V24, P229, DOI 10.1016/0006-3002(57)90186-5; TEIPEL J, 1969, BIOCHEMISTRY-US, V8, P4656, DOI 10.1021/bi00839a064; THOMPSON JE, 1994, BIOCHEMISTRY-US, V33, P7408, DOI 10.1021/bi00189a047; WALKER EJ, 1976, BIOCHEM J, V153, P329, DOI 10.1042/bj1530329; WALKER EJ, 1975, BIOCHEM J, V147, P425, DOI 10.1042/bj1470425; WIEKER HJ, 1967, EUR J BIOCHEM, V1, P251, DOI 10.1111/j.1432-1033.1967.tb00069.x	40	34	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25565	25572		10.1074/jbc.273.40.25565	http://dx.doi.org/10.1074/jbc.273.40.25565			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748220	hybrid			2022-12-27	WOS:000076263100011
J	Nomura, H; Turco, AE; Pei, Y; Kalaydjieva, L; Schiavello, T; Weremowicz, S; Ji, WZ; Morton, CC; Meisler, M; Reeders, ST; Zhou, J				Nomura, H; Turco, AE; Pei, Y; Kalaydjieva, L; Schiavello, T; Weremowicz, S; Ji, WZ; Morton, CC; Meisler, M; Reeders, ST; Zhou, J			Identification of PKDL, a novel polycystic kidney disease 2-like gene whose murine homologue is deleted in mice with kidney and retinal defects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREDICTING COILED COILS; HAJDU-CHENEY-SYNDROME; CA2+ CHANNELS; PROTEIN; ENCODES; LOCUS; SEQUENCES; FAMILY; MODELS; FORM	Polycystin-1 and polycystin-2 are the products of PKD1 and PKD2, genes that are mutated in most cases of autosomal dominant polycystic kidney disease. Polycystin-2 shares similar to 46% homology with pore-forming domains of a number of cation channels. It has been suggested that polycystin-2 may function as a subunit of an ion channel whose activity is regulated by polycystin-1, Here we report the identification of a human gene, PKDL, which encodes a new member of the polycystin protein family designated polycystin-L, Polycystin-L has 50% amino acid sequence identity and 71% homology to polycystin-2 and has striking sequence and structural resemblance to the pore-forming alpha 1 subunits of Ca2+ channels, suggesting that polycystin-L may function as a subunit of an ion channel. The full-length transcript of PKDL is expressed at high levels in fetal tissues, including kidney and liver, and down-regulated in adult tissues. PKDL was assigned to 10q24 by fluorescence in situ hybridization and is linked to D10S603 by radiation hybrid mapping. There is no evidence of linkage to PKDL in six ADPKD families that are unlinked to PKD1 or PKD2, The mouse homologue of PKDL is deleted in Krd mice, a deletion mutant with defects in the kidney and eye. We propose that PKDL is an excellent candidate for as yet unmapped cystic diseases in man and animals.	Brigham & Womens Hosp, Div Renal, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Verona, Sch Med, Inst Genet, I-37134 Verona, Italy; Univ Toronto, Toronto, ON, Canada; Toronto Hosp, Dept Med, Div Nephrol, Toronto, ON, Canada; Edith Cowan Univ, Dept Human Biol, Perth, WA 6027, Australia; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Verona; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Edith Cowan University; University of Michigan System; University of Michigan	Zhou, J (corresponding author), Brigham & Womens Hosp, Div Renal, Dept Med, HIM 522,77 Ave Louis Pasteur, Boston, MA 02115 USA.	zhou@rics.bwh.harvard.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK051050, R01DK051050, R01DK040703] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK51050, DK40703] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ariza M, 1997, J MED GENET, V34, P587, DOI 10.1136/jmg.34.7.587; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Bihoreau MT, 1997, HUM MOL GENET, V6, P609, DOI 10.1093/hmg/6.4.609; BOGDANOVA N, 1995, HUM GENET, V95, P645; BURN TC, 1995, HUM MOL GENET, V4, P575, DOI 10.1093/hmg/4.4.575; DAOUST MC, 1995, GENOMICS, V25, P733, DOI 10.1016/0888-7543(95)80020-M; DeBry RW, 1996, GENOMICS, V33, P337, DOI 10.1006/geno.1996.0209; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Fryns JP, 1997, CLIN GENET, V51, P271; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; Genetic Computer Group, 1994, PROGR MAN WISC PACK; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; Gretz N, 1996, NEPHROL DIAL TRANSPL, V11, P46; GUAYWOODFORD LM, 1995, AM J HUM GENET, V56, P1101; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; KAPLAN P, 1995, AM J MED GENET, V56, P25, DOI 10.1002/ajmg.1320560108; KELLER SA, 1994, GENOMICS, V23, P309, DOI 10.1006/geno.1994.1506; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MARSDEN BJ, 1990, BIOCHEM CELL BIOL, V68, P587, DOI 10.1139/o90-084; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220; Pirson Y, 1996, HEPATOLOGY, V23, P249, DOI 10.1002/hep.510230208; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; Schieren G, 1996, NEPHROL DIAL TRANSPL, V11, P38; Schneider MC, 1996, GENOMICS, V38, P1, DOI 10.1006/geno.1996.0584; Sharp CK, 1997, J AM SOC NEPHROL, V8, P77; Stewart EA, 1997, GENOME RES, V7, P422, DOI 10.1101/gr.7.5.422; STULTZ CM, 1993, PROTEIN SCI, V2, P305; Torres M, 1995, DEVELOPMENT, V121, P4057; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Turco AE, 1996, AM J KIDNEY DIS, V28, P759, DOI 10.1016/S0272-6386(96)90261-9; WHITE JV, 1994, MATH BIOSCI, V119, P35, DOI 10.1016/0025-5564(94)90004-3; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; ZHAO Y, 1995, MOL CELL BIOL, V15, P4353; [No title captured]	39	128	136	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25967	25973		10.1074/jbc.273.40.25967	http://dx.doi.org/10.1074/jbc.273.40.25967			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748274	hybrid			2022-12-27	WOS:000076263100065
J	Sechler, JL; Schwarzbauer, JE				Sechler, JL; Schwarzbauer, JE			Control of cell cycle progression by fibronectin matrix architecture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; TYROSINE PHOSPHORYLATION; FOCAL ADHESIONS; PROTEIN; EXPRESSION; ACTIVATION; INHIBITION; ANCHORAGE; INTEGRINS; RECEPTOR	Developmental patterning and differentiation, maintenance of parenchymal cell function, and the size, shape, and invasiveness of tumors are all orchestrated by cell interactions with the extracellular matrix. Here we show that the fibrillar structure of fibronectin (FN) matrix encodes essential regulatory cues and controls cell proliferation and signaling through changes in matrix architecture. A matrix assembled from native FN stimulated cell growth. In contrast, a mutant FN (FN Delta III1-7) that contains all known cell binding motifs but forms a structurally distinct matrix inhibited progression from G(0)/G(1) into S phase. Furthermore, FN Delta III1-7 suppressed the stimulatory capacity of native FN and induced different levels of tyrosine phosphorylation of pp125(FAK). The differential effects on cell growth were ablated by blocking formation of matrix fibrils. Thus, modification of matrix architecture provides a novel approach to control cell proliferation.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Schwarzbauer, JE (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.	jschwarzbauer@molbio.princeton.edu		Schwarzbauer, Jean/0000-0003-1012-7593	NCI NIH HHS [CA 44627] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044627] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bohmer RM, 1996, MOL BIOL CELL, V7, P101; BOUDREAU N, 1995, TRENDS CELL BIOL, V5, P1, DOI 10.1016/S0962-8924(00)88924-2; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; CHERNOUSOV MA, 1991, J BIOL CHEM, V266, P10851; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 1990, FIBRONECTINS; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; Mercurius KO, 1998, CIRC RES, V82, P548, DOI 10.1161/01.RES.82.5.548; MORLA A, 1992, J CELL BIOL, V118, P421, DOI 10.1083/jcb.118.2.421; MOSHER DF, 1993, CURR OPIN STRUC BIOL, V3, P214, DOI 10.1016/S0959-440X(05)80155-1; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; Pasqualini R, 1996, NAT MED, V2, P1197, DOI 10.1038/nm1196-1197; PATCH LA, 1995, J CELL SCI, V108, P1371; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; SCHWARTZ CC, 1991, WILDLIFE MONOGR, P1; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Sechler JL, 1996, J CELL BIOL, V134, P573, DOI 10.1083/jcb.134.2.573; Sechler JL, 1997, MOL BIOL CELL, V8, P2563, DOI 10.1091/mbc.8.12.2563; Sechler JL, 1996, CELL ADHES COMMUN, V4, P413, DOI 10.3109/15419069709004458; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WU CY, 1993, J BIOL CHEM, V268, P21883; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	33	120	123	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25533	25536		10.1074/jbc.273.40.25533	http://dx.doi.org/10.1074/jbc.273.40.25533			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748212	hybrid			2022-12-27	WOS:000076263100003
J	Tong, JC; Margoliash, E				Tong, JC; Margoliash, E			Cytochrome c heme lyase activity of yeast mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; APOCYTOCHROME-C; SACCHAROMYCES-CEREVISIAE; INTERMEMBRANE SPACE; NEUROSPORA-CRASSA; HOLOCYTOCHROME-C; IMPORT; SYNTHETASE; PROTEINS; SPECIFICITY	A highly efficient in vitro system was established for measuring by high performance liquid chromatography the formation of holocytochrome c by yeast mitochondria. Holocytochrome c formation required reducing agents, of which dithiothreitol was the most effective. With biosynthetically made, pure Drosophila melanogaster apocytochrome c and Saccharomyces cerevisiae mitochondria, the activity of cytochrome c heme lyase amounted to about 800 fmol min(-1) mg(-1) mitochondrial protein. The kinetics were typical Michaelis-Menten (K-m similar to 1 nM), as were those of mitoplasts with broken outer membranes (K-m similar to 3 nM). As tested with mitoplasts, holocytochromes c from a range of species were found to be competitive inhibitors of heme lyase at physiological concentrations, providing a mechanism for controlling this concentration in vivo. Apocytochrome c associated with yeast mitochondria in two phases of K-d, similar to 2 x 10(-10) and 10(-8) M, respectively, whereas mitoplasts had lost the high affinity binding. A site-directed mutant of apocytochrome c (lysines 5, 7, and 8 replaced by glutamine, glutamic acid, and asparagine) was found to be converted to holocytochrome c (K-m similar to 3.3 nM; maximal activity unchanged), even though the mutations completely eliminated the high affinity binding. Thus, the high affinity binding of apocytochrome c to mitochondria is not directly related to holocytochrome c formation.	Univ Illinois, Dept Biol Sci, Mol Biol Lab, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Margoliash, E (corresponding author), Univ Illinois, Dept Biol Sci, Mol Biol Lab, M-C 066,845 W Taylor St, Chicago, IL 60607 USA.	maem@uic.edu						BASILE G, 1980, J BIOL CHEM, V255, P7181; DAUM G, 1982, J BIOL CHEM, V257, P3028; DRYGAS ME, 1989, J BIOL CHEM, V264, P17897; DUMONT ME, 1994, BIOCHEMISTRY-US, V33, P7368, DOI 10.1021/bi00189a043; DUMONT ME, 1991, MOL CELL BIOL, V11, P5487, DOI 10.1128/MCB.11.11.5487; DUMONT ME, 1987, EMBO J, V6, P235, DOI 10.1002/j.1460-2075.1987.tb04744.x; DUMONT ME, 1988, J BIOL CHEM, V263, P15928; DUMONT ME, 1996, ADV MOL CEL, V17, P103; FISHER WR, 1973, J BIOL CHEM, V248, P3188; FORSBURG SL, 1989, ANNU REV CELL BIOL, V5, P153, DOI 10.1146/annurev.cb.05.110189.001101; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; GLICK BS, 1991, METHOD CELL BIOL, V34, P389; HAKVOORT TBM, 1990, P NATL ACAD SCI USA, V87, P4996, DOI 10.1073/pnas.87.13.4996; HENNIG B, 1983, P NATL ACAD SCI-BIOL, V80, P4963, DOI 10.1073/pnas.80.16.4963; HENNIG B, 1981, EUR J BIOCHEM, V121, P203, DOI 10.1111/j.1432-1033.1981.tb06450.x; KORB H, 1978, EUR J BIOCHEM, V91, P609, DOI 10.1111/j.1432-1033.1978.tb12714.x; KOSHY TI, 1992, PROTEIN EXPRES PURIF, V3, P441, DOI 10.1016/1046-5928(92)90061-Z; LILL R, 1992, EMBO J, V11, P449, DOI 10.1002/j.1460-2075.1992.tb05074.x; MARGOLIASH E., 1966, ADVANCE PROTEIN CHEM, V21, P113, DOI 10.1016/S0065-3233(08)60128-X; MARGOLIASH E, 1959, BIOCHEM J, V71, P559, DOI 10.1042/bj0710559; MATSUURA S, 1981, P NATL ACAD SCI-BIOL, V78, P4368, DOI 10.1073/pnas.78.7.4368; MAYER A, 1995, J BIOL CHEM, V270, P12390, DOI 10.1074/jbc.270.21.12390; Moore G. R., 1990, CYTOCHROMES C EVOLUT, P161; NARGANG FE, 1988, J BIOL CHEM, V263, P9388; NICHOLSON DW, 1987, EUR J BIOCHEM, V164, P147, DOI 10.1111/j.1432-1033.1987.tb11006.x; NICHOLSON DW, 1989, P NATL ACAD SCI USA, V86, P4340, DOI 10.1073/pnas.86.12.4340; NICHOLSON DW, 1988, J BIOL CHEM, V263, P19034; Osheroff N. O., 1978, FRONTIERS BIOL ENERG, V1, P439; PEARCE DA, 1995, J BIOL CHEM, V270, P20879, DOI 10.1074/jbc.270.36.20879; Pettigrew G. W, 1987, CYTOCHROMES C BIOL A, P29; RACKER E, 1950, BIOCHIM BIOPHYS ACTA, V4, P211, DOI 10.1016/0006-3002(50)90026-6; SEGEL IH, 1975, ENZYME KINETICS, P18; SPRINKLE JR, 1990, P NATL ACAD SCI USA, V87, P5729, DOI 10.1073/pnas.87.15.5729; SPRINKLE JR, 1994, MODERN ENZYMOLOGY PR, P627; SPRINKLE JR, 1991, NEW TRENDS BIOL CHEM, P99; Steiner H, 1996, J BIOL CHEM, V271, P32605, DOI 10.1074/jbc.271.51.32605; STEINER H, 1995, J BIOL CHEM, V270, P22842, DOI 10.1074/jbc.270.39.22842; STUART RA, 1990, BIOCHEMIE PARIS, P115; SWANSON MS, 1985, P NATL ACAD SCI USA, V82, P1964, DOI 10.1073/pnas.82.7.1964; TAKANO T, 1981, J MOL BIOL, V153, P79, DOI 10.1016/0022-2836(81)90528-3; TANAKA Y, 1990, J BIOCHEM-TOKYO, V108, P7, DOI 10.1093/oxfordjournals.jbchem.a123165; TANAKA Y, 1988, J BIOCHEM-TOKYO, V104, P477, DOI 10.1093/oxfordjournals.jbchem.a122493; TANIUCHI H, 1983, J BIOL CHEM, V258, P963; VELOSO D, 1981, J BIOL CHEM, V256, P8646; VISCO C, 1985, J BIOL CHEM, V260, P6133; Wang K.Z., 1991, CHEM J CHINESE U, V14, P150; ZIMMERMANN R, 1981, EUR J BIOCHEM, V116, P455, DOI 10.1111/j.1432-1033.1981.tb05357.x	47	19	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25695	25702		10.1074/jbc.273.40.25695	http://dx.doi.org/10.1074/jbc.273.40.25695			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748237	hybrid			2022-12-27	WOS:000076263100028
J	Desaubry, L; Johnson, RA				Desaubry, L; Johnson, RA			Adenine nucleoside 3 '-tetraphosphates are novel and potent inhibitors of adenylyl cyclases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-MEDIATED INHIBITION; ADENOSINE; ATP; PURIFICATION; 3'-POLYPHOSPHATES; 2',5'-DIDEOXYADENOSINE; REQUIREMENTS; KINETICS; BINDING; METAL	2'-Deoxyadenosine 3'-tetraphosphate (2'-deoxy-3'-A(4)P) and 2',5'-dideoxyadenosine 3'-tetraphosphate (2',5'-dideoxy-3'-A(4)P) were synthesized, and their effects were tested on crude and purified forms of native adenylyl cyclases isolated from brain. Syntheses combined the method of alkoxide activation with the use of tribromoethyl phosphoromorpholino-chloridate as an initial phosphorylating agent. Inhibition of adenylyl cyclase was rapid in onset. With 2'-d-3'-A(4)P or 2',5'-dd-3'-A(4)P inhibition of a purified native enzyme conformed to a linear noncompetitive behavior with respect to substrate, metal-5'ATP. Order of potency was 2',5'-dideoxy- > 2'-deoxyadenosine and 3'-tetraphosphate > 3'-triphosphate. Both mechanism of inhibition and rank order of potency were consistent with inhibition via the 3'-nucleotide-(P)-site on adenylyl cyclase. Neither 2',5'-dd-3'-ATP nor 2',5'-dd-3'-A(4)P had any effect on the activities of other adenosine nucleotide binding proteins such as Ca2+/calmodulin-sensitive cyclic nucleotide phosphodiesterase, Na+/K+-ATPase, or cAMP-dependent protein kinase. With purified adenylyl cyclase from bovine brain 2',5'-dd-3'-A(4)P and 2'-d-3'-A(4)P gave, respectively, IC50 values of 9.3 and 15 nM and K-i values of 23 and 53 nM. These 3'-nucleotides are the most potent regulators described for adenylyl cyclases.	SUNY Stony Brook, Hlth Sci Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Johnson, RA (corresponding author), Lab Chim Organ Subst Nat, 5 Rue Blaise Pascal, F-67084 Strasbourg, France.		Desaubry, Laurent G/R-5446-2017	Desaubry, Laurent G/0000-0002-1192-2970	NIDDK NIH HHS [DK38828] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038828] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS PR, 1984, J MED CHEM, V27, P1648, DOI 10.1021/jm00378a021; Artymiuk PJ, 1997, NATURE, V388, P33, DOI 10.1038/40310; Bryant SH, 1997, NATURE, V388, P34, DOI 10.1038/40313; BUSHFIELD M, 1990, MOL PHARMACOL, V38, P848; COUTSOGEORGOPOU.C, 1966, BIOCHIM BIOPHYS ACTA, V119, P442; DESAUBRY L, 1995, TETRAHEDRON LETT, V36, P995, DOI 10.1016/0040-4039(94)02424-A; Desaubry L, 1996, J BIOL CHEM, V271, P14028, DOI 10.1074/jbc.271.24.14028; Desaubry L, 1996, J BIOL CHEM, V271, P2380, DOI 10.1074/jbc.271.5.2380; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; Dessauer CW, 1996, J BIOL CHEM, V271, P16967, DOI 10.1074/jbc.271.28.16967; ENGLUND PT, 1969, J BIOL CHEM, V244, P3038; FLOCKHART DA, 1984, EUR J BIOCHEM, V140, P289, DOI 10.1111/j.1432-1033.1984.tb08100.x; FLORIO VA, 1983, MOL PHARMACOL, V24, P195; FLORIO VA, 1983, THESIS U VIRGINIA; GARBERS DL, 1975, J BIOL CHEM, V250, P8449; GILMAN AG, 1970, P NATL ACAD SCI USA, V67, P305, DOI 10.1073/pnas.67.1.305; GOTO Y, 1991, J BIOCHEM-TOKYO, V109, P746, DOI 10.1093/oxfordjournals.jbchem.a123451; Gualix J, 1996, FEBS LETT, V391, P195, DOI 10.1016/0014-5793(96)00732-6; Hempel C. M., 1996, Society for Neuroscience Abstracts, V22, P261; JOHNSON RA, 1977, ARCH BIOCHEM BIOPHYS, V183, P216, DOI 10.1016/0003-9861(77)90435-0; JOHNSON RA, 1989, MOL PHARMACOL, V35, P681; JOHNSON RA, 1990, J BIOL CHEM, V265, P11595; Johnson RA, 1997, J BIOL CHEM, V272, P8962; JOHNSON RA, 1979, J BIOL CHEM, V254, P1094; JOHNSON RA, 1990, J BIOL CHEM, V265, P19035; KERAVIS TM, 1987, J CYCLIC NUCLEOTIDE, V11, P365; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LEE JW, 1996, YONSEI MED J, V36, P487; LONDOS C, 1977, P NATL ACAD SCI USA, V74, P5482, DOI 10.1073/pnas.74.12.5482; PFEUFFER E, 1985, EMBO J, V4, P3675, DOI 10.1002/j.1460-2075.1985.tb04134.x; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; STENGEL D, 1986, EUR J BIOCHEM, V161, P241, DOI 10.1111/j.1432-1033.1986.tb10148.x; TANG WJ, 1991, J BIOL CHEM, V266, P8595; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; VANBOOM JH, 1977, NUCLEIC ACIDS RES, V4, P1047, DOI 10.1093/nar/4.4.1047; WALSETH TF, 1979, BIOCHIM BIOPHYS ACTA, V562, P11, DOI 10.1016/0005-2787(79)90122-9; WEINRYB I, 1974, BIOCHIM BIOPHYS ACTA, V334, P218, DOI 10.1016/0005-2744(74)90165-X; WOLFF J, 1981, ADV CYCL NUCL RES<D>, V14, P199; WOLIN MS, 1981, THESIS YALE U; YEUNG SMH, 1990, J BIOL CHEM, V265, P16745; ZAMECNIK P, 1983, ANAL BIOCHEM, V134, P1, DOI 10.1016/0003-2697(83)90255-5; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0	42	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24972	24977		10.1074/jbc.273.38.24972	http://dx.doi.org/10.1074/jbc.273.38.24972			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733805	hybrid			2022-12-27	WOS:000076007300097
J	Harley, CA; Holt, JA; Turner, R; Tipper, DJ				Harley, CA; Holt, JA; Turner, R; Tipper, DJ			Transmembrane protein insertion orientation in yeast depends on the charge difference across transmembrane segments, their total hydrophobicity, and its distribution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI INNER MEMBRANE; SIGNAL-ANCHOR PROTEINS; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; BETA-LACTAMASE; AMINO-ACIDS; TOPOLOGY; RESIDUES; DOMAIN; DETERMINANTS	The determinants of transmembrane protein insertion orientation at the endoplasmic reticulum have been investigated in Saccharomyces cerevisiae using variants of a Type III (naturally exofacial N terminus (N-exo)) transmembrane fusion protein derived from the N terminus of Ste2p, the alpha-factor receptor. Small positive and negative charges adjacent to the transmembrane segment had equal and opposite effects on orientation, and this effect was independent of N- or C-terminal location, consistent with a purely electrostatic interaction with response mechanisms. A 3:1 bias toward N-exo insertion, observed in the absence of a charge difference, was shown to reflect the N-exo bias conferred by longer transmembrane segments. Orientation correlated best with total hydrophobicity rather than length, but it was also strongly affected by the distribution of hydrophobicity within the transmembrane segment, The most hydrophobic terminus was preferentially translocated, Insertion orientation thus depends on integration of responses to at least three parameters: charge difference across a transmembrane segment, its total hydrophobicity, and its hydrophobicity gradient. Relative signal strengths were estimated, and consequences for topology prediction are discussed. Responses to transmembrane sequence may depend on protein-translocon interactions, but responses to charge difference may be mediated by the electrostatic field provided by anionic phospholipids.	Univ Massachusetts, Med Ctr, Dept Mol Genet & Microbiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Tipper, DJ (corresponding author), Univ Massachusetts, Med Ctr, Dept Mol Genet & Microbiol, Worcester, MA 01655 USA.		Harley, Carol/J-5375-2013	Harley, Carol/0000-0003-3610-0604				ANDERSSON H, 1994, EMBO J, V13, P2267, DOI 10.1002/j.1460-2075.1994.tb06508.x; ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; BELTZER JP, 1991, J BIOL CHEM, V266, P973; CARTWRIGHT CP, 1991, MOL CELL BIOL, V11, P2620, DOI 10.1128/MCB.11.5.2620; CARTWRIGHT CP, 1994, YEAST, V10, P497, DOI 10.1002/yea.320100409; CHAUDHURI B, 1992, FEBS LETT, V304, P41, DOI 10.1016/0014-5793(92)80585-5; DALBEY RE, 1995, TRENDS CELL BIOL, V5, P380, DOI 10.1016/S0962-8924(00)89079-0; Denzer AJ, 1995, EMBO J, V14, P6311, DOI 10.1002/j.1460-2075.1995.tb00321.x; DUNLOP J, 1995, EMBO J, V14, P3609, DOI 10.1002/j.1460-2075.1995.tb00030.x; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; GAFVELIN G, 1994, CELL, V77, P401, DOI 10.1016/0092-8674(94)90155-4; Harley CA, 1996, J BIOL CHEM, V271, P24625, DOI 10.1074/jbc.271.40.24625; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Hegde RS, 1997, CELL, V91, P575, DOI 10.1016/S0092-8674(00)80445-6; Kiefer D, 1997, EMBO J, V16, P2197, DOI 10.1093/emboj/16.9.2197; KOMANO H, 1995, P NATL ACAD SCI USA, V92, P10752, DOI 10.1073/pnas.92.23.10752; KULKARNI MS, 1994, J BIOL CHEM, V269, P13141; LANDOLTMARTICORENA C, 1993, J MOL BIOL, V229, P602, DOI 10.1006/jmbi.1993.1066; MOERSCHELL RP, 1990, J BIOL CHEM, V265, P19638; Nacken V, 1996, GENE, V175, P253, DOI 10.1016/0378-1119(96)00171-0; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; PARKS GD, 1993, J BIOL CHEM, V268, P19101; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; Persson B, 1997, J PROTEIN CHEM, V16, P453, DOI 10.1023/A:1026353225758; Powers T, 1997, SCIENCE, V278, P2072, DOI 10.1126/science.278.5346.2072; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; SAKAGUCHI M, 1992, P NATL ACAD SCI USA, V89, P16, DOI 10.1073/pnas.89.1.16; SATO T, 1990, EMBO J, V9, P2391, DOI 10.1002/j.1460-2075.1990.tb07414.x; Siegel V, 1997, CELL, V90, P5, DOI 10.1016/S0092-8674(00)80307-4; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; vanKlompenburg W, 1997, EMBO J, V16, P4261, DOI 10.1093/emboj/16.14.4261; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; Wahlberg JM, 1997, J CELL BIOL, V137, P555, DOI 10.1083/jcb.137.3.555; WALLIN E, 1995, PROTEIN ENG, V8, P693, DOI 10.1093/protein/8.7.693; WILSON C, 1990, MOL CELL BIOL, V10, P449, DOI 10.1128/MCB.10.2.449	38	52	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24963	24971		10.1074/jbc.273.38.24963	http://dx.doi.org/10.1074/jbc.273.38.24963			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733804	Green Published, hybrid			2022-12-27	WOS:000076007300096
J	Ventoso, I; Barco, A; Carrasco, L				Ventoso, I; Barco, A; Carrasco, L			Mutational analysis of poliovirus 2A(pro) - Distinct inhibitory functions of 2A(pro) on translation and transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC INITIATION FACTOR-4F; CAP-INDEPENDENT TRANSLATION; CELL PROTEIN-SYNTHESIS; POLYMERASE-II TRANSCRIPTION; TATA-BINDING PROTEIN; MAMMALIAN-CELLS; HELA-CELLS; IN-VITRO; HOST TRANSLATION; GENE-EXPRESSION	Transient expression of poliovirus 2A(pro) in mammalian cells by means of the recombinant vaccinia virus vT7 expression system leads to drastic inhibition of both cellular and vaccinia virus gene expression (Aldabe, R., Feduchi, E., Novoa, I., and Carrasco, L. (1995) FEBS Lett. 377, 1-5; Aldabe, R., Feduchi, E., Novoa, I., and Carrasco, L. (1995) Biochem. Biophys. Res. Commun. 215, 928-936). To obtain further insights into the molecular basis of this inhibition, a number of 2A(pro) variants were generated and expressed in COS-1 cells. The effect of these variants on cellular translation, on vaccinia virus-specific translation, and on transcription of the reporter gene luciferase was analyzed. The ability of the different 2A(pro) variants to block cellular translation depends on their capacities to cleave eIF-4G. The blockade exerted by 2A(pro) on transcription of the luciferase gene reinforces the notion that this protease is a potent inhibitor of RNA polymerase II-mediated transcription. Some of the 2A(pro) variants tested failed to block luciferase transcription, despite the fact that eIF-4G cleavage and inhibition of translation were observed. Two reconstituted polioviruses mutated in 2A(pro) were defective in inhibiting luciferase transcription, yet were still able to cleave eIF-4G and block translation. These findings indicate that 2A(pro) interferes with cellular gene expression at both the transcriptional and translational levels. Moreover, these two effects probably reflect the inactivation of different host proteins by poliovirus 2A(pro).	Univ Autonoma Madrid, CSIC, Ctr Biol Mol, Madrid 28049, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Ventoso, I (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol, Canto Blanco, Madrid 28049, Spain.		Carrasco, Luis/H-3001-2017; Barco, Angel/ABF-1864-2021; Carrasco, Luis/E-2435-2012; Barco, Angel/C-3062-2008; Ventoso, Iván/N-4018-2014	Carrasco, Luis/0000-0003-3833-8835; Barco, Angel/0000-0002-0653-3751; Barco, Angel/0000-0002-0653-3751; Ventoso, Iván/0000-0001-7887-3520				ALDABE R, 1995, BIOCHEM BIOPH RES CO, V215, P928, DOI 10.1006/bbrc.1995.2553; Aldabe R, 1995, FEBS LETT, V377, P1, DOI 10.1016/0014-5793(95)01269-9; Barco A, 1997, J BIOL CHEM, V272, P12683, DOI 10.1074/jbc.272.19.12683; BARCO A, 1995, FEBS LETT, V371, P4, DOI 10.1016/0014-5793(95)00841-V; BERNSTEIN HD, 1985, MOL CELL BIOL, V5, P2913, DOI 10.1128/MCB.5.11.2913; BONNEAU AM, 1987, J VIROL, V61, P986, DOI 10.1128/JVI.61.4.986-991.1987; CLARK ME, 1993, MOL CELL BIOL, V13, P1232, DOI 10.1128/MCB.13.2.1232; CLARK ME, 1991, EMBO J, V10, P2941, DOI 10.1002/j.1460-2075.1991.tb07844.x; CRAWFORD N, 1981, CELL, V27, P555, DOI 10.1016/0092-8674(81)90397-4; DAVIES MV, 1991, J BIOL CHEM, V266, P14714; DOUGHERTY WG, 1993, MICROBIOL REV, V57, P781, DOI 10.1128/MMBR.57.4.781-822.1993; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; Favaloro J, 1980, Methods Enzymol, V65, P718; Feduchi E, 1995, EUR J BIOCHEM, V234, P849, DOI 10.1111/j.1432-1033.1995.849_a.x; FERNANDEZTOMAS C, 1982, VIROLOGY, V116, P629, DOI 10.1016/0042-6822(82)90154-4; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Haghighat A, 1996, J VIROL, V70, P8444, DOI 10.1128/JVI.70.12.8444-8450.1996; HAMBIDGE SJ, 1992, P NATL ACAD SCI USA, V89, P10272, DOI 10.1073/pnas.89.21.10272; HELLEN CUT, 1991, J VIROL, V65, P4226, DOI 10.1128/JVI.65.8.4226-4231.1991; IRURZUN A, 1995, J VIROL, V69, P7453, DOI 10.1128/JVI.69.12.7453-7460.1995; JEWELL JE, 1990, J VIROL, V64, P1388, DOI 10.1128/JVI.64.3.1388-1393.1990; Keiper BD, 1997, NUCLEIC ACIDS RES, V25, P395, DOI 10.1093/nar/25.2.395; KRAUSSLICH HG, 1987, J VIROL, V61, P2711; LAMPHEAR BJ, 1993, J BIOL CHEM, V268, P19200; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LEE CK, 1988, VIROLOGY, V166, P405, DOI 10.1016/0042-6822(88)90511-9; LEIBOWITZ R, 1971, J VIROL, V8, P661, DOI 10.1128/JVI.8.5.661-668.1971; LIEBIG HD, 1993, BIOCHEMISTRY-US, V32, P7581, DOI 10.1021/bi00080a033; LU HH, 1994, J VIROL, V68, P7507, DOI 10.1128/JVI.68.11.7507-7515.1994; MACADAM AJ, 1994, EMBO J, V13, P924, DOI 10.1002/j.1460-2075.1994.tb06336.x; MOLLA A, 1993, VIROLOGY, V196, P739, DOI 10.1006/viro.1993.1531; Novoa I, 1996, J VIROL, V70, P3319, DOI 10.1128/JVI.70.5.3319-3324.1996; Novoa I, 1997, BIOCHEMISTRY-US, V36, P7802, DOI 10.1021/bi9631172; Ohlmann T, 1996, EMBO J, V15, P1371, DOI 10.1002/j.1460-2075.1996.tb00479.x; PEREZ L, 1992, VIROLOGY, V189, P178, DOI 10.1016/0042-6822(92)90693-J; Pestova TV, 1996, MOL CELL BIOL, V16, P6870; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNIERLE BS, 1992, VIROLOGY, V188, P931, DOI 10.1016/0042-6822(92)90556-5; Shen YH, 1996, MOL CELL BIOL, V16, P4163; SUN XH, 1989, P NATL ACAD SCI USA, V86, P2143, DOI 10.1073/pnas.86.7.2143; TOYODA H, 1986, CELL, V45, P761, DOI 10.1016/0092-8674(86)90790-7; TURNER PC, 1989, VIROLOGY, V173, P509, DOI 10.1016/0042-6822(89)90563-1; URZAINQUI A, 1989, J VIROL, V63, P4729, DOI 10.1128/JVI.63.11.4729-4735.1989; VENTOSO I, 1995, J VIROL, V69, P6280, DOI 10.1128/JVI.69.10.6280-6288.1995; WET JR, 1987, MOL CELL BIOL, V7, P725; WYCKOFF EE, 1990, P NATL ACAD SCI USA, V87, P9529, DOI 10.1073/pnas.87.24.9529; Yalamanchili P, 1997, J VIROL, V71, P1220, DOI 10.1128/JVI.71.2.1220-1226.1997; Yalamanchili P, 1997, J VIROL, V71, P6881, DOI 10.1128/JVI.71.9.6881-6886.1997; Yalamanchili P, 1996, J VIROL, V70, P2922, DOI 10.1128/JVI.70.5.2922-2929.1996; YU SF, 1991, VIROLOGY, V182, P615, DOI 10.1016/0042-6822(91)90602-8	50	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27960	27967		10.1074/jbc.273.43.27960	http://dx.doi.org/10.1074/jbc.273.43.27960			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774410	hybrid			2022-12-27	WOS:000076549800030
J	Escargueil-Blanc, I; Andrieu-Abadie, N; Caspar-Bauguil, S; Brossmer, R; Levade, T; Negre-Salvayre, A; Salvayre, R				Escargueil-Blanc, I; Andrieu-Abadie, N; Caspar-Bauguil, S; Brossmer, R; Levade, T; Negre-Salvayre, A; Salvayre, R			Apoptosis and activation of the sphingomyelin-ceramide pathway induced by oxidized low density lipoproteins are not causally related in ECV-304 endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA FRAGMENTATION; PROTEASE INHIBITORS; LIPID PEROXIDES; DEATH; LDL; CALCIUM; ATHEROSCLEROSIS; CYTOTOXICITY; OXIDATION; CULTURE	Oxidized low density lipoproteins (oxLDL) are thought to play a central role in the development of atherosclerosis. Toxic concentrations of mildly oxidized LDL elicit massive apoptosis of endothelial cells (Escargueil-Blanc, I., Meilhac, O., Pieraggi, M. T., Amal J. F., Salvayre, R., Negre-Salvayre, A. (1997) Arterioscler. Thromb. Vasc. Biol. 17, 331-339). Since the lipid mediator ceramide emerged as a potent inducer of apoptosis, we aimed at investigating the occurrence of ceramide formation and its potential role in oxLDL-induced apoptosis. In ECV-304 endothelial cells, toxic concentrations of oxLDL triggered an early activation of the sphingomyelin-ceramide pathway, as shown by both sphingomyelin hydrolysis and ceramide formation. N-Tosyl-L-phenylalanyl chloromethyl ketone (TPCK) and dichloroisocoumarin (DCIC), two serine-protease inhibitors (serpins), blocked the oxLDL-induced ceramide generation but, unexpectedly, did not inhibit the oxLDL-induced apoptosis. Conversely, treatment of endothelial cells by bacterial sphingomyelinase, under conditions effectively generating ceramide, did not induce apoptosis, In contrast, short-chain permeant C-2- and C-6-ceramides elicited apoptosis of ECV-304. However, the mechanisms of apoptosis triggered by C-2-ceramide and by oxLDL were (at least in part) different, because C-2 ceramide-induced apoptosis was calcium-independent, whereas oxLDL-induced apoptosis was calcium dependent. In conclusion, it is suggested that oxLDL-induced apoptosis is calcium-dependent but independent of the activation of the sphingomyelin-ceramide pathway and that the toxic effect of short chain permeant ceramides is calcium-independent and does not mimic the effect of natural ceramides induced by oxLDL.	CHU Rangueil, INSERM, U466, Biochim Lab, F-31054 Toulouse, France; CHU Rangueil, Inst Louis Bugnard, Dept Biochem, F-31054 Toulouse, France; Univ Heidelberg, Biochem Ctr, D-69120 Heidelberg, Germany	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Ruprecht Karls University Heidelberg	Escargueil-Blanc, I (corresponding author), CHU Rangueil, INSERM, U466, Biochim Lab, 1 Ave Jean Poulhes, F-31054 Toulouse, France.	salvayre@rangueil.inserm.fr	Levade, Thierry/O-8948-2014; Andrieu-Abadie, Nathalie/N-6793-2013	Andrieu-Abadie, Nathalie/0000-0003-2698-1970; Caspar-Bauguil, Sylvie/0000-0003-2682-0704; Negre-Salvayre, Anne/0000-0003-2136-5706				ARENDS MJ, 1990, AM J PATHOL, V136, P593; Auge N, 1996, J BIOL CHEM, V271, P19251, DOI 10.1074/jbc.271.32.19251; Auge N, 1998, J BIOL CHEM, V273, P12893, DOI 10.1074/jbc.273.21.12893; BOOBIS AR, 1989, TRENDS PHARMACOL SCI, V10, P275, DOI 10.1016/0165-6147(89)90027-8; BORCHARDT RA, 1994, BBA-LIPID LIPID MET, V1212, P327, DOI 10.1016/0005-2760(94)90207-0; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; CATHCART MK, 1989, J IMMUNOL, V142, P1963; CHEN JA, 1995, J NEUROCHEM, V64, P724; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; EscargueilBlanc I, 1997, ARTERIOSCL THROM VAS, V17, P331, DOI 10.1161/01.ATV.17.2.331; ESCARGUEILBLANC I, 1994, FASEB J, V8, P1075, DOI 10.1096/fasebj.8.13.7926374; ESTERBAUER H, 1990, CHEM RES TOXICOL, V3, P77, DOI 10.1021/tx00014a001; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; Haimovitz-Friedman A, 1997, BRIT MED BULL, V53, P539; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Harada-Shiba M, 1998, J BIOL CHEM, V273, P9681, DOI 10.1074/jbc.273.16.9681; HAVEL RI, 1955, J CLIN INVEST, V39, P1345; HENRIKSEN T, 1979, SCAND J CLIN LAB INV, V39, P361, DOI 10.3109/00365517909106120; HESSLER JR, 1979, ATHEROSCLEROSIS, V32, P213, DOI 10.1016/0021-9150(79)90166-7; KAPUSCINSKI J, 1977, ANAL BIOCHEM, V83, P252, DOI 10.1016/0003-2697(77)90533-4; Lotem J, 1996, P NATL ACAD SCI USA, V93, P12507, DOI 10.1073/pnas.93.22.12507; Mansat V, 1997, FASEB J, V11, P695, DOI 10.1096/fasebj.11.8.9240970; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; Modur V, 1996, J BIOL CHEM, V271, P13094, DOI 10.1074/jbc.271.22.13094; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NEGRESALVAYRE A, 1993, ATHEROSCLEROSIS, V99, P207, DOI 10.1016/0021-9150(93)90023-N; NEGRESALVAYRE A, 1990, BIOCHIM BIOPHYS ACTA, V1045, P224, DOI 10.1016/0005-2760(90)90124-G; NEGRESALVAYRE A, 1992, FEBS LETT, V299, P60, DOI 10.1016/0014-5793(92)80101-L; Olivera A, 1997, BBA-LIPID LIPID MET, V1348, P311, DOI 10.1016/S0005-2760(97)00067-2; ORRENIUS S, 1989, TRENDS PHARMACOL SCI, V10, P281, DOI 10.1016/0165-6147(89)90029-1; PRICE P, 1990, CANCER RES, V50, P1392; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SINGH IN, 1993, J LIPID MEDIATOR, V7, P85; SMITH ER, 1995, J BIOL CHEM, V270, P18749, DOI 10.1074/jbc.270.32.18749; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Smyth M J, 1997, Adv Pharmacol, V41, P133, DOI 10.1016/S1054-3589(08)61057-1; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; STEINBRECHER UP, 1990, FREE RADICAL BIO MED, V9, P155, DOI 10.1016/0891-5849(90)90119-4; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; Suc I, 1998, FASEB J, V12, P665, DOI 10.1096/fasebj.12.9.665; Testi R, 1996, TRENDS BIOCHEM SCI, V21, P468, DOI 10.1016/S0968-0004(96)10056-6; Thomas A.P., 1991, CELLULAR CALCIUM PRA, P1; WEAVER VM, 1993, BIOCHEM CELL BIOL, V71, P488, DOI 10.1139/o93-071; Wertz IE, 1996, TRENDS BIOCHEM SCI, V21, P359, DOI 10.1016/0968-0004(96)40002-0; Wieder T, 1997, FEBS LETT, V411, P260, DOI 10.1016/S0014-5793(97)00717-5; WILLIE AH, 1981, CELL DEATH BIOL PATH, P9; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; WOLFF SP, 1994, METHOD ENZYMOL, V233, P182; Wright SC, 1997, J EXP MED, V186, P1107, DOI 10.1084/jem.186.7.1107; WRIGHT SC, 1994, J EXP MED, V180, P2113, DOI 10.1084/jem.180.6.2113; YAGI K, 1987, CHEM PHYS LIPIDS, V45, P337, DOI 10.1016/0009-3084(87)90071-5; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; Zhang P, 1997, J BIOL CHEM, V272, P9609	56	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27389	27395		10.1074/jbc.273.42.27389	http://dx.doi.org/10.1074/jbc.273.42.27389			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765267	hybrid			2022-12-27	WOS:000076448000054
J	Johnson, JD; Mehus, JG; Tews, K; Milavetz, BI; Lambeth, DO				Johnson, JD; Mehus, JG; Tews, K; Milavetz, BI; Lambeth, DO			Genetic evidence for the expression of ATP- and GTP-specific succinyl-CoA synthetases in multicellular eucaryotes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE-DIPHOSPHATE KINASE; ESCHERICHIA-COLI; ALPHA-SUBUNIT; THIOKINASE; CLONING; MITOCHONDRIA; PRECURSOR; COMPLEX; MUSCLE	Highly ATP- and GTP-specific isoforms of succinyl-CoA synthetase in pigeon incorporate the same alpha-subunit, but different beta-subunits (Johnson, J, D., Muhonen, W. W., and Lambeth, D. O, (1998) J. Biol. Chem. 273, 27573-27579), The sequences of the mature subunits were determined by methods based on reverse transcription-polymerase chain reaction. The 306-residue mature alpha-subunit in pigeon shows >88% identity to its homologues in pig and rat. The sequences of the mature ATP- and GTP-specific beta-subunits (A-beta and G-beta, respectively) in pigeon are 54% identical. These sequences were used to identify expressed sequence tags for human and mouse that were highly homologous to G-beta and A-beta, respectively. The sequences for mature A-beta and G-beta in mouse and human were completed and verified by polymerase chain reaction. The sequence of A-beta in pig was also obtained. The mammalian A-beta sequences show >89% identity to each other; the G-beta sequences are similarly related, However, pairwise comparisons of the A-P and G-beta sequences revealed <53% identity. Alignment with two sequences of the beta-subunit in Caenorhabditis elegans suggests that the A-beta and G-beta genes arose by duplication early in the evolution of multicellular eucaryotes, The expression of A-beta is strong in numerous mouse and human tissues, which suggests that ATP-specific succinyl-CoA synthetase also plays an important role in species throughout the animal kingdom.	Univ N Dakota, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, Grand Forks, ND 58202 USA	University of North Dakota Grand Forks	Lambeth, DO (corresponding author), Univ N Dakota, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, POB 9037, Grand Forks, ND 58202 USA.							ALLEN DA, 1986, FEBS LETT, V194, P171, DOI 10.1016/0014-5793(86)80071-0; BAILEY DL, 1993, PROTEIN SCI, V2, P1255, DOI 10.1002/pro.5560020808; BIRNEY MA, 1995, ARCH BIOCHEM BIOPHYS, V319, P93, DOI 10.1006/abbi.1995.1270; BRIDGER WA, 1971, BIOCHEM BIOPH RES CO, V42, P948, DOI 10.1016/0006-291X(71)90522-5; BRIDGER WA, 1969, METHOD ENZYMOL, V13, P70; BUCK D, 1986, J GEN MICROBIOL, V132, P1753; BUCK D, 1985, BIOCHEMISTRY-US, V24, P6245, DOI 10.1021/bi00343a031; *CLONTECH, 1997, US MAN PT3158 1; HAMILTON ML, 1981, FEBS LETT, V123, P252, DOI 10.1016/0014-5793(81)80300-6; HANSFORD RG, 1973, FEBS LETT, V31, P317, DOI 10.1016/0014-5793(73)80130-9; HENNING WD, 1988, P NATL ACAD SCI USA, V85, P1432, DOI 10.1073/pnas.85.5.1432; Johnson JD, 1998, J BIOL CHEM, V273, P27573, DOI 10.1074/jbc.273.42.27573; KADRMAS EF, 1991, BIOCHIM BIOPHYS ACTA, V1074, P339, DOI 10.1016/0304-4165(91)90083-S; KAUFMAN S, 1955, J BIOL CHEM, V216, P141; KAVANAUGHBLACK A, 1994, P NATL ACAD SCI USA, V91, P5883, DOI 10.1073/pnas.91.13.5883; KELLY CJ, 1977, ARCH BIOCHEM BIOPHYS, V178, P208, DOI 10.1016/0003-9861(77)90186-2; KRIVANEK J, 1992, PHYSIOL RES, V41, P345; LABBE RF, 1965, BIOCHIM BIOPHYS ACTA, V111, P403, DOI 10.1016/0304-4165(65)90050-4; LAHTI CJ, 1994, MOL GEN GENET, V226, P1; LAMBETH DO, 1993, ANAL BIOCHEM, V209, P192, DOI 10.1006/abio.1993.1102; LUO GX, 1991, J BIOL CHEM, V266, P20781; MAJUMDAR R, 1990, BIOCHEM CELL BIOL, V68, P292, DOI 10.1139/o90-040; MCCLELLAN JA, 1980, COMP BIOCHEM PHYS B, V67, P679, DOI 10.1016/0305-0491(80)90430-7; OTTAWAY JH, 1981, INT J BIOCHEM, V13, P401, DOI 10.1016/0020-711X(81)90111-7; PORPACZY Z, 1983, BIOCHIM BIOPHYS ACTA, V749, P172, DOI 10.1016/0167-4838(83)90249-2; Ryan DG, 1997, J BIOL CHEM, V272, P21151, DOI 10.1074/jbc.272.34.21151; SEVERIN SE, 1977, ADV ENZYME REGUL, V15, P1, DOI 10.1016/0065-2571(77)90006-1; STEINER AW, 1981, J NEUROCHEM, V37, P582; WEITZMAN PDJ, 1986, FEBS LETT, V199, P57, DOI 10.1016/0014-5793(86)81223-6; WEITZMAN PDJ, 1982, FEBS LETT, V143, P237, DOI 10.1016/0014-5793(82)80107-5; WEITZMAN PDJ, 1978, FEBS LETT, V88, P255, DOI 10.1016/0014-5793(78)80187-2; WOLODKO WT, 1994, J BIOL CHEM, V269, P10883	32	119	133	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27580	27586		10.1074/jbc.273.42.27580	http://dx.doi.org/10.1074/jbc.273.42.27580			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765291	hybrid			2022-12-27	WOS:000076448000078
J	Suo, ZC; Johnson, KA				Suo, ZC; Johnson, KA			DNA secondary structure effects on DNA synthesis catalyzed by HIV-1 reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED DNA; POLYMERASE-ALPHA; ESCHERICHIA-COLI; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; INVITRO; REPLICATION; MECHANISM; STABILITY; SPECIFICITY	The effect of DNA secondary structure on polymerization catalyzed by human immunodeficiency virus (HIV-1) reverse transcriptase (RT) was studied using a synthetic 66-nucleotide DNA template containing a stable hairpin structure. Four RT pause sites were identified within the first half of the hairpin stem. Additionally, five weak pause sites within the second half of the stem and the loop of the hairpin were identified at low temperatures. These weak pause sites were relocated to the site of the first few stem base pairs of two new hairpins formed due to a change in DNA secondary structure. Each pause site was correlated with a high free energy barrier of melting the stem base pair. Pre-steady state kinetic analysis of single nucleotide incorporation showed that polymerization at each pause site occurred by both a fast phase (10-20 s(-1)) and a slow phase (0.02-0.07 s(-1)) during a single binding event. The reaction amplitudes of the fast phase were small (4-10% of enzyme sites), whereas the amplitudes of the slow phase were large (14-40%) at the pause sites. In contrast, only a single phase with a large reaction amplitude (32-50%) and a fast nucleotide incorporation rate (33-87 s(-1)) was observed at the non-pause sites. DNA substrates at all sites had similar dissociation rates (0.14-0.29 s(-1)) and overall binding affinity (16-86 nM). These results suggest that the DNA substrates at pause sites were bound in both productive and non-productive states at the polymerase site of RT. The non-productively bound DNA was slowly converted into a productive state upon melting of the next stem base pair without dissociation of the DNA from RT.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Johnson, KA (corresponding author), Univ Texas, Inst Cellular & Mol Biol, Austin, TX 78712 USA.	kajl@psu.edu			FDA HHS [BM44613] Funding Source: Medline	FDA HHS		BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BEDINGER P, 1989, J BIOL CHEM, V264, P16880; DUDDING LR, 1991, BIOCHEMISTRY-US, V30, P10498, DOI 10.1021/bi00107a019; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; FRY M, 1992, P NATL ACAD SCI USA, V89, P763, DOI 10.1073/pnas.89.2.763; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; HACKER KJ, 1994, J BIOL CHEM, V269, P24221; Hottiger M, 1996, BIOL CHEM H-S, V377, P97; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JACOBOMOLINA A, 1991, BIOCHEMISTRY-US, V30, P6351, DOI 10.1021/bi00240a001; JI JP, 1994, NUCLEIC ACIDS RES, V22, P47, DOI 10.1093/nar/22.1.47; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; KAGUNI LS, 1982, P NATL ACAD SCI-BIOL, V79, P983, DOI 10.1073/pnas.79.4.983; KATI WM, 1992, J BIOL CHEM, V267, P25988; KIELECZAWA J, 1992, SCIENCE, V258, P1787, DOI 10.1126/science.1465615; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; LADUCA RJ, 1983, BIOCHEMISTRY-US, V22, P5177, DOI 10.1021/bi00291a018; LEONTIS NB, 1991, NUCLEIC ACIDS RES, V19, P759, DOI 10.1093/nar/19.4.759; LU M, 1992, J MOL BIOL, V223, P781, DOI 10.1016/0022-2836(92)90989-W; PAPANICOLAOU C, 1991, J MOL BIOL, V221, P805, DOI 10.1016/0022-2836(91)80177-V; SantaLucia J, 1996, BIOCHEMISTRY-US, V35, P3555, DOI 10.1021/bi951907q; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12468, DOI 10.1021/bi971218+; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12459, DOI 10.1021/bi971217h; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P14778, DOI 10.1021/bi971963m; TRINH TQ, 1991, NATURE, V352, P544, DOI 10.1038/352544a0; TRINH TQ, 1993, GENETICS, V134, P409; WEAVER DT, 1982, J BIOL CHEM, V257, P2075; WOHRL BM, 1995, BIOCHEMISTRY-US, V34, P5343; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	35	54	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27259	27267		10.1074/jbc.273.42.27259	http://dx.doi.org/10.1074/jbc.273.42.27259			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765249	hybrid			2022-12-27	WOS:000076448000036
J	Wang-Gillam, A; Pastuszak, I; Elbein, AD				Wang-Gillam, A; Pastuszak, I; Elbein, AD			A 17-amino acid insert changes UDP-N-acetylhexosamine pyrophosphorylase specificity from UDP-GalNAc to UDP-GlcNAc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								We previously reported the purification of a UDP-N-acetylhexosamine (UDP-HexNAc) pyrophosphorylase from pig liver that catalyzed the synthesis of both UDP-GlcNAc and UDP-GalNAc from UTP and the appropriate HexNAc-1-P (Szumilo, T., Zeng, Y., Pastuszak, I., Drake, R., Szumilo, H., and Elbein, A. D. (1996) J. Biol. Chem. 271, 13147-13154), Both sugar nucleotides were synthesized at nearly the same rate, although the K-m for GalNAc-1-P. NAc-1-P was about 3 times higher than for GlcNAc-1-P. Based on native gels and SDS-polyacrylamide gel electrophoresis, the enzyme appeared to be a dimer of 120 kDa composed of two subunits of about 57 and 64 kDa, Three peptides sequenced from the 64-kDa protein and two from the 57-kDa protein showed 100% identity to AGX1, a 57-kDa protein of unknown function from human sperm. An isoform called AGX2 is identical in sequence to AGX1 except that it has a 17-amino acid insert near the carboxyl terminus. We expressed the AGX1 and AGX2 genes in Escherichia coli, The protein isolated from the AGX1 clone comigrated on SDS gels with the liver 57-kDa pyrophosphorylase subunit and was 2-3 times more active with GalNAc-1-P than with GlcNAc-1-P, On the other hand, the protein from the AGX2 clone migrated with the liver 64-kDa pyrophosphorylase subunit and had 8-fold better activity with GlcNAc-1-P than with GalNAc-1-P. These results indicate that insertion of the 17-amino acid peptide modifies the specificity of the pyrophosphorylase from synthesis of UDP-GalNAc to synthesis of UDP-GlcNAc.	Univ Arkansas Med Sci Hosp, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences	Elbein, AD (corresponding author), Univ Arkansas Med Sci Hosp, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL017783] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021800] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-17783] Funding Source: Medline; NIDDK NIH HHS [DK-21800] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		DAVIDSON EA, 1966, AMINOSUGARS, P2; DIEKMAN AB, 1994, BIOL REPROD, V50, P1087, DOI 10.1095/biolreprod50.5.1087; Mio T, 1998, J BIOL CHEM, V273, P14392, DOI 10.1074/jbc.273.23.14392; PATTABIRAMAN T, 1961, BIOCHIM BIOPHYS ACTA, V50, P129, DOI 10.1016/0006-3002(61)91068-X; STROMINGER JL, 1959, J BIOL CHEM, V234, P1822; Szumilo T, 1996, J BIOL CHEM, V271, P13147, DOI 10.1074/jbc.271.22.13147	6	35	37	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27055	27057		10.1074/jbc.273.42.27055	http://dx.doi.org/10.1074/jbc.273.42.27055			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765219	hybrid			2022-12-27	WOS:000076448000006
J	Mazella, J; Zsurger, N; Navarro, V; Chabry, J; Kaghad, M; Caput, D; Ferrara, P; Vita, N; Gully, D; Maffrand, JP; Vincent, JP				Mazella, J; Zsurger, N; Navarro, V; Chabry, J; Kaghad, M; Caput, D; Ferrara, P; Vita, N; Gully, D; Maffrand, JP; Vincent, JP			The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; MOUSE-BRAIN; AFFINITY-CHROMATOGRAPHY; BINDING-PROPERTIES; SORTING RECEPTOR; INTERNALIZATION; SOLUBILIZATION; PURIFICATION; ANTAGONIST; CLONING	In this work, the 100-kDa neurotensin (NT) receptor previously purified from human brain by affinity chromatography (Zsurger, N., Mazella, J., and Vincent, J. P. (1994) Brain Res. 639, 245-252) was cloned from a human brain cDNA library. This cDNA encodes a 833-amino acid protein 100% identical to the recently cloned gp95/sortilin and was then designated NT3 receptor-gp95/sortilin. The N terminus of the purified protein is identical to the sequence of the purified gp95/sortilin located immediately after the furin cleavage site. The binding of iodinated NT to 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonic acid-solubilized extracts of COS-7 cells transfected with the cloned cDNA was saturable and reversible with an affinity of 10-15 nM. The localization of the NT3 receptor-gp95/sortilin into intracellular vesicles was in agreement with previous results obtained with the purified receptor and with gp95/sortilin. Affinity labeling and binding experiments showed that the 110-kDa NT3 receptor can be partly transformed into a higher affinity (K-d = 0.3 nM) 100-kDa protein receptor by cotransfection with furin. This 100-kDa NT receptor corresponded to the mature form of the receptor. The NT3/gp95/sortilin protein is the first transmembrane neuropeptide receptor that does not belong to the superfamily of G-protein-coupled receptors.	CNRS, Inst Pharmacol Mol & Cellulaire, UPR 0411, F-06560 Valbonne, France; Sanofi Rech, F-31676 Labege, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Sanofi-Aventis; Sanofi France	Mazella, J (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, UPR 0411, 660 Route Lucioles, F-06560 Valbonne, France.		Chabry, Joelle/O-2101-2016; Mazella, Jean/A-6767-2012					BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; CHABRY J, 1993, J BIOL CHEM, V268, P17138; CHABRY J, 1994, J NEUROCHEM, V63, P19; Chalon P, 1996, FEBS LETT, V386, P91, DOI 10.1016/0014-5793(96)00397-3; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DUBUC I, 1994, BRIT J PHARMACOL, V112, P352, DOI 10.1111/j.1476-5381.1994.tb13077.x; FEHLMANN M, 1981, ENDOCRINOLOGY, V109, P253, DOI 10.1210/endo-109-1-253; GULLY D, 1993, P NATL ACAD SCI USA, V90, P65, DOI 10.1073/pnas.90.1.65; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin BZ, 1997, J BIOL CHEM, V272, P24145, DOI 10.1074/jbc.272.39.24145; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; MAZELLA J, 1988, J BIOL CHEM, V263, P144; MAZELLA J, 1989, J BIOL CHEM, V264, P5559; Mazella J, 1996, J NEUROSCI, V16, P5613; Morris NJ, 1998, J BIOL CHEM, V273, P3582, DOI 10.1074/jbc.273.6.3582; Petersen CM, 1997, J BIOL CHEM, V272, P3599, DOI 10.1074/jbc.272.6.3599; TANAKA K, 1990, NEURON, V4, P847, DOI 10.1016/0896-6273(90)90137-5; Vincent JP, 1995, CELL MOL NEUROBIOL, V15, P501, DOI 10.1007/BF02071313; VITA N, 1993, FEBS LETT, V335, P1, DOI 10.1016/0014-5793(93)80427-V; VITA N, 1993, FEBS LETT, V317, P139, DOI 10.1016/0014-5793(93)81509-X; ZSURGER N, 1994, BRAIN RES, V639, P245, DOI 10.1016/0006-8993(94)91737-X	22	323	339	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26273	26276		10.1074/jbc.273.41.26273	http://dx.doi.org/10.1074/jbc.273.41.26273			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756851	hybrid			2022-12-27	WOS:000076373300005
J	Wilkens, S; Capaldi, RA				Wilkens, S; Capaldi, RA			Solution structure of the epsilon subunit of the F-1-ATPase from Escherichia coli and interactions of this subunit with beta subunits in the complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP SYNTHASE; BACKBONE DYNAMICS; NMR-SPECTROSCOPY; ADENOSINE-TRIPHOSPHATASE; CRYOELECTRON MICROSCOPY; F1F0-TYPE ATPASE; TERMINAL DOMAIN; CATALYTIC SITES; GAMMA-SUBUNITS; DELTA-SUBUNIT	The solution structure of the epsilon subunit of the Escherichia coli F-1-ATPase has been determined by NMR spectroscopy. This subunit has a two-domain structure with an N-terminal 10-stranded beta sandwich and a C-terminal antiparallel two alpha-helix hairpin, as described previously (Wilkens, S., Dahlquist, F. W., McIntosh, L. P., Donaldson, L, W,, and Capaldi, R. A. (1995) Nat, Struct. Biol. 2, 961-967). New data show that the two domains interact in solution in an interface formed by beta strand 7 and the very C-terminal alpha-helix. This interface involves only hydrophobic interactions. The dynamics of the epsilon subunit in solution were examined. The two domains are relatively tightly associated with little or no flexibility relative to one another. The epsilon subunit can exist in two states in the ECF1F0 complex depending on whether ATP or ADP occupies catalytic sites. Proteolysis of the epsilon subunit in solution and when bound to the core F-1 complex indicates that the conformation of the polypeptide in solution closely resembles the conformation of epsilon when bound to the F, in the ADP state. Chemical and photo-cross-linking show that the epsilon subunit spans and interacts with two beta subunits in the ADP state. These interactions are disrupted on binding of ATP + Mg2+, as is the interaction between the N- and C-terminal domains of the epsilon subunit.	Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA	University of Oregon	Capaldi, RA (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.				PHS HHS [58671] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1990, BIOCHEMISTRY-US, V29, P10387, DOI 10.1021/bi00497a013; Aggeler R, 1997, J BIOL CHEM, V272, P19621, DOI 10.1074/jbc.272.31.19621; Aggeler R, 1996, J BIOL CHEM, V271, P13888, DOI 10.1074/jbc.271.23.13888; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; AGGELER R, 1995, BBA-BIOENERGETICS, V1230, P62, DOI 10.1016/0005-2728(95)00040-P; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; BRUNGER A, 1993, XPLOR VERSION 3 1; Capaldi RA, 1996, J BIOENERG BIOMEMBR, V28, P397, DOI 10.1007/BF02113980; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P7387, DOI 10.1021/bi00484a006; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Engelbrecht S, 1997, FEBS LETT, V414, P485, DOI 10.1016/S0014-5793(97)00997-6; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4717, DOI 10.1021/bi00437a031; GOGOL EP, 1987, FEBS LETT, V219, P274, DOI 10.1016/0014-5793(87)80234-X; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; Haughton MA, 1996, BBA-BIOENERGETICS, V1276, P154, DOI 10.1016/0005-2728(96)00073-4; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4134, DOI 10.1021/bi00313a019; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P10987, DOI 10.1021/bi00109a025; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; PATEL AM, 1990, MOL MICROBIOL, V4, P1941, DOI 10.1111/j.1365-2958.1990.tb02043.x; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; Tang CL, 1996, J BIOL CHEM, V271, P3018, DOI 10.1074/jbc.271.6.3018; Uhlin U, 1997, STRUCTURE, V5, P1219, DOI 10.1016/S0969-2126(97)00272-4; Watts SD, 1996, J BIOL CHEM, V271, P28341, DOI 10.1074/jbc.271.45.28341; WILKENS S, 1994, BIOL CHEM H-S, V375, P43; Wilkens S, 1997, NAT STRUCT BIOL, V4, P198, DOI 10.1038/nsb0397-198; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; ZHANG Y, 1994, J BIOL CHEM, V269, P10221; ZHOU HJ, 1995, BIOCHEMISTRY-US, V34, P13858, DOI 10.1021/bi00042a018	38	90	91	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26645	26651		10.1074/jbc.273.41.26645	http://dx.doi.org/10.1074/jbc.273.41.26645			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756905	hybrid			2022-12-27	WOS:000076373300059
J	Arora, KK; Krsmanovic, LZ; Mores, N; O'Farrell, H; Catt, KJ				Arora, KK; Krsmanovic, LZ; Mores, N; O'Farrell, H; Catt, KJ			Mediation of cyclic AMP signaling by the first intracellular loop of the gonadotropin-releasing hormone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SITE-DIRECTED MUTAGENESIS; THYROTROPIN RECEPTOR; CYTOPLASMIC DOMAINS; ADENYLYL-CYCLASE; PHOSPHOLIPASE-C; TRANSDUCTION; ACTIVATION; EXPRESSION; MUTATIONS	The gonadotropin-releasing hormone (GnRH) receptor, which is a unique G protein-coupled receptor without a C-terminal cytoplasmic domain, activates both inositol phosphate (InsP) and cAMP signaling responses. The function of the highly basic first intracellular (1i) loop of the GnRH receptor in signal transduction was evaluated by mutating selected residues located in its N and C termini, Replacements of Leu(58), Lys(59), Gln(61), and Lys(62) at the N terminus, and Leu(73), Ser(74), and Leu(80) at the C terminus, caused no change in binding affinity. The agonist-induced InsP and cAMP responses of the Q61E and K59Q,K62Q receptors were also unaffected, but the L58A receptor showed a normal InsP response and an 80% decrease in cAMP production. At the C terminus, the InsP response of the L73R receptor was normal, but cAMP production was reduced by 80%, The EC50 for GnRH-induced InsP responses of the S74E and L80A receptors was increased by about one order of magnitude, and the cAMP responses were essentially abolished. These findings indicate that cAMP signaling from the GnRH receptor is dependent on specific residues in the 1i loop that are not essential for activation of the phosphoinositide signaling pathway.	NICHD, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Catt, KJ (corresponding author), NICHD, Endocrinol & Reprod Res Branch, NIH, Bldg 49,Rm 6A36, Bethesda, MD 20892 USA.	catt@helix.nih.gov		MORES, Nadia/0000-0002-4197-0914				Antoni FA, 1997, TRENDS ENDOCRIN MET, V8, P7, DOI 10.1016/S1043-2760(96)00206-8; Arora KK, 1997, MOL ENDOCRINOL, V11, P1203, DOI 10.1210/me.11.9.1203; ARORA KK, 1995, J BIOL CHEM, V270, P22820, DOI 10.1074/jbc.270.39.22820; BOURNE GA, 1987, AM J PHYSIOL, V253, pE290, DOI 10.1152/ajpendo.1987.253.3.E290; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Francesconi A, 1998, J BIOL CHEM, V273, P5615, DOI 10.1074/jbc.273.10.5615; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; GRASSO P, 1995, MOL CELL ENDOCRINOL, V108, P43, DOI 10.1016/0303-7207(94)03461-2; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; HEDIN KE, 1993, CELL SIGNAL, V5, P505, DOI 10.1016/0898-6568(93)90046-O; Herrlich A, 1996, J BIOL CHEM, V271, P16764, DOI 10.1074/jbc.271.28.16764; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; IidaKlein A, 1997, J BIOL CHEM, V272, P6882, DOI 10.1074/jbc.272.11.6882; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KONIG B, 1994, BBA-MOL CELL RES, V1223, P261, DOI 10.1016/0167-4889(94)90235-6; KOSUGI S, 1994, BIOCHEM BIOPH RES CO, V200, P401, DOI 10.1006/bbrc.1994.1463; KOSUGI S, 1992, J BIOL CHEM, V267, P24153; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUPHAL D, 1994, ENDOCRINOLOGY, V135, P315, DOI 10.1210/en.135.1.315; Laugwitz KL, 1996, P NATL ACAD SCI USA, V93, P116, DOI 10.1073/pnas.93.1.116; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; Mores N, 1996, ENDOCRINOLOGY, V137, P5731, DOI 10.1210/en.137.12.5731; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OHYAMA K, 1992, BIOCHEM BIOPH RES CO, V189, P677, DOI 10.1016/0006-291X(92)92254-U; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; PHILLIPS WJ, 1994, BIOCHEM J, V299, P351, DOI 10.1042/bj2990351; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sealfon SC, 1997, ENDOCR REV, V18, P180, DOI 10.1210/er.18.2.180; STOJILKOVIC SS, 1994, ENDOCR REV, V15, P462, DOI 10.1210/er.15.4.462; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; WEISS ER, 1988, J BIOL CHEM, V263, P6150; Wu V, 1997, J BIOL CHEM, V272, P9037	35	80	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25581	25586		10.1074/jbc.273.40.25581	http://dx.doi.org/10.1074/jbc.273.40.25581			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748222	hybrid			2022-12-27	WOS:000076263100013
J	Fontaine, E; Ichas, F; Bernardi, P				Fontaine, E; Ichas, F; Bernardi, P			A ubiquinone-binding site regulates the mitochondrial permeability transition pore	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 SEPARATE SITES; CYCLOSPORINE-A; PYRIDINE-NUCLEOTIDES; INORGANIC-PHOSPHATE; HEART-MITOCHONDRIA; CELL-DEATH; MODULATION; REDUCTION; MEMBRANE; DEPOLARIZATION	We have investigated the regulation of the mitochondrial permeability transition pore (PTP) by ubiquinone analogues. We found that the Ca2+-dependent PTP opening was inhibited by ubiquinone 0 and decylubiquinone, whereas all other tested quinones (ubiquinone 5, 1,4-benzoquinone, 2-methoxy-1,4-benzoquinone, 2,3-dimethoxy-1,4-benzoquinone, and 2,3-dimethoxy-5,6-dimethyl-1,8-benzoquinone) were ineffective. Pore inhibition was observed irrespective of the method used to induce the permeability transition (addition of P-i or atractylate, membrane depolarization, or dithiol cross-linking). Inhibition of PTP opening by decylubiquinone was comparable with that exerted by cyclosporin A, whereas ubiquinone 0 was more potent. Ubiquinone 5, which did not inhibit the PTP per se, specifically counteracted the inhibitory effect of ubiquinone 0 or decylubiquinone but not that of cyclosporin A. These findings define a ubiquinone-binding site directly involved in PTP regulation and indicate that different quinone structural features are required for binding and for stabilizing the pore in the closed conformation. At variance from all other quinones tested, decylubiquinone did not inhibit respiration. Our results define a new structural class of pore inhibitors and may open new perspectives for the pharmacological modulation of the PTP in vivo.	Univ Padua, Sch Med, Dept Biomed Sci, Lab Biophys & Membrane Biol, I-35121 Padua, Italy; Univ Padua, Sch Med, Consiglio Nazl Ric, Unit Study Biomembranes, I-35121 Padua, Italy	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua	Bernardi, P (corresponding author), Dipartimento Sci Biomed Sperimentale, Viale Giuseppe Colombo 3, I-35121 Padua, Italy.		Bernardi, Paolo/C-3656-2008; Ichas, François/ABD-8277-2020; Fontaine, Eric/ABA-8853-2020	Bernardi, Paolo/0000-0001-9187-3736; Ichas, François/0000-0001-8184-5248; Fontaine, Eric/0000-0002-5204-9477	Telethon [847] Funding Source: Medline	Telethon(Fondazione Telethon)		Ankarcrona M, 1996, FEBS LETT, V394, P321, DOI 10.1016/0014-5793(96)00959-3; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BERNARDI P, 1993, J BIOL CHEM, V268, P1005; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; Bernardi P, 1996, J BIOENERG BIOMEMBR, V28, P131, DOI 10.1007/BF02110643; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Chernyak BV, 1996, EUR J BIOCHEM, V238, P623, DOI 10.1111/j.1432-1033.1996.0623w.x; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COSTANTINI P, 1995, FEBS LETT, V362, P239, DOI 10.1016/0014-5793(95)00256-9; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; CROMPTON M, 1988, BIOCHEM J, V255, P357; DIVIRGILIO F, 1982, J BIOL CHEM, V257, P4106; DUCHEN MR, 1993, CARDIOVASC RES, V27, P1790, DOI 10.1093/cvr/27.10.1790; Eriksson O, 1998, J BIOL CHEM, V273, P12669, DOI 10.1074/jbc.273.20.12669; ERNSTER L, 1995, BBA-MOL BASIS DIS, V1271, P195, DOI 10.1016/0925-4439(95)00028-3; Esposti MD, 1998, BBA-BIOENERGETICS, V1364, P222, DOI 10.1016/S0005-2728(98)00029-2; Esposti MD, 1996, BIOCHEM J, V313, P327, DOI 10.1042/bj3130327; EVTODIENKO YV, 1994, CELL CALCIUM, V15, P143, DOI 10.1016/0143-4160(94)90053-1; Fato R, 1996, BIOCHEMISTRY-US, V35, P2705, DOI 10.1021/bi9516034; Fontaine E, 1998, J BIOL CHEM, V273, P12662, DOI 10.1074/jbc.273.20.12662; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P468, DOI 10.1016/0003-9861(79)90373-4; ICHAS F, 1994, FEBS LETT, V348, P211, DOI 10.1016/0014-5793(94)00615-6; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; IMBERTI R, 1993, J PHARMACOL EXP THER, V265, P392; LAPIDUS RG, 1994, J BIOL CHEM, V269, P18931; Nieminen AL, 1996, NEUROSCIENCE, V75, P993; NOVGORODOV SA, 1994, ARCH BIOCHEM BIOPHYS, V311, P219, DOI 10.1006/abbi.1994.1230; PASTORINO JG, 1993, J BIOL CHEM, V268, P13791; PETRONILLI V, 1993, J BIOL CHEM, V268, P1011; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Schinder AF, 1996, J NEUROSCI, V16, P6125; White RJ, 1996, J NEUROSCI, V16, P5688; Yamaguchi M, 1998, J BIOL CHEM, V273, P8094, DOI 10.1074/jbc.273.14.8094; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	38	216	220	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25734	25740		10.1074/jbc.273.40.25734	http://dx.doi.org/10.1074/jbc.273.40.25734			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748242	hybrid			2022-12-27	WOS:000076263100033
J	Hansen, PA; Han, DH; Marshall, BA; Nolte, LA; Chen, MM; Mueckler, M; Holloszy, JO				Hansen, PA; Han, DH; Marshall, BA; Nolte, LA; Chen, MM; Mueckler, M; Holloszy, JO			A high fat diet impairs stimulation of glucose transport in muscle - Functional evaluation of potential mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SKELETAL-MUSCLE; AMINO-ACID-TRANSPORT; INSULIN-RECEPTOR SUBSTRATE-1; PHOSPHATIDYLINOSITOL 3-KINASE; TISSUE DISTRIBUTION; RESPONSIVE TISSUES; TYROSINE KINASE; OBESE SUBJECTS; RAT; RESISTANCE	A high fat diet causes resistance of skeletal muscle glucose transport to insulin and contractions. We tested the hypothesis that fat feeding causes a change in plasma membrane composition that interferes with functioning of glucose transporters and/or insulin receptors, Epitrochlearis muscles of rats fed a high (50% of calories) fat diet for 8 weeks showed similar to 50% decreases in insulin- and contraction-stimulated 3-O-methylglucose transport. Similar decreases in stimulated glucose transport activity occurred in muscles of wild-type mice with 4 weeks of fat feeding. In contrast, GLUT1 overexpressing muscles of transgenic mice fed a high fat diet showed no decreases in their high rates of glucose transport, providing evidence against impaired glucose transporter function. Insulin-stimulated system A amino acid transport, insulin receptor (IR) tyrosine kinase activity, and insulin-stimulated IR and IRS-1 tyrosine phosphorylation were all normal in muscles of rats fed the high fat diet for 8 weeks. However, after 30 weeks on the high fat diet, there was a significant reduction in insulin-stimulated tyrosine phosphorylation in muscle. The increases in GLUT4 at the cell surface induced by insulin or muscle contractions, measured with the H-3-labeled 2-N-4-(1-azi-2,2,2-trifluoroethyl) -benzoyl-1,3-bis-(D-mannose-4-yloxy)-2-propylamine photolabel, were 26-36% smaller in muscles of the 8-week high fat-fed rats as compared with control rats. Our findings provide evidence that (a) impairment of muscle glucose transport by 8 weeks of high fat feeding is not due to plasma membrane composition-related reductions in glucose transporter or insulin receptor function, (b) a defect in insulin receptor signaling is a late event, not a primary cause, of the muscle insulin resistance induced by fat feeding, and (c) impaired GLUT4 translocation to the cell surface plays a major role in the decrease in stimulated glucose transport.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Hansen, PA (corresponding author), Washington Univ, Sch Med, Dept Med, 4566 Scott Ave,Campus Box 8113, St Louis, MO 63110 USA.	phansen@imgate.wustl.edu	Mueckler, Mike M/F-6115-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018986, R01DK038495, K08DK002339] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18986, DK02339, DK38495] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNER P, 1987, DIABETOLOGIA, V30, P437, DOI 10.1007/BF00292549; BAK JF, 1990, BIOCHIM BIOPHYS ACTA, V1052, P306, DOI 10.1016/0167-4889(90)90226-4; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; BORKMAN M, 1993, NEW ENGL J MED, V328, P238, DOI 10.1056/NEJM199301283280404; BOYD JJ, 1990, AM J PHYSIOL, V259, pE111, DOI 10.1152/ajpendo.1990.259.1.E111; BURANT CF, 1984, DIABETES, V33, P704, DOI 10.2337/diabetes.33.7.704; CARO JF, 1987, J CLIN INVEST, V79, P1330, DOI 10.1172/JCI112958; CARRUTHERS A, 1984, BIOCHEMISTRY-US, V23, P6901, DOI 10.1021/bi00321a096; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CLANDININ MT, 1991, FASEB J, V5, P2761, DOI 10.1096/fasebj.5.13.1916101; DESPRES JP, 1989, DIABETES, V38, P304, DOI 10.2337/diabetes.38.3.304; FIELD CJ, 1990, J BIOL CHEM, V265, P11143; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; GOULD RJ, 1982, J BIOL CHEM, V257, P477; GULVE EA, 1991, AM J PHYSIOL, V260, pC88, DOI 10.1152/ajpcell.1991.260.1.C88; Han DH, 1997, DIABETES, V46, P1761, DOI 10.2337/diabetes.46.11.1761; Hansen PA, 1997, AM J PHYSIOL-ENDOC M, V273, pE28, DOI 10.1152/ajpendo.1997.273.1.E28; Holloszy JO, 1996, REV PHYSIOL BIOCH P, V128, P99; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KISSEBAH AH, 1991, INT J OBESITY, V15, P109; KRAEGEN EW, 1986, DIABETOLOGIA, V29, P192, DOI 10.1007/BF02427092; LEE AD, 1995, FEBS LETT, V361, P51, DOI 10.1016/0014-5793(95)00147-2; LEMARCHANDBRUSTEL Y, 1985, NATURE, V315, P676, DOI 10.1038/315676a0; LIU S, 1994, BIOCHEM J, V299, P831, DOI 10.1042/bj2990831; LUND S, 1993, FEBS LETT, V330, P312, DOI 10.1016/0014-5793(93)80895-2; LUND S, 1995, P NATL ACAD SCI USA, V92, P5817, DOI 10.1073/pnas.92.13.5817; MARETTE E, 1992, AM J PHYSIOL, V263, pC443; MARSHALL BA, 1993, J BIOL CHEM, V268, P18442; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; NESHER R, 1985, AM J PHYSIOL, V249, pC226, DOI 10.1152/ajpcell.1985.249.3.C226; OKAMOTO M, 1992, J NUTR BIOCHEM, V3, P241, DOI 10.1016/0955-2863(92)90046-L; PAGLIASSOTTI MJ, 1994, AM J PHYSIOL, V267, pR659, DOI 10.1152/ajpregu.1994.267.3.R659; REN JM, 1993, J BIOL CHEM, V268, P16113; RIGGS TR, 1973, J BIOL CHEM, V248, P6450; ROSHOLT MN, 1994, AM J PHYSIOL, V266, pR95, DOI 10.1152/ajpregu.1994.266.1.R95; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; SANDRA A, 1984, BIOCHIM BIOPHYS ACTA, V778, P511, DOI 10.1016/0005-2736(84)90401-2; Stevenson RW, 1996, DIABETES, V45, P60, DOI 10.2337/diabetes.45.1.60; STORLIEN LH, 1986, AM J PHYSIOL, V251, pE576, DOI 10.1152/ajpendo.1986.251.5.E576; STORLIEN LH, 1991, DIABETES, V40, P280, DOI 10.2337/diabetes.40.2.280; SURWIT RS, 1988, DIABETES, V37, P1163, DOI 10.2337/diabetes.37.9.1163; TSAKIRIDIS T, 1995, ENDOCRINOLOGY, V136, P4315, DOI 10.1210/en.136.10.4315; VANAMELSVOORT JMM, 1986, ANN NUTR METAB, V30, P273, DOI 10.1159/000177204; Wang WC, 1996, J CELL BIOL, V135, P415, DOI 10.1083/jcb.135.2.415; WILSON CM, 1994, BIOCHEM J, V299, P755, DOI 10.1042/bj2990755; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107; YOUNG DA, 1986, J BIOL CHEM, V261, P6049; Zierath JB, 1997, DIABETES, V46, P215, DOI 10.2337/diabetes.46.2.215; ZORZANO A, 1986, AM J PHYSIOL, V251, pE21, DOI 10.1152/ajpendo.1986.251.1.E21	52	117	123	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26157	26163		10.1074/jbc.273.40.26157	http://dx.doi.org/10.1074/jbc.273.40.26157			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748297	hybrid			2022-12-27	WOS:000076263100088
J	Hori, H; Yamazaki, N; Matsumoto, T; Watanabe, Y; Ueda, T; Nishikawa, K; Kumagai, I; Watanabe, K				Hori, H; Yamazaki, N; Matsumoto, T; Watanabe, Y; Ueda, T; Nishikawa, K; Kumagai, I; Watanabe, K			Substrate recognition of tRNA (Guanosine-2 '-)-methyltransferase from Thermus thermophilus HB27	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-GUANINE TRANSGLYCOSYLASE; ESCHERICHIA-COLI; STRUCTURAL REQUIREMENTS; ANTICODON LOOP; METHYLATION; STABILITY; NUCLEOSIDES; SPECIFICITY; POLYMERASE; SEQUENCES	Transfer RNA (guanosine-2'-)-methyltransferase (Gm-methylase, EC 2.1.1.32) from Thermus thermophilus HB27 is one of the tRNA ribose modification enzymes. The broad substrate specificity of Gm-methylase has so far been elucidated using various species of tRNAs from native sources, suggesting that the common structures in tRNAs are recognized by the enzyme. In this study, by using 28 yeast tRNA(Phe) variants obtained by transcription with T7 RNA polymerase, it was revealed that the nucleotide residues G18 and G19 and the D-stem structure are essentially required for Gm-methylase recognition, and that the key sequence for the substrate is pyrimidine (Py)17G18G19. The other conserved sequences were found not to be essential, but U8, G15, G26, G46, U54, U55, and C56 considerably affected the methylation efficiency. These residues are located within a limited space embedded in the L-shaped three-dimensional structure of tRNA Therefore, disruption of the three-dimensional structure of the substrate tRNA is necessary for the catalytic center of Gm methylase to be able to access the target site in the tRNA, suggesting that the interaction of Gm-methylase with tRNA consists of multiple steps. This postulation was confirmed by inhibition experiments using nonsubstrate tRNA variants which functioned as competitive inhibitors against usual substrate tRNAs.	Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan	University of Tokyo	Watanabe, K (corresponding author), Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan.		Ueda, Takuya/K-5217-2014	Ueda, Takuya/0000-0002-7760-8271				Bjork Glenn R., 1995, P165; BJORK GR, 1987, ANNU REV BIOCHEM, V56, P263, DOI 10.1146/annurev.bi.56.070187.001403; Bjork GR, 1992, TRANSFER RNA PROTEIN, P23; CARBON P, 1983, EMBO J, V2, P1093, DOI 10.1002/j.1460-2075.1983.tb01551.x; CURNOW AW, 1993, BIOCHEMISTRY-US, V32, P5239, DOI 10.1021/bi00070a036; DAVANLOO P, 1979, NUCLEIC ACIDS RES, V6, P1571, DOI 10.1093/nar/6.4.1571; Dirheimer G., 1995, P93; DROOGMANS L, 1986, EMBO J, V5, P1105, DOI 10.1002/j.1460-2075.1986.tb04329.x; EDQVIST J, 1993, NUCLEIC ACIDS RES, V21, P413, DOI 10.1093/nar/21.3.413; EDQVIST J, 1992, NUCLEIC ACIDS RES, V20, P6575, DOI 10.1093/nar/20.24.6575; GAMBARYAN AS, 1976, NUCLEIC ACIDS RES, V3, P2079, DOI 10.1093/nar/3.8.2079; GIEGE R, 1993, PROG NUCLEIC ACID RE, V45, P129, DOI 10.1016/S0079-6603(08)60869-7; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; Grosjean H, 1996, J MOL BIOL, V255, P67, DOI 10.1006/jmbi.1996.0007; GROSJEAN H, 1982, BIOCHIMIE, V64, P387, DOI 10.1016/S0300-9084(82)80576-2; GU XG, 1991, BIOCHEMISTRY-US, V30, P2999, DOI 10.1021/bi00226a003; GU XG, 1994, BIOCHEMISTRY-US, V33, P2255, DOI 10.1021/bi00174a036; HOLMES WM, 1992, J BIOL CHEM, V267, P13440; HORI H, 1989, J BIOCHEM-TOKYO, V106, P798, DOI 10.1093/oxfordjournals.jbchem.a122933; JOHNSON PF, 1983, NATURE, V302, P681, DOI 10.1038/302681a0; KEALEY JT, 1995, BIOCHEMISTRY-US, V34, P2441, DOI 10.1021/bi00008a006; KEITH JM, 1980, J BIOL CHEM, V255, P4636; KIM SH, 1974, P NATL ACAD SCI USA, V71, P4970, DOI 10.1073/pnas.71.12.4970; KLINE LK, 1982, ENZYMES, V15, P567; KUMAGAI I, 1980, P NATL ACAD SCI-BIOL, V77, P1922, DOI 10.1073/pnas.77.4.1922; KUMAGAI I, 1982, J BIOL CHEM, V257, P7388; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIMBACH PA, 1994, NUCLEIC ACIDS RES, V22, P2138; MARECHALDROUARD L, 1990, FEBS LETT, V262, P170, DOI 10.1016/0014-5793(90)80181-H; MATSUMOTO T, 1990, J BIOCHEM-TOKYO, V107, P331, DOI 10.1093/oxfordjournals.jbchem.a123047; MELTON DA, 1980, NATURE, V284, P143, DOI 10.1038/284143a0; NAKANISHI S, 1994, J BIOL CHEM, V269, P32221; NISHIMURA S, 1979, TRANSFER RNA STRUCTU, P59; Persson BC, 1997, NUCLEIC ACIDS RES, V25, P4093, DOI 10.1093/nar/25.20.4093; ROBERTS RJ, 1995, CELL, V82, P9, DOI 10.1016/0092-8674(95)90046-2; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; SOLL D, 1982, ENZYMES, V15, P557; STEINBERG S, 1993, NUCLEIC ACIDS RES, V21, P3011, DOI 10.1093/nar/21.13.3011; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SZWEYKOWSKAKULINSKA Z, 1992, EMBO J, V11, P1907, DOI 10.1002/j.1460-2075.1992.tb05243.x; WATANABE K, 1976, BIOCHEM BIOPH RES CO, V72, P1137, DOI 10.1016/S0006-291X(76)80250-1; YAMAZAKI N, 1994, BIOSCI BIOTECH BIOCH, V58, P1128, DOI 10.1271/bbb.58.1128	42	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25721	25727		10.1074/jbc.273.40.25721	http://dx.doi.org/10.1074/jbc.273.40.25721			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748240	hybrid			2022-12-27	WOS:000076263100031
J	Leidich, SD; Ibrahim, AS; Fu, Y; Koul, A; Jessup, C; Vitullo, J; Fonzi, W; Mirbod, F; Nakashima, S; Nozawa, Y; Ghannoum, MA				Leidich, SD; Ibrahim, AS; Fu, Y; Koul, A; Jessup, C; Vitullo, J; Fonzi, W; Mirbod, F; Nakashima, S; Nozawa, Y; Ghannoum, MA			Cloning and disruption of caPLB1, a phospholipase B gene involved in the pathogenicity of Candida albicans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OROTIDINE-5'-PHOSPHATE DECARBOXYLASE; LYSOPHOSPHOLIPASE-TRANSACYLASE; ESCHERICHIA-COLI; ALPHA-AGGLUTININ; CELL-WALL; VIRULENCE; PROTEIN; YEAST; MUTANTS; ACID	The Candida albicans PLB1 gene was cloned using a polymerase chain reaction-based approach relying on degenerate oligonucleotide primers designed according to the amino acid sequences of two peptide fragments obtained from a purified candidal enzyme displaying phospholipase activity (Mirbod, F., Banno, Y., Ghannoum, M. A, Ibrahim, A. S., Nakashima, S., Yasuo, It., Cole, G. T., and Nozawa, Y. (1995) Biochim. Biophys. Acta 1257, 181-188). Sequence analysis of a 6.7-kilobase pair EcoRI-ClaI genomic clone revealed a single open reading frame of 1818 base pairs that predicts for a preprotein of 605 residues. Comparison of the putative candidal phospholipase with those of other proteins in data base revealed significant homology to known fungal phospholipase Bs from Saccharomyces cerevisiae (45%), Penicillium notatum (42%), Torulaspora delbrueckii (48%), and Schizosaccharomyces pombe (38%). Thus, we have cloned the gene encoding a C. albicans phospholipase B homolog. This gene, designated caPLB1, was mapped to chromosome 6. Disruption experiments revealed that the caplb1 null mutant is viable and displays no obvious phenotype. However, the virulence of strains deleted for caPLB1, as assessed in a murine model for hematogenously disseminated candidiasis, was significantly attenuated compared with the isogenic mild-type parental strain. Although deletion of caPLB1 did not produce any detectable effects on candidal adherence to human endothelial or epithelial cells, the ability of the caplb1 null mutant to penetrate host cells was dramatically reduced. Thus, phospholipase B may well contribute to the pathogenicity of C. albicans by abetting the fungus in damaging and traversing host cell membranes, processes which likely increase the rapidity of disseminated infection.	Univ Hosp Cleveland, Ctr Med Mycol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA; Univ Calif Los Angeles, Harbor Med Ctr, Dept Med, Div Infect Dis,St Johns Cardiovasc Res Ctr, Torrance, CA 90509 USA; Georgetown Univ, Med Ctr, Sch Med, Dept Microbiol & Immunol, Washington, DC 20007 USA; Gifu Univ, Sch Med, Dept Biochem, Gifu 500, Japan	University Hospitals of Cleveland; Case Western Reserve University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Georgetown University; Gifu University	Ghannoum, MA (corresponding author), Univ Hosp Cleveland, Ctr Med Mycol, 11100 Euclid Ave, Cleveland, OH 44106 USA.	mag3@po.cwru.edu	Galgiani, John/GLT-7012-2022	Mirbod Donovan, Fariba/0000-0002-6203-5693	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035097] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35097] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALLEN G, 1990, LAB TECHNIQUES BIOCH; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BARRETTBEE K, 1985, J GEN MICROBIOL, V131, P1217; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; CARLO LHP, 1997, YEAST, V13, P1477; CUTLER JE, 1991, ANNU REV MICROBIOL, V45, P187, DOI 10.1146/annurev.mi.45.100191.001155; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DiezOrejas R, 1997, INFECT IMMUN, V65, P833, DOI 10.1128/IAI.65.2.833-837.1997; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FONZI WA, 1993, GENETICS, V134, P717; Gale CA, 1998, SCIENCE, V279, P1355, DOI 10.1126/science.279.5355.1355; GERBER LD, 1992, J BIOL CHEM, V267, P12168; GILLUM AM, 1984, MOL GEN GENET, V198, P179, DOI 10.1007/BF00328721; GOW NAR, 1994, P NATL ACAD SCI USA, V91, P6216, DOI 10.1073/pnas.91.13.6216; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hube B, 1997, INFECT IMMUN, V65, P3529, DOI 10.1128/IAI.65.9.3529-3538.1997; IBRAHIM AS, 1995, INFECT IMMUN, V63, P1993, DOI 10.1128/IAI.63.5.1993-1998.1995; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JARVIS WR, 1995, CLIN INFECT DIS, V20, P1526, DOI 10.1093/clinids/20.6.1526; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE JD, 1995, INFECT IMMUN, V63, P3796, DOI 10.1128/IAI.63.10.3796-3803.1995; LEE KS, 1994, J BIOL CHEM, V269, P19725; LU CF, 1995, J CELL BIOL, V128, P333, DOI 10.1083/jcb.128.3.333; LU CF, 1994, MOL CELL BIOL, V14, P4825, DOI 10.1128/MCB.14.7.4825; MACDONALD F, 1983, J GEN MICROBIOL, V129, P431; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MASUDA N, 1991, EUR J BIOCHEM, V202, P783, DOI 10.1111/j.1432-1033.1991.tb16433.x; MIRBOD F, 1995, BBA-LIPID LIPID MET, V1257, P181, DOI 10.1016/0005-2760(95)00072-K; PRICE MF, 1977, SABOURAUDIA, V15, P179; PUGH D, 1977, SABOURAUDIA, V15, P29; RADVIN JI, 1985, J INFECT DIS, V152, P542; Rose MD., 1990, METHODS YEAST GENETI; ROSS IK, 1990, J GEN MICROBIOL, V136, P687, DOI 10.1099/00221287-136-4-687; SABITINI D, 1962, ANAT REC, V142, P274; SAFFER LD, 1991, J PROTOZOOL, V38, P454, DOI 10.1111/j.1550-7408.1991.tb04816.x; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sanglard D, 1997, INFECT IMMUN, V65, P3539, DOI 10.1128/IAI.65.9.3539-3546.1997; SAPORITOIRWIN SM, 1995, MOL CELL BIOL, V15, P601; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SHIMIZU S, 1980, ANAL BIOCHEM, V107, P193, DOI 10.1016/0003-2697(80)90511-4; SILVERMAN DJ, 1992, INFECT IMMUN, V60, P2733, DOI 10.1128/IAI.60.7.2733-2740.1992; SMITH GA, 1995, INFECT IMMUN, V63, P4231, DOI 10.1128/IAI.63.11.4231-4237.1995; SUGIMOTO H, 1994, J BIOL CHEM, V269, P6252; Verheij HM, 1994, LIPASES THEIR STRUCT, P119; WATANABE Y, 1994, FEMS MICROBIOL LETT, V124, P29, DOI 10.1111/j.1574-6968.1994.tb07257.x; WENZEL RP, 1991, INFECT CONT HOSP EP, V12, P523, DOI 10.1086/646403; WINKLER HH, 1989, INFECT IMMUN, V57, P36, DOI 10.1128/IAI.57.1.36-40.1989; Wysong DR, 1998, INFECT IMMUN, V66, P1953, DOI 10.1128/IAI.66.5.1953-1961.1998; Zhao XJ, 1997, INFECT IMMUN, V65, P829, DOI 10.1128/IAI.65.2.829-832.1997	52	176	190	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26078	26086		10.1074/jbc.273.40.26078	http://dx.doi.org/10.1074/jbc.273.40.26078			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748287	hybrid			2022-12-27	WOS:000076263100078
J	Rowe-Magnus, DA; Spiegelman, GB				Rowe-Magnus, DA; Spiegelman, GB			Contributions of the domains of the Bacillus subtilis response regulator Spo0A to transcription stimulation of the spoIIG operon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE; ACTIVATE TRANSCRIPTION; PROTEIN; BINDING; SPORULATION; PROMOTER; PHOSPHORYLATION; DNA; INITIATION; MECHANISM	Spo0A is a response regulator that controls entry into sporulation by specifically stimulating or repressing transcription of critical developmental genes. Response regulators have at least two domains: an output transcription regulation domain and a receiver domain that inhibits the output domain, Phosphorylation of the receiver domain relieves the inhibition. We examined the in vitro transcription activation mechanism for Spo0A, phosphorylated Spo0A (Spo0A-P), and a deletion mutant that consists solely of the C-terminal output domain (Spo0ABD). Both Spo0A-P and Spo0ABD stimulated transcription from the spoIIG promoter 10-fold more efficiently than Spo0A Spo0A-P and Spo0ABD induced DNA denaturation by RNA polymerase in the -10 recognition region, whereas Spo0A did not. DNase I footprint assays revealed that phosphorylation enhanced binding of intact Spo0A to the OA boxes, while the binding of Spo0ABD was similar to that of Spo0A Thus, activation of Spo0A by phosphorylation is not primarily due to enhanced DNA binding. The presence of a phosphorylated N terminus increased the stability of the ternary complex at the spoIIG promoter. We propose that the primary effect of phosphorylation is to expose an RNA polymerase interaction domain to promote transcription from PspoIIG.	Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Med Genet, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Spiegelman, GB (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, 6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.	spie@unixg.ubc.ca		Rowe-Magnus, Dean/0000-0001-5133-4463				AIBA H, 1989, J BIOCHEM-TOKYO, V106, P5, DOI 10.1093/oxfordjournals.jbchem.a122817; ARAKAWA T, 1984, BIOCHEMISTRY-US, V23, P5912, DOI 10.1021/bi00320a004; ASAYAMA M, 1995, J MOL BIOL, V250, P11, DOI 10.1006/jmbi.1995.0354; BALDUS JM, 1995, MOL MICROBIOL, V17, P281, DOI 10.1111/j.1365-2958.1995.mmi_17020281.x; BALDUS JM, 1994, J BACTERIOL, V176, P296, DOI 10.1128/JB.176.2.296-306.1994; BIRD TH, 1993, MOL MICROBIOL, V9, P741, DOI 10.1111/j.1365-2958.1993.tb01734.x; Bird TH, 1996, J MOL BIOL, V256, P436, DOI 10.1006/jmbi.1996.0099; BUCK M, 1989, NUCLEIC ACIDS RES, V17, P2597, DOI 10.1093/nar/17.7.2597; DOBINSON KF, 1987, BIOCHEMISTRY-US, V26, P8206, DOI 10.1021/bi00399a028; GRIMSLEY JK, 1994, J BIOL CHEM, V269, P16977; HA JH, 1992, J MOL BIOL, V228, P252, DOI 10.1016/0022-2836(92)90504-D; HOCH JA, 1993, ANNU REV MICROBIOL, V47, P441, DOI 10.1146/annurev.micro.47.1.441; HUALA E, 1992, J BACTERIOL, V174, P1428, DOI 10.1128/jb.174.4.1428-1431.1992; Huang KJ, 1997, P NATL ACAD SCI USA, V94, P2828, DOI 10.1073/pnas.94.7.2828; IRETON K, 1993, GENE DEV, V7, P283, DOI 10.1101/gad.7.2.283; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; North AK, 1997, J MOL BIOL, V267, P17, DOI 10.1006/jmbi.1996.0838; OHLSEN KL, 1994, P NATL ACAD SCI USA, V91, P1756, DOI 10.1073/pnas.91.5.1756; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PEREGO M, 1991, GENE, V100, P207, DOI 10.1016/0378-1119(91)90368-L; PEREGO M, 1994, CELL, V79, P1047, DOI 10.1016/0092-8674(94)90035-3; Porter SC, 1995, 2 COMPONENT SIGNAL T, P147; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SATOLA S, 1991, P NATL ACAD SCI USA, V88, P4533, DOI 10.1073/pnas.88.10.4533; SATOLA SW, 1992, J BACTERIOL, V174, P1448, DOI 10.1128/jb.174.5.1448-1453.1992; Schyns G, 1997, J BACTERIOL, V179, P5605, DOI 10.1128/jb.179.17.5605-5608.1997; SPIEGELMAN GB, 1995, 2 COMPONENT SIGNAL T, P159; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; Stragier P, 1996, ANNU REV GENET, V30, P297, DOI 10.1146/annurev.genet.30.1.297; TRACH K, 1991, RES MICROBIOL, V142, P815, DOI 10.1016/0923-2508(91)90060-N; Wang L, 1997, GENE DEV, V11, P2569, DOI 10.1101/gad.11.19.2569	32	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25818	25824		10.1074/jbc.273.40.25818	http://dx.doi.org/10.1074/jbc.273.40.25818			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748255	hybrid			2022-12-27	WOS:000076263100046
J	Singh, AK; Shichi, H				Singh, AK; Shichi, H			A novel glutathione peroxidase in bovine eye - Sequence analysis, mRNA level, and translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYL HYDROPEROXIDE REDUCTASE; SALMONELLA-TYPHIMURIUM; ANTIOXIDANT ENZYMES; NUCLEOTIDE-SEQUENCE; S-TRANSFERASES; TISSUE-REPAIR; CILIARY BODY; RAT-LIVER; SELENIUM; CDNA	Bovine ciliary body contains a selenium-independent glutathione peroxidase (GPX) with a molecular mass of about 100 kDa that is composed of four identical subunits and exhibits no glutathione S-transferase activity. In this study, we isolated cDNA clones and determined the nucleotide sequence to deduce the primary structure of the enzyme. The cDNA contained 672 base pairs encoding a polypeptide with an estimated molecular mass of 25,064 Da, Translation of bovine ciliary mRNA produced a protein which was immunologically indistinguishable from GPX and showed high enzyme activity. The encoded amino acid sequence of the protein was 95% identical with that of a human keratinocyte gene product expressed in response to keratinocyte growth factor. It also showed sequence identity to bacterial alkyl hydroperoxide reductases and thiol specific antioxidant enzymes. GPX mRNA level was highest in the ciliary body, followed by the retina and iris, In various rat organs, the level of GPX mRNA was highest in the lung, followed by the muscle, liver, eye, heart, testis, thymus, kidney, and spleen. A very low level of mRNA was detected in the brain. Enzyme-linked immunosorbent assay with an antibody raised against the NH2-terminal sequence of GPX detected GPX protein in all rat tissues examined.	Wayne State Univ, Sch Med, Kresge Eye Inst, Dept Ophthalmol, Detroit, MI 48201 USA	Wayne State University	Shichi, H (corresponding author), Wayne State Univ, Sch Med, Kresge Eye Inst, Dept Ophthalmol, 4717 St Antoine, Detroit, MI 48201 USA.		Singh, Ashok/HGF-2506-2022		NATIONAL EYE INSTITUTE [R01EY004694] Funding Source: NIH RePORTER; NEI NIH HHS [EY04694] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHU FF, 1993, J BIOL CHEM, V268, P2571; DAS ND, 1981, EXP EYE RES, V33, P525, DOI 10.1016/S0014-4835(81)80127-3; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P13349, DOI 10.1021/bi9713658; Engvall E, 1980, Methods Enzymol, V70, P419; ESWORTHY RS, 1994, GENE, V144, P317, DOI 10.1016/0378-1119(94)90400-6; Frank S, 1997, ONCOGENE, V14, P915, DOI 10.1038/sj.onc.1200905; Harlow E., 1988, ANTIBODIES LAB MANUA; HAWKER FH, 1993, EUR RESPIR J, V6, P1317; Ho YS, 1997, J BIOL CHEM, V272, P16644, DOI 10.1074/jbc.272.26.16644; ISHIDA K, 1987, NUCLEIC ACIDS RES, V15, P10051, DOI 10.1093/nar/15.23.10051; JACOBSON FS, 1989, J BIOL CHEM, V264, P1488; Kishida K, 1985, J Ocul Pharmacol, V1, P85, DOI 10.1089/jop.1985.1.85; Mehlotra RK, 1996, CRIT REV MICROBIOL, V22, P295, DOI 10.3109/10408419609105484; NG MC, 1988, EXP EYE RES, V46, P919, DOI 10.1016/S0014-4835(88)80043-5; PENG B, 1992, CURR EYE RES, V11, P1087, DOI 10.3109/02713689209015080; PROHASKA JR, 1977, BIOCHEM BIOPH RES CO, V76, P437, DOI 10.1016/0006-291X(77)90744-6; ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUCKELT R, 1991, FREE RADICAL RES COM, V14, P343, DOI 10.3109/10715769109093424; SCHWARTZMAN ML, 1987, CURR EYE RES, V6, P623, DOI 10.3109/02713688709025223; SHICHI H, 1990, EXP EYE RES, V50, P513, DOI 10.1016/0014-4835(90)90040-2; Shichi H, 1986, J Ocul Pharmacol, V2, P59, DOI 10.1089/jop.1986.2.59; SHICHI H, 1980, EXTRAHEPATIC METABOL, P333; SHICHI H, 1984, PHARM EYE, P117; Singh AK, 1996, EXP EYE RES, V62, P299, DOI 10.1006/exer.1996.0036; Spector A, 1996, EXP EYE RES, V62, P521, DOI 10.1006/exer.1996.0063; STONE WL, 1982, EXP EYE RES, V35, P405, DOI 10.1016/0014-4835(82)90039-2; TAKAHASHI K, 1986, BLOOD, V68, P640; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; Vuilleumier S, 1997, J BACTERIOL, V179, P1431, DOI 10.1128/jb.179.5.1431-1441.1997; Wan XY, 1997, FEBS LETT, V407, P32, DOI 10.1016/S0014-5793(97)00302-5; Wang JM, 1995, EXP MOL PATHOL, V63, P41, DOI 10.1006/exmp.1995.1029; YOSHIMURA S, 1988, BIOCHEM BIOPH RES CO, V154, P1024, DOI 10.1016/0006-291X(88)90242-2	36	67	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26171	26178		10.1074/jbc.273.40.26171	http://dx.doi.org/10.1074/jbc.273.40.26171			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748299	hybrid			2022-12-27	WOS:000076263100090
J	Tanaka, K; Pracyk, JB; Takeda, K; Yu, ZX; Ferrans, VJ; Deshpande, SS; Ozaki, M; Hwang, PM; Lowenstein, CJ; Irani, K; Finkel, T				Tanaka, K; Pracyk, JB; Takeda, K; Yu, ZX; Ferrans, VJ; Deshpande, SS; Ozaki, M; Hwang, PM; Lowenstein, CJ; Irani, K; Finkel, T			Expression of Id1 results in apoptosis of cardiac myocytes through a redox-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; SENESCENT HUMAN FIBROBLASTS; MEDIATED GENE-TRANSFER; PROGRAMMED CELL-DEATH; DNA-BINDING PROTEINS; RETINOBLASTOMA PROTEIN; HYDROGEN-PEROXIDE; ADENOVIRUS TYPE-5; HEART-FAILURE; MUSCLE	We have constructed a recombinant adenovirus (Ad.Id1) that allows for efficient expression of the helix-loop-helix protein Idl, After infection with Ad.Id1, neonatal cardiac myocytes display a significant reduction in viability, which was proportional to the level of Idl expression, A similar effect was observed in adult myocytes, Morphological and biochemical assays demonstrated that Id1 expression resulted in myocyte apoptosis. In contrast, expression of Idl in endothelial cells, vascular smooth muscle cells, or fibroblasts did not affect the viability of these cells, Along with the induction of apoptosis, the expression of Idl in neonatal cardiac myocytes resulted in an increase in the level of intracellular reactive oxygen species. The source of these reactive oxygen species appears to be the mitochondria, Reducing the ambient oxygen concentration or treatment with a cell-permeant H2O2 scavenger prevented Id1-stimulated apoptosis in cardiac myocytes, These results suggest that the expression of Idl leads to the induction of apoptosis in cardiac myocytes through a redox-dependent mechanism.	NHLBI, Cardiol Branch, NIH, Bethesda, MD 20892 USA; NHLBI, Pathol Sect, NIH, Bethesda, MD 20892 USA; Johns Hopkins Sch Med, Div Cardiol, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Johns Hopkins University; Johns Hopkins Medicine	Finkel, T (corresponding author), NHLBI, Cardiol Branch, NIH, 10 Ctr Dr,Bldg 10,Rm 7B15, Bethesda, MD 20892 USA.			Irani, Kaikobad/0000-0001-9194-7387; Lowenstein, Charles/0000-0003-0485-7514				BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIGGS J, 1992, P NATL ACAD SCI USA, V89, P1512, DOI 10.1073/pnas.89.4.1512; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; Desagher S, 1997, J NEUROSCI, V17, P9060; DHALLA AK, 1994, AM J PHYSIOL, V266, pH1280, DOI 10.1152/ajpheart.1994.266.4.H1280; Dhalla AK, 1996, J AM COLL CARDIOL, V28, P506, DOI 10.1016/0735-1097(96)00140-4; ELLMEIER W, 1992, EMBO J, V11, P2563, DOI 10.1002/j.1460-2075.1992.tb05321.x; EVANS SM, 1993, CIRC RES, V73, P569, DOI 10.1161/01.RES.73.3.569; Giandomenico AR, 1997, FREE RADICAL BIO MED, V23, P426, DOI 10.1016/S0891-5849(97)00113-5; Guidarelli A, 1996, BIOCHEM BIOPH RES CO, V226, P70, DOI 10.1006/bbrc.1996.1312; GUZMAN RJ, 1994, P NATL ACAD SCI USA, V91, P10732, DOI 10.1073/pnas.91.22.10732; GUZMAN RJ, 1993, CIRC RES, V73, P1202, DOI 10.1161/01.RES.73.6.1202; Hara E, 1996, DEV GENET, V18, P161; HARA E, 1994, J BIOL CHEM, V269, P2139; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JACOBSON SL, 1986, J MOL CELL CARDIOL, V18, P661, DOI 10.1016/S0022-2828(86)80939-7; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KassEisler A, 1997, METHOD CELL BIOL, V52, P423, DOI 10.1016/S0091-679X(08)60390-8; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; KRISHENBAUM LA, 1993, J CLIN INVEST, V92, P381, DOI 10.1172/JCI116577; KURABAYASHI M, 1993, J BIOL CHEM, V268, P5524; KURABAYASHI M, 1994, J BIOL CHEM, V269, P6031; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; Mallat Z, 1996, NEW ENGL J MED, V335, P1190, DOI 10.1056/NEJM199610173351604; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; Norton JD, 1998, MOL CELL BIOL, V18, P2371, DOI 10.1128/MCB.18.4.2371; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Pracyk JB, 1997, SURGERY, V122, P404, DOI 10.1016/S0039-6060(97)90033-7; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; ROTHE G, 1991, J IMMUNOL METHODS, V138, P133, DOI 10.1016/0022-1759(91)90074-P; SHIGEOMI S, 1995, NATURE, V374, P811; Silverman HS, 1997, CIRC RES, V80, P699, DOI 10.1161/01.RES.80.5.699; SPRINGHORN JP, 1992, J BIOL CHEM, V267, P14360; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tsai JC, 1996, J BIOL CHEM, V271, P3667; Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887; WANG YQ, 1992, DEV DYNAM, V194, P222, DOI 10.1002/aja.1001940307; Zhong WX, 1996, CELL GROWTH DIFFER, V7, P1175	46	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25922	25928		10.1074/jbc.273.40.25922	http://dx.doi.org/10.1074/jbc.273.40.25922			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748268	hybrid			2022-12-27	WOS:000076263100059
J	Worgall, TS; Sturley, SL; Seo, T; Osborne, TF; Deckelbaum, RJ				Worgall, TS; Sturley, SL; Seo, T; Osborne, TF; Deckelbaum, RJ			Polyunsaturated fatty acids decrease expression of promoters with sterol regulatory elements by decreasing levels of mature sterol regulatory element-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPROTEIN RECEPTOR ACTIVITY; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A SYNTHASE; CHOLESTEROL ACYLTRANSFERASE; TRANSCRIPTION FACTOR; CULTURED-CELLS; SPHINGOMYELIN; IDENTIFICATION; PROTEOLYSIS; HOMEOSTASIS; PATHWAY	Membrane physiology, plasma lipid levels, and intracellular sterol homeostasis are regulated by both fatty acids and cholesterol. Sterols regulate gene expression of key enzymes of cholesterol and fatty acid metabolism through proteolysis of the sterol regulatory element-binding protein (SREBP), which binds to sterol regulatory elements (SRE) contained in promoters of these genes. We investigated the effect of fatty acids on SRE-dependent gene expression and SREBP, Consistent results were obtained in three different cell lines (HepG2, Chinese hamster ovary, and CV-1) transfected with SRE-containing promoters linked to the luciferase expression vector. We show that micromolar concentrations of oleate and other polyunsaturated fatty acids (C18:2-C22:6) dose-dependently (0.075-0.6 mmol) decreased transcription of SRE-regulated genes by 20-75%. Few or no effects were seen with saturated free fatty acids. Fatty acid effects on SRE-dependent gene expression were independent and additive to those of exogenous sterols, Oleate decreased levels of the mature sterol regulatory element-binding proteins SREBP-1 and -2 and HMG-CoA synthase mRNA, Oleate had no effect in sterol regulation defective Chinese hamster ovary cells or in cells transfected with mutant SRE-containing promoters. We hypothesize that unsaturated fatty acids increase intracellular regulatory pools of cholesterol and thus affect mature SREBP levels and expression of SRE-dependent genes.	Columbia Presbyterian Med Ctr, Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA; Columbia Presbyterian Med Ctr, Coll Phys & Surg, Dept Physiol, New York, NY 10032 USA; Columbia Presbyterian Med Ctr, Coll Phys & Surg, Inst Human Nutr, New York, NY 10032 USA; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; University of California System; University of California Irvine	Deckelbaum, RJ (corresponding author), Columbia Presbyterian Med Ctr, Coll Phys & Surg, Dept Pediat, PH-1512,630 W 168th St, New York, NY 10032 USA.				NHLBI NIH HHS [HL 40404, HL 48044] Funding Source: Medline; NIDDK NIH HHS [DK 07715] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048044, R01HL040404] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Cao GQ, 1996, J BIOL CHEM, V271, P14642, DOI 10.1074/jbc.271.24.14642; Clarke SD, 1997, ANN NY ACAD SCI, V827, P178, DOI 10.1111/j.1749-6632.1997.tb51833.x; DAUMERIE CM, 1992, P NATL ACAD SCI USA, V89, P10797, DOI 10.1073/pnas.89.22.10797; DIETSCHY JM, 1993, J LIPID RES, V34, P1637; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; DOOLITTLE GM, 1982, BIOCHIM BIOPHYS ACTA, V713, P529, DOI 10.1016/0005-2760(82)90313-7; GOODMAN DS, 1964, J BIOL CHEM, V239, P1335; HILLGARTNER F, 1995, PHYSIOL REV, V75, P47, DOI 10.1152/physrev.1995.75.1.47; HORTON JD, 1993, J CLIN INVEST, V92, P743, DOI 10.1172/JCI116645; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; JAVITT NB, 1989, BIOCHEM J, V262, P989, DOI 10.1042/bj2620989; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Klansek JJ, 1996, J BIOL CHEM, V271, P4923; LANGE Y, 1989, J BIOL CHEM, V264, P3786; LOPEZ JM, 1996, P NATL ACAD SCI USA, V93, P3786; Magana MM, 1997, J LIPID RES, V38, P1630; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; ROBINSON BS, 1997, IMMUNOLOGY, V91, P271; RUMSEY SC, 1995, J BIOL CHEM, V270, P10008, DOI 10.1074/jbc.270.17.10008; RUSS AP, 1992, BIOCHIM BIOPHYS ACTA, V1132, P329, DOI 10.1016/0167-4781(92)90172-V; SAMBROOK J, 1989, MOL CLONING LABORATO, V2, P16; Scheek S, 1997, P NATL ACAD SCI USA, V94, P11179, DOI 10.1073/pnas.94.21.11179; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; SMITH JR, 1988, J BIOL CHEM, V263, P18480; SPECTOR AA, 1985, J LIPID RES, V26, P1015; STUBBS CD, 1984, BIOCHIM BIOPHYS ACTA, V779, P89, DOI 10.1016/0304-4157(84)90005-4; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; YANG J, 1994, GENE DEV, V15, P1910	33	248	251	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25537	25540		10.1074/jbc.273.40.25537	http://dx.doi.org/10.1074/jbc.273.40.25537			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748213	hybrid			2022-12-27	WOS:000076263100004
J	Saarela, J; Laine, M; Tikkanen, R; Oinonen, C; Jalanko, A; Rouvinen, J; Peltonen, L				Saarela, J; Laine, M; Tikkanen, R; Oinonen, C; Jalanko, A; Rouvinen, J; Peltonen, L			Activation and oligomerization of aspartylglucosaminidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LYSOSOMAL ASPARTYLGLUCOSAMINIDASE; 20S PROTEASOME; CRYSTAL-STRUCTURE; BETA-SUBUNITS; ASSOCIATION; MUTATION; SITE; CALRETICULIN; BIOSYNTHESIS; MECHANISM	Secretory, membrane, and lysosomal proteins undergo covalent modifications and acquire their secondary and tertiary structure in the lumen of the endoplasmic reticulum (ER). In order to pass the ER quality control system and become transported to their final destinations, many of them are also assembled into oligomers, We have recently determined the three-dimensional structure of lysosomal aspartylglucosaminidase (AGA), which belongs to a newly discovered family of homologous amidohydrolases, the N-terminal nucleophile hydrolases. Members of this protein family are activated from an inactive precursor molecule by an autocatalytic proteolytic processing event whose exact mechanism has not been thoroughly determined. Here we have characterized in more detail the initial events in the ER required for the formation of active AGA enzyme using transient expression of polypeptides carrying targeted amino acid substitutions. We show that His(124) at an interface between two heterodimers of AGA is crucial for the thermodynamically stable oligomeric structure of AGA. Furthermore, the side chain of Thr(206) is essential both for the proteolytic activation and enzymatic activity of AGA. Finally, the proper geometry of the residues His(204)-Asp(205) seems to be crucial for the activation of AGA precursor polypeptides. We propose here a reaction mechanism for the activation of AGA which could be valid for homologous enzymes as well.	Univ Helsinki, Dept Med Genet, FIN-00300 Helsinki, Finland; Natl Publ Hlth Inst, Dept Mol Genet, FIN-00300 Helsinki, Finland; Univ Joensuu, Dept Chem, FIN-87101 Joensuu, Finland	University of Helsinki; Finland National Institute for Health & Welfare; University of Eastern Finland	Peltonen, L (corresponding author), Univ Helsinki, Dept Med Genet, Mannerheimintie 166, FIN-00300 Helsinki, Finland.		Saarela, Jani/AAK-5033-2020	Saarela, Jani/0000-0001-7306-7175; Tikkanen, Ritva/0000-0002-8393-1825; Rouvinen, Juha/0000-0003-1843-5718				BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; FISHER KJ, 1993, FEBS LETT, V323, P271, DOI 10.1016/0014-5793(93)81355-4; Guan CD, 1996, J BIOL CHEM, V271, P1732, DOI 10.1074/jbc.271.3.1732; HALILA R, 1991, BIOCHEM J, V276, P251, DOI 10.1042/bj2760251; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; Hebert DN, 1996, EMBO J, V15, P2961, DOI 10.1002/j.1460-2075.1996.tb00659.x; IKONEN E, 1993, EMBO J, V12, P295, DOI 10.1002/j.1460-2075.1993.tb05656.x; IKONEN E, 1991, EMBO J, V10, P51, DOI 10.1002/j.1460-2075.1991.tb07920.x; IKONEN E, 1991, GENOMICS, V11, P206, DOI 10.1016/0888-7543(91)90120-4; Isupov MN, 1996, STRUCTURE, V4, P801, DOI 10.1016/S0969-2126(96)00087-1; Klabunde T, 1998, NAT STRUCT BIOL, V5, P31, DOI 10.1038/nsb0198-31; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MAKINO M, 1968, J BIOCHEM, V63, P186, DOI 10.1093/oxfordjournals.jbchem.a128760; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OINONEN C, 1995, NAT STRUCT BIOL, V2, P1102, DOI 10.1038/nsb1295-1102; Peltola M, 1996, HUM MOL GENET, V5, P737, DOI 10.1093/hmg/5.6.737; PERLER FB, 1994, NUCLEIC ACIDS RES, V22, P1125, DOI 10.1093/nar/22.7.1125; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; PROIA RL, 1984, J BIOL CHEM, V259, P3350; Riikonen A, 1996, J BIOL CHEM, V271, P21340, DOI 10.1074/jbc.271.35.21340; RIIKONEN A, 1995, J BIOL CHEM, V270, P4903, DOI 10.1074/jbc.270.9.4903; Schmidtke G, 1996, EMBO J, V15, P6887, DOI 10.1002/j.1460-2075.1996.tb01081.x; Seemuller E, 1996, NATURE, V382, P468, DOI 10.1038/382468a0; Simons JF, 1998, EMBO J, V17, P396, DOI 10.1093/emboj/17.2.396; SMITH JL, 1994, SCIENCE, V264, P1427, DOI 10.1126/science.8197456; Tikkanen R, 1996, EMBO J, V15, P2954, DOI 10.1002/j.1460-2075.1996.tb00658.x; Tikkanen R, 1997, EMBO J, V16, P6684, DOI 10.1093/emboj/16.22.6684; TIKKANEN R, 1995, DNA CELL BIOL, V14, P305, DOI 10.1089/dna.1995.14.305; Xuan JC, 1998, PROTEIN SCI, V7, P774, DOI 10.1002/pro.5560070327; ZWICKL P, 1994, NAT STRUCT BIOL, V1, P765, DOI 10.1038/nsb1194-765	34	39	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25320	25328		10.1074/jbc.273.39.25320	http://dx.doi.org/10.1074/jbc.273.39.25320			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737998	hybrid			2022-12-27	WOS:000076085400048
J	Souchelnytskyi, S; Nakayama, T; Nakao, A; Moren, A; Heldin, CH; Christian, JL; ten Dijke, P				Souchelnytskyi, S; Nakayama, T; Nakao, A; Moren, A; Heldin, CH; Christian, JL; ten Dijke, P			Physical and functional interaction of murine and Xenopus Smad7 with bone morphogenetic protein receptors and transforming growth factor-beta receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAD-RELATED PROTEIN; SIGNALING PATHWAYS; PHOSPHORYLATION; SUPERFAMILY; ANTAGONIST; ACTIVATION; SER(465); MEMBRANE; FAMILY; BMP	Members of the transforming growth factor-beta (TGF-beta) family transmit signals from membrane to nucleus via intracellular proteins known as Smads. A subclass of Smad proteins has recently been identified that antagonize, rather than transduce, TGF-beta family signals. Smad7, for example, binds to and inhibits signaling downstream of TGF-beta receptors. Here we report that the C-terminal MAD homology domain of murine Smad7 (mSmad7) is sufficient for both of these activities. In addition, we show that mSmad7 interacts with activated bone morphogenetic protein (BMP) type I receptors (BMPR-Is), inhibits BMPR-I-mediated Smad phosphorylation, and phenocopies the effect of known BMP antagonists when overexpressed in ventral cells of Xenopus embryos. Xenopus Smad7 (XSmad7, previously termed Smad8) and mSmad7 are nearly identical within their bioactive C-domain, but have quite distinct N-domains. We found that XSmad7, similar to mSmad7, interacted with BMP and TGF-beta type I receptors and inhibited receptor-mediated phosphorylation of downstream signal-transducing Smads. However, XSmad7 is a less efficient inhibitor of T beta R-I-mediated responses in mammalian cells than is mSmad7. Furthermore, overexpression of XSmad7 in Xenopus embryos produces patterning defects that are not observed following overexpression of mSmad7, suggesting that mSmad7 and XSmad7 may preferentially target distinct signaling pathways. Our results are consistent with the possibility that the C-domain of antagonistic Smads is an effector domain whereas the N-domain may confer specificity for distinct signaling pathways.	Ludwig Inst Canc Res, Ctr Biomed, S-75124 Uppsala, Sweden; Oregon Hlth Sci Univ, Sch Med, Dept Cell & Dev Biol, Portland, OR 97201 USA	Ludwig Institute for Cancer Research; Oregon Health & Science University	ten Dijke, P (corresponding author), Chiba Univ, Sch Med, Dept Internal Med, 1-8-1 Inohana, Chiba 2600856, Japan.	Peter.ten_Dijke@LICR.uu.se	Souchelnytskyi, Serhiy/G-6491-2011; Nakayama, Takuya/J-5812-2015; Nakayama, Toshinori/E-1067-2017; Dijke, Peter ten/AAG-4660-2021; Souchelnytskyi, Serhiy/J-9446-2014	Souchelnytskyi, Serhiy/0000-0001-8243-9276; Nakayama, Takuya/0000-0002-5531-6710; Nakayama, Toshinori/0000-0002-1434-2007; Dijke, Peter ten/0000-0002-7234-342X; 				Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Candia AF, 1997, DEVELOPMENT, V124, P4467; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen Y, 1997, P NATL ACAD SCI USA, V94, P12938, DOI 10.1073/pnas.94.24.12938; Derynck R, 1997, BBA-REV CANCER, V1333, pF105, DOI 10.1016/S0304-419X(97)00017-6; FROLIK CA, 1984, J BIOL CHEM, V259, P995; Graff JM, 1997, CELL, V89, P171, DOI 10.1016/S0092-8674(00)80196-8; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; Moon R. T., 1989, TECHNIQUE, V1, P76; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nakayama T, 1998, GENES CELLS, V3, P387, DOI 10.1046/j.1365-2443.1998.00196.x; Nakayama T, 1998, DEVELOPMENT, V125, P857; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Suzuki A, 1997, DEV BIOL, V184, P402, DOI 10.1006/dbio.1997.8548; Tsuneizumi K, 1997, NATURE, V389, P627, DOI 10.1038/39362; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VIZE PD, 1994, TRENDS GENET, V10, P371, DOI 10.1016/0168-9525(94)90134-1; Watanabe TK, 1997, GENOMICS, V42, P446, DOI 10.1006/geno.1997.4753; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	39	125	135	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25364	25370		10.1074/jbc.273.39.25364	http://dx.doi.org/10.1074/jbc.273.39.25364			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738003	hybrid			2022-12-27	WOS:000076085400053
J	Pavao, MSG; Aiello, KRM; Werneck, CC; Silva, LCF; Valente, AP; Mulloy, B; Colwell, NS; Tollefsen, DM; Mourao, PAS				Pavao, MSG; Aiello, KRM; Werneck, CC; Silva, LCF; Valente, AP; Mulloy, B; Colwell, NS; Tollefsen, DM; Mourao, PAS			Highly sulfated dermatan sulfates from ascidians - Structure versus anticoagulant activity of these glycosaminoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-COFACTOR-II; BRANCHED CHONDROITIN SULFATE; PLICATA CHORDATA-TUNICATA; STYELA-PLICATA; SEA-CUCUMBER; L-GALACTANS; BODY WALL; THROMBIN; POLYSACCHARIDES; BINDING	Dermatan sulfates with the same backbone structure [4-alpha-L-IdceA-1-->3-beta-D-GalNAc-1](n) but with different patterns of sulfation substitutions have been isolated from the ascidian body. All the ascidian dermatan sulfates have a high content of 2-O-sulfated alpha-L-iduronic acid residues but differ in the pattern of sulfation of the N-acetyl-beta-D-galactosamine units. Styela plicata and Halocynthia pyriformis have 4-O-sulfated units, but in Ascidian nigra they are 6-O-sulfated. This collection of ascidian dermatan sulfates (together with native and oversulfated mammalian dermatan sulfate), where the extent and position of sulfate substitution have been fully characterized, were tested in anticoagulant assays. Dermatan sulfate from A. nigra has no discernible anticoagulant activity, which indicates that 4-O-sulfation of the N-acetyl-beta-D-galactosamine is essential for the anticoagulant activity of this glycosaminoglycan, In contrast dermatan sulfates from S. plicata and H. pyriformis are potent anticoagulants due to potentiation of thrombin inhibition by heparin cofactor II. These ascidian dermatan sulfates have similar to 10-fold and similar to 6-fold higher activity with heparin cofactor II than native and an oversulfated mammalian dermatan sulfate, respectively. They have no effect on thrombin or factor Xa inhibition by antithrombin. These naturally oversulfated ascidian dermatan sulfates are sulfated at selected sites required for interaction with heparin cofactor II and thus have specific and potent anticoagulant activity.	Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil; Univ Hosp, Lab Tecido Conjunt, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Dept Bioquim Med, Ctr Nacl Ressonancia Magnet Nucl Macromol, BR-21941590 Rio De Janeiro, Brazil; Natl Inst Biol Stand & Controls, Potters Bar EN6 3QG, Herts, England; Washington Univ, Sch Med, Dept Internal Med, Div Hematol, St Louis, MO 63110 USA	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; National Institute for Biological Standards & Control; Washington University (WUSTL)	Mourao, PAS (corresponding author), Univ Hosp, Lab Tecido Conjunt, Caixa Postal 68041, BR-21941590 Rio De Janeiro, Brazil.	mourao@server.bioqmed.ufrj.br	Mourao, Paulo/AAA-5386-2020; Werneck, Claudio C/C-7568-2012; Pavao, Mauro Sergio Goncalves/B-1979-2010; Valente, Ana Paula/J-3010-2017; Silva, Luiz Claudio/C-2339-2013	Werneck, Claudio C/0000-0002-9413-0572; Pavao, Mauro Sergio Goncalves/0000-0002-1336-4271; Valente, Ana Paula/0000-0001-7219-1123; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055520] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-55520] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBANO RM, 1990, CARBOHYD RES, V208, P163, DOI 10.1016/0008-6215(90)80096-L; ALBANO RM, 1986, J BIOL CHEM, V261, P758; Alves AP, 1997, J BIOL CHEM, V272, P6965, DOI 10.1074/jbc.272.11.6965; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BLINDER MA, 1989, J BIOL CHEM, V264, P5128; BLINDER MA, 1990, J BIOL CHEM, V265, P286; BOSSENNEC V, 1990, BIOCHEM J, V267, P625, DOI 10.1042/bj2670625; CARDOSO LEM, 1994, ARTERIOSCLER THROMB, V14, P115, DOI 10.1161/01.ATV.14.1.115; CARRIE D, 1992, THROMB HAEMOSTASIS, V68, P637; DIETRICH CP, 1975, ANAL CHEM, V70, P645; DOL F, 1988, THROMB RES, V52, P153, DOI 10.1016/0049-3848(88)90094-1; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; FERNANDEZ F, 1986, BRIT J HAEMATOL, V64, P309, DOI 10.1111/j.1365-2141.1986.tb04124.x; LUDWIGBAXTER KG, 1991, CARBOHYD RES, V214, P245, DOI 10.1016/0008-6215(91)80032-I; MAAROUFI RM, 1990, THROMB RES, V59, P749, DOI 10.1016/0049-3848(90)90056-I; Maekawa H, 1996, J BIOL CHEM, V271, P18604, DOI 10.1074/jbc.271.31.18604; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MASCELLANI G, 1993, BIOCHEM J, V296, P639, DOI 10.1042/bj2960639; MOURAO PAS, 1987, EUR J BIOCHEM, V166, P431, DOI 10.1111/j.1432-1033.1987.tb13534.x; Mourao PAS, 1996, J BIOL CHEM, V271, P23973, DOI 10.1074/jbc.271.39.23973; MOURAO PAS, 1987, EUR J BIOCHEM, V166, P639, DOI 10.1111/j.1432-1033.1987.tb13561.x; MULLOY B, 1994, J BIOL CHEM, V269, P22113; MUNAKATA H, 1987, BIOCHIM BIOPHYS ACTA, V925, P325, DOI 10.1016/0304-4165(87)90198-X; OFOSU FA, 1987, BIOCHEM J, V248, P889, DOI 10.1042/bj2480889; PANGRAZZI J, 1987, HAEMATOLOGICA, V72, P459; Pavao MSG, 1995, J BIOL CHEM, V270, P31027, DOI 10.1074/jbc.270.52.31027; PAVAO MSG, 1989, J BIOL CHEM, V264, P9972; PAVAO MSG, 1994, BBA-GEN SUBJECTS, V1199, P229, DOI 10.1016/0304-4165(94)90001-9; PAVAO MSG, 1990, CARBOHYD RES, V208, P153, DOI 10.1016/0008-6215(90)80095-K; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; SANTOS JA, 1992, EUR J BIOCHEM, V204, P669, DOI 10.1111/j.1432-1033.1992.tb16680.x; SCULLY MF, 1988, BIOCHEM J, V254, P547, DOI 10.1042/bj2540547; THOMAS DP, 1982, THROMB RES, V28, P343, DOI 10.1016/0049-3848(82)90116-5; TOLLEFSEN DM, 1982, J BIOL CHEM, V257, P2162; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; VANRYNMCKENNA J, 1989, BRIT J HAEMATOL, V71, P265; VANRYNMCKENNA J, 1989, ANN NY ACAD SCI, V556, P304; VIEIRA RP, 1993, BIOCHEMISTRY-US, V32, P2254, DOI 10.1021/bi00060a018; VIEIRA RP, 1988, J BIOL CHEM, V263, P18176; VIEIRA RP, 1991, J BIOL CHEM, V266, P13530; WHINNA HC, 1991, J BIOL CHEM, V266, P8129	41	146	152	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27848	27857		10.1074/jbc.273.43.27848	http://dx.doi.org/10.1074/jbc.273.43.27848			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774395	hybrid			2022-12-27	WOS:000076549800015
J	Tian, H; Yu, L; Mather, MW; Yu, CA				Tian, H; Yu, L; Mather, MW; Yu, CA			Flexibility of the neck region of the Rieske iron-sulfur protein is functionally important in the cytochrome bc(1) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WATER-SOLUBLE FRAGMENT; BOVINE HEART; RHODOBACTER-SPHAEROIDES; C OXIDOREDUCTASE; QUINOL OXIDATION; MITOCHONDRIAL; SITE; RECONSTITUTION; INVOLVEMENT; CAPSULATUS	The crystal structure of the mitochondrial cytochrome be, complex suggests that movement of the extramembrane (head) domain of the Rieske iron-sulfur protein (ISP) is involved in electron transfer, Such movement requires flexibility in the neck region of ISP. To test this hypothesis, Rhodobacter sphaeroides mutants expressing His-tagged cytochrome be, complexes with altered ISP necks (residues 39-48) were generated and characterized, Mutants with increased rigidity of the neck, generated by a double-proline substitution at Ala-46 and Ala-48 (ALA-PLP) or by a triple-proline substitution of ADV at residues 42-44 (ADV-PPP), have retarded (50%) or no photosynthetic growth, respectively. However, the mutant with a shortened neck, generated by deleting ADV (Delta ADV), has a photosynthetic growth rate comparable to that of complement cells, indicating that the length of the ISP neck is less critical than its flexibility in support of photosynthetic growth. The Delta ADV and ALA-PLP mutant membranes have 10 and 30% of the cytochrome be, complex activity found in the complement membrane, respectively, whereas the ADV-PPP mutant membrane contains no cytochrome be, complex activity, The loss of cytochrome be, complex activity in the Delta ADV membrane is attributed to improper docking of the head domain of ISP on cytochrome b, as indicated by a drastic change in the EPR characteristics of the Rieske iron-sulfur cluster. The loss of cytochrome bc(1) complex activity in the ALA-PLP and ADV-PPP mutant membranes results from the decreased mobility of the ISP head domain due to the increased rigidity of the ISP neck. The ADV-PLP mutant complex has a larger activation energy than the wild-type complex, suggesting that movement of the head domain decreases the activation energy barrier of the cytochrome bc(1) complex. Using the conditions developed for the isolation of the His-tagged complement cytochrome be, complex, a two-subunit complex (cytochromes b and c(1)) was obtained from the Delta ADV and ADV-PPP mutants, indicating that mutations at the neck region of ISP weaken the interactions among cytochrome b, ISP, and subunit IV.	Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA	Oklahoma State University System; Oklahoma State University - Stillwater	Yu, CA (corresponding author), Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA.	cayu@okway.okstate.edu		Mather, Michael/0000-0002-1062-0137	NIGMS NIH HHS [GM 30721] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030721, R37GM030721] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERDEN JA, 1970, BIOCHIM BIOPHYS ACTA, V216, P237, DOI 10.1016/0005-2728(70)90215-X; Brandt U, 1997, BIOCHEMISTRY-US, V36, P11234, DOI 10.1021/bi970968g; CROFTS AR, 1989, PHOTOSYNTH RES, V22, P69, DOI 10.1007/BF00114768; CROFTS AR, 1982, BIOCHEM SOC T, V10, P201, DOI 10.1042/bst0100201; CROFTS AR, 1995, PHOTOSYNTHESIS LIGHT, V2, P493; Cross TA, 1998, BIOPHYS J, V74, pA129; DALDAL F, 1989, EMBO J, V8, P3951, DOI 10.1002/j.1460-2075.1989.tb08578.x; DEGLIESPOSTI M, 1991, ARCH BIOCHEM BIOPHYS, V289, P303; Denke E, 1998, J BIOL CHEM, V273, P9085, DOI 10.1074/jbc.273.15.9085; DEVRIES S, 1981, J BIOL CHEM, V256, P1996; ENGEL WD, 1983, EUR J BIOCHEM, V132, P395, DOI 10.1111/j.1432-1033.1983.tb07376.x; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Iwata S, 1996, STRUCTURE, V4, P567, DOI 10.1016/S0969-2126(96)00062-7; KHOSRAVI M, 1990, PLASMID, V23, P138, DOI 10.1016/0147-619X(90)90032-8; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; Kim H, 1997, FASEB J, V11, pA1084; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liebl U, 1997, BIOCHEMISTRY-US, V36, P11675, DOI 10.1021/bi970776l; Link TA, 1996, EUR J BIOCHEM, V237, P71, DOI 10.1111/j.1432-1033.1996.0071n.x; Link TA, 1997, FEBS LETT, V412, P257, DOI 10.1016/S0014-5793(97)00772-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATHER MW, 1995, J BIOL CHEM, V270, P28668, DOI 10.1074/jbc.270.48.28668; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; *PROM CORP, 1996, ALT SIT IN VITR MUT; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; Tian H, 1997, J BIOL CHEM, V272, P23722, DOI 10.1074/jbc.272.38.23722; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; TSAI AL, 1987, J BIOL CHEM, V262, P8677; USUI S, 1990, BIOCHEM BIOPH RES CO, V167, P575, DOI 10.1016/0006-291X(90)92063-6; VANDOREN SR, 1993, BIOCHEMISTRY-US, V32, P8083, DOI 10.1021/bi00083a005; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Yu CA, 1998, BBA-BIOENERGETICS, V1365, P151, DOI 10.1016/S0005-2728(98)00055-3; Yu CA, 1996, BBA-BIOENERGETICS, V1275, P47, DOI 10.1016/0005-2728(96)00049-7; YU CA, 1982, BIOCHEMISTRY-US, V21, P4096, DOI 10.1021/bi00260a028; YU L, 1991, BIOCHEMISTRY-US, V30, P4934, DOI 10.1021/bi00234a014; YU L, 1986, BIOCHIM BIOPHYS ACTA, V852, P203, DOI 10.1016/0005-2728(86)90225-2; YUN CH, 1990, EUR J BIOCHEM, V194, P399, DOI 10.1111/j.1432-1033.1990.tb15633.x; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	38	98	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27953	27959		10.1074/jbc.273.43.27953	http://dx.doi.org/10.1074/jbc.273.43.27953			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774409	hybrid			2022-12-27	WOS:000076549800029
J	Trapani, JA; Jans, DA; Jans, PJ; Smyth, MJ; Browne, KA; Sutton, VR				Trapani, JA; Jans, DA; Jans, PJ; Smyth, MJ; Browne, KA; Sutton, VR			Efficient nuclear targeting of granzyme B and the nuclear consequences of apoptosis induced by granzyme B and perforin are caspase-dependent, but cell death is caspase-independent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED APOPTOSIS; CYTOTOXICITY; FAMILY; PURIFICATION; LOCALIZATION; SPECIFICITY; SUBSTRATE; PROTEASES; CLEAVAGE; PROTEIN	The secretory lysosomes of cytolytic lymphocytes house the principal apoptotic molecules for eliminating virus-infected cells: a membranolytic agent, perforin, and the serine protease, granzyme B. Perforin allows granzyme B access to cytosolic and nuclear substrates that, when cleaved, result in the characteristic apoptotic phenotype. Key among these substrates is a family of cytoplasmic caspases that mediate cell suicide. We have examined the caspase dependence of several nuclear and cytoplasmic parameters of apoptosis induced by purified perforin and granzyme B. Cell membrane leakage in response to perforin and granzyme B was independent of caspase activation; however, nuclear events such as DNA fragmentation and nuclear condensation and disintegration were abolished by the broad-acting caspase inhibitor, z-VAD-fmk, Despite being spared from nuclear damage, z-VAD-fmk-treated cells exposed to both cytotoxins uniformly died when they were re-cultured, while cells exposed to perforin or granzyme alone survived and proliferated as readily as untreated cells. Pretreatment of cells with z-VAD-fmk also resulted in reduced granzyme B nuclear uptake following addition of perforin; however, its uptake into the cytoplasm in the absence of perforin was unaffected. We conclude that cell death in response to perforin and granzyme B does not require caspase activation and still proceeds efficiently through non-nuclear pathways when nuclear substrate cleavage is inhibited.	Austin Res Inst, John Connell Lab, Heidelberg, Vic 3084, Australia; Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Nucl Targeting Lab, Canberra, ACT 2601, Australia	Austin Research Institute; Australian National University; John Curtin School of Medical Research	Trapani, JA (corresponding author), Austin Res Inst, John Connell Lab, Studley Rd, Heidelberg, Vic 3084, Australia.	j.trapani@ari.unimelb.edu.au	Smyth, Mark J/H-8709-2014	Smyth, Mark J/0000-0001-7098-7240; Trapani, Joseph/0000-0003-0983-1532				Andrade F, 1998, IMMUNITY, V8, P451, DOI 10.1016/S1074-7613(00)80550-6; Darmon AJ, 1996, J BIOL CHEM, V271, P21709, DOI 10.1074/jbc.271.36.21709; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Froelich CJ, 1996, BIOCHEM BIOPH RES CO, V227, P658, DOI 10.1006/bbrc.1996.1565; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; Froelich CJ, 1998, IMMUNOL TODAY, V19, P30, DOI 10.1016/S0167-5699(97)01184-5; Jans DA, 1996, J BIOL CHEM, V271, P30781, DOI 10.1074/jbc.271.48.30781; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Matsumoto M, 1997, J VIROL, V71, P1301, DOI 10.1128/JVI.71.2.1301-1309.1997; Miller LK, 1997, J CELL PHYSIOL, V173, P178, DOI 10.1002/(SICI)1097-4652(199711)173:2<178::AID-JCP17>3.3.CO;2-Z; Nagata S, 1996, ADV EXP MED BIOL, V406, P119; NAKAJIMA H, 1995, J EXP MED, V181, P1905, DOI 10.1084/jem.181.5.1905; Pinkoski MJ, 1996, J BIOL CHEM, V271, P10225, DOI 10.1074/jbc.271.17.10225; POE M, 1991, J BIOL CHEM, V266, P98; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sarin A, 1997, IMMUNITY, V6, P209, DOI 10.1016/S1074-7613(00)80427-6; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; Shi LF, 1997, J EXP MED, V185, P855, DOI 10.1084/jem.185.5.855; SMYTH MJ, 1995, IMMUNOL TODAY, V16, P202, DOI 10.1016/0167-5699(95)80122-7; Sutton VR, 1997, J IMMUNOL, V158, P5783; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; TRAPANI JA, 1993, BIOCHEM BIOPH RES CO, V195, P910, DOI 10.1006/bbrc.1993.2131; Trapani JA, 1998, CELL DEATH DIFFER, V5, P488, DOI 10.1038/sj.cdd.4400373; Trapani JA, 1996, J BIOL CHEM, V271, P4127; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	26	135	136	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27934	27938		10.1074/jbc.273.43.27934	http://dx.doi.org/10.1074/jbc.273.43.27934			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774406	hybrid			2022-12-27	WOS:000076549800026
J	Hui, TY; Frohnert, BI; Smith, AJ; Schaffer, JE; Bernlohr, DA				Hui, TY; Frohnert, BI; Smith, AJ; Schaffer, JE; Bernlohr, DA			Characterization of the murine fatty acid transport protein gene and its insulin response sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE AMINOTRANSFERASE GENE; FACTOR-BINDING PROTEIN-1; RNA-POLYMERASE-II; MESSENGER-RNA; PHOSPHOENOLPYRUVATE CARBOXYKINASE; REGULATED EXPRESSION; MEMBRANE-PROTEIN; HEPATOMA-CELLS; LESS PROMOTER; C-FOS	Fatty acid transport protein (FATP) was identified by expression cloning strategies (Schaffer, J. E., and Lodish, H. F. (1994) Cell 79, 427-436) and shown by transfection analysis to catalyze the transfer of long-chain fatty acids across the plasma membrane of cells. It is expressed highly in tissues exhibiting rapid fatty acid metabolism such as skeletal muscle, heart, and adipose. FATP mRNA levels are down-regulated by insulin in cultured 3T3-L1 adipocytes and up-regulated by nutrient depletion in murine adipose tissue (Man, M. Z., Hui, T. Y., Schaffer, J. E., Lodish, H. F., and Bernlohr, D. A. (1996) Mol.. Endocrinol. 10, 1021-1028). To determine the molecular mechanism of insulin regulation of FATP transcription, we have isolated the murine FATP gene and its 5'-flanking sequences. The FATP gene spans similar to 16 kilobases and contains 13 exons, of which exon 2 is alternatively spliced. S1 nuclease and RNase protection assays revealed the presence of multiple transcription start sites; the DNA sequence upstream of the predominant transcription start sites lacks a typical TATA box. By transient transfection assays in 3T3-L1 adipocytes, the inhibitory action of insulin on FATP transcription was localized to a cis-acting element with the sequence 5'-TGTTTTC-3' from -1347 to -1353, This sequence is very similar to the insulin response sequence found in the regulatory region of other genes negatively regulated by insulin such as those encoding phosphoenolpyruvate carboxykinase, tyrosine aminotransferase, and insulin-like growth factor-binding protein 1. Fluorescence in situ hybridization analysis revealed that the murine FATP gene is localized to chromosome 8, band 8B3.3. Interestingly, this region of chromosome 8 contains a cluster of three other genes important for fatty acid homeostasis, lipoprotein lipase, the mitochondrial uncoupling protein 1 (UCP1) and sterol regulatory element-binding protein 1. These results characterize the murine FATP gene and its insulin responsiveness as well as present a framework for future studies of its role in lipid metabolism, obesity, and type II diabetes mellitus.	Univ Minnesota, Dept Biochem, St Paul, MN 55108 USA; Univ Minnesota, Inst Human Genet, St Paul, MN 55108 USA; Washington Univ, Sch Med, St Louis, MO 63110 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Washington University (WUSTL)	Bernlohr, DA (corresponding author), Univ Minnesota, Dept Biochem, 1479 Gortner Ave, St Paul, MN 55108 USA.	david-b@biosci.cbs.umn.edu		Frohnert, Brigitte/0000-0002-6636-4048	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049807] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 49807] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABUMRAD NA, 1984, J BIOL CHEM, V259, P8945; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ABUMRAD NA, 1981, J BIOL CHEM, V256, P9183; AEBI M, 1987, CELL, V50, P237, DOI 10.1016/0092-8674(87)90219-4; Berk PD, 1997, J BIOL CHEM, V272, P8830, DOI 10.1074/jbc.272.13.8830; BERK PD, 1998, IN PRESS MOL CELL BI; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOODY MC, 1980, BIOCHEMISTRY-US, V19, P108, DOI 10.1021/bi00542a017; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; FUJII S, 1987, J BIOCHEM-TOKYO, V101, P679, DOI 10.1093/jb/101.3.679; GANSS R, 1994, MOL ENDOCRINOL, V8, P895, DOI 10.1210/me.8.7.895; HARMON CM, 1991, J MEMBRANE BIOL, V121, P261, DOI 10.1007/BF01951559; HEDIGER MA, 1994, J EXP BIOL, V196, P15; Ince TA, 1995, J BIOL CHEM, V270, P30249, DOI 10.1074/jbc.270.51.30249; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3799, DOI 10.1093/nar/19.14.3799; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; JACOB M, 1989, NUCLEIC ACIDS RES, V17, P2159, DOI 10.1093/nar/17.6.2159; KAMP F, 1993, BIOCHEMISTRY-US, V32, P11074, DOI 10.1021/bi00092a017; KAMP F, 1992, P NATL ACAD SCI USA, V89, P11367, DOI 10.1073/pnas.89.23.11367; KIM SJ, 1994, J BIOL CHEM, V269, P11887; Kinne R K, 1995, Curr Opin Nephrol Hypertens, V4, P412, DOI 10.1097/00041552-199509000-00007; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; MA L, 1992, NUCLEIC ACIDS RES, V20, P217, DOI 10.1093/nar/20.2.217; MAHADEVAN S, 1974, ARCH BIOCHEM BIOPHYS, V164, P185, DOI 10.1016/0003-9861(74)90021-6; Man MZ, 1996, MOL ENDOCRINOL, V10, P1021, DOI 10.1210/me.10.8.1021; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; MESSINA JL, 1990, J BIOL CHEM, V265, P11700; MIRA E, 1989, J BIOL CHEM, V264, P18209; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Parks CL, 1996, J BIOL CHEM, V271, P4417; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; STRAUS DS, 1987, J BIOL CHEM, V262, P1955; STREMMEL W, 1985, P NATL ACAD SCI USA, V82, P4, DOI 10.1073/pnas.82.1.4; STREMMEL W, 1988, J CLIN INVEST, V81, P844, DOI 10.1172/JCI113393; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; SUWANICKUL A, 1993, J BIOL CHEM, V268, P17063; TRIGATTI BL, 1991, J BIOL CHEM, V266, P22621; Uchiyama A, 1996, J BIOL CHEM, V271, P30360, DOI 10.1074/jbc.271.48.30360; UNTERMAN TG, 1994, BIOCHEM BIOPH RES CO, V203, P1835, DOI 10.1006/bbrc.1994.2401; WAHLE E, 1995, BBA-GENE STRUCT EXPR, V1261, P183, DOI 10.1016/0167-4781(94)00248-2; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794	51	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27420	27429		10.1074/jbc.273.42.27420	http://dx.doi.org/10.1074/jbc.273.42.27420			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765271	hybrid			2022-12-27	WOS:000076448000058
J	Feng, X; Hannun, YA				Feng, X; Hannun, YA			An essential role for autophosphorylation in the dissociation of activated protein kinase C from the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; PHOSPHORYLATION; ALPHA; BINDING	The cellular localization of protein kinase C (PKC) is intimately associated with the regulation of its biological activity. Previously we have demonstrated that the redistribution of PKC to the plasma membrane in response to physiological stimuli is followed by a rapid returning of PKC back to the cytoplasm (Feng, X., Zhang, J,, Barak, L, S., Meyer, T,, Caron, M. G., and Hannun, Y, A. (1998) J. Biol Chem. 273, 10755-10762), Although the process of PKC membrane targeting has been extensively studied, the molecular mechanism underlying the dissociation of membrane-bound PKC remains unclear, In the present study, by examining the dynamic distribution of wild-type PKC PIP and its kinase-deficient mutant (K371R), we demonstrate that kinase activity is required for PKC membrane dissociation. Moreover, the inability of PKC PII(K371R) to dissociate from the plasma membrane in cells overexpressing wild-type PKC Pll suggests that autophosphorylation activity of the kinase might be essential for its membrane dissociation. This was further supported by mutational analysis of two lit vivo autophosphorylation sites on PKC beta II. The replacement of Ser(660) or Thr(641) by alanine (S660A or T641A) was found to synergistically reduce the reversal of PKC beta II membrane translocation, whereas the replacement of the same amino acids by glutamic acid (S660E or T641E), an amino acid commonly used to mimic phosphate, results in mutants behaving similar to wild-type PKC PHI, These findings point to an essential role for autophosphorylation in the dissociation of activated PKC from the plasma membrane and suggest that, like PKC membrane translocation, the returning of PBC to the cytoplasm after its activation is also delicately regulated.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	Duke University; Duke University	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem, 171 Ashley Ave, Charleston, SC 29425 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043707] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43707] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Blobe GC, 1996, CANCER SURV, V27, P213; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; BORNER C, 1989, J BIOL CHEM, V264, P13902; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; Dembinsky A, 1997, J BIOL CHEM, V272, P828, DOI 10.1074/jbc.272.2.828; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; FARRAR WL, 1985, NATURE, V315, P235, DOI 10.1038/315235a0; FARRAR WL, 1985, NATURE, V315, P233, DOI 10.1038/315233a0; Feng X, 1998, J BIOL CHEM, V273, P10755, DOI 10.1074/jbc.273.17.10755; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; HUANG KP, 1986, J BIOL CHEM, V261, P2134; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; Mochly-Rosen D, 1998, FASEB J, V12, P35; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; OHNO S, 1990, J BIOL CHEM, V265, P6296; ORR JW, 1994, J BIOL CHEM, V269, P27715; Sakai N, 1997, J CELL BIOL, V139, P1465, DOI 10.1083/jcb.139.6.1465; TSUTAKAWA SE, 1995, J BIOL CHEM, V270, P26807, DOI 10.1074/jbc.270.45.26807; WARD NE, 1992, MOL PHARMACOL, V41, P387	27	65	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26870	26874		10.1074/jbc.273.41.26870	http://dx.doi.org/10.1074/jbc.273.41.26870			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756933	hybrid			2022-12-27	WOS:000076373300087
J	Guffanti, AA; Cheng, JB; Krulwich, TA				Guffanti, AA; Cheng, JB; Krulwich, TA			Electrogenic antiport activities of the gram-positive tet proteins include a Na+(K+)/K+ mode that mediates net K+ uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-TETRACYCLINE/H+ ANTIPORTER; BACILLUS-SUBTILIS TETA(L); ESCHERICHIA-COLI; NA+/H+ ANTIPORTER; STAPHYLOCOCCUS-AUREUS; POTASSIUM-TRANSPORT; RESISTANCE PROTEIN; MEMBRANE-VESICLES; ACTIVE-TRANSPORT; GENE	Two Gram-positive Tet proteins, TetA(L) from Bacillus subtilis and TetK from a Staphylococcus aureus plasmid, have previously been suggested to have multiple catalytic modes and roles. These include: tetracycline (Tc)-metal/H+ antiport for both proteins (Yamaguchi, A., Shiina, Y,, Fujihira, E., Sawai, T., Noguchi, N., and Sasatsu, M. (1995) FEES Lett. 365, 193-197; Cheng, J. Guffanti, A A., Wang, W., Krulwich, T. A., and Bechhofer, D. H. (1996) J. Bacteriol. 178, 2853-2860); Na+(K+)/H+ antiport for both proteins (Cheng ct at. (1996)); and an electrical potential-dependent K+ leak mode for TetK and highly truncated segments thereof that can facilitate net K+ uptake (Guay, G. G., Tuckman, M., McNicholas, P., and Rothstein, D. M. (1993) J. Bacteriol. 175, 4927-4929). Studies of membrane vesicles from Escherichia coli expressing low levels of complete and 3'-truncated versions of tetA(L) or tetK, now show that the full-length versions of both transporters catalyze electrogenic antiport and that demonstration of electrogenicity depends upon use of a low chloride buffer for the assay. The K+ uptake mode, assayed via Rb-86(+) uptake, was also catalyzed by both full-length TetA(L) and TetK. This mode does not represent a potential-dependent leak. Such a leak was not demonstrable in energized membrane vesicles. Rather, Rb+ uptake occurred in right-side-out vesicles when the intravesicular space contained either Na+ or K+ but not choline. If an outwardly directed gradient of Na+ or K+ was present, Rbi uptake occurred without energization in vesicles from cells transformed with a plasmid containing tetA(L) or tetK but not a control plasmid. Experiments in which a comparable exchange was carried out in low chloride buffers to which oxonol was added confirmed that the exchange was electrogenic. Thus, the K+ uptake mode is proposed to be a mode of the electrogenic monovalent cation/H+ antiport activity of TetA(L) and TetK in which K+ takes the place of the external protons. Truncated TetK and TetA(L) failed to catalyze either Tc-metal/H+ or Na+/H+ antiport in energized everted vesicles. Truncated TetK, but not TetA(L), did, however, exhibit modest, electrogenic Na+(K+)/Rb+ exchange as well as a small, potential-dependent leak of Rb+. The C-terminal halves of the TetA(L) and TetK proteins are thus required both for proton-coupled active transport activities of the multifunctional transporter and, perhaps, for minimizing cation leakiness.	CUNY Mt Sinai Sch Med, Dept Biochem, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Krulwich, TA (corresponding author), CUNY Mt Sinai Sch Med, Dept Biochem, Box 1020,1 Gustave L Levy Pl, New York, NY 10029 USA.				NIGMS NIH HHS [GM52837] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cheng JB, 1996, P NATL ACAD SCI USA, V93, P14446, DOI 10.1073/pnas.93.25.14446; CHENG JB, 1994, J BIOL CHEM, V269, P27365; Cheng JB, 1996, J BACTERIOL, V178, P2853, DOI 10.1128/jb.178.10.2853-2860.1996; Cheng JB, 1996, ANTIMICROB AGENTS CH, V40, P852, DOI 10.1128/AAC.40.4.852; DOSCH DC, 1984, J BACTERIOL, V160, P1188, DOI 10.1128/JB.160.3.1188-1190.1984; EPSTEIN W, 1993, BIOCHEM SOC T, V21, P1006, DOI 10.1042/bst0211006; EPSTEIN W, 1971, J BACTERIOL, V108, P639, DOI 10.1128/JB.108.2.639-644.1971; FIJIHIRA E, 1997, FEBS LETT, V419, P211; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; GRIFFITH JK, 1988, J BACTERIOL, V170, P598, DOI 10.1128/jb.170.2.598-604.1988; GRIFFITH JK, 1994, MOL MEMBR BIOL, V11, P271, DOI 10.3109/09687689409160437; GUAY GG, 1993, J BACTERIOL, V175, P4927, DOI 10.1128/JB.175.15.4927-4929.1993; GUFFANTI AA, 1995, J BACTERIOL, V177, P4557, DOI 10.1128/jb.177.15.4557-4561.1995; HARRINGTON CR, 1984, J BACTERIOL, V159, P925, DOI 10.1128/JB.159.3.925-933.1984; Hirata T, 1997, FEBS LETT, V412, P337, DOI 10.1016/S0014-5793(97)00796-5; IVEY DM, 1992, J BACTERIOL, V174, P4878, DOI 10.1128/JB.174.15.4878-4884.1992; JOLLIFFE LK, 1981, CELL, V25, P753, DOI 10.1016/0092-8674(81)90183-5; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KABACK HR, 1971, J BIOL CHEM, V246, P5523; KANEKO M, 1985, FEBS LETT, V193, P194, DOI 10.1016/0014-5793(85)80149-6; KEYES SR, 1982, J BIOL CHEM, V257, P1172; LENSKI RE, 1994, J BACTERIOL, V176, P3140, DOI 10.1128/jb.176.11.3140-3147.1994; LEVY SB, 1992, ANTIMICROB AGENTS CH, V24, P1; MCMURRY LM, 1992, J BACTERIOL, V174, P6294, DOI 10.1128/JB.174.19.6294-6297.1992; MCNAB RM, 1987, BIOPHYS J, V52, P637; NAKAMURA T, 1986, J BIOL CHEM, V261, P678; NAKAMURA T, 1995, BIOL PHARM BULL, V18, P1189; PADAN E, 1989, J BIOL CHEM, V264, P20297; PAULSEN IT, 1993, GENE, V124, P1, DOI 10.1016/0378-1119(93)90755-R; SCHULDINER S, 1975, BIOCHEMISTRY-US, V14, P5451, DOI 10.1021/bi00696a011; WAGGONER AS, 1979, ANNU REV BIOPHYS BIO, V8, P47, DOI 10.1146/annurev.bb.08.060179.000403; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P4809; YAMAGUCHI A, 1995, FEBS LETT, V365, P193, DOI 10.1016/0014-5793(95)00455-I; YAMAGUCHI A, 1991, ANTIMICROB AGENTS CH, V35, P53, DOI 10.1128/AAC.35.1.53; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P7490	35	31	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26447	26454		10.1074/jbc.273.41.26447	http://dx.doi.org/10.1074/jbc.273.41.26447			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756879	hybrid			2022-12-27	WOS:000076373300033
J	Huang, ZS; Wu, HN				Huang, ZS; Wu, HN			Identification and characterization of the RNA chaperone activity of hepatitis delta antigen peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMMERHEAD RIBOZYME CATALYSIS; VIRUS-RNA; SELF-CLEAVAGE; REPLICATION; PROTEIN; BINDING; GENOME; ASSOCIATION; EXPRESSION; SEQUENCES	In this study, we identified an activity of the hepatitis delta antigen that both modulates the cis-cleaving activities of hepatitis delta virus (HDV) genomic RNA fragments and facilitates the trans-cleavage reactions between hammerhead ribozymes and the cognate substrates of various lengths in vitro. Hepatitis delta antigen peptides exert their effect by accelerating the unfolding and refolding of RNA molecules and by promoting strand annealing and strand dissociation. In addition, the stimulatory effect of hepatitis delta antigen peptide on hammerhead catalysis is observed whether the peptide is removed or not by phenol/chloroform extraction prior to the initiation of trans-cleavage reaction. Therefore, hepatitis delta antigen peptide acts as an RNA chaperone. The RNA chaperone domain of hepatitis delta antigen overlaps with the coiled-coil domain that is rich in lysine residues. The RNA binding domains of hepatitis delta antigen previously identified are not required for the RNA chaperone activity identified herein. The RNA chaperone activity of hepatitis delta antigen may be important for the regulation of HDV replication in vivo.	Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan	Academia Sinica - Taiwan	Wu, HN (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan.	hnwu@gate.sinica.edu.tw	Wu, Huey Nan/ABA-4484-2021	Wu, Huey Nan/0000-0002-1538-7776				BERTRAND EL, 1994, EMBO J, V13, P2904, DOI 10.1002/j.1460-2075.1994.tb06585.x; BONINO F, 1986, J VIROL, V58, P945, DOI 10.1128/JVI.58.3.945-950.1986; BONINO F, 1984, INFECT IMMUN, V43, P1000, DOI 10.1128/IAI.43.3.1000-1005.1984; CHANG MF, 1993, J VIROL, V67, P2529, DOI 10.1128/JVI.67.5.2529-2536.1993; CHAO M, 1990, J VIROL, V64, P5066, DOI 10.1128/JVI.64.10.5066-5069.1990; COETZEE T, 1994, GENE DEV, V8, P1575, DOI 10.1101/gad.8.13.1575; GLENN JS, 1992, SCIENCE, V256, P1331, DOI 10.1126/science.1598578; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; HERSCHLAG D, 1994, EMBO J, V13, P2913, DOI 10.1002/j.1460-2075.1994.tb06586.x; HERTEL KJ, 1994, BIOCHEMISTRY-US, V33, P3374, DOI 10.1021/bi00177a031; Jeng KS, 1996, J VIROL, V70, P4205, DOI 10.1128/JVI.70.7.4205-4209.1996; KUO MYP, 1988, J VIROL, V62, P4439, DOI 10.1128/JVI.62.12.4439-4444.1988; LAZINSKI DW, 1993, J VIROL, V67, P2672, DOI 10.1128/JVI.67.5.2672-2680.1993; LEE CZ, 1995, J VIROL, V69, P5332, DOI 10.1128/JVI.69.9.5332-5336.1995; LEE CZ, 1993, J VIROL, V67, P2221, DOI 10.1128/JVI.67.4.2221-2227.1993; LIN JH, 1990, J VIROL, V64, P4051, DOI 10.1128/JVI.64.9.4051-4058.1990; MACNAUGHTON TB, 1993, J VIROL, V67, P2228, DOI 10.1128/JVI.67.4.2228-2234.1993; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; PERROTTA AT, 1991, NATURE, V350, P434, DOI 10.1038/350434a0; POISSON F, 1993, J GEN VIROL, V74, P2473, DOI 10.1099/0022-1317-74-11-2473; RIZZETTO M, 1980, P NATL ACAD SCI-BIOL, V77, P6124, DOI 10.1073/pnas.77.10.6124; ROSENSTEIN SP, 1991, NUCLEIC ACIDS RES, V19, P5409, DOI 10.1093/nar/19.19.5409; ROZZELLE JE, 1995, P NATL ACAD SCI USA, V92, P382, DOI 10.1073/pnas.92.2.382; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TSUCHIHASHI Z, 1993, SCIENCE, V262, P99, DOI 10.1126/science.7692597; WANG JG, 1993, J VIROL, V67, P446, DOI 10.1128/JVI.67.1.446-454.1993; WANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0; WEINER AJ, 1988, J VIROL, V62, P594, DOI 10.1128/JVI.62.2.594-599.1988; WU HN, 1989, P NATL ACAD SCI USA, V86, P1831, DOI 10.1073/pnas.86.6.1831; WU HN, 1990, MOL CELL BIOL, V10, P5575, DOI 10.1128/MCB.10.10.5575	30	57	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26455	26461		10.1074/jbc.273.41.26455	http://dx.doi.org/10.1074/jbc.273.41.26455			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756880	hybrid			2022-12-27	WOS:000076373300034
J	Ishikawa, R; Yamashiro, S; Kohama, K; Matsumura, F				Ishikawa, R; Yamashiro, S; Kohama, K; Matsumura, F			Regulation of actin binding and actin bundling activities of fascin by caldesmon coupled with tropomyosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT CULTURED-CELLS; SEA-URCHIN EGGS; NONMUSCLE CALDESMON; SMOOTH-MUSCLE; MULTIPLE ISOFORMS; TRANSFORMED-CELLS; ALPHA-ACTININ; CROSS-LINKS; PROTEIN; LOCALIZATION	Human fascin is an actin-bundling protein and is thought to play a role in the formation of microfilament bundles of microspikes and stress fibers in cultured cells. To explore the regulation of fascin-actin interaction, we have examined the effects of culture cell caldesmon and tropomyosin (TM) on actin binding activity of human fascin, Caldesmon alone or TM alone has little or no effect on the actin binding of fascin, However, caldesmon together with TM completely inhibits actin binding of human fascin, When calmodulin is added, the inhibition of fascin-actin interaction by caldesmon and TM becomes Ca2+ dependent because Ca2+/calmodulin blocks actin binding of caldesmon, Furthermore, as phosphorylation of caldesmon by cdc2 kinase inhibits actin binding of caldesmon, phosphorylation can also control actin binding of fascin in the presence of TM. As expected by the inhibition of fascin-actin binding, caldesmon coupled with TM also inhibits actin bundling activity of fascin, Whereas smooth muscle caldesmon alone or TM alone shows no effect, caldesmon together with TM completely inhibits actin bundling activity of fascin. This inhibition is again Ca2+ dependent when calmodulin is added to the system. These results suggest important roles for caldesmon and TM in the regulation of the function of human fascin.	Rutgers State Univ, Dept Mol Biol & Biochem, Nelson Lab, Piscataway, NJ 08854 USA; Gunma Univ, Sch Med, Dept Pharmacol, Maebashi, Gumma 3718511, Japan	Rutgers State University New Brunswick; Gunma University	Matsumura, F (corresponding author), Rutgers State Univ, Dept Mol Biol & Biochem, Nelson Lab, Busch Campus, Piscataway, NJ 08854 USA.	matsumura@mbcl.rutgers.edu		Matsumura, Fumio/0000-0002-8204-153X; Yamashiro, Shigeko/0000-0001-7207-9406	NCI NIH HHS [CA42742] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA042742, R01CA042742] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLATTLER DP, 1972, J CHROMATOGR, V64, P147, DOI 10.1016/S0021-9673(00)92958-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; BRETSCHER A, 1985, J CELL BIOL, V100, P1656, DOI 10.1083/jcb.100.5.1656; BRYAN J, 1986, METHOD ENZYMOL, V134, P13; BRYAN J, 1993, P NATL ACAD SCI USA, V90, P9115, DOI 10.1073/pnas.90.19.9115; Cant K, 1996, GENETICS, V143, P249; CANT K, 1994, J CELL BIOL, V125, P369, DOI 10.1083/jcb.125.2.369; CASTELLINO F, 1995, J CELL BIOL, V131, P1223, DOI 10.1083/jcb.131.5.1223; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; DEROSIER DJ, 1980, EXP CELL RES, V126, P490, DOI 10.1016/0014-4827(80)90295-5; EDWARDS RA, 1995, CELL MOTIL CYTOSKEL, V32, P1, DOI 10.1002/cm.970320102; FRANZA BR, 1984, CANCER CELL, P137; HENDRICKS M, 1981, P NATL ACAD SCI-BIOL, V78, P5633, DOI 10.1073/pnas.78.9.5633; ISHIKAWA R, 1989, J BIOL CHEM, V264, P16764; ISHIKAWA R, 1989, J BIOL CHEM, V264, P7490; KANE RE, 1975, J CELL BIOL, V66, P305, DOI 10.1083/jcb.66.2.305; KOJIOWADA M, 1984, P NATL ACAD SCI USA, V81, P3133; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamb NJC, 1996, EUR J CELL BIOL, V69, P36; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; Lehman W, 1997, J MOL BIOL, V274, P310, DOI 10.1006/jmbi.1997.1422; LEONARDI CL, 1982, BIOCHIM BIOPHYS ACTA, V720, P154, DOI 10.1016/0167-4889(82)90007-6; LIN JJC, 1988, J CELL BIOL, V107, P563, DOI 10.1083/jcb.107.2.563; LIN JJC, 1984, CANCER CELL, V1, P57; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; MATSUMURA F, 1985, J BIOL CHEM, V260, P3851; MATSUMURA F, 1986, J BIOL CHEM, V261, P4655; MATSUMURA F, 1983, J BIOL CHEM, V258, P6636; Matsumura F, 1993, CURR OPIN CELL BIOL, V5, P70, DOI 10.1016/S0955-0674(05)80010-9; MOSIALOS G, 1994, J VIROL, V68, P7320, DOI 10.1128/JVI.68.11.7320-7328.1994; NOVY RE, 1993, CELL MOTIL CYTOSKEL, V26, P248, DOI 10.1002/cm.970260308; NOVY RE, 1991, J BIOL CHEM, V266, P16917; OKAGAKI T, 1991, J BIOCHEM, V109, P858, DOI 10.1093/oxfordjournals.jbchem.a123471; Ono S, 1997, J BIOL CHEM, V272, P2527; OTTO JJ, 1979, CELL, V17, P285, DOI 10.1016/0092-8674(79)90154-5; OTTO JJ, 1994, CURR OPIN CELL BIOL, V6, P105, DOI 10.1016/0955-0674(94)90123-6; OTTO JJ, 1980, CELL MOTIL CYTOSKEL, V1, P31, DOI 10.1002/cm.970010104; PITTENGER MF, 1994, CURR OPIN CELL BIOL, V6, P96, DOI 10.1016/0955-0674(94)90122-8; Sasaki Y, 1996, J NEUROCHEM, V66, P980; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; SOBUE K, 1991, J BIOL CHEM, V266, P12115; STEINHARDT R, 1977, DEV BIOL, V58, P185, DOI 10.1016/0012-1606(77)90084-7; TemmGrove CJ, 1996, CELL MOTIL CYTOSKEL, V33, P223, DOI 10.1002/(SICI)1097-0169(1996)33:3<223::AID-CM6>3.0.CO;2-B; TILNEY LG, 1995, J CELL BIOL, V130, P629, DOI 10.1083/jcb.130.3.629; URBANCIKOVA M, 1994, J BIOL CHEM, V269, P24310; VEIGL ML, 1983, BIOCHIM BIOPHYS ACTA, V738, P21, DOI 10.1016/0304-419X(84)90018-0; VELAZ L, 1989, J BIOL CHEM, V264, P9602; WARREN KS, 1994, J CELL BIOL, V125, P359, DOI 10.1083/jcb.125.2.359; Warren KS, 1996, CELL MOTIL CYTOSKEL, V34, P215, DOI 10.1002/(SICI)1097-0169(1996)34:3<215::AID-CM5>3.0.CO;2-8; Yamakita Y, 1996, J BIOL CHEM, V271, P12632, DOI 10.1074/jbc.271.21.12632; YAMASHIRO S, 1990, NATURE, V344, P675, DOI 10.1038/344675a0; YAMASHIRO S, 1991, NATURE, V349, P169, DOI 10.1038/349169a0; Yamashiro S, 1998, MOL BIOL CELL, V9, P993, DOI 10.1091/mbc.9.5.993; YAMASHIRO S, 1994, INT C BIOPH BIOCH CE, P113; YAMASHIRO-MATSUMURA S, 1988, Protoplasma Supplementum, V2, P9; YAMASHIROMATSUMURA S, 1988, J CELL BIOL, V106, P1973, DOI 10.1083/jcb.106.6.1973; YAMASHIROMATSUMURA S, 1986, J CELL BIOL, V103, P631, DOI 10.1083/jcb.103.2.631; YAMASHIROMATSUMURA S, 1985, J BIOL CHEM, V260, P5087	59	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26991	26997		10.1074/jbc.273.41.26991	http://dx.doi.org/10.1074/jbc.273.41.26991			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756949	hybrid			2022-12-27	WOS:000076373300103
J	Blahos, J; Mary, S; Perroy, J; de Colle, C; Brabet, I; Bockaert, J; Pin, JP				Blahos, J; Mary, S; Perroy, J; de Colle, C; Brabet, I; Bockaert, J; Pin, JP			Extreme C terminus of G protein alpha-subunits contains a site that discriminates between G(i)-coupled metabotropic glutamate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE PHEROMONE RECEPTORS; BETA-GAMMA; COUPLING SELECTIVITY; INOSITOL PHOSPHATES; ADRENERGIC-RECEPTOR; INTRACELLULAR LOOP; SYNTHETIC PEPTIDES; CARBOXYL-TERMINUS; AMINO-ACIDS; ACTIVATION	Metabotropic glutamate receptors (mGlu receptors), the Ca2+-sensing receptor, gamma-aminobutyric acid type B receptors, and one group of pheromone receptors constitute a unique family (also called family 3) of heptahelical receptors, This original family shares no sequence similarity with any other G protein coupled receptors, The identification and comparison of the molecular determinants of receptor/G protein coupling within the different receptor families may help identify general rules involved in this protein/protein interaction. In order to detect possible contact sites important for coupling selectivity between family 3 receptors and the G protein alpha-subunits, we examined the coupling of the cyclase-inhibiting mGlu2 and mGlu4 receptors to chimeric alpha(q)-subunits bearing the 5 extreme C-terminal amino acid residues of either G alpha(qi)(,) G alpha(qo) or G alpha(qz). Whereas mGlu4 receptor activated all three chimeric G proteins, mGlu2 receptor activated G alpha(qi) and G alpha(qo) but not G alpha(qz). The mutation of isoleucine -4 of G alpha(qo) into cysteine was sufficient to recover coupling of the mutant G protein to mGlu2 receptor. Moreover, the mutation of cysteine -4 of G alpha(qo) into isoleucine was sufficient to suppress the coupling to mGlu2 receptor, Mutations at positions -5 and -1 had an effect on coupling efficiency, but not selectivity. Our results emphasize the importance of the residue -4 of the alpha-subunits in their specific interaction to heptahelical receptors by extending this finding on the third family of G protein coupled receptors.	CCIPE, CNRS, UPR 9023, F-34094 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS)	Pin, JP (corresponding author), CCIPE, CNRS, UPR 9023, 141 Rue Cardonille, F-34094 Montpellier 5, France.	pin@ccipe.montp.inserm.fr	Pin, Jean-Philippe/Y-6668-2019; Blahos, Jaroslav/G-4397-2014; Blahos, Jaroslav/G-8325-2017	Pin, Jean-Philippe/0000-0002-1423-345X; Blahos, Jaroslav/0000-0001-9803-0061; Blahos, Jaroslav/0000-0003-3355-1469; perroy, julie/0000-0001-6199-0448				Bae H, 1997, J BIOL CHEM, V272, P32071, DOI 10.1074/jbc.272.51.32071; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BONE EA, 1984, BIOCHEM J, V221, P803, DOI 10.1042/bj2210803; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Conklin BR, 1996, MOL PHARMACOL, V50, P885; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; Francesconi A, 1998, J BIOL CHEM, V273, P5615, DOI 10.1074/jbc.273.10.5615; Gilchrist A, 1998, J BIOL CHEM, V273, P14912, DOI 10.1074/jbc.273.24.14912; Gomeza J, 1996, MOL PHARMACOL, V50, P923; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; Kostenis E, 1997, J BIOL CHEM, V272, P23675, DOI 10.1074/jbc.272.38.23675; Kostenis E, 1997, J BIOL CHEM, V272, P19107, DOI 10.1074/jbc.272.31.19107; Kostenis E, 1997, BIOCHEMISTRY-US, V36, P1487, DOI 10.1021/bi962554d; Lichtarge O, 1996, P NATL ACAD SCI USA, V93, P7507, DOI 10.1073/pnas.93.15.7507; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; Mary S, 1998, J BIOL CHEM, V273, P425, DOI 10.1074/jbc.273.1.425; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; PALM D, 1990, FEBS LETT, V261, P294, DOI 10.1016/0014-5793(90)80575-4; PARKER EM, 1991, J BIOL CHEM, V266, P9987; Parmentier ML, 1998, MOL PHARMACOL, V53, P778, DOI 10.1124/mol.53.4.778; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; PIN JP, 1992, P NATL ACAD SCI USA, V89, P10331, DOI 10.1073/pnas.89.21.10331; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; TAKAHASHI K, 1993, J BIOL CHEM, V268, P19341; Taylor JM, 1996, J BIOL CHEM, V271, P3336; TAYLOR JM, 1994, J BIOL CHEM, V269, P27618; Tsu RC, 1997, MOL PHARMACOL, V52, P38, DOI 10.1124/mol.52.1.38; Umemori H, 1997, SCIENCE, V276, P1878, DOI 10.1126/science.276.5320.1878; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501	44	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25765	25769		10.1074/jbc.273.40.25765	http://dx.doi.org/10.1074/jbc.273.40.25765			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748247	hybrid			2022-12-27	WOS:000076263100038
J	Discher, DJ; Bishopric, NH; Wu, XS; Peterson, CA; Webster, KA				Discher, DJ; Bishopric, NH; Wu, XS; Peterson, CA; Webster, KA			Hypoxia regulates beta-enolase and pyruvate kinase-M promoters by modulating Sp1/Sp3 binding to a conserved GC element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLOTHIONEIN GENE-EXPRESSION; DEPENDENT PROTEIN-KINASE; RESPONSIVE ELEMENT; TRANSCRIPTIONAL REGULATION; INDUCIBLE FACTOR-1; CARDIAC MYOCYTES; NUCLEAR-PROTEIN; MAIZE ADH1; ACTIVATION; SP3	The transcription rates of glycolytic enzyme genes are coordinately induced when cells are exposed to low oxygen tension. This effect has been described in many cell types and is not restricted to species or phyla. In mammalian cells, there are 11 distinct glycolytic enzymes, at least 9 of which are induced by hypoxia. Recent reports described a role for the hypoxia-inducible factor-1 (HIF-1) in the transcriptional activation of lactate dehydrogenase A, aldolase-A, phosphoglycerate kinase, and enolase-l genes. It is not known whether the HIF-1 factor acts exclusively to regulate these genes during hypoxia, or how the other genes of the pathway are regulated. In this paper, we describe analyses of the muscle-specific pyruvate kinase-M and beta-enolase promoters that implicate additional mechanisms for the regulation of glycolytic enzyme gene transcription by hypoxia, Transient transcription of a reporter gene directed by either promoter was activated when transfected muscle cells were exposed to hypoxia. Neither of these promoters contain HIF-1 binding sites. Instead, the hypoxia response was localized to a conserved GC-rich element positioned immediately upstream of a GATAA site in the proximal promoter regions of both genes. The GC element was essential for both basal and hypoxia-induced expression and bound the transcription factors Spl and Sp3. Hypoxia caused the progressive depletion of Sp3 determined by DNA binding studies and Western analyses, whereas Spl protein levels remained unchanged, Overexpression of Sp3 repressed expression of p-enolase promoters. It is concluded that hypoxia activates these glycolytic enzyme gene promoters by down-regulating Sp3, thereby removing the associated transcriptional repression.	Univ Miami, Med Ctr, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; SRI Int, Pharmaceut Discovery, Menlo Park, CA 94025 USA; Univ Arkansas Med Sch, Vet Adm Hosp, Dept Med, Little Rock, AR 72205 USA	University of Miami; SRI International; University of Arkansas System; University of Arkansas Medical Sciences	Webster, KA (corresponding author), Univ Miami, Med Ctr, Dept Mol Pharmacol, Rosenstiel Med Sci Bldg,Rm 6038,1600 NW 10th Av, Miami, FL 33136 USA.	kwebster@chroma.med.miami.edu		Webster, Keith A/0000-0002-6431-3642	NHLBI NIH HHS [HL44578, HL49891] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL044578, R01HL044578, R01HL049891] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AARONSON RM, 1995, J BIOL CHEM, V270, P27752, DOI 10.1074/jbc.270.46.27752; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; Bodi I, 1995, CARDIOVASC RES, V30, P975, DOI 10.1016/S0008-6363(95)00164-6; Boulikas Teni, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P117; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; DALTON T, 1994, NUCLEIC ACIDS RES, V22, P5016, DOI 10.1093/nar/22.23.5016; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; DENNIS ES, 1988, J MOL BIOL, V202, P759, DOI 10.1016/0022-2836(88)90556-6; FERL RJ, 1987, J BIOL CHEM, V262, P7947; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; GOOD AG, 1992, PLANT MOL BIOL, V19, P693, DOI 10.1007/BF00026795; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; Ho VT, 1996, BIOCHEM BIOPH RES CO, V223, P175, DOI 10.1006/bbrc.1996.0865; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KOIZUMI S, 1992, EUR J BIOCHEM, V210, P555, DOI 10.1111/j.1432-1033.1992.tb17454.x; Kumar AP, 1997, NUCLEIC ACIDS RES, V25, P2012, DOI 10.1093/nar/25.10.2012; Laderoute KR, 1997, CIRC RES, V80, P336, DOI 10.1161/01.RES.80.3.336; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MAXAUDIT I, 1993, J BIOL CHEM, V268, P5431; OLIVE MR, 1991, NUCLEIC ACIDS RES, V19, P7053, DOI 10.1093/nar/19.25.7053; Prentice H, 1997, CARDIOVASC RES, V35, P567, DOI 10.1016/S0008-6363(97)00158-2; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SHANNA YL, 1995, CIRC RES, V77, P638; SMITH A, 1993, J BIOL CHEM, V268, P7365; TAKENAKA M, 1989, J BIOL CHEM, V264, P2363; TAYLOR JM, 1995, J BIOL CHEM, V270, P2535, DOI 10.1074/jbc.270.6.2535; WALKER JC, 1987, P NATL ACAD SCI USA, V84, P6624, DOI 10.1073/pnas.84.19.6624; WEBSTER KA, 1990, MOL CELL BIOL, V10, P2402, DOI 10.1128/MCB.10.5.2402; WEBSTER KA, 1987, MOL CELL BIOCHEM, V77, P19; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEBSTER KA, 1993, J BIOL CHEM, V268, P16852; WEBSTER KA, 1988, CAN J ZOOL, V66, P1046, DOI 10.1139/z88-155; WEBSTER KA, 1990, J CELL PHYSIOL, V142, P566, DOI 10.1002/jcp.1041420316; WEBSTER KA, 1992, J MOL CELL CARDIOL, V24, P741, DOI 10.1016/0022-2828(92)93388-Z; Wu XS, 1996, MOL CELL BIOL, V16, P1035; YOUSSOUFIAN H, 1994, BLOOD, V83, P1428	44	146	149	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26087	26093		10.1074/jbc.273.40.26087	http://dx.doi.org/10.1074/jbc.273.40.26087			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748288	hybrid			2022-12-27	WOS:000076263100079
J	Glick, JL; Meigs, TE; Miron, A; Casey, PJ				Glick, JL; Meigs, TE; Miron, A; Casey, PJ			RGSZ1, a G(z)-selective regulator of G protein signaling whose action is sensitive to the phosphorylation state of G(z)alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; HETEROTRIMERIC G-PROTEINS; ALPHA-SUBUNITS; BINDING PROTEIN; PERTUSSIS TOXIN; HUMAN-PLATELETS; 2-HYBRID SYSTEM; BOVINE BRAIN; BETA-GAMMA; RAT-BRAIN	Regulators of G protein signaling (RGS) are a family of proteins that attenuate the activity of the trimeric G proteins, RGS proteins act as GTPase-activating proteins (GAPs) for the alpha subunits of several trimeric G proteins, much like the GAPs that regulate the activity of monomeric G proteins such as Ras. RGS proteins have been cloned from many eukaryotes, and those whose biochemical activity has been characterized regulate the members of the G(i) family of G proteins; some forms can also act on G(q) proteins. In an ongoing effort to elucidate the role of G(z)alpha in cell signaling, the yeast two-hybrid system was employed to identify proteins that could interact with a mutationally activated form of G(z)alpha. A novel RGS, termed RGSZ1, was identified that is most closely related to two existing RGS proteins termed RetRGS1 and GAIP. Northern blot analysis revealed that expression of RGSZ1 was Limited to brain, and expression was particularly high in the caudate nucleus. Biochemical characterization of recombinant RGSZ1 protein revealed that RGSZ1 was indeed a GAP and, most significantly, showed a marked preference for G(z)alpha over other members of the G(i)alpha family. Phosphorylation of G(z)alpha by protein kinase C, an event known to occur in cells and that was previously shown to influence alpha-beta gamma interactions of G(z), rendered the G protein much less susceptible to RGSZ1 action.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Expt Surg, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Casey, PJ (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.	pjc@galactose.mc.duke.edu		Casey, Patrick/0000-0002-7366-9309	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019119] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19119] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; Bai C, 1997, METHOD ENZYMOL, V283, P141; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; DOHLMAN HG, 1998, BIOCHEMISTRY-US, V37, P4815; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; FIELDS TA, 1995, J BIOL CHEM, V270, P23119, DOI 10.1074/jbc.270.39.23119; Fields TA, 1998, CELL SIGNAL, V10, P43, DOI 10.1016/S0898-6568(97)00071-5; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; GAGNON AW, 1991, BLOOD, V78, P1247; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gold SJ, 1997, J NEUROSCI, V17, P8024; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; GUNDERSEN CB, 1994, J BIOL CHEM, V269, P19197; HALL A, 1986, J BIOL CHEM, V261, P963; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; JONES DT, 1987, J BIOL CHEM, V262, P14241; KIKKAWA U, 1983, METHOD ENZYMOL, V99, P288; KISSELEV O, 1995, J BIOL CHEM, V270, P25356, DOI 10.1074/jbc.270.43.25356; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LOUNSBURY KM, 1991, J BIOL CHEM, V266, P22051; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MOOMAW JF, 1995, METHOD ENZYMOL, V250, P12; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Nomoto S, 1997, BIOCHEM BIOPH RES CO, V241, P281, DOI 10.1006/bbrc.1997.7802; Pupier S, 1997, J NEUROSCI, V17, P2722; SCHIMPFF SC, 1993, SUPPORT CARE CANCER, V1, P5, DOI 10.1007/BF00326634; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; Wang J, 1997, J BIOL CHEM, V272, P5732, DOI 10.1074/jbc.272.9.5732; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741	47	110	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26008	26013		10.1074/jbc.273.40.26008	http://dx.doi.org/10.1074/jbc.273.40.26008			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748279	hybrid			2022-12-27	WOS:000076263100070
J	Chen, XY; Reitman, M; Bieker, JJ				Chen, XY; Reitman, M; Bieker, JJ			Chromatin structure and transcriptional control elements of the erythroid Kruppel-like factor (EKLF) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FETAL LIVER HEMATOPOIESIS; LOCUS-CONTROL REGION; BINDING-FACTOR; DEFINITIVE HEMATOPOIESIS; ERYTHROPOIETIN RECEPTOR; HYPERSENSITIVE SITES; BETA-THALASSEMIA; MICE LACKING; IN-VITRO; C-MYB	Erythroid Kruppel-like factor (EKLF) is a red cell-specific transcription factor whose activity is critical for the switch in expression from fetal to adult beta-globin during erythroid ontogeny, We have examined its own regulation using a number of approaches. First, the EKLF transcription unit is in an open chromatin configuration in erythroid cells. Second, in vivo transfection assays demonstrate that the more distal of the two erythroid-specific DNase-hypersensitive sites behaves as an enhancer. Although this conserved element imparts high level transcription to a heterologous promoter in all lines examined, erythroid specificity is retained only when it is fused to the proximal EKLF promoter, which contains an important GATA site. Third, extensive mutagenesis of this enhancer element has delimited its in vivo activity to a core region of 49 base pairs. Finally, in vitro footprint and gel shift assays demonstrate that three distinct DNA binding activities in erythroid cell extracts individually interact with three short sequences within this core enhancer element. These analyses reveal that high level erythroid expression of EKLF relies on the interplay between conserved proximal and distal promoter elements that alter chromatin structure and likely provide a target for genetic control via extracellular induction pathways.	CUNY Mt Sinai Sch Med, Brookdale Ctr Mol Biol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Biochem, New York, NY 10029 USA; NIDDK, Diabet Branch, NIH, Bethesda, MD 20892 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Bieker, JJ (corresponding author), CUNY Mt Sinai Sch Med, Brookdale Ctr Mol Biol, Box 1126,1 Gustave L Levy Pl, New York, NY 10029 USA.		Reitman, Marc/B-4448-2013	Reitman, Marc/0000-0002-0426-9475	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048721, F32DK009391] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48721, DK09391] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; Bieker J J, 1998, Curr Opin Hematol, V5, P145; Bieker JJ, 1996, DNA CELL BIOL, V15, P347, DOI 10.1089/dna.1996.15.347; Bonifer C, 1997, J BIOL CHEM, V272, P26075, DOI 10.1074/jbc.272.42.26075; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BritosBray M, 1997, MOL CELL BIOL, V17, P5127, DOI 10.1128/MCB.17.9.5127; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; Chen XY, 1996, EMBO J, V15, P5888, DOI 10.1002/j.1460-2075.1996.tb00975.x; Coles LS, 1996, NUCLEIC ACIDS RES, V24, P2311, DOI 10.1093/nar/24.12.2311; Cross MA, 1997, CURR OPIN GENET DEV, V7, P609, DOI 10.1016/S0959-437X(97)80007-X; CROSSLEY M, 1994, J BIOL CHEM, V269, P15440; Dillon N, 1997, MOL CELL, V1, P131, DOI 10.1016/S1097-2765(00)80014-3; DONZE D, 1995, J BIOL CHEM, V270, P1955, DOI 10.1074/jbc.270.4.1955; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FENG WC, 1994, J BIOL CHEM, V269, P1493; Gordon DF, 1997, J BIOL CHEM, V272, P24339, DOI 10.1074/jbc.272.39.24339; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; Hallstrom TC, 1998, J BIOL CHEM, V273, P2098, DOI 10.1074/jbc.273.4.2098; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hu M, 1997, GENE DEV, V11, P774, DOI 10.1101/gad.11.6.774; HUG BA, 1992, NUCLEIC ACIDS RES, V20, P5771, DOI 10.1093/nar/20.21.5771; Jenkins NA, 1998, MAMM GENOME, V9, P174, DOI 10.1007/s003359900716; Jenuwein T, 1997, NATURE, V385, P269, DOI 10.1038/385269a0; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; Kioussis D, 1997, CURR OPIN GENET DEV, V7, P614, DOI 10.1016/S0959-437X(97)80008-1; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; KRONSTAD JW, 1987, CELL, V50, P369, DOI 10.1016/0092-8674(87)90491-0; LIM LC, 1992, MOL CELL BIOL, V12, P828, DOI 10.1128/MCB.12.2.828; Lin CS, 1996, GENE DEV, V10, P154, DOI 10.1101/gad.10.2.154; Lyman SD, 1998, BLOOD, V91, P1101, DOI 10.1182/blood.V91.4.1101; MIGLIACCIO G, 1989, J CELL BIOL, V109, P833, DOI 10.1083/jcb.109.2.833; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MOON AM, 1990, P NATL ACAD SCI USA, V87, P7693, DOI 10.1073/pnas.87.19.7693; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; PERKINS AC, 1995, NATURE, V375, P318; Perkins AC, 1996, P NATL ACAD SCI USA, V93, P12267, DOI 10.1073/pnas.93.22.12267; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; Reese TT, 1997, GROWTH FACTORS, V14, P161, DOI 10.3109/08977199709021518; REITMAN M, 1993, MOL CELL BIOL, V13, P3990, DOI 10.1128/MCB.13.7.3990; Sambrook J., 2002, MOL CLONING LAB MANU; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Silver L, 1997, BLOOD, V89, P1154, DOI 10.1182/blood.V89.4.1154; Southwood CM, 1996, DEV DYNAM, V206, P248, DOI 10.1002/(SICI)1097-0177(199607)206:3<248::AID-AJA3>3.0.CO;2-I; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Volker JL, 1997, GENE DEV, V11, P1435, DOI 10.1101/gad.11.11.1435; WALTERS MC, 1995, P NATL ACAD SCI USA, V92, P7125, DOI 10.1073/pnas.92.15.7125; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Wijgerde M, 1996, GENE DEV, V10, P2894, DOI 10.1101/gad.10.22.2894; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; YOON JB, 1994, MOL CELL BIOL, V14, P1776, DOI 10.1128/MCB.14.3.1776	62	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25031	25040		10.1074/jbc.273.39.25031	http://dx.doi.org/10.1074/jbc.273.39.25031			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737959	hybrid			2022-12-27	WOS:000076085400009
J	Dunn, AD; Corsi, CM; Myers, HE; Dunn, JT				Dunn, AD; Corsi, CM; Myers, HE; Dunn, JT			Tyrosine 130 is an important outer ring donor for thyroxine formation in thyroglobulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; THYROID-HORMONE FORMATION; BOVINE THYROGLOBULIN; HORMONOGENIC SITES; DEHYDROALANINE RESIDUES; PORCINE THYROGLOBULIN; IDENTIFICATION; IODINATION; CLEAVAGE; FRAGMENT	The thyroid couples two iodotyrosine molecules to produce thyroid hormone at the acceptor site in thyroglobulin, leaving dehydroalanine or pyruvate at the donor position. Previous work has located the accepters but not the principal iodotyrosine donors. We incorporated [C-14]tyrosine into beef thyroid slices, isolated and iodinated the [C-14]thyroglobulin (Tg I), separated its N-terminal similar to 22-kDa hormone-rich peptide, and digested the latter with trypsin and endoproteinase Glu-C (EC 3.4.21.19). Nonlabeled thyroglobulin (Tg II) was isolated from the same glands and processed similarly, without iodination in vitro. Tg I was used to initially recognize pyruvate in peptide fractions, and Tg II was used to then identify its location in the thyroglobulin polypeptide chain. Sequencing of a tryptic peptide by mass spectrometry and Edman degradation showed a cleavage after Val(129). An endoproteinase Glu-C-generated peptide had the predicted molecular mass of a fragment containing residues 130-146 with Tyr(130) replaced by pyruvate; the identification of this peptide was supported by obtaining the expected shortened fragment after tryptic digestion. C-14-labeled pyruvate was identified in the same fraction as this peptide. We conclude that Tyr(130) is, important donor of the outer iodothyronine ring. Its likely acceptor is Tyr(5), the most important hormonogenic site of thyroglobulin, because Tyr(5) and Tyr(130) are proximate, because they are the most prominent early iodination sites in this part of thyroglobulin, and because the N-terminal region was previously found capable of forming T-4 by itself.	Univ Virginia, Hlth Sci Ctr, Sch Med, Dept Med,Div Endocrinol, Charlottesville, VA 22908 USA	University of Virginia	Dunn, AD (corresponding author), Univ Virginia, Hlth Sci Ctr, Sch Med, Dept Med,Div Endocrinol, Box 511, Charlottesville, VA 22908 USA.	add7k@virginia.edu			NCI NIH HHS [P30 CA45579] Funding Source: Medline; NIDDK NIH HHS [R01 DK11043, T32 DK07320] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007320, R01DK011043] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		DENHARTOG MT, 1995, EUR J ENDOCRINOL, V132, P611, DOI 10.1530/eje.0.1320611; Dunn AD, 1996, ENDOCRINOLOGY, V137, P3279, DOI 10.1210/en.137.8.3279; DUNN JT, 1993, THYROID, V3, P119, DOI 10.1089/thy.1993.3.119; DUNN JT, 1982, J BIOL CHEM, V257, P88; DUNN JT, 1987, J BIOL CHEM, V262, P16948; FASSLER CA, 1988, J BIOL CHEM, V263, P17366; GAVARET JM, 1979, J BIOL CHEM, V254, P1218; GAVARET JM, 1980, J BIOL CHEM, V255, P5281; Gentile F, 1997, J BIOL CHEM, V272, P639; GREGG JD, 1988, J BIOL CHEM, V263, P5190; IEIRI T, 1991, J CLIN INVEST, V88, P1901, DOI 10.1172/JCI115513; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMAS L, 1989, J BIOL CHEM, V264, P13541; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARRIQ C, 1991, MOL CELL ENDOCRINOL, V81, P155, DOI 10.1016/0303-7207(91)90214-D; MARRIQ C, 1989, FEBS LETT, V242, P414, DOI 10.1016/0014-5793(89)80513-7; MARRIQ C, 1982, EMBO J, V1, P397, DOI 10.1002/j.1460-2075.1982.tb01181.x; MARRIQ C, 1983, BIOCHEM BIOPH RES CO, V112, P206, DOI 10.1016/0006-291X(83)91817-X; MERCKEN L, 1985, NATURE, V316, P647, DOI 10.1038/316647a0; OHMIYA Y, 1990, J BIOL CHEM, V265, P9066; PALUMBO G, 1987, J BIOL CHEM, V262, P17182; RAWITCH AB, 1984, BIOCHEM BIOPH RES CO, V118, P423, DOI 10.1016/0006-291X(84)91320-2; RAWITCH AB, 1983, J BIOL CHEM, V258, P2079; ROE MT, 1989, ENDOCRINOLOGY, V124, P1327, DOI 10.1210/endo-124-3-1327; Taurog Alvin, 1996, P47; VEENBOER GJM, 1993, ENDOCRINOLOGY, V132, P377, DOI 10.1210/en.132.1.377; Xiao S, 1996, ARCH BIOCHEM BIOPHYS, V334, P284, DOI 10.1006/abbi.1996.0457; XIAO S, 1995, ARCH BIOCHEM BIOPHYS, V320, P96, DOI 10.1006/abbi.1995.1346	28	48	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25223	25229		10.1074/jbc.273.39.25223	http://dx.doi.org/10.1074/jbc.273.39.25223			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737985	hybrid			2022-12-27	WOS:000076085400035
J	Gregori, C; Porteu, A; Lopez, S; Kahn, A; Pichard, AL				Gregori, C; Porteu, A; Lopez, S; Kahn, A; Pichard, AL			Characterization of the aldolase B intronic enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENYLALANINE-HYDROXYLASE GENE; HORMONE RECEPTOR SUPERFAMILY; LIVER-SPECIFIC TRANSCRIPTION; TISSUE-SPECIFIC EXPRESSION; PYRUVATE-KINASE GENE; ALBUMIN GENE; INVITRO TRANSCRIPTION; MAMMALIAN-CELLS; TRANSGENIC MICE; HEPATOMA-CELLS	The aldolase B gene is transcribed at a high level in the liver, kidney, and small intestine. This high level of gene expression results from cooperation between a weak but liver-specific promoter and an intronic activator. A deletional study of this activator present in the first intron allowed us to ascribe the maximal enhancer function to a 400-base pair (bp) fragment (+1916 to + 2329). This enhancer is highly liver-specific and enhances the activity of heterologous minimal promoters in a position and distance-independent fashion in transiently transfected Hep G2 hepatoma cells. The aldolase B enhancer is composed of two domains, a 200-bp module (Ba) inactive by itself but which synergizes with another 200-bp module (Bb) that alone retains 25% of the total enhancer activity. The Eb sequence is 76% homologous between human and rat genes and contains several binding sites for liver-enriched nuclear factors, By electrophoretic mobility shift assays, we demonstrated that elements 5 and 7 bind hepatic nuclear factor 1 (HNF1), whereas element 2 binds hepatic nuclear factor 4 (HNF4). A functional analysis of the enhancer whose elements have been mutated demonstrated that mutation of any of the HNF1 sites totally suppressed enhancer activity, whereas mutation of the HNF4-binding site reduced it by 80%.	Inst Cochin Genet Mol, INSERM, U129, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Pichard, AL (corresponding author), Inst Cochin Genet Mol, INSERM, U129, 24 Rue Faubourg St Jacques, F-75014 Paris, France.							BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; CAMPOS JR, 1991, EMBO J, V10, P1445; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; COGNET M, 1991, J BIOL CHEM, V266, P7368; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Faust DM, 1996, MOL CELL BIOL, V16, P3125; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GORDON JW, 1983, METHOD ENZYMOL, V101, P411; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREGORI C, 1993, NUCLEIC ACIDS RES, V21, P897, DOI 10.1093/nar/21.4.897; GREGORI C, 1994, NUCLEIC ACIDS RES, V22, P1242, DOI 10.1093/nar/22.7.1242; GREGORI C, 1991, BIOCHEM BIOPH RES CO, V176, P722, DOI 10.1016/S0006-291X(05)80244-X; GUDER WG, 1984, KIDNEY INT, V26, P101, DOI 10.1038/ki.1984.143; HALL RK, 1992, MOL CELL BIOL, V12, P5527, DOI 10.1128/MCB.12.12.5527; Harnish DC, 1996, J BIOL CHEM, V271, P13621, DOI 10.1074/jbc.271.23.13621; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; Lambert M, 1996, EUR J BIOCHEM, V236, P778, DOI 10.1111/j.1432-1033.1996.00778.x; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Lemaigre FP, 1996, P NATL ACAD SCI USA, V93, P9460, DOI 10.1073/pnas.93.18.9460; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUTZ B, 1994, DEVELOPMENT, V120, P25, DOI 10.1242/dev.120.1.25; MILLONIG JH, 1995, MOL CELL BIOL, V15, P3848; MONACI P, 1988, EMBO J, V7, P2075, DOI 10.1002/j.1460-2075.1988.tb03047.x; MUNNICH A, 1985, J CLIN INVEST, V75, P1045, DOI 10.1172/JCI111766; Nakshatri H, 1998, NUCLEIC ACIDS RES, V26, P2491, DOI 10.1093/nar/26.10.2491; NISHIYORI A, 1994, J BIOL CHEM, V269, P1323; PACAUCCARALERTKUN S, 1994, MOL CELL BIOL, V14, P456, DOI 10.1128/MCB.14.1.456; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; Pontoglio M, 1997, MOL CELL BIOL, V17, P4948, DOI 10.1128/MCB.17.9.4948; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; RAYMONDJEAN M, 1991, NUCLEIC ACIDS RES, V19, P6145, DOI 10.1093/nar/19.22.6145; ROUET P, 1995, NUCLEIC ACIDS RES, V23, P395, DOI 10.1093/nar/23.3.395; Sabourin JC, 1996, J BIOL CHEM, V271, P3469, DOI 10.1074/jbc.271.7.3469; SCHAPIRA F, 1975, ISOZYMES, V3, P987; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Stoffel M, 1997, P NATL ACAD SCI USA, V94, P13209, DOI 10.1073/pnas.94.24.13209; TRONCHE F, 1990, MOL BIOL MED, V7, P173; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; Whitelaw C B, 1991, Transgenic Res, V1, P3, DOI 10.1007/BF02512991; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469	46	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25237	25243		10.1074/jbc.273.39.25237	http://dx.doi.org/10.1074/jbc.273.39.25237			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737987	hybrid			2022-12-27	WOS:000076085400037
J	Yasuda, Y; Masuda, S; Chikuma, M; Inoue, K; Nagao, M; Sasaki, R				Yasuda, Y; Masuda, S; Chikuma, M; Inoue, K; Nagao, M; Sasaki, R			Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	4th International Lubeck Conference on the Pathophysiology and Pharmacology of Erythropoietin and Other Hematopoietic Growth Factors	JUN 27-29, 1997	LUBECK, GERMANY				ENDOTHELIAL GROWTH-FACTOR; RECOMBINANT-HUMAN-ERYTHROPOIETIN; RECEPTOR MESSENGER-RNA; RAT UTERUS; LIGAND-BINDING; IN-VITRO; CELLS; EXPRESSION; GENE; BRAIN	Although erythropoietin (Epo) has been shown to possess in vitro angiogenic activity, its physiological significance has not been demonstrated. Normally angiogenesis does not occur actively in adults but an exception is the female reproductive organ. In the uterine endometrium, angiogenesis takes place actively for supporting the endometrial growth that occurs during transition from the diestrus to estrous stage. This transition is under control of 17 beta-estradiol (E-2), an ovarian hormone, and can be mimicked by injection of E-2 to ovariectomized (OVX) mouse. Thus, the uterus is a pertinent site to examine the Epo function in angiogenesis. We found that Epo protein and its mRNA were produced in an E-2-dependent manner, when the uterus from OVX mouse was cultured in vitro. The de novo protein synthesis was not needed for E-2 induction of Epo mRNA. Administration of E-2 to OVX mouse induced a rapid and transient increase in Epo mRNA in the uterus. Injection of Epo into the OVX mouse uterine cavity promoted blood vessel formation in the endometrium. Furthermore, injection of the soluble Epo receptor capable of binding with Epo into the uterine cavity of non-OVX mouse in diestrus stale inhibited the endometrial transition to proestrus stage, whereas heat-inactivated soluble Epo receptor allowed the transition to occur. These results, combined with our finding that the endothelial cells in uterine endometrium express Epo receptor, strongly suggest that Epo is an important factor for the E-2-dependent cyclical angiogenesis in uterus.	Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Kyoto 6068502, Japan; Kinki Univ, Sch Med, Dept Anat, Osaka 5890014, Japan	Kyoto University; Kindai University (Kinki University)	Sasaki, R (corresponding author), Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Kyoto 6068502, Japan.	rsasaki@kais.kyoto-u.ac.jp						ANAGNOSTOU A, 1990, P NATL ACAD SCI USA, V87, P5978, DOI 10.1073/pnas.87.15.5978; ANAGNOSTOU A, 1994, P NATL ACAD SCI USA, V91, P3974, DOI 10.1073/pnas.91.9.3974; ANAGNOSTOU A, 1976, J LAB CLIN MED, V88, P700; AUGUSTIN HG, 1995, AM J PATHOL, V147, P339; AUGUSTIN HG, 1994, BIOESSAYS, V16, P901, DOI 10.1002/bies.950161208; BIKFALVI A, 1994, LEUKEMIA, V8, P523; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; CARLINI RG, 1995, KIDNEY INT, V47, P740, DOI 10.1038/ki.1995.113; CLAFFEY KP, 1992, J BIOL CHEM, V267, P16317; Clark J.H., 1988, P675; CULLINANBOVE K, 1993, ENDOCRINOLOGY, V133, P829, DOI 10.1210/en.133.2.829; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GALSON DL, 1993, BLOOD, V82, P3321; GOTO M, 1989, BLOOD, V74, P1415; GOTO M, 1988, BIO-TECHNOL, V6, P67, DOI 10.1038/nbt0188-67; HAM KN, 1970, J ENDOCRINOL, V46, P71, DOI 10.1677/joe.0.0460071; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HECHTER O, 1941, ENDOCRINOLOGY, V23, P25; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; KIRKLAND JL, 1979, BIOL REPROD, V21, P269, DOI 10.1095/biolreprod21.2.269; KRANTZ SB, 1991, BLOOD, V77, P419; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Lin CS, 1996, GENE DEV, V10, P154, DOI 10.1101/gad.10.2.154; Liu C, 1997, J BIOL CHEM, V272, P32395, DOI 10.1074/jbc.272.51.32395; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; MASUDA S, 1994, J BIOL CHEM, V269, P19488; Masuda S, 1997, BRAIN RES, V746, P63, DOI 10.1016/S0006-8993(96)01186-9; MASUDA S, 1993, J BIOL CHEM, V268, P11208; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; NAGAO M, 1992, BIOCHEM BIOPH RES CO, V188, P888, DOI 10.1016/0006-291X(92)91139-H; NAGAO M, 1993, BLOOD, V81, P2503; OKANO M, 1994, FEBS LETT, V349, P229, DOI 10.1016/0014-5793(94)00673-3; PESCHLE C, 1973, ENDOCRINOLOGY, V92, P358; RISAU W, 1988, DEVELOPMENT, V102, P471; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; SCHOTT RJ, 1993, CARDIOVASC RES, V27, P1155, DOI 10.1093/cvr/27.7.1155; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; STACK G, 1984, ENDOCRINOLOGY, V115, P1141, DOI 10.1210/endo-115-3-1141; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TISCHER E, 1991, J BIOL CHEM, V266, P11947; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Yamaji R, 1996, EUR J BIOCHEM, V239, P494, DOI 10.1111/j.1432-1033.1996.0494u.x; YASUDA Y, 1993, DEV GROWTH DIFFER, V35, P711; YOUSSOUFIAN H, 1993, BLOOD, V81, P2223	46	223	235	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25381	25387		10.1074/jbc.273.39.25381	http://dx.doi.org/10.1074/jbc.273.39.25381			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	122RN	9738005	hybrid			2022-12-27	WOS:000076085400055
J	Daviet, L; Bois, F; Battisti, PL; Gatignol, A				Daviet, L; Bois, F; Battisti, PL; Gatignol, A			Identification of limiting steps for efficient trans-activation of HIV-1 promoter by Tat in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; RNA-POLYMERASE-II; PROTEINS SPECIFICALLY ASSOCIATE; TRANSCRIPTION ACTIVATION DOMAIN; INTACT YEAST-CELLS; IN-VIVO; BINDING PROTEIN; TYPE-1 TAT; BASAL TRANSCRIPTION	Cellular context is an important determinant for the activity of Tat, the trans-activator of human immunodeficiency virus (HIV). We have investigated HIV-1 promoter expression and trans-activation in Saccharomyces cerevisiae to provide clues about the limiting steps for Tat activity in this organism. A minimal 43-nucleotide HIV promoter (HIV43) has the activity of a weak yeast promoter in the presence or absence of various enhancer binding sites (bs), whereas the entire long terminal repeat is not expressed. None of these constructs could be trans-activated by Tat. Fusion proteins Gal4 binding domain (BD)-Tat48 and Ga14BD-Tat72 are active with different efficiencies on various yeast promoters that have Gal4 bs. They have 70 and 50% of Gal4 wild type activity on hybrid HIV promoters fused to Gal4 bs only in the presence of API bs. This study shows that trans-activation of the HIV-1 promoter by Tat occurs in yeast when Tat is targeted to the promoter and a functional enhancer activity is present. Spl function and Tat transfer from the RNA to the promoter are two major elements for in vivo trans-activation of HIV-1 that are defective in S. cerevisiae but can be replaced by functional equivalents.	Inst Cochin Genet Mol, INSERM, U332, F-75014 Paris, France; Inst Cochin Genet Mol, INSERM, CJF 97 03, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Gatignol, A (corresponding author), Inst Cochin Genet Mol, INSERM, U332, 22 rue Mechain, F-75014 Paris, France.	gatignol@icgm.cochin.inserm.fr	Gatignol, Anne/AAA-6501-2020	Gatignol, Anne/0000-0002-4553-0836				ALONSO A, 1994, J VIROL, V68, P6505, DOI 10.1128/JVI.68.10.6505-6513.1994; Ambrosino C, 1997, J BIOL CHEM, V272, P14883, DOI 10.1074/jbc.272.23.14883; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; BENICHOU S, 1994, J BIOL CHEM, V269, P30073; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BERKHOUT B, 1992, J VIROL, V66, P139, DOI 10.1128/JVI.66.1.139-149.1992; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; BERKHOUT B, 1989, J VIROL, V63, P5501, DOI 10.1128/JVI.63.12.5501-5504.1989; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; BOYMARCOTTE E, 1982, GENE, V20, P433, DOI 10.1016/0378-1119(82)90212-8; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Charpentier B, 1997, J MOL BIOL, V266, P950, DOI 10.1006/jmbi.1996.0858; Chun RF, 1996, J BIOL CHEM, V271, P27888, DOI 10.1074/jbc.271.44.27888; Cujec TP, 1997, GENE DEV, V11, P2645, DOI 10.1101/gad.11.20.2645; Cujec TP, 1997, MOL CELL BIOL, V17, P1817, DOI 10.1128/MCB.17.4.1817; DERSE D, 1991, J VIROL, V65, P7012, DOI 10.1128/JVI.65.12.7012-7015.1991; DINGWALL C, 1990, EMBO J, V9, P4145, DOI 10.1002/j.1460-2075.1990.tb07637.x; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GarciaMartinez LF, 1997, J BIOL CHEM, V272, P6951, DOI 10.1074/jbc.272.11.6951; Gatignol A, 1996, GENE EXPRESSION, V5, P217; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; GATIGNOL A, 1990, GENE, V91, P35, DOI 10.1016/0378-1119(90)90159-O; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GUARENTE L, 1995, TRENDS BIOCHEM SCI, V20, P517, DOI 10.1016/S0968-0004(00)89120-3; HART CE, 1989, SCIENCE, V246, P488, DOI 10.1126/science.2683071; HAUBER J, 1988, J VIROL, V62, P673, DOI 10.1128/JVI.62.3.673-679.1988; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; IWABUCHI K, 1993, ONCOGENE, V8, P1693; JEANG KT, 1992, J BIOL CHEM, V267, P17891; JEANG KT, 1993, J VIROL, V67, P6224, DOI 10.1128/JVI.67.10.6224-6233.1993; JEANG KT, 1988, J VIROL, V62, P3874, DOI 10.1128/JVI.62.10.3874-3878.1988; JEANG KT, 1994, HUMAN RETROVIRUSES A, P11; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; KAMINE J, 1991, P NATL ACAD SCI USA, V88, P8510, DOI 10.1073/pnas.88.19.8510; KAMINE J, 1992, J VIROL, V66, P3932, DOI 10.1128/JVI.66.6.3932-3936.1992; KAMINE J, 1993, J VIROL, V67, P6828, DOI 10.1128/JVI.67.11.6828-6834.1993; KANG T, 1993, J BIOL CHEM, V268, P9629; KASHANCHI F, 1994, J VIROL, V68, P3298, DOI 10.1128/JVI.68.5.3298-3307.1994; Keen NJ, 1996, P NATL ACAD SCI USA, V93, P2505, DOI 10.1073/pnas.93.6.2505; Kingsman SM, 1996, EUR J BIOCHEM, V240, P491, DOI 10.1111/j.1432-1033.1996.0491h.x; KUNZLER M, 1994, EMBO J, V13, P641, DOI 10.1002/j.1460-2075.1994.tb06302.x; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LEWIS N, 1990, J VIROL, V64, P1690, DOI 10.1128/JVI.64.4.1690-1697.1990; LIU JS, 1992, J VIROL, V66, P3883, DOI 10.1128/JVI.66.6.3883-3887.1992; LU XB, 1993, J VIROL, V67, P1752, DOI 10.1128/JVI.67.4.1752-1760.1993; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; MCKUNE K, 1995, MOL CELL BIOL, V15, P6895; MEILHOC E, 1990, BIO-TECHNOL, V8, P223, DOI 10.1038/nbt0390-223; MINET M, 1990, CURR GENET, V18, P287, DOI 10.1007/BF00318209; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; NEWSTEIN M, 1990, J VIROL, V64, P4565, DOI 10.1128/JVI.64.9.4565-4567.1990; Pereira DJ, 1997, J VIROL, V71, P1747, DOI 10.1128/JVI.71.3.1747-1756.1997; PONTICELLI AS, 1995, MOL CELL BIOL, V15, P983; Remacle JE, 1997, EMBO J, V16, P5722, DOI 10.1093/emboj/16.18.5722; ROY S, 1990, J VIROL, V64, P1402, DOI 10.1128/JVI.64.3.1402-1406.1990; Sambrook J., 2002, MOL CLONING LAB MANU; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; SIKORSKI RS, 1989, GENETICS, V122, P19; SOUTHGATE C, 1990, NATURE, V345, P640, DOI 10.1038/345640a0; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; SOUTHGATE CD, 1995, J VIROL, V69, P2605, DOI 10.1128/JVI.69.4.2605-2610.1995; STEGER G, 1995, EMBO J, V14, P329, DOI 10.1002/j.1460-2075.1995.tb07007.x; STRUHL K, 1988, NATURE, V332, P649, DOI 10.1038/332649a0; SUBRAMANIAN T, 1994, NUCLEIC ACIDS RES, V22, P1496, DOI 10.1093/nar/22.8.1496; SUNE C, 1995, J VIROL, V69, P6572; TANSEY WP, 1994, GENE DEV, V8, P2756, DOI 10.1101/gad.8.22.2756; TILEY LS, 1992, GENE DEV, V6, P2077, DOI 10.1101/gad.6.11.2077; TOYAMA R, 1992, NUCLEIC ACIDS RES, V20, P2591, DOI 10.1093/nar/20.10.2591; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; VESCHAMBRE P, 1995, J MOL BIOL, V250, P169, DOI 10.1006/jmbi.1995.0368; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Williams RD, 1996, NUCLEIC ACIDS RES, V24, P549, DOI 10.1093/nar/24.4.549; Xiao H, 1997, MOL CELL BIOL, V17, P6898, DOI 10.1128/MCB.17.12.6898; Yang XZ, 1996, J VIROL, V70, P4576, DOI 10.1128/JVI.70.7.4576-4584.1996; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	82	5	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28219	28228		10.1074/jbc.273.43.28219	http://dx.doi.org/10.1074/jbc.273.43.28219			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774443	hybrid			2022-12-27	WOS:000076549800063
J	Corey, S; Clapham, DE				Corey, S; Clapham, DE			Identification of native atrial G-protein-regulated inwardly rectifying K(+) (GIRK4) channel homomultimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; BETA-GAMMA-SUBUNITS; ADULT-RAT BRAIN; POTASSIUM CHANNELS; I-KACH; RECTIFIER; LOCALIZATION; EXPRESSION; CIR; STOICHIOMETRY	G-protein-regulated inwardly rectifying K(+) (GIRK) channels play critical inhibitory roles throughout the nervous system, heart, and pancreas. They are believed to be heterotetramers consisting of GIRK1 (Kir3.1) and either GIRK2 (Kir3.2), GIRKB (Kir3.3), or GIRK4 (Kir3.4) subunits. The GIRK1 subunit is hypothesized to be critical to form GIRK channels with normal channel kinetics based on heterologous expression studies. However, GIRK2 and GIRK3 proteins are present in areas of the brain where no GIRK1 has been detected. Here we demonstrate that GIRK tetramers lacking GIRK1 can be purified from bovine heart atria. We have found that only half of GIRK4 is purified as the GIRK1-GIRK4 heterotetramer, whereas the remaining GIRK4 forms a high molecular weight, SDS-resistant complex that does not contain GIRK1. These GIRK4 complexes, most likely GIRK4 homotetramers, were previously not seen because of their aberrant migration on SDS-polyacrylamide gels. We propose that all of GIRK1 and half of GIRK4 proteins in atria combine to form the heterotetramer I(KACh), whereas the remaining GIRK4 forms a novel tetrameric complex. GIRK4 homotetramers form channels with unusual single channel behavior, and their contribution to native currents requires further investigation.	Harvard Univ, Childrens Hosp, Sch Med, Div Cardiovasc, Boston, MA 02115 USA; Mayo Clin & Mayo Fdn, Program Neurosci, Rochester, MN 55905 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Mayo Clinic	Clapham, DE (corresponding author), Howard Hughes Med Inst, 1309 Enders,320 Longwood Ave, Boston, MA 02115 USA.	clapham@rascal.med.harvard.edu	Clapham, David/S-1123-2019; Clapham, David/R-5974-2019	Clapham, David/0000-0002-4459-9428; 				Arkin IT, 1998, BBA-BIOMEMBRANES, V1369, P131, DOI 10.1016/S0005-2736(97)00219-8; Barry DM, 1996, ANNU REV PHYSIOL, V58, P363, DOI 10.1146/annurev.ph.58.030196.002051; Bausch SB, 1995, RECEPTOR CHANNEL, V3, P221; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Chan KW, 1996, J GEN PHYSIOL, V107, P381, DOI 10.1085/jgp.107.3.381; Dascal N, 1997, CELL SIGNAL, V9, P551, DOI 10.1016/S0898-6568(97)00095-8; Deal KK, 1996, PHYSIOL REV, V76, P49, DOI 10.1152/physrev.1996.76.1.49; Dissmann E, 1996, BIOCHEM BIOPH RES CO, V223, P474, DOI 10.1006/bbrc.1996.0918; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; FUJII J, 1989, J BIOL CHEM, V264, P12950; HALTIA T, 1995, BBA-BIOENERGETICS, V1228, P1, DOI 10.1016/0005-2728(94)00161-W; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; Heginbotham L, 1997, BIOCHEMISTRY-US, V36, P10335, DOI 10.1021/bi970988i; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Iizuka M, 1997, NEUROSCIENCE, V77, P1, DOI 10.1016/S0306-4522(96)00460-5; Iizuka M, 1995, RECEPTOR CHANNEL, V3, P299; Isomoto S, 1997, JPN J PHYSIOL, V47, P11, DOI 10.2170/jjphysiol.47.11; Ji S, 1998, J BIOL CHEM, V273, P1324, DOI 10.1074/jbc.273.3.1324; Karschin C, 1996, J NEUROSCI, V16, P3559; KARSCHIN C, 1994, FEBS LETT, V348, P139, DOI 10.1016/0014-5793(94)00590-7; Kennedy ME, 1996, NEUROPHARMACOLOGY, V35, P831, DOI 10.1016/0028-3908(96)00132-3; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P28777, DOI 10.1074/jbc.270.48.28777; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; LESAGE F, 1995, J BIOL CHEM, V270, P28660, DOI 10.1074/jbc.270.48.28660; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; Liao YJ, 1996, J NEUROSCI, V16, P7137; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; Luscher C, 1997, NEURON, V19, P687, DOI 10.1016/S0896-6273(00)80381-5; Murer G, 1997, NEUROSCIENCE, V80, P345, DOI 10.1016/S0306-4522(97)00001-8; Navarro B, 1996, SCIENCE, V272, P1950, DOI 10.1126/science.272.5270.1950; Ponce A, 1996, J NEUROSCI, V16, P1990; Signorini S, 1997, P NATL ACAD SCI USA, V94, P923, DOI 10.1073/pnas.94.3.923; Silverman SK, 1996, J BIOL CHEM, V271, P30524, DOI 10.1074/jbc.271.48.30524; SLAUGHTER RS, 1983, J BIOL CHEM, V258, P3183; Soulie S, 1996, ANAL BIOCHEM, V236, P363, DOI 10.1006/abio.1996.0183; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; Sui JL, 1996, J GEN PHYSIOL, V108, P381, DOI 10.1085/jgp.108.5.381; Tucker SJ, 1996, AM J PHYSIOL-HEART C, V271, pH379, DOI 10.1152/ajpheart.1996.271.1.H379; Velimirovic BM, 1996, FEBS LETT, V379, P31, DOI 10.1016/0014-5793(95)01465-9; Wickman K, 1998, NEURON, V20, P103, DOI 10.1016/S0896-6273(00)80438-9; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; Wischmeyer E, 1997, MOL CELL NEUROSCI, V9, P194, DOI 10.1006/mcne.1997.0614	46	77	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27499	27504		10.1074/jbc.273.42.27499	http://dx.doi.org/10.1074/jbc.273.42.27499			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765280	hybrid			2022-12-27	WOS:000076448000067
J	Little, MJ; Zappia, C; Gilles, N; Connor, M; Tyler, MI; Martin-Eauclaire, MF; Gordon, D; Nicholson, GM				Little, MJ; Zappia, C; Gilles, N; Connor, M; Tyler, MI; Martin-Eauclaire, MF; Gordon, D; Nicholson, GM			delta-atracotoxins from Australian funnel-web spiders compete with scorpion alpha-toxin binding but differentially modulate alkaloid toxin activation of voltage-gated sodium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE-ENDING PARTICLES; HIGH-AFFINITY BINDING; AMINO-ACID SEQUENCE; RAT-BRAIN; RECEPTOR-SITE; CURRENT INACTIVATION; LETHAL NEUROTOXIN; NA+ CHANNELS; VENOM; VERATRIDINE	delta-Atracotoxins from the venom of Australian funnel-web spiders are a unique group of peptide toxins that slow sodium current inactivation in a manner similar to scorpion alpha-toxins. To analyze their interaction with known sodium channel neurotoxin receptor sites, we studied their effect on [H-3]batrachotoxin and I-125-Lqh II (where Lqh is alpha-toxin II from the venom of the scorpion Leiurus quinquestriatus hebraeus) binding and on alkaloid toxin-stimulated Na-22(+) uptake in rat brain synaptosomes. delta-Atracotoxins significantly increased [H-3]batrachotoxin binding yet decreased maximal batrachotoxin-activated Na-22(+) uptake by 70-80%, the latter in marked contrast to the effect of scorpion alpha-toxins, Unlike the inhibition of batrachotoxin-activated Na-22(+) uptake, delta-atracotoxins increased veratridine-stimulated Na-22(+) uptake by converting veratridine from a partial to a full agonist, analogous to scorpion alpha-toxins. Hence, delta-atracotoxins are able to differentiate between the open state of the sodium channel stabilized by batrachotoxin and veratridine and suggest a distinct sub-conductance state stabilized by delta-atracotoxins. Despite these actions, low concentrations of delta-atracotoxins completely inhibited the binding of the scorpion alpha-toxin, I-125-Lqh Ht indicating that they bind to similar, or partially overlapping, receptor sites. The apparent uncoupling between the increase in binding but inhibition of the effect of batrachotoxin induced by delta-atracotoxins suggests that the binding and action of certain alkaloid toxins may represent at least two distinguishable steps. These results further contribute to the understanding of the complex dynamic interactions between neurotoxin receptor site areas related to sodium channel gating.	Univ Technol Sydney, Dept Hlth Sci, Broadway, NSW 2007, Australia; Univ Sydney, Dept Pharmacol, Sydney, NSW 2006, Australia; CSIRO, Div Food Proc, N Ryde, NSW 2113, Australia; Univ Mediterranee, Biochim Lab, UMR 6560 CNRS, IFR Jean Roche, F-13916 Marseille 20, France; CENS, CEA, Dept Ingn & Etud Prot, F-91911 Gif Sur Yvette, France	University of Technology Sydney; University of Sydney; Commonwealth Scientific & Industrial Research Organisation (CSIRO); UDICE-French Research Universities; Aix-Marseille Universite; CEA; UDICE-French Research Universities; Universite Paris Saclay	Nicholson, GM (corresponding author), Univ Technol Sydney, Dept Hlth Sci, POB 123, Broadway, NSW 2007, Australia.	Graham.Nicholson@uts.edu.au	Nicholson, Graham M/E-8136-2010; Connor, Mark/A-4197-2008	Nicholson, Graham M/0000-0002-4277-4296; Connor, Mark/0000-0003-2538-2001				BROWN MR, 1988, BIOCHEM J, V250, P401, DOI 10.1042/bj2500401; CATTERALL WA, 1981, J BIOL CHEM, V256, P8922; CATTERALL WA, 1986, ANNU REV BIOCHEM, V55, P953, DOI 10.1146/annurev.biochem.55.1.953; CATTERALL WA, 1977, J BIOL CHEM, V252, P8669; CESTELE S, 1995, J BIOL CHEM, V270, P15153, DOI 10.1074/jbc.270.25.15153; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Connor M, 1998, J PHYSIOL-LONDON, V509, P47, DOI 10.1111/j.1469-7793.1998.047bo.x; CORREA AM, 1991, J GEN PHYSIOL, V97, P605, DOI 10.1085/jgp.97.3.605; COURAUD F, 1986, J NEUROSCI, V6, P192; EITAN M, 1990, BIOCHEMISTRY-US, V29, P5941, DOI 10.1021/bi00477a009; FAINZILBER M, 1994, J BIOL CHEM, V269, P2574; Felts PA, 1997, MOL BRAIN RES, V45, P71, DOI 10.1016/S0169-328X(96)00241-0; Fletcher JI, 1997, STRUCTURE, V5, P1525, DOI 10.1016/S0969-2126(97)00301-8; Fletcher JI, 1997, NAT STRUCT BIOL, V4, P559, DOI 10.1038/nsb0797-559; FLETCHER JI, 1998, IN PRESS PERSPECTIVE; FONTECILLACAMPS JC, 1982, TOXICON, V20, P1, DOI 10.1016/0041-0101(82)90137-4; GARBER SS, 1987, J GEN PHYSIOL, V89, P459, DOI 10.1085/jgp.89.3.459; GONOI T, 1984, J NEUROSCI, V4, P2836; GORDON D, 1993, FEBS LETT, V315, P125, DOI 10.1016/0014-5793(93)81147-R; Gordon D, 1996, J BIOL CHEM, V271, P8034, DOI 10.1074/jbc.271.14.8034; Gordon D, 1997, TOXINS SIGNAL TRANSD, P119; GRAY EG, 1962, J ANAT, V96, P79; Hille B, 1987, Soc Gen Physiol Ser, V41, P109; HILLE B, 1992, IONIC CHANNELS EXCIT, P308; Ingram S, 1997, MOL PHARMACOL, V52, P136, DOI 10.1124/mol.52.1.136; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P1207, DOI 10.1021/bi00600a011; MIRANDA F, 1970, EUR J BIOCHEM, V16, P514, DOI 10.1111/j.1432-1033.1970.tb01111.x; NICHOLSON GM, 1994, PFLUG ARCH EUR J PHY, V428, P400, DOI 10.1007/BF00724524; Nicholson GM, 1998, PFLUG ARCH EUR J PHY, V436, P117, DOI 10.1007/s004240050612; Pallaghy PK, 1997, FEBS LETT, V419, P191, DOI 10.1016/S0014-5793(97)01452-X; PALLAGHY PK, 1994, PROTEIN SCI, V3, P1833, DOI 10.1002/pro.5560031022; RAY R, 1978, J BIOL CHEM, V253, P7307; Rogers JC, 1996, J BIOL CHEM, V271, P15950, DOI 10.1074/jbc.271.27.15950; Sautiere P, 1998, TOXICON, V36, P1141, DOI 10.1016/S0041-0101(98)00080-4; SHEUMACK DD, 1985, FEBS LETT, V181, P154, DOI 10.1016/0014-5793(85)81132-7; STRICHARTZ G, 1987, ANNU REV NEUROSCI, V10, P237; STRICHARTZ GR, 1986, J GEN PHYSIOL, V88, P413, DOI 10.1085/jgp.88.3.413; TAMKUN MM, 1981, MOL PHARMACOL, V19, P78; THOMSEN WJ, 1989, P NATL ACAD SCI USA, V86, P10161, DOI 10.1073/pnas.86.24.10161; Trainer VL, 1997, MOL PHARMACOL, V51, P651, DOI 10.1124/mol.51.4.651; Tugarinov V, 1997, BIOCHEMISTRY-US, V36, P2414, DOI 10.1021/bi961497l; WANG G, 1990, MOL PHARMACOL, V37, P144; Wang SY, 1998, P NATL ACAD SCI USA, V95, P2653, DOI 10.1073/pnas.95.5.2653	43	43	44	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27076	27083		10.1074/jbc.273.42.27076	http://dx.doi.org/10.1074/jbc.273.42.27076			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765223	hybrid			2022-12-27	WOS:000076448000010
J	Ajouz, B; Berrier, C; Garrigues, A; Besnard, M; Ghazi, E				Ajouz, B; Berrier, C; Garrigues, A; Besnard, M; Ghazi, E			Release of thioredoxin via the mechanosensitive channel MscL during osmotic downshock of Escherichia coli cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ION CHANNELS; SENSITIVE COMPARTMENT; ACTIVATED CHANNELS; BACILLUS-SUBTILIS; MEMBRANE; SHOCK; LOCALIZATION; ACCUMULATION; PRESSURE; BETAINE	Escherichia cold cells possess several mechanosensitive ion channels but only MscL, the channel with the highest conductance, which is activated at the highest membrane tension, has been cloned. We investigated the putative involvement of MscL in the effluxes caused by osmotic downshock, Osmotic shock caused the release of potassium glutamate, trehalose, and glycine betaine from wild type cells and cells lacking MscL. These was no difference between the two strains, brat the extreme rapidity of the efflux process, as shown herein for glycine betaine, suggests that it is channel-mediated. Osmotic downshock also induces the release of some cytosolic proteins from EDTA-treated cells. We investigated the release of thioredoxin, This protein was totally released from wild type cells but was retained by MscL(-) cells. Release was restored by expression of the gene coding for MscL, Thus MscL is not necessary for the excretion of osmoprotectants, but it does open in vivo during shock and catalyzes the efflux of thioredoxin and possibly other small cytosolic proteins. It follows that the other mechanosensitive channels, which are known to be activated at lower tension, must also open during osmotic shock, Their opening and that of MscL could account for the rapid release of osmolytes.	Univ Paris Sud, Lab Biomembranes, CNRS, ERS 571, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Ghazi, E (corresponding author), Univ Paris Sud, Lab Biomembranes, CNRS, ERS 571, Bat 430, F-91405 Orsay, France.	alexandre.ghazi@biomembr.u-psud.fr						ARMSTRONG JB, 1967, J BACTERIOL, V93, P390, DOI 10.1128/JB.93.1.390-398.1967; BEACHAM IR, 1979, INT J BIOCHEM, V10, P877, DOI 10.1016/0020-711X(79)90117-4; Beautler HO, 1990, METHOD ENZYMAT AN, V8, P369; Berrier C, 1996, J MEMBRANE BIOL, V151, P175, DOI 10.1007/s002329900068; BERRIER C, 1992, EUR J BIOCHEM, V206, P559, DOI 10.1111/j.1432-1033.1992.tb16960.x; BERRIER C, 1989, FEBS LETT, V259, P27, DOI 10.1016/0014-5793(89)81486-3; Blount P, 1996, EMBO J, V15, P4798, DOI 10.1002/j.1460-2075.1996.tb00860.x; BOULANGER P, 1988, J BIOL CHEM, V263, P9767; Cruickshank CC, 1997, BIOPHYS J, V73, P1925, DOI 10.1016/S0006-3495(97)78223-7; Csonka L. N., 1996, ESCHERICHIA COLI SAL, P1210; DINNIBIER U, 1988, ARCH MICROBIOL, V150, P348, DOI 10.1007/BF00408306; ELYAAGOUBI A, 1994, J BACTERIOL, V176, P7074, DOI 10.1128/JB.176.22.7074-7078.1994; EPSTEIN W, 1965, J GEN PHYSIOL, V49, P221, DOI 10.1085/jgp.49.2.221; Glaasker E, 1996, J BIOL CHEM, V271, P10060, DOI 10.1074/jbc.271.17.10060; Hase CC, 1997, BIOCHEM BIOPH RES CO, V232, P777, DOI 10.1006/bbrc.1997.6370; HASE CC, 1995, J BIOL CHEM, V270, P18329, DOI 10.1074/jbc.270.31.18329; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1978, J BIOL CHEM, V253, P430; HOUSSIN C, 1991, BIOCHIM BIOPHYS ACTA, V1056, P76, DOI 10.1016/S0005-2728(05)80075-1; IKUTA S, 1977, J BIOCHEM-TOKYO, V82, P157, DOI 10.1093/oxfordjournals.jbchem.a131664; JACOBSON GR, 1976, NATURE, V261, P23, DOI 10.1038/261023a0; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; KOO SP, 1991, J GEN MICROBIOL, V137, P2617, DOI 10.1099/00221287-137-11-2617; LAMARK T, 1992, FEMS MICROBIOL LETT, V96, P149; LARSEN PI, 1987, ARCH MICROBIOL, V147, P1, DOI 10.1007/BF00492896; Le Dain AC, 1998, J BIOL CHEM, V273, P12116, DOI 10.1074/jbc.273.20.12116; LUNN CA, 1982, J BIOL CHEM, V257, P1424; MCLAGGAN D, 1994, J BIOL CHEM, V269, P1911; MEURY J, 1985, EUR J BIOCHEM, V151, P613, DOI 10.1111/j.1432-1033.1985.tb09148.x; Moe PC, 1998, MOL MICROBIOL, V28, P583, DOI 10.1046/j.1365-2958.1998.00821.x; PERROUD B, 1985, J BACTERIOL, V161, P393, DOI 10.1128/JB.161.1.393-401.1985; Ruffert S, 1997, EUR J BIOCHEM, V247, P572, DOI 10.1111/j.1432-1033.1997.00572.x; Saint N, 1998, J BIOL CHEM, V273, P14667, DOI 10.1074/jbc.273.24.14667; SCHLEYER M, 1993, ARCH MICROBIOL, V160, P424, DOI 10.1007/BF00245302; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; Sukharev SI, 1997, ANNU REV PHYSIOL, V59, P633, DOI 10.1146/annurev.physiol.59.1.633; Szabo I, 1997, J BIOL CHEM, V272, P25275, DOI 10.1074/jbc.272.40.25275; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAPIS A, 1977, BIOCHIM BIOPHYS ACTA, V469, P1, DOI 10.1016/0005-2736(77)90320-0; Verheul A, 1997, J BACTERIOL, V179, P6979, DOI 10.1128/jb.179.22.6979-6985.1997; ZORATTI M, 1988, FEBS LETT, V240, P105, DOI 10.1016/0014-5793(88)80348-X; ZORATTI M, 1990, BIOCHEM BIOPH RES CO, V168, P443, DOI 10.1016/0006-291X(90)92341-V; ZORATTI M, 1993, ALKALI TRANSPORT SYS, P349	43	126	135	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26670	26674		10.1074/jbc.273.41.26670	http://dx.doi.org/10.1074/jbc.273.41.26670			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756908	hybrid			2022-12-27	WOS:000076373300062
J	Couve, A; Filippov, AK; Connolly, CN; Bettler, B; Brown, DA; Moss, SJ				Couve, A; Filippov, AK; Connolly, CN; Bettler, B; Brown, DA; Moss, SJ			Intracellular retention of recombinant GABA(B) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPERIOR CERVICAL-GANGLION; GAMMA-AMINOBUTYRIC-ACID; METABOTROPIC GLUTAMATE RECEPTORS; RAT SYMPATHETIC NEURONS; PUTATIVE PHEROMONE RECEPTORS; A RECEPTORS; INHIBITION; CURRENTS; PROTEIN; PHARMACOLOGY	gamma-Aminobutyric acid type B (GABA(B)) receptors mediate the transmission of slow and prolonged inhibitory signals in the central nervous system, Two splice variants of GABA(B) receptors, GABA(B)R1a and GABA(B)R1b, were recently cloned from a mouse cortical and cerebellar cDNA library. As predicted, these receptors belong to the G protein-coupled receptor superfamily. We have used epitope-tagged versions of GABA(B)R1a receptors to study the cellular distribution of these proteins in a variety of non-neuronal and neuronal cell types. Here we report that recombinant GABA(B) receptors fail to reach the cell surface when expressed in heterologous systems and are retained in the endoplasmic reticulum when introduced into COS cells. In addition, we prove that recombinant GABA(B) receptors are excluded from the cell surface when overexpressed in ganglion neurons and we further demonstrate that they fail to activate in superior cervical ganglion neurons. Together our observations suggest that recombinant GABA(B) receptors require additional information for functional targeting to the plasma membrane.	Univ London Univ Coll, Mol Cell Biol Lab, MRC, London WC1E 6BT, England; Univ London Univ Coll, Dept Pharmacol, London WC1E 6BT, England; Novartis Pharma Inc, Res Dept, Therapeut Area Nervous Syst, CH-4002 Basel, Switzerland	University of London; University College London; University of London; University College London; Novartis	Moss, SJ (corresponding author), Univ London Univ Coll, Mol Cell Biol Lab, MRC, Gower St, London WC1E 6BT, England.		Brown, David A/J-9019-2012; bettler, bernhard/AAO-8018-2020; couve, andres/I-2249-2013	couve, andres/0000-0003-4216-8672; Connolly, Christopher/0000-0002-0445-8874; Bettler, Bernhard/0000-0003-0842-8207	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALKADHI KA, 1993, ARCH INT PHARMACOD T, V322, P66; [Anonymous], [No title captured]; BOWERY NG, 1993, ANNU REV PHARMACOL, V33, P109, DOI 10.1146/annurev.pa.33.040193.000545; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BURGOS GRG, 1994, BRAIN RES, V658, P1; Caddick SJ, 1996, NEUROSCI LETT, V205, P29, DOI 10.1016/0304-3940(96)12362-4; CAULFIELD MP, 1994, J PHYSIOL-LONDON, V477, P415, DOI 10.1113/jphysiol.1994.sp020203; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; Connolly CN, 1996, P NATL ACAD SCI USA, V93, P9899, DOI 10.1073/pnas.93.18.9899; Davies PA, 1997, BRIT J PHARMACOL, V120, P899, DOI 10.1038/sj.bjp.0700987; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Filippov AK, 1997, BRIT J PHARMACOL, V121, P849, DOI 10.1038/sj.bjp.0701270; Filippov AK, 1998, J NEUROSCI, V18, P5170, DOI 10.1523/JNEUROSCI.18-14-05170.1998; FUKUDA A, 1993, J NEUROPHYSIOL, V70, P448, DOI 10.1152/jn.1993.70.1.448; GAIARSA JL, 1995, J NEUROPHYSIOL, V73, P246, DOI 10.1152/jn.1995.73.1.246; HELM R, 1995, NATURE, V373, P663; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; JOLY C, 1995, J NEUROSCI, V15, P3970; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LINDSAY RM, 1988, J NEUROSCI, V8, P2394; Luebke AE, 1996, P NATL ACAD SCI USA, V93, P3455, DOI 10.1073/pnas.93.8.3455; LUHMANN HJ, 1991, J NEUROPHYSIOL, V65, P247, DOI 10.1152/jn.1991.65.2.247; MARRION NV, 1987, NEUROSCI LETT, V77, P55, DOI 10.1016/0304-3940(87)90606-9; MARRION NV, 1989, BRIT J PHARMACOL, V98, P557, DOI 10.1111/j.1476-5381.1989.tb12630.x; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; McLean HA, 1996, J NEUROPHYSIOL, V76, P1036, DOI 10.1152/jn.1996.76.2.1036; MOTT DD, 1994, INT REV NEUROBIOL, V36, P97, DOI 10.1016/S0074-7742(08)60304-9; NEWBERRY NR, 1989, EUR J PHARMACOL, V163, P245, DOI 10.1016/0014-2999(89)90193-3; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; PARDUCZ A, 1990, NEUROSCIENCE, V36, P239, DOI 10.1016/0306-4522(90)90365-B; PICKERING DS, 1993, J NEUROCHEM, V61, P85, DOI 10.1111/j.1471-4159.1993.tb03540.x; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; RABOW LE, 1995, SYNAPSE, V21, P189, DOI 10.1002/syn.890210302; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; SMART TG, 1987, J PHYSIOL-LONDON, V389, P337, DOI 10.1113/jphysiol.1987.sp016660; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TURGEON SM, 1994, NEUROSCIENCE, V62, P601, DOI 10.1016/0306-4522(94)90392-1; Wasterlain CG, 1996, EPILEPSY RES, V26, P255, DOI 10.1016/S0920-1211(96)00058-7; Wooltorton JRA, 1997, EUR J NEUROSCI, V9, P2225, DOI 10.1111/j.1460-9568.1997.tb01641.x; Zhang Y, 1997, P NATL ACAD SCI USA, V94, P12162, DOI 10.1073/pnas.94.22.12162	41	171	177	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26361	26367		10.1074/jbc.273.41.26361	http://dx.doi.org/10.1074/jbc.273.41.26361			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756866	hybrid			2022-12-27	WOS:000076373300020
J	Delot, E; Brodie, SG; King, LM; Wilcox, WR; Cohn, DH				Delot, E; Brodie, SG; King, LM; Wilcox, WR; Cohn, DH			Physiological and pathological secretion of cartilage oligomeric matrix protein by cells in culture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE EPIPHYSEAL DYSPLASIA; ENDOPLASMIC-RETICULUM; EXTRACELLULAR-MATRIX; ARTICULAR-CARTILAGE; PSEUDOACHONDROPLASIA; COMP; GENE; MUTATIONS; THROMBOSPONDIN; FAMILY	Abnormalities in cartilage oligomeric matrix protein (COMP), a pentameric structural protein of the cartilage extracellular matrix, have been identified in pseudoachondroplasia and multiple epiphyseal dysplasia, two human autosomal dominant osteochondrodysplasias. However, the function of the protein remains unknown. With the goal of establishing a model to study the mechanisms by which COMP mutations cause disease, we have analyzed synthesis and secretion of COMP in cultured chondrocytes, tendon, and ligament cells. Pentameric protein detected inside of control cells suggested that pentamerization is an intracellular process. Patient cells expressed mutant and normal RNA and secreted COMP at levels similar to controls, suggesting that abnormal pentamers are likely to be found in the extracellular matrix. Inclusions within patient cartilage stained with anti-COMP antibodies, and cultured cells presented similar inclusions, indicating that presumably abnormal COMP pentamers are less efficiently secreted than normal molecules. We conclude that the COMP disorders are likely to result from a combination of a decreased amount of COMP in the matrix and a dominant negative effect due to the presence of abnormal pentamers in cartilage.	Univ Calif Los Angeles, Sch Med,Ahmanson Dept Pediat, Burns & Allen Cedars Sinai Res Inst, Steven Spielberg Pediat Res Ctr, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Dept Pediat, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Cohn, DH (corresponding author), Cedars Sinai Med Ctr, SSB-3,8700 Beverly Blvd, Los Angeles, CA 90048 USA.	dcohn@xchg.peds.csmc.edu		Delot, Emmanuele/0000-0003-3541-3190	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043139] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR43139] Funding Source: Medline; NICHD NIH HHS [HD22567] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ballo R, 1997, AM J MED GENET, V68, P396, DOI 10.1002/(SICI)1096-8628(19970211)68:4<396::AID-AJMG4>3.3.CO;2-R; BARRON EJ, 1995, GEOTIMES, V40, P12; BRIGGS MD, 1993, GENOMICS, V18, P656, DOI 10.1016/S0888-7543(05)80369-6; BRIGGS MD, 1994, AM J HUM GENET, V55, P678; Briggs MD, 1998, AM J HUM GENET, V62, P311, DOI 10.1086/301713; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; BRODIE SG, 1998, IN PRESS AM J MED GE; DICESARE PE, 1995, J ORTHOPAED RES, V13, P422, DOI 10.1002/jor.1100130316; DICESARE PE, 1994, EUR J BIOCHEM, V223, P927, DOI 10.1111/j.1432-1033.1994.tb19070.x; EFIMOV VP, 1994, FEBS LETT, V341, P54, DOI 10.1016/0014-5793(94)80239-4; FRANZEN A, 1987, DIFFERENTIATION, V36, P199, DOI 10.1111/j.1432-0436.1987.tb00194.x; HAUSER N, 1995, FEBS LETT, V368, P307, DOI 10.1016/0014-5793(95)00675-Y; HECHT JT, 1995, NAT GENET, V10, P325, DOI 10.1038/ng0795-325; HEDBOM E, 1992, J BIOL CHEM, V267, P6132; Loughlin J, 1998, HUM MUTAT, pS10; Maddox BK, 1997, J BIOL CHEM, V272, P30993, DOI 10.1074/jbc.272.49.30993; MAYNARD JA, 1972, LAB INVEST, V26, P40; MORGELIN M, 1992, J BIOL CHEM, V267, P6137; MURAD S, 1981, P NATL ACAD SCI-BIOL, V78, P2879, DOI 10.1073/pnas.78.5.2879; Muragaki Y, 1996, NAT GENET, V12, P103, DOI 10.1038/ng0196-103; NEWTON G, 1994, GENOMICS, V24, P435, DOI 10.1006/geno.1994.1649; OLDBERG A, 1992, J BIOL CHEM, V267, P22346; Prabakaran D, 1996, EUR J CELL BIOL, V70, P134; Recklies AD, 1998, ARTHRITIS RHEUM, V41, P997, DOI 10.1002/1529-0131(199806)41:6<997::AID-ART6>3.0.CO;2-G; RIMOIN DL, 1994, HUM GENET, V93, P236, DOI 10.1007/BF00212015; SAXNE T, 1992, BR J RHEUM, V31, P573; SHARIF M, 1995, BRIT J RHEUMATOL, V34, P306; Shen ZX, 1995, MATRIX BIOL, V14, P773, DOI 10.1016/S0945-053X(05)80020-4; Smith RKW, 1997, MATRIX BIOL, V16, P255, DOI 10.1016/S0945-053X(97)90014-7; STANESCU R, 1993, AM J MED GENET, V45, P501, DOI 10.1002/ajmg.1320450420; STANESCU V, 1982, EUR J PEDIATR, V138, P221, DOI 10.1007/BF00441206; Susic S, 1997, CLIN GENET, V51, P219; VANMOURIK JBA, 1998, IN PRESS ULTRASTRUC	33	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26692	26697		10.1074/jbc.273.41.26692	http://dx.doi.org/10.1074/jbc.273.41.26692			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756911	hybrid			2022-12-27	WOS:000076373300065
J	Pedram, A; Razandi, M; Levin, ER				Pedram, A; Razandi, M; Levin, ER			Extracellular signal-regulated protein kinase Jun kinase cross-talk underlies vascular endothelial cell growth factor-induced endothelial cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; SMOOTH-MUSCLE CELLS; TYROSINE KINASE; CYCLE PROGRESSION; TRANSDUCTION PATHWAYS; MAP KINASES; IN-VIVO; ACTIVATION; MITOGEN; EXPRESSION	Ligand binding to vascular endothelial cell growth factor (VEGF) receptors activates the mitogen-activated protein kinases extracellular signal-regulated kinase (ERK) and c-Jun N-terminal protein kinase (JNK). Possible cross-communication of ERK and JNK effecting endothelial cell (EC) actions of VEGF is poorly understood. Incubation of EC with PD 98059, a specific nitrogen-activated protein kinase kinase inhibitor, or transfection with Y185F, a dominant negative ERK2, strongly inhibited VEGF-activated JNK. JNK was also activated by ERK2 expression in the absence of VEGF, inhibited 82% by co-transfection with dominant negative SEK-1, indicating upstream activation of JNK by ERK. VEGF-stimaulated JNK activity was also reversed by dominant negative SEK-1. Other EC growth factors exhibited similar cross-activation of JNK through ERK. VEGF stimulated the nuclear incorporation of thymidine, reversed 89% by PD 98059 and 72% by Y185F. Dominant negative SEK-1 or JNK-1 also significantly reduced VEGF-stimulated thymidine incorporation Expression of wild type Jip-1, which prevents JNK nuclear translocation, inhibited VEGF-induced EC proliferation by 75%. VEGF stimulated both cyclin D1 synthesis and Cdk4 kinase activity, inhibited by PD 98059 and dominant negative JNK-1. Important events for VEGF-induced G(1)/S progression and cell proliferation are enhanced through a novel ERK to JNK cross-activation and subsequent JNK action.	Long Beach Vet Affairs Med Ctr, Med Serv, Div Endocrinol, Long Beach, CA 90822 USA; Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA; Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92717 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine; University of California System; University of California Irvine	Levin, ER (corresponding author), Long Beach Vet Affairs Med Ctr, Med Serv, Div Endocrinol, 111-I,5901 E 7th St, Long Beach, CA 90822 USA.	elevin@pop.long-beach.va.gov			NINDS NIH HHS [NS-30521] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030521] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Biesiada E, 1996, J BIOL CHEM, V271, P18576, DOI 10.1074/jbc.271.31.18576; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; CUNNINGHAM SA, 1995, J BIOL CHEM, V270, P20254, DOI 10.1074/jbc.270.35.20254; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Higashita R, 1997, J BIOL CHEM, V272, P25845, DOI 10.1074/jbc.272.41.25845; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Liu ZY, 1997, J CLIN INVEST, V99, P1798, DOI 10.1172/JCI119344; LopezIlasaca M, 1997, BIOCHEM BIOPH RES CO, V232, P273, DOI 10.1006/bbrc.1997.6289; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; Lukas J, 1996, MOL CELL BIOL, V16, P6917; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Mitsui H, 1997, J BIOL CHEM, V272, P4904, DOI 10.1074/jbc.272.8.4904; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; Morey AK, 1997, ENDOCRINOLOGY, V138, P3330, DOI 10.1210/en.138.8.3330; Morey AK, 1998, BIOCHEM J, V330, P1097; Moxham CM, 1996, J BIOL CHEM, V271, P30765, DOI 10.1074/jbc.271.48.30765; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Pedram A, 1997, J BIOL CHEM, V272, P17097, DOI 10.1074/jbc.272.27.17097; Pedram A, 1998, J BIOL CHEM, V273, P13966, DOI 10.1074/jbc.273.22.13966; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PRINS BA, 1994, J BIOL CHEM, V269, P11938; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Rao GN, 1996, J BIOL CHEM, V271, P20805, DOI 10.1074/jbc.271.34.20805; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shapiro PS, 1996, J BIOL CHEM, V271, P5750, DOI 10.1074/jbc.271.10.5750; SHIBUYA M, 1990, ONCOGENE, V5, P519; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zanke BW, 1996, J BIOL CHEM, V271, P29876, DOI 10.1074/jbc.271.47.29876; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	58	186	193	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26722	26728		10.1074/jbc.273.41.26722	http://dx.doi.org/10.1074/jbc.273.41.26722			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756915	hybrid			2022-12-27	WOS:000076373300069
J	Roush, DL; Gottardi, CJ; Naim, HY; Roth, MG; Caplan, MJ				Roush, DL; Gottardi, CJ; Naim, HY; Roth, MG; Caplan, MJ			Tyrosine-based membrane protein sorting signals are differentially interpreted by polarized Madin-Darby canine kidney and LLC-PK1 epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; POLYMERIC IMMUNOGLOBULIN RECEPTOR; CYTOPLASMIC DOMAIN DETERMINANT; COATED PIT LOCALIZATION; AMINO-ACID CHANGE; MDCK CELLS; FC-RECEPTORS; TRANSFERRIN RECEPTOR; BASOLATERAL SURFACE; TRANSPORTING ATPASE	Tyrosine-dependent sequence motifs are implicated in sorting membrane proteins to the basolateral domain of Madin-Darby canine kidney (MDCK) cells. We find that these motifs are interpreted differentially in various polarized epithelial cell types. The H,K-ATPase beta subunit, which contains a tyrosine-based motif in its cytoplasmic tail, was expressed in MDCK and LLC-PK1 cells. This protein was restricted to the basolateral membrane in MDCK cells, but was localized to the apical membrane in LLC-PK1 cells. Similarly, HA-Y543, a construct in which a tyrosine-based motif was introduced into the cytoplasmic tail of influenza hemagglutinin, was sorted to the basolateral membrane of MDCK cells and retained at the epical membrane of LLC-PK1 cells. A chimera in which the cytoplasmic tail of the IP,K-ATPase beta subunit protein was replaced with the analogous region of the Na,R-ATPase beta subunit polypeptide was localized to both surface domains of MDCK cells. Mutation of tyrosine-20 of the H,K-ATPase beta subunit cytoplasmic sequence to an alanine was sufficient to disrupt basolateral localization of this polypeptide. In contrast, these constructs all remain localized to the apical membrane in LLC-PK1 cells. The FcRII-B2 protein bears a di-leucine motif and is found at the basolateral membrane of both MDCK and LLC-PK1 cells. These results demonstrate that polarized epithelia are able to discriminate between different classes of specifically defined membrane protein sorting signals.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	Yale University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Roush, DL (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, 333 Cedar St, New Haven, CT 06510 USA.		Gottardi, Cara J./AAU-4691-2021	Gottardi, Cara J./0000-0003-0912-7617; Roth, Michael/0000-0002-9056-332X; Caplan, Michael/0000-0001-5768-4405	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK017433] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042136] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-17433] Funding Source: Medline; NIGMS NIH HHS [GM-42136] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVAREZ E, 1993, BIOCHEM J, V267, P31; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; BUTOR C, 1992, EXP CELL RES, V203, P115, DOI 10.1016/0014-4827(92)90046-B; CAPLAN MJ, 1987, NATURE, V329, P632, DOI 10.1038/329632a0; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; CourtoisCoutry N, 1997, CELL, V90, P501, DOI 10.1016/S0092-8674(00)80510-3; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DeStrooper B, 1995, J BIOL CHEM, V270, P30310, DOI 10.1074/jbc.270.51.30310; FUHRER C, 1991, J CELL BIOL, V114, P423, DOI 10.1083/jcb.114.3.423; GEFFEN I, 1993, J BIOL CHEM, V268, P20772; GIRONES N, 1991, J BIOL CHEM, V266, P19006; GOTTARDI CJ, 1993, J CELL BIOL, V121, P283, DOI 10.1083/jcb.121.2.283; GOTTARDI CJ, 1993, J BIOL CHEM, V268, P14342; GOTTARDI CJ, 1995, AM J PHYSIOL-RENAL, V268, pF285, DOI 10.1152/ajprenal.1995.268.2.F285; GUNDERSEN D, 1991, J CELL BIOL, V112, P863, DOI 10.1083/jcb.112.5.863; HALLER C, 1993, AM J PHYSIOL, V265, pC1069, DOI 10.1152/ajpcell.1993.265.4.C1069; HERZLINGER DA, 1982, J CELL BIOL, V93, P269, DOI 10.1083/jcb.93.2.269; HUNZIKER W, 1989, J CELL BIOL, V109, P3291, DOI 10.1083/jcb.109.6.3291; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; Kundu A, 1996, J VIROL, V70, P6508, DOI 10.1128/JVI.70.9.6508-6515.1996; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; MACHAMER CE, 1990, P NATL ACAD SCI USA, V87, P6944, DOI 10.1073/pnas.87.18.6944; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; MASUZAWA T, 1984, BRAIN RES, V302, P357, DOI 10.1016/0006-8993(84)90250-6; MATLIN KS, 1992, KIDNEY PHYSL PATHOPH, P447; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MCQUEEN N, 1986, P NATL ACAD SCI USA, V83, P9318, DOI 10.1073/pnas.83.24.9318; MIETTINEN HM, 1992, J CELL BIOL, V116, P875, DOI 10.1083/jcb.116.4.875; MOSTOV KE, 1987, J CELL BIOL, V105, P2031, DOI 10.1083/jcb.105.5.2031; Muth TR, 1998, J BIOL CHEM, V273, P25616, DOI 10.1074/jbc.273.40.25616; NAIM HY, 1994, J BIOL CHEM, V269, P3928; Odorizzi G, 1996, J CELL BIOL, V135, P139, DOI 10.1083/jcb.135.1.139; PATHAK RK, 1990, J CELL BIOL, V111, P347, DOI 10.1083/jcb.111.2.347; PFALLER W, 1990, J CELL PHYSIOL, V142, P247, DOI 10.1002/jcp.1041420205; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; REUBEN MA, 1990, P NATL ACAD SCI USA, V87, P6767, DOI 10.1073/pnas.87.17.6767; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; RODRIGUEZBOULAN E, 1978, P NATL ACAD SCI USA, V75, P5071, DOI 10.1073/pnas.75.10.5071; ROTH MG, 1987, J CELL BIOL, V104, P769, DOI 10.1083/jcb.104.3.769; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SCHWARTZ GJ, 1985, J CLIN INVEST, V75, P1638, DOI 10.1172/JCI111871; STEPHENS EB, 1986, EMBO J, V5, P237, DOI 10.1002/j.1460-2075.1986.tb04204.x; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOGEL LK, 1995, J BIOL CHEM, V270, P22933, DOI 10.1074/jbc.270.39.22933; ZURZOLO C, 1993, J CELL BIOL, V121, P1031, DOI 10.1083/jcb.121.5.1031	52	94	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26862	26869		10.1074/jbc.273.41.26862	http://dx.doi.org/10.1074/jbc.273.41.26862			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756932	hybrid			2022-12-27	WOS:000076373300086
J	Treger, JM; Schmitt, AP; Simon, JR; McEntee, K				Treger, JM; Schmitt, AP; Simon, JR; McEntee, K			Transcriptional factor mutations reveal regulatory complexities of heat shock and newly identified stress genes in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSE ELEMENT STRE; PROTEIN-KINASE-A; RNA-POLYMERASE; HSP70 GENE; DNA DAMAGE; PATHWAY; TEMPERATURE; ACTIVATOR; SEQUENCE; FAMILY	A computer-aided pattern search of the entire yeast genome was designed and used to identify 186 putative stress response element-regulated genes in Saccharomyces cerevisiae. Transcript levels of eight of these candidate genes were examined, and three (37%) were shown to be heat shock- and DNA damage-inducible and to require the Msn2p and Msn4p transcriptional activators for stress regulation. Significantly, several heat shock protein (HSP) genes were identified in this computer search. Using a series of single and multiple regulatory mutants, we demonstrate unexpected regulatory complexities among the HSP genes from S. cerevisiae following heat shock.	Univ Calif Los Angeles, Ctr Hlth Sci, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	McEntee, K (corresponding author), Univ Calif Los Angeles, Ctr Hlth Sci, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.			Schmitt, Anthony/0000-0001-9272-058X	NIGMS NIH HHS [GM38456] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; BOORSTEIN WR, 1990, EMBO J, V9, P2543, DOI 10.1002/j.1460-2075.1990.tb07435.x; BOORSTEIN WR, 1990, MOL CELL BIOL, V10, P3262, DOI 10.1128/MCB.10.6.3262; Boy-Marcotte E, 1998, J BACTERIOL, V180, P1044, DOI 10.1128/JB.180.5.1044-1052.1998; FARRELLY FW, 1984, J BIOL CHEM, V259, P5745; GOUNALAKI N, 1994, EMBO J, V13, P4036, DOI 10.1002/j.1460-2075.1994.tb06720.x; GROSS DS, 1990, ANTON LEEUW INT J G, V58, P175, DOI 10.1007/BF00548930; Inoue Y, 1998, J BIOL CHEM, V273, P2977, DOI 10.1074/jbc.273.5.2977; KOBAYASHI N, 1993, MOL CELL BIOL, V13, P248, DOI 10.1128/MCB.13.1.248; LEONHARDT SA, 1993, MOL CELL BIOL, V13, P6304, DOI 10.1128/MCB.13.10.6304; MARCHLER G, 1993, EMBO J, V12, P1997, DOI 10.1002/j.1460-2075.1993.tb05849.x; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; MCCLANAHAN T, 1984, MOL CELL BIOL, V4, P2356, DOI 10.1128/MCB.4.11.2356; NI HT, 1995, MOL MICROBIOL, V16, P1197, DOI 10.1111/j.1365-2958.1995.tb02342.x; OH D, 1990, MOL CELL BIOL, V10, P1415, DOI 10.1128/MCB.10.4.1415; POWERS S, 1984, CELL, V36, P607, DOI 10.1016/0092-8674(84)90340-4; Rose MD., 1990, METHODS YEAST GENETI; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; SASS P, 1986, P NATL ACAD SCI USA, V83, P9303, DOI 10.1073/pnas.83.24.9303; Schmitt AP, 1996, P NATL ACAD SCI USA, V93, P5777, DOI 10.1073/pnas.93.12.5777; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; SMID A, 1995, J BIOL CHEM, V270, P13534, DOI 10.1074/jbc.270.22.13534; SMITH BJ, 1991, MOL CELL BIOL, V11, P2647, DOI 10.1128/MCB.11.5.2647; SORGER PK, 1990, CELL, V62, P793, DOI 10.1016/0092-8674(90)90123-V; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; TAMAI KT, 1994, MOL CELL BIOL, V14, P8155, DOI 10.1128/MCB.14.12.8155; Treger JM, 1998, BIOCHEM BIOPH RES CO, V243, P13, DOI 10.1006/bbrc.1997.8061; TREGER JM, 1990, MOL CELL BIOL, V10, P3174, DOI 10.1128/MCB.10.6.3174; VARELA JCS, 1995, MOL CELL BIOL, V15, P6232; Wotton D, 1996, J BIOL CHEM, V271, P2717, DOI 10.1074/jbc.271.5.2717; WOYCHIK NA, 1989, MOL CELL BIOL, V9, P2854, DOI 10.1128/MCB.9.7.2854	31	83	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26875	26879		10.1074/jbc.273.41.26875	http://dx.doi.org/10.1074/jbc.273.41.26875			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756934	hybrid			2022-12-27	WOS:000076373300088
J	Guadiz, G; Haidaris, CG; Maine, GN; Simpson-Haidaris, PJ				Guadiz, G; Haidaris, CG; Maine, GN; Simpson-Haidaris, PJ			The carboxyl terminus of Pneumocystis carinii glycoprotein A encodes a functional glycosylphosphatidylinositol signal sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR SURFACE GLYCOPROTEIN; CULTURED LUNG-CELLS; SACCHAROMYCES-CEREVISIAE; GLYCOSYL-PHOSPHATIDYLINOSITOL; ALPHA-AGGLUTININ; ANTIGENIC VARIATION; CANDIDA-ALBICANS; EPITHELIAL-CELLS; PLASMA-MEMBRANE; GPI-ANCHORS	Pneumocystis carinii pneumonia is a hallmark disease associated with AIDS. An abundant glycoprotein, termed gpA, on the surface of P. carinii is considered an important factor in host-parasite interactions. The primary structure of ferret P. carinii gpA contains a carboxyl-terminal sequence characteristic of a signal for glycosylphosphatidylinositol (GPI) anchors. Here we report the capacity for this gpA carboxyl sequence to direct attachment of a secreted protein, human growth hormone (hGH), to the membranes of COS cells. A control fusion protein (hGHDAF37) was obtained which, under the direction of the GPI signal from decay accelerating factor, directs hGR cell surface expression. A construct (phGH2-1A30) was created similar to hGHDAF37 by fusing hGH to the putative GPI signal sequence encoded in the terminal 30 residues from a ferret P. carinii gpA cDNA clone. By indirect immunofluorescent staining, hGH was detected on the surface of COS cells transfected with phGH2-1A30; this surface location was confirmed by confocal laser cytometry. Metabolic labeling with [H-3]ethanolamine and subsequent immunopurification of hGH from cells transfected with phGH2-1A30 confirmed that a lipid moiety characteristic of a conventional GPI anchor was linked covalently to hGH, and cell surface hGH2-1A30 fusion protein was sensitive to enzymatic cleavage by phosphatidylinositol-phospholipase C. Furthermore, hGH2-1A30 recombinant protein cofractionated with 5'-nucleotidase, a classical GPI-anchored membrane marker. Together, these results indicate that the carboxyl-terminal residues of ferret P. carinii gpA constitute a biologically functional GPI consensus domain, thus providing a potential mechanism for antigenic variation of P. carinii gpA during P. carinii pneumonia.	Univ Rochester, Dept Med, Vasc Med Unit, Rochester, NY 14642 USA; Univ Rochester, Dept Microbiol & Immunol, Rochester, NY 14642 USA; Univ Rochester, Dept Dent Res, Rochester, NY 14642 USA; Univ Rochester, Dept Pathol & Lab Med, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester	Simpson-Haidaris, PJ (corresponding author), Univ Rochester, Dept Med, Vasc Med Unit, POB 610,601 Elmwood Ave, Rochester, NY 14642 USA.			, PJ/0000-0003-2778-2500	NHLBI NIH HHS [HL50615, HL49610] Funding Source: Medline; NIAID NIH HHS [AI07362] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050615, R01HL049610] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007362] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARMSTRONG MYK, 1994, PNEUMOCYSTIS CARINII, P189; Aronson N N Jr, 1974, Methods Enzymol, V31, P90; BANGS JD, 1985, P NATL ACAD SCI USA, V82, P3207, DOI 10.1073/pnas.82.10.3207; BAUER NL, 1993, INFECT IMMUN, V61, P1315, DOI 10.1128/IAI.61.4.1315-1319.1993; BERGELSON JM, 1994, P NATL ACAD SCI USA, V91, P6245, DOI 10.1073/pnas.91.13.6245; CARAS IW, 1989, J CELL BIOL, V108, P1387, DOI 10.1083/jcb.108.4.1387; CEZANNE L, 1992, BIOCHIM BIOPHYS ACTA, V1112, P205, DOI 10.1016/0005-2736(92)90393-Z; CHEN WX, 1992, INT J EXP PATHOL, V73, P709; CONZELMANN A, 1991, CELL BIOL INT REP, V15, P863, DOI 10.1016/0309-1651(91)90038-K; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; CUSHION MT, 1994, J MED VET MYCOL, V32, P217; De Nobel Hans, 1994, Trends in Cell Biology, V4, P42, DOI 10.1016/0962-8924(94)90003-5; DESTEFANO JA, 1990, J PROTOZOOL, V37, P428; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FISHER DJ, 1991, INFECT IMMUN, V59, P3372, DOI 10.1128/IAI.59.10.3372-3376.1991; FLORINCHRISTENSEN M, 1994, BIOCHEM BIOPH RES CO, V198, P236, DOI 10.1006/bbrc.1994.1033; GARBE TR, 1994, INFECT IMMUN, V62, P3092, DOI 10.1128/IAI.62.8.3092-3101.1994; GIGLIOTTI F, 1988, J CLIN INVEST, V81, P1666, DOI 10.1172/JCI113503; GIGLIOTTI F, 1986, J INFECT DIS, V154, P315, DOI 10.1093/infdis/154.2.315; GIGLIOTTI F, 1992, J INFECT DIS, V165, P329, DOI 10.1093/infdis/165.2.329; Gigliotti F, 1996, INFECT IMMUN, V64, P1892, DOI 10.1128/IAI.64.6.1892-1899.1996; Guadiz G, 1997, BLOOD, V90, P2644, DOI 10.1182/blood.V90.7.2644.2644_2644_2653; GUO ZK, 1995, INFECT IMMUN, V63, P1286, DOI 10.1128/IAI.63.4.1286-1290.1995; Haidaris C G, 1998, DNA Res, V5, P77, DOI 10.1093/dnares/5.2.77; HAIDARIS PJ, 1993, MOL MICROBIOL, V7, P647, DOI 10.1111/j.1365-2958.1993.tb01156.x; HAIDARIS PJ, 1992, J INFECT DIS, V166, P1113, DOI 10.1093/infdis/166.5.1113; HERALD D, 1986, J BIOL CHEM, V261, P13813; HONG ST, 1990, J CLIN MICROBIOL, V28, P1785, DOI 10.1128/JCM.28.8.1785-1795.1990; HOPKIN JM, 1991, PNEUMOCYSTIS CARINII, P1; KANESHIRO ES, 1994, PNEUMOCYSTIS CARINII, P45; KAPTEYN JC, 1994, EUR J CELL BIOL, V65, P402; KODUKULA K, 1993, J CELL BIOL, V120, P657, DOI 10.1083/jcb.120.3.657; KOVACS JA, 1993, J BIOL CHEM, V268, P6034; LIMPER AH, 1993, INFECT IMMUN, V61, P4302, DOI 10.1128/IAI.61.10.4302-4309.1993; LIMPER AH, 1991, J LAB CLIN MED, V118, P492; LOW MG, 1988, J IMMUNOL METHODS, V113, P101, DOI 10.1016/0022-1759(88)90386-9; LU CF, 1995, J CELL BIOL, V128, P333, DOI 10.1083/jcb.128.3.333; LU CF, 1994, MOL CELL BIOL, V14, P4825, DOI 10.1128/MCB.14.7.4825; MATSUMOTO Y, 1989, J PROTOZOOL, V36, pS21, DOI 10.1111/j.1550-7408.1989.tb05814.x; MORAN P, 1994, J CELL BIOL, V125, P333, DOI 10.1083/jcb.125.2.333; MULLER G, 1992, J BIOL CHEM, V267, P25337; NUOFFER C, 1991, MOL CELL BIOL, V11, P27, DOI 10.1128/MCB.11.1.27; PESANTI EL, 1987, INFECT IMMUN, V55, P736, DOI 10.1128/IAI.55.3.736-741.1987; POTTRATZ ST, 1991, J CLIN INVEST, V88, P403, DOI 10.1172/JCI115318; ROSSE WF, 1995, BLOOD, V86, P3277, DOI 10.1182/blood.V86.9.3277.bloodjournal8693277; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; SAPORITOIRWIN SM, 1995, MOL CELL BIOL, V15, P601; SCHREUDER MP, 1993, YEAST, V9, P399, DOI 10.1002/yea.320090410; SPECTOR DL, 1998, CELLS LAB MANUAL, V1; Sunkin SM, 1996, MOL MICROBIOL, V19, P283, DOI 10.1046/j.1365-2958.1996.375905.x; VOSSEN JH, 1995, BBA-GEN SUBJECTS, V1243, P549, DOI 10.1016/0304-4165(95)00002-S; Wada M, 1996, DNA Res, V3, P55, DOI 10.1093/dnares/3.2.55; WADA M, 1995, J INFECT DIS, V171, P1563, DOI 10.1093/infdis/171.6.1563; WALZER PD, 1980, J INFECT DIS, V142, P449, DOI 10.1093/infdis/142.3.449; WEBSTER P, 1991, CELL BIOL INT REP, V15, P799; WOJCIECHOWICZ D, 1993, MOL CELL BIOL, V13, P2554, DOI 10.1128/MCB.13.4.2554; Wright T W, 1995, DNA Res, V2, P77, DOI 10.1093/dnares/2.2.77; WRIGHT TW, 1994, INFECT IMMUN, V62, P1513, DOI 10.1128/IAI.62.5.1513-1519.1994; YONEDA K, 1980, INFECT IMMUN, V29, P692; ZIMMERMAN PE, 1992, J CLIN INVEST, V89, P143, DOI 10.1172/JCI115554	61	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26202	26209		10.1074/jbc.273.40.26202	http://dx.doi.org/10.1074/jbc.273.40.26202			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748303	hybrid			2022-12-27	WOS:000076263100094
J	Meierhans, D; Allemann, RK				Meierhans, D; Allemann, RK			The N-terminal methionine is a major determinant of the DNA binding specificity of MEF-2C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-LOOP-HELIX; BOX TRANSCRIPTION FACTORS; BENDING PROPENSITY; MYOGENIC LINEAGE; GENE-EXPRESSION; ADENINE TRACT; B-DNA; PROTEIN; MEF2; ACTIVATION	Members of the MEF-S family of transcriptional regulators positively modulate the activity of basic helix-loop-helix proteins in both myogenic and neurogenic cell lineages. Previous work had shown that MEF-2C(2-117), a protein fragment comprising the dimerization and DNA-binding domains of MEF-2C but lacking the N-terminal methionine, bound to AT-rich DNA sequences with high affinity. MEF-2C(2-117) did not discriminate between different AT-rich sequences. We now report the in vitro DNA binding properties of a MEF-2C fragment containing the N-terminal methionine. Measurements of the apparent dissociation constants of the complexes of GG-MEF-2C(1-117) revealed that different AT-rich sequences are bound with different affinities; in particular MEF site containing DNA (CTATAAATAG) is bound preferentially to DNA containing a SRF site (CATAAATG). Strikingly, when the shorter AT run consisted of six alternating thymines and adenines, almost wild-type affinity was observed. Irrespective of the particular DNA sequence, all circular dichroism spectra of the DNA complexes of GG-MEF-2C(1-117) were superimposable and characterized by an identical maximal ellipticity at 269.5 nm, suggesting similar DNA conformations. Bending analysis by circular permutation assay revealed that on complex formation MEF-2C(2-117) induced cognate DNA to bend by 49 degrees, while heterologous DNA remained unbent. In the presence of the N-terminal methionine, however, all DNA sequences were bent by 70 degrees. The above results suggest an important function for the N-terminal methionine in properly orientating MEF-2C on the DNA.	Swiss Fed Inst Technol, Dept Chem, CH-8092 Zurich, Switzerland	ETH Zurich	Allemann, RK (corresponding author), Univ Birmingham, Sch Chem, Birmingham B15 2TT, W Midlands, England.							Allemann RK, 1997, CHEM BIOL, V4, P643, DOI 10.1016/S1074-5521(97)90218-0; Berman HM, 1997, BIOPOLYMERS, V44, P23, DOI 10.1002/(SICI)1097-0282(1997)44:1<23::AID-BIP3>3.0.CO;2-1; Black BL, 1996, J BIOL CHEM, V271, P26659, DOI 10.1074/jbc.271.43.26659; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; BRUKNER I, 1995, EMBO J, V14, P1812, DOI 10.1002/j.1460-2075.1995.tb07169.x; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; DELCOURT SG, 1991, J BIOL CHEM, V266, P15160; Dickerson RE, 1996, J MOL BIOL, V256, P108, DOI 10.1006/jmbi.1996.0071; DICKERSON RE, 1994, P NATL ACAD SCI USA, V91, P3579, DOI 10.1073/pnas.91.9.3579; DIGABRIELE AD, 1989, P NATL ACAD SCI USA, V86, P1816, DOI 10.1073/pnas.86.6.1816; DIGABRIELE AD, 1993, J MOL BIOL, V231, P1024, DOI 10.1006/jmbi.1993.1349; ERIE DA, 1994, SCIENCE, V266, P1562, DOI 10.1126/science.7985026; ERIE DA, 1995, SCIENCE, V269, P989, DOI 10.1126/science.269.5226.989-a; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; Gabrielian A, 1996, FEBS LETT, V393, P65, DOI 10.1016/0014-5793(96)00855-1; Gabrielian A, 1996, FEBS LETT, V393, P124, DOI 10.1016/0014-5793(96)00837-X; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GOTOH O, 1981, BIOPOLYMERS, V20, P1043, DOI 10.1002/bip.1981.360200514; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; Kunne AGE, 1996, FEBS LETT, V391, P79, DOI 10.1016/0014-5793(96)00707-7; Mao ZX, 1996, J BIOL CHEM, V271, P14371, DOI 10.1074/jbc.271.24.14371; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; Meierhans D, 1997, NUCLEIC ACIDS RES, V25, P4537, DOI 10.1093/nar/25.22.4537; Meierhans D, 1997, PROTEIN EXPRES PURIF, V11, P297, DOI 10.1006/prep.1997.0795; MEIERHANS D, 1995, BIOCHEMISTRY-US, V34, P11026, DOI 10.1021/bi00035a008; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PELLEGRINI L, 1995, NATURE, V376, P490, DOI 10.1038/376490a0; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; QUINTANA JR, 1992, J MOL BIOL, V225, P379, DOI 10.1016/0022-2836(92)90928-D; Riechmann JL, 1997, BIOL CHEM, V378, P1079; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEPARTZ A, 1995, SCIENCE, V269, P989, DOI 10.1126/science.7638626; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; Sieber M, 1998, BIOL CHEM, V379, P731; Sommer L, 1995, NEURON, V15, P1245, DOI 10.1016/0896-6273(95)90005-5; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; SUZUKI M, 1995, NUCLEIC ACIDS RES, V23, P2083, DOI 10.1093/nar/23.12.2083; Suzuki M, 1996, FEBS LETT, V379, P148, DOI 10.1016/0014-5793(95)01506-X; Tan S, 1998, NATURE, V391, P660, DOI 10.1038/35563; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	49	7	7	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26052	26060		10.1074/jbc.273.40.26052	http://dx.doi.org/10.1074/jbc.273.40.26052			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748284	hybrid			2022-12-27	WOS:000076263100075
J	Ranganathan, S; Kern, PA				Ranganathan, S; Kern, PA			Thiazolidinediones inhibit lipoprotein lipase activity in adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ADIPOSE-TISSUE; PEROXISOME PROLIFERATOR; 3T3-L1 ADIPOCYTES; PPAR-GAMMA; GENE-EXPRESSION; GLUCOSE-UPTAKE; INSULIN; DIFFERENTIATION; CELLS; TROGLITAZONE	The thiazolidinediones troglitazone and BRL 49653 improve insulin sensitivity in humans and animals with insulin resistance. Adipose tissue lipoprotein lipase is an insulin-sensitive enzyme. We examined the effects of thiazolidinediones on lipoprotein lipase expression in adipocytes. When added to 3T3-F442A, 3T3-L1, and rat adipocytes in culture, troglitazone and BRL 49653 inhibited lipoprotein lipase activity. This inhibition was observed at concentrations as low as 0.1 mu M and within 2 h after addition of the drug. Lipoprotein lipase activity was inhibited in differentiated adipocytes as well as the differentiating cells. Despite this decrease in enzyme activity, these drugs increased mRNA levels in undifferentiated 3T3-F442A and 3T3-L1 cells and had no effect on mRNA expression or synthesis of lipoprotein lipase in differentiated cells. Western blot analysis showed that these drugs did not affect the mass of the enzyme protein. Lipoprotein lipase activity in cultured Chinese hamster ovary cells was not inhibited by troglitazone. Glucose transport, biosynthesis of lipids from glucose or the biosynthesis of proteins were unaffected by thiazolidinediones in differentiated cells, whereas glucose transport and lipid biosynthesis were increased when these drugs were added during differentiation. These results show that troglitazone and BRL 49653 have a specific, post-translational inhibitory effect on lipoprotein lipase in adipocytes, yet they promote lipid accumulation and differentiation in preadipocytes.	Univ Arkansas Med Sci, Div Endocrinol, Dept Med, Little Rock, AR 72205 USA; John L McClellan Mem Vet Affairs Med Ctr, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences	Kern, PA (corresponding author), John L McClellan Mem Vet Hosp, ACOS Res,4300 W 7th St, Little Rock, AR 72205 USA.	KernPhilipA@exchange.UAMS.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039176] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK/HL 39176] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELFRAGE P, 1969, J LIPID RES, V10, P341; BENZEEV O, 1992, J BIOL CHEM, V267, P6219; BIERMAN EL, 1992, ARTERIOSCLER THROMB, V12, P647, DOI 10.1161/01.ATV.12.6.647; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Brun RP, 1996, CURR OPIN CELL BIOL, V8, P826, DOI 10.1016/S0955-0674(96)80084-6; Burant CF, 1997, J CLIN INVEST, V100, P2900, DOI 10.1172/JCI119839; CHAWLA A, 1994, P NATL ACAD SCI USA, V91, P1786, DOI 10.1073/pnas.91.5.1786; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLANCY BM, 1990, J BIOL CHEM, V265, P12434; Cominacini L, 1997, DIABETOLOGIA, V40, P165, DOI 10.1007/s001250050658; ENERBACK S, 1993, BIOCHIM BIOPHYS ACTA, V1169, P107, DOI 10.1016/0005-2760(93)90196-G; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Fulgencio JP, 1996, DIABETES, V45, P1556, DOI 10.2337/diabetes.45.11.1556; HARRIS PKW, 1993, MOL PHARMACOL, V45, P439; HOLLENBERG CH, 1966, J CLIN INVEST, V45, P205, DOI 10.1172/JCI105333; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KERN PA, 1985, J CLIN INVEST, V75, P199, DOI 10.1172/JCI111675; KLETZIEN RF, 1992, MOL PHARMACOL, V41, P393; Law RE, 1996, J CLIN INVEST, V98, P1897, DOI 10.1172/JCI118991; Lefebvre AM, 1997, ARTERIOSCL THROM VAS, V17, P1756, DOI 10.1161/01.ATV.17.9.1756; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LIMA FB, 1994, DIABETES, V43, P53, DOI 10.2337/diabetes.43.1.53; NILSSONEHLE P, 1976, J LIPID RES, V17, P536; OLIVECRONA T, 1987, J BIOL CHEM, V262, P10748; ONG JM, 1989, J CLIN INVEST, V84, P305, DOI 10.1172/JCI114155; ONG JM, 1988, J BIOL CHEM, V263, P12933; PFEIFER MA, 1983, DIABETES, V32, P525, DOI 10.2337/diabetes.32.6.525; PYKALISTO OJ, 1975, J CLIN INVEST, V56, P1108, DOI 10.1172/JCI108185; SANDOUK T, 1993, AM J PHYSIOL, V264, pC1600, DOI 10.1152/ajpcell.1993.264.6.C1600; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; SEMENKOVICH CF, 1989, J BIOL CHEM, V264, P9030; SHRAGO E, 1969, J BIOL CHEM, V244, P2761; SIMSOLO RB, 1992, J LIPID RES, V33, P89; SIMSOLO RB, 1992, J LIPID RES, V33, P1777; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; STEVENSON RW, 1990, DIABETES, V39, P1218, DOI 10.2337/diabetes.39.10.1218; SZALKOWSKI D, 1995, ENDOCRINOLOGY, V136, P1474, DOI 10.1210/en.136.4.1474; Tafuri SR, 1996, ENDOCRINOLOGY, V137, P4706, DOI 10.1210/en.137.11.4706; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; WILSON JPD, 1973, METABOLISM, V22, P913, DOI 10.1016/0026-0495(73)90063-2; YUKHT A, 1995, J CLIN INVEST, V96, P2438, DOI 10.1172/JCI118301	41	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26117	26122		10.1074/jbc.273.40.26117	http://dx.doi.org/10.1074/jbc.273.40.26117			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748292	hybrid			2022-12-27	WOS:000076263100083
J	Tibbs, VC; Gray, PC; Catterall, WK; Murphy, BJ				Tibbs, VC; Gray, PC; Catterall, WK; Murphy, BJ			AKAP15 anchors cAMP-dependent protein kinase to brain sodium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SUBUNIT RII; SOMATIC-CELL LINE; RAT-BRAIN; ALPHA-SUBUNIT; SELECTIVE PHOSPHORYLATION; HIPPOCAMPAL-NEURONS; XENOPUS-OOCYTES; IDENTIFICATION; MODULATION; EXPRESSION	The voltage-sensitive sodium channel is regulated by cAMP-dependent protein kinase (PKA) phosphorylation, Using purified preparations of rat brain sodium channels, we have shown that the cu subunit was phosphorylated by a co-purifying protein kinase, The copurifying kinase was stimulated by cAMP and phosphorylated PKA substrate peptides, Both the regulatory and catalytic subunits of PKA were detected by immunoblotting in purified sodium channel preparations. Bound PKA was immunoprecipitated with anti-SP19 antibodies directed against the sodium channel alpha subunit, PKA bound to sodium channels phosphorylated the sodium channel alpha subunit on the same four serine residues as observed with exogenously added PKA, indicating that association with the sodium channel does not restrict the sites of phosphorylation, Analysis of proteins with high affinity for the type II alpha regulatory subunit of PKA in a gel overlay assay identified a 15-kDa cAMP-dependent protein kinase-anchoring protein (AKAP) in these preparations. Determination of its amino acid sequence by mass spectrometry revealed two peptides identical to AKAP15, a recently described AKAP that targets PKA to skeletal muscle calcium channels. The co-purifying AKAP was also immunoreactive with antibodies generated against AKAP15, and antibodies directed against AKAP15 co-immunoprecipitated the sodium channel. Our results indicate that PKA is bound to brain sodium channels through interaction with AKAP15, Association of AKAP1B with both skeletal muscle calcium channels and brain sodium channels suggests that it may have broad specificity in targeting PKA to ion channels for regulation.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Catterall, WK (corresponding author), Univ Washington, Dept Pharmacol, Mailstop 357280, Seattle, WA 98195 USA.				NINDS NIH HHS [NS07332, NS15751] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015751] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; Cantrell AR, 1997, J NEUROSCI, V17, P7330; CARR DW, 1992, J BIOL CHEM, V267, P13376; CARR DW, 1991, J BIOL CHEM, V266, P14188; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; COSTA MRC, 1982, J BIOL CHEM, V257, P7918; COSTA MRC, 1984, J BIOL CHEM, V259, P8210; GOLDIN AL, 1986, P NATL ACAD SCI USA, V83, P7503, DOI 10.1073/pnas.83.19.7503; GORDON D, 1988, BIOCHEMISTRY-US, V27, P7032, DOI 10.1021/bi00418a054; Gray PC, 1998, NEURON, V20, P1017, DOI 10.1016/S0896-6273(00)80482-1; Gray PC, 1997, J BIOL CHEM, V272, P6297, DOI 10.1074/jbc.272.10.6297; HARTSHORNE RP, 1984, J BIOL CHEM, V259, P1667; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; JOHNSON BD, 1994, P NATL ACAD SCI USA, V91, P11492, DOI 10.1073/pnas.91.24.11492; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI M, 1992, NEURON, V8, P1151, DOI 10.1016/0896-6273(92)90135-Z; MURPHY BJ, 1992, J BIOL CHEM, V267, P16129; MURPHY BJ, 1993, J BIOL CHEM, V268, P27355; Murphy BJ, 1998, TRENDS CARDIOVAS MED, V8, P89, DOI 10.1016/S1050-1738(97)00131-X; NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; ROSSIE S, 1987, J BIOL CHEM, V262, P12735; ROSSIE S, 1987, J BIOL CHEM, V262, P17530; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SCHEUER T, 1990, SCIENCE, V247, P854, DOI 10.1126/science.2154850; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Smith RD, 1996, J NEUROSCI, V16, P1965; Smith RD, 1997, J NEUROSCI, V17, P6086; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; WEST JW, 1992, NEURON, V8, P59, DOI 10.1016/0896-6273(92)90108-P; YATES JR, 1995, ANAL CHEM, V67, P3202, DOI 10.1021/ac00114a016	34	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25783	25788		10.1074/jbc.273.40.25783	http://dx.doi.org/10.1074/jbc.273.40.25783			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748250	hybrid			2022-12-27	WOS:000076263100041
J	Jones, AT; Wessling-Resnick, M				Jones, AT; Wessling-Resnick, M			Inhibition of in vitro endosomal vesicle fusion activity by aminoglycoside antibiotics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PHOSPHOLIPASE-D ACTIVITY; GTP-BINDING PROTEIN; LYSOSOMAL PHOSPHOLIPASES; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; GOLGI MEMBRANES; ACIDIC PHOSPHOLIPIDS; DEPENDENT FORMATION; PHOSPHATIDIC-ACID; COATED VESICLES	The effects of two aminoglycoside antibiotics, neomycin and Geneticin, on the endocytic pathway were studied using a cell-free assay that reconstitutes endosome-endosome fusion, Both drugs inhibit the rate and extent of endosome fusion in a dose-dependent manner with IC50 values of similar to 45 mu M and similar to 1 mM, respectively. Because the IC50 for neomycin falls within the range of affinities reported for its binding to acidic phospholipids, notably phosphatidylinositol 4,5-bisphosphate (PIP2), these data suggest that negatively charged lipids are required for endosome fusion. A role for negatively charged lipids in membrane traffic has been postulated to involve the activity of a PIP2-dependent phospholipase D (PLD) stimulated by the GTP-binding protein ADP-ribosylation factor (ARF). Although neomycin blocks endosome fusion at a stage of the in vitro reaction that is temporally related to steps inhibited by cytosolic ARFs when they bind guanosine-5'-gamma-thiophosphate (GTP gamma S), these inhibitors appear to act in a synergistic manner. This idea is confirmed by the fact that addition of a PIP2-independent PLD does not suppress neomycin inhibition of endosome fusion; moreover, in vitro fusion activity is not affected by the pleckstrin homology domain of phosphoinositide-specific phospholipase C delta 1, which binds to acidic phospholipids, particularly PIP2, with high affinity. Thus, although aminoglycoside-sensitive elements of endosome fusion are required at mechanistic stages that are also blocked by GTP gamma S-bound ARF, these effects are unrelated to inhibition of the PIP2-dependent PLD activity stimulated by this GTP-binding protein. These results argue that there are additional mechanistic roles for acidic phospholipids in the endosomal pathway.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Wessling-Resnick, M (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.	wessling@hsph.harvard.edu	Jones, Arwyn T/E-4787-2010; Jones, Arwyn/ABE-8709-2020	Jones, Arwyn T/0000-0003-2781-8905; Jones, Arwyn/0000-0003-2781-8905				Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; BENNETT WM, 1983, NEPHRON, V35, P73, DOI 10.1159/000183050; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAELL WA, 1987, P NATL ACAD SCI USA, V84, P1137, DOI 10.1073/pnas.84.5.1137; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DANIN M, 1993, LIPID METABOLISM SIG, P14; Dittie AS, 1996, J CELL BIOL, V132, P523, DOI 10.1083/jcb.132.4.523; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; GABEV E, 1989, BIOCHIM BIOPHYS ACTA, V979, P105, DOI 10.1016/0005-2736(89)90529-4; GIURGEAMARION L, 1986, TOXICOL APPL PHARM, V86, P271, DOI 10.1016/0041-008X(86)90058-X; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond TG, 1997, AM J PHYSIOL-RENAL, V272, pF117, DOI 10.1152/ajprenal.1997.272.1.F117; HOSTETLER KY, 1982, P NATL ACAD SCI-BIOL, V79, P1663, DOI 10.1073/pnas.79.5.1663; Hudson RT, 1997, MOL BIOL CELL, V8, P1901, DOI 10.1091/mbc.8.10.1901; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Jones AT, 1997, BIOCHEM BIOPH RES CO, V236, P285, DOI 10.1006/bbrc.1997.6962; JONES AT, 1995, BIOCHEM J, V311, P31, DOI 10.1042/bj3110031; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KISHORE BK, 1990, J PHARMACOL EXP THER, V255, P867; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; Liang JO, 1997, J BIOL CHEM, V272, P4141, DOI 10.1074/jbc.272.7.4141; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; MAYORGA LS, 1993, P NATL ACAD SCI USA, V90, P10255, DOI 10.1073/pnas.90.21.10255; MAYORGA LS, 1989, CELL REGUL, V1, P113, DOI 10.1091/mbc.1.1.113; MIGNEOTLECLERCQ MP, 1995, J TOXICOL ENV HLTH, V44, P263; MINGEOTLECLERCQ MP, 1990, BIOCHEM PHARMACOL, V40, P499, DOI 10.1016/0006-2952(90)90548-Y; MINGEOTLECLERCQ MP, 1988, BIOCHEM PHARMACOL, V37, P591, DOI 10.1016/0006-2952(88)90130-X; MINGEOTLECLERCQ MP, 1990, BIOCHEM PHARMACOL, V40, P489, DOI 10.1016/0006-2952(90)90547-X; MOESTRUP SK, 1995, J CLIN INVEST, V96, P1404, DOI 10.1172/JCI118176; MORITZ A, 1992, J BIOL CHEM, V267, P7207; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; SCHACHT J, 1978, J LIPID RES, V19, P1063; SEAMAN MNJ, 1993, J CELL BIOL, V123, P1093, DOI 10.1083/jcb.123.5.1093; Spiro DJ, 1996, MOL BIOL CELL, V7, P355, DOI 10.1091/mbc.7.3.355; SPIRO DJ, 1995, J BIOL CHEM, V270, P13693, DOI 10.1074/jbc.270.23.13693; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; Tsai SC, 1996, P NATL ACAD SCI USA, V93, P305, DOI 10.1073/pnas.93.1.305; Tuscher O, 1997, FEBS LETT, V419, P271, DOI 10.1016/S0014-5793(97)01471-3; WEINSTEIN L, 1965, PHARM BASIC THERAPEU, P1274; WESSLINGRESNICK M, 1990, J BIOL CHEM, V265, P16751; West MA, 1997, J CELL BIOL, V138, P1239, DOI 10.1083/jcb.138.6.1239; WHATMORE J, 1994, FEBS LETT, V352, P113, DOI 10.1016/0014-5793(94)00930-9; WHITNEY JA, 1995, CELL, V83, P703; WILLIAMS SE, 1986, J ANTIBIOT, V39, P457, DOI 10.7164/antibiotics.39.457; Woscholski R, 1995, J BIOL CHEM, V270, P31001, DOI 10.1074/jbc.270.52.31001	56	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25301	25309		10.1074/jbc.273.39.25301	http://dx.doi.org/10.1074/jbc.273.39.25301			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737996	hybrid			2022-12-27	WOS:000076085400046
J	Stewart, C; Bailey, J; Manoil, C				Stewart, C; Bailey, J; Manoil, C			Mutant membrane protein toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; LACTOSE PERMEASE; LAC PERMEASE; RETINITIS-PIGMENTOSA; TRANSPORT PROTEIN; MUTATIONS; SEQUENCES; STABILITY; TOPOLOGY; RESIDUES	This report describes an extensive mutational analysis of the most carboxyl-terminal membrane-spanning sequence of Escherichia coli lac permease (TM12), In addition to identifying residues important for lactose transport function, the analysis revealed that numerous mutations made lac permease highly toxic to cells. In the most extreme cases, production of such proteins at very low steady-state levels reduced cell viability greater than 10(4)-fold. Both frameshift and missense mutations led to toxicity, with the frameshift mutations having the strongest effects observed. The toxic missense mutations corresponded to changes in TM12 expected to interfere with membrane insertion or folding, such as the introduction of charged residues or prolines in the putative helix, The results suggest that cellular toxicity may be a relatively common consequence of mutations altering integral membrane protein folding. An analogous toxicity might contribute to the pathogenesis of several degenerative diseases caused by mutant membrane proteins, such as retinitis pigmentosa, Charcot-Marie-Tooth syndrome, and Alzheimer's disease.	Univ Washington, Dept Genet, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Manoil, C (corresponding author), Univ Washington, Dept Genet, Box 357360, Seattle, WA 98195 USA.							ALMAGHTHEH M, 1993, HUM MUTAT, V2, P249, DOI 10.1002/humu.1380020403; Bailey J, 1998, J MOL BIOL, V277, P199, DOI 10.1006/jmbi.1998.1627; BLONDELLE SE, 1992, BIOCHEMISTRY-US, V31, P12688, DOI 10.1021/bi00165a020; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; Goswitz VC, 1996, J BIOL CHEM, V271, P21927, DOI 10.1074/jbc.271.36.21927; HARRIS SL, 1994, P NATL ACAD SCI USA, V91, P10531, DOI 10.1073/pnas.91.22.10531; He MM, 1996, BIOCHEMISTRY-US, V35, P12909, DOI 10.1021/bi960876b; HINKLE PC, 1990, BIOCHEMISTRY-US, V29, P10989, DOI 10.1021/bi00501a017; HUMPHRIES P, 1992, SCIENCE, V256, P804, DOI 10.1126/science.1589761; JUNG K, 1995, BIOCHEMISTRY-US, V34, P1030, DOI 10.1021/bi00003a038; KABACK HR, 1996, HDB BIOL PHYSICS TRA, P203; Lee MH, 1997, PROTEIN ENG, V10, P715, DOI 10.1093/protein/10.6.715; LIM WA, 1991, J MOL BIOL, V219, P359, DOI 10.1016/0022-2836(91)90570-V; LOPILATO J, 1986, MOL GEN GENET, V205, P285, DOI 10.1007/BF00430440; Manoil C, 1995, ANNU REV GENET, V29, P131; Manoil C, 1997, J MOL BIOL, V267, P250, DOI 10.1006/jmbi.1996.0881; MCKENNA E, 1992, J BIOL CHEM, V267, P6471; MCKENNA E, 1991, P NATL ACAD SCI USA, V88, P2969, DOI 10.1073/pnas.88.8.2969; Miller JH., 1972, EXPT BACTERIAL GENET; REES DC, 1989, SCIENCE, V245, P510, DOI 10.1126/science.2667138; SABERWAL G, 1994, BBA-REV BIOMEMBRANES, V1197, P109, DOI 10.1016/0304-4157(94)90002-7; SELIGMAN L, 1995, J BACTERIOL, V177, P2315, DOI 10.1128/jb.177.9.2315-2320.1995; SUTER U, 1994, HUM MUTAT, V3, P95, DOI 10.1002/humu.1380030203; van Leeuwen FW, 1998, SCIENCE, V279, P242, DOI 10.1126/science.279.5348.242; Varela MF, 1996, BBA-BIOENERGETICS, V1276, P21, DOI 10.1016/0005-2728(96)00030-8	27	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28078	28084		10.1074/jbc.273.43.28078	http://dx.doi.org/10.1074/jbc.273.43.28078			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774425	hybrid			2022-12-27	WOS:000076549800045
J	Keely, SJ; Uribe, JM; Barrett, KE				Keely, SJ; Uribe, JM; Barrett, KE			Carbachol stimulates transactivation of epidermal growth factor receptor and mitogen-activated protein kinase in T-84 cells - Implications for carbachol-stimulated chloride secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC ACINAR-CELLS; MAP KINASE; COUPLED RECEPTORS; ANGIOTENSIN-II; ION-CHANNEL; CASCADE; CALCIUM; PYK2; INHIBITION; PATHWAYS	We have examined the role of tyrosine phosphorylation in regulation of calcium-dependent chloride secretion across T-84 colonic epithelial cells. The calcium-mediated agonist carbachol (CCh, 100 mu M) stimulated a time dependent increase in tyrosine phosphorylation of a range of proteins (with molecular masses ranging up to 180 kDa) in T-84 cells. The tyrosine kinase inhibitor, genistein (5 mu M), significantly potentiated chloride secretory responses to CCh, indicating a role for CCh-stimulated tyrosine phosphorylation in negative regulation of CCh-stimulated secretory responses. Further studies revealed that CCh stimulated an increase in both phosphorylation and activity of the extracellular signal-regulated kinase (ERK) isoforms of mitogen-activated protein kinase, Chloride secretory responses to CCh were also potentiated by the mitogen-activated protein kinase inhibitor, PD98059 (20 mu M), Phosphorylation of ERK in response to CCh was mimicked by the protein kinase C (PKC) activator, phorbol myristate acetate (100 nM), but was not altered by the PKC inhibitor GF 109203X (1 mu M). ERK phosphorylation was also induced by epidermal growth factor (EGF) (100 ng/ml), Immunoprecipitation/Western blot studies revealed that CCh stimulated tyrosine phosphorylation of the EGF receptor (EGFr) and increased co immunoprecipitation of the adapter proteins, Shc and Grb2, with the EGFr, An inhibitor of EGFr phosphorylation, tyrphostin AG1478 (1 mu M), reversed CCh-stimulated phosphorylation of both EGFr and ERK, Tyrphostin AG1478 also potentiated chloride secretory responses to CCh, We conclude that CCh activates ERK in T-84 cells via a mechanism involving transactivation of the EGFr, and that this pathway constitutes an inhibitory signaling pathway by which chloride secretory responses to CCh may be negatively regulated.	Univ Calif San Diego, Med Ctr, Dept Med, Sch Med, San Diego, CA 92103 USA	University of California System; University of California San Diego	Barrett, KE (corresponding author), Univ Calif San Diego, Med Ctr, Dept Med, Sch Med, 8414,200 W Arbor Dr, San Diego, CA 92103 USA.	kbarrett@ucsd.edu	Barrett, Kim/AAE-2794-2022; Barrett, Kim Elaine/AAE-7762-2019	Barrett, Kim Elaine/0000-0002-6704-998X; Keely, Stephen/0000-0002-6315-3587	NIDDK NIH HHS [DK28305, DK07202] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028305, T32DK007202] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Barrett KE, 1997, AM J PHYSIOL-CELL PH, V272, pC1069, DOI 10.1152/ajpcell.1997.272.4.C1069; BISCHOF G, 1995, AM J PHYSIOL-CELL PH, V268, pC154, DOI 10.1152/ajpcell.1995.268.1.C154; Dabrowski A, 1997, AM J PHYSIOL-CELL PH, V273, pC1472, DOI 10.1152/ajpcell.1997.273.5.C1472; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; DHARMSATHAPHORN K, 1986, J CLIN INVEST, V77, P348, DOI 10.1172/JCI112311; DICKINSON KEJ, 1992, EUR J PHARM-MOLEC PH, V225, P291, DOI 10.1016/0922-4106(92)90102-2; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Gamett DC, 1997, J BIOL CHEM, V272, P12052, DOI 10.1074/jbc.272.18.12052; Gerthoffer WT, 1997, AM J PHYSIOL-LUNG C, V272, pL244, DOI 10.1152/ajplung.1997.272.2.L244; HEASLEY LE, 1994, AM J PHYSIOL, V267, pF366, DOI 10.1152/ajprenal.1994.267.3.F366; Illek B, 1996, AM J PHYSIOL-CELL PH, V270, pC265, DOI 10.1152/ajpcell.1996.270.1.C265; ILLEK B, 1995, AM J PHYSIOL-CELL PH, V268, pC886, DOI 10.1152/ajpcell.1995.268.4.C886; LEHRICH RW, 1995, AM J PHYSIOL-RENAL, V269, pF594, DOI 10.1152/ajprenal.1995.269.4.F594; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; Luttrell L M, 1998, Adv Pharmacol, V42, P466; MANDEL KG, 1986, AM J PHYSIOL, V250, pC486, DOI 10.1152/ajpcell.1986.250.3.C486; MANDEL KG, 1986, J BIOL CHEM, V261, P704; Nakamura K, 1996, AM J PHYSIOL-GASTR L, V271, pG640, DOI 10.1152/ajpgi.1996.271.4.G640; OFFERMANNS S, 1993, BIOCHEM J, V294, P545, DOI 10.1042/bj2940545; OMALLEY KE, 1995, EUR J PHARMACOL, V275, P83, DOI 10.1016/0014-2999(94)00758-Y; Reenstra WW, 1996, AM J PHYSIOL-CELL PH, V271, pC650, DOI 10.1152/ajpcell.1996.271.2.C650; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; SEARS CL, 1995, AM J PHYSIOL, V269, pC874; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sugden PH, 1997, CELL SIGNAL, V9, P337, DOI 10.1016/S0898-6568(96)00191-X; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; Uribe JM, 1996, AM J PHYSIOL-CELL PH, V271, pC914, DOI 10.1152/ajpcell.1996.271.3.C914; Uribe JM, 1996, J BIOL CHEM, V271, P26588, DOI 10.1074/jbc.271.43.26588; VAJANAPHANICH M, 1993, GASTROENTEROLOGY, V104, pA286; VAJANAPHANICH M, 1995, J CLIN INVEST, V96, P386, DOI 10.1172/JCI118046; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; WEYMER A, 1985, J CLIN INVEST, V76, P1828, DOI 10.1172/JCI112175; Wilkie N, 1996, J BIOL CHEM, V271, P32447, DOI 10.1074/jbc.271.50.32447; Yamada T., 1995, GASTROENTEROLOGY, P326; YANG I, 1996, AM J PHYSIOL, V272, pC142; Zou YZ, 1996, J BIOL CHEM, V271, P33592, DOI 10.1074/jbc.271.52.33592	41	149	151	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27111	27117		10.1074/jbc.273.42.27111	http://dx.doi.org/10.1074/jbc.273.42.27111			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765228	hybrid			2022-12-27	WOS:000076448000015
J	Palomino, T; Barettino, D; Aranda, A				Palomino, T; Barettino, D; Aranda, A			Role of GHF-1 in the regulation of the rat growth hormone gene promoter by thyroid hormone and retinoic acid receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSE ELEMENTS; TRANSCRIPTIONAL ACTIVATION; SYNERGISTIC INTERACTIONS; ESTROGEN-RECEPTOR; NUCLEAR RECEPTORS; EXPRESSION; PIT-1; BINDING; DOMAIN; TRANSACTIVATION	In non-pituitary HeLa cells the unliganded thyroid hormone or retinoic acid receptors cause a strong activation of the rat growth hormone promoter that is repressed by their ligands, In contrast, after expression of the pituitary-specific transcription factor GHF-1, thyroid hormone and retinoic acid produce a stimulation similar to that found in pituitary cells. Therefore, GHF-1 changes a ligand-dependent inhibition into a ligand-dependent activation. The essential role of GHF-1 on the rat growth hormone promoter was also demonstrated with AF-2-defective T-3 receptor mutants that show a normal activation of this promoter in the presence of GHF-1. Furthermore, a truncated T-3 receptor, which lacks the N-terminus and the DNA binding domain, was able to stimulate this promoter in the presence of GHF-1 and exogenous RXR receptors, suggesting the importance of protein to protein interactions in this regulation, This study shows that the final transcriptional effect depends not only on the type of regulatory promoter response elements but also on the presence of other transcriptional activators, in the case of the growth hormone promoter, the tissue-specific transcription factor GHF-1, which plays a coactivator-like role in this promoter.	CSIC, Inst Invest Biomed, E-28029 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Aranda, A (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.	aaranda@biomed.iib.uam.es	Aranda, Ana/ABG-8820-2020	Aranda, Ana/0000-0002-8338-9589				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BEDO G, 1989, NATURE, V339, P231, DOI 10.1038/339231a0; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chang W, 1996, J BIOL CHEM, V271, P17733, DOI 10.1074/jbc.271.30.17733; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CRONE DE, 1990, J BIOL CHEM, V265, P10851; DAY RN, 1990, MOL ENDOCRINOL, V4, P1964, DOI 10.1210/mend-4-12-1964; FLUG F, 1987, J BIOL CHEM, V262, P6373; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GarciaVillalba P, 1996, MOL CELL BIOL, V16, P318; GARCIAVILLALBA P, 1993, BIOCHEM BIOPH RES CO, V191, P580, DOI 10.1006/bbrc.1993.1257; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Helmer EB, 1996, ENDOCRINOLOGY, V137, P390, DOI 10.1210/en.137.2.390; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; HOLLENBERG AN, 1995, MOL ENDOCRINOL, V9, P540, DOI 10.1210/me.9.5.540; HOLLOWAY JM, 1995, GENE DEV, V9, P1992, DOI 10.1101/gad.9.16.1992; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KUSHNER PJ, 1994, MOL ENDOCRINOL, V8, P405, DOI 10.1210/me.8.4.405; LIRA SA, 1993, MOL ENDOCRINOL, V7, P694, DOI 10.1210/me.7.5.694; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; ODONNELL AL, 1990, MOL ENDOCRINOL, V4, P715, DOI 10.1210/mend-4-5-715; PALOMINO T, 1998, IN PRESS FASEB J; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; Sanchez-Pacheco A, 1998, FEBS LETT, V422, P103, DOI 10.1016/S0014-5793(97)01609-8; SCHAUFELE F, 1992, MOL ENDOCRINOL, V6, P656, DOI 10.1210/me.6.4.656; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; Tagami T, 1997, MOL CELL BIOL, V17, P2642, DOI 10.1128/MCB.17.5.2642; TATE BF, 1994, MOL CELL BIOL, V14, P2323, DOI 10.1128/MCB.14.4.2323; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; THEILL LE, 1993, ENDOCR REV, V14, P670, DOI 10.1210/er.14.6.670; TomicCanic M, 1996, J BIOL CHEM, V271, P1416, DOI 10.1074/jbc.271.3.1416; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WIGHT PA, 1987, J BIOL CHEM, V262, P5659; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P206; YE ZS, 1988, J BIOL CHEM, V263, P7821	51	31	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27541	27547		10.1074/jbc.273.42.27541	http://dx.doi.org/10.1074/jbc.273.42.27541			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765286	hybrid, Green Published			2022-12-27	WOS:000076448000073
J	Pourquier, P; Bjornsti, MA; Pommier, Y				Pourquier, P; Bjornsti, MA; Pommier, Y			Induction of topoisomerase I cleavage complexes by the vinyl chloride adduct 1,N-6-ethenoadenine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE TYROSINE; METABOLITE CHLOROACETALDEHYDE; DNA CLEAVAGE; CAMPTOTHECIN; CELLS; 1,N-6-ETHENODEOXYADENOSINE; MUTAGENESIS; OXIDATION; INVITRO; GENOME	We used purified mammalian topoisomerases I (top1) and oligonucleotides to study top1-mediated cleavage and religation in the presence of a potent carcinogenic adduct, 1,N-6-ethenoadenosine (EA) incorporated immediately downstream of a unique top1 cleavage site. We found tha epsilon A markedly enhanced top1 cleavage complexes when it was incorporated at the +1 position of the top1 cleavage. This enhancement was due to a reduction of the religation step of the top1 reaction. In addition, epsilon A reduced the top1-mediated cleavage and decreased binding of the enzyme to DNA. We also studied the effects of the epsilon A adduct on top1 trapping by camptothecin (CPT), a web known top1 inhibitor. CPT was inactive when epsilon A was present at the +1 position. Alkylation of the top1 cleavage complex by 7-chloromethyl-10,11-methylenedioxycamptothecin (7-ClMe-MDO-CPT) was also blocked by the epsilon A adduct. Altogether, these results demonstrate that the epsilon A carcinogenic ad duct can efficiently trap human top1 and mimic CPT effects. Normal hydrogen bonding of the base pairs immediately downstream from the top1 cleavage site is probably essential for efficient DNA religation and binding of camptothecins in the top1 cleavage complex.	NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA; Thomas Jefferson Univ, Dept Biochem & Mol Pharmacol, Philadelphia, PA 19107 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Jefferson University	Pommier, Y (corresponding author), NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bldg 37,Rm 5D02, Bethesda, MD 20892 USA.	pommier@nih.gov	Pourquier, Philippe/O-8030-2018	Pourquier, Philippe/0000-0001-5326-3005				BASU AK, 1993, BIOCHEMISTRY-US, V32, P12793, DOI 10.1021/bi00210a031; BASU AK, 1987, BIOCHEMISTRY-US, V26, P5626, DOI 10.1021/bi00392a007; BONVEN BJ, 1985, CELL, V41, P541, DOI 10.1016/S0092-8674(85)80027-1; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; CHEN AY, 1994, ANN REV PHARM TOXICO, V94, P194; Cheng CH, 1998, J BIOL CHEM, V273, P11589, DOI 10.1074/jbc.273.19.11589; Cheng CH, 1997, J BIOL CHEM, V272, P8263, DOI 10.1074/jbc.272.13.8263; CHENG KC, 1991, P NATL ACAD SCI USA, V88, P9974, DOI 10.1073/pnas.88.22.9974; DOSANJH MK, 1994, P NATL ACAD SCI USA, V91, P1024, DOI 10.1073/pnas.91.3.1024; ENG WK, 1989, J BIOL CHEM, V264, P13373; Fan Y, 1998, J MED CHEM, V41, P2216, DOI 10.1021/jm9605445; Ghissassi F. E., 1995, CHEM RES TOXICOL, V8, P278; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P168, DOI 10.1021/tx00020a008; GUENGERICH FP, 1992, CHEM RES TOXICOL, V5, P2, DOI 10.1021/tx00025a001; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; Hang B, 1996, CARCINOGENESIS, V17, P155, DOI 10.1093/carcin/17.1.155; JACOBSEN JS, 1990, BIOCHEMISTRY-US, V29, P496, DOI 10.1021/bi00454a025; Kingma PS, 1997, J BIOL CHEM, V272, P1148, DOI 10.1074/jbc.272.2.1148; Kingma PS, 1997, J BIOL CHEM, V272, P7488, DOI 10.1074/jbc.272.11.7488; Langouet S, 1998, BIOCHEMISTRY-US, V37, P5184, DOI 10.1021/bi972327r; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; NAIR J, 1995, CARCINOGENESIS, V16, P613, DOI 10.1093/carcin/16.3.613; Pandya GA, 1996, BIOCHEMISTRY-US, V35, P11487, DOI 10.1021/bi960170h; PARK KK, 1993, CARCINOGENESIS, V14, P441, DOI 10.1093/carcin/14.3.441; POMMIER Y, 1995, MUTAT RES-DNA REPAIR, V337, P135, DOI 10.1016/0921-8777(95)00019-G; Pommier Y, 1996, SEMIN ONCOL, V23, P3; POMMIER Y, 1995, P NATL ACAD SCI USA, V92, P8861, DOI 10.1073/pnas.92.19.8861; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; Pourquier P, 1997, J BIOL CHEM, V272, P26441, DOI 10.1074/jbc.272.42.26441; Pourquier P, 1997, J BIOL CHEM, V272, P7792, DOI 10.1074/jbc.272.12.7792; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; SINGER B, 1988, CHEM CARCINOGENS ACT, P188; Subramanian D, 1998, CANCER RES, V58, P976; SVEJSTRUP JQ, 1991, J MOL BIOL, V222, P669, DOI 10.1016/0022-2836(91)90503-X; TANIZAWA A, 1995, BIOCHEMISTRY-US, V34, P7200, DOI 10.1021/bi00021a035; Valenti M, 1997, MOL PHARMACOL, V52, P82, DOI 10.1124/mol.52.1.82; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; YEH YC, 1994, J BIOL CHEM, V269, P15498; ZHELKOVSKY AM, 1994, PROTEIN EXPRES PURIF, V5, P364, DOI 10.1006/prep.1994.1053	39	35	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27245	27249		10.1074/jbc.273.42.27245	http://dx.doi.org/10.1074/jbc.273.42.27245			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765247	Green Published, hybrid			2022-12-27	WOS:000076448000034
J	Suen, CS; Berrodin, TJ; Mastroeni, R; Cheskis, BJ; Lyttle, CR; Frail, DE				Suen, CS; Berrodin, TJ; Mastroeni, R; Cheskis, BJ; Lyttle, CR; Frail, DE			A transcriptional coactivator, steroid receptor coactivator-3, selectively augments steroid receptor transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; HUMAN ESTROGEN-RECEPTOR; NUCLEAR-RECEPTOR; FACTOR TFIIB; CONSERVED REGION; BINDING PROTEIN; CO-REPRESSOR; ACTIVATION; SUPERFAMILY; COMPLEX	Estrogen receptors ER alpha and ER beta are members of the family of nuclear hormone receptors and act as ligand-inducible transcriptional factors, which regulate the expression of target genes on binding to cognate response elements. We report here the characterization of steroid receptor coactivator-3 (SRC-3), a coactivator of nuclear receptor transcription that is a member of a family of steroid receptor coactivators that includes SRC-1 and transcription intermediate factor-2, SRC-3 enhanced ER alpha and progesterone receptor-stimulated gene transcription in a ligand dependent manner, but stimulation of ER beta-mediated transcription was not observed. Protein-protein interaction assays, including real-time interaction analyses with BIAcore, demonstrated that the affinity of the ERa interaction with SRC-3 was much higher than that observed for the ERP interaction with SRC-S. Mutational analysis suggests a potential interplay between the transactivation function-1 and -2 do mains of ER alpha and SRC-3, Furthermore, an intrinsic transactivation function was observed in the C-terminal half of SRC-3. Finally, SRC-3 was differentially expressed in various tissues and, among several tumor cells examined, was most abundant in the nuclear fraction of MCF-7 breast cancer cells. Therefore, SRC-S, a third member of a family of steroid receptor coactivators, has a distinct tissue distribution and intriguing selectivity between ER alpha and ER beta.	Wyeth Ayerst Res, Womens Hlth Res Inst, Radnor, PA 19087 USA	Pfizer	Frail, DE (corresponding author), Wyeth Ayerst Res, Womens Hlth Res Inst, 145 King Of Prussia Rd,R-4, Radnor, PA 19087 USA.	Fraild@WAR.wyeth.com						Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BLANCO JCG, 1995, P NATL ACAD SCI USA, V92, P1535, DOI 10.1073/pnas.92.5.1535; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Cheskis BJ, 1997, J BIOL CHEM, V272, P11384; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; HADZIC E, 1995, MOL CELL BIOL, V15, P4507; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; ING NH, 1992, J BIOL CHEM, V267, P17617; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; McInerney EM, 1996, P NATL ACAD SCI USA, V93, P10069, DOI 10.1073/pnas.93.19.10069; Mengus G, 1997, GENE DEV, V11, P1381, DOI 10.1101/gad.11.11.1381; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Norris JD, 1998, J BIOL CHEM, V273, P6679, DOI 10.1074/jbc.273.12.6679; ONATE SA, 1995, SCIENCE, V270, P1354; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; SCHWERK C, 1995, J BIOL CHEM, V270, P21331, DOI 10.1074/jbc.270.36.21331; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; SUEN CS, 1993, MOL CELL BIOL, V13, P1719, DOI 10.1128/MCB.13.3.1719; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517	44	202	206	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27645	27653		10.1074/jbc.273.42.27645	http://dx.doi.org/10.1074/jbc.273.42.27645			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765300	hybrid			2022-12-27	WOS:000076448000087
J	Kadrmas, JL; Allaway, D; Studholme, RE; Sullivan, JT; Ronson, CW; Poole, PS; Raetz, CRH				Kadrmas, JL; Allaway, D; Studholme, RE; Sullivan, JT; Ronson, CW; Poole, PS; Raetz, CRH			Cloning and overexpression of glycosyltransferases that generate the lipopolysaccharide core of Rhizobium leguminosarum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DEOXY-D-MANNO-OCTULOSONIC ACID TRANSFERASE; ESCHERICHIA-COLI K-12; ACYL CARRIER PROTEIN; T7 RNA-POLYMERASE; LIPID-A; SALMONELLA-TYPHIMURIUM; OUTER MEMBRANE; CLONED GENES; BIOSYNTHESIS; MUTANTS	The lipopolysaccharide (LPS) core of the Gram-negative bacterium Rhizobium leguminosarum is more amenable to enzymatic study than that of Escherichia coli because much of it is synthesized from readily available sugar nucleotides. The inner portion of the R. leguminosarum core contains mannose, galactose, and three 3-deoxy-D-manno-octulosonate (Kdo) residues, arranged in the order: lipid A-(Kdo)(2)-Man-Gal-Kdo-[O antigen], A mannosyltransferase. ase that uses GDP-mannose and the conserved precursor Kdo(2)-[4'-P-32]lipid IVA (Kadrmas, J. L., Brozek, H. A., and Raetz, C. R. H. (1996) J. Biol. Chem. 271, 32119-32125) is proposed to represent a key early enzyme in R. leguminosarum core assembly, Conditions for demonstrating efficient galactosyl- and distal Kdo-transferase activities are now described using a coupled assay system that starts with GDP-mannose and Kdo(2)-[4'-P-32]lipid IVA. As predicted, mannose incorporation precedes galactose addition, which in turn precedes distal Kdo transfer, LPS core mutants with Tn5 insertions in the genes encoding the putative galactosyltransferase (lpcA) and the distal Kdo-transferase (lpcB) are shown to be defective in the corresponding in vitro glycosylation of Kdo(2)-[4'-P-32]lipid IVA. We have also discovered the new gene (lpcC) that encodes the mannosyltransferase, The gene is separated by several kilobase pairs from the lpcAB cluster, All three glycosyltransferases are carried on cosmid pIJ1848, which contains at least 20 kilobase pairs of R. leguminosarum DNA, Transfer of pIJ1848 into R. meliloti 1021 results in heterologous expression of all three enzymes, which are not normally present in strain 1021, Expression of the lpc genes individually behind the T7 promoter results in the production of each R. leguminosarum glycosyltransferase in E. coli membranes in a catalytically active form, demonstrating that lpcA, lpcB, and lpcC are structural genes.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Univ Otago, Dept Microbiol, Dunedin, New Zealand; Univ Reading, Sch Anim & Microbiol Sci, Div Microbiol, Whiteknights, England	Duke University; University of Otago; University of Reading	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raetz@biochem.duke.edu		Allaway, David/0000-0003-4602-8933; sullivan, john/0000-0001-7716-4159; Ronson, Clive/0000-0002-2217-9676	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM051796, R01GM051796] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-51796, 5T32GM017105] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allaway D, 1996, J BACTERIOL, V178, P6403, DOI 10.1128/jb.178.21.6403-6406.1996; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AMES GF, 1974, J BACTERIOL, V117, P406, DOI 10.1128/JB.117.2.406-416.1974; ANTELMANN H, 1995, J BACTERIOL, V177, P3540, DOI 10.1128/jb.177.12.3540-3545.1995; Ausubel FM, 1988, MOL REPROD DEV; BELUNIS CJ, 1992, J BIOL CHEM, V267, P18702; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; BHAT UR, 1991, CARBOHYD RES, V220, P219, DOI 10.1016/0008-6215(91)80020-N; BREWIN NJ, 1982, J GEN MICROBIOL, V128, P1817; Brozek KA, 1996, J BIOL CHEM, V271, P32112, DOI 10.1074/jbc.271.50.32119; Brozek KA, 1996, J BIOL CHEM, V271, P32126, DOI 10.1074/jbc.271.50.32119; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; BROZEK KA, 1990, J BIOL CHEM, V265, P15410; CARLSON RW, 1995, J BIOL CHEM, V270, P11783, DOI 10.1074/jbc.270.20.11783; CAVA JR, 1990, MOL GEN GENET, V221, P125, DOI 10.1007/BF00280377; CAVA JR, 1989, J BACTERIOL, V171, P8, DOI 10.1128/jb.171.1.8-15.1989; CLEMENTZ T, 1991, J BIOL CHEM, V266, P9687; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; DENARIE J, 1993, CELL, V74, P951, DOI 10.1016/0092-8674(93)90717-5; FINAN TM, 1986, J BACTERIOL, V167, P66, DOI 10.1128/jb.167.1.66-72.1986; FISHER RF, 1992, NATURE, V357, P655, DOI 10.1038/357655a0; Forsberg LS, 1998, J BIOL CHEM, V273, P2747, DOI 10.1074/jbc.273.5.2747; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; GLAZEBROOK J, 1991, METHOD ENZYMOL, V204, P398; GOTSCHLICH EC, 1994, J EXP MED, V180, P2181, DOI 10.1084/jem.180.6.2181; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; JOHNSTON AWB, 1975, J GEN MICROBIOL, V87, P343, DOI 10.1099/00221287-87-2-343; Kadrmas JL, 1996, J BIOL CHEM, V271, P32119, DOI 10.1074/jbc.271.50.32112; Kadrmas JL, 1998, J BIOL CHEM, V273, P2799, DOI 10.1074/jbc.273.5.2799; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; KOPLOW J, 1974, J BACTERIOL, V117, P527, DOI 10.1128/JB.117.2.527-543.1974; LAIRD MW, 1994, J BACTERIOL, V176, P2259, DOI 10.1128/JB.176.8.2259-2264.1994; LONG SR, 1993, CELL, V73, P921, DOI 10.1016/0092-8674(93)90271-Q; MARSH JL, 1984, GENE, V32, P481, DOI 10.1016/0378-1119(84)90022-2; Miller J.H., 1972, EXPT MOL GENETICS; MORRISON DC, 1992, BACTERIAL ENDOTOXIC, V1; NIKAIDO H, 1987, ESCHERICHIA COLI SAL, V1, P7; PEROTTO S, 1994, MOL PLANT MICROBE IN, V7, P99, DOI 10.1094/MPMI-7-0099; POCLE PS, 1994, MICROBIOLOGY, V140, P2797; PRICE NPJ, 1995, P NATL ACAD SCI USA, V92, P7352, DOI 10.1073/pnas.92.16.7352; PRICE NPJ, 1994, J BACTERIOL, V176, P4646, DOI 10.1128/JB.176.15.4646-4655.1994; PRIEFER UB, 1989, J BACTERIOL, V171, P6161, DOI 10.1128/jb.171.11.6161-6168.1989; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RICK PD, 1987, ESCHERICHIA COLI SAL, V1, P648; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; RONCERO C, 1992, J BACTERIOL, V174, P3250, DOI 10.1128/jb.174.10.3250-3260.1992; RONSON CW, 1984, J BACTERIOL, V160, P903, DOI 10.1128/JB.160.3.903-909.1984; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; SIRISENA DM, 1992, J BIOL CHEM, V267, P18874; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; White KA, 1997, J BIOL CHEM, V272, P16555, DOI 10.1074/jbc.272.26.16555; WOOD WB, 1966, J MOL BIOL, V16, P118, DOI 10.1016/S0022-2836(66)80267-X; ZHANG Y, 1992, CARBOHYD RES, V231, P261, DOI 10.1016/0008-6215(92)84024-M	56	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26432	26440		10.1074/jbc.273.41.26432	http://dx.doi.org/10.1074/jbc.273.41.26432			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756877	hybrid, Green Submitted			2022-12-27	WOS:000076373300031
J	Kampranis, SC; Maxwell, A				Kampranis, SC; Maxwell, A			Hydrolysis of ATP at only one GyrB subunit is sufficient to promote supercoiling by DNA gyrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL FRAGMENT; B-PROTEIN; NUCLEOTIDE-BINDING; BASE-PAIRS	Mutation of Glu(42) to Ala in the B subunit of DNA gyrase abolishes ATP hydrolysis but not nucleotide binding. Gyrase complexes that contain one wild-type and one Ala(42) mutant B protein were formed, and the ability of such complexes to hydrolyze ATP was investigated. We found that ATP hydrolysis was able to proceed independently only in the wild-type subunit, albeit at a lower rate. With only one ATP molecule hydrolyzed at a time, gyrase could still perform supercoiling, but the limit of this reaction was lower than that observed when both subunits can hydrolyze the nucleotide.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Leicester	Maxwell, A (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.	ony@le.ac.uk	Kampranis, Sotirios C/G-8374-2016	Kampranis, Sotirios C/0000-0001-6208-1684; Maxwell, Anthony/0000-0002-5756-6430				ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; ALI JA, 1995, BIOCHEMISTRY-US, V34, P9801, DOI 10.1021/bi00030a018; BATES AD, 1989, EMBO J, V8, P1861, DOI 10.1002/j.1460-2075.1989.tb03582.x; CULLIS PM, 1992, BIOCHEMISTRY-US, V31, P9642, DOI 10.1021/bi00155a017; Hammonds TR, 1997, J BIOL CHEM, V272, P32696, DOI 10.1074/jbc.272.51.32696; JACKSON AP, 1993, P NATL ACAD SCI USA, V90, P11232, DOI 10.1073/pnas.90.23.11232; Kampranis SC, 1996, P NATL ACAD SCI USA, V93, P14416, DOI 10.1073/pnas.93.25.14416; Kampranis SC, 1998, J BIOL CHEM, V273, P22615, DOI 10.1074/jbc.273.35.22615; Kampranis SC, 1998, J BIOL CHEM, V273, P22606, DOI 10.1074/jbc.273.35.22606; KIRCHHAUSEN T, 1985, CELL, V41, P933, DOI 10.1016/S0092-8674(85)80074-X; KLEVAN L, 1980, BIOCHEMISTRY-US, V19, P5229, DOI 10.1021/bi00564a012; LINDSLEY JE, 1993, NATURE, V361, P749, DOI 10.1038/361749a0; LIU LF, 1978, P NATL ACAD SCI USA, V75, P2098, DOI 10.1073/pnas.75.5.2098; MAXWELL A, 1984, J BIOL CHEM, V259, P4472; MAXWELL A, 1999, PROTOCOLS DNA TOPOIS, V1, P135; MAXWELL A, 1986, 4TH P CONV BIOM STER, V3, P137; ODea MH, 1996, J BIOL CHEM, V271, P9723, DOI 10.1074/jbc.271.16.9723; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; TAMURA JK, 1992, J BIOL CHEM, V267, P9214; WESTERHOFF HV, 1988, CELL BIOPHYS, V12, P157, DOI 10.1007/BF02918357; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0	21	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26305	26309		10.1074/jbc.273.41.26305	http://dx.doi.org/10.1074/jbc.273.41.26305			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756859	hybrid			2022-12-27	WOS:000076373300013
J	Sarmiento, M; Zhao, Y; Gordon, SJ; Zhang, ZY				Sarmiento, M; Zhao, Y; Gordon, SJ; Zhang, ZY			Molecular basis for substrate specificity of protein-tyrosine phosphatase 1B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; TRANSITION-STATE; KINETIC-ANALYSIS; FOCAL ADHESIONS; YERSINIA; P130(CAS); IDENTIFICATION; PURIFICATION; PEPTIDES; PHOSPHORYLATION	Protein-tyrosine phosphatases can exhibit stringent substrate specificity in vivo, although the molecular basis for this is not well understood. The three-dimensional structure of the catalytically inactive protein-tyrosine phosphate 1B (PTP1B)/C215S complexed with an optimal substrate, DADEpYL-NH2, reveals specific interactions between amino acid residues in the substrate and PTP1B. The goal of this work is to rigorously evaluate the functional significance of Tyr(46), Arg(47), Asp(48) Phe(182), and Gln(262) in substrate binding and catalysis, using site-directed mutagenesis. Combined with structural information, kinetic analysis of the wild type and mutant PTP1B using p-nitrophenyl phosphate and phosphotyrosine-containing peptides has yielded further insight into PTP1B residues, which recognize general features, as well, as specific properties, in peptide substrates, In addition, the kinetic results suggest roles of these residues in E-P hydrolysis, which are not obvious from the structure of PTP1B/peptide complex. Thus, Tyr(46) and Asp(48) recognize common features of peptide substrates and are important for peptide substrate binding and/or E-P formation. Arg47 acts as a determinant of substrate specificity and is responsible for the modest preference of PTP1B for acidic residues NH2-terminal to phosphotyrosine, Phe(182) and the invariant Gln2G2 are not only important for substrate binding and/or E-P formation but also important for the E-P hydrolysis step.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Zhang, ZY (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NCI NIH HHS [CA69202] Funding Source: Medline; NIGMS NIH HHS [5T32 GM07491-21, 5T32 GM07260-22] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007260, T32GM007491] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; CHO HJ, 1993, PROTEIN SCI, V2, P977, DOI 10.1002/pro.5560020611; CHO HJ, 1991, BIOCHEMISTRY-US, V30, P6210, DOI 10.1021/bi00239a019; DECHERT U, 1995, EUR J BIOCHEM, V231, P673, DOI 10.1111/j.1432-1033.1995.0673d.x; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; HENGGE AC, 1995, BIOCHEMISTRY-US, V34, P13982, DOI 10.1021/bi00043a003; HIPPEN KL, 1993, BIOCHEMISTRY-US, V32, P12405, DOI 10.1021/bi00097a019; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Juszczak LJ, 1997, BIOCHEMISTRY-US, V36, P2227, DOI 10.1021/bi9622130; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; PALLEN CJ, 1991, BIOCHEM J, V276, P315, DOI 10.1042/bj2760315; Pannifer ADB, 1998, J BIOL CHEM, V273, P10454, DOI 10.1074/jbc.273.17.10454; Persson C, 1997, EMBO J, V16, P2307, DOI 10.1093/emboj/16.9.2307; Puius YA, 1997, P NATL ACAD SCI USA, V94, P13420, DOI 10.1073/pnas.94.25.13420; RUZZENE M, 1993, EUR J BIOCHEM, V211, P289, DOI 10.1111/j.1432-1033.1993.tb19897.x; SCHUBERT HL, 1995, PROTEIN SCI, V4, P1904, DOI 10.1002/pro.5560040924; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; Wu L, 1997, J BIOL CHEM, V272, P6994, DOI 10.1074/jbc.272.11.6994; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328; Zhang M, 1997, BIOCHEMISTRY-US, V36, P15, DOI 10.1021/bi961804n; ZHANG ZY, 1992, J BIOL CHEM, V267, P23759; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040; ZHANG ZY, 1993, ANAL BIOCHEM, V211, P7, DOI 10.1006/abio.1993.1224; ZHANG ZY, 1995, J BIOL CHEM, V270, P11199, DOI 10.1074/jbc.270.19.11199; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; ZHANG ZY, 1991, J BIOL CHEM, V266, P1516; Zhao Y, 1998, J BIOL CHEM, V273, P5484, DOI 10.1074/jbc.273.10.5484	33	96	98	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26368	26374		10.1074/jbc.273.41.26368	http://dx.doi.org/10.1074/jbc.273.41.26368			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756867	hybrid			2022-12-27	WOS:000076373300021
J	Thiel, G; Lietz, M; Cramer, M				Thiel, G; Lietz, M; Cramer, M			Biological activity and modular structure of RE-1-silencing transcription factor (REST), a repressor of neuronal genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR GENE; RESTRICTIVE SILENCER ELEMENT; CELL-ADHESION MOLECULE; SYNAPSIN-I; MAMMALIAN-CELLS; EXPRESSION; PROMOTER; ENHANCER; DOMAINS; ACTIVATION	The zinc finger protein RE-1-silencing transcription factor (REST)(1) is a transcriptional repressor that represses neuronal genes in nonneuronal tissues. Transfection experiments of neuroblastoma cells using a REST expression vector revealed that synapsin I promoter activity is controlled by REST. The biological activity of REST was further investigated using a battery of model promoters containing strong promoters/enhancers and REST binding sites. REST functioned as a transcriptional repressor when REST binding motifs derived from the genes encoding synapsin I, SCG10, alpha(1)-glycine receptor, the beta 2-subunit of the neuronal nicotinic acetylcholine receptor, and the m4-subunit of the muscarinic acetylcholine receptor were present in the promoter region. No differences in the biological activity of these REST binding motifs tested were detected. Moreover, we found that REST functioned very effectively as a transcriptional repressor at a distance. Thus, REST represents a general transcriptional repressor that blocks transcription regardless of the location or orientation of its binding site relative to the enhancer and promoter. This biological activity could also be attributed to isolated domains of REST. Both repressor domains identified at the N and C termini of REST were transferable to a heterologous DNA binding domain and functioned from proximal and distal positions, similar to the REST protein.	Univ Saarland, Sch Med, D-66421 Homburg, Germany; Univ Cologne, Inst Genet, D-50674 Cologne, Germany	Saarland University; University of Cologne	Thiel, G (corresponding author), Univ Saarland, Sch Med, Bldg 44, D-66421 Homburg, Germany.	bcgthi@med-rz.uni-sb.de						BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BARTSCH D, 1995, CELL, V83, P979, DOI 10.1016/0092-8674(95)90213-9; BLESSIS A, 1997, P NATL ACAD SCI USA, V94, P5906; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Cibelli G, 1996, EUR J BIOCHEM, V237, P311, DOI 10.1111/j.1432-1033.1996.0311n.x; Cibelli G, 1996, EUR J BIOCHEM, V236, P171, DOI 10.1111/j.1432-1033.1996.00171.x; DENERIS ES, 1988, NEURON, V1, P45, DOI 10.1016/0896-6273(88)90208-5; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GRENNINGLOH G, 1990, EMBO J, V9, P771, DOI 10.1002/j.1460-2075.1990.tb08172.x; Harlow E., 1988, ANTIBODIES LAB MANUA; JONES KA, 1985, NATURE, V317, P179, DOI 10.1038/317179a0; KALLUNKI P, 1995, J BIOL CHEM, V270, P21291, DOI 10.1074/jbc.270.36.21291; Kallunki P, 1997, J CELL BIOL, V138, P1343, DOI 10.1083/jcb.138.6.1343; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LIN AY, 1996, MOL CELL BIOL, V6, P1235; Lonnerberg P, 1996, J BIOL CHEM, V271, P33358, DOI 10.1074/jbc.271.52.33358; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; Mieda M, 1996, J BIOL CHEM, V271, P5177; Mieda M, 1997, J BIOL CHEM, V272, P5854, DOI 10.1074/jbc.272.9.5854; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; Palm K, 1998, J NEUROSCI, V18, P1280; RESENDEZ E, 1985, MOL CELL BIOL, V5, P1212, DOI 10.1128/MCB.5.6.1212; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; Schoch S, 1996, J BIOL CHEM, V271, P3317, DOI 10.1074/jbc.271.6.3317; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; Scholl T, 1996, J IMMUNOL, V156, P1448; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; TapiaRamirez J, 1997, P NATL ACAD SCI USA, V94, P1177, DOI 10.1073/pnas.94.4.1177; THIEL G, 1994, J BIOL CHEM, V269, P15294; THIEL G, 1991, P NATL ACAD SCI USA, V88, P3431, DOI 10.1073/pnas.88.8.3431; Thiel G, 1996, GENE, V168, P173, DOI 10.1016/0378-1119(95)00739-3; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; Wood IC, 1996, J BIOL CHEM, V271, P14221, DOI 10.1074/jbc.271.24.14221	35	81	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26891	26899		10.1074/jbc.273.41.26891	http://dx.doi.org/10.1074/jbc.273.41.26891			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756936	hybrid			2022-12-27	WOS:000076373300090
J	Krainc, D; Bai, G; Okamoto, S; Carles, M; Kusiak, JW; Brent, RN; Lipton, SA				Krainc, D; Bai, G; Okamoto, S; Carles, M; Kusiak, JW; Brent, RN; Lipton, SA			Synergistic activation of the N-methyl-D-aspartate receptor subunit 1 promoter by myocyte enhancer factor 2C and Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UPSTREAM REGULATORY ELEMENTS; NEURON-SPECIFIC EXPRESSION; TRANSCRIPTION FACTOR SP1; SODIUM-CHANNEL GENE; NMDA RECEPTOR; DNA-BINDING; RAT-BRAIN; EMBRYONIC-DEVELOPMENT; CORTICAL-NEURONS; NERVOUS-SYSTEM	The N-methyl-D-aspartate (NMDA) subtype of glutamate receptor plays important roles in neuronal development, plasticity, and cell death. NMDA receptor subunit 1 (NR1) is an essential subunit of the NMDA receptor and is developmentally expressed in postnatal neurons of the central nervous system. Here we identify on the NR1 promoter a binding site for myocyte enhancer factor 2C (MEF2C), a developmentally expressed neuron/muscle transcription factor found in cerebrocortical neurons, and study its regulation of the NR1 gene. Co-expression of MEF2C and Sp1 cDNAs in primary neurons or cell lines synergistically activates the NR1 promoter. Disruption of the MEF2 site or the MEF2C DNA binding domain moderately reduces this synergism. Mutation of the Sp1 sites or the activation domains of Sp1 protein strongly reduces the synergism. Results of yeast two-hybrid and co-immunoprecipitation experiments reveal a physical interaction between MEF2C and Sp1 proteins. The MEF2C DNA binding domain is sufficient for this interaction. Dominant-negative MEF2C interferes with expression of NR1 mRNA in neuronally differentiated P19 cells. Growth factors, including epidermal growth factor and basic fibroblast growth factor, can up-regulate NR1 promoter activity in stably transfected PC12 cells, even in the absence of the MEF2 site, but the Sp1 sites are necessary for this growth factor regulation, suggesting that Spl sites may mediate these effects.	Brigham & Womens Hosp, CNS Res Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA; NIA, Mol Neurobiol Unit, Gerontol Res Ctr, NIH, Baltimore, MD 21224 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Lipton, SA (corresponding author), Brigham & Womens Hosp, CNS Res Inst, 221 Longwood Ave,LMRC 1st Floor, Boston, MA 02115 USA.		Carles, Michel/CAH-0065-2022	Lipton, Stuart/0000-0002-3490-1259	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD029587] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY006087, R01EY005477] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY06087, R01 EY05477] Funding Source: Medline; NICHD NIH HHS [P01 HD29587] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AIYAR A, 1993, BIOTECHNIQUES, V14, P366; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Bai G, 1997, J BIOL CHEM, V272, P5936, DOI 10.1074/jbc.272.9.5936; Bai G, 1998, J BIOL CHEM, V273, P1086, DOI 10.1074/jbc.273.2.1086; BAI G, 1995, J BIOL CHEM, V270, P7737, DOI 10.1074/jbc.270.13.7737; BAI G, 1993, BIOCHIM BIOPHYS ACTA, V1152, P197, DOI 10.1016/0005-2736(93)90249-Y; BEAUDET L, 1992, GENE, V116, P205, DOI 10.1016/0378-1119(92)90517-S; Black BL, 1996, J BIOL CHEM, V271, P26659, DOI 10.1074/jbc.271.43.26659; BOECKMAN FA, 1996, NEURAL NOTES, V11, P13; CARCAMO J, 1989, J BIOL CHEM, V264, P7704; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; CHIN LS, 1994, J BIOL CHEM, V269, P18507; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DICHTER MA, 1978, BRAIN RES, V149, P279, DOI 10.1016/0006-8993(78)90476-6; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; FORREST D, 1994, NEURON, V13, P325, DOI 10.1016/0896-6273(94)90350-6; GRAY S, 1994, GENE DEV, V8, P1829, DOI 10.1101/gad.8.15.1829; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HOCHSCHILD A, 1988, NATURE, V336, P353, DOI 10.1038/336353a0; HORLICK RA, 1990, MOL CELL BIOL, V10, P4826, DOI 10.1128/MCB.10.9.4826; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LAURIE DJ, 1994, J NEUROSCI, V14, P3180; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LEI SZ, 1992, NEURON, V8, P1087, DOI 10.1016/0896-6273(92)90130-6; LEIBHAM D, 1994, MOL CELL BIOL, V14, P686, DOI 10.1128/MCB.14.1.686; LEIFER D, 1994, NEUROSCIENCE, V63, P1067, DOI 10.1016/0306-4522(94)90573-8; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; LI YQ, 1994, CELL, V76, P427, DOI 10.1016/0092-8674(94)90108-2; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MORLEY P, 1995, J NEUROCHEM, V65, P1093; MOTEJLEK K, 1994, J BIOL CHEM, V269, P15265; NEMER M, 1993, P NATL ACAD SCI USA, V90, P10851, DOI 10.1073/pnas.90.22.10851; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; RAY WJ, 1993, BIOCHEM BIOPH RES CO, V197, P1475, DOI 10.1006/bbrc.1993.2643; SATO T, 1995, J BIOL CHEM, V270, P10314, DOI 10.1074/jbc.270.17.10314; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; SHORE D, 1983, J MOL BIOL, V170, P957, DOI 10.1016/S0022-2836(83)80198-3; SHORE D, 1981, P NATL ACAD SCI-BIOL, V78, P4833, DOI 10.1073/pnas.78.8.4833; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; SMALL S, 1992, EMBO J, V11, P4047, DOI 10.1002/j.1460-2075.1992.tb05498.x; STANDAERT DG, 1994, J COMP NEUROL, V343, P1, DOI 10.1002/cne.903430102; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WAHLESTEDT C, 1993, NATURE, V363, P260, DOI 10.1038/363260a0; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHONG J, 1995, J NEUROCHEM, V64, P531	71	77	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26218	26224		10.1074/jbc.273.40.26218	http://dx.doi.org/10.1074/jbc.273.40.26218			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748305	hybrid			2022-12-27	WOS:000076263100096
J	Lum, L; Reid, MS; Blobel, CP				Lum, L; Reid, MS; Blobel, CP			Intracellular maturation of the mouse metalloprotease disintegrin MDC15	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; SPERM-EGG FUSION; SUBTILISIN-LIKE ENDOPROTEASE; PLASMA-MEMBRANE; POTENTIAL ROLE; BREFELDIN-A; CYSTEINE SWITCH; SURFACE PROTEIN; CELL-ADHESION; ADAM FAMILY	Metalloprotease disintegrins are a family of membrane-anchored glycoproteins that play a role in fertilization, myoblast fusion, neuronal development, and cleavage of the membrane-anchored cytokine tumor necrosis factor-cu. Here, we report the cloning and cDNA sequencing of the mouse metalloprotease disintegrin MDC15 and an analysis of its processing in the secretory pathway. A notable difference between mMDC15 and its putative human orthologue (hMDC15, metargidin) is the presence of the peptide sequence TDDC instead of the RGDC found in the disintegrin domain of hMDC15. In a Western blot analysis the majority of mMDC15 was found to lack the pro-domain in all mouse tissues examined. Pulse-chase experiments in transiently transfected COS-7 cells suggest that mMDC15 is processed by a pro-protein convertase in a late Golgi compartment, since (i) addition of brefeldin A or monensin blocks prodomain removal, (ii) all detectable processed mMDC15 is endoglycosidase H -resistant, and (iii) a recombinant soluble form of the trans-Golgi network pro-protein convertase furin can mimic mMDC15 processing in vitro. Cell-surface trypsinization revealed that more than half of mature mMDC15 is intracellular. Immunolocalization provided evidence for a strong perinuclear accumulation in a region resembling the trans-Golgi network and/or endosomal compartments. This study provides the first characterization of the intracellular processing of a metalloprotease disintegrin, and highlights the potential role of pro-protein convertases in removal of the inhibitory pro-domain. These results further suggest possible intracellular functions for mMDC15, such as in protein maturation, in addition to a potential role in cell-surface proteolysis or cell adhesion.	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Cellular Biochem & Biophys Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Blobel, CP (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Cellular Biochem & Biophys Program, Box 368,1275 York Ave, New York, NY 10021 USA.				NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007739] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-08748] Funding Source: Medline; NIGMS NIH HHS [5T32GM07739-17] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Blobel Carl P., 1992, Current Opinion in Cell Biology, V4, P760; BLOBEL CP, 1990, J CELL BIOL, V111, P69, DOI 10.1083/jcb.111.1.69; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Bradbury FA, 1997, J BIOL CHEM, V272, P5921, DOI 10.1074/jbc.272.9.5921; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; Decroly E, 1997, FEBS LETT, V405, P68, DOI 10.1016/S0014-5793(97)00156-7; DUBOIS CM, 1995, J BIOL CHEM, V270, P10618, DOI 10.1074/jbc.270.18.10618; Evans JP, 1997, DEV BIOL, V187, P94, DOI 10.1006/dbio.1997.8612; Evans JP, 1997, DEV BIOL, V187, P79, DOI 10.1006/dbio.1997.8611; EVANS JP, 1995, J CELL SCI, V108, P3267; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; Furuta M, 1997, P NATL ACAD SCI USA, V94, P6646, DOI 10.1073/pnas.94.13.6646; GARTEN W, 1994, BIOCHIMIE, V76, P217, DOI 10.1016/0300-9084(94)90149-X; GRAMS F, 1993, FEBS LETT, V335, P76, DOI 10.1016/0014-5793(93)80443-X; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; Inoue D, 1998, J BIOL CHEM, V273, P4180, DOI 10.1074/jbc.273.7.4180; Kratzschmar J, 1996, J BIOL CHEM, V271, P4593; Lehmann M, 1996, BIOCHEM J, V317, P803, DOI 10.1042/bj3170803; Linder B, 1997, DEV GROWTH DIFFER, V39, P243; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Lum L, 1997, DEV BIOL, V191, P131, DOI 10.1006/dbio.1997.8609; Mbikay M, 1997, P NATL ACAD SCI USA, V94, P6842, DOI 10.1073/pnas.94.13.6842; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MYLES DG, 1994, P NATL ACAD SCI USA, V91, P4195, DOI 10.1073/pnas.91.10.4195; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; PATEL YC, 1995, CIBA F SYMP, V190, P26; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; PRIMAKOFF P, 1987, J CELL BIOL, V104, P141, DOI 10.1083/jcb.104.1.141; Rosendahl MS, 1997, J BIOL CHEM, V272, P24588, DOI 10.1074/jbc.272.39.24588; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; Shilling FM, 1997, DEV BIOL, V186, P155, DOI 10.1006/dbio.1997.8586; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WESKAMP G, 1994, P NATL ACAD SCI USA, V91, P2748, DOI 10.1073/pnas.91.7.2748; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; Yuan RY, 1997, J CELL BIOL, V137, P105, DOI 10.1083/jcb.137.1.105; Zhang XP, 1998, J BIOL CHEM, V273, P7345, DOI 10.1074/jbc.273.13.7345	52	135	140	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26236	26247		10.1074/jbc.273.40.26236	http://dx.doi.org/10.1074/jbc.273.40.26236			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748307	hybrid			2022-12-27	WOS:000076263100098
J	Villard, E; Alonso, A; Agrapart, M; Challah, M; Soubrier, F				Villard, E; Alonso, A; Agrapart, M; Challah, M; Soubrier, F			Induction of angiotensin I-converting enzyme transcription by a protein kinase C-dependent mechanism in human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; FIBROBLAST GROWTH-FACTOR; MESSENGER-RNA STABILITY; INTERCELLULAR-ADHESION MOLECULE-1; PHORBOL-MYRISTATE ACETATE; VASCULAR SMOOTH-MUSCLE; GENE-EXPRESSION; PROTEOLYTIC RELEASE; DIABETES-MELLITUS; ALPHA	Angiotensin I-converting enzyme (ACE) has been implicated in various cardiovascular diseases; however, little is known about the ACE gene regulation in endothelial cells. We have investigated the effect of the protein kinase C activator phorbol 12-myristate 13-acetate (PMA) on ACE activity and gene expression in human umbilical vein endothelial cells (HUVEC). Our results showed a 3- and 5-fold increase in ACE activity in the medium and in the cells, respectively, after 24-h stimulation by PMA. We also observed an increase in the cellular ACE mRNA content starting after 6 h and reaching a 10-fold increase at 24 h in response to 100 ng/ml PMA as measured by ribonuclease protection assay. This effect was mediated by an increased transcription of the ACE gene as demonstrated by nuclear run-on experiments and nearly abolished by the specific PHC inhibitor GF 109203X. Our results indicate that PMA-activated PRC strongly increases ACE mRNA level and ACE gene transcription in HUVEC, an effect associated with an increased ACE secretion. A role for early growth response factor-1 (Egr-1) as a factor regulating ACE gene expression is suggested by both the presence of an Egr-1-responsive element in the proximal portion of the ACE promoter and the kinetics of the Egr-1 mRNA increase in HUVEC treated with PMA.	Fac Med Xavier Bichat, INSERM, U460, Paris, France; Hop St Louis, INSERM, U358, F-75475 Paris 10, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Challah, M (corresponding author), Fac Med Xavier Bichat, INSERM, U460, Paris, France.		villard, eric/AAH-2868-2021; Villard, Eric/AAI-2464-2021	Villard, Eric/0000-0001-9801-7297				ALHENCGELAS F, 1991, J LAB CLIN MED, V117, P33; ARNAL JF, 1994, AM J PHYSIOL-HEART C, V267, pH1777, DOI 10.1152/ajpheart.1994.267.5.H1777; BELDENT V, 1993, J BIOL CHEM, V268, P26428; BHANDARI B, 1994, MOL CELL BIOCHEM, V140, P31, DOI 10.1007/BF00928363; BHANDARI B, 1994, MOL CELL ENDOCRINOL, V91, P185; BLUMBERG PM, 1995, AGENT ACTION SUPPL, V47, P87; BOSENBERG MW, 1993, J CELL BIOL, V122, P95, DOI 10.1083/jcb.122.1.95; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSSOLINO F, 1994, J BIOL CHEM, V269, P2877; BUSSOLINO F, 1987, J IMMUNOL, V139, P2439; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CHALLAH M, 1995, CARDIOVASC RES, V30, P231, DOI 10.1016/0008-6363(96)88516-6; CHEN FY, 1994, BIOCHEM J, V302, P125, DOI 10.1042/bj3020125; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORVOL P, 1995, METHOD ENZYMOL, V248, P283; COSTEROUSSE O, 1993, BIOCHEM J, V290, P33, DOI 10.1042/bj2900033; CRAVEN PA, 1989, J CLIN INVEST, V83, P1667, DOI 10.1172/JCI114066; CUSHMAN DW, 1971, BIOCHEM PHARMACOL, V20, P1637, DOI 10.1016/0006-2952(71)90292-9; DANSER AHJ, 1995, CIRCULATION, V92, P1387, DOI 10.1161/01.CIR.92.6.1387; DASARATHY Y, 1992, AM J PHYSIOL, V263, pL645, DOI 10.1152/ajplung.1992.263.6.L645; DEISHER TA, 1993, FEBS LETT, V331, P285, DOI 10.1016/0014-5793(93)80354-W; DHUMIERES S, 1986, EUR J PHARMACOL, V131, P13, DOI 10.1016/0014-2999(86)90510-8; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; EHLERS MRW, 1995, BIOCHEM BIOPH RES CO, V206, P541, DOI 10.1006/bbrc.1995.1077; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; FISHEL RS, 1995, J CLIN INVEST, V95, P377, DOI 10.1172/JCI117666; FISHEL RS, 1995, HYPERTENSION, V25, P343, DOI 10.1161/01.HYP.25.3.343; GILMAN M, 1993, CURRENT PROTOCOLS MO; GonzalezEspinosa C, 1996, BBA-MOL CELL RES, V1310, P217, DOI 10.1016/0167-4889(95)00168-9; GRIGORIAN GY, 1987, CIRC RES, V61, P389, DOI 10.1161/01.RES.61.3.389; HELLER R, 1992, J IMMUNOL, V149, P3682; Hempel A, 1997, CIRC RES, V81, P363, DOI 10.1161/01.RES.81.3.363; HSIEH HJ, 1991, AM J PHYSIOL, V260, pH642, DOI 10.1152/ajpheart.1991.260.2.H642; HUANG DL, 1995, MOL ENDOCRINOL, V9, P994, DOI 10.1210/me.9.8.994; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; HUANG RP, 1994, BIOCHEM BIOPH RES CO, V200, P1271, DOI 10.1006/bbrc.1994.1588; Huang RP, 1998, CELL DEATH DIFFER, V5, P96, DOI 10.1038/sj.cdd.4400322; HUBERT C, 1991, J BIOL CHEM, V266, P15377; HUG H, 1993, BIOCHEM J, V291, P829; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JANDELEIT K, 1992, CLIN EXP PHARMACOL P, V19, P343, DOI 10.1111/j.1440-1681.1992.tb00468.x; KAWAGUCHI H, 1990, J HYPERTENS, V8, P173, DOI 10.1097/00004872-199002000-00012; KAWAGUCHI H, 1990, BIOCHIM BIOPHYS ACTA, V1052, P503, DOI 10.1016/0167-4889(90)90162-7; KENT KC, 1995, CIRC RES, V77, P231, DOI 10.1161/01.RES.77.2.231; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; KHAN J, 1994, J CELL BIOL, V125, P461; KING SJ, 1992, AM J PHYSIOL, V263, pC743, DOI 10.1152/ajpcell.1992.263.4.C743; KRULEWITZ AH, 1984, AM J PHYSIOL, V247, pC163, DOI 10.1152/ajpcell.1984.247.3.C163; KUCHAN MJ, 1993, AM J PHYSIOL, V264, pH150, DOI 10.1152/ajpheart.1993.264.1.H150; LANE TA, 1989, BIOCHEM BIOPH RES CO, V161, P945, DOI 10.1016/0006-291X(89)91334-X; LEE TS, 1989, P NATL ACAD SCI USA, V86, P5141, DOI 10.1073/pnas.86.13.5141; LIBERMAN J, 1980, ANN INTERN MED, V93, P825; MARRE M, 1988, BMJ-BRIT MED J, V297, P1092, DOI 10.1136/bmj.297.6656.1092; Mills I, 1997, J CELL PHYSIOL, V170, P228, DOI 10.1002/(SICI)1097-4652(199703)170:3<228::AID-JCP2>3.0.CO;2-Q; MITSUMATA M, 1993, AM J PHYSIOL, V265, pH3, DOI 10.1152/ajpheart.1993.265.1.H3; MORISHITA R, 1994, J CLIN INVEST, V94, P978, DOI 10.1172/JCI117464; OHH M, 1994, J BIOL CHEM, V269, P30117; OKABE T, 1987, BIOCHEM BIOPH RES CO, V145, P1211, DOI 10.1016/0006-291X(87)91566-X; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PIQUILLO.Y, 1970, BIOCHIM BIOPHYS ACTA, V206, P136, DOI 10.1016/0005-2744(70)90090-2; PORTEU F, 1991, J BIOL CHEM, V266, P18846; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; RAMCHANDRAN R, 1994, J BIOL CHEM, V269, P2125; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; Rozengurt E, 1997, BIOCHEM SOC T, V25, P565, DOI 10.1042/bst0250565; RYAN US, 1976, TISSUE CELL, V8, P125, DOI 10.1016/0040-8166(76)90025-2; SHAI SY, 1992, CIRC RES, V70, P1274, DOI 10.1161/01.RES.70.6.1274; SHIBA T, 1993, AM J PHYSIOL, V265, pE783, DOI 10.1152/ajpendo.1993.265.5.E783; SHIOTA N, 1992, HYPERTENSION, V20, P168, DOI 10.1161/01.HYP.20.2.168; Takemoto M, 1997, J CLIN INVEST, V99, P278, DOI 10.1172/JCI119156; Terry CM, 1996, J LAB CLIN MED, V127, P81, DOI 10.1016/S0022-2143(96)90169-9; VANDYK DJ, 1994, EUR J CLIN INVEST, V24, P463, DOI 10.1111/j.1365-2362.1994.tb02376.x; Villard E, 1996, AM J HUM GENET, V58, P1268; Villard E, 1996, CARDIOVASC RES, V32, P999, DOI 10.1016/S0008-6363(96)00170-8; VUKPAVLOVIC Z, 1989, J LEUKOCYTE BIOL, V45, P503, DOI 10.1002/jlb.45.6.503; WANG DL, 1995, J CELL PHYSIOL, V163, P400, DOI 10.1002/jcp.1041630220; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006	77	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25191	25197		10.1074/jbc.273.39.25191	http://dx.doi.org/10.1074/jbc.273.39.25191			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737980	hybrid			2022-12-27	WOS:000076085400030
J	Westphal, V; Spetzler, JC; Meldal, M; Christensen, U; Winther, JR				Westphal, V; Spetzler, JC; Meldal, M; Christensen, U; Winther, JR			Kinetic analysis of the mechanism and specificity of protein-disulfide isomerase using fluorescence-quenched peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOREDOXIN-LIKE DOMAINS; ACTIVE-SITE CYSTEINE; EFFICIENT CATALYSIS; RIBONUCLEASE-A; BOND FORMATION; HUMAN LYSOZYME; GLUTATHIONE; BINDING; ISOMERIZATION; ENDOPEPTIDASES	Protein-disulfide isomerase (PDI) is an abundant folding catalyst in the endoplasmic reticulum of eukaryotic cells. PDI introduces disulfide bonds into newly synthesized proteins and catalyzes disulfide bond isomerizations, We have synthesized a library of disulfide-linked fluorescence-quenched peptides, individually linked to resin beads, for two purposes: 1) to probe PDI specificity, and 2) to identify simple, sensitive peptide substrates of PDI, Using this library, beads that became rapidly fluorescent by reduction by human PDI were selected. Amino acid sequencing of the bead-linked peptides revealed substantial similarities. Several of the peptides were synthesized in solution, and a quantitative characterization of pre-steady state kinetics was carried out. Interestingly, a greater than 10-fold difference in affinity toward PDI was seen for various substrates of identical length. As opposed to conventional PDI assays involving larger polypeptides, the starting material for this assay is homogenous. It is furthermore simple and highly sensitive (requires less than 0.5 mu g of PDI/assay) and thus opens the possibility for quantitative determination of PDI activity and specificity.	Carlsberg Lab, Dept Yeast Genet, DK-2500 Copenhagen, Denmark; Carlsberg Lab, Dept Chem, DK-2500 Copenhagen, Denmark; Univ Copenhagen, Chem Lab 4, DK-2100 Copenhagen, Denmark	University of Copenhagen	Winther, JR (corresponding author), Carlsberg Lab, Dept Yeast Genet, Gamle Carlsberg Vej 10, DK-2500 Copenhagen, Denmark.	jrw@crc.dk	Meldal, Morten/B-7626-2016; Winther, Jakob R./K-4451-2014	Meldal, Morten/0000-0001-6114-9018; Winther, Jakob R./0000-0001-6995-9154				BREDDAM K, 1992, EUR J BIOCHEM, V206, P103, DOI 10.1111/j.1432-1033.1992.tb16906.x; Creighton TE, 1997, BIOL CHEM, V378, P731; Creighton TE, 1996, FASEB J, V10, P110, DOI 10.1096/fasebj.10.1.8566531; DARBY NJ, 1995, J MOL BIOL, V249, P463, DOI 10.1006/jmbi.1995.0309; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P11725, DOI 10.1021/bi00037a009; DARBY NJ, 1994, BIOCHEMISTRY-US, V33, P7937, DOI 10.1021/bi00191a022; Darby NJ, 1995, BIOCHEMISTRY-US, V34, P16770, DOI 10.1021/bi00051a027; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P3576, DOI 10.1021/bi00011a012; Darby NJ, 1996, BIOCHEMISTRY-US, V35, P10517, DOI 10.1021/bi960763s; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; GIVOL D, 1965, P NATL ACAD SCI USA, V53, P676, DOI 10.1073/pnas.53.3.676; GOLDBERGER RF, 1964, J BIOL CHEM, V239, P1406; HAWKINS HC, 1991, BIOCHEM J, V275, P349, DOI 10.1042/bj2750349; HAWKINS HC, 1991, BIOCHEM J, V275, P341, DOI 10.1042/bj2750341; HAYANO T, 1993, FEBS LETT, V328, P203, DOI 10.1016/0014-5793(93)80993-5; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Kemmink J, 1996, BIOCHEMISTRY-US, V35, P7684, DOI 10.1021/bi960335m; KEMMINK J, 1995, PROTEIN SCI, V4, P2587, DOI 10.1002/pro.5560041216; Kemmink J, 1997, CURR BIOL, V7, P239, DOI 10.1016/S0960-9822(06)00119-9; Klappa P, 1997, EUR J BIOCHEM, V248, P37, DOI 10.1111/j.1432-1033.1997.t01-1-00037.x; Klappa P, 1998, EMBO J, V17, P927, DOI 10.1093/emboj/17.4.927; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LAMBERT N, 1983, BIOCHEM J, V213, P235, DOI 10.1042/bj2130235; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; Meldal M, 1998, METH MOL B, V87, P51; MELDAL M, 1991, ANAL BIOCHEM, V195, P141, DOI 10.1016/0003-2697(91)90309-H; Meldal Morten, 1994, Methods (Orlando), V6, P417, DOI 10.1006/meth.1994.1044; MORJANA NA, 1991, BIOCHEMISTRY-US, V30, P4985, DOI 10.1021/bi00234a021; Nakamura S, 1996, J BIOCHEM-TOKYO, V120, P525; NOIVA R, 1993, J BIOL CHEM, V268, P19210; OLSEN K, 1992, EUR J BIOCHEM, V209, P777, DOI 10.1111/j.1432-1033.1992.tb17348.x; OTSU M, 1994, J BIOL CHEM, V269, P6874; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; RENIL M, 1998, IN PRESS J PEPT SCI; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Ruddon RW, 1997, J BIOL CHEM, V272, P3125, DOI 10.1074/jbc.272.6.3125; Ruoppolo M, 1997, BIOCHEMISTRY-US, V36, P12259, DOI 10.1021/bi970851s; Ruoppolo M, 1996, BIOCHEMISTRY-US, V35, P13636, DOI 10.1021/bi960755b; Spetzler JC, 1998, J PEPT SCI, V4, P128, DOI 10.1002/(SICI)1099-1387(199804)4:2<128::AID-PSC137>3.3.CO;2-5; Walker KW, 1997, J BIOL CHEM, V272, P8845; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0; WUNDERLICH M, 1995, J MOL BIOL, V247, P28, DOI 10.1006/jmbi.1995.0119	46	21	21	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					24992	24999		10.1074/jbc.273.39.24992	http://dx.doi.org/10.1074/jbc.273.39.24992			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737954	hybrid			2022-12-27	WOS:000076085400004
J	He, XH; Shen, L; Villoutreix, BO; Dahlback, B				He, XH; Shen, L; Villoutreix, BO; Dahlback, B			Amino acid residues in thrombin-sensitive region and first epidermal growth factor domain of vitamin K-dependent protein S determining specificity of the activated protein C cofactor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-VA INACTIVATION; C4B-BINDING PROTEIN; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; FACTOR-XA; BINDING; EXPRESSION; DEFICIENCY; MEMBRANES; PLASMA	Human protein S (PS) potentiates the anticoagulant activity of human but not bovine activated protein C (APC), whereas bovine PS is a cofactor to APC from both species. The structural requirements for the specificity of the APC cofactor function of human PS are located in its thrombin-sensitive region (TSR) and the first epidermal growth factor (EGF1)-like module. To elucidate which residues in these two modules determine the specificity of the APC cofactor activity, 41 human PS mutants were expressed. All mutants were cofactors to human APC and some also to bovine APC, Residues in TSR (positions 49 and 52) and EGF1 (residues 97 and 106) together determined the specificity of the APC cofactor function, whereas substitution of individual residues did not change specificity. Bovine PS, and mutants expressing cofactor activity to bovine APC, stimulated phospholipid binding of bovine APC, In contrast, human PS and mutants lacking cofactor activity to bovine APC failed to support binding of bovine APC to phospholipids. These data indicate that residues in TSR and EGF1 cause the specificity of the APC cofactor activity and support the concept that key residues in these two modules interact with APC on the phospholipid surface.	Univ Lund, Hosp MAS, Wallenberg Labs, Dept Clin Chem, S-20502 Malmo, Sweden	Lund University	Dahlback, B (corresponding author), Univ Lund, Hosp MAS, Wallenberg Labs, Dept Clin Chem, S-20502 Malmo, Sweden.		Villoutreix, Bruno/I-4565-2015	Villoutreix, Bruno/0000-0002-6456-7730; Dahlback, Bjorn/0000-0003-1546-0328				BAKKER HM, 1992, EUR J BIOCHEM, V208, P171, DOI 10.1111/j.1432-1033.1992.tb17171.x; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BERG DT, 1992, NUCLEIC ACIDS RES, V20, P5485, DOI 10.1093/nar/20.20.5485; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; CHU MD, 1994, BBA-GENE STRUCT EXPR, V1217, P325, DOI 10.1016/0167-4781(94)90294-1; DAHLBACK B, 1992, BIOCHEMISTRY-US, V31, P12769, DOI 10.1021/bi00166a009; DAHLBACK B, 1986, P NATL ACAD SCI USA, V83, P4199, DOI 10.1073/pnas.83.12.4199; DAHLBACK B, 1995, THROMB RES, V77, P1, DOI 10.1016/0049-3848(94)00138-4; DAHLBACK B, 1986, J BIOL CHEM, V261, P2022; DAHLBACK B, 1981, P NATL ACAD SCI-BIOL, V78, P2512, DOI 10.1073/pnas.78.4.2512; DAHLBACK B, 1990, J BIOL CHEM, V265, P8127; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; DAHLBACK B, 1994, MOL BASIS BLOOD DISE, P599; ESMON CT, 1995, TRENDS CARDIOVAS MED, V5, P141, DOI 10.1016/1050-1738(95)00054-D; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FERNLUND P, 1975, J BIOL CHEM, V250, P6125; GANDRILLE S, 1995, BLOOD, V85, P130, DOI 10.1182/blood.V85.1.130.bloodjournal851130; GIRI TK, 1998, IN PRESS THROMB HEMO; GREENGARD JS, 1995, BIOCHEM J, V305, P397, DOI 10.1042/bj3050397; GRINNELL BW, 1990, BLOOD, V76, P2546; HACKENG TM, 1994, J BIOL CHEM, V269, P21051; HARRIS KW, 1985, J BIOL CHEM, V260, P2007; HE X, 1995, EUR J BIOCHEM, V277, P433; HE XH, 1993, EUR J BIOCHEM, V217, P857, DOI 10.1111/j.1432-1033.1993.tb18314.x; HEEB MJ, 1994, P NATL ACAD SCI USA, V91, P2728, DOI 10.1073/pnas.91.7.2728; HEEB MJ, 1993, J BIOL CHEM, V268, P2872; Leroy-Matheron C, 1998, BLOOD, V91, P4608, DOI 10.1182/blood.V91.12.4608.412k29_4608_4615; Long GL, 1998, J BIOL CHEM, V273, P11521, DOI 10.1074/jbc.273.19.11521; Lu DS, 1997, THROMB HAEMOSTASIS, V77, P1156; LUNDWALL A, 1986, P NATL ACAD SCI USA, V83, P6716, DOI 10.1073/pnas.83.18.6716; MAHASANDANA C, 1990, LANCET, V335, P61, DOI 10.1016/0140-6736(90)90201-F; MALM J, 1990, EUR J BIOCHEM, V187, P737, DOI 10.1111/j.1432-1033.1990.tb15361.x; MALM J, 1994, BIOCHEM J, V302, P845, DOI 10.1042/bj3020845; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; Nyberg P, 1998, FEBS LETT, V433, P28, DOI 10.1016/S0014-5793(98)00877-1; RALEIGH EA, 1986, P NATL ACAD SCI USA, V83, P9070, DOI 10.1073/pnas.83.23.9070; ROSING J, 1995, J BIOL CHEM, V270, P27852, DOI 10.1074/jbc.270.46.27852; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWALBE R, 1990, J BIOL CHEM, V265, P16074; SCHWARZ HP, 1984, BLOOD, V64, P1297; SHEN L, 1994, J BIOL CHEM, V269, P18735; SMIRNOV MD, 1994, J BIOL CHEM, V269, P816; Smirnov MD, 1998, J BIOL CHEM, V273, P9031, DOI 10.1074/jbc.273.15.9031; Stenberg Y, 1998, EUR J BIOCHEM, V251, P558, DOI 10.1046/j.1432-1327.1998.2510558.x; STERN DM, 1986, J BIOL CHEM, V261, P713; SUZUKI K, 1984, J BIOCHEM-TOKYO, V96, P455, DOI 10.1093/oxfordjournals.jbchem.a134857; SUZUKI K, 1983, J BIOCHEM-TOKYO, V94, P699, DOI 10.1093/oxfordjournals.jbchem.a134409; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; Villoutreix BO, 1997, J COMPUT AID MOL DES, V11, P293, DOI 10.1023/A:1007912929828; WALKER FJ, 1981, J BIOL CHEM, V256, P1128; WALKER FJ, 1981, THROMB RES, V22, P321, DOI 10.1016/0049-3848(81)90125-0; YASUDA F, 1995, J BIOCHEM-TOKYO, V117, P374, DOI 10.1093/jb/117.2.374; Yegneswaran S, 1997, J BIOL CHEM, V272, P25013, DOI 10.1074/jbc.272.40.25013	56	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27449	27458		10.1074/jbc.273.42.27449	http://dx.doi.org/10.1074/jbc.273.42.27449			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765274	hybrid			2022-12-27	WOS:000076448000061
J	Decker, EL; Skerka, C; Zipfel, PF				Decker, EL; Skerka, C; Zipfel, PF			The early growth response protein (EGR-1) regulates interleukin-2 transcription by synergistic interaction with the nuclear factor of activated T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; IL-2 GENE-EXPRESSION; DNA-BINDING DOMAINS; NGFI-A; NF-AT; CULTURED-CELLS; PROMOTER; FAMILY; ENCODES; ELEMENT	The early growth response-1 gene (EGR-1) is induced by a wide range of stimuli in diverse cell types; however, EGR-1-regulated genes display a highly restricted pattern of expression. Recently, an overlapping Sp1.EGR-1 binding site has been identified within the interleukin-2 (IL-2) gene promoter directly upstream of the binding site for the nuclear factor of activated T cells (NFAT), We used transfection assays to study how the abundantly and constitutively expressed Sp1 protein and the immediate early EGR-1 zinc finger protein regulate IL-2 gene expression. Here, we identify EGR-1 as an important activator of the IL-2 gene. In Jurkat T cells, EGR-1 but not Sp1 acts as a potent coactivator for IL-2 transcription, and in combination with NFATc, EGR-1 increases transcription of an IL-2 reporter construct 200-fold. Electrophoretic mobility shift assays reveal that recombinant EGR-1 and NFATc bind independently to their target sites within the IL-2 promoter, and the presence of both sites on the same DNA molecule is required for EGR-1.NFATc.DNA complex formation. The transcriptional synergy observed here for EGR-1 and NFATc explains how the abundant nuclear factor EGR-1 contributes to the expression of restrictively expressed genes.	Bernhard Nocht Inst Trop Med, Res Grp Biomol Med, D-20359 Hamburg, Germany	Bernhard Nocht Institut fur Tropenmedizin	Zipfel, PF (corresponding author), Bernhard Nocht Inst Trop Med, Res Grp Biomol Med, Bernhard Nocht Str 74, D-20359 Hamburg, Germany.	zipfel@uke.uni-hamburg.de						ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Avots A, 1997, MOL CELL BIOL, V17, P4381, DOI 10.1128/MCB.17.8.4381; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; CAO XM, 1993, J BIOL CHEM, V268, P16949; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; Cogswell PC, 1997, J EXP MED, V185, P491, DOI 10.1084/jem.185.3.491; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; Dinkel A, 1997, J IMMUNOL, V159, P2678; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FRASER JD, 1993, IMMUNOL TODAY, V14, P357, DOI 10.1016/0167-5699(93)90236-E; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; Huang RP, 1997, J CELL BIOCHEM, V66, P489, DOI 10.1002/(SICI)1097-4644(19970915)66:4<489::AID-JCB8>3.0.CO;2-H; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAIN JN, 1993, J IMMUNOL, V151, P837; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; MAGES HW, 1993, INT IMMUNOL, V5, P63, DOI 10.1093/intimm/5.1.63; Maltzman JS, 1996, J EXP MED, V183, P1747, DOI 10.1084/jem.183.4.1747; Maltzman JS, 1996, MOL CELL BIOL, V16, P2283; McMahon SB, 1996, J LEUKOCYTE BIOL, V60, P159, DOI 10.1002/jlb.60.2.159; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MULLER HJ, 1991, P NATL ACAD SCI USA, V88, P10079, DOI 10.1073/pnas.88.22.10079; Nair P, 1997, J BIOL CHEM, V272, P20131, DOI 10.1074/jbc.272.32.20131; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; NOLAN GP, 1994, CELL, V77, P795, DOI 10.1016/0092-8674(94)90126-0; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; PATWARDHAN S, 1991, ONCOGENE, V6, P917; RAIZIS AM, 1993, BIOCHEM J, V289, P133, DOI 10.1042/bj2890133; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; ROONEY JW, 1994, EMBO J, V13, P625, DOI 10.1002/j.1460-2075.1994.tb06300.x; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; RUSSO MW, 1995, P NATL ACAD SCI USA, V92, P6873, DOI 10.1073/pnas.92.15.6873; Sambrook J., 2002, MOL CLONING LAB MANU; SERFLING E, 1995, BBA-GENE STRUCT EXPR, V1263, P181, DOI 10.1016/0167-4781(95)00112-T; SKERKA C, 1995, J BIOL CHEM, V270, P22500, DOI 10.1074/jbc.270.38.22500; Skerka C, 1997, IMMUNOBIOLOGY, V198, P179, DOI 10.1016/S0171-2985(97)80039-3; SUGGS SV, 1990, NUCLEIC ACIDS RES, V18, P4283, DOI 10.1093/nar/18.14.4283; Svaren J, 1996, MOL CELL BIOL, V16, P3545; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; Timmerman LA, 1997, J IMMUNOL, V159, P2735; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; WILLIAMS GT, 1993, MOL CELL BIOL, V13, P6124, DOI 10.1128/MCB.13.10.6124; WILLIAMS TM, 1991, SCIENCE, V254, P1791, DOI 10.1126/science.1840704; WRIGHT JJ, 1990, SCIENCE, V248, P588, DOI 10.1126/science.2110381; ZHANG LQ, 1994, CYTOKINE, V6, P221, DOI 10.1016/1043-4666(94)90016-7; ZIPFEL PF, 1989, MOL CELL BIOL, V9, P1041, DOI 10.1128/MCB.9.3.1041; Zipfel PF, 1997, BBA-GENE STRUCT EXPR, V1354, P134, DOI 10.1016/S0167-4781(97)00084-5	62	70	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26923	26930		10.1074/jbc.273.41.26923	http://dx.doi.org/10.1074/jbc.273.41.26923			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756940	hybrid			2022-12-27	WOS:000076373300094
J	Kudo, T; Ikehara, Y; Togayachi, A; Kaneko, M; Hiraga, T; Sasaki, K; Narimatsu, H				Kudo, T; Ikehara, Y; Togayachi, A; Kaneko, M; Hiraga, T; Sasaki, K; Narimatsu, H			Expression cloning and characterization of a novel murine alpha 1,3-fucosyltransferase, mFuc-TIX, that synthesizes the Lewis x (CD15) epitope in brain and kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; FUCOSYL-TRANSFERASE GENES; EMBRYONIC ANTIGEN SSEA-1; BLOOD GROUP SYSTEM; MOLECULAR-CLONING; SIALYL-LEWIS; ALPHA(1,3)-FUCOSYL-TRANSFERASE GENE; SUBSTRATE SPECIFICITIES; ALPHA-1,3-FUCOSYL-TRANSFERASE GENE; DETERMINES EXPRESSION	The 3-fucosyl-N-acetyllactosamine (Lewis x, CD15, SSEA-1) carbohydrate epitope is widely distributed in many tissues and is developmentally expressed in some rodent and human tissues, i.e. brain and lung, and mouse early embryo. In such tissues, the Lewis x epitope is considered to be involved in cell-cell interactions. We isolated a novel mouse alpha 1,3-fucosyltransferase gene, named mFuc-TIX, from an adult mouse brain cDNA library using the expression cloning method. On flow cytometric analysis, Namalwa cells transfected stably with the mFuc-TIX gene showed a marked increase in Lewis x epitopes but not sialyl Lewis x epitopes. As seen experiments involving oligosaccharides as acceptor substrates, mFuc-TIX transfers a fucose to lacto-N-neotetraose but not to either alpha 2,3-sialyl lacto-N-neotetraose or lacto-N-tetraose. The substrate specificity of mFuc-TIX was similar to that of mouse myeloid-type alpha 1,3-fucosyltransferase (mFuc-TIV). The deduced amino acid sequence of mFuc-TIX, consisting of 359 residues, indicated a type II membrane protein and shows low degrees of homology to the previously cloned alpha 1,3-fucosyltransferases, i.e. mFuc-TIV (48.4%), mouse Fuc-TVII (39.1%), and human Fuc-TIII (43.0%), at the amino acid sequence level. A phylogenetic tree of the alpha 1,3-fucosyltransferases constructed by the neighbor-joining method showed that mFuc-TIX is quite distant from the other alpha 1,3-fucosyltransferases. Thus, mFuc-TIX does not belong to any subfamilies of known alpha 1,3Fuc-Ts. The mFuc-TIX transcript was mainly detected in brain and kidney with the Northern blotting and competitive re verse transcription-polymerase chain reaction methods, whereas the mFuc-TIV transcript was not detected in brain with these methods. On in situ hybridization, the mFuc-TIX transcript was detected in neuronal cells but not in the glial cells including astrocytes. These results strongly indicated that mFuc-TIX participates in the Lewis x synthesis in neurons of the brain and may be developmentally regulated.	Soka Univ, Inst Life Sci, Div Cell Biol, Hachioji, Tokyo 1928577, Japan; Natl Inst Genet, Grad Univ Adv Studies, Sch Life Sci, Dept Genet, Mishima, Shizuoka 4110801, Japan; Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Machida, Tokyo 1948533, Japan	Soka University; Graduate University for Advanced Studies - Japan; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Kyowa Kirin Ltd	Narimatsu, H (corresponding author), Soka Univ, Inst Life Sci, Div Cell Biol, 1-236 Tangi-cho, Hachioji, Tokyo 1928577, Japan.		Ikehara, yuzuru/L-7696-2018; Ikehara, yuzuru/R-2239-2019	Ikehara, yuzuru/0000-0002-1915-9172; Ikehara, yuzuru/0000-0002-1915-9172; K. Kaneko, Mika/0000-0002-4158-9208				Ashwell KWS, 1997, CELL TISSUE RES, V289, P17, DOI 10.1007/s004410050848; BARTSCH D, 1991, CELL TISSUE RES, V263, P353, DOI 10.1007/BF00318777; CAMERON HS, 1995, J BIOL CHEM, V270, P20112, DOI 10.1074/jbc.270.34.20112; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Costache M, 1997, J BIOL CHEM, V272, P29721, DOI 10.1074/jbc.272.47.29721; DEVRIES T, 1995, J BIOL CHEM, V270, P8712, DOI 10.1074/jbc.270.15.8712; FOSTER CS, 1991, J BIOL CHEM, V266, P3526; FOX N, 1981, DEV BIOL, V83, P391, DOI 10.1016/0012-1606(81)90487-5; Ge ZM, 1997, J BIOL CHEM, V272, P21357, DOI 10.1074/jbc.272.34.21357; GERSTEN KM, 1995, J BIOL CHEM, V270, P25047, DOI 10.1074/jbc.270.42.25047; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GOOI HC, 1981, NATURE, V292, P156, DOI 10.1038/292156a0; HAKOMORI S, 1984, J BIOL CHEM, V259, P4672; HAKOMORI SI, 1992, HISTOCHEM J, V24, P771, DOI 10.1007/BF01046348; HOLMES EH, 1995, J BIOL CHEM, V270, P8145, DOI 10.1074/jbc.270.14.8145; Ito H, 1997, INT J CANCER, V71, P556, DOI 10.1002/(SICI)1097-0215(19970516)71:4<556::AID-IJC9>3.3.CO;2-J; ITZKOWITZ SH, 1986, CANCER RES, V46, P2627; Kaneko M, 1997, BLOOD, V90, P839, DOI 10.1182/blood.V90.2.839.839_839_849; KIMURA H, 1995, GLYCOCONJUGATE J, V12, P802, DOI 10.1007/BF00731242; Kimura H, 1997, BIOCHEM BIOPH RES CO, V237, P131, DOI 10.1006/bbrc.1997.7100; KODA Y, 1993, BLOOD, V82, P2915; KONDO A, 1990, AGR BIOL CHEM TOKYO, V54, P2169, DOI 10.1080/00021369.1990.10870232; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kudo T, 1996, J BIOL CHEM, V271, P9830, DOI 10.1074/jbc.271.16.9830; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; Lee KP, 1996, J BIOL CHEM, V271, P32960, DOI 10.1074/jbc.271.51.32960; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MAI JK, 1992, HISTOCHEM J, V24, P878, DOI 10.1007/BF01046359; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; MARANI E, 1992, HISTOCHEM J, V24, P852, DOI 10.1007/BF01046357; MARGOLSKEE RF, 1988, MOL CELL BIOL, V8, P2837, DOI 10.1128/MCB.8.7.2837; Martin SL, 1997, J BIOL CHEM, V272, P21349, DOI 10.1074/jbc.272.34.21349; MCCURLEY RS, 1995, GENOMICS, V26, P142, DOI 10.1016/0888-7543(95)80094-3; MIYAKE M, 1988, CANCER RES, V48, P7150; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; MORRES SA, 1992, HISTOCHEM J, V24, P902, DOI 10.1007/BF01046361; MURAMATSU H, 1983, FEBS LETT, V163, P181, DOI 10.1016/0014-5793(83)80814-X; Narimatsu H, 1998, CANCER RES, V58, P512; Narimatsu H, 1996, CANCER RES, V56, P330; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NISHIHARA S, 1993, BIOCHEM BIOPH RES CO, V190, P42, DOI 10.1006/bbrc.1993.1008; NISHIHARA S, 1994, J BIOL CHEM, V269, P29271; ORIOL R, 1986, VOX SANG, V51, P161, DOI 10.1111/j.1423-0410.1986.tb01946.x; Orntoft TF, 1996, J BIOL CHEM, V271, P32260, DOI 10.1074/jbc.271.50.32260; OUDEGA M, 1992, HISTOCHEM J, V24, P869, DOI 10.1007/BF01046358; Oulmouden A, 1997, J BIOL CHEM, V272, P8764, DOI 10.1074/jbc.272.13.8764; Ozawa M, 1996, J BIOCHEM-TOKYO, V119, P302; PENNINGTON JE, 1985, J EMBRYOL EXP MORPH, V90, P335; REGUIGNE I, 1994, CYTOGENET CELL GENET, V66, P104, DOI 10.1159/000133677; REGUIGNEARNOULD I, 1995, CYTOGENET CELL GENET, V71, P158, DOI 10.1159/000134098; REIFENBERGER G, 1992, HISTOCHEM J, V24, P890, DOI 10.1007/BF01046360; ROBINSON NE, 1994, GLYCOBIOLOGY, V4, P317, DOI 10.1093/glycob/4.3.317; ROUQUIER S, 1995, J BIOL CHEM, V270, P4632, DOI 10.1074/jbc.270.9.4632; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SajdelSulkowska EM, 1997, GLYCOCONJUGATE J, V14, P249, DOI 10.1023/A:1018550023637; SASAKI K, 1993, J BIOL CHEM, V268, P22782; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SATOH J, 1994, J NEUROSCI RES, V37, P466, DOI 10.1002/jnr.490370406; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; Streit A, 1996, J NEUROCHEM, V66, P834; TETTEROO P, 1992, HISTOCHEM J, V24, P777, DOI 10.1007/BF01046349; Uozumi N, 1996, J BIOL CHEM, V271, P27810, DOI 10.1074/jbc.271.44.27810; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; Yanagidani S, 1997, J BIOCHEM-TOKYO, V121, P626	66	87	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26729	26738		10.1074/jbc.273.41.26729	http://dx.doi.org/10.1074/jbc.273.41.26729			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756916	hybrid			2022-12-27	WOS:000076373300070
J	Misra, S; Ujhazy, P; Gatmaitan, Z; Varticovski, L; Arias, IM				Misra, S; Ujhazy, P; Gatmaitan, Z; Varticovski, L; Arias, IM			The role of phosphoinositide 3-kinase in taurocholate-induced trafficking of ATP-dependent canalicular transporters in rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE PLASMA-MEMBRANE; ORGANIC ANION TRANSPORT; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; BILE SECRETION; GENE FAMILY; VESICLES; KINASE; SYSTEM; TRANSLOCATION	Recent studies indicate that wortmannin, a potent inhibitor of phosphatidylinositol (PI) 3-kinase, interferes with bile acid secretion in rat liver; taurocholate induces recruitment of ATP-dependent transporters to the bile canalicular membrane, and PI 3-kinase products are important in intracellular trafficking. We investigated the role of PI 3-kinase in bile acid secretion by studying the in vivo effect of taurocholate, colchicine, and wortmannin on bile acid secretion, kinase activity, and protein levels in canalicular membrane vesicle (CMV) and sinusoidal membrane vesicle (SMV) fractions from rat lives. Treatment of rats or perfusion of isolated liver with taurocholate significantly increased PI 3-kinase activity in both membrane fractions, Taurocholate increased protein content of ATP-dependent transporters, which were detected only in CMVs, whereas increased levels of p85 and a cell adhesion molecule, cCAM 105, were observed in both fractions. Colchicine prevented taurocholate-induced changes in all proteins studied, as well as the increase in PI 3-kinase activity in CMVs, but it resulted in further accumulation of PI 3-kinase activity, p85, and cCAM 105 in SMVs. These results indicate that taurocholale-mediated changes involve a microtubular system. Wortmannin blocked taurocholate-induced bile acid secretion. The effect was more profound when wortmannin was administered prior to treatment with taurocholate. When wortmannin was given after taurocholate, the protein levels of each ATP-dependent transporter were maintained in CMVs, whereas the levels of p85 and cCAM decreased in both membrane fractions. Perfusion of liver with wortmannin before taurocholate administration blocked accumulation of all proteins studied in CMVs and SMVs. These results indicate that PI 3-kinase is required for intracellular trafficking of itself, as weal as of ATP-dependent canalicular transporters.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA; St Elizabeth Med Ctr, Dept Biomed Res, Brighton, MA 02135 USA	Tufts University; St. Elizabeth's Medical Center	Misra, S (corresponding author), Tufts Univ, Sch Med, Dept Physiol, 136 Harrison Ave, Boston, MA 02111 USA.		Ujhazy, Peter/AAF-9507-2021	Varticovski, Lyuba/0000-0002-5105-9008	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928, R01DK035652, R37DK035652] Funding Source: NIH RePORTER; NCI NIH HHS [CA 94536] Funding Source: Medline; NIDDK NIH HHS [30DK34928, DK35652] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADACHI Y, 1991, HEPATOLOGY, V14, P655, DOI 10.1016/0270-9139(91)90053-X; ANANTHANARAYANAN M, 1994, AM J PHYSIOL-GASTR L, V267, pG637, DOI 10.1152/ajpgi.1994.267.4.G637; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BARR VA, 1993, GASTROENTEROLOGY, V105, P554, DOI 10.1016/0016-5085(93)90734-T; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; CRAWFORD JM, 1988, J LIPID RES, V29, P144; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Endicott J A, 1991, DNA Seq, V2, P89, DOI 10.3109/10425179109039677; Erlinger Serge, 1994, P769; Folli F, 1997, GASTROENTEROLOGY, V113, P954, DOI 10.1016/S0016-5085(97)70192-6; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; Gatmaitan ZC, 1997, AM J PHYSIOL-GASTR L, V272, pG1041, DOI 10.1152/ajpgi.1997.272.5.G1041; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; HEMS R, 1966, BIOCHEM J, V101, P284, DOI 10.1042/bj1010284; Hofmann Alan F., 1994, P677; INOUE M, 1982, HEPATOLOGY, V2, P572; INOUE M, 1983, J BIOL CHEM, V258, P5183; Ito K, 1997, AM J PHYSIOL-GASTR L, V272, pG16, DOI 10.1152/ajpgi.1997.272.1.G16; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; LINCKE CR, 1992, J MOL BIOL, V228, P701, DOI 10.1016/0022-2836(92)90855-E; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; MEIER PJ, 1984, J CELL BIOL, V98, P991, DOI 10.1083/jcb.98.3.991; MULLER M, 1991, J BIOL CHEM, V266, P18920; NATHANSON MH, 1991, HEPATOLOGY, V14, P551, DOI 10.1002/hep.1840140324; Nies AT, 1996, J LIPID RES, V37, P1125; NISHIDA T, 1991, P NATL ACAD SCI USA, V88, P6590, DOI 10.1073/pnas.88.15.6590; NISHIDA T, 1992, AM J PHYSIOL, V262, pG629, DOI 10.1152/ajpgi.1992.262.4.G629; Noe B, 1996, GASTROENTEROLOGY, V110, P858, DOI 10.1053/gast.1996.v110.pm8608896; ORLOWSKI M, 1963, BIOCHIM BIOPHYS ACTA, V73, P679; ROMAN LM, 1983, J CELL BIOL, V96, P1548, DOI 10.1083/jcb.96.6.1548; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; STIEGER B, 1992, BIOCHEM J, V284, P67, DOI 10.1042/bj2840067; STOLZ A, 1993, J BIOL CHEM, V268, P10448; SUSA M, 1992, J BIOL CHEM, V267, P22951; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; VONDIPPE P, 1993, AM J PHYSIOL, V264, pG528, DOI 10.1152/ajpgi.1993.264.3.G528; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Wolkoff AW, 1996, SEMIN LIVER DIS, V16, P121, DOI 10.1055/s-2007-1007225	41	113	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26638	26644		10.1074/jbc.273.41.26638	http://dx.doi.org/10.1074/jbc.273.41.26638			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756904	hybrid			2022-12-27	WOS:000076373300058
J	Pacheco-Rodriguez, G; Meacci, E; Vitale, N; Moss, J; Vaughan, M				Pacheco-Rodriguez, G; Meacci, E; Vitale, N; Moss, J; Vaughan, M			Guanine nucleotide exchange on ADP-ribosylation factors catalyzed by cytohesin-1 and its Sec7 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; PHOSPHOLIPASE-D; BREFELDIN-A; BINDING PROTEIN; CHOLERA-TOXIN; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; SACCHAROMYCES-CEREVISIAE; HOMOLOGY DOMAINS; BOVINE BRAIN; FACTOR ARF	ADP-ribosylation factors (ARFs) are 20-kDa guanine nucleotide-binding proteins that require specific guanine nucleotide-exchange proteins (GEPs) to accelerate the conversion of inactive ARF-GDP to active ARF-GTP, Cytohesin-1, a 46-kDa ARF GEP, contains a central Sec7 domain of 188 amino acids similar in sequence to a region of the yeast Sec7 protein. Cytohesin-1 and its 22-kDa Sec7 domain (C-1 Sec7), synthesized in Escherichia coli, were assayed with recombinant non-myristoylated ARFs and related proteins to compare their GEP activities. Both were effective with native mammalian ARFs 1 and 3. Cytohesin-1 accelerated GTP gamma S (guanosine 5'-3-O-(thio)triphosphate) binding to recombinant human ARF1 (rARF1), yeast ARF3, and ARD1 (a 64-kDa guanine nucleotide-binding protein containing a C-terminal ARF domain). In contrast, C-1 Sec7 enhanced GTP gamma S binding to recombinant human ARFs 1, 5, and 6; yeast ARFs 1, 2, and 3; ARD1; two ARD1 mutants that contain the ARF domain; and Delta 13ARF1, which lacks the N-terminal alpha-helix. Neither C-1 Sec7 nor cytohesin-1 increased GTP gamma S binding to human ARF-like ARL proteins 1, 2, and 3. Thus, ARLs, initially differentiated from ARFs because of their inability to activate cholera toxin, differ also in their failure to interact functionally with C-1 Sec7 or cytohesin-1. As C-1 Sec7 was much less substrate-specific than cytohesin-1, it appears that structure outside of the Sec7 domain is important for ARF specificity. Data obtained with mutant ARF constructs are all consistent with the conclusion that the ARF N terminus is an important determinant of cytohesin-1 specificity.	NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Pacheco-Rodriguez, G (corresponding author), NHLBI, Pulm Crit Care Med Branch, NIH, Rm 5N-307,Bldg 10,10 Ctr Dr,MSC 1434, Bethesda, MD 20892 USA.		Vitale, Nicolas/G-5967-2014; Pacheco, Gustavo/Q-6956-2019	Vitale, Nicolas/0000-0002-4752-4907; 				ACHSTETTER T, 1988, J BIOL CHEM, V263, P11711; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Cherfils J, 1998, NATURE, V392, P101, DOI 10.1038/32210; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Cosson P, 1997, CURR OPIN CELL BIOL, V9, P484, DOI 10.1016/S0955-0674(97)80023-3; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; Ding M, 1996, J BIOL CHEM, V271, P24005, DOI 10.1074/jbc.271.39.24005; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; HAUN RS, 1993, J BIOL CHEM, V268, P7064; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HONG JX, 1994, J BIOL CHEM, V269, P9743; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; LEE FJS, 1994, J BIOL CHEM, V269, P20931; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; LIU L, 1992, BIOCHIM BIOPHYS ACTA, V1132, P75, DOI 10.1016/0167-4781(92)90055-5; MAKLER V, 1995, J BIOL CHEM, V270, P5232, DOI 10.1074/jbc.270.10.5232; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; MISHIMA K, 1993, J BIOL CHEM, V268, P8801; Morinaga N, 1997, P NATL ACAD SCI USA, V94, P12926, DOI 10.1073/pnas.94.24.12926; Morinaga N, 1996, P NATL ACAD SCI USA, V93, P12856, DOI 10.1073/pnas.93.23.12856; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Mossessova E, 1998, CELL, V92, P415, DOI 10.1016/S0092-8674(00)80933-2; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; PATTON WA, 1997, BACTERIAL TOXINS TOO, P15; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; Poon PP, 1996, P NATL ACAD SCI USA, V93, P10074, DOI 10.1073/pnas.93.19.10074; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Roth MG, 1997, CURR OPIN CELL BIOL, V9, P519, DOI 10.1016/S0955-0674(97)80028-2; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sata M, 1998, P NATL ACAD SCI USA, V95, P4204, DOI 10.1073/pnas.95.8.4204; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; TAMKUN JW, 1991, P NATL ACAD SCI USA, V88, P3120, DOI 10.1073/pnas.88.8.3120; TERUI T, 1994, J BIOL CHEM, V269, P28130; Tsai SC, 1996, P NATL ACAD SCI USA, V93, P305, DOI 10.1073/pnas.93.1.305; TSAI SC, 1994, P NATL ACAD SCI USA, V91, P3063, DOI 10.1073/pnas.91.8.3063; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; Vitale N, 1997, J BIOL CHEM, V272, P25077, DOI 10.1074/jbc.272.40.25077; Vitale N, 1996, P NATL ACAD SCI USA, V93, P1941, DOI 10.1073/pnas.93.5.1941; WELSH CF, 1994, J BIOL CHEM, V269, P15583; ZHANG GF, 1995, J BIOL CHEM, V270, P21, DOI 10.1074/jbc.270.1.21; Zhao LY, 1997, P NATL ACAD SCI USA, V94, P4418, DOI 10.1073/pnas.94.9.4418	47	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26543	26548		10.1074/jbc.273.41.26543	http://dx.doi.org/10.1074/jbc.273.41.26543			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756891	hybrid			2022-12-27	WOS:000076373300045
J	Parsons, MA; Sinden, RR; Izban, MG				Parsons, MA; Sinden, RR; Izban, MG			Transcriptional properties of RNA polymerase II within triplet repeat-containing DNA from the human myotonic dystrophy and fragile X loci	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-DISEASE GENES; C-TERMINAL DOMAIN; ELONGATION COMPLEX; TERNARY COMPLEXES; ESCHERICHIA-COLI; MESSENGER-RNA; TRINUCLEOTIDE REPEAT; CHAIN ELONGATION; NASCENT RNA; SITES INVITRO	Expansion of a (CTG)(n) segment within the 3'-untranslated region of the myotonic dystrophy protein kinase gene alters mRNA production. The inherent ability of RNA polymerase II to transcribe (CTG)(17-255) tracts corresponding to DNA from normal, unstable, and affected individuals, and the normal (CGG)(54) fragile X repeat tract, was analyzed using a synchronized in vitro transcription system. Core RNA polymerase II transcribed all repeat units irrespective of repeat length or orientation. However, approximately 50% of polymerases transiently halted transcription (with a half-life of approximately 10 +/- 1 s) within the first and second CTG repeat unit and a more transient barrier to elongation was observed roughly centered within repeats 6-9. Transcription within the remainder of the CTG tracts and within the CCG, CGG, and CAG tracts appeared uniform with average transcription rates of 170, 250, 300, and 410 nucleotides/min, respectively. These differences correlated with changes in the sequence-specific transient pausing pattern within the CNG repeat tracts; individual incorporation rates were slower after incorporation of pyrimidine residues. Unexpectedly, approximately 4% of the run-off transcripts were, depending on the repeat sequence, either 15 or 18 nucleotides longer than expected, However, these products were not produced by transcriptional slippage within the repeat tract.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Dept Obstet & Gynecol, Galveston, TX 77555 USA; Texas A&M Univ, Ctr Genome Res, Inst Biosci & Technol, Dept Biochem & Biophys, Houston, TX 77030 USA	University of Texas System; University of Texas Medical Branch Galveston; Texas A&M University System	Sinden, RR (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, Dept Obstet & Gynecol, Galveston, TX 77555 USA.		Sinden, Richard/AAE-3086-2019		NIGMS NIH HHS [GM50719, GM52982] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIVAZASHVILI VA, 1982, MOL BIOL, V15, P711; Ashley CT, 1995, ANNU REV GENET, V29, P703, DOI 10.1146/annurev.ge.29.120195.003415; ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; Bacolla A, 1997, J BIOL CHEM, V272, P16783, DOI 10.1074/jbc.272.27.16783; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BENGAL E, 1989, J BIOL CHEM, V264, P9791; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; CARANGO P, 1993, GENOMICS, V18, P340, DOI 10.1006/geno.1993.1474; CHAFIN DR, 1995, J BIOL CHEM, V270, P19114, DOI 10.1074/jbc.270.32.19114; Chamberlin M.J., 1994, HARVEY LECT, V88, P1; CHAN CL, 1993, J MOL BIOL, V233, P25, DOI 10.1006/jmbi.1993.1482; Chastain PD, 1998, J MOL BIOL, V275, P405, DOI 10.1006/jmbi.1997.1502; Chastain PD, 1995, BIOCHEMISTRY-US, V34, P16125, DOI 10.1021/bi00049a027; Davis BM, 1997, P NATL ACAD SCI USA, V94, P7388, DOI 10.1073/pnas.94.14.7388; DEDRICK RL, 1987, J BIOL CHEM, V262, P9098; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; ENRIQUEZHARRIS P, 1991, EMBO J, V10, P1833, DOI 10.1002/j.1460-2075.1991.tb07709.x; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; Godde JS, 1996, J BIOL CHEM, V271, P15222, DOI 10.1074/jbc.271.25.15222; Gu WG, 1996, P NATL ACAD SCI USA, V93, P6935, DOI 10.1073/pnas.93.14.6935; GU WG, 1995, J BIOL CHEM, V270, P11238, DOI 10.1074/jbc.270.19.11238; GU WG, 1993, J BIOL CHEM, V268, P25604; GUO HL, 1993, J BIOL CHEM, V268, P18762; Hamshere MG, 1997, P NATL ACAD SCI USA, V94, P7394, DOI 10.1073/pnas.94.14.7394; IWABE N, 1991, J MOL EVOL, V32, P70, DOI 10.1007/BF02099931; Izban MG, 1998, J BIOL CHEM, V273, P27009, DOI 10.1074/jbc.273.41.27009; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; IZBAN MG, 1995, J BIOL CHEM, V270, P2290, DOI 10.1074/jbc.270.5.2290; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KINGSTON RE, 1981, J BIOL CHEM, V256, P2787; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; KRAHE R, 1995, GENOMICS, V28, P1, DOI 10.1006/geno.1995.1099; Landick R, 1997, CELL, V88, P741, DOI 10.1016/S0092-8674(00)81919-4; LEVIN JR, 1987, J MOL BIOL, V196, P61, DOI 10.1016/0022-2836(87)90511-0; LONDON L, 1991, MOL CELL BIOL, V11, P4599, DOI 10.1128/MCB.11.9.4599; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; NOVELLI G, 1993, BIOCHEM MOL BIOL INT, V29, P291; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; OTTEN AD, 1995, P NATL ACAD SCI USA, V92, P5465, DOI 10.1073/pnas.92.12.5465; Pearson CE, 1996, BIOCHEMISTRY-US, V35, P5041, DOI 10.1021/bi9601013; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; PRICE DH, 1987, J BIOL CHEM, V262, P3244; Reeder TC, 1996, CELL, V87, P767, DOI 10.1016/S0092-8674(00)81395-1; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; RHODES G, 1974, J BIOL CHEM, V249, P6675; RICE GA, 1993, NUCLEIC ACIDS RES, V21, P113, DOI 10.1093/nar/21.1.113; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P8057, DOI 10.1073/pnas.91.17.8057; SABOURI LA, 1993, NAT GENET, V4, P233, DOI 10.1038/ng0793-233; Samkurashvili I, 1996, J BIOL CHEM, V271, P23495, DOI 10.1074/jbc.271.38.23495; SMEETS HJM, 1995, HUM MOL GENET, V4, P2103, DOI 10.1093/hmg/4.11.2103; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; WANG YH, 1995, GENOMICS, V25, P570, DOI 10.1016/0888-7543(95)80061-P; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; WIEST DK, 1992, J BIOL CHEM, V267, P7733; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975	66	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26998	27008		10.1074/jbc.273.41.26998	http://dx.doi.org/10.1074/jbc.273.41.26998			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756950	hybrid			2022-12-27	WOS:000076373300104
J	Rhodes, K; Oshima, RG				Rhodes, K; Oshima, RG			A regulatory element of the human keratin 18 gene with AP-1-dependent promoter activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; MESSENGER-RNA; TRANSCRIPTIONAL INSULATION; CRYPTIC PROMOTER; INTRON ENHANCER; C-FOS; EXPRESSION; CELLS; ACTIVATION; SEQUENCES	The human keratin 18 (K18) gene is expressed in a restricted but diverse subset of differentiated epithelial tissues and carcinomas, The 10-kilobase pair K18 gene contains all of the genetic information necessary for tissue-specific, copy number-dependent and integration site-independent expression in transgenic mice. We identified a 100-base pair regulatory element that activates the K18 proximal promoter in the presence of the previously identified first intron enhancer. Deletion of the element greatly diminished K18 expression. This regulatory element also has cryptic, AP-1-dependent promoter activity in the absence of the normal promoter, which results in 10-40-fold higher levels of K18 RNA expression in transgenic mice. The high activity of this cryptic promoter is dependent upon the first intron enhancer. These experiments define interactive regulatory regions of the K18 gene that modulate expression in diverse epithelial cell types and identify an unusual regulatory element with promoter activity that may be useful for high level heterologous gene expression in transgenic animals.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Oshima, RG (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	rgoshima@ljcrf.edu			NCI NIH HHS [5 R01 CA42302, 5 P30 CA30199] Funding Source: Medline; NICHD NIH HHS [N01 HD-0-2911] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD002911] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA042302, P30CA030199] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE M, 1990, J CELL BIOL, V111, P1197, DOI 10.1083/jcb.111.3.1197; ALSHAWI R, 1991, MOL CELL BIOL, V11, P4207, DOI 10.1128/MCB.11.8.4207; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FOUREL G, 1992, MOL CELL BIOL, V12, P5336, DOI 10.1128/MCB.12.12.5336; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, P29; GUNTHER M, 1995, MOL CELL BIOL, V15, P2490; HAGAN KW, 1995, MOL CELL BIOL, V15, P809; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Hansen SK, 1997, CELL, V91, P71, DOI 10.1016/S0092-8674(01)80010-6; HOGAN B, 1987, MANIPULATING MOUSE E; HSU J, 1991, P NATL ACAD SCI USA, V38, P3511; IRNIGER S, 1992, NUCLEIC ACIDS RES, V20, P4733, DOI 10.1093/nar/20.18.4733; KULESH DA, 1988, MOL CELL BIOL, V8, P1540, DOI 10.1128/MCB.8.4.1540; KULESH DA, 1989, GENOMICS, V4, P339, DOI 10.1016/0888-7543(89)90340-6; LEPAGE P, 1995, VIROLOGY, V210, P244, DOI 10.1006/viro.1995.1341; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MORELLO D, 1986, EMBO J, V5, P1877, DOI 10.1002/j.1460-2075.1986.tb04439.x; MULLICK J, 1995, BIOCHEMISTRY-US, V34, P13729, DOI 10.1021/bi00042a003; Neznanov N, 1997, J BIOL CHEM, V272, P27549, DOI 10.1074/jbc.272.44.27549; NEZNANOV N, 1993, MOL CELL BIOL, V13, P2214, DOI 10.1128/MCB.13.4.2214; Neznanov N, 1996, MOL BIOL CELL, V7, P541, DOI 10.1091/mbc.7.4.541; NEZNANOV NS, 1993, MOL CELL BIOL, V13, P1815, DOI 10.1128/MCB.13.3.1815; OSBALDESTON NJ, 1995, BIOCHEM J, V308, P465, DOI 10.1042/bj3080465; OSHIMA RG, 1990, GENE DEV, V4, P835, DOI 10.1101/gad.4.5.835; Oshima RG, 1996, CANCER METAST REV, V15, P445, DOI 10.1007/BF00054012; OSHIMA RG, 1988, GENE DEV, V2, P505, DOI 10.1101/gad.2.5.505; PACHTER JS, 1987, CELL, V51, P283, DOI 10.1016/0092-8674(87)90155-3; PANKOV R, 1994, MOL CELL BIOL, V14, P7744, DOI 10.1128/MCB.14.12.7744; PANKOV R, 1994, P NATL ACAD SCI USA, V91, P873, DOI 10.1073/pnas.91.3.873; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; Sambrook J, 1989, MOL CLONING LAB MANU, P165; TAYLOR JM, 1995, J BIOL CHEM, V270, P2535, DOI 10.1074/jbc.270.6.2535; TEE MK, 1995, HUM MOL GENET, V4, P2109, DOI 10.1093/hmg/4.11.2109; THOREY IS, 1993, DEV BIOL, V160, P519, DOI 10.1006/dbio.1993.1326; THOREY IS, 1993, MOL CELL BIOL, V13, P6742, DOI 10.1128/MCB.13.11.6742; TURPEN T H, 1986, Biotechniques, V4, P14; Umezawa A, 1997, MOL CELL BIOL, V17, P4885, DOI 10.1128/MCB.17.9.4885; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; Yamamoto H, 1998, GENE DEV, V12, P1315, DOI 10.1101/gad.12.9.1315	41	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26534	26542		10.1074/jbc.273.41.26534	http://dx.doi.org/10.1074/jbc.273.41.26534			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756890	hybrid			2022-12-27	WOS:000076373300044
J	Rizzo, V; Sung, A; Oh, P; Schnitzer, JE				Rizzo, V; Sung, A; Oh, P; Schnitzer, JE			Rapid mechanotransduction in situ at the luminal cell surface of vascular endothelium and its caveolae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	13th Bodensee Symposium on Microcirculation	JUN 09-10, 1995	BAD SCHACHEN, GERMANY	Medisan AB, Uppsala			FLUID SHEAR-STRESS; NITRIC-OXIDE SYNTHASE; ACTIVATED PROTEIN-KINASE; GENE-EXPRESSION; TYROSINE PHOSPHORYLATION; PROSTACYCLIN PRODUCTION; INOSITOL TRISPHOSPHATE; SIGNAL-TRANSDUCTION; RAF-1 KINASE; KAPPA-B	The vascular endothelium is uniquely positioned between the blood and tissue compartments to receive directly the fluid forces generated by the blood flowing through the vasculature. These forces invoke specific responses within endothelial cells and serve to modulate their intrinsic structure and function. The mechanisms by which hemodynamic forces are detected and converted by endothelia into a sequence of biological and even pathological responses are presently unknown. By purifying and subfractionating the luminal endothelial cell plasma membrane from tissue, we show, for the first time, that not only does mechanotransduction occur at the endothelial cell surface directly exposed to vascular flow in, vivo but also increased flow in situ induces rapid tyrosine phosphorylation of luminal endothelial cell surface proteins located primarily in the plasmalemmal invaginations called caveolae. Increased flow induces the translocation of signaling molecules primarily to caveolae, ultimately activating the Ras-Raf-mitogen-activated protein kinase pathway. This signaling appears to require intact caveolae. Filipin-induced disassembly of caveolae inhibits both proximal signaling events at the cell surface and downstream activation of the mitogen-activated protein kinase pathway. With the molecular machinery required for mediating rapid flow-induced responses as seen in endothelium, caveolae may be flow-sensing organelles converting mechanical stimuli into chemical signals transmitted into the cell.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Schnitzer, JE (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave, Boston, MA 02215 USA.	jschnitz@bidmc.harvard.edu			NHLBI NIH HHS [HL52766, HL58216, HL09857-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058216, R01HL052766, F32HL009857] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Ayajiki K, 1996, CIRC RES, V78, P750, DOI 10.1161/01.RES.78.5.750; Berk BC, 1995, J BIOMECH, V28, P1439, DOI 10.1016/0021-9290(95)00092-5; BERTHIAUME F, 1992, FEBS LETT, V308, P277, DOI 10.1016/0014-5793(92)81292-T; BHAGYALAKSHMI A, 1992, J VASC RES, V29, P443, DOI 10.1159/000158963; COLLINS T, 1993, LAB INVEST, V68, P499; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; Du W, 1995, J BIOMECH, V28, P1485, DOI 10.1016/0021-9290(95)00096-8; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FRANGOS JA, 1985, SCIENCE, V227, P1477, DOI 10.1126/science.3883488; FRANKE RP, 1984, NATURE, V307, P648, DOI 10.1038/307648a0; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; GEIGER RV, 1992, AM J PHYSIOL, V262, pC1411, DOI 10.1152/ajpcell.1992.262.6.C1411; Gimbrone MA, 1997, ANN NY ACAD SCI, V811, P1, DOI 10.1111/j.1749-6632.1997.tb51983.x; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; LANGILLE BL, 1986, SCIENCE, V231, P405, DOI 10.1126/science.3941904; LANSMAN JB, 1987, NATURE, V325, P811, DOI 10.1038/325811a0; LEE J, 1995, ANN BIOMED ENG, V23, P226, DOI 10.1007/BF02584425; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li YS, 1996, MOL CELL BIOL, V16, P5947; Lindner V, 1996, AM J PATHOL, V148, P427; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Malek AM, 1995, J BIOMECH, V28, P1515, DOI 10.1016/0021-9290(95)00099-2; MELKUMYANTS AM, 1995, NEWS PHYSIOL SCI, V10, P204; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; OLESEN SP, 1988, NATURE, V331, P168, DOI 10.1038/331168a0; RESNICK N, 1995, FASEB J, V9, P874, DOI 10.1096/fasebj.9.10.7615157; Rizzo V, 1998, FASEB J, V12, pA187; ROSALES OR, 1992, AM J PHYSIOL, V262, pC956, DOI 10.1152/ajpcell.1992.262.4.C956; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; Schnitzer J. E., 1997, VASCULAR ENDOTHELIUM, P77; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; Schnitzer JE, 1996, SCIENCE, V274, P239, DOI 10.1126/science.274.5285.239; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; SCHNITZER JE, 1995, ANN BIOMED ENG, V23, pS34; SHEN J, 1992, AM J PHYSIOL, V262, pC384, DOI 10.1152/ajpcell.1992.262.2.C384; SIMIONESCU M, 1984, HDB PHYSL, V4; Skalak Thomas C., 1996, Microcirculation (Philadelphia), V3, P143, DOI 10.3109/10739689609148284; SUMPIO BE, 1994, J CELL PHYSIOL, V158, P133, DOI 10.1002/jcp.1041580117; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TSENG H, 1995, CIRC RES, V77, P869, DOI 10.1161/01.RES.77.5.869; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922	56	135	139	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26323	26329		10.1074/jbc.273.41.26323	http://dx.doi.org/10.1074/jbc.273.41.26323			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	127WJ	9756862	hybrid			2022-12-27	WOS:000076373300016
J	Yokoyama, K; Trobridge, P; Buckner, FS; Van Voorhis, WC; Stuart, KD; Gelb, MH				Yokoyama, K; Trobridge, P; Buckner, FS; Van Voorhis, WC; Stuart, KD; Gelb, MH			Protein farnesyltransferase from Trypanosoma brucei - A heterodimer of 61- and 65-kDa subunits as a new target for antiparasite therapeutics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAB GERANYLGERANYL TRANSFERASE; BINDING PROTEINS; SACCHAROMYCES-CEREVISIAE; TRICYCLIC INHIBITORS; METAL REQUIREMENTS; ALPHA-SUBUNIT; CDNA CLONING; GENE-PRODUCT; ANIMAL-CELLS; COMPONENT-A	We have previously shown that protein prenylation occurs in the Trypanosomatids Trypanosoma brucei (T, brucei), Trypanosoma cruzi, and Leishmania mexicana and that protein farnesyltransferase (PFT) activity can be detected in cytosolic extracts of insect (procyclic) form T, brucei, A PFT that transfers the farnesyl group from farnesyl pyrophosphate to a cysteine that is 4 residues upstream of the C terminus of the Ras GTP-binding protein RAS1-CVIM has now been purified 60,000-fold to near homogeneity from procyclic T, brucei. By screening a mixture of hexapeptides SSCALX (X is 20 different amino acids), it was found that SSCALM binds to T, brucei PFT with sub-micromolar affinity, and affinity chromatography using this peptide was a key step in the purification of this enzyme. On SDS-polyacrylamide gel electrophoresis, the enzyme migrates as a pair of bands with apparent molecular masses of 61 and 65 kDa, and thus its subunits are similar to 30% larger than those of the mammalian homolog, The 61-kDa band was identified as the putative beta-subunit by photoaffinity labeling with a P-32-labeled analog of farnesyl pyrophosphate, Mimetics of the C-terminal tetrapeptide of prenyl accepters have been previously shown to inhibit mammalian PFT, and these compounds also inhibit T. brucei PFT with affinities in the nanomolar to micromolar range, although the structure-activity relationship is very different for parasite versus mammalian enzyme. Unlike mammalian cells, the growth of bloodstream T, brucei is completely inhibited by low micromolar concentrations of two of the PFT inhibitors, and these compounds also block protein farnesylation in cultured parasites. These compounds also potently block the growth of the intracellular (amastigote) form of T, cruzi grown in fibroblast host cells. The results suggest that protein farnesylation is a target for the development of anti-trypanosomatid chemotherapeutics.	Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA; Seattle Biomed Res Inst, Seattle, WA 98109 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Center for Infectious Disease Research; University of Washington; University of Washington Seattle	Gelb, MH (corresponding author), Univ Washington, Dept Chem, Box 351700, Seattle, WA 98195 USA.		Buckner, Frederick/AAF-3938-2020	gelb, michael/0000-0001-7000-5219; Buckner, Frederick/0000-0001-7796-6477	NATIONAL CANCER INSTITUTE [R01CA052874] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI014102, R01AI014102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042188] Funding Source: NIH RePORTER; NCI NIH HHS [CA52874] Funding Source: Medline; NIAID NIH HHS [R01 AI014102, AI14102] Funding Source: Medline; NIGMS NIH HHS [R01 GM042188, GM42188] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN CM, 1985, METHOD ENZYMOL, V110, P117; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARMSTRONG SA, 1993, J BIOL CHEM, V268, P12221; Bishop WR, 1995, J BIOL CHEM, V270, P30611, DOI 10.1074/jbc.270.51.30611; Bubis Jose, 1993, Biological Research, V26, P177; Buckner FS, 1996, ANTIMICROB AGENTS CH, V40, P2592, DOI 10.1128/AAC.40.11.2592; CAPPAI R, 1993, MOL BIOCHEM PARASIT, V62, P73, DOI 10.1016/0166-6851(93)90179-2; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CASSEL D, 1991, EXP PARASITOL, V72, P411, DOI 10.1016/0014-4894(91)90087-D; CHEN GZ, 1993, MOL BIOCHEM PARASIT, V59, P287, DOI 10.1016/0166-6851(93)90226-N; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; COSO OA, 1992, BIOCH J; COULTER LJ, 1995, EXP PARASITOL, V80, P308, DOI 10.1006/expr.1995.1037; EISENSCHLOS CD, 1986, BIOCHEM J, V237, P913, DOI 10.1042/bj2370913; ELSAYED NMA, 1995, MOL BIOCHEM PARASIT, V73, P75, DOI 10.1016/0166-6851(95)00098-L; FARNSWORTH CC, 1994, P NATL ACAD SCI USA, V91, P11963, DOI 10.1073/pnas.91.25.11963; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; Field H, 1996, MOL BIOCHEM PARASIT, V82, P67, DOI 10.1016/0166-6851(96)02723-5; Field H, 1997, J BIOL CHEM, V272, P10498, DOI 10.1074/jbc.272.16.10498; Field MC, 1995, EXP PARASITOL, V81, P313, DOI 10.1006/expr.1995.1122; FINEGOLD AA, 1991, P NATL ACAD SCI USA, V88, P4448, DOI 10.1073/pnas.88.10.4448; Gelb MH, 1998, CURR OPIN CHEM BIOL, V2, P40, DOI 10.1016/S1367-5931(98)80034-3; GLOMSET JA, 1992, BIOCHEM SOC T, V20, P479, DOI 10.1042/bst0200479; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GONZALESPERDOMO M, 1988, EXP PARASITOL, V66, P205, DOI 10.1016/0014-4894(88)90092-6; GOODMAN LE, 1990, P NATL ACAD SCI USA, V87, P9665, DOI 10.1073/pnas.87.24.9665; James G, 1996, P NATL ACAD SCI USA, V93, P4454, DOI 10.1073/pnas.93.9.4454; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; Koblan KS, 1996, BIOCHEM SOC T, V24, P688, DOI 10.1042/bst0240688; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; Leonard DM, 1997, J MED CHEM, V40, P2971, DOI 10.1021/jm970226l; LUJAN HD, 1995, MOL BIOCHEM PARASIT, V72, P121, DOI 10.1016/0166-6851(94)00070-4; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MCGEADY P, 1995, J BIOL CHEM, V270, P26347, DOI 10.1074/jbc.270.44.26347; McGuire TF, 1996, J BIOL CHEM, V271, P27402, DOI 10.1074/jbc.271.44.27402; Mendonca Sergio M., 1993, Biological Research, V26, P3; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; MUSHA T, 1992, J BIOL CHEM, V267, P9821; Njoroge FG, 1997, BIOORGAN MED CHEM, V5, P101, DOI 10.1016/S0968-0896(96)00206-4; Noguchi Y, 1998, J BIOL CHEM, V273, P3649, DOI 10.1074/jbc.273.6.3649; OLIVEIRA MM, 1993, MOL CELL BIOCHEM, V124, P91, DOI 10.1007/BF00929200; OMER CA, 1993, BIOCHEMISTRY-US, V32, P5167, DOI 10.1021/bi00070a028; Otto JC, 1996, J BIOL CHEM, V271, P4569; OZ HS, 1994, AM J TROP MED HYG, V50, P620, DOI 10.4269/ajtmh.1994.50.620; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; POMPLIANO DL, 1993, BIOCHEMISTRY-US, V32, P8341, DOI 10.1021/bi00083a038; Qian YM, 1997, BIOPOLYMERS, V43, P25, DOI 10.1002/(SICI)1097-0282(1997)43:1<25::AID-BIP4>3.0.CO;2-2; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SAKAGAMI Y, 1978, AGR BIOL CHEM TOKYO, V42, P1093, DOI 10.1080/00021369.1978.10863118; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; Siddiqui AA, 1998, J BIOL CHEM, V273, P3712, DOI 10.1074/jbc.273.6.3712; Sun JZ, 1998, ONCOGENE, V16, P1467, DOI 10.1038/sj.onc.1201656; Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224; Vogt A, 1996, ONCOGENE, V13, P1991; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Williams TM, 1996, J MED CHEM, V39, P1345, DOI 10.1021/jm9508090; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; Yokoyama K, 1997, MOL BIOCHEM PARASIT, V87, P61, DOI 10.1016/S0166-6851(97)00043-1; YOKOYAMA K, 1995, BIOCHEMISTRY-US, V34, P1344, DOI 10.1021/bi00004a029; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; YOKOYAMA K, 1993, J BIOL CHEM, V268, P4055; YOKOYAMA K, 1998, IN PRESS MOL BIOCH P; YOKOYAMA K, 1992, BIOCHEM SOC T, V20, P479; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	70	62	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26497	26505		10.1074/jbc.273.41.26497	http://dx.doi.org/10.1074/jbc.273.41.26497			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756885	hybrid			2022-12-27	WOS:000076373300039
J	Boot, RG; Renkema, GH; Verhoek, M; Strijland, A; Bliek, J; de Meulemeester, TMAMO; Mannens, MMAM; Aerts, JMFG				Boot, RG; Renkema, GH; Verhoek, M; Strijland, A; Bliek, J; de Meulemeester, TMAMO; Mannens, MMAM; Aerts, JMFG			The human chitotriosidase gene - Nature of inherited enzyme deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHITINASE PROTEIN FAMILY; MOLECULAR CHARACTERIZATION; ANTIFUNGAL PROPERTIES; PLANT CHITINASES; EXON MUTATION; EXPRESSION; CLONING; PURIFICATION; RESOLUTION; INHIBITORS	The human chitinase, named chitotriosidase, is a member of family 18 of glycosylhydrolases. Following the cloning of the chitotriosidase cDNA (Boot, R. G., Renkema, G. H., Strijland, A., van Zonneveld, A. J., and Aerts, J. M. F. G. (1995) J. Biol. Chem. 270, 26252-26256), the gene and mRNA have been investigated. The chitotriosidase gene is assigned to chromosome 1q31-q32. The gene consists of 12 exons and spans about 20 kilobases, The nature of the common deficiency in chitotriosidase activity is reported. A 24-base pair duplication in exon 10 results in activation of a cryptic 3' splice site, generating a mRNA with an in-frame deletion of 87 nucleotides. All chitotriosidase-deficient individuals tested were homozygous for the duplication. The observed carrier frequency of about 35% indicates that the duplication is the predominant cause of chitotriosidase deficiency, The presence of the duplication in individuals from various ethnic groups suggests that this mutation is relatively old.	Univ Amsterdam, Acad Med Ctr, Dept Biochem, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Inst Anthropogenet, Dept Clin Genet, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	Aerts, JMFG (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Biochem, POB 22700, NL-1100 DE Amsterdam, Netherlands.		Aerts, Johannes/A-1028-2009; Renkema, Herma/L-1489-2015	Aerts, Johannes/0000-0001-8168-2565; Renkema, Herma/0000-0002-8174-6538; Boot, Rolf/0000-0002-7031-3390				ARIAS EB, 1994, BIOL REPROD, V51, P685, DOI 10.1095/biolreprod51.4.685; Barranger J. A., 1989, METABOLIC BASIS INHE, P1677; BENHAMOU N, 1993, CAN J MICROBIOL, V39, P318, DOI 10.1139/m93-045; BOOT RG, 1995, J BIOL CHEM, V270, P26252, DOI 10.1074/jbc.270.44.26252; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BROEKAERT WF, 1988, PHYSIOL MOL PLANT P, V33, P319, DOI 10.1016/0885-5765(88)90001-X; CAMARA VM, 1990, LAB INVEST, V63, P544; COLLINGE DB, 1993, PLANT J, V3, P31, DOI 10.1046/j.1365-313X.1993.t01-1-00999.x; COULSON AFW, 1994, FEBS LETT, V354, P41, DOI 10.1016/0014-5793(94)01084-6; Eiberg H, 1997, HUM GENET, V101, P205, DOI 10.1007/s004390050615; FLACH J, 1992, EXPERIENTIA, V48, P701, DOI 10.1007/BF02124285; Guo YF, 1995, J INHERIT METAB DIS, V18, P717, DOI 10.1007/BF02436762; HASEGAWA Y, 1994, HUM GENET, V93, P415; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HOLLAK CEM, 1994, J CLIN INVEST, V93, P1288, DOI 10.1172/JCI117084; HOOVERS JMN, 1992, GENOMICS, V12, P254, DOI 10.1016/0888-7543(92)90372-Y; Hu B, 1996, J BIOL CHEM, V271, P19415, DOI 10.1074/jbc.271.32.19415; HUYNH QK, 1992, J BIOL CHEM, V267, P6635; JONK LJC, 1992, MECH DEVELOP, V36, P165, DOI 10.1016/0925-4773(92)90067-T; LEHRACH H., 1990, GENOME ANAL, P39; LIGHTENBERG JL, 1991, NUCLEIC ACIDS RES, V19, P297; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; PERRAKIS A, 1994, STRUCTURE, V2, P1169, DOI 10.1016/S0969-2126(94)00119-7; Rehli M, 1997, GENOMICS, V43, P221, DOI 10.1006/geno.1997.4778; RENKEMA GH, 1995, J BIOL CHEM, V270, P2198, DOI 10.1074/jbc.270.5.2198; Renkema GH, 1997, EUR J BIOCHEM, V244, P279, DOI 10.1111/j.1432-1033.1997.00279.x; ROBERTS WK, 1988, J GEN MICROBIOL, V134, P169; SAHAI AS, 1993, FEMS MICROBIOL REV, V11, P317, DOI 10.1111/j.1574-6976.1993.tb00004.x; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLUMBAUM A, 1986, NATURE, V324, P365, DOI 10.1038/324365a0; VANSCHELTINGA ACT, 1994, STRUCTURE, V2, P1181, DOI 10.1016/S0969-2126(94)00120-0; WAKAMATSU N, 1992, J BIOL CHEM, V267, P2406; WIEGANT J, 1991, GENOMICS, V10, P345, DOI 10.1016/0888-7543(91)90318-9	34	327	351	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25680	25685		10.1074/jbc.273.40.25680	http://dx.doi.org/10.1074/jbc.273.40.25680			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748235	hybrid, Green Published			2022-12-27	WOS:000076263100026
J	Hussain, MM; Bakillah, A; Nayak, N; Shelness, GS				Hussain, MM; Bakillah, A; Nayak, N; Shelness, GS			Amino acids 430-570 in apolipoprotein B are critical for its binding to microsomal triglyceride transfer protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; HEPG2 CELLS; SECRETION; ABETALIPOPROTEINEMIA; DEGRADATION; EXPRESSION; INHIBITION; DOMAIN; B-100	Several studies have demonstrated protein-protein interactions between microsomal triglyceride transfer protein (MTP) and apolipoprotein B (apoB). However, the binding sites involved in these interactions have not been elucidated. To identify an MTP binding site in apoB, we have expressed several apoB sequences as fusion proteins with the eight-amino acid FLAG peptide. The chimeras were transiently expressed in COS cells, and conditioned media were used to study the binding of these sequences to either immobilized or soluble MTP. A polypeptide containing amino acids 270-570 (B:270-570), but not 1-300, bound to MTP. AGI-S17, an antagonist of apoB-MTP binding, inhibited the binding of B:270-570 to MTP but not to M2, a monoclonal antibody that recognizes the FLAG peptide. These data indicated that B:270-570 contains an MTP binding site. Next, sequences within 270-570 were subjected to C-terminal truncations at natural proline residues. B:270-509 bound less efficiently than B:270-570, whereas, B:270-430 and other shorter chimeras did not bind to MTP. Furthermore, truncations at amino acids 502 and 509 decreased MTP binding by 73 and 42%, respectively. These data indicate that B:430-570 in the alpha(1)-globular domain of apoB plays a crucial role in MTP binding and presumably in the initiation and maturation of apoB-containing lipoproteins.	Allegheny Univ Hlth Sci, MCP Hahnemann Sch Med, Dept Pathol, Philadelphia, PA 19129 USA; Allegheny Univ Hlth Sci, MCP Hahnemann Sch Med, Dept Biochem, Philadelphia, PA 19129 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Winston Salem, NC 27103 USA	Drexel University; Drexel University; Wake Forest University; Wake Forest Baptist Medical Center	Hussain, MM (corresponding author), Allegheny Univ Hlth Sci, MCP Hahnemann Sch Med, Dept Pathol, 2900 Queen Lane, Philadelphia, PA 19129 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633, P01HL049373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046900, R01DK046900, R29DK046900] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-22633, HL-49373] Funding Source: Medline; NIDDK NIH HHS [DK-46900] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bakillah A, 1998, BIOCHEMISTRY-US, V37, P3727, DOI 10.1021/bi972629t; Bakillah A, 1997, LIPIDS, V32, P1113, DOI 10.1007/s11745-997-0143-8; Benoist F, 1996, EUR J BIOCHEM, V240, P713, DOI 10.1111/j.1432-1033.1996.0713h.x; Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; Boren J, 1998, J CLIN INVEST, V101, P1084, DOI 10.1172/JCI1847; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; EBERT DL, 1988, J LIPID RES, V29, P1501; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; Gordon DA, 1996, J BIOL CHEM, V271, P33047, DOI 10.1074/jbc.271.51.33047; Gregg Richard E., 1994, Current Opinion in Lipidology, V5, P81, DOI 10.1097/00041433-199404000-00003; Gretch DG, 1996, J BIOL CHEM, V271, P8682, DOI 10.1074/jbc.271.15.8682; Haghpassand M, 1996, J LIPID RES, V37, P1468; Huang XF, 1997, J BIOL CHEM, V272, P31872, DOI 10.1074/jbc.272.50.31872; Hussain MM, 1997, BIOCHEMISTRY-US, V36, P13060, DOI 10.1021/bi971395a; HUSSAIN MM, 1995, ARTERIOSCL THROM VAS, V15, P485, DOI 10.1161/01.ATV.15.4.485; Ingram MF, 1997, J BIOL CHEM, V272, P10279; JAMIL H, 1995, J BIOL CHEM, V270, P6549, DOI 10.1074/jbc.270.12.6549; Jamil H, 1996, P NATL ACAD SCI USA, V93, P11991, DOI 10.1073/pnas.93.21.11991; Kane J.B., 1989, METABOLIC BASIS INHE, P1139; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; LINTON MF, 1993, J LIPID RES, V34, P521; Luchoomun J, 1997, ARTERIOSCL THROM VAS, V17, P2955, DOI 10.1161/01.ATV.17.11.2955; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; Sambrook J., 2002, MOL CLONING LAB MANU; SCHONFELD G, 1995, ANNU REV NUTR, V15, P23, DOI 10.1146/annurev.nu.15.070195.000323; Segrest JP, 1998, J LIPID RES, V39, P85; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; Shelness GS, 1996, J LIPID RES, V37, P408; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; Tran K, 1998, J BIOL CHEM, V273, P7244, DOI 10.1074/jbc.273.13.7244; Wang YW, 1997, J BIOL CHEM, V272, P12272, DOI 10.1074/jbc.272.19.12272; WEISGRABER KH, 1987, J BIOL CHEM, V262, P11097; WETTERAU JR, 1985, CHEM PHYS LIPIDS, V38, P205, DOI 10.1016/0009-3084(85)90068-4; Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3; WETTERAU JR, 1990, J BIOL CHEM, V265, P9801	35	80	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25612	25615		10.1074/jbc.273.40.25612	http://dx.doi.org/10.1074/jbc.273.40.25612			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748226	hybrid			2022-12-27	WOS:000076263100017
J	Kasus-Jacobi, A; Perdereau, D; Auzan, C; Clauser, E; Van Obberghen, E; Mauvais-Jarvis, F; Girard, J; Burnol, AF				Kasus-Jacobi, A; Perdereau, D; Auzan, C; Clauser, E; Van Obberghen, E; Mauvais-Jarvis, F; Girard, J; Burnol, AF			Identification of the rat adapter Grb14 as an inhibitor of insulin actions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; IGF-I RECEPTOR; STIMULATES TYROSINE PHOSPHORYLATION; YEAST 2-HYBRID SYSTEM; SH2 DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; GROWTH-HORMONE; CARBOXYL-TERMINUS; CRYSTAL-STRUCTURE; BINDING-PROTEIN	We cloned by interaction with the beta-subunit of the insulin receptor the rat variant of the human adapter Grb14 (rGrb14). rGrb14 is specifically expressed in rat insulin-sensitive tissues and in the brain. The binding of rGrb14 to insulin receptors is insulin-dependent in vivo in Chinese hamster ovary (CHO) cells overexpressing both proteins and importantly, in rat liver expressing physiological levels of proteins. However, rGrbl4 is not a substrate of the tyrosine kinase of the receptor. In the two-hybrid system, two domains of rGrbl4 can mediate the interaction with insulin receptors: the Src homology 2 (SH2) domain and a region between the PH and SH2 domains that we named PIR (for (p) under bar hosphorylated insulin receptor-(i) under bar nteracting (r) under bar egion). In vitro interaction assays using deletion mutants of rGrbl4 show that the PIR, but not the SH2 domain, is able to coprecipitate insulin receptors, suggesting that the PIR is the major binding domain of rGrb14. The interaction between rGrb14 and the insulin receptors is almost abolished by mutating tyrosine residue Tyr(1150) Or Tyr(1151) Of the receptor. The overexpression of rGrb14 in CHO-IR cells decreases insulin stimulation of both DNA and glycogen synthesis. These effects are accompanied by a decrease in insulin-stimulated tyrosine phosphorylation of IRS-1, but insulin receptor autophosphorylation is unaltered. These findings suggest that rGrbl4 could be a new downstream signaling component of the insulin-mediated pathways.	CNRS, UPR 1524, F-92190 Meudon, France; Coll France, INSERM, U36, F-75005 Paris, France; INSERM, U145, F-06107 Nice, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Burnol, AF (corresponding author), CNRS, UPR 1524, 9 Rue Jules Hetzel, F-92190 Meudon, France.	burnol@cnrs-bellevue.fr	Burnol, Anne-Francoise/P-2181-2017; KASUS-JACOBI, Anne/V-7799-2019	KASUS-JACOBI, Anne/0000-0003-3844-0450				ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; BELL GI, 1993, J BIOL CHEM, V268, P19161; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; Burks DJ, 1997, J BIOL CHEM, V272, P27716, DOI 10.1074/jbc.272.44.27716; BURNOL AF, 1990, BIOCHEM J, V270, P277, DOI 10.1042/bj2700277; Chen J, 1997, P NATL ACAD SCI USA, V94, P2295, DOI 10.1073/pnas.94.6.2295; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; Dey BR, 1996, MOL ENDOCRINOL, V10, P631, DOI 10.1210/me.10.6.631; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Hansen H, 1996, J BIOL CHEM, V271, P8882, DOI 10.1074/jbc.271.15.8882; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; Janes PW, 1997, J BIOL CHEM, V272, P8490, DOI 10.1074/jbc.272.13.8490; KasusJacobi A, 1997, J BIOL CHEM, V272, P17166, DOI 10.1074/jbc.272.27.17166; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KowalskiChauvel A, 1996, J BIOL CHEM, V271, P26356, DOI 10.1074/jbc.271.42.26356; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAMOTHE B, 1995, FEBS LETT, V373, P51, DOI 10.1016/0014-5793(95)01011-3; Laviola L, 1997, J CLIN INVEST, V99, P830, DOI 10.1172/JCI119246; LECONTE I, 1992, J BIOL CHEM, V267, P17415; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; LEVYTOLEDANO R, 1994, J BIOL CHEM, V269, P31178; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; MARGOLIS B, 1994, PROG BIOPHYS MOL BIO, V62, P223, DOI 10.1016/0079-6107(94)90013-2; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; Morrione A, 1997, J BIOL CHEM, V272, P26382, DOI 10.1074/jbc.272.42.26382; MYERS MG, 1995, TRENDS ENDOCRIN MET, V6, P209, DOI 10.1016/1043-2760(95)00092-V; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; ONeill TJ, 1997, J BIOL CHEM, V272, P10035; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; OOI J, 1995, ONCOGENE, V10, P1621; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; Ottinger EA, 1998, J BIOL CHEM, V273, P729, DOI 10.1074/jbc.273.2.729; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; Platanias LC, 1996, J BIOL CHEM, V271, P278, DOI 10.1074/jbc.271.1.278; REED BC, 1977, P NATL ACAD SCI USA, V74, P4876, DOI 10.1073/pnas.74.11.4876; Riedel H, 1997, J BIOCHEM-TOKYO, V122, P1105; Rui LY, 1997, MOL CELL BIOL, V17, P6633, DOI 10.1128/MCB.17.11.6633; SAAD MJA, 1994, MOL ENDOCRINOL, V8, P545, DOI 10.1210/me.8.5.545; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; SawkaVerhelle D, 1997, EUR J BIOCHEM, V250, P411, DOI 10.1111/j.1432-1033.1997.0411a.x; SawkaVerhelle D, 1997, J BIOL CHEM, V272, P16414, DOI 10.1074/jbc.272.26.16414; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; SOUZA SC, 1994, J BIOL CHEM, V269, P30085; STAUBS PA, 1994, J BIOL CHEM, V269, P27186; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; TartareDeckert S, 1996, ENDOCRINOLOGY, V137, P1019, DOI 10.1210/en.137.3.1019; Velloso LA, 1996, P NATL ACAD SCI USA, V93, P12490, DOI 10.1073/pnas.93.22.12490; Wang J, 1998, J BIOL CHEM, V273, P3136, DOI 10.1074/jbc.273.6.3136; Waters SB, 1996, TRENDS CELL BIOL, V6, P1, DOI 10.1016/0962-8924(96)81024-5; WHITE MF, 1994, J BIOL CHEM, V269, P1; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; Yokote K, 1996, J BIOL CHEM, V271, P30942, DOI 10.1074/jbc.271.48.30942	68	94	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26026	26035		10.1074/jbc.273.40.26026	http://dx.doi.org/10.1074/jbc.273.40.26026			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748281	hybrid			2022-12-27	WOS:000076263100072
J	Barbero, P; Rovere, C; De Bie, I; Seidah, N; Beaudet, A; Kitabgi, P				Barbero, P; Rovere, C; De Bie, I; Seidah, N; Beaudet, A; Kitabgi, P			PC5-A-mediated processing of pro-neurotensin in early compartments of the regulated secretory pathway of PC5-transfected PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROMEDIN-N-PRECURSOR; PROHORMONE CONVERTASES PC1; SUBTILISIN FAMILY; BIOCHEMICAL-CHARACTERIZATION; ENZYMATIC-PROPERTIES; ADRENAL-MEDULLA; IDENTIFICATION; CDNA; RAT; SEQUENCE	Among the members of the proprotein convertase (PC) family, PC1 and PC2 have well established roles as prohormone convertases. Another good candidate for this role is PC5-A that has been shown to be present in the regulated secretory pathway of certain neuroendocrine tissues, but evidence that it can process prohormones is lacking. To determine whether PC5-A could function as a prohormone convertase and to compare its cleavage specificity with that of PC1 and PC2, we stably transfected the rat pheochromocytoma PC12 cell line with PC5-A and analyzed the biosynthesis and subcellular localization of the enzyme, as well as its ability to process pro-neurotensin/neuromedin N (pro-NT/NN) into active peptides, Our data showed that in transfected PC12 cells, PC5-A was converted from its 126-kDa precursor form into a 117-kDa mature form and, to a lesser extent, into a C-terminally truncated 65-kDa form of the 117-kDa product. Metabolic and immunochemical studies showed that PC5-A was sorted to early compartments of the regulated secretory pathway where it colocalized with immunoreactive NT. Furthermore, pro-NT/NN was processed in these compartments according to a pattern that differed from that previously described in PC1- and PC2-transfected PC12 cells. This pattern resembled that previously reported for pro-NT/NN processing in the adrenal medulla, a tissue known to express high levels of PC5-A. Altogether, these data demonstrate for the first time the ability of PC5-A to function as a prohormone convertase in the regulated secretory pathway and suggest a role for this enzyme in the physiological processing of pro-NT/NN.	Univ Nice Sophia Antipolis, CNRS, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada; Clin Res Inst Montreal, Biochem Neuroendocrinol Lab, Montreal, PQ H2W 1R7, Canada	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; McGill University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Kitabgi, P (corresponding author), Univ Nice Sophia Antipolis, CNRS, Inst Pharmacol Mol & Cellulaire, 660 Route Lucioles, F-06560 Valbonne, France.	kitabgi@ipmc.cnrs.fr	Seidah, Nabil/I-3596-2013; Rovere-Jovene, Carole/O-4557-2016	Seidah, Nabil/0000-0001-6503-9342; Rovere-Jovene, Carole/0000-0001-9400-7972				BAILYES EM, 1992, BIOCHEM J, V285, P391, DOI 10.1042/bj2850391; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENNETT DL, 1992, J BIOL CHEM, V267, P15229; BIDARD JN, 1993, BIOCHEM J, V291, P225, DOI 10.1042/bj2910225; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; Campan M, 1996, BIOCHEMISTRY-US, V35, P3797, DOI 10.1021/bi952552d; CARRAWAY RE, 1990, J BIOL CHEM, V265, P8627; CARRAWAY RE, 1993, REGUL PEPTIDES, V43, P97, DOI 10.1016/0167-0115(93)90412-2; CARRAWAY RE, 1993, PEPTIDES, V14, P991, DOI 10.1016/0196-9781(93)90076-S; CARRAWAY RE, 1992, ANN NY ACAD SCI, V668, P1, DOI 10.1111/j.1749-6632.1992.tb27335.x; CARRAWAY RE, 1991, BIOCHEM BIOPH RES CO, V179, P301, DOI 10.1016/0006-291X(91)91369-N; CORDER R, 1982, NEUROPEPTIDES, V3, P9, DOI 10.1016/0143-4179(82)90061-0; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; DeBie I, 1996, J CELL BIOL, V135, P1261, DOI 10.1083/jcb.135.5.1261; DENADAI F, 1994, NEUROSCIENCE, V60, P159, DOI 10.1016/0306-4522(94)90211-9; DITTIE AS, 1995, BIOCHEM J, V310, P777, DOI 10.1042/bj3100777; DOBNER PR, 1987, P NATL ACAD SCI USA, V84, P3516, DOI 10.1073/pnas.84.10.3516; FISCHERCOLBRIE R, 1992, J NEUROCHEM, V59, P780, DOI 10.1111/j.1471-4159.1992.tb09440.x; GOEDERT M, 1983, NEUROSCI LETT, V35, P155, DOI 10.1016/0304-3940(83)90543-8; GONATAS JO, 1995, J CELL SCI, V108, P457; HALBAN PA, 1994, BIOCHEM J, V299, P1; Jutras I, 1997, J BIOL CHEM, V272, P15184, DOI 10.1074/jbc.272.24.15184; KISLAUSKIS E, 1988, J BIOL CHEM, V263, P4963; LINDBERG I, 1994, MOL CELL NEUROSCI, V5, P614, DOI 10.1006/mcne.1994.1075; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; Nachtigal MW, 1996, P NATL ACAD SCI USA, V93, P7711, DOI 10.1073/pnas.93.15.7711; NAKAGAWA T, 1993, J BIOCHEM-TOKYO, V113, P132, DOI 10.1093/oxfordjournals.jbchem.a124015; NAKAGAWA T, 1993, FEBS LETT, V327, P165, DOI 10.1016/0014-5793(93)80163-O; ROTHENBERG ME, 1995, J BIOL CHEM, V270, P10136, DOI 10.1074/jbc.270.17.10136; ROUILLE Y, 1994, P NATL ACAD SCI USA, V91, P3242, DOI 10.1073/pnas.91.8.3242; ROUILLE Y, 1995, J BIOL CHEM, V270, P26488, DOI 10.1074/jbc.270.44.26488; Rovere C, 1998, BIOCHEM BIOPH RES CO, V246, P155, DOI 10.1006/bbrc.1998.8506; Rovere C, 1996, J BIOL CHEM, V271, P11368, DOI 10.1074/jbc.271.19.11368; ROVERE C, 1993, PEPTIDES, V14, P983, DOI 10.1016/0196-9781(93)90075-R; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHAW C, 1990, PEPTIDES, V11, P227, DOI 10.1016/0196-9781(90)90075-G; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TERENGHI G, 1983, ENDOCRINOLOGY, V112, P226, DOI 10.1210/endo-112-1-226; TOOZE SA, 1991, FEBS LETT, V285, P220, DOI 10.1016/0014-5793(91)80805-D; VINDROLA O, 1992, MOL ENDOCRINOL, V6, P1088, DOI 10.1210/me.6.7.1088; ZHOU A, 1994, J BIOL CHEM, V269, P17440; ZHOU A, 1993, J BIOL CHEM, V268, P1763; ZHOU Y, 1994, J BIOL CHEM, V269, P18408; ZHOU Y, 1995, J BIOL CHEM, V270, P24702, DOI 10.1074/jbc.270.42.24702	50	48	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25339	25346		10.1074/jbc.273.39.25339	http://dx.doi.org/10.1074/jbc.273.39.25339			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738000	hybrid			2022-12-27	WOS:000076085400050
J	Brown, JP; Gee, NS				Brown, JP; Gee, NS			Cloning and deletion mutagenesis of the alpha(2)delta calcium channel subunit from porcine cerebral cortex - Expression of a soluble form of the protein that retains [H-3]gabapentin binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; GABAPENTIN NEURONTIN; H-3 GABAPENTIN; CA2+ CHANNELS; BETA-SUBUNIT; ZINC FINGERS; RAT-BRAIN; ACID; ALPHA-2-SUBUNIT; GABA	The anti-epileptic, anti-hyperalgesic, and anxiolytic agent gabapentin (1-(aminomethyl)-cyclohexane acetic acid or Neurontin) has previously been shown to bind with high affinity to the alpha(2)delta subunit of voltage-dependent calcium channels (Gee, N. S., Brown, J. P., Dissanayake, V. U. K., Offord, J., Thurlow, R., and Woodruff, G.N. (1996) J. Biol. Chem. 271, 5768-5776). We report here the cloning, sequencing, and deletion mutagenesis of the alpha(2)delta subunit from porcine brain. The deduced protein sequence has a 95.9 and 98.2% identity to the rat and human neuronal alpha(2)delta sequences, respectively. [H-3]Gabapentin binds with a K-D of 37.5 +/- 10.4 nM to membranes prepared from COS-7 cells transfected with wild-type porcine alpha(2)delta cDNA. Six deletion mutants (B-G) that lack the delta polypeptide, together with varying amounts of the alpha(2) component, failed to bind [H-3]gabapentin. C-terminal deletion mutagenesis of the delta polypeptide identified a segment (residues 960-994) required for correct assembly of the [H-3]gabapentin binding pocket. Mutant L, which lacks the putative membrane anchor in the delta sequence, was found in both membrane-associated and soluble secreted forms. The soluble form was not proteolytically cleaved into separate alpha(2) and delta chains but still retained a high affinity (K-D = 30.7 +/- 8.1 nM) for [H-3]gabapentin. The production of a soluble alpha(2)delta mutant supports the single transmembrane model of the alpha(2)delta subunit and is an important step toward the large-scale recombinant expression of the protein.	Univ Cambridge, Parke Davis Neurosci Res Ctr, Cambridge CB2 2QB, England	University of Cambridge	Brown, JP (corresponding author), Univ Cambridge, Parke Davis Neurosci Res Ctr, Forvie Site,Robinson Way, Cambridge CB2 2QB, England.							BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brice NL, 1997, EUR J NEUROSCI, V9, P749, DOI 10.1111/j.1460-9568.1997.tb01423.x; BRICKLEY K, 1995, FEBS LETT, V364, P129, DOI 10.1016/0014-5793(95)00371-F; Brown JP, 1998, ANAL BIOCHEM, V255, P236, DOI 10.1006/abio.1997.2447; BRUST PF, 1993, NEUROPHARMACOLOGY, V32, P1089, DOI 10.1016/0028-3908(93)90004-M; BURGESS AJ, 1988, EUR J BIOCHEM, V178, P527, DOI 10.1111/j.1432-1033.1988.tb14479.x; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; CHAUHAN NS, 1993, EUR J PHARMACOL, V244, P293; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; Dissanayake VUK, 1997, BRIT J PHARMACOL, V120, P833, DOI 10.1038/sj.bjp.0700988; DOOLEY DJ, 1986, GOLD JUB C NO EUR EP; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; Gee NS, 1996, J BIOL CHEM, V271, P5768, DOI 10.1074/jbc.271.10.5768; GOTZ E, 1993, ARZNEIMITTEL-FORSCH, V43-1, P636; HENDERSON LE, 1981, J BIOL CHEM, V256, P8400; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HONMOU O, 1995, EPILEPSY RES, V20, P193, DOI 10.1016/0920-1211(94)00076-9; HONMOU O, 1995, BRAIN RES, V692, P273, DOI 10.1016/0006-8993(95)00634-3; ITAGAKI K, 1992, FEBS LETT, V297, P221, DOI 10.1016/0014-5793(92)80542-O; JAY SD, 1991, J BIOL CHEM, V266, P3287; KIM HL, 1992, P NATL ACAD SCI USA, V89, P3251, DOI 10.1073/pnas.89.8.3251; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOSCHER W, 1991, NEUROSCI LETT, V128, P150, DOI 10.1016/0304-3940(91)90249-S; MACDONALD RL, 1993, EPILIPSIA, V34, P1; MELLICK GA, 1995, J PAIN SYMPTOM MANAG, V10, P265, DOI 10.1016/0885-3924(95)00001-F; Mellick GA, 1996, SLEEP, V19, P224, DOI 10.1093/sleep/19.3.224; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Patel J, 1996, CLIN NEUROPHARMACOL, V19, P185, DOI 10.1097/00002826-199619020-00008; PEREZREYES E, 1994, DRUG DEVELOP RES, V33, P295, DOI 10.1002/ddr.430330311; Petroff OAC, 1996, ANN NEUROL, V39, P95, DOI 10.1002/ana.410390114; PIELER T, 1994, MOL BIOL REP, V20, P1, DOI 10.1007/BF00999848; PRESTON RA, 1991, MOL CELL BIOL, V11, P5801, DOI 10.1128/MCB.11.12.5801; RAMSAY RE, 1994, NEUROLOGY, V44, P23; REIMANN W, 1983, EUR J PHARMACOL, V94, P341, DOI 10.1016/0014-2999(83)90425-9; ROCK DM, 1993, EPILEPSY RES, V16, P89, DOI 10.1016/0920-1211(93)90023-Z; SCOTLAND PB, 1993, J CELL BIOL, V123, P719, DOI 10.1083/jcb.123.3.719; Segal AZ, 1996, NEUROLOGY, V46, P1175, DOI 10.1212/WNL.46.4.1175; Shimoyama N, 1997, NEUROSCI LETT, V222, P65, DOI 10.1016/S0304-3940(97)13331-6; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; Singh L, 1996, PSYCHOPHARMACOLOGY, V127, P1, DOI 10.1007/BF02805968; SUMMERS MF, 1992, PROTEIN SCI, V1, P563, DOI 10.1002/pro.5560010502; TAN XQ, 1995, J CELL BIOL, V128, P307, DOI 10.1083/jcb.128.3.307; TAYLOR CP, 1993, EPILEPSY RES, V14, P11, DOI 10.1016/0920-1211(93)90070-N; TAYLOR CP, 1994, NEUROLOGY, V44, P10; THURLOW RJ, 1993, EUR J PHARM-MOLEC PH, V247, P341, DOI 10.1016/0922-4106(93)90204-M; WAMIL A W, 1991, Neurology, V41, P140; WATSON WP, 1995, BRIT J PHARMACOL, V116, pP33; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; Wiser O, 1996, FEBS LETT, V379, P15, DOI 10.1016/0014-5793(95)01475-6; Xiao W.-H., 1995, Society for Neuroscience Abstracts, V21, P897; XU XF, 1994, GENE, V148, P357, DOI 10.1016/0378-1119(94)90713-7	54	58	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25458	25465		10.1074/jbc.273.39.25458	http://dx.doi.org/10.1074/jbc.273.39.25458			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738015	hybrid			2022-12-27	WOS:000076085400065
J	Colby, G; Tu, M; Tzagoloff, A				Colby, G; Tu, M; Tzagoloff, A			MTO1 codes for a mitochondrial protein required for respiration in paromomycin-resistant mutants of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MEMBRANE SYSTEM; YEAST; GENES; DNA; TRANSFORMATION; CLONING; CONSTRUCTION; EXPRESSION; MUTATION	Mutations in MTO1 express a respiratory defect only in the context of a mitochondrial genome with a paromomycin-resistance allele, This phenotype is similar to that described previously for mss1 mutants by Decoster, E. Vassal, A., and Faye, G.(1993) J. Mol. Biol, 232, 79-88, We present evidence that Mto1p and Mss1p are mitochondrial proteins and that they form a heterodimer complex. In a paromomycin-resistant background, mss1 and mto1 mutants are inefficient in processing the mitochondrial COX1 transcript for subunit 1 of cytochrome oxidase, The mutants also fail to synthesize subunit 1 and show a pleiotropic absence of cytochromes a, a(3), and b. In vivo pulse labeling of an mto1 mutant, however, indicate increased rates of synthesis of other mitochondrial translation products. The respiratory defective phenotype of mto1 and mss1 mutants is not seen in a paromomycin-sensitive genetic background. The visible absorption spectra of such strains indicate a higher ratio of cytochromes bla and elevated NADH- and succinate-cytochrome c reductase activities. To explain these phenotypic characteristics, we proposed that the Mto1p.Mss1p complex plays a role in optimizing mitochondrial protein synthesis in yeast, possibly by a proofreading mechanism.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Tzagoloff, A (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.		Colby, Geoffrey/G-2526-2017	Colby, Geoffrey/0000-0002-3376-0933; Wu, Mian/0000-0002-2714-0500	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL022174, R01HL022174, R37HL022174] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL022174, HL22174] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEGGS JD, 1978, NATURE, V275, P104, DOI 10.1038/275104a0; BOTSTEIN D, 1982, MOL BIOL YEAST SACCH, P607; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; DECOSTER E, 1993, J MOL BIOL, V232, P79, DOI 10.1006/jmbi.1993.1371; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HILL J, 1985, J BIOL CHEM, V260, P3235; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI M, 1982, J BIOL CHEM, V257, P5921; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; Mashkevich G, 1997, J BIOL CHEM, V272, P14356, DOI 10.1074/jbc.272.22.14356; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MESSER W, 1992, CHROMOSOMA, V102, pS1, DOI 10.1007/BF02451779; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; OGASAWARA N, 1992, MOL MICROBIOL, V6, P629, DOI 10.1111/j.1365-2958.1992.tb01510.x; PINKHAM JL, 1985, MOL CELL BIOL, V5, P3410, DOI 10.1128/MCB.5.12.3410; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHMIDT RJ, 1984, MOL BIOL EVOL, V1, P317; SERAPHIN B, 1987, P NATL ACAD SCI USA, V84, P6810, DOI 10.1073/pnas.84.19.6810; SOR F, 1982, MITOCHONDRIAL GENES, P255; ten Berge A M, 1974, Mol Gen Genet, V131, P113; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1976, FEBS LETT, V65, P391, DOI 10.1016/0014-5793(76)80154-8; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228	29	76	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27945	27952		10.1074/jbc.273.43.27945	http://dx.doi.org/10.1074/jbc.273.43.27945			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774408	hybrid			2022-12-27	WOS:000076549800028
J	Datta, K; Biswal, SS; Xu, J; Towndrow, KM; Feng, X; Kehrer, JP				Datta, K; Biswal, SS; Xu, J; Towndrow, KM; Feng, X; Kehrer, JP			A relationship between 5-lipoxygenase-activating protein and bcl-x(L) expression in murine pro-B lymphocytic FL5.12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID METABOLISM; MEDIATED APOPTOSIS; N-ACETYLCYSTEINE; GENE-EXPRESSION; FATTY-ACIDS; BCL-2; DEATH; ACTIVATION; PATHWAY; ANTIOXIDANT	Inhibitors of 5-lipoxygenase-activating protein (FLAP) have been found to induce apoptosis, The current study examined the expression of FLAP and bcl family proteins and the induction of apoptosis in interleukin-3-dependent control and bcl-x(L)-overexpressing FL5.12 cell lines after treatment with MK886, a specific FLAP inhibitor. FL5.12 cells contained a substantial amount of FLAP protein and mRNA but surprisingly had no measurable 5-lipoxygenase protein or 5-, 12-, or 15-lipoxygenase activity. The basal level of FLAP protein in cells overexpressing bcLx(L) was 70% less than in controls. FLAP disappeared 4 h after withdrawal of interleukin-3 in bcl-x(L) cells but not in control cells, which underwent apoptosis, A dose- and time-response study revealed that 5 nmol of MK886/10(6) cells was sufficient to induce apoptosis both in control and bcl-x(L) cells, respectively, but to different degrees, bcl-x(L) and bcl-2 proteins, but not bar or FLAP, were decreased by 4 h after 5 nmol of MK886/10(6) cells in both cell lines, although the higher levels of bcl-x(L) in overexpressors took longer to disappear. This early loss of bcl-x(L) and bcl-2 was not attributable to generalized proteoIysis, as shown by Coomassie Blue staining and by the maintenance of bar. Caspase-3 was activated 2 h after MK886 treatment in control cells but not in bcl-x(L) cells. Inhibition of caspase-3 decreased MK886-induced apoptosis by 50% in control cells. Inhibition of this caspase after MK886 treatment was unable to prevent the loss of bcl-x(L) in control cells but did provide partial protection for the loss of the transfected form, but not the endogenous form, in overexpressing cells. These data indicate that MK886 induces extensive apoptosis that is partially caspase-3 dependent and may be related to a rapid loss of bcl-x(L). Although caspase-3 inhibitors had no effect on the loss of bcl-x(L), other caspases or protease systems may still be involved. The absence of 5- lipoxygenase in cells containing FLAP, the lower level of FLAP in bcl-x(L) cells, the apoptosis-inducing activity of MK886, and the rapid loss of bcl-x(L) and bcl-2 proteins after treatment with MK886 strongly indicate that FLAP has activities unrelated to lipoxygenase and suggest a possible functional or regulatory link between these proteins, which share similar subcellular localizations.	Univ Texas, Coll Pharm, Div Pharmacol & Toxicol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Datta, K (corresponding author), Univ Texas, Coll Pharm, Div Pharmacol & Toxicol, Austin, TX 78712 USA.	kaushik@mail.utexas.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51005] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Anderson KM, 1996, ANTICANCER RES, V16, P2589; Aoshima H, 1997, BBA-LIPID LIPID MET, V1345, P35, DOI 10.1016/S0005-2760(96)00159-2; Avis IM, 1996, J CLIN INVEST, V97, P806, DOI 10.1172/JCI118480; Bojes HK, 1997, BIOCHEM J, V325, P315, DOI 10.1042/bj3250315; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; CLAESSON HE, 1993, J LIPID MEDIATOR, V6, P15; CORCORAN GB, 1994, TOXICOL APPL PHARM, V128, P169, DOI 10.1006/taap.1994.1195; DUKE RC, 1992, CURRENT PROTOCOLS IM; ELMAKHOURHOJEIJ Y, 1994, PROSTAGLANDINS, V48, P21, DOI 10.1016/0090-6980(94)90093-0; FAIR A, 1994, BIOCHEM BIOPH RES CO, V201, P1014, DOI 10.1006/bbrc.1994.1803; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FENG W, 1995, J IMMUNOL, V155, P66; Ford-Hutchinson A W, 1994, Adv Prostaglandin Thromboxane Leukot Res, V22, P13; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; HII CST, 1995, J BIOL CHEM, V270, P4201, DOI 10.1074/jbc.270.9.4201; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Ioannou YA, 1996, NUCLEIC ACIDS RES, V24, P992; KARGMAN S, 1993, J LIPID MEDIATOR, V7, P31; KLUCK RM, 1994, BBA-MOL CELL RES, V1223, P247, DOI 10.1016/0167-4889(94)90233-X; KORSMEYER SJ, 1992, CANCER SURV, V15, P105; Korystov YN, 1996, FEBS LETT, V388, P238, DOI 10.1016/0014-5793(96)00538-8; Lafon C, 1996, CELL GROWTH DIFFER, V7, P1095; LEE JC, 1982, J IMMUNOL, V128, P2393; LOS M, 1995, EMBO J, V14, P3731, DOI 10.1002/j.1460-2075.1995.tb00043.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maccarrone M, 1997, CELL DEATH DIFFER, V4, P396, DOI 10.1038/sj.cdd.4400255; Marin MC, 1996, ONCOGENE, V12, P2259; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Mizushima N, 1996, FEBS LETT, V395, P267, DOI 10.1016/0014-5793(96)01050-2; NICOTERA P, 1992, ANNU REV PHARMACOL, V32, P449, DOI 10.1146/annurev.pa.32.040192.002313; Nishio E, 1997, BRIT J PHARMACOL, V121, P665, DOI 10.1038/sj.bjp.0701171; NOGUCHI M, 1995, ONCOLOGY-BASEL, V52, P265; ODONNELL VB, 1995, BIOCHEM J, V310, P133, DOI 10.1042/bj3100133; Ondrey FG, 1996, LARYNGOSCOPE, V106, P129, DOI 10.1097/00005537-199602000-00003; Piomelli D, 1993, CURR OPIN CELL BIOL, V5, P274, DOI 10.1016/0955-0674(93)90116-8; Pouliot M, 1996, EUR J BIOCHEM, V238, P250, DOI 10.1111/j.1432-1033.1996.0250q.x; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SANDSTROM PA, 1995, FEBS LETT, V365, P66, DOI 10.1016/0014-5793(95)00443-D; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Shirahama T, 1997, FEBS LETT, V407, P97, DOI 10.1016/S0014-5793(97)00304-9; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Tang DG, 1997, INT J CANCER, V72, P1078, DOI 10.1002/(SICI)1097-0215(19970917)72:6<1078::AID-IJC24>3.0.CO;2-#; Tang DG, 1996, P NATL ACAD SCI USA, V93, P5241, DOI 10.1073/pnas.93.11.5241; Tang DG, 1997, J CELL PHYSIOL, V172, P155, DOI 10.1002/(SICI)1097-4652(199708)172:2<155::AID-JCP3>3.0.CO;2-N; Tsai JC, 1996, J BIOL CHEM, V271, P3667; Um HD, 1996, J IMMUNOL, V156, P3469; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; VICKERS PJ, 1995, J LIPID MEDIAT CELL, V12, P185, DOI 10.1016/0929-7855(95)00018-L; Wagenknecht B, 1997, FEBS LETT, V409, P17, DOI 10.1016/S0014-5793(97)00468-7; WOODS JW, 1995, J CLIN INVEST, V95, P2035, DOI 10.1172/JCI117889; Zhivotovsky B, 1996, EXPERIENTIA, V52, P968, DOI 10.1007/BF01920106; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	56	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28163	28169		10.1074/jbc.273.43.28163	http://dx.doi.org/10.1074/jbc.273.43.28163			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774436	hybrid			2022-12-27	WOS:000076549800056
J	Ghoshal, K; Wang, YJ; Sheridan, JF; Jacob, ST				Ghoshal, K; Wang, YJ; Sheridan, JF; Jacob, ST			Metallothionein induction in response to restraint stress - Transcriptional control, adaptation to stress, and role of glucocorticoid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA VIRAL-INFECTION; MESSENGER-RNA LEVELS; LIVER METALLOTHIONEIN; FACTOR MTF-1; RAT-LIVER; I GENE; DIFFERENTIALLY AFFECTS; OXIDATIVE STRESS; BINDING-ACTIVITY; INBRED STRAINS	Metallothioneins (MT) have been implicated in the protection of cells from oxidative stress. We studied the molecular mechanism of induction of MT-I and MT-II in response to restraint stress using a mouse model system in which the animals were restrained in well ventilated polypropylene tubes for 12 h each day (one cycle). Here, we show that MT-I and MT-II mRNA levels were elevated as much as 10-20-fold after just one cycle of this simple stress. Stress-mediated MT induction occurred at the transcriptional level. The level of MT mRNA correlated with the stress-induced increase, and not with the diurnal variation, in the level of serum glucocorticoid. Treatment of the mice with RU 486, a glucocorticoid receptor antagonist, prior to restraint stress inhibited MT induction by at least 50%. Furthermore, the glucocorticoid responsive element-binding activity in the liver nuclear extracts from the stressed mice was significantly higher than that in the control mice. The complex formations between the transcription factor Sp1, MTF1, or MLTF/ARE and the respective specific oligonucleotides were not altered in the liver from the stressed mouse. The MT mRNA levels returned to the basal level at the end of nine cycles of stress, indicating habituation of the animals to restraint stress. At this stage, exposure of the animals to another type of stress, treatment with heavy metals, resulted in further induction of MT. These data indicate that glucocorticoid is the primary physiological factor responsible for MT induction following restraint stress, and the glucocorticoid receptor is the major transcription factor involved in this process.	Ohio State Univ, Coll Med, Dept Med Biochem, Columbus, OH 43210 USA; Ohio State Univ, Coll Med, Dept Med Microbiol & Immunol, Columbus, OH 43210 USA; Ohio State Univ, Coll Med, Comprehens Canc Ctr, Columbus, OH 43210 USA; Ohio State Univ, Coll Dent, Sect Oral Biol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Jacob, ST (corresponding author), Ohio State Univ, Coll Med, Dept Med Biochem, 333 Hmailton Hall,1645 Neil Ave, Columbus, OH 43210 USA.			Sheridan, John/0000-0002-6927-0266	NCI NIH HHS [R01 CA061321-05, CA 61321] Funding Source: Medline; NIA NIH HHS [P01 AG011585-040001, P01 AG011585-040004, P01-AG 11585, P01 AG011585-040003] Funding Source: Medline; NIMH NIH HHS [R01 MH046801, R01 MH046801-08, R01-MH 46801] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061321] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH046801] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG011585] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aniskovitch LP, 1997, ARCH BIOCHEM BIOPHYS, V341, P337, DOI 10.1006/abbi.1997.9976; Aniskovitch LP, 1998, ONCOGENE, V16, P1475, DOI 10.1038/sj.onc.1201659; Belloso E, 1996, NEUROENDOCRINOLOGY, V64, P430, DOI 10.1159/000127149; Bittel D, 1998, J BIOL CHEM, V273, P7127, DOI 10.1074/jbc.273.12.7127; BREMNER I, 1991, METHOD ENZYMOL, V205, P584; BRUGNERA E, 1994, NUCLEIC ACIDS RES, V22, P3167, DOI 10.1093/nar/22.15.3167; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CHOUDHURI S, 1995, TOXICOL APPL PHARM, V131, P144, DOI 10.1006/taap.1995.1056; CHUBATSU LS, 1993, BIOCHEM J, V291, P193, DOI 10.1042/bj2910193; Dalton TP, 1996, J BIOL CHEM, V271, P26233, DOI 10.1074/jbc.271.42.26233; DOBBS CM, 1993, J NEUROIMMUNOL, V48, P151, DOI 10.1016/0165-5728(93)90187-4; Dobbs CM, 1996, J IMMUNOL, V157, P1870; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GLANVILLE N, 1981, NATURE, V292, P267, DOI 10.1038/292267a0; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; Gunes C, 1998, EMBO J, V17, P2846, DOI 10.1093/emboj/17.10.2846; HAGER LJ, 1981, NATURE, V291, P340, DOI 10.1038/291340a0; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HERMANN G, 1993, J NEUROIMMUNOL, V47, P83, DOI 10.1016/0165-5728(93)90287-9; HERMANN G, 1994, J NEUROIMMUNOL, V49, P25, DOI 10.1016/0165-5728(94)90177-5; HERMANN G, 1994, J NEUROIMMUNOL, V53, P173, DOI 10.1016/0165-5728(94)90027-2; HERMANN G, 1995, J NEUROIMMUNOL, V56, P179, DOI 10.1016/0165-5728(94)00145-E; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; HIDALGO J, 1990, J NEUROCHEM, V55, P651, DOI 10.1111/j.1471-4159.1990.tb04182.x; HIDALGO J, 1988, AM J PHYSIOL, V254, pE71, DOI 10.1152/ajpendo.1988.254.1.E71; HIDALGO J, 1986, EXPERIENTIA, V42, P1006, DOI 10.1007/BF01940708; HIDALGO J, 1992, HORM METAB RES, V24, P233, DOI 10.1055/s-2007-1003300; KAGI JHR, 1991, METHOD ENZYMOL, V205, P613; Kang YJ, 1997, J CLIN INVEST, V100, P1501, DOI 10.1172/JCI119672; KARIN M, 1985, CELL, V41, P9, DOI 10.1016/0092-8674(85)90051-0; KASAHARA K, 1991, CANCER RES, V51, P3237; Kelly EJ, 1997, P NATL ACAD SCI USA, V94, P10045, DOI 10.1073/pnas.94.19.10045; KELLY SL, 1990, SCIENCE, V35, P1813; LAZO JS, 1995, J BIOL CHEM, V270, P5506, DOI 10.1074/jbc.270.10.5506; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MASTERS BA, 1994, P NATL ACAD SCI USA, V91, P584, DOI 10.1073/pnas.91.2.584; MAYO KE, 1981, J BIOL CHEM, V256, P2621; Moffatt P, 1997, DRUG METAB REV, V29, P261, DOI 10.3109/03602539709037585; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; Palmiter R D, 1987, Experientia Suppl, V52, P63; PALMITER RD, 1992, P NATL ACAD SCI USA, V89, P6333, DOI 10.1073/pnas.89.14.6333; Pitt BR, 1997, AM J PHYSIOL-LUNG C, V273, pL856, DOI 10.1152/ajplung.1997.273.4.L856; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; RADTKE F, 1995, NUCLEIC ACIDS RES, V23, P2277, DOI 10.1093/nar/23.12.2277; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; SCHILDER RJ, 1990, INT J CANCER, V45, P416, DOI 10.1002/ijc.2910450306; SCHWARZ MA, 1994, J BIOL CHEM, V269, P15238; SCHWARZ MA, 1995, P NATL ACAD SCI USA, V92, P4452, DOI 10.1073/pnas.92.10.4452; SHERIDAN JF, 1991, J NEUROIMMUNOL, V31, P245, DOI 10.1016/0165-5728(91)90046-A; THIELE DJ, 1992, NUCLEIC ACIDS RES, V20, P1183, DOI 10.1093/nar/20.6.1183; VALLEE BL, 1995, NEUROCHEM INT, V27, P23, DOI 10.1016/0197-0186(94)00165-Q; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822	52	68	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27904	27910		10.1074/jbc.273.43.27904	http://dx.doi.org/10.1074/jbc.273.43.27904			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774402	hybrid, Green Accepted			2022-12-27	WOS:000076549800022
J	Snajdrova, L; Xu, AD; Narayanan, N				Snajdrova, L; Xu, AD; Narayanan, N			Clotrimazole, an antimycotic drug, inhibits the sarcoplasmic reticulum calcium pump and contractile function in heart muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAST SKELETAL-MUSCLE; CYCLOPIAZONIC ACID; RYANODINE RECEPTORS; IMIDAZOLE; THAPSIGARGIN; BINDING; ATPASE; CA2+-ATPASE; CA2+; CA-2+-ATPASE	Clotrimazole (CLT), an antimycotic drug, has been shown to inhibit proliferation of normal and cancer cell lines and its systemic use as a new tool in the treatment of proliferative disorders is presently under scrutiny (Benzaquen, L. R., Brugnara, C., Byers, H. R., Gattoni-Celli, S., and Halperin, J. A. (1995) Nature Med. 1, 534-540), The action of CLT is thought to involve depletion of intracellular Ca2+ stores but the underlying mechanism has not been defined. The present study utilized membrane vesicles of rabbit cardiac sarcoplasmic reticulum (SR) to determine the mechanism by which CLT depletes intracellular Ca2+ stores. The results revealed a strong, concentration-dependent inhibitory action of CLT on the ATP-energized Ca2+ uptake activity of SR (50% inhibition with similar to 35 mu M CLT). The inhibition was of rapid onset (manifested in <15 s), and was accompanied by a 7-fold decrease in the apparent affinity of the SR Ca2+-ATPase for Ca2+ and a minor decrement in the enzyme's apparent affinity toward ATP. Exposure of SR to CLT in the absence or presence of Ca2+ resulted in irreversible inhibition of Ca2+ uptake demonstrating that the Ca2+-bound and Ca2+-free conformations of the Ca2+-ATPase are CLT-sensitive. Introduction of CLT to the reaction medium subsequent to induction of enzyme turnover with Ca2+ and ATP resulted in instantaneous cessation of Ca2+ transport indicating that an intermediate enzyme species generated during turnover undergoes rapid inactivation by CLT. The inhibition of Ca2+ uptake by CLT was accompanied by inhibition of Ca2+ stimulated ATP hydrolysis and Ca2+-induced phosphoenzyme intermediate formation from ATP in the ATPase catalytic cycle. Phosphorylation of the Ca2+-deprived enzyme with P-i in the reverse direction of catalytic cycle and Ca2+ release from Ca2+-preloaded SR vesicles were unaffected by CLT. It is concluded that CLT depletes intracellular Ca2+ stores by inhibiting Ca2+ sequestration by the Ca2+-ATPase. The mechanism of ATPase inhibition involves a drug-induced alteration in the Ca2+-binding site(s) resulting in paralysis of the enzyme's catalytic and ion transport cycle. CLT (50 mu M) caused marked depression of contractile function in isolated perfused, electrically paced rabbit heart preparations. The contractile function recovered gradually following withdrawal of CLT from the perfusate indicating the existence of mechanisms in the intact cell to inactivate, metabolize, or clear CLT from its target site.	Univ Western Ontario, Dept Physiol, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Narayanan, N (corresponding author), Univ Western Ontario, Dept Physiol, London, ON N6A 5C1, Canada.	nnarayan@physiology.uwo.ca						ALVAREZ J, 1992, J BIOL CHEM, V267, P11789; ALVAREZ J, 1990, BIOCHEM J, V274, P193; AYUB M, 1988, J STEROID BIOCHEM, V31, P65, DOI 10.1016/0022-4731(88)90207-5; BALLARD SA, 1988, BIOCHEM PHARMACOL, V37, P4643, DOI 10.1016/0006-2952(88)90333-4; BENZAQUEN LR, 1995, NAT MED, V1, P534, DOI 10.1038/nm0695-534; BRUGNARA C, 1995, J PHARMACOL EXP THER, V273, P266; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; DEJESUS F, 1993, FEBS LETT, V332, P229, DOI 10.1016/0014-5793(93)80638-B; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FEHER JJ, 1990, CALCIUM HEART, P199; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; GUILLAIN F, 1997, BIOCHIM BIOPHYS ACTA, V1318, P52; HAWKINS C, 1994, BBA-BIOMEMBRANES, V1191, P231, DOI 10.1016/0005-2736(94)90174-0; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; KARON BS, 1994, BIOCHEMISTRY-US, V33, P13928, DOI 10.1021/bi00250a048; KoskKosicka D, 1997, FEBS LETT, V402, P189, DOI 10.1016/S0014-5793(96)01526-8; LOPEZ MM, 1995, J BIOL CHEM, V270, P28239; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYTTON J, 1992, J BIOL CHEM, V267, P14483; LYTTON J, 1992, HEART CARDIOVASCULAR, V2, P1203; Nakamura S, 1997, J BIOL CHEM, V272, P6232, DOI 10.1074/jbc.272.10.6232; Narayanan N, 1996, AM J PHYSIOL-CELL PH, V271, pC1032, DOI 10.1152/ajpcell.1996.271.4.C1032; NARAYANAN N, 1983, BIOCHIM BIOPHYS ACTA, V735, P53, DOI 10.1016/0005-2736(83)90260-2; NARAYANAN N, 1981, BIOCHIM BIOPHYS ACTA, V678, P442, DOI 10.1016/0304-4165(81)90126-4; NARAYANAN N, 1991, BIOCHIM BIOPHYS ACTA, V1070, P83, DOI 10.1016/0005-2736(91)90149-3; NORREGAARD A, 1993, FEBS LETT, V336, P248, DOI 10.1016/0014-5793(93)80813-A; PlengeTellechea F, 1997, J BIOL CHEM, V272, P2794, DOI 10.1074/jbc.272.5.2794; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; SHEETS JJ, 1986, BIOCHEM PHARMACOL, V35, P487, DOI 10.1016/0006-2952(86)90224-8; SULAKHE PV, 1978, BIOCHEM J, V261, P171; SULAKHE SJ, 1979, GEN PHARMACOL, V10, P103, DOI 10.1016/0306-3623(79)90044-2; SUMBILLA C, 1991, J BIOL CHEM, V266, P12682; VANDENBOSSCHE H, 1983, BIOCHEM SOC T, V11, P665, DOI 10.1042/bst0110665; VILLALOBOS C, 1992, FASEB J, V6, P2742, DOI 10.1096/fasebj.6.9.1319362; WICTOME M, 1992, FEBS LETT, V304, P109, DOI 10.1016/0014-5793(92)80599-C; YOSHIDA Y, 1987, BIOCHEM PHARMACOL, V36, P229, DOI 10.1016/0006-2952(87)90694-0	39	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28032	28039		10.1074/jbc.273.43.28032	http://dx.doi.org/10.1074/jbc.273.43.28032			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774419	hybrid			2022-12-27	WOS:000076549800039
J	Vinogradov, EV; Petersen, BO; Thomas-Oates, JE; Duus, JO; Brade, H; Holst, O				Vinogradov, EV; Petersen, BO; Thomas-Oates, JE; Duus, JO; Brade, H; Holst, O			Characterization of a novel branched tetrasaccharide of 3-deoxy-D-manno-oct-2-ulopyranosonic acid - The structure of the carbohydrate backbone of the lipopolysaccharide from Acinetobacter baumannii strain NCTC 10303 (ATCC 17904)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; ESCHERICHIA-COLI; LIPID-A; CONFORMATIONAL-ANALYSIS; CHEMICAL-ANALYSIS; VIBRIO-CHOLERAE; FORCE-FIELDS; IDENTIFICATION; KDO; OLIGOSACCHARIDE	For the first time, the tetrasaccharide Kdo alpha 2-->5Kdo alpha 2-->5(Kdo alpha 2-->4)Kdo (Kdo is 3-deoxy-D-manno-oct-2-ulopyranosonic acid) has been identified in a bacterial lipopolysaccharide (LPS), i.e. in the core region of LPS from Acinetobacter baumannii NCTC 10303, The LPS was analyzed using compositional analysis, mass spectrometry, and NMR spectroscopy. The disaccharide D-GlcpN beta 1-->6D-GlcpN, phosphorylated at O-1 and O-4', was identified as the carbohydrate backbone of the lipid A. The Kdo tetrasaccharide is attached to O-6' of this disaccharide and is further substituted by short L-rhamnoglycans of varying length and by the disaccharide D-GlcpNAc alpha 1-->4D-GlcpNA (GlcpNA, 2-amino-2-deoxy-glucopyranosuronic acid). The core region is not substituted by phosphate residues and represents a novel core type of bacterial LPS, The complete carbohydrate backbone of the LPS is shown in Structure I as follows: [GRAPHICS] where Rha is rhamnose, Except were indicated, monosaccharides possess the D-configuration. Sugars marked with an asterisk are present in non-stoichiometric amounts.	Res Ctr Borstel, Ctr Med & Biosci, Div Med & Biochem Microbiol, D-23845 Borstel, Germany; Carlsberg Lab, Dept Chem, DK-2500 Valby, Denmark; Univ Utrecht, Bijvoet Ctr Biomol Res, Dept Mass Spectrometry, NL-3584 CA Utrecht, Netherlands	Forschungszentrum Borstel; Utrecht University	Holst, O (corresponding author), Res Ctr Borstel, Ctr Med & Biosci, Div Med & Biochem Microbiol, Parkallee 22, D-23845 Borstel, Germany.	oholst@fz-borstel.de	Duus, Jens Øllgaard/N-4279-2013	Duus, Jens Øllgaard/0000-0003-3625-1250				ASENSIO JL, 1995, INT J BIOL MACROMOL, V17, P137, DOI 10.1016/0141-8130(95)92680-O; Aspinall GO, 1995, CARBOHYD RES, V279, P245, DOI 10.1016/0008-6215(95)00284-7; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; BergogneBerezin E, 1996, CLIN MICROBIOL REV, V9, P148, DOI 10.1128/CMR.9.2.148; BIRNBAUM GI, 1987, J CARBOHYD CHEM, V6, P17, DOI 10.1080/07328308708058858; BOCK K, 1992, CARBOHYD RES, V229, P213, DOI 10.1016/S0008-6215(00)90571-8; Bode CE, 1998, EUR J BIOCHEM, V254, P404, DOI 10.1046/j.1432-1327.1998.2540404.x; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BRADE H, 1982, EUR J BIOCHEM, V122, P233, DOI 10.1111/j.1432-1033.1982.tb05871.x; BRADE H, 1987, CARBOHYD RES, V167, P295, DOI 10.1016/0008-6215(87)80287-2; BRADE H, 1988, ZBL BAKT-INT J MED M, V268, P151; CARLSON RW, 1995, J BIOL CHEM, V270, P11783, DOI 10.1074/jbc.270.20.11783; DIJKSHOORN L, 1996, ACINETOBACTER MICROB, P37; Ehrenstein B, 1996, J CLIN MICROBIOL, V34, P2414, DOI 10.1128/JCM.34.10.2414-2420.1996; Forsberg LS, 1998, J BIOL CHEM, V273, P2747, DOI 10.1074/jbc.273.5.2747; GRONBERG G, 1994, CARBOHYD RES, V257, P35, DOI 10.1016/0008-6215(94)84106-3; HAGLER AT, 1979, J AM CHEM SOC, V101, P5122, DOI 10.1021/ja00512a002; Haseley SR, 1998, EUR J BIOCHEM, V251, P189, DOI 10.1046/j.1432-1327.1998.2510189.x; HOLST O, 1995, EUR J BIOCHEM, V229, P194, DOI 10.1111/j.1432-1033.1995.tb20455.x; HOLST O, 1993, EUR J BIOCHEM, V214, P703, DOI 10.1111/j.1432-1033.1993.tb17971.x; HOLST O, 1998, CARBOHYDRATES EUROPE, V21, P30; HOLST O, 1998, ENDOTOXIN HLTH DIS; KACA W, 1988, CARBOHYD RES, V179, P289, DOI 10.1016/0008-6215(88)84125-9; KAWAHARA K, 1987, EUR J BIOCHEM, V163, P489, DOI 10.1111/j.1432-1033.1987.tb10895.x; KJAER M, 1994, METHODS ENZYMOL, V239, P288; LEVI I, 1996, ACINETOBACTER MICROB, P101; LEVITT MH, 1982, J MAGN RESON, V47, P328, DOI 10.1016/0022-2364(82)90124-X; LUDERITZ O, 1982, CURR TOP MEMBR TRANS, V17, P79; MCNICHOLAS PA, 1987, CARBOHYD RES, V165, P17, DOI 10.1016/0008-6215(87)80073-3; PETERS T, 1993, CARBOHYD RES, V238, P49, DOI 10.1016/0008-6215(93)87005-D; PRICE NPJ, 1994, J BACTERIOL, V176, P4646, DOI 10.1128/JB.176.15.4646-4655.1994; RAINEY FA, 1994, FEMS MICROBIOL LETT, V124, P349, DOI 10.1016/0378-1097(94)00453-6; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Seifert H, 1997, J CLIN MICROBIOL, V35, P2819, DOI 10.1128/JCM.35.11.2819-2825.1997; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; STUIKEPRILL R, 1990, EUR J BIOCHEM, V194, P903, DOI 10.1111/j.1432-1033.1990.tb19485.x; Vinogradov E.V., 1994, J ENDOTOXIN RES, V1, P199, DOI [10.1177/096805199400100401, DOI 10.1177/096805199400100401]; VINOGRADOV EV, 1992, EUR J BIOCHEM, V210, P491, DOI 10.1111/j.1432-1033.1992.tb17447.x; Vinogradov EV, 1996, EUR J BIOCHEM, V239, P602, DOI 10.1111/j.1432-1033.1996.0602u.x; ZAHRINGER U, 1993, TETRAHEDRON, V49, P4193, DOI 10.1016/S0040-4020(01)85737-9; [No title captured]	42	32	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28122	28131		10.1074/jbc.273.43.28122	http://dx.doi.org/10.1074/jbc.273.43.28122			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774431	hybrid			2022-12-27	WOS:000076549800051
J	Cooper, DMF; Schell, MJ; Thorn, P; Irvine, RF				Cooper, DMF; Schell, MJ; Thorn, P; Irvine, RF			Regulation of adenylyl cyclase by membrane potential	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; CALCIUM CHANNELS; GRANULE CELLS; CA2+; ENTRY; EXPRESSION; FORSKOLIN; CURRENTS; DOMAINS; VOLTAGE	Mammalian adenylyl cyclases possess 12 transmembrane-spanning domains and bear a superficial resemblance to certain classes of ion channels. Some evidence suggests that bacterial and sea urchin sperm adenylyl cyclases can be regulated by membrane depolarization. In the present study, we explored the effect of altering membrane potential on the adenylyl cyclase activity of cerebellar granule cells with acute potassium depolarization. A biphasic stimulatory and then inhibitory response is evoked by progressive increases in the extracellular [K]:[Na] ratio in the absence of-extracellular Ca2+. This effect does not mimic the linear increase in membrane potential elicited under the same conditions. Instead it appears as though membrane depolarization opens L-type (nimodipine-sensitive) Ca2+ channels, allowing the entry of Na+, which directly stimulates adenylyl cyclase activity. Gramicidin, which generates pores that are permeable to monovalent cations, and concurrently eliminates the membrane potential, permits a similar stimulation by extracellularly applied Na+. Although the results indicate no direct sensitivity of cerebellar granule cell adenylyl cyclase to membrane potential, they do demonstrate that, as a result of membrane depolarization, the influx of Na+, as well as Ca2+, will elevate cAMP levels.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1QJ, England	University of Cambridge	Cooper, DMF (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Box C-236,4200 E 9th Ave, Denver, CO 80262 USA.		Thorn, Peter/F-7030-2010	Thorn, Peter/0000-0002-3228-770X; Schell, Michael/0000-0003-1553-3582	FOGARTY INTERNATIONAL CENTER [F06TW002185] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F32MH011609] Funding Source: NIH RePORTER; FIC NIH HHS [TW02185] Funding Source: Medline; NIMH NIH HHS [F32 MH11609] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Beltran C, 1996, BIOCHEMISTRY-US, V35, P7591, DOI 10.1021/bi952806v; BYRON KL, 1993, J BIOL CHEM, V268, P6945; CALDWELL KK, 1992, CELL CALCIUM, V13, P107, DOI 10.1016/0143-4160(92)90004-C; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; Cooper Dermot M.F., 1998, Advances in Second Messenger and Phosphoprotein Research, V32, P23; Dessauer CW, 1997, J BIOL CHEM, V272, P22272, DOI 10.1074/jbc.272.35.22272; EVANS T, 1984, MOL PHARMACOL, V26, P395; Fagan KA, 1998, J BIOL CHEM, V273, P9297, DOI 10.1074/jbc.273.15.9297; Fagan KA, 1996, J BIOL CHEM, V271, P12438, DOI 10.1074/jbc.271.21.12438; Harrold J, 1997, NEUROSCIENCE, V77, P683, DOI 10.1016/S0306-4522(97)86659-6; JACOBOWITZ O, 1994, METHOD ENZYMOL, V238, P108; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LANSMAN JB, 1986, J GEN PHYSIOL, V88, P321, DOI 10.1085/jgp.88.3.321; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; MONS N, 1993, SYNAPSE, V14, P51, DOI 10.1002/syn.890140108; MONS N, 1995, P NATL ACAD SCI USA, V92, P8473, DOI 10.1073/pnas.92.18.8473; RANDALL A, 1995, J NEUROSCI, V15, P2995; REDDY R, 1995, J BIOL CHEM, V270, P14340, DOI 10.1074/jbc.270.24.14340; SCHULTZ JE, 1992, SCIENCE, V255, P600, DOI 10.1126/science.1371017; SLESINGER PA, 1991, J PHYSIOL-LONDON, V435, P101, DOI 10.1113/jphysiol.1991.sp018500; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; WANG KW, 1995, J MEMBRANE BIOL, V143, P247; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0; Zimprich F, 1996, EUR J NEUROSCI, V8, P467, DOI 10.1111/j.1460-9568.1996.tb01230.x	28	53	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27703	27707		10.1074/jbc.273.42.27703	http://dx.doi.org/10.1074/jbc.273.42.27703			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765307	hybrid			2022-12-27	WOS:000076448000094
J	Harris, JL; Peterson, EP; Hudig, D; Thornberry, NA; Craik, CS				Harris, JL; Peterson, EP; Hudig, D; Thornberry, NA; Craik, CS			Definition and redesign of the extended substrate specificity of granzyme B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOTOXIC LYMPHOCYTES; PHAGE DISPLAY; POLY(ADP-RIBOSE) POLYMERASE; SACCHAROMYCES-CEREVISIAE; PROTEASE SPECIFICITIES; COMBINATORIAL APPROACH; PLASMINOGEN-ACTIVATOR; CONVERTING TRYPSIN; CASPASE FAMILY; TARGET-CELLS	Granzyme B is a protease involved in the induction of rapid target cell death by cytotoxic lymphocytes. Definition of the substrate specificity of granzyme B allows for the identification of in vivo substrates in this process. By using the combinatorial methods of synthetic substrate Libraries and substrate-phage display, an optimal substrate for granzyme B that spans over six subsites was determined to be Ile-Glu-Xaa-(Asp down arrow Xaa)-Gly, with cleavage of the Asp down arrow Xaa peptide bond. Granzyme B proteolysis was shown to be highly dependent on the length and sequence of the substrate, supporting the role of granzyme B as a regulatory protease. Arginine 192 was identified as a determinant of P3-Glu and P1-Asp substrate specificity. Mutagenesis of arginine 192 to glutamate reversed the preference for negatively charged amino acids at P3 to positively charged amino acids. The preferred substrate sequence matches the activation sites of caspase 3 and caspase 7 and thus is consistent with the role of granzyme B in activation of these proteases during apoptosis, The caspase substrate poly(ADP)-ribose polymerase is cleaved by granzyme B in a cell-free assay at two sites that resemble the granzyme B specificity determined by the combinatorial methods. Many caspase substrates contain granzyme B cleavage sites and are proposed as potential granzyme B targets, suggesting a redundant function with certain caspases.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Merck Res Labs, Dept Biochem, Rahway, NJ 07065 USA; Univ Nevada, Cell & Mol Biol Program, Reno, NV 89557 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Merck & Company; Nevada System of Higher Education (NSHE); University of Nevada Reno	Craik, CS (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.	jlh@mutant.ucsf.edu; craik@cgl.ucsf.edu			NATIONAL CANCER INSTITUTE [P01CA072006] Funding Source: NIH RePORTER; NCI NIH HHS [CA72006] Funding Source: Medline; NIGMS NIH HHS [GM083808] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrade F, 1998, IMMUNITY, V8, P451, DOI 10.1016/S1074-7613(00)80550-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAKE AJ, 1984, P NATL ACAD SCI-BIOL, V81, P4642, DOI 10.1073/pnas.81.15.4642; CAPUTO A, 1994, NAT STRUCT BIOL, V1, P364, DOI 10.1038/nsb0694-364; Chinnaiyan AM, 1996, CURR BIOL, V6, P897, DOI 10.1016/S0960-9822(02)00614-0; DARMON AJ, 1994, J BIOL CHEM, V269, P32043; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Froelich CJ, 1996, BIOCHEM BIOPH RES CO, V227, P658, DOI 10.1006/bbrc.1996.1565; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; HUDIG D, 1987, BIOCHEM BIOPH RES CO, V149, P882, DOI 10.1016/0006-291X(87)90490-6; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; Jans DA, 1996, J BIOL CHEM, V271, P30781, DOI 10.1074/jbc.271.48.30781; Ke SH, 1997, J BIOL CHEM, V272, P16603, DOI 10.1074/jbc.272.26.16603; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Kurth T, 1997, BIOCHEMISTRY-US, V36, P10098, DOI 10.1021/bi970937l; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; MATTHEWS DJ, 1994, PROTEIN SCI, V3, P1197, DOI 10.1002/pro.5560030805; MCGRATH ME, 1994, EMBO J, V13, P1502, DOI 10.1002/j.1460-2075.1994.tb06411.x; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; Oei S L, 1997, Rev Physiol Biochem Pharmacol, V131, P127; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Pham CTN, 1998, J BIOL CHEM, V273, P1629, DOI 10.1074/jbc.273.3.1629; PODACK ER, 1995, CURR OPIN IMMUNOL, V7, P11, DOI 10.1016/0952-7915(95)80023-9; POE M, 1991, J BIOL CHEM, V266, P98; Rano TA, 1997, CHEM BIOL, V4, P149, DOI 10.1016/S1074-5521(97)90258-1; REMINGTON SJ, 1988, BIOCHEMISTRY-US, V27, P8097, DOI 10.1021/bi00421a019; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Shi LF, 1997, J EXP MED, V185, P855, DOI 10.1084/jem.185.5.855; Smyth MJ, 1996, J LEUKOCYTE BIOL, V60, P555, DOI 10.1002/jlb.60.5.555; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; VandeCraen M, 1997, EUR J IMMUNOL, V27, P1296, DOI 10.1002/eji.1830270535; WANG CI, 1995, J BIOL CHEM, V270, P12250, DOI 10.1074/jbc.270.20.12250; WENZEL TJ, 1992, YEAST, V8, P667, DOI 10.1002/yea.320080810; WILLIAMS MS, 1994, J IMMUNOL, V153, P4247; ZERNER B, 1964, J AM CHEM SOC, V86, P3674, DOI 10.1021/ja01072a016; ZUNINO SJ, 1990, J IMMUNOL, V144, P2001	45	157	175	3	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27364	27373		10.1074/jbc.273.42.27364	http://dx.doi.org/10.1074/jbc.273.42.27364			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765264	hybrid			2022-12-27	WOS:000076448000051
J	Hosfield, DJ; Frank, G; Weng, YH; Tainer, JA; Shen, B				Hosfield, DJ; Frank, G; Weng, YH; Tainer, JA; Shen, B			Newly discovered archaebacterial flap endonucleases show a structure-specific mechanism for DNA substrate binding and catalysis resembling human flap endonuclease-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; NUCLEOTIDE EXCISION-REPAIR; ESCHERICHIA-COLI; POLYMERASE-I; SACCHAROMYCES-CEREVISIAE; MUTATION AVOIDANCE; REPLICATION; FEN-1; EXONUCLEASE; RAD2	Mammalian flap endonuclease-l (FEN-1) is a structure-specific metalloenzyme that acts in processing of both the Okazaki fragments during lagging strand DNA synthesis and flap intermediates during DNA damage repair. We identified and cloned three open reading frames encoding a flap endonuclease from Archaeglobus fulgidus,,Methanococcus jannaschii, and Pyrococcus furiosus, respectively. The deduced FEN-1 protein sequences share approximately 75% similarity with the human FEN-1 nuclease in the conserved nuclease domains, and extensive biochemical experiments indicate that the substrate specificities and catalytic activities of these enzymes have overall similarities with those of the human enzyme, Thus, FEN-1 enzymes and likely reaction mechanisms are conserved across the eukaryotic and archaeal kingdoms. Detailed comparative analysis, however, reveals subtle differences among these four enzymes including distinctive substrate specificity, tolerance of the archaebacterial enzymes for acidic pHs and elevated temperatures, and variations in the metalion dependence of substrate cleavage. Although the archaebacterial enzymes were inactive at temperatures below 30 degrees C, DNA binding occurred at temperatures as low as 4 degrees C and with or without metal ions. Thus, these archaeal enzymes mag provide a means to dissect the specific binding and catalytic mechanisms of the entire FEN-1 family of structure-specific nucleases.	Scripps Res Inst, Skaggs Inst Chem Biol, Dept Biol Mol, La Jolla, CA 92037 USA; City Hope Natl Med Ctr, Dept Cell & Tumor Biol, Duarte, CA 91010 USA	Scripps Research Institute; City of Hope	Tainer, JA (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, Dept Biol Mol, La Jolla, CA 92037 USA.	jat@scripps.edu	Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429; Shen, Binghui/0000-0002-4408-407X	NATIONAL CANCER INSTITUTE [R01CA073764, R29CA073764] Funding Source: NIH RePORTER; NCI NIH HHS [CA57348, CA 73764-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BORGES KM, 1996, GENOME SCI TECHNOL, V1, P37; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; DOETSCH PW, 1995, TRENDS BIOCHEM SCI, V20, P384, DOI 10.1016/S0968-0004(00)89084-2; FRANK G, 1998, IN PRESS J BIOL CHEM, V273; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; FRIEDBERG EC, 1992, TRENDS BIOCHEM SCI, V17, P347, DOI 10.1016/0968-0004(92)90312-W; Gary R, 1997, J BIOL CHEM, V272, P24522, DOI 10.1074/jbc.272.39.24522; Goldman A, 1995, STRUCTURE, V3, P1277, DOI 10.1016/S0969-2126(01)00263-5; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1995, J BIOL CHEM, V270, P4503, DOI 10.1074/jbc.270.9.4503; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Hennig M, 1995, STRUCTURE, V3, P1295, DOI 10.1016/S0969-2126(01)00267-2; HOLLINGSWORTH HC, 1991, J BIOL CHEM, V266, P1888; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; JACQUIER A, 1992, YEAST, V8, P121, DOI 10.1002/yea.320080207; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Knauf JA, 1996, MUTAT RES-DNA REPAIR, V363, P67, DOI 10.1016/0921-8777(95)00062-3; Kornberg A., 1992, DNA REPLICATION; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; LINDAHL T, 1969, P NATL ACAD SCI USA, V62, P597, DOI 10.1073/pnas.62.2.597; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; Nolan JP, 1996, BIOCHEMISTRY-US, V35, P11668, DOI 10.1021/bi952840+; Park MS, 1996, P NATL ACAD SCI USA, V93, P8368, DOI 10.1073/pnas.93.16.8368; PETRUSKA J, 1988, P NATL ACAD SCI USA, V85, P6252, DOI 10.1073/pnas.85.17.6252; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; ROBINS P, 1994, J BIOL CHEM, V269, P28535; Schweitzer JK, 1998, HUM MOL GENET, V7, P69, DOI 10.1093/hmg/7.1.69; Shen BH, 1998, TRENDS BIOCHEM SCI, V23, P171, DOI 10.1016/S0968-0004(98)01199-2; Shen BH, 1997, NUCLEIC ACIDS RES, V25, P3332, DOI 10.1093/nar/25.16.3332; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; SZANKASI P, 1995, SCIENCE, V267, P1166, DOI 10.1126/science.7855597; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; WAGA S, 1994, J BIOL CHEM, V269, P10923; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036; Xu Y, 1997, J MOL BIOL, V268, P284, DOI 10.1006/jmbi.1997.0967; Zhu FX, 1997, BIOCHEMISTRY-US, V36, P5947, DOI 10.1021/bi962889v; [No title captured]	54	66	78	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27154	27161		10.1074/jbc.273.42.27154	http://dx.doi.org/10.1074/jbc.273.42.27154			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765234	hybrid			2022-12-27	WOS:000076448000021
J	Kakuta, Y; Petrotchenko, EV; Pedersen, LC; Negishi, M				Kakuta, Y; Petrotchenko, EV; Pedersen, LC; Negishi, M			The sulfuryl transfer mechanism - Crystal structure of a vanadate complex of estrogen sulfotransferase and mutational analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE; FLAVONOL 3-SULFOTRANSFERASE; SULFATION; PHOSPHATASE; ENZYMOLOGY; ACTIVATION; ANALOGS; BINDING; BIOLOGY; DOMAIN	Estrogen sulfotransferase (EST) catalyzes transfer of the 5'-sulfuryl group of adenosine 3'-phosphate 5'-phosphosulfate (PAPS) to the 3 alpha-phenol group of estrogenic steroids such as estradiol (E-2), The recent crystal structure of EST adenosine 3',5'-diphosphate (PAP)- E-2 complex has revealed that residues Lys(48), Thr(45) Thr(51), Thr(52), Lys(106), His(108), and Try(240) are in position to play a catalytic role in the sulfuryl transfer reaction of EST (Kakuta Y., Pedersen, L. G., Carter, C. W., Negishi, M., and Pedersen, L. C. (1997) Nat. Struct. BioL. 4, 904-908). Mutation of Lys(48), Lys(106), or His(108) nearly abolishes EST activity, indicating that they play a critical role in catalysis, A present 2.2-A resolution structure of EST-PAP-vanadate complex indicates that the vanadate molecule adopts a trigonal bipyramidal geometry with its equatorial oxygens coordinated to these three residues. The apical positions of the vanadate molecule are occupied by a terminal oxygen of the 5'-phosphate of PAP (2.1 ) and a possible water molecule (2.3 Angstrom), This water molecule superimposes well to the 3 alpha-phenol group of E-2 in the crystal structure of the EST . PAP . E-2 complex. These structures are characteristic of the transition state for an in-line sulfuryl transfer reaction from PAPS to E-2. Moreover, residues Lys(48), Lys(106), His(108) are found to be coordinated with the vanadate molecule at the transition state of EST.	NIEHS, Reprod & Dev Toxicol Lab, Pharmacogenet Sect, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Negishi, M (corresponding author), NIEHS, Reprod & Dev Toxicol Lab, Pharmacogenet Sect, NIH, Res Triangle Pk, NC 27709 USA.	negishi@niehs.nih.gov	Negishi, Masahiko/F-7805-2019; Pedersen, Lars/C-6173-2019	Negishi, Masahiko/0000-0002-2076-8928; Pedersen, Lars/0000-0002-4488-4077				BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; CHAI CLL, 1992, BIOORG CHEM, V20, P1981; DEBELLE F, 1986, NUCLEIC ACIDS RES, V14, P7453, DOI 10.1093/nar/14.18.7453; DUFFEL MW, 1981, J BIOL CHEM, V256, P1123; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Falany CN, 1997, FASEB J, V11, P206, DOI 10.1096/fasebj.11.4.9068609; Glatt H, 1997, FASEB J, V11, P314, DOI 10.1096/fasebj.11.5.9141497; HOBKIRK R, 1993, TRENDS ENDOCRIN MET, V4, P69, DOI 10.1016/S1043-2760(05)80018-9; HOMMA H, 1996, BIOCHIM BIOPHYS ACTA, V1296, P156; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; Kakuta Y, 1998, BIOCHEM PHARMACOL, V55, P313, DOI 10.1016/S0006-2952(97)00465-6; KOBASHI K, 1986, BIOCHEM BIOPH RES CO, V140, P38, DOI 10.1016/0006-291X(86)91054-5; Marsolais F, 1995, J BIOL CHEM, V270, P30458, DOI 10.1074/jbc.270.51.30458; Marsolais F, 1997, EUR J BIOCHEM, V247, P1056, DOI 10.1111/j.1432-1033.1997.01056.x; Matsubayashi Y, 1997, P NATL ACAD SCI USA, V94, P13357, DOI 10.1073/pnas.94.24.13357; MEAGLEY KA, 1996, P NATL ACAD SCI USA, V93, P8160; MEISHERI KD, 1988, J PHARMACOL EXP THER, V245, P751; Mildvan AS, 1997, PROTEINS, V29, P401, DOI 10.1002/(SICI)1097-0134(199712)29:4<401::AID-PROT1>3.3.CO;2-#; Nelson RM, 1995, ANNU REV CELL DEV BI, V11, P601, DOI 10.1146/annurev.cellbio.11.1.601; NULLERDIECKMANN H, 1994, J MOL BIOL, V236, P361; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ouyang YB, 1998, P NATL ACAD SCI USA, V95, P2896, DOI 10.1073/pnas.95.6.2896; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; ROTH JA, 1986, TRENDS BIOCHEM SCI, V11, P404; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; SONG WC, 1995, ENDOCRINOLOGY, V136, P2477, DOI 10.1210/en.136.6.2477; STANKIEWICZ PJ, 1988, BIOCHEMISTRY-US, V27, P206, DOI 10.1021/bi00401a031; Strott CA, 1996, ENDOCR REV, V17, P670, DOI 10.1210/er.17.6.670; SUPERTIFURGA A, 1994, AM J HUM GENET, V55, P1137; Weinshilboum RM, 1997, FASEB J, V11, P3, DOI 10.1096/fasebj.11.1.9034160; Xu YW, 1997, P NATL ACAD SCI USA, V94, P3579, DOI 10.1073/pnas.94.8.3579; Zhang M, 1997, BIOCHEMISTRY-US, V36, P15, DOI 10.1021/bi961804n	35	107	114	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27325	27330		10.1074/jbc.273.42.27325	http://dx.doi.org/10.1074/jbc.273.42.27325			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765259	hybrid			2022-12-27	WOS:000076448000046
J	Liao, W; Yeung, SCJ; Chan, L				Liao, W; Yeung, SCJ; Chan, L			Proteasome-mediated degradation of apolipoprotein B targets both nascent peptides cotranslationally before translocation and full-length apolipoprotein B after translocation into the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; CULTURED LIVER-CELLS; I HEAVY-CHAINS; INTRACELLULAR DEGRADATION; HEPG2 CELLS; SECRETION; PATHWAY; CONFORMATION; DETERMINES; CALNEXIN	A major portion of newly synthesized apolipoprotein B (apoB) is degraded intracellularly, This degradation has been demonstrated to be mediated largely by the ubiquitin-proteasome pathway. We examined whether nascent apoB polypeptides or full-length apoB is selectively retrotranslocated from the endoplasmic reticulum into the cytosol for degradation. Herein, we found that full-length apoB as well as partial-length apoB peptides are ubiquitinated in HepG2 cells, and ubiquitination is an exclusively cytosolic process. Calnexin, which binds specifically to glycoproteins, has been postulated to promote apoB folding and complete translocation; me found that ubiquitinated apoB is bound to calnexin, suggesting that ubiquitinated apoB is glycosylated. In addition to calnexin binding, we have other pieces of evidence that the full-length intracellular ubiquitinated apoB is glycosylated, because (i) it binds to concanavalin A, and (ii) glycan can be demonstrated in the full-length ubiquitinated apoB by a chemical detection method involving oxidation of adjacent hydroxyl groups in the glycan moiety. Because glycosylation occurs inside the endoplasmic reticulum, the full-length glycosylated apoB must have been retrotranslocated into the cytosol for ubiquitination and proteasome-mediated degradation. Next we synchronized translation in HepG2 cells by puromycin treatment. A pulse-chase experiment using [S-35]methionine labeling of intracellular apoB in these synchronized cells demonstrated that nascent partial-length apoB peptides are also ubiquitinated cotranslationally, We conclude that the ubiquitin proteasome mediated degradation of apoB targets both nascent peptides cotranslationally before translocation as well as full-length apoB after its translocation into the endoplasmic reticulum.	Baylor Coll Med, Dept Cell Biol, Div Endocrinol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Div Endocrinol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Chan, L (corresponding author), Baylor Coll Med, Dept Cell Biol, Div Endocrinol, 1 Baylor Plaza, Houston, TX 77030 USA.		Yeung, Sai-Ching/AAP-8079-2020; Yeung, Sai-Ching/AAI-6178-2021	Yeung, Sai-Ching/0000-0001-5170-0822	NHLBI NIH HHS [HL-16512] Funding Source: Medline; NIGMS NIH HHS [GM 17159] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016512, R37HL016512] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017159] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baumeister W, 1997, CURR OPIN STRUC BIOL, V7, P273, DOI 10.1016/S0959-440X(97)80036-X; Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BONNARDEL JA, 1995, J BIOL CHEM, V270, P28892, DOI 10.1074/jbc.270.48.28892; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHEN PF, 1988, EUR J BIOCHEM, V175, P111, DOI 10.1111/j.1432-1033.1988.tb14172.x; Chen Y, 1998, J BIOL CHEM, V273, P11887, DOI 10.1074/jbc.273.19.11887; Ciechanover A, 1998, P NATL ACAD SCI USA, V95, P2727, DOI 10.1073/pnas.95.6.2727; COSGROVE PG, 1993, J LIPID RES, V34, P1983; DIXON JL, 1993, J LIPID RES, V34, P167; DU EZ, 1994, J BIOL CHEM, V269, P24169; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; GINSBERG HN, 1995, CURR OPIN LIPIDOL, V6, P275, DOI 10.1097/00041433-199510000-00006; Halaban R, 1997, P NATL ACAD SCI USA, V94, P6210, DOI 10.1073/pnas.94.12.6210; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; KANE JP, 1995, METABOLIC MOL BASES, P1853; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; YANG CY, 1989, ARTERIOSCLEROSIS, V9, P96, DOI 10.1161/01.ATV.9.1.96; Yao ZM, 1997, J LIPID RES, V38, P1937; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3	24	90	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27225	27230		10.1074/jbc.273.42.27225	http://dx.doi.org/10.1074/jbc.273.42.27225			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765244	hybrid			2022-12-27	WOS:000076448000031
J	Gardner, PR; Costantino, G; Salzman, AL				Gardner, PR; Costantino, G; Salzman, AL			Constitutive and adaptive detoxification of nitric oxide in Escherichia coli - Role of nitric-oxide dioxygenase in the protection of aconitase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; PARACOCCUS-DENITRIFICANS; L-ARGININE; REDUCTASE; SUPEROXIDE; PEROXYNITRITE; REACTIVATION; MACROPHAGES; INHIBITION; ACTIVATION	Nitric oxide (NO.) is a naturally occurring toxin that some organisms adaptively resist. In aerobic or anaerobic Escherichia coli, low levels of NO. exposure inactivated the NO.-sensitive citric acid cycle enzyme aconitase, and inactivation was more effective when the adaptive synthesis of NO.-defensive proteins was blocked with chloramphenicol. Protection of aconitase in aerobically grown E. coli, was dependent upon O-2, was potently inhibited by cyanide, and was correlated with an induced rate of cellular NO. consumption. Constitutive and adaptive cellular NO. consumption in aerobic cells was also dependent upon O-2 and inhibited by cyanide. Exposure of aerobic cells to NO. accordingly elevated the activity of the O-2-dependent and cyanide-sensitive NO. dioxygenase (NOD). Anaerobic E. coli exposed to NO. or nitrate induced a modest O-2-independent and cyanide-resistant NO.-metabolizing activity and a more robust O-2-stimulated cyanide-sensitive activity. The latter activity was attributed to NOD. The results support a role for NOD in the aerobic detoxification of NO. and suggest functions for NOD and a cyanide-resistant NO. scavenging activity in anaerobic cells.	Childrens Hosp, Med Ctr, Div Crit Care Med, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center	Gardner, PR (corresponding author), Childrens Hosp, Med Ctr, Div Crit Care, R045,3333 Burnet Ave, Cincinnati, OH 45229 USA.	gardp0@chmcc.org		Gardner, Paul/0000-0001-8189-0903				Borutaite V, 1996, BIOCHEM J, V315, P295, DOI 10.1042/bj3150295; BRUNELLI L, 1995, ARCH BIOCHEM BIOPHYS, V316, P327, DOI 10.1006/abbi.1995.1044; CARR GJ, 1989, EUR J BIOCHEM, V179, P683, DOI 10.1111/j.1432-1033.1989.tb14601.x; CHAPPELL JB, 1964, BIOCHEM J, V90, P225, DOI 10.1042/bj0900225; Cooper CE, 1997, FEBS LETT, V414, P281, DOI 10.1016/S0014-5793(97)01009-0; COSTA C, 1990, FEBS LETT, V276, P67, DOI 10.1016/0014-5793(90)80508-G; DERMASTIA M, 1991, J BIOL CHEM, V266, P10899; Fang FC, 1997, J CLIN INVEST, V99, P2818, DOI 10.1172/JCI119473; Fujiwara T, 1996, J BACTERIOL, V178, P1866, DOI 10.1128/jb.178.7.1866-1871.1996; GARDNER PR, 1992, J BIOL CHEM, V267, P8757; Gardner PR, 1997, BIOSCIENCE REP, V17, P33, DOI 10.1023/A:1027383100936; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; Gardner PR, 1997, J BIOL CHEM, V272, P25071, DOI 10.1074/jbc.272.40.25071; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; Hurst JK, 1997, CHEM RES TOXICOL, V10, P802, DOI 10.1021/tx970008v; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; IMLAY JA, 1995, J BIOL CHEM, V270, P19767; IUCHI S, 1990, J BACTERIOL, V172, P6020, DOI 10.1128/jb.172.10.6020-6025.1990; JI XB, 1988, BIOCHEM BIOPH RES CO, V157, P106, DOI 10.1016/S0006-291X(88)80018-4; Kennedy MC, 1997, J BIOL CHEM, V272, P20340, DOI 10.1074/jbc.272.33.20340; Kwiatkowski AV, 1996, J BIOL CHEM, V271, P24382, DOI 10.1074/jbc.271.40.24382; MacMicking JD, 1997, P NATL ACAD SCI USA, V94, P5243, DOI 10.1073/pnas.94.10.5243; MANCINELLI RL, 1983, APPL ENVIRON MICROB, V46, P198, DOI 10.1128/AEM.46.1.198-202.1983; Morita H, 1997, J BACTERIOL, V179, P7812, DOI 10.1128/jb.179.24.7812-7815.1997; NAKAHARA K, 1993, J BIOL CHEM, V268, P8350; NUNOSHIBA T, 1995, INFECT IMMUN, V63, P794, DOI 10.1128/IAI.63.3.794-798.1995; NUNOSHIBA T, 1993, P NATL ACAD SCI USA, V90, P9993, DOI 10.1073/pnas.90.21.9993; PACELLI R, 1995, J EXP MED, V182, P1469, DOI 10.1084/jem.182.5.1469; SHANK JL, 1962, APPL MICROBIOL, V10, P185, DOI 10.1128/AEM.10.3.185-189.1962; Stenger S, 1996, J EXP MED, V183, P1501, DOI 10.1084/jem.183.4.1501; Taylor-Robinson AW, 1998, LANCET, V351, P1630, DOI 10.1016/S0140-6736(05)77685-6	32	69	71	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26528	26533		10.1074/jbc.273.41.26528	http://dx.doi.org/10.1074/jbc.273.41.26528			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756889	hybrid			2022-12-27	WOS:000076373300043
J	Soler, C; Felipe, A; Mata, JF; Casado, FJ; Celada, A; Pastor-Anglada, M				Soler, C; Felipe, A; Mata, JF; Casado, FJ; Celada, A; Pastor-Anglada, M			Regulation of nucleoside transport by lipopolysaccharide, phorbol esters, and tumor necrosis factor-alpha in human B-lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GUANINE RIBONUCLEOSIDES; FUNCTIONAL EXPRESSION; URIDINE-TRANSPORT; LEUKEMIA-CELLS; HL-60 CELLS; RAT-LIVER; ACTIVATION; MOUSE; DIFFERENTIATION	Nucleoside transport systems and their regulation in human B-lymphocytes have been characterized using the cell lines Raji and Bare lymphoma syndrome-1 (BLS-1) as experimental models. These cells express at least three different nucleoside transport systems as follows: a nitrobenzylthioinosine-sensitive equilibrative transport system of the es-type, which appears to be associated with hENT1 expression, and two Na+-dependent transport systems that may correspond to N1 and to the recently characterized NS-type, which is nitrobenzylthioinosine-sensitive and guanosine-preferring. B cell activators such as phorbol 12-myristate 13-acetate and lipopolysaccharide (LPS) up-regulate both concentrative transport systems but down-regulate the equilibrative es-type transporter, which correlates with lower hENT1 mRNA levels. These effects are dependent on protein kinase C activity. Phorbol 12-myristate 13-acetate and LPS also induce an increase in tumor necrosis factor-alpha (TNF-alpha) mRNA levels, which suggest that this cytokine may mediate some of the effects triggered by these agents, since addition of TNF-alpha alone can increase N1 and N5 transport activities by a mechanism that also depends on protein kinase C activation. Interestingly, TNF-alpha down-regulates es activity, but this effect cannot be abolished by inhibiting protein kinase C, This study reveals differential regulation of nucleoside transport systems following activation of human B-lymphocyte cell lines by agents of physiological relevance such as TNF-alpha and LPS, Moreover, it indicates that the recently characterized N5 transport system can also be regulated following B cell activation, which may be relevant to lymphocyte physiology and to the treatment of lymphocyte malignancies.	Univ Barcelona, Dept Bioquim & Biol Mol, Inst Invest Biomed August Pi & Sunyer, Barcelona 08071, Spain; Univ Barcelona, Dept Fisiol Immunol, E-08007 Barcelona, Spain; Univ Barcelona, Fdn Pi & Sunyer, E-08007 Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; University of Barcelona	Pastor-Anglada, M (corresponding author), Univ Barcelona, Dept Bioquim & Biol Mol, Inst Invest Biomed August Pi & Sunyer, Avda Diagonal 645, Barcelona 08071, Spain.	mpastor@porthos.bio.ub.es	Soler, Concepció/L-1185-2014; Felipe, Antonio/M-8297-2015; Celada, Antonio/I-1714-2016	Soler, Concepció/0000-0001-6502-5012; Felipe, Antonio/0000-0002-7294-6431; Mata, Joao/0000-0002-6988-9069; Casado Merediz, Francisco Javier/0000-0003-0192-841X; Celada, Antonio/0000-0003-3883-2171				Anderson CM, 1996, MOL BRAIN RES, V42, P358, DOI 10.1016/S0169-328X(96)00244-6; Boleti H, 1997, NEUROPHARMACOLOGY, V36, P1167, DOI 10.1016/S0028-3908(97)00136-6; Borgland SL, 1997, J PHARMACOL EXP THER, V281, P347; BOUSSIOTIS VA, 1994, P NATL ACAD SCI USA, V91, P7007, DOI 10.1073/pnas.91.15.7007; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHE MX, 1995, J BIOL CHEM, V270, P13596, DOI 10.1074/jbc.270.23.13596; CRAWFORD CR, 1990, J BIOL CHEM, V265, P9732; Crawford CR, 1998, J BIOL CHEM, V273, P5288, DOI 10.1074/jbc.273.9.5288; CRAWFORD DH, 1994, IMMUNOLOGY, V82, P357; DAGNINO L, 1991, J BIOL CHEM, V266, P6308; DELICADO EG, 1991, BIOCHEM J, V279, P851; Falzarano G, 1996, BLOOD, V87, P2853, DOI 10.1182/blood.V87.7.2853.bloodjournal8772853; Felipe A, 1998, BIOCHEM J, V330, P997, DOI 10.1042/bj3300997; FELIPE A, 1994, J BIOL CHEM, V269, P30125; FELIPE A, 1993, AM J PHYSIOL, V265, pC1230, DOI 10.1152/ajpcell.1993.265.5.C1230; Flanagan SA, 1997, J BIOL CHEM, V272, P18026, DOI 10.1074/jbc.272.29.18026; GOMEZANGELATS M, 1995, AM J PHYSIOL-ENDOC M, V268, pE368, DOI 10.1152/ajpendo.1995.268.2.E368; GomezAngelats M, 1996, BIOCHEM J, V313, P915, DOI 10.1042/bj3130915; GOODMAN MG, 1983, J IMMUNOL, V130, P551; GOODMAN MG, 1983, P NATL ACAD SCI-BIOL, V80, P3452, DOI 10.1073/pnas.80.11.3452; GOODMAN MG, 1983, J IMMUNOL, V130, P2042; GOODMAN MG, 1983, J IMMUNOL, V130, P2580; GOODMAN MG, 1981, P NATL ACAD SCI-BIOL, V78, P7604, DOI 10.1073/pnas.78.12.7604; GOODMAN MG, 1984, P NATL ACAD SCI-BIOL, V81, P862, DOI 10.1073/pnas.81.3.862; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Griffiths M, 1997, BIOCHEM J, V328, P739, DOI 10.1042/bj3280739; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; Lee Chee-Wee, 1994, In Vivo (Attiki), V8, P795; LEE CW, 1991, BIOCHEM J, V274, P85, DOI 10.1042/bj2740085; LEE CW, 1994, BIOCHEM J, V300, P407, DOI 10.1042/bj3000407; MACLEOD CL, 1990, CELL GROWTH DIFFER, V1, P271; MARTINEZMAS JV, 1993, BIOCHEM J, V293, P819, DOI 10.1042/bj2930819; MCGIVAN JD, 1989, METHOD ENZYMOL, V172, P346; MOND JJ, 1994, CIRC SHOCK, V44, P57; PASTORANGLADA M, 1998, IN PRESS TRENDS PHAR; Paterson A. R. P., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P14; PLAGEMANN PGW, 1990, BIOCHIM BIOPHYS ACTA, V1028, P289, DOI 10.1016/0005-2736(90)90178-Q; PLAGEMANN PGW, 1991, BIOCHEM PHARMACOL, V42, P247, DOI 10.1016/0006-2952(91)90710-M; Ritzel MWL, 1997, AM J PHYSIOL-CELL PH, V272, pC707, DOI 10.1152/ajpcell.1997.272.2.C707; Roovers KI, 1996, J CELL PHYSIOL, V166, P593, DOI 10.1002/(SICI)1097-4652(199603)166:3<593::AID-JCP14>3.0.CO;2-8; RUIZMONTASELL B, 1993, FEBS LETT, V316, P85, DOI 10.1016/0014-5793(93)81741-H; Schaner ME, 1997, PHARMACEUT RES, V14, P1316, DOI 10.1023/A:1012148016794; SCHMID M, 1994, LEUKEMIA LYMPHOMA, V15, P317, DOI 10.3109/10428199409049730; Tangye SG, 1997, IMMUNOL CELL BIOL, V75, P561, DOI 10.1038/icb.1997.87; Wang J, 1997, AM J PHYSIOL-RENAL, V273, pF1058, DOI 10.1152/ajprenal.1997.273.6.F1058; WOODLOCK TJ, 1993, J BIOL CHEM, V268, P16020; Yao SYM, 1997, J BIOL CHEM, V272, P28423, DOI 10.1074/jbc.272.45.28423	48	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26939	26945		10.1074/jbc.273.41.26939	http://dx.doi.org/10.1074/jbc.273.41.26939			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756942	hybrid, Green Published			2022-12-27	WOS:000076373300096
J	Tanaka, T; Tatsuno, I; Noguchi, Y; Uchida, D; Oeda, T; Narumiya, S; Yasuda, T; Higashi, H; Kitagawa, M; Nakayama, K; Saito, Y; Hirai, A				Tanaka, T; Tatsuno, I; Noguchi, Y; Uchida, D; Oeda, T; Narumiya, S; Yasuda, T; Higashi, H; Kitagawa, M; Nakayama, K; Saito, Y; Hirai, A			Activation of cyclin-dependent kinase 2 (Cdk2) in growth-stimulated rat astrocytes - Geranylgeranylated Rho small GTPase(s) are essential for the induction of cyclin E gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; PRIMARY CULTURES; CHOLESTEROL-BIOSYNTHESIS; ADP-RIBOSYLATION; FRTL-5 CELLS; G(1) PHASE; S-PHASE; LATE G1; PROTEIN; PHOSPHORYLATION	The role of the mevalonate cascade in the control of cell cycle progression in astrocytes has been investigated. Serum stimulation of rat astrocytes in primary culture induces the expression of cyclin E followed by the activation of cyclin-dependent kinase 2 (Cdk2) during G(1)/S transition. The expression of p27(hip1) cyclin D1, and the activities of Cdk4 and Cdk-activating kinase (CAB), composed of Cdk7 and cyclin H, mere not affected. Serum did, however, stimulate the expression of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase mRNA at mid-G(1) phase. Moreover, an inhibitor of HMG-CoA reductase, pravastatin, reduced cyclin E expression and Cdk2 activation and caused G(1) arrest in the astro cytes. In contrast, mevalonate and its metabolite, geranylgeranylpyrophosphate (GGPP) but not farnesylpyrophosphate (FPP), reversed the inhibitory effects of pravastatin on cyclin E expression and Cdk2 activation and allowed G(1)/S transition. Rho small GTPase(s) were geranylgeranylated and translocated to membranes in the presence of GGPP during G(1)/S transition. The effect of GGPP on cyclin E expression was abolished by botulinum C3 exoenzyme, which specifically inactivates Rho. These data indicate that geranylgeranylated Rho small GTPase(s) are essential for the induction of cyclin E expression, Cdk2 activation, and G(1)/S transition in rat astrocytes.	Chiba Univ, Sch Med, Dept Internal Med 2, Chiba 260, Japan; Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 606, Japan; Okayama Univ, Sch Med, Inst Cellular & Mol Biol, Dept Cell Chem, Okayama 700, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Fukuoka 81282, Japan; Japan Sci & Technol Corp, CREST, Tokyo, Japan; Merck Res Labs, Banyu Tsukuba Res Inst, Tsukuba, Ibaraki 3002611, Japan	Chiba University; Kyoto University; Okayama University; Kyushu University; Japan Science & Technology Agency (JST); Merck & Company	Tanaka, T (corresponding author), Chiba Univ, Sch Med, Dept Internal Med 2, 1-8-1 Inohana, Chiba 260, Japan.	tomoaki@intmed02.m.chiba-u.ac.jp	Higashi, Hideaki/F-6872-2012					BATES S, 1994, ONCOGENE, V9, P71; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DOBBING J, 1973, ARCH DIS CHILD, V48, P757, DOI 10.1136/adc.48.10.757; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; Drapkin R, 1996, P NATL ACAD SCI USA, V93, P6488, DOI 10.1073/pnas.93.13.6488; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Higashi H, 1996, EUR J BIOCHEM, V237, P460, DOI 10.1111/j.1432-1033.1996.0460k.x; Hirai A, 1997, J BIOL CHEM, V272, P13; JONES JP, 1975, J NEUROCHEM, V24, P123, DOI 10.1111/j.1471-4159.1975.tb07637.x; Kabara J J, 1973, Prog Brain Res, V40, P363; KANAI T, 1987, JPN J CANCER RES, V78, P1314; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; KIMELBERG HK, 1989, SCI AM, V260, P66, DOI 10.1038/scientificamerican0489-66; KITAGAWA M, 1995, ONCOGENE, V10, P229; KITAGAWA M, 1992, ONCOGENE, V7, P1067; KITAGAWA M, 1993, ONCOGENE, V8, P2425; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LANGAN TJ, 1991, J NEUROCHEM, V56, P1058, DOI 10.1111/j.1471-4159.1991.tb02029.x; LANGAN TJ, 1991, BRAIN RES, V548, P9, DOI 10.1016/0006-8993(91)91099-M; LANGAN TJ, 1986, J NEUROCHEM, V46, P1283, DOI 10.1111/j.1471-4159.1986.tb00651.x; LANGAN TJ, 1991, J CELL PHYSIOL, V149, P284, DOI 10.1002/jcp.1041490215; LATOV N, 1979, DEV BIOL, V72, P381, DOI 10.1016/0012-1606(79)90127-1; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MILLER RH, 1986, J NEUROSCI, V6, P22; NEMOTO Y, 1991, J BIOL CHEM, V266, P19312; Noguchi Y, 1998, J BIOL CHEM, V273, P3649, DOI 10.1074/jbc.273.6.3649; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OHTUBO M, 1995, MOL CELL BIOL, V15, P2612; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1994, SEMIN CANCER BIOL, V5, P305; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; TATSUNO I, 1990, BIOCHEM BIOPH RES CO, V168, P1027, DOI 10.1016/0006-291X(90)91132-C; Tatsuno I, 1997, BIOCHEM BIOPH RES CO, V241, P376, DOI 10.1006/bbrc.1997.7825; Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224; Vogt A, 1996, ONCOGENE, V13, P1991; VOLPE JJ, 1977, BIOCHIM BIOPHYS ACTA, V486, P408, DOI 10.1016/0005-2760(77)90090-X; VOLPE JJ, 1985, J NEUROCHEM, V45, P536, DOI 10.1111/j.1471-4159.1985.tb04021.x; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; Yamamoto K, 1996, ENDOCRINOLOGY, V137, P2036, DOI 10.1210/en.137.5.2036; YAMAMOTO M, 1993, ONCOGENE, V8, P1449	56	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26772	26778		10.1074/jbc.273.41.26772	http://dx.doi.org/10.1074/jbc.273.41.26772			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756921	hybrid			2022-12-27	WOS:000076373300075
J	Tigue, NJ; Kay, J				Tigue, NJ; Kay, J			Autoprocessing and peptide substrates for human herpesvirus 6 proteinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CYTOMEGALOVIRUS PROTEASE; CRYSTAL-STRUCTURE; IDENTIFICATION; AGENT; FOLD	Autoprocessing of the precursor form of human herpesvirus 6 (HHV-6) proteinase at two sites (termed M and R) is required to generate the mature enzyme, Kinetic constants were determined for the hydrolysis of a series of synthetic peptide substrates by mature HHV-6 proteinase, purified to homogeneity, Truncation or replacement of individual residues in peptides mimicking the R-site sequence, indicated that the minimum length for effective hydrolysis by the viral enzyme was P-4-P-3-P-2-Ala*Ser-P-2'-P-3'-P-4' and revealed the importance of the P-1 Ala and P-4 Tyr residues. Consequently, relevant (P-1 or P-4) mutations were introduced into the precursor form of the proteinase and the ability of these altered proteins to autoprocess was examined. Introduction of Val in place of the P-1 Ala at the M-site essentially abrogated cleavage but mature HHV-6 proteinase was still generated by cleavage at the R-site, indicating that processing of the M-site is not a prerequisite for cleavage of the R-site in the precursor. At the R-site, mutation of the P-1 Ala, or of the preceding P-4 Tyr residue, prevented processing at the R-site in the precursor so that the mature form of HHV-6 proteinase was not generated. The accumulated data suggest a possible new approach to the design of inhibitors for therapeutic intervention in the life cycle of herpesviruses.	Univ Wales, Sch Mol & Med Biosci, Cardiff CF1 3US, S Glam, Wales	Cardiff University	Kay, J (corresponding author), Univ Wales, Sch Mol & Med Biosci, POB 911, Cardiff CF1 3US, S Glam, Wales.			Tigue, Natalie/0000-0001-9916-0255				BUCHWALD D, 1992, ANN INTERN MED, V116, P103, DOI 10.7326/0003-4819-116-2-103; Chen P, 1996, CELL, V86, P835, DOI 10.1016/S0092-8674(00)80157-9; DILANNI CL, 1993, J BIOL CHEM, V268, P25449; Gibson W., 1995, PERSPECT DRUG DISCOV, V2, P413; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hoog SS, 1997, BIOCHEMISTRY-US, V36, P14023, DOI 10.1021/bi9712697; KRAFFT GA, 1994, METHOD ENZYMOL, V241, P70; McMillan DJ, 1997, J GEN VIROL, V78, P2153, DOI 10.1099/0022-1317-78-9-2153; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; PINKO C, 1995, J BIOL CHEM, V270, P23634, DOI 10.1074/jbc.270.40.23634; PRESTON VG, 1992, VIROLOGY, V186, P87, DOI 10.1016/0042-6822(92)90063-U; QUI X, 1996, NATURE, V383, P275; QUI XY, 1997, P NATL ACAD SCI USA, V94, P287; Roizman B, 1993, HUMAN HERPESVIRUSES, P1795; Shieh HS, 1996, NATURE, V383, P279, DOI 10.1038/383279a0; Soldan SS, 1997, NAT MED, V3, P1394, DOI 10.1038/nm1297-1394; STEVENS JT, 1994, EUR J BIOCHEM, V226, P361, DOI 10.1111/j.1432-1033.1994.tb20060.x; Tigue NJ, 1996, J VIROL, V70, P4136, DOI 10.1128/JVI.70.6.4136-4141.1996; Tong L, 1996, NATURE, V383, P272, DOI 10.1038/383272a0; YAMANISHI K, 1988, LANCET, V1, P1065	20	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26441	26446		10.1074/jbc.273.41.26441	http://dx.doi.org/10.1074/jbc.273.41.26441			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756878	hybrid			2022-12-27	WOS:000076373300032
J	Yethon, JA; Heinrichs, DE; Monteiro, MA; Perry, MB; Whitfield, C				Yethon, JA; Heinrichs, DE; Monteiro, MA; Perry, MB; Whitfield, C			Involvement of waaY, waaQ, and waaP in the modification of Escherichia coli lipopolysaccharide and their role in the formation of a stable outer membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM; KLEBSIELLA-PNEUMONIAE; CORE TYPES; LIPID-A; GENES; K-12; RFAP; SUBSTITUTION; BIOSYNTHESIS; PERMEABILITY	The waaY, waaQ, and waaP genes are located in the central operon of the waa (formerly rfa.) locus on the chromosome of Escherichia coli. This locus contains genes whose products are involved in the assembly of the core region of the lipopolysaccharide molecule. In the R1 core prototype strain, E. coli F470, there are nine genes in this operon, and all but waaY, waaQ, and waaP have been assigned function, In this study, the waaY, waaQ, and waaP genes were independently mutated by insertion of a non-polar antibiotic resistance cassette, and the structures of the resulting mutant core oligosaccharides were determined by chemical analyses and phosphorus-nuclear magnetic resonance spectroscopy. All three of these mutations were shown to affect the modification of the heptose region of the core, a region whose structure is critical to outer membrane stability. Mutation of waaY resulted in a core oligosaccharide devoid of phosphate on HepII. Mutation of waaQ resulted in loss of the branch HepIII residue on HepII and impeded the activity of WaaY. Mutation of waaP resulted in loss of phosphoryl substituents on HepI and obviated WaaQ and WaaY activity. Only mutation of waaP resulted in hypersensitivity to novobiocin and sodium dodecyl sulfate, a characteristic of deep-rough mutations.	Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	University of Guelph; National Research Council Canada	Whitfield, C (corresponding author), Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada.		Heinrichs, David/ABD-5702-2021	Heinrichs, David/0000-0002-7217-2456				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Amor PA, 1997, MOL MICROBIOL, V26, P145, DOI 10.1046/j.1365-2958.1997.5631930.x; APPELMELK BJ, 1994, MICROBIOL-UK, V140, P1119, DOI 10.1099/13500872-140-5-1119; Brabetz W, 1997, EUR J BIOCHEM, V247, P716, DOI 10.1111/j.1432-1033.1997.00716.x; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DROGE W, 1968, EUR J BIOCHEM, V4, P134, DOI 10.1111/j.1432-1033.1968.tb00183.x; GIBB AP, 1992, J INFECT DIS, V166, P1051, DOI 10.1093/infdis/166.5.1051; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HASIN M, 1982, J BIOL CHEM, V257, P2475; HELANDER IM, 1989, EUR J BIOCHEM, V185, P541, DOI 10.1111/j.1432-1033.1989.tb15147.x; HELANDER IM, 1994, MOL MICROBIOL, V11, P481, DOI 10.1111/j.1365-2958.1994.tb00329.x; HOLST O, 1992, BACTERIAL ENDOTOXIC, V1, P134; JANSSON PE, 1981, EUR J BIOCHEM, V115, P571; Kadrmas JL, 1998, J BIOL CHEM, V273, P2799, DOI 10.1074/jbc.273.5.2799; MUHLRADT P, 1968, EUR J BIOCHEM, V4, P139, DOI 10.1111/j.1432-1033.1968.tb00184.x; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; Nikaido H., 1996, ESCHERICHIA COLI SAL, P29; Olsthoorn MMA, 1998, J BIOL CHEM, V273, P3817, DOI 10.1074/jbc.273.7.3817; PARKER CT, 1992, J BACTERIOL, V174, P2525, DOI 10.1128/jb.174.8.2525-2538.1992; PARKER CT, 1992, J BACTERIOL, V174, P930, DOI 10.1128/jb.174.3.930-934.1992; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; Sambrook J., 2002, MOL CLONING LAB MANU; SAWARDEKER JH, 1967, ANAL CHEM, V39, P1602; SCHMIDT G, 1969, EUR J BIOCHEM, V10, P501, DOI 10.1111/j.1432-1033.1969.tb00717.x; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; SCHWEIZER HP, 1993, BIOTECHNIQUES, V15, P831; Severn WB, 1996, J BACTERIOL, V178, P1731, DOI 10.1128/jb.178.6.1731-1741.1996; SIRISENA DM, 1994, J BACTERIOL, V176, P2379, DOI 10.1128/JB.176.8.2379-2385.1994; SUSSKIND M, 1995, CARBOHYD RES, V269, pC1, DOI 10.1016/0008-6215(95)00002-B; VAARA M, 1992, MICROBIOL REV, V56, P395, DOI 10.1128/MMBR.56.3.395-411.1992; WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83; Whitfield C, 1997, MOL MICROBIOL, V23, P629, DOI 10.1046/j.1365-2958.1997.2571614.x; Whitfield C., 1994, P437	35	123	134	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26310	26316		10.1074/jbc.273.41.26310	http://dx.doi.org/10.1074/jbc.273.41.26310			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756860	hybrid			2022-12-27	WOS:000076373300014
J	Morton, NM; Emilsson, V; Liu, YL; Cawthorne, MA				Morton, NM; Emilsson, V; Liu, YL; Cawthorne, MA			Leptin action in intestinal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; OBESE GENE; FOOD-INTAKE; OB/OB MICE; DIABETIC MICE; OB PROTEIN; DB/DB MICE; RECEPTOR; ACTIVATION; IDENTIFICATION	The adipocyte hormone leptin activates signal transducer and activator of transcription 3 (STAT3) in the hypothalamus, mediating increased satiety and increased energy expenditure. To date, leptin-mediated activation of the STAT pathway in vivo has not been established in tissues other than hypothalamus. We now describe leptin receptor expression and in vivo signaling in discrete regions of the mouse gastrointestinal tract. Expression of the functional isoform leptin receptor (OB-Rb) is restricted to the jejunum and is readily detected by RT-PCR in isolated enterocytes from this site. Intravenous injection of leptin rapidly induced nuclear STATE DNA binding activity in jejunum of +/+ and obese (ob/ob) mice but had no effect in the diabetic (db/db) mouse that lacks the OB-Rb isoform. In addition, an induction of the immediate-early gene c-fos is observed in jejunum in vitro. Leptin-mediated induction of a number of immediate-early genes and activation of STAT3 and STATE in a human model of small intestine epithelium, CACO-2 cells, corroborate this effect. Furthermore, intravenous leptin administration caused a significant a-fold reduction in the apolipoprotein AIV transcript levels in jejunum 90 min after a fat load. Our results suggest that the epithelium of jejunum is a direct target of leptin action, and this activity is dependent on the presence of OB-Rb. Lack of leptin or resistance to leptin action in this site may contribute to obesity and its related syndromes by directly affecting lipid handling.	Univ Buckingham, Clore Lab, Buckingham MK18 1EG, England	University of Buckingham	Emilsson, V (corresponding author), Univ Buckingham, Clore Lab, Hunter St, Buckingham MK18 1EG, England.	valur.emilsson@buck.ac.uk	Morton, NICHOLAS/ABF-3774-2020	Emilsson, Valur/0000-0001-9982-0524				Angelin B, 1997, CURR OPIN LIPIDOL, V8, P337, DOI 10.1097/00041433-199712000-00003; BARRACHINA MD, 1997, AM J PHYSIOL-REG I, V41, pR1007; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Cioffi JA, 1996, NAT MED, V2, P585, DOI 10.1038/nm0596-585; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; EMILSSON V, 1997, DIABETES, V4, P17; FEINGOLD KR, 1990, ENDOCRINOLOGY, V127, P2247, DOI 10.1210/endo-127-5-2247; FLINT N, 1991, BIOCHEM J, V280, P331, DOI 10.1042/bj2800331; Ghilardi N, 1997, MOL ENDOCRINOL, V11, P393, DOI 10.1210/me.11.4.393; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Hamann A, 1997, DIABETOLOGIA, V40, P810, DOI 10.1007/s001250050753; Islam MS, 1997, BIOCHEM BIOPH RES CO, V238, P851, DOI 10.1006/bbrc.1997.7399; Kalogeris TJ, 1996, AM J PHYSIOL-GASTR L, V270, pG277, DOI 10.1152/ajpgi.1996.270.2.G277; Kieffer TJ, 1997, DIABETES, V46, P1087, DOI 10.2337/diabetes.46.6.1087; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Levin N, 1996, P NATL ACAD SCI USA, V93, P1726, DOI 10.1073/pnas.93.4.1726; Liu YL, 1997, FEBS LETT, V411, P351, DOI 10.1016/S0014-5793(97)00732-1; Lostao MP, 1998, FEBS LETT, V423, P302, DOI 10.1016/S0014-5793(98)00110-0; Mercer JG, 1996, J NEUROENDOCRINOL, V8, P733, DOI 10.1046/j.1365-2826.1996.05161.x; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; STREAMSON CC, 1996, SCIENCE, V271, P994; Takahashi Y, 1997, J BIOL CHEM, V272, P12897, DOI 10.1074/jbc.272.20.12897; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; White DW, 1997, J BIOL CHEM, V272, P4065, DOI 10.1074/jbc.272.7.4065; White DW, 1997, P NATL ACAD SCI USA, V94, P10657, DOI 10.1073/pnas.94.20.10657; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P6386, DOI 10.1073/pnas.94.12.6386	34	205	214	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26194	26201		10.1074/jbc.273.40.26194	http://dx.doi.org/10.1074/jbc.273.40.26194			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748302	hybrid			2022-12-27	WOS:000076263100093
J	Harhaj, EW; Sun, SC				Harhaj, EW; Sun, SC			I kappa B kinases serve as a target of CD28 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELLS; C-REL; INTERLEUKIN-2 PRODUCTION; ACTIVATION PATHWAY; IL-2 PROMOTER; ALPHA; PHOSPHORYLATION; BETA; DEGRADATION; EXPRESSION	Optimal T cell. activation and interleukin-2 production requires a second signal in addition to antigen-mediated T cell receptor (TCR) signaling. The CD28 molecule has been demonstrated to act as an effective costimulatory molecule upon binding by B7.1 or B7.2 present on antigen-presenting cells, The CD28 signal acts in concert with the TCR signal to significantly augment activation of the NF-kappa B family of transcription factors. The interleukin-a gene is regulated by NF-kappa B among other transcription factors, in part, via a CD28 responsive element (CD28RE) present in the IL-2 promoter. Enhanced activation of NF-kappa B by CD28 is mediated by rapid phosphorylation and proteasome-mediated degradation of the NF-kappa B inhibitory proteins I kappa B alpha and I kappa B beta, which allows for accelerated nuclear expression of the liberated NF-kappa B, Herein, we provide evidence that the catalytic activities of two recently identified I kappa B kinases, IKK alpha and IKK beta, are significantly elevated when T cells are stimulated through CD28 in addition to mitogen treatment. Catalytically inactive forms of IKKs are able to block the in vivo phosphorylation of I kappa B alpha induced by mitogen and CD28, Furthermore, CD28-mediated reporter gene transactivation of the CD28RE/AP-1 composite element is consistently attenuated by the IKK mutants. These findings suggest that cellular signaling pathways initiated at the TCR and CD28 converge at or upstream of IKK, resulting in more robust kinase activity and enhanced and prolonged NF-kappa B activation.	Penn State Univ, Coll Med, Milton S Hershey Med Ctr, Dept Microbiol & Immunol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ, Coll Med, Milton S Hershey Med Ctr, Dept Microbiol & Immunol, POB 850, Hershey, PA 17033 USA.				NATIONAL CANCER INSTITUTE [R01CA068471] Funding Source: NIH RePORTER; NCI NIH HHS [1 R01 CA68471-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; BRYAN RG, 1994, MOL CELL BIOL, V14, P7933, DOI 10.1128/MCB.14.12.7933; Butscher WG, 1998, J BIOL CHEM, V273, P552, DOI 10.1074/jbc.273.1.552; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1054; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; Faris M, 1996, J BIOL CHEM, V271, P27366, DOI 10.1074/jbc.271.44.27366; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; Good L, 1996, BIOCHEM BIOPH RES CO, V223, P123, DOI 10.1006/bbrc.1996.0856; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; Harhaj EW, 1996, MOL CELL BIOL, V16, P6736; Harhaj EW, 1996, ONCOGENE, V12, P2385; HOLBROOK NJ, 1987, VIROLOGY, V157, P211, DOI 10.1016/0042-6822(87)90330-8; Kaga S, 1998, J IMMUNOL, V160, P4182; Kalli K, 1998, MOL CELL BIOL, V18, P3140, DOI 10.1128/MCB.18.6.3140; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; LAI JH, 1994, J BIOL CHEM, V269, P30077; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Matsuda S, 1998, J BIOL CHEM, V273, P12378, DOI 10.1074/jbc.273.20.12378; McGuire KL, 1997, J IMMUNOL, V159, P1319; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nishina H, 1997, J EXP MED, V186, P941, DOI 10.1084/jem.186.6.941; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; Shapiro VS, 1997, MOL CELL BIOL, V17, P4051, DOI 10.1128/MCB.17.7.4051; Shapiro VS, 1996, J EXP MED, V184, P1663, DOI 10.1084/jem.184.5.1663; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; THOMPSON CB, 1989, P NATL ACAD SCI USA, V86, P1333, DOI 10.1073/pnas.86.4.1333; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	48	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25185	25190		10.1074/jbc.273.39.25185	http://dx.doi.org/10.1074/jbc.273.39.25185			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737979	hybrid			2022-12-27	WOS:000076085400029
J	Murray, EW; Robbins, SM				Murray, EW; Robbins, SM			Antibody cross-linking of the glycosylphosphatidylinositol-linked protein CD59 on hematopoietic cells induces signaling pathways resembling activation by complement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; C-CBL PROTOONCOGENE; PHOSPHATIDYLINOSITOL-ANCHORED PROTEINS; TYROSINE-PHOSPHORYLATED PROTEIN; ANTIGEN RECEPTOR; EGF STIMULATION; JURKAT CELLS; SH3 DOMAIN; T-CELLS; KINASE	CD59 is a glycosylphosphatidylinositol-anchored cell surface glycoprotein involved in protecting cells from host-mediated complement attack. Studies have shown that antibody cross-linking of CD59 induces a series of intracellular signaling events including the activation of protein-tyrosine kinases (PTK). To further characterize these events, antibodies and complement 8, one of the natural ligands of CD59, were used to activate CD59, Antibody-induced cross-linking of CD59 on the surface of THP-1 and U937 hematopoietic cell lines as well as exposure to complement 8 induces a rapid increase in the tyrosine phosphorylation of several proteins within the cell. Consistent with an early role for the Src family PTKs in these signaling events, we found that transient activation of Hck- and CD59-mediated signaling was abrogated in the presence of the Src family PTK-selective inhibitor PP1. Although the molecular mechanism by which CD59 communicates to lick is unknown, cellular fractionation studies indicated that both CD59 and Hck are compartmentalized in plasma membrane microdomains. We also detected tyrosine phosphorylation of the adaptor proteins p120(cbl) and Shc, and the cytoplasmic nonreceptor tyrosine kinase Syk. The identification of CD59-mediated signaling events may help explain why paroxysmal nocturnal hemoglobinuria patients, who are deficient in glycosylphosphatidylinositol-linked proteins including CD59, are susceptible to proliferative disorders.	Univ Calgary, Dept Oncol, Canc Biol Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Oncol, Immunol Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary; University of Calgary	Robbins, SM (corresponding author), Univ Calgary, Dept Oncol, Canc Biol Grp, Rm 393 HMRB,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.			Robbins, Stephen/0000-0001-7475-1665; Murray, Elizabeth/0000-0003-3087-7578				Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; Brodsky RA, 1997, P NATL ACAD SCI USA, V94, P8756, DOI 10.1073/pnas.94.16.8756; BROOIMANS RA, 1992, EUR J IMMUNOL, V22, P791, DOI 10.1002/eji.1830220324; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; Crowley MT, 1996, J BIOL CHEM, V271, P1145, DOI 10.1074/jbc.271.2.1145; Crowley MT, 1997, J EXP MED, V186, P1027, DOI 10.1084/jem.186.7.1027; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DAVIES A, 1993, IMMUNOL RES, V12, P258, DOI 10.1007/BF02918257; DAVIES A, 1989, J EXP MED, V170, P637, DOI 10.1084/jem.170.3.637; Davis S, 1993, CURR OPIN CELL BIOL, V5, P281, DOI 10.1016/0955-0674(93)90117-9; DECKERT M, 1995, EUR J IMMUNOL, V25, P1815, DOI 10.1002/eji.1830250704; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DRABEROVA L, 1993, P NATL ACAD SCI USA, V90, P3611, DOI 10.1073/pnas.90.8.3611; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GARNETT D, 1993, EUR J IMMUNOL, V23, P2540, DOI 10.1002/eji.1830231024; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Horikawa K, 1997, BLOOD, V90, P2716, DOI 10.1182/blood.V90.7.2716.2716_2716_2722; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Killeen N, 1997, CURR BIOL, V7, pR774, DOI 10.1016/S0960-9822(06)00402-7; Kinoshita T, 1997, J BIOCHEM-TOKYO, V122, P251; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; Liu L, 1997, J BIOL CHEM, V272, P8983; LUBLIN DM, 1992, CURR TOP MICROBIOL, V178, P141; LUNDJOHANSEN F, 1993, EUR J IMMUNOL, V23, P2782, DOI 10.1002/eji.1830231110; Malek T R, 1994, Semin Immunol, V6, P105, DOI 10.1006/smim.1994.1015; MARCHBANK KJ, 1995, IMMUNOLOGY, V85, P146; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MERI S, 1991, LAB INVEST, V65, P532; MOHNEY RP, 1994, J BIOL CHEM, V269, P6536; MORGAN BP, 1985, BIOCHEM J, V231, P205, DOI 10.1042/bj2310205; MORGAN BP, 1993, EUR J IMMUNOL, V23, P2841, DOI 10.1002/eji.1830231118; MORGAN BP, 1989, BIOCHEM J, V164, P1; Murray EW, 1996, J BIOL CHEM, V271, P15330, DOI 10.1074/jbc.271.26.15330; NINOMIYA H, 1992, J BIOL CHEM, V267, P13675; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Ota Y, 1996, J EXP MED, V184, P1713, DOI 10.1084/jem.184.5.1713; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; Parolini I, 1996, BLOOD, V87, P3783, DOI 10.1182/blood.V87.9.3783.bloodjournal8793783; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; Richards JD, 1996, J BIOL CHEM, V271, P6458, DOI 10.1074/jbc.271.11.6458; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; ROSSE WF, 1995, BLOOD, V86, P3277, DOI 10.1182/blood.V86.9.3277.bloodjournal8693277; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; STAHL N, 1994, J NEUROBIOL, V25, P1454, DOI 10.1002/neu.480251111; STEFANOVA I, 1991, J IMMUNOL, V147, P1587; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; THOMAS PM, 1992, J BIOL CHEM, V267, P12317; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; VANDENBERG CW, 1995, J CELL BIOL, V131, P669, DOI 10.1083/jcb.131.3.669; VANDENBERG CW, 1994, IMMUNOLOGY, V81, P637	61	52	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25279	25284		10.1074/jbc.273.39.25279	http://dx.doi.org/10.1074/jbc.273.39.25279			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737993	hybrid			2022-12-27	WOS:000076085400043
J	Staubs, PA; Nelson, JG; Reichart, DR; Olefsky, JM				Staubs, PA; Nelson, JG; Reichart, DR; Olefsky, JM			Platelet-derived growth factor inhibits insulin stimulation of insulin receptor substrate-1-associated phosphatidylinositol 3-kinase in 3T3-L1 adipocytes without affecting glucose transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; GLUT4 TRANSLOCATION; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; PHOSPHOINOSITIDE 3-KINASE; SIGNALING PATHWAYS; RAT ADIPOCYTES; ACTIVATION; IRS-1; PHOSPHORYLATION; WORTMANNIN	Phosphatidylinositol 3-kinase (PI3K) activation is necessary for insulin-responsive glucose transporter (GLUT4) translocation and glucose transport. Insulin and platelet-derived growth factor (PDGF) stimulate PI3K activity in 3T3-L1 adipocytes, but only insulin is capable of stimulating GLUT4 translocation and glucose transport. We found that PDGF causes serine/threonine phosphorylation of insulin receptor substrate 1 (IRS-1) in 3T3-L1 cells, measured by altered mobility on SDS-polyacrylamide gel, and this leads to a decrease in insulin-stimulated tyrosine phosphorylation of IRS-1. The PI3K inhibitors wortmannin and LY294002 inhibit the PDGF-induced phosphorylation of IRS-1, whereas the MEK inhibitor PD98059 was without a major effect. PDGF pretreatment for 60-90 min led to a marked 80-90% reduction in insulin stimulatable phosphotyrosine and IRS-1-associated PI3K activity. We examined the functional consequences of this decrease in IRS-1-associated PI3K activity. Interestingly, insulin stimulation of GLUT4 translocation and glucose transport was unaffected by 60-90 min of PDGF preincubation. Furthermore, insulin activation of Akt and p70(s6kinase), kinases downstream of PI3K, was unaffected by PDGF pretreatment, Wortmannin was capable of blocking these insulin actions following PDGF pretreatment, suggesting that PI3K was still necessary for these effects. In conclusion, 1) PDGF causes serine/threonine phosphorylation of IRS-1, and PI3K, or a kinase downstream of PI3K, mediates this phosphorylation, 2) This PDGF-induced phosphorylation of IRS-1 leads to a significant decrease in insulin-stimulated PI3K activity. 3) PDGF has no effect on insulin stimulation of Akt, p70(s6kinase), GLUT4 translocation, or glucose transport. 4) This suggests the existence of an IRS-1-independent pathway leading to the activation of PI3K, Akt, and p70(s6kinase); GLUT4 translocation; and glucose transport.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Program Biomed Sci, La Jolla, CA 92093 USA; Whittier Diabet Inst, La Jolla, CA 92093 USA; Vet Adm Res Serv, La Jolla, CA 92161 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Olefsky, JM (corresponding author), Univ Calif San Diego, Dept Med 0673, 9500 Gilman Dr, La Jolla, CA 92093 USA.	jolefsky@ucsd.edu			NIDDK NIH HHS [DK 33651] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033651, R01DK033651] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BERGER J, 1994, BIOCHEM BIOPH RES CO, V205, P570, DOI 10.1006/bbrc.1994.2703; BERNAL D, 1997, DIABETES S1, V46, pA5; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Chen D, 1997, J BIOL CHEM, V272, P27401, DOI 10.1074/jbc.272.43.27401; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; Conricode KM, 1995, BIOCHEM MOL BIOL INT, V36, P835; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; HARUTA T, 1995, J BIOL CHEM, V270, P27991; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; Kaburagi Y, 1997, J BIOL CHEM, V272, P25839, DOI 10.1074/jbc.272.41.25839; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KLIP A, 1984, AM J PHYSIOL, V247, pE291, DOI 10.1152/ajpendo.1984.247.3.E291; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Krook A, 1996, J BIOL CHEM, V271, P7134, DOI 10.1074/jbc.271.12.7134; LAM K, 1994, J BIOL CHEM, V269, P20648; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; MARGALETSANCHEZ V, 1994, BIOCHEM BIOPH RES CO, V204, P446; Morris AJ, 1996, P NATL ACAD SCI USA, V93, P8401, DOI 10.1073/pnas.93.16.8401; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; OKADA T, 1994, J BIOL CHEM, V269, P3568; QUON MJ, 1994, J BIOL CHEM, V269, P27920; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; Ricort JM, 1997, J BIOL CHEM, V272, P19814, DOI 10.1074/jbc.272.32.19814; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sharma PM, 1997, MOL CELL BIOL, V17, P7386, DOI 10.1128/MCB.17.12.7386; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tang XW, 1997, J BIOL CHEM, V272, P14193, DOI 10.1074/jbc.272.22.14193; TANTI JF, 1994, BIOCHEM J, V304, P17, DOI 10.1042/bj3040017; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; Tilton B, 1997, J BIOL CHEM, V272, P28096, DOI 10.1074/jbc.272.44.28096; WALSH JP, 1991, P NATL ACAD SCI USA, V88, P9184, DOI 10.1073/pnas.88.20.9184; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074	42	83	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25139	25147		10.1074/jbc.273.39.25139	http://dx.doi.org/10.1074/jbc.273.39.25139			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737973	hybrid			2022-12-27	WOS:000076085400023
